Our/PRP$
results/NNS
support/VBP
the/DT
idea/NN
that/IN
human/JJ
CD36/NN
mediates/VBZ
signal/NN
transduction/NN
events/NNS
in/IN
response/NN
to/TO
Ox/NN
LDL/NN
./.
====================
UI/LS
-/:
97205335/CD
====================
TI/LS
-/:
TRAMP/NN
,/,
a/DT
novel/JJ
apoptosis-mediating/JJ
receptor/NN
with/IN
sequence/NN
homology/NN
to/TO
tumor/NN
necrosis/NN
factor/NN
receptor/NN
1/CD
and/CC
Fas/NN
(/(
Apo-1/CD95/NN
)/)
./.
====================
AB/LS
-/:
A/DT
novel/JJ
member/NN
of/IN
the/DT
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
)/)
receptor/NN
family/NN
,/,
designated/VBN
TRAMP/NN
,/,
has/VBZ
been/VBN
identified/VBN
./.
====================
The/DT
structural/JJ
organization/NN
of/IN
the/DT
393/CD
amino/NN
acid/NN
long/JJ
human/JJ
TRAMP/NN
is/VBZ
most/RBS
homologous/JJ
to/TO
TNF/NN
receptor/NN
1/CD
./.
====================
TRAMP/NN
is/VBZ
abundantly/RB
expressed/VBN
on/IN
thymocytes/NNS
and/CC
lymphocytes/NNS
./.
====================
Its/PRP$
extracellular/JJ
domain/NN
is/VBZ
composed/VBN
of/IN
four/CD
cysteine-rich/JJ
domains/NNS
,/,
and/CC
the/DT
cytoplasmic/JJ
region/NN
contains/VBZ
a/DT
death/NN
domain/NN
known/VBN
to/TO
signal/NN
apoptosis/NN
./.
====================
Overexpression/NN
of/IN
TRAMP/NN
leads/VBZ
to/TO
two/CD
major/JJ
responses/NNS
,/,
NF-kappaB/NN
activation/NN
and/CC
apoptosis/NN
./.
====================
TRAMP-induced/JJ
cell/NN
death/NN
is/VBZ
inhibited/VBN
by/IN
an/DT
inhibitor/NN
of/IN
ICE-like/JJ
proteases/NNS
,/,
but/CC
not/RB
by/IN
Bcl-2/NN
./.
====================
In/IN
addition/NN
,/,
TRAMP/NN
does/VBZ
not/RB
appear/VB
to/TO
interact/VB
with/IN
any/DT
of/IN
the/DT
known/JJ
apoptosis-inducing/JJ
ligands/NNS
of/IN
the/DT
TNF/NN
family/NN
./.
====================
UI/LS
-/:
97131727/CD
====================
TI/LS
-/:
The/DT
state/NN
of/IN
maturation/NN
of/IN
monocytes/NNS
into/IN
macrophages/NNS
determines/VBZ
the/DT
effects/NNS
of/IN
IL-4/NN
and/CC
IL-13/NN
on/IN
HIV/NN
replication/NN
./.
====================
AB/LS
-/:
The/DT
molecular/JJ
mechanisms/NNS
of/IN
the/DT
effects/NNS
of/IN
IL-4/NN
and/CC
IL-13/NN
on/IN
HIV/NN
infection/NN
in/IN
human/JJ
monocytes/NNS
as/IN
they/PRP
matured/VBD
into/IN
monocyte-derived/JJ
macrophages/NNS
over/IN
7/CD
days/NNS
were/VBD
investigated/VBN
using/VBG
HIV-1/NN
(/(
BaL/NN
)/)
,/,
and/CC
low/JJ
passage/NN
clinical/JJ
strains/NNS
./.
====================
IL-4/NN
and/CC
IL-13/NN
up-regulated/VBD
the/DT
expression/NN
of/IN
both/CC
genomic/JJ
and/CC
spliced/VBN
HIV/NN
mRNA/NN
in/IN
monocytes/NNS
cultured/VBN
on/IN
Teflon/NN
,/,
as/IN
determined/VBN
by/IN
Northern/NN
analysis/NN
and/CC
p24/NN
Ag/NN
assay/NN
./.
====================
Using/VBG
a/DT
nuclear/JJ
run-on/JJ
assay/NN
,/,
IL-4/NN
stimulation/NN
was/VBD
shown/VBN
to/TO
enhance/VB
transcription/NN
by/IN
two-/CD
to/TO
threefold/RB
./.
====================
IL-4/NN
stimulated/VBD
nuclear/JJ
factor-kappaB/NN
nuclear/JJ
translocation/NN
and/CC
binding/NN
before/IN
enhancement/NN
of/IN
HIV/NN
RNA/NN
expression/NN
./.
====================
Conversely/RB
,/,
IL-4/NN
and/CC
IL-13/NN
markedly/RB
and/CC
significantly/RB
inhibited/VBD
HIV/NN
replication/NN
at/IN
the/DT
transcriptional/JJ
level/NN
in/IN
monocyte-derived/JJ
macrophages/NNS
,/,
and/CC
this/DT
occurred/VBD
whether/IN
these/DT
cytokines/NNS
were/VBD
added/VBN
before/IN
or/CC
after/IN
HIV/NN
infection/NN
./.
====================
The/DT
reversal/NN
from/IN
stimulation/NN
to/TO
inhibition/NN
occurred/VBD
after/IN
3/CD
to/TO
5/CD
days/NNS
of/IN
adherence/NN
to/TO
plastic/NN
./.
====================
IL-4/NN
had/VBD
no/DT
significant/JJ
effect/NN
on/IN
HIV/NN
reverse/JJ
transcription/NN
./.
====================
The/DT
effect/NN
of/IN
both/DT
cytokines/NNS
on/IN
the/DT
monocyte/NN
maturation/differentiation/NN
(/(
CD11b/NN
,/,
CD13/NN
,/,
and/CC
CD26/NN
)/)
and/CC
other/JJ
macrophage/NN
markers/NNS
(/(
CD14/NN
and/CC
CD68/NN
)/)
was/VBD
examined/VBN
./.
====================
IL-4/NN
enhanced/VBD
CD11b/NN
,/,
but/CC
inhibited/VBD
CD26/NN
expression/NN
and/CC
delayed/VBD
CD13/NN
loss/NN
./.
====================
IL-13/NN
had/VBD
similar/JJ
effects/NNS
on/IN
CD11b/NN
and/CC
CD13/NN
,/,
but/CC
no/DT
effect/NN
on/IN
CD26/NN
./.
====================
Hence/RB
,/,
these/DT
cytokines/NNS
do/VBP
not/RB
simply/RB
enhance/VB
monocyte/NN
differentiation/NN
,/,
but/CC
have/VBP
complex/JJ
and/CC
slightly/RB
divergent/JJ
effects/NNS
that/WDT
impact/VBP
on/IN
HIV/NN
replication/NN
probably/RB
through/IN
cell/NN
signaling/NN
pathways/NNS
and/CC
nuclear/JJ
factor-kappaB/NN
translocation/NN
./.
====================
UI/LS
-/:
99101008/CD
====================
TI/LS
-/:
Mice/NNS
lacking/VBG
the/DT
transcription/NN
factor/NN
CIITA/NN
--/:
a/DT
second/JJ
look/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
generated/VBN
a/DT
second/JJ
line/NN
of/IN
mice/NNS
lacking/VBG
a/DT
transcription/NN
factor/NN
thought/VBN
to/TO
be/VB
a/DT
critical/JJ
regulator/NN
of/IN
MHC/NN
class/NN
II/CD
gene/NN
expression/NN
,/,
CIITA/NN
(/(
for/IN
class/NN
II/CD
transactivator/NN
)/)
./.
====================
Our/PRP$
and/CC
the/DT
previously/RB
published/VBN
lines/NNS
differ/VBP
in/IN
the/DT
deletion/NN
that/WDT
was/VBD
engineered/VBN
and/CC
by/IN
the/DT
fact/NN
that/IN
we/PRP
removed/VBD
the/DT
neomycin-resistance/JJ
promoter/NN
and/CC
structural/JJ
gene/NN
via/IN
the/DT
cre-loxP/JJ
recombination/NN
system/NN
./.
====================
Characterization/NN
of/IN
our/PRP$
line/NN
led/VBD
to/TO
two/CD
new/JJ
findings/NNS
./.
====================
First/RB
,/,
a/DT
substantial/JJ
number/NN
of/IN
cells/NNS
can/MD
express/VB
class/NN
II/CD
molecules/NNS
in/IN
the/DT
absence/NN
of/IN
CIITA/NN
,/,
albeit/IN
at/IN
5-fold/RB
reduced/VBN
levels/NNS
,/,
most/RBS
notably/RB
dendritic/JJ
cells/NNS
in/IN
s.c./NN
lymph/NN
nodes/NNS
;/:
therefore/RB
,/,
the/DT
CIITA/NN
gene/NN
can/MD
not/RB
be/VB
an/DT
absolute/JJ
'/``
master/NN
gene/NN
'/''
controlling/VBG
the/DT
expression/NN
of/IN
class/NN
II/CD
molecules/NNS
,/,
as/IN
had/VBD
been/VBN
thought/VBN
./.
====================
Second/RB
,/,
in/IN
contrast/NN
to/TO
recent/JJ
results/NNS
on/IN
human/JJ
cell/NN
lines/NNS
,/,
CIITA/NN
is/VBZ
not/RB
critically/RB
involved/VBN
in/IN
the/DT
IFN-gamma-induced/JJ
up-regulation/NN
of/IN
MHC/NN
class/NN
I/CD
genes/NNS
./.
====================
UI/LS
-/:
99087711/CD
====================
TI/LS
-/:
Interleukin-10/NN
stabilizes/VBZ
inhibitory/JJ
kappaB-alpha/NN
in/IN
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
Interleukin-10/NN
(/(
IL-10/NN
)/)
protects/VBZ
animals/NNS
from/IN
lethal/JJ
endotoxemia/NN
./.
====================
This/DT
beneficial/JJ
effect/NN
is/VBZ
mediated/VBN
,/,
in/IN
part/NN
,/,
by/IN
inhibition/NN
of/IN
inflammatory/JJ
cytokine/NN
production/NN
,/,
including/VBG
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
./.
====================
Evidence/NN
suggests/VBZ
that/IN
IL-10/NN
may/MD
inhibit/VB
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
nuclear/JJ
factor-kappaB/NN
(/(
NF-kappaB/NN
)/)
through/IN
an/DT
unknown/JJ
mechanism/NN
./.
====================
NF-kappaB/NN
activation/NN
in/IN
response/NN
to/TO
inflammatory/JJ
signals/NNS
is/VBZ
dependent/JJ
upon/IN
degradation/NN
of/IN
its/PRP$
associated/VBN
inhibitory/JJ
peptide/NN
,/,
inhibitory/JJ
kappaB-alpha/NN
(/(
IkappaB-alpha/NN
)/)
./.
====================
We/PRP
hypothesized/VBD
that/IN
IL-10/NN
prevents/VBZ
human/JJ
monocyte/NN
NF-kappaB/NN
activation/NN
and/CC
resultant/JJ
TNF-alpha/NN
production/NN
by/IN
stabilization/NN
of/IN
IkappaB-alpha/NN
./.
====================
The/DT
purpose/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
determine/VB
the/DT
effect/NN
of/IN
IL-10/NN
on/IN
lipopolysaccharide/NN
(/(
LPS/NN
)/)
-induced/JJ
human/JJ
monocyte/NN
TNF-alpha/NN
production/NN
,/,
NF-kappaB/NN
activation/NN
,/,
and/CC
IkappaB-alpha/NN
degradation/NN
./.
====================
Monocytes/NNS
were/VBD
isolated/VBN
from/IN
human/JJ
donors/NNS
./.
====================
Cells/NNS
were/VBD
stimulated/VBN
with/IN
endotoxin/NN
(/(
LPS/NN
,/,
100/CD
ng/mL/NN
)/)
with/IN
and/CC
without/IN
human/JJ
IL-10/NN
(/(
10/CD
ng/mL/NN
)/)
./.
====================
Following/VBG
stimulation/NN
,/,
TNF-alpha/NN
was/VBD
measured/VBN
in/IN
cell/NN
supernatants/NNS
by/IN
ELISA/NN
,/,
NF-kappaB/NN
activity/NN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
,/,
and/CC
IkappaB-alpha/NN
levels/NNS
by/IN
Western/NN
blot/NN
./.
====================
We/PRP
observed/VBD
that/IN
after/IN
LPS/NN
stimulation/NN
of/IN
human/JJ
monocytes/NNS
,/,
TNF-alpha/NN
increased/VBD
to/TO
798+/-67/CD
pg/mL/NN
(/(
p/NN
</JJR
.001/CD
versus/CC
control/NN
)/)
./.
====================
IL-10/NN
attenuated/VBD
LPS-stimulated/JJ
TNF-alpha/NN
production/NN
(/(
297+/-54/CD
;/:
p/NN
</JJR
.001/CD
versus/CC
LPS/NN
alone/RB
)/)
./.
====================
After/IN
LPS/NN
stimulation/NN
in/IN
human/JJ
monocytes/NNS
,/,
IkappaB-alpha/NN
protein/NN
levels/NNS
decreased/VBD
,/,
and/CC
NF-kappaB/NN
DNA/NN
binding/NN
increased/VBD
./.
====================
IL-10/NN
pretreatment/NN
prevented/VBD
LPS-induced/JJ
decreases/NNS
in/IN
IkappaB-alpha/NN
protein/NN
levels/NNS
and/CC
attenuated/VBD
NF-kappaB/NN
DNA/NN
binding/NN
./.
====================
IL-10/NN
appears/VBZ
to/TO
prevent/VB
activation/NN
of/IN
NF-kappaB/NN
by/IN
preserving/VBG
IkappaB-alpha/NN
protein/NN
levels/NNS
,/,
leading/VBG
to/TO
a/DT
reduction/NN
in/IN
TNF-alpha/NN
release/NN
./.
====================
UI/LS
-/:
99074319/CD
====================
TI/LS
-/:
Down-regulation/NN
of/IN
human/JJ
granzyme/NN
B/NN
expression/NN
by/IN
glucocorticoids/NNS
./.
====================
Dexamethasone/NN
inhibits/VBZ
binding/VBG
to/TO
the/DT
Ikaros/NN
and/CC
AP-1/NN
regulatory/JJ
elements/NNS
of/IN
the/DT
granzyme/NN
B/NN
promoter/NN
./.
====================
AB/LS
-/:
The/DT
serine/NN
protease/NN
granzyme/NN
B/NN
is/VBZ
an/DT
essential/JJ
component/NN
of/IN
the/DT
granule/NN
exocytosis/NN
pathway/NN
,/,
a/DT
major/JJ
apoptotic/JJ
mechanism/NN
used/VBN
by/IN
cytotoxic/JJ
T/NN
lymphocytes/NNS
and/CC
natural/JJ
killer/NN
cells/NNS
to/TO
induce/VB
target/NN
cell/NN
apoptosis/NN
./.
====================
Granzyme/NN
B/NN
gene/NN
transcription/NN
is/VBZ
induced/VBN
in/IN
activated/VBN
lymphocytes/NNS
upon/IN
antigenic/JJ
stimulation/NN
,/,
and/CC
several/JJ
regulatory/JJ
regions/NNS
including/VBG
CBF/NN
,/,
AP-1/NN
,/,
and/CC
Ikaros/NN
binding/NN
sites/NNS
have/VBP
been/VBN
shown/VBN
to/TO
be/VB
essential/JJ
in/IN
the/DT
control/NN
of/IN
granzyme/NN
B/NN
promoter/NN
activation/NN
./.
====================
Dexamethasone/NN
,/,
a/DT
glucocorticoid/NN
that/WDT
is/VBZ
widely/RB
used/VBN
as/IN
an/DT
immunomodulatory/JJ
and/CC
anti-inflammatory/JJ
agent/NN
,/,
inhibits/VBZ
granzyme/NN
B/NN
mRNA/NN
transcript/NN
in/IN
phytohemagglutinin-activated/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
./.
====================
Transfection/NN
of/IN
a/DT
reporter/NN
construct/NN
containing/VBG
the/DT
-148/CD
to/TO
+60/CD
region/NN
of/IN
the/DT
human/JJ
granzyme/NN
B/NN
promoter/NN
demonstrated/VBD
that/IN
this/DT
region/NN
was/VBD
the/DT
target/NN
for/IN
dexamethasone/NN
repression/NN
./.
====================
Mutation/NN
of/IN
Ikaros/NN
or/CC
AP-1/NN
binding/NN
sites/NNS
in/IN
the/DT
context/NN
of/IN
the/DT
granzyme/NN
B/NN
promoter/NN
demonstrated/VBD
that/IN
both/DT
sites/NNS
participate/VBP
in/IN
dexamethasone-mediated/JJ
inhibition/NN
of/IN
the/DT
granzyme/NN
B/NN
promoter/NN
activity/NN
./.
====================
Electromobility/NN
shift/NN
assay/NN
revealed/VBD
that/IN
dexamethasone/NN
abolished/VBD
the/DT
binding/NN
of/IN
nuclear/JJ
transcription/NN
factors/NNS
to/TO
the/DT
Ikaros/NN
binding/NN
site/NN
and/CC
reduced/VBD
AP-1/NN
binding/NN
activity/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
dexamethasone/NN
is/VBZ
able/JJ
to/TO
abrogate/VB
the/DT
transcriptional/JJ
activity/NN
of/IN
the/DT
human/JJ
granzyme/NN
B/NN
gene/NN
promoter/NN
by/IN
inhibiting/VBG
the/DT
binding/NN
of/IN
nuclear/JJ
factors/NNS
at/IN
the/DT
AP-1/NN
and/CC
Ikaros/NN
sites/NNS
./.
====================
UI/LS
-/:
99064961/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptors/NNS
on/IN
mononuclear/JJ
leukocytes/NNS
in/IN
polycystic/JJ
ovary/JJ
syndrome/NN
./.
====================
AB/LS
-/:
OBJECTIVE/NN
:/:
Many/JJ
studies/NNS
have/VBP
suggested/VBN
that/IN
there/EX
is/VBZ
a/DT
possible/JJ
hormonal/JJ
dysregulation/NN
of/IN
hypothalamic-pituitary-adrenal/JJ
(/(
HPA/JJ
)/)
axis/NN
and/CC
an/DT
increased/VBN
cortisol/NN
clearance/NN
in/IN
patients/NNS
with/IN
polycystic/JJ
ovary/JJ
syndrome/NN
(/(
PCOS/NN
)/)
./.
====================
Therefore/RB
in/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
examined/VBN
the/DT
role/NN
of/IN
glucocorticoid/NN
receptor/s/NN|NNS
(/(
GR/NN|NNS
)/)
characteristics/NNS
in/IN
the/DT
developing/NN
of/IN
these/DT
abnormalities/NNS
in/IN
patients/NNS
with/IN
PCOS/NN
./.
====================
METHOD/NN
:/:
For/IN
this/DT
purpose/NN
,/,
the/DT
number/NN
and/CC
affinity/NN
of/IN
GR/NN|NNS
in/IN
peripheral/JJ
mononuclear/JJ
leukocytes/NNS
(/(
MNL/NNS
)/)
of/IN
10/CD
patients/NNS
with/IN
PCOS/NN
and/CC
10/CD
healthy/JJ
women/NNS
(/(
controls/NNS
)/)
were/VBD
determined/VBN
./.
====================
RESULTS/NNS
:/:
There/EX
were/VBD
no/DT
significant/JJ
differences/NNS
in/IN
the/DT
number/NN
(/(
6500+/-1001/CD
sites/cell/NNS
and/CC
6352+/-1697/CD
sites/cell/NNS
,/,
respectively/RB
;/:
P/NN
>/JJR
0.05/CD
)/)
and/CC
affinity/NN
(/(
3.93+/-0.89/CD
nM/NN
and/CC
4.49+/-0.71/CD
nM/NN
,/,
respectively/RB
;/:
P/NN
>/JJR
0.05/CD
)/)
of/IN
GR/NN|NNS
between/IN
the/DT
PCOS/NN
patients/NNS
and/CC
the/DT
controls/NNS
./.
====================
CONCLUSIONS/NNS
:/:
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
alterations/NNS
in/IN
the/DT
HPA/JJ
axis/NN
and/CC
in/IN
the/DT
cortisol/NN
metabolism/NN
observed/VBN
in/IN
PCOS/NN
are/VBP
not/RB
related/JJ
to/TO
GR/NN|NNS
deficiency/NN
./.
====================
UI/LS
-/:
99057097/CD
====================
TI/LS
-/:
Heterogeneous/JJ
expression/NN
of/IN
the/DT
lipocalin/NN
NGAL/NN
in/IN
primary/JJ
breast/NN
cancers/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
neu/NN
oncogene-initiated/JJ
rat/NN
mammary/JJ
carcinomas/NNS
uniquely/RB
over-express/VBP
neu-related/JJ
lipocalin/NN
(/(
NRL/NN
)/)
,/,
a/DT
member/NN
of/IN
the/DT
calycin/NN
protein/NN
superfamily/NN
./.
====================
Here/RB
,/,
we/PRP
characterize/VBP
the/DT
putative/JJ
human/JJ
homolog/NN
of/IN
NRL/NN
,/,
neutrophil/NN
gelatinase-associated/JJ
lipocalin/NN
(/(
NGAL/NN
)/)
./.
====================
ngal/JJ
gene/NN
expression/NN
was/VBD
found/VBN
at/IN
moderate/JJ
levels/NNS
in/IN
only/RB
2/CD
of/IN
17/CD
human/JJ
tissues/NNS
examined/VBN
,/,
breast/NN
and/CC
lung/NN
./.
====================
When/WRB
breast/NN
cancers/NNS
were/VBD
examined/VBN
for/IN
NGAL/NN
mRNA/NN
and/CC
protein/NN
levels/NNS
,/,
they/PRP
were/VBD
found/VBN
to/TO
exhibit/VB
heterogeneous/JJ
expression/NN
./.
====================
NGAL/NN
levels/NNS
varied/VBD
in/IN
these/DT
tumors/NNS
from/IN
undetectable/JJ
to/TO
exceeding/VBG
those/DT
in/IN
normal/JJ
breast/NN
parenchyma/NN
./.
====================
Immuno-histochemical/JJ
analysis/NN
confirmed/VBD
the/DT
presence/NN
of/IN
NGAL/NN
within/IN
breast/NN
carcinoma/NN
cells/NNS
but/CC
detected/VBD
only/RB
low/JJ
levels/NNS
of/IN
this/DT
protein/NN
in/IN
normal/JJ
ductal/JJ
epithelium/NN
./.
====================
In/IN
contrast/NN
,/,
large/JJ
amounts/NNS
of/IN
the/DT
protein/NN
were/VBD
localized/JJ
to/TO
the/DT
lumen/NN
of/IN
normal/JJ
breast/NN
ducts/NNS
in/IN
the/DT
vicinity/NN
of/IN
NGAL-expressing/JJ
tumors/NNS
./.
====================
Interestingly/RB
,/,
unlike/IN
NRL/NN
in/IN
rat/NN
mammary/JJ
carcinomas/NNS
,/,
no/DT
significant/JJ
association/NN
between/IN
NGAL/NN
expression/NN
and/CC
HER-2/neu/NN
activation/NN
was/VBD
found/VBN
in/IN
human/JJ
breast/NN
tumors/NNS
./.
====================
In/IN
contrast/NN
,/,
a/DT
significant/JJ
correlation/NN
between/IN
NGAL/NN
expression/NN
in/IN
breast/NN
cancer/NN
was/VBD
found/VBN
with/IN
several/JJ
other/JJ
markers/NNS
of/IN
poor/JJ
prognosis/NN
,/,
including/VBG
estrogen/NN
and/CC
progesterone/NN
receptor-negative/JJ
status/NN
and/CC
high/JJ
proliferation/NN
(/(
S-phase/NN
fraction/NN
)/)
./.
====================
NGAL/NN
levels/NNS
were/VBD
stratified/VBN
as/IN
high/JJ
or/CC
low/JJ
in/IN
breast/NN
cancers/NNS
from/IN
a/DT
cohort/NN
of/IN
node-positive/JJ
patients/NNS
with/IN
known/JJ
outcome/NN
./.
====================
No/DT
significant/JJ
association/NN
between/IN
NGAL/NN
expression/NN
and/CC
disease-free/JJ
or/CC
overall/JJ
survival/NN
was/VBD
observed/VBN
./.
====================
UI/LS
-/:
99049801/CD
====================
TI/LS
-/:
BASH/NN
,/,
a/DT
novel/JJ
signaling/VBG
molecule/NN
preferentially/RB
expressed/VBN
in/IN
B/NN
cells/NNS
of/IN
the/DT
bursa/NN
of/IN
Fabricius/NN
./.
====================
AB/LS
-/:
The/DT
bursa/NN
of/IN
Fabricius/NN
is/VBZ
a/DT
gut-associated/JJ
lymphoid/JJ
organ/NN
that/WDT
is/VBZ
essential/JJ
for/IN
the/DT
generation/NN
of/IN
a/DT
diversified/JJ
B/NN
cell/NN
repertoire/NN
in/IN
the/DT
chicken/NN
./.
====================
We/PRP
describe/VBP
here/RB
a/DT
novel/JJ
gene/NN
preferentially/RB
expressed/VBN
in/IN
bursal/JJ
B/NN
cells/NNS
./.
====================
The/DT
gene/NN
encodes/VBZ
an/DT
85-kDa/JJ
protein/NN
,/,
designated/VBN
BASH/NN
(/(
B/NN
cell/NN
adaptor/NN
containing/VBG
SH2/NN
domain/NN
)/)
,/,
that/WDT
contains/VBZ
N-terminal/JJ
acidic/JJ
domains/NNS
with/IN
SH2/NN
domain-binding/JJ
phosphotyrosine-based/JJ
motifs/NNS
,/,
a/DT
proline-rich/JJ
domain/NN
,/,
and/CC
a/DT
C-terminal/JJ
SH2/NN
domain/NN
./.
====================
BASH/NN
shows/VBZ
a/DT
substantial/JJ
sequence/NN
similarity/NN
to/TO
SLP-76/NN
,/,
an/DT
adaptor/NN
protein/NN
functioning/VBG
in/IN
TCR-signal/JJ
transduction/NN
./.
====================
BASH/NN
becomes/VBZ
tyrosine-phosphorylated/JJ
with/IN
the/DT
B/NN
cell/NN
Ag/NN
receptor/NN
(/(
BCR/NN
)/)
cross-link/NN
or/CC
by/IN
coexpression/NN
with/IN
Syk/NN
and/CC
Lyn/NN
and/CC
associates/VBZ
with/IN
signaling/VBG
molecules/NNS
including/VBG
Syk/NN
and/CC
a/DT
putative/JJ
chicken/NN
Shc/NN
homologue/NN
./.
====================
Overexpression/NN
of/IN
BASH/NN
results/VBZ
in/IN
suppression/NN
of/IN
the/DT
NF-AT/NN
activation/NN
induced/VBN
by/IN
BCR-cross-linking/NN
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
BASH/NN
is/VBZ
involved/VBN
in/IN
BCR-mediated/JJ
signal/NN
transduction/NN
and/CC
could/MD
play/VB
a/DT
critical/JJ
role/NN
in/IN
B/NN
cell/NN
development/NN
in/IN
the/DT
bursa/NN
./.
====================
UI/LS
-/:
99039380/CD
====================
TI/LS
-/:
Granulocyte/NN
colony-stimulating/JJ
factor/NN
activates/VBZ
a/DT
72-kDa/JJ
isoform/NN
of/IN
STAT3/NN
in/IN
human/JJ
neutrophils/NNS
./.
====================
AB/LS
-/:
Granulocyte/NN
colony-stimulating/JJ
factor/NN
(/(
G-CSF/NN
)/)
signaling/NN
involves/VBZ
activation/NN
of/IN
STATs/NNS
,/,
proteins/NNS
that/WDT
serve/VBP
the/DT
dual/JJ
function/NN
of/IN
signal/NN
transduction/NN
and/CC
activation/NN
of/IN
transcription/NN
./.
====================
We/PRP
previously/RB
demonstrated/VBD
that/IN
G-CSF/NN
activated/VBD
a/DT
distinct/JJ
Stat3-like/JJ
protein/NN
in/IN
immature/JJ
and/CC
mature/JJ
normal/JJ
myeloid/JJ
cells/NNS
,/,
StatG/NN
./.
====================
StatG/NN
in/IN
normal/JJ
immature/JJ
human/JJ
myeloid/JJ
cells/NNS
,/,
i.e./FW
adult/JJ
CD34+/JJ
bone/NN
marrow/NN
cells/NNS
,/,
was/VBD
composed/VBN
of/IN
Stat3beta/NN
./.
====================
This/DT
investigation/NN
was/VBD
undertaken/VBN
to/TO
determine/VB
the/DT
composition/NN
of/IN
StatG/NN
in/IN
mature/JJ
normal/JJ
human/JJ
myeloid/JJ
cells/NNS
,/,
i.e./FW
polymorphonuclear/JJ
neutrophilic/JJ
granulocytes/NNS
(/(
PMN/NNS
)/)
./.
====================
These/DT
studies/NNS
revealed/VBD
that/IN
the/DT
major/JJ
protein/NN
in/IN
extracts/NNS
of/IN
PMN/NN
activated/VBN
by/IN
G-CSF/NN
to/TO
bind/VB
the/DT
high-affinity/JJ
serum-inducible/JJ
element/NN
(/(
hSIE/NN
)/)
is/VBZ
a/DT
72-kDa/JJ
protein/NN
that/WDT
cross-reacts/VBZ
with/IN
Stat3/NN
monoclonal/JJ
antibody/NN
,/,
which/WDT
we/PRP
have/VBP
designated/VBN
Stat3gamma/NN
./.
====================
Stat3gamma/NN
is/VBZ
derived/VBN
from/IN
Stat3alpha/NN
by/IN
limited/JJ
proteolysis/NN
and/CC
lacks/VBZ
the/DT
carboxyl-terminal/JJ
portion/NN
of/IN
Stat3alpha/NN
./.
====================
Because/IN
this/DT
region/NN
of/IN
Stat3alpha/NN
is/VBZ
involved/VBN
in/IN
transcriptional/JJ
activation/NN
,/,
our/PRP$
findings/NNS
suggest/VBP
the/DT
possibility/NN
that/IN
Stat3gamma/NN
may/MD
be/VB
transcriptionally/RB
inactive/JJ
and/CC
may/MD
compete/VB
with/IN
Stat3alpha/NN
for/IN
Stat3/NN
binding/NN
sites/NNS
in/IN
these/DT
terminally/RB
differentiated/VBN
myeloid/JJ
cells/NNS
====================
UI/LS
-/:
97362594/CD
====================
TI/LS
-/:
Association/NN
between/IN
expression/NN
of/IN
intercellular/JJ
adhesion/NN
molecule-1/NN
and/CC
integration/NN
of/IN
human/JJ
T-cell-leukemia/JJ
virus/NN
type/NN
1/CD
in/IN
adult/JJ
T-cell/NN
leukemia/NN
cells/NNS
./.
====================
AB/LS
-/:
It/PRP
is/VBZ
known/VBN
that/IN
the/DT
expression/NN
levels/NNS
of/IN
intercellular/JJ
adhesion/NN
molecule-1/NN
(/(
ICAM-1/NN
)/)
in/IN
adult/JJ
T/NN
cell/NN
leukemia/NN
(/(
ATL/NN
)/)
cells/NNS
are/VBP
high/JJ
,/,
whereas/IN
those/DT
in/IN
T-lymphoid/NN
cells/NNS
are/VBP
not/RB
./.
====================
In/IN
order/NN
to/TO
investigate/VB
the/DT
factors/NNS
that/WDT
influence/VBP
the/DT
induction/NN
of/IN
ICAM-1/NN
molecules/NNS
,/,
Northern/NN
blot/NN
analysis/NN
to/TO
measure/VB
the/DT
expression/NN
level/NN
of/IN
ICAM-1/NN
mRNAs/NNS
and/CC
Southern/NN
blot/NN
hybridization/NN
to/TO
analyze/VB
the/DT
integration/NN
of/IN
human/JJ
T-cell-leukemia/JJ
virus/NN
type/NN
1/CD
(/(
HTLV-1/NN
)/)
provirus/NN
were/VBD
done/VBN
./.
====================
The/DT
levels/NNS
of/IN
ICAM-1/NN
mRNA/NN
expression/NN
of/IN
ATL/NN
cells/NNS
were/VBD
generally/RB
higher/JJR
than/IN
those/DT
of/IN
T-lymphoid/NN
cells/NNS
./.
====================
However/RB
,/,
ILT-mat/NN
cells/NNS
and/CC
ATL16T(-)/JJ
cells/NNS
,/,
although/IN
they/PRP
were/VBD
ATL/NN
cells/NNS
,/,
showed/VBD
rather/RB
low/JJ
surface/NN
ICAM-1/NN
expression/NN
and/CC
ICAM-1/NN
mRNA/NN
expression/NN
./.
====================
Southern/NN
blot/NN
hybridization/NN
showed/VBD
that/IN
only/RB
two/CD
and/CC
four/CD
bands/NNS
were/VBD
found/VBN
in/IN
ILT-mat/NN
and/CC
ATL16T(-)/JJ
cells/NNS
,/,
respectively/RB
,/,
whereas/IN
>/JJR
10/CD
bands/NNS
were/VBD
detected/VBN
in/IN
other/JJ
ATL/NN
cells/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
monoclonal/JJ
integration/NN
of/IN
HTLV-1/NN
provirus/NN
to/TO
the/DT
genome/NN
of/IN
T/NN
cell/NN
,/,
especially/RB
the/DT
number/NN
of/IN
integration/NN
sites/NNS
,/,
is/VBZ
one/CD
of/IN
the/DT
factors/NNS
for/IN
induction/NN
of/IN
ICAM-1/NN
molecules/NNS
./.
====================
UI/LS
-/:
97196961/CD
====================
TI/LS
-/:
Heat-shock/NN
and/CC
cadmium/NN
chloride/NN
increase/VBP
the/DT
vimentin/NN
mRNA/NN
and/CC
protein/NN
levels/NNS
in/IN
U-937/NN
human/JJ
promonocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
Heat-shock/NN
for/IN
2/CD
hours/NNS
at/IN
42/CD
degrees/NNS
C/NN
,/,
or/CC
the/DT
administration/NN
for/IN
3/CD
hours/NNS
of/IN
100/CD
or/CC
150/CD
microM/NN
cadmium/NN
chloride/NN
,/,
inhibited/VBD
the/DT
subsequent/JJ
proliferation/NN
activity/NN
,/,
induced/VBD
the/DT
expression/NN
of/IN
functional/JJ
differentiation/NN
markers/NNS
,/,
and/CC
caused/VBD
an/DT
increase/NN
in/IN
the/DT
amount/NN
of/IN
the/DT
stress-responsive/JJ
HSP70/NN
protein/NN
in/IN
U-937/NN
human/JJ
promonocytic/JJ
cells/NNS
./.
====================
In/IN
addition/NN
,/,
both/CC
heat/NN
and/CC
cadmium/NN
produced/VBD
an/DT
increase/NN
in/IN
the/DT
amount/NN
of/IN
the/DT
intermediate/JJ
filament/NN
protein/NN
vimentin/NN
,/,
as/IN
determined/VBN
by/IN
immunoblot/NN
and/CC
immunofluorescence/NN
assays/NNS
./.
====================
By/IN
contrast/NN
,/,
the/DT
amounts/NNS
of/IN
actin/NN
and/CC
beta-tubulin/NN
were/VBD
not/RB
significantly/RB
altered/VBN
./.
====================
The/DT
amount/NN
of/IN
vimentin/NN
mRNA/NN
was/VBD
also/RB
increased/VBN
during/IN
recovery/NN
from/IN
stress/NN
,/,
indicating/VBG
that/IN
vimentin/NN
expression/NN
was/VBD
not/RB
exclusively/RB
regulated/VBN
at/IN
the/DT
protein/NN
level/NN
./.
====================
Although/IN
cadmium/NN
caused/VBD
an/DT
early/JJ
,/,
transient/JJ
stimulation/NN
of/IN
c-jun/NN
and/CC
c-fos/NN
expression/NN
and/CC
AP-1/NN
binding/NN
activity/NN
,/,
heat-shock/NN
failed/VBD
to/TO
alter/VB
both/CC
protooncogene/NN
expression/NN
and/CC
transcription/NN
factor/NN
binding/NN
,/,
indicating/VBG
that/IN
the/DT
stress-induced/JJ
vimentin/NN
increase/NN
was/VBD
not/RB
the/DT
result/NN
of/IN
AP-1-mediated/JJ
transcriptional/JJ
activation/NN
./.
====================
Finally/RB
,/,
it/PRP
was/VBD
observed/VBN
that/IN
the/DT
rate/NN
of/IN
decay/NN
of/IN
vimentin/NN
mRNA/NN
upon/IN
actinomycin/NN
D/NN
administration/NN
was/VBD
decreased/VBN
in/IN
heat-/NN
and/CC
cadmium-pretreated/JJ
cells/NNS
in/IN
comparison/NN
to/TO
untreated/JJ
cells/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
stress/NN
treatments/NNS
cause/VBP
an/DT
increase/NN
in/IN
vimentin/NN
levels/NNS
in/IN
promonocytic/JJ
cells/NNS
,/,
which/WDT
may/MD
be/VB
explained/VBN
at/IN
least/JJS
in/IN
part/NN
by/IN
transcript/NN
stabilization/NN
./.
====================
UI/LS
-/:
99321124/CD
====================
TI/LS
-/:
Ovarian/JJ
and/CC
breast/NN
cytotoxic/JJ
T/NN
lymphocytes/NNS
can/MD
recognize/VB
peptides/NNS
from/IN
the/DT
amino/NN
enhancer/NN
of/IN
split/JJ
protein/NN
of/IN
the/DT
Notch/NN
complex/NN
./.
====================
AB/LS
-/:
In/IN
this/DT
study/NN
we/PRP
investigated/VBD
recognition/NN
by/IN
ovarian/JJ
tumor/NN
associated/JJ
lymphocyte/NN
(/(
OVTAL/NN
)/)
,/,
and/CC
breast/NN
tumor/NN
associated/JJ
lymphocytes/NNS
(/(
BRTAL/NNS
)/)
,/,
of/IN
peptides/NNS
corresponding/VBG
to/TO
the/DT
sequence/NN
125-135/CD
of/IN
the/DT
Aminoenhancer/NN
of/IN
split/JJ
(/(
AES/NN
)/)
protein/NN
./.
====================
Three/CD
of/IN
these/DT
peptides/NNS
designated/VBN
as/IN
G75:AES1/2/NN
(/(
128-135/CD
)/)
,/,
G60: AES1/2/NN
(/(
127-137/CD
)/)
and/CC
G61: AES1/2/NN
(/(
125-133/CD
)/)
correspond/VBP
to/TO
the/DT
wildtype/JJ
AES/NN
sequence/NN
,/,
while/IN
the/DT
fourth/JJ
G76:GPLTPLPV/NN
,/,
AES1/2/NN
(/(
128-135/CD
)/)
corresponds/VBZ
to/TO
a/DT
variant/JJ
sequence/NN
of/IN
the/DT
peptide/NN
G75/NN
with/IN
the/DT
N-terminal/JJ
Leu/NN
substituted/VBN
to/TO
glycine/NN
./.
====================
These/DT
sequences/NNS
were/VBD
chosen/VBN
for/IN
study/NN
because/IN
mass-spectrometric/JJ
analysis/NN
(/(
MS/NN
)/)
of/IN
a/DT
CTL/NN
active/JJ
HPLC/NN
peptide/NN
fraction/NN
eluted/VBN
from/IN
immunoaffinity/NN
precipitated/JJ
HLA-A2/NN
molecule/NN
,/,
revealed/VBD
:/:
(/(
a/LS
)/)
the/DT
presence/NN
of/IN
an/DT
ion/NN
with/IN
a/DT
mass-to-charge/JJ
ratio/NN
(/(
m/z/NN
)/)
of/IN
793/CD
which/WDT
was/VBD
more/RBR
abundant/JJ
than/IN
other/JJ
ions/NNS
of/IN
similar/JJ
masses/NNS
;/:
(/(
b/LS
)/)
the/DT
tentatively/RB
reconstituted/VBN
sequence/NN
of/IN
the/DT
ion/NN
793/CD
matched/VBD
the/DT
sequence/NN
of/IN
peptide/NN
G76/NN
./.
====================
We/PRP
found/VBD
that/IN
AES/NN
peptides/NNS
G75/NN
(/(
128-135/CD
)/)
and/CC
G76/NN
(/(
128-135/CD
)/)
(/(
L128G/NN
)/)
reconstituted/VBD
CTL/NN
recognition/NN
at/IN
concentrations/NNS
ranging/VBG
between/IN
200-500/CD
nM/NN
./.
====================
These/DT
concentrations/NNS
are/VBP
lower/JJR
than/IN
concentrations/NNS
reported/VBN
to/TO
activate/VB
effector/NN
function/NN
of/IN
CTL/NN
recognizing/VBG
other/JJ
epithelial/JJ
tumor/NN
Ag/NN
./.
====================
Furthermore/RB
,/,
analysis/NN
with/IN
cloned/VBN
CD8+/JJ
T/NN
cells/NNS
indicated/VBD
that/IN
G75/NN
and/CC
G76/NN
were/VBD
not/RB
cross-reactive/JJ
specificities/NNS
,/,
suggesting/VBG
a/DT
key/JJ
role/NN
for/IN
the/DT
N-terminal/JJ
residues/NNS
of/IN
the/DT
variant/JJ
peptide/NN
in/IN
dictating/VBG
specificities/NNS
./.
====================
Since/IN
the/DT
AES/NN
proteins/NNS
are/VBP
part/NN
of/IN
a/DT
set/NN
of/IN
transcriptional/JJ
repressors/NNS
encoded/VBN
by/IN
the/DT
Enhancer/NN
of/IN
split/JJ
[/(
E(spl)/NN
]/)
genes/NNS
,/,
and/CC
since/IN
these/DT
repressors/NNS
are/VBP
activated/VBN
to/TO
suppress/VB
cell/NN
differentiation/NN
in/IN
response/NN
to/TO
Notch/NN
receptors/NNS
signalling/NN
,/,
the/DT
AES/NN
peptides/NNS
may/MD
represent/VB
a/DT
novel/JJ
class/NN
of/IN
self-antigens/NNS
that/WDT
deserve/VBP
further/JJ
consideration/NN
as/IN
tumor/NN
Ag/NN
in/IN
epithelial/JJ
cancers/NNS
./.
====================
UI/LS
-/:
99098435/CD
====================
TI/LS
-/:
Induction/NN
of/IN
the/DT
pro-myelocytic/JJ
leukaemia/NN
gene/NN
by/IN
type/NN
I/CD
and/CC
type/NN
II/CD
interferons/NNS
./.
====================
AB/LS
-/:
The/DT
physiological/JJ
role/NN
of/IN
the/DT
pro-myelocytic/JJ
leukaemia/NN
(/(
PML/NN
)/)
gene/NN
product/NN
is/VBZ
poorly/RB
defined/VBN
./.
====================
Among/IN
other/JJ
functions/NNS
,/,
PML/NN
is/VBZ
involved/VBN
in/IN
haematopoietic/JJ
differentiation/NN
and/CC
in/IN
control/NN
of/IN
cell/NN
growth/NN
and/CC
tumorigenesis/NN
./.
====================
We/PRP
investigated/VBD
the/DT
regulation/NN
of/IN
human/JJ
PML/NN
expression/NN
by/IN
interferons/NNS
(/(
IFNs/NNS
)/)
and/CC
IL-1/NN
in/IN
various/JJ
human/JJ
haematopoietic/JJ
lines/NNS
(/(
U937/NN
,/,
THP1/NN
,/,
HL60/NN
,/,
NB4/NN
)/)
,/,
in/IN
human/JJ
diploid/JJ
fibroblasts/NNS
and/CC
in/IN
human/JJ
peripheral/JJ
blood/NN
leukocytes/NNS
./.
====================
Cytokine-induced/JJ
modulation/NN
of/IN
PML/NN
expression/NN
was/VBD
assessed/VBN
by/IN
Northern/NN
blot/NN
analyses/NNS
,/,
flow/NN
cytometry/NN
studies/NNS
and/CC
in/FW
situ/FW
immunolabelling/NN
./.
====================
Our/PRP$
data/NNS
show/VBP
that/IN
IFNs/NNS
and/CC
IL-1/NN
upregulate/VBP
PML/NN
transcript/NN
and/CC
protein/NN
expression/NN
in/IN
a/DT
time/NN
and/CC
dose-dependent/JJ
manner/NN
./.
====================
In/FW
situ/FW
immunolabelling/NN
revealed/VBD
that/IN
upregulation/NN
of/IN
protein/NN
expression/NN
by/IN
IFN-alpha/NN
is/VBZ
a/DT
consequence/NN
of/IN
a/DT
marked/JJ
increase/NN
in/IN
both/CC
the/DT
number/NN
and/CC
the/DT
intensity/NN
of/IN
the/DT
staining/NN
of/IN
so-called/JJ
PML/NN
nuclear/JJ
bodies/NNS
./.
====================
Our/PRP$
data/NNS
suggest/VBP
that/IN
stimulation/NN
of/IN
PML/NN
expression/NN
by/IN
interferons/NNS
and/CC
IL-1/NN
may/MD
account/VB
for/IN
upregulation/NN
of/IN
PML/NN
proteins/NNS
observed/VBN
in/IN
inflammatory/JJ
tissues/NNS
and/CC
in/IN
proliferative/JJ
states/NNS
./.
====================
UI/LS
-/:
99086128/CD
====================
TI/LS
-/:
The/DT
position/NN
of/IN
the/DT
ZEBRA/NN
activation/NN
domain/NN
does/VBZ
not/RB
influence/VB
its/PRP$
biological/JJ
activity/NN
./.
====================
AB/LS
-/:
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
is/VBZ
a/DT
human/JJ
herpesvirus/NN
which/WDT
latently/RB
infects/VBZ
B/NN
lymphocytes/NNS
./.
====================
EBV/NN
encodes/VBZ
a/DT
unique/JJ
transcriptional/JJ
activator/NN
,/,
known/VBN
as/IN
ZEBRA/NN
,/,
which/WDT
can/MD
disrupt/VB
viral/JJ
latency/NN
in/IN
B/NN
cells/NNS
and/CC
induce/VB
lytic/JJ
viral/JJ
replication/NN
./.
====================
Furthermore/RB
,/,
ZEBRA/NN
has/VBZ
been/VBN
shown/VBN
to/TO
bind/VB
at/IN
the/DT
EBV/NN
origin/NN
of/IN
lytic/JJ
replication/NN
,/,
and/CC
is/VBZ
necessary/JJ
for/IN
viral/JJ
DNA/NN
replication/NN
to/TO
occur/VB
./.
====================
Previously/RB
we/PRP
demonstrated/VBD
that/IN
heterologous/JJ
activation/NN
domains/NNS
can/MD
fully/RB
substitute/VB
for/IN
the/DT
ZEBRA/NN
activation/NN
domain/NN
./.
====================
Here/RB
we/PRP
extend/VBP
those/DT
results/NNS
by/IN
showing/VBG
that/IN
the/DT
position/NN
of/IN
the/DT
ZEBRA/NN
activation/NN
domain/NN
or/CC
a/DT
heterologous/JJ
replacement/NN
domain/NN
does/VBZ
not/RB
influence/VB
its/PRP$
ability/NN
to/TO
function/VB
in/IN
the/DT
disruption/NN
of/IN
EBV/NN
latency/NN
./.
====================
In/IN
this/DT
study/NN
three/CD
novel/JJ
clones/NNS
were/VBD
constructed/VBN
in/IN
which/WDT
the/DT
ZEBRA/NN
activation/NN
region/NN
was/VBD
repositioned/VBN
to/TO
the/DT
carboxy/NN
terminus/NN
of/IN
the/DT
protein/NN
./.
====================
These/DT
mutants/NNS
were/VBD
used/VBN
to/TO
demonstrate/VB
that/IN
the/DT
ability/NN
of/IN
ZEBRA/NN
's/POS
wild/JJ
type/NN
domain/NN
to/TO
function/VB
in/IN
the/DT
complex/JJ
biological/JJ
process/NN
of/IN
virus/NN
activation/NN
is/VBZ
not/RB
compromised/VBN
by/IN
altering/VBG
its/PRP$
position/NN
within/IN
the/DT
protein/NN
./.
====================
UI/LS
-/:
99071844/CD
====================
TI/LS
-/:
The/DT
modulation/NN
of/IN
glucocorticoid/NN
receptor/NN
content/NN
by/IN
3-O-methyl-D-glucose/NN
transport/NN
in/IN
human/JJ
mononuclear/JJ
leukocyte/NN
in/IN
obesity/NN
./.
====================
AB/LS
-/:
Glucocorticoid/NN
receptors/NNS
(/(
GR/NNS
)/)
and/CC
3-O-methyl-D/JJ
glucose/NN
(/(
3-O-MG/NN
)/)
transport/NN
were/VBD
determined/VBN
in/IN
mononuclear/JJ
leukocytes/NNS
(/(
MNL/NNS
)/)
from/IN
11/CD
abdominal/JJ
obese/JJ
subjects/NNS
,/,
10/CD
pituitary-dependent/JJ
Cushing/NN
's/POS
syndrome/NN
(/(
Cushing/NN
's/POS
disease/NN
)/)
and/CC
10/CD
healthy/JJ
controls/NNS
./.
====================
Using/VBG
a/DT
whole-cell/JJ
competitive/JJ
binding/NN
assay/NN
and/CC
3H-dexamethasone/NN
as/IN
tracer/NN
,/,
MNL/NNS
of/IN
abdominal/JJ
obese/JJ
subjects/NNS
were/VBD
found/VBN
to/TO
have/VB
4855/CD
+/-/CC
1389/CD
sites/cell/NNS
which/WDT
was/VBD
significantly/RB
lower/JJR
(/(
p/NN
</JJR
0.05/CD
)/)
than/IN
controls/NNS
(/(
6234/CD
+/-/CC
1568/CD
sites/cell/NNS
)/)
,/,
although/IN
no/DT
significant/JJ
difference/NN
was/VBD
found/VBN
in/IN
the/DT
mean/JJ
serum/NN
cortisol/NN
level/NN
./.
====================
Their/PRP$
mean/JJ
Kd/NN
(/(
affinity/NN
)/)
was/VBD
also/RB
significantly/RB
lower/JJR
than/IN
that/DT
found/VBN
in/IN
the/DT
healthy/JJ
controls/NNS
(/(
obese/JJ
Kd/NN
:/:
2.92/CD
+/-/CC
0.84/CD
nmol/l/NN
,/,
control/JJ
Kd/NN
:/:
4.55/CD
+/-/CC
0.67/CD
nM/NN
,/,
p/NN
</JJR
0.05/CD
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
receptor/NN
characteristics/NNS
in/IN
Cushing/NN
's/POS
disease/NN
patients/NNS
were/VBD
within/IN
the/DT
normal/JJ
range/NN
./.
====================
At/IN
the/DT
same/JJ
time/NN
,/,
3-O-MG/NN
transport/NN
was/VBD
determined/VBN
in/IN
the/DT
same/JJ
subjects/NNS
./.
====================
In/IN
Cushing/NN
's/POS
disease/NN
,/,
3-O-MG/NN
transport/NN
was/VBD
within/IN
the/DT
normal/JJ
range/NN
,/,
whereas/IN
in/IN
abdominal/JJ
obesity/NN
this/DT
value/NN
was/VBD
significantly/RB
lower/JJR
than/IN
the/DT
healthy/JJ
controls/NNS
(/(
abdominal/JJ
obese/JJ
:/:
31.90/CD
+/-/CC
8.20/CD
;/:
control/NN
:/:
46.26/CD
+/-/CC
12.91/CD
fmol/10(6)/NN
cell/NN
,/,
min/NN
,/,
p/NN
</JJR
0.05/CD
)/)
./.
====================
We/PRP
also/RB
found/VBD
a/DT
positive/JJ
correlation/NN
between/IN
3-O-MG/JJ
transport/NN
and/CC
GR/NNS
binding/NN
capacity/NN
in/IN
abdominal/JJ
subjects/NNS
(/(
r/NN
=/JJ
0.89/CD
,/,
p/NN
</JJR
0.001/CD
)/)
,/,
however/RB
we/PRP
did/VBD
not/RB
find/VB
such/JJ
a/DT
correlation/NN
in/IN
Cushing/NN
's/POS
disease/NN
(/(
r/NN
=/JJ
0.60/CD
,/,
p/NN
>/JJR
0.05/CD
)/)
./.
====================
These/DT
results/NNS
indicated/VBD
that/IN
,/,
in/IN
abdominal/JJ
obesity/NN
,/,
the/DT
GR/NNS
binding/NN
capacity/NN
in/IN
MNL/NNS
is/VBZ
influenced/VBN
by/IN
the/DT
changes/NNS
in/IN
glucose/NN
transport/NN
./.
====================
UI/LS
-/:
99065678/CD
====================
TI/LS
-/:
Interleukin-10/NN
and/CC
transforming/VBG
growth/NN
factor-beta/NN
promoter/NN
polymorphisms/NNS
in/IN
allergies/NNS
and/CC
asthma/NN
./.
====================
AB/LS
-/:
Interleukin-10/NN
(/(
IL-10/NN
)/)
and/CC
transforming/VBG
growth/NN
factor/NN
beta/NN
(/(
TGF-beta/NN
)/)
are/VBP
inhibitory/JJ
for/IN
B/NN
and/CC
T/NN
cells/NNS
,/,
IgE/NN
production/NN
,/,
and/CC
mast/NN
cell/NN
proliferation/NN
,/,
and/CC
they/PRP
induce/VBP
apoptosis/NN
in/IN
eosinophils/NNS
./.
====================
These/DT
cytokines/NNS
are/VBP
therefore/RB
candidate/NN
genes/NNS
which/WDT
could/MD
contribute/VB
to/TO
the/DT
development/NN
of/IN
asthma/NN
or/CC
allergies/NNS
./.
====================
We/PRP
investigated/VBD
the/DT
hypothesis/NN
that/IN
polymorphic/JJ
nucleotides/NNS
within/IN
the/DT
IL-10/NN
and/CC
TGF-beta/NN
gene/NN
promoters/NNS
would/MD
link/VB
to/TO
the/DT
expression/NN
of/IN
allergies/NNS
and/CC
asthma/NN
./.
====================
DNA/NN
taken/VBN
from/IN
families/NNS
with/IN
an/DT
asthmatic/JJ
proband/NN
was/VBD
examined/VBN
for/IN
base/NN
exchanges/NNS
by/IN
single-stranded/JJ
conformational/JJ
polymorphism/NN
(/(
SSCP/NN
)/)
./.
====================
We/PRP
demonstrated/VBD
the/DT
presence/NN
of/IN
a/DT
polymorphism/NN
in/IN
the/DT
promoter/NN
region/NN
of/IN
the/DT
IL-10/NN
gene/NN
and/CC
four/CD
in/IN
the/DT
TGF-beta/NN
gene/NN
promoters/NNS
(/(
3/CD
in/IN
TGF-beta1/NN
and/CC
1/CD
in/IN
TGF-beta2/NN
)/)
./.
====================
The/DT
IL-10/NN
gene/NN
polymorphism/NN
was/VBD
a/DT
C-to-A/JJ
exchange/NN
571/CD
base/NN
pairs/NNS
upstream/JJ
from/IN
the/DT
translation/NN
start/NN
site/NN
and/CC
was/VBD
present/JJ
between/IN
consensus/NN
binding/NN
sequences/NNS
for/IN
Sp1/NN
and/CC
elevated/JJ
total/JJ
serum/NN
./.
====================
This/DT
polymorphism/NN
was/VBD
associated/VBN
with/IN
elevated/JJ
total/JJ
serum/NN
IgE/NN
in/IN
subjects/NNS
heterozygotic/JJ
or/CC
homozygotic/JJ
for/IN
this/DT
base/NN
exchange/NN
(/(
p/NN
</JJR
0.009/CD
)/)
./.
====================
The/DT
base/NN
exchange/NN
at/IN
-509/CD
(/(
from/IN
the/DT
transcription/NN
initiation/NN
site/NN
)/)
in/IN
the/DT
TGF-beta/NN
promoter/NN
also/RB
linked/VBD
to/TO
elevated/JJ
total/JJ
IgE/NN
(/(
p/NN
</JJR
0.01/CD
)/)
./.
====================
This/DT
polymorphism/NN
represented/VBD
a/DT
C-to-T/JJ
base/NN
exchange/NN
which/WDT
induced/VBD
a/DT
YY1/NN
consensus/NN
sequence/NN
and/CC
is/VBZ
present/JJ
in/IN
a/DT
region/NN
of/IN
the/DT
promoter/NN
associated/VBN
with/IN
negative/JJ
transcription/NN
regulation/NN
./.
====================
UI/LS
-/:
99054659/CD
====================
TI/LS
-/:
Tpl-2/NN
induces/VBZ
IL-2/NN
expression/NN
in/IN
T-cell/NN
lines/NNS
by/IN
triggering/VBG
multiple/JJ
signaling/NN
pathways/NNS
that/WDT
activate/VBP
NFAT/NN
and/CC
NF-kappaB/NN
./.
====================
AB/LS
-/:
The/DT
Tpl-2/NN
kinase/NN
activates/VBZ
the/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFAT/NN
)/)
and/CC
induces/VBZ
IL-2/NN
expression/NN
in/IN
T-cell/NN
lines/NNS
./.
====================
Here/RB
we/PRP
show/VBP
that/IN
the/DT
activation/NN
of/IN
the/DT
IL-2/NN
promoter/NN
by/IN
Tpl-2/NN
is/VBZ
inhibited/VBN
by/IN
mutant/JJ
signaling/VBG
molecules/NNS
that/WDT
inhibit/VBP
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
(/(
MAPK/NN
)/)
or/CC
the/DT
calcineurin/NFAT/NN
pathways/NNS
and/CC
is/VBZ
promoted/VBN
by/IN
combinations/NNS
of/IN
signaling/VBG
molecules/NNS
that/WDT
activate/VBP
these/DT
pathways/NNS
./.
====================
We/PRP
,/,
therefore/RB
,/,
conclude/VBP
that/IN
signals/NNS
generated/VBN
by/IN
the/DT
convergence/NN
of/IN
the/DT
MAPK/NN
and/CC
the/DT
calcineurin/NFAT/NN
pathway/NN
are/VBP
necessary/JJ
and/CC
sufficient/JJ
for/IN
the/DT
activation/NN
of/IN
the/DT
IL-2/NN
promoter/NN
by/IN
Tpl-2/NN
./.
====================
The/DT
activation/NN
of/IN
both/CC
the/DT
IL-2/NN
promoter/NN
and/CC
an/DT
NFAT-driven/JJ
minimal/JJ
promoter/NN
were/VBD
shown/VBN
to/TO
depend/VB
on/IN
signals/NNS
transduced/VBN
by/IN
Raf1/NN
./.
====================
However/RB
,/,
it/PRP
was/VBD
only/RB
the/DT
IL-2/NN
promoter/NN
whose/WP$
activation/NN
by/IN
Tpl-2/NN
was/VBD
fully/RB
blocked/VBN
by/IN
the/DT
dominant/JJ
negative/JJ
mutant/JJ
MEK1S218/222A/NN
and/CC
the/DT
MEK1/MEK2/NN
inhibitor/NN
PD098059/NN
./.
====================
Since/IN
the/DT
activation/NN
of/IN
NFAT/NN
is/VBZ
MAPK-dependent/JJ
these/DT
findings/NNS
suggested/VBD
that/IN
the/DT
activation/NN
of/IN
MAPK/NN
by/IN
Tpl-2/NN
is/VBZ
either/CC
independent/JJ
or/CC
only/RB
partially/RB
dependent/JJ
on/IN
MEK1/NN
and/CC
MEK2/NN
./.
====================
In/IN
addition/NN
,/,
they/PRP
suggested/VBD
that/IN
the/DT
activation/NN
of/IN
the/DT
IL-2/NN
promoter/NN
is/VBZ
under/IN
the/DT
control/NN
of/IN
not/RB
only/RB
NFAT/NN
but/CC
also/RB
a/DT
second/JJ
factor/NN
whose/WP$
activation/NN
is/VBZ
MEK-dependent/JJ
./.
====================
Experiments/NNS
in/IN
COS-1/NN
and/CC
EL-4/NN
cells/NNS
confirmed/VBD
both/DT
hypotheses/NNS
and/CC
revealed/VBD
that/IN
the/DT
second/JJ
factor/NN
activated/VBN
by/IN
Tpl-2/NN
is/VBZ
NF-kappaB/NN
./.
====================
While/IN
the/DT
activation/NN
of/IN
the/DT
IL-2/NN
promoter/NN
and/CC
an/DT
NFAT-driven/JJ
minimal/JJ
promoter/NN
by/IN
Tpl-2/NN
was/VBD
fully/RB
blocked/VBN
by/IN
the/DT
dominant/JJ
negative/JJ
mutant/JJ
NFAT/NN
delta418/NN
,/,
it/PRP
was/VBD
only/RB
partially/RB
blocked/VBN
by/IN
the/DT
calcineurin/NN
inhibitor/NN
cyclosporin/NN
A/NN
suggesting/VBG
that/IN
the/DT
Tpl-2-mediated/JJ
NFAT/NN
activation/NN
is/VBZ
under/IN
the/DT
control/NN
of/IN
a/DT
combination/NN
of/IN
calcineurin-dependent/JJ
and/CC
independent/JJ
pathways/NNS
./.
====================
Both/DT
pathways/NNS
were/VBD
fully/RB
blocked/VBN
by/IN
Bcl-2/NN
or/CC
Bcl-X(L)/NN
./.
====================
UI/LS
-/:
99048705/CD
====================
TI/LS
-/:
Differential/JJ
activation/NN
of/IN
functionally/RB
distinct/JJ
STAT5/NN
proteins/NNS
by/IN
IL-5/NN
and/CC
GM-CSF/NN
during/IN
eosinophil/NN
and/CC
neutrophil/NN
differentiation/NN
from/IN
human/JJ
CD34+/JJ
hematopoietic/JJ
stem/NN
cells/NNS
./.
====================
AB/LS
-/:
Interleukin-5/NN
(/(
IL-5/NN
)/)
and/CC
granulocyte/NN
macrophage-colony/NN
stimulating/NN
factor/NN
(/(
GM-CSF/NN
)/)
are/VBP
important/JJ
cytokines/NNS
for/IN
the/DT
proliferation/NN
,/,
differentiation/NN
,/,
and/CC
activation/NN
of/IN
myeloid/JJ
lineages/NNS
./.
====================
The/DT
JAK/STAT/NN
pathway/NN
is/VBZ
one/CD
of/IN
the/DT
signaling/NN
pathways/NNS
implicated/VBN
in/IN
mediating/VBG
biological/JJ
responses/NNS
induced/VBN
by/IN
these/DT
cytokines/NNS
./.
====================
Previous/JJ
studies/NNS
have/VBP
demonstrated/VBN
that/IN
these/DT
cytokines/NNS
predominantly/RB
activate/VBP
an/DT
80/CD
kDa/NN
STAT5/NN
isoform/NN
in/IN
mature/JJ
granulocytes/NNS
./.
====================
To/TO
better/RBR
understand/VB
the/DT
role/NN
of/IN
STAT/NN
proteins/NNS
during/IN
growth/NN
and/CC
differentiation/NN
of/IN
granulocytes/NNS
,/,
we/PRP
evaluated/VBD
differentiation/NN
of/IN
human/JJ
CD34+/JJ
hematopoietic/JJ
stem/NN
cells/NNS
ex/FW
vivo/FW
toward/IN
eosinophils/NNS
and/CC
neutrophils/NNS
./.
====================
Bandshift/NN
experiments/NNS
showed/VBD
that/IN
in/IN
an/DT
early/JJ
stage/NN
of/IN
both/DT
differentiation/NN
pathways/NNS
(/(
14/CD
days/NNS
)/)
,/,
the/DT
94/CD
kDa/NN
STAT5B/NN
protein/NN
was/VBD
activated/VBN
by/IN
both/CC
IL-5/NN
(/(
eosinophil/NN
lineage/NN
)/)
and/CC
GM-CSF/NN
(/(
neutrophil/NN
lineage/NN
)/)
./.
====================
However/RB
,/,
during/IN
maturation/NN
of/IN
both/DT
lineages/NNS
(/(
days/NNS
21/CD
and/CC
28/CD
)/)
,/,
increased/VBN
expression/NN
of/IN
a/DT
functionally/RB
distinct/JJ
80/CD
kDa/NN
STAT5/NN
isoform/NN
was/VBD
observed/VBN
,/,
resulting/VBG
in/IN
heterodimer/NN
DNA-binding/JJ
complexes/NNS
containing/VBG
both/CC
the/DT
94/CD
and/CC
80/CD
kDa/NN
STAT5/NN
proteins/NNS
./.
====================
The/DT
finding/NN
that/IN
functionally/RB
distinct/JJ
isoforms/NNS
of/IN
STAT5/NN
are/VBP
activated/VBN
during/IN
the/DT
early/JJ
and/CC
late/JJ
differentiation/NN
stages/NNS
of/IN
granulocytes/NNS
suggests/VBZ
that/IN
they/PRP
might/MD
be/VB
involved/VBN
in/IN
regulating/VBG
different/JJ
biological/JJ
functions/NNS
in/IN
these/DT
cells/NNS
./.
====================
UI/LS
-/:
99038208/CD
====================
TI/LS
-/:
The/DT
T-cell/NN
oncogenic/JJ
protein/NN
HOX11/NN
activates/VBZ
Aldh1/NN
expression/NN
in/IN
NIH/NN
3T3/NN
cells/NNS
but/CC
represses/VBZ
its/PRP$
expression/NN
in/IN
mouse/NN
spleen/NN
development/NN
./.
====================
AB/LS
-/:
Hox11/NN
is/VBZ
a/DT
homeobox/NN
gene/NN
essential/JJ
for/IN
spleen/NN
formation/NN
in/IN
mice/NNS
,/,
since/IN
atrophy/NN
of/IN
the/DT
anlage/NN
of/IN
a/DT
developing/VBG
spleen/NN
occurs/VBZ
in/IN
early/JJ
embryonic/JJ
development/NN
in/IN
Hox11/NN
null/JJ
mice/NNS
./.
====================
HOX11/NN
is/VBZ
also/RB
expressed/VBN
in/IN
a/DT
subset/NN
of/IN
T-cell/NN
acute/JJ
leukemias/NNS
after/IN
specific/JJ
chromosomal/JJ
translocations/NNS
./.
====================
Since/IN
the/DT
protein/NN
has/VBZ
a/DT
homeodomain/NN
and/CC
can/MD
activate/VB
transcription/NN
,/,
it/PRP
probably/RB
exerts/VBZ
at/IN
least/JJS
some/DT
of/IN
its/PRP$
effects/NNS
in/FW
vivo/FW
by/IN
regulation/NN
of/IN
target/NN
genes/NNS
./.
====================
Representational/JJ
difference/NN
analysis/NN
has/VBZ
been/VBN
used/VBN
to/TO
isolate/VB
cDNA/NN
clones/NNS
corresponding/VBG
to/TO
mRNA/NN
species/NNS
activated/VBN
following/VBG
stable/JJ
expression/NN
of/IN
HOX11/NN
in/IN
NIH/NN
3T3/NN
cells/NNS
./.
====================
The/DT
gene/NN
encoding/VBG
the/DT
retinoic/JJ
acid-synthesizing/JJ
enzyme/NN
aldehyde/NN
dehydrogenase/NN
1/CD
(/(
Aldh1/NN
)/)
,/,
initially/RB
called/VBN
Hdg-1/NN
,/,
was/VBD
found/VBN
to/TO
be/VB
ectopically/RB
activated/VBN
by/IN
HOX11/NN
in/IN
this/DT
system/NN
./.
====================
Study/NN
of/IN
Aldh1/NN
gene/NN
expression/NN
during/IN
spleen/NN
development/NN
showed/VBD
that/IN
the/DT
presence/NN
of/IN
Aldh1/NN
mRNA/NN
inversely/RB
correlated/VBD
with/IN
Hox11/NN
./.
====================
Hox11/NN
null/JJ
mouse/NN
embryos/NNS
have/VBP
elevated/JJ
Aldh1/NN
mRNA/NN
in/IN
spleen/NN
primordia/NN
prior/JJ
to/TO
atrophy/NN
,/,
while/IN
Aldh1/NN
seems/VBZ
to/TO
be/VB
repressed/VBN
by/IN
Hox11/NN
during/IN
organogenesis/NN
of/IN
the/DT
spleens/NNS
of/IN
wild-type/JJ
mice/NNS
./.
====================
This/DT
result/NN
suggests/VBZ
that/IN
expression/NN
of/IN
Aldh1/NN
protein/NN
is/VBZ
negatively/RB
regulated/VBN
by/IN
Hox11/NN
and/CC
that/IN
abnormal/JJ
expression/NN
of/IN
Aldh1/NN
in/IN
Hox11/NN
null/JJ
mice/NNS
may/MD
cause/VB
loss/NN
of/IN
splenic/JJ
precursor/NN
cells/NNS
by/IN
aberrant/JJ
retinoic/JJ
acid/NN
metabolism/NN
====================
UI/LS
-/:
97364688/CD
====================
TI/LS
-/:
Role/NN
of/IN
the/DT
X2/NN
box/NN
in/IN
activated/VBN
transcription/NN
from/IN
the/DT
DRA/NN
promoter/NN
in/IN
B/NN
cells/NNS
./.
====================
AB/LS
-/:
We/PRP
investigated/VBD
the/DT
function/NN
of/IN
the/DT
evolutionary/JJ
conserved/VBN
X2/NN
box/NN
in/IN
the/DT
promoter/NN
of/IN
the/DT
HLA-DRA/NN
gene/NN
from/IN
the/DT
human/JJ
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
in/IN
resting/VBG
and/CC
activated/VBN
B/NN
cells/NNS
./.
====================
NF-X2/NN
,/,
which/WDT
contains/VBZ
members/NNS
of/IN
the/DT
AP-1/ATF/CREB/NN
families/NNS
of/IN
transcription/NN
factors/NNS
,/,
interacts/VBZ
with/IN
the/DT
X2/NN
box/NN
(/(
5'-TGCGTCA-3'/NN
)/)
from/IN
positions/NNS
-97/CD
to/TO
-91/CD
in/IN
the/DT
DRA/NN
promoter/NN
./.
====================
In/IN
resting/VBG
Raji/NN
cells/NNS
,/,
little/JJ
to/TO
no/DT
binding/NN
to/TO
the/DT
X2/NN
box/NN
was/VBD
observed/VBN
./.
====================
In/IN
sharp/JJ
contrast/NN
,/,
in/IN
B/NN
cells/NNS
treated/VBN
with/IN
the/DT
phorbol/NN
ester/NN
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
,/,
strong/JJ
interactions/NNS
between/IN
the/DT
X2/NN
box/NN
and/CC
NF-X2/NN
containing/VBG
c-Fos/NN
were/VBD
observed/VBN
./.
====================
As/IN
determined/VBN
by/IN
transient/JJ
expression/NN
and/CC
RNA/NN
analyses/NNS
,/,
the/DT
activation/NN
of/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
also/RB
increased/VBD
rates/NNS
of/IN
transcription/NN
from/IN
the/DT
wild-type/JJ
DRA/NN
promoter/NN
but/CC
not/RB
from/IN
a/DT
DRA/NN
promoter/NN
bearing/VBG
clustered/JJ
point/NN
mutations/NNS
in/IN
the/DT
X2/NN
box/NN
./.
====================
Since/IN
the/DT
co-expression/NN
with/IN
a/DT
dominant/JJ
negative/JJ
c-Fos/NN
abolished/VBD
the/DT
responsiveness/NN
to/TO
TPA/NN
,/,
we/PRP
conclude/VBP
that/IN
activated/VBN
transcription/NN
of/IN
the/DT
DRA/NN
gene/NN
depends/VBZ
on/IN
interactions/NNS
between/IN
the/DT
X2/NN
box/NN
and/CC
NF-X2/NN
,/,
which/WDT
contains/VBZ
c-Fos/NN
./.
====================
UI/LS
-/:
97196870/CD
====================
TI/LS
-/:
Thymocytes/NNS
control/VBP
the/DT
CD4/NN
gene/NN
differently/RB
from/IN
mature/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
We/PRP
analyzed/VBD
the/DT
activity/NN
of/IN
the/DT
enhancer/NN
,/,
the/DT
promoter/NN
and/CC
the/DT
silencer/NN
of/IN
the/DT
human/JJ
CD4/NN
gene/NN
during/IN
T/NN
cell/NN
development/NN
using/VBG
transgenic/JJ
mice/NNS
./.
====================
Immunofluorescence/NN
studies/NNS
on/IN
thymic/JJ
populations/NNS
of/IN
mice/NNS
carrying/VBG
transgenes/NNS
in/IN
various/JJ
combinations/NNS
of/IN
these/DT
regulatory/JJ
DNA/NN
elements/NNS
revealed/VBD
that/IN
thymocytes/NNS
control/VBP
the/DT
CD4/NN
gene/NN
in/IN
a/DT
different/JJ
manner/NN
than/IN
mature/JJ
peripheral/JJ
T/NN
lymphocytes/NNS
./.
====================
The/DT
5'-positive/JJ
regulatory/JJ
unit/NN
,/,
consisting/VBG
of/IN
the/DT
promoter/NN
and/CC
the/DT
5'/JJ
enhancer/NN
,/,
is/VBZ
already/RB
active/JJ
at/IN
the/DT
CD4-CD8-double-negative/JJ
(/(
DN/JJ
)/)
stage/NN
of/IN
development/NN
./.
====================
However/RB
,/,
its/PRP$
activity/NN
becomes/VBZ
lower/JJR
in/IN
the/DT
double-positive/JJ
and/CC
a/DT
fraction/NN
of/IN
the/DT
CD4+/JJ
CD8int/-/JJ
cell/NN
population/NN
,/,
indicating/VBG
that/IN
an/DT
additional/JJ
enhancer/NN
,/,
located/JJ
in/IN
either/CC
the/DT
first/JJ
or/CC
the/DT
third/JJ
intron/NN
of/IN
the/DT
CD4/NN
gene/NN
,/,
is/VBZ
required/VBN
for/IN
CD4/NN
gene/NN
expression/NN
in/IN
this/DT
population/NN
./.
====================
The/DT
other/JJ
studied/VBN
regulatory/JJ
element/NN
is/VBZ
the/DT
minimal/JJ
CD4/NN
silencer/NN
which/WDT
inhibits/VBZ
CD4/NN
gene/NN
expression/NN
in/IN
peripheral/JJ
CD8/NN
T/NN
lymphocytes/NNS
./.
====================
This/DT
silencer/NN
is/VBZ
inactive/JJ
in/IN
the/DT
most/RBS
immature/JJ
DN/JJ
thymocytes/NNS
,/,
which/WDT
probably/RB
use/VBP
a/DT
distinct/JJ
silencer/NN
mechanism/NN
to/TO
down-regulate/VB
CD4/NN
gene/NN
expression/NN
./.
====================
Unexpectedly/RB
,/,
the/DT
CD4/NN
silencer/NN
is/VBZ
also/RB
active/JJ
in/IN
CD4+/JJ
CD8int/-/JJ
cells/NNS
of/IN
the/DT
thymus/NN
,/,
implying/VBG
that/IN
an/DT
anti-silencer/NN
may/MD
be/VB
required/VBN
to/TO
resume/VB
CD4/NN
expression/NN
in/IN
this/DT
cell/NN
population/NN
./.
====================
Altogether/RB
,/,
the/DT
CD4/NN
gene/NN
is/VBZ
regulated/VBN
by/IN
several/JJ
positive/JJ
and/CC
negative/JJ
regulatory/JJ
mechanisms/NNS
which/WDT
come/VBP
into/IN
play/NN
in/IN
a/DT
developmentally/RB
coordinated/VBN
manner/NN
./.
====================
UI/LS
-/:
99201818/CD
====================
TI/LS
-/:
[/(
Induction/NN
of/IN
apoptosis/NN
in/IN
lymphocytes/NNS
by/IN
glucocorticoids/NNS
:/:
between/IN
physiology/NN
and/CC
pharmacology/NN
]/)
====================
AB/LS
-/:
Glucocorticoids/NNS
are/VBP
physiological/JJ
molecules/NNS
that/WDT
are/VBP
also/RB
extensively/RB
used/VBN
in/IN
clinics/NNS
as/IN
anti-inflammatory/JJ
,/,
immunosuppressive/JJ
or/CC
anti-tumoral/JJ
agents/NNS
./.
====================
Glucocorticoids/NNS
can/MD
induce/VB
apoptosis/NN
on/IN
normal/JJ
lymphoid/JJ
cells/NNS
and/CC
play/VB
a/DT
key/JJ
role/NN
in/IN
the/DT
physiology/NN
of/IN
thymic/JJ
selection/NN
./.
====================
In/IN
clinics/NNS
these/DT
molecules/NNS
are/VBP
also/RB
used/VBN
for/IN
their/PRP$
potencies/NNS
in/IN
inducing/VBG
apoptosis/NN
of/IN
malignant/JJ
lymphoid/JJ
cells/NNS
./.
====================
Glucocorticoids/NNS
are/VBP
mediating/VBG
their/PRP$
effects/NNS
after/IN
binding/VBG
to/TO
an/DT
intracellular/JJ
receptor/NN
belonging/VBG
to/TO
the/DT
steroid/NN
receptor/NN
superfamily/NN
:/:
the/DT
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
./.
====================
Once/IN
activated/VBN
,/,
the/DT
GR/NN
,/,
can/MD
mediate/VB
his/PRP$
effects/NNS
through/IN
direct/JJ
binding/NN
on/IN
the/DT
DNA/NN
or/CC
via/IN
protein/protein/NN
interactions/NNS
with/IN
transcription/NN
factors/NNS
./.
====================
Depending/VBG
on/IN
the/DT
type/NN
of/IN
lymphocytes/NNS
,/,
the/DT
mechanism/NN
of/IN
apoptosis/NN
induced/VBN
by/IN
glucocorticoids/NNS
fall/VBP
roughly/RB
in/IN
two/CD
categories/NNS
:/:
induction/NN
of/IN
"/``
death/NN
genes/NNS
"/''
by/IN
the/DT
activated/VBN
GR/NN
(/(
I/NN
kappa/NN
B/NN
,/,
c-jun/NN
)/)
or/CC
repression/NN
of/IN
survival/NN
factors/NNS
(/(
AP-1/NN
,/,
c-Myc/NN
)/)
./.
====================
In/IN
the/DT
case/NN
of/IN
thymic/JJ
selection/NN
the/DT
mechanism/NN
is/VBZ
more/RBR
subtle/JJ
depending/VBG
on/IN
the/DT
mutual/JJ
repression/NN
of/IN
Nur77/NN
and/CC
GR/NN
./.
====================
UI/LS
-/:
99096304/CD
====================
TI/LS
-/:
Direct/JJ
suppression/NN
of/IN
Stat1/NN
function/NN
during/IN
adenoviral/JJ
infection/NN
./.
====================
AB/LS
-/:
The/DT
action/NN
of/IN
adenoviral/JJ
E1A/NN
oncoprotein/NN
on/IN
host/NN
immune-response/JJ
genes/NNS
has/VBZ
been/VBN
attributed/VBN
to/TO
interaction/NN
with/IN
p300/CBP-type/JJ
transcriptional/JJ
coactivators/NNS
in/IN
competition/NN
with/IN
endogenous/JJ
transcription/NN
factors/NNS
such/JJ
as/IN
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
(/(
STAT/NN
)/)
proteins/NNS
./.
====================
However/RB
,/,
we/PRP
show/VBP
that/IN
mutant/JJ
forms/NNS
of/IN
E1A/NN
that/WDT
no/RB
longer/RBR
bind/VBP
p300/CBP/NN
can/MD
still/RB
interact/VB
directly/RB
with/IN
Stat1/NN
(/(
via/IN
E1A/NN
N-terminal/JJ
and/CC
Stat1/NN
C-terminal/JJ
residues/NNS
)/)
and/CC
block/VB
IFNgamma-driven/JJ
,/,
Stat1-dependent/JJ
gene/NN
activation/NN
and/CC
consequent/JJ
function/NN
during/IN
early-phase/JJ
infection/NN
in/IN
the/DT
natural/JJ
host/NN
cell/NN
./.
====================
The/DT
results/NNS
provide/VBP
a/DT
distinct/JJ
and/CC
more/RBR
specific/JJ
mechanism/NN
for/IN
E1A-mediated/JJ
immune/JJ
suppression/NN
and/CC
an/DT
alternative/JJ
model/NN
of/IN
IFNgamma-driven/JJ
enhanceosome/NN
formation/NN
that/WDT
may/MD
allow/VB
for/IN
other/JJ
adaptors/NNS
(/(
in/IN
addition/NN
to/TO
p300/CBP/NN
)/)
to/TO
link/VB
Stat1/NN
to/TO
the/DT
basal/JJ
transcription/NN
complex/NN
./.
====================
UI/LS
-/:
99083144/CD
====================
TI/LS
-/:
Effect/NN
of/IN
environmental/JJ
estrogens/NNS
on/IN
IL-1beta/NN
promoter/NN
activity/NN
in/IN
a/DT
macrophage/NN
cell/NN
line/NN
./.
====================
AB/LS
-/:
Environmental/JJ
estrogens/NNS
or/CC
estrogen/NN
disrupters/NNS
have/VBP
recently/RB
received/VBN
a/DT
great/JJ
deal/NN
of/IN
attention/NN
because/IN
of/IN
their/PRP$
potential/JJ
health/NN
impact/NN
on/IN
reproductive/JJ
tissues/NNS
./.
====================
Few/JJ
,/,
if/IN
any/DT
,/,
studies/NNS
have/VBP
been/VBN
made/VBN
on/IN
the/DT
impact/NN
of/IN
these/DT
compounds/NNS
on/IN
the/DT
immune/JJ
system/NN
./.
====================
We/PRP
sought/VBD
to/TO
determine/VB
the/DT
activities/NNS
of/IN
various/JJ
environmental/JJ
estrogens/NNS
on/IN
the/DT
modulation/NN
of/IN
the/DT
interleukin-1beta/NN
(/(
IL-1beta/NN
)/)
gene/NN
in/IN
a/DT
model/NN
monocytic/JJ
cell/NN
line/NN
,/,
hER+IL-1beta-CAT+/NN
./.
====================
This/DT
cell/NN
line/NN
stably/RB
transfected/VBN
with/IN
the/DT
human/JJ
estrogen/NN
receptor/NN
,/,
and/CC
an/DT
IL-1beta/NN
promoter/NN
construct/NN
fused/VBN
to/TO
the/DT
CAT/NN
reporter/NN
gene/NN
allows/VBZ
us/PRP
to/TO
monitor/VB
the/DT
effect/NN
of/IN
estrogenic/JJ
compounds/NNS
on/IN
IL-1beta/NN
promoter/NN
activity/NN
./.
====================
17beta-estradiol/NN
(/(
E2/NN
)/)
markedly/RB
enhanced/VBD
lipopolysaccharide-/NN
(/(
LPS/NN
)/)
induced/JJ
IL-1beta/NN
promoter-driven/JJ
CAT/NN
activity/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
./.
====================
The/DT
mycotoxins/NNS
alpha-zearalenol/NN
and/CC
zearalenone/NN
both/DT
exhibited/VBD
full/JJ
agonist/NN
activity/NN
,/,
but/CC
at/IN
lower/JJR
potencies/NNS
,/,
with/IN
EC50/NN
values/NNS
of/IN
1.8/CD
and/CC
54/CD
nM/NN
,/,
respectively/RB
,/,
compared/VBN
with/IN
E2/NN
at/IN
0.5/CD
nM/NN
./.
====================
In/IN
addition/NN
,/,
genistein/NN
was/VBD
a/DT
very/RB
low-potency/JJ
agonist/NN
,/,
having/VBG
an/DT
EC50/NN
of/IN
1.5/CD
microM/NN
./.
====================
Similar/JJ
to/TO
the/DT
E2/NN
response/NN
,/,
the/DT
slope/NN
factors/NNS
for/IN
alpha-zearalenol/NN
,/,
zearalenone/NN
,/,
and/CC
genistein/NN
were/VBD
close/JJ
to/TO
3.0/CD
,/,
suggesting/VBG
positive/JJ
cooperativity/NN
in/IN
the/DT
estrogenic/JJ
response/NN
./.
====================
The/DT
activity/NN
of/IN
the/DT
mycotoxins/NNS
appeared/VBD
to/TO
be/VB
mediated/VBN
through/IN
the/DT
estrogen/NN
receptor/NN
,/,
since/IN
both/CC
the/DT
antiestrogens/NNS
H1285/NN
and/CC
ICI/NN
182/CD
,/,
780/CD
effectively/RB
inhibited/VBD
their/PRP$
agonist/NN
activity/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
./.
====================
Representative/JJ
environmental/JJ
estrogenic/JJ
compounds/NNS
both/CC
from/IN
plant/NN
and/CC
industrial/JJ
sources/NNS
were/VBD
also/RB
tested/VBN
./.
====================
Unlike/IN
the/DT
mycoestrogens/NNS
,/,
none/NN
of/IN
the/DT
compounds/NNS
,/,
with/IN
the/DT
exception/NN
of/IN
genistein/NN
,/,
synergized/VBD
with/IN
LPS/NN
to/TO
enhance/VB
IL-1beta/NN
promoter/NN
activity/NN
./.
====================
When/WRB
tested/VBN
for/IN
antiestrogenic/JJ
activity/NN
,/,
the/DT
industrial/JJ
compound/NN
4-octylphenol/NN
was/VBD
able/JJ
to/TO
antagonize/VB
the/DT
response/NN
to/TO
E2/NN
;/:
however/RB
,/,
the/DT
response/NN
was/VBD
three/CD
orders/NNS
of/IN
magnitude/NN
less/RBR
potent/JJ
than/IN
H/NN
1285/CD
./.
====================
Naringenin/NN
,/,
a/DT
plant/NN
flavonoid/NN
,/,
showed/VBD
little/JJ
or/CC
no/DT
ability/NN
to/TO
antagonize/VB
the/DT
response/NN
to/TO
E2/NN
./.
====================
Overall/RB
,/,
the/DT
results/NNS
show/VBP
that/IN
some/DT
environmental/JJ
estrogens/NNS
that/WDT
display/VBP
agonist/NN
activity/NN
in/IN
reproductive/JJ
tissue/NN
also/RB
have/VBP
an/DT
effect/NN
on/IN
IL-1/NN
gene/NN
expression/NN
in/IN
hemopoietic-derived/JJ
tissue/NN
./.
====================
UI/LS
-/:
99070073/CD
====================
TI/LS
-/:
Isolation/NN
and/CC
utilization/NN
of/IN
human/JJ
dendritic/JJ
cells/NNS
from/IN
peripheral/JJ
blood/NN
to/TO
assay/VB
an/DT
in/FW
vitro/FW
primary/JJ
immune/JJ
response/NN
to/TO
varicella-zoster/NN
virus/NN
peptides/NNS
./.
====================
AB/LS
-/:
A/DT
human/JJ
dendritic/JJ
cell-based/JJ
assay/NN
used/VBN
to/TO
monitor/VB
a/DT
T/NN
cell/NN
proliferation/NN
response/NN
to/TO
viral/JJ
peptides/NNS
in/FW
vitro/FW
is/VBZ
described/VBN
./.
====================
Dendritic/JJ
cells/NNS
and/CC
autologous/JJ
CD4+/JJ
T/NN
cells/NNS
were/VBD
isolated/VBN
from/IN
peripheral/JJ
blood/NN
by/IN
a/DT
series/NN
of/IN
density-gradient/JJ
centrifugations/NNS
or/CC
magnetic/JJ
bead/NN
separations/NNS
(/(
or/CC
both/DT
)/)
./.
====================
Peptides/NNS
corresponding/VBG
to/TO
residues/NNS
of/IN
the/DT
immediate/JJ
early/JJ
protein/NN
,/,
IE62/NN
,/,
of/IN
varicella-zoster/NN
virus/NN
(/(
VZV/NN
)/)
were/VBD
used/VBN
as/IN
stimulating/VBG
antigens/NNS
,/,
and/CC
persons/NNS
with/IN
no/DT
history/NN
of/IN
varicella/NN
and/CC
no/DT
humoral/JJ
or/CC
cellular/JJ
immunity/NN
to/TO
VZV/NN
served/VBD
as/IN
naive/JJ
donors/NNS
for/IN
the/DT
assays/NNS
./.
====================
Three/CD
VZV-susceptible/JJ
donors/NNS
were/VBD
tested/VBN
,/,
and/CC
all/DT
demonstrated/VBD
an/DT
in/FW
vitro/FW
response/NN
to/TO
multiple/JJ
VZV/NN
peptides/NNS
./.
====================
This/DT
assay/NN
has/VBZ
potential/NN
as/IN
a/DT
screen/NN
to/TO
establish/VB
the/DT
immunogenicity/NN
of/IN
viral/JJ
antigens/NNS
in/FW
vitro/FW
using/VBG
T/NN
cells/NNS
from/IN
naive/JJ
donors/NNS
./.
====================
UI/LS
-/:
98168578/CD
====================
TI/LS
-/:
Xenogeneic/JJ
human/JJ
serum/NN
promotes/VBZ
leukocyte/NN
adhesion/NN
to/TO
porcine/NN
endothelium/NN
under/IN
flow/NN
conditions/NNS
,/,
possibly/RB
through/IN
the/DT
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
./.
====================
AB/LS
-/:
Endothelial/JJ
cell/NN
activation/NN
and/CC
leukocyte/NN
infiltration/NN
are/VBP
a/DT
consistent/JJ
feature/NN
of/IN
discordant/JJ
xenograft/NN
rejection/NN
./.
====================
Here/RB
we/PRP
evaluated/VBD
whether/IN
xenogeneic/JJ
serum/NN
,/,
as/IN
a/DT
source/NN
of/IN
xenoreactive/JJ
natural/JJ
antibodies/NNS
and/CC
complement/NN
,/,
induced/VBD
endothelial/JJ
cell/NN
activation/NN
with/IN
consequent/JJ
leukocyte/NN
adhesion/NN
under/IN
flow/NN
conditions/NNS
./.
====================
Porcine/JJ
aortic/JJ
endothelial/JJ
cells/NNS
(/(
PAEC/NNS
)/)
were/VBD
incubated/VBN
for/IN
1/CD
hr/NN
30/CD
min/NN
or/CC
5/CD
hr/NN
with/IN
10/CD
%/NN
homologous/JJ
porcine/JJ
serum/NN
(/(
control/NN
)/)
or/CC
10/CD
%/NN
xenogeneic/JJ
human/JJ
serum/NN
and/CC
then/RB
perfused/VBN
with/IN
total/JJ
human/JJ
leukocytes/NNS
in/IN
a/DT
parallel/NN
plate/NN
flow/NN
chamber/NN
under/IN
laminar/JJ
flow/NN
(/(
1.5/CD
dynes/cm2/NNS
)/)
./.
====================
Adherent/JJ
cells/NNS
were/VBD
counted/VBN
by/IN
digital/JJ
image/NN
analysis/NN
./.
====================
Xenogeneic/JJ
human/JJ
serum/NN
significantly/RB
(/(
P/NN
</JJR
0.01/CD
)/)
increased/VBD
the/DT
number/NN
of/IN
adherent/JJ
leukocytes/NNS
as/IN
compared/VBN
with/IN
porcine/JJ
serum/NN
./.
====================
A/DT
similar/JJ
adhesive/JJ
response/NN
was/VBD
elicited/VBN
by/IN
TNF/NN
alpha/NN
(/(
100/CD
U/ml/NN
)/)
,/,
one/CD
of/IN
the/DT
most/RBS
potent/JJ
inducers/NNS
of/IN
endothelial/JJ
cell/NN
adhesive/JJ
properties/NNS
,/,
here/RB
used/VBN
as/IN
positive/JJ
control/NN
./.
====================
In/IN
order/NN
to/TO
elucidate/VB
possible/JJ
mechanisms/NNS
underlying/VBG
endothelial/JJ
cell/NN
activation/NN
by/IN
xenogeneic/JJ
serum/NN
,/,
we/PRP
focussed/VBD
on/IN
transcription/NN
factor/NN
NF-kappa/NN
B/NN
,/,
a/DT
central/JJ
regulator/NN
for/IN
the/DT
induction/NN
of/IN
different/JJ
genes/NNS
,/,
including/VBG
adhesive/JJ
molecules/NNS
and/CC
chemoattractants/NNS
./.
====================
By/IN
confocal/JJ
fluorescence/NN
microscopy/NN
,/,
we/PRP
observed/VBD
a/DT
positive/JJ
staining/NN
for/IN
NF-kappa/NN
B/NN
(/(
p65/NN
subunit/NN
)/)
in/IN
the/DT
nuclei/NNS
of/IN
PAEC/NNS
exposed/VBN
for/IN
1/CD
hr/NN
30/CD
min/NN
to/TO
human/JJ
serum/NN
,/,
which/WDT
indicated/VBD
NF-kappa/NN
B/NN
activation/NN
in/IN
this/DT
setting/NN
./.
====================
At/IN
variance/NN
,/,
in/IN
PAEC/NNS
incubated/VBN
with/IN
the/DT
homologous/JJ
serum/NN
,/,
NF-kappa/NN
B/NN
was/VBD
strictly/RB
localized/JJ
in/IN
the/DT
cell/NN
cytoplasm/NN
./.
====================
Treatment/NN
of/IN
PAEC/NNS
exposed/VBN
to/TO
xenogeneic/JJ
serum/NN
with/IN
the/DT
NF-kappa/NN
B/NN
inhibitors/NNS
pyrrolidinedithiocarbamate/NN
(/(
PDTC/NN
,/,
25/CD
microM/NN
)/)
and/CC
tosyl-phechloromethylketone/NN
(/(
TPCK/NN
,/,
25/CD
microM/NN
)/)
significantly/RB
(/(
P/NN
</JJR
0.01/CD
)/)
reduced/VBD
leukocyte/NN
adhesion/NN
in/IN
respect/NN
to/TO
PAEC/NNS
treated/VBN
with/IN
human/JJ
serum/NN
alone/RB
./.
====================
Findings/NNS
that/IN
xenogeneic/JJ
serum/NN
promotes/VBZ
leukocyte-endothelium/JJ
interaction/NN
possibly/RB
through/IN
NF-kappa/NN
B/NN
activation/NN
might/MD
be/VB
relevant/JJ
for/IN
designing/VBG
future/JJ
therapeutic/JJ
strategies/NNS
aimed/VBN
at/IN
prolonging/VBG
xenograft/NN
survival/NN
./.
====================
UI/LS
-/:
99057586/CD
====================
TI/LS
-/:
Anaphylatoxins/NNS
C5a/NN
and/CC
C3a/NN
induce/VBP
nuclear/JJ
factor/NN
kappaB/NN
activation/NN
in/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
./.
====================
AB/LS
-/:
The/DT
anaphylatoxins/NNS
C5a/NN
and/CC
C3a/NN
are/VBP
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
cytokine/NN
production/NN
./.
====================
In/IN
this/DT
study/NN
the/DT
capability/NN
of/IN
C5a/NN
and/CC
C3a/NN
to/TO
induce/VB
transcription/NN
factor/NN
activation/NN
was/VBD
examined/VBN
./.
====================
C5a/NN
and/CC
C3a/NN
stimulation/NN
of/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
resulted/VBD
in/IN
nuclear/JJ
expression/NN
of/IN
a/DT
DNA/NN
binding/NN
activity/NN
with/IN
specificity/NN
to/TO
the/DT
kappaB/NN
sequence/NN
./.
====================
The/DT
p50/NN
and/CC
p65/NN
proteins/NNS
,/,
constituents/NNS
of/IN
the/DT
prototypic/JJ
nuclear/JJ
factor/NN
kappaB/NN
,/,
were/VBD
identified/VBN
as/IN
components/NNS
of/IN
the/DT
DNA-protein/JJ
complexes/NNS
by/IN
anti-peptide/JJ
antibodies/NNS
in/IN
gel/NN
supershift/NN
assays/NNS
./.
====================
C5a/NN
induced/JJ
kappaB/NN
binding/NN
activity/NN
was/VBD
detected/VBN
15/CD
min/NN
after/IN
agonist/NN
stimulation/NN
,/,
peaked/VBD
at/IN
30-40/CD
min/NN
,/,
and/CC
remained/VBD
detectable/JJ
at/IN
2/CD
h/NN
./.
====================
Binding/NN
to/TO
kappaB/NN
sequence/NN
was/VBD
accompanied/VBN
by/IN
an/DT
initial/JJ
decrease/NN
and/CC
subsequent/JJ
increase/NN
in/IN
the/DT
cytoplasmic/JJ
IkappaBalpha/NN
levels/NNS
,/,
as/IN
detected/VBN
by/IN
Western/NN
blotting/NN
using/VBG
an/DT
anti-IkappaBalpha/JJ
antibody/NN
./.
====================
Pertussis/NN
toxin/NN
treatment/NN
markedly/RB
decreased/VBD
kappaB/NN
binding/NN
activities/NNS
induced/VBN
by/IN
both/CC
C5a/NN
and/CC
C3a/NN
,/,
whereas/IN
cholera/NN
toxin/NN
displayed/VBD
no/DT
inhibitory/JJ
effect/NN
./.
====================
Neither/DT
of/IN
the/DT
two/CD
toxins/NNS
affected/VBD
kappaB/NN
binding/NN
activity/NN
induced/VBN
by/IN
TNFalpha/NN
in/IN
the/DT
same/JJ
cells/NNS
./.
====================
These/DT
results/NNS
imply/VBP
a/DT
potential/JJ
role/NN
of/IN
the/DT
anaphylatoxins/NNS
C5a/NN
and/CC
C3a/NN
in/IN
regulating/VBG
leukocytes/NNS
gene/NN
expression/NN
through/IN
G/NN
protein-coupled/JJ
transcription/NN
factor/NN
activation/NN
./.
====================
UI/LS
-/:
99047055/CD
====================
TI/LS
-/:
Thrombopoietin/NN
and/CC
its/PRP$
receptor/NN
./.
====================
AB/LS
-/:
Thrombopoietin/NN
(/(
TPO/NN
)/)
,/,
the/DT
primary/JJ
physiological/JJ
regulator/NN
of/IN
platelet/NN
production/NN
,/,
was/VBD
initially/RB
thought/VBN
to/TO
be/VB
a/DT
lineage-specific/JJ
factor/NN
acting/VBG
predominantly/RB
on/IN
megakaryocytopoiesis/NN
./.
====================
Detailed/JJ
studies/NNS
establish/VBP
that/IN
this/DT
cytokine/NN
mediates/VBZ
biological/JJ
effects/NNS
on/IN
a/DT
broad/JJ
spectrum/NN
of/IN
hematopoietic/JJ
progenitor/NN
cells/NNS
,/,
including/VBG
stem/NN
cells/NNS
./.
====================
TPO/NN
is/VBZ
a/DT
hormone/NN
constitutively/RB
produced/VBN
mainly/RB
by/IN
the/DT
liver/NN
and/CC
kidney/NN
./.
====================
Plasma/NN
TPO/NN
levels/NNS
are/VBP
regulated/VBN
by/IN
the/DT
platelet/NN
and/CC
megakaryocyte/NN
mass/NN
through/IN
Mpl/NN
receptor/NN
binding/NN
,/,
internalization/NN
and/CC
degradation/NN
./.
====================
The/DT
Mpl/NN
receptor/NN
is/VBZ
a/DT
member/NN
of/IN
the/DT
hematopoietin/NN
receptor/NN
superfamily/NN
lacking/VBG
intrinsic/JJ
kinase/NN
activity/NN
./.
====================
Upon/IN
ligand-induced/JJ
Mpl/NN
homodimerization/NN
,/,
the/DT
major/JJ
signaling/NN
events/NNS
for/IN
proliferation/NN
are/VBP
mediated/VBN
through/IN
the/DT
JAK2/STAT5/NN
pathway/NN
,/,
while/IN
differentiation/NN
might/MD
occur/VB
through/IN
a/DT
prolonged/JJ
activation/NN
of/IN
the/DT
MAPK/NN
pathway/NN
./.
====================
Preclinical/JJ
and/CC
clinical/JJ
studies/NNS
demonstrate/VBP
the/DT
potential/JJ
use/NN
of/IN
TPO/NN
in/IN
a/DT
variety/NN
of/IN
contexts/NNS
,/,
but/CC
it/PRP
is/VBZ
too/RB
early/JJ
to/TO
evaluate/VB
its/PRP$
benefit/NN
in/IN
reducing/VBG
platelet/NN
transfusion/NN
./.
====================
UI/LS
-/:
99038200/CD
====================
TI/LS
-/:
TAL1/NN
and/CC
LIM-only/JJ
proteins/NNS
synergistically/RB
induce/VBP
retinaldehyde/NN
dehydrogenase/NN
2/CD
expression/NN
in/IN
T-cell/NN
acute/JJ
lymphoblastic/JJ
leukemia/NN
by/IN
acting/VBG
as/IN
cofactors/NNS
for/IN
GATA3/NN
./.
====================
AB/LS
-/:
Previously/RB
,/,
we/PRP
have/VBP
shown/VBN
that/IN
TAL1/NN
and/CC
the/DT
LIM-only/JJ
protein/NN
gene/NN
(/(
LMO/NN
)/)
are/VBP
regularly/RB
coactivated/VBN
in/IN
T-cell/NN
acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
T-ALL/NN
)/)
./.
====================
This/DT
observation/NN
is/VBZ
likely/JJ
to/TO
relate/VB
to/TO
the/DT
findings/NNS
that/IN
TAL1/NN
and/CC
LMO/NN
are/VBP
highly/RB
synergistic/JJ
in/IN
T-cell/NN
tumorigenesis/NN
in/IN
double-transgenic/JJ
mice/NNS
./.
====================
To/TO
understand/VB
the/DT
molecular/JJ
mechanisms/NNS
of/IN
functional/JJ
synergy/NN
between/IN
TAL1/NN
and/CC
LMO/NN
in/IN
tumorigenesis/NN
and/CC
transcriptional/JJ
regulation/NN
,/,
we/PRP
tried/VBD
to/TO
identify/VB
downstream/JJ
target/NN
genes/NNS
regulated/VBN
by/IN
TAL1/NN
and/CC
LMO/NN
by/IN
a/DT
subtractive/JJ
PCR/NN
method/NN
./.
====================
One/CD
of/IN
the/DT
isolated/VBN
genes/NNS
,/,
that/DT
for/IN
retinaldehyde/NN
dehydrogenase/NN
2/CD
(/(
RALDH2/NN
)/)
,/,
was/VBD
regularly/RB
expressed/VBN
in/IN
most/JJS
of/IN
the/DT
T-ALL/NN
cell/NN
lines/NNS
that/WDT
coexpressed/VBD
TAL1/NN
and/CC
LMO/NN
./.
====================
Exogenously/RB
transfected/VBN
TAL1/NN
and/CC
LMO/NN
,/,
but/CC
not/RB
either/DT
alone/RB
,/,
induced/VBD
RALDH2/NN
expression/NN
in/IN
a/DT
T-ALL/NN
cell/NN
line/NN
,/,
HPB-ALL/NN
,/,
not/RB
expressing/VBG
endogeneous/JJ
TAL1/NN
or/CC
LMO/NN
./.
====================
The/DT
RALDH2/NN
transcripts/NNS
in/IN
T-ALL/NN
were/VBD
,/,
however/RB
,/,
mostly/RB
initiated/VBN
within/IN
the/DT
second/JJ
intron/NN
./.
====================
Promoter/NN
analysis/NN
revealed/VBD
that/IN
a/DT
GATA/NN
site/NN
in/IN
a/DT
cryptic/JJ
promoter/NN
in/IN
the/DT
second/JJ
intron/NN
was/VBD
essential/JJ
and/CC
sufficient/JJ
for/IN
the/DT
TAL1-/NN
and/CC
LMO-dependent/JJ
transcriptional/JJ
activation/NN
,/,
and/CC
GATA3/NN
binds/VBZ
to/TO
this/DT
site/NN
./.
====================
In/IN
addition/NN
,/,
forced/VBN
expression/NN
of/IN
GATA3/NN
potentiated/VBD
the/DT
induction/NN
of/IN
RALDH2/NN
by/IN
TAL1/NN
and/CC
LMO/NN
,/,
and/CC
these/DT
three/CD
factors/NNS
formed/VBD
a/DT
complex/NN
in/FW
vivo/FW
./.
====================
Furthermore/RB
,/,
a/DT
TAL1/NN
mutant/NN
not/RB
binding/VBG
to/TO
DNA/NN
also/RB
activated/VBD
the/DT
transcription/NN
of/IN
RALDH2/NN
in/IN
the/DT
presence/NN
of/IN
LMO/NN
and/CC
GATA3/NN
./.
====================
Collectively/RB
,/,
we/PRP
have/VBP
identified/VBN
the/DT
RALDH2/NN
gene/NN
as/IN
a/DT
first/JJ
example/NN
of/IN
direct/JJ
transcriptional/JJ
target/NN
genes/NNS
regulated/VBN
by/IN
TAL1/NN
and/CC
LMO/NN
in/IN
T-ALL/NN
./.
====================
In/IN
this/DT
case/NN
,/,
TAL1/NN
and/CC
LMO/NN
act/VBP
as/IN
cofactors/NNS
for/IN
GATA3/NN
to/TO
activate/VB
the/DT
transcription/NN
of/IN
RALDH2/NN
====================
UI/LS
-/:
97360262/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptors/NNS
in/IN
human/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
in/IN
relation/NN
to/TO
age/NN
and/CC
to/TO
sport/NN
activity/NN
./.
====================
AB/LS
-/:
Glucocorticoid/NN
receptors/NNS
(/(
GR/NNS
)/)
are/VBP
ubiquitous/JJ
molecules/NNS
and/CC
are/VBP
present/JJ
also/RB
in/IN
the/DT
hippocampus/NN
and/CC
in/IN
several/JJ
other/JJ
nervous/JJ
and/CC
immune/JJ
tissues/NNS
./.
====================
Peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMCs/NNS
)/)
are/VBP
a/DT
good/JJ
model/NN
for/IN
studies/NNS
of/IN
GR/NNS
in/IN
humans/NNS
./.
====================
Glucocorticoids/NNS
are/VBP
important/JJ
for/IN
maintaining/VBG
cellular/JJ
and/CC
humoral/JJ
homeostasis/NN
and/CC
are/VBP
key/JJ
mediators/NNS
of/IN
neuroendocrine-immune/JJ
regulatory/JJ
interactions/NNS
./.
====================
The/DT
increase/NN
of/IN
cortisol/NN
is/VBZ
immunosuppressive/JJ
and/CC
reduces/VBZ
GR/NNS
concentration/NN
both/CC
in/IN
nervous/JJ
and/CC
immune/JJ
systems/NNS
./.
====================
Variation/NN
of/IN
glucocorticoids/NNS
in/IN
healthy/JJ
aged/JJ
subjects/NNS
and/CC
athletes/NNS
has/VBZ
been/VBN
shown/VBN
./.
====================
Prompted/VBN
by/IN
these/DT
results/NNS
,/,
we/PRP
have/VBP
investigated/VBN
in/IN
man/NN
a/DT
possible/JJ
relationship/NN
between/IN
GR/NNS
binding/NN
capacity/NN
in/IN
the/DT
PBMCs/NNS
and/CC
age/NN
,/,
in/IN
relation/NN
also/RB
to/TO
plasma/NN
testosterone/NN
and/CC
cortisol/NN
./.
====================
The/DT
same/JJ
parameters/NNS
have/VBP
been/VBN
examined/VBN
in/IN
a/DT
group/NN
of/IN
soccer/NN
players/NNS
for/IN
comparison/NN
with/IN
the/DT
sedentary/JJ
group/NN
./.
====================
GR/NNS
binding/NN
capacity/NN
was/VBD
higher/JJR
in/IN
younger/JJR
subjects/NNS
than/IN
in/IN
older/JJR
ones/NNS
,/,
and/CC
lower/JJR
in/IN
the/DT
group/NN
of/IN
athletes/NNS
than/IN
in/IN
the/DT
younger/JJR
and/CC
older/JJR
sedentary/JJ
subjects/NNS
./.
====================
In/IN
the/DT
sedentary/JJ
group/NN
a/DT
negative/JJ
correlation/NN
was/VBD
present/JJ
between/IN
GR/NNS
binding/NN
capacity/NN
and/CC
age/NN
./.
====================
Plasma/NN
cortisol/NN
was/VBD
higher/JJR
and/CC
testosterone/NN
lower/JJR
in/IN
the/DT
athletes/NNS
;/:
they/PRP
were/VBD
negatively/RB
correlated/VBN
in/IN
athletes/NNS
and/CC
positively/RB
correlated/VBN
in/IN
the/DT
sedentary/JJ
subjects/NNS
./.
====================
The/DT
results/NNS
for/IN
athletes/NNS
agree/VBP
with/IN
their/PRP$
lower/JJR
anabolic/catabolic/JJ
balance/NN
./.
====================
The/DT
mechanism/NN
of/IN
reduced/VBN
GR/NNS
levels/NNS
in/IN
relation/NN
to/TO
age/NN
and/CC
sport/NN
activity/NN
could/MD
involve/VB
a/DT
loss/NN
or/CC
an/DT
involution/NN
of/IN
receptor/NN
synthesis/NN
./.
====================
However/RB
other/JJ
possibilities/NNS
,/,
such/JJ
as/IN
altered/JJ
distribution/NN
of/IN
lymphocyte/NN
subpopulations/NNS
with/IN
different/JJ
receptor/NN
concentrations/NNS
and/CC
with/IN
different/JJ
cytokine/NN
production/NN
,/,
can/MD
not/RB
be/VB
excluded/VBN
./.
====================
Several/JJ
neuroendocrine-immune/JJ
interactions/NNS
could/MD
be/VB
responsible/JJ
for/IN
reduced/VBN
GR/NNS
levels/NNS
with/IN
age/NN
and/CC
sport/NN
activity/NN
in/IN
man/NN
./.
====================
UI/LS
-/:
97148782/CD
====================
TI/LS
-/:
Glycation-dependent/JJ
,/,
reactive/JJ
oxygen/NN
species-mediated/JJ
suppression/NN
of/IN
the/DT
insulin/NN
gene/NN
promoter/NN
activity/NN
in/IN
HIT/NN
cells/NNS
./.
====================
AB/LS
-/:
Prolonged/JJ
poor/JJ
glycemic/JJ
control/NN
in/IN
non-insulin-dependent/JJ
diabetes/NN
mellitus/NN
patients/NNS
often/RB
leads/VBZ
to/TO
a/DT
decline/NN
in/IN
insulin/NN
secretion/NN
from/IN
pancreatic/JJ
beta/NN
cells/NNS
,/,
accompanied/VBN
by/IN
a/DT
decrease/NN
in/IN
the/DT
insulin/NN
content/NN
of/IN
the/DT
cells/NNS
./.
====================
As/IN
a/DT
step/NN
toward/IN
elucidating/VBG
the/DT
pathophysiological/JJ
background/NN
of/IN
the/DT
so-called/JJ
glucose/NN
toxicity/NN
to/TO
pancreatic/JJ
beta/NN
cells/NNS
,/,
we/PRP
induced/VBD
glycation/NN
in/IN
HIT-T15/NN
cells/NNS
using/VBG
a/DT
sugar/NN
with/IN
strong/JJ
deoxidizing/NN
activity/NN
,/,
D-ribose/NN
,/,
and/CC
examined/VBD
the/DT
effects/NNS
on/IN
insulin/NN
gene/NN
transcription/NN
./.
====================
The/DT
results/NNS
of/IN
reporter/NN
gene/NN
analyses/NNS
revealed/VBD
that/IN
the/DT
insulin/NN
gene/NN
promoter/NN
is/VBZ
more/RBR
sensitive/JJ
to/TO
glycation/NN
than/IN
the/DT
control/JJ
beta-actin/NN
gene/NN
promoter/NN
;/:
approximately/RB
50/CD
and/CC
80/CD
%/NN
of/IN
the/DT
insulin/NN
gene/NN
promoter/NN
activity/NN
was/VBD
lost/VBN
when/WRB
the/DT
cells/NNS
were/VBD
kept/VBN
for/IN
3/CD
d/NN
in/IN
the/DT
presence/NN
of/IN
40/CD
and/CC
60/CD
mM/NN
D-ribose/NN
,/,
respectively/RB
./.
====================
In/IN
agreement/NN
with/IN
this/DT
,/,
decrease/NN
in/IN
the/DT
insulin/NN
mRNA/NN
and/CC
insulin/NN
content/NN
was/VBD
observed/VBN
in/IN
the/DT
glycation-induced/JJ
cells/NNS
./.
====================
Also/RB
,/,
gel/NN
mobility/NN
shift/NN
analyses/NNS
using/VBG
specific/JJ
antiserum/NN
revealed/VBD
decrease/NN
in/IN
the/DT
DNA-binding/NN
activity/NN
of/IN
an/DT
insulin/NN
gene/NN
transcription/NN
factor/NN
,/,
PDX-1/IPF1/STF-1/NN
./.
====================
These/DT
effects/NNS
of/IN
D-ribose/NN
seemed/VBD
almost/RB
irreversible/JJ
but/CC
could/MD
be/VB
prevented/VBN
by/IN
addition/NN
of/IN
1/CD
mM/NN
aminoguanidine/NN
or/CC
10/CD
mM/NN
N-acetylcysteine/NN
,/,
thus/RB
suggesting/VBG
that/IN
glycation/NN
and/CC
reactive/JJ
oxygen/NN
species/NNS
,/,
generated/VBN
through/IN
the/DT
glycation/NN
reaction/NN
,/,
serve/VBP
as/IN
mediators/NNS
of/IN
the/DT
phenomena/NNS
./.
====================
These/DT
observations/NNS
suggest/VBP
that/IN
protein/NN
glycation/NN
in/IN
pancreatic/JJ
beta/NN
cells/NNS
,/,
which/WDT
occurs/VBZ
in/FW
vivo/FW
under/IN
chronic/JJ
hyperglycemia/NN
,/,
suppresses/VBZ
insulin/NN
gene/NN
transcription/NN
and/CC
thus/RB
can/MD
explain/VB
part/NN
of/IN
the/DT
beta/NN
cell/NN
glucose/NN
toxicity/NN
./.
====================
UI/LS
-/:
99169427/CD
====================
TI/LS
-/:
Nuclear/JJ
factor-kappa/NN
B/NN
activity/NN
in/IN
T/NN
cells/NNS
from/IN
patients/NNS
with/IN
rheumatic/JJ
diseases/NNS
:/:
a/DT
preliminary/JJ
report/NN
./.
====================
AB/LS
-/:
OBJECTIVE/NN
:/:
The/DT
NF-kappa/NN
B/Rel/NN
family/NN
of/IN
transcription/NN
factors/NNS
regulates/VBZ
the/DT
expression/NN
of/IN
many/JJ
genes/NNS
involved/VBN
in/IN
the/DT
immune/JJ
or/CC
inflammatory/JJ
response/NN
at/IN
the/DT
transcriptional/JJ
level/NN
./.
====================
The/DT
aim/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
determine/VB
whether/IN
distinctive/JJ
patterns/NNS
of/IN
NF-kappa/NN
B/NN
activation/NN
are/VBP
seen/VBN
in/IN
different/JJ
forms/NNS
of/IN
joint/NN
disease/NN
./.
====================
METHODS/NNS
:/:
The/DT
DNA/NN
binding/NN
activity/NN
of/IN
these/DT
nucleoproteins/NNS
was/VBD
examined/VBN
in/IN
purified/VBN
synovial/JJ
and/CC
peripheral/JJ
T/NN
cells/NNS
from/IN
patients/NNS
with/IN
various/JJ
chronic/JJ
rheumatic/JJ
diseases/NNS
(/(
12/CD
:/:
four/CD
with/IN
rheumatoid/JJ
arthritis/NN
;/:
five/CD
with/IN
spondyloarthropathies/NNS
;/:
and/CC
three/CD
with/IN
osteoarthritis/NN
)/)
./.
====================
RESULTS/NNS
:/:
Electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
disclosed/VBD
two/CD
specific/JJ
complexes/NNS
bound/VBN
to/TO
a/DT
NF-kappa/NN
B/NN
specific/JJ
32P-labelled/JJ
oligonucleotide/NN
in/IN
nucleoproteins/NNS
extracted/VBN
from/IN
purified/VBN
T/NN
cells/NNS
isolated/VBN
from/IN
synovial/JJ
fluid/NN
and/CC
peripheral/JJ
blood/NN
of/IN
patients/NNS
with/IN
rheumatoid/JJ
arthritis/NN
./.
====================
The/DT
complexes/NNS
consisted/VBD
of/IN
p50/p50/NN
homodimers/NNS
and/CC
p50/p65/NN
heterodimers/NNS
./.
====================
Increased/VBN
NF-kappa/NN
B/NN
binding/NN
to/TO
DNA/NN
in/IN
synovial/JJ
T/NN
cells/NNS
was/VBD
observed/VBN
relative/JJ
to/TO
peripheral/JJ
T/NN
cells/NNS
./.
====================
In/IN
non-rheumatoid/JJ
arthritis/NN
,/,
binding/NN
of/IN
NF-kappa/NN
B/NN
in/IN
synovial/JJ
T/NN
cells/NNS
was/VBD
exclusively/RB
mediated/VBN
by/IN
p50/p50/NN
homodimers/NNS
./.
====================
CONCLUSION/NN
:/:
Overall/RB
,/,
the/DT
results/NNS
suggest/VBP
that/IN
NF-kappa/NN
B/NN
may/MD
play/VB
a/DT
central/JJ
part/NN
in/IN
the/DT
activation/NN
of/IN
infiltrating/VBG
T/NN
cells/NNS
in/IN
chronic/JJ
rheumatoid/JJ
arthritis/NN
./.
====================
The/DT
activation/NN
of/IN
this/DT
nuclear/JJ
factor/NN
is/VBZ
qualitatively/RB
different/JJ
in/IN
rheumatoid/JJ
synovial/JJ
T/NN
cells/NNS
to/TO
that/DT
in/IN
other/JJ
forms/NNS
of/IN
non-rheumatoid/JJ
arthritis/NN
(/(
for/IN
example/NN
,/,
osteoarthritis/NN
,/,
spondyloarthropathies/NNS
)/)
./.
====================
UI/LS
-/:
99097163/CD
====================
TI/LS
-/:
X/NN
chromosome/NN
inactivation/NN
patterns/NNS
in/IN
normal/JJ
females/NNS
./.
====================
AB/LS
-/:
Since/IN
one/CD
of/IN
the/DT
two/CD
X/NN
chromosomes/NNS
is/VBZ
randomly/RB
inactivated/VBN
at/IN
an/DT
early/JJ
stage/NN
of/IN
female/NN
embryonic/JJ
development/NN
,/,
X-linked/JJ
markers/NNS
have/VBP
been/VBN
used/VBN
to/TO
study/VB
the/DT
origin/NN
and/CC
development/NN
of/IN
various/JJ
neoplastic/JJ
disorders/NNS
in/IN
affected/VBN
heterozygous/JJ
women/NNS
;/:
clonality/NN
assays/NNS
have/VBP
provided/VBN
a/DT
useful/JJ
tool/NN
to/TO
the/DT
understanding/NN
of/IN
the/DT
mechanisms/NNS
underlying/VBG
the/DT
development/NN
of/IN
neoplasia/NN
./.
====================
Recently/RB
,/,
a/DT
technique/NN
of/IN
clonal/JJ
analysis/NN
has/VBZ
been/VBN
devised/VBN
that/WDT
takes/VBZ
advantage/NN
of/IN
a/DT
highly/RB
polymorphic/JJ
short/JJ
tandem/JJ
repeat/NN
within/IN
the/DT
X-linked/JJ
human/JJ
androgen/NN
receptor/NN
(/(
AR/NN
)/)
gene/NN
,/,
resulting/VBG
in/IN
a/DT
heterozygosity/NN
rate/NN
approaching/VBG
90/CD
%/NN
./.
====================
The/DT
rapid/JJ
expansion/NN
of/IN
the/DT
number/NN
of/IN
women/NNS
now/RB
suitable/JJ
for/IN
X/NN
inactivation/NN
analysis/NN
has/VBZ
however/RB
given/VBN
rise/NN
to/TO
new/JJ
controversies/NNS
,/,
one/CD
of/IN
the/DT
more/RBR
troublesome/JJ
being/VBG
the/DT
possibility/NN
of/IN
a/DT
modification/NN
of/IN
the/DT
pattern/NN
of/IN
X- chromosome/NN
inactivation/NN
pattern/NN
in/IN
blood/NN
cells/NNS
of/IN
elderly/JJ
women/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
we/PRP
analyze/VBP
with/IN
the/DT
AR/NN
assay/NN
a/DT
group/NN
of/IN
166/CD
healthy/JJ
females/NNS
aged/JJ
between/IN
8/CD
and/CC
94/CD
years/NNS
,/,
with/IN
no/DT
history/NN
of/IN
genetic/JJ
or/CC
neoplastic/JJ
familial/JJ
disorders/NNS
./.
====================
We/PRP
failed/VBD
to/TO
find/VB
any/DT
correlation/NN
between/IN
age/NN
and/CC
X- chromosome/NN
inactivation/NN
pattern/NN
(/(
r/NN
=/JJ
0.17/CD
)/)
,/,
even/RB
subdividing/VBG
the/DT
subjects/NNS
in/IN
different/JJ
age/NN
groups/NNS
according/VBG
to/TO
the/DT
criteria/NNS
used/VBN
by/IN
other/JJ
researchers/NNS
,/,
and/CC
therefore/RB
reaffirm/VBP
that/IN
,/,
when/WRB
tested/VBN
for/IN
with/IN
well-standardized/JJ
and/CC
accurate/JJ
criteria/NNS
,/,
extremely/RB
unbalanced/JJ
inactivation/NN
of/IN
the/DT
X/NN
chromosome/NN
is/VBZ
a/DT
truly/RB
uncommon/JJ
phenomenon/NN
in/IN
normal/JJ
women/NNS
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
99077519/CD
====================
TI/LS
-/:
The/DT
role/NN
of/IN
Stat4/NN
in/IN
species-specific/JJ
regulation/NN
of/IN
Th/NN
cell/NN
development/NN
by/IN
type/NN
I/CD
IFNs/NNS
./.
====================
AB/LS
-/:
Type/NN
I/CD
IFNs/NNS
(/(
IFN-alpha/beta/NN
)/)
,/,
in/IN
addition/NN
to/TO
IL-12/NN
,/,
have/VBP
been/VBN
shown/VBN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
differentiation/NN
of/IN
human/JJ
,/,
but/CC
not/RB
mouse/NN
,/,
Th/NN
cells/NNS
./.
====================
We/PRP
show/VBP
here/RB
that/IN
IFN-alpha/beta/NN
act/VBP
directly/RB
on/IN
human/JJ
T/NN
cells/NNS
to/TO
drive/VB
Th1/NN
development/NN
,/,
bypassing/VBG
the/DT
need/NN
for/IN
IL-12-induced/JJ
signaling/NN
,/,
whereas/IN
IFN-alpha/NN
can/MD
not/RB
substitute/VB
IL-12/NN
for/IN
mouse/NN
Th1/NN
development/NN
./.
====================
The/DT
molecular/JJ
basis/NN
for/IN
this/DT
species/NNS
specificity/NN
is/VBZ
that/IN
IFN-alpha/beta/NN
activate/VBP
Stat4/NN
in/IN
differentiating/VBG
human/JJ
,/,
but/CC
not/RB
mouse/NN
,/,
Th/NN
cells/NNS
./.
====================
Unlike/IN
IL-12/NN
,/,
which/WDT
acts/VBZ
only/RB
on/IN
Th1/NN
cells/NNS
,/,
IFN-alpha/beta/NN
can/MD
activate/VB
Stat4/NN
not/RB
only/RB
in/IN
human/JJ
Th1/NN
,/,
but/CC
also/RB
in/IN
Th2/NN
cells/NNS
./.
====================
However/RB
,/,
restimulation/NN
of/IN
human/JJ
Th2/NN
lines/NNS
and/CC
clones/NNS
in/IN
the/DT
presence/NN
of/IN
IFN-alpha/NN
does/VBZ
not/RB
induce/VB
the/DT
production/NN
of/IN
IFN-gamma/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
activation/NN
of/IN
Stat4/NN
,/,
which/WDT
is/VBZ
necessary/JJ
for/IN
the/DT
differentiation/NN
of/IN
naive/JJ
T/NN
cells/NNS
into/IN
polarized/VBN
Th1/NN
cells/NNS
,/,
is/VBZ
not/RB
sufficient/JJ
to/TO
induce/VB
phenotype/NN
reversal/NN
of/IN
human/JJ
Th2/NN
cells/NNS
./.
====================
UI/LS
-/:
99070060/CD
====================
TI/LS
-/:
Molecular/JJ
cloning/NN
of/IN
FKHRL1P2/NN
,/,
a/DT
member/NN
of/IN
the/DT
developmentally/RB
regulated/VBN
fork/NN
head/NN
domain/NN
transcription/NN
factor/NN
family/NN
./.
====================
AB/LS
-/:
Here/RB
we/PRP
report/VBP
the/DT
expression/NN
of/IN
a/DT
fork/NN
head/NN
domain/NN
protein/NN
in/IN
human/JJ
T/NN
helper/NN
cells/NNS
./.
====================
We/PRP
cloned/VBD
and/CC
characterized/VBD
a/DT
fork/NN
head/NN
cDNA/NN
from/IN
human/JJ
T/NN
helper/NN
cell/NN
mRNA/NN
using/VBG
differential/JJ
display/NN
RT-PCR/NN
./.
====================
The/DT
cDNA/NN
contains/VBZ
a/DT
546-nucleotide/JJ
(/(
nt/NN
)/)
open/JJ
reading/NN
frame/NN
(/(
ORF/NN
)/)
that/WDT
codes/VBZ
for/IN
the/DT
carboxyl-terminal/JJ
180/CD
amino/NN
acids/NNS
(/(
aa/NNS
)/)
of/IN
the/DT
recently/RB
identified/VBN
fkhrl1/NN
gene/NN
./.
====================
This/DT
ORF/NN
does/VBZ
not/RB
contain/VB
the/DT
characteristic/JJ
DNA-binding/JJ
domain/NN
found/VBN
in/IN
members/NNS
of/IN
the/DT
forkhead/NN
protein/NN
family/NN
./.
====================
In-vitro/FW
transcription/translation/NN
of/IN
this/DT
cDNA/NN
expressed/VBD
a/DT
protein/NN
of/IN
approximately/RB
20/CD
kDa/NN
./.
====================
We/PRP
have/VBP
generated/VBN
antibodies/NNS
that/WDT
specifically/RB
immunoprecipitated/VBD
the/DT
in-vitro-translated/JJ
20-kDa/JJ
protein/NN
./.
====================
This/DT
antibody/NN
also/RB
recognizes/VBZ
in/IN
human/JJ
T/NN
lymphocytes/NNS
a/DT
70-kDa/JJ
protein/NN
corresponding/VBG
in/IN
size/NN
to/TO
that/DT
predicted/VBN
for/IN
the/DT
fkhrl1/NN
gene/NN
product/NN
./.
====================
The/DT
mRNA/NN
levels/NNS
for/IN
fkhrl1/NN
is/VBZ
elevated/JJ
in/IN
T/NN
helper-induced/JJ
lymphocytes/NNS
in/IN
comparison/NN
to/TO
PHA-stimulated/JJ
T/NN
lymphocytes/NNS
./.
====================
Further/JJ
characterization/NN
of/IN
FKHRL1/NN
and/CC
its/PRP$
related/JJ
family/NN
members/NNS
should/MD
shed/VB
light/NN
on/IN
the/DT
transcriptional/JJ
mechanisms/NNS
of/IN
this/DT
fork/NN
head/NN
gene/NN
subfamily/NN
and/CC
their/PRP$
role/NN
in/IN
T/NN
helper/NN
cell/NN
differentiation/NN
and/CC
regulation/NN
of/IN
cell/NN
growth/NN
./.
====================
UI/LS
-/:
99060929/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
Th1/NN
development/NN
mediated/VBN
by/IN
GATA-3/NN
through/IN
an/DT
IL-4-independent/JJ
mechanism/NN
./.
====================
AB/LS
-/:
Recently/RB
,/,
the/DT
transcription/NN
factor/NN
GATA-3/NN
was/VBD
shown/VBN
to/TO
be/VB
selectively/RB
expressed/VBN
in/IN
Th2/NN
but/CC
not/RB
Th1/NN
cells/NNS
and/CC
to/TO
augment/VB
Th2-specific/JJ
cytokines/NNS
./.
====================
Here/RB
,/,
we/PRP
show/VBP
that/IN
loss/NN
of/IN
GATA-3/NN
expression/NN
by/IN
developing/VBG
Th1/NN
cells/NNS
requires/VBZ
IL-12/NN
signaling/NN
through/IN
Stat4/NN
and/CC
does/VBZ
not/RB
simply/RB
result/VB
from/IN
an/DT
absence/NN
of/IN
IL-4/NN
./.
====================
Moreover/RB
,/,
we/PRP
demonstrate/VBP
a/DT
novel/JJ
role/NN
for/IN
GATA-3/NN
in/IN
directly/RB
repressing/VBG
Th1/NN
development/NN
distinct/JJ
from/IN
its/PRP$
positive/JJ
actions/NNS
on/IN
Th2-specific/JJ
cytokines/NNS
./.
====================
GATA-3/NN
inhibits/VBZ
Th1/NN
cytokines/NNS
by/IN
a/DT
cell-intrinsic/JJ
mechanism/NN
that/WDT
is/VBZ
not/RB
dependent/JJ
on/IN
IL-4/NN
and/CC
that/WDT
may/MD
involve/VB
repression/NN
of/IN
IL-12/NN
signaling/NN
./.
====================
Thus/RB
,/,
GATA-3/NN
expression/NN
and/CC
IL-12/NN
signaling/NN
are/VBP
mutually/RB
antagonistic/JJ
,/,
which/WDT
facilitates/VBZ
rapid/JJ
dominance/NN
of/IN
one/CD
pathway/NN
during/IN
early/JJ
Th/NN
development/NN
,/,
producing/VBG
a/DT
stable/JJ
divergence/NN
in/IN
cytokine/NN
profiles/NNS
./.
====================
UI/LS
-/:
99058080/CD
====================
TI/LS
-/:
Conserved/VBN
elements/NNS
containing/VBG
NF-E2/NN
and/CC
tandem/JJ
GATA/NN
binding/NN
sites/NNS
are/VBP
required/VBN
for/IN
erythroid-specific/JJ
chromatin/NN
structure/NN
reorganization/NN
within/IN
the/DT
human/JJ
beta-globin/NN
locus/NN
control/NN
region/NN
./.
====================
AB/LS
-/:
Proper/JJ
expression/NN
of/IN
the/DT
genes/NNS
of/IN
the/DT
human/JJ
beta-globin/NN
gene/NN
locus/NN
requires/VBZ
the/DT
associated/VBN
locus/NN
control/NN
region/NN
(/(
LCR/NN
)/)
./.
====================
Structurally/RB
,/,
the/DT
LCR/NN
is/VBZ
defined/VBN
by/IN
the/DT
presence/NN
of/IN
four/CD
domains/NNS
of/IN
erythroid-specific/JJ
chromatin/NN
structure/NN
./.
====================
These/DT
domains/NNS
,/,
which/WDT
have/VBP
been/VBN
characterized/VBN
as/IN
DNase/NN
I/CD
hypersensitive/JJ
sites/NNS
(/(
HSs/NNS
)/)
,/,
comprise/VBP
the/DT
active/JJ
elements/NNS
of/IN
the/DT
LCR/NN
./.
====================
The/DT
major/JJ
focus/NN
of/IN
this/DT
research/NN
is/VBZ
to/TO
define/VB
the/DT
cis -acting/JJ
elements/NNS
which/WDT
are/VBP
required/VBN
for/IN
the/DT
formation/NN
of/IN
these/DT
domains/NNS
of/IN
unique/JJ
chromatin/NN
structure/NN
./.
====================
Our/PRP$
previous/JJ
investigations/NNS
on/IN
the/DT
formation/NN
of/IN
LCR/NN
HS4/NN
demonstrated/VBD
that/IN
NF-E2/NN
and/CC
tandem/JJ
,/,
inverted/JJ
GATA/NN
binding/NN
sites/NNS
are/VBP
required/VBN
for/IN
the/DT
formation/NN
of/IN
the/DT
native/JJ
HS/NN
./.
====================
Similarly/RB
arranged/VBN
NF-E2/NN
and/CC
tandem/JJ
GATA/NN
sites/NNS
are/VBP
present/JJ
within/IN
the/DT
core/NN
regions/NNS
of/IN
the/DT
other/JJ
human/JJ
LCR/NN
HSs/NNS
and/CC
are/VBP
evolutionarily/RB
conserved/VBN
./.
====================
Using/VBG
site-directed/JJ
mutagenesis/NN
of/IN
human/JJ
HSs/NNS
2/CD
and/CC
3/CD
we/PRP
have/VBP
tested/VBN
the/DT
hypothesis/NN
that/IN
these/DT
NF-E2/NN
and/CC
GATA/NN
sites/NNS
are/VBP
common/JJ
requirements/NNS
for/IN
the/DT
formation/NN
of/IN
all/DT
LCR/NN
HSs/NNS
./.
====================
We/PRP
find/VBP
that/IN
mutation/NN
of/IN
these/DT
elements/NNS
,/,
and/CC
particularly/RB
the/DT
GATA/NN
elements/NNS
,/,
results/VBZ
in/IN
a/DT
decrease/NN
or/CC
complete/JJ
loss/NN
of/IN
DNase/NN
I/CD
hypersensitivity/NN
./.
====================
These/DT
data/NNS
imply/VBP
the/DT
presence/NN
of/IN
common/JJ
structural/JJ
elements/NNS
within/IN
the/DT
core/NN
of/IN
each/DT
LCR/NN
HS/NN
which/WDT
are/VBP
required/VBN
for/IN
erythroid-specific/JJ
chromatin/NN
structure/NN
reorganization/NN
./.
====================
UI/LS
-/:
99047534/CD
====================
TI/LS
-/:
Cloning/NN
of/IN
ARE-containing/JJ
genes/NNS
by/IN
AU-motif-directed/JJ
display/NN
./.
====================
AB/LS
-/:
A/DT
procedure/NN
suitable/JJ
for/IN
cloning/VBG
labile/JJ
mRNAs/NNS
that/WDT
contain/VBP
AU/NN
motifs/NNS
is/VBZ
presented/VBN
(/(
AU-DD/NN
)/)
./.
====================
These/DT
motifs/NNS
are/VBP
regulatory/JJ
sequences/NNS
within/IN
the/DT
so-called/JJ
AU-rich/JJ
elements/NNS
(/(
AREs/NNS
)/)
often/RB
found/VBN
in/IN
3'/JJ
untranslated/JJ
regions/NNS
of/IN
genes/NNS
such/JJ
as/IN
cytokines/NNS
,/,
proto-oncogenes/NNS
,/,
and/CC
transcription/NN
factors/NNS
./.
====================
AU-DD/NN
is/VBZ
an/DT
AU-motif-directed/JJ
differential/JJ
display/NN
that/WDT
permits/VBZ
the/DT
identification/NN
of/IN
ARE-containing/JJ
genes/NNS
differentially/RB
expressed/VBN
after/IN
cell/NN
activation/NN
./.
====================
It/PRP
has/VBZ
been/VBN
applied/VBN
to/TO
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
a/DT
T/NN
cell/NN
clone/NN
to/TO
isolate/VB
59/CD
cDNA/NN
fragments/NNS
associated/VBN
to/TO
activation/NN
./.
====================
Fourteen/CD
percent/NN
of/IN
isolated/VBN
fragments/NNS
belong/VBP
to/TO
already/RB
known/JJ
genes/NNS
that/WDT
certainly/RB
are/VBP
cytokines/NNS
and/CC
transduction/transcription/NN
factors/NNS
./.
====================
The/DT
remaining/VBG
86/CD
%/NN
correspond/VBP
to/TO
unknown/JJ
genes/NNS
of/IN
which/WDT
92/CD
%/NN
have/VBP
been/VBN
confirmed/VBN
to/TO
be/VB
differentially/RB
expressed/VBN
./.
====================
These/DT
data/NNS
demonstrate/VBP
the/DT
efficiency/NN
of/IN
the/DT
system/NN
and/CC
support/VBP
the/DT
notion/NN
that/IN
numerous/JJ
genes/NNS
falling/VBG
into/IN
those/DT
categories/NNS
remain/VBP
unidentified/JJ
and/CC
that/IN
they/PRP
can/MD
be/VB
cloned/VBN
by/IN
this/DT
method/NN
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
99034460/CD
====================
TI/LS
-/:
Transcription/NN
factor/NN
NF-kappaB/NN
regulation/NN
of/IN
renal/JJ
fibrosis/NN
during/IN
ureteral/JJ
obstruction/NN
./.
====================
AB/LS
-/:
Irrespective/RB
of/IN
the/DT
etiology/NN
,/,
many/JJ
kidney/NN
diseases/NNS
result/VBP
in/IN
inflammation/NN
and/CC
fibrosis/NN
of/IN
the/DT
tubulointerstitium/NN
,/,
with/IN
the/DT
subsequent/JJ
loss/NN
of/IN
renal/JJ
function/NN
./.
====================
To/TO
initiate/VB
any/DT
disease/NN
process/NN
or/CC
for/IN
any/DT
disease/NN
process/NN
to/TO
progress/VB
,/,
there/EX
must/MD
be/VB
changes/NNS
in/IN
the/DT
transcription/NN
of/IN
genes/NNS
within/IN
the/DT
affected/VBN
tissue/NN
./.
====================
The/DT
nuclear/JJ
factor-kappa/NN
B/NN
(/(
NF-kappaB/NN
)/)
family/NN
of/IN
transcription/NN
factors/NNS
regulates/VBZ
genes/NNS
involved/VBN
in/IN
inflammation/NN
,/,
cell/NN
proliferation/NN
,/,
and/CC
cell/NN
differentiation/NN
./.
====================
This/DT
review/NN
discusses/VBZ
the/DT
NF-kappaB/NN
transcription/NN
factor/NN
family/NN
in/IN
general/JJ
and/CC
the/DT
association/NN
of/IN
NF-kappaB/NN
activation/NN
with/IN
cellular/molecular/JJ
events/NNS
of/IN
renal/JJ
inflammation/NN
and/CC
fibrosis/NN
====================
UI/LS
-/:
97358652/CD
====================
TI/LS
-/:
Expression/NN
of/IN
transcription/NN
factors/NNS
during/IN
sodium/NN
phenylacetate/NN
induced/VBD
erythroid/JJ
differentiation/NN
in/IN
K562/NN
cells/NNS
./.
====================
AB/LS
-/:
During/IN
15/CD
days/NNS
of/IN
treatment/NN
of/IN
K562/NN
cells/NNS
with/IN
sodium/NN
phenylacetate/NN
,/,
we/PRP
observed/VBD
an/DT
increase/NN
in/IN
the/DT
cellular/JJ
hemoglobin/NN
concentration/NN
with/IN
a/DT
similar/JJ
increase/NN
in/IN
the/DT
expression/NN
of/IN
gamma-globin/NN
mRNA/NN
./.
====================
Morphological/JJ
studies/NNS
demonstrated/VBD
characteristic/JJ
features/NNS
of/IN
erythroid/JJ
differentiation/NN
and/CC
maturation/NN
./.
====================
At/IN
the/DT
same/JJ
time/NN
there/EX
was/VBD
no/DT
change/NN
in/IN
the/DT
level/NN
of/IN
expression/NN
of/IN
the/DT
cell/NN
surface/NN
antigenes/NNS
CD33/NN
,/,
CD34/NN
,/,
CD45/NN
,/,
CD71/NN
and/CC
glycophorin/NN
A/NN
./.
====================
Likewise/RB
,/,
the/DT
level/NN
of/IN
expression/NN
of/IN
the/DT
erythroid/JJ
transcription/NN
factors/NNS
GATA-1/NN
,/,
GATA-2/NN
,/,
NF-E2/NN
,/,
SCL/NN
and/CC
RBTN2/NN
,/,
all/DT
expressed/VBN
in/IN
untreated/JJ
K562/NN
cells/NNS
,/,
did/VBD
not/RB
increase/VB
during/IN
sodium/NN
phenylacetate/NN
induced/JJ
erythroid/JJ
differentiation/NN
./.
====================
The/DT
expression/NN
of/IN
the/DT
nuclear/JJ
factors/NNS
Evi-1/NN
and/CC
c-myb/NN
,/,
known/VBN
to/TO
inhibit/VB
erythroid/JJ
differentiation/NN
,/,
did/VBD
not/RB
decrease/VB
./.
====================
We/PRP
conclude/VBP
that/IN
sodium/NN
phenylacetate/NN
treatment/NN
of/IN
K562/NN
cells/NNS
increases/VBZ
gamma-globin/NN
mRNA/NN
and/CC
induces/VBZ
cell/NN
maturation/NN
as/IN
judged/VBN
by/IN
morphology/NN
without/IN
affecting/VBG
the/DT
expression/NN
of/IN
the/DT
erythroid/JJ
transcription/NN
factors/NNS
,/,
some/DT
of/IN
which/WDT
are/VBP
known/VBN
to/TO
be/VB
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
beta-like/JJ
globin/NN
genes/NNS
./.
====================
UI/LS
-/:
97155934/CD
====================
TI/LS
-/:
Isolation/NN
of/IN
a/DT
B-cell-specific/JJ
promoter/NN
for/IN
the/DT
human/JJ
class/NN
II/CD
transactivator/NN
./.
====================
AB/LS
-/:
The/DT
class/NN
II/CD
transactivator/NN
(/(
CIITA/NN
)/)
is/VBZ
essential/JJ
for/IN
the/DT
expression/NN
of/IN
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
class/NN
II/CD
antigens/NNS
./.
====================
The/DT
tissular/JJ
patterns/NNS
of/IN
CIITA/NN
and/CC
MHC/NN
class/NN
II/CD
gene/NN
expression/NN
are/VBP
tightly/RB
correlated/VBN
:/:
CIITA/NN
mRNA/NN
is/VBZ
highly/RB
expressed/VBN
in/IN
B/NN
cells/NNS
,/,
and/CC
is/VBZ
induced/VBN
by/IN
interferon/NN
gamma/NN
(/(
IFN-gamma/NN
)/)
in/IN
macrophage/NN
and/CC
epithelial/JJ
cell/NN
lines/NNS
./.
====================
We/PRP
first/RB
isolated/VBD
two/CD
overlapping/VBG
cosmids/NNS
encoding/VBG
human/JJ
CIITA/NN
which/WDT
,/,
when/WRB
co-transfected/VBN
,/,
are/VBP
able/JJ
to/TO
restore/VB
MHC/NN
class/NN
II/CD
expression/NN
in/IN
a/DT
B-lymphoblastoid/JJ
cell/NN
line/NN
(/(
B-LCL/NN
)/)
defective/JJ
for/IN
CIITA/NN
./.
====================
Subsequently/RB
,/,
a/DT
1.8/CD
kilobase/NN
(/(
kb/NN
)/)
fragment/NN
of/IN
the/DT
CIITA/NN
promoter/NN
was/VBD
isolated/VBN
and/CC
sequenced/VBN
./.
====================
A/DT
motif/NN
presenting/VBG
a/DT
strong/JJ
similarity/NN
to/TO
an/DT
initiator/NN
was/VBD
detected/VBN
,/,
as/RB
well/RB
as/IN
putative/JJ
binding/VBG
sites/NNS
for/IN
Sp1/NN
,/,
GATA-2/NN
,/,
LyF-1/NN
,/,
ets-1/NN
,/,
AP1/NN
,/,
and/CC
MZF1/NN
transcription/NN
factors/NNS
,/,
and/CC
two/CD
GAS/NN
motifs/NNS
./.
====================
When/WRB
introduced/VBN
in/IN
front/NN
of/IN
a/DT
luciferase/NN
reporter/NN
gene/NN
,/,
this/DT
promoter/NN
is/VBZ
able/JJ
to/TO
direct/VB
a/DT
high/JJ
luciferase/NN
activity/NN
in/IN
a/DT
human/JJ
B-LCL/NN
./.
====================
In/IN
contrast/NN
,/,
luciferase/NN
expression/NN
was/VBD
not/RB
stimulated/VBN
after/IN
IFN-gamma/NN
treatment/NN
when/WRB
the/DT
construct/NN
was/VBD
transfected/VBN
in/IN
macrophage/NN
or/CC
in/IN
epithelial/JJ
cell/NN
lines/NNS
./.
====================
However/RB
,/,
an/DT
induction/NN
of/IN
the/DT
human/JJ
CIITA/NN
gene/NN
was/VBD
observed/VBN
in/IN
mouse/NN
macrophage/NN
and/CC
fibrosarcoma/NN
cell/NN
lines/NNS
,/,
when/WRB
the/DT
cells/NNS
were/VBD
transfected/VBN
with/IN
a/DT
cosmid/NN
containing/VBG
the/DT
human/JJ
CIITA/NN
gene/NN
,/,
but/CC
lacking/VBG
the/DT
1.8/CD
kb/NN
promoter/NN
described/VBN
above/RB
./.
====================
Taken/VBN
together/RB
,/,
these/DT
data/NNS
suggest/VBP
the/DT
existence/NN
of/IN
an/DT
intragenic/JJ
promoter/NN
driving/VBG
an/DT
IFN-gamma-inducible/JJ
expression/NN
of/IN
CIITA/NN
./.
====================
UI/LS
-/:
99149869/CD
====================
TI/LS
-/:
Phenotypic/JJ
and/CC
functional/JJ
studies/NNS
of/IN
leukocytes/NNS
in/IN
human/JJ
endometrium/NN
and/CC
endometriosis/NN
./.
====================
AB/LS
-/:
The/DT
aetiology/NN
of/IN
endometriosis/NN
,/,
a/DT
common/JJ
and/CC
disabling/VBG
disorder/NN
,/,
is/VBZ
presently/RB
unknown/JJ
,/,
although/IN
immune/JJ
dysfunction/NN
could/MD
allow/VB
ectopic/JJ
endometrial/JJ
fragments/NNS
to/TO
survive/VB
outside/IN
the/DT
uterine/JJ
cavity/NN
./.
====================
These/DT
studies/NNS
investigate/VBP
the/DT
relationship/NN
between/IN
leukocyte/NN
populations/NNS
,/,
steroid/NN
hormone/NN
receptor/NN
expression/NN
,/,
proliferative/JJ
activity/NN
,/,
bcl-2/NN
expression/NN
and/CC
apoptosis/NN
in/IN
eutopic/JJ
and/CC
ectopic/JJ
endometrium/NN
from/IN
women/NNS
with/IN
endometriosis/NN
or/CC
adenomyosis/NN
at/IN
different/JJ
phases/NNS
of/IN
the/DT
menstrual/JJ
cycle/NN
./.
====================
Significantly/RB
increased/VBN
oestrogen/NN
receptor/NN
expression/NN
,/,
bcl-2/NN
expression/NN
and/CC
numbers/NNS
of/IN
CD8+/JJ
leukocytes/NNS
were/VBD
found/VBN
in/IN
ectopic/JJ
compared/VBN
with/IN
eutopic/JJ
endometrium/NN
in/IN
endometriosis/NN
,/,
and/CC
CD56+/JJ
endometrial/JJ
granulated/JJ
lymphocytes/NNS
(/(
eGLs/NNS
)/)
were/VBD
significantly/RB
reduced/VBN
in/IN
ectopic/JJ
endometrium/NN
./.
====================
Apoptotic/JJ
cells/NNS
were/VBD
rarely/RB
found/VBN
in/IN
control/JJ
and/CC
subject/NN
endometria/NN
./.
====================
In/IN
contrast/NN
with/IN
endometriosis/NN
,/,
adenomyotic/JJ
lesions/NNS
showed/VBD
identical/JJ
steroid/NN
hormone/NN
receptor/NN
expression/NN
,/,
proliferative/JJ
activity/NN
,/,
bcl-2/NN
expression/NN
and/CC
leukocyte/NN
subpopulations/NNS
to/TO
eutopic/JJ
endometrium/NN
,/,
indicating/VBG
different/JJ
aetiologies/NNS
for/IN
these/DT
disorders/NNS
./.
====================
The/DT
unusual/JJ
CD56+/JJ
CD16-/JJ
eGLs/NNS
present/JJ
in/IN
large/JJ
numbers/NNS
in/IN
late/JJ
secretory/JJ
phase/NN
eutopic/JJ
endometrium/NN
were/VBD
highly/RB
purified/VBN
(/(
>/JJR
98/CD
%/NN
)/)
by/IN
immunomagnetic/JJ
separation/NN
./.
====================
Except/IN
for/IN
a/DT
negligible/JJ
cytotoxic/JJ
activity/NN
of/IN
eGLs/NNS
from/IN
early/JJ
proliferative/JJ
samples/NNS
,/,
cytotoxic/JJ
activity/NN
of/IN
eGLs/NNS
from/IN
non-pregnant/JJ
endometrium/NN
during/IN
the/DT
menstrual/JJ
cycle/NN
was/VBD
comparable/JJ
with/IN
those/DT
in/IN
peripheral/JJ
blood/NN
,/,
predominantly/RB
CD56+/JJ
CD16+/JJ
natural/JJ
killer/NN
cells/NNS
./.
====================
eGLs/NNS
from/IN
non-pregnant/JJ
endometrium/NN
and/CC
early/JJ
pregnancy/NN
showed/VBD
a/DT
variable/JJ
proliferative/JJ
response/NN
to/TO
5/CD
and/CC
100/CD
U/ml/NN
interleukin-2/NN
over/IN
48-h/JJ
and/CC
120-h/JJ
time/NN
courses/NNS
./.
====================
eGLs/NNS
are/VBP
evidently/RB
functionally/RB
important/JJ
in/IN
the/DT
eutopic/JJ
endometrium/NN
./.
====================
Their/PRP$
absence/NN
in/IN
endometriotic/JJ
lesions/NNS
together/RB
with/IN
increased/VBN
CD+8/JJ
T-cell/NN
numbers/NNS
and/CC
increased/VBN
oestrogen/NN
receptor/NN
and/CC
bcl-2/NN
expression/NN
may/MD
have/VB
significant/JJ
effects/NNS
on/IN
the/DT
development/NN
and/CC
progression/NN
of/IN
endometriosis/NN
./.
====================
UI/LS
-/:
99097447/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
interleukin-1beta/NN
transcription/NN
by/IN
Epstein-Barr/JJ
virus/NN
involves/VBZ
a/DT
number/NN
of/IN
latent/JJ
proteins/NNS
via/IN
their/PRP$
interaction/NN
with/IN
RBP/NN
./.
====================
AB/LS
-/:
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
infects/VBZ
B/NN
cells/NNS
,/,
resulting/VBG
in/IN
the/DT
outgrowth/NN
of/IN
immortalised/JJ
lymphoblastoid/JJ
cell/NN
lines/NNS
(/(
LCLs/NNS
)/)
./.
====================
Here/RB
,/,
we/PRP
demonstrate/VBP
through/IN
the/DT
use/NN
of/IN
intracellular/JJ
staining/NN
that/IN
interleukin-1beta/NN
(/(
IL-1beta/NN
)/)
is/VBZ
expressed/VBN
in/IN
LCLs/NNS
and/CC
investigate/VBP
the/DT
influence/NN
of/IN
the/DT
individual/JJ
latent/JJ
proteins/NNS
on/IN
the/DT
expression/NN
of/IN
IL-1beta/NN
./.
====================
Using/VBG
RT-PCR/NN
,/,
IL-1beta/NN
was/VBD
shown/VBN
to/TO
be/VB
up-regulated/VBN
in/IN
EBV-transformed/JJ
LCLs/NNS
as/RB
well/RB
as/IN
in/IN
group/NN
III/CD
Burkitt/NN
's/POS
lymphoma/NN
(/(
BL/NN
)/)
cell/NN
lines/NNS
,/,
compared/VBN
with/IN
group/NN
I/CD
BL/NN
cell/NN
lines/NNS
./.
====================
The/DT
up-regulation/NN
of/IN
IL-1beta/NN
message/NN
could/MD
be/VB
mediated/VBN
by/IN
the/DT
latent/JJ
membrane/NN
protein-1/NN
,/,
EBV/NN
nuclear/JJ
proteins/NNS
2/CD
,/,
3/CD
,/,
4/CD
,/,
and/CC
6/CD
genes/NNS
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
(/(
EMSAs/NNS
)/)
demonstrated/VBD
that/IN
the/DT
-300/CD
region/NN
of/IN
the/DT
IL-1beta/NN
promoter/NN
,/,
which/WDT
contains/VBZ
a/DT
nuclear/JJ
factor-kappaB/NN
(/(
NF-kappaB/NN
)/)
binding/NN
site/NN
,/,
contained/VBD
a/DT
functional/JJ
RBP/NN
binding/NN
site/NN
./.
====================
Binding/NN
of/IN
RBP/NN
to/TO
this/DT
site/NN
could/MD
be/VB
inhibited/VBN
by/IN
addition/NN
of/IN
EBV/NN
nuclear/JJ
proteins/NNS
3/CD
and/CC
6/CD
,/,
suggesting/VBG
that/IN
these/DT
proteins/NNS
displace/VBP
RBP/NN
from/IN
its/PRP$
recognition/NN
sequence/NN
,/,
removing/VBG
transcriptional/JJ
repression/NN
and/CC
allowing/VBG
gene/NN
transcription/NN
to/TO
occur/VB
./.
====================
In/IN
group/NN
I/CD
BL/NN
cells/NNS
,/,
containing/VBG
low/JJ
levels/NNS
of/IN
NF-kappaB/NN
,/,
only/RB
RBP/NN
binding/NN
was/VBD
observed/VBN
in/IN
EMSAs/NNS
,/,
whereas/IN
NF-kappaB/NN
binding/NN
could/MD
be/VB
demonstrated/VBN
in/IN
EBV-transformed/JJ
B/NN
cell/NN
lines/NNS
containing/VBG
high/JJ
levels/NNS
of/IN
activated/VBN
NF-kappaB/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
expression/NN
of/IN
latent/JJ
membrane/NN
protein-1/NN
led/VBD
to/TO
activation/NN
of/IN
NF-kappaB/NN
that/WDT
was/VBD
capable/JJ
of/IN
binding/VBG
the/DT
IL-1beta/NN
promoter/NN
./.
====================
The/DT
study/NN
demonstrates/VBZ
that/IN
EBV/NN
can/MD
up-regulate/VB
IL-1beta/NN
expression/NN
,/,
possibly/RB
by/IN
using/VBG
RBP/NN
,/,
NF-kappaB/NN
,/,
or/CC
both/DT
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
99077509/CD
====================
TI/LS
-/:
CD27/CD70/NN
interaction/NN
augments/VBZ
IgE/NN
secretion/NN
by/IN
promoting/VBG
the/DT
differentiation/NN
of/IN
memory/NN
B/NN
cells/NNS
into/IN
plasma/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
induction/NN
of/IN
IgE/NN
switching/NN
in/IN
B/NN
cells/NNS
requires/VBZ
several/JJ
signals/NNS
given/VBN
by/IN
cytokines/NNS
and/CC
cell/NN
contact-delivered/JJ
signals/NNS
./.
====================
Here/RB
,/,
we/PRP
investigated/VBD
the/DT
role/NN
of/IN
CD27/CD70/NN
interaction/NN
in/IN
B/NN
cell/NN
IgE/NN
synthesis/NN
./.
====================
The/DT
addition/NN
of/IN
CD27/NN
ligand/NN
(/(
CD70/NN
)/)
transfectants/NNS
to/TO
B/NN
cell/NN
cultures/NNS
increased/VBD
the/DT
IgE/NN
synthesis/NN
synergistically/RB
in/IN
the/DT
presence/NN
of/IN
IL-4/NN
plus/CC
anti-CD40/JJ
mAb/NN
(/(
anti-CD40/NN
)/)
./.
====================
The/DT
effect/NN
of/IN
CD70/NN
transfectants/NNS
was/VBD
dose/NN
dependent/JJ
and/CC
was/VBD
completely/RB
blocked/VBN
by/IN
anti-CD70/JJ
mAb/NN
./.
====================
CD27+/JJ
B/NN
cells/NNS
had/VBD
the/DT
ability/NN
to/TO
produce/VB
IgE/NN
,/,
which/WDT
was/VBD
increased/VBN
by/IN
contact/NN
with/IN
CD70/NN
transfectants/NNS
,/,
whereas/IN
CD27- B/NN
cells/NNS
did/VBD
not/RB
produce/VB
IgE/NN
./.
====================
CD27/CD70/NN
interaction/NN
enhanced/VBD
B/NN
cell/NN
proliferation/NN
in/IN
the/DT
presence/NN
of/IN
IL-4/NN
or/CC
IL-4/NN
plus/CC
anti-CD40/NN
./.
====================
The/DT
augmentation/NN
of/IN
B/NN
cell/NN
proliferation/NN
by/IN
CD70/NN
transfectants/NNS
was/VBD
apparent/JJ
in/IN
CD27+/JJ
B/NN
cells/NNS
,/,
but/CC
was/VBD
mild/JJ
in/IN
CD27- B/NN
cells/NNS
./.
====================
The/DT
helper/NN
activity/NN
for/IN
IgE/NN
synthesis/NN
by/IN
the/DT
CD27/CD70/NN
interaction/NN
did/VBD
not/RB
contribute/VB
to/TO
the/DT
enhancement/NN
of/IN
germline/NN
epsilon/NN
transcripts/NNS
./.
====================
Flow/NN
cytometric/JJ
and/CC
morphological/JJ
analyses/NNS
demonstrated/VBD
that/IN
the/DT
addition/NN
of/IN
CD70/NN
transfectants/NNS
to/TO
B/NN
cell/NN
cultures/NNS
remarkably/RB
promoted/VBD
differentiation/NN
into/IN
plasma/NN
cells/NNS
in/IN
the/DT
presence/NN
of/IN
IL-4/NN
and/CC
CD40/NN
signaling/NN
./.
====================
Finally/RB
,/,
CD27/NN
cross-linking/NN
resulted/VBD
in/IN
the/DT
up-regulation/NN
of/IN
positive/JJ
regulatory/JJ
domain/NN
I-binding/JJ
factor-1/NN
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
findings/NNS
indicate/VBP
that/IN
signaling/NN
via/IN
CD27/NN
on/IN
B/NN
cells/NNS
induces/VBZ
IgE/NN
synthesis/NN
,/,
in/IN
cooperation/NN
with/IN
IL-4/NN
and/CC
CD40/NN
signaling/NN
,/,
by/IN
promoting/VBG
the/DT
generation/NN
of/IN
plasma/NN
cells/NNS
through/IN
up-regulation/NN
of/IN
positive/JJ
regulatory/JJ
domain/NN
I-binding/JJ
factor-1/NN
./.
====================
UI/LS
-/:
99074502/CD
====================
TI/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
type-1/NN
transcription/NN
:/:
role/NN
of/IN
the/DT
5'-untranslated/JJ
leader/NN
region/NN
(/(
review/NN
)/)
./.
====================
AB/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
type-1/NN
(/(
HIV-1/NN
)/)
transcription/NN
is/VBZ
dependent/JJ
on/IN
the/DT
interaction/NN
of/IN
host-cell/JJ
transcription/NN
factors/NNS
with/IN
cis-regulatory/JJ
DNA/NN
elements/NNS
within/IN
the/DT
viral/JJ
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
./.
====================
Much/JJ
attention/NN
has/VBZ
focused/VBN
on/IN
the/DT
series/NN
of/IN
sequence/NN
elements/NNS
upstream/JJ
of/IN
the/DT
transcriptional/JJ
initiation/NN
site/NN
in/IN
the/DT
U3/NN
region/NN
of/IN
the/DT
LTR/NN
including/VBG
the/DT
Sp1/NN
and/CC
NF-kappaB/NN
binding/NN
sites/NNS
./.
====================
Recent/JJ
studies/NNS
,/,
however/RB
,/,
demonstrate/VBP
that/IN
the/DT
transcribed/VBN
5'-untranslated/JJ
leader/NN
region/NN
(/(
5'-UTR/NN
)/)
also/RB
contains/VBZ
important/JJ
transcriptional/JJ
elements/NNS
./.
====================
These/DT
regulatory/JJ
elements/NNS
situated/JJ
downstream/JJ
of/IN
transcription/NN
interact/VBP
with/IN
constitutive/JJ
and/CC
inducible/JJ
transcription/NN
factors/NNS
,/,
mediate/VBP
transmission/NN
of/IN
cellular/JJ
activation/NN
signals/NNS
,/,
and/CC
are/VBP
important/JJ
for/IN
efficient/JJ
HIV-1/NN
transcription/NN
and/CC
replication/NN
./.
====================
The/DT
5'-UTR/NN
contains/VBZ
binding/VBG
sites/NNS
for/IN
the/DT
transcription/NN
factors/NNS
AP-1/NN
,/,
NF-kappaB/NN
,/,
NF-AT/NN
,/,
IRF/NN
,/,
and/CC
Sp1/NN
./.
====================
Mutations/NNS
in/IN
these/DT
binding/VBG
sites/NNS
can/MD
interfere/VB
with/IN
the/DT
viral/JJ
response/NN
to/TO
cell/NN
activation/NN
signals/NNS
,/,
decrease/VB
LTR/NN
transcription/NN
,/,
and/CC
inhibit/VB
viral/JJ
replication/NN
./.
====================
The/DT
5'-UTR/NN
also/RB
interacts/VBZ
with/IN
a/DT
specific/JJ
nucleosome/NN
that/WDT
is/VBZ
rapidly/RB
displaced/VBN
during/IN
transcriptional/JJ
activation/NN
of/IN
the/DT
latent/JJ
provirus/NN
./.
====================
We/PRP
propose/VBP
that/IN
the/DT
inducible/JJ
transcription/NN
factor/NN
binding/NN
sites/NNS
in/IN
the/DT
5'-UTR/NN
comprise/VBP
a/DT
downstream/JJ
enhancer/NN
domain/NN
that/WDT
can/MD
function/VB
independent/JJ
of/IN
,/,
or/CC
in/IN
concert/NN
with/IN
,/,
the/DT
LTR/NN
promoter/NN
to/TO
rapidly/RB
increase/VB
latent/JJ
proviral/JJ
transcription/NN
in/IN
response/NN
to/TO
cell/NN
activation/NN
signals/NNS
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
describe/VBP
the/DT
host-cell/JJ
transcription/NN
factors/NNS
that/WDT
interact/VBP
with/IN
the/DT
5'-UTR/NN
and/CC
discuss/VBP
their/PRP$
role/NN
in/IN
the/DT
transcriptional/JJ
regulation/NN
of/IN
HIV-1/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
99060916/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
PAK/NN
activation/NN
and/CC
the/DT
T/NN
cell/NN
cytoskeleton/NN
by/IN
the/DT
linker/NN
protein/NN
SLP-76/NN
./.
====================
AB/LS
-/:
Tyrosine/NN
phosphorylation/NN
of/IN
linker/NN
proteins/NNS
enables/VBZ
the/DT
T/NN
cell/NN
antigen/NN
receptor/NN
(/(
TCR/NN
)/)
-associated/JJ
protein/NN
tyrosine/NN
kinases/NNS
to/TO
phosphorylate/VB
and/CC
regulate/VB
effector/NN
molecules/NNS
that/WDT
generate/VBP
second/JJ
messengers/NNS
./.
====================
We/PRP
demonstrate/VBP
here/RB
that/IN
the/DT
SLP-76/NN
linker/NN
protein/NN
interacts/VBZ
with/IN
both/CC
nck/NN
,/,
an/DT
adaptor/NN
protein/NN
,/,
and/CC
Vav/NN
,/,
a/DT
guanine/JJ
nucleotide/NN
exchange/NN
factor/NN
for/IN
Rho-family/JJ
GTPases/NNS
./.
====================
The/DT
assembly/NN
of/IN
this/DT
tri-molecular/JJ
complex/NN
permits/VBZ
the/DT
activated/VBN
Rho-family/JJ
GTPases/NNS
to/TO
regulate/VB
target/NN
effectors/NNS
that/WDT
interact/VBP
through/IN
nck/NN
./.
====================
In/IN
turn/NN
,/,
assembly/NN
of/IN
this/DT
complex/NN
mediates/VBZ
the/DT
enzymatic/JJ
activation/NN
of/IN
the/DT
p21-activated/JJ
protein/NN
kinase/NN
1/CD
and/CC
facilitates/VBZ
actin/NN
polymerization/NN
./.
====================
Hence/RB
,/,
phosphorylation/NN
of/IN
linker/NN
proteins/NNS
not/RB
only/RB
bridges/VBZ
the/DT
TCR-associated/JJ
PTK/NN
,/,
ZAP-70/NN
,/,
with/IN
downstream/JJ
effector/NN
proteins/NNS
,/,
but/CC
also/RB
provides/VBZ
a/DT
scaffold/NN
to/TO
integrate/VB
distinct/JJ
signaling/VBG
complexes/NNS
to/TO
regulate/VB
T/NN
cell/NN
function/NN
./.
====================
UI/LS
-/:
99057540/CD
====================
TI/LS
-/:
Interleukin-12/NN
expression/NN
in/IN
B/NN
cells/NNS
by/IN
transformation/NN
with/IN
Epstein-Barr/JJ
virus/NN
./.
====================
AB/LS
-/:
Although/IN
interleukin/NN
(/(
IL/NN
)/)
-12/CD
was/VBD
originally/RB
purified/VBN
from/IN
an/DT
Epstein-Barr/JJ
(/(
EBV/NN
)/)
-transformed/JJ
B/NN
cell/NN
line/NN
and/CC
the/DT
high/JJ
correlation/NN
of/IN
EBV/NN
infection/NN
and/CC
IL-12/NN
expression/NN
has/VBZ
been/VBN
suggested/VBN
,/,
no/DT
study/NN
has/VBZ
reported/VBN
whether/IN
EBV/NN
infection/NN
is/VBZ
directly/RB
linked/VBN
to/TO
IL-12/NN
expression/NN
./.
====================
To/TO
address/VB
this/DT
issue/NN
,/,
we/PRP
have/VBP
investigated/VBN
IL-12/NN
expression/NN
in/IN
B/NN
cells/NNS
during/IN
in/FW
vitro/FW
transformation/NN
with/IN
EBV/NN
./.
====================
Human/JJ
peripheral/JJ
B/NN
cells/NNS
became/VBD
capable/JJ
of/IN
constitutively/RB
producing/VBG
p40/NN
by/IN
in/FW
vitro/FW
transformation/NN
with/IN
EBV/NN
,/,
coincident/JJ
with/IN
the/DT
expression/NN
of/IN
latent/JJ
membrane/NN
protein/NN
1/CD
(/(
LMP1/NN
)/)
of/IN
EBV/NN
./.
====================
These/DT
B/NN
cells/NNS
expressed/VBD
p40/NN
and/CC
p35/NN
mRNA/NN
,/,
and/CC
phorbol/NN
myristate/NN
acetate/NN
(/(
PMA/NN
)/)
stimulation/NN
strongly/RB
enhanced/VBD
p40/NN
and/CC
p70/NN
production/NN
./.
====================
Furthermore/RB
,/,
transfection/NN
with/IN
LMP1/NN
expression/NN
vector/NN
into/IN
a/DT
human/JJ
B/NN
lymphoma/NN
cell/NN
line/NN
,/,
Daudi/NN
,/,
led/VBD
to/TO
p40/NN
production/NN
with/IN
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
-kappaB/NN
activation/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
transformation/NN
of/IN
primary/JJ
B/NN
cells/NNS
with/IN
EBV/NN
induces/VBZ
IL-12/NN
expression/NN
potentially/RB
through/IN
LMP1/NN
expression/NN
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
99047525/CD
====================
TI/LS
-/:
The/DT
human/JJ
gene/NN
encoding/VBG
the/DT
lectin-type/JJ
oxidized/VBN
LDL/NN
receptor/NN
(/(
OLR1/NN
)/)
is/VBZ
a/DT
novel/JJ
member/NN
of/IN
the/DT
natural/JJ
killer/NN
gene/NN
complex/NN
with/IN
a/DT
unique/JJ
expression/NN
profile/NN
./.
====================
AB/LS
-/:
LOX-1/NN
is/VBZ
an/DT
endothelial/JJ
receptor/NN
for/IN
oxidized/VBN
low-density/JJ
lipoprotein/NN
that/WDT
plays/VBZ
essential/JJ
roles/NNS
in/IN
atherogenesis/NN
./.
====================
LOX-1/NN
has/VBZ
the/DT
highest/JJS
homology/NN
with/IN
C-type/JJ
lectin/NN
receptors/NNS
expressed/VBN
on/IN
natural/JJ
killer/NN
cells/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
cloned/VBD
and/CC
characterized/VBD
the/DT
human/JJ
LOX-1/NN
gene/NN
(/(
HGMW-approved/JJ
symbol/NN
OLR1/NN
)/)
./.
====================
The/DT
gene/NN
structure/NN
of/IN
LOX-1/NN
resembles/VBZ
that/DT
of/IN
the/DT
natural/JJ
killer/NN
cell/NN
receptors/NNS
./.
====================
Fluorescence/NN
in/FW
situ/FW
hybridization/NN
and/CC
analyses/NNS
of/IN
a/DT
yeast/NN
artificial/JJ
chromosome/NN
contig/NN
revealed/VBD
that/IN
the/DT
human/JJ
LOX-1/NN
gene/NN
is/VBZ
located/JJ
in/IN
the/DT
natural/JJ
killer/NN
gene/NN
complex/NN
on/IN
chromosome/NN
12p12-p13/NN
,/,
where/WRB
the/DT
genes/NNS
of/IN
the/DT
natural/JJ
killer/NN
cell/NN
receptors/NNS
cluster/VBP
./.
====================
In/IN
contrast/NN
,/,
the/DT
expression/NN
pattern/NN
of/IN
LOX-1/NN
is/VBZ
different/JJ
from/IN
that/DT
of/IN
the/DT
natural/JJ
killer/NN
cell/NN
receptors/NNS
;/:
LOX-1/NN
is/VBZ
expressed/VBN
in/IN
vascular-rich/JJ
organs/NNS
,/,
but/CC
not/RB
in/IN
lymphocytes/NNS
./.
====================
A/DT
1753-bp/JJ
fragment/NN
of/IN
the/DT
5'/JJ
flanking/JJ
region/NN
of/IN
the/DT
LOX-1/NN
gene/NN
had/VBD
a/DT
functional/JJ
promoter/NN
activity/NN
./.
====================
This/DT
region/NN
contains/VBZ
binding/VBG
sites/NNS
for/IN
several/JJ
transcription/NN
factors/NNS
,/,
including/VBG
the/DT
STAT/NN
family/NN
and/CC
NF-IL6/NN
,/,
and/CC
the/DT
expression/NN
of/IN
LOX-1/NN
was/VBD
upregulated/VBN
by/IN
several/JJ
cytokines/NNS
./.
====================
These/DT
results/NNS
demonstrate/VBP
that/IN
the/DT
human/JJ
LOX-1/NN
gene/NN
is/VBZ
a/DT
new/JJ
member/NN
of/IN
the/DT
natural/JJ
killer/NN
gene/NN
complex/NN
with/IN
a/DT
unique/JJ
expression/NN
profile/NN
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
99032541/CD
====================
TI/LS
-/:
Transcriptional/JJ
regulation/NN
of/IN
the/DT
beta-casein/NN
gene/NN
by/IN
cytokines/NNS
:/:
cross-talk/NN
between/IN
STAT5/NN
and/CC
other/JJ
signaling/VBG
molecules/NNS
./.
====================
AB/LS
-/:
The/DT
beta-casein/NN
promoter/NN
has/VBZ
been/VBN
widely/RB
used/VBN
to/TO
monitor/VB
the/DT
activation/NN
of/IN
STAT/NN
(/(
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
)/)
5/CD
since/IN
STAT5/NN
was/VBD
originally/RB
found/VBN
as/IN
a/DT
mediator/NN
of/IN
PRL-inducible/JJ
beta-casein/NN
expression/NN
./.
====================
However/RB
,/,
not/RB
only/RB
is/VBZ
expression/NN
of/IN
the/DT
beta-casein/NN
gene/NN
regulated/VBN
by/IN
STAT5/NN
but/CC
it/PRP
is/VBZ
also/RB
affected/VBN
by/IN
other/JJ
molecules/NNS
such/JJ
as/IN
glucocorticoid/NN
and/CC
Ras/NN
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
describe/VBP
the/DT
transcriptional/JJ
regulation/NN
of/IN
the/DT
beta-casein/NN
gene/NN
by/IN
cytokines/NNS
in/IN
T/NN
cells/NNS
./.
====================
We/PRP
have/VBP
found/VBN
that/IN
the/DT
beta-casein/NN
gene/NN
is/VBZ
expressed/VBN
in/IN
a/DT
cytotoxic/JJ
T/NN
cell/NN
line/NN
,/,
CTLL-2/NN
,/,
in/IN
response/NN
to/TO
interleukin-2/NN
(/(
IL-2/NN
)/)
,/,
which/WDT
activates/VBZ
STAT5/NN
./.
====================
While/IN
IL-4/NN
does/VBZ
not/RB
activate/VB
STAT5/NN
,/,
it/PRP
induces/VBZ
expression/NN
of/IN
STAT5-regulated/JJ
genes/NNS
in/IN
CTLL-2/NN
,/,
i.e./FW
beta-casein/NN
,/,
a/DT
cytokine-inducible/JJ
SH2-containing/JJ
protein/NN
(/(
CIS/NN
)/)
,/,
and/CC
oncostatin/NN
M/NN
(/(
OSM/NN
)/)
,/,
suggesting/VBG
that/IN
STAT6/NN
activated/VBN
by/IN
IL-4/NN
substitutes/VBZ
for/IN
the/DT
function/NN
of/IN
STAT5/NN
in/IN
T/NN
cells/NNS
./.
====================
IL-2-induced/JJ
beta-casein/NN
expression/NN
was/VBD
enhanced/VBN
by/IN
dexamethasone/NN
,/,
and/CC
this/DT
synergistic/JJ
effect/NN
of/IN
Dexamethasone/NN
requires/VBZ
the/DT
sequence/NN
between/IN
-155/CD
and/CC
-193/CD
in/IN
the/DT
beta-casein/NN
promoter/NN
./.
====================
Coincidentally/RB
,/,
a/DT
deletion/NN
of/IN
this/DT
region/NN
enhanced/VBD
the/DT
IL-2-induced/JJ
expression/NN
of/IN
beta-casein/NN
./.
====================
Expression/NN
of/IN
an/DT
active/JJ
form/NN
of/IN
Ras/NN
,/,
Ras(G12V)/NN
,/,
suppressed/VBD
the/DT
IL-2-induced/JJ
beta-casein/NN
and/CC
OSM/NN
gene/NN
expression/NN
,/,
and/CC
the/DT
negative/JJ
effect/NN
of/IN
Ras/NN
is/VBZ
mediated/VBN
by/IN
the/DT
region/NN
between/IN
-105/CD
and/CC
-193/CD
in/IN
the/DT
beta-casein/NN
promoter/NN
./.
====================
In/IN
apparent/JJ
contradiction/NN
,/,
expression/NN
of/IN
a/DT
dominant/JJ
negative/JJ
form/NN
of/IN
Ras/NN
,/,
RasN17/NN
,/,
also/RB
inhibited/VBD
IL-2-induced/JJ
activation/NN
of/IN
the/DT
promoter/NN
containing/VBG
the/DT
minimal/JJ
beta-casein/NN
STAT5/NN
element/NN
as/RB
well/RB
as/IN
the/DT
promoters/NNS
of/IN
CIS/NN
and/CC
OSM/NN
./.
====================
In/IN
addition/NN
,/,
Ras(G12V)/NN
complemented/VBD
signaling/NN
by/IN
an/DT
erythropoietin/NN
receptor/NN
mutant/NN
defective/JJ
in/IN
Ras/NN
activation/NN
and/CC
augmented/VBD
the/DT
activation/NN
of/IN
the/DT
beta-casein/NN
promoter/NN
by/IN
the/DT
mutant/JJ
erythropoietin/NN
receptor/NN
signaling/NN
,/,
suggesting/VBG
a/DT
possible/JJ
role/NN
of/IN
Ras/NN
in/IN
Stat5-mediated/JJ
gene/NN
expression/NN
./.
====================
These/DT
results/NNS
collectively/RB
reveal/VBP
a/DT
complex/JJ
interaction/NN
of/IN
STAT5/NN
with/IN
other/JJ
signaling/NN
pathways/NNS
and/CC
illustrate/VBP
that/IN
regulation/NN
of/IN
gene/NN
expression/NN
requires/VBZ
integration/NN
of/IN
opposing/JJ
signals/NNS
====================
UI/LS
-/:
99015774/CD
====================
TI/LS
-/:
GATA-3/NN
represses/VBZ
gp91phox/NN
gene/NN
expression/NN
in/IN
eosinophil-committed/JJ
HL-60-C15/NN
cells/NNS
./.
====================
AB/LS
-/:
To/TO
study/VB
the/DT
regulatory/JJ
mechanism/NN
of/IN
gp91phox/NN
gene/NN
expression/NN
in/IN
eosinophils/NNS
,/,
we/PRP
transiently/RB
transfected/VBD
eosinophil-committed/JJ
HL-60-C15/NN
cells/NNS
with/IN
gp91phox/NN
promoter/NN
constructs/NNS
,/,
and/CC
identified/VBD
a/DT
negative/JJ
element/NN
from/IN
bp/NN
-267/CD
to/TO
-246/CD
of/IN
the/DT
gp91phox/NN
gene/NN
,/,
the/DT
deletion/NN
of/IN
which/WDT
caused/VBD
an/DT
83/CD
%/NN
increase/NN
in/IN
promoter/NN
activity/NN
./.
====================
Electrophoresis/NN
mobility/NN
shift/NN
assays/NNS
demonstrated/VBD
GATA-3/NN
binds/VBZ
to/TO
the/DT
GATA/NN
consensus/NN
site/NN
from/IN
bp/NN
-256/CD
to/TO
-250/CD
./.
====================
An/DT
81/CD
%/NN
increment/NN
in/IN
promoter/NN
activity/NN
was/VBD
obtained/VBN
when/WRB
a/DT
mutation/NN
was/VBD
introduced/VBN
in/IN
the/DT
GATA-3/NN
binding/NN
site/NN
of/IN
the/DT
bp/NN
-267/CD
to/TO
+12/CD
construct/NN
,/,
which/WDT
is/VBZ
comparable/JJ
to/TO
that/DT
of/IN
the/DT
bp/NN
-245/CD
to/TO
+12/CD
construct/NN
./.
====================
We/PRP
therefore/RB
conclude/VBP
that/IN
GATA-3/NN
specifically/RB
binding/VBG
to/TO
the/DT
GATA/NN
site/NN
negatively/RB
regulates/VBZ
the/DT
expression/NN
of/IN
the/DT
gene/NN
in/IN
HL-60-C15/NN
cells/NNS
./.
====================
UI/LS
-/:
99008506/CD
====================
TI/LS
-/:
Uncoupling/VBG
activation-dependent/JJ
HS1/NN
phosphorylation/NN
from/IN
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
transcriptional/JJ
activation/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
:/:
differential/JJ
signaling/NN
through/IN
CD3/NN
and/CC
the/DT
costimulatory/JJ
receptors/NNS
CD2/NN
and/CC
CD28/NN
./.
====================
AB/LS
-/:
CD3/NN
,/,
CD2/NN
,/,
and/CC
CD28/NN
are/VBP
functionally/RB
distinct/JJ
receptors/NNS
on/IN
T/NN
lymphocytes/NNS
./.
====================
Engagement/NN
of/IN
any/DT
of/IN
these/DT
receptors/NNS
induces/VBZ
the/DT
rapid/JJ
tyrosine/NN
phosphorylation/NN
of/IN
a/DT
shared/JJ
group/NN
of/IN
intracellular/JJ
signaling/NN
proteins/NNS
,/,
including/VBG
Vav/NN
,/,
Cbl/NN
,/,
p85/NN
phosphoinositide/NN
3-kinase/NN
,/,
and/CC
the/DT
Src/NN
family/NN
kinases/NNS
Lck/NN
and/CC
Fyn/NN
./.
====================
Ligation/NN
of/IN
CD3/NN
also/RB
induces/VBZ
the/DT
tyrosine/NN
phosphorylation/NN
of/IN
HS1/NN
,/,
a/DT
75-kDa/JJ
hematopoietic/JJ
cell-specific/JJ
intracellular/JJ
signaling/NN
protein/NN
of/IN
unknown/JJ
function/NN
./.
====================
We/PRP
have/VBP
examined/VBN
changes/NNS
in/IN
HS1/NN
phosphorylation/NN
after/IN
differential/JJ
stimulation/NN
of/IN
CD3/NN
,/,
CD2/NN
,/,
and/CC
CD28/NN
to/TO
elucidate/VB
its/PRP$
role/NN
in/IN
T/NN
cells/NNS
and/CC
to/TO
further/RB
delineate/VB
the/DT
signaling/NN
pathways/NNS
recruited/VBN
by/IN
these/DT
receptors/NNS
./.
====================
Unlike/IN
ligation/NN
of/IN
CD3/NN
,/,
stimulation/NN
with/IN
anti-CD28/JJ
mAb/NN
or/CC
CHO/NN
cells/NNS
expressing/VBG
the/DT
CD28/NN
ligands/NNS
CD80/NN
or/CC
CD86/NN
did/VBD
not/RB
lead/VB
to/TO
tyrosine/NN
phosphorylation/NN
of/IN
HS1/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
./.
====================
Additionally/RB
,/,
no/DT
tyrosine/NN
phosphorylation/NN
of/IN
HS1/NN
was/VBD
induced/VBN
by/IN
mitogenic/JJ
pairs/NNS
of/IN
anti-CD2/JJ
mAbs/NNS
capable/JJ
of/IN
activating/VBG
the/DT
transcription/NN
factor/NN
NFAT/NN
(/(
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
)/)
./.
====================
Costimulation/NN
through/IN
CD28/NN
and/or/CC
CD2/NN
did/VBD
not/RB
modulate/VB
the/DT
CD3-dependent/JJ
phosphorylation/NN
of/IN
HS1/NN
./.
====================
In/FW
vivo/FW
studies/NNS
indicated/VBD
that/IN
CD3-induced/JJ
HSI/NN
phosphorylation/NN
was/VBD
dependent/JJ
upon/IN
both/CC
the/DT
Src/NN
family/NN
tyrosine/NN
kinase/NN
Lck/NN
and/CC
the/DT
tyrosine/NN
phosphatase/NN
CD45/NN
,/,
did/VBD
not/RB
require/VB
MEK1/NN
kinase/NN
activity/NN
,/,
and/CC
was/VBD
regulated/VBN
by/IN
protein/NN
kinase/NN
C/NN
activation/NN
./.
====================
Thus/RB
,/,
although/IN
CD3/NN
,/,
CD28/NN
,/,
and/CC
CD2/NN
activate/VBP
many/JJ
of/IN
the/DT
same/JJ
signaling/NN
molecules/NNS
,/,
they/PRP
differed/VBD
in/IN
their/PRP$
capacity/NN
to/TO
induce/VB
the/DT
tyrosine/NN
phosphorylation/NN
of/IN
HSI/NN
./.
====================
Furthermore/RB
,/,
activation-dependent/JJ
tyrosine/NN
phosphorylation/NN
of/IN
HS1/NN
was/VBD
not/RB
required/VBN
for/IN
NFAT/NN
transcriptional/JJ
activation/NN
./.
====================
UI/LS
-/:
99003459/CD
====================
TI/LS
-/:
c-fos/NN
and/CC
c-jun/NN
mRNA/NN
expression/NN
in/IN
activated/VBN
cord/NN
and/CC
adult/JJ
lymphocytes/NNS
:/:
an/DT
analysis/NN
by/IN
Northern/NN
hybridization/NN
./.
====================
AB/LS
-/:
BACKGROUND/NN
AND/CC
OBJECTIVES/NNS
:/:
To/TO
further/RB
analyze/VB
the/DT
neonatal/JJ
immune/JJ
response/NN
to/TO
an/DT
antigenic/JJ
challenge/NN
such/JJ
as/IN
blood/NN
transfusion/NN
,/,
c-fos/NN
and/CC
c-jun/NN
mRNA/NN
expression/NN
were/VBD
analyzed/VBN
in/IN
twelve/CD
in-vitro-stimulated/JJ
normal/JJ
cord/NN
blood/NN
and/CC
ten/CD
in-vitro-stimulated/JJ
normal/JJ
adult/JJ
peripheral/JJ
blood/NN
lymphocyte/NN
samples/NNS
./.
====================
MATERIALS/NNS
AND/CC
METHODS/NNS
:/:
Lymphocyte/NN
samples/NNS
were/VBD
stimulated/VBN
by/IN
either/CC
the/DT
mitogen/NN
phytohemagglutinin/NN
(/(
PHA/NN
)/)
or/CC
the/DT
monoclonal/JJ
antibody/NN
alphaCD3/NN
./.
====================
Proliferation/NN
rate/NN
and/CC
Northern/NN
blot/NN
hybridization/NN
were/VBD
employed/VBN
./.
====================
RESULTS/NNS
:/:
Cord/NN
lymphocytes/NNS
revealed/VBD
a/DT
greater/JJR
proliferation/NN
rate/NN
with/IN
PHA/NN
and/CC
alphaCD3/NN
than/IN
adult/JJ
lymphocytes/NNS
(/(
p/NN
=/JJ
0.0081/CD
and/CC
0.0023/CD
,/,
respectively/RB
)/)
./.
====================
In/IN
addition/NN
,/,
Northern/NN
blot/NN
analysis/NN
of/IN
cord/NN
and/CC
adult/JJ
samples/NNS
revealed/VBD
similar/JJ
maximal/JJ
increases/NNS
in/IN
c-fos/NN
(/(
99+/-15/CD
and/CC
126+/-11/CD
%/NN
,/,
p/NN
=/JJ
0.0126/CD
)/)
and/CC
c-jun/NN
(/(
123+/-9/CD
and/CC
185+/-38/CD
%/NN
,/,
p/NN
=/JJ
0.0291/CD
)/)
mRNA/NN
expression/NN
,/,
respectively/RB
,/,
as/RB
early/RB
as/IN
15/CD
min/NN
post-alphaCD3/JJ
stimulation/NN
./.
====================
Adult/JJ
lymphocytes/NNS
showed/VBD
an/DT
equivalent/JJ
increase/NN
in/IN
mRNA/NN
expression/NN
of/IN
c-fos/NN
and/CC
c-jun/NN
(/(
140+/-25/CD
and/CC
155+/-31/CD
%/NN
)/)
at/IN
30/CD
min/NN
post-PHA/JJ
stimulation/NN
,/,
while/IN
cord/NN
lymphocyte/NN
maximum/NN
c-fos/NN
and/CC
c-jun/NN
expression/NN
(/(
82+/-6/CD
and/CC
142+/-12/CD
%/NN
)/)
occurred/VBD
at/IN
15/CD
min/NN
post-PHA/JJ
stimulation/NN
(/(
c-fos/NN
,/,
p/NN
=/JJ
0.0354/CD
;/:
c-jun/NN
,/,
p/NN
=/JJ
0.0112/CD
)/)
./.
====================
CONCLUSION/NN
:/:
Although/IN
cord/JJ
lymphocyte/NN
proliferation/NN
rates/NNS
were/VBD
significantly/RB
greater/JJR
than/IN
those/DT
of/IN
adult/JJ
lymphocytes/NNS
following/VBG
stimulation/NN
,/,
lymphocyte/NN
activation/NN
,/,
as/IN
analyzed/VBN
by/IN
c-fos/NN
and/CC
c-jun/NN
mRNA/NN
expression/NN
,/,
appears/VBZ
similar/JJ
in/IN
both/CC
cord/NN
and/CC
adult/JJ
samples/NNS
./.
====================
We/PRP
conclude/VBP
that/IN
cord/NN
lymphocyte/NN
activation/NN
exhibits/VBZ
an/DT
adult-type/JJ
profile/NN
./.
====================
UI/LS
-/:
98438540/CD
====================
TI/LS
-/:
Fcgamma/NN
receptor-mediated/JJ
mitogen-activated/JJ
protein/NN
kinase/NN
activation/NN
in/IN
monocytes/NNS
is/VBZ
independent/JJ
of/IN
Ras/NN
./.
====================
AB/LS
-/:
Receptors/NNS
for/IN
the/DT
Fc/NN
portion/NN
of/IN
immunoglobulin/NN
molecules/NNS
(/(
FcR/NNS
)/)
present/JJ
on/IN
leukocyte/NN
cell/NN
membranes/NNS
mediate/VBP
a/DT
large/JJ
number/NN
of/IN
cellular/JJ
responses/NNS
that/WDT
are/VBP
very/RB
important/JJ
in/IN
host/NN
defense/NN
,/,
including/VBG
phagocytosis/NN
,/,
cell/NN
cytotoxicity/NN
,/,
production/NN
and/CC
secretion/NN
of/IN
inflammatory/JJ
mediators/NNS
,/,
and/CC
modulation/NN
of/IN
the/DT
immune/JJ
response/NN
./.
====================
Cross-linking/NN
of/IN
FcR/NNS
with/IN
immune/JJ
complexes/NNS
leads/VBZ
,/,
first/RB
to/TO
activation/NN
of/IN
protein-tyrosine/JJ
kinases/NNS
./.
====================
The/DT
molecular/JJ
events/NNS
that/WDT
follow/VBP
and/CC
that/WDT
transduce/VBP
signals/NNS
from/IN
these/DT
receptors/NNS
to/TO
the/DT
nucleus/NN
are/VBP
still/RB
poorly/RB
defined/VBN
./.
====================
We/PRP
have/VBP
investigated/VBN
the/DT
signal/NN
transduction/NN
pathway/NN
from/IN
Fc/NN
receptors/NNS
that/WDT
leads/VBZ
to/TO
gene/NN
activation/NN
and/CC
production/NN
of/IN
cytokines/NNS
in/IN
monocytes/NNS
./.
====================
Cross-linking/NN
of/IN
FcR/NNS
,/,
on/IN
the/DT
THP-1/NN
monocytic/JJ
cell/NN
line/NN
,/,
by/IN
immune/JJ
complexes/NNS
resulted/VBD
in/IN
both/CC
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappaB/NN
and/CC
interleukin/NN
1/CD
production/NN
./.
====================
These/DT
responses/NNS
were/VBD
completely/RB
blocked/VBN
by/IN
tyrosine/NN
kinase/NN
inhibitors/NNS
./.
====================
In/IN
contrast/NN
,/,
expression/NN
of/IN
dominant/JJ
negative/JJ
mutants/NNS
of/IN
Ras/NN
and/CC
Raf-1/NN
,/,
in/IN
these/DT
cells/NNS
,/,
did/VBD
not/RB
have/VB
any/DT
effect/NN
on/IN
FcR-mediated/JJ
nuclear/JJ
factor/NN
activation/NN
,/,
suggesting/VBG
that/IN
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
(/(
MAPK/NN
)/)
signaling/NN
pathway/NN
was/VBD
not/RB
used/VBN
by/IN
these/DT
receptors/NNS
./.
====================
However/RB
,/,
MAPK/NN
activation/NN
was/VBD
easily/RB
detected/VBN
by/IN
in/FW
vitro/FW
kinase/NN
assays/NNS
,/,
after/IN
FcR/NNS
cross-linking/NN
with/IN
immune/JJ
complexes/NNS
./.
====================
Using/VBG
the/DT
specific/JJ
MAPK/extracellular/JJ
signal-regulated/JJ
kinase/NN
kinase/NN
(/(
MAPK/NN
kinase/NN
)/)
inhibitor/NN
PD98059/NN
,/,
we/PRP
found/VBD
that/IN
MAPK/NN
activation/NN
is/VBZ
necessary/JJ
for/IN
FcR-dependent/JJ
activation/NN
of/IN
the/DT
nuclear/JJ
factor/NN
NF-kappaB/NN
./.
====================
These/DT
results/NNS
strongly/RB
suggest/VBP
that/IN
the/DT
signaling/NN
pathway/NN
from/IN
Fc/NN
receptors/NNS
leading/VBG
to/TO
expression/NN
of/IN
different/JJ
genes/NNS
important/JJ
to/TO
leukocyte/NN
biology/NN
,/,
initiates/VBZ
with/IN
tyrosine/NN
kinases/NNS
and/CC
requires/VBZ
MAPK/NN
activation/NN
;/:
but/CC
in/IN
contrast/NN
to/TO
other/JJ
tyrosine/NN
kinase/NN
receptors/NNS
,/,
FcR-mediated/JJ
MAPK/NN
activation/NN
does/VBZ
not/RB
involve/VB
Ras/NN
and/CC
Raf/NN
./.
====================
UI/LS
-/:
98426236/CD
====================
TI/LS
-/:
BCL-6/NN
mutations/NNS
in/IN
normal/JJ
germinal/JJ
center/NN
B/NN
cells/NNS
:/:
evidence/NN
of/IN
somatic/JJ
hypermutation/NN
acting/VBG
outside/IN
Ig/NN
loci/NNS
./.
====================
AB/LS
-/:
The/DT
molecular/JJ
mechanism/NN
involved/VBN
in/IN
the/DT
process/NN
of/IN
antigen-driven/JJ
somatic/JJ
hypermutation/NN
of/IN
Ig/NN
genes/NNS
is/VBZ
unknown/JJ
,/,
but/CC
it/PRP
is/VBZ
commonly/RB
believed/VBN
that/IN
this/DT
mechanism/NN
is/VBZ
restricted/JJ
to/TO
the/DT
Ig/NN
loci/NNS
./.
====================
B/NN
cell/NN
lymphomas/NNS
commonly/RB
display/VBP
multiple/JJ
somatic/JJ
mutations/NNS
clustering/VBG
in/IN
the/DT
5'-regulatory/JJ
region/NN
of/IN
BCL-6/NN
,/,
a/DT
proto-oncogene/NN
encoding/VBG
for/IN
a/DT
POZ/Zinc/NN
finger/NN
transcriptional/JJ
repressor/NN
expressed/VBN
in/IN
germinal/JJ
center/NN
(/(
GC/NN
)/)
B/NN
cells/NNS
and/CC
required/VBN
for/IN
GC/NN
formation/NN
./.
====================
To/TO
determine/VB
whether/IN
BCL-6/NN
mutations/NNS
represent/VBP
a/DT
tumor-associated/JJ
phenomenon/NN
or/CC
reflect/VBP
a/DT
physiologic/JJ
mechanism/NN
,/,
we/PRP
screened/VBD
single/JJ
human/JJ
tonsillar/JJ
GC/NN
B/NN
cells/NNS
for/IN
mutations/NNS
occurring/VBG
in/IN
the/DT
BCL-6/NN
5'-noncoding/JJ
region/NN
and/CC
in/IN
the/DT
Ig/NN
variable/JJ
heavy/JJ
chain/NN
sequences/NNS
./.
====================
Thirty/CD
percent/NN
of/IN
GC/NN
B/NN
cells/NNS
,/,
but/CC
not/RB
naive/JJ
B/NN
cells/NNS
,/,
displayed/VBD
mutations/NNS
in/IN
the/DT
742/CD
bp/NN
region/NN
analyzed/VBN
within/IN
the/DT
first/JJ
intron/NN
of/IN
BCL-6/NN
(/(
overall/JJ
frequency/NN
:/:
5/CD
x/CC
10(-4)/bp/NN
)/)
./.
====================
Accordingly/RB
,/,
an/DT
expanded/VBN
survey/NN
in/IN
lymphoid/JJ
malignancies/NNS
showed/VBD
that/IN
BCL-6/NN
mutations/NNS
are/VBP
restricted/JJ
to/TO
B/NN
cell/NN
tumors/NNS
displaying/VBG
GC/NN
or/CC
post-GC/JJ
phenotype/NN
and/CC
carrying/VBG
mutated/VBN
Ig/NN
variable/JJ
heavy/JJ
chain/NN
sequences/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
the/DT
somatic/JJ
hypermutation/NN
mechanism/NN
active/JJ
in/IN
GC/NN
B/NN
cells/NNS
physiologically/RB
targets/VBZ
non-Ig/JJ
sequences/NNS
./.
====================
UI/LS
-/:
98414619/CD
====================
TI/LS
-/:
The/DT
AD1/NN
and/CC
AD2/NN
transactivation/NN
domains/NNS
of/IN
E2A/NN
are/VBP
essential/JJ
for/IN
the/DT
antiapoptotic/JJ
activity/NN
of/IN
the/DT
chimeric/JJ
oncoprotein/NN
E2A-HLF/NN
./.
====================
AB/LS
-/:
The/DT
chimeric/JJ
oncoprotein/NN
E2A-HLF/NN
,/,
generated/VBN
by/IN
the/DT
t(17;19)/NN
chromosomal/JJ
translocation/NN
in/IN
pro-B-cell/JJ
acute/JJ
lymphoblastic/JJ
leukemia/NN
,/,
incorporates/VBZ
the/DT
transactivation/NN
domains/NNS
of/IN
E2A/NN
and/CC
the/DT
basic/JJ
leucine/NN
zipper/NN
(/(
bZIP/NN
)/)
DNA-binding/NN
and/CC
protein/NN
dimerization/NN
domain/NN
of/IN
HLF/NN
(/(
hepatic/JJ
leukemic/JJ
factor/NN
)/)
./.
====================
The/DT
ability/NN
of/IN
E2A-HLF/NN
to/TO
prolong/VB
the/DT
survival/NN
of/IN
interleukin-3/NN
(/(
IL-3/NN
)/)
-dependent/JJ
murine/JJ
pro-B/JJ
cells/NNS
after/IN
IL-3/NN
withdrawal/NN
suggests/VBZ
that/IN
it/PRP
disrupts/VBZ
signaling/NN
pathways/NNS
normally/RB
responsible/JJ
for/IN
cell/NN
suicide/NN
,/,
allowing/VBG
the/DT
cells/NNS
to/TO
accumulate/VB
as/IN
transformed/VBN
lymphoblasts/NNS
./.
====================
To/TO
determine/VB
the/DT
structural/JJ
motifs/NNS
that/WDT
contribute/VBP
to/TO
this/DT
antiapoptotic/JJ
effect/NN
,/,
we/PRP
constructed/VBD
a/DT
panel/NN
of/IN
E2A-HLF/NN
mutants/NNS
and/CC
programmed/VBD
their/PRP$
expression/NN
in/IN
IL-3-dependent/JJ
murine/JJ
pro-B/JJ
cells/NNS
(/(
FL5.12/NN
line/NN
)/)
,/,
using/VBG
a/DT
zinc-inducible/JJ
vector/NN
./.
====================
Neither/RB
the/DT
E12/NN
nor/CC
the/DT
E47/NN
product/NN
of/IN
the/DT
E2A/NN
gene/NN
nor/CC
the/DT
wild-type/JJ
HLF/NN
protein/NN
was/VBD
able/JJ
to/TO
protect/VB
the/DT
cells/NNS
from/IN
apoptosis/NN
induced/VBN
by/IN
IL-3/NN
deprivation/NN
./.
====================
Surprisingly/RB
,/,
different/JJ
combinations/NNS
of/IN
disabling/VBG
mutations/NNS
within/IN
the/DT
HLF/NN
bZIP/NN
domain/NN
had/VBD
little/JJ
effect/NN
on/IN
the/DT
antiapoptotic/JJ
property/NN
of/IN
the/DT
chimeric/JJ
protein/NN
,/,
so/RB
long/RB
as/IN
the/DT
amino-terminal/JJ
portion/NN
of/IN
E2A/NN
remained/VBD
intact/JJ
./.
====================
In/IN
the/DT
context/NN
of/IN
a/DT
bZIP/NN
domain/NN
defective/JJ
in/IN
DNA/NN
binding/NN
,/,
mutants/NNS
retaining/VBG
either/DT
of/IN
the/DT
two/CD
transactivation/NN
domains/NNS
of/IN
E2A/NN
were/VBD
able/JJ
to/TO
extend/VB
cell/NN
survival/NN
after/IN
growth/NN
factor/NN
deprivation/NN
./.
====================
Thus/RB
,/,
the/DT
block/NN
of/IN
apoptosis/NN
imposed/VBN
by/IN
E2A-HLF/NN
in/IN
pro-B/JJ
lymphocytes/NNS
depends/VBZ
critically/RB
on/IN
the/DT
transactivating/JJ
regions/NNS
of/IN
E2A/NN
./.
====================
Since/IN
neither/CC
DNA/NN
binding/NN
nor/CC
protein/NN
dimerization/NN
through/IN
the/DT
bZIP/NN
domain/NN
of/IN
HLF/NN
is/VBZ
required/VBN
for/IN
this/DT
effect/NN
,/,
we/PRP
propose/VBP
mechanisms/NNS
whereby/IN
protein-protein/JJ
interactions/NNS
with/IN
the/DT
amino-terminal/JJ
region/NN
of/IN
E2A/NN
allow/VBP
the/DT
chimera/NN
to/TO
act/VB
as/IN
a/DT
transcriptional/JJ
cofactor/NN
to/TO
alter/VB
the/DT
expression/NN
of/IN
genes/NNS
regulating/VBG
the/DT
apoptotic/JJ
machinery/NN
in/IN
pro-B/JJ
cells/NNS
./.
====================
UI/LS
-/:
98400847/CD
====================
TI/LS
-/:
Induction/NN
of/IN
Mn/NN
SOD/NN
in/IN
human/JJ
monocytes/NNS
without/IN
inflammatory/JJ
cytokine/NN
production/NN
by/IN
a/DT
mutant/JJ
endotoxin/NN
./.
====================
AB/LS
-/:
Endotoxin/NN
selectively/RB
induces/VBZ
monocyte/NN
Mn/NN
superoxide/NN
dismutase/NN
(/(
SOD/NN
)/)
without/IN
affecting/VBG
levels/NNS
of/IN
Cu/NN
,/,
Zn/NN
SOD/NN
,/,
catalase/NN
,/,
or/CC
glutathione/NN
peroxidase/NN
./.
====================
However/RB
,/,
little/JJ
is/VBZ
known/VBN
about/IN
the/DT
structure-activity/JJ
relationship/NN
and/CC
the/DT
mechanism/NN
by/IN
which/WDT
endotoxin/NN
induces/VBZ
Mn/JJ
SOD/NN
./.
====================
In/IN
this/DT
study/NN
we/PRP
demonstrated/VBD
that/IN
a/DT
mutant/JJ
Escherichia/FW
coli/FW
endotoxin/NN
lacking/VBG
myristoyl/NN
fatty/NN
acid/NN
at/IN
the/DT
3'/JJ
R-3-hydroxymyristate/NN
position/NN
of/IN
the/DT
lipid/NN
A/NN
moiety/NN
retained/VBD
its/PRP$
full/JJ
capacity/NN
to/TO
coagulate/VB
Limulus/JJ
amoebocyte/NN
lysate/NN
compared/VBN
with/IN
the/DT
wild-type/JJ
E./FW
coli/FW
endotoxin/NN
and/CC
markedly/RB
stimulated/VBD
the/DT
activation/NN
of/IN
human/JJ
monocyte/NN
nuclear/JJ
factor-kappaB/NN
and/CC
the/DT
induction/NN
of/IN
Mn/NN
SOD/NN
mRNA/NN
and/CC
enzyme/NN
activity/NN
./.
====================
However/RB
,/,
in/IN
contrast/NN
to/TO
the/DT
wild-type/JJ
endotoxin/NN
,/,
it/PRP
failed/VBD
to/TO
induce/VB
significant/JJ
production/NN
of/IN
tumor/NN
necrosis/NN
factor-alpha/NN
and/CC
macrophage/NN
inflammatory/JJ
protein-1alpha/NN
by/IN
monocytes/NNS
and/CC
did/VBD
not/RB
induce/VB
the/DT
phosphorylation/NN
and/CC
nuclear/JJ
translocation/NN
of/IN
mitogen-activated/JJ
protein/NN
kinase/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
1/LS
)/)
lipid/NN
A/NN
myristoyl/NN
fatty/NN
acid/NN
,/,
although/IN
it/PRP
is/VBZ
important/JJ
for/IN
the/DT
induction/NN
of/IN
inflammatory/JJ
cytokine/NN
production/NN
by/IN
human/JJ
monocytes/NNS
,/,
is/VBZ
not/RB
necessary/JJ
for/IN
the/DT
induction/NN
of/IN
Mn/NN
SOD/NN
,/,
2/CD
)/)
endotoxin-mediated/JJ
induction/NN
of/IN
Mn/NN
SOD/NN
and/CC
inflammatory/JJ
cytokines/NNS
are/VBP
regulated/VBN
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
through/IN
different/JJ
signal/NN
transduction/NN
pathways/NNS
,/,
and/CC
3/CD
)/)
failure/NN
of/IN
the/DT
mutant/JJ
endotoxin/NN
to/TO
induce/VB
tumor/NN
necrosis/NN
factor-alpha/NN
production/NN
is/VBZ
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
due/JJ
to/TO
its/PRP$
inability/NN
to/TO
activate/VB
mitogen-activated/JJ
protein/NN
kinase/NN
./.
====================
UI/LS
-/:
98389282/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
the/DT
vitellogenin/NN
gene/NN
B1/NN
promoter/NN
after/IN
transfer/NN
into/IN
hepatocytes/NNS
in/IN
primary/JJ
cultures/NNS
./.
====================
AB/LS
-/:
The/DT
estrogen-dependent/JJ
and/CC
tissue-specific/JJ
regulation/NN
of/IN
the/DT
Xenopus/NN
laevis/NN
vitellogenin/NN
gene/NN
B1/NN
promoter/NN
has/VBZ
been/VBN
studied/VBN
by/IN
lipid-mediated/JJ
DNA/NN
transfer/NN
into/IN
Xenopus/NN
hepatocytes/NNS
in/IN
primary/JJ
culture/NN
./.
====================
Hepatocytes/NNS
achieve/VBP
an/DT
efficient/JJ
hormonal/JJ
control/NN
of/IN
this/DT
promoter/NN
through/IN
a/DT
functional/JJ
interaction/NN
between/IN
the/DT
estrogen/NN
responsive/JJ
elements/NNS
and/CC
a/DT
promoter/NN
proximal/JJ
region/NN
upstream/JJ
of/IN
the/DT
TATA/NN
box/NN
,/,
which/WDT
is/VBZ
characterized/VBN
by/IN
a/DT
high/JJ
density/NN
of/IN
binding/VBG
sites/NNS
for/IN
the/DT
transcription/NN
factors/NNS
CTF/NF-1/NN
,/,
C/EBP/NN
and/CC
HNF3/NN
./.
====================
DNA/NN
accessibility/NN
to/TO
restriction/NN
enzymes/NNS
within/IN
the/DT
chromosomal/JJ
copy/NN
of/IN
the/DT
vitellogenin/NN
gene/NN
B1/NN
promoter/NN
shows/VBZ
that/IN
the/DT
estrogen/NN
responsive/JJ
unit/NN
and/CC
the/DT
promoter/NN
proximal/JJ
region/NN
are/VBP
sensitive/JJ
to/TO
digestion/NN
in/IN
uninduced/JJ
and/CC
estrogen-induced/JJ
hepatocytes/NNS
but/CC
not/RB
in/IN
erythrocyte/NN
nuclei/NNS
./.
====================
Together/RB
,/,
these/DT
findings/NNS
support/VBP
the/DT
notion/NN
that/IN
chromatin/NN
configuration/NN
as/RB
well/RB
as/IN
the/DT
interplay/NN
of/IN
promoter/NN
elements/NNS
mediate/VBP
proper/JJ
hormone-dependent/JJ
and/CC
tissue-specific/JJ
expression/NN
of/IN
the/DT
B1/NN
vitellogenin/NN
gene/NN
./.
====================
UI/LS
-/:
98380997/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
cytokine/NN
differential/JJ
induction/NN
of/IN
STAT/NN
complexes/NNS
in/IN
primary/JJ
human/JJ
T/NN
and/CC
NK/NN
cells/NNS
./.
====================
AB/LS
-/:
Cytokines/NNS
,/,
IL-2/NN
,/,
IL-4/NN
,/,
IL-6/NN
,/,
IL-7/NN
,/,
IL-12/NN
,/,
and/CC
IL-15/NN
are/VBP
key/JJ
regulators/NNS
of/IN
human/JJ
peripheral/JJ
blood/NN
T/NN
and/CC
NK/NN
cell/NN
activation/NN
and/CC
differentiation/NN
but/CC
the/DT
precise/JJ
mechanisms/NNS
that/WDT
give/VBP
rise/VBP
to/TO
their/PRP$
differential/JJ
activities/NNS
within/IN
these/DT
cells/NNS
are/VBP
not/RB
clear/JJ
./.
====================
Recent/JJ
studies/NNS
reveal/VBP
that/IN
a/DT
family/NN
of/IN
transcription/NN
factors/NNS
,/,
signal/NN
transducers/NNS
and/CC
activators/NNS
of/IN
transcription/NN
(/(
STATs/NNS
)/)
directly/RB
mediate/VB
many/JJ
cytokine/NN
signals/NNS
./.
====================
We/PRP
analyzed/VBD
the/DT
activation/NN
of/IN
STATs/NNS
in/IN
primary/JJ
human/JJ
T/NN
and/CC
NK/NN
cells/NNS
by/IN
a/DT
variety/NN
of/IN
specific/JJ
cytokines/NNS
./.
====================
We/PRP
demonstrate/VBP
that/IN
IL-12/NN
induces/VBZ
STAT4/NN
only/RB
in/IN
freshly/RB
isolated/VBN
primary/JJ
NK/NN
cells/NNS
,/,
but/CC
not/RB
in/IN
primary/JJ
T/NN
cells/NNS
,/,
consistent/JJ
with/IN
the/DT
lack/NN
of/IN
the/DT
IL-12/NN
receptor/NN
in/IN
resting/VBG
T/NN
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
IL-4/NN
induces/VBZ
different/JJ
C/NN
epsilon/NN
GAS/NN
DNA-protein/JJ
binding/NN
complexes/NNS
in/IN
both/CC
T/NN
and/CC
NK/NN
cells/NNS
./.
====================
Moreover/RB
,/,
IL-4/NN
costimulation/NN
with/IN
IL-2/NN
or/CC
IL-12/NN
does/VBZ
not/RB
alter/VB
their/PRP$
own/JJ
preferential/JJ
GAS-like/JJ
DNA/NN
binding/NN
patterns/NNS
when/WRB
C/NN
epsilon-/NN
,/,
Fc/NN
gamma/NN
RI-/NN
,/,
and/CC
SIE/NN
GAS/NN
motif/NN
containing/VBG
oligonucleotide/NN
probes/NNS
are/VBP
compared/VBN
,/,
suggesting/VBG
that/IN
induction/NN
of/IN
GAS-like/JJ
DNA-protein/JJ
binding/NN
complexes/NNS
by/IN
IL-2/NN
,/,
IL-4/NN
,/,
and/CC
IL-12/NN
is/VBZ
highly/RB
selective/JJ
and/CC
represents/VBZ
one/CD
important/JJ
factor/NN
in/IN
determining/VBG
specific/JJ
gene/NN
activation/NN
./.
====================
In/IN
addition/NN
,/,
IL-6/NN
and/CC
IL-2/NN
synergistically/RB
induce/VBP
homo-/JJ
and/CC
heterodimerized/JJ
STAT1/NN
alpha/NN
and/CC
STAT3/NN
in/IN
both/CC
NK/NN
and/CC
T/NN
cells/NNS
,/,
consistent/JJ
with/IN
their/PRP$
reported/VBN
synergism/NN
in/IN
modulating/VBG
perforin/NN
gene/NN
expression/NN
./.
====================
We/PRP
further/RB
demonstrated/VBD
that/IN
IL-2/NN
,/,
-7/CD
,/,
and/CC
-15/CD
induce/VBP
multiple/JJ
STAT/NN
proteins/NNS
,/,
including/VBG
STAT5a/NN
,/,
STAT5b/NN
,/,
STAT1/NN
alpha/NN
,/,
STAT3/NN
,/,
and/CC
another/DT
unidentified/JJ
Fc/NN
gamma/NN
RI/NN
GAS/NN
DNA-binding/NN
protein/NN
./.
====================
Finally/RB
,/,
we/PRP
observed/VBD
that/IN
activated/VBN
STAT5a/NN
and/CC
STAT5b/NN
proteins/NNS
form/VBP
distinct/JJ
Fc/NN
gamma/NN
RI/NN
GAS/NN
binding/NN
patterns/NNS
in/IN
T/NN
and/CC
NK/NN
cells/NNS
,/,
suggesting/VBG
that/IN
they/PRP
might/MD
have/VB
different/JJ
roles/NNS
in/IN
gene/NN
regulation/NN
./.
====================
Our/PRP$
data/NNS
provide/VBP
evidence/NN
that/IN
the/DT
differential/JJ
responses/NNS
in/IN
gene/NN
expression/NN
and/CC
cell/NN
activation/NN
seen/VBN
in/IN
primary/JJ
NK/NN
and/CC
T/NN
cells/NNS
on/IN
direct/JJ
stimulation/NN
with/IN
different/JJ
cytokines/NNS
may/MD
be/VB
a/DT
direct/JJ
result/NN
of/IN
distinct/JJ
activation/NN
of/IN
STAT/NN
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
98373989/CD
====================
TI/LS
-/:
A/DT
regulatory/JJ
element/NN
in/IN
the/DT
CD95/NN
(/(
APO-1/Fas/NN
)/)
ligand/NN
promoter/NN
is/VBZ
essential/JJ
for/IN
responsiveness/NN
to/TO
TCR-mediated/JJ
activation/NN
./.
====================
AB/LS
-/:
Expression/NN
of/IN
the/DT
CD95/NN
(/(
APO-1/Fas/NN
)/)
ligand/NN
(/(
CD95L/NN
)/)
in/IN
activated/VBN
T/NN
cells/NNS
is/VBZ
a/DT
major/JJ
cause/NN
of/IN
T/NN
cell/NN
activation-induced/JJ
apoptosis/NN
./.
====================
To/TO
study/VB
the/DT
molecular/JJ
mechanisms/NNS
of/IN
transcriptional/JJ
control/NN
of/IN
CD95L/NN
expression/NN
in/IN
T/NN
cells/NNS
,/,
we/PRP
investigated/VBD
the/DT
human/JJ
CD95L/NN
promoter/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
./.
====================
Deletion/NN
studies/NNS
revealed/VBD
that/IN
the/DT
CD95L/NN
proximal/JJ
promoter/NN
sequence/NN
from/IN
-220/CD
to/TO
the/DT
transcription/NN
start/NN
site/NN
is/VBZ
essential/JJ
for/IN
T/NN
cell/NN
stimulation-induced/JJ
expression/NN
of/IN
CD95L/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
discovered/VBD
a/DT
novel/JJ
regulatory/JJ
element/NN
located/JJ
at/IN
-120/CD
of/IN
the/DT
CD95L/NN
promoter/NN
which/WDT
contains/VBZ
DNA/NN
binding/NN
sites/NNS
for/IN
SP-1/NN
and/CC
a/DT
yet/RB
unknown/JJ
inducible/JJ
factor/NN
./.
====================
Mutation/NN
analysis/NN
demonstrated/VBD
that/IN
binding/NN
of/IN
the/DT
inducible/JJ
factor/NN
to/TO
the/DT
-120/CD
region/NN
is/VBZ
crucial/JJ
for/IN
the/DT
biological/JJ
function/NN
of/IN
the/DT
CD95L/NN
promoter/NN
upon/IN
T/NN
cell/NN
stimulation/NN
./.
====================
The/DT
DNA/NN
sequence/NN
at/IN
-120/CD
also/RB
contains/VBZ
two/CD
DNA/NN
motifs/NNS
homologous/JJ
to/TO
the/DT
binding/VBG
site/NN
for/IN
NF-AT/NN
./.
====================
NF-AT/NN
does/VBZ
not/RB
directly/RB
bind/VB
to/TO
this/DT
element/NN
./.
====================
However/RB
,/,
cotransfection/NN
studies/NNS
with/IN
an/DT
NF-AT/NN
expression/NN
vector/NN
showed/VBD
that/IN
NF-AT/NN
may/MD
confer/VB
a/DT
strong/JJ
inducible/JJ
activity/NN
to/TO
the/DT
CD95L/NN
promoter/NN
at/IN
this/DT
regulatory/JJ
region/NN
./.
====================
Our/PRP$
data/NNS
also/RB
show/VBP
that/IN
the/DT
immunosuppressive/JJ
agent/NN
cyclosporin/NN
A/NN
down-regulates/VBZ
CD95L/NN
transcription/NN
by/IN
inhibiting/VBG
the/DT
function/NN
of/IN
this/DT
positive/JJ
regulatory/JJ
element/NN
====================
UI/LS
-/:
99021680/CD
====================
TI/LS
-/:
A/DT
nongenomic/JJ
mechanism/NN
for/IN
progesterone-mediated/JJ
immunosuppression/NN
:/:
inhibition/NN
of/IN
K+/NN
channels/NNS
,/,
Ca2+/NN
signaling/NN
,/,
and/CC
gene/NN
expression/NN
in/IN
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
The/DT
mechanism/NN
by/IN
which/WDT
progesterone/NN
causes/VBZ
localized/JJ
suppression/NN
of/IN
the/DT
immune/JJ
response/NN
during/IN
pregnancy/NN
has/VBZ
remained/VBN
elusive/JJ
./.
====================
Using/VBG
human/JJ
T/NN
lymphocytes/NNS
and/CC
T/NN
cell/NN
lines/NNS
,/,
we/PRP
show/VBP
that/IN
progesterone/NN
,/,
at/IN
concentrations/NNS
found/VBN
in/IN
the/DT
placenta/NN
,/,
rapidly/RB
and/CC
reversibly/RB
blocks/VBZ
voltage-gated/JJ
and/CC
calcium-activated/JJ
K+/NN
channels/NNS
(/(
KV/NN
and/CC
KCa/NN
,/,
respectively/RB
)/)
,/,
resulting/VBG
in/IN
depolarization/NN
of/IN
the/DT
membrane/NN
potential/NN
./.
====================
As/IN
a/DT
result/NN
,/,
Ca2+/NN
signaling/NN
and/CC
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NF-AT/NN
)/)
-driven/JJ
gene/NN
expression/NN
are/VBP
inhibited/VBN
./.
====================
Progesterone/NN
acts/VBZ
distally/RB
to/TO
the/DT
initial/JJ
steps/NNS
of/IN
T/NN
cell/NN
receptor/NN
(/(
TCR/NN
)/)
-mediated/JJ
signal/NN
transduction/NN
,/,
since/IN
it/PRP
blocks/VBZ
sustained/JJ
Ca2+/NN
signals/NNS
after/IN
thapsigargin/NN
stimulation/NN
,/,
as/RB
well/RB
as/IN
oscillatory/JJ
Ca2+/NN
signals/NNS
,/,
but/CC
not/RB
the/DT
Ca2+/NN
transient/JJ
after/IN
TCR/NN
stimulation/NN
./.
====================
K+/NN
channel/NN
blockade/NN
by/IN
progesterone/NN
is/VBZ
specific/JJ
;/:
other/JJ
steroid/NN
hormones/NNS
had/VBD
little/JJ
or/CC
no/DT
effect/NN
,/,
although/IN
the/DT
progesterone/NN
antagonist/NN
RU/NN
486/CD
also/RB
blocked/VBD
KV/NN
and/CC
KCa/NN
channels/NNS
./.
====================
Progesterone/NN
effectively/RB
blocked/VBD
a/DT
broad/JJ
spectrum/NN
of/IN
K+/NN
channels/NNS
,/,
reducing/VBG
both/CC
Kv1.3/NN
and/CC
charybdotoxin-resistant/JJ
components/NNS
of/IN
KV/NN
current/NN
and/CC
KCa/NN
current/NN
in/IN
T/NN
cells/NNS
,/,
as/RB
well/RB
as/IN
blocking/VBG
several/JJ
cloned/VBN
KV/NN
channels/NNS
expressed/VBN
in/IN
cell/NN
lines/NNS
./.
====================
Progesterone/NN
had/VBD
little/JJ
or/CC
no/DT
effect/NN
on/IN
a/DT
cloned/VBN
voltage-gated/JJ
Na+/NN
channel/NN
,/,
an/DT
inward/JJ
rectifier/NN
K+/NN
channel/NN
,/,
or/CC
on/IN
lymphocyte/NN
Ca2+/NN
and/CC
Cl-/NN
channels/NNS
./.
====================
We/PRP
propose/VBP
that/IN
direct/JJ
inhibition/NN
of/IN
K+/NN
channels/NNS
in/IN
T/NN
cells/NNS
by/IN
progesterone/NN
contributes/VBZ
to/TO
progesterone-induced/JJ
immunosuppression/NN
./.
====================
UI/LS
-/:
99008517/CD
====================
TI/LS
-/:
A/DT
mouse/NN
carrying/VBG
genetic/JJ
defect/NN
in/IN
the/DT
choice/NN
between/IN
T/NN
and/CC
B/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Transgenic/JJ
mice/NNS
with/IN
human/JJ
CD3epsilon/NN
gene/NN
have/VBP
been/VBN
shown/VBN
to/TO
exhibit/VB
early/JJ
arrest/NN
of/IN
T/NN
cell/NN
development/NN
in/IN
the/DT
thymus/NN
./.
====================
The/DT
present/JJ
study/NN
shows/VBZ
that/IN
,/,
instead/RB
of/IN
T/NN
cells/NNS
,/,
B/NN
cells/NNS
are/VBP
generated/VBN
in/IN
the/DT
thymus/NN
of/IN
a/DT
line/NN
,/,
tg/NN
epsilon26/NN
,/,
of/IN
the/DT
human/JJ
CD3epsilon/NN
transgenic/JJ
mice/NNS
./.
====================
The/DT
accumulation/NN
of/IN
mature/JJ
B/NN
cells/NNS
in/IN
the/DT
thymus/NN
was/VBD
found/VBN
only/RB
in/IN
tg/NN
epsilon26/NN
mice/NNS
,/,
not/RB
in/IN
other/JJ
human/JJ
CD3epsilon/NN
transgenic/JJ
mouse/NN
lines/NNS
or/CC
other/JJ
T/NN
cell-deficient/JJ
mice/NNS
,/,
including/VBG
CD3-epsilon/NN
knockout/JJ
mice/NNS
and/CC
TCR-beta/TCR-delta/NN
double/JJ
knockout/JJ
mice/NNS
./.
====================
Hanging/VBG
drop-mediated/JJ
transfer/NN
into/IN
2-deoxyguanosine-treated/JJ
thymus/NN
lobes/NNS
showed/VBD
that/IN
lymphoid/JJ
progenitor/NN
cells/NNS
rather/RB
than/IN
thymus/NN
stromal/JJ
cells/NNS
were/VBD
responsible/JJ
for/IN
abnormal/JJ
B/NN
cell/NN
development/NN
in/IN
tg/NN
epsilon26/NN
thymus/NN
,/,
and/CC
that/IN
tg/NN
epsilon26/NN
fetal/JJ
liver/NN
cells/NNS
were/VBD
destined/VBN
to/TO
become/VB
B/NN
cells/NNS
in/IN
normal/JJ
thymus/NN
even/RB
in/IN
the/DT
presence/NN
of/IN
normal/JJ
progenitor/NN
cells/NNS
undergoing/VBG
T/NN
cell/NN
development/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
lymphoid/JJ
progenitor/NN
cells/NNS
in/IN
tg/NN
epsilon26/NN
mice/NNS
are/VBP
genetically/RB
defective/JJ
in/IN
thymic/JJ
choice/NN
between/IN
T/NN
cells/NNS
and/CC
B/NN
cells/NNS
,/,
generating/VBG
B/NN
cells/NNS
even/RB
in/IN
normal/JJ
thymus/NN
environment/NN
./.
====================
Interestingly/RB
,/,
tg/NN
epsilon26/NN
thymocytes/NNS
expressed/VBD
GATA-3/NN
and/CC
TCF-1/NN
,/,
but/CC
not/RB
LEF-1/NN
and/CC
PEBP-2alpha/NN
,/,
among/IN
T/NN
cell-specific/JJ
transcription/NN
factors/NNS
that/WDT
are/VBP
involved/VBN
in/IN
early/JJ
T/NN
cell/NN
development/NN
,/,
indicating/VBG
that/IN
GATA-3/NN
and/CC
TCF-1/NN
expressed/VBN
during/IN
thymocyte/NN
development/NN
do/VBP
not/RB
necessarily/RB
determine/VB
the/DT
cell/NN
fate/NN
into/IN
T/NN
cell/NN
lineage/NN
./.
====================
Thus/RB
,/,
tg/NN
epsilon26/NN
mice/NNS
provide/VBP
a/DT
novel/JJ
mouse/NN
model/NN
in/IN
that/IN
lineage/NN
choice/NN
between/IN
T/NN
and/CC
B/NN
lymphocytes/NNS
is/VBZ
genetically/RB
defective/JJ
./.
====================
UI/LS
-/:
99003230/CD
====================
TI/LS
-/:
Downstream/JJ
activation/NN
of/IN
a/DT
TATA-less/JJ
promoter/NN
by/IN
Oct-2/NN
,/,
Bob1/NN
,/,
and/CC
NF-kappaB/NN
directs/VBZ
expression/NN
of/IN
the/DT
homing/JJ
receptor/NN
BLR1/NN
to/TO
mature/JJ
B/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
chemokine/NN
receptor/NN
,/,
BLR1/NN
,/,
is/VBZ
a/DT
major/JJ
regulator/NN
of/IN
the/DT
microenvironmental/JJ
homing/NN
of/IN
B/NN
cells/NNS
in/IN
lymphoid/JJ
organs/NNS
./.
====================
In/FW
vitro/FW
studies/NNS
identify/VBP
three/CD
essential/JJ
elements/NNS
of/IN
the/DT
TATA-less/JJ
blr1/NN
core/NN
promoter/NN
that/WDT
confer/VBP
cell/NN
type-/NN
and/CC
differentiation-specific/JJ
expression/NN
in/IN
the/DT
B/NN
cells/NNS
of/IN
both/CC
humans/NNS
and/CC
mice/NNS
,/,
a/DT
functional/JJ
promoter/NN
region/NN
(/(
-36/CD
with/IN
respect/NN
to/TO
the/DT
transcription/NN
start/NN
site/NN
)/)
,/,
a/DT
NF-kappaB/NN
motif/NN
(/(
+44/CD
)/)
,/,
and/CC
a/DT
noncanonical/JJ
octamer/NN
motif/NN
(/(
+157/CD
)/)
./.
====================
The/DT
importance/NN
of/IN
these/DT
sites/NNS
was/VBD
confirmed/VBN
by/IN
in/FW
vivo/FW
studies/NNS
in/IN
gene-targeted/JJ
mice/NNS
deficient/JJ
of/IN
either/CC
Oct-2/NN
,/,
Bob1/NN
,/,
or/CC
both/CC
NF-kappaB/NN
subunits/NNS
p50/NN
and/CC
p52/NN
./.
====================
In/IN
all/DT
of/IN
these/DT
animals/NNS
,/,
the/DT
expression/NN
of/IN
BLR1/NN
was/VBD
reduced/VBN
or/CC
absent/JJ
./.
====================
In/IN
mice/NNS
deficient/JJ
only/RB
of/IN
p52/NF-kappaB/NN
,/,
BLR1/NN
expression/NN
was/VBD
unaffected/JJ
./.
====================
Thus/RB
our/PRP$
data/NNS
demonstrate/VBP
that/IN
BLR1/NN
is/VBZ
a/DT
target/NN
gene/NN
for/IN
Oct-2/NN
,/,
Bob1/NN
,/,
and/CC
members/NNS
of/IN
the/DT
NF-kappaB/Rel/NN
family/NN
and/CC
provides/VBZ
a/DT
link/NN
to/TO
the/DT
impaired/JJ
B/NN
cell/NN
functions/NNS
in/IN
mice/NNS
deficient/JJ
for/IN
these/DT
factors/NNS
./.
====================
UI/LS
-/:
98440543/CD
====================
TI/LS
-/:
CD4/NN
promoter/NN
transactivation/NN
by/IN
human/JJ
herpesvirus/NN
6/CD
./.
====================
AB/LS
-/:
The/DT
observation/NN
that/IN
human/JJ
herpesvirus/NN
6/CD
(/(
HHV-6/NN
)/)
can/MD
induce/VB
CD4/NN
gene/NN
transcription/NN
and/CC
expression/NN
in/IN
CD4(-)/JJ
cells/NNS
was/VBD
reported/VBN
several/JJ
years/NNS
ago/RB
(/(
P.Lusso/NNP
,/,
A.De/NNP
Maria/NNP
,/,
M.Malnati/NNP
,/,
F.Lori/NNP
,/,
S.E.DeRocco/NNP
,/,
M./NNP
Baseler/NNP
,/,
and/CC
R.C.Gallo/NNP
,/,
Nature/NNP
349/CD
:/:
533-535/CD
,/,
1991/CD
)/)
and/CC
subsequently/RB
confirmed/VBN
(/(
P.Lusso/NNP
,/,
M.S.Malnati/NNP
,/,
A.Garzino-Demo/NNP
,/,
R.W.Crowley/NNP
,/,
E./NNP
O.Long/NNP
,/,
and/CC
R.C.Gallo/NNP
,/,
Nature/NNP
362/CD
:/:
458-462/CD
,/,
1993/CD
;/:
G.Furlini/NNP
,/,
M./NNP
Vignoli/NNP
,/,
E.Ramazzotti/NNP
,/,
M.C.Re/NNP
,/,
G.Visani/NNP
,/,
and/CC
M.LaPlaca/NNP
,/,
Blood/NNP
87/CD
:/:
4737-4745/CD
,/,
1996/CD
)/)
./.
====================
Our/PRP$
objective/JJ
was/VBD
to/TO
identify/VB
the/DT
mechanisms/NNS
underlying/VBG
such/JJ
phenomena/NNS
./.
====================
Using/VBG
reporter/NN
gene/NN
constructs/NNS
driven/VBN
by/IN
the/DT
CD4/NN
promoter/NN
,/,
we/PRP
report/VBP
that/IN
HHV-6/NN
can/MD
efficiently/RB
transactivate/VB
such/JJ
genetic/JJ
elements/NNS
./.
====================
Activation/NN
of/IN
the/DT
CD4/NN
promoter/NN
occurs/VBZ
in/IN
the/DT
presence/NN
of/IN
the/DT
viral/JJ
DNA/NN
polymerase/NN
inhibitor/NN
phosphonoformic/JJ
acid/NN
,/,
which/WDT
limits/VBZ
expression/NN
to/TO
the/DT
immediate-early/JJ
and/CC
early/JJ
classes/NNS
of/IN
viral/JJ
genes/NNS
./.
====================
Using/VBG
deletion/NN
mutants/NNS
and/CC
specific/JJ
CD4/NN
promoter/NN
mutants/NNS
,/,
we/PRP
identified/VBD
an/DT
ATF/CRE/NN
binding/NN
site/NN
located/JJ
at/IN
nucleotides/NNS
-67/CD
to/TO
-60/CD
upstream/JJ
of/IN
the/DT
CD4/NN
gene/NN
transcription/NN
start/NN
site/NN
that/WDT
is/VBZ
important/JJ
for/IN
HHV-6/NN
transactivation/NN
./.
====================
The/DT
ATF/CRE/NN
site/NN
is/VBZ
also/RB
essential/JJ
for/IN
CD4/NN
promoter/NN
activation/NN
by/IN
forskolin/NN
,/,
an/DT
activator/NN
of/IN
adenylate/NN
cyclase/NN
./.
====================
Using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
and/CC
specific/JJ
antibodies/NNS
,/,
we/PRP
showed/VBD
that/IN
CREB-1/NN
binds/VBZ
specifically/RB
to/TO
the/DT
-79/CD
to/TO
-52/CD
region/NN
of/IN
the/DT
CD4/NN
promoter/NN
./.
====================
Last/RB
,/,
we/PRP
have/VBP
identified/VBN
two/CD
open/JJ
reading/NN
frames/NNS
(/(
ORFs/NNS
)/)
of/IN
HHV-6/NN
,/,
U86/NN
and/CC
U89/NN
from/IN
the/DT
immediate-early/JJ
locus/NN
A/NN
,/,
that/WDT
can/MD
transactivate/VB
the/DT
CD4/NN
promoter/NN
in/IN
HeLa/NN
cells/NNS
./.
====================
However/RB
,/,
transactivation/NN
of/IN
the/DT
CD4/NN
promoter/NN
by/IN
ORFs/NNS
U86/NN
and/CC
U89/NN
is/VBZ
independent/JJ
of/IN
the/DT
CRE/NN
element/NN
,/,
suggesting/VBG
that/IN
additional/JJ
HHV-6/NN
ORFs/NNS
are/VBP
likely/JJ
to/TO
contribute/VB
to/TO
CD4/NN
gene/NN
activation/NN
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
results/NNS
will/MD
help/VB
to/TO
understand/VB
the/DT
complex/JJ
interactions/NNS
occurring/VBG
between/IN
HHV-6/NN
and/CC
the/DT
CD4/NN
promoter/NN
and/CC
provide/VB
additional/JJ
information/NN
regarding/VBG
the/DT
class/NN
of/IN
transcription/NN
factors/NNS
involved/VBN
in/IN
the/DT
control/NN
of/IN
CD4/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
98426244/CD
====================
TI/LS
-/:
The/DT
PEBP2betaMYH11/NN
fusion/NN
created/VBN
by/IN
Inv(16)(p13;q22)/NN
in/IN
myeloid/JJ
leukemia/NN
impairs/VBZ
neutrophil/NN
maturation/NN
and/CC
contributes/VBZ
to/TO
granulocytic/JJ
dysplasia/NN
./.
====================
AB/LS
-/:
Chromosomal/JJ
translocations/NNS
involving/VBG
the/DT
genes/NNS
encoding/VBG
the/DT
alpha/NN
and/CC
beta/NN
subunits/NNS
of/IN
the/DT
Pebp2/Cbf/NN
transcription/NN
factor/NN
have/VBP
been/VBN
associated/VBN
with/IN
human/JJ
acute/JJ
myeloid/JJ
leukemia/NN
and/CC
the/DT
preleukemic/JJ
condition/NN
,/,
myelodysplasia/NN
./.
====================
Inv(16)(p13;q22)/NN
fuses/VBZ
the/DT
gene/NN
encoding/VBG
the/DT
beta/NN
subunit/NN
of/IN
Pebp2/NN
to/TO
the/DT
MYH11/NN
gene/NN
encoding/VBG
a/DT
smooth/JJ
muscle/NN
myosin/NN
heavy/NN
chain/NN
(/(
Smmhc/NN
)/)
./.
====================
To/TO
examine/VB
the/DT
effect/NN
of/IN
the/DT
inv(16)(p13;q22)/NN
on/IN
myelopoiesis/NN
,/,
we/PRP
used/VBD
the/DT
hMRP8/NN
promoter/NN
element/NN
to/TO
generate/VB
transgenic/JJ
mice/NNS
expressing/VBG
the/DT
Pebp2betaSmmhc/NN
chimeric/JJ
fusion/NN
protein/NN
in/IN
myeloid/JJ
cells/NNS
./.
====================
Neutrophil/NN
maturation/NN
was/VBD
impaired/JJ
in/IN
PEBP2betaMYH11/NN
transgenic/JJ
mice/NNS
./.
====================
Although/IN
the/DT
transgenic/JJ
mice/NNS
had/VBD
normal/JJ
numbers/NNS
of/IN
circulating/VBG
neutrophils/NNS
,/,
their/PRP$
bone/NN
marrow/NN
contained/VBD
increased/VBN
numbers/NNS
of/IN
immature/JJ
neutrophilic/JJ
cells/NNS
,/,
which/WDT
exhibited/VBD
abnormal/JJ
characteristics/NNS
./.
====================
In/IN
addition/NN
,/,
PEBP2betaMYH11/NN
inhibited/VBD
neutrophilic/JJ
differentiation/NN
in/IN
colonies/NNS
derived/VBN
from/IN
hematopoietic/JJ
progenitors/NNS
./.
====================
Coexpression/NN
of/IN
both/CC
PEBP2betaMYH11/NN
and/CC
activated/VBN
NRAS/NNS
induced/VBD
a/DT
more/RBR
severe/JJ
phenotype/NN
characterized/VBN
by/IN
abnormal/JJ
nuclear/JJ
morphology/NN
indicative/JJ
of/IN
granulocytic/JJ
dysplasia/NN
./.
====================
These/DT
results/NNS
show/VBP
that/IN
PEBP2betaMYH11/NN
can/MD
impair/VB
neutrophil/NN
development/NN
and/CC
provide/VBP
evidence/NN
that/IN
alterations/NNS
of/IN
Pebp2/NN
can/MD
contribute/VB
to/TO
the/DT
genesis/NN
of/IN
myelodysplasia/NN
./.
====================
UI/LS
-/:
98414302/CD
====================
TI/LS
-/:
Human/JJ
T/NN
cell/NN
leukemia/NN
virus-I/NN
(/(
HTLV-I/NN
)/)
Tax-mediated/JJ
apoptosis/NN
in/IN
activated/VBN
T/NN
cells/NNS
requires/VBZ
an/DT
enhanced/VBN
intracellular/JJ
prooxidant/JJ
state/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
shown/VBN
that/IN
an/DT
estradiol-dependent/JJ
activation/NN
of/IN
human/JJ
T/NN
cell/NN
leukemia/NN
virus-I/NN
Tax/NN
leads/VBZ
to/TO
the/DT
inhibition/NN
of/IN
cell/NN
proliferation/NN
and/CC
to/TO
the/DT
induction/NN
of/IN
apoptosis/NN
./.
====================
The/DT
present/JJ
study/NN
demonstrates/VBZ
that/IN
a/DT
hormone-dependent/JJ
activation/NN
of/IN
Tax/NN
promotes/VBZ
an/DT
enhanced/VBN
prooxidant/JJ
state/NN
in/IN
stably/RB
transfected/VBN
Jurkat/NN
cells/NNS
as/IN
measured/VBN
by/IN
changes/NNS
in/IN
the/DT
intracellular/JJ
levels/NNS
of/IN
glutathione/NN
and/CC
H2O2/NN
;/:
these/DT
changes/NNS
are/VBP
followed/VBN
by/IN
apoptotic/JJ
cell/NN
death/NN
./.
====================
Additional/JJ
stimulation/NN
of/IN
the/DT
CD3/TCR/NN
pathway/NN
enhances/VBZ
the/DT
oxidative/JJ
and/CC
apoptotic/JJ
effects/NNS
./.
====================
Both/CC
Tax-mediated/JJ
apoptosis/NN
and/CC
oxidative/JJ
stress/NN
can/MD
be/VB
potently/RB
suppressed/VBN
by/IN
antioxidants/NNS
,/,
as/IN
is/VBZ
seen/VBN
with/IN
the/DT
administration/NN
of/IN
recombinant/JJ
thioredoxin/NN
(/(
adult/JJ
T/NN
cell/NN
leukemia-derived/JJ
factor/NN
)/)
or/CC
pyrrolidine/NN
dithiocarbamate/NN
./.
====================
Hormone-induced/JJ
Tax/NN
activation/NN
induces/VBZ
a/DT
long-lasting/JJ
activation/NN
of/IN
NF-kappaB/NN
,/,
which/WDT
is/VBZ
a/DT
major/JJ
target/NN
of/IN
reactive/JJ
oxygen/NN
intermediates/NNS
./.
====================
The/DT
long-term/JJ
exposure/NN
of/IN
Jurkat/NN
cells/NNS
to/TO
hormone/NN
eventually/RB
results/VBZ
in/IN
a/DT
selection/NN
of/IN
cell/NN
clones/NNS
that/WDT
have/VBP
lost/VBN
Tax/NN
activity/NN
./.
====================
A/DT
subsequent/JJ
transfection/NN
of/IN
these/DT
apparently/RB
"/``
nonresponsive/JJ
"/''
clones/NNS
allows/VBZ
the/DT
recovery/NN
of/IN
Tax/NN
responses/NNS
in/IN
these/DT
cells/NNS
./.
====================
Our/PRP$
observations/NNS
indicate/VBP
that/IN
changes/NNS
in/IN
the/DT
intracellular/JJ
redox/NN
status/NN
may/MD
be/VB
a/DT
determining/VBG
factor/NN
in/IN
Tax-mediated/JJ
DNA/NN
damage/NN
,/,
apoptosis/NN
,/,
and/CC
selection/NN
against/IN
the/DT
long-term/JJ
expression/NN
of/IN
Tax/NN
function/NN
./.
====================
UI/LS
-/:
98401161/CD
====================
TI/LS
-/:
An/DT
allosteric/JJ
drug/NN
,/,
o,o'-bismyristoyl/NN
thiamine/NN
disulfide/NN
,/,
suppresses/VBZ
HIV-1/NN
replication/NN
through/IN
prevention/NN
of/IN
nuclear/JJ
translocation/NN
of/IN
both/CC
HIV-1/NN
Tat/NN
and/CC
NF-kappa/NN
B/NN
./.
====================
AB/LS
-/:
The/DT
efficacy/NN
of/IN
o/NN
,/,
o'-bismyristoyl/NN
thiamine/NN
disulfide/NN
(/(
BMT/NN
)/)
was/VBD
examined/VBN
in/IN
detail/NN
against/IN
HIV-1/NN
laboratory/JJ
isolates/NNS
(/(
HTLV-IIIB/NN
,/,
JRFL/NNP
,/,
and/CC
MN/NN
)/)
,/,
primary/JJ
isolates/NNS
(/(
KMT/NN
and/CC
KMO/NN
)/)
,/,
and/CC
simian/JJ
immunodeficiency/NN
virus/NN
(/(
SIVmac251/NN
)/)
in/FW
vitro/FW
./.
====================
BMT/NN
inhibited/VBD
the/DT
replication/NN
of/IN
HIV-1/NN
in/IN
both/CC
laboratory/JJ
and/CC
primary/JJ
isolates/NNS
in/FW
vitro/FW
./.
====================
In/IN
addition/NN
,/,
BMT/NN
exhibited/VBD
antiviral/JJ
activity/NN
against/IN
SIVmac251/NN
./.
====================
Minimizing/VBG
energy/NN
studies/NNS
of/IN
BMT/NN
structure/NN
reveal/VBP
that/IN
a/DT
trans-disulfide/NN
of/IN
thiamine/NN
(/(
holo/NN
drug/NN
)/)
disulfide/NN
(/(
TDS/NN
,/,
protodrug/NN
)/)
is/VBZ
allosterically/RB
transited/VBN
to/TO
the/DT
reactive/JJ
twisted/JJ
disulfide/NN
of/IN
BMT/NN
(/(
allo/NN
drug/NN
)/)
by/IN
o/NN
,/,
o'-bismyristoyl/JJ
esterification/NN
of/IN
TDS/NN
./.
====================
BMT/NN
inhibits/VBZ
nuclear/JJ
translocation/NN
of/IN
both/CC
HIV-1/NN
transactivator/NN
(/(
TAT/NN
)/)
and/CC
the/DT
cellular/JJ
transcriptional/JJ
nuclear/JJ
factor-KB/NN
(/(
NF-kappa/NN
B/NN
)/)
,/,
resulting/VBG
in/IN
the/DT
suppression/NN
of/IN
HIV-1/NN
replication/NN
./.
====================
UI/LS
-/:
98389427/CD
====================
TI/LS
-/:
Glucocorticoid-induced/JJ
apoptosis/NN
and/CC
regulation/NN
of/IN
NF-kappaB/NN
activity/NN
in/IN
human/JJ
leukemic/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Glucocorticoid-induced/JJ
apoptosis/NN
was/VBD
investigated/VBN
in/IN
glucocorticoid-sensitive/JJ
6TG1.1/NN
and/CC
resistant/JJ
ICR27TK.3/NN
human/JJ
leukemic/JJ
T/NN
cells/NNS
./.
====================
Following/VBG
glucocorticoid/NN
treatment/NN
of/IN
6TG1.1/NN
cells/NNS
,/,
chromatin/NN
fragmentation/NN
was/VBD
observed/VBN
after/IN
a/DT
delay/NN
of/IN
24/CD
h/NN
./.
====================
Fragmentation/NN
was/VBD
not/RB
observed/VBN
in/IN
ICR27TK.3/NN
cells/NNS
containing/VBG
mutant/JJ
glucocorticoid/NN
receptors/NNS
(/(
L753F/NN
)/)
that/WDT
are/VBP
activation-deficient/JJ
but/CC
retain/VBP
the/DT
ability/NN
to/TO
repress/VB
AP-1/NN
activity/NN
./.
====================
Nor/CC
was/VBD
fragmentation/NN
observed/VBN
after/IN
treatment/NN
with/IN
RU38486/NN
,/,
indicating/VBG
that/IN
repression/NN
of/IN
AP-1/NN
activity/NN
is/VBZ
not/RB
involved/VBN
./.
====================
As/IN
described/VBN
in/IN
other/JJ
systems/NNS
,/,
fragmentation/NN
required/VBD
ongoing/JJ
protein/NN
synthesis/NN
./.
====================
However/RB
,/,
inhibition/NN
of/IN
protein/NN
synthesis/NN
with/IN
cycloheximide/NN
anytime/RB
during/IN
the/DT
first/JJ
18/CD
h/NN
of/IN
steroid/NN
treatment/NN
was/VBD
as/IN
effective/JJ
in/IN
blocking/VBG
chromatin/NN
fragmentation/NN
as/IN
inhibition/NN
for/IN
the/DT
entire/JJ
period/NN
,/,
suggesting/VBG
that/IN
synthesis/NN
of/IN
a/DT
component/NN
with/IN
a/DT
rapid/JJ
turnover/NN
rate/NN
is/VBZ
required/VBN
./.
====================
Dexamethasone/NN
treatment/NN
completely/RB
blocked/VBD
12-O-tetradecanoylphorbol/NN
13-acetate/NN
induction/NN
of/IN
nuclear/JJ
factor-kappaB/NN
(/(
NF-kappaB/NN
)/)
activity/NN
and/CC
elicited/VBD
an/DT
increase/NN
in/IN
the/DT
amount/NN
of/IN
immunoreactive/JJ
IkappaB/NN
alpha/NN
in/IN
sensitive/JJ
6TG1.1/NN
cells/NNS
but/CC
not/RB
in/IN
resistant/JJ
ICR27TK.3/NN
cells/NNS
./.
====================
In/IN
addition/NN
,/,
mild/JJ
detergent/NN
treatment/NN
of/IN
cell/NN
extracts/NNS
indicated/VBD
that/IN
a/DT
substantial/JJ
amount/NN
of/IN
cytoplasmic/JJ
NF-kappaB/NN
is/VBZ
complexed/VBN
with/IN
IkappaB/NN
alpha/NN
or/CC
some/DT
other/JJ
inhibitory/JJ
factor/NN
./.
These/DT
results/NNS
suggest/VBP
that/IN
induction/NN
of/IN
a/DT
labile/JJ
inhibitory/JJ
factor/NN
such/JJ
as/IN
IkappaB/NN
alpha/NN
may/MD
contribute/VB
to/TO
glucocorticoid-induced/JJ
apoptosis/NN
./.
====================
UI/LS
-/:
98379695/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
HIV-1/NN
replication/NN
by/IN
combination/NN
of/IN
a/DT
novel/JJ
inhibitor/NN
of/IN
TNF-alpha/NN
with/IN
AZT/NN
./.
====================
AB/LS
-/:
The/DT
small/JJ
molecule/NN
S9a/NN
was/VBD
derived/VBN
from/IN
an/DT
established/JJ
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
inhibitor/NN
(/(
Canventol/NN
)/)
by/IN
replacement/NN
of/IN
the/DT
isopropylidine/NN
group/NN
with/IN
a/DT
phenyl/NN
ring/NN
./.
====================
S9a/NN
at/IN
10/CD
to/TO
100/CD
nM/NN
inhibited/VBD
HIV/NN
production/NN
as/RB
potently/RB
as/IN
3'-azido-3'-deoxythymidine/NN
(/(
AZT/NN
)/)
,/,
an/DT
inhibitor/NN
of/IN
viral/JJ
reverse/JJ
transcriptase/NN
./.
====================
Furthermore/RB
,/,
S9a/NN
and/CC
AZT/NN
in/IN
combination/NN
,/,
at/IN
noncytoxic/JJ
concentrations/NNS
strongly/RB
inhibited/VBD
HIV-1/NN
replication/NN
that/WDT
was/VBD
more/RBR
than/IN
additive/JJ
and/CC
substantially/RB
prolonged/VBD
the/DT
appearance/NN
of/IN
virus/NN
both/CC
in/IN
acutely/RB
infected/JJ
CD4+/JJ
lymphocytes/NNS
(/(
SupT/NN
)/)
in/IN
culture/NN
and/CC
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMCs/NNS
)/)
infected/VBN
with/IN
a/DT
primary/JJ
HIV-1/NN
isolate/NN
./.
====================
S9a/NN
inhibited/VBD
TNF-alpha/NN
promoter-driven/JJ
reporter/NN
gene/NN
activity/NN
./.
====================
It/PRP
was/VBD
proposed/VBN
that/IN
the/DT
mechanism/NN
of/IN
antiviral/JJ
action/NN
of/IN
S9a/NN
was/VBD
on/IN
the/DT
host/NN
cell/NN
,/,
by/IN
blocking/VBG
TNF-alpha/NN
transcription/NN
via/IN
a/DT
Tat-induced/JJ
tar-independent/JJ
loop/NN
,/,
which/WDT
decreases/VBZ
downstream/JJ
NF-kappaB/NN
activation/NN
of/IN
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
./.
====================
S9a/NN
was/VBD
superior/JJ
to/TO
the/DT
first/JJ
generation/NN
compound/JJ
Canventol/NN
,/,
which/WDT
was/VBD
superior/JJ
to/TO
the/DT
natural/JJ
compound/NN
sarcophytol/NN
A/NN
,/,
demonstrating/VBG
that/IN
further/JJ
structure-based/JJ
enhancement/NN
of/IN
potency/NN
of/IN
these/DT
compounds/NNS
is/VBZ
feasible/JJ
./.
====================
This/DT
study/NN
suggests/VBZ
a/DT
therapeutic/JJ
approach/NN
against/IN
AIDS/NN
by/IN
application/NN
of/IN
two/CD
drugs/NNS
,/,
one/CD
against/IN
a/DT
cellular/JJ
and/CC
the/DT
other/JJ
a/DT
viral/JJ
target/NN
,/,
which/WDT
may/MD
provide/VB
an/DT
approach/NN
to/TO
the/DT
problem/NN
of/IN
frequent/JJ
emergence/NN
of/IN
resistant/JJ
variants/NNS
to/TO
combinations/NNS
of/IN
drugs/NNS
that/WDT
target/VBP
only/RB
HIV/NN
genes/NNS
./.
====================
UI/LS
-/:
98376488/CD
====================
TI/LS
-/:
Highly/RB
polarized/VBN
HLA/NN
class/NN
II/CD
antigen/NN
processing/NN
and/CC
presentation/NN
by/IN
human/JJ
intestinal/JJ
epithelial/JJ
cells/NNS
./.
====================
AB/LS
-/:
The/DT
high/JJ
concentration/NN
of/IN
foreign/JJ
antigen/NN
in/IN
the/DT
lumen/NN
of/IN
the/DT
gastrointestinal/JJ
tract/NN
is/VBZ
separated/VBN
from/IN
the/DT
underlying/VBG
lymphocytes/NNS
by/IN
a/DT
single/JJ
cell/NN
layer/NN
of/IN
polarized/VBN
epithelium/NN
./.
====================
Intestinal/JJ
epithelial/JJ
cells/NNS
can/MD
express/VB
HLA/NN
class/NN
II/CD
antigens/NNS
and/CC
may/MD
function/VB
as/IN
antigen-presenting/JJ
cells/NNS
to/TO
CD4(+)/JJ
T/NN
cells/NNS
within/IN
the/DT
intestinal/JJ
mucosa/NN
./.
====================
Using/VBG
tetanus/NN
toxoid/NN
specific/JJ
and/CC
HLA-DR-restricted/JJ
T/NN
lymphocytes/NNS
,/,
we/PRP
show/VBP
that/IN
polarized/VBN
intestinal/JJ
epithelial/JJ
cells/NNS
directed/VBN
to/TO
express/VB
HLA-DR/NN
molecules/NNS
are/VBP
able/JJ
to/TO
initiate/VB
class/NN
II/CD
processing/NN
only/RB
after/IN
internalization/NN
of/IN
antigen/NN
from/IN
their/PRP$
apical/JJ
surface/NN
./.
====================
Coexpression/NN
of/IN
the/DT
class/NN
II/CD
transactivator/NN
CIITA/NN
in/IN
these/DT
cells/NNS
,/,
which/WDT
stimulates/VBZ
highly/RB
efficient/JJ
class/NN
II/CD
processing/NN
without/IN
the/DT
characteristic/JJ
decline/NN
in/IN
barrier/NN
function/NN
seen/VBN
in/IN
polarized/VBN
monolayers/NNS
treated/VBN
with/IN
the/DT
proinflammatory/JJ
cytokine/NN
gamma-IFN/NN
,/,
facilitates/VBZ
antigen/NN
processing/NN
from/IN
the/DT
basolateral/JJ
surface/NN
./.
====================
In/IN
both/DT
cases/NNS
,/,
peptide/NN
presentation/NN
to/TO
T/NN
cells/NNS
via/IN
class/NN
II/CD
molecules/NNS
was/VBD
restricted/JJ
to/TO
the/DT
basolateral/JJ
surface/NN
./.
====================
These/DT
data/NNS
indicate/VBP
a/DT
highly/RB
polarized/VBN
functional/JJ
architecture/NN
for/IN
antigen/NN
processing/NN
and/CC
presentation/NN
by/IN
intestinal/JJ
epithelial/JJ
cells/NNS
,/,
and/CC
suggest/VBP
that/IN
the/DT
functional/JJ
outcome/NN
of/IN
antigen/NN
processing/NN
by/IN
the/DT
intestinal/JJ
epithelium/NN
is/VBZ
both/CC
dependent/JJ
on/IN
the/DT
cellular/JJ
surface/NN
at/IN
which/WDT
the/DT
foreign/JJ
antigen/NN
is/VBZ
internalized/VBN
and/CC
by/IN
the/DT
underlying/JJ
degree/NN
of/IN
mucosal/JJ
inflammation/NN
====================
UI/LS
-/:
99032837/CD
====================
TI/LS
-/:
Tobacco/NN
smoke/NN
induces/VBZ
coordinate/JJ
activation/NN
of/IN
HSF/NN
and/CC
inhibition/NN
of/IN
NFkappaB/NN
in/IN
human/JJ
monocytes/NNS
:/:
effects/NNS
on/IN
TNFalpha/NN
release/NN
./.
====================
AB/LS
-/:
Tobacco/NN
smoke/NN
(/(
TS/NN
)/)
exposure/NN
is/VBZ
a/DT
major/JJ
risk/NN
factor/NN
for/IN
human/JJ
disease/NN
,/,
and/CC
macrophages/NNS
of/IN
healthy/JJ
smokers/NNS
have/VBP
a/DT
depressed/VBN
capacity/NN
to/TO
release/VB
cytokines/NNS
,/,
including/VBG
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
)/)
alpha/NN
./.
====================
TS/NN
induces/VBZ
the/DT
synthesis/NN
of/IN
heat/NN
shock/NN
(/(
HS/NN
)/)
/stress/NN
proteins/NNS
(/(
HSP/NN
)/)
,/,
and/CC
,/,
in/IN
particular/JJ
,/,
of/IN
Hsp70/NN
./.
====================
We/PRP
determined/VBD
whether/IN
Hsp70/NN
induction/NN
by/IN
TS/NN
was/VBD
mediated/VBN
by/IN
the/DT
activation/NN
of/IN
the/DT
HS/NN
transcription/NN
factor/NN
,/,
HSF/NN
./.
====================
HSF/NN
activation/NN
has/VBZ
been/VBN
shown/VBN
to/TO
inhibit/VB
NFkappaB/NN
./.
====================
Thus/RB
,/,
we/PRP
also/RB
determined/VBD
the/DT
effects/NNS
of/IN
TS/NN
on/IN
NFkappaB/NN
./.
====================
U937/NN
cells/NNS
and/CC
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
were/VBD
exposed/VBN
to/TO
TS/NN
,/,
binding/NN
activities/NNS
of/IN
the/DT
respective/JJ
transcription/NN
factors/NNS
were/VBD
analyzed/VBN
,/,
and/CC
Hsp70/NN
expression/NN
and/CC
TNFalpha/NN
release/NN
were/VBD
determined/VBN
in/IN
parallel/NN
./.
====================
TS/NN
activated/VBD
HSF/NN
,/,
which/WDT
was/VBD
associated/VBN
with/IN
Hsp70/NN
overexpression/NN
and/CC
inhibition/NN
of/IN
NFkappaB/NN
binding/NN
activity/NN
and/CC
TNFalpha/NN
release/NN
./.
====================
The/DT
altered/JJ
cytokine/NN
profile/NN
observed/VBN
in/IN
smokers/NNS
may/MD
relate/VB
to/TO
an/DT
HSF/Hsp70-mediated/JJ
inhibition/NN
of/IN
NFkappaB/NN
activity/NN
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
99016857/CD
====================
TI/LS
-/:
[/(
Molecular/JJ
mechanism/NN
of/IN
cytokine/NN
gene/NN
expression/NN
in/IN
Th1/NN
and/CC
Th2/NN
]/)
====================
AB/LS
-/:
Upon/IN
activation/NN
by/IN
antigens/NNS
,/,
helper/NN
T/NN
cells/NNS
differentiate/VBP
into/IN
one/CD
of/IN
several/JJ
subsets/NNS
,/,
characterized/VBN
by/IN
their/PRP$
distinct/JJ
cytokine-production/NN
patterns/NNS
./.
====================
Among/IN
these/DT
subsets/NNS
,/,
Th1/NN
cells/NNS
are/VBP
known/VBN
to/TO
activate/VB
cellular/JJ
immunity/NN
resulting/VBG
in/IN
inflammatory/JJ
response/NN
,/,
whereas/IN
Th2/NN
cells/NNS
induce/VBP
humoral/JJ
and/CC
allergic/JJ
responses/NNS
and/CC
suppress/VBP
inflammation/NN
./.
====================
Th1/NN
and/CC
Th2/NN
effector/NN
functions/NNS
and/CC
their/PRP$
development/NN
are/VBP
attributable/JJ
to/TO
their/PRP$
distinct/JJ
cytokine/NN
expression/NN
patterns/NNS
./.
====================
Recent/JJ
reports/NNS
have/VBP
demonstrated/VBN
that/IN
differential/JJ
expression/NN
of/IN
cell/NN
surface/NN
molecules/NNS
,/,
such/JJ
as/IN
adhesion/NN
molecule/NN
and/CC
chemokine/NN
receptor/NN
,/,
is/VBZ
involved/VBN
in/IN
their/PRP$
recruitment/NN
into/IN
target/NN
tissues/NNS
./.
====================
It/PRP
is/VBZ
,/,
therefore/RB
,/,
suggested/VBN
that/IN
clarification/NN
of/IN
the/DT
mechanisms/NNS
of/IN
differential/JJ
gene/NN
expression/NN
in/IN
Th1/Th2/NN
should/MD
lead/VB
to/TO
rational/JJ
strategies/NNS
for/IN
manipulating/VBG
pathological/JJ
immune/JJ
responses/NNS
./.
====================
Activation/NN
of/IN
helper/NN
T/NN
cells/NNS
mediated/VBN
by/IN
the/DT
T/NN
cell/NN
receptor/NN
induces/VBZ
a/DT
series/NN
of/IN
biochemical/JJ
events/NNS
./.
====================
Among/IN
them/PRP
,/,
both/CC
the/DT
activation/NN
of/IN
PKC/Ras-/NN
and/CC
CaM/CN-mediated/JJ
pathways/NNS
play/VBP
a/DT
central/JJ
role/NN
in/IN
the/DT
signal/NN
transduction/NN
of/IN
cytokine/NN
gene/NN
expression/NN
./.
====================
Closer/JJR
examination/NN
using/VBG
non-transformed/JJ
murine/JJ
Th1/NN
and/CC
Th2/NN
clones/NNS
suggested/VBD
that/IN
a/DT
balance/NN
between/IN
the/DT
activities/NNS
of/IN
the/DT
two/CD
signaling/NN
pathways/NNS
contributes/VBZ
to/TO
cytokine/NN
gene/NN
expression/NN
./.
====================
We/PRP
propose/VBP
that/IN
one/CD
of/IN
the/DT
targets/NNS
of/IN
PGE2/NN
,/,
whose/WP$
effect/NN
distinguishes/VBZ
Th1/NN
from/IN
Th2/NN
,/,
resides/VBZ
in/IN
the/DT
downstream/JJ
PKC/Ras-mediated/JJ
pathway/NN
./.
====================
UI/LS
-/:
99008372/CD
====================
TI/LS
-/:
Signalling/NN
into/IN
the/DT
T-cell/NN
nucleus/NN
:/:
NFAT/NN
regulation/NN
./.
====================
AB/LS
-/:
The/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFAT/NN
)/)
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
T-cell/NN
biology/NN
./.
====================
Activation/NN
of/IN
T/NN
cells/NNS
results/VBZ
in/IN
the/DT
rapid/JJ
calcineurin-dependent/JJ
translocation/NN
of/IN
NFAT/NN
transcription/NN
factors/NNS
from/IN
the/DT
cytoplasm/NN
to/TO
the/DT
nucleus/NN
./.
====================
This/DT
translocation/NN
process/NN
coupled/VBN
to/TO
the/DT
subsequent/JJ
active/JJ
maintenance/NN
of/IN
NFAT/NN
in/IN
the/DT
nucleus/NN
compartment/NN
is/VBZ
critical/JJ
for/IN
the/DT
induction/NN
of/IN
expression/NN
of/IN
several/JJ
genes/NNS
encoding/VBG
cytokines/NNS
and/CC
membrane/NN
proteins/NNS
that/WDT
modulate/VBP
immune/JJ
responses/NNS
./.
====================
The/DT
molecular/JJ
cloning/NN
of/IN
the/DT
NFAT/NN
family/NN
of/IN
transcription/NN
factors/NNS
has/VBZ
facilitated/VBN
rapid/JJ
progress/NN
in/IN
the/DT
understanding/NN
of/IN
the/DT
signalling/NN
mechanisms/NNS
that/WDT
control/VBP
the/DT
activity/NN
of/IN
NFAT/NN
./.
====================
UI/LS
-/:
98455230/CD
====================
TI/LS
-/:
Differential/JJ
RNA/NN
display/NN
identifies/VBZ
novel/JJ
genes/NNS
associated/VBN
with/IN
decreased/VBN
vitamin/NN
D/NN
receptor/NN
expression/NN
./.
====================
AB/LS
-/:
To/TO
characterize/VB
further/RB
the/DT
function/NN
of/IN
the/DT
intracellular/JJ
vitamin/NN
D/NN
receptor/NN
(/(
VDR/NN
)/)
,/,
we/PRP
have/VBP
developed/VBN
stable/JJ
transfectant/JJ
variants/NNS
of/IN
a/DT
vitamin/NN
D-responsive/JJ
cell/NN
line/NN
(/(
U937/NN
)/)
which/WDT
express/VBP
either/CC
decreased/VBN
or/CC
increased/VBN
numbers/NNS
of/IN
VDR/NN
./.
====================
In/IN
this/DT
study/NN
we/PRP
have/VBP
analyzed/VBN
changes/NNS
in/IN
gene/NN
expression/NN
associated/VBN
with/IN
this/DT
variable/JJ
VDR/NN
expression/NN
./.
====================
Initial/JJ
experiments/NNS
indicated/VBD
that/IN
a/DT
50/CD
%/NN
decrease/NN
in/IN
VDR/NN
levels/NNS
was/VBD
associated/VBN
with/IN
a/DT
2-fold/JJ
increase/NN
in/IN
cell/NN
proliferation/NN
and/CC
a/DT
similar/JJ
rise/NN
in/IN
c-myc/NN
mRNA/NN
expression/NN
./.
====================
Further/JJ
studies/NNS
were/VBD
carried/VBN
out/RP
using/VBG
differential/JJ
RNA/NN
display/NN
(/(
DD/NN
)/)
./.
====================
Sequence/NN
analysis/NN
of/IN
DD/NN
products/NNS
revealed/VBD
two/CD
cDNAs/NNS
with/IN
identity/NN
to/TO
known/VBN
gene/NN
products/NNS
:/:
the/DT
catalytic/JJ
sub-unit/NN
of/IN
DNA-protein/JJ
kinase/NN
(/(
DNA-PK(CS)/NN
)/)
,/,
and/CC
the/DT
peroxisomal/JJ
enzyme/NN
17beta-hydroxysteroid/NN
dehydrogenase/NN
type/NN
IV/CD
(/(
17beta-HSD/NN
IV/CD
)/)
./.
====================
Northern/NN
analysis/NN
confirmed/VBD
that/IN
expression/NN
of/IN
both/DT
mRNAs/NNS
was/VBD
reduced/VBN
in/IN
cells/NNS
with/IN
decreased/VBN
numbers/NNS
of/IN
VDR/NN
./.
====================
Down-regulation/NN
of/IN
17beta-HSD/NN
IV/CD
mRNA/NN
expression/NN
was/VBD
associated/VBN
with/IN
enhanced/VBN
estradiol/NN
inactivation/NN
by/IN
U937/NN
cells/NNS
,/,
suggesting/VBG
a/DT
link/NN
between/IN
estrogenic/JJ
pathways/NNS
and/CC
cell/NN
proliferation/NN
./.
====================
Further/JJ
Northern/NN
analyses/NNS
indicated/VBD
that/IN
there/EX
was/VBD
no/DT
significant/JJ
change/NN
in/IN
17beta-HSD/NN
IV/CD
or/CC
DNA-PK(CS)/NN
mRNA/NN
levels/NNS
following/VBG
treatment/NN
with/IN
1,25(OH)2D3/NN
,/,
although/IN
expression/NN
of/IN
both/DT
genes/NNS
varied/VBD
with/IN
changes/NNS
in/IN
cell/NN
proliferation/NN
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
,/,
in/IN
addition/NN
to/TO
its/PRP$
established/JJ
role/NN
as/IN
a/DT
hormone-dependent/JJ
trans-activator/NN
,/,
VDR/NN
may/MD
influence/VB
gene/NN
expression/NN
by/IN
ligand-independent/JJ
mechanisms/NNS
./.
====================
UI/LS
-/:
98438501/CD
====================
TI/LS
-/:
Prostaglandin/NN
E2/NN
Up-regulates/VBZ
HIV-1/NN
long/JJ
terminal/JJ
repeat-driven/JJ
gene/NN
activity/NN
in/IN
T/NN
cells/NNS
via/IN
NF-kappaB-dependent/JJ
and/CC
-independent/JJ
signaling/NN
pathways/NNS
./.
====================
AB/LS
-/:
Replication/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type-1/NN
(/(
HIV-1/NN
)/)
is/VBZ
highly/RB
dependent/JJ
on/IN
the/DT
state/NN
of/IN
activation/NN
of/IN
the/DT
infected/JJ
cells/NNS
and/CC
is/VBZ
modulated/VBN
by/IN
interactions/NNS
between/IN
viral/JJ
and/CC
host/NN
cellular/JJ
factors/NNS
./.
====================
Prostaglandin/NN
E2/NN
(/(
PGE2/NN
)/)
,/,
a/DT
pleiotropic/JJ
immunomodulatory/JJ
molecule/NN
,/,
is/VBZ
observed/VBN
at/IN
elevated/JJ
levels/NNS
during/IN
HIV-1/NN
infection/NN
as/RB
well/RB
as/IN
during/IN
the/DT
course/NN
of/IN
other/JJ
pathogenic/JJ
infections/NNS
./.
====================
In/IN
1G5/NN
,/,
a/DT
Jurkat-derived/JJ
T/NN
cell/NN
line/NN
stably/RB
transfected/VBN
with/IN
a/DT
luciferase/NN
gene/NN
driven/VBN
by/IN
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
,/,
we/PRP
found/VBD
that/IN
PGE2/NN
markedly/RB
enhanced/VBD
HIV-1/NN
LTR-mediated/JJ
reporter/NN
gene/NN
activity/NN
./.
====================
Experiments/NNS
have/VBP
been/VBN
conducted/VBN
to/TO
identify/VB
second/JJ
messengers/NNS
involved/VBN
in/IN
this/DT
PGE2-dependent/JJ
up-regulating/VBG
effect/NN
on/IN
the/DT
regulatory/JJ
element/NN
of/IN
HIV-1/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
present/VBP
evidence/NN
indicating/VBG
that/IN
signal/NN
transduction/NN
pathways/NNS
induced/VBN
by/IN
PGE2/NN
necessitate/VBP
the/DT
participation/NN
of/IN
cyclic/JJ
AMP/NN
,/,
protein/NN
kinase/NN
A/NN
,/,
and/CC
Ca2+/NN
./.
====================
Experiments/NNS
conducted/VBN
with/IN
different/JJ
HIV-1/NN
LTR-based/NN
vectors/NNS
suggested/VBD
that/IN
PGE2-mediated/JJ
activation/NN
effect/NN
on/IN
HIV-1/NN
transcription/NN
was/VBD
transduced/VBN
via/IN
both/CC
NF-kappaB-dependent/JJ
and/CC
-independent/JJ
signaling/NN
pathways/NNS
./.
====================
The/DT
involvement/NN
of/IN
NF-kappaB/NN
in/IN
the/DT
PGE2-dependent/JJ
activating/VBG
effect/NN
on/IN
HIV-1/NN
transcription/NN
was/VBD
further/RB
confirmed/VBN
using/VBG
a/DT
kappaB-regulated/JJ
luciferase/NN
encoding/NN
vector/NN
and/CC
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
./.
====================
Results/NNS
from/IN
Northern/NN
blot/NN
and/CC
flow/NN
cytometric/JJ
analyses/NNS
,/,
as/RB
well/RB
as/IN
the/DT
use/NN
of/IN
a/DT
selective/JJ
antagonist/NN
indicated/VBD
that/IN
PGE2/NN
modulation/NN
of/IN
HIV-1/NN
LTR-driven/JJ
reporter/NN
gene/NN
activity/NN
in/IN
studied/VBN
T/NN
lymphoid/JJ
cells/NNS
is/VBZ
transduced/VBN
via/IN
the/DT
EP4/NN
receptor/NN
subtype/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
secretion/NN
of/IN
PGE2/NN
by/IN
macrophages/NNS
in/IN
response/NN
to/TO
infection/NN
or/CC
inflammatory/JJ
activators/NNS
could/MD
induce/VB
signaling/NN
events/NNS
resulting/VBG
in/IN
activation/NN
of/IN
proviral/JJ
DNA/NN
present/JJ
into/IN
T/NN
cells/NNS
latently/RB
infected/VBN
with/IN
HIV-1/NN
./.
====================
UI/LS
-/:
98422270/CD
====================
TI/LS
-/:
Activation/NN
of/IN
distinct/JJ
transcription/NN
factors/NNS
in/IN
neutrophils/NNS
by/IN
bacterial/JJ
LPS/NN
,/,
interferon-gamma/NN
,/,
and/CC
GM-CSF/NN
and/CC
the/DT
necessity/NN
to/TO
overcome/VB
the/DT
action/NN
of/IN
endogenous/JJ
proteases/NNS
./.
====================
AB/LS
-/:
Human/JJ
neutrophils/NNS
can/MD
be/VB
induced/VBN
to/TO
actively/RB
transcribe/VB
a/DT
number/NN
of/IN
early-response/JJ
genes/NNS
,/,
in/IN
particular/JJ
those/DT
encoding/VBG
cytokines/NNS
,/,
chemokines/NNS
,/,
and/CC
the/DT
high-affinity/JJ
surface/NN
receptor/NN
for/IN
IgG/NN
,/,
FcgammaRI/NN
./.
====================
Although/IN
little/JJ
is/VBZ
known/VBN
to/TO
date/NN
about/IN
the/DT
regulation/NN
of/IN
gene/NN
transcription/NN
in/IN
neutrophils/NNS
,/,
several/JJ
indications/NNS
point/VBP
to/TO
a/DT
role/NN
for/IN
distinct/JJ
transcription/NN
factors/NNS
,/,
such/JJ
as/IN
members/NNS
of/IN
the/DT
NF-kappaB/NN
and/CC
STAT/NN
families/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
investigated/VBD
whether/IN
these/DT
transcription/NN
factors/NNS
become/VBP
activated/VBN
under/IN
stimulatory/JJ
conditions/NNS
which/WDT
are/VBP
known/VBN
to/TO
induce/VB
gene/NN
transcription/NN
in/IN
neutrophils/NNS
./.
====================
Unexpectedly/RB
,/,
we/PRP
found/VBD
that/IN
conventional/JJ
procedures/NNS
employed/VBN
to/TO
prepare/VB
cellular/JJ
extracts/NNS
cause/VBP
the/DT
release/NN
of/IN
proteolytic/JJ
activities/NNS
that/WDT
are/VBP
normally/RB
stored/VBN
in/IN
intracellular/JJ
granules/NNS
,/,
resulting/VBG
in/IN
the/DT
degradation/NN
of/IN
various/JJ
NF-kappaB/Rel/NN
and/CC
STAT/NN
proteins/NNS
./.
====================
To/TO
circumvent/VB
this/DT
problem/NN
,/,
we/PRP
developed/VBD
an/DT
alternative/JJ
procedure/NN
which/WDT
allowed/VBD
us/PRP
to/TO
show/VB
that/IN
in/IN
neutrophils/NNS
,/,
LPS/NN
and/CC
TNFalpha/NN
induce/VBP
a/DT
NF-kappaB/NN
DNA-binding/JJ
activity/NN
which/WDT
essentially/RB
consists/VBZ
of/IN
p50/RelA/NN
dimers/NNS
,/,
and/CC
that/IN
IFNgamma/NN
promotes/VBZ
the/DT
binding/NN
of/IN
STAT1/NN
homodimers/NNS
to/TO
the/DT
IFNgamma/NN
response/NN
region/NN
of/IN
the/DT
FcgammaRI/NN
promoter/NN
./.
====================
Moreover/RB
,/,
we/PRP
report/VBP
that/IN
neutrophil/NN
stimulation/NN
with/IN
GM-CSF/NN
results/VBZ
in/IN
the/DT
formation/NN
of/IN
a/DT
STAT5-containing/JJ
DNA-binding/JJ
activity/NN
./.
====================
Collectively/RB
,/,
the/DT
current/JJ
findings/NNS
open/VBP
new/JJ
perspectives/NNS
about/IN
mechanisms/NNS
that/WDT
are/VBP
likely/JJ
to/TO
regulate/VB
gene/NN
transcription/NN
in/IN
neutrophils/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
procedure/NN
described/VBN
herein/RB
could/MD
prove/VB
useful/JJ
in/IN
other/JJ
cell/NN
types/NNS
that/WDT
express/VBP
high/JJ
levels/NNS
of/IN
endogenous/JJ
proteases/NNS
./.
====================
UI/LS
-/:
98413772/CD
====================
TI/LS
-/:
Low/JJ
CD3+CD28-induced/JJ
interleukin-2/NN
production/NN
correlates/VBZ
with/IN
decreased/VBN
reactive/JJ
oxygen/NN
intermediate/JJ
formation/NN
in/IN
neonatal/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
capacity/NN
of/IN
neonatal/JJ
T/NN
cells/NNS
to/TO
secrete/VB
interleukin-2/NN
(/(
IL-2/NN
)/)
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
variable/JJ
./.
====================
We/PRP
analysed/VBD
IL-2/NN
production/NN
in/IN
purified/VBN
neonatal/JJ
and/CC
adult/JJ
T/NN
cells/NNS
using/VBG
polyclonal/JJ
activator/NN
phorbol/NN
ester/NN
+/CC
calcium/NN
ionophore/NN
(/(
PDBu/NN
+/CC
iono/NN
)/)
or/CC
receptor-mediated/JJ
anti-CD3/anti-CD3+/JJ
anti-CD28/JJ
stimulation/NN
./.
====================
PDBu/NN
+/CC
iono/NN
induced/VBD
equally/RB
high/JJ
IL-2/NN
levels/NNS
in/IN
both/DT
groups/NNS
and/CC
,/,
when/WRB
stimulated/VBN
with/IN
plate-bound/JJ
anti-CD3/JJ
monoclonal/JJ
antibody/NN
(/(
mAb/NN
)/)
,/,
the/DT
IL-2/NN
secretion/NN
by/IN
neonatal/JJ
cells/NNS
was/VBD
undetectable/JJ
and/CC
adult/JJ
cells/NNS
produced/VBD
low/JJ
amounts/NNS
of/IN
IL-2/NN
(/(
mean/NN
331/CD
+/-/CC
86/CD
pg/ml/NN
)/)
./.
====================
The/DT
addition/NN
of/IN
anti-CD28/JJ
mAb/NN
to/TO
anti-CD3-stimulated/JJ
cells/NNS
markedly/RB
increased/VBD
IL-2/NN
production/NN
in/IN
both/DT
cell/NN
types/NNS
,/,
but/CC
levels/NNS
of/IN
IL-2/NN
in/IN
neonatal/JJ
T/NN
cells/NNS
remained/VBD
clearly/RB
lower/JJR
than/IN
those/DT
of/IN
adult/JJ
T/NN
cells/NNS
(/(
respective/JJ
mean/JJ
values/NNS
:/:
385/CD
+/-/CC
109/CD
pg/ml/NN
and/CC
4494/CD
+/-/CC
1199/CD
pg/ml/NN
)/)
./.
====================
As/IN
NF-kappa/NN
B/NN
is/VBZ
a/DT
critical/JJ
transcription/NN
factor/NN
in/IN
the/DT
control/NN
of/IN
IL-2/NN
expression/NN
,/,
we/PRP
next/RB
analysed/VBD
its/PRP$
nuclear/JJ
translocation/NN
in/IN
neonatal/JJ
and/CC
adult/JJ
T/NN
cells/NNS
using/VBG
the/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
and/CC
,/,
because/IN
induction/NN
of/IN
reactive/JJ
oxygen/NN
intermediates/NNS
(/(
ROI/NNS
)/)
is/VBZ
required/VBN
for/IN
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
,/,
we/PRP
also/RB
analysed/VBD
levels/NNS
of/IN
intracellular/JJ
ROI/NNS
in/IN
these/DT
cells/NNS
using/VBG
the/DT
ROI-reactive/JJ
fluorochrome/NN
DCFH-DA/NN
and/CC
flow/NN
cytometry/NN
./.
====================
In/IN
neonatal/JJ
T/NN
cells/NNS
NF-kappa/NN
B/NN
activation/NN
and/CC
ROI/NNS
formation/NN
after/IN
anti-CD3/JJ
stimulation/NN
were/VBD
low/JJ
compared/VBN
with/IN
adult/JJ
T/NN
cells/NNS
and/CC
,/,
although/IN
addition/NN
of/IN
anti-CD28/JJ
mAb/NN
increased/VBD
induction/NN
of/IN
NF-kappa/NN
B/NN
and/CC
ROI/NNS
formation/NN
,/,
levels/NNS
similar/JJ
to/TO
those/DT
of/IN
adults/NNS
were/VBD
not/RB
achieved/VBN
./.
====================
After/IN
PDBu/NN
+/CC
iono/NN
stimulation/NN
,/,
the/DT
cells/NNS
showed/VBD
similar/JJ
ROI/NNS
formation/NN
and/CC
IL-2/NN
secretion/NN
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
reduced/VBN
IL-2/NN
production/NN
by/IN
neonatal/JJ
T/NN
cells/NNS
is/VBZ
specific/JJ
for/IN
anti-CD3/JJ
and/CC
anti-CD3+/JJ
anti-CD28-mediated/JJ
stimulation/NN
and/CC
that/IN
these/DT
activators/NNS
can/MD
not/RB
effectively/RB
activate/VB
the/DT
ROI-NF-kappa/NN
B/NN
signalling/NN
pathway/NN
in/IN
neonatal/JJ
T/NN
cells/NNS
./.
====================
UI/LS
-/:
98397262/CD
====================
TI/LS
-/:
CD30/NN
is/VBZ
a/DT
CD40-inducible/JJ
molecule/NN
that/WDT
negatively/RB
regulates/VBZ
CD40-mediated/JJ
immunoglobulin/NN
class/NN
switching/NN
in/IN
non-antigen-selected/JJ
human/JJ
B/NN
cells/NNS
./.
====================
AB/LS
-/:
We/PRP
used/VBD
our/PRP$
monoclonal/JJ
model/NN
of/IN
germinal/JJ
center/NN
maturation/NN
,/,
CL-01/NN
B/NN
cells/NNS
,/,
to/TO
investigate/VB
the/DT
role/NN
of/IN
CD30/NN
in/IN
human/JJ
B/NN
cell/NN
differentiation/NN
./.
====================
CL-01/NN
cells/NNS
are/VBP
IgM+/JJ
IgD+/JJ
CD30+/JJ
and/CC
switch/VBP
to/TO
IgG/NN
,/,
IgA/NN
,/,
and/CC
IgE/NN
when/WRB
exposed/VBN
to/TO
CD40L/NN
and/CC
IL-4/NN
./.
====================
Switching/NN
is/VBZ
hampered/VBN
by/IN
CD30/NN
coengagement/NN
,/,
possibly/RB
through/IN
interference/NN
with/IN
the/DT
CD40-mediated/JJ
NF-kappaB-dependent/JJ
transcriptional/JJ
activation/NN
of/IN
downstream/JJ
C(H)/NN
genes/NNS
./.
====================
The/DT
physiological/JJ
relevance/NN
of/IN
this/DT
phenomenon/NN
is/VBZ
emphasized/VBN
by/IN
similar/JJ
CD30-mediated/JJ
effects/NNS
in/IN
naive/JJ
B/NN
cells/NNS
./.
====================
Expression/NN
of/IN
CD30/NN
by/IN
these/DT
cells/NNS
is/VBZ
induced/VBN
by/IN
CD40L/NN
but/CC
is/VBZ
inhibited/VBN
by/IN
B/NN
cell/NN
receptor/NN
coengagement/NN
and/or/CC
exposure/NN
to/TO
IL-6/NN
and/CC
IL-12/NN
./.
====================
Our/PRP$
data/NNS
suggest/VBP
that/IN
CD30/NN
critically/RB
regulates/VBZ
the/DT
CD40-mediated/JJ
differentiation/NN
of/IN
non-antigen-selected/JJ
human/JJ
B/NN
cells/NNS
./.
====================
UI/LS
-/:
98390872/CD
====================
TI/LS
-/:
Calcineurin/NN
and/CC
the/DT
biological/JJ
effect/NN
of/IN
cyclosporine/NN
and/CC
tacrolimus/NN
./.
====================
AB/LS
-/:
The/DT
mechanism/NN
of/IN
the/DT
immunosuppressive/JJ
effect/NN
of/IN
CyA/NN
and/CC
FK/NN
506/CD
can/MD
be/VB
monitored/VBN
in/FW
vivo/FW
in/IN
humans/NNS
./.
====================
The/DT
picture/NN
emerging/VBG
is/VBZ
of/IN
a/DT
close/JJ
relationship/NN
between/IN
drug/NN
concentrations/NNS
and/CC
CN/NN
inhibition/NN
./.
====================
But/CC
many/JJ
puzzles/NNS
of/IN
the/DT
drugs/NNS
remain/VBP
./.
====================
What/WP
is/VBZ
the/DT
role/NN
of/IN
CyA/NN
in/IN
the/DT
activation/NN
of/IN
transforming/VBG
growth/NN
factor-beta/NN
(/(
TGF-beta/NN
)/)
,/,
particularly/RB
in/IN
relationship/NN
to/TO
nephrotoxicity/NN
and/CC
fibrogenesis/NN
?/.
====================
How/WRB
important/JJ
are/VBP
the/DT
anti-inflammatory/JJ
(/(
non/JJ
T/NN
)/)
effects/NNS
of/IN
CyA/NN
,/,
and/CC
which/WDT
cells/NNS
do/VBP
they/PRP
operate/VB
in/IN
?/.
====================
Are/VBP
there/EX
effects/NNS
of/IN
CyA/NN
and/CC
FK/NN
506/CD
all/DT
attributable/JJ
to/TO
CN/NN
inhibition/NN
,/,
and/CC
how/WRB
much/JJ
of/IN
them/PRP
are/VBP
mediated/VBN
through/IN
the/DT
NFATC/NN
family/NN
of/IN
transcription/NN
factors/NNS
?/.
====================
Finally/RB
,/,
it/PRP
would/MD
be/VB
useful/JJ
to/TO
know/VB
what/WP
the/DT
inhibitory/JJ
effects/NNS
of/IN
CyA/NN
are/VBP
on/IN
tolerance/NN
and/CC
negative/JJ
regulatory/JJ
events/NNS
./.
====================
UI/LS
-/:
98380286/CD
====================
TI/LS
-/:
Stimulation/NN
of/IN
B/NN
and/CC
T/NN
cells/NNS
activates/VBZ
expression/NN
of/IN
transcription/NN
and/CC
differentiation/NN
factors/NNS
./.
====================
AB/LS
-/:
During/IN
B/NN
and/CC
T/NN
cell/NN
differentiation/NN
and/CC
proliferation/NN
many/JJ
genes/NNS
are/VBP
induced/VBN
or/CC
repressed/VBN
while/IN
certain/JJ
genes/NNS
are/VBP
constitutively/RB
expressed/VBN
./.
====================
To/TO
investigate/VB
processes/NNS
related/JJ
to/TO
B/NN
and/CC
T/NN
cell/NN
activation/NN
,/,
the/DT
gene/NN
expression/NN
of/IN
stimulated/VBN
and/CC
nonstimulated/JJ
Ramos/NN
and/CC
Jurkat/NN
cells/NNS
was/VBD
studied/VBN
using/VBG
cDNA/NN
microarray/NN
technology/NN
./.
====================
Simultaneous/JJ
analysis/NN
of/IN
close/JJ
to/TO
600/CD
genes/NNS
indicated/VBD
highest/JJS
increase/NN
in/IN
the/DT
expression/NN
of/IN
certain/JJ
transcription/NN
,/,
differentiation/NN
and/CC
proliferation/NN
factors/NNS
./.
====================
Many/JJ
of/IN
these/DT
genes/NNS
have/VBP
not/RB
previously/RB
been/VBN
shown/VBN
to/TO
funcion/VB
in/IN
the/DT
stimulated/VBN
lymphocytes/NNS
./.
====================
Also/RB
genes/NNS
encoding/VBG
proteins/NNS
involved/VBN
in/IN
DNA/NN
replication/NN
,/,
binding/NN
,/,
transcription/NN
and/CC
translation/NN
were/VBD
induced/VBN
./.
====================
Large/JJ
part/NN
of/IN
the/DT
activated/VBN
genes/NNS
were/VBD
under/IN
very/RB
stringent/JJ
regulation/NN
being/VBG
expressed/VBN
only/RB
after/IN
stimulation/NN
./.
====================
The/DT
mechanism/NN
and/CC
function/NN
of/IN
the/DT
expressed/VBN
genes/NNS
during/IN
lymphocyte/NN
differentiation/NN
and/CC
in/IN
disorders/NNS
is/VBZ
discussed/VBN
./.
====================
UI/LS
-/:
99030136/CD
====================
TI/LS
-/:
Interleukin/NN
2/CD
and/CC
15/CD
activate/VBP
Stat3alpha/NN
in/IN
human/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
3/CD
(/(
Stat3/NN
)/)
has/VBZ
recently/RB
been/VBN
shown/VBN
to/TO
exist/VB
in/IN
two/CD
alternatively/RB
spliced/VBN
isoforms/NNS
,/,
a/DT
short/JJ
form/NN
,/,
Stat3beta/NN
,/,
and/CC
a/DT
longer/JJR
form/NN
,/,
Stat3alpha/NN
,/,
displaying/VBG
differences/NNS
in/IN
transcriptional/JJ
activity/NN
./.
====================
It/PRP
is/VBZ
unknown/JJ
which/WDT
Stat3/NN
isoform/NN
(/(
s/NNS
)/)
is/VBZ
activated/VBN
in/IN
response/NN
to/TO
interleukin/NN
(/(
IL/NN
)/)
-2/CD
and/CC
IL-15/NN
./.
====================
Here/RB
,/,
cytokine-induced/JJ
activation/NN
of/IN
Stat3/NN
in/IN
previously/RB
activated/VBN
CD4(+)/JJ
human/JJ
T/NN
cells/NNS
was/VBD
examined/VBN
using/VBG
Stat3/NN
antibodies/NNS
directed/VBN
against/IN
different/JJ
regions/NNS
of/IN
Stat3/NN
./.
====================
As/IN
determined/VBN
by/IN
tyrosine/NN
phosphorylation/NN
,/,
nuclear/JJ
translocation/NN
and/CC
binding/VBG
to/TO
an/DT
hSIE-oligonucleotide/NN
probe/NN
,/,
IL-2/NN
and/CC
IL-15/NN
activated/VBD
the/DT
slowly/RB
migrating/VBG
isoform/NN
,/,
Stat3alpha/NN
./.
====================
In/IN
contrast/NN
,/,
minimal/JJ
or/CC
no/DT
activation/NN
of/IN
Stat3beta/NN
was/VBD
observed/VBN
,/,
suggesting/VBG
that/IN
IL-2/NN
and/CC
IL-15/NN
predominantly/RB
activate/VBP
Stat3alpha/NN
in/IN
human/JJ
CD4(+)/JJ
T/NN
cells/NNS
./.
====================
In/IN
this/DT
way/NN
,/,
diversity/NN
in/IN
the/DT
expression/NN
and/CC
activation/NN
of/IN
Stat3/NN
proteins/NNS
may/MD
provide/VB
additional/JJ
means/NNS
of/IN
regulating/VBG
cytokine-induced/JJ
T/NN
cell/NN
responses/NNS
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
99018025/CD
====================
TI/LS
-/:
Transcriptional/JJ
regulation/NN
of/IN
lysosomal/JJ
acid/NN
lipase/NN
in/IN
differentiating/VBG
monocytes/NNS
is/VBZ
mediated/VBN
by/IN
transcription/NN
factors/NNS
Sp1/NN
and/CC
AP-2/NN
./.
====================
AB/LS
-/:
Human/JJ
lysosomal/JJ
acid/NN
lipase/NN
(/(
LAL/NN
)/)
is/VBZ
a/DT
hydrolase/NN
required/VBN
for/IN
the/DT
cleavage/NN
of/IN
cholesteryl/NN
esters/NNS
and/CC
triglycerides/NNS
derived/VBN
from/IN
plasma/NN
lipoproteins/NNS
./.
====================
It/PRP
is/VBZ
shown/VBN
here/RB
that/IN
during/IN
monocyte/NN
to/TO
macrophage/NN
differentiation/NN
,/,
the/DT
expression/NN
of/IN
LAL-mRNA/NN
is/VBZ
induced/VBN
./.
====================
This/DT
induction/NN
is/VBZ
dependent/JJ
on/IN
protein/NN
kinase/NN
C/NN
activity/NN
and/CC
protein/NN
synthesis/NN
./.
====================
The/DT
cell/NN
type-specific/JJ
increase/NN
in/IN
LAL/NN
expression/NN
is/VBZ
further/RB
investigated/VBN
in/IN
the/DT
THP-1/NN
cell/NN
line/NN
with/IN
respect/NN
to/TO
transcriptional/JJ
regulation/NN
./.
====================
The/DT
human/JJ
monocytic/JJ
leukemia/NN
cell/NN
line/NN
THP-1/NN
differentiates/VBZ
into/IN
macrophage-like/JJ
cells/NNS
when/WRB
treated/VBN
with/IN
phorbol/NN
esters/NNS
./.
====================
In/IN
order/NN
to/TO
determine/VB
the/DT
cis-acting/JJ
elements/NNS
necessary/JJ
for/IN
both/CC
basal/JJ
and/CC
phorbol/NN
12-myristate-13/JJ
acetate/NN
(/(
PMA/NN
)/)
-enhanced/JJ
promoter/NN
activity/NN
,/,
we/PRP
performed/VBD
deletion/NN
analysis/NN
and/CC
reporter/NN
gene/NN
assays/NNS
./.
====================
A/DT
PMA/NN
responsive/JJ
element/NN
has/VBZ
been/VBN
identified/VBN
between/IN
-182/CD
bp/NN
and/CC
-107/CD
bp/NN
upstream/RB
of/IN
the/DT
major/JJ
transcription/NN
start/NN
site/NN
./.
====================
Gel/NN
mobility/NN
shift/NN
assays/NNS
demonstrated/VBD
that/IN
binding/NN
of/IN
Sp1/NN
and/CC
AP-2/NN
to/TO
the/DT
LAL/NN
promoter/NN
is/VBZ
increased/VBN
by/IN
PMA/NN
in/IN
THP-1/NN
cells/NNS
./.
====================
Co-transfections/NNS
with/IN
expression/NN
plasmids/NNS
for/IN
Sp1/NN
and/CC
AP-2/NN
further/RB
emphasized/VBD
the/DT
important/JJ
role/NN
of/IN
these/DT
transcription/NN
factors/NNS
in/IN
both/CC
basal/JJ
and/CC
PMA-enhanced/JJ
LAL/NN
expression/NN
./.
====================
Our/PRP$
data/NNS
suggest/VBP
that/IN
differentiation/NN
dependent/JJ
increase/NN
of/IN
lysosomal/JJ
acid/NN
lipase/NN
(/(
LAL/NN
)/)
expression/NN
in/IN
THP-1/NN
cells/NNS
is/VBZ
mediated/VBN
by/IN
a/DT
concerted/JJ
action/NN
of/IN
Sp1/NN
and/CC
AP-2/NN
./.
====================
UI/LS
-/:
99008340/CD
====================
TI/LS
-/:
Relationship/NN
between/IN
IkappaBalpha/NN
constitutive/JJ
expression/NN
,/,
TNFalpha/NN
synthesis/NN
,/,
and/CC
apoptosis/NN
in/IN
EBV-infected/JJ
lymphoblastoid/JJ
cells/NNS
./.
====================
AB/LS
-/:
In/IN
order/NN
to/TO
understand/VB
the/DT
role/NN
of/IN
NF-kappaB/NN
in/IN
EBV/NN
transformation/NN
we/PRP
have/VBP
established/VBN
stably/RB
transfected/VBN
IkappaBalpha/NN
into/IN
lymphoblastoid/JJ
cells/NNS
./.
====================
Two/CD
clones/NNS
were/VBD
obtained/VBN
in/IN
which/WDT
the/DT
loss/NN
of/IN
NF-kappaB/NN
binding/NN
activity/NN
correlated/VBD
with/IN
the/DT
constitutive/JJ
expression/NN
of/IN
the/DT
transgenic/JJ
IkappaBalpha/NN
./.
====================
Protein/NN
latency/NN
expression/NN
was/VBD
determined/VBN
by/IN
immunocytochemistry/NN
./.
====================
Expression/NN
of/IN
surface/NN
markers/NNS
,/,
intracytoplasmic/JJ
content/NN
of/IN
cytokines/NNS
cell/NN
cycle/NN
analysis/NN
after/IN
BrdU/NN
incorporation/NN
and/CC
DNA/NN
staining/NN
with/IN
propidium/NN
iodide/NN
were/VBD
studied/VBN
by/IN
flow/NN
cytometry/NN
./.
====================
Percentage/NN
of/IN
apoptotic/JJ
cells/NNS
was/VBD
determined/VBN
by/IN
in-situ/FW
labelling/NN
of/IN
DNA/NN
strand/NN
breaks/NNS
./.
====================
No/DT
significative/JJ
changes/NNS
in/IN
EBV/NN
latency/NN
nor/CC
in/IN
cell/NN
surface/NN
marker/NN
expression/NN
was/VBD
found/VBN
./.
====================
In/IN
contrast/NN
,/,
intracytoplasmic/JJ
TNFalpha/NN
levels/NNS
were/VBD
strongly/RB
reduced/VBN
in/IN
transfected/VBN
clones/NNS
./.
====================
Furthermore/RB
,/,
30/CD
%/NN
of/IN
IkappaBalpha/NN
transfected/JJ
cells/NNS
were/VBD
apoptotic/JJ
after/IN
8/CD
h/NN
of/IN
TNFalpha/NN
treatment/NN
./.
====================
This/DT
correlated/VBD
with/IN
a/DT
strong/JJ
reduction/NN
of/IN
BrdU/NN
incorporation/NN
after/IN
24/CD
h/NN
of/IN
TNFalpha/NN
treatment/NN
./.
====================
No/DT
effect/NN
was/VBD
seen/VBN
with/IN
non/JJ
transfected/JJ
cells/NNS
or/CC
with/IN
cells/NNS
transfected/VBN
with/IN
a/DT
control/JJ
plasmid/NN
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
the/DT
TNFalpha/NN
gene/NN
could/MD
be/VB
one/CD
of/IN
the/DT
targets/NNS
of/IN
NF-kappaB/NN
in/IN
EBV/NN
infected/JJ
cells/NNS
and/CC
that/IN
NF-kappaB/NN
protects/VBZ
EBV-infected/JJ
cells/NNS
from/IN
apoptosis/NN
induced/VBN
by/IN
TNFalpha/NN
,/,
which/WDT
may/MD
favour/VB
the/DT
proliferative/JJ
effect/NN
of/IN
this/DT
cytokine/NN
./.
====================
UI/LS
-/:
98455033/CD
====================
TI/LS
-/:
Seminoma/NN
in/IN
a/DT
postmenopausal/JJ
woman/NN
with/IN
a/DT
Y;15/NN
translocation/NN
in/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
and/CC
a/DT
t(Y;15)/45,X/NN
Turner/NN
mosaic/JJ
pattern/NN
in/IN
skin/NN
fibroblasts/NNS
./.
====================
AB/LS
-/:
We/PRP
report/VBP
an/DT
unusual/JJ
case/NN
of/IN
a/DT
55/CD
year/NN
old/JJ
Japanese/NN
woman/NN
with/IN
a/DT
seminoma/NN
but/CC
relatively/RB
normal/JJ
menses/NNS
./.
====================
The/DT
patient/NN
was/VBD
a/DT
phenotypic/JJ
female/NN
with/IN
late/JJ
onset/NN
menarche/NN
(/(
18/CD
years/NNS
of/IN
age/NN
)/)
,/,
who/WP
was/VBD
amenorrhoeic/JJ
for/IN
the/DT
first/JJ
year/NN
,/,
followed/VBN
by/IN
menses/NNS
of/IN
one/CD
to/TO
three/CD
days/NNS
'/POS
slight/JJ
flow/NN
with/IN
dysmenorrhoea/NN
,/,
but/CC
an/DT
otherwise/RB
normal/JJ
menstrual/JJ
history/NN
./.
====================
A/DT
typical/JJ
seminoma/NN
was/VBD
removed/VBN
from/IN
the/DT
left/JJ
adnexal/JJ
region/NN
and/CC
an/DT
immature/JJ
testis/NN
was/VBD
identified/VBN
separately/RB
as/IN
an/DT
associated/VBN
right/JJ
adnexal/JJ
mass/NN
./.
====================
Repeated/JJ
karyotypic/JJ
studies/NNS
on/IN
peripheral/JJ
blood/NN
lymphocyte/NN
cultures/NNS
showed/VBD
only/RB
46,X,-Y,t(Y;15)(q12;p13)/NN
./.
====================
Cytogenetic/JJ
examination/NN
of/IN
the/DT
patient/NN
's/POS
younger/JJR
brother/NN
,/,
who/WP
had/VBD
fathered/VBN
three/CD
healthy/JJ
children/NNS
,/,
showed/VBD
an/DT
identical/JJ
karyotype/NN
./.
====================
Mosaicism/NN
of/IN
46,X,-Y,t(Y;15)(q12;p13)/45,X/NN
cell/NN
lines/NNS
was/VBD
found/VBN
in/IN
skin/NN
samples/NNS
from/IN
the/DT
patient/NN
's/POS
elbow/NN
and/CC
genital/JJ
regions/NNS
,/,
although/IN
there/EX
were/VBD
no/DT
clinical/JJ
stigmata/NN
of/IN
Turner/NN
syndrome/NN
./.
====================
An/DT
androgen/NN
receptor/NN
binding/NN
assay/NN
of/IN
cultured/VBN
genital/JJ
skin/NN
fibroblasts/NNS
was/VBD
negative/JJ
./.
====================
Molecular/JJ
analysis/NN
using/VBG
Southern/NN
blot/NN
hybridisation/NN
,/,
PCR/NN
,/,
and/CC
direct/JJ
DNA/NN
sequencing/NN
showed/VBD
that/IN
neither/CC
the/DT
patient/NN
nor/CC
her/PRP$
brother/NN
had/VBD
a/DT
detectable/JJ
deletion/NN
or/CC
other/JJ
abnormalities/NNS
of/IN
Y/NN
chromosome/NN
sequences/NNS
,/,
including/VBG
the/DT
SRY/NN
(/(
sex/NN
determining/NN
region/NN
of/IN
the/DT
Y/NN
chromosome/NN
)/)
gene/NN
sequence/NN
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
Turner/NN
mosaicism/NN
of/IN
the/DT
45,X/NN
cell/NN
line/NN
may/MD
have/VB
contributed/VBN
to/TO
this/DT
atypical/JJ
presentation/NN
in/IN
an/DT
XY/NN
female/NN
,/,
although/IN
we/PRP
can/MD
not/RB
exclude/VB
abnormalities/NNS
of/IN
other/JJ
genes/NNS
related/JJ
to/TO
sex/NN
differentiation/NN
./.
====================
UI/LS
-/:
98435936/CD
====================
TI/LS
-/:
Potent/JJ
inhibition/NN
of/IN
HIV/NN
type/NN
1/CD
replication/NN
by/IN
an/DT
antiinflammatory/JJ
alkaloid/NN
,/,
cepharanthine/NN
,/,
in/IN
chronically/RB
infected/JJ
monocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
Cepharanthine/NN
is/VBZ
a/DT
biscoclaurine/JJ
alkaloid/NN
isolated/VBN
from/IN
Stephania/FW
cepharantha/FW
Hayata/FW
and/CC
has/VBZ
been/VBN
shown/VBN
to/TO
have/VB
antiinflammatory/JJ
,/,
antiallergic/JJ
,/,
and/CC
immunomodulatory/JJ
activities/NNS
in/FW
vivo/FW
./.
====================
As/IN
several/JJ
inflammatory/JJ
cytokines/NNS
and/CC
oxidative/JJ
stresses/NNS
are/VBP
involved/VBN
in/IN
the/DT
pathogenesis/NN
of/IN
HIV-1/NN
infection/NN
,/,
we/PRP
investigated/VBD
the/DT
inhibitory/JJ
effects/NNS
of/IN
cepharanthine/NN
on/IN
tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF-alpha/NN
)/)
-/CC
and/CC
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
-induced/JJ
HIV-1/NN
replication/NN
in/IN
chronically/RB
infected/JJ
cell/NN
lines/NNS
./.
====================
Two/CD
chronically/RB
HIV-1-infected/JJ
cell/NN
lines/NNS
,/,
U1/NN
(/(
monocytic/JJ
)/)
and/CC
ACH-2/NN
(/(
T/NN
lymphocytic/JJ
)/)
,/,
were/VBD
stimulated/VBN
with/IN
TNF-alpha/NN
or/CC
PMA/NN
and/CC
cultured/VBN
in/IN
the/DT
presence/NN
of/IN
various/JJ
concentrations/NNS
of/IN
the/DT
compound/NN
./.
====================
HIV-1/NN
replication/NN
was/VBD
determined/VBN
by/IN
p24/NN
antigen/NN
level/NN
./.
====================
The/DT
inhibitory/JJ
effects/NNS
of/IN
cepharanthine/NN
on/IN
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
-driven/JJ
gene/NN
expression/NN
and/CC
nuclear/JJ
factor/NN
kappaB/NN
(/(
NF-kappaB/NN
)/)
activation/NN
were/VBD
also/RB
examined/VBN
./.
====================
Cepharanthine/NN
dose/NN
dependently/RB
inhibited/VBD
HIV-1/NN
replication/NN
in/IN
TNF-alpha-/NN
and/CC
PMA-stimulated/JJ
U1/NN
cells/NNS
but/CC
not/RB
in/IN
ACH-2/NN
cells/NNS
./.
====================
Its/PRP$
50/CD
%/NN
effective/JJ
and/CC
cytotoxic/JJ
concentrations/NNS
were/VBD
0.016/CD
and/CC
2.2/CD
microg/ml/NN
in/IN
PMA-stimulated/JJ
U1/NN
cells/NNS
,/,
respectively/RB
./.
====================
Cepharanthine/NN
was/VBD
found/VBN
to/TO
suppress/VB
HIV-1/NN
LTR-driven/JJ
gene/NN
expression/NN
through/IN
the/DT
inhibition/NN
of/IN
NF-kappaB/NN
activation/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
cepharanthine/NN
is/VBZ
a/DT
highly/RB
potent/JJ
inhibitor/NN
of/IN
HIV-1/NN
replication/NN
in/IN
a/DT
chronically/RB
infected/JJ
monocytic/JJ
cell/NN
line/NN
./.
====================
Since/IN
biscoclaurine/NN
alkaloids/NNS
,/,
containing/VBG
cepharanthine/NN
as/IN
a/DT
major/JJ
component/NN
,/,
are/VBP
widely/RB
used/VBN
for/IN
the/DT
treatment/NN
of/IN
patients/NNS
with/IN
various/JJ
inflammatory/JJ
diseases/NNS
in/IN
Japan/NNP
,/,
cepharanthine/NN
should/MD
be/VB
further/RB
pursued/VBN
for/IN
its/PRP$
chemotherapeutic/JJ
potential/NN
in/IN
HIV-1-infected/JJ
patients/NNS
./.
====================
UI/LS
-/:
98418492/CD
====================
TI/LS
-/:
NF-kappaB/NN
only/RB
partially/RB
mediates/VBZ
Epstein-Barr/JJ
virus/NN
latent/JJ
membrane/NN
protein/NN
1/CD
activation/NN
of/IN
B/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
latent/JJ
membrane/NN
protein/NN
1/CD
(/(
LMP1/NN
)/)
of/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
is/VBZ
required/VBN
for/IN
EBV-induced/JJ
immortalization/NN
of/IN
human/JJ
B/NN
cells/NNS
and/CC
causes/VBZ
tumorigenic/JJ
transformation/NN
of/IN
cell/NN
lines/NNS
./.
====================
LMP1/NN
expression/NN
induces/VBZ
phenotypic/JJ
changes/NNS
resembling/VBG
B/NN
cell/NN
activation/NN
,/,
such/JJ
as/IN
cell/NN
size/NN
increase/NN
and/CC
up-regulation/NN
of/IN
cell/NN
surface/NN
activation/NN
markers/NNS
./.
====================
LMP1/NN
contains/VBZ
two/CD
domains/NNS
that/WDT
activate/VBP
the/DT
transcription/NN
factor/NN
NF-kappaB/NN
,/,
one/CD
through/IN
interactions/NNS
with/IN
TRAF/NN
proteins/NNS
and/CC
the/DT
other/JJ
with/IN
the/DT
TRADD/NN
protein/NN
./.
====================
The/DT
purpose/NN
of/IN
the/DT
present/JJ
study/NN
was/VBD
to/TO
investigate/VB
the/DT
importance/NN
of/IN
NF-kappaB/NN
induction/NN
in/IN
the/DT
up-regulation/NN
of/IN
the/DT
B/NN
cell/NN
activation/NN
markers/NNS
ICAM-1/NN
and/CC
CD71/NN
by/IN
LMP1/NN
./.
====================
This/DT
study/NN
shows/VBZ
that/IN
expression/NN
of/IN
LMP1/NN
activates/VBZ
transcription/NN
from/IN
p50/p65-/NN
and/CC
c-Rel-responsive/JJ
promoters/NNS
,/,
and/CC
that/IN
this/DT
activity/NN
can/MD
be/VB
completely/RB
inhibited/VBN
by/IN
expression/NN
of/IN
a/DT
dominant/JJ
inhibitory/JJ
IkappaB/NN
mutant/NN
./.
====================
ICAM-1/NN
and/CC
CD71/NN
are/VBP
nevertheless/RB
up-regulated/VBN
by/IN
LMP1/NN
in/IN
primary/JJ
B/NN
cells/NNS
and/CC
cell/NN
lines/NNS
expressing/VBG
the/DT
dominant/JJ
IkappaB/NN
./.
====================
Furthermore/RB
,/,
LMP1-induced/JJ
cell/NN
size/NN
increase/NN
of/IN
primary/JJ
B/NN
cells/NNS
was/VBD
unaffected/VBN
by/IN
IkappaB/NN
expression/NN
./.
====================
It/PRP
was/VBD
concluded/VBN
that/IN
even/RB
when/WRB
LMP1/NN
is/VBZ
unable/JJ
to/TO
activate/VB
NF-kappaB/NN
,/,
it/PRP
is/VBZ
still/RB
capable/JJ
of/IN
inducing/VBG
certain/JJ
characteristics/NNS
of/IN
activated/VBN
B/NN
cells/NNS
,/,
strongly/RB
suggesting/VBG
that/IN
LMP1/NN
can/MD
also/RB
activate/VB
cells/NNS
independently/RB
of/IN
NF-kappaB/NN
./.
====================
UI/LS
-/:
98407711/CD
====================
TI/LS
-/:
Models/NNS
of/IN
lineage/NN
switching/NN
in/IN
hematopoietic/JJ
development/NN
:/:
a/DT
new/JJ
myeloid-committed/JJ
eosinophil/NN
cell/NN
line/NN
(/(
YJ/NN
)/)
demonstrates/VBZ
trilineage/NN
potential/NN
./.
====================
AB/LS
-/:
A/DT
new/JJ
human/JJ
leukemia/NN
cell/NN
line/NN
with/IN
an/DT
eosinophilic/JJ
phenotype/NN
,/,
designated/VBN
YJ/NN
,/,
was/VBD
established/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
cells/NNS
of/IN
a/DT
patient/NN
with/IN
chronic/JJ
myelomonocytic/JJ
leukemia/NN
(/(
CMMoL/NN
)/)
with/IN
eosinophilia/NN
./.
====================
When/WRB
cultured/VBN
in/IN
RPMI/NN
1640/CD
medium/NN
containing/VBG
10/CD
%/NN
fetal/JJ
bovine/JJ
serum/NN
,/,
most/JJS
YJ/NN
cells/NNS
were/VBD
myeloblastoid/JJ
with/IN
a/DT
small/JJ
number/NN
of/IN
the/DT
cells/NNS
having/VBG
eosinophilic/JJ
granules/NNS
./.
====================
Cell/NN
surface/NN
markers/NNS
in/IN
the/DT
YJ/NN
cells/NNS
were/VBD
positive/JJ
for/IN
CD33/NN
and/CC
were/VBD
negative/JJ
for/IN
CD34/NN
,/,
CD16/NN
and/CC
CD23/NN
./.
====================
The/DT
eosinophilic/JJ
characteristics/NNS
of/IN
YJ/NN
cells/NNS
were/VBD
confirmed/VBN
by/IN
histochemical/JJ
staining/NN
with/IN
Fast-Green/Neutral-Red/NN
and/CC
by/IN
the/DT
expression/NN
of/IN
mRNAs/NNS
for/IN
eosinophil-associated/JJ
granule/NN
proteins/NNS
,/,
eosinophil/NN
cationic/JJ
protein/NN
(/(
ECP/NN
)/)
,/,
eosinophil-derived/JJ
neurotoxin/NN
(/(
EDN/NN
)/)
,/,
eosinophil/NN
peroxidase/NN
(/(
EPO/NN
)/)
,/,
and/CC
major/JJ
basic/JJ
protein/NN
(/(
MBP/NN
)/)
,/,
and/CC
for/IN
the/DT
Charcot-Leyden/NN
crystal/NN
(/(
CLC/NN
)/)
protein/NN
./.
====================
The/DT
YJ/NN
cells/NNS
could/MD
be/VB
induced/VBN
towards/IN
monocytic/JJ
differentiation/NN
by/IN
stimulation/NN
with/IN
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
./.
====================
The/DT
monocytic/JJ
characteristics/NNS
of/IN
YJ/NN
cells/NNS
treated/VBN
with/IN
PMA/NN
were/VBD
confirmed/VBN
by/IN
morphological/JJ
analysis/NN
with/IN
alpha-naphthyl/NN
butyrate/NN
esterase/NN
staining/NN
,/,
by/IN
CD14/NN
expression/NN
,/,
and/CC
by/IN
increased/VBN
expression/NN
of/IN
Egr-1/NN
mRNA/NN
./.
====================
Furthermore/RB
,/,
YJ/NN
cells/NNS
could/MD
be/VB
differentiated/VBN
towards/IN
the/DT
neutrophil/NN
lineage/NN
by/IN
stimulation/NN
with/IN
all-trans/JJ
retinoic/JJ
acid/NN
(/(
RA/NN
)/)
./.
====================
YJ/NN
cells/NNS
treated/VBN
in/FW
vitro/FW
with/IN
2/CD
microM/NN
RA/NN
differentiated/VBD
into/IN
metamyelocytes/NNS
and/CC
band/NN
neutrophils/NNS
,/,
and/CC
increased/VBD
the/DT
number/NN
of/IN
nitroblue/JJ
tetrazolium/NN
(/(
NBT/NN
)/)
-positive/JJ
cells/NNS
and/CC
increased/VBD
gp91phox/NN
mRNA/NN
expression/NN
./.
====================
Thus/RB
,/,
the/DT
YJ/NN
cell/NN
line/NN
exhibited/VBD
eosinophilic/JJ
characteristics/NNS
,/,
but/CC
was/VBD
able/JJ
to/TO
differentiate/VB
to/TO
the/DT
monocytic/JJ
or/CC
neutrophilic/JJ
lineages/NNS
in/IN
response/NN
to/TO
PMA/NN
or/CC
RA/NN
,/,
respectively/RB
./.
====================
The/DT
expression/NN
of/IN
genes/NNS
for/IN
transcription/NN
factors/NNS
involved/VBN
in/IN
myeloid/JJ
differentiation/NN
was/VBD
evaluated/VBN
by/IN
Northern/NN
blot/NN
analysis/NN
./.
====================
Increased/VBN
expression/NN
of/IN
Egr-1/NN
was/VBD
observed/VBN
with/IN
macrophage/NN
differentiation/NN
./.
====================
In/IN
contrast/NN
,/,
increased/VBN
expressions/NNS
of/IN
C/EBPbeta/NN
and/CC
MZF-1/NN
mRNA/NN
occurred/VBD
with/IN
neutrophilic/JJ
differentiation/NN
./.
====================
The/DT
YJ/NN
cell/NN
line/NN
should/MD
be/VB
useful/JJ
for/IN
elucidating/VBG
the/DT
molecular/JJ
mechanisms/NNS
governing/VBG
lineage/NN
switching/NN
from/IN
the/DT
eosinophil/NN
to/TO
monocytic/JJ
or/CC
neutrophil/NN
lineages/NNS
./.
====================
UI/LS
-/:
98400938/CD
====================
TI/LS
-/:
Interleukin-6/NN
production/NN
in/IN
hemorrhagic/JJ
shock/NN
is/VBZ
accompanied/VBN
by/IN
neutrophil/NN
recruitment/NN
and/CC
lung/NN
injury/NN
./.
====================
AB/LS
-/:
Hemorrhagic/JJ
shock/NN
(/(
HS/NN
)/)
initiates/VBZ
an/DT
inflammatory/JJ
cascade/NN
that/WDT
includes/VBZ
the/DT
production/NN
of/IN
cytokines/NNS
and/CC
recruitment/NN
of/IN
neutrophils/NNS
(/(
PMN/NN
)/)
and/CC
may/MD
progress/VB
to/TO
organ/JJ
failure/NN
,/,
inducing/VBG
acute/JJ
respiratory/JJ
distress/NN
syndrome/NN
(/(
ARDS/NN
)/)
./.
====================
To/TO
examine/VB
the/DT
hypothesis/NN
that/IN
interleukin-6/NN
(/(
IL-6/NN
)/)
contributes/VBZ
to/TO
PMN/NN
infiltration/NN
and/CC
lung/NN
damage/NN
in/IN
HS/NN
,/,
we/PRP
examined/VBD
the/DT
lungs/NNS
of/IN
rats/NNS
subjected/VBN
to/TO
unresuscitated/JJ
and/CC
resuscitated/VBN
HS/NN
for/IN
the/DT
production/NN
of/IN
IL-6/NN
and/CC
activation/NN
of/IN
Stat3/NN
./.
====================
Using/VBG
semiquantitative/JJ
RT-PCR/NN
,/,
we/PRP
found/VBD
a/DT
striking/JJ
increase/NN
in/IN
IL-6/NN
mRNA/NN
levels/NNS
only/RB
in/IN
resuscitated/JJ
HS/NN
,/,
with/IN
peak/NN
levels/NNS
observed/VBN
1/CD
h/NN
after/IN
initiation/NN
of/IN
resuscitation/NN
./.
====================
Increased/VBN
IL-6/NN
protein/NN
expression/NN
was/VBD
localized/JJ
to/TO
bronchial/JJ
and/CC
alveolar/JJ
cells/NNS
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
of/IN
protein/NN
extracts/NNS
from/IN
shock/NN
lungs/NNS
exhibited/VBD
an/DT
increase/NN
in/IN
Stat3/NN
activation/NN
with/IN
kinetics/NN
similar/JJ
to/TO
IL-6/NN
mRNA/NN
./.
====================
In/FW
situ/FW
DNA/NN
binding/NN
assay/NN
determined/VBD
Stat3/NN
activation/NN
predominantly/RB
within/IN
alveoli/NNS
./.
====================
Intratracheal/JJ
instillation/NN
of/IN
IL-6/NN
alone/RB
into/IN
normal/JJ
rats/NNS
resulted/VBD
in/IN
PMN/NN
infiltration/NN
into/IN
lung/NN
interstitium/NN
and/CC
alveoli/NNS
,/,
marked/JJ
elevation/NN
of/IN
bronchoalveolar/JJ
lavage/NN
cellularity/NN
,/,
and/CC
increased/VBN
wet-to-dry/JJ
ratio/NN
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
IL-6/NN
production/NN
and/CC
Stat3/NN
activation/NN
occur/VBP
early/RB
in/IN
HS/NN
and/CC
may/MD
contribute/VB
to/TO
PMN-mediated/JJ
lung/NN
injury/NN
,/,
including/VBG
ARDS/NN
after/IN
HS/NN
./.
====================
UI/LS
-/:
98391735/CD
====================
TI/LS
-/:
The/DT
MHC/NN
class/NN
II/CD
transactivator/NN
(/(
CIITA/NN
)/)
requires/VBZ
conserved/VBN
leucine/NN
charged/JJ
domains/NNS
for/IN
interactions/NNS
with/IN
the/DT
conserved/VBN
W/NN
box/NN
promoter/NN
element/NN
./.
====================
AB/LS
-/:
The/DT
class/NN
II/CD
transactivator/NN
CIITA/NN
is/VBZ
required/VBN
for/IN
transcriptional/JJ
activation/NN
of/IN
the/DT
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
class/NN
II/CD
genes/NNS
./.
====================
Aside/IN
from/IN
an/DT
N-terminal/JJ
acidic/JJ
transcriptional/JJ
activation/NN
domain/NN
,/,
little/JJ
is/VBZ
known/VBN
about/IN
how/WRB
this/DT
factor/NN
functions/VBZ
./.
====================
Extensive/JJ
mutagenesis/NN
of/IN
CIITA/NN
was/VBD
undertaken/VBN
to/TO
identify/VB
structural/JJ
motifs/NNS
required/VBN
for/IN
function/NN
./.
====================
The/DT
ability/NN
of/IN
mutants/NNS
to/TO
activate/VB
a/DT
reporter/NN
gene/NN
under/IN
the/DT
control/NN
of/IN
MHC/NN
class/NN
II/CD
conserved/JJ
W-X-Y/NN
or/CC
X-Y/NN
regulatory/JJ
elements/NNS
was/VBD
determined/VBN
./.
====================
Two/CD
mutants/NNS
displayed/VBD
differential/JJ
activity/NN
between/IN
the/DT
two/CD
promoters/NNS
,/,
activating/VBG
transcription/NN
with/IN
the/DT
W-X-Y/NN
but/CC
not/RB
the/DT
X-Y/NN
elements/NNS
./.
====================
All/DT
mutants/NNS
were/VBD
tested/VBN
for/IN
their/PRP$
ability/NN
to/TO
interfere/VB
with/IN
wild-type/JJ
CIITA/NN
activity/NN
./.
====================
Five/CD
CIITA/NN
mutant/JJ
constructions/NNS
were/VBD
able/JJ
to/TO
down-regulate/VB
wild-type/JJ
CIITA/NN
activity/NN
./.
====================
Three/CD
of/IN
these/DT
mutants/NNS
contained/VBD
targeted/VBN
disruptions/NNS
of/IN
potential/JJ
functional/JJ
motifs/NNS
:/:
the/DT
acidic/JJ
activation/NN
domain/NN
,/,
a/DT
putative/JJ
GTP-binding/JJ
motif/NN
and/CC
two/CD
leucine/NN
charged/JJ
domains/NNS
(/(
LCD/NNS
motifs/NNS
)/)
./.
====================
The/DT
other/JJ
two/CD
contained/VBD
mutations/NNS
in/IN
regions/NNS
that/WDT
do/VBP
not/RB
have/VB
homology/NN
to/TO
described/VBN
proteins/NNS
./.
====================
The/DT
characterization/NN
of/IN
CIITA/NN
mutants/NNS
that/WDT
are/VBP
able/JJ
to/TO
discriminate/VB
between/IN
promoters/NNS
with/IN
or/CC
without/IN
the/DT
W/NN
box/NN
strongly/RB
suggests/VBZ
that/IN
CIITA/NN
requires/VBZ
such/JJ
interactions/NNS
for/IN
function/NN
./.
====================
The/DT
identification/NN
of/IN
LCD/NNS
motifs/NNS
required/VBN
for/IN
CIITA/NN
function/NN
brings/VBZ
to/TO
light/NN
a/DT
previously/RB
undefined/VBN
role/NN
of/IN
these/DT
motifs/NNS
in/IN
CIITA/NN
function/NN
./.
====================
UI/LS
-/:
98380268/CD
====================
TI/LS
-/:
The/DT
peroxisome/NN
proliferator-activated/JJ
receptor/NN
alpha/NN
(/(
PPARalpha/NN
)/)
ligand/NN
WY/NN
14,643/CD
does/VBZ
not/RB
interfere/VB
with/IN
leukotriene/NN
B4/NN
induced/JJ
adhesion/NN
of/IN
neutrophils/NNS
to/TO
endothelial/JJ
cells/NNS
./.
====================
AB/LS
-/:
Peroxisome/NN
proliferator-activated/JJ
receptors/NNS
(/(
PPAR/NNS
)/)
control/VBP
discrete/JJ
genes/NNS
involved/VBN
in/IN
fatty/JJ
acid/NN
and/CC
lipid/NN
metabolism/NN
./.
====================
Recently/RB
,/,
it/PRP
was/VBD
suggested/VBN
that/IN
activation/NN
of/IN
the/DT
alpha/NN
isoform/NN
of/IN
PPAR/NNS
by/IN
the/DT
potent/JJ
proinflammatory/JJ
mediator/NN
leukotriene/NN
B4/NN
(/(
LTB4/NN
)/)
enhanced/VBD
degradation/NN
of/IN
this/DT
eicosanoid/NN
,/,
offersuggesting/VBG
a/DT
new/JJ
aspect/NN
of/IN
down-regulation/NN
of/IN
inflammation/NN
./.
====================
Here/RB
,/,
we/PRP
studied/VBD
whether/IN
PPARalpha/NN
activation/NN
(/(
by/IN
means/NNS
of/IN
the/DT
selective/JJ
agonist/NN
WY/NN
14,643/CD
)/)
of/IN
endothelial/JJ
cells/NNS
,/,
pivotal/JJ
in/IN
the/DT
regulation/NN
of/IN
inflammatory/JJ
responses/NNS
,/,
interfered/VBN
with/IN
LTB4/NN
induced/VBD
adhesion/NN
of/IN
PMN/NN
neutrophil/NN
granulocytes/NNS
in/FW
vitro/FW
./.
====================
When/WRB
endothelial/JJ
cells/NNS
were/VBD
treated/VBN
with/IN
WY/NN
14,643/CD
prior/RB
to/TO
activation/NN
with/IN
LTB4/NN
(/(
or/CC
fMLP/NN
,/,
IL-1beta/NN
or/CC
TNFalpha/NN
,/,
as/IN
controls/NNS
)/)
we/PRP
could/MD
not/RB
document/VB
any/DT
effect/NN
on/IN
the/DT
number/NN
of/IN
adhering/JJ
PMN/NN
or/CC
duration/NN
of/IN
the/DT
response/NN
./.
====================
Thus/RB
,/,
this/DT
study/NN
provides/VBZ
no/DT
evidence/NN
indicating/VBG
a/DT
regulatory/JJ
function/NN
of/IN
PPARalpha/NN
in/IN
LTB4/NN
induced/JJ
adhesive/JJ
interactions/NNS
between/IN
endothelial/JJ
cells/NNS
and/CC
neutrophils/NNS
====================
UI/LS
-/:
99025966/CD
====================
TI/LS
-/:
Interaction/NN
of/IN
sickle/NN
erythrocytes/NNS
with/IN
endothelial/JJ
cells/NNS
in/IN
the/DT
presence/NN
of/IN
endothelial/JJ
cell/NN
conditioned/JJ
medium/NN
induces/VBZ
oxidant/JJ
stress/NN
leading/VBG
to/TO
transendothelial/JJ
migration/NN
of/IN
monocytes/NNS
./.
====================
AB/LS
-/:
The/DT
abnormal/JJ
adherence/NN
of/IN
sickle/NN
red/JJ
blood/NN
cells/NNS
(/(
SS/NN
RBC/NNS
)/)
to/TO
endothelial/JJ
cells/NNS
has/VBZ
been/VBN
thought/VBN
to/TO
contribute/VB
to/TO
vascular/JJ
occlusion/NN
,/,
a/DT
major/JJ
cause/NN
of/IN
morbidity/NN
in/IN
sickle/NN
cell/NN
disease/NN
(/(
SCD/NN
)/)
./.
====================
We/PRP
determined/VBD
whether/IN
the/DT
interaction/NN
of/IN
SS/NN
RBC/NNS
with/IN
cultured/VBN
endothelial/JJ
cells/NNS
induced/VBD
cellular/JJ
oxidant/JJ
stress/NN
that/WDT
would/MD
culminate/VB
in/IN
expression/NN
of/IN
cell/NN
adhesion/NN
molecules/NNS
(/(
CAMs/NNS
)/)
involved/VBN
in/IN
the/DT
adhesion/NN
and/CC
diapedesis/NN
of/IN
monocytes/NNS
and/CC
the/DT
adherence/NN
of/IN
SS/NN
reticulocytes/NNS
./.
====================
We/PRP
showed/VBD
that/IN
the/DT
interaction/NN
of/IN
SS/NN
RBC/NNS
at/IN
2/CD
%/NN
concentration/NN
in/IN
the/DT
presence/NN
of/IN
multimers/NNS
of/IN
von/NN
Willebrand/NN
factor/NN
(/(
vWf/NN
)/)
,/,
derived/VBN
from/IN
endothelial/JJ
cell-derived/JJ
conditioned/VBN
medium/NN
(/(
E-CM/NN
)/)
with/IN
cultured/VBN
human/JJ
umbilical/JJ
vein/NN
endothelial/JJ
cells/NNS
(/(
HUVEC/NN
)/)
,/,
resulted/VBD
in/IN
a/DT
fivefold/RB
increased/VBN
formation/NN
of/IN
thiobarbituric/JJ
acid-reactive/JJ
substances/NNS
(/(
TBARS/NNS
)/)
and/CC
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kB/NN
,/,
both/DT
indicators/NNS
of/IN
cellular/JJ
oxidant/JJ
stress/NN
./.
====================
Normal/JJ
RBC/NNS
show/VBP
none/DT
of/IN
these/DT
phenomena/NNS
./.
====================
The/DT
oxidant/JJ
stress-induced/JJ
signaling/NN
resulted/VBD
in/IN
an/DT
increased/VBN
surface/NN
expression/NN
of/IN
a/DT
subset/NN
of/IN
CAMs/NNS
,/,
ICAM-1/NN
,/,
E-selectin/NN
,/,
and/CC
VCAM-1/NN
in/IN
HUVEC/NN
./.
====================
The/DT
addition/NN
of/IN
oxygen/NN
radical/JJ
scavenger/NN
enzymes/NNS
(/(
catalase/NN
,/,
superoxide/NN
dismutase/NN
)/)
and/CC
antioxidant/NN
(/(
probucol/NN
)/)
inhibited/VBD
these/DT
events/NNS
./.
====================
Additionally/RB
,/,
preincubation/NN
of/IN
HUVEC/NN
with/IN
a/DT
synthetic/JJ
peptide/NN
Arg-Gly-Asp/NN
(/(
RGD/NN
)/)
that/WDT
prevents/VBZ
vWf-mediated/JJ
adhesion/NN
of/IN
SS/NN
RBC/NNS
reduced/VBD
the/DT
surface/NN
expression/NN
of/IN
VCAM-1/NN
and/CC
NF-kB/NN
activation/NN
./.
====================
Furthermore/RB
,/,
SS/NN
RBC-induced/JJ
oxidant/JJ
stress/NN
resulted/VBD
in/IN
a/DT
twofold/JJ
increase/NN
in/IN
the/DT
transendothelial/JJ
migration/NN
of/IN
both/CC
monocyte-like/JJ
HL-60/NN
cells/NNS
and/CC
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
,/,
and/CC
approximately/RB
a/DT
sixfold/JJ
increase/NN
in/IN
platelet-endothelial/JJ
cell/NN
adhesion/NN
molecule-1/NN
(/(
PECAM-1/NN
)/)
phosphorylation/NN
,/,
each/DT
of/IN
which/WDT
was/VBD
blocked/VBN
by/IN
protein/NN
kinase/NN
C/NN
inhibitor/NN
and/CC
antioxidants/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
adherence/contact/NN
of/IN
SS/NN
RBC/NNS
to/TO
endothelial/JJ
cells/NNS
in/IN
large/JJ
vessel/NN
can/MD
generate/VB
enhanced/VBN
oxidant/JJ
stress/NN
leading/VBG
to/TO
increased/VBN
adhesion/NN
and/CC
diapedesis/NN
of/IN
monocytes/NNS
,/,
as/RB
well/RB
as/IN
heightened/VBN
adherence/NN
of/IN
SS/NN
reticulocytes/NNS
,/,
indicating/VBG
that/IN
injury/activation/NN
of/IN
endothelium/NN
can/MD
contribute/VB
to/TO
vaso-occlusion/NN
in/IN
SCD/NN
./.
====================
UI/LS
-/:
99010987/CD
====================
TI/LS
-/:
Signal/NN
transduction/NN
abnormalities/NNS
in/IN
T/NN
lymphocytes/NNS
from/IN
patients/NNS
with/IN
advanced/JJ
renal/JJ
carcinoma/NN
:/:
clinical/JJ
relevance/NN
and/CC
effects/NNS
of/IN
cytokine/NN
therapy/NN
./.
====================
AB/LS
-/:
Studies/NNS
have/VBP
demonstrated/VBN
abnormalities/NNS
of/IN
the/DT
CD3/T-cell/NN
antigen/NN
receptor/NN
(/(
TCR/NN
)/)
and/CC
pathways/NNS
of/IN
signal/NN
transduction/NN
in/IN
T/NN
lymphocytes/NNS
from/IN
animals/NNS
and/CC
patients/NNS
with/IN
advanced/JJ
malignancy/NN
./.
====================
Diminished/VBN
expression/NN
of/IN
TCRzeta/NN
and/CC
p56(lck)/NN
that/WDT
are/VBP
associated/VBN
with/IN
the/DT
TCR/NN
and/CC
reduced/VBN
nuclear/JJ
localization/NN
of/IN
RelA/NN
containing/VBG
nuclear/JJ
factor/NN
kappaB/NN
(/(
NFkappaB/NN
)/)
complexes/NNS
have/VBP
been/VBN
noted/VBN
./.
====================
These/DT
defects/NNS
have/VBP
been/VBN
described/VBN
in/IN
T/NN
cells/NNS
from/IN
patients/NNS
with/IN
malignant/JJ
melanoma/NN
,/,
renal/JJ
cell/NN
carcinoma/NN
(/(
RCC/NN
)/)
,/,
ovarian/JJ
cancer/NN
,/,
and/CC
colorectal/JJ
cancer/NN
./.
====================
Preliminary/JJ
observations/NNS
also/RB
indicate/VBP
possible/JJ
correlation/NN
with/IN
clinical/JJ
variables/NNS
such/JJ
as/IN
stage/NN
in/IN
selected/VBN
instances/NNS
./.
====================
To/TO
further/RB
characterize/VB
altered/JJ
expression/NN
of/IN
TCRzeta/NN
,/,
p56(lck)/NN
,/,
and/CC
impaired/JJ
activation/NN
of/IN
NFkappaB/NN
,/,
T/NN
lymphocytes/NNS
were/VBD
obtained/VBN
from/IN
65/CD
patients/NNS
with/IN
RCC/NN
,/,
the/DT
majority/NN
of/IN
whom/WP
were/VBD
receiving/VBG
combination/NN
cytokine/NN
therapy/NN
[/(
interleukin/NN
(/(
IL/NN
)/)
-2/CD
,/,
IFN/NN
alpha-containing/JJ
regimens/NNS
]/)
and/CC
37/CD
control/JJ
individuals/NNS
./.
====================
In/IN
29/CD
of/IN
these/DT
patients/NNS
,/,
levels/NNS
of/IN
TCRzeta/NN
and/CC
p56(lck)/NN
were/VBD
determined/VBN
by/IN
Western/NN
blots/NNS
of/IN
T-cell/NN
lysates/NNS
and/CC
semiquantitated/VBN
using/VBG
densitometry/NN
./.
====================
Relative/JJ
levels/NNS
were/VBD
then/RB
correlated/VBN
with/IN
a/DT
series/NN
of/IN
clinical/JJ
variables/NNS
including/VBG
response/NN
to/TO
therapy/NN
,/,
performance/NN
status/NN
,/,
survival/NN
,/,
disease/NN
sites/NNS
,/,
age/NN
,/,
and/CC
others/NNS
./.
====================
In/IN
another/DT
group/NN
of/IN
28/CD
patients/NNS
(/(
three/CD
individuals/NNS
from/IN
the/DT
first/JJ
group/NN
)/)
,/,
the/DT
frequency/NN
of/IN
abnormal/JJ
NFkappaB/NN
activation/NN
was/VBD
studied/VBN
using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
after/IN
activation/NN
of/IN
T/NN
cells/NNS
with/IN
phorbol/NN
myristate/NN
acetate/ionomycin/NN
or/CC
anti-CD3/JJ
monoclonal/JJ
antibody/NN
./.
====================
Changes/NNS
in/IN
these/DT
signaling/VBG
molecules/NNS
during/IN
cytokine/NN
treatment/NN
were/VBD
also/RB
investigated/VBN
./.
====================
TCRzeta/NN
and/CC
p56(lck)/NN
were/VBD
detected/VBN
in/IN
the/DT
peripheral/JJ
blood/NN
T/NN
cells/NNS
in/IN
27/CD
of/IN
29/CD
patients/NNS
,/,
and/CC
overall/RB
,/,
reduced/VBN
levels/NNS
were/VBD
noted/VBN
visually/RB
in/IN
12/CD
of/IN
29/CD
(/(
41/CD
%/NN
)/)
and/CC
13/CD
of/IN
29/CD
(/(
45/CD
%/NN
)/)
individuals/NNS
,/,
respectively/RB
./.
====================
When/WRB
levels/NNS
were/VBD
semiquantitated/VBN
using/VBG
densitometry/NN
,/,
significant/JJ
decreases/NNS
of/IN
TCRzeta/NN
(/(
P/NN
=/JJ
0.029/CD
)/)
and/CC
p56(lck)/NN
(/(
P/NN
=/JJ
0.029/CD
)/)
but/CC
not/RB
CD3epsilon/NN
(/(
P/NN
=/JJ
0.131/CD
)/)
,/,
compared/VBN
with/IN
control/NN
levels/NNS
,/,
were/VBD
found/VBN
./.
====================
In/IN
patients/NNS
treated/VBN
with/IN
IL-2/IFN/NN
alpha-based/JJ
therapy/NN
,/,
relative/JJ
levels/NNS
of/IN
TCRzeta/NN
increased/VBD
significantly/RB
(/(
P/NN
=/JJ
0.002/CD
)/)
on/IN
day/NN
15/CD
of/IN
cycle/NN
one/CD
compared/VBN
with/IN
the/DT
baseline/NN
./.
====================
Correlations/NNS
of/IN
TCRzeta/NN
or/CC
p56(lck)/NN
levels/NNS
with/IN
response/NN
or/CC
disease/NN
variables/NNS
,/,
except/IN
for/IN
lower/JJR
TCRzeta/NN
levels/NNS
(/(
P/NN
</JJR
0.001/CD
)/)
in/IN
the/DT
presence/NN
of/IN
bone/NN
metastases/NNS
,/,
were/VBD
not/RB
found/VBN
./.
====================
Abnormal/JJ
NFkappaB/NN
activation/NN
after/IN
stimulation/NN
with/IN
phorbol/NN
myristate/NN
acetate/ionomycin/NN
and/or/CC
anti-CD3/JJ
monoclonal/JJ
antibody/NN
was/VBD
found/VBN
in/IN
59/CD
%/NN
of/IN
patients/NNS
(/(
17/CD
of/IN
28/CD
)/)
and/CC
was/VBD
not/RB
accounted/VBN
for/IN
by/IN
the/DT
advanced/JJ
age/NN
of/IN
the/DT
study/NN
cohort/NN
./.
====================
Activation/NN
of/IN
NFkappaB/NN
in/IN
peripheral/JJ
blood/NN
T/NN
cells/NNS
was/VBD
inducible/JJ
during/IN
cytokine/NN
therapy/NN
in/IN
four/CD
of/IN
six/CD
individuals/NNS
who/WP
displayed/VBD
impaired/JJ
NFkappaB/NN
activity/NN
prior/RB
to/TO
therapy/NN
./.
====================
Moreover/RB
,/,
impaired/JJ
activation/NN
of/IN
NFkappaB/NN
does/VBZ
not/RB
appear/VB
linked/VBN
to/TO
a/DT
reduction/NN
of/IN
TCRzeta/NN
expression/NN
,/,
because/IN
in/IN
five/CD
patients/NNS
,/,
normal/JJ
TCRzeta/NN
levels/NNS
were/VBD
present/JJ
although/IN
kappaB/NN
binding/NN
was/VBD
not/RB
inducible/JJ
./.
====================
In/IN
the/DT
majority/NN
of/IN
patients/NNS
with/IN
advanced/JJ
RCC/NN
,/,
peripheral/JJ
blood/NN
T/NN
cells/NNS
express/VBP
TCRzeta/NN
and/CC
p56(lck)/NN
,/,
and/CC
in/IN
a/DT
subset/NN
,/,
reduced/VBN
levels/NNS
of/IN
these/DT
TCRzeta/NN
associated/JJ
molecules/NNS
are/VBP
seen/VBN
that/WDT
may/MD
increase/VB
during/IN
cytokine-based/JJ
therapy/NN
./.
====================
Abnormal/JJ
activation/NN
of/IN
NFkappaB/NN
is/VBZ
also/RB
present/JJ
in/IN
>/JJR
50/CD
%/NN
of/IN
patients/NNS
and/CC
may/MD
also/RB
revert/VB
to/TO
normal/JJ
during/IN
IL-2/IFN/NN
alpha-based/JJ
treatment/NN
./.
====================
This/DT
alteration/NN
in/IN
NFkappaB/NN
activation/NN
occurred/VBD
in/IN
the/DT
presence/NN
of/IN
normal/JJ
expression/NN
of/IN
TCRzeta-associated/JJ
signaling/NN
elements/NNS
./.
====================
The/DT
clinical/JJ
significance/NN
of/IN
these/DT
findings/NNS
remains/VBZ
unclear/JJ
./.
====================
UI/LS
-/:
99006780/CD
====================
TI/LS
-/:
Identification/NN
of/IN
transcription/NN
factors/NNS
expressed/VBN
during/IN
ATRA-induced/JJ
neutrophil/NN
differentiation/NN
of/IN
HL60/NN
cells/NNS
./.
====================
AB/LS
-/:
A/DT
recent/JJ
clinical/JJ
therapeutic/JJ
initiative/NN
has/VBZ
been/VBN
the/DT
use/NN
of/IN
chemical/JJ
agents/NNS
which/WDT
induce/VBP
the/DT
leukaemic/JJ
cells/NNS
to/TO
overcome/VB
their/PRP$
block/NN
in/IN
differentiation/NN
./.
====================
In/IN
order/NN
to/TO
understand/VB
this/DT
block/NN
the/DT
cascade/NN
of/IN
molecular/JJ
events/NNS
needs/VBZ
to/TO
be/VB
characterized/VBN
./.
====================
Haemopoietic/JJ
differentiation/NN
is/VBZ
ultimately/RB
controlled/VBN
at/IN
the/DT
level/NN
of/IN
gene/NN
transcription/NN
which/WDT
is/VBZ
mediated/VBN
by/IN
an/DT
array/NN
of/IN
transcription/NN
factors/NNS
./.
====================
Many/JJ
transcription/NN
factors/NNS
contain/VBP
similar/JJ
structural/JJ
protein/NN
sequences/NNS
,/,
and/CC
we/PRP
have/VBP
used/VBN
an/DT
RT-PCR-based/JJ
approach/NN
to/TO
isolate/VB
sequences/NNS
,/,
from/IN
transcription/NN
factor/NN
gene/NN
families/NNS
which/WDT
share/VBP
similar/JJ
domains/NNS
./.
====================
Degenerate/NN
primers/NNS
corresponding/VBG
to/TO
the/DT
TFIIIA/NN
zinc-finger/JJ
consensus/NN
amino/NN
acid/NN
sequences/NNS
and/CC
to/TO
the/DT
POU-homeodomain/NN
and/CC
POU-specific/JJ
domain/NN
were/VBD
used/VBN
to/TO
amplify/VB
genes/NNS
on/IN
the/DT
basis/NN
that/IN
they/PRP
contained/VBD
similarities/NNS
in/IN
structural/JJ
motifs/NNS
shared/VBN
within/IN
these/DT
families/NNS
of/IN
transcription/NN
factors/NNS
./.
====================
A/DT
serum-independent/JJ
HL60/NN
cell/NN
line/NN
was/VBD
induced/VBN
towards/IN
the/DT
neutrophil/NN
lineage/NN
by/IN
treatment/NN
with/IN
all-trans/JJ
retinoic/JJ
acid/NN
(/(
ATRA/NN
)/)
for/IN
24/CD
h/NN
./.
====================
CD38+/JJ
cells/NNS
committed/VBN
towards/IN
this/DT
lineage/NN
were/VBD
enriched/JJ
and/CC
a/DT
population/NN
of/IN
these/DT
cells/NNS
treated/VBN
with/IN
dihydroxyvitamin/NN
D3/NN
to/TO
induce/VB
neutrophil/NN
maturation/NN
./.
====================
RNA/NN
extracted/VBN
from/IN
uninduced/JJ
,/,
ATRA-induced/JJ
CD38+/JJ
cells/NNS
,/,
and/CC
vitamin/NN
D3/NN
treated/JJ
maturing/JJ
cell/NN
cultures/NNS
were/VBD
amplified/VBN
using/VBG
the/DT
degenerate/NN
primers/NNS
./.
====================
PCR/NN
fragments/NNS
were/VBD
cloned/VBN
,/,
sequenced/VBN
,/,
clustered/VBN
into/IN
homologous/JJ
groups/NNS
,/,
and/CC
the/DT
group/NN
sequences/NNS
searched/VBN
on/IN
the/DT
GenBank/NN
database/NN
./.
====================
The/DT
Oct/NN
1/CD
transcription/NN
factor/NN
,/,
and/CC
a/DT
very/RB
close/JJ
homologue/NN
,/,
KIAA0144/NN
,/,
was/VBD
identified/VBN
using/VBG
the/DT
POU/NN
family/NN
primers/NNS
./.
====================
The/DT
zinc-finger/JJ
primers/NNS
identified/VBD
three/CD
zinc-finger/JJ
genes/NNS
./.
====================
The/DT
pattern/NN
of/IN
gene/NN
expression/NN
was/VBD
suggested/VBN
from/IN
the/DT
number/NN
of/IN
clones/NNS
in/IN
each/DT
group/NN
at/IN
neutrophil/NN
commitment/NN
and/CC
maturation/NN
./.
====================
The/DT
differential/JJ
expression/NN
of/IN
the/DT
genes/NNS
in/IN
the/DT
zinc/NN
finger/NN
and/CC
POU/NN
families/NNS
will/MD
lead/VB
to/TO
a/DT
better/JJR
understanding/NN
of/IN
the/DT
cascade/NN
of/IN
gene/NN
expression/NN
which/WDT
occurs/VBZ
following/VBG
ATRA-induced/JJ
differentiation/NN
./.
====================
UI/LS
-/:
98451426/CD
====================
TI/LS
-/:
GATA-3-dependent/JJ
enhancer/NN
activity/NN
in/IN
IL-4/NN
gene/NN
regulation/NN
./.
====================
AB/LS
-/:
Previously/RB
,/,
we/PRP
analyzed/VBD
the/DT
proximal/JJ
IL-4/NN
promoter/NN
in/IN
directing/VBG
Th2-specific/JJ
activity/NN
./.
====================
An/DT
800-base/JJ
pair/NN
proximal/JJ
promoter/NN
conferred/VBD
some/DT
Th2-selective/JJ
expression/NN
in/IN
transgenic/JJ
mice/NNS
./.
====================
However/RB
,/,
this/DT
region/NN
directed/VBD
extremely/RB
low/JJ
reporter/NN
mRNA/NN
levels/NNS
relative/JJ
to/TO
endogenous/JJ
IL-4/NN
mRNA/NN
,/,
suggesting/VBG
that/IN
full/JJ
gene/NN
activity/NN
requires/VBZ
additional/JJ
enhancer/NN
elements/NNS
./.
====================
Here/RB
,/,
we/PRP
analyzed/VBD
large/JJ
genomic/JJ
IL-4/NN
regions/NNS
for/IN
enhancer/NN
activity/NN
and/CC
interaction/NN
with/IN
transcription/NN
factors/NNS
./.
====================
The/DT
proximal/JJ
IL-4/NN
promoter/NN
is/VBZ
only/RB
moderately/RB
augmented/VBN
by/IN
GATA-3/NN
,/,
but/CC
certain/JJ
genomic/JJ
regions/NNS
significantly/RB
enhanced/VBD
GATA-3/NN
promoter/NN
transactivation/NN
./.
====================
Some/DT
enhancing/VBG
regions/NNS
contained/VBD
consensus/NN
,/,
GATA/NN
sites/NNS
that/WDT
bound/VBD
Th2-specific/JJ
complexes/NNS
./.
====================
However/RB
,/,
retroviral/JJ
transduction/NN
of/IN
GATA-3/NN
into/IN
developing/VBG
T/NN
cells/NNS
induced/VBD
IL-5/NN
to/TO
full/JJ
Th2/NN
levels/NNS
,/,
but/CC
only/RB
partially/RB
restored/VBD
IL-4/NN
production/NN
./.
====================
Thus/RB
,/,
we/PRP
propose/VBP
that/IN
GATA-3/NN
is/VBZ
permissive/JJ
,/,
but/CC
not/RB
sufficient/JJ
,/,
for/IN
full/JJ
IL-4/NN
enhancement/NN
and/CC
may/MD
act/VB
through/IN
GATA/NN
elements/NNS
surrounding/VBG
the/DT
IL-13/IL-4/NN
gene/NN
locus/NN
./.
====================
UI/LS
-/:
98438422/CD
====================
TI/LS
-/:
Position/NN
effect/NN
of/IN
translocations/NNS
involving/VBG
the/DT
inactive/JJ
X/NN
chromosome/NN
:/:
physical/JJ
linkage/NN
to/TO
XIC/XIST/NN
does/VBZ
not/RB
lead/VB
to/TO
long-range/JJ
de/FW
novo/FW
inactivation/NN
in/IN
human/JJ
differentiated/VBN
cells/NNS
./.
====================
AB/LS
-/:
Given/VBN
the/DT
reported/VBN
long-range/JJ
cis-inactivating/JJ
effect/NN
of/IN
the/DT
XIST/NN
gene/NN
in/IN
early/JJ
embryonic/JJ
development/NN
and/CC
the/DT
lack/NN
of/IN
requirement/NN
of/IN
X-/NN
chromosome-specific/JJ
elements/NNS
for/IN
propagating/VBG
the/DT
inactive/JJ
state/NN
,/,
there/EX
exists/VBZ
the/DT
possibility/NN
of/IN
cis/JJ
inactivation/NN
of/IN
autosomal/JJ
material/JJ
after/IN
de/FW
novo/FW
translocation/NN
to/TO
an/DT
inactive/JJ
X/NN
chromosome/NN
(/(
Xi/NN
)/)
in/IN
differentiated/VBN
cells/NNS
./.
====================
We/PRP
have/VBP
analyzed/VBN
de/FW
novo/FW
radiation-induced/JJ
translocations/NNS
between/IN
the/DT
Xi/NN
and/CC
autosomes/NNS
to/TO
study/VB
the/DT
maintenance/NN
and/CC
spreading/NN
of/IN
X-chromosome/NN
inactivation/NN
(/(
X/NN
inactivation/NN
)/)
in/IN
relation/NN
to/TO
the/DT
position/NN
of/IN
the/DT
X-inactivation/NN
center/NN
(/(
XIC/NN
)/)
/XIST/NN
in/IN
differentiated/VBN
cells/NNS
./.
====================
Autosome/Xi/NN
translocations/NNS
were/VBD
detected/VBN
by/IN
fluorescence/NN
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
./.
====================
The/DT
activation/NN
status/NN
of/IN
the/DT
chromosomes/NNS
involved/VBN
in/IN
the/DT
translocation/NN
was/VBD
determined/VBN
by/IN
simultaneous/JJ
immunocytogenetic/JJ
studies/NNS
using/VBG
antibodies/NNS
against/IN
either/CC
BrdU/NN
incorporated/VBN
at/IN
late/JJ
S/NN
phase/NN
or/CC
acetylated/VBN
histone/NN
H4/NN
./.
====================
The/DT
position/NN
of/IN
XIC/XIST/NN
in/IN
the/DT
reciprocal/JJ
products/NNS
of/IN
the/DT
translocation/NN
was/VBD
determined/VBN
by/IN
XIST-specific/JJ
FISH/NN
and/CC
computer/NN
enhancement/NN
./.
====================
In/IN
other/JJ
experiments/NNS
,/,
the/DT
Xq13/NN
region/NN
carrying/VBG
XIC/XIST/NN
was/VBD
localized/VBN
by/IN
computer/NN
enhancement/NN
of/IN
the/DT
DAPI/NN
banding/NN
pattern/NN
./.
====================
Our/PRP$
study/NN
in/IN
differentiated/VBN
cells/NNS
provides/VBZ
a/DT
visual/JJ
demonstration/NN
that/IN
physical/JJ
separation/NN
from/IN
XIC/XIST/NN
does/VBZ
not/RB
result/VB
in/IN
reactivation/NN
of/IN
inactive/JJ
X-chromosome/NN
material/NN
and/CC
that/IN
X/NN
inactivation/NN
is/VBZ
not/RB
spread/VBN
to/TO
the/DT
translocated/VBN
autosomes/NNS
irrespective/RB
of/IN
the/DT
position/NN
of/IN
XIC/XIST/NN
./.
====================
This/DT
observation/NN
suggests/VBZ
that/IN
physical/JJ
linkage/NN
to/TO
XIC/XIST/NN
does/VBZ
not/RB
lead/VB
to/TO
de/FW
novo/FW
inactivation/NN
of/IN
autosomal/JJ
material/JJ
./.
====================
UI/LS
-/:
98421396/CD
====================
TI/LS
-/:
Interleukin-4/NN
and/CC
-13/CD
induce/VBP
upregulation/NN
of/IN
the/DT
murine/JJ
macrophage/NN
12/15-lipoxygenase/NN
activity/NN
:/:
evidence/NN
for/IN
the/DT
involvement/NN
of/IN
transcription/NN
factor/NN
STAT6/NN
./.
====================
AB/LS
-/:
When/WRB
human/JJ
monocytes/NNS
or/CC
alveolar/JJ
macrophages/NNS
are/VBP
cultured/VBN
in/IN
the/DT
presence/NN
of/IN
interleukin/NN
(/(
IL/NN
)/)
-4/CD
or/CC
IL-13/NN
,/,
the/DT
expression/NN
of/IN
the/DT
reticulocyte-type/JJ
15-lipoxygenase/NN
is/VBZ
induced/VBN
./.
====================
In/IN
mice/NNS
a/DT
15-lipoxygenase/NN
is/VBZ
not/RB
expressed/VBN
,/,
but/CC
a/DT
leukocyte-type/NN
12-lipoxygenase/NN
is/VBZ
present/JJ
in/IN
peritoneal/JJ
macrophages/NNS
./.
====================
To/TO
investigate/VB
whether/IN
both/CC
lipoxygenase/NN
isoforms/NNS
exhibit/VBP
a/DT
similar/JJ
regulatory/JJ
response/NN
toward/IN
cytokine/NN
stimulation/NN
,/,
we/PRP
studied/VBD
the/DT
regulation/NN
of/IN
the/DT
leukocyte-type/NN
12-lipoxygenase/NN
of/IN
murine/JJ
peritoneal/JJ
macrophages/NNS
by/IN
interleukins/NNS
and/CC
found/VBD
that/IN
the/DT
activity/NN
of/IN
this/DT
enzyme/NN
is/VBZ
upregulated/VBN
in/IN
a/DT
dose-dependent/JJ
manner/NN
when/WRB
the/DT
cells/NNS
were/VBD
cultured/VBN
in/IN
the/DT
presence/NN
of/IN
the/DT
IL-4/NN
or/CC
IL-13/NN
but/CC
not/RB
by/IN
IL-10/NN
./.
====================
When/WRB
peripheral/JJ
murine/JJ
monocytes/NNS
that/WDT
do/VBP
not/RB
express/VB
the/DT
lipoxygenase/NN
were/VBD
treated/VBN
with/IN
IL-4/NN
expression/NN
of/IN
12/15-lipoxygenase/NN
mRNA/NN
was/VBD
induced/VBN
,/,
suggesting/VBG
pretranslational/JJ
control/NN
mechanisms/NNS
./.
====================
In/IN
contrast/NN
,/,
no/DT
upregulation/NN
of/IN
the/DT
lipoxygenase/NN
activity/NN
was/VBD
observed/VBN
when/WRB
the/DT
macrophages/NNS
were/VBD
prepared/VBN
from/IN
homozygous/JJ
STAT6-deficient/JJ
mice/NNS
./.
====================
Peritoneal/JJ
macrophages/NNS
of/IN
transgenic/JJ
mice/NNS
that/WDT
systemically/RB
overexpress/VBP
IL-4/NN
exhibited/VBD
a/DT
threefold/RB
to/TO
fourfold/RB
higher/JJR
12-lipoxygenase/NN
activity/NN
than/IN
cells/NNS
prepared/VBN
from/IN
control/JJ
animals/NNS
./.
====================
A/DT
similar/JJ
upregulation/NN
of/IN
12-lipoxygenase/NN
activity/NN
was/VBD
detected/VBN
in/IN
heart/NN
,/,
spleen/NN
,/,
and/CC
lung/NN
of/IN
the/DT
transgenic/JJ
animals/NNS
./.
====================
Moreover/RB
,/,
a/DT
strong/JJ
induction/NN
of/IN
the/DT
enzyme/NN
was/VBD
observed/VBN
in/IN
red/JJ
cells/NNS
during/IN
experimental/JJ
anemia/NN
in/IN
mice/NNS
./.
====================
The/DT
data/NNS
presented/VBN
here/RB
indicate/VBP
that/IN
(/(
1/LS
)/)
the/DT
12-lipoxygenase/NN
activity/NN
of/IN
murine/JJ
macrophages/NNS
is/VBZ
upregulated/VBN
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
by/IN
IL-4/NN
and/or/CC
IL-13/NN
,/,
(/(
2/LS
)/)
this/DT
upregulation/NN
requires/VBZ
expression/NN
of/IN
the/DT
transcription/NN
factor/NN
STAT6/NN
,/,
and/CC
(/(
3/LS
)/)
the/DT
constitutive/JJ
expression/NN
of/IN
the/DT
enzyme/NN
appears/VBZ
to/TO
be/VB
STAT6/NN
independent/JJ
./.
====================
The/DT
cytokine-dependent/JJ
upregulation/NN
of/IN
the/DT
murine/JJ
macrophage/NN
12-lipoxygenase/NN
and/CC
its/PRP$
induction/NN
during/IN
experimental/JJ
anemia/NN
suggests/VBZ
its/PRP$
close/JJ
relatedness/NN
with/IN
the/DT
human/JJ
reticulocyte-type/NN
15-lipoxygenase/NN
despite/IN
their/PRP$
differences/NNS
in/IN
the/DT
positional/JJ
specificity/NN
of/IN
arachidonic/JJ
acid/NN
oxygenation/NN
./.
====================
UI/LS
-/:
98405747/CD
====================
TI/LS
-/:
Interferon-gamma-induced/JJ
factor/NN
binding/VBG
to/TO
the/DT
interleukin-4-responsive/JJ
element/NN
of/IN
CD23b/NN
promoter/NN
in/IN
human/JJ
tonsillar/JJ
mononuclear/JJ
cells/NNS
:/:
role/NN
in/IN
transient/JJ
up-regulation/NN
of/IN
the/DT
interleukin-4-induced/JJ
CD23b/NN
mRNA/NN
./.
====================
AB/LS
-/:
Stimulation/NN
of/IN
human/JJ
tonsillar/JJ
mononuclear/JJ
cells/NNS
with/IN
interleukin-4/NN
(/(
IL-4/NN
)/)
and/CC
interferon-gamma/NN
(/(
IFN-gamma/NN
)/)
rapidly/RB
induced/VBD
the/DT
activation/NN
of/IN
distinct/JJ
nuclear/JJ
factors/NNS
with/IN
different/JJ
mobilities/NNS
,/,
both/DT
of/IN
which/WDT
bind/VBP
the/DT
IL-4/NN
response/NN
element/NN
(/(
IL-4RE/NN
)/)
of/IN
CD23b/NN
promoter/NN
as/IN
examined/VBN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
(/(
EMSA/NNS
)/)
./.
====================
Co-treatment/NN
of/IN
IL-4/NN
and/CC
IFN-gamma/NN
induced/VBD
,/,
in/IN
addition/NN
to/TO
the/DT
two/CD
distinct/JJ
complexes/NNS
,/,
a/DT
new/JJ
complex/NN
with/IN
an/DT
intermediate/JJ
mobility/NN
./.
====================
The/DT
IL-4-induced/JJ
complex/NN
reacted/VBD
with/IN
anti-STAT/NN
(/(
signal/NN
transducers/NNS
and/CC
activators/NNS
of/IN
transcription/NN
)/)
6/CD
,/,
resulting/VBG
in/IN
a/DT
supershift/NN
whereas/IN
the/DT
formation/NN
of/IN
the/DT
IFN-gamma-induced/JJ
complex/NN
was/VBD
inhibited/VBN
by/IN
anti-STAT/NN
1/CD
./.
====================
The/DT
intermediate/JJ
complex/NN
appeared/VBD
to/TO
react/VB
with/IN
both/CC
anti-STAT/NN
6/CD
and/CC
anti-STAT/NN
1/CD
./.
====================
Although/IN
IFN-gamma/NN
alone/RB
did/VBD
not/RB
induce/VB
CD23/NN
mRNA/NN
transcription/NN
,/,
Northern/NN
blot/NN
analysis/NN
revealed/VBD
a/DT
transient/JJ
up-regulation/NN
of/IN
the/DT
IL-4-induced/JJ
CD23/NN
mRNA/NN
by/IN
IFN-gamma/NN
within/IN
2/CD
h/NN
of/IN
IFN-gamma/NN
treatment/NN
in/IN
these/DT
tonsillar/JJ
cells/NNS
./.
====================
The/DT
results/NNS
suggest/VBP
that/IN
the/DT
IL-4RE/NN
of/IN
the/DT
IL-4-inducible/JJ
gene/NN
can/MD
accommodate/VB
both/CC
IL-4-/NN
and/CC
IFN-gamma-activated/JJ
factors/NNS
,/,
such/JJ
as/IN
STAT/NNS
6/CD
and/CC
STAT/NN
1/CD
,/,
either/CC
in/IN
homodimeric/JJ
or/CC
heterodimeric/JJ
forms/NNS
and/CC
the/DT
binding/NN
of/IN
these/DT
different/JJ
proteins/NNS
to/TO
the/DT
respective/JJ
promoter/NN
may/MD
play/VB
a/DT
potential/JJ
regulatory/JJ
role/NN
in/IN
the/DT
IL-4-/NN
inducible/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
98395152/CD
====================
TI/LS
-/:
A/DT
p56lck-independent/JJ
pathway/NN
of/IN
CD2/NN
signaling/NN
involves/VBZ
Jun/NN
kinase/NN
./.
====================
AB/LS
-/:
The/DT
p56/NN
Src/NN
family/NN
non-receptor/JJ
tyrosine/NN
kinase/NN
has/VBZ
been/VBN
shown/VBN
to/TO
be/VB
critical/JJ
for/IN
T/NN
lymphocyte/NN
differentiation/NN
and/CC
activation/NN
./.
====================
Hence/RB
in/IN
the/DT
absence/NN
of/IN
p56/NN
,/,
T/NN
cell/NN
receptor/NN
triggered/JJ
activation/NN
does/VBZ
not/RB
occur/VB
./.
====================
We/PRP
now/RB
provide/VBP
evidence/NN
for/IN
a/DT
CD2-based/JJ
signaling/NN
pathway/NN
which/WDT
,/,
in/IN
contrast/NN
to/TO
that/DT
of/IN
the/DT
T/NN
cell/NN
receptor/NN
,/,
is/VBZ
independent/JJ
of/IN
p56/NN
./.
====================
CD2-mediated/JJ
interleukin-2/NN
production/NN
occurs/VBZ
via/IN
activation/NN
of/IN
Jun/NN
kinase/NN
in/IN
cell/NN
lines/NNS
lacking/VBG
p56/NN
./.
====================
Jun/NN
kinase/NN
then/RB
facilitates/VBZ
the/DT
binding/NN
of/IN
c-Jun/c-Fos/NN
heterodimers/NNS
to/TO
the/DT
AP-1/NN
consensus/NN
site/NN
and/CC
the/DT
subsequent/JJ
transcriptional/JJ
activity/NN
of/IN
the/DT
interleukin-2/NN
promoter/NN
./.
====================
These/DT
data/NNS
elucidate/VBP
differences/NNS
between/IN
TCR/NN
and/CC
CD2/NN
signaling/NN
pathways/NNS
in/IN
the/DT
same/JJ
T/NN
cells/NNS
./.
====================
UI/LS
-/:
98389801/CD
====================
TI/LS
-/:
Activation/NN
of/IN
E2F-mediated/JJ
transcription/NN
by/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
Tax/NN
protein/NN
in/IN
a/DT
p16/NN
(/(
INK4A/NN
)/)
-negative/JJ
T-cell/NN
line/NN
./.
====================
AB/LS
-/:
The/DT
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
is/VBZ
a/DT
causative/JJ
agent/NN
of/IN
adult/JJ
T-cell/NN
leukemia/NN
./.
====================
Although/IN
the/DT
exact/NN
mechanism/NN
by/IN
which/WDT
HTLV-I/NN
contributes/VBZ
to/TO
leukemogenesis/NN
is/VBZ
still/RB
unclear/JJ
,/,
the/DT
Tax/NN
protein/NN
is/VBZ
thought/VBN
to/TO
play/VB
a/DT
major/JJ
role/NN
in/IN
this/DT
process/NN
./.
====================
This/DT
40-kDa/JJ
polypeptide/NN
is/VBZ
able/JJ
to/TO
interact/VB
with/IN
the/DT
tumor/NN
suppressor/NN
p16/NN
(/(
INK4A/NN
)/)
./.
====================
Consequently/RB
,/,
Tax/NN
can/MD
activate/VB
the/DT
signaling/NN
pathway/NN
that/WDT
lead/VBP
to/TO
the/DT
release/NN
of/IN
E2F/NN
that/WDT
in/IN
turn/NN
induces/VBZ
expression/NN
of/IN
factors/NNS
required/VBN
for/IN
cell/NN
cycle/NN
progression/NN
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
demonstrate/VBP
that/IN
Tax/NN
can/MD
also/RB
activate/VB
E2F-mediated/JJ
transcription/NN
independently/RB
of/IN
p16/NN
(/(
INK4A/NN
)/)
./.
====================
Indeed/RB
,/,
when/WRB
Tax/NN
is/VBZ
coexpressed/VBN
with/IN
the/DT
E2F-1/NN
transcription/NN
factor/NN
in/IN
CEM/NN
T-cells/NNS
,/,
which/WDT
lack/VBP
expression/NN
of/IN
p16/NN
(/(
INK4A/NN
)/)
,/,
it/PRP
strongly/RB
potentiates/VBZ
the/DT
E2F-dependent/JJ
activation/NN
of/IN
a/DT
reporter/NN
construct/NN
driven/VBN
by/IN
a/DT
promoter/NN
containing/VBG
E2F/NN
binding/NN
sites/NNS
./.
====================
This/DT
stimulation/NN
is/VBZ
abrogated/VBN
by/IN
mutations/NNS
affecting/VBG
the/DT
E2F-binding/JJ
sites/NNS
./.
====================
In/IN
addition/NN
,/,
Tax/NN
also/RB
stimulates/VBZ
the/DT
transcription/NN
of/IN
the/DT
E2F-1/NN
gene/NN
itself/PRP
./.
====================
Using/VBG
Tax/NN
mutants/NNS
that/WDT
fail/VBP
to/TO
activate/VB
either/CC
ATF-/NN
or/CC
NF-kappaB-dependent/JJ
promoters/NNS
and/CC
different/JJ
5'/JJ
truncation/NN
mutants/NNS
of/IN
the/DT
E2F-1/NN
promoter/NN
,/,
we/PRP
show/VBP
that/IN
the/DT
Tax-dependent/JJ
transcriptional/JJ
control/NN
of/IN
the/DT
E2F1/NN
gene/NN
involves/VBZ
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
the/DT
ATF/NN
binding/NN
site/NN
located/JJ
in/IN
the/DT
E2F-1/NN
promoter/NN
./.
====================
UI/LS
-/:
98375886/CD
====================
TI/LS
-/:
Inducible/JJ
nitric/JJ
oxide/NN
:/:
an/DT
autoregulatory/JJ
feedback/NN
inhibitor/NN
of/IN
vascular/JJ
inflammation/NN
./.
====================
AB/LS
-/:
Inducible/JJ
nitric/JJ
oxide/NN
(/(
iNO/NN
)/)
is/VBZ
produced/VBN
at/IN
sites/NNS
of/IN
vascular/JJ
inflammation/NN
by/IN
resident/JJ
and/CC
nonresident/JJ
vascular/JJ
wall/NN
cells/NNS
,/,
but/CC
its/PRP$
role/NN
in/IN
the/DT
inflammatory/JJ
process/NN
is/VBZ
not/RB
known/VBN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
show/VBP
that/IN
a/DT
novel/JJ
function/NN
of/IN
iNO/NN
is/VBZ
to/TO
terminate/VB
inflammatory/JJ
processes/NNS
./.
====================
We/PRP
find/VBP
that/IN
iNO/NN
produced/VBN
by/IN
murine/JJ
macrophage-like/JJ
cells/NNS
,/,
RAW264.7/NN
,/,
can/MD
inhibit/VB
cytokine-induced/JJ
endothelial/JJ
cell/NN
activation/NN
in/IN
a/DT
separated/JJ
and/CC
mixed/JJ
endothelial-RAW264.7/NN
coculture/NN
system/NN
./.
====================
Both/CC
iNO/NN
production/NN
and/CC
endothelial/JJ
VCAM-1/NN
expression/NN
were/VBD
induced/VBN
simultaneously/RB
with/IN
bacterial/JJ
LPS/NN
and/CC
murine-specific/JJ
IFN-gamma/NN
./.
====================
Inhibition/NN
of/IN
iNO/NN
synthase/NN
(/(
iNOS/NN
)/)
activity/NN
with/IN
N/NN
omega-monomethyl-L-arginine/NN
in/IN
endothelial-RAW264.7/NN
cocultures/NNS
,/,
stimulated/VBN
with/IN
murine-specific/JJ
IFN-gamma/NN
and/CC
LPS/NN
,/,
decreased/VBD
iNO/NN
production/NN
by/IN
86/CD
%/NN
,/,
augmented/VBD
VCAM-1/NN
and/CC
iNOS/NN
expression/NN
in/IN
endothelial/JJ
and/CC
RAW264.7/NN
cells/NNS
,/,
respectively/RB
,/,
and/CC
increased/VBD
monocyte/NN
adhesion/NN
to/TO
the/DT
endothelial/JJ
cell/NN
surface/NN
./.
====================
Transient/JJ
transfection/NN
studies/NNS
using/VBG
various/JJ
VCAM-1/NN
promoter/NN
constructs/NNS
demonstrated/VBD
that/IN
inhibitory/JJ
effects/NNS
of/IN
iNO/NN
on/IN
VCAM-1/NN
gene/NN
transcription/NN
were/VBD
mediated/VBN
,/,
in/IN
part/NN
,/,
by/IN
inhibitory/JJ
effects/NNS
of/IN
iNO/NN
on/IN
kappa/NN
B/NN
cis-acting/JJ
elements/NNS
./.
====================
Immunofluorescence/NN
studies/NNS
using/VBG
an/DT
Ab/NN
to/TO
the/DT
RelA/NN
(/(
p65/NN
)/)
subunit/NN
of/IN
nuclear/JJ
factor-kappa/NN
B/NN
revealed/VBD
that/IN
iNO/NN
inhibited/VBD
the/DT
activation/NN
of/IN
nuclear/JJ
factor-kappa/NN
B/NN
./.
====================
These/DT
studies/NNS
indicate/VBP
that/IN
iNO/NN
attenuates/VBZ
iNOS/NN
expression/NN
in/IN
macrophages/NNS
and/CC
inhibits/VBZ
monocyte/NN
adhesion/NN
to/TO
endothelial/JJ
cells/NNS
,/,
and/CC
suggest/VBP
that/IN
endogenously/RB
derived/VBN
iNO/NN
may/MD
be/VB
an/DT
important/JJ
autoregulatory/JJ
inhibitor/NN
of/IN
vascular/JJ
inflammation/NN
====================
UI/LS
-/:
99023607/CD
====================
TI/LS
-/:
Detection/NN
of/IN
oestrogen/NN
receptor/NN
variants/NNS
in/IN
endometrium/NN
,/,
myometrium/NN
,/,
leiomyoma/NN
and/CC
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
:/:
comparison/NN
to/TO
variants/NNS
present/JJ
in/IN
breast/NN
cancer/NN
./.
====================
AB/LS
-/:
Oestradiol/NN
has/VBZ
mitogenic/JJ
and/CC
regulatory/JJ
effects/NNS
on/IN
various/JJ
organs/NNS
and/CC
cells/NNS
,/,
mediated/VBN
mainly/RB
by/IN
its/PRP$
nuclear/JJ
receptor/NN
(/(
ER/NN
)/)
./.
====================
The/DT
presence/NN
of/IN
aberrant/JJ
ER/NN
forms/NNS
in/IN
Oestrogen-dependent/JJ
tumours/NNS
has/VBZ
been/VBN
discussed/VBN
in/IN
correlation/NN
with/IN
tumour/NN
progression/NN
./.
====================
ER/NN
variants/NNS
,/,
generated/VBN
by/IN
alternative/JJ
splicing/NN
,/,
have/VBP
been/VBN
detected/VBN
in/IN
human/JJ
breast/NN
cancer/NN
,/,
but/CC
also/RB
in/IN
normal/JJ
mammary/JJ
glands/NNS
,/,
therefore/RB
their/PRP$
role/NN
in/IN
tumorigenesis/NN
has/VBZ
been/VBN
questioned/VBN
./.
====================
We/PRP
have/VBP
investigated/VBN
,/,
by/IN
the/DT
use/NN
of/IN
the/DT
reverse/JJ
transcription/NN
polymerase/NN
chain/NN
reaction/NN
amplification/NN
technique/NN
,/,
the/DT
possible/JJ
existence/NN
of/IN
ER/NN
variants/NNS
in/IN
other/JJ
normal/JJ
oestrogen/NN
target/NN
organs/NNS
and/CC
cells/NNS
,/,
such/JJ
as/IN
uterus/NN
(/(
myometrium/NN
and/CC
endometrium/NN
)/)
,/,
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
and/CC
in/IN
a/DT
benign/JJ
uterus/NN
tumour/NN
(/(
leiomyoma/NN
)/)
./.
====================
We/PRP
have/VBP
detected/VBN
variant/JJ
ER/NN
in/IN
these/DT
samples/NNS
and/CC
have/VBP
compared/VBN
the/DT
variant/JJ
profile/NN
to/TO
that/DT
observed/VBN
in/IN
breast/NN
cancer/NN
./.
====================
All/DT
tissues/NNS
and/CC
cells/NNS
studied/VBN
expressed/VBD
both/CC
wild-type/JJ
ER/NN
and/CC
variant/JJ
species/NNS
./.
====================
Variant/JJ
forms/NNS
encompassed/VBD
ER/NN
with/IN
deletions/NNS
of/IN
exons/NNS
2/CD
,/,
5/CD
and/CC
7/CD
./.
====================
Variants/NNS
with/IN
exon/NN
5/CD
deleted/VBN
were/VBD
detected/VBN
only/RB
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
and/CC
in/IN
breast/NN
cancer/NN
./.
====================
Variants/NNS
with/IN
exons/NNS
2/CD
and/CC
7/CD
deleted/VBN
were/VBD
present/JJ
in/IN
all/DT
specimens/NNS
tested/VBN
./.
====================
These/DT
results/NNS
corroborate/VBP
previous/JJ
findings/NNS
that/IN
the/DT
presence/NN
of/IN
ER/NN
variants/NNS
is/VBZ
not/RB
a/DT
characteristic/NN
of/IN
breast/NN
cancer/NN
./.
====================
The/DT
physiological/JJ
significance/NN
and/CC
possible/JJ
clinical/JJ
relevance/NN
of/IN
the/DT
variant/JJ
ER/NN
forms/NNS
remain/VBP
to/TO
be/VB
elucidated/VBN
./.
====================
UI/LS
-/:
99010726/CD
====================
TI/LS
-/:
p21ras/NN
initiates/VBZ
Rac-1/NN
but/CC
not/RB
phosphatidyl/NN
inositol/NN
3/CD
kinase/PKB/NN
,/,
mediated/VBN
signaling/NN
pathways/NNS
in/IN
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
p21ras/NN
is/VBZ
activated/VBN
by/IN
the/DT
T/NN
cell/NN
antigen/NN
receptor/NN
(/(
TCR/NN
)/)
and/CC
then/RB
co-ordinates/VBZ
important/JJ
signaling/NN
pathways/NNS
for/IN
T/NN
lymphocyte/NN
activation/NN
./.
====================
Effector/NN
pathways/NNS
for/IN
this/DT
guanine/NN
nucleotide/NN
binding/NN
protein/NN
in/IN
T/NN
cells/NNS
are/VBP
mediated/VBN
by/IN
the/DT
serine/threonine/NN
kinase/NN
Raf-1/NN
and/CC
the/DT
Ras-related/JJ
GTPase/NN
Rac-1/NN
./.
====================
In/IN
fibroblasts/NNS
,/,
an/DT
important/JJ
effector/NN
for/IN
the/DT
Ras/NN
oncogene/NN
is/VBZ
Phosphatidylinositol/NN
3-kinase/NN
(/(
PtdIns/NN
3-kinase/NN
)/)
./.
====================
Activation/NN
of/IN
this/DT
lipid/NN
kinase/NN
is/VBZ
able/JJ
to/TO
induce/VB
critical/JJ
Rac-1/NN
signaling/NN
pathways/NNS
and/CC
can/MD
couple/VB
p21ras/NN
to/TO
cell/NN
survival/NN
mechanisms/NNS
via/IN
the/DT
serine/threonine/NN
kinase/NN
Akt/PKB/NN
./.
====================
The/DT
role/NN
of/IN
PtdIns/NN
3-kinase/NN
in/IN
Ras/NN
signaling/NN
in/IN
T/NN
cells/NNS
has/VBZ
not/RB
been/VBN
explored/VBN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
examined/VBD
the/DT
ability/NN
of/IN
PtdIns/NN
3-kinase/NN
to/TO
initiate/VB
the/DT
Rac-1/NN
signaling/NN
pathways/NNS
important/JJ
for/IN
T/NN
cell/NN
activation/NN
./.
====================
We/PRP
also/RB
examined/VBD
the/DT
possibility/NN
that/IN
Akt/PKB/NN
is/VBZ
regulated/VBN
by/IN
Ras/NN
signaling/NN
pathways/NNS
in/IN
T/NN
lymphocytes/NNS
./.
====================
The/DT
results/NNS
show/VBP
that/IN
Ras/NN
can/MD
initiate/VB
a/DT
Rac-1/NN
mediated/JJ
pathway/NN
that/WDT
regulates/VBZ
the/DT
transcriptional/JJ
function/NN
of/IN
AP-1/NN
complexes/NNS
./.
====================
PtdIns/NN
3-kinase/NN
signals/NNS
can/MD
not/RB
mimic/VB
p21ras/NN
and/CC
induce/VB
the/DT
Rac/NN
mediated/JJ
responses/NNS
of/IN
AP-1/NN
transcriptional/JJ
activation/NN
./.
====================
Moreover/RB
,/,
neither/CC
TCR/NN
or/CC
Ras/NN
activation/NN
of/IN
AP-1/NN
is/VBZ
dependent/JJ
on/IN
PtdIns/NN
3-kinase/NN
./.
====================
PKB/NN
is/VBZ
activated/VBN
in/IN
response/NN
to/TO
triggering/NN
of/IN
the/DT
T/NN
cell/NN
antigen/NN
receptor/NN
;/:
PtdIns/NN
3-kinase/NN
activity/NN
is/VBZ
both/CC
required/VBN
and/CC
sufficient/JJ
for/IN
this/DT
TCR/NN
response/NN
./.
====================
In/IN
contrast/NN
,/,
p21ras/NN
signals/NNS
are/VBP
unable/JJ
to/TO
induce/VB
Akt/PKB/NN
activity/NN
in/IN
T/NN
cell/NN
nor/CC
is/VBZ
Ras/NN
function/NN
required/VBN
for/IN
Akt/PKB/NN
activation/NN
in/IN
response/NN
to/TO
the/DT
TCR/NN
./.
====================
The/DT
present/JJ
data/NNS
thus/RB
highlight/VBP
that/IN
PtdIns/NN
3-kinase/NN
and/CC
Akt/PKB/NN
are/VBP
not/RB
universal/JJ
Ras/NN
effector/NN
molecules/NNS
./.
====================
Ras/NN
can/MD
initiate/VB
Rac-1/NN
regulated/JJ
signaling/NN
pathways/NNS
in/IN
the/DT
context/NN
of/IN
T/NN
cell/NN
antigen/NN
receptor/NN
function/NN
independently/RB
of/IN
PtdIns/NN
3-kinase/NN
activity/NN
./.
====================
UI/LS
-/:
99006628/CD
====================
TI/LS
-/:
Interleukin/NN
1beta/NN
mediates/VBZ
the/DT
modulatory/JJ
effects/NNS
of/IN
monocytes/NNS
on/IN
LNCaP/NN
human/JJ
prostate/NN
cancer/NN
cells/NNS
./.
====================
AB/LS
-/:
Proliferative/JJ
and/CC
secretory/JJ
responses/NNS
in/IN
androgen-sensitive/JJ
prostate/NN
cancer/NN
LNCaP/NN
cells/NNS
are/VBP
regulated/VBN
by/IN
steroid/NN
and/CC
peptide/NN
hormones/NNS
and/CC
by/IN
differentiation-promoting/JJ
substances/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
evaluated/VBD
whether/IN
peripheral/JJ
blood/NN
monocytes/NNS
that/WDT
exhibit/VBP
anti-tumour/JJ
activity/NN
in/IN
haematopoietic/JJ
and/CC
solid/JJ
tumours/NNS
influence/VBP
growth/NN
and/CC
secretion/NN
in/IN
the/DT
LNCaP/NN
cell/NN
line/NN
./.
====================
For/IN
this/DT
purpose/NN
,/,
LNCaP/NN
cells/NNS
were/VBD
incubated/VBN
with/IN
monocyte-conditioned/JJ
medium/NN
(/(
MCM/NN
)/)
,/,
and/CC
proliferation/NN
as/RB
well/RB
as/IN
expression/NN
of/IN
androgen/NN
receptor/NN
(/(
AR/NN
)/)
and/CC
secretion/NN
of/IN
prostate-specific/JJ
antigen/NN
(/(
PSA/NN
)/)
were/VBD
assessed/VBN
./.
====================
Conditioned/JJ
medium/NN
from/IN
monocytes/NNS
reduced/VBD
proliferation/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
./.
====================
Incubation/NN
with/IN
40/CD
%/NN
MCM/NN
caused/VBD
a/DT
50/CD
%/NN
reduction/NN
in/IN
cell/NN
proliferation/NN
./.
====================
AR/NN
protein/NN
decreased/VBD
by/IN
70/CD
%/NN
and/CC
PSA/NN
levels/NNS
in/IN
supernatants/NNS
from/IN
LNCaP/NN
cells/NNS
were/VBD
reduced/VBN
by/IN
approximately/RB
80/CD
%/NN
following/VBG
treatment/NN
with/IN
MCM/NN
./.
====================
We/PRP
focused/VBD
on/IN
the/DT
contribution/NN
of/IN
two/CD
major/JJ
products/NNS
of/IN
activated/VBN
monocytes/NNS
,/,
prostaglandin/NN
E2/NN
and/CC
interleukin/NN
1beta/NN
(/(
IL-1beta/NN
)/)
,/,
to/TO
the/DT
MCM/NN
modulatory/JJ
action/NN
./.
====================
LNCaP/NN
cells/NNS
treated/VBN
with/IN
prostaglandin/NN
E2/NN
showed/VBD
neither/CC
a/DT
reduction/NN
in/IN
proliferation/NN
nor/CC
a/DT
down-regulation/NN
of/IN
AR/NN
and/CC
PSA/NN
levels/NNS
./.
====================
The/DT
effects/NNS
of/IN
MCM/NN
on/IN
cellular/JJ
proliferation/NN
,/,
AR/NN
protein/NN
and/CC
PSA/NN
secretion/NN
were/VBD
abolished/VBN
by/IN
pretreatment/NN
of/IN
MCM/NN
with/IN
a/DT
neutralizing/VBG
anti-IL-1beta/NN
antibody/NN
./.
====================
In/IN
addition/NN
,/,
recombinant/JJ
IL-1beta/NN
was/VBD
able/JJ
to/TO
replace/VB
MCM/NN
for/IN
the/DT
inhibition/NN
of/IN
proliferation/NN
and/CC
down-regulation/NN
of/IN
AR/NN
and/CC
PSA/NN
proteins/NNS
./.
====================
LNCaP/NN
cells/NNS
were/VBD
shown/VBN
to/TO
express/VB
the/DT
IL-1beta/NN
receptor/NN
type/NN
1/CD
,/,
which/WDT
transduces/VBZ
IL-1beta/NN
signal/NN
./.
====================
Our/PRP$
findings/NNS
reveal/VBP
that/IN
monocyte-derived/JJ
IL-1beta/NN
inhibits/VBZ
the/DT
proliferation/NN
of/IN
androgen-responsive/JJ
prostate/NN
tumour/NN
cells/NNS
and/CC
reduces/VBZ
AR/NN
and/CC
PSA/NN
levels/NNS
./.
====================
UI/LS
-/:
98451425/CD
====================
TI/LS
-/:
Differential/JJ
responsiveness/NN
of/IN
the/DT
IL-5/NN
and/CC
IL-4/NN
genes/NNS
to/TO
transcription/NN
factor/NN
GATA-3/NN
./.
====================
AB/LS
-/:
The/DT
cytokines/NNS
IL-4/NN
and/CC
IL-5/NN
are/VBP
often/RB
coordinately/RB
produced/VBN
by/IN
Th2/NN
cells/NNS
as/IN
in/IN
asthma/NN
./.
====================
However/RB
,/,
it/PRP
is/VBZ
unclear/JJ
whether/IN
similar/JJ
molecular/JJ
mechanisms/NNS
underlie/VBP
transcription/NN
of/IN
the/DT
two/CD
genes/NNS
./.
====================
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
the/DT
transcription/NN
factor/NN
GATA-3/NN
is/VBZ
expressed/VBN
in/IN
Th2/NN
but/CC
not/RB
Th1/NN
cells/NNS
and/CC
is/VBZ
crucial/JJ
for/IN
activation/NN
of/IN
the/DT
IL-5/NN
promoter/NN
by/IN
different/JJ
stimuli/NNS
./.
====================
In/IN
a/DT
different/JJ
study/NN
,/,
GATA-3/NN
was/VBD
shown/VBN
to/TO
be/VB
sufficient/JJ
for/IN
the/DT
expression/NN
of/IN
IL-4/NN
and/CC
other/JJ
Th2/NN
cytokine/NN
genes/NNS
./.
====================
Here/RB
,/,
we/PRP
show/VBP
that/IN
ectopic/JJ
expression/NN
of/IN
GATA-3/NN
is/VBZ
sufficient/JJ
to/TO
drive/VB
IL-5/NN
but/CC
not/RB
IL-4/NN
gene/NN
expression/NN
./.
====================
Also/RB
,/,
in/IN
Th2/NN
cells/NNS
,/,
antisense/JJ
GATA-3/NN
RNA/NN
inhibits/VBZ
IL-5/NN
but/CC
not/RB
IL-4/NN
promoter/NN
activation/NN
./.
====================
The/DT
induction/NN
of/IN
IL-5/NN
gene/NN
expression/NN
by/IN
GATA-3/NN
involves/VBZ
high/JJ
affinity/NN
binding/NN
of/IN
GATA-3/NN
to/TO
an/DT
inverted/JJ
GATA/NN
repeat/NN
in/IN
the/DT
IL-5/NN
promoter/NN
./.
====================
UI/LS
-/:
98438586/CD
====================
TI/LS
-/:
The/DT
interleukin/NN
2/CD
receptor/NN
alpha/NN
chain/CD25/NN
promoter/NN
is/VBZ
a/DT
target/NN
for/IN
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
expression/NN
of/IN
the/DT
murine/JJ
interleukin/NN
(/(
IL/NN
)/)
-2/CD
receptor/NN
alpha/NN
chain/CD25/NN
is/VBZ
strongly/RB
induced/VBN
at/IN
the/DT
transcriptional/JJ
level/NN
after/IN
T/NN
cell/NN
activation/NN
./.
====================
We/PRP
show/VBP
here/RB
that/IN
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cell/NN
(/(
NF-AT/NN
)/)
factors/NNS
are/VBP
involved/VBN
in/IN
the/DT
control/NN
of/IN
CD25/NN
promoter/NN
induction/NN
in/IN
T/NN
cells/NNS
./.
====================
NF-ATp/NN
and/CC
NF-ATc/NN
bind/VBP
to/TO
two/CD
sites/NNS
around/IN
positions/NNS
-585/CD
and/CC
-650/CD
located/JJ
upstream/JJ
of/IN
the/DT
proximal/JJ
CD25/NN
promoter/NN
./.
====================
Immediately/RB
3'/JJ
from/IN
these/DT
NF-AT/NN
motifs/NNS
,/,
nonconsensus/JJ
sites/NNS
are/VBP
located/JJ
for/IN
the/DT
binding/NN
of/IN
AP-1-like/JJ
factors/NNS
./.
====================
Mutations/NNS
of/IN
sites/NNS
that/WDT
suppress/VBP
NF-AT/NN
binding/NN
impair/VBP
the/DT
induction/NN
and/CC
strong/JJ
NF-ATp-mediated/JJ
transactivation/NN
of/IN
the/DT
CD25/NN
promoter/NN
in/IN
T/NN
cells/NNS
./.
====================
In/IN
T/NN
lymphocytes/NNS
from/IN
NF-ATp-deficient/JJ
mice/NNS
,/,
the/DT
expression/NN
of/IN
CD25/NN
is/VBZ
severely/RB
impaired/JJ
,/,
leading/VBG
to/TO
a/DT
delayed/VBN
IL-2/NN
receptor/NN
expression/NN
after/IN
T/NN
cell/NN
receptor/NN
(/(
TCR/NN
)/)
/CD3/NN
stimulation/NN
./.
====================
Our/PRP$
data/NNS
indicate/VBP
an/DT
important/JJ
role/NN
for/IN
NF-AT/NN
in/IN
the/DT
faithful/JJ
expression/NN
of/IN
high/JJ
affinity/NN
IL-2/NN
receptors/NNS
and/CC
a/DT
close/JJ
link/NN
between/IN
the/DT
TCR-mediated/JJ
induction/NN
of/IN
IL-2/NN
and/CC
IL-2/NN
receptor/NN
alpha/NN
chain/NN
promoters/NNS
,/,
both/DT
of/IN
which/WDT
are/VBP
regulated/VBN
by/IN
NF-AT/NN
factors/NNS
./.
====================
UI/LS
-/:
98421365/CD
====================
TI/LS
-/:
A/DT
novel/JJ
mutation/NN
in/IN
the/DT
coding/VBG
sequence/NN
of/IN
the/DT
FY*B/NN
allele/NN
of/IN
the/DT
Duffy/NN
chemokine/NN
receptor/NN
gene/NN
is/VBZ
associated/VBN
with/IN
an/DT
altered/JJ
erythrocyte/NN
phenotype/NN
./.
====================
AB/LS
-/:
The/DT
Duffy/NN
blood/NN
group/NN
system/NN
is/VBZ
of/IN
clinical/JJ
and/CC
biological/JJ
significance/NN
./.
====================
Antibodies/NNS
to/TO
Duffy/NN
antigens/NNS
are/VBP
responsible/JJ
for/IN
some/DT
cases/NNS
of/IN
transfusion/NN
incompatibility/NN
and/CC
newborn/JJ
hemolytic/JJ
disease/NN
./.
====================
The/DT
Duffy/NN
protein/NN
is/VBZ
a/DT
receptor/NN
for/IN
the/DT
Plasmodium/NN
vivax/NN
erythrocyte-binding/JJ
protein/NN
and/CC
is/VBZ
also/RB
a/DT
receptor/NN
for/IN
various/JJ
chemokines/NNS
(/(
thus/RB
renamed/VBN
Duffy/NN
Antigen/NN
Receptor/NN
for/IN
Chemokines/NNS
[/(
DARC/NN
]/)
)/)
./.
====================
The/DT
two/CD
Duffy/NN
polymorphic/JJ
antigens/NNS
,/,
Fya/NN
and/CC
Fyb/NN
(/(
coded/VBN
by/IN
the/DT
FY*A/NN
and/CC
FY*B/NN
alleles/NNS
)/)
,/,
are/VBP
present/JJ
on/IN
erythrocyte/NN
membranes/NNS
./.
====================
The/DT
Fy(a-b-)/NN
phenotype/NN
is/VBZ
the/DT
predominant/JJ
one/CD
in/IN
populations/NNS
of/IN
black/JJ
people/NN
and/CC
also/RB
occurs/VBZ
in/IN
other/JJ
populations/NNS
,/,
including/VBG
some/DT
non-Ashkenazi/JJ
Jewish/JJ|NN
groups/NNS
./.
====================
The/DT
Fy(a-b-)/NN
phenotype/NN
has/VBZ
been/VBN
associated/VBN
with/IN
a/DT
mutation/NN
in/IN
the/DT
FY*B/NN
promoter/NN
at/IN
the/DT
GATA/NN
box/NN
that/WDT
abolishes/VBZ
the/DT
expression/NN
of/IN
erythrocyte/NN
Duffy/NN
protein/NN
./.
====================
We/PRP
describe/VBP
here/RB
a/DT
novel/JJ
mutation/NN
,/,
present/JJ
in/IN
the/DT
FY*B/NN
coding/VBG
sequence/NN
(/(
271C/NN
-->/TO
T/NN
)/)
,/,
that/WDT
is/VBZ
associated/VBN
with/IN
some/DT
Fy(b-)/NN
phenotypes/NNS
among/IN
non-Ashkenazi/JJ
Jews/NNS
and/CC
among/IN
Brazilian/JJ
blacks/NNS
./.
====================
The/DT
mutation/NN
is/VBZ
present/JJ
in/IN
Fy(b-)/NN
individuals/NNS
,/,
who/WP
have/VBP
wild-type/JJ
FY*B/NN
GATA/NN
and/CC
carry/VBP
the/DT
previously/RB
described/VBN
304G/NN
-->/TO
A/NN
substitution/NN
./.
====================
The/DT
271C/NN
-->/TO
T/NN
and/CC
304G/NN
-->/TO
A/NN
can/MD
be/VB
identified/VBN
by/IN
restriction/NN
enzyme-generated/JJ
restriction/NN
fragment/NN
length/NN
polymorphisms/NNS
./.
====================
The/DT
271C/NN
-->/TO
T/NN
substitution/NN
represents/VBZ
a/DT
considerable/JJ
change/NN
in/IN
chemical/JJ
nature/NN
(/(
Arg91/NN
-->/TO
Cys/NN
)/)
,/,
one/CD
which/WDT
may/MD
affect/VB
the/DT
antigenic/JJ
determinants/NNS
of/IN
DARC/NN
,/,
and/CC
thus/RB
be/VB
of/IN
clinical/JJ
significance/NN
./.
====================
The/DT
mutation/NN
may/MD
have/VB
implications/NNS
for/IN
some/DT
physiological/JJ
roles/NNS
of/IN
DARC/NN
and/CC
be/VB
of/IN
interest/NN
in/IN
malaria/NN
research/NN
and/CC
in/IN
studies/NNS
of/IN
population/NN
genetics/NNS
./.
====================
UI/LS
-/:
98403730/CD
====================
TI/LS
-/:
Establishment/NN
and/CC
characterization/NN
of/IN
EBV-positive/JJ
and/CC
EBV-negative/JJ
primary/JJ
effusion/NN
lymphoma/NN
cell/NN
lines/NNS
harbouring/VBG
human/JJ
herpesvirus/NN
type-8/NN
./.
====================
AB/LS
-/:
In/IN
this/DT
study/NN
we/PRP
report/VBP
on/IN
the/DT
establishment/NN
and/CC
characterization/NN
of/IN
two/CD
novel/JJ
lymphoma/NN
cell/NN
lines/NNS
(/(
CRO-AP/3/NN
and/CC
CRO-AP/5/NN
)/)
which/WDT
carry/VBP
infection/NN
by/IN
human/JJ
herpesvirus/NN
type-8/NN
(/(
HHV-8/NN
)/)
and/CC
have/VBP
derived/VBN
from/IN
AIDS-related/JJ
primary/JJ
effusion/NN
lymphoma/NN
(/(
PEL/NN
)/)
./.
====================
These/DT
two/CD
cell/NN
lines/NNS
are/VBP
representative/JJ
of/IN
different/JJ
virologic/JJ
subtypes/NNS
of/IN
PEL/NN
,/,
i.e./FW
HHV-8+/EBV-/JJ
PEL/NN
in/IN
the/DT
case/NN
of/IN
CRO-AP/3/NN
and/CC
HHV-8+/EBV+/JJ
PEL/NN
in/IN
the/DT
case/NN
of/IN
CRO-AP/5/NN
./.
====================
Consistent/JJ
with/IN
the/DT
diagnosis/NN
of/IN
PEL/NN
,/,
both/CC
CRO-AP/3/NN
and/CC
CRO-AP/5/NN
expressed/VBD
indeterminate/JJ
(/(
i.e./FW
non-B/JJ
,/,
non-T/JJ
)/)
phenotypes/NNS
although/IN
immunogenotypic/JJ
studies/NNS
documented/VBD
their/PRP$
B-cell/NN
origin/NN
./.
====================
Both/DT
cell/NN
lines/NNS
are/VBP
devoid/JJ
of/IN
genetic/JJ
lesions/NNS
of/IN
c-MYC/NN
,/,
BCL-2/NN
and/CC
p53/NN
as/RB
well/RB
as/IN
gross/JJ
rearrangements/NNS
of/IN
BCL-6/NN
./.
====================
Detailed/JJ
histogenetic/JJ
characterization/NN
of/IN
these/DT
novel/JJ
PEL/NN
cell/NN
lines/NNS
suggests/VBZ
that/IN
PEL/NN
may/MD
derive/VB
from/IN
a/DT
post-germinal/JJ
centre/NN
B/NN
cell/NN
which/WDT
has/VBZ
undergone/VBN
pre-terminal/JJ
differentiation/NN
./.
====================
The/DT
CRO-AP/3/NN
and/CC
CRO-AP/5/NN
cell/NN
lines/NNS
may/MD
provide/VB
a/DT
valuable/JJ
model/NN
for/IN
clarifying/VBG
the/DT
pathogenesis/NN
of/IN
PEL/NN
./.
====================
In/IN
particular/JJ
,/,
these/DT
cell/NN
lines/NNS
may/MD
help/VB
understand/VB
the/DT
relative/JJ
contribution/NN
of/IN
HHV-8/NN
and/CC
EBV/NN
to/TO
PEL/NN
growth/NN
and/CC
development/NN
and/CC
may/MD
facilitate/VB
the/DT
identification/NN
of/IN
recurrent/JJ
cytogenetic/JJ
abnormalities/NNS
highlighting/VBG
putative/JJ
novel/JJ
cancer/NN
related/JJ
loci/NNS
relevant/JJ
to/TO
PEL/NN
./.
====================
UI/LS
-/:
98395103/CD
====================
TI/LS
-/:
Two-site/JJ
interaction/NN
of/IN
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
with/IN
activated/VBN
calcineurin/NN
./.
====================
AB/LS
-/:
Transcription/NN
factors/NNS
belonging/VBG
to/TO
the/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFAT/NN
)/)
family/NN
regulate/VBP
the/DT
expression/NN
of/IN
cytokine/NN
genes/NNS
and/CC
other/JJ
inducible/JJ
genes/NNS
during/IN
the/DT
immune/JJ
response/NN
./.
====================
The/DT
functions/NNS
of/IN
NFAT/NN
proteins/NNS
are/VBP
directly/RB
controlled/VBN
by/IN
the/DT
calcium-/NN
and/CC
calmodulin-dependent/JJ
phosphatase/NN
calcineurin/NN
./.
====================
Here/RB
we/PRP
show/VBP
that/IN
the/DT
binding/NN
of/IN
calcineurin/NN
to/TO
NFAT/NN
is/VBZ
substantially/RB
increased/VBN
when/WRB
calcineurin/NN
is/VBZ
activated/VBN
with/IN
calmodulin/NN
and/CC
calcium/NN
./.
====================
FK506.FKBP12/NN
drug-immunophilin/NN
complexes/NNS
inhibited/VBD
the/DT
interaction/NN
of/IN
NFAT/NN
with/IN
activated/VBN
calcineurin/NN
much/RB
more/RBR
effectively/RB
than/IN
they/PRP
inhibited/VBD
the/DT
interaction/NN
with/IN
inactive/JJ
calcineurin/NN
,/,
suggesting/VBG
that/IN
part/NN
of/IN
the/DT
interaction/NN
with/IN
activated/VBN
calcineurin/NN
involved/VBD
the/DT
enzyme/NN
active/JJ
site/NN
./.
====================
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
NFAT/NN
is/VBZ
targeted/VBN
to/TO
inactive/JJ
calcineurin/NN
at/IN
a/DT
region/NN
distinct/JJ
from/IN
the/DT
calcineurin/NN
active/JJ
site/NN
(/(
Aramburu/NNP
,/,
J./NNP
,/,
Garcia-Cozar/NNP
,/,
F./NNP
J./NNP
,/,
Raghavan/NNP
,/,
A./NNP
,/,
Okamura/NNP
,/,
H./NNP
,/,
Rao/NNP
,/,
A./NNP
,/,
and/CC
Hogan/NNP
,/,
P./NNP
G./NNP
(/(
1998/CD
)/)
Mol./NNP
Cell/NNP
1/CD
,/,
627-637/CD
)/)
;/:
this/DT
region/NN
is/VBZ
also/RB
involved/VBN
in/IN
NFAT/NN
binding/NN
to/TO
activated/VBN
calcineurin/NN
,/,
since/IN
binding/NN
is/VBZ
inhibited/VBN
by/IN
an/DT
NFAT/NN
peptide/NN
spanning/VBG
the/DT
calcineurin/NN
docking/NN
site/NN
on/IN
NFAT/NN
./.
====================
The/DT
interacting/VBG
surfaces/NNS
are/VBP
located/JJ
on/IN
the/DT
catalytic/JJ
domain/NN
of/IN
the/DT
calcineurin/NN
A/NN
chain/NN
and/CC
on/IN
an/DT
86-amino/NN
acid/NN
fragment/NN
of/IN
the/DT
NFAT/NN
regulatory/JJ
domain/NN
./.
====================
NFAT/NN
binding/NN
to/TO
the/DT
calcineurin/NN
catalytic/JJ
domain/NN
was/VBD
inhibited/VBN
by/IN
the/DT
calcineurin/NN
autoinhibitory/JJ
domain/NN
and/CC
the/DT
RII/NN
substrate/NN
peptide/NN
,/,
which/WDT
bind/VBP
in/IN
the/DT
calcineurin/NN
active/JJ
site/NN
,/,
as/RB
well/RB
as/IN
by/IN
the/DT
NFAT/NN
docking/NN
site/NN
peptide/NN
,/,
which/WDT
binds/VBZ
to/TO
a/DT
region/NN
of/IN
calcineurin/NN
distinct/JJ
from/IN
the/DT
active/JJ
site/NN
./.
====================
We/PRP
propose/VBP
that/IN
,/,
in/IN
resting/VBG
cells/NNS
,/,
NFAT/NN
is/VBZ
targeted/VBN
to/TO
a/DT
region/NN
of/IN
the/DT
calcineurin/NN
catalytic/JJ
domain/NN
that/WDT
does/VBZ
not/RB
overlap/VB
the/DT
calcineurin/NN
active/JJ
site/NN
./.
====================
Upon/IN
cell/NN
activation/NN
,/,
displacement/NN
of/IN
the/DT
autoinhibitory/JJ
domain/NN
by/IN
calmodulin/NN
binding/NN
allows/VBZ
NFAT/NN
to/TO
bind/VB
additionally/RB
to/TO
the/DT
calcineurin/NN
active/JJ
site/NN
,/,
thus/RB
positioning/VBG
NFAT/NN
for/IN
immediate/JJ
dephosphorylation/NN
at/IN
functional/JJ
phosphoserine/NN
residues/NNS
./.
====================
UI/LS
-/:
98385602/CD
====================
TI/LS
-/:
Nuclear/JJ
factor-kappaB/NN
induction/NN
in/IN
CD45RO+/JJ
and/CC
CD45RA+/JJ
T/NN
cell/NN
subsets/NNS
during/IN
aging/NN
./.
====================
AB/LS
-/:
An/DT
increase/NN
in/IN
the/DT
ratio/NN
of/IN
memory/NN
to/TO
naive/JJ
T/NN
cells/NNS
has/VBZ
been/VBN
postulated/VBN
to/TO
underlie/VB
immune/JJ
hyporesponsiveness/NN
accompanying/VBG
aging/NN
./.
====================
Our/PRP$
analyses/NNS
of/IN
the/DT
induction/NN
of/IN
nuclear/JJ
factor-kappaB/NN
(/(
NFkappaB/NN
)/)
in/IN
activated/VBN
memory/NN
(/(
CD45RO+/JJ
)/)
and/CC
naive/JJ
(/(
CD45RA+/JJ
)/)
T/NN
cell/NN
subsets/NNS
from/IN
young/JJ
and/CC
elderly/JJ
donors/NNS
has/VBZ
demonstrated/VBN
that/IN
,/,
regardless/RB
of/IN
donor/NN
age/NN
,/,
memory/NN
T/NN
cells/NNS
are/VBP
not/RB
significantly/RB
altered/VBN
in/IN
their/PRP$
responsiveness/NN
to/TO
TNF-alpha-mediated/JJ
induction/NN
of/IN
NFkappaB/NN
./.
====================
Although/IN
treatment/NN
with/IN
TNF-alpha/NN
induced/VBD
nuclear/JJ
localization/NN
of/IN
NFkappaB/NN
in/IN
both/CC
memory/NN
and/CC
naive/JJ
T/NN
cell/NN
subsets/NNS
,/,
irrespective/RB
of/IN
the/DT
age/NN
of/IN
the/DT
donor/NN
,/,
the/DT
levels/NNS
of/IN
induced/VBN
NFkappaB/NN
were/VBD
significantly/RB
lower/JJR
in/IN
both/DT
subsets/NNS
of/IN
T/NN
cells/NNS
obtained/VBN
from/IN
the/DT
elderly/JJ
,/,
when/WRB
compared/VBN
to/TO
those/DT
in/IN
young/JJ
./.
====================
Examination/NN
of/IN
IkappaB/NN
alpha/NN
regulation/NN
revealed/VBD
that/IN
TNF-alpha-mediated/JJ
degradation/NN
of/IN
IkappaB/NN
alpha/NN
in/IN
both/CC
memory/NN
and/CC
naive/JJ
T/NN
cells/NNS
from/IN
the/DT
elderly/JJ
was/VBD
severely/RB
impaired/JJ
,/,
thus/RB
contributing/VBG
to/TO
the/DT
lowered/JJ
induction/NN
of/IN
the/DT
observed/VBN
NFkappaB/NN
./.
====================
In/IN
addition/NN
,/,
this/DT
age-related/JJ
decrease/NN
in/IN
induction/NN
of/IN
nuclear/JJ
NFkappaB/NN
correlated/VBD
with/IN
decrease/NN
in/IN
intracellular/JJ
IL-2/NN
receptor/NN
expression/NN
and/CC
anti-CD3-induced/JJ
proliferation/NN
of/IN
both/CC
memory/NN
and/CC
naive/JJ
T/NN
cells/NNS
subsets/NNS
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
results/NNS
suggest/VBP
that/IN
the/DT
age-related/JJ
hyporesponsiveness/NN
can/MD
not/RB
be/VB
attributed/VBN
to/TO
a/DT
skewing/NN
of/IN
the/DT
T/NN
cell/NN
population/NN
towards/IN
a/DT
memory/NN
phenotype/NN
in/IN
the/DT
elderly/JJ
./.
====================
UI/LS
-/:
98375865/CD
====================
TI/LS
-/:
Cyclosporin/NN
A-resistant/JJ
transactivation/NN
of/IN
the/DT
IL-2/NN
promoter/NN
requires/VBZ
activity/NN
of/IN
okadaic/JJ
acid-sensitive/JJ
serine/threonine/NN
phosphatases/NNS
./.
====================
AB/LS
-/:
Expression/NN
of/IN
the/DT
IL-2/NN
gene/NN
requires/VBZ
activation/NN
of/IN
T/NN
cells/NNS
through/IN
stimulation/NN
of/IN
the/DT
TCR/NN
and/CC
costimulation/NN
through/IN
accessory/NN
receptors/NNS
./.
====================
We/PRP
have/VBP
found/VBN
recently/RB
that/IN
okadaic/JJ
acid-sensitive/JJ
Ser/Thr/NN
phosphatases/NNS
are/VBP
involved/VBN
in/IN
a/DT
cyclosporin/NN
A-insensitive/JJ
pathway/NN
that/WDT
selectively/RB
transmits/VBZ
costimulatory/JJ
signals/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
analyzed/VBD
whether/IN
activities/NNS
of/IN
these/DT
phosphatases/NNS
are/VBP
necessary/JJ
for/IN
the/DT
expression/NN
of/IN
the/DT
IL-2/NN
gene/NN
./.
====================
In/IN
both/CC
activated/VBN
peripheral/JJ
blood/NN
T/NN
lymphocytes/NNS
and/CC
activated/VBN
tumorigenic/JJ
T/NN
cell/NN
lines/NNS
,/,
IL-2/NN
gene/NN
expression/NN
was/VBD
blocked/VBN
at/IN
the/DT
transcriptional/JJ
level/NN
by/IN
okadaic/JJ
acid/NN
./.
====================
The/DT
transcription/NN
factors/NNS
active/JJ
at/IN
the/DT
IL-2/NN
promoter/NN
were/VBD
differentially/RB
influenced/VBN
:/:
upon/IN
down-modulation/NN
of/IN
okadaic/JJ
acid-sensitive/JJ
phosphatases/NNS
,/,
transactivation/NN
by/IN
octamer/NN
,/,
NF-kappa/NN
B/NN
,/,
and/CC
NF/NN
of/IN
activated/VBN
T/NN
cells/NNS
proteins/NNS
was/VBD
abrogated/VBN
,/,
while/IN
transactivation/NN
by/IN
AP-1/NN
proteins/NNS
was/VBD
even/RB
enhanced/VBN
./.
====================
UI/LS
-/:
99023506/CD
====================
TI/LS
-/:
YM268/NN
increases/VBZ
the/DT
glucose/NN
uptake/NN
,/,
cell/NN
differentiation/NN
,/,
and/CC
mRNA/NN
expression/NN
of/IN
glucose/NN
transporter/NN
in/IN
3T3-L1/NN
adipocytes/NNS
./.
====================
AB/LS
-/:
The/DT
purpose/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
examine/VB
the/DT
effects/NNS
of/IN
bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]/NN
methane/NN
(/(
YM-268/NN
)/)
,/,
a/DT
thiazolidinedione/JJ
derivative/NN
,/,
on/IN
glucose/NN
uptake/NN
,/,
adipocyte/NN
differentiation/NN
through/IN
peroxisome/NN
proliferator-activated/JJ
receptor/NN
gamma/NN
(/(
PPARgamma/NN
)/)
,/,
and/CC
phosphatidylinositol/NN
3-kinase/NN
(/(
PI/NN
3-kinase/NN
)/)
activity/NN
in/IN
cultured/VBN
cells/NNS
./.
====================
YM268/NN
and/CC
pioglitazone/NN
dose-dependently/RB
increased/VBD
the/DT
2-deoxyglucose/NN
uptake/NN
in/IN
3T3-L1/NN
cells/NNS
./.
====================
YM268/NN
facilitated/VBD
the/DT
insulin-stimulated/JJ
triglyceride/NN
accumulation/NN
in/IN
3T3-L1/NN
adipocytes/NNS
and/CC
increased/VBD
the/DT
mRNA/NN
expression/NN
of/IN
fatty/JJ
acid-binding/JJ
protein/NN
./.
====================
YM268/NN
,/,
with/IN
and/CC
without/IN
insulin/NN
,/,
increased/VBD
the/DT
mRNA/NN
expression/NN
of/IN
glucose/NN
transporter/NN
isoforms/NNS
such/JJ
as/IN
GLUT1/NN
and/CC
GLUT4/NN
,/,
indicating/VBG
enhancement/NN
of/IN
adipocyte/NN
differentiation/NN
./.
====================
Additionally/RB
,/,
YM268/NN
and/CC
pioglitazone/NN
showed/VBD
activity/NN
of/IN
the/DT
PPARgamma/NN
ligand/NN
,/,
a/DT
member/NN
of/IN
the/DT
nuclear/JJ
receptor/NN
superfamily/NN
responsible/JJ
for/IN
adipogenesis/NN
./.
====================
To/TO
examine/VB
the/DT
possible/JJ
involvement/NN
of/IN
the/DT
increased/VBN
activity/NN
of/IN
PI/NN
3-kinase/NN
in/IN
YM268-stimulated/JJ
glucose/NN
uptake/NN
,/,
the/DT
enzyme/NN
activity/NN
was/VBD
estimated/VBN
by/IN
measuring/VBG
the/DT
phosphatidylinositol-3,4,5-trisphosphate/NN
(/(
PI-3,4,5-P3/NN
)/)
concentration/NN
in/IN
human/JJ
monocytic/JJ
cells/NNS
./.
====================
Insulin/NN
dose-dependently/RB
increased/VBD
the/DT
PI-3,4,5-P3/NN
production/NN
but/CC
YM268/NN
had/VBD
no/DT
significant/JJ
effect/NN
on/IN
the/DT
insulin-dependent/JJ
and/CC
-independent/JJ
PI/NN
3-kinase/NN
activation/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
the/DT
mechanism/NN
by/IN
which/WDT
YM268/NN
increased/VBD
glucose/NN
uptake/NN
,/,
may/MD
be/VB
accounted/VBN
for/IN
in/IN
part/NN
by/IN
the/DT
enhancement/NN
of/IN
GLUT1/NN
and/CC
GLUT4/NN
expression/NN
through/IN
PPARgamma/NN
activation/NN
./.
====================
UI/LS
-/:
99014176/CD
====================
TI/LS
-/:
The/DT
nuclear/JJ
receptor/NN
PPARgamma/NN
-/:
bigger/JJR
than/IN
fat/NN
./.
====================
AB/LS
-/:
Work/NN
reported/VBD
over/IN
the/DT
past/JJ
year/NN
has/VBZ
provided/VBN
insights/NNS
into/IN
the/DT
mechanisms/NNS
whereby/WRB
ligand/NN
activation/NN
of/IN
the/DT
nuclear/JJ
receptor/NN
peroxisome/NN
proliferator-activated/JJ
receptor/NN
gamma/NN
(/(
PPARgamma/NN
)/)
regulates/VBZ
systemic/JJ
glucose/NN
and/CC
lipid/NN
homeostasis/NN
./.
====================
PPARgamma/NN
has/VBZ
also/RB
been/VBN
implicated/VBN
recently/RB
in/IN
the/DT
biology/NN
of/IN
monocytes/NNS
and/CC
in/IN
cell-cycle/JJ
regulation/NN
and/CC
cancer/NN
./.
====================
Polyunsaturated/JJ
fatty/JJ
acids/NNS
and/CC
eicosanoids/NNS
bind/VBP
and/CC
activate/VBP
PPARgamma/NN
,/,
suggesting/VBG
that/IN
these/DT
lipids/NNS
may/MD
serve/VB
as/IN
hormonal/JJ
regulators/NNS
of/IN
a/DT
variety/NN
of/IN
biological/JJ
processes/NNS
./.
====================
UI/LS
-/:
99007753/CD
====================
TI/LS
-/:
The/DT
role/NN
of/IN
caspases/NNS
in/IN
T/NN
cell/NN
development/NN
and/CC
the/DT
control/NN
of/IN
immune/JJ
responses/NNS
./.
====================
AB/LS
-/:
Apoptosis/NN
is/VBZ
responsible/JJ
for/IN
the/DT
removal/NN
of/IN
potentially/RB
autoreactive/JJ
or/CC
useless/JJ
T/NN
cells/NNS
during/IN
thymic/JJ
selection/NN
and/CC
activated/VBN
T/NN
cells/NNS
in/IN
the/DT
periphery/NN
./.
====================
Specific/JJ
families/NNS
of/IN
receptors/NNS
,/,
kinases/NNS
,/,
transcription/NN
factors/NNS
,/,
and/CC
cysteine/NN
proteases/NNS
,/,
termed/VBN
caspases/NNS
,/,
are/VBP
involved/VBN
in/IN
the/DT
apoptotic/JJ
cascade/NN
leading/VBG
to/TO
proteolysis/NN
of/IN
specific/JJ
substrates/NNS
and/CC
to/TO
morphological/JJ
changes/NNS
associated/VBN
with/IN
programmed/VBN
cell/NN
death/NN
./.
====================
Although/IN
common/JJ
members/NNS
of/IN
the/DT
apoptotic/JJ
cascade/NN
are/VBP
shared/VBN
between/IN
different/JJ
cell/NN
types/NNS
,/,
it/PRP
appears/VBZ
that/IN
cell-specific/JJ
factors/NNS
can/MD
influence/VB
the/DT
response/NN
to/TO
a/DT
given/JJ
apoptotic/JJ
stimuli/NNS
./.
====================
Characterization/NN
and/CC
understanding/NN
of/IN
the/DT
basic/JJ
mechanisms/NNS
involved/VBN
in/IN
the/DT
different/JJ
pathways/NNS
protecting/VBG
or/CC
leading/VBG
to/TO
cell/NN
death/NN
may/MD
provide/VB
novel/JJ
ways/NNS
to/TO
control/VB
inappropriate/JJ
apoptosis/NN
involved/VBN
in/IN
several/JJ
diseases/NNS
./.
====================
UI/LS
-/:
98451423/CD
====================
TI/LS
-/:
Cross-priming/NN
of/IN
CTL/NN
responses/NNS
in/FW
vivo/FW
does/VBZ
not/RB
require/VB
antigenic/JJ
peptides/NNS
in/IN
the/DT
endoplasmic/JJ
reticulum/NN
of/IN
immunizing/JJ
cells/NNS
./.
====================
AB/LS
-/:
It/PRP
has/VBZ
been/VBN
proposed/VBN
that/IN
the/DT
cross-priming/NN
of/IN
CTL/NN
responses/NNS
in/FW
vivo/FW
involves/VBZ
the/DT
transfer/NN
to/TO
host/NN
APCs/NNS
of/IN
heat/NN
shock/NN
protein/NN
glycoprotein/NN
96-chaperoned/JJ
antigenic/JJ
peptides/NNS
released/VBN
from/IN
the/DT
endoplasmic/JJ
reticulum/NN
(/(
ER/NN
)/)
of/IN
dying/VBG
or/CC
infected/JJ
cells/NNS
./.
====================
We/PRP
have/VBP
tested/VBN
this/DT
possibility/NN
directly/RB
using/VBG
TAP-deficient/JJ
cell/NN
lines/NNS
lacking/VBG
antigenic/JJ
ER/NN
peptides/NNS
derived/VBN
from/IN
two/CD
model/NN
Ags/NNS
,/,
the/DT
human/JJ
adenovirus/NN
type/NN
5/CD
early/JJ
regions/NNS
E1A/NN
and/CC
E1B/NN
./.
====================
Although/IN
both/DT
proteins/NNS
were/VBD
well/RB
expressed/VBN
,/,
the/DT
cells/NNS
were/VBD
not/RB
recognized/VBN
by/IN
E1A-/NN
or/CC
E1B-specific/JJ
CTLs/NNS
unless/IN
the/DT
relevant/JJ
epitope/NN
was/VBD
either/CC
provided/VBN
exogenously/RB
as/IN
a/DT
synthetic/JJ
peptide/NN
or/CC
targeted/VBN
to/TO
the/DT
ER/NN
in/IN
a/DT
TAP-independent/JJ
fashion/NN
./.
====================
Despite/IN
the/DT
absence/NN
of/IN
these/DT
ER/NN
peptides/NNS
,/,
the/DT
TAP1-/-/JJ
cells/NNS
were/VBD
able/JJ
to/TO
efficiently/RB
cross-prime/VB
E1A-/NN
and/CC
E1B-specific/JJ
CTLs/NNS
following/VBG
immunization/NN
of/IN
syngeneic/JJ
mice/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
,/,
although/IN
purified/VBN
peptide/glycoprotein/NN
96/CD
complexes/NNS
are/VBP
potent/JJ
immunogens/NNS
,/,
the/DT
mechanism/NN
of/IN
CTL/NN
cross-priming/NN
in/FW
vivo/FW
does/VBZ
not/RB
depend/VB
upon/IN
antigenic/JJ
peptides/NNS
in/IN
the/DT
ER/NN
of/IN
immunizing/JJ
cells/NNS
./.
====================
UI/LS
-/:
98438583/CD
====================
TI/LS
-/:
A/DT
critical/JJ
role/NN
of/IN
the/DT
p75/NN
tumor/NN
necrosis/NN
factor/NN
receptor/NN
(/(
p75TNF-R/NN
)/)
in/IN
organ/NN
inflammation/NN
independent/JJ
of/IN
TNF/NN
,/,
lymphotoxin/NN
alpha/NN
,/,
or/CC
the/DT
p55TNF-R/NN
./.
====================
AB/LS
-/:
Despite/IN
overwhelming/JJ
evidence/NN
that/IN
enhanced/VBN
production/NN
of/IN
the/DT
p75/NN
tumor/NN
necrosis/NN
factor/NN
receptor/NN
(/(
p75TNF-R/NN
)/)
accompanies/VBZ
development/NN
of/IN
specific/JJ
human/JJ
inflammatory/JJ
pathologies/NNS
such/JJ
as/IN
multi-organ/JJ
failure/NN
during/IN
sepsis/NN
,/,
inflammatory/JJ
liver/NN
disease/NN
,/,
pancreatitis/NN
,/,
respiratory/JJ
distress/NN
syndrome/NN
,/,
or/CC
AIDS/NN
,/,
the/DT
function/NN
of/IN
this/DT
receptor/NN
remains/VBZ
poorly/RB
defined/VBN
in/FW
vivo/FW
./.
====================
We/PRP
show/VBP
here/RB
that/IN
at/IN
levels/NNS
relevant/JJ
to/TO
human/JJ
disease/NN
,/,
production/NN
of/IN
the/DT
human/JJ
p75TNF-R/NN
in/IN
transgenic/JJ
mice/NNS
results/VBZ
in/IN
a/DT
severe/JJ
inflammatory/JJ
syndrome/NN
involving/VBG
mainly/RB
the/DT
pancreas/NN
,/,
liver/NN
,/,
kidney/NN
,/,
and/CC
lung/NN
,/,
and/CC
characterized/VBN
by/IN
constitutively/RB
increased/VBN
NF-kappaB/NN
activity/NN
in/IN
the/DT
peripheral/JJ
blood/NN
mononuclear/JJ
cell/NN
compartment/NN
./.
====================
This/DT
process/NN
is/VBZ
shown/VBN
to/TO
evolve/VB
independently/RB
of/IN
the/DT
presence/NN
of/IN
TNF/NN
,/,
lymphotoxin/NN
alpha/NN
,/,
or/CC
the/DT
p55TNF-R/NN
,/,
although/IN
coexpression/NN
of/IN
a/DT
human/JJ
TNF/NN
transgene/NN
accelerated/VBD
pathology/NN
./.
====================
These/DT
results/NNS
establish/VBP
an/DT
independent/JJ
role/NN
for/IN
enhanced/VBN
p75TNF-R/NN
production/NN
in/IN
the/DT
pathogenesis/NN
of/IN
inflammatory/JJ
disease/NN
and/CC
implicate/VBP
the/DT
direct/JJ
involvement/NN
of/IN
this/DT
receptor/NN
in/IN
a/DT
wide/JJ
range/NN
of/IN
human/JJ
inflammatory/JJ
pathologies/NNS
./.
====================
UI/LS
-/:
98421363/CD
====================
TI/LS
-/:
Expression/NN
status/NN
of/IN
BCL-6/NN
and/CC
syndecan-1/NN
identifies/VBZ
distinct/JJ
histogenetic/JJ
subtypes/NNS
of/IN
Hodgkin/NN
's/POS
disease/NN
./.
====================
AB/LS
-/:
The/DT
tumor/NN
cells/NNS
in/IN
most/JJS
cases/NNS
of/IN
Hodgkin/NN
's/POS
disease/NN
(/(
HD/NN
)/)
have/VBP
been/VBN
recently/RB
recognized/VBN
to/TO
originate/VB
from/IN
the/DT
B-cell/NN
lineage/NN
,/,
but/CC
their/PRP$
precise/JJ
differentiation/NN
stage/NN
is/VBZ
not/RB
fully/RB
clarified/VBN
./.
====================
Recently/RB
,/,
we/PRP
have/VBP
reported/VBN
that/IN
the/DT
histogenesis/NN
of/IN
B-cell/NN
lymphomas/NNS
may/MD
be/VB
assessed/VBN
by/IN
monitoring/VBG
the/DT
expression/NN
pattern/NN
of/IN
BCL-6/NN
,/,
a/DT
transcription/NN
factor/NN
expressed/VBN
in/IN
germinal/JJ
center/NN
(/(
GC/NN
)/)
B/NN
cells/NNS
,/,
and/CC
CD138/syndecan-1/NN
(/(
syn-1/NN
)/)
,/,
a/DT
proteoglycan/NN
associated/VBN
with/IN
post-GC/JJ
,/,
terminal/JJ
B-cell/NN
differentiation/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
applied/VBN
these/DT
two/CD
markers/NNS
to/TO
the/DT
study/NN
of/IN
HD/NN
histogenesis/NN
./.
====================
We/PRP
have/VBP
found/VBN
that/IN
in/IN
nodular/JJ
lymphocyte/NN
predominance/NN
HD/NN
(/(
NLPHD/NN
)/)
tumor/NN
cells/NNS
consistently/RB
display/VBP
the/DT
BCL-6(+)/syn-1(-)/JJ
phenotype/NN
,/,
indicating/VBG
their/PRP$
derivation/NN
from/IN
GC/NN
B/NN
cells/NNS
./.
====================
Conversely/RB
,/,
classic/JJ
HD/NN
(/(
CHD/NN
)/)
is/VBZ
heterogeneous/JJ
because/IN
the/DT
tumor/NN
cells/NNS
of/IN
a/DT
fraction/NN
of/IN
CHD/NN
display/VBP
the/DT
BCL-6(-)/syn-1(+)/JJ
phenotype/NN
of/IN
post-GC/JJ
B-cells/NNS
,/,
whereas/IN
another/DT
fraction/NN
of/IN
CHD/NN
is/VBZ
constituted/VBN
by/IN
a/DT
mixture/NN
of/IN
tumor/NN
cells/NNS
reflecting/VBG
the/DT
GC/NN
(/(
BCL-6(+)/syn-1(-)/JJ
)/)
or/CC
post-GC/JJ
(/(
BCL-6(-)/syn-1(+)/JJ
)/)
phenotypes/NNS
./.
====================
BCL-6(-)/syn-1(+)/JJ
tumor/NN
cells/NNS
of/IN
CHD/NN
are/VBP
mostly/RB
found/VBN
surrounded/VBN
by/IN
T/NN
cells/NNS
expressing/VBG
CD40L/NN
,/,
consistent/JJ
with/IN
the/DT
observation/NN
that/IN
CD40/NN
signaling/NN
downregulates/VBZ
BCL-6/NN
expression/NN
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
tumor/NN
cells/NNS
of/IN
NLPHD/NN
uniformly/RB
display/VBP
a/DT
GC/NN
B-cell/NN
phenotype/NN
,/,
whereas/IN
the/DT
phenotype/NN
of/IN
tumor/NN
cells/NNS
of/IN
CHD/NN
appears/VBZ
to/TO
be/VB
modulated/VBN
by/IN
the/DT
surrounding/JJ
cellular/JJ
background/NN
,/,
particularly/RB
CD40L+/JJ
reactive/JJ
T/NN
cells/NNS
./.
====================
UI/LS
-/:
98406210/CD
====================
TI/LS
-/:
Molecular/JJ
and/CC
cellular/JJ
analysis/NN
of/IN
human/JJ
immunodeficiency/NN
virus-induced/JJ
apoptosis/NN
in/IN
lymphoblastoid/JJ
T-cell-line-expressing/JJ
wild-type/JJ
and/CC
mutated/VBN
CD4/NN
receptors/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
the/DT
presence/NN
of/IN
the/DT
CD4/NN
cytoplasmic/JJ
tail/NN
is/VBZ
critical/JJ
for/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
-induced/JJ
apoptosis/NN
(/(
J.Corbeil/NNP
,/,
M.Tremblay/NNP
,/,
and/CC
D.D.Richman/NNP
,/,
J.Exp.Med.183/NNP
:/:
39-48/CD
,/,
1996/CD
)/)
./.
====================
We/PRP
have/VBP
pursued/VBN
our/PRP$
investigation/NN
of/IN
the/DT
role/NN
of/IN
the/DT
CD4/NN
transduction/NN
pathway/NN
in/IN
HIV-induced/JJ
apoptosis/NN
./.
====================
To/TO
do/VBP
this/DT
,/,
wild-type/JJ
and/CC
mutant/JJ
forms/NNS
of/IN
the/DT
CD4/NN
cytoplasmic/JJ
tail/NN
were/VBD
stably/RB
expressed/VBN
in/IN
the/DT
lymphoblastoid/JJ
T-cell/NN
line/NN
A2.01/NN
./.
====================
Apoptosis/NN
was/VBD
prevented/VBN
when/WRB
CD4/NN
truncated/VBN
at/IN
residue/NN
402/CD
was/VBD
expressed/VBN
;/:
however/RB
,/,
cells/NNS
expressing/VBG
mutated/VBN
receptors/NNS
that/WDT
do/VBP
not/RB
associate/VB
with/IN
p56(lck)/NN
(/(
mutated/VBN
at/IN
the/DT
dicysteine/NN
motif/NN
and/CC
truncated/VBN
at/IN
residue/NN
418/CD
)/)
but/CC
which/WDT
conserved/VBD
proximal/JJ
domains/NNS
of/IN
the/DT
cytoplasmic/JJ
tail/NN
underwent/VBD
apoptosis/NN
like/IN
wild- type/JJ
CD4/NN
./.
====================
The/DT
differences/NNS
between/IN
wild-type/JJ
and/CC
mutated/VBN
receptors/NNS
in/IN
the/DT
induction/NN
of/IN
apoptosis/NN
were/VBD
not/RB
related/JJ
to/TO
levels/NNS
of/IN
p56(lck)/NN
or/CC
NF- kappaB/NN
activation/NN
./.
====================
Initial/JJ
signaling/NN
through/IN
the/DT
CD4/NN
receptor/NN
played/VBD
a/DT
major/JJ
role/NN
in/IN
the/DT
sensitization/NN
of/IN
HIV-infected/JJ
T/NN
cells/NNS
to/TO
undergo/VB
apoptosis/NN
./.
====================
Incubation/NN
of/IN
HIV-infected/JJ
cells/NNS
with/IN
monoclonal/JJ
antibody/NN
(/(
MAb/NN
)/)
13B8-2/NN
,/,
which/WDT
binds/VBZ
to/TO
CD4/NN
in/IN
a/DT
region/NN
critical/JJ
for/IN
dimerization/NN
of/IN
the/DT
receptor/NN
,/,
prevented/VBD
apoptosis/NN
without/IN
inhibiting/VBG
HIV/NN
replication/NN
./.
====================
Moreover/RB
,/,
the/DT
apoptotic/JJ
process/NN
was/VBD
not/RB
related/JJ
to/TO
Fas-Fas/JJ
ligand/NN
interaction/NN
;/:
however/RB
,/,
an/DT
antagonistic/JJ
anti-Fas/JJ
MAb/NN
(/(
ZB-4/NN
)/)
enhanced/VBD
apoptosis/NN
in/IN
HIV-infected/JJ
cells/NNS
without/IN
inducing/VBG
apoptosis/NN
in/IN
uninfected/JJ
cells/NNS
./.
====================
These/DT
observations/NNS
demonstrate/VBP
that/IN
CD4/NN
signaling/NN
mediates/VBZ
HIV-induced/JJ
apoptosis/NN
by/IN
a/DT
mechanism/NN
independent/JJ
of/IN
Fas-Fas/JJ
ligand/NN
interaction/NN
,/,
does/VBZ
not/RB
require/VB
p56(lck)/NN
signaling/NN
,/,
and/CC
may/MD
involve/VB
a/DT
critical/JJ
region/NN
for/IN
CD4/NN
dimerization/NN
./.
====================
UI/LS
-/:
98395073/CD
====================
TI/LS
-/:
p130/NN
,/,
p107/NN
,/,
and/CC
pRb/NN
are/VBP
differentially/RB
regulated/VBN
in/IN
proliferating/VBG
cells/NNS
and/CC
during/IN
cell/NN
cycle/NN
arrest/NN
by/IN
alpha-interferon/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
determined/VBN
how/WRB
the/DT
phosphorylation/NN
of/IN
the/DT
retinoblastoma/NN
family/NN
(/(
pRb/NN
,/,
p107/NN
,/,
and/CC
p130/NN
)/)
is/VBZ
governed/VBN
in/IN
individual/JJ
cell/NN
cycle/NN
phases/NNS
of/IN
Daudi/NN
B-cells/NNS
during/IN
cell/NN
cycle/NN
exit/NN
triggered/VBN
by/IN
alpha-interferon/NN
(/(
alpha-IFN/NN
)/)
./.
====================
alpha-IFN/NN
causes/VBZ
dephosphorylation/NN
of/IN
pRb/NN
and/CC
loss/NN
of/IN
p130/NN
phosphorylated/JJ
Form/NN
3/CD
./.
====================
However/RB
,/,
the/DT
change/NN
in/IN
p130/NN
phosphorylation/NN
in/IN
response/NN
to/TO
alpha-IFN/NN
occurs/VBZ
before/IN
dephosphorylation/NN
of/IN
pRb/NN
is/VBZ
complete/JJ
because/IN
loss/NN
of/IN
p130/NN
Form/NN
3/CD
occurs/VBZ
throughout/IN
the/DT
cell/NN
cycle/NN
prior/JJ
to/TO
complete/JJ
arrest/NN
in/IN
G1/NN
,/,
whereas/IN
pRb/NN
is/VBZ
dephosphorylated/VBN
only/RB
in/IN
G1/NN
./.
====================
In/IN
contrast/NN
,/,
p107/NN
is/VBZ
dephosphorylated/VBN
and/CC
is/VBZ
then/RB
depleted/VBN
from/IN
cells/NNS
as/IN
they/PRP
exit/VBP
the/DT
cell/NN
cycle/NN
./.
====================
p130/NN
,/,
predominantly/RB
in/IN
Form/NN
1/CD
,/,
and/CC
hypophosphorylated/VBN
pRb/NN
bind/VBP
an/DT
E2F/NN
DNA/NN
binding/NN
site/NN
;/:
p130/NN
complexes/NNS
E2F-4/NN
,/,
whereas/IN
pRb/NN
binds/VBZ
both/CC
E2F-4/NN
and/CC
E2F-1/NN
./.
====================
The/DT
phosphorylated/JJ
forms/NNS
of/IN
E2F-4/NN
that/WDT
bind/VBP
to/TO
the/DT
E2F/NN
DNA/NN
site/NN
are/VBP
different/JJ
from/IN
hyperphosphorylated/VBN
E2F-4/NN
,/,
which/WDT
predominates/VBZ
in/IN
primary/JJ
hemopoietic/JJ
cells/NNS
in/IN
G0/NN
./.
====================
We/PRP
conclude/VBP
that/IN
although/IN
cell/NN
cycle/NN
arrest/NN
induced/VBN
by/IN
alpha-IFN/NN
may/MD
be/VB
mediated/VBN
in/IN
part/NN
by/IN
formation/NN
of/IN
a/DT
complex/NN
containing/VBG
p130/NN
and/CC
E2F-4/NN
,/,
alpha-IFN/NN
does/VBZ
not/RB
induce/VB
hyperphosphorylation/NN
of/IN
E2F-4/NN
,/,
which/WDT
characterizes/VBZ
primary/JJ
hemopoietic/JJ
cells/NNS
in/IN
G0/NN
./.
====================
UI/LS
-/:
98383419/CD
====================
TI/LS
-/:
The/DT
transcription/NN
factors/NNS
c-myb/NN
and/CC
C/EBP/NN
alpha/NN
regulate/VBP
the/DT
monocytic/myeloic/JJ
gene/NN
MRP14/NN
./.
====================
AB/LS
-/:
The/DT
entry/NN
of/IN
microorganisms/NNS
into/IN
the/DT
body/NN
induces/VBZ
inflammatory/JJ
processes/NNS
./.
====================
During/IN
this/DT
process/NN
a/DT
sequence/NN
of/IN
cellular/JJ
,/,
humoral/JJ
,/,
non-specific/JJ
and/CC
specific/JJ
actions/NNS
are/VBP
evoked/VBN
to/TO
combat/VB
the/DT
infection/NN
./.
====================
Macrophages/NNS
and/CC
granulocytes/NNS
,/,
which/WDT
are/VBP
developed/VBN
from/IN
a/DT
common/JJ
progenitor/NN
cell/NN
,/,
are/VBP
the/DT
cellular/JJ
components/NNS
of/IN
the/DT
specific/JJ
and/CC
non-specific/JJ
immunoreaction/NN
./.
====================
MRP14/NN
(/(
Macrophage/NN
migration/NN
inhibitory/JJ
related/JJ
protein/NN
)/)
and/CC
MRP8/NN
,/,
two/CD
S-100/NN
proteins/NNS
contained/VBN
in/IN
high/JJ
concentrations/NNS
in/IN
these/DT
cells/NNS
are/VBP
obviously/RB
essential/JJ
for/IN
adhesion/NN
and/CC
migration/NN
of/IN
monocytes/NNS
and/CC
granulocytes/NNS
./.
====================
To/TO
investigate/VB
the/DT
transcriptional/JJ
regulation/NN
of/IN
these/DT
genes/NNS
we/PRP
cotransfected/VBD
constructs/NNS
expressing/VBG
CAT/NN
under/IN
control/NN
of/IN
the/DT
MRP14/NN
promoter/NN
and/CC
expression/NN
constructs/NNS
of/IN
C/EBP/NN
alpha/NN
and/CC
v-myb/NN
,/,
two/CD
transcription/NN
factors/NNS
involved/VBN
in/IN
myeloid/monocytic/JJ
differentiation/NN
./.
====================
Transfection/NN
with/IN
C/EBP/NN
alpha/NN
revealed/VBD
a/DT
massive/JJ
enhancement/NN
of/IN
the/DT
MRP14/NN
promoter/NN
in/IN
both/CC
,/,
HL/NN
60/CD
cells/NNS
(/(
granulocytic/JJ
differentiated/VBN
)/)
and/CC
L132/NN
fibroblasts/NNS
./.
====================
In/IN
contrast/NN
,/,
v-myb/NN
reduces/VBZ
MRP14/NN
promoter/NN
activity/NN
./.
====================
Northern/NN
blot/NN
analysis/NN
of/IN
L132/NN
cells/NNS
transfected/VBN
with/IN
the/DT
C/EBP/NN
alpha/NN
expression/NN
vector/NN
demonstrate/VBP
that/IN
C/EBP/NN
alpha/NN
is/VBZ
sufficient/JJ
to/TO
enhance/VB
MRP14/NN
expression/NN
in/IN
the/DT
context/NN
of/IN
the/DT
whole/JJ
genome/NN
./.
====================
UI/LS
-/:
98375844/CD
====================
TI/LS
-/:
A/DT
CD28-associated/JJ
signaling/NN
pathway/NN
leading/VBG
to/TO
cytokine/NN
gene/NN
transcription/NN
and/CC
T/NN
cell/NN
proliferation/NN
without/IN
TCR/NN
engagement/NN
./.
====================
AB/LS
-/:
Stimulation/NN
of/IN
resting/VBG
human/JJ
T/NN
cells/NNS
with/IN
the/DT
CD28-specific/JJ
mAb/NN
BW/NN
828/CD
induces/VBZ
proliferation/NN
and/CC
cytokine/NN
synthesis/NN
without/IN
further/JJ
requirement/NN
for/IN
TCR/NN
coengagement/NN
./.
====================
This/DT
observation/NN
prompted/VBD
us/PRP
to/TO
postulate/VB
that/IN
signal/NN
2/CD
(/(
costimulatory/JJ
signal/NN
)/)
alone/RB
without/IN
signal/NN
1/CD
(/(
TCR/NN
signal/NN
)/)
can/MD
activate/VB
T/NN
cells/NNS
./.
====================
To/TO
test/VB
whether/IN
this/DT
putative/JJ
function/NN
of/IN
CD28/NN
is/VBZ
mediated/VBN
via/IN
a/DT
particular/JJ
signaling/NN
pathway/NN
,/,
we/PRP
compared/VBD
early/JJ
signaling/NN
events/NNS
initiated/VBN
in/IN
resting/VBG
T/NN
cells/NNS
by/IN
the/DT
stimulatory/JJ
mAb/NN
BW/NN
828/CD
with/IN
signals/NNS
triggered/VBN
by/IN
the/DT
nonstimulating/JJ
CD28/NN
mAb/NN
9.3/CD
./.
====================
Stimulation/NN
of/IN
T/NN
cells/NNS
with/IN
BW/NN
828/CD
induced/VBD
an/DT
increase/NN
in/IN
intracellular/JJ
Ca2+/NN
,/,
but/CC
did/VBD
not/RB
lead/VB
to/TO
detectable/JJ
activation/NN
of/IN
the/DT
protein/NN
kinases/NNS
p56(lck)/NN
and/CC
c-Raf-1/NN
./.
====================
This/DT
pathway/NN
resulted/VBD
in/IN
the/DT
induction/NN
of/IN
the/DT
transcription/NN
factors/NNS
NF-kappa/NN
B/NN
,/,
NF-AT/NN
,/,
and/CC
proteins/NNS
binding/VBG
to/TO
the/DT
CD28/NN
response/NN
element/NN
of/IN
the/DT
IL-2/NN
promoter/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
stimulation/NN
of/IN
T/NN
cells/NNS
with/IN
mAb/NN
9.3/CD
increased/VBD
the/DT
level/NN
of/IN
intracellular/JJ
Ca2+/NN
and/CC
triggered/VBD
the/DT
activation/NN
of/IN
p56(lck)/NN
and/CC
c-Raf-1/NN
,/,
but/CC
was/VBD
unable/JJ
to/TO
induce/VB
the/DT
binding/NN
of/IN
transcription/NN
factors/NNS
to/TO
the/DT
IL-2/NN
promoter/NN
./.
====================
In/IN
contrast/NN
to/TO
the/DT
differential/JJ
signaling/NN
of/IN
BW/NN
828/CD
and/CC
9.3/CD
in/IN
resting/VBG
T/NN
cells/NNS
,/,
the/DT
two/CD
mAbs/NNS
exhibited/VBD
a/DT
similar/JJ
pattern/NN
of/IN
early/JJ
signaling/NN
events/NNS
in/IN
activated/VBN
T/NN
cells/NNS
and/CC
Jurkat/NN
cells/NNS
(/(
p56(lck)/NN
activation/NN
,/,
association/NN
of/IN
phosphatidylinositol/NN
3-kinase/NN
with/IN
CD28/NN
)/)
,/,
indicating/VBG
that/IN
the/DT
signaling/NN
capacity/NN
of/IN
CD28/NN
changes/VBZ
with/IN
activation/NN
./.
====================
These/DT
data/NNS
support/VBP
the/DT
view/NN
that/IN
stimulation/NN
through/IN
CD28/NN
can/MD
induce/VB
some/DT
effector/NN
functions/NNS
in/IN
T/NN
cells/NNS
and/CC
suggest/VBP
that/IN
this/DT
capacity/NN
is/VBZ
associated/VBN
with/IN
a/DT
particular/JJ
pattern/NN
of/IN
early/JJ
signaling/NN
events/NNS
====================
UI/LS
-/:
99023375/CD
====================
TI/LS
-/:
Decreased/VBN
IL-12/NN
production/NN
and/CC
Th1/NN
cell/NN
development/NN
by/IN
acetyl/NN
salicylic/JJ
acid-mediated/JJ
inhibition/NN
of/IN
NF-kappaB/NN
./.
====================
AB/LS
-/:
IL-12/NN
is/VBZ
a/DT
75-kDa/JJ
heterodimeric/JJ
cytokine/NN
composed/VBN
of/IN
two/CD
covalently/RB
linked/VBN
p35/NN
and/CC
p40/NN
chains/NNS
./.
====================
This/DT
pro-inflammatory/JJ
cytokine/NN
plays/VBZ
a/DT
prominent/JJ
role/NN
in/IN
the/DT
development/NN
of/IN
Th1/NN
cell-mediated/JJ
immune/JJ
responses/NNS
./.
====================
Th1/NN
cell-mediated/JJ
immune/JJ
responses/NNS
have/VBP
been/VBN
implicated/VBN
in/IN
the/DT
pathogenesis/NN
of/IN
chronic/JJ
inflammatory/JJ
autoimmune/JJ
diseases/NNS
./.
====================
Thus/RB
,/,
IL-12/NN
appears/VBZ
to/TO
be/VB
a/DT
critical/JJ
factor/NN
in/IN
the/DT
generation/NN
and/CC
maintenance/NN
of/IN
chronic/JJ
inflammatory/JJ
conditions/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
investigated/VBD
the/DT
effects/NNS
of/IN
a/DT
commonly/RB
prescribed/VBN
anti-inflammatory/JJ
drug/NN
,/,
acetyl/NN
salicylic/JJ
acid/NN
(/(
ASA/NN
)/)
,/,
on/IN
IL-12/NN
production/NN
and/CC
Th1/NN
cell/NN
development/NN
./.
====================
ASA/NN
was/VBD
found/VBN
to/TO
inhibit/VB
secretion/NN
of/IN
the/DT
IL-12/NN
heterodimer/NN
as/RB
well/RB
as/IN
p40/NN
monomer/NN
by/IN
human/JJ
monocytic/JJ
cells/NNS
./.
====================
This/DT
was/VBD
associated/VBN
with/IN
the/DT
down-regulation/NN
of/IN
IL-12p40/NN
mRNA/NN
expression/NN
./.
====================
Analysis/NN
of/IN
the/DT
regulation/NN
of/IN
the/DT
p40/NN
gene/NN
promoter/NN
revealed/VBD
that/IN
ASA/NN
inhibited/VBD
NF-kappaB/NN
activation/NN
and/CC
binding/NN
to/TO
the/DT
p40-kappaB/NN
site/NN
in/IN
the/DT
p40/NN
promoter/NN
,/,
leading/VBG
to/TO
transcriptional/JJ
repression/NN
of/IN
the/DT
p40/NN
gene/NN
./.
====================
Addition/NN
of/IN
ASA/NN
to/TO
an/DT
in/FW
vitro/FW
T/NN
helper/NN
cell/NN
differentiation/NN
system/NN
,/,
at/IN
concentrations/NNS
compatible/JJ
with/IN
plasma/NN
levels/NNS
reached/VBN
during/IN
anti-inflammatory/JJ
therapy/NN
,/,
resulted/VBD
in/IN
reduced/VBN
development/NN
of/IN
Th1/NN
cells/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
inhibition/NN
of/IN
NF-kappaB/NN
activation/NN
by/IN
ASA/NN
leads/VBZ
to/TO
down-regulation/NN
of/IN
IL-12/NN
production/NN
and/CC
inhibition/NN
of/IN
Th1/NN
cell/NN
development/NN
./.
====================
UI/LS
-/:
99008553/CD
====================
TI/LS
-/:
Attenuation/NN
of/IN
HLA-DR/NN
expression/NN
by/IN
mononuclear/JJ
phagocytes/NNS
infected/VBN
with/IN
Mycobacterium/NN
tuberculosis/NN
is/VBZ
related/JJ
to/TO
intracellular/JJ
sequestration/NN
of/IN
immature/JJ
class/NN
II/CD
heterodimers/NNS
./.
====================
AB/LS
-/:
MHC/NN
class/NN
II/CD
expression/NN
was/VBD
examined/VBN
in/IN
macrophages/NNS
infected/VBN
with/IN
Mycobacterium/NN
tuberculosis/NN
./.
====================
IFN-gamma/NN
increased/VBD
the/DT
surface/NN
expression/NN
of/IN
class/NN
II/CD
molecules/NNS
in/IN
THP-1/NN
cells/NNS
and/CC
this/DT
was/VBD
markedly/RB
reduced/VBN
in/IN
cells/NNS
infected/VBN
with/IN
M./NN
tuberculosis/NN
./.
====================
Despite/IN
this/DT
effect/NN
,/,
steady/JJ
state/NN
levels/NNS
of/IN
HLA-DRalpha/NN
,/,
HLA-DRbeta/NN
,/,
and/CC
invariant/JJ
(/(
Ii/NN
)/)
chains/NNS
were/VBD
equivalent/JJ
in/IN
control/JJ
and/CC
infected/JJ
cells/NNS
./.
====================
Metabolic/JJ
labeling/NN
combined/VBN
with/IN
pulse-chase/JJ
experiments/NNS
and/CC
biochemical/JJ
analysis/NN
showed/VBD
that/IN
the/DT
majority/NN
of/IN
class/NN
II/CD
molecules/NNS
in/IN
infected/JJ
cells/NNS
became/VBD
resistant/JJ
to/TO
endoglycosidase/NN
H/NN
,/,
consistent/JJ
with/IN
normal/JJ
Golgi/NN
processing/NN
./.
====================
However/RB
,/,
results/NNS
of/IN
intracellular/JJ
staining/NN
and/CC
dual/JJ
color/NN
confocal/JJ
microscopy/NN
revealed/VBD
a/DT
significant/JJ
defect/NN
in/IN
transport/NN
of/IN
newly/RB
synthesized/VBN
class/NN
II/CD
molecules/NNS
through/IN
the/DT
endocytic/JJ
compartment/NN
./.
====================
Thus/RB
,/,
compared/VBN
with/IN
findings/NNS
in/IN
control/JJ
cells/NNS
,/,
class/NN
II/CD
molecules/NNS
in/IN
infected/JJ
cells/NNS
colocalized/VBD
to/TO
a/DT
minimal/JJ
extent/NN
with/IN
a/DT
lysosomal-associated/JJ
membrane/NN
protein-1+/JJ
endosomal/JJ
compartment/NN
./.
====================
In/IN
addition/NN
,/,
in/IN
contrast/NN
to/TO
control/JJ
cells/NNS
,/,
class/NN
II/CD
molecules/NNS
in/IN
infected/JJ
cells/NNS
failed/VBD
to/TO
colocalize/VB
with/IN
endocytosed/VBN
BSA/NN
under/IN
conditions/NNS
where/WRB
this/DT
marker/NN
is/VBZ
known/VBN
to/TO
label/VB
late/JJ
endosomes/NNS
,/,
lysosomes/NNS
,/,
and/CC
the/DT
MHC/NN
class/NN
II/CD
compartment/NN
./.
====================
Consistent/JJ
with/IN
defective/JJ
transport/NN
along/IN
the/DT
endocytic/JJ
pathway/NN
,/,
the/DT
maturation/NN
of/IN
SDS-stable/JJ
class/NN
II/CD
alphabeta/NN
dimers/NNS
--/:
dependent/JJ
upon/IN
removal/NN
of/IN
Ii/NN
chain/NN
and/CC
peptide/NN
loading/NN
of/IN
class/NN
II/CD
dimers/NNS
in/IN
the/DT
MHC/NN
class/NN
II/CD
compartment/NN
--/:
was/VBD
markedly/RB
impaired/JJ
in/IN
M./NN
tuberculosis-infected/JJ
cells/NNS
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
defective/JJ
transport/NN
and/CC
processing/NN
of/IN
class/NN
II/CD
molecules/NNS
through/IN
the/DT
endosomal/lysosomal/JJ
system/NN
is/VBZ
responsible/JJ
for/IN
diminished/VBN
cell/NN
surface/NN
expression/NN
of/IN
MHC/NN
class/NN
II/CD
molecules/NNS
in/IN
cells/NNS
infected/VBN
with/IN
M./NN
tuberculosis/NN
./.
====================
UI/LS
-/:
99187985/CD
====================
TI/LS
-/:
Identification/NN
of/IN
upstream/JJ
regulatory/JJ
elements/NNS
that/WDT
repress/VBP
expression/NN
of/IN
adult/JJ
beta-like/JJ
globin/NN
genes/NNS
in/IN
a/DT
primitive/JJ
erythroid/JJ
environment/NN
./.
====================
AB/LS
-/:
Our/PRP$
investigations/NNS
have/VBP
focused/VBN
on/IN
localizing/VBG
cis-elements/NNS
responsible/JJ
for/IN
the/DT
down/JJ
regulation/NN
of/IN
the/DT
adult/JJ
beta-like/JJ
globin/NN
genes/NNS
(/(
delta/NN
and/CC
beta/NN
)/)
in/IN
immature/JJ
,/,
or/CC
primitive/JJ
erythroid/JJ
tissues/NNS
./.
====================
We/PRP
studied/VBD
their/PRP$
activity/NN
after/IN
transfection/NN
into/IN
K562/NN
cells/NNS
,/,
an/DT
erythroleukemia/NN
cell/NN
line/NN
with/IN
an/DT
embryonic-fetal/JJ
phenotype/NN
./.
====================
Analyzed/VBN
DNA/NN
sequences/NNS
included/VBD
delta/NN
and/CC
beta/NN
5'/JJ
flanking/NN
regions/NNS
extending/VBG
from/IN
approximately/RB
-500/CD
to/TO
+50bp/NN
(/(
promoter/NN
regions/NNS
)/)
,/,
truncated/JJ
delta/NN
and/CC
beta/NN
5'/JJ
flanking/NN
regions/NNS
extending/VBG
from/IN
approximately/RB
-250/CD
to/TO
+50/CD
bp/NN
,/,
and/CC
chimeric/JJ
promoter/NN
constructions/NNS
,/,
which/WDT
consisted/VBD
of/IN
a/DT
distal/JJ
delta/NN
or/CC
beta/NN
fragment/NN
fused/VBN
to/TO
a/DT
proximal/JJ
beta/NN
or/CC
delta/NN
sequence/NN
./.
====================
In/IN
CAT/NN
reporter/NN
constructions/NNS
no/DT
appreciable/JJ
level/NN
of/IN
CAT/NN
activity/NN
was/VBD
supported/VBN
by/IN
the/DT
beta/NN
globin/NN
promoter/NN
,/,
and/CC
only/RB
low/JJ
level/NN
activity/NN
by/IN
the/DT
delta/NN
promoter/NN
./.
====================
Truncation/NN
of/IN
the/DT
beta/NN
globin/NN
promoter/NN
led/VBD
to/TO
a/DT
2-3/CD
fold/JJ
increase/NN
in/IN
promoter/NN
activity/NN
./.
====================
In/IN
contrast/NN
,/,
deletion/NN
of/IN
the/DT
upstream/JJ
portion/NN
of/IN
the/DT
delta/NN
promoter/NN
led/VBD
to/TO
a/DT
10/CD
fold/JJ
decrease/NN
in/IN
expression/NN
./.
====================
Coupling/NN
of/IN
the/DT
upstream/JJ
beta/NN
globin/NN
sequence/NN
from/IN
approximately/RB
-500/CD
to/TO
-250/CD
bp/NN
to/TO
the/DT
truncated/VBN
delta/NN
promoter/NN
fragment/NN
led/VBD
to/TO
complete/JJ
extinction/NN
of/IN
transcription/NN
activity/NN
,/,
consistent/JJ
with/IN
a/DT
negative/JJ
regulatory/JJ
effect/NN
of/IN
the/DT
beta/NN
globin/NN
gene/NN
upstream/JJ
element/NN
(/(
s/NNS
)/)
./.
====================
Fusion/NN
of/IN
the/DT
upstream/JJ
portion/NN
of/IN
the/DT
delta/NN
promoter/NN
to/TO
the/DT
truncated/VBN
beta/NN
globin/NN
promoter/NN
yielded/VBD
a/DT
modest/JJ
increase/NN
in/IN
promoter/NN
strength/NN
relative/JJ
to/TO
the/DT
truncated/VBN
beta/NN
gene/NN
promoter/NN
,/,
indicating/VBG
the/DT
presence/NN
of/IN
a/DT
positive/JJ
transcriptional/JJ
element/NN
(/(
s/NNS
)/)
in/IN
the/DT
upstream/JJ
delta/NN
globin/NN
regulatory/JJ
region/NN
./.
====================
Site-directed/JJ
mutagenesis/NN
of/IN
binding/VBG
sites/NNS
for/IN
the/DT
repressor/NN
proteins/NNS
BP1/NN
and/CC
BP2/NN
in/IN
the/DT
upstream/JJ
portion/NN
of/IN
the/DT
beta/NN
globin/NN
gene/NN
flanking/NN
region/NN
led/VBD
to/TO
a/DT
4-6/CD
fold/JJ
increase/NN
in/IN
promoter/NN
activity/NN
./.
====================
DNase/NN
I/CD
footprinting/NN
of/IN
the/DT
upstream/JJ
delta-globin/JJ
region/NN
revealed/VBD
protected/JJ
sequences/NNS
corresponding/VBG
to/TO
consensus/NN
binding/NN
sites/NNS
for/IN
GATA-1/NN
and/CC
BP2/NN
./.
====================
These/DT
results/NNS
confirm/VBP
that/IN
sequences/NNS
in/IN
the/DT
upstream/JJ
promoter/NN
region/NN
of/IN
the/DT
adult/JJ
beta/NN
globin/NN
gene/NN
contribute/VBP
to/TO
its/PRP$
factor-mediated/JJ
suppression/NN
early/JJ
in/IN
development/NN
and/CC
then/RB
may/MD
modulate/VB
its/PRP$
expression/NN
at/IN
a/DT
later/JJ
stage/NN
./.
====================
UI/LS
-/:
98439530/CD
====================
TI/LS
-/:
Analysis/NN
of/IN
cytokine/NN
signaling/NN
in/IN
patients/NNS
with/IN
extrinsic/JJ
asthma/NN
and/CC
hyperimmunoglobulin/NN
E/NN
./.
====================
AB/LS
-/:
BACKGROUND/NN
:/:
Recent/JJ
data/NNS
suggest/VBP
that/IN
the/DT
regulation/NN
of/IN
class/NN
switching/NN
to/TO
IgE/NN
by/IN
cytokines/NNS
is/VBZ
mediated/VBN
by/IN
STAT/NN
transcription/NN
factors/NNS
./.
====================
The/DT
induction/NN
of/IN
IgE/NN
by/IN
IL-4/NN
and/CC
IL-13/NN
occurs/VBZ
through/IN
the/DT
activation/NN
of/IN
the/DT
intracellular/JJ
signal-transducing/JJ
protein/NN
Stat6/NN
,/,
whereas/IN
the/DT
inhibition/NN
of/IN
IgE/NN
class/NN
switching/NN
by/IN
interferon-y/NN
(/(
IFN-gamma/NN
)/)
occurs/VBZ
through/IN
the/DT
activation/NN
of/IN
Statl/NN
./.
====================
OBJECTIVE/NN
:/:
We/PRP
hypothesized/VBD
that/IN
in/IN
extrinsic/JJ
asthma/NN
or/CC
in/IN
cases/NNS
of/IN
markedly/RB
elevated/JJ
IgE/NN
(/(
ie/NN
,/,
hyperimmunoglobulin/NN
E/NN
[/(
HIE/NN
]/)
)/)
increased/VBN
levels/NNS
of/IN
IgE/NN
may/MD
be/VB
associated/VBN
with/IN
alterations/NNS
in/IN
the/DT
cytokine/NN
levels/NNS
or/CC
the/DT
activation/NN
of/IN
Stat6/NN
./.
====================
METHODS/NNS
:/:
PBMCs/NNS
and/CC
sera/NNS
from/IN
8/CD
patients/NNS
with/IN
extrinsic/JJ
asthma/NN
(/(
mean/JJ
IgE/NN
,/,
285+/-100/CD
IU/mL/NN
)/)
,/,
3/CD
patients/NNS
with/IN
HIE/NN
(/(
mean/JJ
IgE/NN
,/,
7050+/-1122/CD
IU/mL/NN
)/)
,/,
and/CC
14/CD
nonatopic/JJ
control/JJ
subjects/NNS
(/(
mean/JJ
IgE/NN
,/,
112+/-28/CD
IU/mL/NN
)/)
were/VBD
analyzed/VBN
./.
====================
RESULTS/NNS
:/:
The/DT
mean/JJ
IL-4/NN
level/NN
detected/VBN
by/IN
ELISA/NN
was/VBD
much/RB
greater/JJR
in/IN
patients/NNS
with/IN
HIE/NN
than/IN
control/JJ
subjects/NNS
(/(
88.6+/-11.5/CD
pg/mL/NN
vs/CC
11.5+/-7.1/CD
pg/mL/NN
,/,
P/NN
=/JJ
.005/NN
)/)
,/,
and/CC
increased/VBN
IL-4/NN
levels/NNS
among/IN
patients/NNS
with/IN
both/CC
asthma/NN
and/CC
HIE/NN
correlated/VBD
with/IN
the/DT
increased/VBN
IgE/NN
levels/NNS
./.
====================
In/IN
contrast/NN
,/,
IL-13/NN
levels/NNS
were/VBD
not/RB
elevated/JJ
./.
====================
Levels/NNS
of/IN
Stat6/NN
protein/NN
present/JJ
in/IN
PBMCs/NNS
did/VBD
not/RB
differ/VB
in/IN
the/DT
patients/NNS
and/CC
control/JJ
subjects/NNS
./.
====================
Examination/NN
of/IN
Stat6/NN
DNA-binding/NN
activity/NN
demonstrated/VBD
no/DT
activation/NN
of/IN
IL-4/NN
signaling/NN
in/IN
patients/NNS
with/IN
either/CC
HIE/NN
or/CC
acute/JJ
asthma/NN
./.
====================
Interestingly/RB
,/,
evidence/NN
for/IN
the/DT
presence/NN
of/IN
B/NN
cells/NNS
that/WDT
have/VBP
already/RB
switched/VBN
to/TO
IgE/NN
was/VBD
seen/VBN
in/IN
PBMCs/NNS
of/IN
several/JJ
patients/NNS
with/IN
asthma/NN
or/CC
HIE/NN
./.
====================
CONCLUSION/NN
:/:
These/DT
results/NNS
indicate/VBP
that/IN
(/(
1/LS
)/)
IgE/NN
production/NN
in/IN
asthma/NN
and/CC
HIE/NN
usually/RB
is/VBZ
associated/VBN
with/IN
elevated/JJ
levels/NNS
of/IN
IL-4/NN
,/,
but/CC
not/RB
IL-13/NN
,/,
in/IN
the/DT
peripheral/JJ
blood/NN
;/:
(/(
2/LS
)/)
the/DT
increased/VBN
sera/NNS
IL-4/NN
levels/NNS
in/IN
asthma/NN
and/CC
HIE/NN
are/VBP
not/RB
sufficient/JJ
to/TO
induce/VB
Stat6/NN
activation/NN
in/IN
PBMCs/NNS
;/:
and/CC
(/(
3/LS
)/)
evidence/NN
of/IN
switch/NN
recombination/NN
to/TO
epsilon/NN
may/MD
be/VB
detected/VBN
in/IN
isolated/VBN
cases/NNS
of/IN
elevated/JJ
IgE/NN
./.
====================
This/DT
implies/VBZ
that/IN
high/JJ
levels/NNS
of/IN
IgE/NN
in/IN
these/DT
patients/NNS
either/CC
results/VBZ
from/IN
B/NN
cells/NNS
that/WDT
have/VBP
already/RB
undergone/VBN
class/NN
switching/NN
,/,
from/IN
Ig/NN
class/NN
switching/NN
that/WDT
is/VBZ
localized/JJ
to/TO
target/NN
tissues/NNS
,/,
or/CC
both/DT
./.
====================
UI/LS
-/:
98430664/CD
====================
TI/LS
-/:
Carboxyl-terminal/JJ
15-amino/JJ
acid/NN
sequence/NN
of/IN
NFATx1/NN
is/VBZ
possibly/RB
created/VBN
by/IN
tissue-specific/JJ
splicing/NN
and/CC
is/VBZ
essential/JJ
for/IN
transactivation/NN
activity/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
NFAT/NN
regulates/VBZ
transcription/NN
of/IN
a/DT
number/NN
of/IN
cytokine/NN
and/CC
other/JJ
immunoregulatory/JJ
genes/NNS
./.
====================
We/PRP
have/VBP
isolated/VBN
NFATx/NN
,/,
which/WDT
is/VBZ
one/CD
of/IN
four/CD
members/NNS
of/IN
the/DT
NFAT/NN
family/NN
of/IN
transcription/NN
factors/NNS
and/CC
is/VBZ
preferentially/RB
expressed/VBN
in/IN
the/DT
thymus/NN
and/CC
peripheral/JJ
blood/NN
leukocytes/NNS
,/,
and/CC
an/DT
isoform/NN
of/IN
NFATx/NN
,/,
NFATx1/NN
./.
====================
Here/RB
we/PRP
provide/VBP
evidence/NN
showing/VBG
that/IN
15/CD
amino/NN
acids/NNS
in/IN
the/DT
carboxyl-terminal/JJ
end/NN
of/IN
NFATx1/NN
are/VBP
required/VBN
for/IN
its/PRP$
maximum/JJ
transactivation/NN
activity/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
./.
====================
A/DT
fusion/NN
between/IN
these/DT
15/CD
amino/NN
acids/NNS
and/CC
the/DT
GAL4/NN
DNA/NN
binding/NN
domain/NN
was/VBD
capable/JJ
of/IN
transactivating/VBG
reporters/NNS
driven/VBN
by/IN
the/DT
GAL4/NN
DNA/NN
binding/NN
site/NN
./.
====================
Interestingly/RB
,/,
this/DT
15-amino/JJ
acid/NN
transactivation/NN
sequence/NN
is/VBZ
well/RB
conserved/VBN
in/IN
NFAT/NN
family/NN
proteins/NNS
,/,
although/IN
the/DT
sequences/NNS
contiguous/JJ
to/TO
the/DT
carboxyl-terminal/JJ
regions/NNS
of/IN
the/DT
NFAT/NN
family/NN
are/VBP
much/JJ
less/RBR
conserved/VBN
./.
====================
We/PRP
also/RB
report/VBP
three/CD
additional/JJ
isoforms/NNS
of/IN
NFATx/NN
,/,
designated/VBN
NFATx2/NN
,/,
NFATx3/NN
,/,
and/CC
NFATx4/NN
./.
====================
This/DT
transactivation/NN
sequence/NN
is/VBZ
altered/VBN
by/IN
tissue-specific/JJ
alternative/JJ
splicing/NN
in/IN
newly/RB
isolated/VBN
NFATx/NN
isoforms/NNS
,/,
resulting/VBG
in/IN
lower/JJR
transactivation/NN
activity/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
./.
====================
NFATx1/NN
is/VBZ
expressed/VBN
predominantly/RB
in/IN
the/DT
thymus/NN
and/CC
peripheral/JJ
blood/NN
leukocyte/NN
,/,
while/IN
the/DT
skeletal/JJ
muscle/NN
expressed/VBD
primarily/RB
NFATx2/NN
./.
====================
In/IN
Jurkat/NN
cells/NNS
,/,
transcription/NN
from/IN
the/DT
NFAT/NN
site/NN
of/IN
the/DT
IL-2/NN
promoter/NN
is/VBZ
activated/VBN
strongly/RB
by/IN
NFATx1/NN
but/CC
only/RB
weakly/RB
by/IN
NFATx2/NN
./.
====================
These/DT
data/NNS
demonstrate/VBP
that/IN
the/DT
15-amino/JJ
acid/NN
sequence/NN
of/IN
NFATx1/NN
is/VBZ
a/DT
major/JJ
transactivation/NN
sequence/NN
required/VBN
for/IN
induction/NN
of/IN
genes/NNS
by/IN
NFATx1/NN
in/IN
T/NN
cells/NNS
and/CC
possibly/RB
regulates/VBZ
NFAT/NN
activity/NN
through/IN
tissue-specific/JJ
alternative/JJ
splicing/NN
./.
====================
UI/LS
-/:
98417611/CD
====================
TI/LS
-/:
Altered/JJ
DNA-binding/JJ
specificity/NN
mutants/NNS
of/IN
EKLF/NN
and/CC
Sp1/NN
show/VBP
that/IN
EKLF/NN
is/VBZ
an/DT
activator/NN
of/IN
the/DT
beta-globin/NN
locus/NN
control/NN
region/NN
in/FW
vivo/FW
./.
====================
AB/LS
-/:
The/DT
locus/NN
control/NN
region/NN
of/IN
the/DT
beta-globin/NN
cluster/NN
contains/VBZ
five/CD
DNase/NN
I/CD
hypersensitive/JJ
sites/NNS
(/(
5'HS1-5/NN
)/)
required/VBN
for/IN
locus/NN
activation/NN
./.
====================
5'HS3/NN
contains/VBZ
six/CD
G-rich/JJ
motifs/NNS
that/WDT
are/VBP
essential/JJ
for/IN
its/PRP$
activity/NN
./.
====================
Members/NNS
of/IN
a/DT
protein/NN
family/NN
,/,
characterized/VBN
by/IN
three/CD
zinc/NN
fingers/NNS
highly/RB
homologous/JJ
to/TO
those/DT
found/VBN
in/IN
transcription/NN
factor/NN
Sp1/NN
,/,
interact/VBP
with/IN
these/DT
motifs/NNS
./.
====================
Because/IN
point/NN
mutagenesis/NN
can/MD
not/RB
distinguish/VB
between/IN
family/NN
members/NNS
,/,
it/PRP
is/VBZ
not/RB
known/VBN
which/WDT
protein/NN
activates/VBZ
5'HS3/NN
./.
====================
We/PRP
show/VBP
that/IN
the/DT
function/NN
of/IN
such/JJ
closely/RB
related/JJ
proteins/NNS
can/MD
be/VB
distinguished/VBN
in/FW
vivo/FW
by/IN
matching/VBG
point/NN
mutations/NNS
in/IN
5'HS3/NN
with/IN
amino/NN
acid/NN
changes/NNS
in/IN
the/DT
zinc/NN
fingers/NNS
of/IN
Sp1/NN
and/CC
EKLF/NN
./.
====================
Testing/VBG
their/PRP$
activity/NN
in/IN
transgenic/JJ
mice/NNS
shows/VBZ
that/IN
EKLF/NN
is/VBZ
a/DT
direct/JJ
activator/NN
of/IN
5'HS3/NN
./.
====================
UI/LS
-/:
98406200/CD
====================
TI/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
Rta/NN
protein/NN
activates/VBZ
lytic/JJ
cycle/NN
genes/NNS
and/CC
can/MD
disrupt/VB
latency/NN
in/IN
B/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
The/DT
transition/NN
of/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
from/IN
latency/NN
into/IN
the/DT
lytic/JJ
cycle/NN
is/VBZ
associated/VBN
with/IN
the/DT
expression/NN
of/IN
two/CD
immediate-early/JJ
viral/JJ
genes/NNS
,/,
BZLF1/NN
and/CC
BRLF1/NN
./.
====================
Overexpression/NN
of/IN
ZEBRA/NN
,/,
the/DT
product/NN
of/IN
BZLF1/NN
,/,
is/VBZ
sufficient/JJ
to/TO
disrupt/VB
latency/NN
in/IN
B/NN
lymphocytes/NNS
and/CC
epithelial/JJ
cells/NNS
by/IN
stimulating/VBG
expression/NN
of/IN
lytic/JJ
cycle/NN
genes/NNS
,/,
including/VBG
BRLF1/NN
./.
====================
The/DT
BRLF1/NN
product/NN
Rta/NN
functions/VBZ
as/IN
a/DT
transcriptional/JJ
activator/NN
in/IN
both/CC
B/NN
lymphocytes/NNS
and/CC
epithelial/JJ
cells/NNS
./.
====================
However/RB
,/,
Rta/NN
has/VBZ
recently/RB
been/VBN
reported/VBN
to/TO
disrupt/VB
latency/NN
in/IN
an/DT
epithelial/JJ
specific/JJ
manner/NN
(/(
S./NNP
Zalani/NNP
,/,
E./NNP
Holley-Guthrie/NNP
,/,
and/CC
S./NNP
Kenney/NNP
,/,
Proc./NNP
Natl./NNP
Acad./NNP
Sci./NNP
USA/NNP
93/CD
:/:
9194-9199/CD
,/,
1996/CD
)/)
./.
====================
Here/RB
we/PRP
demonstrate/VBP
that/IN
expression/NN
of/IN
Rta/NN
is/VBZ
also/RB
sufficient/JJ
for/IN
disruption/NN
of/IN
latency/NN
in/IN
a/DT
permissive/JJ
B-cell/NN
line/NN
./.
====================
In/IN
HH514-16/NN
cells/NNS
,/,
transfection/NN
of/IN
Rta/NN
leads/VBZ
to/TO
synthesis/NN
of/IN
ZEBRA/NN
,/,
viral/JJ
DNA/NN
replication/NN
,/,
and/CC
late/JJ
gene/NN
expression/NN
./.
====================
However/RB
,/,
Rta/NN
by/IN
itself/PRP
is/VBZ
less/RBR
potent/JJ
than/IN
ZEBRA/NN
in/IN
the/DT
ability/NN
to/TO
activate/VB
most/RBS
early/JJ
and/CC
late/JJ
lytic/JJ
cycle/NN
genes/NNS
./.
====================
In/IN
light/NN
of/IN
previous/JJ
work/NN
implicating/VBG
ZEBRA/NN
in/IN
the/DT
activation/NN
of/IN
Rta/NN
,/,
we/PRP
suggest/VBP
a/DT
cooperative/JJ
model/NN
for/IN
EBV/NN
entry/NN
into/IN
the/DT
lytic/JJ
cycle/NN
./.
====================
Expression/NN
of/IN
either/CC
BZLF1/NN
or/CC
BRLF1/NN
triggers/VBZ
expression/NN
of/IN
the/DT
other/JJ
immediate-early/JJ
factor/NN
,/,
and/CC
together/RB
these/DT
activators/NNS
act/VBP
individually/RB
or/CC
in/IN
synergy/NN
on/IN
downstream/JJ
targets/NNS
to/TO
activate/VB
the/DT
viral/JJ
lytic/JJ
cycle/NN
./.
====================
UI/LS
-/:
98391036/CD
====================
TI/LS
-/:
Transcription/NN
of/IN
a/DT
minimal/JJ
promoter/NN
from/IN
the/DT
NF-IL6/NN
gene/NN
is/VBZ
regulated/VBN
by/IN
CREB/ATF/NN
and/CC
SP1/NN
proteins/NNS
in/IN
U937/NN
promonocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
NF-IL6/NN
is/VBZ
an/DT
important/JJ
transcriptional/JJ
regulator/NN
of/IN
genes/NNS
induced/VBN
in/IN
activated/VBN
monocytes/macrophages/NNS
,/,
and/CC
NF-IL6/NN
is/VBZ
the/DT
only/RB
CCAAT/enhancer-binding/JJ
protein/NN
(/(
C/EBP/NN
)/)
family/NN
member/NN
whose/WP$
steady-state/JJ
mRNA/NN
levels/NNS
increase/VBP
upon/IN
activation/NN
of/IN
monocytes/NNS
(/(
1/CD
)/)
./.
====================
We/PRP
show/VBP
that/IN
increased/VBN
transcription/NN
of/IN
the/DT
NF-IL6/NN
gene/NN
is/VBZ
responsible/JJ
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
for/IN
induction/NN
of/IN
NF-IL6/NN
mRNA/NN
following/VBG
activation/NN
of/IN
U937/NN
promonocytic/JJ
cells/NNS
./.
====================
We/PRP
have/VBP
identified/VBN
a/DT
104-bp/JJ
minimal/JJ
promoter/NN
region/NN
of/IN
the/DT
NF-IL6/NN
gene/NN
that/WDT
is/VBZ
sufficient/JJ
for/IN
basal/JJ
and/CC
activation-dependent/JJ
induction/NN
of/IN
transcription/NN
in/IN
U937/NN
cells/NNS
./.
====================
This/DT
region/NN
contains/VBZ
binding/VBG
sites/NNS
for/IN
the/DT
cAMP/NN
response/NN
element-binding/JJ
protein/activation/NN
transcription/NN
factor/NN
(/(
CREB/ATF/NN
)/)
and/CC
Sp1/NN
families/NNS
of/IN
transcription/NN
factors/NNS
./.
====================
Each/JJ
site/NN
is/VBZ
functionally/RB
important/JJ
and/CC
contributes/VBZ
independently/RB
to/TO
transcription/NN
of/IN
the/DT
NF-IL6/NN
gene/NN
in/IN
U937/NN
cells/NNS
./.
====================
UI/LS
-/:
98384373/CD
====================
TI/LS
-/:
CIITA/NN
B-cell-specific/JJ
promoter/NN
suppression/NN
in/IN
MHC/NN
class/NN
II-silenced/JJ
cell/NN
hybrids/NNS
./.
====================
AB/LS
-/:
In/IN
this/DT
study/NN
,/,
various/JJ
sets/NNS
of/IN
somatic/JJ
cell/NN
hybrids/NNS
,/,
generated/VBN
by/IN
the/DT
fusion/NN
of/IN
epithelial/JJ
cell/NN
lines/NNS
with/IN
B-lymphoblastoid/JJ
cell/NN
lines/NNS
,/,
were/VBD
analyzed/VBN
for/IN
the/DT
expression/NN
of/IN
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
class/NN
II/CD
antigens/NNS
./.
====================
We/PRP
first/RB
demonstrate/VBP
,/,
in/IN
human/JJ
and/CC
mouse/NN
intraspecies/NNS
hybrids/NNS
,/,
the/DT
coordinate/JJ
suppression/NN
of/IN
MHC/NN
class/NN
II/CD
,/,
Ii/NN
(/(
invariant/JJ
chain/NN
)/)
and/CC
HLA-DM/NN
gene/NN
transcription/NN
,/,
and/CC
the/DT
release/NN
of/IN
the/DT
silencing/NN
by/IN
the/DT
addition/NN
of/IN
interferon/NN
gamma/NN
./.
====================
Using/VBG
interspecies/NNS
hybrids/NNS
,/,
the/DT
segregation/NN
of/IN
human/JJ
chromosomes/NNS
allowed/VBD
us/PRP
to/TO
establish/VB
that/IN
MHC/NN
class/NN
II/CD
extinction/NN
is/VBZ
linked/VBN
to/TO
the/DT
presence/NN
in/IN
the/DT
hybrids/NNS
of/IN
the/DT
chromosomes/NNS
from/IN
the/DT
epithelial/JJ
fusion/NN
partner/NN
./.
====================
Moreover/RB
,/,
our/PRP$
data/NNS
provide/VBP
evidence/NN
that/IN
the/DT
expression/NN
pattern/NN
of/IN
MHC/NN
class/NN
II/CD
mRNA/NN
is/VBZ
correlated/VBN
with/IN
that/DT
of/IN
the/DT
class/NN
II/CD
transactivator/NN
(/(
CIITA/NN
)/)
,/,
suggesting/VBG
that/IN
CIITA/NN
is/VBZ
the/DT
actual/JJ
target/NN
of/IN
the/DT
silencing/NN
./.
====================
To/TO
gain/VB
further/JJ
insight/NN
into/IN
the/DT
suppression/NN
phenomenon/NN
we/PRP
performed/VBD
luciferase/NN
assays/NNS
which/WDT
show/VBP
that/IN
silencing/NN
affects/VBZ
the/DT
activity/NN
of/IN
the/DT
B-cell-specific/JJ
promoter/NN
of/IN
CIITA/NN
./.
====================
These/DT
results/NNS
therefore/RB
demonstrate/VBP
that/IN
the/DT
MHC/NN
class/NN
II/CD
gene/NN
silencing/NN
in/IN
somatic/JJ
cell/NN
hybrids/NNS
is/VBZ
due/JJ
to/TO
an/DT
active/JJ
suppression/NN
of/IN
one/CD
of/IN
the/DT
promoters/NNS
of/IN
the/DT
CIITA/NN
gene/NN
,/,
mediated/VBN
by/IN
the/DT
epithelial/JJ
cell/NN
fusion/NN
partner/NN
./.
====================
UI/LS
-/:
98375837/CD
====================
TI/LS
-/:
Class/NN
II/CD
transactivator-independent/JJ
endothelial/JJ
cell/NN
MHC/NN
class/NN
II/CD
gene/NN
activation/NN
induced/VBN
by/IN
lymphocyte/NN
adhesion/NN
./.
====================
AB/LS
-/:
NK/NN
cells/NNS
induce/VBP
MHC/NN
class/NN
II/CD
molecules/NNS
on/IN
the/DT
surface/NN
of/IN
allogeneic/JJ
endothelial/JJ
cells/NNS
in/IN
an/DT
adhesion-dependent/JJ
,/,
IFN-gamma-independent/JJ
manner/NN
./.
====================
Here/RB
,/,
we/PRP
demonstrate/VBP
that/IN
NK/NN
cells/NNS
induce/VBP
HLA-DR/NN
on/IN
the/DT
surface/NN
of/IN
a/DT
mutant/JJ
cell/NN
line/NN
that/WDT
is/VBZ
defective/JJ
in/IN
IFN-gamma-induced/JJ
MHC/NN
class/NN
II/CD
expression/NN
./.
====================
RNA/NN
analysis/NN
in/IN
these/DT
cells/NNS
and/CC
in/IN
a/DT
cell/NN
line/NN
that/WDT
is/VBZ
defective/JJ
in/IN
class/NN
II/CD
transactivator/NN
(/(
CIITA/NN
)/)
demonstrates/VBZ
that/IN
NK/NN
cell-induced/JJ
HLA-DR/NN
alpha/NN
mRNA/NN
expression/NN
is/VBZ
also/RB
CIITA-independent/JJ
./.
====================
The/DT
Janus/NN
kinase-1-deficient/JJ
cell/NN
line/NN
U4A/NN
expresses/VBZ
HLA-DR/NN
alpha/NN
mRNA/NN
in/IN
response/NN
to/TO
NK/NN
cell/NN
activation/NN
,/,
and/CC
HLA-DR/NN
alpha/NN
promoter/NN
constructs/NNS
transfected/VBN
into/IN
these/DT
cells/NNS
are/VBP
induced/VBN
by/IN
NK/NN
cells/NNS
but/CC
not/RB
IFN-gamma/NN
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
the/DT
IFN-gamma-independent/JJ
component/NN
of/IN
the/DT
target/NN
cell/NN
HLA-DR/NN
expression/NN
induced/VBN
by/IN
lymphocyte/NN
adhesion/NN
uses/VBZ
a/DT
signaling/NN
pathway/NN
that/WDT
is/VBZ
distinct/JJ
from/IN
the/DT
IFN-gamma-dependent/JJ
mechanism/NN
and/CC
also/RB
suggest/VBP
that/IN
CIITA/NN
is/VBD
not/RB
required/VBN
./.
====================
UI/LS
-/:
99023364/CD
====================
TI/LS
-/:
Effects/NNS
of/IN
overexpression/NN
of/IN
IL-1/NN
receptor-associated/JJ
kinase/NN
on/IN
NFkappaB/NN
activation/NN
,/,
IL-2/NN
production/NN
and/CC
stress-activated/JJ
protein/NN
kinases/NNS
in/IN
the/DT
murine/JJ
T/NN
cell/NN
line/NN
EL4/NN
./.
====================
AB/LS
-/:
The/DT
association/NN
and/CC
activation/NN
of/IN
the/DT
IL-1/NN
receptor-associated/JJ
protein/NN
kinase/NN
(/(
IRAK/NN
)/)
to/TO
the/DT
IL-1/NN
receptor/NN
complex/NN
is/VBZ
one/CD
of/IN
the/DT
earliest/JJS
events/NNS
detectable/JJ
in/IN
IL-1/NN
signal/NN
transduction/NN
./.
====================
We/PRP
generated/VBD
permanent/JJ
clones/NNS
of/IN
the/DT
murine/JJ
T/NN
cell/NN
line/NN
EL4/NN
6.1/CD
overexpressing/VBG
human/JJ
(/(
h/NN
)/)
IRAK/NN
to/TO
evaluate/VB
the/DT
role/NN
of/IN
this/DT
kinase/NN
in/IN
IL-1/NN
signaling/NN
./.
====================
Overexpression/NN
of/IN
hIRAK/NN
enhanced/VBD
IL-1-stimulated/JJ
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NFkappaB/NN
,/,
whereas/IN
a/DT
truncated/VBN
form/NN
(/(
N-IRAK/NN
)/)
specifically/RB
inhibited/VBD
IL-1-dependent/JJ
NFkappaB/NN
activity/NN
./.
====================
In/IN
clones/NNS
stably/RB
overexpressing/VBG
hIRAK/NN
a/DT
weak/JJ
constitutive/JJ
activation/NN
of/IN
NFkappaB/NN
correlated/VBD
with/IN
a/DT
low/JJ
basal/JJ
IL-2/NN
production/NN
which/WDT
was/VBD
enhanced/VBN
in/IN
an/DT
IL-1-dependent/JJ
manner/NN
./.
====================
Compared/VBN
to/TO
the/DT
parental/JJ
cell/NN
line/NN
the/DT
dose-response/JJ
curve/NN
of/IN
IL-1-induced/JJ
IL-2/NN
production/NN
was/VBD
shifted/VBN
in/IN
both/CC
potency/NN
and/CC
efficacy/NN
./.
====================
These/DT
results/NNS
demonstrate/VBP
that/IN
IRAK/NN
directly/RB
triggers/VBZ
NFkappaB-mediated/JJ
gene/NN
expression/NN
in/IN
EL4/NN
cells/NNS
./.
====================
Qualitatively/RB
different/JJ
effects/NNS
were/VBD
observed/VBN
for/IN
the/DT
IL-1-induced/JJ
activation/NN
of/IN
stress-activated/JJ
protein/NN
(/(
SAP/NN
)/)
kinases/NNS
:/:
permanent/JJ
overexpression/NN
of/IN
IRAK/NN
did/VBD
not/RB
affect/VB
the/DT
dose/NN
dependence/NN
but/CC
prolonged/VBD
the/DT
kinetics/NN
of/IN
IL-1-induced/JJ
activation/NN
of/IN
SAP/NN
kinases/NNS
,/,
suggesting/VBG
that/IN
this/DT
signaling/VBG
branch/NN
may/MD
be/VB
regulated/VBN
by/IN
distinct/JJ
mechanisms/NNS
./.
====================
UI/LS
-/:
99008545/CD
====================
TI/LS
-/:
The/DT
role/NN
of/IN
protein/NN
kinase/NN
C/NN
signaling/NN
in/IN
activated/VBN
DRA/NN
transcription/NN
./.
====================
AB/LS
-/:
Expression/NN
of/IN
human/JJ
MHC/NN
HLA-DRA/NN
class/NN
II/CD
gene/NN
can/MD
be/VB
up-regulated/VBN
in/IN
B/NN
cells/NNS
by/IN
Ig/NN
cross-linking/NN
as/RB
well/RB
as/IN
by/IN
phorbol/NN
esters/NNS
such/JJ
as/IN
12-O-tetradecanoyl/NN
phorbol/NN
13-acetate/NN
(/(
TPA/NN
)/)
./.
====================
Induced/VBN
DRA/NN
expression/NN
involves/VBZ
activation/NN
of/IN
restricted/JJ
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
isoforms/NNS
,/,
resulting/VBG
in/IN
activated/VBN
activator/NN
protein-1-dependent/JJ
transcription/NN
./.
====================
In/IN
this/DT
report/NN
expression/NN
profiles/NNS
and/CC
activation/NN
of/IN
PKC/NN
were/VBD
analyzed/VBN
in/IN
human/JJ
Raji/NN
B/NN
lymphoblastoid/JJ
cells/NNS
./.
====================
Transient/JJ
transfection/NN
analysis/NN
with/IN
target/NN
plasmids/NNS
containing/VBG
either/CC
DRA/NN
promoter/NN
(/(
wild-type/JJ
or/CC
mutated/VBN
)/)
or/CC
TPA/NN
response/NN
elements/NNS
demonstrated/VBD
that/IN
pretreatment/NN
with/IN
the/DT
selective/JJ
PKC/NN
inhibitor/NN
GF/NN
109203X/NN
repressed/VBD
TPA-mediated/JJ
activation/NN
./.
====================
Western/NN
analysis/NN
performed/VBN
on/IN
cellular/JJ
fractions/NNS
of/IN
resting/VBG
cells/NNS
and/CC
of/IN
TPA-activated/JJ
cells/NNS
revealed/VBD
abundant/JJ
expression/NN
of/IN
classical/JJ
PKC-alpha/NN
(/(
cPKC-alpha/NN
)/)
,/,
cPKC-betaII/NN
,/,
and/CC
atypical/JJ
PKC-zeta/NN
isoforms/NNS
and/CC
identified/VBD
a/DT
sustained/JJ
translocation/NN
of/IN
cPKC-alpha/NN
and/CC
cPKC-betaII/NN
from/IN
the/DT
cytosolic/JJ
compartment/NN
to/TO
membranes/NNS
./.
====================
As/IN
expected/VBN
,/,
the/DT
distribution/NN
of/IN
atypical/JJ
PKC-zeta/NN
was/VBD
unaffected/JJ
by/IN
TPA/NN
treatment/NN
and/CC
displayed/VBD
an/DT
even/JJ
distribution/NN
between/IN
cytosol/NN
and/CC
membranes/NNS
./.
====================
This/DT
finding/NN
was/VBD
confirmed/VBN
by/IN
immunofluorescence/NN
microscopy/NN
./.
====================
The/DT
TPA-mediated/JJ
translocation/NN
of/IN
cPKC-alpha/NN
and/CC
cPKC-betaII/NN
was/VBD
not/RB
influenced/VBN
by/IN
pretreatment/NN
with/IN
GF/NN
109203X/NN
./.
====================
Finally/RB
,/,
functional/JJ
activation/NN
and/CC
translocation/NN
of/IN
PKC/NN
were/VBD
investigated/VBN
with/IN
a/DT
selective/JJ
in/FW
vitro/FW
kinase/NN
assay/NN
./.
====================
Together/RB
,/,
these/DT
results/NNS
show/VBP
that/IN
activated/VBN
HLA-DRA/NN
expression/NN
in/IN
response/NN
to/TO
TPA/NN
treatment/NN
is/VBZ
strictly/RB
dependent/JJ
on/IN
PKC/NN
activation/NN
acting/VBG
on/IN
the/DT
X2/NN
box/NN
of/IN
the/DT
DRA/NN
promoter/NN
and/CC
that/IN
selective/JJ
inhibition/NN
of/IN
PKC/NN
enzymatic/JJ
activity/NN
does/VBZ
not/RB
influence/VB
subcellular/JJ
localization/NN
of/IN
expressed/VBN
PKC/NN
isoenzymes/NNS
./.
====================
Thus/RB
,/,
the/DT
translocation/NN
event/NN
per/FW
se/FW
occurs/VBZ
independently/RB
of/IN
PKC/NN
activation/NN
in/IN
these/DT
cells/NNS
./.
====================
UI/LS
-/:
99007236/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
RNA/NN
polymerase/NN
II/CD
transcription/NN
in/IN
human/JJ
cells/NNS
by/IN
synthetic/JJ
DNA-binding/JJ
ligands/NNS
[/(
see/VB
comments/NNS
]/)
====================
AB/LS
-/:
Sequence-specific/JJ
DNA-binding/JJ
small/JJ
molecules/NNS
that/WDT
can/MD
permeate/VB
human/JJ
cells/NNS
potentially/RB
could/MD
regulate/VB
transcription/NN
of/IN
specific/JJ
genes/NNS
./.
====================
Multiple/JJ
cellular/JJ
DNA-binding/JJ
transcription/NN
factors/NNS
are/VBP
required/VBN
by/IN
HIV/NN
type/NN
1/CD
for/IN
RNA/NN
synthesis/NN
./.
====================
Two/CD
pyrrole-imidazole/JJ
polyamides/NNS
were/VBD
designed/VBN
to/TO
bind/VB
DNA/NN
sequences/NNS
immediately/RB
adjacent/JJ
to/TO
binding/VBG
sites/NNS
for/IN
the/DT
transcription/NN
factors/NNS
Ets-1/NN
,/,
lymphoid-enhancer/JJ
binding/NN
factor/NN
1/CD
,/,
and/CC
TATA-box/NN
binding/NN
protein/NN
./.
====================
These/DT
synthetic/JJ
ligands/NNS
specifically/RB
inhibit/VBP
DNA-binding/NN
of/IN
each/DT
transcription/NN
factor/NN
and/CC
HIV/NN
type/NN
1/CD
transcription/NN
in/IN
cell-free/JJ
assays/NNS
./.
====================
When/WRB
used/VBN
in/IN
combination/NN
,/,
the/DT
polyamides/NNS
inhibit/VBP
virus/NN
replication/NN
by/IN
>/JJR
99/CD
%/NN
in/IN
isolated/VBN
human/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
,/,
with/IN
no/DT
detectable/JJ
cell/NN
toxicity/NN
./.
====================
The/DT
ability/NN
of/IN
small/JJ
molecules/NNS
to/TO
target/VB
predetermined/JJ
DNA/NN
sequences/NNS
located/JJ
within/IN
RNA/NN
polymerase/NN
II/CD
promoters/NNS
suggests/VBZ
a/DT
general/JJ
approach/NN
for/IN
regulation/NN
of/IN
gene/NN
expression/NN
,/,
as/RB
well/RB
as/IN
a/DT
mechanism/NN
for/IN
the/DT
inhibition/NN
of/IN
viral/JJ
replication/NN
./.
====================
UI/LS
-/:
98440284/CD
====================
TI/LS
-/:
musculin/NN
:/:
a/DT
murine/JJ
basic/JJ
helix-loop-helix/JJ
transcription/NN
factor/NN
gene/NN
expressed/VBN
in/IN
embryonic/JJ
skeletal/JJ
muscle/NN
./.
====================
AB/LS
-/:
We/PRP
describe/VBP
the/DT
embryonic/JJ
expression/NN
of/IN
musculin/NN
,/,
a/DT
new/JJ
murine/JJ
member/NN
of/IN
the/DT
bHLH/JJ
family/NN
of/IN
transcription/NN
factors/NNS
./.
====================
Musculin/NN
protein/NN
is/VBZ
closely/RB
related/JJ
to/TO
human/JJ
ABF-1/NN
,/,
which/WDT
is/VBZ
expressed/VBN
in/IN
activated/VBN
B/NN
cells/NNS
,/,
and/CC
to/TO
epicardin/capsulin/Pod-1/NN
,/,
which/WDT
is/VBZ
expressed/VBN
in/IN
branchial/JJ
myoblasts/NNS
,/,
visceral/JJ
and/CC
urogenital/JJ
mesoderm/NN
and/CC
epicardium/NN
./.
====================
In/FW
situ/FW
hybridisation/NN
revealed/VBD
musculin/NN
expression/NN
in/IN
embryos/NNS
was/VBD
largely/RB
restricted/JJ
to/TO
the/DT
embryonic/JJ
skeletal/JJ
muscle/NN
lineage/NN
./.
====================
While/IN
all/DT
skeletal/JJ
muscles/NNS
expressed/VBD
the/DT
gene/NN
,/,
only/RB
a/DT
subset/NN
of/IN
myocytes/NNS
within/IN
each/DT
muscle/NN
were/VBD
positive/JJ
,/,
indicating/VBG
molecular/JJ
heterogeneity/NN
within/IN
fetal/JJ
muscle/NN
./.
====================
Copyright/NN
1998/CD
Elsevier/NNP
Science/NNP
Ireland/NNP
Ltd/NNP
./.
====================
All/DT
Rights/NNS
Reserved/VBN
./.
====================
UI/LS
-/:
98437269/CD
====================
TI/LS
-/:
Induction/NN
of/IN
T/NN
cell/NN
anergy/NN
by/IN
high/JJ
concentrations/NNS
of/IN
immunodominant/JJ
native/JJ
peptide/NN
is/VBZ
accompanied/VBN
by/IN
IL-10/NN
production/NN
and/CC
a/DT
block/NN
in/IN
JNK/NN
activity/NN
./.
====================
AB/LS
-/:
The/DT
ability/NN
to/TO
induce/VB
anergy/NN
in/IN
antigen-specific/JJ
T/NN
cells/NNS
has/VBZ
potential/JJ
therapeutic/JJ
value/NN
for/IN
altering/VBG
pathologic/JJ
immune/JJ
responses/NNS
./.
====================
This/DT
study/NN
was/VBD
undertaken/VBN
to/TO
further/RB
analyze/VB
changes/NNS
in/IN
cytokine/NN
production/NN
and/CC
intracellular/JJ
signaling/NN
during/IN
anergy/NN
induction/NN
using/VBG
high/JJ
concentrations/NNS
of/IN
native/JJ
peptide/NN
ligand/NN
of/IN
tetanus/NN
toxoid/NN
(/(
TT/NN
)/)
-/:
and/CC
myelin/JJ
basic/JJ
protein/NN
(/(
MBP/NN
)/)
-specific/JJ
human/JJ
T/NN
cell/NN
lines/NNS
./.
====================
The/DT
TT-selected/JJ
T/NN
cell/NN
line/NN
could/MD
be/VB
rendered/VBN
unresponsive/JJ
to/TO
its/PRP$
dominant/JJ
epitope/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
(/(
IC50/NN
=/JJ
0.03/CD
microg/ml/NN
)/)
./.
====================
The/DT
TT-selected/JJ
line/NN
,/,
as/RB
well/RB
as/IN
three/CD
T/NN
cell/NN
clones/NNS
established/VBN
from/IN
this/DT
line/NN
,/,
continued/VBD
to/TO
produce/VB
IFN-gamma/NN
and/CC
significantly/RB
increased/VBD
IL-4/NN
and/CC
IL-10/NN
production/NN
when/WRB
anergy/NN
was/VBD
induced/VBN
with/IN
high/JJ
concentrations/NNS
of/IN
the/DT
immunodominant/JJ
epitope/NN
./.
====================
JNK/NN
enzymatic/JJ
activity/NN
was/VBD
blocked/VBN
in/IN
anergized/VBN
T/NN
cells/NNS
./.
====================
The/DT
MBP-selected/JJ
line/NN
could/MD
likewise/RB
be/VB
rendered/VBN
unresponsive/JJ
by/IN
incubation/NN
with/IN
supraoptimal/JJ
concentrations/NNS
of/IN
immunodominant/JJ
peptide/NN
and/CC
anergy/NN
induction/NN
was/VBD
accompanied/VBN
by/IN
IL-10/NN
release/NN
./.
====================
Both/DT
T/NN
cell/NN
lines/NNS
could/MD
be/VB
anergized/VBN
by/IN
the/DT
autopresentation/NN
of/IN
native/JJ
peptide/NN
since/IN
anergy/NN
was/VBD
induced/VBN
in/IN
cultures/NNS
lacking/VBG
fresh/JJ
antigen-presenting/JJ
cells/NNS
./.
====================
This/DT
study/NN
shows/VBZ
that/IN
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
cascade/NN
is/VBZ
blocked/VBN
when/WRB
anergy/NN
is/VBZ
induced/VBN
to/TO
high/JJ
concentrations/NNS
of/IN
soluble/JJ
peptide/NN
./.
====================
Copyright/NN
1998/CD
Academic/NNP
Press/NNP
./.
====================
UI/LS
-/:
98416180/CD
====================
TI/LS
-/:
Upregulation/NN
of/IN
interleukin/NN
6/CD
and/CC
granulocyte/NN
colony-stimulating/JJ
factor/NN
receptors/NNS
by/IN
transcription/NN
factor/NN
CCAAT/NN
enhancer/NN
binding/NN
protein/NN
alpha/NN
(/(
C/EBP/NN
alpha/NN
)/)
is/VBZ
critical/JJ
for/IN
granulopoiesis/NN
./.
====================
AB/LS
-/:
Cytokines/NNS
stimulate/VBP
granulopoiesis/NN
through/IN
signaling/NN
via/IN
receptors/NNS
whose/WP$
expression/NN
is/VBZ
controlled/VBN
by/IN
lineage-specific/JJ
transcription/NN
factors/NNS
./.
====================
Previously/RB
,/,
we/PRP
demonstrated/VBD
that/IN
granulocyte/NN
colony-stimulating/JJ
factor/NN
(/(
G-CSF/NN
)/)
receptor/NN
mRNA/NN
was/VBD
undetectable/JJ
and/CC
granulocyte/NN
maturation/NN
blocked/VBN
in/IN
CCAAT/NN
enhancer/NN
binding/NN
protein/NN
alpha/NN
(/(
C/EBPalpha/NN
)/)
-deficient/JJ
mice/NNS
./.
====================
This/DT
phenotype/NN
is/VBZ
distinct/JJ
from/IN
that/DT
of/IN
G-CSF/NN
receptor-/-/JJ
mice/NNS
,/,
suggesting/VBG
that/IN
other/JJ
genes/NNS
are/VBP
likely/JJ
to/TO
be/VB
adversely/RB
affected/VBN
by/IN
loss/NN
of/IN
C/EBPalpha/NN
./.
====================
Here/RB
we/PRP
demonstrate/VBP
loss/NN
of/IN
interleukin/NN
6/CD
(/(
IL-6/NN
)/)
receptor/NN
and/CC
IL-6-responsive/JJ
colony-forming/JJ
units/NNS
(/(
CFU-IL6/NNS
)/)
in/IN
C/EBPalpha-/-/JJ
mice/NNS
./.
====================
The/DT
observed/VBN
failure/NN
of/IN
granulopoiesis/NN
could/MD
be/VB
rescued/VBN
by/IN
the/DT
addition/NN
of/IN
soluble/JJ
IL-6/NN
receptor/NN
and/CC
IL-6/NN
or/CC
by/IN
retroviral/JJ
transduction/NN
of/IN
G-CSF/NN
receptors/NNS
,/,
demonstrating/VBG
that/IN
loss/NN
of/IN
both/DT
of/IN
these/DT
receptors/NNS
contributes/VBZ
to/TO
the/DT
absolute/JJ
block/NN
in/IN
granulocyte/NN
maturation/NN
observed/VBN
in/IN
C/EBPalpha-deficient/JJ
hematopoietic/JJ
cells/NNS
./.
====================
The/DT
results/NNS
of/IN
these/DT
and/CC
other/JJ
studies/NNS
suggest/VBP
that/IN
additional/JJ
C/EBPalpha/NN
target/NN
genes/NNS
,/,
possibly/RB
other/JJ
cytokine/NN
receptors/NNS
,/,
are/VBP
also/RB
important/JJ
for/IN
the/DT
block/NN
in/IN
granulocyte/NN
differentiation/NN
observed/VBN
in/FW
vivo/FW
in/IN
C/EBPalpha-deficient/JJ
mice/NNS
./.
====================
UI/LS
-/:
98406066/CD
====================
TI/LS
-/:
Phosphatidylinositides/NNS
bind/VBP
to/TO
plasma/NN
membrane/NN
CD14/NN
and/CC
can/MD
prevent/VB
monocyte/NN
activation/NN
by/IN
bacterial/JJ
lipopolysaccharide/NN
./.
====================
AB/LS
-/:
Although/IN
bacterial/JJ
lipopolysaccharides/NNS
(/(
LPS/NNS
)/)
and/CC
several/JJ
other/JJ
microbial/JJ
agonists/NNS
can/MD
bind/VB
to/TO
mCD14/NN
(/(
membrane/NN
CD14/NN
)/)
,/,
a/DT
cell-surface/JJ
receptor/NN
found/VBN
principally/RB
on/IN
monocytes/NNS
and/CC
neutrophils/NNS
,/,
host-derived/JJ
mCD14/NN
ligands/NNS
are/VBP
poorly/RB
defined/VBN
./.
====================
We/PRP
report/VBP
here/RB
that/IN
phosphatidylinositol/NN
(/(
PtdIns/NN
)/)
,/,
phosphatidylinositol-4-phosphate/NN
,/,
and/CC
other/JJ
phosphatidylinositides/NNS
can/MD
bind/VB
to/TO
mCD14/NN
./.
====================
Phosphatidylserine/NN
(/(
PS/NN
)/)
,/,
another/DT
anionic/JJ
glycerophospholipid/NN
,/,
binds/VBZ
to/TO
mCD14/NN
with/IN
lower/JJR
apparent/JJ
affinity/NN
than/IN
does/VBZ
PtdIns/NN
./.
====================
LPS-binding/JJ
protein/NN
,/,
a/DT
lipid/NN
transfer/NN
protein/NN
found/VBN
in/IN
serum/NN
,/,
facilitates/VBZ
both/CC
PS-/NN
and/CC
PtdIns-mCD14/NN
binding/NN
./.
====================
PtdIns/NN
binding/VBG
to/TO
mCD14/NN
can/MD
be/VB
blocked/VBN
by/IN
anti-CD14/JJ
monoclonal/JJ
antibodies/NNS
that/WDT
inhibit/VBP
LPS-mCD14/NN
binding/NN
,/,
and/CC
PtdIns/NN
can/MD
inhibit/VB
both/CC
LPS-mCD14/NN
binding/NN
and/CC
LPS-induced/JJ
responses/NNS
in/IN
monocytes/NNS
./.
====================
Serum-equilibrated/JJ
PtdIns/NN
also/RB
binds/VBZ
to/TO
mCD14-expressing/JJ
cells/NNS
,/,
raising/VBG
the/DT
possibility/NN
that/IN
endogenous/JJ
PtdIns/NN
may/MD
modulate/VB
cellular/JJ
responses/NNS
to/TO
LPS/NNS
and/CC
other/JJ
mCD14/NN
ligands/NNS
in/FW
vivo/FW
./.
====================
UI/LS
-/:
98391028/CD
====================
TI/LS
-/:
Protein/NN
kinase/NN
C/NN
regulates/VBZ
Fas/NN
(/(
CD95/APO-1/NN
)/)
expression/NN
./.
====================
AB/LS
-/:
Fas/NN
(/(
CD95/APO-1/NN
)/)
is/VBZ
a/DT
transmembrane/JJ
protein/NN
of/IN
the/DT
TNF/neuron/NN
growth/NN
factor/NN
receptor/NN
family/NN
./.
====================
Ligation/NN
of/IN
Fas/NN
by/IN
specific/JJ
Abs/NNS
or/CC
Fas/NN
ligand/NN
(/(
FasL/CD95/NN
ligand/NN
)/)
induces/VBZ
rapid/JJ
apoptotic/JJ
cell/NN
death/NN
in/IN
a/DT
variety/NN
of/IN
cell/NN
types/NNS
./.
====================
Despite/IN
progress/NN
in/IN
understanding/VBG
the/DT
death/NN
signals/NNS
transduced/VBN
from/IN
Fas/NN
,/,
very/RB
little/JJ
is/VBZ
known/VBN
with/IN
regard/NN
to/TO
the/DT
mechanisms/NNS
by/IN
which/WDT
Fas/NN
expression/NN
is/VBZ
regulated/VBN
./.
====================
Using/VBG
our/PRP$
previously/RB
established/JJ
murine/JJ
T/NN
cell/NN
hybridoma/NN
model/NN
A1.1/NN
,/,
we/PRP
show/VBP
that/IN
specific/JJ
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
inhibitors/NNS
could/MD
block/VB
activation-induced/JJ
Fas/NN
expression/NN
and/CC
apoptosis/NN
./.
====================
The/DT
activation/NN
of/IN
PKC/NN
with/IN
PMA/NN
or/CC
1-oleoyl-2-acetyl-sn-glycerol/NN
could/MD
mimic/VB
the/DT
TCR/NN
signal/NN
by/IN
inducing/VBG
the/DT
expression/NN
of/IN
Fas/NN
but/CC
not/RB
FasL/NN
./.
====================
PKC-dependent/JJ
Fas/NN
expression/NN
was/VBD
also/RB
observed/VBN
in/IN
several/JJ
murine/JJ
and/CC
human/JJ
tumor/NN
cell/NN
lines/NNS
./.
====================
Since/IN
the/DT
inhibition/NN
of/IN
Ca2+/NN
redistribution/NN
by/IN
an/DT
inhibitor/NN
of/IN
intracellular/JJ
Ca2+/NN
mobilization/NN
,/,
8-(diethylamino)-octyl-3,4,5-trimethoxybenzoate/NN
hydrochloride/NN
,/,
inhibited/VBD
TCR-induced/JJ
FasL/NN
but/CC
not/RB
Fas/NN
,/,
the/DT
expression/NN
of/IN
Fas/NN
appears/VBZ
to/TO
be/VB
independent/JJ
of/IN
Ca2+/NN
mobilization/NN
./.
====================
Significantly/RB
,/,
expression/NN
of/IN
the/DT
newly/RB
identified/VBN
Fas-regulatory/JJ
gene/NN
,/,
TDAG51/NN
,/,
was/VBD
found/VBN
to/TO
be/VB
dependent/JJ
upon/IN
the/DT
activity/NN
of/IN
PKC/NN
./.
====================
PKC/NN
activation/NN
only/RB
induced/VBD
Fas/NN
expression/NN
in/IN
cells/NNS
expressing/VBG
wild-type/JJ
TDAG51/NN
./.
====================
Thus/RB
,/,
Fas/NN
expression/NN
is/VBZ
likely/RB
mediated/VBN
by/IN
PKC/NN
through/IN
TDAG51/NN
./.
====================
UI/LS
-/:
98384235/CD
====================
TI/LS
-/:
Retinoic/JJ
acid/NN
inhibits/VBZ
CD40/NN
+/CC
interleukin-4-mediated/JJ
IgE/NN
production/NN
in/FW
vitro/FW
./.
====================
AB/LS
-/:
To/TO
elucidate/VB
the/DT
role/NN
of/IN
retinoic/JJ
acid/NN
(/(
RA/NN
)/)
in/IN
anti-CD40/NN
+/CC
interleukin-4/NN
(/(
IL-4/NN
)/)
-mediated/JJ
B-cell/NN
activation/NN
,/,
the/DT
effect/NN
of/IN
10(-12)/CD
to/TO
10(-6)/CD
mol/L/NN
RA/NN
was/VBD
studied/VBN
in/IN
anti-CD40/NN
(/(
1/CD
microgram/mL/NN
)/)
+/CC
IL-4/NN
(/(
5/CD
ng/mL/NN
)/)
-mediated/JJ
proliferation/NN
and/CC
Ig/NN
synthesis/NN
by/IN
human/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NNS
)/)
and/CC
B/NN
cells/NNS
in/IN
healthy/JJ
donors/NNS
./.
====================
Anti-CD40/NN
+/CC
IL-4-mediated/JJ
proliferation/NN
of/IN
PBMC/NNS
and/CC
B/NN
cells/NNS
was/VBD
inhibited/VBN
by/IN
RA/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
,/,
with/IN
maximal/JJ
inhibition/NN
of/IN
62/CD
%/NN
+/-/CC
5/CD
%/NN
in/IN
PBMC/NNS
and/CC
55/CD
%/NN
+/-/CC
4.4/CD
%/NN
in/IN
B/NN
cells/NNS
by/IN
all-trans/JJ
RA/NN
,/,
and/CC
58/CD
%/NN
+/-/CC
6.7/CD
%/NN
and/CC
51/CD
%/NN
+/-/CC
4.7/CD
%/NN
,/,
respectively/RB
by/IN
13-cis/JJ
RA/NN
./.
====================
IgE/NN
synthesis/NN
was/VBD
even/RB
more/RBR
markedly/RB
inhibited/VBN
by/IN
RA/NN
starting/VBG
at/IN
concentrations/NNS
of/IN
>/JJR
10(-14)/CD
mol/L/NN
for/IN
B/NN
cells/NNS
and/CC
>/JJR
10(-10)/CD
mol/L/NN
for/IN
PBMC/NNS
./.
====================
Maximal/JJ
inhibition/NN
of/IN
IgE/NN
production/NN
for/IN
B/NN
cells/NNS
was/VBD
at/IN
10(-8)/CD
mol/L/NN
for/IN
all-trans/JJ
RA/NN
(/(
94/CD
%/NN
+/-/CC
1.8/CD
%/NN
)/)
and/CC
96/CD
%/NN
+/-/CC
3.2/CD
%/NN
for/IN
13-cis/JJ
RA/NN
./.
====================
Low/JJ
concentrations/NNS
of/IN
RA/NN
inhibiting/VBG
IgE/NN
synthesis/NN
(/(
10(-10)/CD
mol/L/NN
)/)
affected/VBD
neither/CC
B-cell/NN
proliferation/NN
nor/CC
the/DT
production/NN
of/IN
IgA/NN
,/,
IgG/NN
,/,
and/CC
IgM/NN
./.
====================
Elucidation/NN
of/IN
the/DT
mechanism/NN
involved/VBN
in/IN
this/DT
inhibition/NN
of/IN
IgE/NN
production/NN
shows/VBZ
that/IN
epsilon/NN
germline/NN
transcription/NN
is/VBZ
decreased/VBN
by/IN
RA/NN
,/,
whereas/IN
production/NN
of/IN
interferon-gamma/NN
(/(
IFN-gamma/NN
)/)
was/VBD
not/RB
enhanced/VBN
in/IN
the/DT
presence/NN
of/IN
RA/NN
./.
====================
To/TO
differentiate/VB
whether/IN
the/DT
RA/NN
effect/NN
was/VBD
mediated/VBN
by/IN
RA/NN
receptors/NNS
alpha/NN
,/,
beta/NN
,/,
and/CC
gamma/NN
,/,
the/DT
expression/NN
of/IN
the/DT
retinoic/JJ
acid/NN
receptors/NNS
(/(
RAR/NNS
)/)
was/VBD
examined/VBN
by/IN
reverse/JJ
transcriptase-polymerase/JJ
chain/NN
reaction/NN
(/(
RT-PCR/NN
)/)
./.
====================
The/DT
data/NNS
show/VBP
that/IN
unstimulated/JJ
human/JJ
peripheral/JJ
B/NN
cells/NNS
express/VBP
mRNA/NN
of/IN
the/DT
RA/NN
receptor/NN
alpha/NN
,/,
beta/NN
,/,
and/CC
gamma/NN
./.
====================
Using/VBG
retinoids/NNS
with/IN
different/JJ
receptor/NN
binding/NN
specificity/NN
(/(
CD336/NN
,/,
CD437/NN
,/,
CD2019/NN
,/,
CD367/NN
)/)
,/,
dose-dependent/JJ
inhibition/NN
of/IN
IgE/NN
synthesis/NN
was/VBD
shown/VBN
by/IN
all/DT
four/CD
derivates/NNS
,/,
but/CC
was/VBD
most/RBS
marked/VBN
by/IN
an/DT
RA/NN
binding/VBG
the/DT
alpha/NN
receptor/NN
with/IN
high/JJ
specificity/NN
./.
====================
Taken/VBN
together/RB
,/,
this/DT
study/NN
shows/VBZ
that/IN
RA/NN
inhibits/VBZ
IgE/NN
production/NN
of/IN
anti-CD40/NN
+/CC
IL-4-stimulated/JJ
B/NN
cells/NNS
in/FW
vitro/FW
./.
====================
Copyright/NN
1998/CD
by/IN
The/NNP
American/NNP
Society/NNP
of/IN
Hematology/NNP
./.
====================
UI/LS
-/:
98378528/CD
====================
TI/LS
-/:
Human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
1/CD
Tax/NN
induction/NN
of/IN
NF-kappaB/NN
involves/VBZ
activation/NN
of/IN
the/DT
IkappaB/NN
kinase/NN
alpha/NN
(/(
IKKalpha/NN
)/)
and/CC
IKKbeta/NN
cellular/JJ
kinases/NNS
./.
====================
AB/LS
-/:
Tax/NN
corresponds/VBZ
to/TO
a/DT
40-kDa/JJ
transforming/VBG
protein/NN
from/IN
the/DT
pathogenic/JJ
retrovirus/NN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
1/CD
(/(
HTLV-1/NN
)/)
that/WDT
activates/VBZ
nuclear/JJ
expression/NN
of/IN
the/DT
NF-kappaB/Rel/NN
family/NN
of/IN
transcription/NN
factors/NNS
by/IN
an/DT
unknown/JJ
mechanism/NN
./.
====================
Tax/NN
expression/NN
promotes/VBZ
N-terminal/JJ
phosphorylation/NN
and/CC
degradation/NN
of/IN
IkappaB/NN
alpha/NN
,/,
a/DT
principal/JJ
cytoplasmic/JJ
inhibitor/NN
of/IN
NF-kappaB/NN
./.
====================
Our/PRP$
studies/NNS
now/RB
demonstrate/VBP
that/IN
HTLV-1/NN
Tax/NN
activates/VBZ
the/DT
recently/RB
identified/VBN
cellular/JJ
kinases/NNS
IkappaB/NN
kinase/NN
alpha/NN
(/(
IKKalpha/NN
)/)
and/CC
IKKbeta/NN
,/,
which/WDT
normally/RB
phosphorylate/VBP
IkappaB/NN
alpha/NN
on/IN
both/DT
of/IN
its/PRP$
N-terminal/JJ
regulatory/JJ
serines/NNS
in/IN
response/NN
to/TO
tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF-alpha/NN
)/)
and/CC
interleukin-1/NN
(/(
IL-1/NN
)/)
stimulation/NN
./.
====================
In/IN
contrast/NN
,/,
a/DT
mutant/NN
of/IN
Tax/NN
termed/VBN
M22/NN
,/,
which/WDT
does/VBZ
not/RB
induce/VB
NF-kappaB/NN
,/,
fails/VBZ
to/TO
activate/VB
either/CC
IKKalpha/NN
or/CC
IKKbeta/NN
./.
====================
Furthermore/RB
,/,
endogenous/JJ
IKK/NN
enzymatic/JJ
activity/NN
was/VBD
significantly/RB
elevated/JJ
in/IN
HTLV-1-infected/JJ
and/CC
Tax-expressing/JJ
T-cell/NN
lines/NNS
./.
====================
Transfection/NN
of/IN
kinase-deficient/JJ
mutants/NNS
of/IN
IKKalpha/NN
and/CC
IKKbeta/NN
into/IN
either/CC
human/JJ
Jurkat/NN
T/NN
or/CC
293/CD
cells/NNS
also/RB
inhibits/VBZ
NF-kappaB-dependent/JJ
reporter/NN
gene/NN
expression/NN
induced/VBN
by/IN
Tax/NN
./.
====================
Similarly/RB
,/,
a/DT
kinase-deficient/JJ
mutant/NN
of/IN
NIK/NN
(/(
NF-kappaB-inducing/NN
kinase/NN
)/)
,/,
which/WDT
represents/VBZ
an/DT
upstream/JJ
kinase/NN
in/IN
the/DT
TNF-alpha/NN
and/CC
IL-1/NN
signaling/NN
pathways/NNS
leading/VBG
to/TO
IKKalpha/NN
and/CC
IKKbeta/NN
activation/NN
,/,
blocks/VBZ
Tax/NN
induction/NN
of/IN
NF-kappaB/NN
./.
====================
However/RB
,/,
plasma/NN
membrane-proximal/JJ
elements/NNS
in/IN
these/DT
proinflammatory/JJ
cytokine/NN
pathways/NNS
are/VBP
apparently/RB
not/RB
involved/VBN
since/IN
dominant/JJ
negative/JJ
mutants/NNS
of/IN
the/DT
TRAF2/NN
and/CC
TRAF6/NN
adaptors/NNS
,/,
which/WDT
effectively/RB
block/VBP
signaling/NN
through/IN
the/DT
cytoplasmic/JJ
tails/NNS
of/IN
the/DT
TNF-alpha/NN
and/CC
IL-1/NN
receptors/NNS
,/,
respectively/RB
,/,
do/VBP
not/RB
inhibit/VB
Tax/NN
induction/NN
of/IN
NF-kappaB/NN
./.
====================
Together/RB
,/,
these/DT
studies/NNS
demonstrate/VBP
that/IN
HTLV-1/NN
Tax/NN
exploits/VBZ
a/DT
distal/JJ
part/NN
of/IN
the/DT
proinflammatory/JJ
cytokine/NN
signaling/NN
cascade/NN
leading/VBG
to/TO
induction/NN
of/IN
NF-kappaB/NN
./.
====================
The/DT
pathological/JJ
alteration/NN
of/IN
this/DT
cytokine/NN
pathway/NN
leading/VBG
to/TO
NF-kappaB/NN
activation/NN
by/IN
Tax/NN
may/MD
play/VB
a/DT
central/JJ
role/NN
in/IN
HTLV-1-mediated/JJ
transformation/NN
of/IN
human/JJ
T/NN
cells/NNS
,/,
clinically/RB
manifested/VBN
as/IN
the/DT
adult/JJ
T-cell/NN
leukemia/NN
====================
UI/LS
-/:
99023967/CD
====================
TI/LS
-/:
Role/NN
of/IN
IKK1/NN
and/CC
IKK2/NN
in/IN
lipopolysaccharide/NN
signaling/NN
in/IN
human/JJ
monocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
Mononuclear/JJ
phagocytes/NNS
play/VBP
a/DT
major/JJ
role/NN
in/IN
immune/JJ
and/CC
inflammatory/JJ
responses/NNS
./.
====================
Bacterial/JJ
lipopolysaccharide/NN
(/(
LPS/NN
)/)
induces/VBZ
monocytes/NNS
to/TO
express/VB
a/DT
variety/NN
of/IN
genes/NNS
by/IN
activating/VBG
the/DT
NF-kappaB/Rel/NN
transcription/NN
factor/NN
family/NN
./.
====================
Recently/RB
,/,
we/PRP
have/VBP
reported/VBN
that/IN
the/DT
tumor/NN
necrosis/NN
factor/NN
and/CC
interleukin/NN
1/CD
signaling/NN
pathways/NNS
activate/VBP
two/CD
kinases/NNS
,/,
IKK1/NN
and/CC
IKK2/NN
./.
====================
Phosphorylation/NN
of/IN
the/DT
IkappaB/NN
cytoplasmic/JJ
inhibitors/NNS
,/,
IkappaBalpha/NN
,/,
IkappaBbeta/NN
,/,
and/CC
IkappaBepsilon/NN
,/,
by/IN
these/DT
kinases/NNS
triggers/VBZ
proteolytic/JJ
degradation/NN
and/CC
the/DT
release/NN
of/IN
NF-kappaB/Rel/NN
proteins/NNS
into/IN
the/DT
nucleus/NN
./.
====================
At/IN
present/NN
,/,
the/DT
role/NN
of/IN
the/DT
IKKs/NNS
in/IN
LPS/NN
signaling/NN
has/VBZ
not/RB
been/VBN
investigated/VBN
./.
====================
Here/RB
,/,
we/PRP
report/VBP
that/IN
LPS/NN
induces/VBZ
IKK/NN
activity/NN
in/IN
human/JJ
monocytes/NNS
and/CC
THP-1/NN
monocytic/JJ
cells/NNS
./.
====================
The/DT
kinetics/NN
of/IN
activation/NN
of/IN
kinase/NN
activity/NN
in/IN
monocytic/JJ
cells/NNS
are/VBP
relatively/RB
slow/JJ
with/IN
maximal/JJ
activity/NN
observed/VBN
at/IN
60/CD
min/NN
,/,
which/WDT
coincides/VBZ
with/IN
the/DT
degradation/NN
of/IN
IkappaBs/NNS
and/CC
the/DT
nuclear/JJ
translocation/NN
of/IN
NF-kappaB/NN
./.
====================
In/IN
transfection/NN
experiments/NNS
,/,
overexpression/NN
of/IN
wild/JJ
type/NN
IKK1/NN
,/,
a/DT
dominant/JJ
negative/JJ
mutant/JJ
IKK1/NN
(/(
K44M/NN
)/)
,/,
or/CC
wild/JJ
type/NN
IKK2/NN
did/VBD
not/RB
affect/VB
LPS-induced/JJ
kappaB-dependent/JJ
transcription/NN
in/IN
monocytic/JJ
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
a/DT
dominant/JJ
negative/JJ
mutant/NN
of/IN
IKK2/NN
inhibited/VBD
LPS/NN
induction/NN
of/IN
kappaB-dependent/JJ
transcription/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
LPS/NN
induction/NN
of/IN
kappaB-dependent/JJ
gene/NN
expression/NN
in/IN
human/JJ
monocytic/JJ
cells/NNS
requires/VBZ
activation/NN
of/IN
IKK2/NN
./.
====================
UI/LS
-/:
99008520/CD
====================
TI/LS
-/:
IL-7/NN
reconstitutes/VBZ
multiple/JJ
aspects/NNS
of/IN
v-Abl-mediated/JJ
signaling/NN
./.
====================
AB/LS
-/:
The/DT
mechanism/NN
by/IN
which/WDT
early/JJ
lymphoid/JJ
cells/NNS
are/VBP
selectively/RB
transformed/VBN
by/IN
v-Abl/NN
is/VBZ
currently/RB
unknown/JJ
./.
====================
Previous/JJ
studies/NNS
have/VBP
shown/VBN
constitutive/JJ
activation/NN
of/IN
IL-4/NN
and/CC
IL-7/NN
signaling/NN
pathways/NNS
,/,
as/IN
measured/VBN
by/IN
activation/NN
of/IN
Janus/NN
protein/NN
kinase/NN
(/(
JAK/NN
)/)
1/CD
,/,
JAK3/NN
,/,
STAT5/NN
,/,
and/CC
STAT6/NN
,/,
in/IN
pre-B/JJ
cells/NNS
transformed/VBN
by/IN
v-Abl/NN
./.
====================
To/TO
determine/VB
whether/IN
activation/NN
of/IN
these/DT
cytokine/NN
signaling/NN
pathways/NNS
by/IN
v-Abl/NN
is/VBZ
important/JJ
in/IN
the/DT
cellular/JJ
events/NNS
induced/VBN
by/IN
the/DT
Abelson/NN
murine/JJ
leukemia/NN
virus/NN
,/,
the/DT
effects/NNS
of/IN
IL-4/NN
and/CC
IL-7/NN
on/IN
pre-B/JJ
cells/NNS
transformed/VBN
with/IN
a/DT
temperature-sensitive/JJ
v-Abl/NN
mutant/NN
were/VBD
examined/VBN
./.
====================
Whereas/IN
IL-4/NN
had/VBD
little/JJ
or/CC
no/DT
effect/NN
,/,
IL-7/NN
delayed/VBD
both/CC
the/DT
apoptosis/NN
and/CC
cell/NN
cycle/NN
arrest/NN
that/WDT
occur/VBP
upon/IN
v-Abl/NN
kinase/NN
inactivation/NN
./.
====================
IL-7/NN
also/RB
delayed/VBD
the/DT
decreases/NNS
in/IN
the/DT
levels/NNS
of/IN
c-Myc/NN
,/,
Bcl-2/NN
,/,
and/CC
Bcl-xL/NN
that/WDT
occur/VBP
upon/IN
loss/NN
of/IN
v-Abl/NN
kinase/NN
activity/NN
./.
====================
IL-7/NN
did/VBD
not/RB
maintain/VB
v-Abl-mediated/JJ
differentiation/NN
arrest/NN
of/IN
the/DT
pre-B/JJ
cells/NNS
,/,
as/IN
activation/NN
of/IN
NF-kappaB/NN
and/CC
RAG/NN
gene/NN
transcription/NN
was/VBD
unaffected/JJ
by/IN
IL-7/NN
./.
====================
These/DT
results/NNS
identify/VBP
a/DT
potential/JJ
role/NN
for/IN
IL-7/NN
signaling/NN
pathways/NNS
in/IN
transformation/NN
by/IN
v-Abl/NN
while/IN
demonstrating/VBG
that/IN
a/DT
combination/NN
of/IN
IL-4/NN
and/CC
IL-7/NN
signaling/NN
can/MD
not/RB
substitute/VB
for/IN
an/DT
active/JJ
v-Abl/NN
kinase/NN
in/IN
transformed/VBN
pre-B/JJ
cells/NNS
./.
====================
UI/LS
-/:
99005376/CD
====================
TI/LS
-/:
Differential/JJ
regulation/NN
of/IN
coproporphyrinogen/NN
oxidase/NN
gene/NN
between/IN
erythroid/JJ
and/CC
nonerythroid/JJ
cells/NNS
./.
====================
AB/LS
-/:
Coproporphyrinogen/NN
oxidase/NN
(/(
CPO/NN
)/)
catalyzes/VBZ
the/DT
sixth/JJ
step/NN
of/IN
the/DT
heme/NN
biosynthetic/JJ
pathway/NN
./.
====================
To/TO
assess/VB
the/DT
tissue-specific/JJ
regulation/NN
of/IN
the/DT
CPO/NN
gene/NN
promoter/NN
,/,
mouse/NN
genomic/JJ
DNA/NN
clones/NNS
for/IN
CPO/NN
were/VBD
isolated/VBN
./.
====================
Structural/JJ
analysis/NN
demonstrated/VBD
that/IN
the/DT
mouse/NN
CPO/NN
gene/NN
spans/VBZ
approximately/RB
11/CD
kb/NN
and/CC
consists/VBZ
of/IN
seven/CD
exons/NNS
,/,
just/RB
like/IN
its/PRP$
human/JJ
counterpart/NN
./.
====================
Functional/JJ
analysis/NN
of/IN
the/DT
promoter/NN
by/IN
transient/JJ
transfection/NN
assays/NNS
indicated/VBD
that/IN
synergistic/JJ
action/NN
between/IN
an/DT
SP-1-like/JJ
element/NN
at/IN
-21/-12/CD
,/,
a/DT
GATA/NN
site/NN
at/IN
-59/-54/CD
,/,
and/CC
a/DT
novel/JJ
regulatory/JJ
element/NN
,/,
CPRE/NN
(/(
-GGACTACAG-/NN
)/)
at/IN
-49/-41/CD
,/,
is/VBZ
essential/JJ
for/IN
the/DT
promoter/NN
activity/NN
in/IN
murine/JJ
erythroleukemia/NN
(/(
MEL/NN
)/)
cells/NNS
./.
====================
In/IN
nonerythroid/JJ
NIH3T3/NN
cells/NNS
,/,
however/RB
,/,
the/DT
GATA/NN
site/NN
is/VBZ
not/RB
required/VBN
./.
====================
Gel/NN
mobility/NN
shift/NN
assays/NNS
demonstrated/VBD
that/IN
specific/JJ
DNA-protein/JJ
complexes/NNS
can/MD
be/VB
formed/VBN
with/IN
each/DT
element/NN
,/,
and/CC
that/IN
there/EX
are/VBP
cell-specific/JJ
differences/NNS
in/IN
factors/NNS
,/,
which/WDT
bind/VBP
to/TO
the/DT
SP-1-like/JJ
element/NN
between/IN
MEL/NN
and/CC
NIH3T3/NN
cells/NNS
./.
====================
These/DT
results/NNS
provide/VBP
evidence/NN
for/IN
differential/JJ
regulation/NN
of/IN
the/DT
promoter/NN
function/NN
of/IN
CPO/NN
gene/NN
between/IN
erythroid/JJ
and/CC
nonerythroid/JJ
cells/NNS
./.
====================
Copyright/NN
1998/CD
by/IN
The/NNP
American/NNP
Society/NNP
of/IN
Hematology/NNP
====================
UI/LS
-/:
98438043/CD
====================
TI/LS
-/:
Tumor/NN
suppressor/NN
proteins/NNS
as/IN
regulators/NNS
of/IN
cell/NN
differentiation/NN
./.
====================
AB/LS
-/:
The/DT
products/NNS
of/IN
the/DT
tumor/NN
suppressor/NN
genes/NNS
are/VBP
considered/VBN
to/TO
function/VB
as/IN
specific/JJ
inhibitors/NNS
of/IN
tumor/NN
cell/NN
growth/NN
./.
====================
In/IN
this/DT
communication/NN
,/,
we/PRP
present/VBP
evidence/NN
to/TO
show/VB
that/IN
these/DT
proteins/NNS
inhibit/VBP
tumor/NN
cell/NN
proliferation/NN
by/IN
participating/VBG
in/IN
the/DT
activation/NN
of/IN
tumor/NN
cell/NN
differentiation/NN
./.
====================
The/DT
ML-1/NN
human/JJ
myeloblastic/JJ
leukemia/NN
cells/NNS
used/VBN
in/IN
this/DT
study/NN
proliferate/VBP
when/WRB
treated/VBN
with/IN
insulin-like/JJ
growth/NN
factor/NN
I/CD
and/CC
transferrin/NN
but/CC
differentiate/VBP
to/TO
monocytes/NNS
when/WRB
exposed/VBN
to/TO
tumor/NN
necrosis/NN
factor/NN
alpha/NN
or/CC
transforming/VBG
growth/NN
factor/NN
beta1/NN
,/,
or/CC
to/TO
macrophage-like/JJ
cells/NNS
when/WRB
treated/VBN
with/IN
both/DT
these/DT
cytokines/NNS
./.
====================
Initiation/NN
of/IN
proliferation/NN
but/CC
not/RB
of/IN
differentiation/NN
was/VBD
followed/VBN
by/IN
a/DT
20-/CD
to/TO
25-fold/JJ
increase/NN
in/IN
the/DT
nuclear/JJ
level/NN
of/IN
the/DT
DNA/NN
polymerase-associated/JJ
processivity/NN
factor/NN
PCNA/NN
and/CC
of/IN
the/DT
proliferation-specific/JJ
transcription/NN
factor/NN
E2F1/NN
./.
====================
In/IN
contrast/NN
,/,
induction/NN
of/IN
differentiation/NN
but/CC
not/RB
of/IN
proliferation/NN
was/VBD
followed/VBN
by/IN
a/DT
25-/CD
to/TO
30-fold/JJ
increase/NN
in/IN
the/DT
nuclear/JJ
level/NN
of/IN
the/DT
tumor/NN
suppressor/NN
proteins/NNS
p53/NN
(/(
wild/JJ
type/NN
)/)
,/,
pRb/NN
,/,
and/CC
p130/Rb2/NN
and/CC
of/IN
the/DT
p53-dependent/JJ
cyclin/NN
kinase/NN
inhibitor/NN
p21/Cip1/NN
./.
====================
p53/NN
and/CC
p21/Cip1/NN
,/,
respectively/RB
,/,
inhibit/VBP
the/DT
expression/NN
and/CC
activation/NN
of/IN
PCNA/NN
,/,
whereas/IN
p130/NN
and/CC
pRb/NN
,/,
respectively/RB
,/,
inhibit/VBP
the/DT
expression/NN
and/CC
activation/NN
of/IN
E2F1/NN
./.
====================
As/IN
a/DT
result/NN
,/,
G1-S-associated/JJ
DNA/NN
and/CC
mRNA/NN
synthesis/NN
is/VBZ
inhibited/VBN
,/,
growth/NN
uncoupled/VBD
from/IN
differentiation/NN
,/,
and/CC
maturation/NN
enabled/VBD
to/TO
proceed/VB
./.
====================
Where/WRB
this/DT
function/NN
of/IN
the/DT
tumor/NN
suppressor/NN
proteins/NNS
is/VBZ
impaired/JJ
,/,
the/DT
capacity/NN
for/IN
differentiation/NN
is/VBZ
lost/VBN
,/,
which/WDT
leads/VBZ
to/TO
the/DT
sustained/JJ
proliferation/NN
that/WDT
is/VBZ
characteristic/JJ
of/IN
the/DT
cancer/NN
cell/NN
./.
====================
UI/LS
-/:
98427848/CD
====================
TI/LS
-/:
Transcription/NN
factor/NN
activation/NN
in/IN
lymphokine/NN
activated/JJ
killer/NN
cells/NNS
and/CC
lymphocytes/NNS
from/IN
patients/NNS
receiving/VBG
IL-2/NN
immunotherapy/NN
./.
====================
AB/LS
-/:
Administration/NN
of/IN
the/DT
cytokine/NN
interleukin-2/NN
(/(
IL-2/NN
)/)
can/MD
result/VB
in/IN
therapeutic/JJ
benefits/NNS
for/IN
individuals/NNS
with/IN
renal/JJ
cell/NN
carcinoma/NN
and/CC
melanoma/NN
./.
====================
Here/RB
we/PRP
report/VBP
an/DT
analysis/NN
of/IN
the/DT
transcription/NN
factor/NN
families/NNS
AP-1/NN
,/,
Sp1/NN
,/,
NF-kappaB/NN
,/,
and/CC
signal/NN
transducers/NNS
and/CC
activators/NNS
of/IN
transcription/NN
(/(
STAT/NN
)/)
in/IN
cancer/NN
patients/NNS
'/POS
lymphocytes/NNS
before/IN
and/CC
after/IN
IL-2/NN
immunotherapy/NN
,/,
as/IN
assessed/VBN
by/IN
a/DT
gel-shift/JJ
assay/NN
./.
====================
An/DT
in/FW
vitro/FW
surrogate/NN
of/IN
IL-2/NN
immunotherapy/NN
is/VBZ
the/DT
incubation/NN
of/IN
fresh/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NNS
)/)
from/IN
healthy/JJ
individuals/NNS
in/IN
IL-2/NN
for/IN
several/JJ
days/NNS
,/,
resulting/VBG
in/IN
the/DT
production/NN
of/IN
lymphokine-activated/JJ
killer/NN
(/(
LAK/NN
)/)
activity/NN
in/IN
these/DT
cultures/NNS
./.
====================
One/CD
purpose/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
describe/VB
the/DT
profile/NN
of/IN
transcription/NN
factor/NN
activation/NN
in/IN
these/DT
different/JJ
populations/NNS
,/,
and/CC
assess/VB
whether/IN
the/DT
patterns/NNS
observed/VBN
correlated/VBD
with/IN
functional/JJ
differences/NNS
in/IN
these/DT
cells/NNS
./.
====================
Prior/JJ
to/TO
in/FW
vivo/FW
IL-2/NN
administration/NN
,/,
the/DT
typical/JJ
binding/NN
pattern/NN
of/IN
transcription/NN
factors/NNS
in/IN
PBMC/NNS
from/IN
patients/NNS
resembled/VBD
that/DT
seen/VBN
in/IN
fresh/JJ
PBMC/NNS
from/IN
healthy/JJ
individuals/NNS
./.
====================
Over/IN
a/DT
3-week/JJ
course/NN
of/IN
IL-2/NN
therapy/NN
,/,
in/IN
most/JJS
patients/NNS
the/DT
binding/NN
patterns/NNS
of/IN
AP-1/NN
,/,
Sp1/NN
,/,
and/CC
NF-kappaB/NN
proteins/NNS
changed/VBD
to/TO
resemble/VB
those/DT
seen/VBN
in/IN
PBMC/NNS
activated/VBN
by/IN
IL-2/NN
in/FW
vitro/FW
./.
====================
However/RB
,/,
the/DT
cells/NNS
obtained/VBN
from/IN
IL-2-treated/JJ
patients/NNS
did/VBD
not/RB
have/VB
low-level/JJ
constitutive/JJ
expression/NN
of/IN
STAT/NN
binding/NN
factors/NNS
as/IN
did/VBD
LAK/NN
cells/NNS
./.
====================
When/WRB
these/DT
patient/NN
cells/NNS
were/VBD
further/RB
stimulated/VBN
by/IN
IL-2/NN
in/FW
vitro/FW
,/,
additional/JJ
differences/NNS
in/IN
STAT/NN
induction/NN
patterns/NNS
were/VBD
noted/VBN
./.
====================
These/DT
data/NNS
provide/VBP
further/JJ
information/NN
on/IN
the/DT
molecular/JJ
events/NNS
occurring/VBG
in/IN
immune/JJ
cells/NNS
generated/VBN
through/IN
in/FW
vivo/FW
and/CC
in/FW
vitro/FW
administration/NN
of/IN
IL-2/NN
,/,
and/CC
further/RB
document/VBP
that/IN
there/EX
is/VBZ
not/RB
a/DT
precise/JJ
congruence/NN
between/IN
PBMC/NNS
activated/VBN
in/FW
vivo/FW
and/CC
in/FW
vitro/FW
by/IN
IL-2/NN
./.
====================
UI/LS
-/:
98416141/CD
====================
TI/LS
-/:
Activated/VBN
platelets/NNS
induce/VBP
monocyte/NN
chemotactic/JJ
protein-1/NN
secretion/NN
and/CC
surface/NN
expression/NN
of/IN
intercellular/JJ
adhesion/NN
molecule-1/NN
on/IN
endothelial/JJ
cells/NNS
[/(
see/VB
comments/NNS
]/)
====================
AB/LS
-/:
BACKGROUND/NN
:/:
Platelet/endothelium/NN
interaction/NN
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
the/DT
pathophysiology/NN
of/IN
inflammation/NN
and/CC
atherosclerosis/NN
./.
====================
The/DT
role/NN
of/IN
platelets/NNS
for/IN
monocyte/NN
chemotactic/JJ
protein-1/NN
(/(
MCP-1/NN
)/)
secretion/NN
and/CC
surface/NN
expression/NN
of/IN
intercellular/JJ
adhesion/NN
molecule-1/NN
(/(
ICAM-1/NN
)/)
on/IN
endothelial/JJ
cells/NNS
has/VBZ
been/VBN
assessed/VBN
./.
====================
METHODS/NNS
AND/CC
RESULTS/NNS
:/:
Monolayers/NNS
of/IN
human/JJ
umbilical/JJ
vein/NN
endothelial/JJ
cells/NNS
were/VBD
incubated/VBN
with/IN
nonstimulated/JJ
or/CC
ADP-activated/JJ
platelets/NNS
for/IN
6/CD
hours/NNS
,/,
and/CC
secretion/NN
of/IN
MCP-1/NN
and/CC
surface/NN
expression/NN
of/IN
ICAM-1/NN
were/VBD
determined/VBN
by/IN
ELISA/NN
and/CC
flow/NN
cytometry/NN
,/,
respectively/RB
./.
====================
In/IN
the/DT
presence/NN
of/IN
ADP-activated/JJ
platelets/NNS
,/,
both/CC
MCP-1/NN
secretion/NN
and/CC
ICAM-1/NN
surface/NN
expression/NN
were/VBD
significantly/RB
increased/VBN
compared/VBN
with/IN
nonstimulated/JJ
platelets/NNS
(/(
P/NN
</JJR
0.02/CD
)/)
./.
====================
Activation/NN
of/IN
the/DT
transcription/NN
factor/NN
nuclear/JJ
factor-kappaB/NN
(/(
NF-kappaB/NN
)/)
determined/VBN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
and/CC
kappaB-dependent/JJ
transcriptional/JJ
activity/NN
was/VBD
enhanced/VBN
in/IN
the/DT
presence/NN
of/IN
activated/VBN
platelets/NNS
./.
====================
In/IN
addition/NN
,/,
ADP-activated/JJ
platelets/NNS
induced/VBD
MCP-1/NN
and/CC
ICAM-1/NN
promoter-dependent/JJ
transcription/NN
./.
====================
Liposomal/JJ
transfection/NN
of/IN
a/DT
double-stranded/JJ
kappaB/NN
phosphorothioate/NN
oligonucleotide/NN
,/,
but/CC
not/RB
of/IN
the/DT
mutated/JJ
form/NN
,/,
inhibited/VBD
MCP-1/NN
secretion/NN
and/CC
surface/NN
expression/NN
of/IN
ICAM-1/NN
on/IN
activated/VBN
endothelium/NN
(/(
P/NN
</JJR
0.05/CD
)/)
./.
====================
CONCLUSIONS/NNS
:/:
The/DT
present/JJ
study/NN
indicates/VBZ
that/IN
activated/VBN
platelets/NNS
modulate/VBP
chemotactic/JJ
(/(
MCP-1/NN
)/)
and/CC
adhesive/JJ
(/(
ICAM-1/NN
)/)
properties/NNS
of/IN
endothelial/JJ
cells/NNS
via/IN
an/DT
NF-kappaB-dependent/JJ
mechanism/NN
./.
====================
Platelet-induced/JJ
activation/NN
of/IN
the/DT
NF-kappaB/NN
system/NN
might/MD
contribute/VB
to/TO
early/JJ
inflammatory/JJ
events/NNS
in/IN
atherogenesis/NN
./.
====================
UI/LS
-/:
98400423/CD
====================
TI/LS
-/:
Retinoid/NN
X/NN
receptor/NN
and/CC
c-cerbA/thyroid/NN
hormone/NN
receptor/NN
regulate/VBP
erythroid/JJ
cell/NN
growth/NN
and/CC
differentiation/NN
./.
====================
AB/LS
-/:
Nuclear/JJ
receptors/NNS
are/VBP
important/JJ
regulators/NNS
of/IN
erythroid/JJ
cell/NN
development/NN
./.
====================
Here/RB
we/PRP
investigated/VBD
the/DT
impact/NN
of/IN
retinoid/NN
X/NN
receptor/NN
(/(
RXR/NN
)/)
,/,
retinoic/JJ
acid/NN
receptor/NN
(/(
RAR/NN
)/)
,/,
and/CC
of/IN
the/DT
c-erbA/thyroid/NN
hormone/NN
(/(
T3/NN
)/)
receptor/NN
(/(
c-erbA/TR/NN
)/)
on/IN
growth/NN
and/CC
differentiation/NN
of/IN
erythroid/JJ
cells/NNS
using/VBG
an/DT
in/FW
vitro/FW
culture/NN
system/NN
of/IN
stem/NN
cell/NN
factor-dependent/JJ
erythroid/JJ
progenitors/NNS
./.
====================
RXR/NN
,/,
RAR/NN
,/,
and/CC
c-erbA/TR-specific/JJ
ligands/NNS
were/VBD
found/VBN
to/TO
induce/VB
erythroid-specific/JJ
gene/NN
expression/NN
and/CC
to/TO
accelerate/VB
erythroid/JJ
differentiation/NN
in/IN
culture/NN
,/,
with/IN
T3/NN
being/VBG
most/RBS
effective/JJ
./.
====================
Furthermore/RB
,/,
while/IN
ligand-activated/JJ
c-erbA/TR/NN
accelerated/VBD
differentiation/NN
,/,
unliganded/JJ
c-erbA/TR/NN
effectively/RB
blocked/VBD
differentiation/NN
and/CC
supported/VBD
sustained/JJ
progenitor/NN
growth/NN
in/IN
culture/NN
./.
====================
Thus/RB
,/,
c-erbA/TR/NN
appears/VBZ
to/TO
act/VB
as/IN
a/DT
binary/JJ
switch/NN
affecting/VBG
erythroid/JJ
cell/NN
fate/NN
:/:
unliganded/JJ
c-erbA/TR/NN
supports/VBZ
growth/NN
while/IN
ligand-activated/JJ
c-erbA/TR/NN
induces/VBZ
differentiation/NN
./.
====================
Additionally/RB
,/,
to/TO
determine/VB
the/DT
impact/NN
of/IN
RXR/NN
for/IN
erythroid/JJ
cell/NN
development/NN
,/,
dominant/JJ
interfering/VBG
mutant/JJ
RXRs/NNS
,/,
lacking/VBG
the/DT
transcriptional/JJ
activator/NN
functions/NNS
AF-1/NN
and/CC
AF-2/NN
,/,
or/CC
AF-2/NN
only/RB
,/,
or/CC
the/DT
entire/JJ
DNA-binding/JJ
domain/NN
,/,
were/VBD
introduced/VBN
into/IN
erythroid/JJ
progenitor/NN
cells/NNS
via/IN
recombinant/JJ
retrovirus/NN
vectors/NNS
and/CC
analyzed/VBN
for/IN
RXR-specific/JJ
effects/NNS
./.
====================
It/PRP
was/VBD
found/VBN
that/IN
expression/NN
of/IN
wild-type/JJ
RXR/NN
and/CC
of/IN
the/DT
RXR/NN
mutants/NNS
devoid/JJ
of/IN
AF-1/NN
and/or/CC
AF-2/NN
supported/VBD
a/DT
transient/JJ
outgrowth/NN
of/IN
erythroid/JJ
cells/NNS
./.
====================
In/IN
marked/JJ
contrast/NN
,/,
expression/NN
of/IN
the/DT
dominant/JJ
interfering/VBG
deltaDNA-binding/JJ
domain/NN
RXR/NN
,/,
containing/VBG
a/DT
deletion/NN
of/IN
the/DT
entire/JJ
DNA-binding/JJ
domain/NN
,/,
was/VBD
incompatible/JJ
with/IN
erythroid/JJ
cell/NN
growth/NN
in/FW
vitro/FW
,/,
suggesting/VBG
a/DT
pivotal/JJ
role/NN
of/IN
RXR/NN
for/IN
erythroid/JJ
cell/NN
development/NN
./.
====================
UI/LS
-/:
98389481/CD
====================
TI/LS
-/:
Peripheral/JJ
T/NN
lymphocytes/NNS
from/IN
women/NNS
with/IN
breast/NN
cancer/NN
exhibit/VBP
abnormal/JJ
protein/NN
expression/NN
of/IN
several/JJ
signaling/VBG
molecules/NNS
./.
====================
AB/LS
-/:
We/PRP
examined/VBD
signaling/VBG
molecules/NNS
of/IN
peripheral/JJ
blood/NN
T/NN
lymphocytes/NNS
obtained/VBN
from/IN
women/NNS
with/IN
breast/NN
cancer/NN
./.
====================
In/IN
6/CD
of/IN
14/CD
patients/NNS
,/,
T/NN
lymphocytes/NNS
displayed/VBD
an/DT
impaired/JJ
ability/NN
to/TO
translocate/VB
NFeB/NN
p65/NN
(/(
Rel-A/NN
)/)
following/VBG
activation/NN
by/IN
anti-CD3/NN
and/CC
IL-2/NN
./.
====================
This/DT
observation/NN
was/VBD
made/VBN
despite/IN
normal/JJ
cytoplasmic/JJ
levels/NNS
of/IN
the/DT
Rel-A/NN
protein/NN
./.
====================
We/PRP
also/RB
detected/VBD
abnormally/RB
low/JJ
levels/NNS
of/IN
the/DT
signaling/VBG
molecules/NNS
T-cell/NN
receptor/NN
(/(
TCR/NN
)/)
-zeta/NN
,/,
ZAP-70/NN
and/CC
p56lck/NN
in/IN
4/CD
of/IN
14/CD
breast/NN
cancer/NN
patients/NNS
,/,
i.e./FW
,/,
defects/NNS
in/IN
T-cell/NN
signaling/VBG
molecules/NNS
./.
====================
T/NN
lymphocytes/NNS
from/IN
6/CD
of/IN
the/DT
14/CD
patients/NNS
also/RB
exhibited/VBD
an/DT
increased/VBN
expression/NN
of/IN
the/DT
dual/JJ
specificity/NN
phosphatase/NN
,/,
map/NN
kinase/NN
phosphatase-1/NN
(/(
MKP-1/NN
)/)
./.
====================
MKP-1/NN
inactivates/VBZ
MAP/NN
kinase/NN
and/CC
therefore/RB
may/MD
interfere/VB
with/IN
the/DT
activation/NN
of/IN
c-jun/NN
and/CC
c-fos/NN
./.
====================
Abnormalities/NNS
of/IN
I/CD
or/CC
more/RBR
signaling/VBG
molecules/NNS
were/VBD
found/VBN
in/IN
9/CD
of/IN
14/CD
patients/NNS
;/:
however/RB
,/,
only/RB
3/CD
patients/NNS
had/VBD
T/NN
cells/NNS
that/WDT
exhibited/VBD
all/DT
5/CD
defects/NNS
./.
====================
Our/PRP$
data/NNS
have/VBP
implications/NNS
for/IN
the/DT
detection/NN
of/IN
potentially/RB
dysfunctional/JJ
T/NN
cells/NNS
in/IN
patients/NNS
with/IN
cancer/NN
./.
====================
For/IN
example/NN
,/,
the/DT
analysis/NN
of/IN
only/RB
1/CD
signaling/VBG
molecule/NN
may/MD
allow/VB
patients/NNS
with/IN
significant/JJ
defects/NNS
in/IN
T-cell/NN
signaling/NN
to/TO
go/VB
unnoticed/JJ
./.
====================
Finally/RB
,/,
despite/IN
impaired/JJ
Rel-A/NN
translocation/NN
,/,
T/NN
cells/NNS
were/VBD
capable/JJ
of/IN
transcribing/VBG
IL-2/NN
./.
====================
Impairments/NNS
in/IN
the/DT
translocation/NN
of/IN
Rel-B/NN
and/CC
c-Rel/NN
further/RB
suggest/VBP
that/IN
the/DT
NFKB/NN
family/NN
members/NNS
Rel-A/NN
,/,
Rel-B/NN
and/CC
c-Rel/NN
are/VBP
not/RB
required/VBN
for/IN
the/DT
transcription/NN
of/IN
IL-2/NN
in/IN
the/DT
peripheral/JJ
T/NN
lymphocytes/NNS
of/IN
patients/NNS
with/IN
breast/NN
cancer/NN
./.
====================
UI/LS
-/:
98379823/CD
====================
TI/LS
-/:
Specific/JJ
glucocorticoid/NN
binding/NN
at/IN
different/JJ
levels/NNS
of/IN
human/JJ
motor/NN
activity/NN
./.
====================
AB/LS
-/:
We/PRP
studied/VBD
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
and/CC
dissociation/NN
constant/NN
in/IN
isolated/VBN
human/JJ
lymphocytes/NNS
as/RB
well/RB
as/IN
blood/NN
concentrations/NNS
of/IN
hormones/NNS
produced/VBN
by/IN
the/DT
hypothalamic-hypophyseal-adrenocortical/JJ
system/NN
in/IN
three/CD
experimental/JJ
series/NNS
:/:
at/IN
normal/JJ
(/(
17/CD
subjects/NNS
)/)
,/,
decreased/VBN
(/(
10/CD
subjects/NNS
,/,
a/DT
360-d/JJ
head-down/JJ
bed/NN
rest/NN
)/)
and/CC
increased/VBN
(/(
8/CD
subjects/NNS
,/,
physical/JJ
exercise/NN
on/IN
bicycle/NN
ergometer/NN
)/)
levels/NNS
of/IN
motor/NN
activity/NN
./.
====================
In/IN
the/DT
first/JJ
series/NN
we/PRP
found/VBD
that/IN
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
and/CC
dissociation/NN
constant/NN
did/VBD
not/RB
depend/VB
on/IN
the/DT
season/NN
,/,
on/IN
the/DT
age/NN
of/IN
subjects/NNS
nor/CC
on/IN
cortisol/NN
concentrations/NNS
in/IN
blood/NN
./.
====================
In/IN
the/DT
second/JJ
series/NN
we/PRP
observed/VBD
the/DT
following/NN
:/:
at/IN
the/DT
end/NN
of/IN
the/DT
first/JJ
month/NN
of/IN
bed/NN
rest/NN
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
and/CC
receptor/NN
affinity/NN
significantly/RB
increased/VBD
;/:
at/IN
the/DT
beginning/NN
of/IN
the/DT
third/JJ
month/NN
of/IN
bed/NN
rest/NN
specific/JJ
glucocorticoid/NN
binding/NN
significantly/RB
decreased/VBD
and/CC
circadian/JJ
rhythms/NNS
of/IN
adrenocorticotropin/NN
and/CC
cortisol/NN
in/IN
blood/NN
varied/VBD
markedly/RB
;/:
at/IN
the/DT
end/NN
of/IN
the/DT
sixth/JJ
month/NN
of/IN
bed/NN
rest/NN
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
returned/VBD
to/TO
prebed/JJ
rest/NN
levels/NNS
and/CC
dissociation/NN
constant/NN
decreased/VBD
./.
====================
In/IN
the/DT
third/JJ
series/NN
physical/JJ
exercises/NNS
that/WDT
induced/VBD
an/DT
activation/NN
of/IN
the/DT
hypothalamic-hypophyseal-adrenocortical/JJ
system/NN
(/(
maximal/JJ
physical/JJ
exercises/NNS
and/CC
prolonged/JJ
submaximal/JJ
exercises/NNS
at/IN
70/CD
%/NN
of/IN
maximal/JJ
oxygen/NN
uptake/NN
)/)
led/VBD
to/TO
a/DT
significant/JJ
increase/NN
in/IN
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
without/IN
changes/NNS
of/IN
dissociation/NN
constant/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
both/CC
a/DT
decrease/NN
and/CC
an/DT
increase/NN
of/IN
human/JJ
motor/NN
activity/NN
resulted/VBD
in/IN
significant/JJ
changes/NNS
of/IN
specific/JJ
glucocorticoid/NN
binding/NN
which/WDT
were/VBD
not/RB
influenced/VBN
by/IN
changes/NNS
of/IN
circulating/VBG
hormone/NN
concentrations/NNS
in/IN
blood/NN
but/CC
by/IN
some/DT
other/JJ
factors/NNS
affected/VBN
by/IN
physical/JJ
activity/NN
./.
====================
UI/LS
-/:
98378510/CD
====================
TI/LS
-/:
The/DT
small/JJ
GTP-binding/JJ
protein/NN
Rho/NN
potentiates/VBZ
AP-1/NN
transcription/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
Rho/NN
family/NN
of/IN
small/JJ
GTP-binding/JJ
proteins/NNS
is/VBZ
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
cytoskeletal/JJ
structure/NN
,/,
gene/NN
transcription/NN
,/,
specific/JJ
cell/NN
fate/NN
development/NN
,/,
and/CC
transformation/NN
./.
====================
We/PRP
demonstrate/VBP
in/IN
this/DT
report/NN
that/IN
overexpression/NN
of/IN
an/DT
activated/JJ
form/NN
of/IN
Rho/NN
enhances/VBZ
AP-1/NN
activity/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
in/IN
the/DT
presence/NN
of/IN
phorbol/NN
myristate/NN
acetate/NN
(/(
PMA/NN
)/)
,/,
but/CC
activated/VBN
Rho/NN
(/(
V14Rho/NN
)/)
has/VBZ
little/JJ
or/CC
no/DT
effect/NN
on/IN
NFAT/NN
,/,
Oct-1/NN
,/,
and/CC
NF-kappaB/NN
enhancer/NN
element/NN
activities/NNS
under/IN
similar/JJ
conditions/NNS
./.
====================
Overexpression/NN
of/IN
a/DT
V14Rho/NN
construct/NN
incapable/JJ
of/IN
membrane/NN
localization/NN
(/(
CAAX/NN
deleted/VBN
)/)
abolishes/VBZ
PMA-induced/JJ
AP-1/NN
transcriptional/JJ
activation/NN
./.
====================
The/DT
effect/NN
of/IN
Rho/NN
on/IN
AP-1/NN
is/VBZ
independent/JJ
of/IN
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
pathway/NN
,/,
as/IN
a/DT
dominant-negative/JJ
MEK/NN
and/CC
a/DT
MEK/NN
inhibitor/NN
(/(
PD98059/NN
)/)
did/VBD
not/RB
affect/VB
Rho-induced/JJ
AP-1/NN
activity/NN
./.
====================
V14Rho/NN
binds/VBZ
strongly/RB
to/TO
protein/NN
kinase/NN
Calpha/NN
(/(
PKCalpha/NN
)/)
in/FW
vivo/FW
;/:
however/RB
,/,
deletion/NN
of/IN
the/DT
CAAX/NN
site/NN
on/IN
V14Rho/NN
severely/RB
diminished/VBD
this/DT
association/NN
./.
====================
Evidence/NN
for/IN
a/DT
role/NN
for/IN
PKCalpha/NN
as/IN
an/DT
effector/NN
of/IN
Rho/NN
was/VBD
obtained/VBN
by/IN
the/DT
observation/NN
that/IN
coexpression/NN
of/IN
the/DT
N-terminal/JJ
domain/NN
of/IN
PKCalpha/NN
blocked/VBD
the/DT
effects/NNS
of/IN
activated/VBN
Rho/NN
plus/CC
PMA/NN
on/IN
AP-1/NN
transcriptional/JJ
activity/NN
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
Rho/NN
potentiates/VBZ
AP-1/NN
transcription/NN
during/IN
T-cell/NN
activation/NN
====================
UI/LS
-/:
98365377/CD
====================
TI/LS
-/:
Changes/NNS
in/IN
PKC/NN
isoforms/NNS
in/IN
human/JJ
alveolar/JJ
macrophages/NNS
compared/VBN
with/IN
blood/NN
monocytes/NNS
./.
====================
AB/LS
-/:
Alveolar/JJ
macrophages/NNS
play/VBP
an/DT
important/JJ
role/NN
in/IN
host/NN
defense/NN
and/CC
in/IN
other/JJ
types/NNS
of/IN
inflammatory/JJ
processes/NNS
in/IN
the/DT
lung/NN
./.
====================
These/DT
cells/NNS
exhibit/VBP
many/JJ
alterations/NNS
in/IN
function/NN
compared/VBN
with/IN
their/PRP$
precursor/NN
cells/NNS
,/,
blood/NN
monocytes/NNS
./.
====================
To/TO
evaluate/VB
a/DT
potential/JJ
mechanism/NN
for/IN
these/DT
differences/NNS
in/IN
function/NN
,/,
we/PRP
evaluated/VBD
expression/NN
of/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
isoforms/NNS
./.
====================
We/PRP
found/VBD
an/DT
increase/NN
in/IN
Ca2+-dependent/JJ
PKC/NN
isoforms/NNS
in/IN
monocytes/NNS
compared/VBN
with/IN
alveolar/JJ
macrophages/NNS
./.
====================
We/PRP
also/RB
found/VBD
differential/JJ
expression/NN
of/IN
the/DT
Ca2+-independent/JJ
isoforms/NNS
in/IN
alveolar/JJ
macrophages/NNS
compared/VBN
with/IN
monocytes/NNS
./.
====================
One/CD
consequence/NN
of/IN
the/DT
activation/NN
of/IN
PKC/NN
can/MD
be/VB
increased/VBN
expression/NN
of/IN
mitogen-activated/JJ
protein/NN
(/(
MAP/NN
)/)
kinase/NN
pathways/NNS
./.
====================
Therefore/RB
,/,
we/PRP
also/RB
evaluated/VBD
activation/NN
of/IN
the/DT
MAP/NN
kinase/NN
extracellular/JJ
signal-regulated/JJ
kinase/NN
(/(
ERK/NN
)/)
2/CD
by/IN
the/DT
phorbol/NN
ester/NN
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
./.
====================
PMA/NN
activated/JJ
ERK2/NN
kinase/NN
in/IN
both/CC
alveolar/JJ
macrophages/NNS
and/CC
monocytes/NNS
;/:
however/RB
,/,
monocytes/NNS
consistently/RB
showed/VBD
a/DT
significantly/RB
greater/JJR
activation/NN
of/IN
ERK2/NN
kinase/NN
by/IN
PMA/NN
compared/VBN
with/IN
alveolar/JJ
macrophages/NNS
./.
====================
Another/DT
known/JJ
consequence/NN
of/IN
the/DT
activation/NN
of/IN
PKC/NN
and/CC
subsequent/JJ
activation/NN
of/IN
ERK/NN
kinase/NN
is/VBZ
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
activator/NN
protein-1/NN
(/(
AP-1/NN
)/)
./.
====================
We/PRP
evaluated/VBD
the/DT
activation/NN
of/IN
AP-1/NN
by/IN
PMA/NN
in/IN
both/CC
monocytes/NNS
and/CC
macrophages/NNS
./.
====================
We/PRP
found/VBD
very/RB
little/JJ
detectable/JJ
activation/NN
of/IN
AP-1/NN
,/,
as/IN
assessed/VBN
in/IN
a/DT
gel/NN
shift/NN
assay/NN
,/,
in/IN
alveolar/JJ
macrophages/NNS
,/,
whereas/IN
monocytes/NNS
showed/VBD
a/DT
substantial/JJ
activation/NN
of/IN
AP-1/NN
by/IN
PMA/NN
./.
====================
These/DT
studies/NNS
show/VBP
that/IN
the/DT
differential/JJ
expression/NN
of/IN
PKC/NN
isoforms/NNS
in/IN
alveolar/JJ
macrophages/NNS
and/CC
blood/NN
monocytes/NNS
is/VBZ
associated/VBN
with/IN
important/JJ
functional/JJ
alterations/NNS
in/IN
the/DT
cells/NNS
./.
====================
UI/LS
-/:
98353227/CD
====================
TI/LS
-/:
Expression/NN
of/IN
gamma-IFN/NN
responsive/JJ
genes/NNS
in/IN
scavenger/NN
receptor/NN
over-expressing/NN
monocytes/NNS
is/VBZ
associated/VBN
with/IN
xanthomatosis/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
recently/RB
described/VBN
an/DT
inherited/VBN
over-expression/NN
of/IN
the/DT
macrophage/NN
scavenger/NN
receptor/NN
(/(
SR/NN
)/)
in/IN
blood/NN
monocytes/NNS
from/IN
members/NNS
of/IN
a/DT
kindred/NN
,/,
only/RB
two/CD
of/IN
whom/WP
displayed/VBD
extensive/JJ
xanthomatosis/NN
./.
====================
Using/VBG
mRNA/NN
differential/JJ
display/NN
we/PRP
demonstrated/VBD
abnormally/RB
high/JJ
expression/NN
of/IN
the/DT
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
(/(
STAT1alpha/NN
)/)
in/IN
monocytes/NNS
from/IN
the/DT
proband/NN
II-2/NN|CD
./.
====================
Expression/NN
of/IN
gamma-interferon/NN
inducible/JJ
protein/NN
10/CD
(/(
IP-10/NN
)/)
,/,
a/DT
STAT1alpha-responsive/JJ
gene/NN
and/CC
mediator/NN
of/IN
inflammatory/JJ
response/NN
,/,
was/VBD
also/RB
abnormally/RB
expressed/VBN
in/IN
the/DT
monocytes/NNS
from/IN
II-2/NN|CD
./.
====================
Over-expression/NN
of/IN
both/DT
genes/NNS
was/VBD
restricted/JJ
to/TO
monocytes/NNS
from/IN
II-2/NN|CD
and/CC
was/VBD
not/RB
observed/VBN
in/IN
monocytes/NNS
from/IN
the/DT
clinically/RB
unaffected/JJ
family/NN
members/NNS
,/,
unlike/IN
that/DT
of/IN
SR/NN
./.
====================
Gel/NN
retardation/NN
assays/NNS
with/IN
THP-1/NN
cell/NN
extracts/NNS
identified/VBD
gamma-IFN/NN
inducible/JJ
DNA/NN
binding/NN
activity/NN
to/TO
three/CD
potential/JJ
STATI/NN
DNA/NN
binding/NN
elements/NNS
in/IN
the/DT
human/JJ
IP-10/NN
promoter/NN
region/NN
from/IN
nucleotides/NNS
- 245/CD
to/TO
- 188/CD
./.
====================
Taken/VBN
together/RB
these/DT
results/NNS
suggest/VBP
that/IN
gamma-interferon/NN
mediated/VBD
cell/NN
activation/NN
is/VBZ
responsible/JJ
for/IN
STAT1alpha-induced/JJ
transcription/NN
of/IN
the/DT
IP-10/NN
gene/NN
in/IN
THP-1/NN
macrophages/NNS
as/RB
well/RB
as/IN
in/IN
monocytes/NNS
from/IN
II-2/NN|CD
./.
====================
Analysis/NN
of/IN
monocytes/NNS
from/IN
familial/JJ
hypercholesterolemic/JJ
(/(
FH/NN
)/)
subjects/NNS
,/,
who/WP
frequently/RB
develop/VBP
xanthomatosis/NN
,/,
revealed/VBD
a/DT
significant/JJ
number/NN
of/IN
subjects/NNS
with/IN
elevated/JJ
STAT1alpha/NN
and/CC
IP-10/NN
expression/NN
./.
====================
Our/PRP$
data/NNS
suggest/VBP
that/IN
the/DT
inflammatory/JJ
effects/NNS
of/IN
gamma-IFN/NN
signaling/NN
could/MD
play/VB
a/DT
role/NN
in/IN
foam/NN
cell/NN
formation/NN
and/CC
xanthomatosis/NN
./.
====================
UI/LS
-/:
98343775/CD
====================
TI/LS
-/:
Redox/NN
signals/NNS
and/CC
NF-kappaB/NN
activation/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Accumulating/JJ
data/NNS
from/IN
a/DT
number/NN
of/IN
laboratories/NNS
have/VBP
recently/RB
indicated/VBN
that/IN
the/DT
response/NN
of/IN
transcription/NN
factor/NN
NF-kappaB/NN
to/TO
alterations/NNS
in/IN
the/DT
redox/NN
homeostasis/NN
of/IN
cells/NNS
may/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
modulating/VBG
immune/JJ
function/NN
./.
====================
The/DT
activation/NN
of/IN
NF-kappaB/NN
has/VBZ
been/VBN
recognized/VBN
to/TO
regulate/VB
a/DT
number/NN
of/IN
genes/NNS
necessary/JJ
for/IN
normal/JJ
T/NN
cell/NN
responses/NNS
including/VBG
IL-2/NN
,/,
IL-6/NN
,/,
IL-8/NN
,/,
and/CC
several/JJ
T/NN
cell/NN
surface/NN
receptors/NNS
./.
====================
Diminished/JJ
NF-kappaB/NN
activity/NN
has/VBZ
been/VBN
shown/VBN
to/TO
occur/VB
in/IN
T/NN
cells/NNS
with/IN
aging/NN
,/,
suggesting/VBG
that/IN
impaired/JJ
activation/NN
of/IN
NF-kappaB/NN
might/MD
occur/VB
during/IN
cellular/JJ
senescence/NN
./.
====================
In/IN
addition/NN
,/,
aberrancies/NNS
in/IN
NF-kappaB/NN
activity/NN
have/VBP
been/VBN
implicated/VBN
in/IN
the/DT
immunopathogenesis/NN
of/IN
diseases/NNS
involving/VBG
immune/JJ
or/CC
inflammatory/JJ
processes/NNS
such/JJ
as/IN
atherosclerosis/NN
and/CC
HIV-1/NN
infection/NN
./.
====================
The/DT
role/NN
of/IN
H2O2/NN
and/CC
other/JJ
reactive/JJ
oxygen/NN
species/NNS
(/(
ROS/NN
)/)
as/IN
an/DT
integratory/JJ
secondary/JJ
messenger/NN
for/IN
divergent/JJ
T/NN
cell/NN
signals/NNS
has/VBZ
been/VBN
complicated/VBN
by/IN
the/DT
fact/NN
that/IN
various/JJ
T/NN
cell/NN
lines/NNS
and/CC
peripheral/JJ
blood/NN
T/NN
cells/NNS
differ/VBP
markedly/RB
in/IN
the/DT
levels/NNS
of/IN
NF-kappaB/NN
activation/NN
induced/VBN
by/IN
oxidant/JJ
stress/NN
./.
====================
Additionally/RB
,/,
proposed/JJ
pathways/NNS
of/IN
NF-kappaB/NN
activation/NN
have/VBP
been/VBN
based/VBN
on/IN
indirect/JJ
evidence/NN
provided/VBN
by/IN
experiments/NNS
which/WDT
used/VBD
antioxidants/NNS
to/TO
inhibit/VB
active/JJ
NF-kappaB/NN
formation/NN
./.
====================
Further/RB
,/,
complete/JJ
activation/NN
of/IN
T/NN
cells/NNS
requires/VBZ
at/IN
least/JJS
two/CD
signals/NNS
,/,
one/CD
that/IN
stimulates/VBZ
an/DT
increase/NN
in/IN
intracellular/JJ
calcium/NN
and/CC
one/CD
that/WDT
stimulates/VBZ
enzymatic/JJ
processes/NNS
including/VBG
kinases/NNS
./.
====================
Similarly/RB
,/,
substantial/JJ
evidence/NN
indicates/VBZ
that/IN
full/JJ
activation/NN
of/IN
NF-kappaB/NN
requires/VBZ
dual/JJ
signals/NNS
./.
====================
The/DT
ability/NN
of/IN
H2O2/NN
or/CC
other/JJ
ROS/NN
to/TO
induce/VB
T/NN
cell/NN
signals/NNS
and/CC
functional/JJ
responses/NNS
by/IN
these/DT
two/CD
mechanisms/NNS
is/VBZ
reviewed/VBN
and/CC
the/DT
specific/JJ
response/NN
of/IN
NF-kappaB/NN
to/TO
redox/NN
changes/NNS
in/IN
T/NN
cells/NNS
is/VBZ
examined/VBN
./.
====================
Data/NNS
are/VBP
also/RB
presented/VBN
to/TO
suggest/VB
that/IN
the/DT
redox/NN
regulation/NN
in/IN
NF-kappaB/NN
activation/NN
may/MD
be/VB
relevant/JJ
to/TO
immune-related/JJ
diseases/NNS
and/CC
to/TO
aging/NN
./.
====================
UI/LS
-/:
98332778/CD
====================
TI/LS
-/:
Uncoupling/NN
of/IN
nonreceptor/JJ
tyrosine/NN
kinases/NNS
from/IN
PLC-gamma1/NN
in/IN
an/DT
SLP-76-deficient/JJ
T/NN
cell/NN
./.
====================
AB/LS
-/:
Activation/NN
of/IN
nonreceptor/JJ
protein/NN
tyrosine/NN
kinases/NNS
(/(
PTKs/NN
)/)
is/VBZ
essential/JJ
for/IN
T/NN
cell/NN
receptor/NN
(/(
TCR/NN
)/)
responsiveness/NN
;/:
however/RB
,/,
the/DT
function/NN
of/IN
individual/JJ
PTK/NN
substrates/NNS
is/VBZ
often/RB
uncertain/JJ
./.
====================
A/DT
mutant/JJ
T/NN
cell/NN
line/NN
was/VBD
isolated/VBN
that/WDT
lacked/VBD
expression/NN
of/IN
SLP-76/NN
(/(
SH2/NN
domain-containing/JJ
leukocyte/NN
protein/NN
of/IN
76/CD
kilodaltons/NNS
)/)
,/,
a/DT
hematopoietically/RB
expressed/VBN
adaptor/NN
protein/NN
and/CC
PTK/NN
substrate/NN
./.
====================
SLP-76/NN
was/VBD
not/RB
required/VBN
for/IN
TCR-induced/JJ
tyrosine/NN
phosphorylation/NN
of/IN
most/JJS
proteins/NNS
,/,
but/CC
was/VBD
required/VBN
for/IN
optimal/JJ
tyrosine/NN
phosphorylation/NN
and/CC
activation/NN
of/IN
phospholipase/NN
C-gamma1/NN
(/(
PLC-gamma1/NN
)/)
,/,
as/RB
well/RB
as/IN
Ras/NN
pathway/NN
activation/NN
./.
====================
TCR-inducible/JJ
gene/NN
expression/NN
was/VBD
dependent/JJ
on/IN
SLP-76/NN
./.
====================
Thus/RB
,/,
coupling/NN
of/IN
TCR-regulated/JJ
PTKs/NN
to/TO
downstream/JJ
signaling/NN
pathways/NNS
requires/VBZ
SLP-76/NN
./.
====================
UI/LS
-/:
98322151/CD
====================
TI/LS
-/:
A/DT
novel/JJ
function/NN
of/IN
Stat1/NN
and/CC
Stat3/NN
proteins/NNS
in/IN
erythropoietin-induced/JJ
erythroid/JJ
differentiation/NN
of/IN
a/DT
human/JJ
leukemia/NN
cell/NN
line/NN
./.
====================
AB/LS
-/:
We/PRP
recently/RB
determined/VBD
that/IN
erythropoietin/NN
(/(
EPO/NN
)/)
activates/VBZ
3/CD
members/NNS
of/IN
the/DT
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
(/(
STAT/NN
)/)
family/NN
,/,
Stat1alpha/NN
,/,
Stat3/NN
,/,
and/CC
Stat5/NN
,/,
in/IN
the/DT
human/JJ
EPO-dependent/JJ
cell/NN
lines/NNS
,/,
UT-7/NN
and/CC
UT-7/EPO/NN
(/(
Kirito/NNP
et/FW
al/FW
,/,
J/NNP
Biol/NNP
Chem/NNP
272/CD
:/:
16507/CD
,/,
1997/CD
)/)
./.
====================
In/IN
addition/NN
,/,
we/PRP
have/VBP
shown/VBN
that/IN
Stat1alpha/NN
,/,
but/CC
not/RB
Stat3/NN
,/,
is/VBZ
involved/VBN
in/IN
EPO-induced/JJ
cellular/JJ
proliferation/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
examined/VBD
the/DT
roles/NNS
of/IN
Stat1alpha/NN
and/CC
Stat3/NN
in/IN
EPO-induced/JJ
erythroid/JJ
differentiation/NN
./.
====================
UT-7/GM/NN
was/VBD
used/VBN
as/IN
a/DT
model/NN
system/NN
,/,
because/IN
this/DT
cell/NN
line/NN
can/MD
differentiate/VB
into/IN
erythroid-lineage/JJ
cells/NNS
with/IN
EPO/NN
treatment/NN
(/(
Komatsu/NN
et/FW
al/FW
,/,
Blood/NNP
89/CD
:/:
4021/CD
,/,
1997/CD
)/)
./.
====================
We/PRP
found/VBD
that/IN
EPO/NN
did/VBD
not/RB
activate/VB
Stat1alpha/NN
or/CC
Stat3/NN
in/IN
UT-7/GM/NN
cells/NNS
./.
====================
Transfection/NN
experiments/NNS
showed/VBD
that/IN
both/CC
Stat1alpha/NN
and/CC
Stat3/NN
inhibited/VBD
the/DT
induction/NN
by/IN
EPO/NN
of/IN
gamma-globin/NN
and/CC
erythroid-specific/JJ
5-aminolevulinate/JJ
synthetase/NN
transcripts/NNS
,/,
resulting/VBG
in/IN
a/DT
reduction/NN
of/IN
the/DT
percentage/NN
of/IN
hemoglobin-positive/JJ
cells/NNS
./.
====================
Dominant/JJ
negative/JJ
forms/NNS
of/IN
Stat1alpha/NN
or/CC
Stat3/NN
promoted/VBD
the/DT
EPO-induced/JJ
erythroid/JJ
differentiation/NN
of/IN
UT-7/GM/NN
cells/NNS
,/,
even/RB
in/IN
the/DT
presence/NN
of/IN
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
,/,
although/IN
this/DT
cytokine/NN
never/RB
induced/VBD
erythroid/JJ
differentiation/NN
of/IN
the/DT
parent/JJ
UT-7/GM/NN
cells/NNS
with/IN
or/CC
without/IN
EPO/NN
./.
====================
A/DT
cell/NN
cycle/NN
analysis/NN
showed/VBD
that/IN
the/DT
constitutive/JJ
activation/NN
of/IN
Stat1alpha/NN
,/,
but/CC
not/RB
Stat3/NN
,/,
shortened/VBD
the/DT
period/NN
of/IN
G0/G1/NN
prolongation/NN
caused/VBN
by/IN
EPO/NN
stimulation/NN
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
data/NNS
suggest/VBP
that/IN
Stat1alpha/NN
and/CC
Stat3/NN
act/VBP
as/IN
negative/JJ
regulators/NNS
in/IN
EPO-induced/JJ
erythroid/JJ
differentiation/NN
./.
====================
Specifically/RB
,/,
Stat1alpha/NN
may/MD
activate/VB
a/DT
cell/NN
cycle-associated/JJ
gene/NN
(/(
s/NNS
)/)
,/,
leading/VBG
to/TO
the/DT
entry/NN
of/IN
cells/NNS
into/IN
the/DT
cell/NN
cycle/NN
./.
====================
UI/LS
-/:
98313295/CD
====================
TI/LS
-/:
Ro/NN
09-2210/CD
exhibits/VBZ
potent/JJ
anti-proliferative/JJ
effects/NNS
on/IN
activated/VBN
T/NN
cells/NNS
by/IN
selectively/RB
blocking/VBG
MKK/NN
activity/NN
./.
====================
AB/LS
-/:
By/IN
using/VBG
high/JJ
throughput/NN
screening/NN
of/IN
microbial/JJ
broths/NNS
,/,
we/PRP
have/VBP
identified/VBN
a/DT
compound/NN
,/,
designated/VBN
Ro/NN
09-2210/CD
,/,
which/WDT
is/VBZ
able/JJ
to/TO
block/VB
anti-CD3/JJ
induced/JJ
peripheral/JJ
blood/NN
T/NN
cell/NN
activation/NN
with/IN
an/DT
IC50/NN
=/JJ
40/CD
nM/NN
./.
====================
Ro/NN
09-2210/CD
was/VBD
also/RB
able/JJ
to/TO
block/VB
antigen-induced/JJ
IL-2/NN
secretion/NN
with/IN
an/DT
IC50/NN
=/JJ
30/CD
nM/NN
,/,
but/CC
was/VBD
considerably/RB
less/RBR
potent/JJ
at/IN
blocking/VBG
Ca2+/NN
flux/NN
stimulated/VBN
by/IN
anti-CD3/JJ
treatment/NN
./.
====================
To/TO
determine/VB
the/DT
mechanism/NN
of/IN
action/NN
of/IN
Ro/NN
09-2210/CD
,/,
we/PRP
set/VBD
up/IN
a/DT
transient/JJ
expression/NN
system/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
using/VBG
a/DT
variety/NN
of/IN
reporter/NN
gene/NN
constructs/NNS
and/CC
showed/VBD
effective/JJ
inhibition/NN
of/IN
phorbol/NN
ester/ionomycin-induced/JJ
NF-AT/NN
activation/NN
and/CC
anti-CD3/NN
induced/VBD
NF-AT/NN
with/IN
IC50/NN
=/JJ
7.7/CD
and/CC
10/CD
nM/NN
,/,
respectively/RB
./.
====================
Ro/NN
09-2210/CD
was/VBD
also/RB
able/JJ
to/TO
inhibit/VB
phorbol/NN
ester/ionomycin-induced/JJ
activation/NN
of/IN
AP1/NN
with/IN
IC50/NN
=/JJ
</JJR
10/CD
nM/NN
./.
====================
We/PRP
further/RB
showed/VBD
that/IN
Ro/NN
09-2210/CD
was/VBD
unable/JJ
to/TO
inhibit/VB
c-jun/NN
induced/JJ
expression/NN
of/IN
AP1-dependent/JJ
reporter/NN
constructs/NNS
(/(
IC50/NN
>/JJR
500/CD
nM/NN
)/)
,/,
but/CC
was/VBD
able/JJ
to/TO
potently/RB
inhibit/VB
ras-induced/JJ
AP1/NN
activation/NN
(/(
IC50/NN
=/JJ
20/CD
nM/NN
)/)
./.
====================
This/DT
suggested/VBD
that/IN
Ro/NN
09-2210/CD
was/VBD
inhibiting/VBG
an/DT
activator/NN
of/IN
AP-1/NN
which/WDT
was/VBD
upstream/JJ
of/IN
c-jun/NN
and/CC
downstream/RB
of/IN
ras/NN
signaling/NN
./.
====================
To/TO
investigate/VB
further/RB
,/,
we/PRP
then/RB
purified/VBN
a/DT
number/NN
of/IN
different/JJ
kinases/NNS
,/,
including/VBG
PKC/NN
,/,
PhK/NN
,/,
ZAP-70/NN
,/,
ERK/NN
,/,
and/CC
MEK/NN
1/CD
(/(
a/NN|DT
MKK/NN
)/)
,/,
and/CC
showed/VBD
that/IN
Ro/NN
09-2210/CD
was/VBD
a/DT
selective/JJ
inhibitor/NN
of/IN
MEK1/NN
in/FW
vitro/FW
(/(
IC50/NN
=/JJ
59/CD
nM/NN
)/)
./.
====================
UI/LS
-/:
98298224/CD
====================
TI/LS
-/:
Coactivation/NN
by/IN
OCA-B/NN
:/:
definition/NN
of/IN
critical/JJ
regions/NNS
and/CC
synergism/NN
with/IN
general/JJ
cofactors/NNS
./.
====================
AB/LS
-/:
Molecular/JJ
dissection/NN
of/IN
the/DT
B-cell-specific/JJ
transcription/NN
coactivator/NN
OCA-B/NN
has/VBZ
revealed/VBN
distinct/JJ
regions/NNS
important/JJ
,/,
respectively/RB
,/,
for/IN
recruitment/NN
to/TO
immunoglobulin/NN
promoters/NNS
through/IN
interaction/NN
with/IN
octamer-bound/JJ
Oct-1/NN
and/CC
for/IN
subsequent/JJ
coactivator/NN
function/NN
./.
====================
Further/JJ
analysis/NN
of/IN
general/JJ
coactivator/NN
requirements/NNS
showed/VBD
that/IN
selective/JJ
removal/NN
of/IN
PC4/NN
from/IN
the/DT
essential/JJ
USA/NN
fraction/NN
severely/RB
impairs/VBZ
Oct-1/NN
and/CC
OCA-B/NN
function/NN
in/IN
a/DT
cell-free/JJ
system/NN
reconstituted/VBN
with/IN
partially/RB
purified/VBN
factors/NNS
./.
====================
Full/JJ
activity/NN
can/MD
be/VB
restored/VBN
by/IN
the/DT
combined/JJ
action/NN
of/IN
recombinant/JJ
PC4/NN
and/CC
the/DT
PC4-depleted/JJ
USA/NN
fraction/NN
,/,
thus/RB
suggesting/VBG
a/DT
joint/NN
requirement/NN
for/IN
PC4/NN
and/CC
another/DT
,/,
USA-derived/JJ
component/NN
(/(
s/NNS
)/)
for/IN
optimal/JJ
function/NN
of/IN
Oct-1/OCA-B/NN
in/IN
the/DT
reconstituted/JJ
system/NN
./.
====================
Indeed/RB
,/,
USA-derived/JJ
PC2/NN
was/VBD
found/VBN
to/TO
act/VB
synergistically/RB
with/IN
PC4/NN
in/IN
reproducing/VBG
the/DT
function/NN
of/IN
intact/JJ
USA/NN
in/IN
the/DT
assay/NN
system/NN
./.
====================
Consistent/JJ
with/IN
the/DT
requirement/NN
for/IN
PC4/NN
in/IN
the/DT
reconstituted/JJ
system/NN
,/,
OCA-B/NN
was/VBD
found/VBN
to/TO
interact/VB
directly/RB
with/IN
PC4/NN
./.
====================
Surprisingly/RB
,/,
however/RB
,/,
removal/NN
of/IN
PC4/NN
from/IN
the/DT
unfractionated/JJ
nuclear/JJ
extract/NN
has/VBZ
no/DT
detrimental/JJ
effect/NN
on/IN
OCA-B/Oct-1-dependent/JJ
transcription/NN
./.
====================
These/DT
results/NNS
lead/VBP
to/TO
a/DT
general/JJ
model/NN
for/IN
the/DT
synergistic/JJ
function/NN
of/IN
activation/NN
domains/NNS
in/IN
Oct-1/NN
and/CC
OCA-B/NN
(/(
mediated/VBN
by/IN
the/DT
combined/JJ
action/NN
of/IN
the/DT
multiple/JJ
USA/NN
components/NNS
)/)
and/CC
,/,
further/RB
,/,
suggest/VBP
a/DT
functional/JJ
redundancy/NN
in/IN
general/JJ
coactivators/NNS
./.
====================
UI/LS
-/:
98241397/CD
====================
TI/LS
-/:
Activation/NN
of/IN
Stat-3/NN
is/VBZ
involved/VBN
in/IN
the/DT
induction/NN
of/IN
apoptosis/NN
after/IN
ligation/NN
of/IN
major/JJ
histocompatibility/NN
complex/NN
class/NN
I/NN
molecules/NNS
on/IN
human/JJ
Jurkat/NN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Activation/NN
of/IN
Janus/NN
tyrosine/NN
kinases/NNS
(/(
Jak/NN
)/)
and/CC
Signal/NN
transducers/NNS
and/CC
activators/NNS
of/IN
transcription/NN
(/(
Stat/NNS
)/)
after/IN
ligation/NN
of/IN
major/JJ
histocompatibility/NN
complex/NN
class/NN
I/CD
(/(
MHC-I/NN
)/)
was/VBD
explored/VBN
in/IN
Jurkat/NN
T/NN
cells/NNS
./.
====================
Cross-linking/NN
of/IN
MHC-I/NN
mediated/VBD
tyrosine/NN
phosphorylation/NN
of/IN
Tyk2/NN
,/,
but/CC
not/RB
Jak1/NN
,/,
Jak2/NNP
,/,
and/CC
Jak3/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
transcription/NN
factor/NN
Stat-3/NN
was/VBD
tyrosine/NN
phosphorylated/VBN
in/IN
the/DT
cytoplasm/NN
and/CC
subsequently/RB
translocated/VBN
to/TO
the/DT
cell/NN
nucleus/NN
./.
====================
Data/NN
obtained/VBN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
suggested/VBD
that/IN
the/DT
activated/VBN
Stat-3/NN
protein/NN
associates/VBZ
with/IN
the/DT
human/JJ
serum-inducible/JJ
element/NN
(/(
hSIE/NN
)/)
DNA-probe/NN
derived/VBN
from/IN
the/DT
interferon-gamma/NN
activated/JJ
site/NN
(/(
GAS/NN
)/)
in/IN
the/DT
c-fos/NN
promoter/NN
,/,
a/DT
common/JJ
DNA/NN
sequence/NN
for/IN
Stat/NNS
protein/NN
binding/NN
./.
====================
An/DT
association/NN
between/IN
hSIE/NN
and/CC
Stat-3/NN
after/IN
MHC-I/NN
ligation/NN
was/VBD
directly/RB
demonstrated/VBN
by/IN
precipitating/VBG
Stat-3/NN
from/IN
nuclear/JJ
extracts/NNS
with/IN
biotinylated/VBN
hSIE/NN
probe/NN
and/CC
avidin-coupled/JJ
agarose/NN
./.
====================
To/TO
investigate/VB
the/DT
function/NN
of/IN
the/DT
activated/VBN
Stat-3/NN
,/,
Jurkat/NN
T/NN
cells/NNS
were/VBD
transiently/RB
transfected/VBN
with/IN
a/DT
Stat-3/NN
isoform/NN
lacking/VBG
the/DT
transactivating/VBG
domain/NN
./.
====================
This/DT
dominant-negative/JJ
acting/VBG
Stat-3/NN
isoform/NN
significantly/RB
inhibited/VBD
apoptosis/NN
induced/VBN
by/IN
ligation/NN
of/IN
MHC-I/NN
./.
====================
In/IN
conclusion/NN
,/,
our/PRP$
data/NNS
suggest/VBP
the/DT
involvement/NN
of/IN
the/DT
Jak/Stat/NN
signal/NN
pathway/NN
in/IN
MHC-I-induced/JJ
signal/NN
transduction/NN
in/IN
T/NN
cells/NNS
./.
====================
UI/LS
-/:
98281217/CD
====================
TI/LS
-/:
IL-2-induced/JJ
growth/NN
of/IN
CD8+/JJ
T/NN
cell/NN
prolymphocytic/JJ
leukemia/NN
cells/NNS
mediated/VBN
by/IN
NF-kappaB/NN
induction/NN
and/CC
IL-2/NN
receptor/NN
alpha/NN
expression/NN
./.
====================
AB/LS
-/:
The/DT
binding/NN
of/IN
interleukin-2/NN
(/(
IL-2/NN
)/)
to/TO
its/PRP$
receptor/NN
on/IN
normal/JJ
T/NN
cells/NNS
induces/VBZ
nuclear/JJ
expression/NN
of/IN
nuclear/JJ
factor/NN
kappaB/NN
(/(
NF-kappaB/NN
)/)
,/,
activation/NN
of/IN
the/DT
IL-2/NN
receptor/NN
(/(
IL-2R/NN
)/)
alpha/NN
chain/NN
gene/NN
,/,
and/CC
cell/NN
proliferation/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
the/DT
role/NN
of/IN
IL-2R/NN
signaling/NN
in/IN
the/DT
growth/NN
of/IN
CD8+/JJ
T/NN
cell/NN
prolymphocytic/JJ
leukemia/NN
(/(
T-PLL/NN
)/)
cells/NNS
has/VBZ
been/VBN
investigated/VBN
./.
====================
Flow/NN
cytometry/NN
revealed/VBD
that/IN
primary/JJ
leukemia/NN
cells/NNS
from/IN
a/DT
patient/NN
with/IN
CD8+/JJ
T-PLL/NN
expressed/VBD
IL-2Ralpha/NN
and/CC
beta/NN
chains/NNS
,/,
and/CC
the/DT
cells/NNS
showed/VBD
a/DT
proliferative/JJ
response/NN
and/CC
an/DT
increase/NN
in/IN
IL-2Ralpha/NN
expression/NN
on/IN
culture/NN
with/IN
exogeneous/JJ
IL-2/NN
./.
====================
Northern/NN
blot/NN
analysis/NN
failed/VBD
to/TO
detect/VB
IL-2/NN
mRNA/NN
,/,
suggesting/VBG
that/IN
IL-2/NN
may/MD
act/VB
in/IN
a/DT
paracrine/JJ
manner/NN
in/FW
vivo/FW
./.
====================
Electrophoretic/JJ
mobility-shift/NN
assays/NNS
revealed/VBD
that/IN
recombinant/JJ
IL-2/NN
increased/VBD
NF-kappaB/NN
binding/NN
activity/NN
in/IN
nuclear/JJ
extracts/NNS
of/IN
the/DT
leukemia/NN
cells/NNS
,/,
and/CC
Northern/NN
blot/NN
analysis/NN
showed/VBD
that/IN
IL-2/NN
increased/VBD
the/DT
abundance/NN
of/IN
mRNAs/NNS
encoding/VBG
the/DT
NF-kappaB/NN
components/NNS
c-Rel/NN
and/CC
KBF1/NN
in/IN
these/DT
cells/NNS
./.
====================
IL-2/NN
binding/NN
analysis/NN
demonstrated/VBD
that/IN
IL-2/NN
markedly/RB
increased/VBD
the/DT
number/NN
of/IN
low/JJ
affinity/NN
IL-2Rs/NNS
on/IN
the/DT
leukemia/NN
cells/NNS
,/,
without/IN
an/DT
effect/NN
on/IN
the/DT
number/NN
of/IN
high-affinity/JJ
IL-2Rs/NNS
./.
====================
These/DT
results/NNS
show/VBP
that/IN
IL-2/NN
is/VBZ
capable/JJ
of/IN
inducing/VBG
the/DT
nuclear/JJ
expression/NN
of/IN
NF-kappaB/NN
in/IN
primary/JJ
CD8+/JJ
T-PLL/NN
cells/NNS
,/,
and/CC
that/IN
this/DT
effect/NN
is/VBZ
mediated/VBN
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
at/IN
a/DT
pretranslational/JJ
level/NN
====================
UI/LS
-/:
98373923/CD
====================
TI/LS
-/:
Dimethyldithiocarbamate/NN
inhibits/VBZ
in/FW
vitro/FW
activation/NN
of/IN
primary/JJ
human/JJ
CD4+/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Dithiocarbamates/NNS
(/(
DTC/NN
)/)
,/,
a/DT
diverse/JJ
group/NN
of/IN
industrial/JJ
and/CC
therapeutic/JJ
chemicals/NNS
,/,
have/VBP
been/VBN
reported/VBN
to/TO
inhibit/VB
,/,
enhance/VBP
or/CC
have/VBP
no/DT
effect/NN
on/IN
the/DT
immune/JJ
system/NN
./.
====================
These/DT
apparent/JJ
inconsistencies/NNS
reflect/VBP
the/DT
complexity/NN
of/IN
the/DT
DTCs/NNS
biological/JJ
activities/NNS
and/CC
are/VBP
probably/RB
due/JJ
in/IN
part/NN
to/TO
differences/NNS
in/IN
dose/NN
,/,
route/NN
of/IN
exposure/NN
,/,
animal/JJ
species/NNS
used/VBN
and/or/CC
specific/JJ
compound/NN
tested/VBN
./.
====================
The/DT
studies/NNS
described/VBN
herein/RB
were/VBD
undertaken/VBN
to/TO
investigate/VB
the/DT
immunotoxicity/NN
of/IN
one/CD
member/NN
of/IN
this/DT
family/NN
,/,
dimethyldithiocarbamate/NN
(/(
DMDTC/NN
)/)
./.
====================
We/PRP
demonstrate/VBP
that/IN
0.1-0.5/CD
microM/NN
DMDTC/NN
inhibits/VBZ
TNF-alpha-induced/JJ
activation/NN
of/IN
NF-kappaB/NN
in/IN
primary/JJ
human/JJ
CD4+/JJ
T/NN
cells/NNS
./.
====================
This/DT
inhibition/NN
is/VBZ
not/RB
accompanied/VBN
by/IN
a/DT
loss/NN
in/IN
viability/NN
,/,
and/CC
DMDTC-treated/JJ
T/NN
cells/NNS
retain/VBP
other/JJ
active/JJ
signaling/NN
pathways/NNS
throughout/IN
the/DT
exposure/NN
duration/NN
./.
====================
The/DT
inhibition/NN
of/IN
NF-kappaB/NN
is/VBZ
apparently/RB
permanent/JJ
as/IN
DMDTC-treated/JJ
T/NN
cells/NNS
did/VBD
not/RB
regain/VB
normal/JJ
TNF-alpha/NN
activation/NN
,/,
even/RB
after/IN
72/CD
h/NN
in/IN
culture/NN
./.
====================
DMDTC/NN
does/VBZ
not/RB
appear/VB
to/TO
alter/VB
NF-kappaB/NN
directly/RB
as/IN
pre-incubation/NN
of/IN
nuclear/JJ
extracts/NNS
with/IN
DMDTC/NN
does/VBZ
not/RB
diminish/VB
binding/NN
activity/NN
of/IN
this/DT
protein/NN
./.
====================
We/PRP
further/RB
demonstrate/VBP
that/IN
0.1-0.5/CD
microM/NN
DMDTC/NN
inhibits/VBZ
intracellular/JJ
IL-2/NN
production/NN
and/CC
decreases/VBZ
surface/NN
expression/NN
of/IN
CD25/NN
(/(
the/DT
alpha/NN
subunit/NN
of/IN
the/DT
IL-2/NN
receptor/NN
)/)
in/IN
T/NN
cells/NNS
stimulated/VBN
with/IN
phorbol/NN
ester/NN
./.
====================
These/DT
data/NNS
demonstrate/VBP
that/IN
DMDTC/NN
is/VBZ
a/DT
potent/JJ
immunosuppressive/JJ
compound/NN
in/FW
vitro/FW
./.
====================
UI/LS
-/:
98363633/CD
====================
TI/LS
-/:
Human/JJ
15-lipoxygenase/NN
gene/NN
promoter/NN
:/:
analysis/NN
and/CC
identification/NN
of/IN
DNA/NN
binding/NN
sites/NNS
for/IN
IL-13-induced/JJ
regulatory/JJ
factors/NNS
in/IN
monocytes/NNS
./.
====================
AB/LS
-/:
In/IN
order/NN
to/TO
study/VB
the/DT
transcriptional/JJ
control/NN
of/IN
15-LO/NN
expression/NN
,/,
we/PRP
have/VBP
cloned/VBN
and/CC
sequenced/VBD
the/DT
human/JJ
15-LO/NN
promoter/NN
region/NN
./.
====================
The/DT
15-LO/NN
promoter/NN
is/VBZ
associated/VBN
with/IN
a/DT
CpG/NN
island/NN
at/IN
the/DT
5'-end/NN
of/IN
the/DT
gene/NN
,/,
and/CC
sequence/NN
analysis/NN
reveals/VBZ
putative/JJ
Sp1/NN
and/CC
Ap2/NN
binding/NN
site/s/NNS
and/CC
absence/NN
of/IN
TATA/NN
or/CC
CAAT/NN
motifs/NNS
./.
====================
Transcription/NN
is/VBZ
initiated/VBN
at/IN
one/CD
major/JJ
site/NN
./.
====================
Using/VBG
deletion/NN
constructs/NNS
,/,
we/PRP
have/VBP
defined/VBN
an/DT
active/JJ
promoter/NN
region/NN
of/IN
1056/CD
bp/NN
./.
====================
Gel-shift/NN
assays/NNS
revealed/VBD
that/IN
transcriptional/JJ
factor/NN
(/(
s/NNS
)/)
induced/VBN
only/RB
in/IN
response/NN
to/TO
IL-13/NN
treatment/NN
of/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
bind/VBP
to/TO
the/DT
15-LO/NN
promoter/NN
DNA/NN
./.
====================
Two/CD
regions/NNS
,/,
DP1/NN
(/(
-140/CD
to/TO
-92/CD
bp/NN
)/)
and/CC
DP2/NN
(/(
-353/CD
to/TO
-304/CD
bp/NN
)/)
of/IN
the/DT
promoter/NN
were/VBD
essential/JJ
for/IN
transcription/NN
in/IN
HeLa/NN
cells/NNS
and/CC
human/JJ
peripheral/JJ
monocytes/NNS
./.
====================
Hela/NN
nuclear/JJ
extracts/NNS
contained/VBD
a/DT
specific/JJ
nuclear/JJ
factor/NN
(/(
s/NNS
)/)
binding/VBG
to/TO
15-LO/NN
promoter/NN
DNA/NN
which/WDT
are/VBP
distinct/JJ
from/IN
those/DT
derived/VBN
from/IN
IL-13-treated/JJ
human/JJ
peripheral/JJ
monocyte/NN
nuclear/JJ
extracts/NNS
./.
====================
In/IN
addition/NN
,/,
fluorescent/JJ
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
results/VBZ
refined/VBD
the/DT
previous/JJ
localization/NN
of/IN
15-LO/NN
to/TO
human/JJ
chromosome/NN
17p13.3/NN
./.
====================
UI/LS
-/:
98352765/CD
====================
TI/LS
-/:
Ex/FW
vivo/FW
activation/NN
of/IN
tumor-draining/JJ
lymph/NN
node/NN
T/NN
cells/NNS
reverses/VBZ
defects/VBZ
in/IN
signal/NN
transduction/NN
molecules/NNS
./.
====================
AB/LS
-/:
The/DT
adoptive/JJ
transfer/NN
of/IN
tumor-draining/JJ
lymph/NN
node/NN
(/(
LN/NN
)/)
T/NN
cells/NNS
activated/VBD
ex/FW
vivo/FW
with/IN
anti-CD3/NN
and/CC
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
mediates/VBZ
the/DT
regression/NN
of/IN
the/DT
poorly/RB
immunogenic/JJ
murine/JJ
melanoma/NN
D5/NN
./.
====================
The/DT
efficacy/NN
of/IN
the/DT
activated/VBN
LN/NN
cells/NNS
is/VBZ
augmented/VBN
when/WRB
the/DT
sensitizing/VBG
tumor/NN
is/VBZ
a/DT
genetically/RB
modified/VBN
variant/NN
(/(
designated/VBN
D5G6/NN
)/)
that/WDT
secretes/VBZ
granulocyte/macrophage-colony-stimulating/JJ
factor/NN
./.
====================
In/IN
contrast/NN
to/TO
anti-CD3/IL-2-activated/JJ
LN/NN
cells/NNS
,/,
adoptive/JJ
transfer/NN
of/IN
freshly/RB
isolated/VBN
tumor-draining/JJ
LN/NN
T/NN
cells/NNS
has/VBZ
no/DT
therapeutic/JJ
activity/NN
./.
====================
To/TO
determine/VB
whether/IN
the/DT
acquisition/NN
of/IN
antitumor/JJ
function/NN
during/IN
ex/FW
vivo/FW
activation/NN
is/VBZ
associated/VBN
with/IN
modifications/NNS
in/IN
signal/NN
transduction/NN
capacity/NN
,/,
the/DT
protein/NN
tyrosine/NN
kinases/NNS
p56lck/NN
and/CC
p59fyn/NN
and/CC
proteins/NNS
of/IN
the/DT
NF-kappaB/NN
family/NN
were/VBD
analyzed/VBN
in/IN
tumor-draining/JJ
LN/NN
T/NN
cells/NNS
./.
====================
The/DT
levels/NNS
of/IN
p56lck/NN
and/CC
p59fyn/NN
were/VBD
lower/JJR
in/IN
tumor-draining/JJ
than/IN
in/IN
normal/JJ
LN/NN
T/NN
cells/NNS
and/CC
production/NN
of/IN
tyrosine-phosphorylated/JJ
substrates/NNS
was/VBD
markedly/RB
depressed/VBN
following/VBG
anti-CD3/JJ
stimulation/NN
./.
====================
After/IN
5-day/JJ
anti-CD3/IL-2/JJ
activation/NN
,/,
levels/NNS
of/IN
p56lck/NN
and/CC
p59fyn/NN
and/CC
protein/NN
tyrosine/NN
kinase/NN
activity/NN
increased/VBN
./.
====================
Interestingly/RB
,/,
the/DT
levels/NNS
of/IN
p56lck/NN
,/,
p59fyn/NN
,/,
and/CC
tyrosine/NN
kinase/NN
activity/NN
were/VBD
higher/JJR
in/IN
activated/VBN
T/NN
cells/NNS
derived/VBN
from/IN
LN/NN
that/IN
drained/VBD
D5G6/NN
than/IN
they/PRP
were/VBD
in/IN
those/DT
from/IN
D5/NN
tumors/NNS
./.
====================
In/IN
contrast/NN
,/,
the/DT
cytoplasmic/JJ
levels/NNS
of/IN
c-Rel/NN
and/CC
Rel/NN
A/NN
were/VBD
normal/JJ
in/IN
freshly/RB
isolated/VBN
tumor-draining/JJ
LN/NN
,/,
as/IN
was/VBD
nuclear/JJ
kappaB/NN
DNA-binding/JJ
activity/NN
induced/VBN
by/IN
anti-CD3/JJ
mAb/NN
or/CC
phorbol/NN
myristate/NN
acetate/NN
./.
====================
Stimulation/NN
of/IN
activated/VBN
LN/NN
cells/NNS
with/IN
D5/NN
tumor/NN
cells/NNS
induced/VBD
the/DT
nuclear/JJ
translocation/NN
of/IN
NF-kappaB/NN
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
the/DT
recovery/NN
of/IN
proteins/NNS
mediating/VBG
signal/NN
transduction/NN
through/IN
the/DT
T/NN
cell/NN
receptor/CD3/NN
complex/NN
in/IN
LN/NN
T/NN
cells/NNS
activated/VBD
ex/FW
vivo/FW
was/VBD
associated/VBN
with/IN
the/DT
acquisition/NN
of/IN
antitumor/JJ
function/NN
./.
====================
UI/LS
-/:
98343423/CD
====================
TI/LS
-/:
Suppression/NN
of/IN
human/JJ
anti-porcine/JJ
T-cell/NN
immune/JJ
responses/NNS
by/IN
major/JJ
histocompatibility/NN
complex/NN
class/NN
II/CD
transactivator/NN
constructs/NNS
lacking/VBG
the/DT
amino/NN
terminal/JJ
domain/NN
./.
====================
AB/LS
-/:
BACKGROUND/NN
:/:
The/DT
class/NN
II/CD
transactivator/NN
(/(
CIITA/NN
)/)
is/VBZ
a/DT
bi-/JJ
or/CC
multifunctional/JJ
domain/NN
protein/NN
that/WDT
acts/VBZ
as/IN
a/DT
transcriptional/JJ
activator/NN
and/CC
plays/VBZ
a/DT
critical/JJ
role/NN
in/IN
the/DT
expression/NN
of/IN
MHC/NN
class/NN
II/CD
genes/NNS
./.
====================
We/PRP
have/VBP
previously/RB
demonstrated/VBN
that/IN
a/DT
mutated/VBN
form/NN
of/IN
the/DT
human/JJ
CIITA/NN
gene/NN
,/,
coding/VBG
for/IN
a/DT
protein/NN
lacking/VBG
the/DT
amino/NN
terminal/JJ
151/CD
amino/NN
acids/NNS
,/,
acts/VBZ
as/IN
a/DT
potent/JJ
dominant-negative/JJ
suppressor/NN
of/IN
HLA/NN
class/NN
II/CD
expression/NN
./.
====================
Porcine/NN
MHC/NN
class/NN
II/CD
antigens/NNS
are/VBP
potent/JJ
stimulators/NNS
of/IN
direct/JJ
T-cell/NN
recognition/NN
by/IN
human/JJ
CD4+/JJ
T/NN
cells/NNS
and/CC
are/VBP
,/,
therefore/RB
,/,
likely/JJ
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
rejection/NN
responses/NNS
to/TO
transgenic/JJ
pig/NN
donors/NNS
in/IN
clinical/JJ
xenotransplantation/NN
./.
====================
We/PRP
were/VBD
,/,
therefore/RB
,/,
interested/VBD
in/IN
examining/VBG
mutated/VBN
CIITA/NN
constructs/NNS
for/IN
their/PRP$
effect/NN
on/IN
porcine/NN
MHC/NN
class/NN
II/CD
expression/NN
./.
====================
METHODS/NNS
:/:
Stable/JJ
transfectants/NNS
of/IN
the/DT
porcine/NN
vascular/JJ
endothelial/JJ
cell/NN
line/NN
PIEC/NN
with/IN
mutated/VBN
CIITA/NN
constructs/NNS
were/VBD
tested/VBN
for/IN
SLA-DR/NN
and/CC
SLA-DQ/NN
induction/NN
by/IN
recombinant/JJ
porcine/NN
interferon-gamma/NN
./.
====================
Transient/JJ
transfectants/NNS
of/IN
the/DT
porcine/NN
B-cell/NN
line/NN
L23/NN
with/IN
the/DT
mutated/VBN
CIITA/NN
constructs/NNS
were/VBD
tested/VBN
for/IN
the/DT
suppression/NN
of/IN
constitutive/JJ
SLA-DR/NN
and/CC
SLA-DQ/NN
expression/NN
./.
====================
T-cell/NN
proliferation/NN
studies/NNS
were/VBD
performed/VBN
using/VBG
highly/RB
purified/VBN
human/JJ
CD4+/JJ
T/NN
cells/NNS
./.
====================
RESULTS/NNS
:/:
In/FW
preliminary/JJ
studies/NNS
,/,
we/PRP
demonstrated/VBD
that/IN
transfection/NN
of/IN
the/DT
PIEC/NN
line/NN
with/IN
full-length/JJ
human/JJ
CIITA/NN
constructs/NNS
resulted/VBD
in/IN
strong/JJ
expression/NN
of/IN
SLA-DR/NN
and/CC
SLA-DQ/NN
antigens/NNS
,/,
thus/RB
establishing/VBG
the/DT
cross-species/JJ
effectiveness/NN
of/IN
human/JJ
CIITA/NN
in/IN
the/DT
pig/NN
./.
====================
The/DT
mutated/VBN
human/JJ
CIITA/NN
constructs/NNS
were/VBD
,/,
therefore/RB
,/,
tested/VBN
in/IN
the/DT
pig/NN
./.
====================
PIEC/NN
clones/NNS
stably/RB
transfected/VBN
with/IN
one/CD
of/IN
these/DT
constructs/NNS
showed/VBD
up/RB
to/TO
99/CD
%/NN
suppression/NN
of/IN
SLA-DR/NN
and/CC
SLA-DQ/NN
antigen/NN
induction/NN
and/CC
marked/JJ
suppression/NN
of/IN
SLA-DRA/NN
mRNA/NN
induction/NN
./.
====================
Moreover/RB
,/,
transient/JJ
transfection/NN
of/IN
the/DT
porcine/NN
B-cell/NN
line/NN
L23/NN
showed/VBD
up/RB
to/TO
90/CD
%/NN
suppression/NN
of/IN
constitutive/JJ
SLA-DR/NN
and/CC
SLA-DQ/NN
antigen/NN
expression/NN
in/IN
5-8/CD
days/NNS
./.
====================
In/IN
functional/JJ
studies/NNS
,/,
interferon-gamma-stimulated/JJ
PIEC/NN
clones/NNS
transfected/VBN
with/IN
this/DT
mutated/VBN
CIITA/NN
construct/NN
failed/VBD
to/TO
stimulate/VB
purified/VBN
human/JJ
CD4+/JJ
T/NN
lymphocytes/NNS
./.
====================
CONCLUSION/NN
:/:
Mutated/JJ
human/JJ
CIITA/NN
constructs/NNS
are/VBP
potent/JJ
suppressors/NNS
of/IN
porcine/NN
MHC/NN
class/NN
II/CD
expression/NN
./.
====================
UI/LS
-/:
98328397/CD
====================
TI/LS
-/:
Macrophages/NNS
in/IN
human/JJ
atheroma/NN
contain/VBP
PPARgamma/NN
:/:
differentiation-dependent/JJ
peroxisomal/JJ
proliferator-activated/JJ
receptor/NN
gamma/NN
(/(
PPARgamma/NN
)/)
expression/NN
and/CC
reduction/NN
of/IN
MMP-9/NN
activity/NN
through/IN
PPARgamma/NN
activation/NN
in/IN
mononuclear/JJ
phagocytes/NNS
in/FW
vitro/FW
./.
====================
AB/LS
-/:
Mononuclear/JJ
phagocytes/NNS
play/VBP
an/DT
important/JJ
role/NN
in/IN
atherosclerosis/NN
and/CC
its/PRP$
sequela/NN
plaque/NN
rupture/NN
in/IN
part/NN
by/IN
their/PRP$
secretion/NN
of/IN
matrix/NN
metalloproteinases/NNS
(/(
MMPs/NNS
)/)
,/,
including/VBG
MMP-9/NN
./.
====================
Peroxisomal/JJ
proliferator-activated/JJ
receptor/NN
gamma/NN
(/(
PPARgamma/NN
)/)
,/,
a/DT
transcription/NN
factor/NN
in/IN
the/DT
nuclear/JJ
receptor/NN
superfamily/NN
,/,
regulates/VBZ
gene/NN
expression/NN
in/IN
response/NN
to/TO
various/JJ
activators/NNS
,/,
including/VBG
15-deoxy-delta12,14-prostaglandin/NN
J2/NN
and/CC
the/DT
antidiabetic/JJ
agent/NN
troglitazone/NN
./.
====================
The/DT
role/NN
of/IN
PPARgamma/NN
in/IN
human/JJ
atherosclerosis/NN
is/VBZ
unexplored/JJ
./.
====================
We/PRP
report/VBP
here/RB
that/IN
monocytes/macrophages/NNS
in/IN
human/JJ
atherosclerotic/JJ
lesions/NNS
(/(
n/NN
=/JJ
12/CD
)/)
express/VBP
immunostainable/JJ
PPARgamma/NN
./.
====================
Normal/JJ
artery/NN
specimens/NNS
(/(
n/NN
=/JJ
6/CD
)/)
reveal/VBP
minimal/JJ
immunoreactive/JJ
PPARgamma/NN
./.
====================
Human/JJ
monocytes/NNS
and/CC
monocyte-derived/JJ
macrophages/NNS
cultured/VBN
for/IN
6/CD
days/NNS
in/IN
5/CD
%/NN
human/JJ
serum/NN
expressed/VBD
PPARgamma/NN
mRNA/NN
and/CC
protein/NN
by/IN
reverse/JJ
transcription-polymerase/NN
chain/NN
reaction/NN
and/CC
Western/NN
blotting/NN
,/,
respectively/RB
./.
====================
In/IN
addition/NN
,/,
PPARgamma/NN
mRNA/NN
expression/NN
in/IN
U937/NN
cells/NNS
increased/VBN
during/IN
phorbol/NN
12-myristate/NN
13/CD
acetate-induced/JJ
differentiation/NN
./.
====================
Stimulation/NN
of/IN
PPARgamma/NN
with/IN
troglitazone/NN
or/CC
15-deoxy-delta12,14-prostaglandin/NN
J2/NN
in/IN
human/JJ
monocyte-derived/JJ
macrophages/NNS
inhibited/VBD
MMP-9/NN
gelatinolytic/JJ
activity/NN
in/IN
a/DT
concentration-dependent/JJ
fashion/NN
as/IN
revealed/VBN
by/IN
zymography/NN
./.
====================
This/DT
inhibition/NN
correlates/VBZ
with/IN
decreased/VBN
MMP-9/NN
secretion/NN
as/IN
determined/VBN
by/IN
Western/NN
blotting/NN
./.
====================
Thus/RB
,/,
PPARgamma/NN
is/VBZ
present/JJ
in/IN
macrophages/NNS
in/IN
human/JJ
atherosclerotic/JJ
lesions/NNS
and/CC
may/MD
regulate/VB
expression/NN
and/CC
activity/NN
of/IN
MMP-9/NN
,/,
an/DT
enzyme/NN
implicated/VBN
in/IN
plaque/NN
rupture/NN
./.
====================
PPARgamma/NN
is/VBZ
likely/JJ
to/TO
be/VB
an/DT
important/JJ
regulator/NN
of/IN
monocyte/macrophage/NN
function/NN
with/IN
relevance/NN
for/IN
human/JJ
atherosclerotic/JJ
disease/NN
./.
====================
UI/LS
-/:
98322149/CD
====================
TI/LS
-/:
Erythropoietin/NN
induces/VBZ
tyrosine/NN
phosphorylation/NN
of/IN
Jak2/NN
,/,
STAT5A/NN
,/,
and/CC
STAT5B/NN
in/IN
primary/JJ
cultured/VBN
human/JJ
erythroid/JJ
precursors/NNS
./.
====================
AB/LS
-/:
We/PRP
examined/VBD
signaling/NN
by/IN
erythropoietin/NN
in/IN
highly/RB
purified/VBN
human/JJ
colony/NN
forming/NN
unit-erythroid/JJ
cells/NNS
,/,
generated/VBN
in/FW
vitro/FW
from/IN
CD34(+)/JJ
cells/NNS
./.
====================
We/PRP
found/VBD
that/IN
erythropoietin/NN
induces/VBZ
tyrosine/NN
phosphorylation/NN
of/IN
Jak2/NN
,/,
STAT5A/NN
,/,
and/CC
STAT5B/NN
./.
====================
Tyrosine/NN
phosphorylation/NN
of/IN
Jak2/NN
reaches/VBZ
a/DT
peak/NN
around/IN
10/CD
minutes/NNS
after/IN
stimulation/NN
and/CC
is/VBZ
maximum/JJ
at/IN
5/CD
U/mL/NN
of/IN
erythropoietin/NN
./.
====================
Tyrosine/NN
phosphorylation/NN
of/IN
STAT5/NN
is/VBZ
accompanied/VBN
by/IN
the/DT
translocation/NN
of/IN
activated/VBN
STAT5/NN
to/TO
the/DT
nucleus/NN
as/IN
shown/VBN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
(/(
EMSA/NN
)/)
using/VBG
32Pi-labeled/JJ
STAT5/NN
binding/NN
site/NN
in/IN
the/DT
beta-casein/NN
promoter/NN
./.
====================
Tyrosine/NN
phosphorylation/NN
STAT1/NN
or/CC
STAT3/NN
was/VBD
not/RB
detected/VBN
in/IN
human/JJ
erythroid/JJ
precursors/NNS
after/IN
stimulation/NN
with/IN
erythropoietin/NN
./.
====================
Crkl/NN
,/,
an/DT
SH2/SH3/NN
adapter/NN
protein/NN
,/,
becomes/VBZ
coimmunoprecipitated/VBN
specifically/RB
with/IN
STAT5/NN
from/IN
erythropoietin-stimulated/JJ
erythroid/JJ
cells/NNS
;/:
although/IN
it/PRP
was/VBD
shown/VBN
to/TO
become/VB
associated/VBN
with/IN
c-Cbl/NN
in/IN
the/DT
studies/NNS
using/VBG
cell/NN
lines/NNS
./.
====================
Thus/RB
,/,
human/JJ
erythroid/JJ
precursors/NNS
can/MD
be/VB
expanded/VBN
in/FW
vitro/FW
in/IN
sufficient/JJ
numbers/NNS
and/CC
purity/NN
to/TO
allow/VB
its/PRP$
usage/NN
in/IN
signal/NN
transduction/NN
studies/NNS
./.
====================
This/DT
report/NN
sets/VBZ
a/DT
basis/NN
for/IN
further/JJ
studies/NNS
on/IN
signaling/NN
in/IN
primary/JJ
cultured/VBN
human/JJ
erythroid/JJ
precursors/NNS
,/,
which/WDT
in/IN
turn/NN
contribute/VBP
to/TO
our/PRP$
better/JJR
understanding/NN
in/IN
the/DT
differentiation/NN
processes/NNS
of/IN
erythrocytes/NNS
and/CC
their/PRP$
precursors/NNS
./.
====================
UI/LS
-/:
98311520/CD
====================
TI/LS
-/:
Oxidative/JJ
stress/NN
suppresses/VBZ
transcription/NN
factor/NN
activities/NNS
in/IN
stimulated/VBN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Effects/NNS
of/IN
oxidative/JJ
stress/NN
on/IN
stimulation-dependent/JJ
signal/NN
transduction/NN
,/,
leading/VBG
to/TO
IL-2/NN
expression/NN
,/,
were/VBD
studied/VBN
./.
====================
Purified/VBN
quiescent/JJ
human/JJ
blood/NN
T/NN
lymphocytes/NNS
were/VBD
subjected/VBN
to/TO
:/:
(/(
i/LS
)/)
acute/JJ
exposure/NN
to/TO
hydrogen/NN
peroxide/NN
;/:
(/(
ii/LS
)/)
chronic/JJ
exposure/NN
to/TO
hydrogen/NN
peroxide/NN
;/:
and/CC
(/(
iii/LS
)/)
acute/JJ
exposure/NN
to/TO
ionizing/VBG
radiation/NN
./.
====================
The/DT
cells/NNS
were/VBD
then/RB
stimulated/VBN
for/IN
6/CD
h/NN
./.
====================
DNA-binding/JJ
activities/NNS
(/(
determined/VBN
by/IN
the/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
)/)
of/IN
three/CD
transcription/NN
factors/NNS
:/:
NFkappaB/NN
,/,
AP-1/NN
and/CC
NFAT/NN
,/,
were/VBD
abolished/VBN
in/IN
the/DT
lymphocytes/NNS
by/IN
all/DT
three/CD
modes/NNS
of/IN
oxidative/JJ
stress/NN
./.
====================
The/DT
lymphocytes/NNS
exhibited/VBD
lipid/NN
peroxidation/NN
only/RB
upon/IN
exposure/NN
to/TO
the/DT
lowest/JJS
level/NN
of/IN
hydrogen/NN
peroxide/NN
used/VBN
(/(
20/CD
microM/NN
)/)
./.
====================
All/DT
three/CD
modes/NNS
of/IN
oxidative/JJ
stress/NN
induced/VBD
catalase/NN
activity/NN
in/IN
the/DT
lymphocytes/NNS
./.
====================
The/DT
only/RB
exception/NN
was/VBD
hydrogen/NN
peroxide/NN
at/IN
20/CD
microM/NN
,/,
which/WDT
did/VBD
not/RB
induce/VB
catalase/NN
activity/NN
./.
====================
We/PRP
conclude/VBP
that/IN
:/:
(/(
i/LS
)/)
suppression/NN
of/IN
specific/JJ
transcription/NN
factor/NN
functions/NNS
can/MD
potentially/RB
serve/VB
as/IN
a/DT
marker/NN
of/IN
exposure/NN
to/TO
oxidative/JJ
stress/NN
and/CC
its/PRP$
effects/NNS
on/IN
human/JJ
lymphocytes/NNS
;/:
(/(
ii/LS
)/)
lipid/NN
peroxidation/NN
is/VBZ
only/RB
detectable/JJ
in/IN
human/JJ
lymphocytes/NNS
upon/IN
exposure/NN
to/TO
weak/JJ
oxidative/JJ
stress/NN
which/WDT
does/VBZ
not/RB
induce/VB
catalase/NN
activity/NN
;/:
(/(
iii/LS
)/)
therefore/RB
,/,
transcription/NN
factor/NN
DNA-binding/JJ
activities/NNS
are/VBP
more/RBR
sensitive/JJ
to/TO
oxidative/JJ
stress/NN
than/IN
lipid/NN
peroxidation/NN
./.
====================
UI/LS
-/:
98299642/CD
====================
TI/LS
-/:
IL-4-dependent/JJ
regulation/NN
of/IN
TGF-alpha/NN
and/CC
TGF-beta1/NN
expression/NN
in/IN
human/JJ
eosinophils/NNS
./.
====================
AB/LS
-/:
TGFs/NNS
play/VBP
important/JJ
roles/NNS
in/IN
wound/NN
healing/NN
and/CC
carcinogenesis/NN
./.
====================
We/PRP
have/VBP
previously/RB
demonstrated/VBN
that/IN
eosinophils/NNS
infiltrating/VBG
into/IN
different/JJ
pathologic/JJ
processes/NNS
elaborate/VBP
TGF-alpha/NN
and/CC
TGF-beta1/NN
./.
====================
Eosinophils/NNS
infiltrating/VBG
hamster/NN
cutaneous/JJ
wounds/NNS
were/VBD
found/VBN
to/TO
express/VB
TGFs/NNS
sequentially/RB
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
examined/VBD
the/DT
biologic/JJ
mediators/NNS
that/WDT
may/MD
regulate/VB
the/DT
expression/NN
of/IN
TGF-alpha/NN
and/CC
-beta1/NN
by/IN
eosinophils/NNS
./.
====================
Eosinophils/NNS
were/VBD
isolated/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
of/IN
healthy/JJ
donors/NNS
and/CC
cultured/VBN
in/IN
the/DT
absence/NN
or/CC
presence/NN
of/IN
IL-3/NN
,/,
IL-4/NN
,/,
and/CC
IL-5/NN
./.
====================
Cells/NNS
were/VBD
analyzed/VBN
by/IN
in/FW
situ/FW
hybridization/NN
and/CC
immunohistochemistry/NN
./.
====================
Supernatants/NNS
from/IN
these/DT
cultures/NNS
were/VBD
assayed/VBN
for/IN
secreted/VBN
TGF-alpha/NN
and/CC
TGF-beta1/NN
using/VBG
TGF-specific/JJ
ELISAs/NNS
./.
====================
IL-3/NN
,/,
IL-4/NN
,/,
and/CC
IL-5/NN
independently/RB
up-regulated/VBD
TGF-beta1/NN
mRNA/NN
and/CC
product/NN
expression/NN
by/IN
eosinophils/NNS
in/IN
all/DT
donors/NNS
./.
====================
Interestingly/RB
,/,
TGF-alpha/NN
production/NN
by/IN
eosinophils/NNS
was/VBD
up-regulated/VBN
by/IN
IL-3/NN
and/CC
IL-5/NN
but/CC
was/VBD
down-regulated/VBN
by/IN
IL-4/NN
./.
====================
Consistent/JJ
with/IN
the/DT
ability/NN
of/IN
IL-4/NN
to/TO
regulate/VB
eosinophil/NN
responses/NNS
,/,
IL-4/NN
signaling/NN
molecules/NNS
are/VBP
present/JJ
in/IN
human/JJ
eosinophils/NNS
./.
====================
The/DT
observation/NN
that/IN
IL-4/NN
can/MD
differentially/RB
regulate/VB
the/DT
expression/NN
of/IN
TGF-alpha/NN
and/CC
TGF-beta1/NN
suggests/VBZ
that/IN
IL-4/NN
may/MD
serve/VB
as/IN
a/DT
physiologic/JJ
molecular/JJ
switch/NN
of/IN
TGF/NN
expression/NN
by/IN
the/DT
infiltrating/VBG
eosinophils/NNS
in/IN
wound/NN
healing/NN
and/CC
carcinogenesis/NN
./.
====================
UI/LS
-/:
98282210/CD
====================
TI/LS
-/:
MLL/NN
and/CC
CALM/NN
are/VBP
fused/VBN
to/TO
AF10/NN
in/IN
morphologically/RB
distinct/JJ
subsets/NNS
of/IN
acute/JJ
leukemia/NN
with/IN
translocation/NN
t(10;11)/NN
:/:
both/DT
rearrangements/NNS
are/VBP
associated/VBN
with/IN
a/DT
poor/JJ
prognosis/NN
./.
====================
AB/LS
-/:
The/DT
translocation/NN
t(10;11)(p13;q14)/NN
has/VBZ
been/VBN
observed/VBN
in/IN
acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
ALL/NN
)/)
as/RB
well/RB
as/IN
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
./.
====================
A/DT
recent/JJ
study/NN
showed/VBD
a/DT
MLL/AF10/NN
fusion/NN
in/IN
all/DT
cases/NNS
of/IN
AML/NN
with/IN
t(10;11)/NN
and/CC
various/JJ
breakpoints/NNS
on/IN
chromosome/NN
11/CD
ranging/VBG
from/IN
q13/NN
to/TO
q23/NN
./.
====================
We/PRP
recently/RB
cloned/VBN
CALM/NN
(/(
Clathrin/NN
Assembly/NN
Lymphoid/JJ
Myeloid/JJ
leukemia/NN
gene/NN
)/)
,/,
the/DT
fusion/NN
partner/NN
of/IN
AF10/NN
at/IN
11q14/NN
in/IN
the/DT
monocytic/JJ
cell/NN
line/NN
U937/NN
./.
====================
To/TO
further/RB
define/VB
the/DT
role/NN
of/IN
these/DT
genes/NNS
in/IN
acute/JJ
leukemias/NNS
,/,
10/CD
cases/NNS
(/(
9/CD
AML/NN
and/CC
1/CD
ALL/NN
)/)
with/IN
cytogenetically/RB
proven/JJ
t(10;11)(p12-14;q13-21)/NN
and/CC
well-characterized/VBD
morphology/NN
,/,
immunophenotype/NN
,/,
and/CC
clinical/JJ
course/NN
were/VBD
analyzed/VBN
./.
====================
Interphase/NN
fluorescence/NN
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
was/VBD
performed/VBN
with/IN
2/CD
YACs/NNS
flanking/VBG
the/DT
CALM/NN
region/NN
,/,
a/DT
YAC/NN
contig/NN
of/IN
the/DT
MLL/NN
region/NN
,/,
and/CC
a/DT
YAC/NN
spanning/VBG
the/DT
AF10/NN
breakpoint/NN
./.
====================
Rearrangement/NN
of/IN
at/IN
least/JJS
one/CD
of/IN
these/DT
genes/NNS
was/VBD
detected/VBN
in/IN
all/DT
cases/NNS
with/IN
balanced/JJ
t(10;11)/NN
./.
====================
In/IN
4/CD
cases/NNS
,/,
including/VBG
3/CD
AML/NN
with/IN
immature/JJ
morphology/NN
(/(
1/CD
AML-M0/NN
and/CC
2/CD
AML-M1/NN
)/)
and/CC
1/CD
ALL/NN
,/,
the/DT
signals/NNS
of/IN
the/DT
CALM/NN
YACS/NNS
were/VBD
separated/VBN
in/IN
interphase/NN
cells/NNS
,/,
indicating/VBG
a/DT
translocation/NN
breakpoint/NN
within/IN
the/DT
CALM/NN
region/NN
./.
====================
MLL/NN
was/VBD
rearranged/VBN
in/IN
3/CD
AML/NN
with/IN
myelomonocytic/JJ
differentiation/NN
(/(
2/CD
AML-M2/NN
and/CC
1/CD
AML-M5/NN
)/)
,/,
including/VBG
1/CD
secondary/JJ
AML/NN
./.
====================
In/IN
all/DT
3/CD
cases/NNS
,/,
a/DT
characteristic/JJ
immunophenotype/NN
was/VBD
identified/VBN
(/(
CD4+/JJ
,/,
CD13-/NN
,/,
CD33+/JJ
,/,
CD65s+/JJ
)/)
./.
====================
AF-10/NN
was/VBD
involved/VBN
in/IN
5/CD
of/IN
6/CD
evaluable/JJ
cases/NNS
,/,
including/VBG
1/CD
case/NN
without/IN
detectable/JJ
CALM/NN
or/CC
MLL/NN
rearrangement/NN
./.
====================
In/IN
2/CD
complex/NN
translocations/NNS
,/,
none/NN
of/IN
the/DT
three/CD
genes/NNS
was/VBD
rearranged/VBN
./.
====================
All/DT
cases/NNS
had/VBD
a/DT
remarkably/RB
poor/JJ
prognosis/NN
,/,
with/IN
a/DT
mean/NN
survival/NN
of/IN
9.6/CD
+/-/CC
6.6/CD
months/NNS
./.
====================
For/IN
the/DT
7/CD
AML/NN
cases/NNS
that/WDT
were/VBD
uniformly/RB
treated/VBN
according/VBG
to/TO
the/DT
AMLCG86/92/NN
protocols/NNS
,/,
disease-free/JJ
and/CC
overall/JJ
survival/NN
was/VBD
significantly/RB
worse/JJ
than/IN
for/IN
the/DT
overall/JJ
study/NN
group/NN
(/(
P/NN
=/JJ
.03/CD
and/CC
P/NN
=/JJ
.01/CD
,/,
respectively/RB
)/)
./.
====================
We/PRP
conclude/VBP
that/IN
the/DT
t(10;11)(p13;q14)/NN
indicates/VBZ
CALM/NN
and/CC
MLL/NN
rearrangements/NNS
in/IN
morphologically/RB
distinct/JJ
subsets/NNS
of/IN
acute/JJ
leukemia/NN
and/CC
may/MD
be/VB
associated/VBN
with/IN
a/DT
poor/JJ
prognosis/NN
./.
====================
UI/LS
-/:
98282482/CD
====================
TI/LS
-/:
The/DT
role/NN
of/IN
E-proteins/NNS
in/IN
B-/NN
and/CC
T-lymphocyte/NN
development/NN
./.
====================
AB/LS
-/:
Department/NN
of/IN
lymphocytes/NNS
from/IN
hematopoietic/JJ
stem/NN
cells/NNS
is/VBZ
controlled/VBN
,/,
in/IN
part/NN
,/,
by/IN
the/DT
activity/NN
of/IN
transcriptional/JJ
regulatory/JJ
proteins/NNS
./.
====================
In/IN
particular/JJ
,/,
one/CD
class/NN
of/IN
helix-loop-helix/JJ
proteins/NNS
,/,
termed/VBN
E-proteins/NNS
,/,
have/VBP
been/VBN
implicated/VBN
in/IN
the/DT
regulation/NN
of/IN
gene/NN
expression/NN
during/IN
B-cell/NN
development/NN
./.
====================
Recent/JJ
analysis/NN
of/IN
gene-targeted/JJ
mice/NNS
has/VBZ
allowed/VBN
a/DT
direct/JJ
assessment/NN
of/IN
the/DT
functional/JJ
roles/NNS
of/IN
several/JJ
E-protein/NN
family/NN
members/NNS
in/IN
hematopoiesis/NN
./.
====================
In/IN
this/DT
review/NN
we/PRP
describe/VBP
the/DT
defects/NNS
in/IN
B-/NN
and/CC
T-lymphocyte/NN
development/NN
in/IN
mice/NNS
carrying/VBG
targeted/VBN
mutations/NNS
in/IN
the/DT
E-protein/NN
genes/NNS
and/CC
discuss/VBP
our/PRP$
current/JJ
understanding/NN
of/IN
the/DT
role/NN
of/IN
these/DT
proteins/NNS
in/IN
lymphoid/JJ
development/NN
====================
UI/LS
-/:
98374313/CD
====================
TI/LS
-/:
Epstein-Barr/JJ
virus-transforming/JJ
protein/NN
latent/JJ
infection/NN
membrane/NN
protein/NN
1/CD
activates/VBZ
transcription/NN
factor/NN
NF-kappaB/NN
through/IN
a/DT
pathway/NN
that/WDT
includes/VBZ
the/DT
NF-kappaB-inducing/NN
kinase/NN
and/CC
the/DT
IkappaB/NN
kinases/NNS
IKKalpha/NN
and/CC
IKKbeta/NN
./.
====================
AB/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
oncoprotein/NN
latent/JJ
infection/NN
membrane/NN
protein/NN
1/CD
(/(
LMP1/NN
)/)
is/VBZ
a/DT
constitutively/RB
aggregated/VBN
pseudo-tumor/NN
necrosis/NN
factor/NN
receptor/NN
(/(
TNFR/NN
)/)
that/WDT
activates/VBZ
transcription/NN
factor/NN
NF-kappaB/NN
through/IN
two/CD
sites/NNS
in/IN
its/PRP$
C-terminal/JJ
cytoplasmic/JJ
domain/NN
./.
====================
One/CD
site/NN
is/VBZ
similar/JJ
to/TO
activated/VBN
TNFRII/NN
in/IN
associating/VBG
with/IN
TNFR-associated/JJ
factors/NNS
TRAF1/NN
and/CC
TRAF2/NN
,/,
and/CC
the/DT
second/JJ
site/NN
is/VBZ
similar/JJ
to/TO
TNFRI/NN
in/IN
associating/VBG
with/IN
the/DT
TNFRI/NN
death/NN
domain/NN
interacting/VBG
protein/NN
TRADD/NN
./.
====================
TNFRI/NN
has/VBZ
been/VBN
recently/RB
shown/VBN
to/TO
activate/VB
NF-kappaB/NN
through/IN
association/NN
with/IN
TRADD/NN
,/,
RIP/NN
,/,
and/CC
TRAF2/NN
;/:
activation/NN
of/IN
the/DT
NF-kappaB-inducing/NN
kinase/NN
(/(
NIK/NN
)/)
;/:
activation/NN
of/IN
the/DT
IkappaB/NN
alpha/NN
kinases/NNS
(/(
IKKalpha/NN
and/CC
IKKbeta/NN
)/)
;/:
and/CC
phosphorylation/NN
of/IN
IkappaB/NN
alpha/NN
./.
====================
IkappaB/NN
alpha/NN
phosphorylation/NN
on/IN
Ser-32/NN
and/CC
Ser-36/NN
is/VBZ
followed/VBN
by/IN
its/PRP$
degradation/NN
and/CC
NF-kappaB/NN
activation/NN
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
show/VBP
that/IN
NF-kappaB/NN
activation/NN
by/IN
LMP1/NN
or/CC
by/IN
each/DT
of/IN
its/PRP$
effector/NN
sites/NNS
is/VBZ
mediated/VBN
by/IN
a/DT
pathway/NN
that/WDT
includes/VBZ
NIK/NN
,/,
IKKalpha/NN
,/,
and/CC
IKKbeta/NN
./.
====================
Dominant/JJ
negative/JJ
mutants/NNS
of/IN
NIK/NN
,/,
IKKalpha/NN
,/,
or/CC
IKKbeta/NN
substantially/RB
inhibited/VBD
NF-kappaB/NN
activation/NN
by/IN
LMP1/NN
or/CC
by/IN
each/DT
of/IN
its/PRP$
effector/NN
sites/NNS
./.
====================
UI/LS
-/:
98361309/CD
====================
TI/LS
-/:
Targeted/JJ
disruption/NN
of/IN
the/DT
MyD88/NN
gene/NN
results/VBZ
in/IN
loss/NN
of/IN
IL-1-/NN
and/CC
IL-18-mediated/JJ
function/NN
./.
====================
AB/LS
-/:
MyD88/NN
,/,
originally/RB
isolated/VBN
as/IN
a/DT
myeloid/JJ
differentiation/NN
primary/JJ
response/NN
gene/NN
,/,
is/VBZ
shown/VBN
to/TO
act/VB
as/IN
an/DT
adaptor/NN
in/IN
interleukin-1/NN
(/(
IL-1/NN
)/)
signaling/NN
by/IN
interacting/VBG
with/IN
both/CC
the/DT
IL-1/NN
receptor/NN
complex/NN
and/CC
IL-1/NN
receptor-associated/JJ
kinase/NN
(/(
IRAK/NN
)/)
./.
====================
Mice/NNS
generated/VBN
by/IN
gene/NN
targeting/NN
to/TO
lack/VB
MyD88/NN
have/VBP
defects/VBZ
in/IN
T/NN
cell/NN
proliferation/NN
as/RB
well/RB
as/IN
induction/NN
of/IN
acute/JJ
phase/NN
proteins/NNS
and/CC
cytokines/NNS
in/IN
response/NN
to/TO
IL-1/NN
./.
====================
Increases/NNS
in/IN
interferon-gamma/NN
production/NN
and/CC
natural/JJ
killer/NN
cell/NN
activity/NN
in/IN
response/NN
to/TO
IL-18/NN
are/VBP
abrogated/VBN
./.
====================
In/FW
vivo/FW
Th1/NN
response/NN
is/VBZ
also/RB
impaired/JJ
./.
====================
Furthermore/RB
,/,
IL-18-induced/JJ
activation/NN
of/IN
NF-kappaB/NN
and/CC
c-Jun/NN
N-terminal/JJ
kinase/NN
(/(
JNK/NN
)/)
is/VBZ
blocked/VBN
in/IN
MyD88-/-/JJ
Th1-developing/NN
cells/NNS
./.
====================
Taken/VBN
together/RB
,/,
these/DT
results/NNS
demonstrate/VBP
that/IN
MyD88/NN
is/VBZ
a/DT
critical/JJ
component/NN
in/IN
the/DT
signaling/NN
cascade/NN
that/WDT
is/VBZ
mediated/VBN
by/IN
IL-1/NN
receptor/NN
as/RB
well/RB
as/IN
IL-18/NN
receptor/NN
./.
====================
UI/LS
-/:
98353313/CD
====================
TI/LS
-/:
Ciprofloxacin/NN
induces/VBZ
an/DT
immunomodulatory/JJ
stress/NN
response/NN
in/IN
human/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Exposure/NN
of/IN
cells/NNS
to/TO
adverse/JJ
environmental/JJ
conditions/NNS
invokes/VBZ
a/DT
genetically/RB
programmed/VBN
series/NNS
of/IN
events/NNS
resulting/VBG
in/IN
the/DT
induction/NN
of/IN
specific/JJ
genes/NNS
./.
====================
The/DT
fluoroquinolone/NN
antibiotic/JJ
ciprofloxacin/NN
has/VBZ
recently/RB
been/VBN
reported/VBN
to/TO
upregulate/VB
interleukin-2/NN
(/(
IL-2/NN
)/)
gene/NN
induction/NN
./.
====================
In/IN
the/DT
present/JJ
investigation/NN
,/,
the/DT
effect/NN
of/IN
ciprofloxacin/NN
at/IN
supratherapeutic/JJ
concentrations/NNS
on/IN
immediate-early/JJ
(/(
</JJR
2/CD
h/NN
)/)
gene/NN
expression/NN
in/IN
primary/JJ
human/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
was/VBD
studied/VBN
with/IN
Northern/NN
blots/NNS
./.
====================
In/IN
addition/NN
,/,
transcriptional/JJ
activity/NN
of/IN
IL-2/NN
and/CC
metallothionein/NN
enhancer/NN
and/CC
promoter/NN
regions/NNS
and/CC
transcription/NN
factors/NNS
AP-1/NN
,/,
NF-kappaB/NN
,/,
and/CC
NF-AT/NN
were/VBD
analyzed/VBN
by/IN
chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
and/CC
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
,/,
respectively/RB
./.
====================
The/DT
concentration/NN
of/IN
c-fos/NN
,/,
c-jun/NN
,/,
c-myc/NN
,/,
junB/NN
,/,
and/CC
fra-1/NN
mRNAs/NNS
was/VBD
increased/VBN
in/IN
activated/VBN
peripheral/JJ
blood/NN
lymphocytes/NNS
incubated/VBN
with/IN
ciprofloxacin/NN
compared/VBN
to/TO
that/DT
in/IN
untreated/JJ
controls/NNS
./.
====================
Ciprofloxacin/NN
increased/VBD
CAT/NN
activity/NN
in/IN
stimulated/VBN
lymphocytes/NNS
transfected/VBN
with/IN
plasmids/NNS
containing/VBG
either/CC
the/DT
IL-2/NN
or/CC
metallothionein/NN
enhancer/NN
./.
====================
Furthermore/RB
,/,
among/IN
the/DT
transcription/NN
factors/NNS
tested/VBN
,/,
AP-1/NN
activity/NN
was/VBD
increased/VBN
in/IN
stimulated/VBN
purified/VBN
T/NN
helper/NN
lymphocytes/NNS
incubated/VBN
with/IN
ciprofloxacin/NN
compared/VBN
to/TO
drug-free/JJ
controls/NNS
./.
====================
Taken/VBN
together/RB
,/,
ciprofloxacin/NN
increased/VBD
the/DT
levels/NNS
of/IN
immediate-early/JJ
transcripts/NNS
,/,
enhanced/VBD
IL-2/NN
and/CC
metallothionein/NN
promoter/NN
induction/NN
,/,
and/CC
upregulated/VBD
AP-1/NN
concentrations/NNS
in/IN
primary/JJ
lymphocytes/NNS
,/,
reflecting/VBG
a/DT
program/NN
commonly/RB
observed/VBN
in/IN
mammalian/JJ
stress/NN
responses/NNS
./.
====================
UI/LS
-/:
98341858/CD
====================
TI/LS
-/:
A/DT
novel/JJ
retinoic/JJ
acid/NN
receptor/NN
(/(
RAR/NN
)/)
-selective/JJ
antagonist/NN
inhibits/VBZ
differentiation/NN
and/CC
apoptosis/NN
of/IN
HL-60/NN
cells/NNS
:/:
implications/NNS
of/IN
RARalpha-mediated/JJ
signals/NNS
in/IN
myeloid/JJ
leukemic/JJ
cells/NNS
./.
====================
AB/LS
-/:
Retinoic/JJ
acid/NN
(/(
RA/NN
)/)
induces/VBZ
HL-60/NN
cells/NNS
to/TO
differentiate/VB
terminally/RB
into/IN
mature/JJ
granulocytes/NNS
,/,
which/WDT
subsequently/RB
die/VBP
by/IN
apoptosis/NN
./.
====================
The/DT
biological/JJ
effects/NNS
of/IN
RA/NN
are/VBP
mediated/VBN
by/IN
two/CD
distinct/JJ
families/NNS
of/IN
transcription/NN
factors/NNS
:/:
retinoic/JJ
acid/NN
receptors/NNS
(/(
RARs/NNS
)/)
and/CC
retinoid/NN
X/NN
receptors/NNS
(/(
RXRs/NNS
)/)
./.
====================
RARs/NNS
and/CC
RXRs/NNS
form/NN
heterodimers/NNS
and/CC
regulate/VBP
retinoid-mediated/JJ
gene/NN
expression/NN
./.
====================
We/PRP
have/VBP
recently/RB
developed/VBN
a/DT
novel/JJ
RAR-selective/JJ
antagonist/NN
(/(
ER27191/NN
)/)
which/WDT
prevents/VBZ
RAR/NN
activation/NN
by/IN
retinoids/NNS
./.
====================
Using/VBG
this/DT
RAR-selective/JJ
antagonist/NN
,/,
and/CC
RXR/NN
and/CC
RAR/NN
agonist/NN
,/,
we/PRP
demonstrate/VBP
the/DT
RAR-mediated/JJ
signaling/NN
pathway/NN
is/VBZ
important/JJ
for/IN
differentiation/NN
and/CC
apoptosis/NN
of/IN
myeloid/JJ
leukemic/JJ
cells/NNS
./.
====================
Simple/JJ
activation/NN
of/IN
RXRs/NNS
is/VBZ
not/RB
sufficient/JJ
to/TO
induce/VB
apoptosis/NN
of/IN
the/DT
cells/NNS
./.
====================
Interestingly/RB
,/,
the/DT
combination/NN
of/IN
the/DT
RAR-selective/JJ
antagonist/NN
and/CC
9-cis/JJ
RA/NN
resulted/VBD
in/IN
partial/JJ
differentiation/NN
and/CC
apoptosis/NN
of/IN
HL-60/NN
and/CC
NB4/NN
cells/NNS
,/,
whereas/IN
the/DT
RAR/NN
antagonist/NN
completely/RB
blocked/VBD
all-trans/JJ
RA-induced/JJ
differentiation/NN
and/CC
apoptosis/NN
of/IN
the/DT
cells/NNS
./.
====================
Additional/JJ
experiments/NNS
showed/VBD
that/IN
levels/NNS
of/IN
BCL-2/NN
protein/NN
decreased/VBD
during/IN
differentiation/NN
of/IN
myeloid/JJ
leukemic/JJ
cells/NNS
./.
====================
Furthermore/RB
,/,
HL-60/NN
cells/NNS
transduced/VBN
with/IN
a/DT
bcl-2/NN
expression/NN
vector/NN
showed/VBD
the/DT
same/JJ
differentiation/NN
response/NN
to/TO
retinoids/NNS
as/IN
did/VBD
parental/JJ
HL-60/NN
cells/NNS
even/RB
though/IN
apoptosis/NN
was/VBD
inhibited/VBN
in/IN
these/DT
bcl-2-transduced/JJ
cells/NNS
,/,
suggesting/VBG
that/IN
differentiation/NN
and/CC
apoptosis/NN
are/VBP
regulated/VBN
independently/RB
in/IN
myeloid/JJ
leukemic/JJ
cells/NNS
./.
====================
UI/LS
-/:
98326600/CD
====================
TI/LS
-/:
Thrombopoietin/NN
supports/VBZ
in/FW
vitro/FW
erythroid/JJ
differentiation/NN
via/IN
its/PRP$
specific/JJ
receptor/NN
c-Mpl/NN
in/IN
a/DT
human/JJ
leukemia/NN
cell/NN
line/NN
./.
====================
AB/LS
-/:
Thrombopoietin/NN
(/(
TPO/NN
)/)
acts/VBZ
on/IN
megakaryopoiesis/NN
and/CC
erythropoiesis/NN
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
./.
====================
We/PRP
isolated/VBD
a/DT
novel/JJ
subline/NN
,/,
UT-7/GMT/NN
,/,
from/IN
the/DT
human/JJ
leukemia/NN
cell/NN
line/NN
UT-7/GM/NN
(/(
N./NN
Komatsu/NN
,/,
et/FW
al./FW
,/,
Blood/NN
,/,
89/CD
:/:
4021-4033/CD
,/,
1997/CD
)/)
./.
====================
A/DT
small/JJ
population/NN
of/IN
UT-7/GM/NN
cells/NNS
positively/RB
stained/VBN
for/IN
hemoglobin/NN
(/(
Hb/NN
)/)
after/IN
a/DT
7-day/JJ
exposure/NN
to/TO
TPO/NN
./.
====================
More/JJR
than/IN
50/CD
%/NN
of/IN
TPO-treated/JJ
UT-7/GMT/NN
cells/NNS
positively/RB
stained/VBN
for/IN
Hb/NN
./.
====================
Using/VBG
UT-7/GMT/NN
cells/NNS
,/,
we/PRP
examined/VBD
how/WRB
TPO/NN
promotes/VBZ
hemoglobinization/NN
./.
====================
TPO/NN
induced/VBD
tyrosine/NN
phosphorylation/NN
of/IN
the/DT
TPO/NN
receptor/NN
but/CC
not/RB
the/DT
erythropoietin/NN
(/(
EPO/NN
)/)
receptor/NN
./.
====================
There/EX
was/VBD
no/DT
competition/NN
between/IN
TPO/NN
and/CC
EPO/NN
for/IN
binding/NN
to/TO
EPO/NN
receptor/NN
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
TPO/NN
has/VBZ
a/DT
direct/JJ
effect/NN
on/IN
hemoglobinization/NN
via/IN
a/DT
specific/JJ
receptor/NN
on/IN
UT-7/GMT/NN
cells/NNS
./.
====================
Isoelectric/JJ
focusing/NN
demonstrated/VBD
that/IN
TPO/NN
induced/VBD
fetal/JJ
and/CC
adult/JJ
Hb/NN
synthesis/NN
,/,
whereas/IN
EPO/NN
induced/VBD
embryonic/JJ
,/,
fetal/JJ
,/,
and/CC
adult/JJ
Hb/NN
synthesis/NN
./.
====================
Thus/RB
,/,
our/PRP$
data/NNS
suggest/VBP
that/IN
TPO/NN
has/VBZ
a/DT
distinct/JJ
action/NN
on/IN
erythropoiesis/NN
./.
====================
UI/LS
-/:
98322148/CD
====================
TI/LS
-/:
Role/NN
of/IN
GATA-1/NN
in/IN
proliferation/NN
and/CC
differentiation/NN
of/IN
definitive/JJ
erythroid/JJ
and/CC
megakaryocytic/JJ
cells/NNS
in/FW
vivo/FW
./.
====================
AB/LS
-/:
To/TO
elucidate/VB
the/DT
contributions/NNS
of/IN
GATA-1/NN
to/TO
definitive/JJ
hematopoiesis/NN
in/FW
vivo/FW
,/,
we/PRP
have/VBP
examined/VBN
adult/JJ
mice/NNS
that/WDT
were/VBD
rendered/VBN
genetically/RB
defective/JJ
in/IN
GATA-1/NN
synthesis/NN
(/(
Takahashi/NNP
et/FW
al/FW
,/,
J/NNP
Biol/NNP
Chem/NNP
272/CD
:/:
12611/CD
,/,
1997/CD
)/)
./.
====================
Because/IN
the/DT
GATA-1/NN
gene/NN
is/VBZ
located/JJ
on/IN
the/DT
X/NN
chromosome/NN
,/,
which/WDT
is/VBZ
randomly/RB
inactivated/VBN
in/IN
every/JJ
cell/NN
,/,
heterozygous/JJ
females/NNS
can/MD
bear/VB
either/CC
an/DT
active/JJ
wild-type/JJ
or/CC
mutant/JJ
(/(
referred/VBN
to/TO
as/IN
GATA-1.05/NN
)/)
GATA-1/NN
allele/NN
,/,
consequently/RB
leading/VBG
to/TO
variable/JJ
anemic/JJ
severity/NN
./.
====================
These/DT
heterozygous/JJ
mutant/JJ
mice/NNS
usually/RB
developed/VBN
normally/RB
,/,
but/CC
they/PRP
began/VBD
to/TO
die/VB
after/IN
5/CD
months/NNS
./.
====================
These/DT
affected/VBN
animals/NNS
displayed/VBD
marked/JJ
splenomegaly/NN
,/,
anemia/NN
,/,
and/CC
thrombocytopenia/NN
./.
====================
Proerythroblasts/NNS
and/CC
megakaryocytes/NNS
massively/RB
accumulated/VBN
in/IN
the/DT
spleens/NNS
of/IN
the/DT
heterozygotes/NNS
,/,
and/CC
we/PRP
showed/VBD
that/IN
the/DT
neomycin/NN
resistance/NN
gene/NN
(/(
which/WDT
is/VBZ
the/DT
positive/JJ
selection/NN
marker/NN
in/IN
ES/NN
cells/NNS
)/)
was/VBD
expressed/VBN
profusely/RB
in/IN
the/DT
abnormally/RB
abundant/JJ
cells/NNS
generated/VBN
in/IN
the/DT
GATA-1.05/NN
mutant/JJ
females/NNS
./.
====================
We/PRP
also/RB
observed/VBD
hematopoiesis/NN
outside/NN
of/IN
the/DT
bone/NN
marrow/NN
in/IN
the/DT
affected/VBN
mutant/JJ
mice/NNS
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
a/DT
small/JJ
number/NN
of/IN
GATA-1.05/NN
mutant/JJ
hematopoietic/JJ
progenitor/NN
cells/NNS
begin/VBP
to/TO
proliferate/VB
vigorously/RB
during/IN
early/JJ
adulthood/NN
,/,
but/CC
because/IN
the/DT
cells/NNS
are/VBP
unable/JJ
to/TO
terminally/RB
differentiate/VB
,/,
this/DT
leads/VBZ
to/TO
progenitor/NN
proliferation/NN
in/IN
the/DT
spleen/NN
and/CC
consequently/RB
death/NN
./.
====================
Thus/RB
,/,
GATA-1/NN
plays/VBZ
important/JJ
in/FW
vivo/FW
roles/NNS
for/IN
directing/VBG
definitive/JJ
hematopoietic/JJ
progenitors/NNS
to/TO
differentiate/VB
along/IN
both/CC
the/DT
erythroid/JJ
and/CC
megakaryocytic/JJ
pathways/NNS
./.
====================
The/DT
GATA-1/NN
heterozygous/JJ
mutant/JJ
mouse/NN
shows/VBZ
a/DT
phenotype/NN
that/WDT
is/VBZ
analogous/JJ
to/TO
human/JJ
myelodysplastic/JJ
syndrome/NN
and/CC
thus/RB
may/MD
serve/VB
as/IN
a/DT
useful/JJ
model/NN
for/IN
this/DT
disorder/NN
./.
====================
UI/LS
-/:
98309442/CD
====================
TI/LS
-/:
Differential/JJ
regulation/NN
of/IN
the/DT
Janus/NN
kinase-STAT/NN
pathway/NN
and/CC
biologic/JJ
function/NN
of/IN
IL-13/NN
in/IN
primary/JJ
human/JJ
NK/NN
and/CC
T/NN
cells/NNS
:/:
a/DT
comparative/JJ
study/NN
with/IN
IL-4/NN
./.
====================
AB/LS
-/:
IL-13/NN
,/,
a/DT
cytokine/NN
similar/JJ
to/TO
IL-4/NN
,/,
is/VBZ
a/DT
regulator/NN
of/IN
human/JJ
B/NN
cell/NN
and/CC
monocyte/NN
functions/NNS
./.
====================
Biologic/JJ
effects/NNS
of/IN
IL-13/NN
on/IN
primary/JJ
human/JJ
NK/NN
and/CC
T/NN
cells/NNS
have/VBP
not/RB
been/VBN
well/RB
defined/VBN
./.
====================
We/PRP
demonstrate/VBP
that/IN
,/,
in/IN
primary/JJ
NK/NN
cells/NNS
,/,
IL-13/NN
,/,
but/CC
not/RB
IL-4/NN
,/,
may/MD
induce/VB
low/JJ
levels/NNS
of/IN
IFN-gamma/NN
secretion/NN
./.
====================
When/WRB
NK/NN
cells/NNS
were/VBD
costimulated/VBN
with/IN
IL-13/NN
and/CC
IL-2/NN
,/,
IL-13/NN
generally/RB
resulted/VBD
in/IN
two/CD
types/NNS
of/IN
reactivity/NN
:/:
IL-13/NN
synergized/VBD
with/IN
IL-2/NN
to/TO
stimulate/VB
IFN-gamma/NN
production/NN
or/CC
it/PRP
modestly/RB
inhibited/VBD
IL-2-/NN
mediated/JJ
IFN-gamma/NN
production/NN
./.
====================
In/IN
both/DT
types/NNS
of/IN
donors/NNS
,/,
the/DT
effect/NN
of/IN
IL-13/NN
on/IN
IL-2-induced/JJ
IFN-gamma/NN
production/NN
was/VBD
in/IN
marked/JJ
contrast/NN
to/TO
the/DT
strong/JJ
inhibition/NN
seen/VBN
with/IN
IL-4/NN
in/IN
NK/NN
cells/NNS
./.
====================
Additionally/RB
,/,
IL-13/NN
suppresses/VBZ
IL-2-induced/JJ
NK/NN
cytolytic/JJ
and/CC
proliferative/JJ
activities/NNS
although/IN
less/JJR
efficiently/RB
than/IN
IL-4/NN
./.
====================
In/IN
T/NN
cells/NNS
,/,
IL-13/NN
inhibits/VBZ
anti-CD3/JJ
mAb/IL-2-/NN
or/CC
PHA-mediated/JJ
IFN-gamma/NN
production/NN
and/CC
enhances/VBZ
cytolytic/JJ
potential/NN
./.
====================
Furthermore/RB
,/,
we/PRP
demonstrate/VBP
that/IN
IL-13/NN
,/,
like/IN
IL-4/NN
,/,
induces/VBZ
distinct/JJ
STAT6-DNA/NN
binding/NN
complexes/NNS
and/CC
tyrosine/NN
phosphorylation/NN
of/IN
STAT6/NN
and/CC
Janus/NN
kinase/NN
3/CD
(/(
JAK3/NN
)/)
in/IN
NK/NN
and/CC
T/NN
cells/NNS
./.
====================
We/PRP
observed/VBD
that/IN
Abs/NNS
directed/VBN
against/IN
unique/JJ
domains/NNS
of/IN
STAT6/NN
have/VBP
differential/JJ
effects/NNS
on/IN
complexes/NNS
in/IN
T/NN
cells/NNS
but/CC
not/RB
in/IN
NK/NN
cells/NNS
,/,
suggesting/VBG
different/JJ
STAT6/NN
isoforms/NNS
./.
====================
These/DT
findings/NNS
show/VBP
that/IN
IL-13/NN
and/CC
IL-4/NN
have/VBP
the/DT
ability/NN
to/TO
regulate/VB
NK/NN
and/CC
T/NN
cell/NN
activation/NN
and/CC
that/IN
IL-/NN
13/CD
is/VBZ
a/DT
potent/JJ
regulator/NN
of/IN
STAT6/NN
and/CC
JAK3/NN
in/IN
these/DT
cell/NN
types/NNS
./.
====================
UI/LS
-/:
98290745/CD
====================
TI/LS
-/:
The/DT
human/JJ
toll/NN
signaling/NN
pathway/NN
:/:
divergence/NN
of/IN
nuclear/JJ
factor/NN
kappaB/NN
and/CC
JNK/SAPK/NN
activation/NN
upstream/RB
of/IN
tumor/NN
necrosis/NN
factor/NN
receptor-associated/JJ
factor/NN
6/CD
(/(
TRAF6/NN
)/)
./.
====================
AB/LS
-/:
The/DT
human/JJ
homologue/NN
of/IN
Drosophila/FW
Toll/NN
(/(
hToll/NN
)/)
is/VBZ
a/DT
recently/RB
cloned/VBN
receptor/NN
of/IN
the/DT
interleukin/NN
1/CD
receptor/NN
(/(
IL-1R/NN
)/)
superfamily/NN
,/,
and/CC
has/VBZ
been/VBN
implicated/VBN
in/IN
the/DT
activation/NN
of/IN
adaptive/JJ
immunity/NN
./.
====================
Signaling/NN
by/IN
hToll/NN
is/VBZ
shown/VBN
to/TO
occur/VB
through/IN
sequential/JJ
recruitment/NN
of/IN
the/DT
adapter/NN
molecule/NN
MyD88/NN
and/CC
the/DT
IL-1R-associated/JJ
kinase/NN
./.
====================
Tumor/NN
necrosis/NN
factor/NN
receptor-activated/JJ
factor/NN
6/CD
(/(
TRAF6/NN
)/)
and/CC
the/DT
nuclear/JJ
factor/NN
kappaB/NN
(/(
NF-kappaB/NN
)/)
-inducing/JJ
kinase/NN
(/(
NIK/NN
)/)
are/VBP
both/CC
involved/VBN
in/IN
subsequent/JJ
steps/NNS
of/IN
NF-kappaB/NN
activation/NN
./.
====================
Conversely/RB
,/,
a/DT
dominant/JJ
negative/JJ
version/NN
of/IN
TRAF6/NN
failed/VBD
to/TO
block/VB
hToll-induced/JJ
activation/NN
of/IN
stress-activated/JJ
protein/NN
kinase/c-Jun/NN
NH2-terminal/JJ
kinases/NNS
,/,
thus/RB
suggesting/VBG
an/DT
early/JJ
divergence/NN
of/IN
the/DT
two/CD
pathways/NNS
./.
====================
UI/LS
-/:
98282206/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
nuclear/JJ
factor/NN
kappaB/NN
activation/NN
attenuates/VBZ
apoptosis/NN
resistance/NN
in/IN
lymphoid/JJ
cells/NNS
./.
====================
AB/LS
-/:
Death-inducing/NN
ligands/NNS
(/(
DILs/NNS
)/)
such/JJ
as/IN
tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNFalpha/NN
)/)
or/CC
the/DT
cytotoxic/JJ
drug/NN
doxorubicin/NN
have/VBP
been/VBN
shown/VBN
to/TO
activate/VB
a/DT
nuclear/JJ
factor/NN
kappaB/NN
(/(
NFkappaB/NN
)/)
-dependent/JJ
program/NN
that/WDT
may/MD
rescue/VB
cells/NNS
from/IN
apoptosis/NN
induction/NN
./.
====================
We/PRP
demonstrate/VBP
here/RB
that/IN
TRAIL/NN
(/(
TNF-related/JJ
apoptosis-inducing/NN
ligand/NN
)/)
,/,
a/DT
recently/RB
identified/VBN
DIL/NN
,/,
also/RB
activates/VBZ
NFkappaB/NN
in/IN
lymphoid/JJ
cell/NN
lines/NNS
in/IN
a/DT
kinetic/JJ
similar/JJ
to/TO
TNFalpha/NN
./.
====================
NFkappaB/NN
activity/NN
is/VBZ
independent/JJ
from/IN
FADD/NN
,/,
caspases/NNS
,/,
and/CC
apoptosis/NN
induction/NN
./.
====================
To/TO
study/VB
the/DT
influence/NN
of/IN
NFkappaB/NN
activity/NN
on/IN
apoptosis/NN
mediated/VBN
by/IN
TRAIL/NN
,/,
CD95/NN
,/,
TNFalpha/NN
,/,
or/CC
doxorubicin/NN
,/,
NFkappaB/NN
activation/NN
was/VBD
inhibited/VBN
using/VBG
the/DT
proteasome/NN
inhibitor/NN
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal/NN
or/CC
transient/JJ
overexpression/NN
of/IN
mutant/JJ
IkappaBalpha/NN
./.
====================
Sensitivity/NN
for/IN
induction/NN
of/IN
apoptosis/NN
was/VBD
markedly/RB
increased/VBN
by/IN
these/DT
treatments/NNS
in/IN
apoptosis/NN
sensitive/JJ
cell/NN
lines/NNS
./.
====================
Moreover/RB
,/,
both/CC
in/IN
cell/NN
lines/NNS
and/CC
in/IN
primary/JJ
leukemia/NN
cells/NNS
that/WDT
are/VBP
resistant/JJ
towards/IN
induction/NN
of/IN
apoptosis/NN
by/IN
DILs/NN
and/CC
doxorubicin/NN
,/,
antagonization/NN
of/IN
NFkappaB/NN
activity/NN
partially/RB
restored/VBD
apoptosis/NN
sensitivity/NN
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
inhibition/NN
of/IN
NFkappaB/NN
activation/NN
may/MD
provide/VB
a/DT
molecular/JJ
approach/NN
to/TO
increase/VB
apoptosis/NN
sensitivity/NN
in/IN
anticancer/JJ
treatment/NN
./.
====================
UI/LS
-/:
98282481/CD
====================
TI/LS
-/:
Loss-/NN
and/CC
gain-of-function/NN
mutations/NNS
reveal/VBP
an/DT
important/JJ
role/NN
of/IN
BSAP/NN
(/(
Pax-5/NN
)/)
at/IN
the/DT
start/NN
and/CC
end/NN
of/IN
B/NN
cell/NN
differentiation/NN
./.
====================
AB/LS
-/:
Pax-5/NN
codes/VBZ
for/IN
the/DT
transcription/NN
factor/NN
BSAP/NN
which/WDT
is/VBZ
expressed/VBN
throughout/IN
B/NN
cell/NN
development/NN
except/NN
in/IN
terminally/RB
differentiated/VBN
plasma/NN
cells/NNS
./.
====================
Gene/NN
targeting/NN
experiments/NNS
in/IN
the/DT
mouse/NN
revealed/VBD
a/DT
differential/JJ
dependency/NN
of/IN
fetal/JJ
and/CC
adult/JJ
B-lymphopoiesis/NN
on/IN
this/DT
transcription/NN
factor/NN
./.
====================
BSAP/NN
is/VBZ
required/VBN
for/IN
B-lineage/NN
commitment/NN
in/IN
the/DT
fetal/JJ
liver/NN
and/CC
for/IN
progression/NN
beyond/IN
an/DT
early/JJ
pro-B/NN
cell/NN
stage/NN
in/IN
adult/JJ
bone/NN
marrow/NN
./.
====================
The/DT
characterization/NN
of/IN
Pax-5-deficient/JJ
pro-B/NN
cells/NNS
demonstrated/VBD
an/DT
important/JJ
role/NN
of/IN
BSAP/NN
in/IN
the/DT
regulation/NN
of/IN
the/DT
CD19/NN
,/,
mb-1/NN
(/(
Ig/NN
alpha/NN
)/)
and/CC
N-myc/NN
genes/NNS
as/RB
well/RB
as/IN
in/IN
the/DT
developmental/JJ
pathway/NN
controlling/VBG
VH-to-DHJH/JJ
recombination/NN
at/IN
the/DT
immunoglobulin/NN
heavy-chain/JJ
(/(
IgH/NN
)/)
locus/NN
./.
====================
The/DT
human/JJ
PAX-5/NN
gene/NN
was/VBD
recently/RB
shown/VBN
to/TO
participate/VB
together/RB
with/IN
the/DT
IgH/NN
locus/NN
in/IN
the/DT
chromosomal/JJ
translocation/NN
t(9;14)(p13;q32)/NN
./.
====================
This/DT
translocation/NN
is/VBZ
characteristic/JJ
of/IN
a/DT
small/JJ
subset/NN
of/IN
non-Hodgkin/JJ
lymphomas/NNS
exhibiting/VBG
plasmacytoid/JJ
differentiation/NN
./.
====================
The/DT
translocated/JJ
PAX-5/NN
gene/NN
is/VBZ
deregulated/VBN
by/IN
the/DT
insertion/NN
of/IN
IgH/NN
regulatory/JJ
elements/NNS
into/IN
its/PRP$
5'/JJ
region/NN
,/,
which/WDT
may/MD
contribute/VB
to/TO
tumorigenesis/NN
by/IN
interfering/VBG
with/IN
the/DT
shut-down/NN
of/IN
PAX-5/NN
transcription/NN
and/CC
thus/RB
with/IN
the/DT
completion/NN
of/IN
plasma/NN
cell/NN
differentiation/NN
====================
UI/LS
-/:
98374270/CD
====================
TI/LS
-/:
Acetylation/NN
and/CC
modulation/NN
of/IN
erythroid/JJ
Kruppel-like/JJ
factor/NN
(/(
EKLF/NN
)/)
activity/NN
by/IN
interaction/NN
with/IN
histone/NN
acetyltransferases/NNS
./.
====================
AB/LS
-/:
Erythroid/JJ
Kruppel-like/JJ
factor/NN
(/(
EKLF/NN
)/)
is/VBZ
a/DT
red/JJ
cell-specific/JJ
transcriptional/JJ
activator/NN
that/WDT
is/VBZ
crucial/JJ
for/IN
consolidating/VBG
the/DT
switch/NN
to/TO
high/JJ
levels/NNS
of/IN
adult/JJ
beta-globin/NN
expression/NN
during/IN
erythroid/JJ
ontogeny/NN
./.
====================
EKLF/NN
is/VBZ
required/VBN
for/IN
integrity/NN
of/IN
the/DT
chromatin/NN
structure/NN
at/IN
the/DT
beta-like/JJ
globin/NN
locus/NN
,/,
and/CC
it/PRP
interacts/VBZ
with/IN
a/DT
positive-acting/JJ
factor/NN
in/FW
vivo/FW
./.
====================
We/PRP
find/VBP
that/IN
EKLF/NN
is/VBZ
an/DT
acetylated/VBN
transcription/NN
factor/NN
,/,
and/CC
that/IN
it/PRP
interacts/VBZ
in/FW
vivo/FW
with/IN
CBP/NN
,/,
p300/NN
,/,
and/CC
P/CAF/NN
./.
====================
However/RB
,/,
its/PRP$
interactions/NNS
with/IN
these/DT
histone/NN
acetyltransferases/NNS
are/VBP
not/RB
equivalent/JJ
,/,
as/IN
CBP/NN
and/CC
p300/NN
,/,
but/CC
not/RB
P/CAF/NN
,/,
utilize/VBP
EKLF/NN
as/IN
a/DT
substrate/NN
for/IN
in/FW
vitro/FW
acetylation/NN
within/IN
its/PRP$
trans-activation/NN
region/NN
./.
====================
The/DT
functional/JJ
effects/NNS
of/IN
these/DT
interactions/NNS
are/VBP
that/IN
CBP/NN
and/CC
p300/NN
,/,
but/CC
not/RB
P/CAF/NN
,/,
enhance/VBP
EKLF/NN
's/POS
transcriptional/JJ
activation/NN
of/IN
the/DT
beta-globin/NN
promoter/NN
in/IN
erythroid/JJ
cells/NNS
./.
====================
These/DT
results/NNS
establish/VBP
EKLF/NN
as/IN
a/DT
tissue-specific/JJ
transcription/NN
factor/NN
that/WDT
undergoes/VBZ
post-translational/JJ
acetylation/NN
and/CC
suggest/VBP
a/DT
mechanism/NN
by/IN
which/WDT
EKLF/NN
is/VBZ
able/JJ
to/TO
alter/VB
chromatin/NN
structure/NN
and/CC
induce/VB
beta-globin/NN
expression/NN
within/IN
the/DT
beta-like/JJ
globin/NN
cluster/NN
./.
====================
UI/LS
-/:
98362153/CD
====================
TI/LS
-/:
Recognition/NN
of/IN
herpes/NN
simplex/NN
virus/NN
type/NN
2/CD
tegument/NN
proteins/NNS
by/IN
CD4/NN
T/NN
cells/NNS
infiltrating/VBG
human/JJ
genital/JJ
herpes/NN
lesions/NNS
./.
====================
AB/LS
-/:
The/DT
local/JJ
cellular/JJ
immune/JJ
response/NN
to/TO
herpes/NN
simplex/NN
virus/NN
(/(
HSV/NN
)/)
is/VBZ
important/JJ
in/IN
the/DT
control/NN
of/IN
recurrent/JJ
HSV/NN
infection/NN
./.
====================
The/DT
antiviral/JJ
functions/NNS
of/IN
infiltrating/VBG
CD4-bearing/JJ
T/NN
cells/NNS
may/MD
include/VBP
cytotoxicity/NN
,/,
inhibition/NN
of/IN
viral/JJ
growth/NN
,/,
lymphokine/NN
secretion/NN
,/,
and/CC
support/NN
of/IN
humoral/JJ
and/CC
CD8/NN
responses/NNS
./.
====================
The/DT
antigens/NNS
recognized/VBN
by/IN
many/JJ
HSV-specific/JJ
CD4/NN
T/NN
cells/NNS
localizing/VBG
to/TO
genital/JJ
HSV-2/NN
lesions/NNS
are/VBP
unknown/JJ
./.
====================
T/NN
cells/NNS
recognizing/VBG
antigens/NNS
encoded/VBN
within/IN
map/NN
units/NNS
0/CD
./.
67/CD
to/TO
0.73/CD
of/IN
HSV/NN
DNA/NN
are/VBP
frequently/RB
recovered/VBN
from/IN
herpetic/JJ
lesions/NNS
./.
====================
Expression/NN
cloning/NN
with/IN
this/DT
region/NN
of/IN
DNA/NN
now/RB
shows/VBZ
that/IN
tegument/NN
protein/NN
VP22/NN
and/CC
the/DT
viral/JJ
dUTPase/NN
,/,
encoded/VBN
by/IN
genes/NNS
UL49/NN
and/CC
UL50/NN
,/,
respectively/RB
,/,
are/VBP
T-cell/NN
antigens/NNS
./.
====================
Separate/JJ
epitopes/NNS
in/IN
VP22/NN
were/VBD
defined/VBN
for/IN
T-cell/NN
clones/NNS
from/IN
each/DT
of/IN
three/CD
patients/NNS
./.
====================
Reactivity/NN
with/IN
the/DT
tegument/JJ
protein/NN
encoded/VBN
by/IN
UL21/NN
was/VBD
identified/VBN
for/IN
an/DT
additional/JJ
patient/NN
./.
====================
Three/CD
new/JJ
epitopes/NNS
were/VBD
identified/VBN
in/IN
VP16/NN
,/,
a/DT
tegument/JJ
protein/NN
associated/VBN
with/IN
VP22/NN
./.
====================
Some/DT
tegument-specific/JJ
CD4/NN
T-cell/NN
clones/NNS
exhibited/VBD
cytotoxic/JJ
activity/NN
against/IN
HSV-infected/JJ
cells/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
herpes/NN
simplex/NN
tegument/NN
proteins/NNS
are/VBP
processed/VBN
for/IN
antigen/NN
presentation/NN
in/FW
vivo/FW
and/CC
are/VBP
possible/JJ
candidate/NN
compounds/NNS
for/IN
herpes/NN
simplex/NN
vaccines/NNS
./.
====================
UI/LS
-/:
98349401/CD
====================
TI/LS
-/:
Fibrinogen/NN
activates/VBZ
NF-kappa/NN
B/NN
transcription/NN
factors/NNS
in/IN
mononuclear/JJ
phagocytes/NNS
./.
====================
AB/LS
-/:
Adhesion/NN
to/TO
extracellular/JJ
matrices/NNS
is/VBZ
known/VBN
to/TO
modulate/VB
leukocyte/NN
activation/NN
,/,
although/IN
the/DT
mechanisms/NNS
are/VBP
not/RB
fully/RB
understood/VBN
./.
====================
Mononuclear/JJ
phagocytes/NNS
are/VBP
exposed/VBN
to/TO
fibrinous/JJ
provisional/JJ
matrix/NN
throughout/IN
migration/NN
into/IN
inflammatory/JJ
foci/NNS
,/,
so/RB
this/DT
study/NN
was/VBD
undertaken/VBN
to/TO
determine/VB
whether/IN
fibrinogen/NN
triggers/VBZ
activation/NN
of/IN
NF-kappa/NN
B/NN
transcription/NN
factors/NNS
./.
====================
U937/NN
cells/NNS
differentiated/VBN
with/IN
PMA/NN
in/IN
nonadherent/JJ
culture/NN
were/VBD
shown/VBN
to/TO
express/VB
two/CD
fibrinogen-binding/JJ
integrins/NNS
,/,
predominately/RB
CD11b/CD18/NN
,/,
and/CC
to/TO
a/DT
lesser/JJR
extent/NN
,/,
CD11c/CD18/NN
./.
====================
Cells/NNS
stimulated/VBN
with/IN
fibrinogen/NN
(/(
10-100/CD
microg/ml/NN
)/)
/Mn2+/JJ
(/(
50/CD
microM/NN
)/)
for/IN
2/CD
h/NN
were/VBD
examined/VBN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
./.
====================
NF-kappa/NN
B/NN
activation/NN
,/,
minimal/JJ
in/IN
unstimulated/JJ
cells/NNS
,/,
was/VBD
substantially/RB
up-regulated/VBN
by/IN
fibrinogen/NN
./.
====================
Fibrinogen/NN
also/RB
caused/VBD
activation/NN
of/IN
AP-1/NN
,/,
but/CC
not/RB
SP1/NN
or/CC
cAMP/NN
response/NN
element-binding/JJ
protein/NN
(/(
CREB/NN
)/)
factors/NNS
./.
====================
Blocking/NN
mAbs/NNS
against/IN
CD18/NN
and/CC
CD11b/NN
abrogated/VBD
fibrinogen-induced/JJ
NF-kappa/NN
B/NN
activation/NN
./.
====================
To/TO
determine/VB
the/DT
effects/NNS
on/IN
transcriptional/JJ
regulation/NN
,/,
U937/NN
cells/NNS
were/VBD
transfected/VBN
with/IN
a/DT
plasmid/NN
containing/VBG
the/DT
HIV-1/NN
enhancer/NN
(/(
bearing/VBG
two/CD
NF-kappa/NN
B/NN
sites/NNS
)/)
coupled/VBN
to/TO
a/DT
chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
reporter/NN
./.
====================
Cells/NNS
were/VBD
subsequently/RB
stimulated/VBN
with/IN
1/LS
)/)
PMA/NN
for/IN
24/CD
h/NN
,/,
inducing/VBG
CAT/NN
activity/NN
by/IN
2.6-fold/JJ
,/,
2/LS
)/)
fibrinogen/Mn2+/NN
for/IN
2/CD
h/NN
,/,
inducing/VBG
CAT/NN
activity/NN
by/IN
3.2-fold/JJ
,/,
or/CC
3/LS
)/)
costimulation/NN
with/IN
fibrinogen/NN
and/CC
PMA/NN
,/,
inducing/VBG
5.7-fold/JJ
the/DT
CAT/NN
activity/NN
induced/VBN
by/IN
PMA/NN
alone/RB
./.
====================
We/PRP
conclude/VBP
that/IN
contact/NN
with/IN
fibrinogen-derived/JJ
proteins/NNS
may/MD
contribute/VB
to/TO
mononuclear/JJ
phagocyte/NN
activation/NN
by/IN
signaling/NN
through/IN
CD11b/CD18/NN
,/,
resulting/VBG
in/IN
selective/JJ
activation/NN
of/IN
transcriptional/JJ
regulatory/JJ
factors/NNS
,/,
including/VBG
NF-kappa/NN
B/NN
./.
====================
UI/LS
-/:
98339383/CD
====================
TI/LS
-/:
Peripheral/JJ
blood/NN
T/NN
cells/NNS
and/CC
monocytes/NNS
and/CC
B/NN
cell/NN
lines/NNS
derived/VBN
from/IN
patients/NNS
with/IN
lupus/NN
express/VBP
estrogen/NN
receptor/NN
transcripts/NNS
similar/JJ
to/TO
those/DT
of/IN
normal/JJ
cells/NNS
./.
====================
AB/LS
-/:
OBJECTIVE/NN
:/:
To/TO
identify/VB
and/CC
characterize/VB
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
transcripts/NNS
expressed/VBN
in/IN
immune/JJ
cells/NNS
of/IN
patients/NNS
with/IN
systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
and/CC
healthy/JJ
donors/NNS
./.
====================
METHODS/NNS
:/:
Peripheral/JJ
blood/NN
monocytes/NNS
and/CC
T/NN
cells/NNS
were/VBD
prepared/VBN
from/IN
patients/NNS
with/IN
SLE/NN
(/(
n/NN
=/JJ
6/CD
)/)
and/CC
healthy/JJ
donors/NNS
(/(
n/NN
=/JJ
8/CD
)/)
./.
====================
T/NN
cells/NNS
were/VBD
separated/VBN
into/IN
CD4/NN
and/CC
CD8/NN
./.
====================
Some/DT
monocytes/NNS
and/CC
T/NN
cells/NNS
were/VBD
stimulated/VBN
with/IN
estradiol/NN
,/,
PMA/NN
,/,
and/CC
ionomycin/NN
./.
====================
Epstein-Barr/JJ
virus-transformed/JJ
B/NN
cell/NN
lines/NNS
(/(
n/NN
=/JJ
7/CD
)/)
and/CC
B/NN
cell/NN
hybridomas/NNS
(/(
n/NN
=/JJ
2/LS
)/)
established/VBN
from/IN
patients/NNS
with/IN
SLE/NN
and/CC
a/DT
healthy/JJ
individual/JJ
were/VBD
used/VBN
as/IN
a/DT
B/NN
cell/NN
source/RB
./.
====================
These/DT
cells/NNS
were/VBD
examined/VBN
for/IN
ER/NN
mRNA/NN
by/IN
reverse/JJ
transcription/NN
nested/JJ
polymerase/NN
chain/NN
reaction/NN
./.
====================
Amplified/JJ
cDNA/NN
were/VBD
sequenced/VBN
by/IN
standard/JJ
methods/NNS
./.
====================
RESULTS/NNS
:/:
In/IN
all/DT
cells/NNS
tested/VBN
,/,
ER/NN
mRNA/NN
was/VBD
expressed/VBN
without/IN
prior/JJ
in/FW
vitro/FW
stimulation/NN
./.
====================
Partial/JJ
sequences/NNS
from/IN
exons/NNS
1-8/CD
were/VBD
nearly/RB
identical/JJ
to/TO
the/DT
published/VBN
sequence/NN
of/IN
the/DT
human/JJ
ER/NN
mRNA/NN
./.
====================
There/EX
were/VBD
no/DT
notable/JJ
differences/NNS
in/IN
the/DT
ER/NN
transcripts/NNS
between/IN
patients/NNS
and/CC
healthy/JJ
controls/NNS
./.
====================
Variant/JJ
receptor/NN
transcripts/NNS
lacking/VBG
exon/NN
5/CD
or/CC
exon/NN
7/CD
,/,
which/WDT
encodes/VBZ
the/DT
hormone/NN
binding/NN
domain/NN
,/,
were/VBD
identified/VBN
in/IN
the/DT
majority/NN
of/IN
the/DT
cells/NNS
./.
====================
Precise/JJ
deletion/NN
of/IN
the/DT
exons/NNS
suggests/VBZ
that/IN
they/PRP
are/VBP
alternatively/RB
spliced/VBN
transcripts/NNS
./.
====================
Whether/IN
the/DT
detected/JJ
transcripts/NNS
are/VBP
translated/VBN
into/IN
functional/JJ
receptor/NN
proteins/NNS
remains/VBZ
to/TO
be/VB
determined/VBN
./.
====================
In/FW
vitro/FW
stimulation/NN
did/VBD
not/RB
affect/VB
ER/NN
mRNA/NN
expression/NN
./.
====================
The/DT
presence/NN
of/IN
variants/NNS
did/VBD
not/RB
correlate/VB
with/IN
disease/NN
activity/NN
or/CC
medication/NN
./.
====================
CONCLUSION/NN
:/:
Monocytes/NNS
,/,
T/NN
cells/NNS
,/,
and/CC
B/NN
cells/NNS
in/IN
patients/NNS
express/VBP
transcripts/NNS
of/IN
the/DT
normal/JJ
wild/JJ
type/NN
ER/NN
and/CC
the/DT
hormone/NN
binding/NN
domain/NN
variants/NNS
in/FW
vivo/FW
./.
====================
UI/LS
-/:
98325368/CD
====================
TI/LS
-/:
DNA/NN
damaging/NN
agents/NNS
induce/VBP
expression/NN
of/IN
Fas/NN
ligand/NN
and/CC
subsequent/JJ
apoptosis/NN
in/IN
T/NN
lymphocytes/NNS
via/IN
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
and/CC
AP-1/NN
./.
====================
AB/LS
-/:
Apoptosis/NN
induced/VBN
by/IN
DNA/NN
damage/NN
and/CC
other/JJ
stresses/NNS
can/MD
proceed/VB
via/IN
expression/NN
of/IN
Fas/NN
ligand/NN
(/(
FasL/NN
)/)
and/CC
ligation/NN
of/IN
its/PRP$
receptor/NN
,/,
Fas/NN
(/(
CD95/NN
)/)
./.
====================
We/PRP
report/VBP
that/IN
activation/NN
of/IN
the/DT
two/CD
transcription/NN
factors/NNS
NF-kappa/NN
B/NN
and/CC
AP-1/NN
is/VBZ
crucially/RB
involved/VBN
in/IN
FasL/NN
expression/NN
induced/VBN
by/IN
etoposide/NN
,/,
teniposide/NN
,/,
and/CC
UV/NN
irradiation/NN
./.
====================
A/DT
nondegradable/JJ
mutant/NN
of/IN
I/NN
kappa/NN
B/NN
blocked/VBD
both/CC
FasL/NN
expression/NN
and/CC
apoptosis/NN
induced/VBN
by/IN
DNA/NN
damage/NN
but/CC
not/RB
Fas/NN
ligation/NN
./.
====================
These/DT
stimuli/NNS
also/RB
induced/VBD
the/DT
stress-activated/JJ
kinase/NN
pathway/NN
(/(
SAPK/JNK/NN
)/)
,/,
which/WDT
was/VBD
required/VBN
for/IN
the/DT
maximal/JJ
induction/NN
of/IN
apoptosis/NN
./.
====================
A/DT
1.2/CD
kb/NN
FasL/NN
promoter/NN
responded/VBD
to/TO
DNA/NN
damage/NN
,/,
as/RB
well/RB
as/IN
coexpression/NN
with/IN
p65/NN
Rel/NN
or/CC
Fos/Jun/NN
./.
====================
Mutations/NNS
in/IN
the/DT
relevant/JJ
NF-kappa/NN
B/NN
and/CC
AP-1/NN
binding/NN
sites/NNS
eliminated/VBD
these/DT
responses/NNS
./.
====================
Thus/RB
,/,
activation/NN
of/IN
NF-kappa/NN
B/NN
and/CC
AP-1/NN
contributes/VBZ
to/TO
stress-induced/JJ
apoptosis/NN
via/IN
the/DT
expression/NN
of/IN
FasL/NN
./.
====================
UI/LS
-/:
98322350/CD
====================
TI/LS
-/:
A/DT
small/JJ
,/,
nonpeptidyl/JJ
mimic/NN
of/IN
granulocyte-colony-stimulating/JJ
factor/NN
[/(
see/VB
commetns/NNS
]/)
====================
AB/LS
-/:
A/DT
nonpeptidyl/JJ
small/JJ
molecule/NN
SB/NN
247464/CD
,/,
capable/JJ
of/IN
activating/VBG
granulocyte-colony-stimulating/JJ
factor/NN
(/(
G-CSF/NN
)/)
signal/NN
transduction/NN
pathways/NNS
,/,
was/VBD
identified/VBN
in/IN
a/DT
high-throughput/JJ
assay/NN
in/IN
cultured/VBN
cells/NNS
./.
====================
Like/IN
G-CSF/NN
,/,
SB/NN
247464/CD
induced/VBD
tyrosine/NN
phosphorylation/NN
of/IN
multiple/JJ
signaling/NN
proteins/NNS
and/CC
stimulated/VBN
primary/JJ
murine/JJ
bone/NN
marrow/NN
cells/NNS
to/TO
form/VB
granulocytic/JJ
colonies/NNS
in/FW
vitro/FW
./.
====================
It/PRP
also/RB
elevated/JJ
peripheral/JJ
blood/NN
neutrophil/NN
counts/NNS
in/IN
mice/NNS
./.
====================
The/DT
extracellular/JJ
domain/NN
of/IN
the/DT
murine/JJ
G-CSF/NN
receptor/NN
was/VBD
required/VBN
for/IN
the/DT
activity/NN
of/IN
SB/NN
247464/CD
,/,
suggesting/VBG
that/IN
the/DT
compound/NN
acts/VBZ
by/IN
oligomerizing/VBG
receptor/NN
chains/NNS
./.
====================
The/DT
results/NNS
indicate/VBP
that/IN
a/DT
small/JJ
molecule/NN
can/MD
activate/VB
a/DT
receptor/NN
that/WDT
normally/RB
binds/VBZ
a/DT
relatively/RB
large/JJ
protein/NN
ligand/NN
./.
====================
UI/LS
-/:
98305722/CD
====================
TI/LS
-/:
Minimal/JJ
residual/JJ
disease/NN
in/IN
acute/JJ
myelogenous/JJ
leukemia/NN
with/IN
PML/RAR/NN
alpha/NN
or/CC
AML1/ETO/NN
mRNA/NN
and/CC
phenotypic/JJ
analysis/NN
of/IN
possible/JJ
T/NN
and/CC
natural/JJ
killer/NN
cells/NNS
in/IN
bone/NN
marrow/NN
./.
====================
AB/LS
-/:
Here/RB
we/PRP
studied/VBN
minimal/JJ
residual/JJ
disease/NN
(/(
MRD/NN
)/)
of/IN
patients/NNS
with/IN
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
who/WP
have/VBP
PML/RAR/NN
alpha/NN
or/CC
AML1/ETO/NN
as/RB
well/RB
as/IN
the/DT
phenotypic/JJ
analysis/NN
of/IN
lymphocyte/NN
subsets/NNS
involved/VBN
in/IN
antitumor/NN
immunity/NN
./.
====================
Eight/CD
patients/NNS
in/IN
long-term/JJ
(/(
LT/JJ
;/:
3/CD
to/TO
15/CD
years/NNS
)/)
and/CC
15/CD
patients/NNS
in/IN
short-term/JJ
(/(
ST/JJ
;/:
up/RB
to/TO
3/CD
years/NN
)/)
remission/NN
were/VBD
studied/VBN
./.
====================
Using/VBG
the/DT
reverse/JJ
transcription-polymerase/NN
chain/NN
reaction/NN
(/(
RT/NN
)/)
assay/NN
,/,
the/DT
limit/NN
of/IN
detection/NN
was/VBD
10(-5)/CD
to/TO
10(-6)/CD
for/IN
PML/RAR/NN
alpha/NN
transcript/NN
and/CC
10(-4)/CD
to/TO
10(-5)/CD
for/IN
the/DT
AML1/ETO/NN
transcript/NN
./.
====================
Simultaneously/RB
,/,
T/NN
lymphocyte/NN
subsets/NNS
and/CC
NK/NN
cells/NNS
from/IN
the/DT
peripheral/JJ
blood/NN
(/(
PB/NN
)/)
and/CC
bone/NN
marrow/NN
(/(
BM/NN
)/)
were/VBD
investigated/VBN
by/IN
flow/NN
cytometric/JJ
analysis/NN
./.
====================
Four/CD
of/IN
the/DT
eight/CD
patients/NNS
in/IN
LT/JJ
and/CC
7/CD
of/IN
the/DT
15/CD
patients/NNS
in/IN
ST/JJ
remission/NN
were/VBD
MRD-positive/JJ
./.
====================
Although/IN
all/DT
MRD-positive/JJ
patients/NNS
in/IN
LT/JJ
remission/NN
are/VBP
still/RB
until/IN
now/RB
event-free/RB
,/,
3/CD
of/IN
the/DT
7/CD
MRD-positive/JJ
(/(
MRD+/JJ
)/)
patients/NNS
in/IN
ST/JJ
remission/NN
soon/IN
relapsed/NN
./.
====================
The/DT
total/JJ
populations/NNS
of/IN
CD4+/JJ
,/,
CD8+/JJ
and/CC
CD56+/JJ
[/(
possible/JJ
T-cell/NN
and/CC
natural/JJ
killer/NN
(/(
T/NK/NN
)/)
populations/NNS
]/)
in/IN
the/DT
BM/NN
of/IN
ST/JJ
patients/NNS
and/CC
MRD+/LT/JJ
patients/NNS
were/VBD
significantly/RB
(/(
p/NN
</JJR
.01/CD
)/)
low/JJ
./.
====================
The/DT
CD8+/JJ
CD28+/JJ
population/NN
showed/VBD
the/DT
same/JJ
tendency/NN
(/(
p/NN
</JJR
.01-.02/CD
)/)
./.
====================
The/DT
T/NK/NN
subsets/NNS
in/IN
the/DT
BM/NN
of/IN
MRD-negative/JJ
(/(
MRD-/JJ
)/)
LT/JJ
(/(
MRD-/LT/JJ
)/)
patients/NNS
showed/VBD
similar/JJ
numbers/NNS
of/IN
cells/NNS
as/IN
normal/JJ
volunteers/NNS
./.
====================
Basically/RB
,/,
the/DT
total/JJ
percentage/NN
of/IN
the/DT
CD4+/JJ
,/,
CD8+/JJ
and/CC
CD56+/JJ
cell/NN
populations/NNS
in/IN
the/DT
BM/NN
was/VBD
increased/VBN
and/CC
in/IN
the/DT
following/VBG
order/NN
:/:
MRD-/LT/JJ
patients/NNS
,/,
normal/JJ
volunteers/NNS
,/,
MRD+/LT/JJ
patients/NNS
and/CC
MRD+/JJ
or/CC
-/ST/JJ
patients/NNS
./.
====================
The/DT
percentages/NNS
of/IN
the/DT
T/NK-cell/NN
subsets/NNS
in/IN
the/DT
PB/NN
were/VBD
not/RB
significantly/RB
different/JJ
among/IN
these/DT
groups/NNS
./.
====================
Thus/RB
,/,
the/DT
difference/NN
of/IN
the/DT
possible/JJ
T/NK-cell/JJ
phenotype/NN
in/IN
the/DT
BM/NN
may/MD
strongly/RB
influence/VB
clinical/JJ
and/CC
molecular/JJ
remission/NN
./.
====================
These/DT
results/NNS
still/RB
remain/VBP
to/TO
be/VB
confirmed/VBN
by/IN
further/JJ
studies/NNS
of/IN
the/DT
functional/JJ
anti-tumor/JJ
immunity/NN
of/IN
T/NK/NN
cells/NNS
of/IN
AML/NN
in/IN
remission/NN
./.
====================
UI/LS
-/:
98295832/CD
====================
TI/LS
-/:
Mycobacterium/FW
tuberculosis/FW
mannose-capped/JJ
lipoarabinomannan/NN
can/MD
induce/VB
NF-kappaB-dependent/JJ
activation/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Tuberculosis/NN
has/VBZ
emerged/VBN
as/IN
an/DT
epidemic/JJ
,/,
extended/VBN
by/IN
the/DT
large/JJ
number/NN
of/IN
individuals/NNS
infected/VBN
with/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
./.
====================
The/DT
major/JJ
goal/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
determine/VB
whether/IN
the/DT
mycobacterial/JJ
cell/NN
wall/NN
component/NN
mannose-capped/JJ
lipoarabinomannan/NN
(/(
ManLAM/NN
)/)
of/IN
Mycobacterium/FW
tuberculosis/FW
(/(
M./FW
tuberculosis/FW
)/)
could/MD
activate/VB
transcription/NN
of/IN
HIV-1/NN
in/IN
T/NN
cells/NNS
with/IN
the/DT
use/NN
of/IN
an/DT
in/FW
vitro/FW
cell/NN
culture/NN
system/NN
./.
====================
These/DT
experiments/NNS
are/VBP
of/IN
prime/JJ
importance/NN
considering/VBG
that/IN
CD4-expressing/JJ
T/NN
lymphocytes/NNS
represent/VBP
the/DT
major/JJ
virus/NN
reservoir/NN
in/IN
the/DT
peripheral/JJ
blood/NN
of/IN
infected/JJ
individuals/NNS
./.
====================
Using/VBG
the/DT
1G5/NN
cell/NN
line/NN
harbouring/VBG
the/DT
luciferase/NN
reporter/NN
gene/NN
under/IN
the/DT
control/NN
of/IN
the/DT
HIV-1/NN
LTR/NN
,/,
it/PRP
was/VBD
first/RB
found/VBN
that/IN
culture/NN
protein/NN
filtrates/NNS
(/(
CFP/NNS
)/)
from/IN
M./FW
tuberculosis/FW
or/CC
purified/VBN
ManLAM/NN
could/MD
activate/VB
HIV-1/NN
LTR-dependent/JJ
gene/NN
expression/NN
unlike/IN
similarly/RB
prepared/VBN
CFP/NN
extracts/NNS
devoid/JJ
of/IN
ManLAM/NN
./.
====================
The/DT
implication/NN
of/IN
protein/NN
tyrosine/NN
kinase/NN
(/(
s/NNS
)/)
,/,
protein/NN
kinase/NN
A/NN
and/or/CC
protein/NN
kinase/NN
C/NN
was/VBD
highlighted/VBN
by/IN
the/DT
abrogation/NN
of/IN
the/DT
ManLAM-mediated/JJ
activation/NN
of/IN
HIV-1/NN
LTR-driven/JJ
gene/NN
expression/NN
using/VBG
herbimycin/NN
A/NN
and/CC
H7/NN
./.
====================
It/PRP
was/VBD
also/RB
determined/VBN
,/,
using/VBG
electrophoresis/NN
mobility/NN
shift/NN
assays/NNS
,/,
that/IN
M./FW
tuberculosis/FW
ManLAM/NN
led/VBD
to/TO
the/DT
nuclear/JJ
translocation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappaB/NN
./.
====================
M./FW
tuberculosis/FW
ManLAM/NN
resulted/VBD
in/IN
clear/JJ
induction/NN
of/IN
the/DT
luciferase/NN
gene/NN
placed/VBN
under/IN
the/DT
control/NN
of/IN
the/DT
wild-type/JJ
,/,
but/CC
not/RB
the/DT
kappaB-mutated/JJ
,/,
HIV-1/NN
LTR/NN
region/NN
./.
====================
Finally/RB
,/,
the/DT
ManLAM-mediated/JJ
activation/NN
of/IN
HIV-1/NN
LTR/NN
transcription/NN
was/VBD
found/VBN
to/TO
be/VB
independent/JJ
of/IN
the/DT
autocrine/JJ
or/CC
paracrine/JJ
action/NN
of/IN
endogenous/JJ
TNF-alpha/NN
./.
====================
The/DT
results/NNS
suggest/VBP
that/IN
M./FW
tuberculosis/FW
can/MD
upregulate/VB
HIV-1/NN
expression/NN
in/IN
T/NN
cells/NNS
and/CC
could/MD
thus/RB
have/VB
the/DT
potential/NN
to/TO
influence/VB
the/DT
pathogenesis/NN
of/IN
HIV-1/NN
infection/NN
./.
====================
UI/LS
-/:
98230439/CD
====================
TI/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
quasispecies/NNS
differ/VBP
in/IN
basal/JJ
transcription/NN
and/CC
nuclear/JJ
factor/NN
recruitment/NN
in/IN
human/JJ
glial/JJ
cells/NNS
and/CC
lymphocytes/NNS
./.
====================
AB/LS
-/:
The/DT
generation/NN
of/IN
genomic/JJ
diversity/NN
during/IN
the/DT
course/NN
of/IN
infection/NN
has/VBZ
the/DT
potential/NN
to/TO
affect/VB
all/DT
aspects/NNS
of/IN
HIV-1/NN
replication/NN
,/,
including/VBG
expression/NN
of/IN
the/DT
proviral/JJ
genome/NN
./.
====================
To/TO
gain/VB
a/DT
better/JJR
understanding/NN
of/IN
the/DT
impact/NN
of/IN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
sequence/NN
diversity/NN
on/IN
LTR-directed/JJ
gene/NN
expression/NN
in/IN
cells/NNS
of/IN
the/DT
central/JJ
nervous/JJ
system/NN
(/(
CNS/NN
)/)
and/CC
immune/JJ
system/NN
,/,
we/PRP
amplified/VBD
and/CC
cloned/VBN
LTRs/NNS
from/IN
proviral/JJ
DNA/NN
in/IN
HIV-1-infected/JJ
peripheral/JJ
blood/NN
./.
====================
Sequence/NN
analysis/NN
of/IN
nineteen/CD
LTRs/NNS
cloned/VBN
from/IN
2/CD
adult/JJ
and/CC
3/CD
pediatric/JJ
patients/NNS
revealed/VBD
an/DT
average/NN
of/IN
33/CD
nucleotide/NN
changes/NNS
(/(
with/IN
respect/NN
to/TO
the/DT
sequence/NN
of/IN
the/DT
LAI/NN
LTR/NN
)/)
within/IN
the/DT
455-bp/JJ
U3/NN
region/NN
./.
====================
Transient/JJ
expression/NN
analyses/NNS
in/IN
cells/NNS
of/IN
neuroglial/JJ
and/CC
lymphocytic/JJ
origin/NN
demonstrated/VBD
that/IN
some/DT
of/IN
these/DT
LTRs/NNS
had/VBD
activities/NNS
which/WDT
varied/VBD
significantly/RB
from/IN
the/DT
LAI/NN
LTR/NN
in/IN
U-373/NN
MG/NN
cells/NNS
(/(
an/DT
astrocytoma/NN
cell/NN
line/NN
)/)
as/RB
well/RB
as/IN
in/IN
Jurkat/NN
cells/NNS
(/(
a/DT
CD4-/JJ
positive/JJ
lymphocyte/NN
cell/NN
line/NN
)/)
./.
====================
While/IN
LTRs/NNS
which/WDT
demonstrated/VBD
the/DT
highest/JJS
activities/NNS
in/IN
U-373/NN
MG/NN
cells/NNS
also/RB
yielded/VBD
high/JJ
activities/NNS
in/IN
Jurkat/NN
cells/NNS
,/,
the/DT
LTRs/NNS
were/VBD
generally/RB
more/RBR
active/JJ
in/IN
Jurkat/NN
cells/NNS
when/WRB
compared/VBN
to/TO
the/DT
LAI/NN
LTR/NN
./.
====================
Differences/NNS
in/IN
LTR/NN
sequence/NN
also/RB
resulted/VBD
in/IN
differences/NNS
in/IN
transcription/NN
factor/NN
recruitment/NN
to/TO
cis-acting/JJ
sites/NNS
within/IN
the/DT
U3/NN
region/NN
of/IN
the/DT
LTR/NN
,/,
as/IN
demonstrated/VBN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
./.
====================
In/IN
particular/JJ
,/,
naturally/RB
occurring/VBG
sequence/NN
variation/NN
impacted/JJ
transcription/NN
factor/NN
binding/VBG
to/TO
an/DT
activating/VBG
transcription/NN
factor/cAMP/NN
response/NN
element/NN
binding/NN
(/(
ATF/CREB/NN
)/)
binding/NN
site/NN
(/(
located/JJ
between/IN
the/DT
LEF-1/NN
and/CC
distal/JJ
NF-kappaB/NN
transcription/NN
factor/NN
binding/NN
sites/NNS
)/)
that/WDT
we/PRP
identified/VBN
in/IN
previous/JJ
studies/NNS
of/IN
the/DT
HIV-1/NN
LTR/NN
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
LTR/NN
sequence/NN
changes/NNS
can/MD
significantly/RB
affect/VB
basal/JJ
LTR/NN
function/NN
and/CC
transcription/NN
factor/NN
recruitment/NN
,/,
which/WDT
may/MD
,/,
in/IN
turn/NN
,/,
alter/VB
the/DT
course/NN
of/IN
viral/JJ
replication/NN
in/IN
cells/NNS
of/IN
CNS/NN
and/CC
immune/JJ
system/NN
origin/NN
./.
====================
UI/LS
-/:
98282480/CD
====================
TI/LS
-/:
HMG/NN
box/NN
containing/VBG
transcription/NN
factors/NNS
in/IN
lymphocyte/NN
differentiation/NN
./.
====================
AB/LS
-/:
The/DT
identification/NN
of/IN
the/DT
mammalian/JJ
sex-determining/JJ
gene/NN
Sry/NN
has/VBZ
led/VBN
to/TO
the/DT
discovery/NN
of/IN
a/DT
large/JJ
family/NN
of/IN
related/JJ
(/(
'/``
HMG/NN
box/NN
'/''
)/)
transcription/NN
factors/NNS
that/WDT
control/VBP
developmental/JJ
events/NNS
in/IN
yeast/NN
,/,
C./FW
elegans/FW
,/,
Drosophila/FW
and/CC
vertebrates/NNS
./.
====================
In/IN
lymphocyte/NN
differentiation/NN
,/,
several/JJ
HMG/NN
box/NN
proteins/NNS
play/VBP
a/DT
decisive/JJ
role/NN
./.
====================
Sox-4/NN
is/VBZ
important/JJ
for/IN
very/RB
early/JJ
B-cell/NN
differentiation/NN
,/,
while/IN
TCF-1/LEF-1/NN
play/VBP
a/DT
crucial/JJ
role/NN
in/IN
early/JJ
thymocyte/NN
development/NN
./.
====================
TCF/LEF/NN
proteins/NNS
have/VBP
recently/RB
been/VBN
found/VBN
to/TO
constitute/VB
a/DT
downstream/JJ
component/NN
of/IN
the/DT
Wingless/Wnt/NN
signal/NN
transduction/NN
pathway/NN
./.
====================
In/IN
flies/NNS
,/,
this/DT
pathway/NN
controls/VBZ
segment/NN
polarity/NN
;/:
in/IN
Xenopus/FW
it/PRP
controls/VBZ
the/DT
definition/NN
of/IN
the/DT
body/NN
axis/NN
./.
====================
Deregulation/NN
of/IN
the/DT
pathway/NN
occurs/VBZ
in/IN
several/JJ
human/JJ
tumors/NNS
./.
====================
These/DT
insights/VBZ
in/IN
the/DT
molecular/JJ
events/NNS
that/WDT
are/VBP
involved/VBN
in/IN
TCF/LEF/NN
function/NN
in/IN
these/DT
organisms/NNS
may/MD
eventually/RB
lead/VB
to/TO
the/DT
understanding/NN
of/IN
the/DT
function/NN
of/IN
these/DT
HMG/NN
box/NN
proteins/NNS
in/IN
lymphoid/JJ
development/NN
====================
UI/LS
-/:
93315600/CD
====================
TI/LS
-/:
Single/JJ
strand/NN
conformation/NN
polymorphism/NN
analysis/NN
of/IN
androgen/NN
receptor/NN
gene/NN
mutations/NNS
in/IN
patients/NNS
with/IN
androgen/NN
insensitivity/NN
syndromes/NNS
:/:
application/NN
for/IN
diagnosis/NN
,/,
genetic/JJ
counseling/NN
,/,
and/CC
therapy/NN
./.
====================
AB/LS
-/:
Recent/JJ
studies/NNS
indicate/VBP
that/IN
mutations/NNS
in/IN
the/DT
androgen/NN
receptor/NN
gene/NN
are/VBP
associated/VBN
with/IN
androgen/NN
insensitivity/NN
syndromes/NNS
,/,
a/DT
heterogeneous/JJ
group/NN
of/IN
related/JJ
disorders/NNS
involving/VBG
defective/JJ
sexual/JJ
differentiation/NN
in/IN
karyotypic/JJ
males/NNS
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
address/VBP
the/DT
possibility/NN
of/IN
rapid/JJ
mutational/JJ
analysis/NN
of/IN
the/DT
androgen/NN
receptor/NN
gene/NN
for/IN
initial/JJ
diagnosis/NN
,/,
genetic/JJ
counseling/NN
,/,
and/CC
molecular/JJ
subclassification/NN
of/IN
affected/VBN
patients/NNS
and/CC
their/PRP$
families/NNS
./.
====================
DNA/NN
from/IN
peripheral/JJ
blood/NN
leukocytes/NNS
of/IN
six/CD
patients/NNS
from/IN
five/CD
families/NNS
with/IN
various/JJ
degrees/NNS
of/IN
androgen/NN
insensitivity/NN
was/VBD
studied/VBN
./.
====================
Exons/NNS
2/CD
to/TO
8/CD
of/IN
the/DT
androgen/NN
receptor/NN
gene/NN
were/VBD
analyzed/VBN
using/VBG
a/DT
combination/NN
of/IN
single/JJ
strand/NN
conformation/NN
polymorphism/NN
analysis/NN
and/CC
direct/JJ
DNA/NN
sequencing/NN
./.
====================
Female/JJ
family/NN
members/NNS
were/VBD
also/RB
studied/VBN
to/TO
identify/VB
heterozygote/NN
carriers/NNS
./.
====================
Point/NN
mutations/NNS
in/IN
the/DT
AR/NN
gene/NN
were/VBD
identified/VBN
in/IN
all/DT
six/CD
patients/NNS
,/,
and/CC
all/DT
mutations/NNS
caused/VBD
amino/NN
acid/NN
substitutions/NNS
./.
====================
One/CD
patient/NN
with/IN
incomplete/JJ
androgen/NN
insensitivity/NN
was/VBD
a/DT
mosaic/NN
for/IN
the/DT
mutation/NN
./.
====================
Four/CD
of/IN
the/DT
five/CD
mothers/NNS
,/,
as/RB
well/RB
as/IN
a/DT
young/JJ
sister/NN
of/IN
one/CD
patient/NN
,/,
were/VBD
carriers/NNS
of/IN
the/DT
mutation/NN
present/JJ
in/IN
the/DT
affected/VBN
child/NN
./.
====================
Our/PRP$
data/NNS
show/VBP
that/IN
new/JJ
mutations/NNS
may/MD
occur/VB
in/IN
the/DT
androgen/NN
receptor/NN
gene/NN
leading/VBG
to/TO
sporadic/JJ
androgen/NN
insensitivity/NN
syndrome/NN
./.
====================
Molecular/JJ
genetic/JJ
characterization/NN
of/IN
the/DT
variant/JJ
allele/NN
can/MD
serve/VB
as/IN
a/DT
primary/JJ
tool/NN
for/IN
diagnosis/NN
and/CC
subsequent/JJ
therapy/NN
,/,
and/CC
can/MD
provide/VB
a/DT
basis/NN
for/IN
distinguishing/VBG
heterozygous/JJ
carriers/NNS
in/IN
familial/JJ
androgen/NN
resistance/NN
./.
====================
The/DT
identification/NN
of/IN
carriers/NNS
is/VBZ
of/IN
substantial/JJ
clinical/JJ
importance/NN
for/IN
genetic/JJ
counseling/NN
./.
====================
UI/LS
-/:
93284506/CD
====================
TI/LS
-/:
Proliferation/NN
index/NN
as/IN
a/DT
prognostic/JJ
marker/NN
in/IN
breast/NN
cancer/NN
./.
====================
AB/LS
-/:
BACKGROUND/NN
./.
====================
The/DT
proliferative/JJ
activity/NN
of/IN
tumors/NNS
has/VBZ
been/VBN
extensively/RB
investigated/VBN
with/IN
different/JJ
approaches/NNS
,/,
among/IN
which/WDT
the/DT
use/NN
of/IN
the/DT
monoclonal/JJ
antibody/NN
Ki-67/NN
represents/VBZ
an/DT
easy/JJ
and/CC
reliable/JJ
means/NN
of/IN
assessing/VBG
cell/NN
proliferation/NN
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
proliferative/JJ
activity/NN
of/IN
129/CD
primary/JJ
breast/NN
cancers/NNS
was/VBD
investigated/VBN
,/,
and/CC
the/DT
results/NNS
were/VBD
related/JJ
to/TO
prognosis/NN
./.
====================
METHODS/NNS
./.
====================
Tumor/NN
samples/NNS
,/,
obtained/VBN
from/IN
129/CD
patients/NNS
who/WP
underwent/VBD
surgery/NN
between/IN
January/NNP
1987/CD
and/CC
December/NNP
1988/CD
,/,
were/VBD
processed/VBN
for/IN
staining/VBG
by/IN
an/DT
immunohistochemical/JJ
procedure/NN
(/(
avidin-biotin/NN
complex/NN
)/)
./.
====================
The/DT
median/JJ
time/NN
of/IN
observation/NN
was/VBD
42/CD
months/NNS
(/(
range/NN
,/,
31-55/CD
months/NNS
)/)
./.
====================
Life-table/JJ
analysis/NN
(/(
Mantel-Cox/NN
)/)
was/VBD
used/VBN
to/TO
assess/VB
the/DT
probability/NN
of/IN
disease-free/JJ
survival/NN
(/(
DFS/NN
)/)
and/CC
overall/JJ
survival/NN
(/(
OS/NN
)/)
./.
====================
RESULTS/NNS
./.
====================
Tumors/NNS
with/IN
high/JJ
Ki-67/NN
proliferation/NN
indices/NNS
(/(
>/JJR
20/CD
%/NN
)/)
were/VBD
associated/VBN
with/IN
a/DT
higher/JJR
4-year/JJ
probability/NN
of/IN
relapse/NN
of/IN
disease/NN
(/(
55.3/CD
%/NN
versus/CC
79.1/CD
%/NN
;/:
P/NN
=/JJ
0.003/CD
)/)
and/CC
death/NN
(/(
71/CD
%/NN
versus/CC
95.6/CD
%/NN
;/:
P/NN
=/JJ
0.00005/CD
)/)
when/WRB
compared/VBN
with/IN
tumors/NNS
with/IN
low/JJ
Ki-67/NN
values/NNS
./.
====================
In/IN
addition/NN
,/,
this/DT
proliferative/JJ
parameter/NN
maintained/VBD
its/PRP$
prognostic/JJ
significance/NN
when/WRB
the/DT
patients/NNS
were/VBD
stratified/VBN
according/VBG
to/TO
lymph/NN
node/NN
involvement/NN
,/,
menopausal/JJ
status/NN
,/,
and/CC
nuclear/JJ
estrogen/NN
receptor/NN
content/NN
./.
====================
CONCLUSIONS/NNS
./.
====================
Tumor/NN
proliferative/JJ
activity/NN
as/IN
evaluated/VBN
by/IN
the/DT
monoclonal/JJ
antibody/NN
Ki-67/NN
seems/VBZ
to/TO
be/VB
an/DT
effective/JJ
indicator/NN
of/IN
prognosis/NN
in/IN
breast/NN
cancer/NN
for/IN
DFS/NN
and/CC
OS/NN
./.
====================
UI/LS
-/:
93262492/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
the/DT
Ets-related/JJ
transcription/NN
factor/NN
Elf-1/NN
by/IN
binding/VBG
to/TO
the/DT
retinoblastoma/NN
protein/NN
./.
====================
AB/LS
-/:
The/DT
retinoblastoma/NN
gene/NN
product/NN
(/(
Rb/NN
)/)
is/VBZ
a/DT
nuclear/JJ
phosphoprotein/NN
that/WDT
regulates/VBZ
cell/NN
cycle/NN
progression/NN
./.
====================
Elf-1/NN
is/VBZ
a/DT
lymphoid-specific/JJ
Ets/NN
transcription/NN
factor/NN
that/WDT
regulates/VBZ
inducible/JJ
gene/NN
expression/NN
during/IN
T/NN
cell/NN
activation/NN
./.
====================
In/IN
this/DT
report/NN
,/,
it/PRP
is/VBZ
demonstrated/VBN
that/IN
Elf-1/NN
contains/VBZ
a/DT
sequence/NN
motif/NN
that/WDT
is/VBZ
highly/RB
related/JJ
to/TO
the/DT
Rb/NN
binding/NN
sites/NNS
of/IN
several/JJ
viral/JJ
oncoproteins/NNS
and/CC
binds/VBZ
to/TO
the/DT
pocket/NN
region/NN
of/IN
Rb/NN
both/CC
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
./.
====================
Elf-1/NN
binds/VBZ
exclusively/RB
to/TO
the/DT
underphosphorylated/JJ
form/NN
of/IN
Rb/NN
and/CC
fails/VBZ
to/TO
bind/VB
to/TO
Rb/NN
mutants/NNS
derived/VBN
from/IN
patients/NNS
with/IN
retinoblastoma/NN
./.
====================
Co-immunoprecipitation/NN
experiments/NNS
demonstrated/VBD
an/DT
association/NN
between/IN
Elf-1/NN
and/CC
Rb/NN
in/IN
resting/VBG
normal/JJ
human/JJ
T/NN
cells/NNS
./.
====================
After/IN
T/NN
cell/NN
activation/NN
,/,
the/DT
phosphorylation/NN
of/IN
Rb/NN
results/VBZ
in/IN
the/DT
release/NN
of/IN
Elf-1/NN
,/,
which/WDT
is/VBZ
correlated/VBN
temporally/RB
with/IN
the/DT
activation/NN
of/IN
Elf-1-mediated/JJ
transcription/NN
./.
====================
Overexpression/NN
of/IN
a/DT
phosphorylation-defective/JJ
form/NN
of/IN
Rb/NN
inhibited/VBD
Elf-1-dependent/JJ
transcription/NN
during/IN
T/NN
cell/NN
activation/NN
./.
====================
These/DT
results/NNS
demonstrate/VBP
that/IN
Rb/NN
interacts/VBZ
specifically/RB
with/IN
a/DT
lineage-restricted/JJ
Ets/NN
transcription/NN
factor/NN
./.
====================
This/DT
regulated/JJ
interaction/NN
may/MD
be/VB
important/JJ
for/IN
the/DT
coordination/NN
of/IN
lineage-specific/JJ
effector/NN
functions/NNS
such/JJ
as/IN
lymphokine/NN
production/NN
with/IN
cell/NN
cycle/NN
progression/NN
in/IN
activated/VBN
T/NN
cells/NNS
./.
====================
UI/LS
-/:
93238864/CD
====================
TI/LS
-/:
Human/JJ
CD3-CD16+/JJ
natural/JJ
killer/NN
cells/NNS
express/VBP
the/DT
hGATA-3/NN
T/NN
cell/NN
transcription/NN
factor/NN
and/CC
an/DT
unrearranged/JJ
2.3-kb/JJ
TcR/NN
delta/NN
transcript/NN
./.
====================
AB/LS
-/:
In/IN
this/DT
study/NN
we/PRP
analyzed/VBD
the/DT
T/NN
cell/NN
receptor/NN
(/(
TcR/NN
)/)
delta/NN
transcripts/NNS
expressed/VBN
by/IN
CD3-CD16+/JJ
cells/NNS
and/CC
we/PRP
investigated/VBD
whether/IN
these/DT
cells/NNS
expressed/VBD
the/DT
hGATA-3/NN
T/NN
cell/NN
transcription/NN
factor/NN
and/CC
the/DT
recombination-activating/JJ
gene/NN
(/(
RAG/NN
)/)
-1/CD
./.
====================
Multiple/JJ
TcR/NN
delta/NN
transcripts/NNS
deriving/VBG
from/IN
an/DT
unrearranged/JJ
TcR/NN
delta/NN
gene/NN
were/VBD
detected/VBN
in/IN
both/CC
polyclonal/JJ
and/CC
clonal/JJ
CD3-CD16+/JJ
natural/JJ
killer/NN
(/(
NK/NN
)/)
cell/NN
lines/NNS
./.
====================
Two/CD
unrearranged/JJ
TcR/NN
delta/NN
transcripts/NNS
had/VBD
a/DT
size/NN
similar/JJ
to/TO
that/DT
of/IN
the/DT
functional/JJ
TcR/NN
delta/NN
mRNA/NN
(/(
2.3/CD
and/CC
1.3/CD
kb/NN
)/)
found/VBN
in/IN
TcR/NN
gamma/delta+/JJ
T/NN
lymphocytes/NNS
./.
====================
Sequence/NN
analysis/NN
of/IN
nine/CD
different/JJ
2.3-kb/JJ
cDNA/NN
clones/NNS
obtained/VBN
from/IN
NK-derived/JJ
polyA+/JJ
RNA/NN
confirmed/VBD
that/IN
they/PRP
corresponded/VBD
to/TO
an/DT
unrearranged/JJ
TcR/NN
delta/NN
gene/NN
./.
====================
These/DT
cDNA/NN
were/VBD
2343/CD
bp/NN
long/JJ
and/CC
their/PRP$
transcription/NN
initiation/NN
site/NN
was/VBD
located/JJ
814/CD
bp/NN
upstream/RB
from/IN
the/DT
J/NN
delta/NN
1/CD
segment/NN
./.
====================
The/DT
sequence/NN
located/JJ
upstream/RB
of/IN
the/DT
J/NN
delta/NN
1/CD
segment/NN
corresponded/VBD
to/TO
the/DT
previously/RB
reported/VBN
germ-line/JJ
sequence/NN
./.
====================
The/DT
J/NN
delta/NN
1/CD
segment/NN
was/VBD
correctly/RB
spliced/VBN
to/TO
C/NN
delta/NN
;/:
in/IN
addition/NN
the/DT
four/CD
C/NN
delta/NN
exons/NNS
were/VBD
found/VBN
to/TO
be/VB
already/RB
assembled/VBN
./.
====================
Two/CD
polyadenylation/NN
sites/NNS
were/VBD
present/JJ
in/IN
the/DT
fourth/JJ
C/NN
delta/NN
exon/NN
./.
====================
However/RB
,/,
only/JJ
that/WDT
located/JJ
at/IN
the/DT
3'/JJ
end/NN
appeared/VBD
to/TO
be/VB
utilized/VBN
in/IN
the/DT
2.3-kb/JJ
cDNA/NN
./.
====================
The/DT
expression/NN
of/IN
hGATA-3/NN
,/,
a/DT
T/NN
cell-specific/JJ
factor/NN
known/VBN
to/TO
be/VB
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
the/DT
transcription/NN
of/IN
TcR/NN
delta/NN
locus/NN
,/,
was/VBD
analyzed/VBN
by/IN
Northern/NN
blot/NN
,/,
in/IN
cultured/VBN
NK/NN
cell/NN
population/NN
and/CC
clones/NNS
(/(
but/CC
not/RB
in/IN
freshly/RB
derived/VBN
cell/NN
populations/NNS
)/)
./.
====================
All/DT
NK/NN
clones/NNS
and/CC
cell/NN
lines/NNS
studied/VBN
were/VBD
found/VBN
to/TO
express/VB
hGATA-3-specific/JJ
mRNA/NN
,/,
suggesting/VBG
that/IN
hGATA-3/NN
may/MD
be/VB
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
the/DT
unrearranged/JJ
TcR/NN
delta/NN
gene/NN
expression/NN
in/IN
NK/NN
cells/NNS
./.
====================
Finally/RB
,/,
no/DT
transcription/NN
of/IN
the/DT
RAG-1/NN
gene/NN
could/MD
be/VB
detected/VBN
in/IN
all/DT
NK/NN
cell/NN
lines/NNS
or/CC
clones/NNS
analyzed/VBN
./.
====================
UI/LS
-/:
93232271/CD
====================
TI/LS
-/:
Negative/JJ
transcriptional/JJ
regulation/NN
of/IN
human/JJ
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
gene/NN
by/IN
glucocorticoids/NNS
through/IN
interference/NN
with/IN
nuclear/JJ
transcription/NN
factors/NNS
AP-1/NN
and/CC
NF-AT/NN
./.
====================
AB/LS
-/:
IL-2/NN
gene/NN
transcription/NN
is/VBZ
affected/VBN
by/IN
several/JJ
nuclear/JJ
proteins/NNS
./.
====================
We/PRP
asked/VBD
whether/IN
dexamethasone/NN
(/(
Dex/NN
)/)
and/CC
cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
inhibit/VBP
IL-2/NN
gene/NN
transcription/NN
by/IN
interfering/VBG
with/IN
the/DT
activity/NN
of/IN
nuclear/JJ
proteins/NNS
that/WDT
bind/VBP
to/TO
the/DT
IL-2/NN
promoter/NN
./.
====================
Nuclear/JJ
extracts/NNS
from/IN
primary/JJ
human/JJ
T/NN
lymphocytes/NNS
were/VBD
analyzed/VBN
by/IN
electrophoretic/JJ
DNA/NN
mobility/NN
shift/NN
assays/NNS
./.
====================
Both/CC
Dex/NN
and/CC
CsA/NN
inhibited/VBD
the/DT
binding/NN
of/IN
transcription/NN
factors/NNS
AP-1/NN
and/CC
NF-AT/NN
,/,
but/CC
not/RB
of/IN
NF-kB/NN
and/CC
OCT-1/OAF/NN
,/,
to/TO
their/PRP$
corresponding/JJ
sites/NNS
on/IN
the/DT
IL-2/NN
gene/NN
promoter/NN
./.
====================
To/TO
correlate/VB
changes/NNS
in/IN
nuclear/JJ
factor/NN
binding/NN
in/FW
vitro/FW
with/IN
transcriptional/JJ
activity/NN
in/FW
vivo/FW
and/CC
define/VB
the/DT
structural/JJ
requirements/NNS
for/IN
IL-2/NN
promoter/NN
repression/NN
,/,
we/PRP
used/VBD
transient/JJ
DNA/NN
transfections/NNS
./.
====================
Jurkat/NN
cells/NNS
were/VBD
transfected/VBN
with/IN
plasmids/NNS
containing/VBG
either/CC
the/DT
intact/JJ
IL-2/NN
promoter/NN
or/CC
its/PRP$
AP-1/NN
,/,
NF-AT/NN
,/,
and/CC
NF-kB/NN
motifs/NNS
./.
====================
Dex/NN
inhibited/VBD
the/DT
IL-2/NN
promoter/NN
and/CC
the/DT
AP-1/NN
,/,
but/CC
not/RB
the/DT
NF-AT/NN
and/CC
NF-kB/NN
plasmids/NNS
./.
====================
In/IN
contrast/NN
,/,
CsA/NN
inhibited/VBD
the/DT
IL-2/NN
promoter/NN
and/CC
the/DT
NF-AT/NN
,/,
but/CC
not/RB
the/DT
AP-1/NN
and/CC
NF-kB/NN
plasmids/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
in/IN
human/JJ
T/NN
lymphocytes/NNS
both/CC
Dex/NN
and/CC
CsA/NN
inhibited/VBD
IL-2/NN
gene/NN
transcription/NN
through/IN
interference/NN
with/IN
transcription/NN
factors/NNS
AP-1/NN
and/CC
NF-AT/NN
./.
====================
We/PRP
propose/VBP
that/IN
,/,
while/IN
maximum/NN
inhibition/NN
may/MD
involve/VB
interaction/NN
with/IN
both/DT
transcription/NN
factors/NNS
,/,
AP-1/NN
is/VBZ
the/DT
primary/JJ
target/NN
of/IN
Dex/NN
./.
====================
UI/LS
-/:
93322080/CD
====================
TI/LS
-/:
Nuclear/JJ
factor/NN
kappa/NN
B/NN
,/,
a/DT
mediator/NN
of/IN
lipopolysaccharide/NN
effects/NNS
./.
====================
AB/LS
-/:
Exposure/NN
of/IN
certain/JJ
cell/NN
types/NNS
to/TO
bacterial/JJ
lipopolysaccharide/NN
(/(
LPS/NN
)/)
leads/VBZ
to/TO
activation/NN
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
,/,
an/DT
inducible/JJ
transcription/NN
factor/NN
./.
====================
One/CD
of/IN
NF-kappa/NN
B/NN
's/POS
unique/JJ
properties/NNS
is/VBZ
its/PRP$
posttranslational/JJ
activation/NN
via/IN
release/NN
of/IN
an/DT
inhibitory/JJ
subunit/NN
,/,
called/VBN
inhibitor/NN
of/IN
NF-kappa/NN
B/NN
(/(
I/NN
kappa/NN
B/NN
)/)
,/,
from/IN
a/DT
sequestered/JJ
cytoplasmic/JJ
form/NN
./.
====================
This/DT
event/NN
is/VBZ
also/RB
triggered/VBN
under/IN
various/JJ
other/JJ
conditions/NNS
of/IN
biomedical/JJ
importance/NN
./.
====================
Other/JJ
bacterial/JJ
toxins/NNS
,/,
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF/NN
)/)
,/,
interleukin-1/NN
(/(
IL-1/NN
)/)
,/,
T/NN
cell/NN
mitogens/NNS
,/,
UV/NN
light/NN
,/,
gamma/NN
rays/NNS
and/CC
oxidative/JJ
stress/NN
were/VBD
reported/VBN
to/TO
induce/VB
NF-kappa/NN
B/NN
./.
====================
The/DT
activated/JJ
form/NN
of/IN
NF-kappa/NN
B/NN
,/,
which/WDT
is/VBZ
rapidly/RB
taken/VBN
up/RP
into/IN
nuclei/NNS
,/,
initiates/VBZ
transcription/NN
from/IN
immediate/JJ
early/JJ
genes/NNS
in/IN
a/DT
wide/JJ
variety/NN
of/IN
cell/NN
types/NNS
./.
====================
Most/JJS
of/IN
the/DT
target/NN
genes/NNS
for/IN
NF-kappa/NN
B/NN
are/VBP
of/IN
relevance/NN
for/IN
the/DT
immune/JJ
response/NN
and/CC
can/MD
be/VB
grouped/VBN
into/IN
those/DT
encoding/JJ
cytokines/NNS
,/,
cell/NN
surface/NN
receptors/NNS
,/,
acute/JJ
phase/NN
proteins/NNS
and/CC
viral/JJ
genomes/NNS
,/,
such/JJ
as/IN
that/DT
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
./.
====================
We/PRP
will/MD
discuss/VB
recent/JJ
experimental/JJ
evidences/NNS
suggesting/VBG
that/IN
LPS/NN
might/MD
share/VB
a/DT
pathway/NN
of/IN
NF-kappa/NN
B/NN
activation/NN
with/IN
other/JJ
inducers/NNS
of/IN
the/DT
factor/NN
./.
====================
This/DT
common/JJ
pathway/NN
may/MD
involve/VB
reactive/JJ
oxygen/NN
intermediates/NNS
(/(
ROI/NN
)/)
as/IN
messenger/NN
molecules/NNS
./.
====================
UI/LS
-/:
93260875/CD
====================
TI/LS
-/:
[/(
The/DT
trend/NN
of/IN
molecular/JJ
biology/NN
study/NN
on/IN
eosinophils/NNS
]/)
====================
AB/LS
-/:
Recently/RB
,/,
many/JJ
investigators/NNS
have/VBP
been/VBN
interested/JJ
in/IN
the/DT
study/NN
on/IN
eosinophil/NN
biology/NN
since/IN
genes/NNS
association/NN
with/IN
eosinophils/NNS
such/JJ
as/IN
interleukin-5/NN
or/CC
eosinophil/NN
granule/NN
proteins/NNS
(/(
EPO/NN
,/,
ECP/NN
,/,
EDN/NN
,/,
MBP/NN
,/,
and/CC
CLC/NN
)/)
,/,
were/VBD
isolated/VBN
./.
====================
However/RB
,/,
the/DT
molecular/JJ
basis/NN
for/IN
the/DT
commitment/NN
of/IN
progenitors/NNS
to/TO
the/DT
eosinophil/NN
lineage/NN
has/VBZ
not/RB
been/VBN
determined/VBN
./.
====================
The/DT
mechanism/NN
by/IN
which/WDT
eosinophil-specific/JJ
genes/NNS
encoding/VBG
primary/JJ
and/CC
secondary/JJ
granule/NN
proteins/NNS
(/(
e.g./FW
ECP/NN
,/,
EDN/NN
,/,
EPO/NN
,/,
MBP/NN
,/,
and/CC
CLC/NN
)/)
are/VBP
expressed/VBN
and/CC
regulated/VBN
during/IN
eosinophilopoiesis/NN
is/VBZ
also/RB
unknown/JJ
./.
====================
In/IN
this/DT
paper/NN
,/,
I/PRP
described/VBD
the/DT
characterization/NN
of/IN
genes/NNS
encoding/VBG
eosinophil/NN
granule/NN
proteins/NNS
and/CC
the/DT
mRNA/NN
expression/NN
of/IN
GATA-1/NN
binding/NN
transcription/NN
factor/NN
during/IN
eosinophil/NN
differentiation/NN
./.
====================
UI/LS
-/:
93155114/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
the/DT
nuclear/JJ
and/CC
cytoplasmic/JJ
components/NNS
of/IN
the/DT
lymphoid-specific/JJ
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NF-AT/NN
)/)
complex/NN
./.
====================
AB/LS
-/:
The/DT
lymphoid-specific/JJ
transcription/NN
complex/NN
,/,
NF-AT/NN
,/,
is/VBZ
involved/VBN
in/IN
early/JJ
gene/NN
activation/NN
in/IN
T/NN
cells/NNS
and/CC
is/VBZ
assembled/VBN
from/IN
a/DT
pre-existing/JJ
,/,
T/NN
cell/NN
restricted/JJ
cytoplasmic/JJ
factor/NN
and/CC
an/DT
inducible/JJ
ubiquitous/JJ
nuclear/JJ
component/NN
within/IN
30/CD
min/NN
after/IN
activation/NN
through/IN
the/DT
antigen/NN
receptor/NN
./.
====================
Recent/JJ
studies/NNS
have/VBP
implicated/VBN
the/DT
family/NN
of/IN
AP1/NN
factors/NNS
as/IN
components/NNS
of/IN
the/DT
murine/JJ
NF-AT/NN
complex/NN
./.
====================
Evidence/NN
is/VBZ
provided/VBN
here/RB
that/IN
the/DT
nuclear/JJ
component/NN
of/IN
human/JJ
NF-AT/NN
contains/VBZ
the/DT
phorbol/NN
ester-inducible/JJ
transcription/NN
factor/NN
AP1/NN
(/(
Jun/Fos/NN
)/)
./.
====================
We/PRP
further/RB
characterize/VBP
which/WDT
AP1/NN
family/NN
members/NNS
can/MD
assume/VB
this/DT
role/NN
./.
====================
Antisera/NN
to/TO
Fos/NN
inhibits/VBZ
NF-AT/NN
DNA/NN
binding/NN
as/IN
does/VBZ
an/DT
oligonucleotide/NN
containing/VBG
a/DT
binding/VBG
site/NN
for/IN
AP1/NN
./.
====================
Constitutive/JJ
expression/NN
in/FW
vivo/FW
of/IN
Fos/NN
,/,
and/CC
to/TO
a/DT
lesser/JJR
extent/NN
Fra-1/NN
,/,
eliminates/VBZ
the/DT
requirement/NN
for/IN
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
stimulation/NN
,/,
leaving/VBG
NF-AT-directed/JJ
transcription/NN
responsive/JJ
to/TO
calcium/NN
ionophore/NN
alone/RB
./.
====================
Overexpression/NN
of/IN
cJun/NN
or/CC
JunD/NN
,/,
but/CC
not/RB
JunB/NN
,/,
also/RB
eliminates/VBZ
the/DT
requirement/NN
for/IN
PMA/NN
,/,
indicating/VBG
that/IN
many/JJ
but/CC
not/RB
all/DT
Jun-/NN
and/CC
Fos-related/JJ
proteins/NNS
functionally/RB
activate/VBP
NF-AT-dependent/JJ
transcription/NN
in/IN
the/DT
presence/NN
of/IN
the/DT
cytoplasmic/JJ
component/NN
./.
====================
NF-AT/NN
DNA/NN
binding/NN
can/MD
be/VB
reconstituted/VBN
in/FW
vitro/FW
using/VBG
semi-purified/JJ
AP1/NN
proteins/NNS
mixed/VBN
with/IN
cytosol/NN
from/IN
T/NN
lymphocytes/NNS
./.
====================
Fos/NN
proteins/NNS
are/VBP
not/RB
needed/VBN
for/IN
this/DT
reconstitution/NN
,/,
and/CC
although/IN
JunB/NN
is/VBZ
not/RB
functional/JJ
,/,
it/PRP
can/MD
participate/VB
in/IN
the/DT
NF-AT/NN
DNA/NN
binding/NN
complex/NN
./.
====================
Finally/RB
,/,
we/PRP
have/VBP
partially/RB
purified/VBN
the/DT
cytoplasmic/JJ
component/NN
of/IN
NF-AT/NN
and/CC
show/VBP
by/IN
elution/NN
and/CC
renaturation/NN
from/IN
SDS-polyacrylamide/NN
gel/NN
electrophoresis/NN
gels/NNS
that/IN
it/PRP
has/VBZ
a/DT
molecular/JJ
mass/NN
between/IN
94/CD
and/CC
116/CD
kDa/NN
and/CC
may/MD
have/VB
multiple/JJ
differentially/RB
modified/JJ
forms/NNS
./.
====================
UI/LS
-/:
93289270/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptors/NNS
in/IN
mononuclear/JJ
cells/NNS
of/IN
patients/NNS
with/IN
sepsis/NN
./.
====================
AB/LS
-/:
Glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
hormone-binding/NN
activity/NN
was/VBD
studied/VBN
by/IN
a/DT
whole-cell/JJ
method/NN
in/IN
mononuclear/JJ
cells/NNS
(/(
MNC/NN
)/)
from/IN
peripheral/JJ
blood/NN
of/IN
7/CD
patients/NNS
during/IN
the/DT
hemodynamic/JJ
compensatory/JJ
phase/NN
of/IN
sepsis/NN
./.
====================
4/CD
patients/NNS
were/VBD
receiving/VBG
dopamine/NN
,/,
which/WDT
did/VBD
not/RB
affect/VB
the/DT
GR/NN
count/NN
./.
====================
The/DT
patients/NNS
'/POS
plasma/NN
cortisol/NN
concentrations/NNS
were/VBD
normal/JJ
or/CC
slightly/RB
elevated/JJ
./.
====================
Despite/IN
a/DT
wide/JJ
range/NN
,/,
the/DT
mean/NN
GR/NN
count/NN
and/CC
affinity/NN
in/IN
MNC/NN
from/IN
septic/JJ
patients/NNS
did/VBD
not/RB
differ/VB
from/IN
those/DT
in/IN
normal/JJ
controls/NNS
,/,
suggesting/VBG
that/IN
glucocorticoids/NNS
could/MD
still/RB
be/VB
effective/JJ
in/IN
the/DT
hemodynamic/JJ
compensatory/JJ
phase/NN
of/IN
sepsis/NN
./.
====================
UI/LS
-/:
94026053/CD
====================
TI/LS
-/:
The/DT
impaired/JJ
transcription/NN
factor/NN
AP-1/NN
DNA/NN
binding/NN
activity/NN
in/IN
lymphocytes/NNS
derived/VBN
from/IN
subjects/NNS
with/IN
some/DT
symptoms/NNS
of/IN
premature/JJ
aging/NN
./.
====================
AB/LS
-/:
The/DT
study/NN
of/IN
human/JJ
disorders/NNS
known/VBN
as/IN
premature/JJ
aging/NN
syndromes/NNS
may/MD
provide/VB
insight/NN
into/IN
the/DT
mechanisms/NNS
of/IN
cellular/JJ
senescence/NN
./.
====================
The/DT
main/JJ
feature/NN
of/IN
cellular/JJ
senescence/NN
in/FW
vitro/FW
is/VBZ
cessation/NN
of/IN
cell/NN
proliferation/NN
./.
====================
Down/NN
syndrome/NN
(/(
DS/NN
)/)
and/CC
neuronal/JJ
ceroid-lypofuscinosis/NN
(/(
NCL/NN
)/)
are/VBP
clinically/RB
characterized/VBN
by/IN
the/DT
premature/JJ
onset/NN
of/IN
numerous/JJ
features/NNS
normally/RB
associated/VBN
with/IN
human/JJ
aging/NN
./.
====================
Phytohemagglutinin/NN
stimulated/JJ
lymphocytes/NNS
derived/VBN
from/IN
DS/NN
subjects/NNS
showed/VBD
a/DT
statistically/RB
significant/JJ
diminished/VBN
proliferation/NN
capacity/NN
in/IN
comparison/NN
with/IN
lymphocytes/NNS
derived/VBN
from/IN
NCL/NN
and/CC
healthy/JJ
individuals/NNS
./.
====================
We/PRP
demonstrated/VBD
,/,
by/IN
applying/VBG
the/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
,/,
slightly/RB
impaired/JJ
AP-1/NN
DNA/NN
binding/NN
activity/NN
in/IN
NCL/NN
lymphocytes/NNS
and/CC
strong/JJ
in/IN
DS/NN
ones/NNS
./.
====================
Our/PRP$
results/NNS
showed/VBD
that/IN
the/DT
same/JJ
molecular/JJ
mechanisms/NNS
of/IN
proliferation/NN
cessation/NN
could/MD
exist/VB
in/IN
fibroblasts/NNS
characterized/VBN
by/IN
replicative/JJ
senescence/NN
and/CC
in/IN
lymphocytes/NNS
derived/VBN
from/IN
individuals/NNS
with/IN
premature/JJ
aging/NN
syndromes/NNS
(/(
Down/NN
====================
UI/LS
-/:
93287269/CD
====================
TI/LS
-/:
Differential/JJ
contribution/NN
of/IN
herpes/NN
simplex/NN
virus/NN
type/NN
1/CD
gene/NN
products/NNS
and/CC
cellular/JJ
factors/NNS
to/TO
the/DT
activation/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
provirus/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
previously/RB
reported/VBN
that/IN
infection/NN
with/IN
herpes/NN
simplex/NN
virus/NN
type/NN
1/CD
(/(
HSV-1/NN
)/)
activates/VBZ
expression/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
provirus/NN
in/IN
T/NN
cells/NNS
./.
====================
Activation/NN
of/IN
the/DT
HIV-1/NN
provirus/NN
correlated/VBD
with/IN
the/DT
activation/NN
of/IN
binding/NN
of/IN
55-/CD
and/CC
85-kDa/JJ
proteins/NNS
to/TO
the/DT
kappa/NN
B/NN
enhancer/NN
and/CC
binding/NN
of/IN
the/DT
50-kDa/JJ
HLP-1/NN
protein/NN
to/TO
the/DT
LBP-1/NN
sequences/NNS
of/IN
the/DT
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
./.
====================
Further/RB
examination/NN
of/IN
this/DT
system/NN
has/VBZ
shown/VBN
that/IN
the/DT
inhibition/NN
of/IN
HSV-1/NN
replication/NN
by/IN
the/DT
antiviral/JJ
drug/NN
acyclovir/NN
does/VBZ
not/RB
inhibit/VB
HSV-1-mediated/JJ
induction/NN
of/IN
HIV-1/NN
provirus/NN
./.
====================
Surprisingly/RB
,/,
the/DT
NF-kappa/NN
B/NN
and/CC
HLP-1/NN
binding/NN
activities/NNS
were/VBD
substantially/RB
inhibited/VBN
in/IN
acyclovir-treated/JJ
cells/NNS
./.
====================
In/IN
the/DT
transient-transfection/JJ
assay/NN
,/,
ICP0/NN
,/,
but/CC
not/RB
ICP4/NN
,/,
activated/VBD
the/DT
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
promoter/NN
region/NN
and/CC
the/DT
effect/NN
of/IN
ICP0/NN
was/VBD
greatly/RB
enhanced/VBN
in/IN
the/DT
presence/NN
of/IN
the/DT
NF-kappa/NN
B/NN
binding/NN
proteins/NNS
,/,
suggesting/VBG
that/IN
induction/NN
of/IN
the/DT
HIV-1/NN
provirus/NN
involves/VBZ
cooperation/NN
between/IN
the/DT
HSV-1-activated/JJ
cellular/JJ
factor/NN
,/,
NF-kappa/NN
B/NN
,/,
and/CC
the/DT
virus-encoded/JJ
transactivator/NN
,/,
ICP0/NN
./.
====================
UI/LS
-/:
93294310/CD
====================
TI/LS
-/:
Transcriptional/JJ
activation/NN
of/IN
the/DT
macrophage/NN
colony-stimulating/JJ
factor/NN
gene/NN
by/IN
IL-2/NN
is/VBZ
associated/VBN
with/IN
secretion/NN
of/IN
bioactive/JJ
macrophage/NN
colony-stimulating/JJ
factor/NN
protein/NN
by/IN
monocytes/NNS
and/CC
involves/VBZ
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
./.
====================
AB/LS
-/:
Human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
(/(
Mo/NN
)/)
constitutively/RB
display/VBP
the/DT
beta-chain/NN
of/IN
the/DT
receptor/NN
for/IN
IL-2/NN
,/,
whereas/IN
expression/NN
of/IN
the/DT
IL-2R/NN
alpha-chain/NN
is/VBZ
not/RB
constitutive/JJ
but/CC
inducible/JJ
with/IN
IL-2/NN
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
binding/NN
of/IN
human/JJ
IL-2/NN
to/TO
its/PRP$
binding/VBG
site/NN
leads/VBZ
to/TO
transcriptional/JJ
activation/NN
of/IN
the/DT
macrophage/NN
CSF/NN
(/(
M-CSF/NN
)/)
gene/NN
in/IN
Mo/NN
resulting/VBG
in/IN
accumulation/NN
of/IN
M-CSF/NN
mRNA/NN
and/CC
subsequent/JJ
release/NN
of/IN
bioactive/JJ
M-CSF/NN
protein/NN
as/IN
demonstrated/VBN
by/IN
ELISA/NN
and/CC
inhibition/NN
of/IN
IL-2/NN
induced/JJ
release/NN
of/IN
an/DT
activity-stimulating/JJ
growth/NN
of/IN
monocyte-type/JJ
colonies/NNS
by/IN
a/DT
neutralizing/VBG
anti-M-CSF/JJ
antibody/NN
./.
====================
Transcriptional/JJ
activation/NN
of/IN
the/DT
M-CSF/NN
gene/NN
by/IN
IL-2/NN
is/VBZ
preceded/VBN
by/IN
enhanced/VBN
binding/NN
activity/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
to/TO
its/PRP$
recognition/NN
sequence/NN
in/IN
the/DT
5'/JJ
regulatory/JJ
enhancer/NN
region/NN
of/IN
the/DT
M-CSF/NN
gene/NN
./.
====================
Moreover/RB
,/,
using/VBG
a/DT
heterologous/JJ
promoter/NN
(/(
herpes/NN
thymidine/NN
kinase/NN
)/)
construct/NN
containing/VBG
the/DT
NF-kappa/NN
B/NN
consensus/NN
sequence/NN
,/,
it/PRP
is/VBZ
shown/VBN
that/IN
NF-kappa/NN
B/NN
binding/NN
by/IN
an/DT
IL-2-induced/JJ
monocyte-derived/JJ
nuclear/JJ
protein/NN
confers/VBZ
reporter/NN
gene/NN
(/(
human/JJ
growth/NN
hormone/NN
)/)
activity/NN
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
findings/NNS
indicate/VBP
that/IN
IL-2/NN
induces/VBZ
gene/NN
expression/NN
of/IN
M-CSF/NN
in/IN
human/JJ
blood-derived/JJ
Mo/NN
and/CC
provide/VBP
evidence/NN
for/IN
involvement/NN
of/IN
NF-kappa/NN
B/NN
in/IN
transcriptional/JJ
regulation/NN
of/IN
this/DT
gene/NN
./.
====================
UI/LS
-/:
93268332/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
the/DT
interleukin-1/NN
beta/NN
(/(
IL-1/NN
beta/NN
)/)
gene/NN
by/IN
mycobacterial/JJ
components/NNS
and/CC
lipopolysaccharide/NN
is/VBZ
mediated/VBN
by/IN
two/CD
nuclear/JJ
factor-IL6/JJ
motifs/NNS
./.
====================
AB/LS
-/:
The/DT
cytokines/NNS
interleukin-1/NN
beta/NN
(/(
IL-1/NN
beta/NN
)/)
and/CC
tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF-alpha/NN
)/)
are/VBP
released/VBN
by/IN
mononuclear/JJ
phagocytes/NNS
in/FW
vitro/FW
after/IN
stimulation/NN
with/IN
mycobacteria/NNS
and/CC
are/VBP
considered/VBN
to/TO
mediate/VB
pathophysiologic/JJ
events/NNS
,/,
including/VBG
granuloma/NN
formation/NN
and/CC
systemic/JJ
symptoms/NNS
./.
====================
We/PRP
demonstrated/VBD
that/IN
the/DT
Mycobacterium/NN
tuberculosis/NN
cell/NN
wall/NN
component/NN
lipoarabinomannan/NN
(/(
LAM/NN
)/)
is/VBZ
a/DT
very/RB
potent/JJ
inducer/NN
of/IN
IL-1/NN
beta/NN
gene/NN
expression/NN
in/IN
human/JJ
monocytes/NNS
and/CC
investigated/VBD
the/DT
mechanism/NN
of/IN
this/DT
effect/NN
./.
====================
We/PRP
localized/VBD
the/DT
LAM-/NN
,/,
lipopolysaccharide/NN
(/(
LPS/NN
)/)
-/:
,/,
and/CC
TNF-alpha-inducible/JJ
promoter/NN
activity/NN
to/TO
a/DT
-131/+15/CD
(/(
positions/NNS
-131/CD
to/TO
+15/CD
)/)
DNA/NN
fragment/NN
of/IN
the/DT
IL-1/NN
beta/NN
gene/NN
by/IN
deletion/NN
analysis/NN
and/CC
chloramphenicol/NN
acetyltransferase/NN
assay/NN
./.
====================
Within/IN
this/DT
DNA/NN
fragment/NN
,/,
there/EX
were/VBD
two/CD
novel/JJ
9-bp/JJ
motifs/NNS
(/(
-90/-82/CD
and/CC
-40/-32/CD
)/)
with/IN
high/JJ
homology/NN
to/TO
the/DT
nuclear/JJ
factor-IL6/NN
(/(
NF-IL6/NN
)/)
binding/NN
site/NN
./.
====================
Site-directed/JJ
mutagenesis/NN
demonstrated/VBD
that/IN
the/DT
two/CD
NF-IL-6/NN
motifs/NNS
could/MD
be/VB
independently/RB
activated/VBN
by/IN
LAM/NN
,/,
LPS/NN
,/,
or/CC
TNF-alpha/NN
and/CC
that/IN
they/PRP
acted/VBD
in/IN
an/DT
orientation-independent/JJ
manner/NN
./.
====================
DNA/NN
mobility/NN
shift/NN
assay/NN
revealed/VBD
specific/JJ
binding/NN
of/IN
nuclear/JJ
protein/NN
(/(
s/NNS
)/)
from/IN
LAM-/NN
,/,
LPS-/NN
,/,
or/CC
TNF-alpha-stimulated/JJ
THP-1/NN
cells/NNS
to/TO
the/DT
NF-IL6/NN
motifs/NNS
./.
====================
We/PRP
conclude/VBP
that/IN
the/DT
two/CD
NF-IL6/NN
sites/NNS
mediate/VBP
induction/NN
of/IN
IL-1/NN
beta/NN
in/IN
response/NN
to/TO
the/DT
stimuli/NNS
LAM/NN
,/,
LPS/NN
,/,
and/CC
TNF-alpha/NN
./.
====================
UI/LS
-/:
93242763/CD
====================
TI/LS
-/:
HIV-1/NN
Nef/NN
protein/NN
inhibits/VBZ
the/DT
recruitment/NN
of/IN
AP-1/NN
DNA-binding/JJ
activity/NN
in/IN
human/JJ
T-cells/NNS
./.
====================
AB/LS
-/:
The/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
,/,
HIV-1-LTR/NN
,/,
contains/VBZ
binding/VBG
sites/NNS
for/IN
several/JJ
cellular/JJ
transcription/NN
factors/NNS
which/WDT
contribute/VBP
to/TO
HIV-1/NN
gene/NN
expression/NN
./.
====================
Our/PRP$
previous/JJ
studies/NNS
on/IN
the/DT
function/NN
of/IN
the/DT
HIV-1-encoded/JJ
Nef/NN
protein/NN
suggested/VBD
that/IN
Nef/NN
may/MD
be/VB
an/DT
inhibitor/NN
HIV-1/NN
transcription/NN
./.
====================
To/TO
determine/VB
whether/IN
Nef/NN
affects/VBZ
the/DT
binding/NN
of/IN
cellular/JJ
factors/NNS
implicated/VBN
in/IN
HIV-1/NN
regulation/NN
,/,
32P-labeled/JJ
oligonucleotides/NNS
corresponding/VBG
to/TO
the/DT
binding/VBG
sites/NNS
were/VBD
incubated/VBN
with/IN
nuclear/JJ
extracts/NNS
prepared/VBN
from/IN
Nef-expressing/JJ
T-cell/NN
lines/NNS
that/WDT
were/VBD
not/RB
stimulated/VBN
or/CC
were/VBD
stimulated/VBN
with/IN
T-cell/NN
mitogens/NNS
./.
====================
We/PRP
found/VBD
that/IN
Nef/NN
inhibited/VBD
the/DT
recruitment/NN
of/IN
AP-1/NN
DNA-binding/JJ
activity/NN
in/IN
mitogen-stimulated/JJ
human/JJ
T-cells/NNS
./.
====================
Additionally/RB
,/,
Nef/NN
expressing/NN
cells/NNS
were/VBD
transiently/RB
transfected/VBN
with/IN
a/DT
plasmid/NN
in/IN
which/WDT
HIV-1/NN
AP-1/NN
DNA/NN
recognition/NN
sequences/NNS
were/VBD
cloned/VBN
downstream/RB
of/IN
the/DT
chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
gene/NN
./.
====================
Mitogen-mediated/JJ
transcriptional/JJ
activation/NN
of/IN
the/DT
CAT/NN
gene/NN
in/IN
this/DT
construct/NN
was/VBD
inhibited/VBN
in/IN
Nef-expressing/JJ
cells/NNS
but/CC
not/RB
in/IN
control/NN
cells/NNS
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
,/,
by/IN
inhibiting/VBG
AP-1/NN
activation/NN
,/,
Nef/NN
may/MD
play/VB
a/DT
role/NN
in/IN
regulating/VBG
HIV-1/NN
gene/NN
expression/NN
in/IN
infected/JJ
T-cells/NNS
./.
====================
UI/LS
-/:
93278095/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
the/DT
beta-globin/NN
locus/NN
./.
====================
AB/LS
-/:
Transcription/NN
of/IN
the/DT
human/JJ
beta-globin/NN
gene/NN
cluster/NN
depends/VBZ
upon/IN
upstream/JJ
regulatory/JJ
sequences/NNS
,/,
which/WDT
are/VBP
collectively/RB
termed/VBN
the/DT
locus/NN
control/NN
region/NN
./.
====================
Recent/JJ
studies/NNS
have/VBP
provided/VBN
new/JJ
insights/NNS
into/IN
how/WRB
the/DT
individual/JJ
genes/NNS
of/IN
the/DT
cluster/NN
are/VBP
regulated/VBN
through/IN
development/NN
./.
====================
The/DT
crux/NN
of/IN
transcriptional/JJ
activation/NN
is/VBZ
how/WRB
the/DT
locus/NN
control/NN
region/NN
communicates/VBZ
with/IN
the/DT
gene-proximal/JJ
regulatory/JJ
elements/NNS
./.
====================
UI/LS
-/:
93346062/CD
====================
TI/LS
-/:
Enhancing/NN
effect/NN
of/IN
17/CD
beta-estradiol/NN
on/IN
human/JJ
NK/NN
cell/NN
activity/NN
./.
====================
AB/LS
-/:
The/DT
in/FW
vitro/FW
effect/NN
of/IN
17/CD
beta-estradiol/NN
on/IN
NK/NN
activity/NN
was/VBD
studied/VBN
./.
====================
The/DT
proliferation/NN
and/CC
NK/NN
activity/NN
of/IN
YT-N17/NN
(/(
a/DT
human/JJ
NK-like/JJ
cell/NN
line/NN
)/)
were/VBD
enhanced/VBN
by/IN
17/CD
beta-estradiol/NN
(/(
E2/NN
)/)
,/,
and/CC
the/DT
enhancement/NN
was/VBD
blocked/VBN
by/IN
tamoxifen/NN
(/(
Tx/NN
)/)
,/,
an/DT
antagonist/NN
of/IN
E2/NN
./.
====================
On/IN
the/DT
contrary/NN
,/,
other/JJ
steroid/NN
hormones/NNS
such/JJ
as/IN
Tx/NN
,/,
progesterone/NN
,/,
and/CC
testosterone/NN
had/VBD
no/DT
effect/NN
./.
====================
YT-N17/NN
contained/VBD
11.8/CD
fmol/mg/NN
protein/NN
of/IN
estrogen/NN
receptor/NN
(/(
mean/NN
of/IN
two/CD
independent/JJ
assays/NNS
)/)
,/,
a/DT
value/NN
which/WDT
was/VBD
5-10-fold/RB
higher/JJR
than/IN
that/DT
of/IN
other/JJ
hematopoietic/JJ
cell/NN
lines/NNS
./.
====================
An/DT
enhancement/NN
of/IN
NK/NN
activity/NN
by/IN
E2/NN
was/VBD
also/RB
seen/VBN
in/IN
large/JJ
granular/JJ
lymphocytes/NNS
obtained/VBN
from/IN
normal/JJ
subjects/NNS
,/,
and/CC
it/PRP
was/VBD
again/RB
suppressed/VBN
by/IN
Tx/NN
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
E2/NN
is/VBZ
one/CD
of/IN
the/DT
activating/VBG
factors/NNS
for/IN
NK/LGL/NN
cells/NNS
./.
====================
UI/LS
-/:
93186809/CD
====================
TI/LS
-/:
A/DT
serum/NN
response/NN
element/NN
and/CC
a/DT
binding/VBG
site/NN
for/IN
NF-Y/NN
mediate/VB
the/DT
serum/NN
response/NN
of/IN
the/DT
human/JJ
thrombospondin/NN
1/CD
gene/NN
./.
====================
AB/LS
-/:
The/DT
expression/NN
of/IN
thrombospondin/NN
1/CD
(/(
TSP/NN
1/CD
)/)
,/,
a/DT
member/NN
of/IN
the/DT
TSP/NN
gene/NN
family/NN
,/,
is/VBZ
rapidly/RB
induced/VBN
by/IN
growth/NN
factors/NNS
./.
====================
We/PRP
tested/VBD
the/DT
ability/NN
of/IN
human/JJ
TSP/NN
1-chloramphenicol/JJ
acetyltransferase/NN
constructs/NNS
to/TO
respond/VB
to/TO
serum/NN
in/IN
stably/RB
transfected/VBN
NIH-3T3/NN
cells/NNS
./.
====================
Two/CD
transcriptional/JJ
elements/NNS
in/IN
the/DT
TSP/NN
1/CD
promoter/NN
,/,
a/DT
distal/JJ
element/NN
at/IN
-1280/CD
and/CC
a/DT
proximal/JJ
element/NN
at/IN
-65/CD
,/,
were/VBD
required/VBN
for/IN
the/DT
response/NN
of/IN
the/DT
human/JJ
TSP/NN
1/CD
gene/NN
to/TO
serum/NN
./.
====================
The/DT
distal/JJ
element/NN
contains/VBZ
the/DT
5'-CC(A + T)6GG-3'/NN
consensus/NN
sequence/NN
characteristic/JJ
of/IN
a/DT
serum-response/JJ
element/NN
(/(
SRE/NN
)/)
./.
====================
Deletions/NNS
or/CC
mutations/NNS
in/IN
this/DT
element/NN
reduced/VBD
the/DT
serum/NN
response/NN
of/IN
the/DT
TSP/NN
1/CD
gene/NN
by/IN
80-90/CD
%/NN
./.
====================
In/IN
gel-shift/JJ
assays/NNS
,/,
the/DT
-1280/CD
element/NN
and/CC
the/DT
c-fos/NN
SRE/NN
cross-competed/VBD
,/,
whereas/IN
their/PRP$
functional/JJ
and/CC
binding/VBG
mutants/NNS
did/VBD
not/RB
./.
====================
The/DT
proximal/JJ
element/NN
contains/VBZ
the/DT
sequence/NN
5'-GGCCAATGGG-3'/NN
,/,
which/WDT
closely/RB
resembles/VBZ
the/DT
consensus/NN
binding/NN
motif/NN
for/IN
the/DT
CCAAT-binding/JJ
factor/NN
NF-Y/NN
(/(
CBF/NN
,/,
CP1/NN
,/,
alpha/NN
CP1/NN
)/)
./.
====================
Deletions/NNS
or/CC
mutations/NNS
in/IN
this/DT
element/NN
also/RB
reduced/VBD
the/DT
serum/NN
response/NN
by/IN
80-90/CD
%/NN
./.
====================
Methylation/NN
interference/NN
analysis/NN
of/IN
the/DT
-65/CD
region/NN
identified/VBD
a/DT
pattern/NN
of/IN
contacts/NNS
with/IN
nuclear/JJ
factors/NNS
resembling/VBG
that/DT
for/IN
NF-Y/NN
,/,
and/CC
an/DT
NF-Y-binding/JJ
site/NN
and/CC
the/DT
proximal/JJ
TSP/NN
1/CD
element/NN
cross-competed/VBD
in/IN
gel-shift/JJ
assays/NNS
,/,
whereas/IN
their/PRP$
binding/VBG
mutants/NNS
did/VBD
not/RB
./.
====================
Finally/RB
,/,
an/DT
abbreviated/VBN
TSP/NN
1/CD
promoter/5'-flank/NN
,/,
containing/VBG
the/DT
SRE-/NN
and/CC
NF-Y-binding/JJ
sites/NNS
,/,
mediated/VBD
a/DT
serum/NN
response/NN
that/WDT
was/VBD
close/JJ
in/IN
magnitude/NN
to/TO
that/DT
of/IN
the/DT
parent/NN
promoter/NN
./.
====================
We/PRP
conclude/VBP
that/IN
the/DT
serum/NN
response/NN
of/IN
the/DT
human/JJ
TSP/NN
1/CD
gene/NN
requires/VBZ
the/DT
coordinated/VBN
function/NN
of/IN
an/DT
SRE-/NN
and/CC
NF-Y-binding/JJ
site/NN
./.
====================
UI/LS
-/:
93152870/CD
====================
TI/LS
-/:
Cell-type-specific/JJ
transactivation/NN
of/IN
the/DT
parathyroid/JJ
hormone-related/JJ
protein/NN
gene/NN
promoter/NN
by/IN
the/DT
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
tax/NN
and/CC
HTLV-II/NN
tax/NN
proteins/NNS
./.
====================
AB/LS
-/:
The/DT
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
and/CC
HTLV-II/NN
Tax/NN
proteins/NNS
are/VBP
potent/JJ
transactivators/NNS
of/IN
viral/JJ
and/CC
cellular/JJ
gene/NN
expression/NN
./.
====================
Using/VBG
deletion/NN
mutants/NNS
,/,
the/DT
downstream/JJ
parathyroid/JJ
hormone-related/JJ
protein/NN
(/(
PTHrP/NN
)/)
promoter/NN
is/VBZ
shown/VBN
to/TO
be/VB
responsive/JJ
to/TO
both/CC
HTLV-I/NN
and/CC
HTLV-II/NN
Tax/NN
as/RB
well/RB
as/IN
the/DT
AP1/c-jun/NN
proto-oncogene/NN
./.
====================
Transactivation/NN
of/IN
PTHrP/NN
by/IN
Tax/NN
was/VBD
seen/VBN
in/IN
T/NN
cells/NNS
but/CC
not/RB
in/IN
B-cell/NN
lines/NNS
or/CC
fibroblasts/NNS
./.
====================
A/DT
carboxy/NN
terminal/JJ
Tax/NN
deletion/NN
mutant/NN
was/VBD
deficient/JJ
in/IN
transactivation/NN
of/IN
both/CC
the/DT
PTHrP/NN
and/CC
IL2R/NN
alpha/NN
promoters/NNS
but/CC
not/RB
the/DT
HTLV-I/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
./.
====================
Exogenous/JJ
provision/NN
of/IN
NFkB/NN
rescued/VBD
IL2R/NN
alpha/NN
expression/NN
but/CC
not/RB
the/DT
PTHrP/NN
promoter/NN
./.
====================
Thus/RB
,/,
HTLV-I/NN
Tax/NN
,/,
HTLV-II/NN
Tax/NN
,/,
and/CC
c-jun/NN
transactivate/VBP
PTHrP/NN
and/CC
may/MD
contribute/VB
to/TO
the/DT
pathogenesis/NN
of/IN
hypercalcemia/NN
in/IN
adult/JJ
T-cell/NN
leukemia/NN
./.
====================
UI/LS
-/:
93123257/CD
====================
TI/LS
-/:
Involvement/NN
of/IN
Alu/NN
sequences/NNS
in/IN
the/DT
cell-specific/JJ
regulation/NN
of/IN
transcription/NN
of/IN
the/DT
gamma/NN
chain/NN
of/IN
Fc/NN
and/CC
T/NN
cell/NN
receptors/NNS
./.
====================
AB/LS
-/:
The/DT
Fc/NN
epsilon/NN
RI-gamma/NN
chains/NNS
are/VBP
expressed/VBN
in/IN
a/DT
variety/NN
of/IN
hematopoietic/JJ
cells/NNS
where/WRB
they/PRP
play/VBP
a/DT
critical/JJ
role/NN
in/IN
signal/NN
transduction/NN
./.
====================
They/PRP
are/VBP
part/NN
of/IN
the/DT
high/JJ
affinity/NN
IgE/NN
receptor/NN
in/IN
mast/NN
cells/NNS
,/,
basophils/NNS
,/,
Langerhans/NN
cells/NNS
,/,
and/CC
possibly/RB
other/JJ
cells/NNS
;/:
a/DT
component/NN
of/IN
the/DT
low/JJ
affinity/NN
receptor/NN
for/IN
IgG/NN
(/(
Fc/NN
gamma/NN
RIIIA/NN
or/CC
CD16/NN
)/)
in/IN
natural/JJ
killer/NN
cells/NNS
and/CC
macrophages/NNS
;/:
and/CC
part/NN
of/IN
the/DT
T/NN
cell/NN
antigen/NN
receptor/NN
in/IN
subsets/NNS
of/IN
T/NN
cells/NNS
./.
====================
Here/RB
we/PRP
have/VBP
investigated/VBN
the/DT
transcriptional/JJ
regulation/NN
of/IN
the/DT
gamma/NN
chain/NN
gene/NN
by/IN
analyzing/VBG
the/DT
2.5-kilobase/JJ
sequence/NN
upstream/JJ
of/IN
the/DT
transcription/NN
start/NN
site/NN
./.
====================
This/DT
sequence/NN
contains/VBZ
a/DT
promoter/NN
specific/JJ
to/TO
cells/NNS
of/IN
hematopoietic/JJ
lineage/NN
./.
====================
However/RB
,/,
the/DT
tissue/NN
specificity/NN
of/IN
this/DT
promoter/NN
is/VBZ
only/RB
partial/JJ
because/IN
it/PRP
is/VBZ
active/JJ
in/IN
all/DT
of/IN
the/DT
hematopoietic/JJ
cells/NNS
tested/VBN
here/RB
,/,
regardless/RB
of/IN
whether/IN
they/PRP
constitutively/RB
express/VBP
Fc/NN
epsilon/NN
RI-gamma/NN
chain/NN
transcripts/NNS
./.
====================
We/PRP
have/VBP
identified/VBN
two/CD
adjacent/JJ
cis-acting/JJ
regulatory/JJ
elements/NNS
,/,
both/DT
of/IN
which/WDT
are/VBP
part/NN
of/IN
an/DT
Alu/NN
repeat/NN
./.
====================
The/DT
first/JJ
(/(
-445/-366/CD
)/)
is/VBZ
a/DT
positive/JJ
element/NN
active/JJ
in/IN
both/CC
basophils/NNS
and/CC
T/NN
cells/NNS
./.
====================
The/DT
second/JJ
(/(
-365/-264/CD
)/)
binds/VBZ
to/TO
nuclear/JJ
factors/NNS
,/,
which/WDT
appear/VBP
to/TO
be/VB
different/JJ
in/IN
basophils/NNS
and/CC
T/NN
cells/NNS
,/,
and/CC
acts/VBZ
as/IN
a/DT
negative/JJ
element/NN
in/IN
basophils/NNS
and/CC
as/IN
a/DT
positive/JJ
one/NN
in/IN
T/NN
cells/NNS
./.
====================
Thus/RB
,/,
this/DT
Alu/NN
repeat/NN
(/(
90/CD
%/NN
identical/JJ
to/TO
Alu/NN
consensus/NN
sequences/NNS
)/)
has/VBZ
evolved/VBN
to/TO
become/VB
both/CC
a/DT
positive/JJ
and/CC
negative/JJ
regulator/NN
./.
====================
UI/LS
-/:
94077003/CD
====================
TI/LS
-/:
Chlorinated/VBN
dibenzo-p-dioxins/NNS
and/CC
dibenzofurans/NNS
and/CC
the/DT
human/JJ
immune/JJ
system/NN
./.
====================
1/LS
./.
Blood/NN
cell/NN
receptors/NNS
in/IN
volunteers/NNS
with/IN
moderately/RB
increased/VBN
body/NN
burdens/NNS
./.
====================
AB/LS
-/:
Using/VBG
monoclonal/JJ
antibodies/NNS
(/(
mAbs/NNS
)/)
and/CC
flow/NN
cytometry/NN
,/,
we/PRP
studied/VBD
a/DT
variety/NN
of/IN
surface/NN
receptors/NNS
on/IN
lymphocyte/NN
subpopulations/NNS
of/IN
workers/NNS
with/IN
moderately/RB
increased/VBN
body/NN
burdens/NNS
of/IN
2,3,7,8-tetrachlorodibenzo-p-dioxin/NN
(/(
TCDD/NN
)/)
and/CC
of/IN
other/JJ
polychlorinated/VBN
dibenzo-p-dioxins/NNS
and/CC
dibenzofurans/NNS
(/(
PCDD/PCDF/NN
)/)
,/,
expressed/VBN
here/RB
as/IN
International-Toxicity/NN
Equivalencies/NN
(/(
I-TE/NN
)/)
./.
====================
The/DT
hypothesis/NN
to/TO
be/VB
tested/VBN
was/VBD
whether/IN
or/CC
not/RB
humans/NNS
exhibit/VBP
a/DT
similar/JJ
susceptibility/NN
to/TO
PCDDs/PCDFs/NNS
with/IN
respect/NN
to/TO
the/DT
surface/NN
receptors/NNS
found/VBN
previously/RB
to/TO
respond/VB
to/TO
small/JJ
doses/NNS
of/IN
2,3,7,8-tetrachlorodibenzo-p-dioxin/NN
(/(
TCDD/NN
)/)
in/IN
Callithrix/FW
jacchus/FW
./.
====================
These/DT
are/VBP
:/:
helper-inducer/JJ
(/(
memory/NN
)/)
T/NN
cells/NNS
(/(
CD4+CD45R0+CD45RA-CD29highCD11a+/JJ
)/)
,/,
CD20+/JJ
B/NN
cells/NNS
,/,
and/CC
cytotoxic/JJ
T/NN
cells/NNS
(/(
CD8+CD56+/CD57+/JJ
)/)
./.
====================
Furthermore/RB
,/,
68/CD
triple-labellings/NNS
with/IN
mAbs/NNS
were/VBD
performed/VBN
on/IN
the/DT
cells/NNS
of/IN
each/DT
volunteer/NN
to/TO
possibly/RB
generate/VB
further/JJ
hypotheses/NNS
./.
====================
It/PRP
was/VBD
evaluated/VBN
whether/IN
any/DT
of/IN
the/DT
variables/NNS
might/MD
be/VB
used/VBN
as/IN
a/DT
biomarker/NN
of/IN
effects/NNS
for/IN
this/DT
class/NN
of/IN
compounds/NNS
./.
====================
There/EX
were/VBD
two/CD
main/JJ
goals/NNS
:/:
(/(
1/LS
)/)
to/TO
evaluate/VB
whether/IN
workers/NNS
with/IN
a/DT
moderately/RB
increased/VBN
PCDD/PCDF-body/NN
burden/NN
[/(
25-140/CD
ppt/NN
TCDD/NN
or/CC
104-522/CD
ppt/NN
I-TE/NN
in/IN
blood/NN
fat/NN
]/)
exhibit/VBP
changes/NNS
in/IN
the/DT
surface/NN
receptors/NNS
of/IN
white/JJ
blood/NN
cells/NNS
,/,
as/IN
observed/VBN
in/IN
previous/JJ
studies/NNS
in/IN
non-human/JJ
primates/NNS
,/,
and/CC
(/(
2/LS
)/)
to/TO
clarify/VB
whether/IN
persons/NNS
at/IN
the/DT
upper/JJ
range/NN
[/(
10-23/CD
ppt/NN
TCDD/NN
or/CC
30-90/CD
ppt/NN
I-TE/NN
in/IN
blood/NN
fat/NN
]/)
of/IN
the/DT
body/NN
burden/NN
reference/NN
values/NNS
of/IN
a/DT
not/RB
particularly/RB
exposed/VBN
population/NN
show/VBP
detectable/JJ
deviations/NNS
in/IN
these/DT
immunological/JJ
variables/NNS
,/,
when/WRB
compared/VBN
with/IN
persons/NNS
at/IN
the/DT
lower/JJR
and/CC
medium/NN
range/NN
[/(
1-3/CD
ppt/NN
TCDD/NN
or/CC
9-29/CD
ppt/NN
I-TE/NN
]/)
of/IN
these/DT
body/NN
burden/NN
reference/NN
values/NNS
./.
====================
Regression/NN
analysis/NN
of/IN
our/PRP$
data/NNS
revealed/VBD
slight/JJ
trends/NNS
for/IN
some/DT
of/IN
the/DT
biomarkers/NNS
(/(
e.g./FW
CD45R0+/JJ
)/)
./.
====================
With/IN
one/CD
exception/NN
,/,
these/DT
were/VBD
all/DT
increases/NNS
./.
====================
None/NN
of/IN
the/DT
alterations/NNS
observed/VBN
are/VBP
of/IN
medical/JJ
relevance/NN
./.
====================
The/DT
slight/JJ
increase/NN
in/IN
the/DT
percentage/NN
of/IN
CD4+CD45R0+/JJ
cells/NNS
remained/VBD
significant/JJ
even/RB
after/IN
covariant/JJ
analysis/NN
taking/VBG
age-related/JJ
changes/NNS
into/IN
account/NN
./.
====================
Altogether/RB
,/,
the/DT
data/NNS
do/VBP
not/RB
provide/VB
any/DT
evidence/NN
to/TO
support/VB
an/DT
assumption/NN
that/IN
moderately/RB
increased/VBN
body/NN
burdens/NNS
of/IN
PCDDs/PCDFs/NNS
in/IN
adults/NNS
induce/VBP
decreases/NNS
in/IN
the/DT
cellular/JJ
components/NNS
of/IN
the/DT
human/JJ
immune/JJ
system/NN
./.
====================
Adult/JJ
humans/NNS
certainly/RB
are/VBP
less/RBR
susceptible/JJ
to/TO
this/DT
action/NN
of/IN
PCDDs/PCDFs/NNS
than/IN
adolescent/JJ
Callithrix/FW
jacchus/FW
====================
UI/LS
-/:
94031267/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
HIV-1/NN
latency/NN
reactivation/NN
by/IN
dehydroepiandrosterone/NN
(/(
DHEA/NN
)/)
and/CC
an/DT
analog/NN
of/IN
DHEA/NN
./.
====================
AB/LS
-/:
The/DT
initial/JJ
infection/NN
with/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
in/IN
most/JJS
individuals/NNS
usually/RB
results/VBZ
in/IN
the/DT
establishment/NN
of/IN
a/DT
latent/JJ
or/CC
chronic/JJ
infection/NN
before/IN
eventual/JJ
progression/NN
toward/IN
acquired/VBN
immunodeficiency/NN
syndrome/NN
./.
====================
HIV-1/NN
can/MD
also/RB
establish/VB
a/DT
latent/JJ
or/CC
persistent/JJ
infection/NN
in/IN
some/DT
T/NN
cell/NN
lines/NNS
that/WDT
show/VBP
minimal/JJ
constitutive/JJ
virus/NN
expression/NN
./.
====================
However/RB
,/,
activation/NN
of/IN
the/DT
T/NN
cell/NN
lines/NNS
leading/VBG
to/TO
enhanced/VBN
HIV-1/NN
replication/NN
can/MD
be/VB
induced/VBN
by/IN
antigens/NNS
,/,
mitogens/NNS
,/,
and/CC
cytokines/NNS
(/(
tumor/NN
necrosis/NN
factor/NN
alpha/NN
[/(
TNF-alpha/NN
]/)
,/,
interleukin/NN
1/CD
,/,
and/CC
interleukin-2/NN
)/)
./.
====================
Various/JJ
gene/NN
products/NNS
from/IN
other/JJ
viruses/NNS
(/(
HTLV-1/NN
,/,
HSV/NN
,/,
EBV/NN
,/,
CMV/NN
,/,
HBV/NN
,/,
and/CC
HHV-6/NN
)/)
can/MD
also/RB
enhance/VB
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
-driven/JJ
reporter/NN
gene/NN
activity/NN
./.
====================
On/IN
the/DT
basis/NN
of/IN
these/DT
observations/NNS
,/,
it/PRP
has/VBZ
been/VBN
proposed/VBN
that/IN
reactivation/NN
of/IN
latent/JJ
HIV-1/NN
harbored/VBN
in/IN
chronically/RB
infected/JJ
T/NN
lymphocytes/NNS
,/,
monocytes/NNS
,/,
or/CC
macrophages/NNS
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
the/DT
pathogenesis/NN
of/IN
AIDS/NN
./.
====================
So/RB
far/RB
,/,
there/EX
are/VBP
no/DT
drugs/NNS
or/CC
therapy/NN
available/JJ
that/WDT
can/MD
provide/VB
protection/NN
against/IN
HIV-1/NN
latency/NN
reactivation/NN
./.
====================
ACH-2/NN
,/,
derived/VBN
from/IN
a/DT
human/JJ
T/NN
cell/NN
line/NN
(/(
CEM/NN
)/)
,/,
is/VBZ
chronically/RB
infected/VBN
with/IN
HIV-1/NN
,/,
with/IN
low/JJ
levels/NNS
of/IN
constitutive/JJ
virus/NN
expression/NN
./.
====================
ACH-2/NN
can/MD
be/VB
converted/VBN
to/TO
productive/JJ
infection/NN
by/IN
stimulation/NN
of/IN
the/DT
cells/NNS
with/IN
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
,/,
mitogen/NN
or/CC
cytokines/NNS
(/(
TNF-alpha/NN
)/)
,/,
or/CC
infection/NN
with/IN
HSV/NN
./.
====================
Therefore/RB
the/DT
ACH-2/NN
cell/NN
line/NN
is/VBZ
a/DT
good/JJ
candidate/NN
for/IN
studying/VBG
the/DT
effects/NNS
of/IN
drugs/NNS
on/IN
HIV-1/NN
activation/NN
./.
====================
Previously/RB
,/,
we/PRP
have/VBP
reported/VBN
that/IN
DHEA/NN
and/CC
synthetic/JJ
analogs/NNS
of/IN
DHEA/NN
can/MD
be/VB
modest/JJ
inhibitors/NNS
of/IN
HIV-1/NN
IIIB/NN
replication/NN
in/IN
phytohemagglutinin-stimulated/JJ
peripheral/JJ
blood/NN
lymphocyte/NN
cultures/NNS
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
93314685/CD
====================
TI/LS
-/:
Occurrence/NN
of/IN
a/DT
silencer/NN
of/IN
the/DT
interleukin-2/NN
gene/NN
in/IN
naive/JJ
but/CC
not/RB
in/IN
memory/NN
resting/VBG
T/NN
helper/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
In/IN
the/DT
immune/JJ
system/NN
the/DT
first/JJ
activation/NN
of/IN
a/DT
naive/JJ
T/NN
cell/NN
by/IN
antigen/NN
is/VBZ
a/DT
key/JJ
step/NN
in/IN
the/DT
shaping/NN
of/IN
the/DT
peripheral/JJ
T/NN
cell/NN
specificity/NN
repertoire/NN
and/CC
maintenance/NN
of/IN
self-tolerance/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
analysis/NN
of/IN
the/DT
interleukin-2/NN
(/(
IL-2/NN
)/)
gene/NN
activation/NN
shows/VBZ
that/IN
naive/JJ
human/JJ
helper/NN
T/NN
cells/NNS
(/(
cord/NN
blood/NN
CD4+/JJ
T/NN
cells/NNS
,/,
adult/JJ
CD4+CD45RO-/JJ
T/NN
cells/NNS
)/)
regulate/VBP
IL-2/NN
transcription/NN
by/IN
a/DT
mechanism/NN
involving/VBG
both/CC
a/DT
silencer/NN
and/CC
an/DT
activator/NN
acting/VBG
on/IN
the/DT
purine-rich/JJ
IL-2/NN
promoter/NN
elements/NNS
(/(
NF-AT/NN
binding/NN
sites/NNS
)/)
./.
====================
By/IN
contrast/NN
,/,
memory/NN
cells/NNS
,/,
either/CC
in/FW
vitro/FW
activated/VBN
helper/NN
T/NN
cells/NNS
reverting/VBG
to/TO
a/DT
resting/JJ
state/NN
,/,
or/CC
CD4+/JJ
T/NN
(/(
memory/NN
)/)
clones/NNS
,/,
or/CC
CD4+CD45RO+/JJ
T/NN
cells/NNS
isolated/VBN
ex/FW
vivo/FW
,/,
no/RB
longer/RB
have/VBP
a/DT
silencer/NN
./.
====================
Their/PRP$
IL-2/NN
transcription/NN
seems/VBZ
to/TO
be/VB
controlled/VBN
solely/RB
by/IN
the/DT
transition/NN
from/IN
inactive/JJ
to/TO
active/JJ
functional/JJ
state/NN
of/IN
a/DT
positive/JJ
transcription/NN
factor/NN
binding/VBG
to/TO
these/DT
promoter/NN
elements/NNS
as/RB
well/RB
as/IN
its/PRP$
cytoplasmic/JJ
or/CC
nuclear/JJ
location/NN
:/:
in/IN
resting/VBG
memory/NN
T/NN
cells/NNS
the/DT
activator/NN
is/VBZ
located/JJ
in/IN
the/DT
cytoplasm/NN
and/CC
is/VBZ
inactive/JJ
,/,
whereas/IN
in/IN
stimulated/VBN
cells/NNS
it/PRP
is/VBZ
functional/JJ
in/IN
promoting/VBG
transcription/NN
and/CC
now/RB
resides/VBZ
in/IN
the/DT
nucleus/NN
./.
====================
Thus/RB
,/,
the/DT
regulation/NN
of/IN
the/DT
gene/NN
coding/VBG
for/IN
the/DT
main/JJ
T/NN
cell/NN
growth/NN
factor/NN
changes/VBZ
irreversibly/RB
after/IN
the/DT
first/JJ
encounter/NN
of/IN
T/NN
cells/NNS
with/IN
antigen/NN
./.
====================
It/PRP
is/VBZ
most/RBS
likely/JJ
that/IN
the/DT
presence/NN
of/IN
a/DT
silencer/NN
contributes/VBZ
to/TO
the/DT
more/RBR
stringent/JJ
activation/NN
requirements/NNS
of/IN
naive/JJ
CD4+/JJ
T/NN
cells/NNS
./.
====================
UI/LS
-/:
93283670/CD
====================
TI/LS
-/:
Expression/NN
of/IN
mRNA/NN
for/IN
the/DT
GATA-binding/JJ
proteins/NNS
in/IN
human/JJ
eosinophils/NNS
and/CC
basophils/NNS
:/:
potential/JJ
role/NN
in/IN
gene/NN
transcription/NN
./.
====================
AB/LS
-/:
The/DT
expression/NN
of/IN
the/DT
hematopoietic/JJ
transcription/NN
factors/NNS
GATA-1/NN
,/,
GATA-2/NN
,/,
and/CC
GATA-3/NN
was/VBD
studied/VBN
in/IN
eosinophils/NNS
and/CC
basophils/NNS
./.
====================
Eosinophils/NNS
express/VBP
mRNA/NN
for/IN
GATA-1/NN
,/,
GATA-2/NN
,/,
and/CC
GATA-3/NN
./.
====================
Basophils/NNS
express/VBP
GATA-2/NN
and/CC
GATA-3/NN
./.
====================
Treatment/NN
of/IN
HL-60/NN
eosinophilic/JJ
sublines/NNS
with/IN
either/CC
interleukin-5/NN
or/CC
butyric/JJ
acid/NN
increased/VBD
the/DT
expression/NN
of/IN
GATA-1/NN
mRNA/NN
concomitant/JJ
with/IN
the/DT
expression/NN
of/IN
eosinophil-specific/JJ
genes/NNS
,/,
whereas/IN
levels/NNS
of/IN
GATA-2/NN
mRNA/NN
remained/VBD
relatively/RB
constant/JJ
./.
====================
The/DT
presence/NN
of/IN
mRNA/NN
for/IN
these/DT
proteins/NNS
in/IN
eosinophils/NNS
and/CC
basophils/NNS
suggests/VBZ
that/IN
gene/NN
transcription/NN
in/IN
these/DT
lineages/NNS
may/MD
be/VB
regulated/VBN
by/IN
GATA-binding/JJ
proteins/NNS
./.
====================
UI/LS
-/:
93266597/CD
====================
TI/LS
-/:
Oxidoreductive/JJ
regulation/NN
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
./.
====================
Involvement/NN
of/IN
a/DT
cellular/JJ
reducing/NN
catalyst/NN
thioredoxin/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
investigated/VBN
an/DT
oxidoreductive/JJ
regulatory/JJ
pathway/NN
for/IN
the/DT
DNA/NN
binding/NN
activity/NN
of/IN
a/DT
pleiotropic/JJ
cellular/JJ
transcription/NN
factor/NN
,/,
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF/NN
kappa/NN
B/NN
)/)
,/,
has/VBZ
been/VBN
investigated/VBN
by/IN
using/VBG
NF/NN
kappa/NN
B/NN
prepared/VBN
from/IN
the/DT
nucleus/NN
and/CC
the/DT
cytosol/NN
of/IN
the/DT
primary/JJ
human/JJ
T/NN
lymphocytes/NNS
./.
====================
We/PRP
show/VBP
that/IN
a/DT
cellular/JJ
reducing/NN
catalyst/NN
thioredoxin/NN
(/(
Trx/NN
)/)
plays/VBZ
a/DT
major/JJ
role/NN
in/IN
activation/NN
of/IN
the/DT
DNA/NN
binding/NN
of/IN
NF/NN
kappa/NN
B/NN
in/FW
vitro/FW
and/CC
stimulation/NN
of/IN
transcription/NN
from/IN
the/DT
NF/NN
kappa/NN
B-dependent/JJ
gene/NN
expression/NN
./.
====================
We/PRP
demonstrate/VBP
evidence/NN
suggesting/VBG
that/IN
redox/NN
regulation/NN
of/IN
NF/NN
kappa/NN
B/NN
by/IN
Trx/NN
might/MD
be/VB
exerted/VBN
at/IN
a/DT
step/NN
after/IN
dissociation/NN
of/IN
the/DT
inhibitory/JJ
molecule/NN
I/NN
kappa/NN
B/NN
,/,
a/DT
cytosolic-anchoring/JJ
protein/NN
for/IN
NF/NN
kappa/NN
B/NN
./.
====================
To/TO
examine/VB
the/DT
effect/NN
of/IN
Trx/NN
in/IN
intact/JJ
cells/NNS
,/,
we/PRP
performed/VBD
transient/JJ
assay/NN
with/IN
a/DT
chloramphenicol/NN
acetyltransferase-expressing/JJ
plasmid/NN
under/IN
the/DT
control/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
long/JJ
terminal/JJ
repeat/NN
and/CC
an/DT
effector/NN
plasmid/NN
expressing/VBG
human/JJ
Trx/NN
./.
====================
The/DT
promoter/NN
activity/NN
from/IN
HIV/NN
long/JJ
terminal/JJ
repeat/NN
was/VBD
greatly/RB
augmented/VBN
by/IN
co-transfecting/VBG
the/DT
Trx-expressing/NN
plasmid/NN
,/,
whose/WP$
effect/NN
was/VBD
dependent/JJ
on/IN
the/DT
NF/NN
kappa/NN
B-binding/NN
sites/NNS
./.
====================
These/DT
findings/NNS
have/VBP
suggested/VBN
that/IN
cysteine/NN
residue/NN
(/(
s/NNS
)/)
of/IN
NF/NN
kappa/NN
B/NN
might/MD
be/VB
involved/VBN
in/IN
the/DT
DNA-recognition/NN
by/IN
NF/NN
kappa/NN
B/NN
and/CC
that/IN
the/DT
redox/NN
control/NN
mechanism/NN
mediated/VBN
by/IN
Trx/NN
might/MD
have/VB
a/DT
regulatory/JJ
role/NN
in/IN
the/DT
NF/NN
kappa/NN
B-mediated/JJ
gene/NN
expression/NN
./.
====================
These/DT
results/NNS
may/MD
also/RB
provide/VB
a/DT
clue/NN
to/TO
understanding/NN
of/IN
the/DT
molecular/JJ
process/NN
of/IN
AIDS/NN
pathogenesis/NN
and/CC
its/PRP$
possible/JJ
biochemical/JJ
intervention/NN
./.
====================
UI/LS
-/:
93269273/CD
====================
TI/LS
-/:
Synergism/NN
between/IN
the/DT
CD3/NN
antigen-/NN
and/CC
CD2/NN
antigen-derived/JJ
signals/NNS
./.
====================
Exploration/NN
at/IN
the/DT
level/NN
of/IN
induction/NN
of/IN
DNA-binding/JJ
proteins/NNS
and/CC
characterization/NN
of/IN
the/DT
inhibitory/JJ
activity/NN
of/IN
cyclosporine/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
demonstrated/VBN
earlier/RBR
that/IN
the/DT
crosslinkage/NN
of/IN
the/DT
CD3/TCR/NN
complex/NN
with/IN
the/DT
CD2/NN
antigen/NN
results/VBZ
in/IN
the/DT
proliferation/NN
of/IN
normal/JJ
human/JJ
T/NN
cells/NNS
./.
====================
The/DT
effect/NN
of/IN
this/DT
synergism/NN
was/VBD
perceptible/JJ
at/IN
the/DT
level/NN
of/IN
induction/NN
of/IN
the/DT
IL-2/NN
gene/NN
,/,
a/DT
process/NN
critical/JJ
for/IN
T/NN
cell/NN
growth/NN
./.
====================
To/TO
further/RB
understand/VB
the/DT
molecular/JJ
and/CC
nuclear/JJ
basis/NN
for/IN
this/DT
synergism/NN
,/,
we/PRP
have/VBP
explored/VBN
the/DT
induction/NN
of/IN
DNA-binding/JJ
proteins/NNS
in/IN
highly/RB
purified/VBN
normal/JJ
human/JJ
T/NN
cells/NNS
signaled/VBN
via/IN
the/DT
CD3/NN
and/or/CC
CD2/NN
proteins/NNS
./.
====================
The/DT
effect/NN
of/IN
transmembrane/NN
signaling/NN
of/IN
T/NN
cells/NNS
with/IN
ionomycin/NN
,/,
and/or/CC
sn-1/NN
,/,
2/CD
dioctanoyl/NN
glycerol/NN
,/,
was/VBD
also/RB
determined/VBN
./.
====================
The/DT
emergence/NN
of/IN
nuclear/JJ
binding/NN
proteins/NNS
was/VBD
investigated/VBN
using/VBG
interleukin-2/NN
sequence/NN
specific/JJ
oligonucleotide/NN
probes/NNS
in/IN
the/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
./.
====================
Our/PRP$
studies/NNS
demonstrate/VBP
for/IN
the/DT
first/JJ
time/NN
that/IN
CD3/NN
antigen-derived/JJ
signals/NNS
and/CC
CD2/NN
antigen-derived/JJ
signals/NNS
are/VBP
synergistic/JJ
in/IN
inducing/VBG
the/DT
emergence/NN
of/IN
transcription/NN
factors/NNS
that/WDT
bind/VBP
to/TO
the/DT
NF-AT1/NN
,/,
AP-1/NN
,/,
and/CC
NF-kB/NN
sites/NNS
located/JJ
in/IN
the/DT
promoter/enhancer/NN
region/NN
of/IN
the/DT
IL-2/NN
gene/NN
./.
====================
Moreover/RB
,/,
cyclosporine/NN
,/,
at/IN
concentrations/NNS
readily/RB
accomplished/VBN
in/IN
clinical/JJ
practice/NN
,/,
was/VBD
found/VBN
to/TO
inhibit/VB
the/DT
emergence/NN
of/IN
these/DT
DNA-binding/JJ
proteins/NNS
in/IN
normal/JJ
human/JJ
T/NN
cells/NNS
signaled/VBN
via/IN
cell/NN
surface/NN
proteins/NNS
implicated/VBN
in/IN
antigen-dependent/JJ
T/NN
cell/NN
activation/NN
and/CC
in/IN
T/NN
cells/NNS
stimulated/VBN
by/IN
mobilization/NN
of/IN
cellular/JJ
calcium/NN
and/CC
activation/NN
of/IN
protein/NN
kinase/NN
C/NN
./.
====================
UI/LS
-/:
93215800/CD
====================
TI/LS
-/:
Induced/VBN
myeloid/JJ
differentiation/NN
of/IN
K562/NN
cells/NNS
with/IN
downregulation/NN
of/IN
erythroid/JJ
and/CC
megakaryocytic/JJ
transcription/NN
factors/NNS
:/:
a/DT
novel/JJ
experimental/JJ
model/NN
for/IN
hemopoietic/JJ
lineage/NN
restriction/NN
./.
====================
AB/LS
-/:
The/DT
human/JJ
erythroleukemia/NN
cell/NN
line/NN
K562/NN
can/MD
be/VB
induced/VBN
to/TO
differentiate/VB
along/IN
the/DT
erythroid/JJ
and/CC
megakaryocytic/JJ
lineages/NNS
./.
====================
Here/RB
we/PRP
demonstrate/VBP
that/IN
hexamethylene/NN
bisacetamide/NN
(/(
HMBA/NN
)/)
induced/VBD
K562/NN
cells/NNS
to/TO
differentiate/VB
along/IN
a/DT
third/JJ
pathway/NN
./.
====================
This/DT
was/VBD
accompanied/VBN
by/IN
downregulation/NN
of/IN
two/CD
transcription/NN
factors/NNS
normally/RB
expressed/VBN
in/IN
erythroid/JJ
,/,
mast/NN
and/CC
megakaryocyte/NN
lineages/NNS
./.
====================
Northern/NN
analysis/NN
demonstrated/VBD
coordinate/JJ
downregulation/NN
of/IN
alpha/NN
globin/NN
and/CC
gamma/NN
globin/NN
in/IN
addition/NN
to/TO
the/DT
two/CD
lineage-restricted/JJ
transcription/NN
factors/NNS
,/,
SCL/NN
and/CC
GATA-1/NN
./.
====================
Proliferation/NN
of/IN
the/DT
K562/NN
cells/NNS
was/VBD
also/RB
suppressed/VBN
./.
====================
Clonal/JJ
assay/NN
showed/VBD
that/IN
the/DT
suppression/NN
was/VBD
irreversible/JJ
and/CC
appeared/VBD
analogous/JJ
to/TO
the/DT
commitment/NN
of/IN
murine/JJ
erythroleukemia/NN
(/(
MEL/NN
)/)
cells/NNS
to/TO
terminal/JJ
differentiation/NN
./.
====================
In/IN
contrast/NN
to/TO
MEL/NN
cells/NNS
,/,
however/RB
,/,
K562/NN
cells/NNS
acquired/VBD
a/DT
macrophage-like/JJ
morphology/NN
and/CC
exhibited/VBD
a/DT
complete/JJ
failure/NN
to/TO
generate/VB
benzidine-positive/JJ
cells/NNS
./.
====================
Electron/NN
microscopy/NN
revealed/VBD
a/DT
marked/JJ
increase/NN
in/IN
granules/NNS
resembling/VBG
those/DT
specific/JJ
for/IN
eosinophils/NNS
./.
====================
Surface/NN
marker/NN
analysis/NN
showed/VBD
that/IN
HMBA-induced/JJ
cells/NNS
expressed/VBD
reduced/VBN
levels/NNS
of/IN
glycophorin/NN
A/NN
,/,
CD5/NN
,/,
CD7/NN
and/CC
CD11b/NN
./.
====================
No/DT
upregulation/NN
of/IN
megakaryocyte/NN
or/CC
lymphoid/JJ
markers/NNS
occurred/VBD
./.
====================
Thus/RB
the/DT
response/NN
of/IN
K562/NN
cells/NNS
to/TO
HMBA/NN
may/MD
provide/VB
a/DT
useful/JJ
experimental/JJ
system/NN
for/IN
studying/VBG
the/DT
molecular/JJ
mechanisms/NNS
responsible/JJ
for/IN
downmodulation/NN
of/IN
lineage-restricted/JJ
transcription/NN
factors/NNS
during/IN
hemopoietic/JJ
lineage/NN
commitment/NN
./.
====================
UI/LS
-/:
93264305/CD
====================
TI/LS
-/:
Activation/NN
of/IN
primary/JJ
human/JJ
T-lymphocytes/NNS
through/IN
CD2/NN
plus/CC
CD28/NN
adhesion/NN
molecules/NNS
induces/VBZ
long-term/JJ
nuclear/JJ
expression/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
AB/LS
-/:
Stimulation/NN
of/IN
highly/RB
purified/VBN
human/JJ
T-cells/NNS
via/IN
CD2/NN
and/CC
CD28/NN
adhesion/NN
molecules/NNS
induces/VBZ
and/CC
maintains/VBZ
proliferation/NN
for/IN
more/JJR
than/IN
3/CD
weeks/NNS
./.
====================
This/DT
potent/JJ
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
-dependent/JJ
activation/NN
does/VBZ
not/RB
require/VB
monocytes/NNS
or/CC
accessory/JJ
cells/NNS
./.
====================
Long-lasting/JJ
IL-2/NN
receptivity/NN
is/VBZ
associated/VBN
with/IN
high-level/JJ
expression/NN
of/IN
the/DT
inducible/JJ
IL-2/NN
receptor/NN
alpha/NN
chain/NN
(/(
IL-2R/NN
alpha/NN
)/)
gene/NN
that/WDT
is/VBZ
regulated/VBN
at/IN
both/CC
transcriptional/JJ
and/CC
posttranscriptional/JJ
levels/NNS
./.
====================
Increase/NN
of/IN
IL-2R/NN
alpha/NN
gene/NN
transcription/NN
involves/VBZ
the/DT
enhanced/VBN
binding/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
to/TO
its/PRP$
consensus/NN
sequence/NN
in/IN
the/DT
5'-regulatory/JJ
region/NN
of/IN
the/DT
IL-2R/NN
alpha/NN
gene/NN
./.
====================
To/TO
dissect/VB
the/DT
molecular/JJ
basis/NN
for/IN
the/DT
unusually/RB
persistent/JJ
transcription/NN
of/IN
the/DT
IL-2R/NN
alpha/NN
gene/NN
,/,
we/PRP
analyzed/VBD
nuclear/JJ
NF-kappa/NN
B/NN
binding/VBG
to/TO
a/DT
radiolabeled/VBN
IL-2R/NN
alpha/NN
kappa/NN
B-specific/JJ
oligonucleotide/NN
probe/NN
during/IN
the/DT
time/NN
course/NN
of/IN
CD2/NN
+/CC
CD28/NN
activation/NN
./.
====================
Resting/VBG
T-cell/NN
nuclear/JJ
extracts/NNS
contained/VBD
KBF1/p50/NN
homodimer/NN
./.
====================
After/IN
stimulation/NN
,/,
two/CD
new/JJ
kappa/NN
B-specific/JJ
complexes/NNS
were/VBD
identified/VBN
as/IN
NF-kappa/NN
B/NN
p50-p65/NN
heterodimer/NN
and/CC
putative/JJ
c-Rel/NN
homodimer/NN
or/CC
c-Rel-p65/NN
heterodimer/NN
./.
====================
Both/DT
inducible/JJ
complexes/NNS
persisted/VBD
for/IN
at/IN
least/JJS
3/CD
weeks/NNS
./.
====================
Their/PRP$
relative/JJ
levels/NNS
were/VBD
very/RB
similar/JJ
for/IN
the/DT
duration/NN
of/IN
proliferation/NN
./.
====================
In/IN
parallel/NN
,/,
CD2/NN
+/CC
CD28/NN
activation/NN
triggered/VBD
a/DT
significant/JJ
intracellular/JJ
thiol/NN
decrease/NN
,/,
suggesting/VBG
that/IN
oxygen/NN
radicals/NNS
are/VBP
involved/VBN
in/IN
the/DT
signaling/NN
pathway/NN
of/IN
adhesion/NN
molecules/NNS
./.
====================
Finally/RB
,/,
micromolar/JJ
amounts/NNS
of/IN
pyrrolidine/NN
dithiocarbamate/NN
,/,
an/DT
oxygen/NN
radical/NN
scavenger/NN
that/WDT
efficiently/RB
blocked/VBD
the/DT
nuclear/JJ
appearance/NN
of/IN
NF-kappa/NN
B/NN
in/IN
T-lymphocytes/NNS
,/,
also/RB
inhibited/VBD
IL-2/NN
secretion/NN
,/,
IL-2R/NN
alpha/NN
cell/NN
surface/NN
expression/NN
,/,
and/CC
T-cell/NN
proliferation/NN
./.
====================
Together/RB
,/,
these/DT
results/NNS
suggest/VBP
that/IN
NF-kappa/NN
B/NN
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
long-term/JJ
activation/NN
of/IN
human/JJ
primary/JJ
T-lymphocytes/NNS
via/IN
CD2/NN
+/CC
CD28/NN
./.
====================
UI/LS
-/:
93228833/CD
====================
TI/LS
-/:
Immobilization/NN
and/CC
recovery/NN
of/IN
fusion/NN
proteins/NNS
and/CC
B-lymphocyte/NN
cells/NNS
using/VBG
magnetic/JJ
separation/NN
./.
====================
AB/LS
-/:
A/DT
new/JJ
approach/NN
to/TO
facilitate/VB
immobilization/NN
and/CC
affinity/NN
purification/NN
of/IN
recombinant/JJ
proteins/NNS
and/CC
selected/VBN
human/JJ
B/NN
lymphocytes/NNS
has/VBZ
been/VBN
developed/VBN
./.
====================
Using/VBG
magnetic/JJ
beads/NNS
with/IN
attached/VBN
DNA/NN
containing/VBG
the/DT
Escherichia/FW
coli/FW
lac/NN
operator/NN
,/,
fusion/NN
proteins/NNS
comprising/VBG
the/DT
DNA-binding/JJ
lac/NN
repressor/NN
could/MD
be/VB
affinity-purified/JJ
and/CC
recovered/VBN
by/IN
gentle/JJ
elution/NN
conditions/NNS
,/,
such/JJ
as/IN
with/IN
a/DT
lactose/NN
analogue/NN
or/CC
by/IN
enzymatic/JJ
means/NNS
using/VBG
either/CC
deoxyribonuclease/NN
(/(
DNase/NN
)/)
or/CC
restriction/NN
endonucleases/NNS
./.
====================
The/DT
results/NNS
show/VBP
for/IN
the/DT
first/JJ
time/NN
that/IN
a/DT
DNA-binding/JJ
protein/NN
can/MD
be/VB
used/VBN
for/IN
affinity/NN
purification/NN
of/IN
fusion/NN
proteins/NNS
as/IN
exemplified/VBN
by/IN
the/DT
specific/JJ
and/CC
gentle/JJ
recovery/NN
of/IN
beta-galactosidase/NN
and/CC
alkaline/NN
phosphatase/NN
from/IN
bacterial/JJ
lysates/NNS
using/VBG
immunomagnetic/JJ
separation/NN
./.
====================
The/DT
approach/NN
was/VBD
further/RB
extended/VBN
to/TO
cell/NN
separation/NN
by/IN
the/DT
efficient/JJ
recovery/NN
and/CC
elution/NN
of/IN
human/JJ
CD37/NN
B/NN
lymphocytes/NNS
from/IN
peripheral/JJ
blood/NN
./.
====================
UI/LS
-/:
93155082/CD
====================
TI/LS
-/:
ras/NN
protein/NN
activity/NN
is/VBZ
essential/JJ
for/IN
T-cell/NN
antigen/NN
receptor/NN
signal/NN
transduction/NN
./.
====================
AB/LS
-/:
In/IN
a/DT
Jurkat/NN
cell/NN
model/NN
of/IN
T-cell/NN
activation/NN
an/DT
interleukin-2/NN
promoter/reporter/NN
gene/NN
construct/NN
was/VBD
activated/VBN
by/IN
antigen/NN
receptor/NN
agonism/NN
in/IN
combination/NN
with/IN
the/DT
lymphokine/NN
interleukin-1/NN
./.
====================
Antigen/NN
receptor/NN
signals/NNS
could/MD
be/VB
mimicked/VBN
by/IN
suboptimal/JJ
activation/NN
of/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
with/IN
phorbol/NN
esters/NNS
in/IN
combination/NN
with/IN
calcium/NN
mobilization/NN
by/IN
an/DT
ionophore/NN
./.
====================
In/IN
cotransfection/NN
experiments/NNS
,/,
oncogenic/JJ
rats/NNS
obviated/VBD
the/DT
need/NN
for/IN
PKC/NN
stimulation/NN
but/CC
did/VBD
not/RB
replace/VB
either/CC
the/DT
calcium/NN
signal/NN
or/CC
interleukin-1/NN
./.
====================
Activated/VBN
ras/NN
expression/NN
also/RB
replaced/VBD
the/DT
requirement/NN
for/IN
PKC/NN
stimulation/NN
in/IN
activation/NN
of/IN
the/DT
T-cell/NN
transcription/NN
factor/NN
NF-AT/NN
./.
====================
A/DT
dominant/JJ
inhibitory/JJ
ras/NN
mutant/NN
specifically/RB
blocked/VBD
antigen/NN
receptor/NN
agonism/NN
,/,
indicating/VBG
that/IN
ras/NN
activity/NN
is/VBZ
required/VBN
for/IN
antigen/NN
receptor/NN
signaling/NN
./.
====================
In/IN
addition/NN
,/,
an/DT
inhibitor/NN
of/IN
PKC/NN
blocked/VBD
both/CC
activated/VBD
ras/NN
and/CC
phorbol/NN
ester/NN
stimulation/NN
,/,
suggesting/VBG
a/DT
role/NN
for/IN
ras/NN
upstream/JJ
of/IN
PKC/NN
./.
====================
UI/LS
-/:
93189882/CD
====================
TI/LS
-/:
Expression/NN
of/IN
the/DT
Tat/NN
protein/NN
of/IN
HIV1/NN
in/IN
human/JJ
promonocytic/JJ
U937/NN
cells/NNS
./.
====================
AB/LS
-/:
Numerous/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
,/,
upon/IN
HIV1/NN
infection/NN
,/,
human/JJ
promonocytic/JJ
U937/NN
cells/NNS
were/VBD
induced/VBN
to/TO
differentiate/VB
,/,
as/IN
indicated/VBN
,/,
for/IN
example/NN
,/,
by/IN
increased/VBN
expression/NN
of/IN
adhesion/NN
molecules/NNS
./.
====================
One/CD
of/IN
the/DT
viral/JJ
proteins/NNS
involved/VBN
in/IN
this/DT
process/NN
might/MD
be/VB
the/DT
Tat/NN
protein/NN
./.
====================
Indeed/RB
,/,
this/DT
viral/JJ
protein/NN
,/,
which/WDT
is/VBZ
essential/JJ
for/IN
productive/JJ
infection/NN
,/,
has/VBZ
also/RB
been/VBN
shown/VBN
to/TO
display/VB
growth-stimulating/JJ
properties/NNS
and/CC
immunomodulatory/JJ
activities/NNS
./.
====================
In/IN
order/NN
to/TO
apprehend/VB
the/DT
role/NN
of/IN
the/DT
HIV1/NN
tat/NN
gene/NN
in/IN
inducing/VBG
the/DT
differentiation/NN
of/IN
HIV1-infected/JJ
U937/NN
cells/NNS
,/,
we/PRP
have/VBP
successfully/RB
introduced/VBN
this/DT
gene/NN
into/IN
U937/NN
cells/NNS
by/IN
infecting/VBG
them/PRP
with/IN
retroviral/JJ
particles/NNS
transducing/VBG
tat/NN
./.
====================
The/DT
effect/NN
of/IN
the/DT
Tat/NN
protein/NN
constitutively/RB
expressed/VBN
by/IN
these/DT
cells/NNS
upon/IN
their/PRP$
differentiation/NN
was/VBD
then/RB
evaluated/VBN
by/IN
looking/VBG
for/IN
the/DT
expression/NN
of/IN
the/DT
c-fos/NN
and/CC
of/IN
the/DT
c-fms/NN
proto-oncogenes/NNS
which/WDT
are/VBP
linked/VBN
to/TO
the/DT
differentiation/NN
of/IN
myelomonoblastic/JJ
cells/NNS
./.
====================
Northern/NN
blot/NN
analysis/NN
revealed/VBD
in/IN
these/DT
cells/NNS
,/,
an/DT
increase/NN
in/IN
the/DT
transcription/NN
of/IN
these/DT
two/CD
proto-oncogenes/NNS
,/,
and/CC
this/DT
increase/NN
was/VBD
amplified/VBN
after/IN
treatment/NN
with/IN
phorbol/NN
myristate/NN
acetate/NN
./.
====================
No/DT
such/JJ
increase/NN
was/VBD
observed/VBN
in/IN
control/NN
U937/NN
cells/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
,/,
among/IN
HIV1/NN
gene/NN
products/NNS
,/,
the/DT
Tat/NN
protein/NN
appears/VBZ
to/TO
trigger/VB
monocytic/JJ
differentiation/NN
,/,
and/CC
suggests/VBZ
that/IN
this/DT
viral/JJ
protein/NN
directs/VBZ
progenitors/NNS
of/IN
the/DT
monocyte/macrophage/NN
lineage/NN
towards/IN
a/DT
differentiation/NN
stage/NN
in/IN
which/WDT
production/NN
of/IN
viral/JJ
antigens/NNS
and/CC
virions/NNS
might/MD
be/VB
more/RBR
efficient/JJ
./.
====================
UI/LS
-/:
93329079/CD
====================
TI/LS
-/:
Analysis/NN
of/IN
the/DT
preexisting/JJ
and/CC
nuclear/JJ
forms/NNS
of/IN
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NF-AT/NN
)/)
3/CD
is/VBZ
an/DT
inducible/JJ
DNA-binding/JJ
protein/NN
that/WDT
is/VBZ
essential/JJ
for/IN
transcriptional/JJ
induction/NN
of/IN
the/DT
IL-2/NN
gene/NN
during/IN
T/NN
cell/NN
activation/NN
./.
====================
NF-AT/NN
is/VBZ
thought/VBN
to/TO
consist/VB
of/IN
two/CD
components/NNS
:/:
a/DT
ubiquitous/JJ
,/,
inducible/JJ
nuclear/JJ
component/NN
that/WDT
we/PRP
have/VBP
identified/VBN
as/IN
Fos/NN
and/CC
Jun/NN
proteins/NNS
,/,
and/CC
a/DT
preexisting/VBG
,/,
T/NN
cell-specific/JJ
component/NN
(/(
NF-ATp/NN
)/)
which/WDT
is/VBZ
the/DT
target/NN
for/IN
the/DT
immunosuppressive/JJ
agents/NNS
cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
and/CC
FK506/NN
./.
====================
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
nuclear/JJ
extracts/NNS
from/IN
activated/VBN
T/NN
cells/NNS
form/VBP
two/CD
inducible/JJ
NF-AT/NN
complexes/NNS
with/IN
an/DT
oligonucleotide/NN
corresponding/VBG
to/TO
the/DT
distal/JJ
NF-AT/NN
site/NN
of/IN
the/DT
murine/JJ
IL-2/NN
promoter/NN
,/,
although/IN
hypotonic/JJ
extracts/NNS
of/IN
unstimulated/JJ
T/NN
cells/NNS
form/VBP
a/DT
single/JJ
complex/NN
containing/VBG
NF-ATp/NN
./.
====================
We/PRP
show/VBP
that/IN
the/DT
ability/NN
to/TO
detect/VB
NF-ATp/NN
in/IN
a/DT
gel/NN
shift/NN
assay/NN
,/,
which/WDT
is/VBZ
essential/JJ
for/IN
purification/NN
and/CC
biochemical/JJ
studies/NNS
of/IN
this/DT
protein/NN
,/,
is/VBZ
strikingly/RB
dependent/JJ
on/IN
the/DT
precise/JJ
sequence/NN
of/IN
the/DT
NF-AT/NN
oligonucleotide/NN
used/VBN
as/IN
the/DT
labeled/JJ
probe/NN
./.
====================
Moreover/RB
we/PRP
present/VBP
evidence/NN
that/IN
the/DT
component/NN
that/WDT
forms/VBZ
the/DT
faster-migrating/JJ
(/(
"/``
lower/JJR
"/''
)/)
nuclear/JJ
NF-AT/NN
complex/NN
is/VBZ
derived/VBN
by/IN
a/DT
calcium-dependent/JJ
,/,
cyclosporin-sensitive/JJ
,/,
posttranslational/JJ
modification/NN
of/IN
NF-ATp/NN
,/,
and/CC
that/IN
Fos/NN
and/CC
Jun/NN
proteins/NNS
stabilize/VBP
its/PRP$
interaction/NN
with/IN
DNA/NN
./.
====================
The/DT
results/NNS
are/VBP
discussed/VBN
in/IN
the/DT
context/NN
of/IN
a/DT
model/NN
relating/VBG
the/DT
two/CD
nuclear/JJ
NF-AT/NN
complexes/NNS
to/TO
NF-ATp/NN
./.
====================
UI/LS
-/:
93309430/CD
====================
TI/LS
-/:
Cell/NN
cycle/NN
analysis/NN
of/IN
E2F/NN
in/IN
primary/JJ
human/JJ
T/NN
cells/NNS
reveals/VBZ
novel/JJ
E2F/NN
complexes/NNS
and/CC
biochemically/RB
distinct/JJ
forms/NNS
of/IN
free/JJ
E2F/NN
./.
====================
AB/LS
-/:
The/DT
transcription/NN
factor/NN
E2F/NN
activates/VBZ
the/DT
expression/NN
of/IN
multiple/JJ
genes/NNS
involved/VBN
in/IN
cell/NN
proliferation/NN
,/,
such/JJ
as/IN
c-myc/NN
and/CC
the/DT
dihydrofolate/JJ
reductase/NN
gene/NN
./.
====================
Regulation/NN
of/IN
E2F/NN
involves/VBZ
its/PRP$
interactions/NNS
with/IN
other/JJ
cellular/JJ
proteins/NNS
,/,
including/VBG
the/DT
retinoblastoma/NN
protein/NN
(/(
Rb/NN
)/)
,/,
the/DT
Rb-related/JJ
protein/NN
p107/NN
,/,
cyclin/NN
A/NN
,/,
and/CC
cdk2/NN
./.
====================
We/PRP
undertook/VBD
a/DT
detailed/JJ
analysis/NN
of/IN
E2F/NN
DNA-binding/JJ
activities/NNS
and/CC
their/PRP$
cell/NN
cycle/NN
behavior/NN
in/IN
primary/JJ
human/JJ
T/NN
cells/NNS
./.
====================
Three/CD
E2F/NN
DNA-binding/JJ
activities/NNS
were/VBD
identified/VBN
in/IN
resting/VBG
(/(
G0/NN
)/)
T/NN
cells/NNS
with/IN
mobilities/NNS
in/IN
gel/NN
shift/NN
assays/NNS
distinct/JJ
from/IN
those/DT
of/IN
previously/RB
defined/VBN
E2F/NN
complexes/NNS
./.
====================
One/CD
of/IN
these/DT
activities/NNS
was/VBD
found/VBN
to/TO
be/VB
a/DT
novel/JJ
,/,
less/RBR
abundant/JJ
,/,
Rb-E2F/NN
complex/NN
./.
====================
The/DT
most/RBS
prominent/JJ
E2F/NN
activity/NN
in/IN
resting/VBG
T/NN
cells/NNS
(/(
termed/VBN
complex/JJ
X/NN
)/)
was/VBD
abundant/JJ
in/IN
both/CC
G0/NN
and/CC
G1/NN
but/CC
disappeared/VBD
as/IN
cells/NNS
entered/VBD
S/NN
phase/NN
,/,
suggesting/VBG
a/DT
possible/JJ
role/NN
in/IN
negatively/RB
regulating/VBG
E2F/NN
function/NN
./.
====================
Complex/NN
X/NN
could/MD
be/VB
dissociated/VBN
by/IN
adenovirus/NN
E1A/NN
with/IN
a/DT
requirement/NN
for/IN
an/DT
intact/JJ
E1A/NN
conserved/VBN
region/NN
2/CD
./.
====================
However/RB
,/,
X/NN
failed/VBD
to/TO
react/VB
with/IN
a/DT
variety/NN
of/IN
antibodies/NNS
against/IN
Rb/NN
or/CC
p107/NN
,/,
implicating/VBG
the/DT
involvement/NN
of/IN
an/DT
E1A-binding/JJ
protein/NN
other/JJ
than/IN
Rb/NN
or/CC
p107/NN
./.
====================
In/IN
addition/NN
to/TO
these/DT
novel/JJ
E2F/NN
complexes/NNS
,/,
three/CD
distinct/JJ
forms/NNS
of/IN
unbound/JJ
(/(
free/JJ
)/)
E2F/NN
were/VBD
resolved/VBN
in/IN
gel/NN
shift/NN
experiments/NNS
./.
====================
These/DT
species/NNS
showed/VBD
different/JJ
cell/NN
cycle/NN
kinetics/NNS
./.
====================
UV/NN
cross-linking/JJ
experiments/NNS
suggested/VBD
that/IN
a/DT
distinct/JJ
E2F/NN
DNA-binding/JJ
protein/NN
is/VBZ
uniquely/RB
associated/VBN
with/IN
the/DT
S-phase/NN
p107/NN
complex/NN
and/CC
is/VBZ
not/RB
associated/VBN
with/IN
Rb/NN
./.
====================
Together/RB
,/,
these/DT
results/NNS
suggest/VBP
that/IN
E2F/NN
consists/VBZ
of/IN
multiple/JJ
,/,
biochemically/RB
distinct/JJ
DNA-binding/JJ
proteins/NNS
which/WDT
function/VBP
at/IN
different/JJ
points/NNS
in/IN
the/DT
cell/NN
cycle/NN
./.
====================
UI/LS
-/:
93286051/CD
====================
TI/LS
-/:
Defective/JJ
translocation/NN
of/IN
protein/NN
kinase/NN
C/NN
in/IN
multidrug-resistant/JJ
HL-60/NN
cells/NNS
confers/VBZ
a/DT
reversible/JJ
loss/NN
of/IN
phorbol/NN
ester-induced/JJ
monocytic/JJ
differentiation/NN
./.
====================
AB/LS
-/:
Previous/JJ
studies/NNS
have/VBP
demonstrated/VBN
that/IN
human/JJ
HL-60/NN
myeloid/JJ
leukemia/NN
cells/NNS
differentiate/VBP
in/IN
response/NN
to/TO
phorbol/NN
esters/NNS
./.
====================
This/DT
event/NN
is/VBZ
associated/VBN
with/IN
induction/NN
of/IN
the/DT
c-jun/NN
early/JJ
response/NN
gene/NN
and/CC
appearance/NN
of/IN
a/DT
monocytic/JJ
phenotype/NN
./.
====================
The/DT
present/JJ
studies/NNS
have/VBP
examined/VBN
the/DT
effects/NNS
of/IN
vincristine-selected/JJ
,/,
multidrug/JJ
resistance/NN
on/IN
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
-induced/JJ
HL-60/NN
cell/NN
differentiation/NN
./.
====================
The/DT
results/NNS
demonstrate/VBP
that/IN
multidrug-resistant/JJ
HL-60/NN
cells/NNS
,/,
designated/VBN
HL-60/vinc/NN
,/,
fail/VBP
to/TO
respond/VB
to/TO
TPA/NN
with/IN
an/DT
increase/NN
in/IN
c-jun/NN
transcripts/NNS
or/CC
other/JJ
phenotypic/JJ
characteristics/NNS
of/IN
monocytic/JJ
differentiation/NN
./.
====================
By/IN
contrast/NN
,/,
treatment/NN
of/IN
HL-60/vinc/NN
cells/NNS
with/IN
okadaic/JJ
acid/NN
,/,
an/DT
inhibitor/NN
of/IN
serine/threonine/NN
protein/NN
phosphatases/NNS
,/,
induces/VBZ
c-jun/NN
transcription/NN
,/,
growth/NN
arrest/NN
,/,
and/CC
expression/NN
of/IN
the/DT
c-fms/NN
gene/NN
./.
====================
Studies/NNS
were/VBD
also/RB
performed/VBN
with/IN
an/DT
HL-60/vinc/NN
revertant/NN
(/(
HL-60/vinc/R/NN
)/)
line/NN
that/WDT
has/VBZ
regained/VBN
partial/JJ
sensitivity/NN
to/TO
vincristine/NN
./.
====================
The/DT
finding/NN
that/IN
HL-60/vinc/R/NN
cells/NNS
respond/VBP
to/TO
TPA/NN
with/IN
induction/NN
of/IN
a/DT
monocytic/JJ
phenotype/NN
,/,
but/CC
not/RB
c-jun/NN
expression/NN
,/,
suggests/VBZ
that/IN
c-jun/NN
induction/NN
is/VBZ
not/RB
obligatory/JJ
for/IN
monocytic/JJ
differentiation/NN
./.
====================
Other/JJ
studies/NNS
further/RB
demonstrate/VBP
that/IN
the/DT
jun-B/NN
and/CC
fra-1/NN
genes/NNS
are/VBP
induced/VBN
by/IN
TPA/NN
in/IN
both/CC
HL-60/vinc/NN
and/CC
HL-60/vinc/R/NN
cells/NNS
,/,
whereas/IN
c-fos/NN
expression/NN
is/VBZ
attenuated/VBN
in/IN
the/DT
HL-60/vinc/NN
line/NN
./.
====================
Since/IN
TPA/NN
activates/VBZ
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
,/,
we/PRP
examined/VBD
translocation/NN
of/IN
PKC/NN
from/IN
the/DT
cytosol/NN
to/TO
the/DT
membrane/NN
fraction/NN
./.
====================
Although/IN
HL-60/NN
and/CC
HL-60/vinc/R/NN
cells/NNS
demonstrated/VBD
translocation/NN
of/IN
PKC/NN
activity/NN
,/,
this/DT
subcellular/JJ
redistribution/NN
was/VBD
undetectable/JJ
in/IN
HL-60/vinc/NN
cells/NNS
./.
====================
Activity/NN
of/IN
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
family/NN
with/IN
associated/JJ
phosphorylation/NN
of/IN
c-Jun/NN
Y-peptide/NN
was/VBD
markedly/RB
diminished/VBN
in/IN
TPA-treated/JJ
HL-60/vinc/NN
cells/NNS
,/,
but/CC
not/RB
in/IN
response/NN
to/TO
okadaic/JJ
acid/NN
./.
====================
Taken/VBN
together/RB
,/,
these/DT
findings/NNS
suggest/VBP
that/IN
vincristine/NN
resistance/NN
confers/VBZ
insensitivity/NN
to/TO
TPA-induced/JJ
differentiation/NN
and/CC
can/MD
include/VB
defects/NNS
in/IN
PKC-mediated/JJ
signaling/NN
events/NNS
and/CC
induction/NN
of/IN
jun/fos/NN
early/JJ
response/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
93281652/CD
====================
TI/LS
-/:
Molecular/JJ
basis/NN
of/IN
a/DT
multiple/JJ
lymphokine/NN
deficiency/NN
in/IN
a/DT
patient/NN
with/IN
severe/JJ
combined/JJ
immunodeficiency/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
previously/RB
reported/VBN
that/IN
the/DT
T/NN
lymphocytes/NNS
of/IN
a/DT
child/NN
with/IN
severe/JJ
combined/JJ
immunodeficiency/NN
are/VBP
defective/JJ
in/IN
the/DT
transcription/NN
of/IN
several/JJ
lymphokine/NN
genes/NNS
that/WDT
include/VBP
IL2/NN
,/,
IL3/NN
,/,
IL4/NN
,/,
and/CC
IL5/NN
,/,
which/WDT
encode/VBP
interleukins/NNS
2/CD
,/,
3/CD
,/,
4/CD
,/,
and/CC
5/CD
(/(
IL-2/NN
,/,
-3/CD
,/,
-4/CD
,/,
and/CC
-5/CD
)/)
./.
====================
To/TO
determine/VB
whether/IN
the/DT
defect/NN
in/IN
the/DT
patient/NN
's/POS
T/NN
lymphocytes/NNS
involved/VBD
a/DT
trans-acting/JJ
factor/NN
common/JJ
to/TO
the/DT
affected/VBN
lymphokine/NN
genes/NNS
,/,
we/PRP
examined/VBD
the/DT
ability/NN
of/IN
nuclear/JJ
factors/NNS
from/IN
the/DT
patient/NN
's/POS
T/NN
lymphocytes/NNS
to/TO
bind/VB
response/NN
elements/NNS
present/JJ
in/IN
the/DT
regulatory/JJ
region/NN
of/IN
IL2/NN
./.
====================
Nuclear/JJ
factor/NN
NF-kB/NN
,/,
activation/NN
protein/NN
1/CD
(/(
AP-1/NN
)/)
,/,
OCT-1/NN
,/,
and/CC
NF-IL-2B/NN
binding/NN
activity/NN
were/VBD
normal/JJ
./.
====================
In/IN
contrast/NN
,/,
the/DT
binding/NN
of/IN
the/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NF-AT/NN
)/)
to/TO
its/PRP$
response/NN
element/NN
in/IN
the/DT
IL2/NN
enhancer/NN
and/CC
to/TO
an/DT
NF-AT-like/JJ
response/NN
element/NN
present/JJ
in/IN
the/DT
IL4/NN
enhancer/NN
was/VBD
abnormal/JJ
./.
====================
To/TO
ascertain/VB
whether/IN
the/DT
abnormal/JJ
NF-AT/NN
binding/NN
activity/NN
was/VBD
related/JJ
to/TO
an/DT
impaired/JJ
function/NN
,/,
we/PRP
transfected/VBD
patient/NN
and/CC
control/NN
T/NN
lymphocytes/NNS
with/IN
constructs/NNS
containing/VBG
the/DT
reporter/NN
gene/NN
encoding/JJ
chloramphenicol/NN
acetyl/NN
transferase/NN
(/(
CAT/NN
)/)
under/IN
the/DT
control/NN
of/IN
the/DT
entire/JJ
IL2/NN
regulatory/JJ
region/NN
or/CC
of/IN
multimers/NNS
of/IN
individual/JJ
enhancer/NN
sequences/NNS
./.
====================
CAT/NN
expression/NN
directed/VBN
by/IN
the/DT
IL2/NN
regulatory/JJ
region/NN
or/CC
by/IN
a/DT
multimer/NN
of/IN
the/DT
NF-AT-binding/JJ
site/NN
was/VBD
markedly/RB
lower/JJR
in/IN
the/DT
patient/NN
relative/JJ
to/TO
controls/NNS
./.
====================
In/IN
contrast/NN
,/,
CAT/NN
gene/NN
expression/NN
directed/VBN
by/IN
a/DT
multimer/NN
of/IN
the/DT
OCT-1/NN
proximal/NN
(/(
OCT-1p/NN
)/)
-binding/JJ
site/NN
was/VBD
equivalent/JJ
in/IN
patient/NN
and/CC
controls/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
an/DT
abnormality/NN
of/or/IN|CC
influencing/JJ
NF-AT/NN
may/MD
underlie/VB
the/DT
multiple/JJ
lymphokine/NN
deficiency/NN
in/IN
this/DT
patient/NN
./.
====================
UI/LS
-/:
94025289/CD
====================
TI/LS
-/:
FK506/NN
and/CC
ciclosporin/NN
:/:
molecular/JJ
probes/NNS
for/IN
studying/VBG
intracellular/JJ
signal/NN
transduction/NN
./.
====================
AB/LS
-/:
The/DT
immunosuppressants/NNS
ciclosporin/NN
and/CC
FK506/NN
block/VBP
the/DT
Ca(2+)-dependent/JJ
signal-transduction/NN
pathway/NN
emanating/VBG
from/IN
the/DT
T-cell/NN
receptor/NN
,/,
thereby/RB
inhibiting/VBG
the/DT
activation/NN
of/IN
helper/NN
T/NN
cells/NNS
./.
====================
Using/VBG
these/DT
drugs/NNS
as/IN
probes/NNS
,/,
chemists/NNS
and/CC
biologists/NNS
have/VBP
uncovered/VBN
several/JJ
intracellular/JJ
signalling/NN
molecules/NNS
bridging/VBG
the/DT
generation/NN
of/IN
second-messenger/NN
Ca2+/NN
ions/NNS
and/CC
the/DT
transcriptional/JJ
activation/NN
of/IN
IL-2/NN
,/,
among/IN
which/WDT
are/VBP
calmodulin/NN
,/,
calcineurin/NN
and/CC
the/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NF-AT/NN
)/)
./.
====================
Hence/RB
,/,
Ca2+/NN
binds/VBZ
to/TO
calmodulin/NN
,/,
leading/VBG
to/TO
the/DT
binding/NN
of/IN
calmodulin/NN
to/TO
calcineurin/NN
;/:
the/DT
activated/VBN
calcineurin/NN
,/,
in/IN
turn/NN
,/,
may/MD
dephosphorylate/VB
the/DT
cytoplasmic/JJ
subunit/NN
of/IN
NF-AT/NN
,/,
resulting/VBG
in/IN
its/PRP$
translocation/NN
from/IN
the/DT
cytoplasm/NN
into/IN
the/DT
nucleus/NN
to/TO
form/VB
a/DT
competent/JJ
transcriptional/JJ
activator/NN
./.
====================
As/IN
described/VBN
by/IN
Jun/NNP
Liu/NNP
,/,
these/DT
drugs/NNS
manifest/VBP
their/PRP$
effects/NNS
in/IN
an/DT
unprecedented/JJ
fashion/NN
./.
====================
They/PRP
do/VBP
not/RB
directly/RB
intercept/VB
intracellular/JJ
signalling/NN
molecules/NNS
./.
====================
Instead/RB
,/,
they/PRP
form/VBP
tight/JJ
complexes/NNS
with/IN
two/CD
different/JJ
classes/NNS
of/IN
abundant/JJ
cytosolic/JJ
receptors/NNS
called/VBN
immunophilins/NNS
upon/IN
entering/VBG
the/DT
cell/NN
,/,
and/CC
consequently/RB
inhibit/VBP
their/PRP$
peptidyl/JJ
prolyl/JJ
cis-trans/JJ
isomerase/NN
activities/NNS
./.
====================
The/DT
two/CD
structurally/RB
distinct/JJ
immunophilin-drug/JJ
complexes/NNS
bind/VBP
to/TO
,/,
and/CC
inhibit/VBP
,/,
the/DT
phosphatase/JJ
activity/NN
of/IN
calcineurin/NN
./.
====================
UI/LS
-/:
93209552/CD
====================
TI/LS
-/:
p105/NN
and/CC
p98/NN
precursor/NN
proteins/NNS
play/VBP
an/DT
active/JJ
role/NN
in/IN
NF-kappa/NN
B-mediated/JJ
signal/NN
transduction/NN
./.
====================
AB/LS
-/:
The/DT
Rel/NF-kappa/NN
B/NN
family/NN
of/IN
transcription/NN
factors/NNS
is/VBZ
composed/VBN
of/IN
two/CD
distinct/JJ
subgroups/NNS
,/,
proteins/NNS
that/WDT
undergo/VBP
proteolytic/JJ
processing/NN
and/CC
contain/VBP
SWI6/ankyrin/NN
repeats/NNS
in/IN
their/PRP$
carboxyl/NN
termini/NNS
(/(
p105/NN
,/,
p98/NN
)/)
,/,
and/CC
those/DT
without/IN
such/JJ
repeats/NNS
that/WDT
do/VBP
not/RB
require/VB
processing/NN
(/(
p65/NN
,/,
c-Rel/NN
,/,
RelB/NN
,/,
and/CC
Dorsal/NN
)/)
./.
====================
We/PRP
demonstrate/VBP
that/IN
the/DT
p105/NN
and/CC
p98/NN
precursors/NNS
share/VBP
functional/JJ
properties/NNS
with/IN
the/DT
I/NN
kappa/NN
B/NN
proteins/NNS
,/,
which/WDT
also/RB
contain/VBP
SWI6/ankyrin/NN
repeats/NNS
./.
====================
Both/CC
p105/NN
and/CC
p98/NN
were/VBD
found/VBN
to/TO
form/VB
stable/JJ
complexes/NNS
with/IN
other/JJ
Rel/NF-kappa/NN
B/NN
family/NN
members/NNS
,/,
including/VBG
p65/NN
and/CC
c-Rel/NN
./.
====================
Association/NN
with/IN
the/DT
precursors/NNS
is/VBZ
sufficient/JJ
for/IN
cytoplasmic/JJ
retention/NN
of/IN
either/CC
p65/NN
or/CC
c-Rel/NN
,/,
both/DT
of/IN
which/WDT
are/VBP
otherwise/RB
nuclear/JJ
./.
====================
These/DT
complexes/NNS
undergo/VBP
stimulus-responsive/JJ
processing/NN
to/TO
produce/VB
active/JJ
p50/c-Rel/NN
and/CC
p55/c-Rel/NN
complexes/NNS
./.
====================
These/DT
observations/NNS
suggest/VBP
a/DT
second/JJ
pathway/NN
leading/VBG
to/TO
NF-kappa/NN
B/NN
induction/NN
,/,
in/IN
which/WDT
processing/NN
of/IN
the/DT
precursors/NNS
rather/RB
than/IN
phosphorylation/NN
of/IN
I/NN
kappa/NN
B/NN
plays/VBZ
a/DT
major/JJ
role/NN
./.
====================
UI/LS
-/:
93206138/CD
====================
TI/LS
-/:
NF-kappa/NN
B/NN
controls/VBZ
expression/NN
of/IN
inhibitor/NN
I/NN
kappa/NN
B/NN
alpha/NN
:/:
evidence/NN
for/IN
an/DT
inducible/JJ
autoregulatory/JJ
pathway/NN
./.
====================
AB/LS
-/:
The/DT
eukaryotic/JJ
transcription/NN
factor/NN
nuclear/JJ
factor-kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
participates/VBZ
in/IN
many/JJ
parts/NNS
of/IN
the/DT
genetic/JJ
program/NN
mediating/VBG
T/NN
lymphocyte/NN
activation/NN
and/CC
growth/NN
./.
====================
Nuclear/JJ
expression/NN
of/IN
NF-kappa/NN
B/NN
occurs/VBZ
after/IN
its/PRP$
induced/VBN
dissociation/NN
from/IN
its/PRP$
cytoplasmic/JJ
inhibitor/NN
I/NN
kappa/NN
B/NN
alpha/NN
./.
====================
Phorbol/NN
ester/NN
and/CC
tumor/NN
necrosis/NN
factor-alpha/NN
induction/NN
of/IN
nuclear/JJ
NF-kappa/NN
B/NN
is/VBZ
associated/VBN
with/IN
both/CC
the/DT
degradation/NN
of/IN
performed/VBN
I/NN
kappa/NN
B/NN
alpha/NN
and/CC
the/DT
activation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
gene/NN
expression/NN
./.
====================
Transfection/NN
studies/NNS
indicate/VBP
that/IN
the/DT
I/NN
kappa/NN
B/NN
alpha/NN
gene/NN
is/VBZ
specifically/RB
induced/VBN
by/IN
the/DT
65-kilodalton/JJ
transactivating/VBG
subunit/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
Association/NN
of/IN
the/DT
newly/RB
synthesized/VBN
I/NN
kappa/NN
B/NN
alpha/NN
with/IN
p65/NN
restores/VBZ
intracellular/JJ
inhibition/NN
of/IN
NF-kappa/NN
B/NN
DNA/NN
binding/NN
activity/NN
and/CC
prolongs/VBZ
the/DT
survival/NN
of/IN
this/DT
labile/JJ
inhibitor/NN
./.
====================
Together/RB
,/,
these/DT
results/NNS
show/VBP
that/IN
NF-kappa/NN
B/NN
controls/VBZ
the/DT
expression/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
by/IN
means/NNS
of/IN
an/DT
inducible/JJ
autoregulatory/JJ
pathway/NN
./.
====================
UI/LS
-/:
93180777/CD
====================
TI/LS
-/:
The/DT
human/JJ
prointerleukin/NN
1/CD
beta/NN
gene/NN
requires/VBZ
DNA/NN
sequences/NNS
both/CC
proximal/JJ
and/CC
distal/JJ
to/TO
the/DT
transcription/NN
start/NN
site/NN
for/IN
tissue-specific/JJ
induction/NN
./.
====================
AB/LS
-/:
In/IN
these/DT
studies/NNS
,/,
we/PRP
have/VBP
identified/VBN
DNA/NN
sequences/NNS
and/CC
specific/JJ
protein/NN
interactions/NNS
necessary/JJ
for/IN
transcriptional/JJ
regulation/NN
of/IN
the/DT
human/JJ
prointerleukin/NN
1/CD
beta/NN
(/(
proIL-1/NN
beta/NN
)/)
gene/NN
./.
====================
A/DT
cell-type-independent/JJ
lipopolysaccharide/NN
(/(
LPS/NN
)/)
-responsive/JJ
enhancer/NN
element/NN
located/JJ
between/IN
-3757/CD
and/CC
-2729/CD
bp/NN
upstream/RB
from/IN
the/DT
transcription/NN
start/NN
site/NN
(/(
cap/NN
site/NN
)/)
consisted/VBD
of/IN
at/IN
least/JJS
six/CD
discrete/JJ
subregions/NNS
which/WDT
were/VBD
essential/JJ
to/TO
the/DT
maximal/JJ
induction/NN
by/IN
LPS/NN
in/IN
transfected/VBN
monocytes/NNS
./.
====================
The/DT
enhancer/NN
also/RB
appeared/VBD
to/TO
mediate/VB
phorbol/NN
myristate/NN
acetate/NN
induction/NN
in/IN
monocytes/NNS
and/CC
IL-1/NN
responsiveness/NN
in/IN
fibroblasts/NNS
./.
====================
Deletion/NN
and/CC
base/NN
substitution/NN
mutations/NNS
along/IN
with/IN
DNA/NN
binding/NN
studies/NNS
demonstrated/VBD
that/IN
the/DT
enhancer/NN
contained/VBD
a/DT
minimum/NN
of/IN
three/CD
functional/JJ
protein/NN
binding/NN
sequences/NNS
,/,
two/CD
of/IN
which/WDT
appeared/VBD
to/TO
be/VB
important/JJ
for/IN
gene/NN
induction/NN
./.
====================
One/CD
of/IN
the/DT
essential/JJ
proteins/NNS
which/WDT
bound/VBD
to/TO
the/DT
enhancer/NN
was/VBD
similar/JJ
or/CC
identical/JJ
to/TO
members/NNS
of/IN
the/DT
C/EBP/NN
family/NN
of/IN
transcription/NN
factors/NNS
required/VBN
for/IN
both/CC
IL-1-/NN
and/CC
LPS-specific/JJ
induction/NN
of/IN
the/DT
IL-6/NN
gene/NN
(/(
i.e./FW
,/,
the/DT
NF-IL6/NN
proteins/NNS
)/)
./.
====================
When/WRB
ligated/VBN
to/TO
the/DT
proIL-1/NN
beta/NN
cap/NN
site-proximal/JJ
region/NN
(/(
located/JJ
between/IN
-131/CD
to/TO
+12/CD
)/)
,/,
both/CC
the/DT
proIL-1/NN
beta/NN
and/CC
the/DT
simian/JJ
virus/NN
40/CD
enhancer/NN
elements/NNS
functioned/VBD
more/RBR
efficiently/RB
in/IN
monocytes/NNS
than/IN
in/IN
HeLa/NN
cells/NNS
,/,
which/WDT
are/VBP
not/RB
normally/RB
competent/JJ
for/IN
IL-1/NN
beta/NN
expression/NN
./.
====================
When/WRB
ligated/VBN
to/TO
the/DT
murine/JJ
c-fos/NN
promoter/NN
,/,
however/RB
,/,
the/DT
proIL-1/NN
beta/NN
enhancer/NN
was/VBD
inducible/JJ
in/IN
phorbol/NN
myristate/NN
acetate-stimulated/JJ
HeLa/NN
cells/NNS
,/,
suggesting/VBG
the/DT
existence/NN
of/IN
a/DT
proIL-1/NN
beta/NN
promoter-proximal/JJ
requirement/NN
for/IN
tissue/NN
specificity/NN
./.
====================
UI/LS
-/:
93233083/CD
====================
TI/LS
-/:
Lymphocytes/NNS
from/IN
the/DT
site/NN
of/IN
disease/NN
suggest/VBP
adenovirus/NN
is/VBZ
one/CD
cause/NN
of/IN
persistent/JJ
or/CC
recurrent/JJ
inflammatory/JJ
arthritis/NN
./.
====================
AB/LS
-/:
The/DT
assessment/NN
of/IN
synovial/JJ
lymphocyte/NN
reactivity/NN
to/TO
adenovirus/NN
antigen/NN
stimulation/NN
was/VBD
undertaken/VBN
in/IN
patients/NNS
with/IN
persistent/JJ
or/CC
recurrent/JJ
inflammatory/JJ
arthritis/NN
./.
====================
The/DT
3H-thymidine/JJ
uptake/NN
procedure/NN
was/VBD
employed/VBN
,/,
incorporating/VBG
multiple/JJ
microbiological/JJ
antigens/NNS
./.
====================
Five/CD
patients/NNS
were/VBD
found/VBN
with/IN
repeated/VBN
maximal/JJ
responses/NNS
to/TO
adenovirus/NN
antigen/NN
;/:
in/IN
one/CD
of/IN
these/DT
adenovirus/NN
nucleotide/NN
sequences/NNS
were/VBD
present/JJ
in/IN
a/DT
synovial/JJ
biopsy/NN
specimen/NN
./.
====================
It/PRP
is/VBZ
concluded/VBN
that/IN
adenovirus/NN
may/MD
be/VB
one/CD
cause/NN
of/IN
persistent/JJ
or/CC
recurrent/JJ
inflammatory/JJ
arthritis/NN
./.
====================
UI/LS
-/:
93183827/CD
====================
TI/LS
-/:
Expression/NN
of/IN
PILOT/NN
,/,
a/DT
putative/JJ
transcription/NN
factor/NN
,/,
requires/VBZ
two/CD
signals/NNS
and/CC
is/VBZ
cyclosporin/NN
A/NN
sensitive/JJ
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Few/JJ
known/JJ
genes/NNS
(/(
IL-2/NN
,/,
members/NNS
of/IN
the/DT
IL-8/NN
family/NN
,/,
interferon-gamma/NN
)/)
are/VBP
induced/VBN
in/IN
T/NN
cells/NNS
only/RB
through/IN
the/DT
combined/JJ
effect/NN
of/IN
phorbol/NN
myristic/JJ
acetate/NN
(/(
PMA/NN
)/)
and/CC
a/DT
Ca(2+)-ionophore/NN
,/,
and/CC
expression/NN
of/IN
only/RB
these/DT
genes/NNS
can/MD
be/VB
fully/RB
suppressed/VBN
by/IN
Cyclosporin/NN
A/NN
(/(
CyA/NN
)/)
./.
====================
We/PRP
have/VBP
identified/VBN
a/DT
putative/JJ
transcription/NN
factor/NN
,/,
designated/VBN
PILOT/NN
,/,
with/IN
an/DT
identical/JJ
dual/JJ
signal/NN
requirement/NN
for/IN
expression/NN
./.
====================
Induction/NN
of/IN
the/DT
PILOT/NN
gene/NN
is/VBZ
detectable/JJ
in/IN
human/JJ
T/NN
cells/NNS
20/CD
min/NN
following/VBG
activation/NN
in/IN
the/DT
presence/NN
of/IN
cycloheximide/NN
and/CC
is/VBZ
fully/RB
suppressed/VBN
by/IN
CyA/NN
./.
====================
The/DT
PILOT/NN
protein/NN
has/VBZ
a/DT
calculated/VBN
M(r)/NN
of/IN
42.6/CD
kDa/NN
and/CC
contains/VBZ
three/CD
zinc/NN
fingers/NNS
of/IN
the/DT
C2H2-type/NN
at/IN
the/DT
carboxyl-terminus/NN
which/WDT
are/VBP
highly/RB
homologous/JJ
to/TO
the/DT
zinc/NN
finger/NN
regions/NNS
of/IN
the/DT
transcription/NN
factors/NNS
EGR1/NNS
,/,
EGR2/NNS
,/,
and/CC
pAT/NN
133/CD
./.
====================
In/IN
contrast/NN
to/TO
T/NN
cells/NNS
,/,
in/IN
fibroblasts/NNS
PILOT/NN
gene/NN
expression/NN
requires/VBZ
only/RB
one/CD
signal/NN
(/(
PMA/NN
)/)
and/CC
is/VBZ
not/RB
affected/VBN
by/IN
CyA/NN
./.
====================
This/DT
observation/NN
directly/RB
demonstrates/VBZ
the/DT
existence/NN
of/IN
a/DT
Ca2+/NN
signal-dependent/JJ
regulatory/JJ
element/NN
obligatory/JJ
for/IN
expression/NN
of/IN
some/DT
genes/NNS
in/IN
T/NN
cells/NNS
but/CC
not/RB
in/IN
fibroblasts/NNS
./.
====================
This/DT
differential/JJ
expression/NN
model/NN
will/MD
be/VB
valuable/JJ
in/IN
the/DT
dissection/NN
of/IN
the/DT
dual/JJ
signal/NN
pathway/NN
in/IN
T/NN
cells/NNS
and/CC
the/DT
effects/NNS
of/IN
CyA/NN
upon/IN
it/PRP
./.
====================
UI/LS
-/:
93320446/CD
====================
TI/LS
-/:
Antisense/JJ
oligonucleotides/NNS
to/TO
the/DT
p65/NN
subunit/NN
of/IN
NF-kappa/NN
B/NN
block/VBP
CD11b/NN
expression/NN
and/CC
alter/VBP
adhesion/NN
properties/NNS
of/IN
differentiated/VBN
HL-60/NN
granulocytes/NNS
./.
====================
AB/LS
-/:
NF-kappa/NN
B/NN
is/VBZ
a/DT
pleiotropic/JJ
regulator/NN
of/IN
a/DT
variety/NN
of/IN
genes/NNS
implicated/VBN
in/IN
the/DT
cellular/JJ
response/NN
to/TO
injury/NN
./.
====================
This/DT
function/NN
has/VBZ
been/VBN
attributed/VBN
to/TO
the/DT
coordinated/VBN
binding/NN
of/IN
subunits/NNS
of/IN
NF-kappa/NN
B/NN
to/TO
distinct/JJ
regions/NNS
of/IN
the/DT
promoter/JJ
elements/NNS
of/IN
numerous/JJ
genes/NNS
,/,
including/VBG
cytokines/NNS
,/,
growth/NN
factor/NN
receptors/NNS
,/,
and/CC
adhesion/NN
molecules/NNS
./.
====================
Antisense/JJ
phosphorothioate/JJ
oligonucleotides/NNS
to/TO
the/DT
p50/NN
and/CC
p65/NN
subunits/NNS
of/IN
the/DT
NF-kappa/NN
B/NN
complex/NN
were/VBD
used/VBN
to/TO
define/VB
the/DT
physiologic/JJ
role/NN
of/IN
this/DT
transcription/NN
factor/NN
in/IN
resting/VBG
and/CC
stimulated/VBN
granulocytes/NNS
./.
====================
A/DT
reduction/NN
in/IN
the/DT
expression/NN
of/IN
p65/NN
was/VBD
produced/VBN
by/IN
treatment/NN
with/IN
the/DT
phosphorothioate/JJ
antisense/JJ
oligodeoxynucleotide/NN
./.
====================
This/DT
reduction/NN
was/VBD
accompanied/VBN
by/IN
rapid/JJ
changes/NNS
in/IN
the/DT
cellular/JJ
adhesion/NN
of/IN
dimethyl/JJ
sulfoxide-differentiated/JJ
HL-60/NN
leukemia/NN
cells/NNS
stimulated/VBN
by/IN
12-O-tetradecanoylphorbol/NN
13-acetate/NN
(/(
TPA/NN
)/)
./.
====================
These/DT
effects/NNS
were/VBD
characterized/VBN
by/IN
a/DT
marked/JJ
reduction/NN
in/IN
CD11b/NN
integrin/JJ
expression/NN
on/IN
the/DT
surface/NN
of/IN
treated/VBN
cells/NNS
./.
====================
Furthermore/RB
,/,
the/DT
p65/NN
antisense/JJ
oligomer/NN
effectively/RB
abolished/VBD
an/DT
upregulation/NN
of/IN
CD11b/NN
that/WDT
was/VBD
produced/VBN
by/IN
formyl-met-leu-phe/NN
and/CC
TPA/NN
./.
====================
However/RB
,/,
the/DT
p65/NN
antisense/JJ
phosphorothioate/JJ
oligodeoxynucleotide/NN
had/VBD
no/DT
significant/JJ
effect/NN
on/IN
the/DT
production/NN
of/IN
reactive/JJ
oxygen/NN
intermediates/NNS
or/CC
on/IN
phagocytosis/NNS
by/IN
these/DT
cells/NNS
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
antisense/JJ
oligomers/NNS
to/TO
p65/NN
can/MD
be/VB
used/VBN
to/TO
define/VB
the/DT
role/NN
of/IN
NF-kappa/NN
B/NN
in/IN
the/DT
activation/NN
pathways/NNS
of/IN
neutrophils/NNS
./.
====================
UI/LS
-/:
93307660/CD
====================
TI/LS
-/:
The/DT
p65/NN
subunit/NN
of/IN
NF-kappa/NN
B/NN
regulates/VBZ
I/NN
kappa/NN
B/NN
by/IN
two/CD
distinct/JJ
mechanisms/NNS
./.
====================
AB/LS
-/:
Transcription/NN
factor/NN
NF-kappa/NN
B/NN
(/(
p50/p65/NN
)/)
is/VBZ
generally/RB
localized/JJ
to/TO
the/DT
cytoplasm/NN
by/IN
its/PRP$
inhibitor/NN
I/NN
kappa/NN
B/NN
./.
====================
Overproduced/JJ
I/NN
kappa/NN
B/NN
,/,
free/JJ
from/IN
NF-kappa/NN
B/NN
,/,
is/VBZ
rapidly/RB
degraded/VBN
./.
====================
Overexpression/NN
of/IN
p65/NN
increases/VBZ
endogenous/JJ
I/NN
kappa/NN
B/NN
protein/NN
in/IN
both/CC
carcinoma/NN
and/CC
lymphoid/JJ
cells/NNS
by/IN
two/CD
mechanisms/NNS
:/:
protein/NN
stabilization/NN
and/CC
increased/VBN
transcription/NN
of/IN
I/NN
kappa/NN
B/NN
mRNA/NN
./.
====================
In/IN
contrast/NN
,/,
p65/NN
delta/NN
,/,
a/DT
naturally/RB
occurring/VBG
splice/NN
variant/NN
,/,
fails/VBZ
to/TO
markedly/RB
augment/VB
I/NN
kappa/NN
B/NN
protein/NN
levels/NNS
./.
====================
Both/CC
overexpressed/JJ
p65/NN
and/CC
coexpressed/JJ
p50/NN
are/VBP
cytoplasmic/JJ
,/,
whereas/IN
p65/NN
delta/NN
is/VBZ
partly/RB
nuclear/JJ
,/,
indicating/VBG
that/IN
the/DT
I/NN
kappa/NN
B/NN
induced/VBN
by/IN
p65/NN
can/MD
maintain/VB
NF-kappa/NN
B/NN
in/IN
the/DT
cytoplasm/NN
./.
====================
Thus/RB
,/,
p65/NN
and/CC
I/NN
kappa/NN
B/NN
are/VBP
linked/VBN
in/IN
an/DT
autoregulatory/JJ
loop/NN
,/,
ensuring/VBG
that/IN
NF-kappa/NN
B/NN
is/VBZ
held/VBN
in/IN
the/DT
cytoplasm/NN
until/IN
cells/NNS
are/VBP
specifically/RB
induced/VBN
to/TO
translocate/VB
it/PRP
to/TO
the/DT
nucleus/NN
./.
====================
UI/LS
-/:
93280143/CD
====================
TI/LS
-/:
Lipopolysaccharide/NN
induces/VBZ
phosphorylation/NN
of/IN
MAD3/NN
and/CC
activation/NN
of/IN
c-Rel/NN
and/CC
related/JJ
NF-kappa/NN
B/NN
proteins/NNS
in/IN
human/JJ
monocytic/JJ
THP-1/NN
cells/NNS
./.
====================
AB/LS
-/:
Many/JJ
effects/NNS
of/IN
lipopolysaccharide/NN
(/(
LPS/NN
)/)
on/IN
gene/NN
expression/NN
,/,
including/VBG
that/DT
of/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
,/,
in/IN
monocytic/JJ
cells/NNS
are/VBP
mediated/VBN
by/IN
activation/NN
of/IN
kappa/NN
B/NN
DNA-binding/JJ
proteins/NNS
./.
====================
However/RB
,/,
the/DT
specific/JJ
members/NNS
of/IN
the/DT
NF-kappa/NN
B/Rel/NN
transcription/NN
factor/NN
family/NN
involved/VBN
in/IN
the/DT
LPS/NN
response/NN
,/,
and/CC
the/DT
mechanisms/NNS
through/IN
which/WDT
LPS-generated/JJ
signals/NNS
are/VBP
transduced/VBN
remain/VBP
unclear/JJ
./.
====================
Here/RB
we/PRP
show/VBP
that/IN
LPS/NN
induces/VBZ
nuclear/JJ
expression/NN
of/IN
c-Rel/p50/NN
heterodimers/NNS
as/RB
well/RB
as/IN
p50/p65/NN
(/(
NF-kappa/NN
B/NN
)/)
kappa/NN
B/NN
DNA-binding/JJ
complexes/NNS
in/IN
human/JJ
monocytic/JJ
THP-1/NN
cells/NNS
./.
====================
Nuclear/JJ
localization/NN
of/IN
these/DT
proteins/NNS
occurred/VBD
concomitantly/RB
with/IN
a/DT
rapid/JJ
decrease/NN
in/IN
their/PRP$
cytosolic/JJ
levels/NNS
and/CC
was/VBD
independent/JJ
of/IN
phorbol/NN
ester-sensitive/JJ
protein/NN
kinase/NN
C/NN
./.
====================
Within/IN
24/CD
h/NN
following/VBG
LPS/NN
stimulation/NN
there/EX
was/VBD
a/DT
striking/JJ
increase/NN
in/IN
the/DT
levels/NNS
of/IN
c-Rel/NN
,/,
p105/NN
,/,
and/CC
p50/NN
in/IN
the/DT
cytosol/NN
./.
====================
The/DT
increased/VBN
levels/NNS
of/IN
these/DT
proteins/NNS
correlated/VBD
with/IN
increases/NNS
in/IN
the/DT
amounts/NNS
of/IN
their/PRP$
mRNAs/NNS
during/IN
LPS/NN
activation/NN
of/IN
THP-1/NN
cells/NNS
./.
====================
LPS/NN
activation/NN
of/IN
THP-1/NN
cells/NNS
resulted/VBD
in/IN
phosphorylation/NN
of/IN
MAD3/NN
(/(
an/DT
I/NN
kappa/NN
B-like/JJ
protein/NN
)/)
,/,
a/DT
rapid/JJ
increase/NN
in/IN
MAD3/NN
mRNA/NN
,/,
and/CC
an/DT
increase/NN
in/IN
MAD3/NN
protein/NN
by/IN
2/CD
h/NN
./.
====================
Thus/RB
,/,
LPS/NN
activation/NN
of/IN
human/JJ
monocytic/JJ
cells/NNS
results/VBZ
in/IN
nuclear/JJ
expression/NN
of/IN
c-Rel/p50/NN
and/CC
p50/p65/NN
(/(
NF-kappa/NN
B/NN
)/)
and/CC
induces/VBZ
phosphorylation/NN
of/IN
MAD3/NN
./.
====================
UI/LS
-/:
93252936/CD
====================
TI/LS
-/:
A/DT
chimeric/JJ
type/NN
II/CD
//:
type/NN
I/CD
interleukin-1/NN
receptor/NN
can/MD
mediate/VB
interleukin-1/NN
induction/NN
of/IN
gene/NN
expression/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
type/NN
I/CD
interleukin-1/NN
receptor/NN
(/(
IL-1R/NN
)/)
is/VBZ
capable/JJ
of/IN
transducing/VBG
a/DT
signal/NN
resulting/VBG
in/IN
promoter/NN
activation/NN
in/IN
T/NN
cells/NNS
./.
====================
This/DT
signal/NN
transduction/NN
is/VBZ
dependent/JJ
on/IN
the/DT
cytoplasmic/JJ
domain/NN
,/,
which/WDT
consists/VBZ
of/IN
213/CD
amino/NN
acids/NNS
./.
====================
In/IN
contrast/NN
to/TO
the/DT
type/NN
I/CD
receptor/NN
,/,
the/DT
type/NN
II/CD
IL-1R/NN
has/VBZ
a/DT
small/JJ
cytoplasmic/JJ
tail/NN
,/,
and/CC
it/PRP
is/VBZ
not/RB
clear/JJ
whether/IN
this/DT
receptor/NN
is/VBZ
a/DT
signal-transducing/JJ
or/CC
a/DT
regulatory/JJ
molecule/NN
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
the/DT
type/NN
II/CD
IL-1R/NN
does/VBZ
not/RB
mediate/VB
gene/NN
activation/NN
in/IN
Jurkat/NN
cells/NNS
./.
====================
However/RB
,/,
a/DT
hybrid/NN
receptor/NN
composed/VBN
of/IN
the/DT
extracellular/JJ
and/CC
transmembrane/NN
regions/NNS
of/IN
the/DT
human/JJ
type/NN
II/CD
interleukin-1/NN
fused/VBN
to/TO
the/DT
cytoplasmic/JJ
domain/NN
of/IN
the/DT
human/JJ
type/NN
I/CD
IL-1R/NN
was/VBD
capable/JJ
of/IN
transducing/VBG
a/DT
signal/NN
across/IN
the/DT
membrane/NN
resulting/VBG
in/IN
a/DT
pattern/NN
of/IN
gene/NN
activation/NN
identical/JJ
to/TO
that/DT
mediated/VBN
by/IN
the/DT
type/NN
I/CD
IL-1R/NN
./.
====================
Our/PRP$
results/NNS
indicated/VBD
that/IN
the/DT
extracellular/JJ
domain/NN
of/IN
the/DT
type/NN
II/CD
IL-1R/NN
was/VBD
capable/JJ
of/IN
functionally/RB
interacting/VBG
with/IN
interleukin-1/NN
and/CC
transmitting/VBG
the/DT
resulting/VBG
signal/NN
to/TO
a/DT
heterologous/JJ
cytoplasmic/JJ
domain/NN
./.
====================
UI/LS
-/:
93253031/CD
====================
TI/LS
-/:
A/DT
mutation/NN
of/IN
the/DT
glucocorticoid/NN
receptor/NN
in/IN
primary/JJ
cortisol/NN
resistance/NN
./.
====================
AB/LS
-/:
The/DT
precise/JJ
molecular/JJ
abnormalities/NNS
that/WDT
cause/VBP
primary/JJ
cortisol/NN
resistance/NN
have/VBP
not/RB
been/VBN
completely/RB
described/VBN
./.
====================
In/IN
a/DT
subject/NN
with/IN
primary/JJ
cortisol/NN
resistance/NN
we/PRP
have/VBP
observed/VBN
glucocorticoid/NN
receptors/NNS
(/(
hGR/NN
)/)
with/IN
a/DT
decreased/VBN
affinity/NN
for/IN
dexamethasone/NN
./.
====================
We/PRP
hypothesize/VBP
that/IN
a/DT
mutation/NN
of/IN
the/DT
hGR/NN
glucocorticoid-binding/JJ
domain/NN
is/VBZ
the/DT
cause/NN
of/IN
cortisol/NN
resistance/NN
./.
====================
Total/JJ
RNA/NN
isolated/VBN
from/IN
the/DT
index/NN
subject/NN
's/POS
mononuclear/JJ
leukocytes/NNS
was/VBD
used/VBN
to/TO
produce/VB
first/JJ
strand/NN
hGR/NN
cDNAs/NNS
,/,
and/CC
the/DT
entire/JJ
hGR/NN
cDNA/NN
was/VBD
amplified/VBN
in/IN
segments/NNS
and/CC
sequenced/VBN
./.
====================
At/IN
nucleotide/NN
2/CD
,/,
317/CD
we/PRP
identified/VBD
a/DT
homozygous/JJ
A/NN
for/IN
G/NN
point/NN
mutation/NN
that/WDT
predicts/VBZ
an/DT
isoleucine/NN
(/(
ATT/NN
)/)
for/IN
valine/NN
(/(
GTT/NN
)/)
substitution/NN
at/IN
amino/NN
acid/NN
729/CD
./.
====================
When/WRB
the/DT
wild-type/JJ
hGR/NN
and/CC
hGR-Ile/NN
729/CD
were/VBD
expressed/VBN
in/IN
COS-1/NN
cells/NNS
and/CC
assayed/VBN
for/IN
[3H]-Dexamethasone/NN
binding/NN
,/,
the/DT
dissociation/NN
constants/NNS
were/VBD
0.799/CD
+/-/CC
0.068/CD
and/CC
1.54/CD
+/-/CC
0.06/CD
nM/NN
(/(
mean/NN
+/-/CC
SEM/NN
)/)
(/(
P/NN
</JJR
0.01/CD
)/)
,/,
respectively/RB
./.
====================
When/WRB
the/DT
wild-type/JJ
hGR/NN
and/CC
hGR-Ile/NN
729/CD
were/VBD
expressed/VBN
in/IN
CV-1/NN
cells/NNS
that/WDT
were/VBD
cotransfected/VBN
with/IN
the/DT
mouse/NN
mammary/JJ
tumor/NN
virus/NN
long/JJ
terminal/JJ
repeat/NN
fused/VBN
to/TO
the/DT
chloramphenicol/NN
acetyl/NN
transferase/NN
(/(
CAT/NN
)/)
gene/NN
,/,
the/DT
hGR-Ile/NN
729/CD
conferred/VBD
a/DT
fourfold/JJ
decrease/NN
in/IN
apparent/JJ
potency/NN
on/IN
dexamethasone/NN
stimulation/NN
of/IN
CAT/NN
activity/NN
./.
====================
The/DT
isoleucine/NN
for/IN
valine/NN
substitution/NN
at/IN
amino/NN
acid/NN
729/CD
impairs/VBZ
the/DT
function/NN
of/IN
the/DT
hGR/NN
and/CC
is/VBZ
the/DT
likely/JJ
cause/NN
of/IN
primary/JJ
cortisol/NN
resistance/NN
in/IN
this/DT
subject/NN
./.
====================
UI/LS
-/:
93205400/CD
====================
TI/LS
-/:
The/DT
transcriptionally/RB
active/JJ
factors/NNS
mediating/VBG
the/DT
effect/NN
of/IN
the/DT
HTLV-I/NN
Tax/NN
transactivator/NN
on/IN
the/DT
IL-2R/NN
alpha/NN
kappa/NN
B/NN
enhancer/NN
include/VBP
the/DT
product/NN
of/IN
the/DT
c-rel/NN
proto-oncogene/NN
./.
====================
AB/LS
-/:
The/DT
transactivator/NN
HTLV-I/NN
Tax/NN
activates/VBZ
the/DT
promoter/NN
of/IN
the/DT
gene/NN
coding/VBG
for/IN
the/DT
interleukin/NN
2/CD
alpha-chain/JJ
receptor/NN
(/(
IL-2R/NN
alpha/NN
)/)
via/IN
a/DT
kappa/NN
B/NN
site/NN
that/WDT
can/MD
bind/VB
several/JJ
protein/NN
species/NNS
of/IN
the/DT
rel/NN
family/NN
./.
====================
Tax1/NN
strongly/RB
activates/VBZ
the/DT
enhancer/NN
activity/NN
of/IN
this/DT
motif/NN
,/,
in/IN
both/CC
epithelial/JJ
HeLa/NN
and/CC
lymphoid/JJ
Jurkat/NN
cells/NNS
./.
====================
This/DT
activation/NN
was/VBD
not/RB
observed/VBN
in/IN
undifferentiated/JJ
embryocarcinoma/NN
F9/NN
cells/NNS
./.
====================
Overexpression/NN
of/IN
the/DT
p50/NN
,/,
p65/NN
and/CC
Rel/NN
proteins/NNS
in/IN
these/DT
cells/NNS
showed/VBD
that/IN
significant/JJ
activation/NN
of/IN
the/DT
IL-2R/NN
alpha/NN
kappa/NN
B/NN
site/NN
was/VBD
observed/VBN
only/RB
with/IN
Rel/NN
and/CC
Rel/NN
plus/CC
p65/NN
./.
====================
Moreover/RB
,/,
whereas/IN
both/CC
Tax/NN
and/CC
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
are/VBP
able/JJ
to/TO
efficiently/RB
induce/VB
the/DT
binding/NN
of/IN
NF-kappa/NN
B/NN
to/TO
the/DT
IL-2R/NN
alpha/NN
kappa/NN
B/NN
site/NN
,/,
PMA/NN
is/VBZ
functionally/RB
inactive/JJ
./.
====================
Using/VBG
the/DT
DNA/NN
affinity/NN
precipitation/NN
assay/NN
,/,
we/PRP
observed/VBD
that/IN
Tax1/NN
is/VBZ
able/JJ
to/TO
efficiently/RB
induce/VB
the/DT
binding/NN
of/IN
Rel/NN
,/,
whereas/IN
PMA/NN
is/VBZ
not/RB
./.
====================
This/DT
established/VBD
a/DT
clear/JJ
difference/NN
between/IN
both/DT
stimuli/NNS
,/,
indicating/VBG
that/IN
Rel/NN
is/VBZ
the/DT
functionally/RB
active/JJ
factor/NN
./.
====================
We/PRP
conclude/VBP
from/IN
these/DT
results/NNS
that/IN
the/DT
functional/JJ
activity/NN
of/IN
members/NNS
of/IN
the/DT
rel/NN
family/NN
is/VBZ
regulated/VBN
by/IN
their/PRP$
interaction/NN
with/IN
DNA/NN
and/CC
that/IN
Rel/NN
can/MD
be/VB
a/DT
potent/JJ
transcriptional/JJ
activator/NN
on/IN
specific/JJ
kappa/NN
B/NN
sites/NNS
./.
====================
UI/LS
-/:
93203219/CD
====================
TI/LS
-/:
Transcriptional/JJ
regulation/NN
of/IN
interleukin/NN
3/CD
(/(
IL3/NN
)/)
in/IN
primary/JJ
human/JJ
T/NN
lymphocytes/NNS
./.
====================
Role/NN
of/IN
AP-1-/NN
and/CC
octamer-binding/JJ
proteins/NNS
in/IN
control/NN
of/IN
IL3/NN
gene/NN
expression/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
investigated/VBN
the/DT
molecular/JJ
and/CC
biochemical/JJ
basis/NN
for/IN
activation/NN
of/IN
interleukin/NN
3/CD
(/(
IL3/NN
)/)
gene/NN
expression/NN
in/IN
primary/JJ
human/JJ
T/NN
lymphocytes/NNS
following/VBG
CD3/NN
and/CC
CD2/NN
receptor/NN
stimulation/NN
or/CC
activation/NN
by/IN
phytohemagglutinin/NN
plus/CC
phorbol/NN
12-myristate/NN
13-acetate/NN
./.
====================
Using/VBG
transfection/NN
and/CC
reporter/NN
gene/NN
assays/NNS
specifically/RB
designed/VBN
for/IN
primary/JJ
T/NN
lymphocytes/NNS
in/IN
conjunction/NN
with/IN
gel/NN
retardation/NN
assays/NNS
,/,
Western/NN
blot/NN
analyses/NNS
and/CC
UV/NN
cross-linking/JJ
studies/NNS
,/,
we/PRP
found/VBD
that/IN
c-Jun/NN
,/,
c-Fos/NN
,/,
and/CC
octamer-binding/NN
proteins/NNS
play/VBP
a/DT
major/JJ
role/NN
in/IN
transcriptional/JJ
activation/NN
of/IN
the/DT
IL3/NN
gene/NN
via/IN
their/PRP$
interaction/NN
with/IN
two/CD
specific/JJ
regions/NNS
contained/VBN
within/IN
the/DT
IL3/NN
5'-flanking/JJ
sequence/NN
./.
====================
Additionally/RB
,/,
the/DT
region/NN
between/IN
bases/NNS
-107/CD
and/CC
-59/CD
of/IN
the/DT
IL3/NN
promoter/NN
containing/VBG
putative/JJ
AP-2/NN
and/CC
Sp1/NN
binding/NN
motifs/NNS
appears/VBZ
necessary/JJ
for/IN
basal/JJ
level/NN
expression/NN
of/IN
the/DT
IL3/NN
gene/NN
./.
====================
The/DT
data/NNS
also/RB
indicate/VBP
that/IN
CD2/NN
receptor/NN
activation/NN
and/CC
phytohemagglutinin/NN
plus/CC
phorbol/NN
12-myristate/NN
13-acetate/NN
stimulation/NN
augment/VBP
T/NN
cell/NN
IL3/NN
gene/NN
expression/NN
through/IN
the/DT
same/JJ
cis-/JJ
and/CC
trans-activating/JJ
signals/NNS
./.
====================
These/DT
results/NNS
should/MD
contribute/VB
to/TO
a/DT
better/JJR
understanding/NN
of/IN
the/DT
regulation/NN
of/IN
IL3/NN
gene/NN
expression/NN
in/IN
human/JJ
T/NN
lymphocytes/NNS
./.
====================
UI/LS
-/:
93180775/CD
====================
TI/LS
-/:
Dimerization/NN
of/IN
NF-KB2/NN
with/IN
RelA/NN
(/(
p65/NN
)/)
regulates/VBZ
DNA/NN
binding/NN
,/,
transcriptional/JJ
activation/NN
,/,
and/CC
inhibition/NN
by/IN
an/DT
I/NN
kappa/NN
B-alpha/NN
(/(
MAD-3/NN
)/)
./.
====================
AB/LS
-/:
Inducible/JJ
expression/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
is/VBZ
regulated/VBN
by/IN
a/DT
cellular/JJ
transcription/NN
factor/NN
,/,
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
./.
====================
NF-kappa/NN
B/NN
is/VBZ
composed/VBN
of/IN
distinct/JJ
subunits/NNS
;/:
five/CD
independent/JJ
genes/NNS
,/,
NFKB1/NN
(/(
p105/NN
)/)
,/,
NFKB2/NN
(/(
p100/NN
)/)
,/,
RelA/NN
(/(
p65/NN
)/)
,/,
c-rel/NN
and/CC
relB/NN
,/,
that/WDT
encode/VBP
related/JJ
proteins/NNS
that/WDT
bind/VBP
to/TO
kappa/NN
B/NN
DNA/NN
elements/NNS
have/VBP
been/VBN
isolated/VBN
./.
====================
We/PRP
have/VBP
previously/RB
found/VBN
that/IN
NFKB2/NN
(/(
p49/p52/NN
)/)
acts/VBZ
in/IN
concert/NN
with/IN
RelA/NN
(/(
p65/NN
)/)
to/TO
stimulate/VB
the/DT
HIV/NN
enhancer/NN
in/IN
Jurkat/NN
T-leukemia/NN
cells/NNS
./.
====================
Here/RB
we/PRP
examine/VBP
the/DT
biochemical/JJ
basis/NN
for/IN
the/DT
transcriptional/JJ
regulation/NN
of/IN
HIV/NN
by/IN
NFKB2/NN
./.
====================
Using/VBG
Scatchard/NN
analysis/NN
,/,
we/PRP
have/VBP
determined/VBN
the/DT
dissociation/NN
constants/NNS
of/IN
homodimeric/JJ
p49/NN
and/CC
heterodimeric/JJ
p49/p65/NN
for/IN
binding/NN
to/TO
the/DT
HIV/NN
kappa/NN
B/NN
site/NN
./.
====================
p49/NN
has/VBZ
a/DT
approximately/RB
18-fold-lower/JJ
affinity/NN
for/IN
the/DT
HIV/NN
kappa/NN
B/NN
site/NN
(/(
KD/NN
=/JJ
69.1/CD
pM/NN
)/)
than/IN
does/VBZ
the/DT
approximately/RB
50-kDa/JJ
protein/NN
NFKB1/NN
(/(
p50/NN
)/)
derived/VBN
from/IN
p105/NN
(/(
KD/NN
=/JJ
3.9/CD
pM/NN
)/)
./.
====================
In/IN
contrast/NN
,/,
the/DT
affinity/NN
of/IN
heterodimeric/JJ
NFKB2/NN
(/(
p49/NN
)/)
/RelA/NN
(/(
p65/NN
)/)
for/IN
this/DT
site/NN
is/VBZ
approximately/RB
6-fold/RB
higher/JJR
(/(
KD/NN
=/JJ
11.8/CD
pM/NN
)/)
than/IN
that/DT
of/IN
p49/NN
alone/RB
./.
====================
Consistent/JJ
with/IN
these/DT
findings/NNS
,/,
in/FW
vitro/FW
transcription/NN
was/VBD
stimulated/VBN
18-fold/RB
by/IN
the/DT
addition/NN
of/IN
preformed/JJ
,/,
heterodimeric/JJ
NFKB2/NN
(/(
p49/NN
)/)
/RelA/NN
(/(
p65/NN
)/)
protein/NN
./.
====================
Transcriptional/JJ
activation/NN
of/IN
the/DT
HIV/NN
enhancer/NN
was/VBD
also/RB
subject/JJ
to/TO
regulation/NN
by/IN
recently/RB
cloned/VBN
I/NN
kappa/NN
B-alpha/NN
(/(
MAD-3/NN
)/)
./.
====================
Recombinant/JJ
I/NN
kappa/NN
B-alpha/NN
(/(
MAD-3/NN
)/)
inhibited/VBD
the/DT
DNA/NN
binding/NN
activity/NN
of/IN
p65/NN
,/,
p49/p65/NN
,/,
and/CC
p50/p65/NN
but/CC
stimulated/VBD
the/DT
binding/NN
of/IN
NFKB2/NN
(/(
p49/NN
)/)
or/CC
NFKB1/NN
(/(
p50/NN
)/)
./.
====================
Functional/JJ
activation/NN
of/IN
an/DT
HIV/NN
reporter/NN
plasmid/NN
by/IN
p49/p65/NN
in/IN
transiently/RB
transfected/VBN
Jurkat/NN
T-leukemia/JJ
cells/NNS
was/VBD
also/RB
inhibited/VBN
by/IN
coexpression/NN
of/IN
MAD-3/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
93157335/CD
====================
TI/LS
-/:
The/DT
c-rel/NN
protooncogene/NN
product/NN
represses/VBZ
NF-kappa/NN
B/NN
p65-mediated/JJ
transcriptional/JJ
activation/NN
of/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
of/IN
type/NN
1/CD
human/JJ
immunodeficiency/NN
virus/NN
./.
====================
AB/LS
-/:
The/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
of/IN
the/DT
type/NN
1/CD
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV-1/NN
)/)
and/CC
the/DT
5'/JJ
regulatory/JJ
region/NN
of/IN
the/DT
gene/NN
encoding/VBG
the/DT
interleukin/NN
2/CD
receptor/NN
alpha/NN
subunit/NN
(/(
IL-2R/NN
alpha/NN
)/)
share/NN
functional/JJ
kappa/NN
B/NN
enhancer/NN
elements/NNS
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
these/DT
inducible/JJ
transcription/NN
units/NNS
during/IN
T-cell/NN
activation/NN
./.
====================
These/DT
kappa/NN
B/NN
enhancer/NN
elements/NNS
are/VBP
recognized/VBN
by/IN
a/DT
structurally/RB
related/JJ
family/NN
of/IN
interactive/JJ
proteins/NNS
that/WDT
includes/VBZ
p50/NN
,/,
p65/NN
,/,
and/CC
the/DT
product/NN
of/IN
the/DT
c-rel/NN
protooncogene/NN
(/(
c-Rel/NN
)/)
./.
====================
Recent/JJ
biochemical/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
p65/NN
and/CC
p50/NN
form/VBP
the/DT
prototypical/JJ
NF-kappa/NN
B/NN
complex/NN
,/,
which/WDT
is/VBZ
rapidly/RB
translocated/VBN
from/IN
the/DT
cytoplasm/NN
to/TO
the/DT
nucleus/NN
during/IN
T-cell/NN
activation/NN
./.
====================
This/DT
intracellular/JJ
signaling/NN
complex/NN
potently/RB
stimulates/VBZ
kappa/NN
B-directed/JJ
transcription/NN
from/IN
either/CC
the/DT
HIV-1/NN
LTR/NN
or/CC
the/DT
IL-2R/NN
alpha/NN
promoter/NN
via/IN
the/DT
strong/JJ
transactivation/NN
domain/NN
present/JJ
in/IN
p65/NN
./.
====================
We/PRP
now/RB
demonstrate/VBP
that/IN
nuclear/JJ
expression/NN
of/IN
human/JJ
c-Rel/NN
,/,
which/WDT
is/VBZ
induced/VBN
by/IN
either/DT
phorbol/NN
ester/NN
or/CC
tumor/NN
necrosis/NN
factor/NN
alpha/NN
with/IN
delayed/VBN
kinetics/NNS
relative/JJ
to/TO
p65/NN
,/,
markedly/RB
represses/VBZ
p65-mediated/JJ
activation/NN
of/IN
these/DT
transcription/NN
units/NNS
./.
====================
These/DT
inhibitory/JJ
effects/NNS
of/IN
c-Rel/NN
correlate/VBP
with/IN
its/PRP$
DNA-binding/JJ
activity/NN
but/CC
not/RB
with/IN
its/PRP$
ability/NN
to/TO
heterodimerize/VB
with/IN
p50/NN
,/,
suggesting/VBG
that/IN
c-Rel/NN
inhibition/NN
involves/VBZ
competition/NN
with/IN
p50/p65/NN
for/IN
occupancy/NN
of/IN
the/DT
kappa/NN
B/NN
enhancer/NN
element/NN
./.
====================
Together/RB
,/,
these/DT
findings/NNS
suggest/VBP
that/IN
one/CD
function/NN
of/IN
c-Rel/NN
is/VBZ
as/IN
a/DT
physiologic/JJ
repressor/NN
of/IN
the/DT
HIV-1/NN
LTR/NN
and/CC
IL-2R/NN
alpha/NN
promoters/NNS
,/,
serving/VBG
to/TO
efficiently/RB
counter/VB
the/DT
strong/JJ
transcriptional/JJ
activating/JJ
effects/NNS
of/IN
p65/NN
./.
====================
UI/LS
-/:
93141262/CD
====================
TI/LS
-/:
Ras/NN
oncogene/NN
transformation/NN
of/IN
human/JJ
B/NN
lymphoblasts/NNS
is/VBZ
associated/VBN
with/IN
lymphocyte/NN
activation/NN
and/CC
with/IN
a/DT
block/NN
of/IN
differentiation/NN
./.
====================
AB/LS
-/:
The/DT
p21ras/NN
small/JJ
GTP/NN
binding/NN
proteins/NNS
participate/VBP
in/IN
signal/JJ
transduction/NN
from/IN
cell/NN
surface/NN
receptors/NNS
and/CC
affect/VB
neoplastic/JJ
transformation/NN
and/CC
development/NN
in/IN
many/JJ
different/JJ
cell/NN
types/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
examined/VBD
the/DT
relationship/NN
between/IN
ras/NN
transformation/NN
and/CC
differentiation/NN
of/IN
human/JJ
B/NN
lymphocytes/NNS
./.
====================
We/PRP
show/VBP
that/IN
the/DT
constitutive/JJ
expression/NN
of/IN
the/DT
T24/NN
Ha-ras/NN
oncogene/NN
in/IN
EBV-immortalized/JJ
B/NN
lymphoblasts/NNS
was/VBD
associated/VBN
with/IN
the/DT
induction/NN
of/IN
the/DT
interleukin/NN
2/CD
receptor/NN
alpha/NN
subunit/NN
,/,
with/IN
an/DT
impaired/JJ
immunoglobulin/NN
gene/NN
expression/NN
,/,
altered/JJ
adhesion/NN
properties/NNS
and/CC
increased/VBN
survival/NN
in/IN
serum-free/JJ
medium/NN
./.
====================
Since/IN
induction/NN
of/IN
the/DT
IL-2/NN
receptor/NN
alpha/NN
subunit/NN
is/VBZ
a/DT
hallmark/NN
of/IN
lymphocyte/NN
activation/NN
,/,
we/PRP
suggest/VBP
that/IN
p21ras/NN
naturally/RB
triggers/VBZ
B/NN
cell/NN
activation/NN
./.
====================
The/DT
ras-transformed/JJ
lymphocytes/NNS
displayed/VBD
a/DT
fully/RB
functional/JJ
IL-2r/NN
,/,
as/IN
assessed/VBN
by/IN
c-fos/NN
induction/NN
following/VBG
treatment/NN
with/IN
IL-2/NN
;/:
nevertheless/RB
,/,
they/PRP
were/VBD
not/RB
growth/NN
stimulated/VBN
by/IN
this/DT
lymphokine/NN
./.
====================
The/DT
decreased/VBN
expression/NN
of/IN
immunoglobulin/NN
genes/NNS
indicates/VBZ
that/IN
the/DT
ras/NN
oncogene/NN
blocks/VBZ
terminal/JJ
differentiation/NN
to/TO
plasma/NN
cells/NNS
,/,
possibly/RB
by/IN
inhibiting/VBG
the/DT
activity/NN
of/IN
lymphocyte-specific/JJ
transcription/NN
factors/NNS
./.
====================
Somewhat/RB
unexpectedly/RB
,/,
the/DT
constitutive/JJ
p21ras/NN
activity/NN
did/VBD
not/RB
cause/VB
an/DT
increased/VBN
DNA/NN
binding/NN
of/IN
transcription/NN
factors/NNS
PEA1/NN
(/(
AP1/NN
)/)
,/,
PEA3/NN
,/,
Oct-2/NN
or/CC
NF-kB/NN
====================
UI/LS
-/:
93300824/CD
====================
TI/LS
-/:
Comparative/JJ
analysis/NN
of/IN
NFAT/NN
(/(
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
)/)
complex/JJ
in/IN
human/JJ
T/NN
and/CC
B/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFAT/NN
)/)
is/VBZ
a/DT
transcriptional/JJ
activator/NN
that/WDT
binds/VBZ
to/TO
sequences/NNS
in/IN
the/DT
interleukin-2/NN
(/(
IL-2/NN
)/)
promoter/NN
and/CC
is/VBZ
thought/VBN
to/TO
be/VB
largely/RB
responsible/JJ
for/IN
the/DT
T/NN
cell-specific/JJ
inducibility/NN
of/IN
IL-2/NN
expression/NN
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
(/(
EMSA/NN
)/)
showed/VBD
that/IN
specific/JJ
NFAT/NN
binding/NN
activity/NN
could/MD
also/RB
be/VB
induced/VBN
in/IN
human/JJ
B/NN
cells/NNS
./.
====================
The/DT
B/NN
cell/NN
NFAT/NN
complex/NN
,/,
however/RB
,/,
was/VBD
not/RB
functional/JJ
,/,
since/IN
it/PRP
failed/VBD
to/TO
activate/VB
transcription/NN
from/IN
an/DT
NFAT-driven/JJ
chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
construct/NN
./.
====================
Competition/NN
with/IN
an/DT
AP-1/NN
motif/NN
or/CC
with/IN
anti-Jun/JJ
and/CC
anti-Fos/JJ
antibodies/NNS
abolished/VBD
binding/NN
to/TO
the/DT
NFAT/NN
motif/NN
in/IN
both/CC
T/NN
and/CC
B/NN
cells/NNS
,/,
indicating/VBG
that/IN
Jun/NN
and/CC
Fos/NN
are/VBP
critical/JJ
for/IN
NFAT/NN
complex/NN
formation/NN
in/IN
both/DT
cell/NN
types/NNS
./.
====================
Purified/VBN
recombinant/JJ
Jun/NN
and/CC
Fos/NN
proteins/NNS
failed/VBD
to/TO
bind/VB
directly/RB
to/TO
the/DT
NFAT/NN
motif/NN
./.
====================
However/RB
,/,
when/WRB
combined/VBN
with/IN
unstimulated/JJ
B/NN
or/CC
T/NN
cell/NN
extracts/NNS
,/,
full-length/JJ
,/,
but/CC
not/RB
truncated/VBN
,/,
Jun/Fos/NN
heterodimers/NNS
were/VBD
able/JJ
to/TO
form/VB
an/DT
NFAT/NN
complex/NN
,/,
indicating/VBG
the/DT
presence/NN
of/IN
a/DT
constitutively/RB
expressed/VBN
nuclear/JJ
factor/NN
(/(
s/NNS
)/)
in/IN
B/NN
and/CC
T/NN
cells/NNS
necessary/JJ
for/IN
the/DT
formation/NN
of/IN
the/DT
NFAT/NN
complex/NN
in/IN
both/DT
cell/NN
types/NNS
./.
====================
An/DT
NFAT/NN
oligonucleotide/NN
carrying/VBG
mutations/NNS
in/IN
the/DT
5'/JJ
purine-rich/JJ
part/NN
of/IN
the/DT
NFAT/NN
sequence/NN
failed/VBD
to/TO
form/VB
a/DT
complex/NN
and/CC
to/TO
compete/VB
with/IN
the/DT
wild/JJ
type/NN
motif/NN
for/IN
NFAT/NN
complex/NN
formation/NN
in/IN
both/CC
T/NN
and/CC
B/NN
cells/NNS
./.
====================
We/PRP
therefore/RB
propose/VBP
a/DT
model/NN
whereby/WRB
a/DT
core/NN
NFAT/NN
complex/NN
consisting/VBG
of/IN
Jun/NN
,/,
Fos/NN
,/,
and/CC
a/DT
constitutive/JJ
nuclear/JJ
factor/NN
is/VBZ
formed/VBN
in/IN
both/DT
T/NN
and/CC
B/NN
cells/NNS
,/,
but/CC
an/DT
additional/JJ
factor/NN
and/or/CC
post-translational/JJ
modification/NN
of/IN
a/DT
factor/NN
,/,
missing/VBG
in/IN
B/NN
cells/NNS
,/,
might/MD
be/VB
required/VBN
for/IN
transactivation/NN
by/IN
NFAT/NN
./.
====================
UI/LS
-/:
93307152/CD
====================
TI/LS
-/:
Differential/JJ
autoregulation/NN
of/IN
glucocorticoid/NN
receptor/NN
expression/NN
in/IN
human/JJ
T-/NN
and/CC
B-cell/NN
lines/NNS
./.
====================
AB/LS
-/:
Regulation/NN
of/IN
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
expression/NN
by/IN
its/PRP$
cognate/JJ
ligand/NN
was/VBD
examined/VBN
in/IN
the/DT
glucocorticoid-sensitive/JJ
human/JJ
leukemic/JJ
T-cell/NN
line/NN
6TG1.1/NN
and/CC
in/IN
the/DT
human/JJ
B-cell/NN
line/NN
IM-9/NN
./.
====================
In/IN
contrast/NN
to/TO
the/DT
decrease/NN
in/IN
GR/NN
mRNA/NN
seen/VBN
in/IN
IM-9/NN
cells/NNS
after/IN
treatment/NN
with/IN
1/CD
microM/NN
dexamethasone/NN
for/IN
16-18/CD
h/NN
,/,
treatment/NN
of/IN
6TG1.1/NN
cells/NNS
resulted/VBD
in/IN
an/DT
8-fold/JJ
increase/NN
in/IN
GR/NN
mRNA/NN
,/,
as/IN
determined/VBN
by/IN
Northern/NN
blot/NN
and/CC
RNase/NN
protection/NN
analysis/NN
,/,
with/IN
a/DT
corresponding/JJ
3-/CD
to/TO
4-fold/JJ
increase/NN
in/IN
GR/NN
protein/NN
./.
====================
Half-maximal/JJ
induction/NN
of/IN
GR/NN
mRNA/NN
and/CC
protein/NN
in/IN
6TG1.1/NN
cells/NNS
was/VBD
observed/VBN
between/IN
10-100/CD
nM/NN
dexamethasone/NN
,/,
and/CC
inclusion/NN
of/IN
1/CD
microM/NN
RU/NN
38486/CD
completely/RB
blocked/VBD
the/DT
effects/NNS
of/IN
100/CD
nM/NN
dexamethasone/NN
,/,
demonstrating/VBG
that/IN
positive/JJ
autoregulation/NN
of/IN
GR/NN
expression/NN
in/IN
6TG1.1/NN
cells/NNS
is/VBZ
a/DT
receptor-mediated/JJ
response/NN
./.
====================
Positive/JJ
autoregulation/NN
of/IN
GR/NN
expression/NN
was/VBD
also/RB
observed/VBN
in/IN
glucocorticoid-resistant/JJ
CEM-C1/NN
cells/NNS
,/,
which/WDT
contain/VBP
functional/JJ
GR/NN
,/,
but/CC
whose/WP$
growth/NN
is/VBZ
unaffected/VBN
by/IN
glucocorticoids/NNS
./.
====================
Thus/RB
,/,
positive/JJ
autoregulation/NN
is/VBZ
neither/CC
a/DT
consequence/NN
nor/CC
the/DT
sole/JJ
cause/NN
of/IN
growth/NN
arrest/NN
./.
====================
The/DT
degree/NN
of/IN
negative/JJ
autoregulation/NN
in/IN
IM-9/NN
cells/NNS
and/CC
positive/JJ
autoregulation/NN
in/IN
6TG1.1/NN
cells/NNS
was/VBD
unaffected/VBN
by/IN
inhibition/NN
of/IN
protein/NN
synthesis/NN
with/IN
cycloheximide/NN
./.
====================
Measurement/NN
of/IN
GR/NN
mRNA/NN
turnover/NN
in/IN
6TG1.1/NN
cells/NNS
treated/VBN
with/IN
actinomycin-D/NN
revealed/VBD
a/DT
half-life/NN
of/IN
2.5/CD
h/NN
,/,
which/WDT
was/VBD
unaffected/JJ
by/IN
dexamethasone/NN
treatment/NN
./.
====================
A/DT
similar/JJ
half-life/NN
was/VBD
determined/VBN
in/IN
IM-9/NN
cells/NNS
and/CC
was/VBD
also/RB
unaffected/JJ
by/IN
steroid/NN
treatment/NN
./.
====================
These/DT
results/NNS
are/VBP
consistent/JJ
with/IN
the/DT
interpretation/NN
that/IN
glucocorticoid-mediated/JJ
autoregulation/NN
of/IN
GR/NN
expression/NN
is/VBZ
a/DT
tissue-specific/JJ
primary/JJ
transcriptional/JJ
response/NN
./.
====================
UI/LS
-/:
93280865/CD
====================
TI/LS
-/:
Induction/NN
of/IN
CD8/NN
antigen/NN
and/CC
suppressor/NN
activity/NN
by/IN
glucocorticoids/NNS
in/IN
a/DT
CEM/NN
human/JJ
leukemic/JJ
cell/NN
clone/NN
./.
====================
AB/LS
-/:
The/DT
relationship/NN
between/IN
glucocorticoid/NN
effect/NN
and/CC
regulation/NN
of/IN
cell/NN
surface/NN
antigens/NNS
was/VBD
investigated/VBN
in/IN
two/CD
models/NNS
of/IN
leukemic/JJ
cell/NN
lines/NNS
,/,
CEM/NN
C7/NN
denoted/VBN
(/(
r+/JJ
,/,
ly+/JJ
)/)
and/CC
CEM/NN
C1/NN
(/(
r+/JJ
,/,
ly-/JJ
)/)
./.
====================
The/DT
reactivity/NN
of/IN
murine/JJ
monoclonal/JJ
antibodies/NNS
,/,
anti-CD4-FITC/NN
,/,
anti-CD8-FITC/NN
,/,
anti-CD2-FITC/NN
and/CC
anti-calla-FITC/NN
,/,
were/VBD
analyzed/VBN
using/VBG
flow/NN
cytometry/NN
./.
====================
The/DT
suppressor/NN
function/NN
was/VBD
determined/VBN
using/VBG
[3H]thymidine/NN
incorporation/NN
into/IN
phytohemagglutinin-activated/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
./.
====================
Dexamethasone/NN
treatment/NN
of/IN
a/DT
human/JJ
leukemic/JJ
cell/NN
clone/NN
CEM/NN
C7/NN
caused/VBD
an/DT
increase/NN
in/IN
a/DT
subset/NN
of/IN
cells/NNS
expressing/VBG
the/DT
surface/NN
antigen/NN
CD8/NN
,/,
which/WDT
is/VBZ
present/JJ
on/IN
suppressor/NN
and/CC
cytotoxic/JJ
T-lymphocytes/NNS
./.
====================
By/IN
comparison/NN
,/,
there/EX
was/VBD
no/DT
modification/NN
of/IN
the/DT
expression/NN
of/IN
CD4/NN
antigen/NN
,/,
which/WDT
is/VBZ
expressed/VBN
at/IN
high/JJ
levels/NNS
in/IN
these/DT
cells/NNS
./.
====================
After/IN
two/CD
days/NNS
of/IN
treatment/NN
with/IN
5/CD
x/NN
10/CD
(/(
-8/CD
)/)
M/NN
dexamethasone/NN
,/,
CEM/NN
C7/NN
cells/NNS
showed/VBD
a/DT
two-fold/JJ
increase/NN
in/IN
suppressor/NN
activity/NN
compared/VBN
to/TO
untreated/JJ
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
there/EX
was/VBD
no/DT
regulation/NN
by/IN
glucocorticoids/NNS
of/IN
either/CC
the/DT
CD8/NN
or/CC
CD4/NN
antigens/NNS
in/IN
the/DT
leukemic/JJ
clone/NN
CEM/NN
C1/NN
./.
====================
Furthermore/RB
,/,
no/DT
modification/NN
of/IN
the/DT
suppressor/NN
function/NN
in/IN
CEM/NN
C1/NN
cells/NNS
by/IN
dexamethasone/NN
was/VBD
observed/VBN
./.
====================
In/IN
the/DT
human/JJ
leukemic/JJ
cells/NNS
studied/VBN
here/RB
,/,
the/DT
ability/NN
to/TO
induce/VB
CD8/NN
antigen/NN
expression/NN
in/IN
a/DT
CD4+/JJ
cells/NNS
correlates/VBZ
with/IN
the/DT
ability/NN
to/TO
induce/VB
cell/NN
lysis/NN
in/IN
a/DT
glucocorticoid/NN
receptor/NN
positive/JJ
cell/NN
population/NN
./.
====================
UI/LS
-/:
93246644/CD
====================
TI/LS
-/:
Adenovirus/NN
E1A/NN
inhibits/VBZ
IFN-induced/JJ
resistance/NN
to/TO
cytolysis/NN
by/IN
natural/JJ
killer/NN
cells/NNS
./.
====================
AB/LS
-/:
Infection/NN
of/IN
target/NN
cells/NNS
with/IN
cytopathic/JJ
viruses/NNS
inhibits/VBZ
IFN/NN
induction/NN
of/IN
cytolytic/JJ
resistance/NN
to/TO
NK/NN
cell-mediated/JJ
cytolysis/NN
[/(
IFN-mediated/JJ
cytoprotection/NN
(/(
IFN-MCP/NN
)/)
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
thought/VBN
that/IN
the/DT
virally/RB
induced/VBN
inhibition/NN
of/IN
IFN-MCP/NN
is/VBZ
secondary/JJ
to/TO
the/DT
shutdown/NN
of/IN
cellular/JJ
macromolecular/JJ
synthesis/NN
that/WDT
accompanies/VBZ
cytopathic/JJ
virus/NN
infections/NNS
./.
====================
Group/NN
C/NN
,/,
adenovirus/NN
serotype/NN
5/CD
(/(
Ad5/NN
)/)
infection/NN
inhibits/VBZ
both/CC
IFN-MCP/NN
and/CC
cellular/JJ
protein/NN
synthesis/NN
./.
====================
This/DT
study/NN
determined/VBD
if/IN
the/DT
Ad5-induced/JJ
inhibition/NN
of/IN
IFN-MCP/NN
was/VBD
independent/JJ
of/IN
adenovirus/NN
(/(
Ad/NN
)/)
infection/NN
and/CC
secondary/JJ
only/RB
to/TO
the/DT
expression/NN
of/IN
the/DT
Ad/NN
early/JJ
region/NN
1A/NN
gene/NN
(/(
E1A/NN
)/)
./.
====================
To/TO
test/VB
this/DT
hypothesis/NN
,/,
4-h/JJ
NK/NN
cytolysis/NN
assays/NNS
were/VBD
performed/VBN
on/IN
IFN-gamma-treated/JJ
human/JJ
cells/NNS
infected/VBN
with/IN
an/DT
Ad5/NN
E1A/NN
deletion/NN
mutant/NN
,/,
dl343/NN
,/,
or/CC
transfected/VBN
with/IN
the/DT
Ad5/NN
E1A/NN
gene/NN
./.
====================
IFN-MCP/NN
was/VBD
not/RB
inhibited/VBN
by/IN
infection/NN
with/IN
dl343/NN
,/,
despite/IN
the/DT
production/NN
of/IN
large/JJ
amounts/NNS
of/IN
both/CC
early/JJ
(/(
E1B/NN
,/,
p55/NN
)/)
and/CC
late/JJ
(/(
hexon/NN
)/)
Ad/NN
proteins/NNS
./.
====================
In/IN
contrast/NN
to/TO
E1A-negative/JJ
,/,
parental/JJ
cell/NN
lines/NNS
,/,
IFN-MCP/NN
was/VBD
blocked/VBN
in/IN
Ad5/NN
E1A-transfected/JJ
epithelial/JJ
and/CC
fibroblastic/JJ
cell/NN
lines/NNS
./.
====================
Genetic/JJ
mapping/NN
studies/NNS
within/IN
the/DT
E1A/NN
gene/NN
demonstrated/VBD
that/IN
expression/NN
of/IN
only/RB
the/DT
first/JJ
exon/NN
of/IN
E1A/NN
was/VBD
sufficient/JJ
to/TO
inhibit/VB
IFN-MCP/NN
./.
====================
DNA/NN
sequence/NN
homology/NN
of/IN
E1A/NN
genes/NNS
between/IN
different/JJ
Ad/NN
groups/NNS
(/(
group/NN
A/NN
,/,
Ad12/NN
;/:
group/NN
C/NN
,/,
Ad5/NN
)/)
is/VBZ
limited/VBN
almost/RB
entirely/RB
to/TO
three/CD
conserved/VBN
regions/NNS
located/JJ
within/IN
the/DT
first/JJ
exon/NN
of/IN
E1A/NN
./.
====================
Because/IN
IFN-MCP/NN
was/VBD
also/RB
blocked/VBN
in/IN
Ad12/NN
E1A-transfected/JJ
cell/NN
lines/NNS
,/,
expression/NN
of/IN
one/CD
or/CC
more/JJR
of/IN
the/DT
E1A-conserved/JJ
regions/NNS
may/MD
be/VB
necessary/JJ
to/TO
inhibit/VB
IFN-MCP/NN
./.
====================
In/IN
summary/NN
,/,
the/DT
expression/NN
of/IN
E1A/NN
gene/NN
products/NNS
inhibited/VBD
IFN-MCP/NN
independently/RB
of/IN
virus/NN
infection/NN
./.
====================
E1A/NN
's/POS
inhibition/NN
of/IN
IFN-MCP/NN
has/VBZ
the/DT
net/JJ
effect/NN
of/IN
promoting/VBG
the/DT
selective/JJ
NK/NN
cell-mediated/JJ
clearance/NN
of/IN
Ad-infected/JJ
or/CC
Ad-transformed/JJ
human/JJ
cells/NNS
./.
====================
UI/LS
-/:
93224733/CD
====================
TI/LS
-/:
A/DT
protein/NN
of/IN
the/DT
AP-1/NN
family/NN
is/VBZ
a/DT
component/NN
of/IN
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NF-AT/NN
)/)
is/VBZ
a/DT
transcriptional/JJ
activator/NN
involved/VBN
in/IN
the/DT
induction/NN
of/IN
IL-2/NN
gene/NN
expression/NN
./.
====================
The/DT
response/NN
element/NN
for/IN
NF-AT/NN
is/VBZ
a/DT
sequence/NN
localized/JJ
between/IN
-285/-254/CD
in/IN
the/DT
IL-2/NN
regulatory/JJ
region/NN
./.
====================
The/DT
composition/NN
of/IN
NF-AT/NN
protein/NN
is/VBZ
still/RB
not/RB
fully/RB
elucidated/VBN
./.
====================
We/PRP
demonstrate/VBP
that/IN
,/,
in/IN
normal/JJ
human/JJ
T/NN
cells/NNS
,/,
an/DT
AP-1/NN
protein/NN
is/VBZ
a/DT
component/NN
of/IN
the/DT
NF-AT/NN
protein/NN
complex/NN
./.
====================
This/DT
was/VBD
evidenced/VBN
by/IN
the/DT
ability/NN
of/IN
the/DT
AP-1/NN
site/NN
to/TO
compete/VB
with/IN
the/DT
NF-AT/NN
site/NN
for/IN
binding/NN
to/TO
NF-AT/NN
and/CC
by/IN
the/DT
capacity/NN
of/IN
immobilized/VBN
anti-Jun/JJ
and/CC
anti-Fos/JJ
antibodies/NNS
to/TO
deplete/VB
NF-AT-binding/NN
activity/NN
from/IN
nuclear/JJ
extracts/NNS
of/IN
activated/VBN
T/NN
cells/NNS
./.
====================
There/EX
was/VBD
no/DT
detectable/JJ
binding/NN
of/IN
in/FW
vitro/FW
translated/VBN
Jun/Fos/NN
heterodimer/NN
(/(
AP-1/NN
)/)
to/TO
the/DT
NF-AT/NN
sequence/NN
,/,
and/CC
the/DT
NF-AT/NN
sequence/NN
was/VBD
unable/JJ
to/TO
inhibit/VB
the/DT
binding/NN
of/IN
Jun/Fos/NN
to/TO
the/DT
AP-1/NN
sequence/NN
./.
====================
The/DT
presence/NN
of/IN
an/DT
AP-1/NN
protein/NN
in/IN
the/DT
NF-AT/NN
protein/NN
complex/NN
may/MD
regulate/VB
NF-AT-binding/JJ
activity/NN
through/IN
protein-protein/JJ
interaction/NN
./.
====================
UI/LS
-/:
93204999/CD
====================
TI/LS
-/:
Interaction/NN
between/IN
NF-kappa/NN
B-/NN
and/CC
serum/NN
response/NN
factor-binding/JJ
elements/NNS
activates/VBZ
an/DT
interleukin-2/NN
receptor/NN
alpha-chain/JJ
enhancer/NN
specifically/RB
in/IN
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
We/PRP
find/VBP
that/IN
a/DT
short/JJ
enhancer/NN
element/NN
containing/VBG
the/DT
NF-kappa/NN
B/NN
binding/NN
site/NN
from/IN
the/DT
interleukin-2/NN
receptor/NN
alpha-chain/JJ
gene/NN
(/(
IL-2R/NN
alpha/NN
)/)
is/VBZ
preferentially/RB
activated/VBN
in/IN
T/NN
cells/NNS
./.
====================
The/DT
IL-2R/NN
alpha/NN
enhancer/NN
binds/VBZ
NF-kappa/NN
B/NN
poorly/RB
and/CC
is/VBZ
only/RB
weakly/RB
activated/VBN
by/IN
the/DT
NF-kappa/NN
B/NN
site/NN
alone/RB
./.
====================
Serum/NN
response/NN
factor/NN
(/(
SRF/NN
)/)
binds/VBZ
to/TO
a/DT
site/NN
adjacent/JJ
to/TO
the/DT
NF-kappa/NN
B/NN
site/NN
in/IN
the/DT
IL-2R/NN
enhancer/NN
,/,
and/CC
both/DT
sites/NNS
together/RB
have/VBP
strong/JJ
transcriptional/JJ
activity/NN
specifically/RB
in/IN
T/NN
cells/NNS
./.
====================
Surprisingly/RB
,/,
the/DT
levels/NNS
of/IN
SRF/NN
constitutively/RB
expressed/VBN
in/IN
T/NN
cells/NNS
are/VBP
consistently/RB
higher/JJR
than/IN
in/IN
other/JJ
cell/NN
types/NNS
./.
====================
Overexpression/NN
of/IN
SRF/NN
in/IN
B/NN
cells/NNS
causes/VBZ
the/DT
IL-2R/NN
enhancer/NN
to/TO
function/VB
as/RB
well/RB
as/IN
it/PRP
does/VBZ
in/IN
T/NN
cells/NNS
,/,
suggesting/VBG
that/IN
the/DT
high/JJ
level/NN
of/IN
SRF/NN
binding/NN
in/IN
T/NN
cells/NNS
is/VBZ
functionally/RB
important/JJ
./.
====================
UI/LS
-/:
93211996/CD
====================
TI/LS
-/:
Mutual/JJ
regulation/NN
of/IN
the/DT
transcriptional/JJ
activator/NN
NF-kappa/NN
B/NN
and/CC
its/PRP$
inhibitor/NN
,/,
I/NN
kappa/NN
B-alpha/NN
./.
====================
AB/LS
-/:
The/DT
NK-kappa/NN
B/NN
transcription/NN
factor/NN
complex/NN
is/VBZ
sequestered/VBN
in/IN
the/DT
cytoplasm/NN
by/IN
the/DT
inhibitory/JJ
protein/NN
I/NN
kappa/NN
B-alpha/NN
(/(
MAD-3/NN
)/)
./.
====================
Various/JJ
cellular/JJ
stimuli/NNS
relieve/VBP
this/DT
inhibition/NN
by/IN
mechanisms/NNS
largely/RB
unknown/JJ
,/,
leading/VBG
to/TO
NF-kappa/NN
B/NN
nuclear/JJ
localization/NN
and/CC
transactivation/NN
of/IN
its/PRP$
target/NN
genes/NNS
./.
====================
It/PRP
is/VBZ
demonstrated/VBN
here/RB
with/IN
human/JJ
T/NN
lymphocytes/NNS
and/CC
monocytes/NNS
that/IN
different/JJ
stimuli/NNS
,/,
including/VBG
tumor/NN
necrosis/NN
factor/NN
alpha/NN
and/CC
phorbol/NN
12-myristate/NN
13-acetate/NN
,/,
cause/VB
rapid/JJ
degradation/NN
of/IN
I/NN
kappa/NN
B-alpha/NN
,/,
with/IN
concomitant/JJ
activation/NN
of/IN
NF-kappa/NN
B/NN
,/,
followed/VBN
by/IN
a/DT
dramatic/JJ
increase/NN
in/IN
I/NN
kappa/NN
B-alpha/NN
mRNA/NN
and/CC
protein/NN
synthesis/NN
./.
====================
Transfection/NN
studies/NNS
reveal/VBP
that/IN
the/DT
I/NN
kappa/NN
B-alpha/NN
mRNA/NN
and/CC
the/DT
encoded/VBN
protein/NN
are/VBP
potently/RB
induced/VBN
by/IN
NF-kappa/NN
B/NN
and/CC
by/IN
homodimers/NNS
of/IN
p65/NN
and/CC
of/IN
c-Rel/NN
./.
====================
We/PRP
propose/VBP
a/DT
model/NN
in/IN
which/WDT
NF-kappa/NN
B/NN
and/CC
I/NN
kappa/NN
B-alpha/NN
mutually/RB
regulate/VBP
each/DT
other/JJ
in/IN
a/DT
cycle/NN
:/:
saturating/JJ
amounts/NNS
of/IN
the/DT
inhibitory/JJ
I/NN
kappa/NN
B-alpha/NN
protein/NN
are/VBP
destroyed/VBN
upon/IN
stimulation/NN
,/,
allowing/VBG
rapid/JJ
activation/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
Subsequently/RB
,/,
I/NN
kappa/NN
B-alpha/NN
mRNA/NN
and/CC
protein/NN
levels/NNS
are/VBP
quickly/RB
induced/VBN
by/IN
the/DT
activated/VBN
NF-kappa/NN
B/NN
./.
====================
This/DT
resurgence/NN
of/IN
I/NN
kappa/NN
B-alpha/NN
protein/NN
acts/VBZ
to/TO
restore/VB
an/DT
equilibrium/NN
in/IN
which/WDT
NF-kappa/NN
B/NN
is/VBZ
again/RB
inhibited/VBN
./.
====================
UI/LS
-/:
93172387/CD
====================
TI/LS
-/:
Replication/NN
of/IN
type/NN
1/CD
human/JJ
immunodeficiency/NN
viruses/NNS
containing/VBG
linker/NN
substitution/NN
mutations/NNS
in/IN
the/DT
-201/CD
to/TO
-130/CD
region/NN
of/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
./.
====================
AB/LS
-/:
In/IN
previous/JJ
transfection/NN
analyses/NNS
using/VBG
the/DT
chloramphenicol/JJ
acetyltransferase/NN
reporter/NN
gene/NN
system/NN
,/,
we/PRP
determined/VBD
that/IN
linker/NN
substitution/NN
(/(
LS/NN
)/)
mutations/NNS
between/IN
-201/CD
and/CC
-130/CD
(/(
relative/JJ
to/TO
the/DT
transcription/NN
start/NN
site/NN
)/)
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
caused/VBD
moderate/JJ
decreases/NNS
in/IN
LTR/NN
transcriptional/JJ
activity/NN
in/IN
a/DT
T-cell/NN
line/NN
(/(
S.L.Zeichner/NNP
,/,
J.Y.H./NNP
Kim/NNP
,/,
and/CC
J.C.Alwine/NNP
,/,
J.Virol.65/NNP
:/:
2436-2444/CD
,/,
1991/CD
)/)
./.
====================
In/IN
order/NN
to/TO
confirm/VB
the/DT
significance/NN
of/IN
this/DT
region/NN
in/IN
the/DT
context/NN
of/IN
viral/JJ
replication/NN
,/,
we/PRP
constructed/VBD
several/JJ
of/IN
these/DT
LS/NN
mutations/NNS
(/(
-201/CD
to/TO
- 184/CD
,/,
-183/CD
to/TO
-166/CD
,/,
-165/CD
to/TO
-148/CD
,/,
and/CC
-148/CD
to/TO
-130/CD
)/)
in/IN
proviruses/NNS
and/CC
prepared/VBD
viral/JJ
stocks/NNS
by/IN
cocultivation/NN
of/IN
transfected/VBN
RD/NN
cells/NNS
with/IN
CEMx174/NN
cells/NNS
./.
====================
In/IN
addition/NN
,/,
two/CD
mutations/NNS
between/IN
-93/CD
and/CC
-76/CD
and/CC
between/IN
-75/CD
and/CC
-58/CD
were/VBD
utilized/VBN
,/,
since/IN
they/PRP
affect/VBP
the/DT
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
-/:
and/CC
Sp1-binding/JJ
sites/NNS
and/CC
were/VBD
expected/VBN
to/TO
diminish/VB
viral/JJ
replication/NN
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
while/IN
transfection/NN
analyses/NNS
offer/VBP
an/DT
adequate/JJ
approximation/NN
of/IN
the/DT
effects/NNS
of/IN
the/DT
LS/NN
mutations/NNS
,/,
the/DT
analysis/NN
of/IN
viral/JJ
replication/NN
using/VBG
a/DT
mutant/JJ
viral/JJ
stock/NN
presents/VBZ
a/DT
more/RBR
accurate/JJ
picture/NN
,/,
which/WDT
is/VBZ
sometimes/RB
at/IN
variance/NN
with/IN
the/DT
transfection/NN
results/NNS
./.
====================
Three/CD
mutants/NNS
(/(
-201/-184/CD
NXS/NN|NNS
,/,
-165/-148/CD
NXS/NN|NNS
,/,
and/CC
-147/-130/CD
NXS/NN|NNS
)/)
had/VBD
effects/NNS
on/IN
viral/JJ
replication/NN
that/WDT
were/VBD
much/RB
more/RBR
severe/JJ
than/IN
the/DT
effects/NNS
predicted/VBN
from/IN
their/PRP$
performance/NN
in/IN
transfection/NN
analyses/NNS
,/,
and/CC
the/DT
effects/NNS
of/IN
two/CD
LS/NN
mutations/NNS
(/(
-201/-184/CD
NXS/NN
and/CC
-183/-166/CD
NXS/NN
)/)
were/VBD
not/RB
predicted/VBN
by/IN
their/PRP$
effects/NNS
in/IN
transfection/NN
./.
====================
In/IN
addition/NN
,/,
we/PRP
observed/VBD
cell/NN
type-specific/JJ
permissiveness/NN
to/TO
replication/NN
of/IN
some/DT
mutant/JJ
viruses/NNS
./.
====================
In/IN
the/DT
cell/NN
types/NNS
tested/VBN
,/,
the/DT
LS/NN
mutations/NNS
indicated/VBD
an/DT
apparent/JJ
requirement/NN
not/RB
only/RB
for/IN
the/DT
intact/JJ
NF-kappa/NN
B/NN
and/CC
SP1-binding/JJ
sites/NNS
but/CC
also/RB
for/IN
several/JJ
regions/NNS
between/IN
-201/CD
and/CC
-130/CD
not/RB
previously/RB
associated/VBN
with/IN
viral/JJ
infectivity/NN
./.
====================
UI/LS
-/:
93141620/CD
====================
TI/LS
-/:
Transcription/NN
factor/NN
GATA-1/NN
and/CC
erythroid/JJ
development/NN
./.
====================
AB/LS
-/:
In/IN
summary/NN
,/,
we/PRP
derived/VBD
an/DT
experimental/JJ
system/NN
that/WDT
allows/VBZ
us/PRP
to/TO
dissect/VB
the/DT
function/NN
of/IN
GATA-1/NN
in/IN
red/JJ
cell/NN
development/NN
at/IN
a/DT
genetic/JJ
level/NN
./.
====================
We/PRP
have/VBP
established/VBN
the/DT
essential/JJ
nature/NN
of/IN
GATA-1/NN
during/IN
both/CC
primitive/JJ
and/CC
definitive/JJ
erythropoiesis/NN
./.
====================
By/IN
ablating/VBG
the/DT
expression/NN
of/IN
the/DT
endogenous/JJ
GATA-1/NN
gene/NN
,/,
we/PRP
are/VBP
in/IN
a/DT
position/NN
to/TO
introduce/VB
a/DT
variety/NN
of/IN
constructs/NNS
that/WDT
harbor/VBP
subtle/JJ
modifications/NNS
in/IN
flanking/JJ
or/CC
protein-coding/JJ
sequences/NNS
./.
====================
We/PRP
can/MD
now/RB
study/VB
regulatory/JJ
regions/NNS
and/CC
functional/JJ
domains/NNS
of/IN
the/DT
protein/NN
in/IN
the/DT
context/NN
of/IN
a/DT
true/JJ
erythroid/JJ
environment/NN
,/,
experiments/NNS
that/WDT
have/VBP
not/RB
been/VBN
possible/JJ
heretofore/RB
./.
====================
Although/IN
the/DT
assay/NN
involves/VBZ
the/DT
dramatic/JJ
loss/NN
of/IN
red/JJ
cell/NN
production/NN
,/,
it/PRP
should/MD
be/VB
possible/JJ
to/TO
define/VB
important/JJ
regulatory/JJ
domains/NNS
that/WDT
can/MD
then/RB
be/VB
assayed/VBN
using/VBG
less/RBR
stringent/JJ
systems/NNS
,/,
such/JJ
as/IN
cell-free/JJ
extracts/NNS
for/IN
in/FW
vitro/FW
transcription/NN
./.
====================
The/DT
ideal/JJ
situation/NN
would/MD
be/VB
analyses/NNS
conducted/VBN
in/IN
GATA-1-erythroid/JJ
cells/NNS
./.
====================
However/RB
,/,
these/DT
cells/NNS
have/VBP
been/VBN
impossible/JJ
to/TO
generate/VB
given/VBN
the/DT
requirement/NN
of/IN
GATA-1/NN
for/IN
Epo/NN
receptor/NN
expression/NN
and/CC
red/JJ
cell/NN
viability/NN
(/(
C./NNP
Simon/NNP
and/CC
S./NNP
Orkin/NNP
,/,
unpublished/JJ
observations/NNS
)/)
./.
====================
It/PRP
may/MD
be/VB
possible/JJ
to/TO
produce/VB
such/JJ
cells/NNS
by/IN
first/RB
expressing/VBG
the/DT
Epo/NN
receptor/NN
under/IN
the/DT
influence/NN
of/IN
a/DT
constitutive/JJ
promoter/NN
and/CC
then/RB
targeting/VBG
the/DT
GATA-1/NN
gene/NN
./.
====================
If/IN
GATA-1-red/JJ
cells/NNS
were/VBD
available/JJ
,/,
the/DT
analyses/NNS
would/MD
involve/VB
the/DT
actual/JJ
transcription/NN
of/IN
or/CC
chromatin/NN
structure/NN
surrounding/VBG
the/DT
globin/NN
genes/NNS
./.
====================
Structure-function/JJ
studies/NNS
of/IN
the/DT
GATA-1/NN
protein/NN
could/MD
be/VB
greatly/RB
simplified/VBN
and/CC
a/DT
larger/JJR
number/NN
of/IN
mutants/NNS
studied/VBN
./.
====================
However/RB
,/,
the/DT
ES/NN
cell/NN
system/NN
can/MD
be/VB
used/VBN
as/IN
an/DT
alternative/NN
until/IN
targeted/VBN
erythroleukemia/NN
cells/NNS
become/VBP
available/JJ
./.
====================
Other/JJ
applications/NNS
involve/VBP
the/DT
introduction/NN
of/IN
other/JJ
GATA-binding/JJ
protein/NN
family/NN
members/NNS
to/TO
determine/VB
whether/IN
they/PRP
rescue/VBP
the/DT
mutation/NN
./.
====================
If/IN
they/PRP
can/MD
not/RB
,/,
chimeric/JJ
proteins/NNS
can/MD
be/VB
tested/VBN
to/TO
identify/VB
which/WDT
amino/NN
acids/NNS
distinguish/VBP
the/DT
different/JJ
family/NN
members/NNS
./.
====================
We/PRP
feel/VBP
that/IN
these/DT
experiments/NNS
are/VBP
vital/JJ
to/TO
understanding/VBG
the/DT
function/NN
of/IN
GATA-1/NN
during/IN
erythroid/JJ
ontogeny/NN
./.
====================
How/WRB
does/VBZ
GATA-1/NN
regulate/VB
red/JJ
cell/NN
genes/NNS
like/IN
globin/NN
or/CC
the/DT
Epo/NN
receptor/NN
?/.
Once/IN
we/PRP
identify/VB
the/DT
functional/JJ
domains/NNS
of/IN
the/DT
GATA-binding/JJ
proteins/NNS
,/,
we/PRP
hope/VBP
to/TO
learn/VB
what/WP
proteins/NNS
GATA-1/NN
binds/VBZ
to/TO
in/IN
the/DT
basic/JJ
transcription/NN
machinery/NN
or/CC
in/IN
chromatin/NN
./.
====================
Is/VBZ
GATA-1/NN
necessary/JJ
for/IN
globin/NN
gene/NN
switching/NN
?/.
GATA-1/NN
may/MD
be/VB
modified/VBN
differently/RB
during/IN
development/NN
so/IN
that/IN
the/DT
locus/NN
control/NN
region/NN
can/MD
interact/VB
with/IN
different/JJ
globin/NN
promoters/NNS
./.
====================
We/PRP
may/MD
find/VB
that/IN
one/CD
region/NN
of/IN
the/DT
protein/NN
is/VBZ
required/VBN
for/IN
embryonic/JJ
expression/NN
and/CC
another/DT
for/IN
adult/JJ
globin/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
93135830/CD
====================
TI/LS
-/:
A/DT
human/JJ
putative/JJ
lymphocyte/NN
G0/G1/NN
switch/VBP
gene/NN
homologous/JJ
to/TO
a/DT
rodent/JJ
gene/NN
encoding/VBG
a/DT
zinc-binding/JJ
potential/JJ
transcription/NN
factor/NN
./.
====================
AB/LS
-/:
G0S24/NN
is/VBZ
a/DT
member/NN
of/IN
a/DT
set/NN
of/IN
genes/NNS
(/(
putative/JJ
G0/G1/NN
switch/NN
regulatory/JJ
genes/NNS
)/)
that/WDT
are/VBP
expressed/VBN
transiently/RB
within/IN
1-2/CD
hr/NN
of/IN
the/DT
addition/NN
of/IN
lectin/NN
or/CC
cycloheximide/NN
to/TO
human/JJ
blood/NN
mononuclear/JJ
cells/NNS
./.
====================
Comparison/NN
of/IN
a/DT
full-length/JJ
cDNA/NN
sequence/NN
with/IN
the/DT
corresponding/JJ
genomic/JJ
sequence/NN
reveals/VBZ
an/DT
open/JJ
reading/NN
frame/NN
of/IN
326/CD
amino/NN
acids/NNS
,/,
distributed/VBN
across/IN
two/CD
exons/NNS
./.
====================
Potential/JJ
phosphorylation/NN
sites/NNS
include/VBP
the/DT
sequence/NN
PSPTSPT/NN
,/,
which/WDT
resembles/VBZ
an/DT
RNA/NN
polymerase/NN
II/CD
repeat/NN
reported/VBN
to/TO
be/VB
a/DT
target/NN
of/IN
the/DT
cell/NN
cycle/NN
control/NN
kinase/NN
cdc2/NN
./.
====================
Comparison/NN
of/IN
the/DT
derived/VBN
protein/NN
sequence/NN
with/IN
those/DT
of/IN
rodent/JJ
homologs/NNS
allows/VBZ
classification/NN
into/IN
three/CD
groups/NNS
./.
====================
Group/NN
1/CD
contains/VBZ
G0S24/NN
and/CC
the/DT
rat/NN
and/CC
mouse/NN
TIS11/NN
genes/NNS
(/(
also/RB
known/VBN
as/IN
TTP/NN
,/,
Nup475/NN
,/,
and/CC
Zfp36/NN
)/)
./.
====================
Members/NNS
of/IN
this/DT
group/NN
have/VBP
three/CD
tetraproline/JJ
repeats/NNS
./.
====================
Groups/NNS
1/CD
and/CC
2/CD
have/VBP
a/DT
serine-rich/JJ
region/NN
and/CC
an/DT
"/``
arginine/NN
element/NN
"/''
(/(
RRLPIF/NN
)/)
at/IN
the/DT
carboxyl/NN
terminus/NN
./.
====================
All/DT
groups/NNS
contain/VBP
cysteine-/NN
and/CC
histidine-rich/JJ
putative/JJ
zinc/NN
finger/NN
domains/NNS
and/CC
a/DT
serine-phenylalanine/JJ
"/``
SFS/NNS
"/''
domain/NN
similar/JJ
to/TO
part/NN
of/IN
the/DT
large/JJ
subunit/NN
of/IN
eukaryotic/JJ
RNA/NN
polymerase/NN
II/CD
./.
====================
Comparison/NN
of/IN
group/NN
1/CD
human/JJ
and/CC
mouse/NN
genomic/JJ
sequences/NNS
shows/VBZ
high/JJ
conservation/NN
in/IN
the/DT
5'/JJ
flank/NN
and/CC
exons/NNS
./.
====================
A/DT
CpG/NN
island/NN
suggests/VBZ
expression/NN
in/IN
the/DT
germ/NN
line/NN
./.
====================
G0S24/NN
has/VBZ
potential/JJ
sites/NNS
for/IN
transcription/NN
factors/NNS
in/IN
the/DT
5'/JJ
flank/NN
and/CC
intron/NN
;/:
these/DT
include/VBP
a/DT
serum/NN
response/NN
element/NN
./.
====================
Protein/NN
and/CC
genomic/JJ
sequences/NNS
show/VBP
similarities/NNS
with/IN
those/DT
of/IN
a/DT
variety/NN
of/IN
proteins/NNS
involved/VBN
in/IN
transcription/NN
,/,
suggesting/VBG
that/IN
the/DT
G0S24/NN
product/NN
has/VBZ
a/DT
similar/JJ
role/NN
./.
====================
UI/LS
-/:
93303626/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
lymphoid-specific/JJ
immunoglobulin/NN
mu/NN
heavy/NN
chain/NN
gene/NN
enhancer/NN
by/IN
ETS-domain/JJ
proteins/NNS
./.
====================
AB/LS
-/:
The/DT
enhancer/NN
for/IN
the/DT
immunoglobulin/NN
mu/NN
heavy/NN
chain/NN
gene/NN
(/(
IgH/NN
)/)
activates/VBZ
a/DT
heterologous/JJ
gene/NN
at/IN
the/DT
pre-B/JJ
cell/NN
stage/NN
of/IN
B/NN
lymphocyte/NN
differentiation/NN
./.
====================
A/DT
lymphoid-specific/JJ
element/NN
,/,
microB/NN
,/,
is/VBZ
necessary/JJ
for/IN
enhancer/NN
function/NN
in/IN
pre-B/JJ
cells/NNS
./.
====================
A/DT
microB/NN
binding/NN
protein/NN
is/VBZ
encoded/VBN
by/IN
the/DT
PU.1/Spi-1/NN
proto-oncogene/NN
./.
====================
Another/DT
sequence/NN
element/NN
,/,
microA/NN
,/,
was/VBD
identified/VBN
in/IN
the/DT
mu/NN
enhancer/NN
that/WDT
binds/VBZ
the/DT
product/NN
of/IN
the/DT
ets-1/NN
proto-oncogene/NN
./.
====================
The/DT
microA/NN
motif/NN
was/VBD
required/VBN
for/IN
microB-dependent/JJ
enhancer/NN
activity/NN
,/,
which/WDT
suggests/VBZ
that/IN
a/DT
minimal/JJ
B/NN
cell-specific/JJ
enhancer/NN
is/VBZ
composed/VBN
of/IN
both/CC
the/DT
PU.1/NN
and/CC
Ets-1/NN
binding/NN
sites/NNS
./.
====================
Co-expression/NN
of/IN
both/CC
PU.1/NN
and/CC
Ets-1/NN
in/IN
nonlymphoid/JJ
cells/NNS
trans-activated/JJ
reporter/NN
plasmids/NNS
that/WDT
contained/VBD
the/DT
minimal/JJ
mu/NN
enhancer/NN
./.
====================
These/DT
results/NNS
implicate/VBP
two/CD
members/NNS
of/IN
the/DT
Ets/NN
family/NN
in/IN
the/DT
activation/NN
of/IN
IgH/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
93300929/CD
====================
TI/LS
-/:
1,25-Dihydroxy/NN
vitamin/NN
D3/NN
and/CC
12-O-tetradecanoyl/NN
phorbol-13-acetate/NN
synergistically/RB
induce/VBP
monocytic/JJ
cell/NN
differentiation/NN
:/:
FOS/NN
and/CC
RB/NN
expression/NN
./.
====================
AB/LS
-/:
1,25-dihydroxy/NN
vitamin/NN
D3/NN
and/CC
12-O-tetradecanoyl/NN
phorbol-13-acetate/NN
(/(
TPA/NN
)/)
interact/VBP
synergistically/RB
to/TO
induce/VB
monocytic/JJ
differentiation/NN
of/IN
U937/NN
histiocytic/JJ
lymphoma/NN
cells/NNS
./.
====================
Addition/NN
of/IN
TPA/NN
causes/VBZ
an/DT
otherwise/JJ
ineffective/JJ
dose/NN
of/IN
1,25-dihydroxy/NN
vitamin/NN
D3/NN
to/TO
induce/VB
differentiation/NN
./.
====================
The/DT
induced/VBD
differentiation/NN
depends/VBZ
on/IN
the/DT
simultaneous/JJ
(/(
vs./CC
sequential/JJ
)/)
presence/NN
of/IN
both/DT
agents/NNS
./.
====================
The/DT
kinetics/NNS
of/IN
induced/JJ
differentiation/NN
are/VBP
consistent/JJ
with/IN
a/DT
G1/NN
specific/JJ
cellular/JJ
response/NN
to/TO
initiate/VB
the/DT
metabolic/JJ
cascade/NN
culminating/VBG
in/IN
cell/NN
differentiation/NN
./.
====================
The/DT
induced/VBD
differentiation/NN
occurs/VBZ
with/IN
down-regulation/NN
of/IN
c-fos/NN
protein/NN
and/CC
an/DT
accompanying/VBG
up-regulation/NN
of/IN
RB/NN
protein/NN
expression/NN
,/,
consistent/JJ
with/IN
a/DT
possible/JJ
need/NN
for/IN
up-regulated/JJ
RB/NN
expression/NN
to/TO
maintain/VB
a/DT
given/JJ
differentiated/VBN
phenotype/NN
and/CC
suppress/VB
transcriptional/JJ
activators/NNS
that/WDT
might/MD
typically/RB
be/VB
associated/VBN
with/IN
proliferation/NN
./.
====================
UI/LS
-/:
93279468/CD
====================
TI/LS
-/:
Ectopic/JJ
expression/NN
of/IN
a/DT
conditional/JJ
GATA-2/estrogen/NN
receptor/NN
chimera/NN
arrests/VBZ
erythroid/JJ
differentiation/NN
in/IN
a/DT
hormone-dependent/JJ
manner/NN
./.
====================
AB/LS
-/:
The/DT
GATA/NN
factors/NNS
are/VBP
a/DT
family/NN
of/IN
transcriptional/JJ
regulatory/JJ
proteins/NNS
in/IN
eukaryotes/NNS
that/WDT
share/VBP
extensive/JJ
homology/NN
in/IN
their/PRP$
DNA-binding/JJ
domains/NNS
./.
====================
One/CD
enigmatic/JJ
aspect/NN
of/IN
GATA/NN
factor/NN
expression/NN
is/VBZ
that/IN
several/JJ
GATA/NN
proteins/NNS
,/,
which/WDT
ostensibly/RB
share/VBP
the/DT
same/JJ
DNA-binding/JJ
site/NN
specificity/NN
,/,
are/VBP
coexpressed/VBN
in/IN
erythroid/JJ
cells/NNS
./.
====================
To/TO
elucidate/VB
the/DT
roles/NNS
of/IN
individual/JJ
GATA/NN
factors/NNS
in/IN
erythropoiesis/NN
,/,
conditional/JJ
alleles/NNS
of/IN
GATA-1/NN
,/,
GATA-2/NN
,/,
and/CC
GATA-3/NN
were/VBD
prepared/VBN
by/IN
fusing/VBG
each/DT
of/IN
the/DT
factors/NNS
to/TO
the/DT
hormone-binding/JJ
domain/NN
of/IN
the/DT
human/JJ
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
./.
====================
These/DT
GATA/ER/NN
chimeric/JJ
factors/NNS
were/VBD
shown/VBN
to/TO
be/VB
hormone-inducible/JJ
trans-activating/JJ
proteins/NNS
in/IN
transient/JJ
transfection/NN
assays/NNS
./.
====================
When/WRB
stably/RB
introduced/VBN
into/IN
primary/JJ
erythroblasts/NNS
or/CC
conditionally/RB
transformed/VBN
erythroid/JJ
progenitors/NNS
cells/NNS
,/,
exogenous/JJ
GATA-2/ER/NN
promoted/VBD
proliferation/NN
and/CC
inhibited/VBD
terminal/JJ
differentiation/NN
in/IN
an/DT
estrogen-dependent/JJ
manner/NN
./.
====================
These/DT
phenotypic/JJ
effects/NNS
are/VBP
specifically/RB
attributable/JJ
to/TO
the/DT
action/NN
of/IN
ectopically/RB
expressed/VBN
GATA-2/ER/NN
because/IN
erythroblasts/NNS
expressing/VBG
exogenous/JJ
GATA-2/NN
are/VBP
constitutively/RB
arrested/VBN
in/IN
differentiation/NN
and/CC
because/IN
erythroid/JJ
progenitors/NNS
expressing/VBG
either/CC
Gal/ER/NN
or/CC
GATA-3/ER/NN
do/VBP
not/RB
display/VB
a/DT
hormone-responsive/JJ
block/NN
in/IN
differentiation/NN
./.
====================
Thus/RB
,/,
the/DT
GATA-2/NN
transcription/NN
factor/NN
appears/VBZ
to/TO
play/VB
a/DT
role/NN
in/IN
regulating/VBG
the/DT
self-renewal/JJ
capacity/NN
of/IN
early/JJ
erythroid/JJ
progenitor/NN
cells/NNS
./.
====================
UI/LS
-/:
93258811/CD
====================
TI/LS
-/:
Mice/NNS
deficient/NN
for/IN
the/DT
55/CD
kd/JJ
tumor/NN
necrosis/NN
factor/NN
receptor/NN
are/VBP
resistant/JJ
to/TO
endotoxic/JJ
shock/NN
,/,
yet/RB
succumb/VBP
to/TO
L./FW
monocytogenes/NNS
infection/NN
./.
====================
AB/LS
-/:
The/DT
multiple/JJ
biological/JJ
activities/NNS
of/IN
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
)/)
are/VBP
mediated/VBN
by/IN
two/CD
distinct/JJ
cell/NN
surface/NN
receptors/NNS
of/IN
55/CD
kd/NNS
(/(
TNFRp55/NN
)/)
and/CC
75/CD
kd/NN
(/(
TNFRp75/NN
)/)
./.
====================
Using/VBG
gene/NN
targeting/NN
,/,
we/PRP
generated/VBD
a/DT
TNFRp55-deficient/JJ
mouse/NN
strain/NN
./.
====================
Cells/NNS
from/IN
TNFRp55-/-mutant/JJ
mice/NNS
lack/VBP
expression/NN
of/IN
TNFRp55/NN
but/CC
display/VBP
normal/JJ
numbers/NNS
of/IN
high/JJ
affinity/NN
TNFRp75/NN
molecules/NNS
./.
====================
Thymocyte/NN
development/NN
and/CC
lymphocyte/NN
populations/NNS
are/VBP
unaltered/JJ
,/,
and/CC
clonal/JJ
deletion/NN
of/IN
potentially/RB
self-reactive/JJ
T/NN
cells/NNS
is/VBZ
not/RB
impaired/JJ
./.
====================
However/RB
,/,
TNF/NN
signaling/NN
is/VBZ
largely/RB
abolished/VBN
,/,
as/IN
judged/VBN
by/IN
the/DT
failure/NN
of/IN
TNF/NN
to/TO
induce/VB
NF-kappa/NN
B/NN
in/IN
T/NN
lymphocytes/NNS
from/IN
TNFRp55-deficient/JJ
mice/NNS
./.
====================
The/DT
loss/NN
of/IN
TNFRp55/NN
function/NN
renders/VBZ
mice/NNS
resistant/JJ
to/TO
lethal/JJ
dosages/NNS
of/IN
either/CC
lipopolysaccharides/NNS
or/CC
S./FW
aureus/FW
enterotoxin/NN
B/NN
./.
====================
In/IN
contrast/NN
,/,
TNFRp55-deficient/JJ
mice/NNS
are/VBP
severely/RB
impaired/JJ
to/TO
clear/VB
L./FW
monocytogenes/FW
and/CC
readily/RB
succumb/VBP
to/TO
infection/NN
./.
====================
Thus/RB
,/,
the/DT
55/CD
kd/NN
TNFR/NN
plays/VBZ
a/DT
decisive/JJ
role/NN
in/IN
the/DT
host/NN
's/POS
defense/NN
against/IN
microorganisms/NNS
and/CC
their/PRP$
pathogenic/JJ
factors/NNS
./.
====================
UI/LS
-/:
93224719/CD
====================
TI/LS
-/:
Costimulation/NN
of/IN
peripheral/JJ
blood/NN
T/NN
cell/NN
activation/NN
by/IN
human/JJ
endothelial/JJ
cells/NNS
./.
====================
Enhanced/VBD
IL-2/NN
transcription/NN
correlates/VBZ
with/IN
increased/VBN
c-fos/NN
synthesis/NN
and/CC
increased/VBN
Fos/NN
content/NN
of/IN
AP-1/NN
./.
====================
AB/LS
-/:
Endothelial/JJ
cells/NNS
(/(
EC/NN
)/)
act/VBP
as/IN
APC/NN
for/IN
resting/VBG
PBL/NN
in/FW
vitro/FW
,/,
and/CC
may/MD
have/VB
important/JJ
roles/NNS
in/FW
vivo/FW
in/IN
the/DT
pathogenesis/NN
of/IN
allograft/NN
rejection/NN
and/CC
delayed/VBN
hypersensitivity/NN
./.
====================
We/PRP
previously/RB
reported/VBD
that/IN
human/JJ
umbilical/JJ
vein/NN
EC/NN
provide/VBP
costimulatory/JJ
signals/NNS
to/TO
PHA-stimulated/JJ
PBL/NN
via/IN
CD2/NN
:/:
lymphocyte/NN
function-associated/JJ
Ag-3/NN
and/CC
an/DT
unidentified/JJ
ligand/NN
pair/NN
,/,
resulting/VBG
in/IN
a/DT
three-/CD
to/TO
eight-fold/JJ
enhancement/NN
of/IN
IL-2/NN
production/NN
./.
====================
The/DT
physiologic/JJ
relevance/NN
of/IN
this/DT
increase/NN
was/VBD
demonstrated/VBN
by/IN
the/DT
proliferative/JJ
advantage/NN
provided/VBN
by/IN
EC/NN
to/TO
PBL/NN
suboptimally/RB
stimulated/VBN
with/IN
mAb/NN
OKT3/NN
./.
====================
We/PRP
now/RB
report/VBP
that/IN
EC/NN
costimulation/NN
causes/VBZ
increased/VBN
levels/NNS
of/IN
IL-2/NN
mRNA/NN
as/IN
a/DT
result/NN
of/IN
increased/VBN
IL-2/NN
transcription/NN
in/IN
PBL/NN
./.
====================
We/PRP
therefore/RB
examined/VBD
the/DT
effects/NNS
of/IN
EC/NN
on/IN
T/NN
cell/NN
nuclear/JJ
factors/NNS
known/VBN
to/TO
regulate/VB
IL-2/NN
transcription/NN
,/,
including/VBG
c-jun/NN
and/CC
c-fos-two/NN
components/NNS
of/IN
the/DT
transcription/NN
factor/NN
AP-1/NN
,/,
NFAT/NN
,/,
and/CC
others/NNS
./.
====================
PBL/NN
constitutively/RB
express/VBP
c-jun/NN
transcripts/NNS
,/,
and/CC
the/DT
level/NN
of/IN
c-jun/NN
mRNA/NN
is/VBZ
not/RB
altered/VBN
by/IN
PHA/NN
activation/NN
in/IN
the/DT
absence/NN
or/CC
presence/NN
of/IN
EC/NN
./.
====================
In/IN
contrast/NN
,/,
c-fos/NN
mRNA/NN
is/VBZ
absent/JJ
from/IN
resting/VBG
T/NN
cells/NNS
and/CC
is/VBZ
induced/VBN
on/IN
PHA/NN
activation/NN
./.
====================
EC/NN
alone/RB
do/VBP
not/RB
induce/VB
c-fos/NN
mRNA/NN
but/CC
augment/VBP
the/DT
level/NN
of/IN
c-fos/NN
mRNA/NN
in/IN
PHA-activated/JJ
T/NN
cells/NNS
by/IN
3-/CD
to/TO
10-fold/RB
./.
====================
This/DT
effect/NN
is/VBZ
largely/RB
independent/JJ
of/IN
the/DT
CD2/NN
:/:
lymphocyte/NN
function-/NN
associated/VBN
Ag-3/NN
pathway/NN
./.
====================
Gel-shift/NN
analysis/NN
reveals/VBZ
the/DT
constitutive/JJ
presence/NN
of/IN
nuclear/JJ
factors/NNS
in/IN
resting/VBG
PBL/NN
that/WDT
bind/VBP
to/TO
the/DT
proximal/JJ
AP-1/NN
site/NN
of/IN
the/DT
IL-2/NN
promoter/NN
and/CC
that/IN
contain/VBP
immunoreactive/JJ
c-Jun/NN
but/CC
not/RB
c-Fos/NN
protein/NN
./.
====================
In/IN
contrast/NN
,/,
AP-1/NN
from/IN
PHA-activated/JJ
cells/NNS
contains/VBZ
c-Jun/NN
and/CC
low/JJ
levels/NNS
of/IN
c-Fos/NN
./.
====================
Strikingly/RB
,/,
costimulation/NN
with/IN
EC/NN
results/VBZ
in/IN
a/DT
dramatic/JJ
increase/NN
(/(
up/NN
to/TO
15-fold/JJ
)/)
in/IN
the/DT
c-Fos/NN
content/NN
of/IN
AP-1/NN
./.
====================
Levels/NNS
of/IN
other/JJ
nuclear/JJ
factors/NNS
involved/VBN
in/IN
IL-2/NN
regulation/NN
were/VBD
not/RB
altered/VBN
by/IN
EC/NN
,/,
although/IN
NFAT-DNA/NN
complexes/NNS
migrated/VBD
at/IN
a/DT
slightly/RB
different/JJ
mobility/NN
./.
====================
In/IN
summary/NN
,/,
our/PRP$
data/NNS
suggest/VBP
that/IN
changes/NNS
in/IN
the/DT
composition/NN
of/IN
transcription/NN
factor/NN
AP-1/NN
is/VBZ
a/DT
key/JJ
molecular/JJ
mechanism/NN
for/IN
increasing/VBG
IL-2/NN
transcription/NN
and/CC
may/MD
underlie/VB
the/DT
phenomenon/NN
of/IN
costimulation/NN
by/IN
EC/NN
./.
====================
UI/LS
-/:
93204975/CD
====================
TI/LS
-/:
Transcriptional/JJ
activation/NN
of/IN
human/JJ
zeta/NN
2/CD
globin/NN
promoter/NN
by/IN
the/DT
alpha/NN
globin/NN
regulatory/JJ
element/NN
(/(
HS-40/NN
)/)
:/:
functional/JJ
role/NN
of/IN
specific/JJ
nuclear/JJ
factor-DNA/JJ
complexes/NNS
./.
====================
AB/LS
-/:
We/PRP
studied/VBD
the/DT
functional/JJ
interaction/NN
between/IN
human/JJ
embryonic/JJ
zeta/NN
2/CD
globin/NN
promoter/NN
and/CC
the/DT
alpha/NN
globin/NN
regulatory/JJ
element/NN
(/(
HS-40/NN
)/)
located/JJ
40/CD
kb/NN
upstream/RB
of/IN
the/DT
zeta/NN
2/CD
globin/NN
gene/NN
./.
====================
It/PRP
was/VBD
shown/VBN
by/IN
transient/JJ
expression/NN
assay/NN
that/IN
HS-40/NN
behaved/VBD
as/IN
an/DT
authentic/JJ
enhancer/NN
for/IN
high-level/JJ
zeta/NN
2/CD
globin/NN
promoter/NN
activity/NN
in/IN
K562/NN
cells/NNS
,/,
an/DT
erythroid/JJ
cell/NN
line/NN
of/IN
embryonic/JJ
and/or/CC
fetal/JJ
origin/NN
./.
====================
Although/IN
sequences/NNS
located/JJ
between/IN
-559/CD
and/CC
-88/CD
of/IN
the/DT
zeta/NN
2/CD
globin/NN
gene/NN
were/VBD
dispensable/JJ
for/IN
its/PRP$
expression/NN
on/IN
enhancerless/NN
plasmids/NNS
,/,
they/PRP
were/VBD
required/VBN
for/IN
the/DT
HS-40/NN
enhancer-mediated/JJ
activity/NN
of/IN
the/DT
zeta/NN
2/CD
globin/NN
promoter/NN
./.
====================
Site-directed/JJ
mutagenesis/NN
demonstrated/VBD
that/IN
this/DT
HS-40/NN
enhancer-zeta/NN
2/CD
globin/NN
promoter/NN
interaction/NN
is/VBZ
mediated/VBN
by/IN
the/DT
two/CD
GATA-1/NN
factor/NN
binding/NN
motifs/NNS
located/JJ
at/IN
-230/CD
and/CC
-104/CD
,/,
respectively/RB
./.
====================
The/DT
functional/JJ
domains/NNS
of/IN
HS-40/NN
were/VBD
also/RB
mapped/VBN
./.
====================
Bal/NN
31/CD
deletion/NN
mapping/VBG
data/NNS
suggested/VBD
that/IN
one/CD
GATA-1/NN
motif/NN
,/,
one/CD
GT/NN
motif/NN
,/,
and/CC
two/CD
NF-E2/AP1/NN
motifs/NNS
together/RB
formed/VBD
the/DT
functional/JJ
core/NN
of/IN
HS-40/NN
in/IN
the/DT
erythroid-specific/JJ
activation/NN
of/IN
the/DT
zeta/NN
2/CD
globin/NN
promoter/NN
./.
====================
Site-directed/JJ
mutagenesis/NN
further/RBR
demonstrated/VBD
that/IN
the/DT
enhancer/NN
function/NN
of/IN
one/CD
of/IN
the/DT
two/CD
NF-E2/AP1/NN
motifs/NNS
of/IN
HS-40/NN
is/VBZ
mediated/VBN
through/IN
its/PRP$
binding/NN
to/TO
NF-E2/NN
but/CC
not/RB
AP1/NN
transcription/NN
factor/NN
./.
====================
Finally/RB
,/,
we/PRP
did/VBD
genomic/JJ
footprinting/NN
of/IN
the/DT
HS-40/NN
enhancer/NN
region/NN
in/IN
K562/NN
cells/NNS
,/,
adult/JJ
nucleated/JJ
erythroblasts/NNS
,/,
and/CC
different/JJ
nonerythroid/JJ
cells/NNS
./.
====================
All/DT
sequence/NN
motifs/NNS
within/IN
the/DT
functional/JJ
core/NN
of/IN
HS-40/NN
,/,
as/IN
mapped/VBN
by/IN
transient/JJ
expression/NN
analysis/NN
,/,
appeared/VBD
to/TO
bind/VB
a/DT
nuclear/JJ
factor/NN
(/(
s/NNS
)/)
in/IN
living/VBG
K562/NN
cells/NNS
but/CC
not/RB
in/IN
nonerythroid/JJ
cells/NNS
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
only/RB
one/CD
of/IN
the/DT
apparently/RB
nonfunctional/JJ
sequence/NN
motifs/NNS
was/VBD
bound/VBN
with/IN
factors/NNS
in/FW
vivo/FW
./.
====================
In/IN
comparison/NN
to/TO
K562/NN
,/,
nucleated/JJ
erythroblasts/NNS
from/IN
adult/JJ
human/JJ
bone/NN
marrow/NN
exhibited/VBD
a/DT
similar/JJ
but/CC
nonidentical/JJ
pattern/NN
of/IN
nuclear/JJ
factor/NN
binding/NN
in/FW
vivo/FW
at/IN
the/DT
HS-40/NN
region/NN
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
transcriptional/JJ
activation/NN
of/IN
human/JJ
embryonic/JJ
zeta/NN
2/CD
globin/NN
gene/NN
and/CC
the/DT
fetal/adult/JJ
alpha/NN
globin/NN
genes/NNS
is/VBZ
mediated/VBN
by/IN
erythroid/JJ
cell-specific/JJ
and/CC
developmental/JJ
stage-specific/JJ
nuclear/JJ
factor-DNA/NN
complexes/NNS
which/WDT
form/VBP
at/IN
the/DT
enhancer/NN
(/(
HS-40/NN
)/)
and/CC
the/DT
globin/NN
promoters/NNS
./.
====================
UI/LS
-/:
93194832/CD
====================
TI/LS
-/:
Transcriptional/JJ
regulation/NN
of/IN
the/DT
pyruvate/NN
kinase/NN
erythroid-specific/JJ
promoter/NN
./.
====================
AB/LS
-/:
Mammal/JJ
pyruvate/NN
kinases/NNS
are/VBP
encoded/VBN
by/IN
two/CD
genes/NNS
./.
====================
The/DT
L/NN
gene/NN
produces/VBZ
the/DT
erythroid/JJ
(/(
R-PK/NN
)/)
or/CC
the/DT
hepatic/JJ
(/(
L-PK/JJ
)/)
isozymes/NNS
by/IN
the/DT
alternative/JJ
use/NN
of/IN
two/CD
promoters/NNS
./.
====================
We/PRP
report/VBP
the/DT
characterization/NN
of/IN
the/DT
cis-/JJ
and/CC
trans-acting/JJ
elements/NNS
involved/VBN
in/IN
the/DT
tissue-specific/JJ
activity/NN
of/IN
the/DT
L/NN
gene/NN
erythroid/JJ
promoter/NN
./.
====================
A/DT
R-PK/NN
DNA/NN
fragment/NN
extending/VBG
from/IN
-870/CD
to/TO
+54/CD
relative/JJ
to/TO
the/DT
cap/NN
site/NN
confers/VBZ
erythroid/JJ
specificity/NN
to/TO
a/DT
reporter/NN
gene/NN
./.
====================
Within/IN
this/DT
region/NN
,/,
we/PRP
define/VBP
a/DT
minimal/JJ
promoter/NN
(/(
-62/CD
to/TO
+54/CD
)/)
that/WDT
displays/VBZ
erythroid-specific/JJ
activity/NN
and/CC
contains/VBZ
two/CD
DNA/NN
binding/NN
sites/NNS
./.
====================
One/CD
,/,
located/JJ
at/IN
-50/CD
,/,
binds/VBZ
members/NNS
of/IN
the/DT
CCACC/Sp1/NN
family/NN
and/CC
the/DT
other/JJ
,/,
located/JJ
at/IN
-20/CD
,/,
binds/VBZ
the/DT
erythroid/JJ
factor/NN
GATA-1/NN
./.
====================
Although/IN
the/DT
-20/CD
GATA/NN
binding/NN
site/NN
(/(
AGATAA/NN
)/)
is/VBZ
also/RB
a/DT
potential/JJ
TFIID/NN
binding/NN
site/NN
,/,
it/PRP
does/VBZ
not/RB
bind/VB
TFIID/NN
./.
====================
Furthermore/RB
,/,
the/DT
substitution/NN
of/IN
this/DT
GATA/NN
binding/NN
site/NN
by/IN
a/DT
canonical/JJ
TFIID/NN
binding/NN
site/NN
suppresses/VBZ
the/DT
promoter/NN
activity/NN
./.
====================
Mutations/NNS
and/CC
deletions/NNS
of/IN
both/DT
sites/NNS
indicate/VBP
that/IN
only/RB
the/DT
association/NN
of/IN
CCACC/Sp1/NN
and/CC
GATA/NN
binding/NN
sites/NNS
can/MD
drive/VB
efficient/JJ
and/CC
tissue-specific/JJ
expression/NN
of/IN
this/DT
R-PK/NN
minimal/JJ
promoter/NN
./.
====================
Finally/RB
,/,
by/IN
co-transfection/NN
experiments/NNS
,/,
we/PRP
study/VBD
the/DT
elements/NNS
involved/VBN
in/IN
the/DT
hGATA-1/NN
transactivation/NN
of/IN
the/DT
R-PK/NN
promoter/NN
in/IN
HeLa/NN
cells/NNS
./.
====================
UI/LS
-/:
93171603/CD
====================
TI/LS
-/:
Protease/NN
treatment/NN
of/IN
nuclear/JJ
extracts/NNS
distinguishes/VBZ
between/IN
class/NN
II/CD
MHC/NN
X1/NN
box/NN
DNA-binding/JJ
proteins/NNS
in/IN
wild-type/JJ
and/CC
class/NN
II-deficient/JJ
B/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
X/NN
box/NN
region/NN
is/VBZ
critical/JJ
for/IN
directing/VBG
the/DT
expression/NN
of/IN
class/NN
II/CD
major/JJ
histocompatibility/NN
complex/NN
genes/NNS
in/IN
B/NN
lymphocytes/NNS
./.
====================
Although/IN
several/JJ
class/NN
II/CD
promoter-specific/JJ
DNA/NN
binding/NN
factors/NNS
have/VBP
been/VBN
described/VBN
,/,
only/RB
the/DT
X/NN
box/NN
region/NN
factor/NN
,/,
RFX/NN
,/,
shows/VBZ
a/DT
genetic/JJ
correlation/NN
with/IN
class/NN
II/CD
expression/NN
,/,
being/VBG
deficient/JJ
in/IN
some/DT
B/NN
cell/NN
lines/NNS
derived/VBN
from/IN
patients/NNS
with/IN
class/NN
II-deficient/JJ
congenital/JJ
immunodeficiency/NN
./.
====================
To/TO
further/RB
evaluate/VB
the/DT
role/NN
of/IN
X/NN
box/NN
DNA-binding/JJ
proteins/NNS
in/IN
class/NN
II/CD
gene/NN
expression/NN
,/,
the/DT
role/NN
of/IN
the/DT
X/NN
box/NN
region/NN
was/VBD
examined/VBN
in/IN
both/DT
class/NN
II-positive/JJ
and/CC
-negative/JJ
lymphoid/JJ
cells/NNS
./.
====================
In/IN
addition/NN
to/TO
the/DT
wild-type/JJ
B/NN
cell/NN
line/NN
Raji/NN
,/,
two/CD
class/NN
II/CD
transcriptional/JJ
mutant/JJ
cell/NN
lines/NNS
,/,
SJO/NN
and/CC
RJ2.2.5/NN
,/,
and/CC
Jurkat/NN
,/,
a/DT
class/NN
II/CD
negative/JJ
T/NN
cell/NN
line/NN
,/,
were/VBD
examined/VBN
./.
====================
In/IN
contrast/NN
to/TO
wild-type/JJ
B/NN
cells/NNS
,/,
neither/DT
of/IN
the/DT
class/NN
II/CD
mutant/JJ
cell/NN
lines/NNS
could/MD
use/VB
the/DT
X/NN
box/NN
region/NN
to/TO
direct/VB
the/DT
expression/NN
of/IN
a/DT
transiently/RB
transfected/VBN
reporter/NN
gene/NN
,/,
indicating/VBG
that/IN
the/DT
X/NN
box-dependent/JJ
transcriptional/JJ
pathway/NN
is/VBZ
defective/JJ
in/IN
these/DT
cells/NNS
./.
====================
The/DT
binding/NN
activity/NN
of/IN
the/DT
X1/NN
box/NN
DNA-binding/JJ
protein/NN
RFX/NN
was/VBD
examined/VBN
and/CC
found/VBN
to/TO
be/VB
present/JJ
in/IN
wild-type/JJ
B/NN
cells/NNS
and/CC
the/DT
mutant/JJ
RJ2.2.5/NN
but/CC
was/VBD
absent/JJ
in/IN
SJO/NN
and/CC
Jurkat/NN
./.
====================
However/RB
,/,
other/JJ
X1/NN
box-specific/JJ
activities/NNS
were/VBD
detected/VBN
in/IN
all/DT
these/DT
cell/NN
lines/NNS
./.
====================
To/TO
determine/VB
whether/IN
these/DT
different/JJ
X1/NN
box/NN
activities/NNS
represented/VBD
distinct/JJ
DNA/NN
binding/NN
proteins/NNS
or/CC
multimeric/JJ
forms/NNS
of/IN
the/DT
same/JJ
factor/NN
(/(
s/NNS
)/)
,/,
protease/NN
treatment/NN
of/IN
the/DT
crude/JJ
nuclear/JJ
extracts/NNS
followed/VBN
by/IN
DNA-binding/JJ
assays/NNS
were/VBD
carried/VBN
out/RP
and/CC
demonstrated/VBD
that/IN
B/NN
cell/NN
extracts/NNS
contain/VBP
at/IN
least/JJS
two/CD
X1-specific/JJ
factors/NNS
./.
====================
One/CD
of/IN
these/DT
cleaved/VBN
products/NNS
(/(
band/NN
1/CD
pk/NN
)/)
correlates/VBZ
with/IN
RFX/NN
activity/NN
./.
====================
A/DT
similar/JJ
comparison/NN
with/IN
protease-treated/JJ
extracts/NNS
prepared/VBN
from/IN
Jurkat/NN
cells/NNS
demonstrated/VBD
the/DT
presence/NN
of/IN
the/DT
band/NN
1pk/NN
activity/NN
despite/IN
an/DT
absence/NN
of/IN
the/DT
native/JJ
RFX/NN
activity/NN
./.
====================
In/IN
contrast/NN
,/,
protease/NN
treatment/NN
and/CC
analysis/NN
of/IN
SJO/NN
extracts/NNS
showed/VBD
no/DT
detectable/JJ
levels/NNS
of/IN
the/DT
band/NN
1pk/NN
activity/NN
./.
====================
These/DT
results/NNS
demonstrate/VBP
that/IN
multiple/JJ
X1/NN
box-specific/JJ
DNA-binding/JJ
activities/NNS
exist/VBP
in/IN
all/DT
lymphoid/JJ
cells/NNS
,/,
but/CC
the/DT
presence/NN
of/IN
an/DT
actively/RB
binding/NN
RFX/NN
species/NNS
correlates/VBZ
with/IN
class/NN
II/CD
transcription/NN
./.
====================
UI/LS
-/:
93124567/CD
====================
TI/LS
-/:
Human/JJ
immunodeficiency/NN
viruses/NNS
containing/VBG
heterologous/JJ
enhancer/promoters/NNS
are/VBP
replication/NN
competent/JJ
and/CC
exhibit/VBP
different/JJ
lymphocyte/NN
tropisms/NNS
./.
====================
AB/LS
-/:
The/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
contains/VBZ
binding/VBG
sites/NNS
for/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
and/CC
the/DT
constitutively/RB
expressed/VBN
transcription/NN
factor/NN
Sp1/NN
,/,
both/DT
of/IN
which/WDT
are/VBP
highly/RB
conserved/VBN
in/IN
HIV/NN
and/CC
simian/JJ
immunodeficiency/NN
virus/NN
isolates/NNS
./.
====================
To/TO
delineate/VB
the/DT
effects/NNS
of/IN
these/DT
motifs/NNS
on/IN
the/DT
replicative/JJ
capacity/NN
of/IN
HIV/NN
and/CC
to/TO
explore/VB
the/DT
possibility/NN
of/IN
extending/VBG
the/DT
virus/NN
host/NN
range/NN
,/,
known/VBN
heterologous/JJ
enhancer/promoters/NNS
were/VBD
inserted/VBN
into/IN
the/DT
HIV-1/NN
LTR/NN
in/IN
place/NN
of/IN
the/DT
NF-kappa/NN
B/NN
and/CC
Sp1/NN
binding/NN
sites/NNS
./.
====================
The/DT
effects/NNS
of/IN
these/DT
substitutions/NNS
on/IN
viral/JJ
replication/NN
in/IN
transfected/VBN
HeLa/NN
cells/NNS
and/CC
on/IN
HIV/NN
infection/NN
of/IN
human/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
or/CC
continuous/JJ
T-leukemia/NN
cell/NN
lines/NNS
were/VBD
evaluated/VBN
./.
====================
HIVs/NN
in/IN
which/WDT
the/DT
NF-/NN
kappa/NN
B/Sp1/NN
enhancer/NN
plus/CC
the/DT
downstream/JJ
TATA/NN
element/NN
were/VBD
replaced/VBN
with/IN
heterologous/JJ
enhancer/promoters/NNS
were/VBD
also/RB
constructed/VBN
./.
====================
Viruses/NNS
containing/VBG
the/DT
human/JJ
cytomegalovirus/NN
immediate-early/JJ
enhancer/NN
exhibited/VBD
infectious/JJ
kinetics/NNS
similar/JJ
to/TO
that/DT
of/IN
wild-type/JJ
HIV/NN
in/IN
activated/VBN
human/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
and/CC
AA2/NN
cells/NNS
but/CC
replicated/VBD
less/RBR
efficiently/RB
in/IN
H9/NN
and/CC
CEM/NN
cells/NNS
./.
====================
These/DT
studies/NNS
indicate/VBP
that/IN
heterologous/JJ
enhancer/NN
elements/NNS
are/VBP
capable/JJ
of/IN
restoring/VBG
Tat/NN
responsiveness/NN
to/TO
the/DT
HIV/NN
LTR/NN
in/IN
the/DT
context/NN
of/IN
directing/VBG
reporter/NN
gene/NN
expression/NN
as/RB
well/RB
as/IN
in/IN
the/DT
production/NN
of/IN
infectious/JJ
progeny/NN
virions/NNS
./.
====================
UI/LS
-/:
93126354/CD
====================
TI/LS
-/:
Tyrosine/NN
phosphorylation/NN
is/VBZ
a/DT
mandatory/JJ
proximal/JJ
step/NN
in/IN
radiation-induced/JJ
activation/NN
of/IN
the/DT
protein/NN
kinase/NN
C/NN
signaling/NN
pathway/NN
in/IN
human/JJ
B-/NN
lymphocyte/NN
precursors/NNS
[/(
published/VBN
erratum/NN
appears/VBZ
in/IN
Proc/NNP
Natl/NNP
Acad/NNP
Sci/NNP
U/NNP
S/NNP
A/NNP
1993/CD
Apr/NNP
15/CD
;/:
90/CD
(/(
8/CD
)/)
:/:
3775/CD
]/)
====================
AB/LS
-/:
Ionizing/VBG
radiation/NN
triggers/VBZ
a/DT
signal/NN
in/IN
human/JJ
B-lymphocyte/NN
precursors/NNS
that/WDT
is/VBZ
intimately/RB
linked/VBN
to/TO
an/DT
active/JJ
protein-tyrosine/NN
kinase/NN
regulatory/JJ
pathway/NN
./.
====================
We/PRP
show/VBP
that/IN
in/IN
B-lymphocyte/NN
precursors/NNS
,/,
irradiation/NN
with/IN
gamma-rays/NNS
leads/VBZ
to/TO
(/(
i/LS
)/)
stimulation/NN
of/IN
phosphatidylinositol/NN
turnover/NN
;/:
(/(
ii/LS
)/)
downstream/JJ
activation/NN
by/IN
covalent/JJ
modification/NN
of/IN
multiple/JJ
serine-specific/JJ
protein/NN
kinases/NNS
,/,
including/VBG
protein/NN
kinase/NN
C/NN
;/:
and/CC
(/(
iii/LS
)/)
activation/NN
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
./.
====================
All/DT
of/IN
the/DT
radiation-induced/JJ
signals/NNS
were/VBD
effectively/RB
prevented/VBN
by/IN
the/DT
protein-tyrosine/NN
kinase/NN
inhibitors/NNS
genistein/NN
and/CC
herbimycin/NN
A/NN
./.
====================
Thus/RB
,/,
tyrosine/NN
phosphorylation/NN
is/VBZ
an/DT
important/JJ
and/CC
perhaps/RB
mandatory/JJ
proximal/JJ
step/NN
in/IN
the/DT
activation/NN
of/IN
the/DT
protein/NN
kinase/NN
C/NN
signaling/NN
cascade/NN
in/IN
human/JJ
B-lymphocyte/NN
precursors/NNS
./.
====================
Our/PRP$
report/VBP
expands/NNS
current/JJ
knowledge/NN
of/IN
the/DT
radiation-induced/JJ
signaling/NN
cascade/NN
by/IN
clarifying/VBG
the/DT
chronological/JJ
sequence/NN
of/IN
biochemical/JJ
events/NNS
that/WDT
follow/VBP
irradiation/NN
./.
====================
UI/LS
-/:
97218353/CD
====================
TI/LS
-/:
Detection/NN
of/IN
adenovirus/NN
DNA/NN
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
by/IN
polymerase/NN
chain/NN
reaction/NN
assay/NN
./.
====================
AB/LS
-/:
Adenovirus/NN
can/MD
establish/VB
persistent/JJ
infections/NNS
which/WDT
may/MD
reactivate/VB
and/CC
cause/VB
disease/NN
in/IN
immunocompromised/JJ
hosts/NNS
./.
====================
Lymphocytes/NNS
have/VBP
been/VBN
postulated/VBN
to/TO
serve/VB
as/IN
a/DT
site/NN
of/IN
adenoviral/JJ
persistence/NN
based/VBN
upon/IN
the/DT
ability/NN
to/TO
isolate/VB
adenovirus/NN
from/IN
tonsils/NNS
and/CC
to/TO
detect/VB
adenovirus/NN
DNA/NN
by/IN
Southern/NN
blot/NN
hybridization/NN
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NN
)/)
./.
====================
To/TO
test/VB
this/DT
hypothesis/NN
,/,
a/DT
more/RBR
sensitive/JJ
and/CC
specific/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
assay/NN
was/VBD
developed/VBN
to/TO
detect/VB
adenovirus/NN
DNA/NN
./.
====================
Two/CD
sets/NNS
of/IN
nested/VBD
primers/NNS
were/VBD
designed/VBN
to/TO
conserved/VBN
sequences/NNS
in/IN
the/DT
adenovirus/NN
E1A/NN
and/CC
hexon/NN
genes/NNS
./.
====================
The/DT
E1A/NN
and/CC
hexon/NN
primers/NNS
amplified/VBD
DNA/NN
from/IN
representative/JJ
adenoviral/JJ
serotypes/NNS
in/IN
all/DT
six/CD
adenoviral/JJ
groups/NNS
(/(
A-F/NNS
)/)
./.
====================
Both/DT
primers/NNS
detected/VBD
a/DT
single/JJ
copy/NN
of/IN
the/DT
adenovirus/NN
type/NN
2/CD
genome/NN
but/CC
were/VBD
less/RBR
sensitive/JJ
for/IN
the/DT
group/NN
B/NN
type/NN
35/CD
./.
====================
None/NN
of/IN
33/CD
PBMC/NN
specimens/NNS
from/IN
healthy/JJ
adults/NNS
and/CC
only/RB
one/CD
of/IN
40/CD
pediatric/JJ
samples/NNS
was/VBD
positive/JJ
(/(
at/IN
a/DT
low/JJ
level/NN
)/)
for/IN
adenovirus/NN
DNA/NN
by/IN
nested/JJ
PCR/NN
assay/NN
./.
====================
In/IN
comparison/NN
,/,
PBMC/NN
from/IN
two/CD
children/NNS
with/IN
fatal/JJ
adenoviral/JJ
infection/NN
were/VBD
both/RB
strongly/RB
positive/JJ
for/IN
adenovirus/NN
DNA/NN
./.
====================
It/PRP
is/VBZ
concluded/VBN
that/IN
,/,
in/IN
contrast/NN
to/TO
a/DT
previous/JJ
study/NN
,/,
PBMC/NN
are/VBP
not/RB
a/DT
common/JJ
site/NN
of/IN
persistent/JJ
group/NN
C/NN
adenoviral/JJ
infection/NN
./.
====================
In/IN
addition/NN
,/,
assay/NN
of/IN
PBMC/NN
by/IN
the/DT
adenovirus-specific/JJ
PCR/NN
may/MD
help/VB
detect/VB
early/JJ
invasive/JJ
disease/NN
and/CC
warrants/VBZ
further/JJ
evaluation/NN
./.
====================
UI/LS
-/:
93363253/CD
====================
TI/LS
-/:
Tumor/NN
necrosis/NN
factor/NN
receptor/NN
expression/NN
and/CC
signal/NN
transduction/NN
in/IN
HIV-1-infected/JJ
cells/NNS
./.
====================
AB/LS
-/:
OBJECTIVE/NN
:/:
To/TO
examine/VB
the/DT
inter-relationship/NN
between/IN
HIV-1/NN
infection/NN
and/CC
the/DT
cell/NN
surface/NN
receptors/NNS
for/IN
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
)/)
-alpha/NN
,/,
an/DT
immunoregulatory/JJ
cytokine/NN
that/WDT
can/MD
enhance/VB
HIV-1/NN
replication/NN
./.
====================
DESIGN/NN
:/:
Infected/JJ
promyelocytic/JJ
and/CC
promonocytic/JJ
cells/NNS
were/VBD
examined/VBN
because/IN
they/PRP
normally/RB
express/VBP
both/DT
types/NNS
of/IN
TNF/NN
receptors/NNS
./.
====================
METHODS/NNS
:/:
TNF/NN
receptor/NN
surface/NN
expression/NN
was/VBD
determined/VBN
by/IN
specific/JJ
monoclonal/JJ
antibody/NN
recognition/NN
and/CC
flow/NN
cytometry/NN
,/,
and/CC
signal/NN
transduction/NN
was/VBD
detected/VBN
by/IN
gel/NN
shift/NN
analysis/NN
./.
====================
HIV-1/NN
activation/NN
and/CC
expression/NN
was/VBD
quantitated/VBN
by/IN
reverse/JJ
transcriptase/NN
assay/NN
./.
====================
RESULTS/NNS
:/:
In/IN
the/DT
OM-10.1/NN
promyelocytic/JJ
model/NN
of/IN
chronic/JJ
infection/NN
,/,
TNF-alpha-induced/JJ
HIV-1/NN
expression/NN
also/RB
resulted/VBD
in/IN
a/DT
substantial/JJ
increase/NN
in/IN
75/CD
kd/NN
TNF/NN
receptor/NN
(/(
TR75/NN
)/)
expression/NN
although/IN
55/CD
kD/NN
TNF/NN
receptor/NN
(/(
TR55/NN
)/)
levels/NNS
were/VBD
not/RB
dramatically/RB
altered/VBN
./.
====================
A/DT
series/NN
of/IN
uninfected/JJ
parental/JJ
HL-60/NN
subclones/NNS
all/DT
reduced/VBD
TR75/NN
surface/NN
expression/NN
in/IN
response/NN
to/TO
TNF-alpha/NN
treatment/NN
./.
====================
Enhanced/VBN
TR75/NN
expression/NN
on/IN
OM-10.1/NN
cells/NNS
followed/VBD
the/DT
same/JJ
TNF-alpha-dose/NN
dependency/NN
as/IN
that/WDT
observed/VBN
for/IN
HIV-1/NN
production/NN
./.
====================
An/DT
increase/NN
in/IN
TR75/NN
expression/NN
was/VBD
also/RB
evident/JJ
during/IN
the/DT
peak/NN
of/IN
an/DT
acute/JJ
HIV-1/NN
infection/NN
of/IN
HL-60/NN
promyelocytes/NNS
./.
====================
Although/IN
TR55/NN
expression/NN
was/VBD
unaltered/JJ
during/IN
TNF-alpha-induced/JJ
HIV/NN
activation/NN
,/,
this/DT
receptor/NN
was/VBD
still/RB
involved/VBN
in/IN
the/DT
viral/JJ
activation/NN
process/NN
./.
====================
Antibody/NN
cross-linking/NN
of/IN
TR55/NN
,/,
in/IN
the/DT
absence/NN
of/IN
exogenous/JJ
TNF-alpha/NN
,/,
induced/VBN
maximal/JJ
HIV-1/NN
expression/NN
,/,
an/DT
up-modulation/NN
of/IN
surface/NN
TR75/NN
,/,
and/CC
nuclear/JJ
NF-kappa/NN
B/NN
activity/NN
in/IN
OM-10.1/NN
cultures/NNS
./.
====================
Surprisingly/RB
,/,
this/DT
was/VBD
the/DT
case/NN
even/RB
when/WRB
an/DT
antagonistic/JJ
anti-TR55/JJ
antibody/NN
was/VBD
used/VBN
./.
====================
Anti-TR55/JJ
antibody/NN
cross-linking/NN
in/IN
chronically/RB
infected/JJ
U1/NN
promonocytic/JJ
cultures/NNS
could/MD
only/RB
partially/RB
substitute/VB
for/IN
TNF-alpha-induced/JJ
HIV-1/NN
expression/NN
./.
====================
CONCLUSIONS/NNS
:/:
Our/PRP$
results/NNS
demonstrated/VBD
that/IN
HIV-1/NN
infection/NN
can/MD
selectively/RB
influence/VB
the/DT
surface/NN
expression/NN
of/IN
TNF/NN
receptors/NNS
,/,
potentially/RB
influencing/VBG
its/PRP$
own/JJ
expression/NN
and/CC
altering/VBG
normal/JJ
immunoregulatory/JJ
signal/NN
transduction/NN
./.
====================
UI/LS
-/:
94191916/CD
====================
TI/LS
-/:
Comparative/JJ
mapping/NN
of/IN
SRY/NN
in/IN
the/DT
great/JJ
apes/NNS
./.
====================
AB/LS
-/:
Cytogenetic/JJ
studies/NNS
of/IN
the/DT
primate/JJ
Y/NN
chromosomes/NNS
have/VBP
suggested/VBN
that/IN
extensive/JJ
rearrangements/NNS
have/VBP
occurred/VBN
during/IN
evolution/NN
of/IN
the/DT
great/JJ
apes/NNS
./.
====================
We/PRP
have/VBP
used/VBN
in/FW
situ/FW
hybridization/NN
to/TO
define/VB
these/DT
rearrangements/NNS
at/IN
the/DT
molecular/JJ
level/NN
./.
====================
pHU-14/NN
,/,
a/DT
probe/NN
including/VBG
sequences/NNS
from/IN
the/DT
sex/NN
determining/JJ
gene/NN
SRY/NN
,/,
hybridizes/VBZ
close/RB
to/TO
the/DT
early/JJ
replicating/VBG
pseudoautosomal/JJ
segment/NN
in/IN
a/DT
telomeric/JJ
or/CC
subtelomeric/JJ
position/NN
of/IN
the/DT
Y/NN
chromosomes/NNS
of/IN
all/DT
great/JJ
apes/NNS
./.
====================
The/DT
low/JJ
copy/NN
repeat/NN
detected/VBN
by/IN
the/DT
probe/NN
Fr35-II/NN
is/VBZ
obviously/RB
included/VBN
in/IN
Y/NN
chromosomal/NN
rearrangements/NNS
during/IN
hominid/NN
evolution/NN
./.
====================
These/DT
results/NNS
,/,
combined/VBN
with/IN
previous/JJ
studies/NNS
,/,
suggest/VBP
that/IN
the/DT
Y/NN
chromosome/NN
in/IN
great/JJ
apes/NNS
has/VBZ
a/DT
conserved/VBN
region/NN
including/VBG
the/DT
pseudoautosomal/JJ
region/NN
and/CC
the/DT
testis-determining/JJ
region/NN
./.
====================
The/DT
rest/NN
of/IN
the/DT
Y/NN
chromosome/NN
has/VBZ
undergone/VBN
several/JJ
rearrangements/NNS
in/IN
the/DT
different/JJ
great/JJ
apes/NNS
./.
====================
UI/LS
-/:
93272960/CD
====================
TI/LS
-/:
Calcium/NN
dependent/JJ
activation/NN
of/IN
the/DT
NF-AT/NN
transcription/NN
factor/NN
by/IN
p59fyn/NN
./.
====================
AB/LS
-/:
A/DT
reporter/NN
gene/NN
under/IN
the/DT
control/NN
of/IN
a/DT
T-cell/NN
antigen/NN
receptor/NN
element/NN
was/VBD
activated/VBN
in/IN
Jurkat/NN
cells/NNS
by/IN
antigen/NN
receptor/NN
triggering/NN
or/CC
by/IN
a/DT
combination/NN
of/IN
phorbol/NN
myristate/NN
acetate/NN
,/,
which/WDT
activates/VBZ
protein/NN
kinase/NN
C/NN
,/,
and/CC
a/DT
calcium/NN
ionophore/NN
./.
====================
Both/DT
these/DT
signals/NNS
were/VBD
necessary/JJ
for/IN
expression/NN
of/IN
the/DT
reporter/NN
gene/NN
./.
====================
When/WRB
co-transfected/VBN
with/IN
a/DT
construct/NN
capable/JJ
of/IN
overexpressing/VBG
the/DT
tyrosine/NN
kinase/NN
p59fyn/NN
,/,
the/DT
reporter/NN
gene/NN
was/VBD
activated/VBN
by/IN
PMA/NN
alone/RB
./.
====================
Thus/RB
p59fyn/NN
could/MD
replace/VB
the/DT
calcium/NN
ionophore/NN
but/CC
not/RB
activation/NN
of/IN
protein/NN
kinase/NN
C/NN
./.
====================
The/DT
activation/NN
by/IN
p59fyn/NN
plus/CC
PMA/NN
was/VBD
blocked/VBN
by/IN
EGTA/NN
and/CC
by/IN
the/DT
immunosuppressant/JJ
drug/NN
cyclosporin/NN
A/NN
./.
====================
UI/LS
-/:
93292612/CD
====================
TI/LS
-/:
Dependence/NN
for/IN
the/DT
proliferative/JJ
response/NN
to/TO
erythropoietin/NN
on/IN
an/DT
established/JJ
erythroid/JJ
differentiation/NN
program/NN
in/IN
a/DT
human/JJ
hematopoietic/JJ
cell/NN
line/NN
,/,
UT-7/NN
./.
====================
AB/LS
-/:
Erythroid/JJ
differentiation/NN
involves/VBZ
the/DT
activation/NN
of/IN
a/DT
number/NN
of/IN
erythroid-specific/JJ
genes/NNS
,/,
most/JJS
of/IN
which/WDT
,/,
including/VBG
the/DT
globin/NN
genes/NNS
and/CC
the/DT
erythropoietin/NN
receptor/NN
(/(
Epo-R/NN
)/)
gene/NN
,/,
are/VBP
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
regulated/VBN
by/IN
the/DT
transcription/NN
factor/NN
GATA-1/NN
./.
====================
In/IN
order/NN
to/TO
understand/VB
the/DT
relationship/NN
,/,
if/IN
any/DT
,/,
between/IN
expression/NN
of/IN
GATA-1/NN
,/,
response/NN
to/TO
Epo/NN
and/CC
erythroid/JJ
differentiation/NN
,/,
we/PRP
analyzed/VBD
the/DT
expression/NN
of/IN
GATA-1/NN
,/,
Epo-R/NN
and/CC
globin/NN
genes/NNS
in/IN
an/DT
Epo-dependent/JJ
human/JJ
cell/NN
line/NN
,/,
UT-7/NN
Epo/NN
./.
====================
The/DT
results/NNS
were/VBD
compared/VBN
to/TO
those/DT
obtained/VBN
with/IN
the/DT
parental/JJ
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
-dependent/JJ
cell/NN
line/NN
,/,
UT-7/NN
,/,
which/WDT
has/VBZ
a/DT
predominantly/RB
megakaryoblastic/JJ
phenotype/NN
and/CC
is/VBZ
unable/JJ
to/TO
proliferate/VB
continuously/RB
in/IN
the/DT
presence/NN
of/IN
Epo/NN
./.
====================
UT-7/NN
Epo/NN
and/CC
UT-7/NN
expressed/VBD
similar/JJ
levels/NNS
of/IN
GATA-1/NN
mRNA/NN
and/CC
binding/NN
activity/NN
./.
====================
The/DT
two/CD
lines/NNS
also/RB
expressed/VBD
comparable/JJ
levels/NNS
of/IN
Epo-R/NN
mRNA/NN
while/IN
the/DT
number/NN
of/IN
Epo-binding/JJ
sites/NNS
on/IN
UT-7/NN
Epo/NN
cells/NNS
was/VBD
one-sixth/CD
the/DT
number/NN
of/IN
UT-7/NN
cells/NNS
(/(
2400/CD
+/-/CC
3/CD
vs./CC
13/CD
,/,
800/CD
+/-/CC
300/CD
)/)
./.
====================
This/DT
difference/NN
in/IN
the/DT
number/NN
of/IN
binding/VBG
sites/NNS
could/MD
be/VB
due/JJ
to/TO
differences/NNS
in/IN
cell/NN
surface/NN
(/(
UT-7/NN
cells/NNS
are/VBP
20/CD
%/NN
smaller/JJR
than/IN
the/DT
parental/JJ
UT-7/NN
cells/NNS
)/)
or/CC
in/IN
receptor/NN
turnover/NN
./.
====================
By/IN
Northern/NN
analysis/NN
,/,
UT-7/NN
cells/NNS
expressed/VBD
detectable/JJ
levels/NNS
of/IN
beta-/NN
and/CC
gamma-globin/NN
but/CC
not/RB
alpha-globin/NN
./.
====================
In/IN
comparison/NN
,/,
UT-7/NN
Epo/NN
cells/NNS
expressed/VBD
alpha-globin/NN
and/CC
higher/JJR
levels/NNS
of/IN
gamma-globin/NN
(/(
5-fold/JJ
)/)
and/CC
beta-globin/NN
(/(
from/IN
barely/RB
to/TO
clearly/RB
detectable/JJ
)/)
./.
====================
Globin/NN
chains/NNS
(/(
alpha/NN
,/,
beta/NN
and/CC
gamma/NN
)/)
were/VBD
clearly/RB
detectable/JJ
by/IN
affinity/NN
chromatography/NN
in/IN
UT-7/NN
Epo/NN
but/CC
not/RB
in/IN
UT-7/NN
cells/NNS
./.
====================
The/DT
frequency/NN
of/IN
the/DT
cells/NNS
which/WDT
expressed/VBD
beta-/NN
and/CC
gamma-globin/NN
genes/NNS
in/IN
the/DT
two/CD
cell/NN
populations/NNS
was/VBD
measured/VBN
by/IN
immunofluorescence/NN
with/IN
beta-/NN
and/CC
gamma-specific/JJ
antibodies/NNS
./.
====================
The/DT
number/NN
of/IN
gamma-positive/JJ
cells/NNS
and/CC
their/PRP$
fluorescence/NN
intensity/NN
were/VBD
higher/JJR
in/IN
UT-7/NN
Epo/NN
than/IN
in/IN
UT-7/NN
cells/NNS
(/(
0/CD
to/TO
17/CD
%/NN
barely/RB
positive/JJ
cells/NNS
and/CC
23/CD
to/TO
40/CD
%/NN
clearly/RB
positive/JJ
cells/NNS
,/,
respectively/RB
)/)
,/,
indicating/VBG
that/IN
the/DT
increase/NN
in/IN
globin/NN
mRNA/NN
observed/VBN
in/IN
UT-7/NN
Epo/NN
is/VBZ
due/JJ
to/TO
both/CC
an/DT
increase/NN
of/IN
gene/NN
expression/NN
per/IN
cell/NN
and/CC
an/DT
increase/NN
in/IN
numbers/NNS
of/IN
cells/NNS
containing/VBG
gamma-globin/NN
./.
====================
The/DT
levels/NNS
of/IN
GATA-1/NN
,/,
Epo-R/NN
and/CC
globin/NN
mRNA/NN
expressed/VBN
were/VBD
not/RB
affected/VBN
by/IN
a/DT
24-hour/JJ
incubation/NN
of/IN
either/CC
cell/NN
line/NN
with/IN
Epo/NN
,/,
GM-CSF/NN
or/CC
interleukin-3/NN
(/(
IL-3/NN
)/)
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
400/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
93216805/CD
====================
TI/LS
-/:
The/DT
Sp1/NN
transcription/NN
factor/NN
binds/VBZ
the/DT
CD11b/NN
promoter/NN
specifically/RB
in/IN
myeloid/JJ
cells/NNS
in/FW
vivo/FW
and/CC
is/VBZ
essential/JJ
for/IN
myeloid-specific/JJ
promoter/NN
activity/NN
./.
====================
AB/LS
-/:
The/DT
myeloid/JJ
integrin/NN
CD11b/NN
is/VBZ
expressed/VBN
selectively/RB
on/IN
the/DT
surface/NN
of/IN
mature/JJ
macrophages/NNS
,/,
monocytes/NNS
,/,
neutrophils/NNS
,/,
and/CC
natural/JJ
killer/NN
cells/NNS
./.
====================
Lineage-specific/JJ
expression/NN
is/VBZ
controlled/VBN
at/IN
the/DT
level/NN
of/IN
mRNA/NN
transcription/NN
./.
====================
Recent/JJ
isolation/NN
of/IN
the/DT
CD11b/NN
promoter/NN
shows/VBZ
that/IN
92/CD
base/NN
pairs/NNS
(/(
bp/NN
)/)
of/IN
5'-flanking/JJ
DNA/NN
are/VBP
sufficient/JJ
to/TO
direct/VB
myeloid-specific/JJ
expression/NN
of/IN
a/DT
reporter/NN
gene/NN
./.
====================
To/TO
characterize/VB
regulatory/JJ
sequences/NNS
important/JJ
for/IN
promoter/NN
activity/NN
,/,
we/PRP
performed/VBD
linker/NN
scanning/NN
analysis/NN
of/IN
the/DT
92-bp/JJ
CD11b/NN
promoter/NN
and/CC
demonstrate/VB
that/IN
a/DT
sequence/NN
at/IN
bp/NN
-60/CD
is/VBZ
essential/JJ
for/IN
CD11b/NN
promoter/NN
activity/NN
./.
====================
We/PRP
show/VBP
that/IN
this/DT
sequence/NN
binds/VBZ
the/DT
transcription/NN
factor/NN
Sp1/NN
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
./.
====================
In/FW
vivo/FW
the/DT
Sp1/NN
site/NN
is/VBZ
bound/VBN
only/RB
in/IN
myeloid/JJ
(/(
U937/NN
)/)
cells/NNS
,/,
not/RB
in/IN
cervical/JJ
carcinoma/NN
(/(
HeLa/NN
)/)
cells/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
macrophage/NN
transcription/NN
factor/NN
PU.1/NN
binds/VBZ
the/DT
CD11b/NN
promoter/NN
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
close/RB
to/TO
the/DT
Sp1/NN
site/NN
./.
====================
We/PRP
propose/VBP
a/DT
model/NN
in/IN
which/WDT
binding/NN
of/IN
a/DT
myeloid-specific/JJ
factor/NN
(/(
PU.1/NN
)/)
allows/VBZ
a/DT
general/JJ
factor/NN
(/(
Sp1/NN
)/)
to/TO
bind/VB
in/IN
a/DT
tissue-specific/JJ
fashion/NN
thereby/RB
contributing/VBG
to/TO
the/DT
myeloid-specific/JJ
expression/NN
of/IN
CD11b/NN
./.
====================
UI/LS
-/:
93202345/CD
====================
TI/LS
-/:
Transcription/NN
factor/NN
jun-B/NN
is/VBZ
target/NN
of/IN
autoreactive/JJ
T-cells/NNS
in/IN
IDDM/NN
./.
====================
AB/LS
-/:
Target/NN
antigens/NNS
defined/VBN
by/IN
autoantibodies/NNS
in/IN
IDDM/NN
include/VBP
insulin/NN
,/,
a/DT
putative/JJ
glycolipid/NN
that/WDT
reacts/VBZ
with/IN
islet/NN
cell/NN
antibodies/NNS
,/,
and/CC
a/DT
64,000-M(r)/JJ
protein/NN
recently/RB
identified/VBN
as/IN
glutamic/JJ
acid/NN
decarboxylase/NN
./.
====================
In/IN
addition/NN
,/,
some/DT
IDDM/NN
sera/NN
that/WDT
contain/VBP
antibodies/NNS
to/TO
glutamic/JJ
acid/NN
decarboxylase/NN
also/RB
coprecipitate/VBP
a/DT
38,000-M(r)/JJ
protein/NN
from/IN
islets/NNS
./.
====================
This/DT
study/NN
used/VBD
a/DT
high/JJ
titer/NN
anti-38,000-M(r)/JJ
serum/NN
to/TO
screen/VB
bacteriophage/NN
lambda/NN
cDNA/NN
expression/NN
libraries/NNS
and/CC
identified/VBD
human/JJ
islet/NN
and/CC
placental/JJ
clones/NNS
encoding/VBG
jun-B/NN
,/,
the/DT
nuclear/JJ
transcription/NN
protein/NN
,/,
of/IN
predicted/VBN
38,000/CD
M(r)/NN
./.
====================
Peripheral/JJ
blood/NN
T-cells/NNS
exhibited/VBD
significant/JJ
proliferation/NN
in/IN
response/NN
to/TO
a/DT
recombinant/JJ
fragment/NN
of/IN
jun-B/NN
(/(
amino/NN
acids/NNS
1-180/CD
)/)
in/IN
12/CD
of/IN
17/CD
(/(
71/CD
%/NN
)/)
recent-onset/JJ
IDDM/NN
subjects/NNS
,/,
8/CD
of/IN
16/CD
(/(
50/CD
%/NN
)/)
ICA-positive/JJ
first-degree/JJ
relatives/NNS
of/IN
IDDM/NN
subjects/NNS
who/WP
were/VBD
at/IN
risk/NN
,/,
3/CD
of/IN
12/CD
(/(
25/CD
%/NN
)/)
other/JJ
autoimmune/JJ
disease/NN
subjects/NNS
,/,
and/CC
0/CD
of/IN
10/CD
healthy/JJ
control/NN
subjects/NNS
./.
====================
Proliferation/NN
to/TO
tetanus/NN
toxoid/NN
did/VBD
not/RB
differ/VB
significantly/RB
between/IN
the/DT
groups/NNS
./.
====================
Responses/NNS
to/TO
jun-B/NN
were/VBD
not/RB
related/JJ
to/TO
age/NN
,/,
sex/NN
,/,
or/CC
human/JJ
leukocyte/NN
antigen/NN
status/NN
./.
====================
Thus/RB
,/,
autoreactive/JJ
T-cells/NNS
identify/VBP
a/DT
novel/JJ
antigen/NN
,/,
p38/NN
jun-B/NN
,/,
in/IN
IDDM/NN
and/CC
appear/VBP
to/TO
indicate/VB
subjects/NNS
at/IN
risk/NN
for/IN
the/DT
development/NN
of/IN
clinical/JJ
disease/NN
./.
====================
UI/LS
-/:
93194883/CD
====================
TI/LS
-/:
Stimulation/NN
of/IN
interleukin-1/NN
alpha/NN
and/CC
interleukin-1/NN
beta/NN
production/NN
in/IN
human/JJ
monocytes/NNS
by/IN
protein/NN
phosphatase/NN
1/CD
and/CC
2A/NN
inhibitors/NNS
./.
====================
AB/LS
-/:
Protein/NN
phosphatases/NNS
1/CD
and/CC
2A/NN
are/VBP
important/JJ
in/IN
regulating/VBG
cellular/JJ
functions/NNS
by/IN
controlling/VBG
the/DT
phosphorylation/NN
state/NN
of/IN
their/PRP$
substrates/NNS
./.
====================
In/IN
human/JJ
monocytes/NNS
,/,
the/DT
inhibitors/NNS
of/IN
these/DT
phosphatases/NNS
,/,
okadaic/JJ
acid/NN
and/CC
calyculin/NN
A/NN
,/,
were/VBD
found/VBN
to/TO
increase/VB
the/DT
mRNA/NN
accumulation/NN
and/CC
cytokine/NN
production/NN
of/IN
interleukin-1/NN
beta/NN
and/CC
interleukin-1/NN
alpha/NN
./.
====================
The/DT
increased/VBN
mRNA/NN
accumulation/NN
was/VBD
found/VBN
to/TO
be/VB
primarily/RB
because/IN
of/IN
the/DT
increase/NN
in/IN
the/DT
transcription/NN
rate/NN
of/IN
the/DT
interleukin-1/NN
genes/NNS
./.
====================
Stimulation/NN
of/IN
interleukin-1/NN
gene/NN
transcription/NN
may/MD
be/VB
caused/VBN
by/IN
the/DT
stimulation/NN
of/IN
transcription/NN
factor/NN
activities/NNS
,/,
including/VBG
those/DT
of/IN
AP-1/NN
,/,
by/IN
these/DT
protein/NN
phosphatase/NN
inhibitors/NNS
./.
====================
Okadaic/JJ
acid/NN
increased/VBD
the/DT
synthesis/NN
of/IN
the/DT
interleukin-1/NN
beta/NN
precursor/NN
and/CC
mature/JJ
forms/NNS
and/CC
their/PRP$
secretion/NN
./.
====================
This/DT
increased/VBD
processing/NN
and/CC
secretion/NN
correlated/VBN
with/IN
the/DT
stimulation/NN
of/IN
IL-1/NN
beta/NN
convertase/NN
mRNA/NN
accumulation/NN
./.
====================
The/DT
stimulation/NN
of/IN
interleukin-1/NN
alpha/NN
production/NN
by/IN
okadaic/JJ
acid/NN
was/VBD
more/RBR
modest/JJ
than/IN
that/DT
of/IN
interleukin-1/NN
beta/NN
./.
====================
However/RB
,/,
the/DT
phosphorylation/NN
of/IN
the/DT
precursor/NN
interleukin-1/NN
alpha/NN
cytokine/NN
was/VBD
increased/VBN
./.
====================
These/DT
results/NNS
show/VBP
that/IN
protein/NN
phosphatase/NN
1/CD
and/CC
2A/NN
inhibitors/NNS
exert/VBP
multiple/JJ
effects/NNS
on/IN
cytokine/NN
production/NN
in/IN
human/JJ
monocytes/NNS
and/CC
suggest/VBP
that/IN
these/DT
two/CD
phosphatases/NNS
play/VBP
important/JJ
roles/NNS
in/IN
regulating/VBG
interleukin-1/NN
production/NN
./.
====================
UI/LS
-/:
93189564/CD
====================
TI/LS
-/:
The/DT
interleukin/NN
2/CD
CD28-responsive/JJ
complex/NN
contains/VBZ
at/IN
least/JJS
three/CD
members/NNS
of/IN
the/DT
NF/NN
kappa/NN
B/NN
family/NN
:/:
c-Rel/NN
,/,
p50/NN
,/,
and/CC
p65/NN
./.
====================
AB/LS
-/:
Optimal/JJ
activation/NN
of/IN
T/NN
cells/NNS
requires/VBZ
at/IN
least/JJS
two/CD
signals/NNS
./.
====================
One/CD
signal/NN
can/MD
be/VB
delivered/VBN
by/IN
the/DT
antigen-specific/JJ
T-cell/NN
receptor/NN
,/,
and/CC
the/DT
second/JJ
signal/NN
is/VBZ
provided/VBN
by/IN
the/DT
costimulatory/JJ
molecule/NN
(/(
s/NNS
)/)
delivered/VBN
by/IN
the/DT
antigen-presenting/JJ
cell/NN
./.
====================
CD28/NN
is/VBZ
a/DT
T-cell/NN
surface/NN
molecule/NN
and/CC
stimulation/NN
through/IN
this/DT
protein/NN
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
delivering/VBG
the/DT
second/JJ
activation/NN
signal/NN
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
show/VBP
that/IN
in/IN
human/JJ
peripheral/JJ
blood/NN
T/NN
cells/NNS
,/,
CD28-mediated/JJ
signal/NN
transduction/NN
involves/VBZ
the/DT
rel/NN
family/NN
proteins/NNS
--/:
c-Rel/NN
,/,
p50/NN
,/,
and/CC
p65/NN
./.
====================
Treatment/NN
of/IN
peripheral/JJ
blood/NN
T/NN
cells/NNS
with/IN
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
and/CC
anti-CD28/JJ
monoclonal/JJ
antibody/NN
(/(
mAb/NN
)/)
results/VBZ
in/IN
augmentation/NN
of/IN
nuclear/JJ
c-Rel/NN
,/,
p50/NN
,/,
and/CC
p65/NN
,/,
and/CC
this/DT
augmentation/NN
can/MD
occur/VB
in/IN
the/DT
presence/NN
of/IN
the/DT
immunosuppressant/JJ
cyclosporin/NN
A/NN
./.
====================
It/PRP
is/VBZ
also/RB
shown/VBN
in/IN
this/DT
report/NN
that/IN
,/,
in/IN
response/NN
to/TO
PMA/anti-CD28/JJ
mAb/NN
or/CC
anti-CD3/anti-CD28/JJ
mAb/NN
,/,
c-Rel/NN
,/,
p50/NN
,/,
and/CC
p65/NN
are/VBP
associated/VBN
with/IN
CD28-responsive/JJ
element/NN
present/JJ
in/IN
the/DT
promoter/NN
of/IN
the/DT
human/JJ
interleukin/NN
2/CD
gene/NN
./.
====================
The/DT
functional/JJ
significance/NN
of/IN
c-Rel/NN
involvement/NN
in/IN
the/DT
CD28-responsive/JJ
complex/NN
is/VBZ
demonstrated/VBN
by/IN
transient/JJ
transfection/NN
analysis/NN
,/,
where/WRB
cotransfection/NN
of/IN
c-Rel/NN
augments/VBZ
the/DT
level/NN
of/IN
expression/NN
of/IN
a/DT
chloramphenicol/JJ
acetyltransferase/NN
reporter/NN
gene/NN
linked/VBN
to/TO
the/DT
CD28-responsive/JJ
element/NN
./.
====================
UI/LS
-/:
93152834/CD
====================
TI/LS
-/:
Expression/NN
of/IN
tal-1/NN
and/CC
GATA-binding/JJ
proteins/NNS
during/IN
human/JJ
hematopoiesis/NN
./.
====================
AB/LS
-/:
Tal-1/NN
rearrangements/NNS
are/VBP
associated/VBN
with/IN
nearly/RB
30/CD
%/NN
of/IN
human/JJ
T/NN
acute/JJ
lymphoblastic/JJ
leukemia/NN
./.
====================
Tal-1/NN
gene/NN
encodes/VBZ
a/DT
putative/JJ
transcription/NN
factor/NN
with/IN
a/DT
basic/JJ
helix-loop-helix/JJ
domain/NN
and/CC
is/VBZ
known/VBN
to/TO
be/VB
predominantly/RB
expressed/VBN
in/IN
hematopoietic/JJ
cells/NNS
./.
====================
We/PRP
investigated/VBD
the/DT
pattern/NN
of/IN
tal-1/NN
expression/NN
in/IN
purified/VBN
human/JJ
hematopoietic/JJ
cells/NNS
by/IN
in/FW
situ/FW
hybridization/NN
and/CC
reverse/JJ
transcriptase/NN
polymerase/NN
chain/NN
reaction/NN
analysis/NN
./.
====================
Both/DT
methods/NNS
demonstrated/VBD
that/IN
the/DT
tal-1/NN
gene/NN
is/VBZ
expressed/VBN
in/IN
megakaryocytes/NNS
and/CC
erythroblasts/NNS
as/RB
well/RB
as/IN
in/IN
basophilic/JJ
granulocytes/NNS
./.
====================
In/IN
addition/NN
,/,
our/PRP$
results/NNS
indicate/VBP
that/IN
the/DT
tal-1/NN
1A/NN
promoter/NN
,/,
which/WDT
contains/VBZ
two/CD
consensus/NN
GATA-binding/JJ
sites/NNS
,/,
is/VBZ
active/JJ
mainly/RB
in/IN
these/DT
lineages/NNS
./.
====================
Because/IN
the/DT
GATA-1/NN
gene/NN
is/VBZ
known/VBN
to/TO
transactivate/VB
several/JJ
genes/NNS
specific/JJ
for/IN
the/DT
erythroid/JJ
,/,
megakaryocytic/JJ
,/,
and/CC
mastocytic/basophilic/JJ
lineages/NNS
,/,
we/PRP
studied/VBD
GATA-1/NN
expression/NN
in/IN
these/DT
purified/VBN
hematopoietic/JJ
cells/NNS
./.
====================
We/PRP
found/VBD
that/IN
GATA-1/NN
and/CC
tal-1/NN
genes/NNS
are/VBP
coexpressed/VBN
in/IN
these/DT
three/CD
lineages/NNS
./.
====================
Remarkably/RB
,/,
the/DT
expression/NN
of/IN
both/DT
genes/NNS
is/VBZ
downmodulated/VBN
during/IN
erythroid/JJ
and/CC
megakaryocytic/JJ
terminal/JJ
maturation/NN
./.
====================
In/IN
immature/JJ
hematopoietic/JJ
cells/NNS
,/,
tal-1/NN
and/CC
GATA-1/NN
genes/NNS
are/VBP
coexpressed/VBN
in/IN
committed/VBN
progenitors/NNS
cells/NNS
(/(
CD34+/CD38(2+)/JJ
)/)
,/,
whereas/IN
they/PRP
are/VBP
not/RB
detectable/JJ
in/IN
the/DT
most/RBS
primitive/JJ
cells/NNS
(/(
CD34(2+)/CD38-/JJ
)/)
./.
====================
In/IN
contrast/NN
,/,
GATA-2/NN
is/VBZ
strongly/RB
expressed/VBN
in/IN
both/CC
most/RBS
primitive/JJ
and/CC
committed/VBN
progenitors/NNS
cells/NNS
,/,
whereas/IN
GATA-3/NN
is/VBZ
mostly/RB
detected/VBN
in/IN
most/RBS
primitive/JJ
ones/NNS
./.
====================
Altogether/RB
our/PRP$
results/NNS
strongly/RB
suggest/VBP
that/IN
GATA-1/NN
modulates/VBZ
the/DT
transcription/NN
of/IN
tal-1/NN
during/IN
the/DT
differentiation/NN
of/IN
the/DT
erythroid/JJ
,/,
megakaryocytic/JJ
,/,
and/CC
basosophilic/JJ
lineages/NNS
./.
====================
UI/LS
-/:
93228445/CD
====================
TI/LS
-/:
The/DT
lytic/JJ
transition/NN
of/IN
Epstein-Barr/JJ
virus/NN
is/VBZ
imitated/VBN
by/IN
recombinant/JJ
B-cells/NNS
./.
====================
AB/LS
-/:
Lytic/JJ
transition/NN
of/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
is/VBZ
initiated/VBN
by/IN
distinct/JJ
immediate/JJ
early/JJ
regulators/NNS
of/IN
the/DT
viral/JJ
cycle/NN
,/,
in/IN
synchronization/NN
to/TO
temporary/JJ
,/,
permissive/JJ
conditions/NNS
during/IN
host/NN
cell/NN
differentiation/NN
./.
====================
We/PRP
developed/VBD
eukaryotic/JJ
vectors/NNS
suitable/JJ
to/TO
imitate/VB
the/DT
processes/NNS
involved/VBN
in/IN
lytic/JJ
transition/NN
in/IN
cell/NN
culture/NN
systems/NNS
./.
====================
Two/CD
stable/JJ
B/NN
cell/NN
lines/NNS
were/VBD
established/VBN
:/:
R59Z/NN
activator/NN
cells/NNS
were/VBD
used/VBN
to/TO
induce/VB
lytic/JJ
EBV/NN
expression/NN
in/IN
a/DT
constitutive/JJ
manner/NN
by/IN
the/DT
production/NN
of/IN
the/DT
BZLF/NN
1/CD
trans-activator/NN
(/(
Zta/NN
)/)
./.
====================
R7-57/NN
reporter/NN
cells/NNS
,/,
on/IN
the/DT
other/JJ
hand/NN
,/,
signaled/VBD
induced/VBN
activity/NN
of/IN
the/DT
lytic/JJ
origin/NN
of/IN
EBV/NN
replication/NN
(/(
ori/NN
Lyt/NN
)/)
./.
====================
Different/JJ
modes/NNS
,/,
like/IN
chemical/JJ
induction/NN
,/,
lytic/JJ
superinfection/NN
with/IN
EBV/NN
and/CC
single/JJ
gene/NN
trans-activation/NN
converted/VBD
the/DT
recombinant/JJ
ori/NN
Lyt/NN
element/NN
in/IN
R7-57/NN
reporter/NN
cells/NNS
./.
====================
BZLF/NN
1/CD
,/,
transiently/RB
expressed/VBN
in/IN
R7-57/NN
reporter/NN
cells/NNS
,/,
was/VBD
the/DT
only/JJ
EBV/NN
trans-activator/NN
found/VBN
,/,
sufficient/JJ
in/NN
inducing/VBG
the/DT
viral/JJ
lytic/JJ
cycle/NN
./.
====================
Basing/VBG
on/IN
these/DT
experiments/NNS
,/,
trans-cellular/JJ
activation/NN
of/IN
EBV/NN
was/VBD
tested/VBN
by/IN
cocultivation/NN
of/IN
BZLF/NN
1-expressing/JJ
R59Z/NN
activator/NN
cells/NNS
with/IN
the/DT
R7-57/NN
reporter/NN
line/NN
./.
====================
No/DT
lytic/JJ
effect/NN
on/IN
the/DT
reporter/NN
cells/NNS
could/MD
be/VB
measured/VBN
,/,
neither/CC
by/IN
cocultivation/NN
of/IN
activator/NN
cells/NNS
nor/CC
by/IN
coincubation/NN
of/IN
BZLF/NN
1-containing/JJ
cell/NN
lysates/NNS
./.
====================
Latency/NN
breaking/NN
activity/NN
,/,
however/RB
,/,
was/VBD
transferred/VBN
from/IN
activator/NN
to/TO
reporter/NN
cells/NNS
when/WRB
active/JJ
,/,
exogenous/JJ
virus/NN
was/VBD
added/VBN
./.
====================
The/DT
cell/NN
system/NN
described/VBN
in/IN
these/DT
experiments/NNS
provides/VBZ
a/DT
tool/NN
for/IN
the/DT
detection/NN
of/IN
EBV/NN
reactivation/NN
and/CC
demonstrates/VBZ
the/DT
potential/NN
of/IN
the/DT
lytic/JJ
regulatory/JJ
gene/NN
BZLF/NN
1/CD
====================
UI/LS
-/:
93321228/CD
====================
TI/LS
-/:
Costimulation/NN
of/IN
cAMP/NN
and/CC
protein/NN
kinase/NN
C/NN
pathways/NNS
inhibits/VBZ
the/DT
CD3-dependent/JJ
T/NN
cell/NN
activation/NN
and/CC
leads/VBZ
to/TO
a/DT
persistent/JJ
expression/NN
of/IN
the/DT
AP-1/NN
transcription/NN
factor/NN
./.
====================
AB/LS
-/:
The/DT
effects/NNS
mediated/VBN
by/IN
a/DT
combined/JJ
stimulation/NN
of/IN
cAMP-/NN
and/CC
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
-dependent/JJ
pathways/NNS
have/VBP
been/VBN
investigated/VBN
in/IN
different/JJ
cellular/JJ
systems/NNS
,/,
and/CC
it/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
they/PRP
may/MD
complement/VB
each/DT
other/JJ
in/IN
activating/VBG
cell/NN
proliferation/NN
and/CC
differentiation/NN
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
show/VBP
that/IN
upon/IN
the/DT
stimulation/NN
of/IN
both/DT
pathways/NNS
T/NN
lymphocytes/NNS
became/VBD
refractory/JJ
to/TO
activation/NN
via/IN
the/DT
CD3/T/NN
cell/NN
receptor/NN
(/(
TcR/NN
)/)
complex/NN
./.
====================
T/NN
cells/NNS
preincubated/VBN
with/IN
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
and/CC
dibutyryl/NN
cAMP/NN
(/(
Bt2cAMP/NN
)/)
displayed/VBD
a/DT
deficient/JJ
proliferative/JJ
ability/NN
in/IN
response/NN
to/TO
anti-CD3/JJ
mAb/NN
stimulation/NN
,/,
whereas/IN
lymphocytes/NNS
treated/VBN
individually/RB
with/IN
either/CC
Bt2cAMP/NN
or/CC
PMA/NN
responded/VBD
comparably/RB
to/TO
untreated/JJ
samples/NNS
./.
====================
We/PRP
detected/VBD
an/DT
association/NN
between/IN
the/DT
reduced/VBN
mitogenic/JJ
response/NN
and/CC
low/JJ
expression/NN
of/IN
both/CC
interleukin-2/NN
(/(
IL-2/NN
)/)
and/CC
the/DT
alpha/NN
chain/NN
(/(
CD25/NN
)/)
of/IN
the/DT
IL-2/NN
receptor/NN
(/(
IL-2R/NN
)/)
./.
====================
Analysis/NN
of/IN
intracellular/JJ
Ca2+/NN
mobilization/NN
suggested/VBD
that/IN
the/DT
CD3/TcR-dependent/JJ
signal/NN
transduction/NN
was/VBD
impaired/JJ
in/IN
PMA/Bt2cAMP-treated/JJ
cells/NNS
./.
====================
Remarkably/RB
,/,
we/PRP
observed/VBD
that/IN
these/DT
samples/NNS
displayed/VBD
a/DT
persistent/JJ
expression/NN
of/IN
the/DT
c-fos/NN
protooncogene/NN
,/,
associated/VBN
to/TO
an/DT
increased/VBN
AP-1/NN
DNA-binding/JJ
activity/NN
,/,
whereas/IN
no/DT
variations/NNS
of/IN
CREB/NN
or/CC
NF-kB/NN
were/VBD
detected/VBN
./.
====================
Neither/CC
Bt2cAMP/NN
nor/CC
PMA/NN
individually/RB
mediated/VBD
these/DT
sustained/JJ
effects/NNS
,/,
which/WDT
therefore/RB
appear/VBP
as/IN
a/DT
consequence/NN
of/IN
the/DT
interplay/NN
between/IN
both/DT
metabolic/JJ
stimuli/NNS
./.
====================
Altogether/RB
,/,
the/DT
data/NNS
provide/VBP
the/DT
evidence/NN
that/IN
both/DT
pathways/NNS
complement/VBP
each/DT
other/JJ
in/IN
regulating/VBG
gene/NN
expression/NN
and/CC
,/,
conversely/RB
,/,
downregulate/VBP
the/DT
TcR/NN
transduction/NN
mechanisms/NNS
./.
====================
UI/LS
-/:
94083530/CD
====================
TI/LS
-/:
The/DT
lymphotoxin/NN
promoter/NN
is/VBZ
stimulated/VBN
by/IN
HTLV-I/NN
tax/NN
activation/NN
of/IN
NF-kappa/NN
B/NN
in/IN
human/JJ
T-cell/NN
lines/NNS
./.
====================
AB/LS
-/:
The/DT
HTLV-I/NN
transcriptional/JJ
activator/NN
tax/NN
was/VBD
used/VBN
to/TO
gain/VB
insight/NN
into/IN
the/DT
mechanism/NN
of/IN
lymphotoxin/NN
(/(
LT/NN
;/:
TNF-beta/NN
)/)
gene/NN
induction/NN
./.
====================
Tax-expressing/JJ
cell/NN
lines/NNS
produce/VBP
LT/NN
biologic/JJ
activity/NN
./.
====================
An/DT
LT/NN
promoter/NN
(/(
LT-293/NN
)/)
CAT/NN
construct/NN
that/WDT
contained/VBD
an/DT
NF-kappa/NN
B/NN
site/NN
was/VBD
active/JJ
in/IN
the/DT
LT-producing/JJ
C81-66-45/NN
cell/NN
line/NN
,/,
which/WDT
contains/VBZ
defective/JJ
HTLV-I/NN
but/CC
expresses/VBZ
tax/NN
./.
====================
The/DT
observation/NN
that/IN
a/DT
mutated/VBN
LT-kappa/NN
B/NN
construct/NN
(/(
M1-CAT/NN
)/)
was/VBD
inactive/JJ
in/IN
C81-66-45/NN
,/,
confirmed/VBD
the/DT
importance/NN
of/IN
NF-kappa/NN
B/NN
in/IN
LT/NN
gene/NN
expression/NN
./.
====================
Tax/NN
was/VBD
transfected/VBN
into/IN
HTLV-I-negative/JJ
human/JJ
T-cell/NN
lines/NNS
./.
====================
Jurkat/NN
T/NN
cells/NNS
stably/RB
expressing/VBG
tax/NN
contained/VBD
elevated/JJ
levels/NNS
of/IN
NF-kappa/NN
B/NN
that/WDT
directly/RB
bound/VBD
to/TO
the/DT
LT-kappa/NN
B/NN
site/NN
./.
====================
Tax/NN
co-transfected/VBN
with/IN
reporter/NN
constructs/NNS
into/IN
Jurkat/NN
cells/NNS
maximally/RB
activated/VBD
HTLV-I-LTR-CAT/NN
and/CC
kappa/NN
B-fos-CAT/NN
and/CC
also/RB
activated/VBD
LT-293/NN
to/TO
a/DT
lesser/JJR
extent/NN
./.
====================
In/IN
JM/NN
T/NN
cells/NNS
,/,
tax/NN
induced/JJ
LT-293/NN
activity/NN
by/IN
two-/CD
to/TO
four-fold/JJ
,/,
though/IN
there/EX
was/VBD
no/DT
induction/NN
of/IN
M1-CAT/NN
./.
====================
The/DT
increase/NN
in/IN
LT-293/NN
CAT/NN
activity/NN
mirrored/VBD
the/DT
increase/NN
in/IN
LT/NN
biologic/JJ
activity/NN
seen/VBN
under/IN
these/DT
conditions/NNS
./.
====================
These/DT
studies/NNS
,/,
the/DT
first/JJ
to/TO
demonstrate/VB
induction/NN
of/IN
LT/NN
promoter/NN
activity/NN
over/IN
basal/JJ
levels/NNS
,/,
indicate/VBP
that/IN
HTLV-I/NN
tax/NN
causes/VBZ
low-level/JJ
activation/NN
of/IN
both/CC
endogenous/JJ
LT/NN
and/CC
the/DT
LT/NN
promoter/NN
,/,
at/IN
least/JJS
in/IN
part/NN
through/IN
activation/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
UI/LS
-/:
93276575/CD
====================
TI/LS
-/:
A/DT
concatenated/JJ
form/NN
of/IN
Epstein-Barr/JJ
viral/JJ
DNA/NN
in/IN
lymphoblastoid/JJ
cell/NN
lines/NNS
induced/VBN
by/IN
transfection/NN
with/IN
BZLF1/NN
./.
====================
AB/LS
-/:
The/DT
replicative/JJ
form/NN
of/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
DNA/NN
was/VBD
studied/VBN
using/VBG
two/CD
lymphoblastoid/JJ
cell/NN
lines/NNS
,/,
X50-7/NN
and/CC
6F11/NN
,/,
which/WDT
are/VBP
latently/RB
infected/VBN
by/IN
Epstein-Barr/JJ
virus/NN
./.
====================
The/DT
lytic/JJ
cycle/NN
of/IN
EBV/NN
infection/NN
was/VBD
induced/VBN
by/IN
transfection/NN
of/IN
the/DT
cells/NNS
with/IN
the/DT
BRLF1/BZLF1/NN
coding/NN
region/NN
of/IN
the/DT
P3HR-1/NN
defective/JJ
genome/NN
./.
====================
We/PRP
combined/VBD
two/CD
techniques/NNS
to/TO
identify/VB
the/DT
productive/JJ
replicative/JJ
form/NN
of/IN
Epstein-Barr/JJ
viral/JJ
DNA/NN
in/IN
the/DT
lytic/JJ
cycle-induced/JJ
cells/NNS
./.
====================
Restriction/NN
enzyme/NN
analysis/NN
followed/VBN
by/IN
Southern/NN
blot/NN
hybridization/NN
identified/VBD
a/DT
significant/JJ
increase/NN
in/IN
the/DT
fused/VBN
fragment/NN
encompassing/VBG
both/DT
ends/NNS
of/IN
EBV/NN
DNA/NN
./.
====================
This/DT
indicates/VBZ
an/DT
increase/NN
in/IN
either/CC
episomal/JJ
DNA/NN
or/CC
concatameric/JJ
linear/JJ
DNA/NN
./.
====================
Southern/NN
blot/NN
analysis/NN
of/IN
in/FW
situ/FW
lysing/VBG
gels/NNS
revealed/VBD
that/IN
the/DT
cellular/JJ
content/NN
of/IN
linear/JJ
EBV/NN
DNA/NN
was/VBD
also/RB
increased/VBN
significantly/RB
after/IN
the/DT
initiation/NN
of/IN
the/DT
viral/JJ
lytic/JJ
cycle/NN
,/,
while/IN
the/DT
amount/NN
of/IN
circular/JJ
DNA/NN
remained/VBD
approximately/RB
constant/JJ
./.
====================
We/PRP
propose/VBP
from/IN
these/DT
results/NNS
that/IN
the/DT
source/NN
of/IN
the/DT
fused/VBN
fragment/NN
encompassing/VBG
both/DT
ends/NNS
of/IN
EBV/NN
DNA/NN
is/VBZ
a/DT
concatenated/VBN
linear/JJ
EBV/NN
DNA/NN
molecule/NN
,/,
and/CC
that/IN
such/PDT
a/DT
concatenated/VBN
molecule/NN
most/RBS
likely/RB
represents/VBZ
a/DT
replicative/JJ
form/NN
of/IN
EBV/NN
DNA/NN
in/IN
productively/RB
infected/JJ
cells/NNS
./.
====================
UI/LS
-/:
93266777/CD
====================
TI/LS
-/:
Expression/NN
levels/NNS
of/IN
the/DT
thyrotropin/NN
receptor/NN
gene/NN
in/IN
autoimmune/JJ
thyroid/NN
disease/NN
:/:
coregulation/NN
with/IN
parameters/NNS
of/IN
thyroid/NN
function/NN
and/CC
inverse/JJ
relation/NN
to/TO
major/JJ
histocompatibility/NN
complex/NN
classes/NNS
I/CD
and/CC
II/CD
./.
====================
AB/LS
-/:
Using/VBG
a/DT
human/JJ
TSH/NN
receptor/NN
(/(
TSH-R/NN
)/)
cDNA/NN
probe/NN
,/,
we/PRP
investigated/VBD
TSH-R/NN
transcript/NN
levels/NNS
in/IN
13/CD
human/JJ
thyroid/NN
fragments/NNS
by/IN
Northern/NN
blot/NN
analysis/NN
;/:
7/CD
Graves/NN
'/POS
disease/NN
,/,
2/CD
Hashimoto/NN
's/POS
disease/NN
,/,
3/CD
endemic/JJ
goiter/NN
,/,
and/CC
1/CD
healthy/JJ
thyroid/NN
gland/NN
were/VBD
studied/VBN
./.
====================
TSH-R/NN
expression/NN
levels/NNS
were/VBD
variable/JJ
,/,
but/CC
displayed/VBD
a/DT
close/JJ
correlation/NN
to/TO
the/DT
expression/NN
of/IN
thyroid/NN
peroxidase/NN
(/(
r/NN
=/JJ
0.703/CD
;/:
P/NN
</JJR
0.05/CD
)/)
,/,
thyroglobulin/NN
(/(
r/NN
=/JJ
0.817/CD
;/:
P/NN
</JJR
0.01/CD
)/)
,/,
and/CC
the/DT
nuclear/JJ
oncogene/NN
c-fos/NN
(/(
r/NN
=/JJ
0.935/CD
;/:
P/NN
</JJR
0.001/CD
)/)
,/,
but/CC
not/RB
c-myc/NN
./.
====================
Overall/RB
,/,
TSH-R/NN
transcript/NN
levels/NNS
were/VBD
low/JJ
or/CC
absent/JJ
in/IN
those/DT
thyroids/NNS
in/IN
which/WDT
expression/NN
of/IN
the/DT
major/JJ
histocompatibility/NN
complex/NN
class/NN
I/CD
or/CC
II/CD
(/(
MHC/NN
I/CD
or/CC
II/CD
)/)
was/VBD
high/JJ
,/,
thus/RB
establishing/VBG
an/DT
inverse/JJ
relation/NN
(/(
MHC/NN
I/NN
,/,
r/NN
=/JJ
-0.791/CD
;/:
P/NN
</JJR
0.01/CD
;/:
MHC/NN
II/CD
,/,
r/NN
=/JJ
-0.784/NN
;/:
P/NN
</JJR
0.01/CD
)/)
./.
====================
In/FW
situ/FW
hybridization/NN
showed/VBD
that/IN
apart/RB
from/IN
lymphocytes/NNS
,/,
thyroid/NN
cells/NNS
themselves/PRP
were/VBD
the/DT
source/NN
of/IN
MHC/NN
II/CD
transcripts/NNS
./.
====================
gamma-Interferon/NN
expression/NN
was/VBD
only/RB
detectable/JJ
in/IN
1/CD
Hashimoto/NN
's/POS
goiter/NN
./.
====================
Our/PRP$
findings/NNS
suggest/VBP
that/IN
next/JJ
to/TO
lymphocyte/NN
infiltration/NN
,/,
active/JJ
regulatory/JJ
events/NNS
in/IN
the/DT
thyrocyte/NN
are/VBP
responsible/JJ
for/IN
the/DT
inverse/JJ
relation/NN
between/IN
functional/JJ
parameters/NNS
(/(
TSH-R/NN
,/,
thyroid/NN
peroxidase/NN
,/,
thyroglobulin/NN
,/,
and/CC
c-fos/NN
)/)
and/CC
immunological/JJ
markers/NNS
(/(
MHC/NN
I/CD
and/CC
II/CD
)/)
./.
====================
UI/LS
-/:
93224755/CD
====================
TI/LS
-/:
Functional/JJ
antagonism/NN
between/IN
vitamin/NN
D3/NN
and/CC
retinoic/JJ
acid/NN
in/IN
the/DT
regulation/NN
of/IN
CD14/NN
and/CC
CD23/NN
expression/NN
during/IN
monocytic/JJ
differentiation/NN
of/IN
U-937/NN
cells/NNS
./.
====================
AB/LS
-/:
1,25/CD
alpha-Dihydroxicholecalciferol/NN
(/(
VitD3/NN
)/)
and/CC
retinoic/JJ
acid/NN
(/(
RA/NN
)/)
are/VBP
important/JJ
regulators/NNS
of/IN
the/DT
proliferation/NN
and/CC
differentiation/NN
of/IN
several/JJ
cell/NN
types/NNS
./.
====================
This/DT
paper/NN
describes/VBZ
how/WRB
the/DT
expression/NN
of/IN
the/DT
monocyte-macrophage/JJ
Ag/NN
,/,
CD14/NN
,/,
and/CC
the/DT
low/JJ
affinity/NN
Fc/NN
receptor/NN
for/IN
IgE/NN
,/,
CD23/NN
,/,
were/VBD
inversely/RB
regulated/VBN
during/IN
VitD3-/NN
and/CC
RA-induced/JJ
monocytic/JJ
differentiation/NN
of/IN
human/JJ
U-937/NN
monoblasts/NNS
./.
====================
PMA/NN
induced/VBD
the/DT
expression/NN
of/IN
both/CC
CD14/NN
and/CC
CD23/NN
mRNA/NN
and/CC
protein/NN
./.
====================
Exposure/NN
to/TO
VitD3/NN
rapidly/RB
induced/VBD
the/DT
de/FW
novo/FW
expression/NN
of/IN
CD14/NN
mRNA/NN
and/CC
protein/NN
./.
====================
The/DT
addition/NN
of/IN
cycloheximide/NN
completely/RB
blocked/VBD
the/DT
VitD3/NN
induction/NN
of/IN
CD14/NN
mRNA/NN
expression/NN
,/,
indicating/VBG
that/IN
the/DT
induction/NN
was/VBD
dependent/JJ
on/IN
ongoing/JJ
protein/NN
synthesis/NN
./.
====================
While/IN
inducing/VBG
CD14/NN
expression/NN
,/,
VitD3/NN
concomitantly/RB
suppressed/VBD
the/DT
basal/JJ
,/,
PMA-/NN
,/,
and/CC
RA-inducible/JJ
CD23/NN
expression/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
./.
====================
In/IN
contrast/NN
,/,
U-937/NN
cells/NNS
induced/VBN
by/IN
RA/NN
strongly/RB
increased/VBD
their/PRP$
expression/NN
of/IN
CD23/NN
mRNA/NN
and/CC
protein/NN
,/,
whereas/IN
they/PRP
completely/RB
lacked/VBD
detectable/JJ
CD14/NN
cell/NN
surface/NN
or/CC
mRNA/NN
expression/NN
./.
====================
Furthermore/RB
,/,
the/DT
VitD3-/NN
and/CC
the/DT
PMA-induced/JJ
CD14/NN
expression/NN
was/VBD
inhibited/VBN
as/IN
a/DT
temporal/JJ
consequence/NN
of/IN
the/DT
RA-induced/JJ
differentiation/NN
./.
====================
The/DT
results/NNS
suggest/VBP
that/IN
there/EX
exists/VBZ
a/DT
functional/JJ
antagonism/NN
between/IN
VitD3/NN
and/CC
RA/NN
that/WDT
may/MD
have/VB
important/JJ
implications/NNS
for/IN
the/DT
regulation/NN
of/IN
certain/JJ
immune/JJ
and/CC
inflammatory/JJ
responses/NNS
through/IN
their/PRP$
inverse/JJ
effects/NNS
on/IN
CD14/NN
and/CC
CD23/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
93275333/CD
====================
TI/LS
-/:
Cell-specific/JJ
bifunctional/JJ
role/NN
of/IN
Jun/NN
oncogene/NN
family/NN
members/NNS
on/IN
glucocorticoid/NN
receptor-dependent/JJ
transcription/NN
./.
====================
AB/LS
-/:
Interaction/NN
between/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
-/:
and/CC
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
-mediated/JJ
signaling/NN
is/VBZ
suggested/VBN
by/IN
the/DT
ability/NN
of/IN
the/DT
PKC/NN
activating/NN
phorbol/NN
ester/NN
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
to/TO
inhibit/VB
GR-dependent/JJ
transcription/NN
of/IN
the/DT
mouse/NN
mammary/JJ
tumor/NN
virus/NN
(/(
MMTV/NN
)/)
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
this/DT
interference/NN
is/VBZ
cell/NN
specific/JJ
,/,
as/IN
TPA/NN
augmented/VBD
dexamethasone-induced/JJ
transcriptional/JJ
activation/NN
of/IN
the/DT
MMTV/NN
LTR/NN
in/IN
several/JJ
T/NN
cell/NN
lines/NNS
but/CC
was/VBD
inhibitory/JJ
in/IN
NIH-3T3/NN
fibroblasts/NNS
./.
====================
TPA-GR/NN
synergism/NN
was/VBD
determined/VBN
to/TO
have/VB
occurred/VBN
at/IN
the/DT
GR-responsive/JJ
element/NN
(/(
GRE/NN
)/)
level/NN
by/IN
functional/JJ
analysis/NN
of/IN
deletion/NN
mutants/NNS
or/CC
synthetic/JJ
GRE/NN
oligonucleotides/NNS
driving/VBG
chloramphenicol/NN
acetyl-transferase/NN
expression/NN
./.
====================
Synergism/NN
required/VBD
an/DT
intact/JJ
GR/NN
DNA-binding/JJ
domain/NN
,/,
whereas/IN
amino-/NN
or/CC
carboxyl-terminal/JJ
domains/NNS
were/VBD
dispensable/JJ
./.
====================
The/DT
effect/NN
was/VBD
abrogated/VBN
by/IN
the/DT
PKC/NN
inhibitor/NN
staurosporine/NN
,/,
suggesting/VBG
a/DT
role/NN
for/IN
PKC/NN
./.
====================
Increased/VBN
c-jun/NN
,/,
jun-B/NN
,/,
and/CC
jun-D/NN
expression/NN
above/IN
basal/JJ
levels/NNS
and/CC
increased/VBN
transcriptional/JJ
activity/NN
of/IN
AP-1/TPA/NN
responsive/JJ
elements/NNS
fused/VBN
to/TO
chloramphenicol/NN
acetyl-transferase/NN
vectors/NNS
were/VBD
observed/VBN
in/IN
T/NN
cells/NNS
treated/VBN
with/IN
TPA/NN
alone/RB
or/CC
in/IN
combination/NN
with/IN
dexamethasone/NN
./.
====================
The/DT
ability/NN
of/IN
Jun/NN
proteins/NNS
to/TO
cooperate/VB
with/IN
GR/NN
in/IN
T/NN
cells/NNS
has/VBZ
been/VBN
investigated/VBN
after/IN
transfection/NN
of/IN
c-jun/NN
,/,
jun-B/NN
,/,
or/CC
jun-D/NN
expression/NN
vectors/NNS
,/,
which/WDT
augmented/VBD
GR-dependent/JJ
transcription/NN
from/IN
either/CC
MMTV/NN
LTR/NN
or/CC
GRE/NN
./.
====================
Conversely/RB
,/,
c-jun/NN
and/CC
jun-B/NN
transfection/NN
blunted/VBD
GR-dependent/JJ
transcription/NN
in/IN
HeLa/NN
cells/NNS
./.
====================
The/DT
presence/NN
of/IN
c-fos/NN
had/VBD
a/DT
negative/JJ
influence/NN
on/IN
GR/NN
function/NN
and/CC
correlated/VBD
with/IN
the/DT
cell-specific/JJ
synergistic/JJ
or/CC
antagonistic/JJ
activity/NN
of/IN
Jun/NN
with/IN
respect/NN
to/TO
GR/NN
;/:
high/JJ
basal/JJ
expression/NN
of/IN
c-fos/NN
as/RB
well/RB
as/IN
AP-1/NN
DNA/NN
binding/NN
and/CC
transcriptional/JJ
activity/NN
were/VBD
observed/VBN
in/IN
HeLa/NN
cells/NNS
,/,
but/CC
not/RB
in/IN
T/NN
cells/NNS
./.
====================
Furthermore/RB
overexpression/NN
of/IN
exogenous/JJ
c-fos/NN
has/VBZ
an/DT
inhibitory/JJ
effect/NN
on/IN
GR-dependent/JJ
transcription/NN
from/IN
GRE/NN
in/IN
T/NN
cells/NNS
./.
====================
We/PRP
propose/VBP
that/IN
Jun/NN
plays/VBZ
a/DT
bifunctional/JJ
role/NN
on/IN
GR-dependent/JJ
transcriptional/JJ
activation/NN
of/IN
GRE/NN
,/,
selecting/VBG
either/CC
synergistic/JJ
or/CC
antagonistic/JJ
activity/NN
depending/VBG
on/IN
the/DT
cell-specific/JJ
microenvironment/NN
./.
====================
In/IN
this/DT
regard/NN
,/,
intracellular/JJ
levels/NNS
of/IN
c-fos/NN
appear/VBP
to/TO
be/VB
influential/JJ
./.
====================
UI/LS
-/:
93194904/CD
====================
TI/LS
-/:
Cell/NN
type-/NN
and/CC
stage-specific/JJ
expression/NN
of/IN
the/DT
CD20/B1/NN
antigen/NN
correlates/VBZ
with/IN
the/DT
activity/NN
of/IN
a/DT
diverged/JJ
octamer/NN
DNA/NN
motif/NN
present/JJ
in/IN
its/PRP$
promoter/NN
./.
====================
AB/LS
-/:
The/DT
CD20/NN
(/(
B1/NN
)/)
gene/NN
encodes/VBZ
a/DT
B/NN
cell-specific/JJ
protein/NN
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
human/JJ
B/NN
cell/NN
proliferation/NN
and/CC
differentiation/NN
./.
====================
Studies/NNS
with/IN
5'/JJ
deletion/NN
CD20/NN
promoter-CAT/NN
constructs/NNS
have/VBP
previously/RB
revealed/VBN
two/CD
regions/NNS
of/IN
the/DT
promoter/NN
between/IN
bases/NNS
-186/CD
and/CC
-280/CD
and/CC
between/IN
bases/NNS
-280/CD
and/CC
-454/CD
which/WDT
contained/VBD
positive/JJ
regulatory/JJ
elements/NNS
./.
====================
In/IN
this/DT
study/NN
we/PRP
identified/VBD
a/DT
sequence/NN
element/NN
present/JJ
in/IN
the/DT
most/RBS
proximal/JJ
region/NN
located/JJ
between/IN
bases/NNS
-214/CD
and/CC
-201/CD
,/,
TTCTTCTAATTAA/NN
,/,
which/WDT
is/VBZ
important/JJ
in/IN
the/DT
high/JJ
constitutive/JJ
expression/NN
of/IN
CD20/NN
in/IN
mature/JJ
B/NN
cells/NNS
and/CC
the/DT
induction/NN
of/IN
CD20/NN
in/IN
pre-B/JJ
cells/NNS
./.
====================
This/DT
sequence/NN
element/NN
was/VBD
referred/VBN
to/TO
as/IN
the/DT
BAT/NN
box/NN
and/CC
its/PRP$
deletion/NN
significantly/RB
reduced/VBD
the/DT
activity/NN
of/IN
a/DT
CD20/NN
promoter-CAT/JJ
construct/NN
in/IN
B/NN
cells/NNS
./.
====================
Mobility/NN
shift/NN
assays/NNS
with/IN
various/JJ
mutant/JJ
probes/NNS
and/CC
B/NN
cell/NN
nuclear/JJ
extracts/NNS
demonstrated/VBD
that/IN
the/DT
core/NN
sequence/NN
TAAT/NN
was/VBD
essential/JJ
for/IN
binding/VBG
to/TO
this/DT
site/NN
./.
====================
Cross/NN
competition/NN
experiments/NNS
with/IN
an/DT
octamer/NN
sequence/NN
from/IN
the/DT
Ig/NN
heavy/JJ
chain/NN
promoter/NN
,/,
the/DT
BAT/NN
box/NN
,/,
and/CC
a/DT
TA-rich/JJ
sequence/NN
present/JJ
in/IN
the/DT
CD21/NN
promoter/NN
revealed/VBD
that/IN
all/DT
three/CD
sequences/NNS
bound/VBD
the/DT
same/JJ
nuclear/JJ
proteins/NNS
suggesting/VBG
that/IN
the/DT
BAT/NN
box/NN
binding/NN
proteins/NNS
were/VBD
Oct-1/NN
and/CC
Oct-2/NN
./.
====================
Southwestern/NN
blotting/NN
and/CC
UV/NN
cross-linking/NN
studies/NNS
confirmed/VBD
that/IN
the/DT
BAT/NN
box/NN
binding/NN
proteins/NNS
were/VBD
Oct-1/NN
and/CC
Oct-2/NN
./.
====================
The/DT
affinity/NN
of/IN
the/DT
BAT/NN
box/NN
binding/NN
proteins/NNS
for/IN
the/DT
BAT/NN
box/NN
was/VBD
approximately/RB
25-fold/RB
less/JJR
than/IN
for/IN
the/DT
octamer/NN
sequence/NN
and/CC
the/DT
BAT/NN
box/NN
binding/NN
proteins/NNS
dissociated/VBD
from/IN
the/DT
BAT/NN
box/NN
10-fold/RB
more/RBR
rapidly/RB
than/IN
from/IN
the/DT
octamer/NN
sequence/NN
./.
====================
Despite/IN
this/DT
lower/JJR
affinity/NN
,/,
a/DT
trimer/NN
of/IN
the/DT
BAT/NN
box/NN
sequence/NN
was/VBD
as/IN
efficiently/RB
transactivated/VBN
by/IN
an/DT
Oct-2/NN
expression/NN
vector/NN
as/IN
was/VBD
a/DT
trimer/NN
of/IN
the/DT
octamer/NN
sequence/NN
in/IN
HeLa/NN
cells/NNS
./.
====================
The/DT
BAT/NN
box/NN
and/CC
Oct-2/NN
were/VBD
also/RB
implicated/VBN
in/IN
the/DT
induction/NN
of/IN
CD20/NN
in/IN
the/DT
pre-B/JJ
cell/NN
line/NN
,/,
PB-697/NN
,/,
via/IN
phorbol/NN
esters/NNS
./.
====================
The/DT
induction/NN
of/IN
CD20/NN
mRNA/NN
was/VBD
temporally/RB
associated/VBN
with/IN
induction/NN
of/IN
Oct-2/NN
mRNA/NN
and/CC
a/DT
BAT/NN
box-deleted/JJ
CD20-CAT/NN
construct/NN
,/,
in/IN
contrast/NN
to/TO
the/DT
wild/JJ
type/NN
,/,
was/VBD
poorly/RB
induced/VBN
by/IN
phorbol/NN
esters/NNS
./.
====================
Together/RB
these/DT
results/NNS
suggest/VBP
that/IN
the/DT
BAT/NN
box/NN
binding/NN
proteins/NNS
are/VBP
important/JJ
in/IN
the/DT
B/NN
cell/NN
specific/JJ
expression/NN
of/IN
CD20/NN
and/CC
perhaps/RB
CD21/NN
./.
====================
UI/LS
-/:
93184333/CD
====================
TI/LS
-/:
Human/JJ
CD4/NN
lymphocytes/NNS
specifically/RB
recognize/VBP
a/DT
peptide/NN
representing/VBG
the/DT
fusion/NN
region/NN
of/IN
the/DT
hybrid/NN
protein/NN
pml/RAR/NN
alpha/NN
present/JJ
in/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
cells/NNS
./.
====================
AB/LS
-/:
Fusion/NN
proteins/NNS
present/JJ
in/IN
leukemic/JJ
cells/NNS
frequently/RB
contain/VBP
a/DT
new/JJ
amino/NN
acid/NN
at/IN
the/DT
fusion/NN
point/NN
./.
====================
We/PRP
tested/VBD
whether/IN
a/DT
peptide/NN
(/(
BCR1/25/NN
)/)
encompassing/VBG
the/DT
fusion/NN
region/NN
of/IN
the/DT
hybrid/NN
molecule/NN
pml/RAR/NN
alpha/NN
,/,
which/WDT
is/VBZ
selectively/RB
expressed/VBN
by/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
(/(
APL/NN
)/)
cells/NNS
,/,
can/MD
be/VB
recognized/VBN
by/IN
human/JJ
T/NN
lymphocytes/NNS
in/FW
vitro/FW
./.
====================
CD4+/JJ
lymphocytes/NNS
,/,
at/IN
both/CC
polyclonal/JJ
and/CC
clonal/JJ
level/NN
,/,
recognized/VBD
peptide/NN
BCR1/25/NN
in/IN
an/DT
HLA-DR/NN
--/:
restricted/JJ
fashion/NN
on/IN
presentation/NN
by/IN
autologous/JJ
antigen-presenting/JJ
cell/NN
(/(
APC/NN
)/)
or/CC
by/IN
APC/NN
expressing/VBG
the/DT
HLA-DR11/NN
restricting/NN
molecule/NN
./.
====================
Control/NN
peptides/NNS
corresponding/VBG
to/TO
the/DT
normal/JJ
pml/NN
and/CC
RAR/NN
alpha/NN
proteins/NNS
were/VBD
not/RB
recognized/VBN
./.
====================
One/CD
clone/NN
(/(
DEG5/NN
)/)
also/RB
exerted/VBD
a/DT
high/JJ
and/CC
specific/JJ
cytotoxicity/NN
against/IN
autologous/JJ
cells/NNS
pulsed/VBN
with/IN
BCR1/25/NN
./.
====================
The/DT
autologous/JJ
DE/NN
LCL/NN
containing/VBG
a/DT
transduced/VBN
pml/RAR/NN
alpha/NN
fusion/NN
gene/NN
and/CC
expressing/VBG
a/DT
bcr1/NN
type/NN
of/IN
the/DT
pml/RAR/NN
alpha/NN
hybrid/NN
protein/NN
induced/VBD
the/DT
proliferation/NN
of/IN
DE/NN
anti-BCR1/25/CD
T/NN
cell/NN
clones/NNS
./.
====================
It/PRP
is/VBZ
concluded/VBN
that/IN
the/DT
bcr1/NN
type-pml/RAR/NN
alpha/NN
fusion/NN
protein/NN
of/IN
APL/NN
contains/VBZ
an/DT
antigenic/JJ
site/NN
,/,
absent/JJ
from/IN
the/DT
normal/JJ
parent/NN
molecules/NNS
and/CC
recognized/VBN
by/IN
human/JJ
CD4+/JJ
lymphocytes/NNS
./.
====================
UI/LS
-/:
93145322/CD
====================
TI/LS
-/:
The/DT
zinc/NN
finger/NN
transcription/NN
factor/NN
Egr-1/NN
is/VBZ
essential/JJ
for/IN
and/CC
restricts/VBZ
differentiation/NN
along/IN
the/DT
macrophage/NN
lineage/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
isolated/VBN
cDNA/NN
clones/NNS
of/IN
myeloid/JJ
differentiation/NN
primary/JJ
response/NN
(/(
MyD/NN
)/)
genes/NNS
,/,
activated/VBN
in/IN
the/DT
absence/NN
of/IN
de/FW
novo/FW
protein/NN
synthesis/NN
following/VBG
induction/NN
for/IN
differentiation/NN
along/IN
either/CC
the/DT
macrophage/NN
or/CC
granulocyte/NN
lineage/NN
in/IN
human/JJ
myeloblastic/JJ
leukemia/NN
HL-60/NN
cells/NNS
./.
====================
One/CD
cDNA/NN
clone/NN
of/IN
a/DT
primary/JJ
response/NN
gene/NN
,/,
expressed/VBN
upon/IN
macrophage/NN
differentiation/NN
,/,
encoded/VBD
for/IN
Egr-1/NN
,/,
a/DT
zinc/NN
finger/NN
transcription/NN
factor/NN
./.
====================
The/DT
Egr-1/NN
gene/NN
was/VBD
observed/VBN
to/TO
be/VB
transcriptionally/RB
silent/JJ
in/IN
HL-60/NN
cells/NNS
,/,
but/CC
active/JJ
in/IN
U-937/NN
and/CC
M1/NN
cells/NNS
,/,
the/DT
latter/JJ
two/CD
being/VBG
predetermined/VBN
for/IN
macrophage/NN
differentiation/NN
./.
====================
Egr-1/NN
antisense/JJ
oligomers/NNS
in/IN
the/DT
culture/NN
media/NNS
blocked/VBD
macrophage/NN
differentiation/NN
in/IN
both/DT
myeloid/JJ
leukemia/NN
cell/NN
lines/NNS
and/CC
normal/JJ
myeloblasts/NNS
./.
====================
HL-60/NN
cells/NNS
constitutively/RB
expressing/VBG
an/DT
Egr-1/NN
transgene/NN
(/(
HL-60Egr-1/NN
)/)
could/MD
be/VB
induced/VBN
for/IN
macrophage/NN
,/,
but/CC
not/RB
granulocyte/NN
,/,
differentiation/NN
./.
====================
These/DT
observations/NNS
indicate/VBP
that/IN
expression/NN
of/IN
Egr-1/NN
is/VBZ
essential/JJ
for/IN
and/CC
restricts/VBZ
differentiation/NN
of/IN
myeloblasts/NNS
along/IN
the/DT
macrophage/NN
lineage/NN
./.
====================
UI/LS
-/:
93154317/CD
====================
TI/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
nuclear/JJ
antigen/NN
2/CD
interacts/VBZ
with/IN
an/DT
EBNA2/NN
responsive/JJ
cis-element/NN
of/IN
the/DT
terminal/JJ
protein/NN
1/CD
gene/NN
promoter/NN
./.
====================
AB/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
protein/NN
EBNA2/NN
acts/VBZ
as/IN
a/DT
transcriptional/JJ
activator/NN
of/IN
cellular/JJ
and/CC
viral/JJ
genes/NNS
and/CC
plays/VBZ
a/DT
crucial/JJ
role/NN
in/IN
the/DT
immortalization/NN
of/IN
human/JJ
primary/JJ
B-cells/NNS
by/IN
EBV/NN
./.
====================
We/PRP
have/VBP
shown/VBN
previously/RB
that/IN
EBNA2/NN
transactivates/VBZ
the/DT
promoters/NNS
of/IN
the/DT
latent/JJ
membrane/NN
antigens/NNS
LMP/NN
,/,
TP1/NN
and/CC
TP2/NN
./.
====================
The/DT
promoter/NN
of/IN
the/DT
TP1/NN
gene/NN
was/VBD
chosen/VBN
as/IN
a/DT
model/JJ
system/NN
to/TO
study/VB
the/DT
molecular/JJ
mechanism/NN
of/IN
EBNA2/NN
mediated/JJ
transactivation/NN
./.
====================
To/TO
identify/VB
an/DT
EBNA2/NN
dependent/JJ
cis-acting/JJ
element/NN
,/,
various/JJ
TP1/NN
promoter-reporter/NN
gene/NN
constructs/NNS
were/VBD
transfected/VBN
in/IN
the/DT
absence/NN
and/CC
presence/NN
of/IN
an/DT
EBNA2/NN
expression/NN
vector/NN
into/IN
the/DT
established/JJ
B-cell/NN
line/NN
BL41-P3HR1/NN
./.
====================
We/PRP
were/VBD
able/JJ
to/TO
delineate/VB
an/DT
81/CD
bp/NN
EBNA2/NN
responsive/JJ
region/NN
between/IN
-258/CD
and/CC
-177/CD
relative/JJ
to/TO
the/DT
TP1/NN
RNA/NN
start/NN
site/NN
./.
====================
The/DT
element/NN
worked/VBD
in/IN
either/DT
orientation/NN
and/CC
could/MD
mediate/VB
EBNA2/NN
dependent/JJ
transactivation/NN
on/IN
a/DT
heterologous/JJ
promoter/NN
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
revealed/VBD
three/CD
specific/JJ
protein-DNA/NN
complexes/NNS
formed/VBN
with/IN
sequences/NNS
of/IN
the/DT
EBNA2/NN
responsive/JJ
element/NN
./.
====================
Two/CD
of/IN
these/DT
were/VBD
not/RB
cell/NN
type/NN
specific/JJ
,/,
but/CC
the/DT
third/JJ
was/VBD
detected/VBN
only/RB
in/IN
EBNA2/NN
positive/JJ
cell/NN
extracts/NNS
./.
====================
Gel-shift/JJ
analysis/NN
in/IN
the/DT
presence/NN
of/IN
EBNA2/NN
specific/JJ
monoclonal/JJ
antibodies/NNS
revealed/VBD
that/IN
EBNA2/NN
is/VBZ
a/DT
component/NN
of/IN
the/DT
third/JJ
complex/NN
./.
====================
Thus/RB
,/,
these/DT
experiments/NNS
demonstrate/VBP
that/IN
EBNA2/NN
interacts/VBZ
with/IN
an/DT
EBNA2/NN
responsive/JJ
cis-element/NN
of/IN
the/DT
TP1/NN
promoter/NN
====================
UI/LS
-/:
93315684/CD
====================
TI/LS
-/:
Minimally/RB
modified/VBN
low/JJ
density/NN
lipoprotein-induced/JJ
inflammatory/JJ
responses/NNS
in/IN
endothelial/JJ
cells/NNS
are/VBP
mediated/VBN
by/IN
cyclic/JJ
adenosine/NN
monophosphate/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
minimally/RB
oxidized/VBN
LDL/NN
(/(
MM-LDL/NN
)/)
activated/VBD
endothelial/JJ
cells/NNS
to/TO
increase/VB
their/PRP$
interaction/NN
with/IN
monocytes/NNS
but/CC
not/RB
neutrophils/NNS
,/,
inducing/VBG
monocyte/NN
but/CC
not/RB
neutrophil/NN
binding/NN
and/CC
synthesis/NN
of/IN
monocyte/NN
chemotactic/JJ
protein-1/NN
and/CC
monocyte/NN
colony-stimulating/JJ
factor/NN
(/(
M-CSF/NN
)/)
./.
====================
In/IN
the/DT
present/JJ
studies/NNS
we/PRP
have/VBP
examined/VBN
the/DT
signaling/NN
pathways/NNS
by/IN
which/WDT
this/DT
monocyte-specific/JJ
response/NN
is/VBZ
induced/VBN
./.
====================
Both/CC
induction/NN
of/IN
monocyte/NN
binding/NN
and/CC
mRNA/NN
levels/NNS
for/IN
M-CSF/NN
by/IN
MM-LDL/NN
were/VBD
not/RB
inhibited/VBN
in/IN
protein/NN
kinase/NN
C-depleted/JJ
endothelial/JJ
cells/NNS
./.
====================
A/DT
number/NN
of/IN
our/PRP$
studies/NNS
indicate/VBP
that/IN
cAMP/NN
is/VBZ
the/DT
second/JJ
messenger/NN
for/IN
the/DT
effects/NNS
of/IN
MM-LDL/NN
cited/VBN
above/RB
./.
====================
Incubation/NN
of/IN
endothelial/JJ
cells/NNS
with/IN
MM-LDL/NN
caused/VBD
a/DT
173/CD
%/NN
increase/NN
in/IN
intracellular/JJ
cAMP/NN
levels/NNS
./.
====================
Agents/NNS
which/WDT
increased/VBD
cAMP/NN
levels/NNS
,/,
including/VBG
cholera/NN
toxin/NN
,/,
pertussis/NN
toxin/NN
,/,
dibutyryl/NN
cAMP/NN
,/,
and/CC
isoproterenol/NN
mimicked/VBD
the/DT
actions/NNS
of/IN
MM-LDL/NN
./.
====================
Agents/NNS
which/WDT
elevated/VBD
cAMP/NN
were/VBD
also/RB
shown/VBN
to/TO
activate/VB
NF/NN
kappa/NN
B/NN
,/,
suggesting/VBG
a/DT
role/NN
for/IN
this/DT
transcription/NN
factor/NN
in/IN
activation/NN
of/IN
monocyte-endothelial/JJ
interactions/NNS
./.
====================
Although/IN
endothelial/JJ
leukocyte/NN
adhesion/NN
molecule/NN
(/(
ELAM/NN
)/)
mRNA/NN
synthesis/NN
can/MD
be/VB
regulated/VBN
by/IN
NF/NN
kappa/NN
B/NN
,/,
ELAM/NN
was/VBD
not/RB
expressed/VBN
and/CC
ELAM/NN
mRNA/NN
was/VBD
only/RB
slightly/RB
elevated/JJ
in/IN
response/NN
to/TO
MM-LDL/NN
./.
====================
We/PRP
present/VBP
evidence/NN
that/IN
induction/NN
of/IN
neutrophil/NN
binding/NN
by/IN
LPS/NN
is/VBZ
actually/RB
suppressed/VBN
by/IN
agents/NNS
that/WDT
elevated/VBD
cAMP/NN
levels/NNS
./.
====================
UI/LS
-/:
93324366/CD
====================
TI/LS
-/:
Human/JJ
T/NN
cell/NN
transcription/NN
factor/NN
GATA-3/NN
stimulates/VBZ
HIV-1/NN
expression/NN
./.
====================
AB/LS
-/:
A/DT
family/NN
of/IN
transcriptional/JJ
activating/VBG
proteins/NNS
,/,
the/DT
GATA/NN
factors/NNS
,/,
has/VBZ
been/VBN
shown/VBN
to/TO
bind/VB
to/TO
a/DT
consensus/NN
motif/NN
through/IN
a/DT
highly/RB
conserved/VBN
C4/NN
zinc/NN
finger/NN
DNA/NN
binding/NN
domain/NN
./.
====================
One/CD
member/NN
of/IN
this/DT
multigene/JJ
family/NN
,/,
GATA-3/NN
,/,
is/VBZ
most/RBS
abundantly/RB
expressed/VBN
in/IN
T/NN
lymphocytes/NNS
,/,
a/DT
cellular/JJ
target/NN
for/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
infection/NN
and/CC
replication/NN
./.
====================
In/FW
vitro/FW
DNase/NN
I/CD
footprinting/NN
analysis/NN
revealed/VBD
six/CD
hGATA-3/NN
binding/NN
sites/NNS
in/IN
the/DT
U3/NN
region/NN
(/(
the/DT
transcriptional/JJ
regulatory/JJ
domain/NN
)/)
of/IN
the/DT
HIV-1/NN
LTR/NN
./.
====================
Cotransfection/NN
of/IN
an/DT
hGATA-3/NN
expression/NN
plasmid/NN
with/IN
a/DT
reporter/NN
plasmid/NN
whose/WP$
transcription/NN
is/VBZ
directed/VBN
by/IN
the/DT
HIV-1/NN
LTR/NN
resulted/VBD
in/IN
6-/CD
to/TO
10-fold/JJ
stimulation/NN
of/IN
LTR-mediated/JJ
transcription/NN
,/,
whereas/IN
site/NN
specific/JJ
mutation/NN
of/IN
these/DT
GATA/NN
sites/NNS
resulted/VBD
in/IN
virtual/JJ
abrogation/NN
of/IN
the/DT
activation/NN
by/IN
hGATA-3/NN
./.
====================
Further/RB
,/,
deletion/NN
of/IN
the/DT
hGATA-3/NN
transcriptional/JJ
activation/NN
domain/NN
abolished/VBD
GATA-dependent/JJ
HIV-1/NN
trans-activation/NN
,/,
showing/VBG
that/IN
the/DT
stimulation/NN
of/IN
viral/JJ
transcription/NN
observed/VBN
is/VBZ
a/DT
direct/JJ
effect/NN
of/IN
cotransfected/VBN
hGATA-3/NN
./.
====================
Introduction/NN
of/IN
the/DT
HIV-1/NN
plasmids/NNS
in/IN
which/WDT
the/DT
GATA/NN
sites/NNS
have/VBP
been/VBN
mutated/VBN
into/IN
human/JJ
T/NN
lymphocytes/NNS
also/RB
caused/VBD
a/DT
significant/JJ
reduction/NN
in/IN
LTR-mediated/JJ
transcription/NN
at/IN
both/CC
the/DT
basal/JJ
level/NN
and/CC
in/IN
(/(
PHA-/NN
plus/CC
PMA-/NN
)/)
stimulated/JJ
T/NN
cells/NNS
./.
====================
These/DT
observations/NNS
suggest/VBP
that/IN
in/IN
addition/NN
to/TO
its/PRP$
normal/JJ
role/NN
in/IN
T/NN
lymphocyte/NN
gene/NN
regulation/NN
,/,
hGATA-3/NN
may/MD
also/RB
play/VB
a/DT
significant/JJ
role/NN
in/IN
HIV-1/NN
transcriptional/JJ
activation/NN
./.
====================
UI/LS
-/:
93350203/CD
====================
TI/LS
-/:
Cytokine/NN
modulation/NN
of/IN
HIV/NN
expression/NN
./.
====================
AB/LS
-/:
Cytokines/NNS
,/,
the/DT
peptide/NN
hormones/NNS
which/WDT
control/VBP
the/DT
homeostasis/NN
of/IN
the/DT
immune/JJ
system/NN
and/CC
also/RB
play/VBP
a/DT
fundamental/JJ
role/NN
in/IN
inflammatory/JJ
and/CC
immune/JJ
mediated/JJ
reactions/NNS
,/,
have/VBP
been/VBN
involved/VBN
at/IN
multiple/JJ
levels/NNS
in/IN
the/DT
pathogenesis/NN
of/IN
the/DT
acquired/VBN
immune/JJ
deficiency/NN
syndrome/NN
(/(
AIDS/NN
)/)
./.
====================
Infection/NN
with/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
has/VBZ
been/VBN
shown/VBN
to/TO
induce/VB
production/NN
of/IN
several/JJ
cytokines/NNS
both/CC
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
./.
====================
Conversely/RB
,/,
several/JJ
cytokines/NNS
modulate/VBP
the/DT
levels/NNS
of/IN
HIV/NN
expression/NN
in/IN
infected/JJ
cells/NNS
of/IN
both/CC
T/NN
lymphocytic/JJ
and/CC
mononuclear/JJ
phagocytic/JJ
lineage/NN
./.
====================
Activated/VBN
mononuclear/JJ
cells/NNS
,/,
particularly/RB
B/NN
cells/NNS
which/WDT
are/VBP
in/IN
a/DT
state/NN
of/IN
chronic/JJ
activation/NN
in/IN
HIV/NN
infected/JJ
individuals/NNS
,/,
release/VBP
HIV-inductive/JJ
cytokines/NNS
and/CC
thus/RB
play/VBP
a/DT
potentially/RB
important/JJ
role/NN
in/IN
the/DT
pathogenesis/NN
of/IN
HIV/NN
infection/NN
./.
====================
UI/LS
-/:
93259462/CD
====================
TI/LS
-/:
Cloning/NN
and/CC
functional/JJ
characterization/NN
of/IN
early/JJ
B-cell/NN
factor/NN
,/,
a/DT
regulator/NN
of/IN
lymphocyte-specific/JJ
gene/NN
expression/NN
./.
====================
AB/LS
-/:
Early/JJ
B-cell/NN
factor/NN
(/(
EBF/NN
)/)
was/VBD
identified/VBN
previously/RB
as/IN
a/DT
tissue-specific/JJ
and/CC
differentiation/NN
stage-specific/JJ
DNA-binding/JJ
protein/NN
that/WDT
participates/VBZ
in/IN
the/DT
regulation/NN
of/IN
the/DT
pre-B/JJ
and/CC
B/NN
lymphocyte-specific/JJ
mb-1/NN
gene/NN
./.
====================
Partial/JJ
amino/NN
acid/NN
sequences/NNS
obtained/VBN
from/IN
purified/VBN
EBF/NN
were/VBD
used/VBN
to/TO
isolate/VB
cDNA/NN
clones/NNS
,/,
which/WDT
by/IN
multiple/JJ
criteria/NNS
encode/VB
EBF/NN
./.
====================
The/DT
recombinant/JJ
polypeptide/NN
formed/VBD
sequence-specific/JJ
complexes/NNS
with/IN
the/DT
EBF-binding/NN
site/NN
in/IN
the/DT
mb-1/NN
promoter/NN
./.
====================
The/DT
cDNA/NN
hybridized/VBD
to/TO
multiple/JJ
transcripts/NNS
in/IN
pre-B/JJ
and/CC
B-cell/NN
lines/NNS
,/,
but/CC
transcripts/NNS
were/VBD
not/RB
detected/VBN
at/IN
significant/JJ
levels/NNS
in/IN
plasmacytoma/NN
,/,
T-cell/NN
,/,
and/CC
nonlymphoid/JJ
cell/NN
lines/NNS
./.
====================
Expression/NN
of/IN
recombinant/JJ
EBF/NN
in/IN
transfected/VBN
nonlymphoid/JJ
cells/NNS
strongly/RB
activated/VBD
transcription/NN
from/IN
reporter/NN
plasmids/NNS
containing/VBG
functional/JJ
EBF-binding/JJ
sites/NNS
./.
====================
Analysis/NN
of/IN
DNA/NN
binding/NN
by/IN
deletion/NN
mutants/NNS
of/IN
EBF/NN
identified/VBD
an/DT
amino-terminal/JJ
cysteine-rich/JJ
DNA-binding/JJ
domain/NN
lacking/VBG
obvious/JJ
sequence/NN
similarity/NN
to/TO
known/JJ
transcription/NN
factors/NNS
./.
====================
DNA-binding/JJ
assays/NNS
with/IN
cotranslated/VBN
wild-type/JJ
and/CC
truncated/JJ
forms/NNS
of/IN
EBF/NN
indicated/VBD
that/IN
the/DT
protein/NN
interacts/VBZ
with/IN
its/PRP$
site/NN
as/IN
a/DT
homodimer/NN
./.
====================
Deletions/NNS
delineated/VBD
a/DT
carboxy-terminal/JJ
dimerization/NN
region/NN
containing/VBG
two/CD
repeats/NNS
of/IN
15/CD
amino/NN
acids/NNS
that/WDT
show/VBP
similarity/NN
with/IN
the/DT
dimerization/NN
domains/NNS
of/IN
basic-helix-loop-helix/JJ
proteins/NNS
./.
====================
Together/RB
,/,
these/DT
data/NNS
suggest/VBP
that/IN
EBF/NN
represents/VBZ
a/DT
novel/JJ
regulator/NN
of/IN
B/NN
lymphocyte-specific/JJ
gene/NN
expression/NN
./.
====================
UI/LS
-/:
93241941/CD
====================
TI/LS
-/:
Cell-specific/JJ
expression/NN
of/IN
helix-loop-helix/JJ
transcription/NN
factors/NNS
encoded/VBN
by/IN
the/DT
E2A/NN
gene/NN
./.
====================
AB/LS
-/:
The/DT
E2A/NN
gene/NN
encodes/VBZ
transcription/NN
factors/NNS
of/IN
the/DT
helix-loop-helix/JJ
family/NN
that/WDT
are/VBP
implicated/VBN
in/IN
cell-specific/JJ
gene/NN
expression/NN
as/IN
part/NN
of/IN
dimeric/JJ
complexes/NNS
that/WDT
interact/VBP
with/IN
E/NN
box/NN
enhancer/NN
elements/NNS
./.
====================
It/PRP
has/VBZ
previously/RB
been/VBN
shown/VBN
that/IN
transcripts/NNS
of/IN
the/DT
E2A/NN
gene/NN
can/MD
be/VB
detected/VBN
in/IN
a/DT
wide/JJ
range/NN
of/IN
cell/NN
types/NNS
./.
====================
We/PRP
have/VBP
now/RB
examined/VBN
expression/NN
of/IN
the/DT
mouse/NN
E2A/NN
gene/NN
at/IN
the/DT
protein/NN
level/NN
using/VBG
polyclonal/JJ
antisera/NNS
directed/VBN
against/IN
distinct/JJ
portions/NNS
of/IN
the/DT
E2A/NN
protein/NN
to/TO
probe/NN
blots/NNS
of/IN
cellular/JJ
extracts/NNS
./.
====================
A/DT
73/CD
kDa/NN
protein/NN
was/VBD
identified/VBN
by/IN
this/DT
analysis/NN
:/:
this/DT
protein/NN
is/VBZ
highly/RB
enriched/VBN
in/IN
cell/NN
lines/NNS
of/IN
B/NN
lymphoid/JJ
origin/NN
as/IN
compared/VBN
to/TO
pancreatic/JJ
beta-cells/NNS
and/CC
fibroblast/NN
cells/NNS
./.
====================
The/DT
detection/NN
of/IN
this/DT
protein/NN
selectively/RB
in/IN
extracts/NNS
of/IN
lymphoid/JJ
cells/NNS
correlates/VBZ
with/IN
the/DT
presence/NN
of/IN
the/DT
E/NN
box-binding/JJ
activity/NN
LEF1/BCF1/NN
in/IN
these/DT
cells/NNS
;/:
this/DT
binding/NN
activity/NN
was/VBD
previously/RB
shown/VBN
to/TO
be/VB
efficiently/RB
recognized/VBN
by/IN
antiserum/NN
directed/VBN
against/IN
E2A/NN
gene/NN
products/NNS
./.
====================
Transfection/NN
of/IN
cells/NNS
with/IN
full/JJ
length/NN
E2A/NN
cDNA/NN
leads/VBZ
to/TO
appearance/NN
of/IN
protein/NN
co-migrating/VBG
with/IN
the/DT
73/CD
kDa/NN
protein/NN
on/IN
SDS/NN
gel/NN
electrophoresis/NN
and/CC
co-migrating/VBG
with/IN
LEF1/BCF1/NN
on/IN
mobility/NN
shift/NN
analysis/NN
./.
====================
Our/PRP$
results/NNS
are/VBP
consistent/JJ
with/IN
the/DT
view/NN
that/IN
the/DT
DNA-binding/JJ
activity/NN
LEF1/BCF1/NN
is/VBZ
a/DT
homodimer/NN
of/IN
E2A/NN
proteins/NNS
;/:
the/DT
selective/JJ
appearance/NN
of/IN
this/DT
putative/JJ
cell-specific/JJ
transcription/NN
factor/NN
in/IN
B/NN
lymphoid/JJ
cells/NNS
seems/VBZ
to/TO
be/VB
attributable/JJ
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
to/TO
the/DT
elevated/JJ
E2A/NN
protein/NN
concentrations/NNS
in/IN
these/DT
cells/NNS
./.
====================
UI/LS
-/:
93244226/CD
====================
TI/LS
-/:
Hypertension/NN
in/IN
pregnancy/NN
./.
====================
AB/LS
-/:
Pregnancy-induced/JJ
hypertension/NN
(/(
PIH/NN
)/)
is/VBZ
a/DT
frequent/JJ
cause/NN
of/IN
maternal/JJ
and/CC
neonatal/JJ
morbidity/NN
and/CC
mortality/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
we/PRP
focused/VBD
on/IN
the/DT
pathophysiology/NN
of/IN
PIH/NN
,/,
mainly/RB
on/IN
the/DT
role/NN
of/IN
mineralocorticoids/NNS
,/,
reversed/VBN
blood/NN
pressure/NN
patterns/NNS
,/,
and/CC
the/DT
resulting/VBG
necessity/NN
of/IN
continuous/JJ
monitoring/NN
of/IN
the/DT
preeclamptic/JJ
mother/NN
./.
====================
Problems/NNS
of/IN
antihypertensive/JJ
therapy/NN
are/VBP
discussed/VBN
and/CC
the/DT
first/JJ
results/NNS
of/IN
a/DT
pilot/NN
study/NN
with/IN
Urapidil/NN
are/VBP
presented/VBN
./.
====================
To/TO
examine/VB
the/DT
role/NN
of/IN
mineralocorticoids/NNS
in/IN
the/DT
pathophysiology/NN
of/IN
PIH/NN
,/,
we/PRP
studied/VBD
plasma/NN
aldosterone/NN
and/CC
18-hydroxy-corticosterone/NN
(/(
18-OH-B/NN
)/)
levels/NNS
in/IN
25/CD
women/NNS
with/IN
PIH/NN
and/CC
in/IN
25/CD
healthy/JJ
pregnant/JJ
women/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
evaluated/VBD
the/DT
mineralocorticoid/NN
receptor/NN
(/(
MR/NN
)/)
count/NN
in/IN
mononuclear/JJ
leukocytes/NNS
in/IN
the/DT
2/CD
groups/NNS
./.
====================
The/DT
MR-count/NN
was/VBD
significantly/RB
decreased/VBN
in/IN
the/DT
PIH-group/NN
./.
====================
The/DT
values/NNS
of/IN
plasma/NN
aldosterone/NN
and/CC
18-OH-B/NN
were/VBD
also/RB
low/JJ
./.
====================
These/DT
results/NNS
can/MD
not/RB
be/VB
explained/VBN
by/IN
receptor/NN
down-regulation/NN
due/JJ
to/TO
higher/JJR
level/NN
of/IN
mineralocorticoids/NNS
of/IN
the/DT
zona/NN
glomerulosa/NN
./.
====================
Perhaps/RB
deoxycorticosterone/NN
or/CC
a/DT
hitherto/RB
unknown/JJ
mineralocorticoid/NN
is/VBZ
responsible/JJ
for/IN
the/DT
hypertension/NN
and/CC
altered/JJ
MR-status/NN
./.
====================
The/DT
first/JJ
results/NNS
of/IN
continuous/JJ
blood/NN
pressure/NN
measurements/NNS
with/IN
a/DT
noninvasive/JJ
,/,
real-time/JJ
blood/NN
pressure/NN
monitor/NN
(/(
Finapres/NN
)/)
are/VBP
presented/VBN
./.
====================
The/DT
comparison/NN
of/IN
the/DT
obtained/VBN
values/NNS
with/IN
intraarterial/JJ
measurements/NNS
demonstrates/VBZ
a/DT
good/JJ
correlation/NN
between/IN
the/DT
two/CD
methods/NNS
./.
====================
We/PRP
also/RB
report/VBP
on/IN
the/DT
first/JJ
experiences/NNS
with/IN
Urapidil/NN
in/IN
the/DT
treatment/NN
of/IN
hypertension/NN
in/IN
severe/JJ
preeclampsia/NN
./.
====================
The/DT
data/NNS
show/VBP
that/IN
hypertension/NN
in/IN
preeclamptic/JJ
women/NNS
can/MD
be/VB
treated/VBN
by/IN
Urapidil/NN
without/IN
side/JJ
effects/NNS
or/CC
reflex-tachycardia/NN
./.
====================
Further/JJ
studies/NNS
will/MD
have/VB
to/TO
prove/VB
if/IN
Urapidil/NN
is/VBZ
suited/VBN
for/IN
prepartal/JJ
treatment/NN
of/IN
PIH/NN
as/RB
well/RB
./.
====================
UI/LS
-/:
93186822/CD
====================
TI/LS
-/:
Suppression/NN
of/IN
a/DT
cellular/JJ
differentiation/NN
program/NN
by/IN
phorbol/NN
esters/NNS
coincides/VBZ
with/IN
inhibition/NN
of/IN
binding/NN
of/IN
a/DT
cell-specific/JJ
transcription/NN
factor/NN
(/(
NF-E2/NN
)/)
to/TO
an/DT
enhancer/NN
element/NN
required/VBN
for/IN
expression/NN
of/IN
an/DT
erythroid-specific/JJ
gene/NN
./.
====================
AB/LS
-/:
Induction/NN
by/IN
hemin/NN
increases/VBZ
,/,
while/IN
induction/NN
with/IN
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
represses/VBZ
,/,
erythroid-specific/JJ
gene/NN
expression/NN
in/IN
the/DT
human/JJ
cell/NN
line/NN
K562/NN
./.
====================
We/PRP
analyzed/VBD
the/DT
effects/NNS
of/IN
hemin/NN
or/CC
TPA/NN
induction/NN
on/IN
the/DT
binding/NN
and/CC
activity/NN
of/IN
transcription/NN
factors/NNS
at/IN
a/DT
regulatory/JJ
element/NN
found/VBN
within/IN
the/DT
transcriptional/JJ
regulatory/JJ
sequences/NNS
of/IN
many/JJ
erythroid-specific/JJ
genes/NNS
./.
====================
TPA/NN
induction/NN
increases/VBZ
the/DT
binding/NN
of/IN
ubiquitous/JJ
AP-1/NN
factors/NNS
to/TO
this/DT
element/NN
./.
====================
TPA/NN
induction/NN
inhibits/VBZ
the/DT
binding/NN
of/IN
the/DT
lineage/NN
limited/JJ
transcription/NN
factor/NN
NF-E2/NN
to/TO
this/DT
transcriptional/JJ
control/NN
element/NN
./.
====================
Hemin/NN
induction/NN
of/IN
K562/NN
cells/NNS
does/VBZ
not/RB
facilitate/VB
the/DT
binding/NN
of/IN
NF-E2/NN
to/TO
its/PRP$
recognition/NN
site/NN
./.
====================
Hemin/NN
induction/NN
appears/VBZ
to/TO
nonspecifically/RB
increase/VB
the/DT
expression/NN
of/IN
transiently/RB
transfected/VBN
genes/NNS
in/IN
K562/NN
cells/NNS
./.
====================
Beyond/IN
this/DT
nonspecific/JJ
increase/NN
in/IN
gene/NN
expression/NN
,/,
hemin/NN
induction/NN
acts/VBZ
to/TO
increase/VB
the/DT
activity/NN
of/IN
the/DT
lineage/NN
limited/JJ
transcription/NN
factor/NN
NF-E2/NN
./.
====================
The/DT
divergent/JJ
effects/NNS
of/IN
hemin/NN
and/CC
TPA/NN
on/IN
gene/NN
expression/NN
in/IN
K562/NN
cells/NNS
are/VBP
mediated/VBN
,/,
in/IN
part/NN
,/,
by/IN
their/PRP$
contrasting/JJ
effects/NNS
on/IN
the/DT
transcription/NN
factor/NN
NF-E2/NN
./.
====================
UI/LS
-/:
93152894/CD
====================
TI/LS
-/:
Interleukin-3/NN
expression/NN
by/IN
activated/VBN
T/NN
cells/NNS
involves/VBZ
an/DT
inducible/JJ
,/,
T-cell-specific/JJ
factor/NN
and/CC
an/DT
octamer/NN
binding/NN
protein/NN
./.
====================
AB/LS
-/:
Interleukin-3/NN
(/(
IL-3/NN
)/)
is/VBZ
exclusively/RB
expressed/VBN
by/IN
activated/VBN
T/NN
and/CC
natural/JJ
killer/NN
cells/NNS
,/,
a/DT
function/NN
that/WDT
is/VBZ
tightly/RB
controlled/VBN
both/CC
in/IN
a/DT
lineage-specific/JJ
and/CC
in/IN
a/DT
stimulation-dependent/JJ
manner/NN
./.
====================
We/PRP
have/VBP
investigated/VBN
the/DT
protein/NN
binding/NN
characteristics/NNS
and/CC
functional/JJ
importance/NN
of/IN
the/DT
ACT-1-activating/JJ
region/NN
of/IN
the/DT
IL-3/NN
promoter/NN
./.
====================
This/DT
region/NN
binds/VBZ
an/DT
inducible/JJ
,/,
T-cell-specific/JJ
factor/NN
over/IN
its/PRP$
5'/JJ
end/NN
,/,
a/DT
site/NN
that/WDT
is/VBZ
necessary/JJ
for/IN
the/DT
expression/NN
of/IN
IL-3/NN
in/IN
the/DT
absence/NN
of/IN
other/JJ
upstream/JJ
elements/NNS
./.
====================
Over/IN
its/PRP$
3'/JJ
end/NN
,/,
it/PRP
binds/VBZ
a/DT
factor/NN
that/WDT
is/VBZ
ubiquitously/RB
and/CC
constitutively/RB
expressed/VBN
./.
====================
This/DT
factor/NN
is/VBZ
Oct-1/NN
or/CC
an/DT
immunologically/RB
related/JJ
octamer-binding/JJ
protein/NN
,/,
and/CC
it/PRP
plays/VBZ
a/DT
role/NN
in/IN
coordinating/VBG
the/DT
activity/NN
of/IN
several/JJ
regulatory/JJ
elements/NNS
./.
====================
These/DT
characteristics/NNS
make/VBP
the/DT
ACT-1/NN
site/NN
analogous/JJ
to/TO
the/DT
activating/VBG
ARRE-1/NN
site/NN
in/IN
the/DT
IL-2/NN
promoter/NN
./.
====================
Furthermore/RB
,/,
and/CC
despite/IN
a/DT
lack/NN
of/IN
sequence/NN
homology/NN
,/,
the/DT
promoters/NNS
of/IN
IL-3/NN
and/CC
IL-2/NN
share/VBP
an/DT
organizational/JJ
pattern/NN
of/IN
regulatory/JJ
elements/NNS
that/WDT
is/VBZ
likely/JJ
to/TO
be/VB
important/JJ
for/IN
the/DT
T-cell-specific/JJ
expression/NN
of/IN
these/DT
genes/NNS
./.
====================
UI/LS
-/:
93136418/CD
====================
TI/LS
-/:
Interleukin-4/NN
inhibits/VBZ
the/DT
lipopolysaccharide-induced/JJ
expression/NN
of/IN
c-jun/NN
and/CC
c-fos/NN
messenger/NN
RNA/NN
and/CC
activator/NN
protein-1/NN
binding/NN
activity/NN
in/IN
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
We/PRP
studied/VBD
the/DT
effect/NN
of/IN
interleukin-4/NN
(/(
IL-4/NN
)/)
on/IN
the/DT
lipopolysaccharide/NN
(/(
LPS/NN
)/)
induction/NN
of/IN
two/CD
immediate/JJ
early/JJ
genes/NNS
c-fos/NN
and/CC
c-jun/NN
./.
====================
These/DT
genes/NNS
encode/VBP
proteins/NNS
that/WDT
form/VBP
the/DT
dimeric/JJ
complex/NN
activator/NN
protein-1/NN
(/(
AP-1/NN
)/)
,/,
which/WDT
is/VBZ
active/JJ
as/IN
a/DT
transcriptional/JJ
factor/NN
./.
====================
Maximal/JJ
accumulation/NN
of/IN
either/CC
c-fos/NN
and/CC
c-jun/NN
messenger/NN
RNA/NN
(/(
mRNA/NN
)/)
occurred/VBD
30/CD
minutes/NNS
after/IN
LPS/NN
addition/NN
./.
====================
When/WRB
cells/NNS
were/VBD
treated/VBN
with/IN
IL-4/NN
for/IN
5/CD
hours/NNS
before/IN
LPS/NN
activation/NN
,/,
both/CC
the/DT
c-fos/NN
and/CC
the/DT
c-jun/NN
mRNA/NN
expression/NN
was/VBD
decreased/VBN
./.
====================
The/DT
inhibition/NN
of/IN
c-fos/NN
and/CC
c-jun/NN
expression/NN
by/IN
IL-4/NN
in/IN
LPS-treated/JJ
cells/NNS
was/VBD
shown/VBN
to/TO
be/VB
due/JJ
to/TO
a/DT
lower/JJR
transcription/NN
rate/NN
of/IN
the/DT
c-fos/NN
and/CC
c-jun/NN
genes/NNS
./.
====================
IL-4/NN
did/VBD
not/RB
affect/VB
the/DT
stability/NN
of/IN
the/DT
c-fos/NN
and/CC
c-jun/NN
transcripts/NNS
./.
====================
Finally/RB
,/,
using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
,/,
evidence/NN
was/VBD
obtained/VBN
that/IN
IL-4/NN
inhibits/VBZ
LPS-induced/JJ
expression/NN
of/IN
AP-1/NN
protein/NN
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
IL-4/NN
suppresses/VBZ
the/DT
induction/NN
of/IN
transcription/NN
factors/NNS
in/IN
human/JJ
activated/VBN
monocytes/NNS
./.
====================
UI/LS
-/:
94085904/CD
====================
TI/LS
-/:
Transient/JJ
pseudohypoaldosteronism/NN
in/IN
obstructive/JJ
renal/JJ
disease/NN
with/IN
transient/JJ
reduction/NN
of/IN
lymphocytic/JJ
aldosterone/NN
receptors/NNS
./.
====================
Results/NNS
in/IN
two/CD
affected/JJ
infants/NNS
./.
====================
AB/LS
-/:
We/PRP
report/VBP
two/CD
patients/NNS
with/IN
transient/JJ
pseudohypoaldosteronism/NN
due/JJ
to/TO
obstructive/JJ
renal/JJ
disease/NN
./.
====================
Both/DT
patients/NNS
presented/VBD
with/IN
a/DT
salt-losing/JJ
episode/NN
simulating/VBG
adrenal/JJ
insufficiency/NN
./.
====================
In/IN
one/CD
patient/NN
,/,
transient/JJ
reduction/NN
of/IN
aldosterone/NN
receptors/NNS
could/MD
be/VB
documented/VBN
,/,
while/IN
in/IN
the/DT
second/JJ
patient/NN
the/DT
clinical/JJ
and/CC
biochemical/JJ
parameters/NNS
were/VBD
consistent/JJ
with/IN
transient/JJ
pseudohypoaldosteronism/NN
./.
====================
Aldosterone/NN
receptors/NNS
were/VBD
normal/JJ
in/IN
both/DT
patients/NNS
====================
UI/LS
-/:
93246027/CD
====================
TI/LS
-/:
Aldosterone-specific/JJ
membrane/NN
receptors/NNS
and/CC
rapid/JJ
non-genomic/JJ
actions/NNS
of/IN
mineralocorticoids/NNS
./.
====================
AB/LS
-/:
Functional/JJ
studies/NNS
in/IN
extrarenal/JJ
,/,
non-epithelial/JJ
cells/NNS
such/JJ
as/IN
smooth/JJ
muscle/NN
cells/NNS
and/CC
more/RBR
recently/RB
circulating/VBG
human/JJ
lymphocytes/NNS
have/VBP
provided/VBN
increasing/VBG
evidence/NN
that/IN
aldosterone/NN
produces/VBZ
not/RB
only/RB
classical/JJ
genomic/JJ
effects/NNS
,/,
but/CC
also/RB
rapid/JJ
,/,
non-genomic/JJ
effects/NNS
on/IN
transmembrane/NN
electrolyte/NN
movements/NNS
./.
====================
These/DT
involve/VBP
activation/NN
of/IN
the/DT
sodium/proton/NN
exchanger/NN
of/IN
the/DT
cell/NN
membrane/NN
at/IN
very/RB
low/JJ
,/,
physiological/JJ
concentrations/NNS
of/IN
aldosterone/NN
with/IN
an/DT
acute/JJ
onset/NN
within/IN
1-2/CD
min/NN
./.
====================
A/DT
second/JJ
messenger/NN
cascade/NN
involved/VBN
is/VBZ
the/DT
inositol/NN
1,4,5-trisphosphate/calcium/NN
pathway/NN
which/WDT
responds/VBZ
over/IN
the/DT
same/JJ
rapid/JJ
time/NN
course/NN
./.
====================
Such/JJ
changes/NNS
clearly/RB
can/MD
not/RB
be/VB
explained/VBN
by/IN
genomic/JJ
mechanisms/NNS
,/,
which/WDT
are/VBP
responsible/JJ
for/IN
later/JJ
effects/NNS
than/IN
the/DT
membrane/NN
related/JJ
rapid/JJ
responses/NNS
./.
====================
The/DT
mechanisms/NNS
underlying/VBG
these/DT
rapid/JJ
effects/NNS
of/IN
aldosterone/NN
on/IN
electrolytes/NNS
have/VBP
been/VBN
extensively/RB
studied/VBN
in/IN
human/JJ
lymphocytes/NNS
,/,
which/WDT
thus/RB
may/MD
represent/VB
valuable/JJ
tools/NNS
in/IN
the/DT
delineation/NN
of/IN
the/DT
receptor-effector/JJ
mechanisms/NNS
involved/VBN
./.
====================
The/DT
unique/JJ
characteristics/NNS
of/IN
this/DT
new/JJ
pathway/NN
for/IN
steroid/NN
action/NN
include/VBP
its/PRP$
rapid/JJ
time/NN
course/NN
,/,
10,000-fold/JJ
selectivity/NN
for/IN
aldosterone/NN
over/IN
cortisol/NN
and/CC
the/DT
ineffectiveness/NN
of/IN
spironolactones/NNS
,/,
classical/JJ
mineralocorticoid/NN
antagonists/NNS
,/,
as/IN
antagonists/NNS
of/IN
the/DT
response/NN
./.
====================
UI/LS
-/:
92408021/CD
====================
TI/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
Nef/NN
protein/NN
inhibits/VBZ
NF-kappa/NN
B/NN
induction/NN
in/IN
human/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
can/MD
establish/VB
a/DT
persistent/JJ
and/CC
latent/JJ
infection/NN
in/IN
CD4+/JJ
T/NN
lymphocytes/NNS
(/(
W.C.Greene/NNP
,/,
N.Engl.J./NNP
Med.324/NNP
:/:
308-317/CD
,/,
1991/CD
;/:
S.M.Schnittman/NNP
,/,
M.C.Psallidopoulos/NNP
,/,
H.C./NNP
Lane/NNP
,/,
L.Thompson/NNP
,/,
M.Baseler/NNP
,/,
F.Massari/NNP
,/,
C.H.Fox/NNP
,/,
N.P.Salzman/NNP
,/,
and/CC
A.S.Fauci/NNP
,/,
Science/NNP
245/CD
:/:
305-308/CD
,/,
1989/CD
)/)
./.
====================
Production/NN
of/IN
HIV-1/NN
from/IN
latently/RB
infected/JJ
cells/NNS
requires/VBZ
host/NN
cell/NN
activation/NN
by/IN
T-cell/NN
mitogens/NNS
(/(
T.Folks/NNP
,/,
D.M.Powell/NNP
,/,
M.M.Lightfoote/NNP
,/,
S.Benn/NNP
,/,
M.A./NNP
Martin/NNP
,/,
and/CC
A.S.Fauci/NNP
,/,
Science/NNP
231/CD
:/:
600-602/CD
,/,
1986/CD
;/:
D.Zagury/NNP
,/,
J./NNP
Bernard/NNP
,/,
R.Leonard/NNP
,/,
R.Cheynier/NNP
,/,
M.Feldman/NNP
,/,
P.S.Sarin/NNP
,/,
and/CC
R.C./NNP
Gallo/NNP
,/,
Science/NNP
231/CD
:/:
850-853/CD
,/,
1986/CD
)/)
./.
====================
This/DT
activation/NN
is/VBZ
mediated/VBN
by/IN
the/DT
host/NN
transcription/NN
factor/NN
NF-kappa/NN
B/NN
[/(
G.Nabel/NNP
and/CC
D.Baltimore/NNP
,/,
Nature/NNP
(/(
London/NNP
)/)
326/CD
:/:
711-717/CD
,/,
1987/CD
]/)
./.
====================
We/PRP
report/VBP
here/RB
that/IN
the/DT
HIV-1-encoded/JJ
Nef/NN
protein/NN
inhibits/VBZ
the/DT
induction/NN
of/IN
NF-kappa/NN
B/NN
DNA-binding/JJ
activity/NN
by/IN
T- cell/NN
mitogens/NNS
./.
====================
However/RB
,/,
Nef/NN
does/VBZ
not/RB
affect/VB
the/DT
DNA-binding/JJ
activity/NN
of/IN
other/JJ
transcription/NN
factors/NNS
implicated/VBN
in/IN
HIV-1/NN
regulation/NN
,/,
including/VBG
SP-1/NN
,/,
USF/NN
,/,
URS/NN
,/,
and/CC
NF-AT/NN
./.
====================
Additionally/RB
,/,
Nef/NN
inhibits/VBZ
the/DT
induction/NN
of/IN
HIV-1-/NN
and/CC
interleukin/NN
2-directed/JJ
gene/NN
expression/NN
,/,
and/CC
the/DT
effect/NN
on/IN
HIV-1/NN
transcription/NN
depends/VBZ
on/IN
an/DT
intact/JJ
NF-kappa/NN
B-binding/JJ
site/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
defective/JJ
recruitment/NN
of/IN
NF-kappa/NN
B/NN
may/MD
underlie/VB
Nef/NN
's/POS
negative/JJ
transcriptional/JJ
effects/NNS
on/IN
the/DT
HIV-1/NN
and/CC
interleukin/NN
2/CD
promoters/NNS
./.
====================
Further/JJ
evidence/NN
suggests/VBZ
that/IN
Nef/NN
inhibits/VBZ
NF-kappa/NN
B/NN
induction/NN
by/IN
interfering/VBG
with/IN
a/DT
signal/NN
derived/VBN
from/IN
the/DT
T-cell/NN
receptor/NN
complex/NN
./.
====================
UI/LS
-/:
93061407/CD
====================
TI/LS
-/:
Expression/NN
of/IN
c-fos/NN
,/,
c-jun/NN
and/CC
jun/NN
B/NN
in/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
from/IN
young/JJ
and/CC
elderly/JJ
adults/NNS
./.
====================
AB/LS
-/:
The/DT
expression/NN
of/IN
c-fos/NN
,/,
c-jun/NN
and/CC
jun/NN
B/NN
proto-oncogenes/NNS
was/VBD
studied/VBN
in/IN
phytohemagglutinin/NN
(/(
PHA/NN
)/)
activated/VBN
peripheral/JJ
blood/NN
lymphocytes/NNS
(/(
PBL/NN
)/)
from/IN
young/JJ
and/CC
aged/JJ
humans/NNS
./.
====================
Specific/JJ
mRNAs/NNS
for/IN
c-fos/NN
and/CC
c-jun/NN
were/VBD
detectable/JJ
within/IN
30/CD
min/NN
after/IN
cell/NN
activation/NN
and/CC
reached/VBD
maximal/JJ
levels/NNS
within/IN
2/CD
h/NN
./.
====================
Both/CC
c-fos/NN
and/CC
jun/NN
B/NN
mRNAs/NNS
decreased/VBD
to/TO
pre-activation/NN
levels/NNS
within/IN
6/CD
h/NN
,/,
while/IN
c-jun/NN
mRNA/NN
remained/VBD
elevated/JJ
./.
====================
In/IN
PHA-activated/JJ
PBL/NN
,/,
no/DT
age-related/JJ
differences/NNS
were/VBD
observed/VBN
in/IN
c-fos/NN
or/CC
jun/NN
B/NN
mRNA/NN
expression/NN
./.
====================
However/RB
,/,
c-jun/NN
mRNA/NN
levels/NNS
decreased/VBD
significantly/RB
(/(
1.73/CD
+/-/CC
0.08/CD
vs./CC
1.16/CD
+/-/CC
0.09/CD
arbitrary/JJ
units/NNS
,/,
P/NN
</JJR
0.01/CD
,/,
young/JJ
vs./CC
old/JJ
)/)
in/IN
PBL/NN
from/IN
elderly/JJ
individuals/NNS
activated/VBN
with/IN
PHA/NN
./.
====================
Because/IN
previous/JJ
work/NN
has/VBZ
demonstrated/VBN
that/IN
T/NN
cells/NNS
from/IN
elderly/JJ
individuals/NNS
may/MD
display/VB
normal/JJ
proliferative/JJ
responses/NNS
when/WRB
activated/VBN
via/IN
the/DT
anti-CD2/JJ
pathway/NN
,/,
c-jun/NN
and/CC
jun/NN
B/NN
mRNA/NN
expression/NN
was/VBD
also/RB
studied/VBN
in/IN
anti-CD2-activated/JJ
purified/VBN
T/NN
cells/NNS
./.
====================
No/DT
age-related/JJ
differences/NNS
were/VBD
found/VBN
in/IN
the/DT
expression/NN
of/IN
either/DT
of/IN
these/DT
two/CD
proto-oncogenes/NNS
by/IN
anti-CD2/NN
activated/JJ
T/NN
cells/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
decreased/VBN
IL-2/NN
production/NN
and/CC
proliferative/JJ
response/NN
displayed/VBN
by/IN
PHA-activated/JJ
PBL/NN
from/IN
elderly/JJ
adults/NNS
may/MD
be/VB
related/JJ
to/TO
age-related/JJ
changes/NNS
in/IN
c-jun/NN
mRNA/NN
expression/NN
and/CC
in/IN
the/DT
ratio/NN
of/IN
c-fos/NN
to/TO
c-jun/NN
mRNA/NN
./.
====================
UI/LS
-/:
92318928/CD
====================
TI/LS
-/:
Oct2/NN
transactivation/NN
from/IN
a/DT
remote/JJ
enhancer/NN
position/NN
requires/VBZ
a/DT
B-cell-restricted/JJ
activity/NN
./.
====================
AB/LS
-/:
Previous/JJ
cotransfection/NN
experiments/NNS
had/VBD
demonstrated/VBN
that/IN
ectopic/JJ
expression/NN
of/IN
the/DT
lymphocyte-specific/JJ
transcription/NN
factor/NN
Oct2/NN
could/MD
efficiently/RB
activate/VB
a/DT
promoter/NN
containing/VBG
an/DT
octamer/NN
motif/NN
./.
====================
Oct2/NN
expression/NN
was/VBD
unable/JJ
to/TO
stimulate/VB
a/DT
multimerized/JJ
octamer/NN
enhancer/NN
element/NN
in/IN
HeLa/NN
cells/NNS
,/,
however/RB
./.
====================
We/PRP
have/VBP
tested/VBN
a/DT
variety/NN
of/IN
Oct2/NN
isoforms/VBZ
generated/VBN
by/IN
alternative/JJ
splicing/NN
for/IN
the/DT
capability/NN
to/TO
activate/VB
an/DT
octamer/NN
enhancer/NN
in/IN
nonlymphoid/JJ
cells/NNS
and/CC
a/DT
B-cell/NN
line/NN
./.
====================
Our/PRP$
analyses/NNS
show/VBP
that/IN
several/JJ
Oct2/NN
isoforms/NNS
can/MD
stimulate/VB
from/IN
a/DT
remote/JJ
position/NN
but/CC
that/IN
this/DT
stimulation/NN
is/VBZ
restricted/JJ
to/TO
B/NN
cells/NNS
./.
====================
This/DT
result/NN
indicates/VBZ
the/DT
involvement/NN
of/IN
either/CC
a/DT
B-cell-specific/JJ
cofactor/NN
or/CC
a/DT
specific/JJ
modification/NN
of/IN
a/DT
cofactor/NN
or/CC
the/DT
Oct2/NN
protein/NN
in/IN
Oct2-mediated/JJ
enhancer/NN
activation/NN
./.
====================
Mutational/JJ
analyses/NNS
indicate/VBP
that/IN
the/DT
carboxy-terminal/JJ
domain/NN
of/IN
Oct2/NN
is/VBZ
critical/JJ
for/IN
enhancer/NN
activation/NN
./.
====================
Moreover/RB
,/,
this/DT
domain/NN
conferred/VBD
enhancing/NN
activity/NN
when/WRB
fused/VBN
to/TO
the/DT
Oct1/NN
protein/NN
,/,
which/WDT
by/IN
itself/PRP
was/VBD
unable/JJ
to/TO
stimulate/VB
from/IN
a/DT
remote/JJ
position/NN
./.
====================
The/DT
glutamine-rich/JJ
activation/NN
domain/NN
present/JJ
in/IN
the/DT
amino-terminal/JJ
portion/NN
of/IN
Oct2/NN
and/CC
the/DT
POU/NN
domain/NN
contribute/VBP
only/RB
marginally/RB
to/TO
the/DT
transactivation/NN
function/NN
from/IN
a/DT
distal/JJ
position/NN
./.
====================
UI/LS
-/:
92269839/CD
====================
TI/LS
-/:
The/DT
promoter/NN
of/IN
the/DT
CD19/NN
gene/NN
is/VBZ
a/DT
target/NN
for/IN
the/DT
B-cell-specific/JJ
transcription/NN
factor/NN
BSAP/NN
./.
====================
AB/LS
-/:
The/DT
CD19/NN
protein/NN
is/VBZ
expressed/VBN
on/IN
the/DT
surface/NN
of/IN
all/DT
B-lymphoid/JJ
cells/NNS
with/IN
the/DT
exception/NN
of/IN
terminally/RB
differentiated/VBN
plasma/NN
cells/NNS
and/CC
has/VBZ
been/VBN
implicated/VBN
as/IN
a/DT
signal-transducing/JJ
receptor/NN
in/IN
the/DT
control/NN
of/IN
proliferation/NN
and/CC
differentiation/NN
./.
====================
Here/RB
we/PRP
demonstrate/VBP
complete/JJ
correlation/NN
between/IN
the/DT
expression/NN
pattern/NN
of/IN
the/DT
CD19/NN
gene/NN
and/CC
the/DT
B-cell-specific/JJ
transcription/NN
factor/NN
BSAP/NN
in/IN
a/DT
large/JJ
panel/NN
of/IN
B-lymphoid/JJ
cell/NN
lines/NNS
./.
====================
The/DT
human/JJ
CD19/NN
gene/NN
has/VBZ
been/VBN
cloned/VBN
,/,
and/CC
several/JJ
BSAP-binding/JJ
sites/NNS
have/VBP
been/VBN
mapped/VBN
by/IN
in/FW
vitro/FW
protein-DNA/JJ
binding/NN
studies/NNS
./.
====================
In/IN
particular/JJ
,/,
a/DT
high-affinity/JJ
BSAP-binding/JJ
site/NN
instead/RB
of/IN
a/DT
TATA/NN
sequence/NN
is/VBZ
located/JJ
in/IN
the/DT
-30/CD
promoter/NN
region/NN
upstream/JJ
of/IN
a/DT
cluster/NN
of/IN
heterogeneous/JJ
transcription/NN
start/NN
sites/NNS
./.
====================
Moreover/RB
,/,
this/DT
site/NN
is/VBZ
occupied/VBN
by/IN
BSAP/NN
in/FW
vivo/FW
in/IN
a/DT
CD19-expressing/JJ
B-cell/NN
line/NN
but/CC
not/RB
in/IN
plasma/NN
or/CC
HeLa/NN
cells/NNS
./.
====================
This/DT
high-affinity/JJ
site/NN
has/VBZ
been/VBN
conserved/VBN
in/IN
the/DT
promoters/NNS
of/IN
both/CC
human/JJ
and/CC
mouse/NN
CD19/NN
genes/NNS
and/CC
was/VBD
furthermore/RB
shown/VBN
to/TO
confer/VB
B-cell/NN
specificity/NN
to/TO
a/DT
beta-globin/NN
reporter/NN
gene/NN
in/IN
transient/JJ
transfection/NN
experiments/NNS
./.
====================
In/IN
addition/NN
,/,
BSAP/NN
was/VBD
found/VBN
to/TO
be/VB
the/DT
only/RB
abundant/JJ
DNA-binding/JJ
activity/NN
of/IN
B-cell/NN
nuclear/JJ
extracts/NNS
that/WDT
interacts/VBZ
with/IN
the/DT
CD19/NN
promoter/NN
./.
====================
Together/RB
,/,
this/DT
evidence/NN
strongly/RB
implicates/VBZ
BSAP/NN
in/IN
the/DT
regulation/NN
of/IN
the/DT
CD19/NN
gene/NN
./.
====================
UI/LS
-/:
92294188/CD
====================
TI/LS
-/:
Eicosanoids/NNS
in/IN
breast/NN
cancer/NN
patients/NNS
before/IN
and/CC
after/IN
mastectomy/NN
./.
====================
AB/LS
-/:
In/IN
19/CD
patients/NNS
with/IN
a/DT
malignant/JJ
breast/NN
tumor/NN
,/,
tumor/NN
tissue/NN
and/CC
blood/NN
were/VBD
taken/VBN
to/TO
determine/VB
the/DT
eicosanoid/NN
profile/NN
and/CC
platelet/NN
aggregation/NN
./.
====================
Values/NNS
were/VBD
compared/VBN
with/IN
those/DT
of/IN
patients/NNS
with/IN
benign/JJ
tumors/NNS
(/(
n/NN
=/JJ
4/CD
)/)
,/,
or/CC
undergoing/VBG
a/DT
mammary/JJ
reduction/NN
(/(
n/NN
=/JJ
7/CD
)/)
./.
====================
Postoperatively/RB
,/,
blood/NN
was/VBD
taken/VBN
as/RB
well/RB
in/IN
order/NN
to/TO
compare/VB
pre-/JJ
and/CC
postoperative/JJ
values/NNS
./.
====================
Eicosanoids/NNS
were/VBD
measured/VBN
in/IN
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
mammary/JJ
tissue/NN
by/IN
means/NNS
of/IN
HPLC/NN
;/:
furthermore/RBR
,/,
TXA2/NN
,/,
6-keto-PGF1/NN
alpha/NN
,/,
and/CC
PGE2/NN
were/VBD
determined/VBN
by/IN
RIA/NN
./.
====================
Differences/NNS
in/IN
pre-/JJ
and/CC
postoperative/JJ
values/NNS
of/IN
cancer/NN
patients/NNS
were/VBD
seen/VBN
in/IN
plasma/NN
RIA/NN
values/NNS
:/:
PGE2/NN
and/CC
6-k-PGF1/NN
alpha/NN
were/VBD
significantly/RB
higher/JJR
preoperatively/RB
when/WRB
compared/VBN
with/IN
postoperatively/RB
,/,
however/RB
,/,
such/JJ
differences/NNS
were/VBD
seen/VBN
in/IN
the/DT
control/NN
groups/NNS
as/RB
well/RB
./.
====================
Compared/VBN
to/TO
benign/JJ
tumor/NN
or/CC
mammary/JJ
reduction/NN
test/NN
material/NN
the/DT
eicosanoid/NN
profile/NN
of/IN
tissue/NN
obtained/VBN
from/IN
malignant/JJ
mammary/JJ
tumors/NNS
showed/VBD
important/JJ
differences/NNS
./.
====================
Except/IN
for/IN
PGF2/NN
alpha/NN
,/,
HHT/NN
and/CC
15-HETE/NN
no/DT
detectable/JJ
quantities/NNS
of/IN
eicosanoids/NNS
were/VBD
found/VBN
in/IN
the/DT
non-tumor/JJ
material/NN
,/,
whereas/IN
in/IN
the/DT
malignant/JJ
tumor/NN
material/NN
substantial/JJ
quantities/NNS
of/IN
a/DT
number/NN
of/IN
eicosanoid/NN
metabolites/NNS
were/VBD
present/JJ
./.
====================
Statistically/RB
significant/JJ
correlations/NNS
could/MD
be/VB
established/VBN
between/IN
patient/histopathology/NN
data/NNS
and/CC
the/DT
results/NNS
of/IN
the/DT
platelet/NN
aggregation/NN
assays/NNS
,/,
e.g./FW
between/IN
menopausal/JJ
status/NN
and/CC
ADP/NN
aggregation/NN
;/:
oestrogen/NN
receptor/NN
(/(
+/-/CC
)/)
and/CC
collagen/NN
and/CC
arachidonic/JJ
acid/NN
aggregation/NN
,/,
inflammatory/JJ
cell/NN
infiltration/NN
score/NN
and/CC
arachidonic/JJ
acid/NN
aggregation/NN
and/CC
fibrosis/NN
score/NN
and/CC
ADP/NN
aggregation/NN
./.
====================
The/DT
results/NNS
show/VBP
that/IN
eicosanoid/NN
synthesis/NN
in/IN
material/NN
from/IN
mammary/JJ
cancer/NN
patients/NNS
is/VBZ
different/JJ
from/IN
that/DT
in/IN
benign/JJ
mammary/JJ
tissue/NN
./.
====================
The/DT
implications/NNS
,/,
in/IN
particular/JJ
,/,
in/IN
relation/NN
to/TO
future/JJ
prognosis/NN
of/IN
the/DT
patient/NN
,/,
remain/VBP
obscure/JJ
./.
====================
UI/LS
-/:
92193465/CD
====================
TI/LS
-/:
Mineralocorticoids/NNPS
and/CC
mineralocorticoid/NN
receptors/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
in/IN
patients/NNS
with/IN
pregnancy-induced/JJ
hypertension/NN
./.
====================
AB/LS
-/:
To/TO
examine/VB
the/DT
role/NN
of/IN
mineralocorticoids/NNS
in/IN
the/DT
pathophysiology/NN
of/IN
pregnancy-induced/JJ
hypertension/NN
(/(
PIH/NN
)/)
,/,
we/PRP
studied/VBD
plasma/NN
aldosterone/NN
and/CC
18-hydroxycorticosterone/NN
levels/NNS
in/IN
25/CD
women/NNS
with/IN
PIH/NN
and/CC
25/CD
normal/JJ
pregnant/JJ
women/NNS
,/,
as/IN
controls/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
evaluated/VBD
the/DT
mineralocorticoid/NN
receptor/NN
(/(
MR/NN
)/)
status/NN
in/IN
mononuclear/JJ
leukocytes/NNS
in/IN
the/DT
2/CD
groups/NNS
./.
====================
MR/NN
count/NN
was/VBD
significantly/RB
(/(
P/NN
less/JJR
than/IN
0.0005/CD
)/)
decreased/VBN
in/IN
the/DT
PIH/NN
group/NN
(/(
148/CD
+/-/CC
9/CD
binding/VBG
sites/cell/NNS
)/)
compared/VBN
with/IN
the/DT
control/NN
group/NN
(/(
300/CD
+/-/CC
17/CD
binding/VBG
sites/cell/NNS
;/:
mean/NN
+/-/CC
SEM/NN
)/)
./.
====================
Plasma/NN
aldosterone/NN
in/IN
women/NNS
with/IN
PIH/NN
was/VBD
281/CD
+/-/CC
61/CD
pmol/L/NN
;/:
in/IN
normal/JJ
pregnant/JJ
women/NNS
it/PRP
was/VBD
697/CD
+/-/CC
172/CD
pmol/L/NN
(/(
P/NN
less/JJR
than/IN
0.025/CD
)/)
./.
====================
Plasma/NN
18-hydroxycorticosterone/NN
was/VBD
also/RB
significantly/RB
(/(
P/NN
less/JJR
than/IN
0.025/CD
)/)
lower/JJR
(/(
PIH/NN
,/,
1071/CD
+/-/CC
149/CD
pmol/L/NN
;/:
controls/NNS
,/,
1907/CD
+/-/CC
318/CD
pmol/L/NN
)/)
./.
====================
These/DT
values/NNS
were/VBD
determined/VBN
at/IN
the/DT
onset/NN
of/IN
clinical/JJ
symptoms/NNS
of/IN
PIH/NN
./.
====================
These/DT
results/NNS
can/MD
not/RB
be/VB
explained/VBN
by/IN
receptor/NN
down-regulation/NN
due/JJ
to/TO
higher/JJR
levels/NNS
of/IN
mineralocorticoids/NNS
in/IN
PIH/NN
;/:
a/DT
hitherto/RB
unknown/JJ
mineralocorticoid/NN
may/MD
,/,
thus/RB
,/,
be/VB
responsible/JJ
for/IN
the/DT
hypertension/NN
and/CC
altered/JJ
MR/NN
status/NN
./.
====================
UI/LS
-/:
92147648/CD
====================
TI/LS
-/:
Structure/NN
function/NN
analysis/NN
of/IN
vitamin/NN
D/NN
analogs/NNS
with/IN
C-ring/NN
modifications/NNS
./.
====================
AB/LS
-/:
Analogs/NNS
of/IN
1/CD
alpha,25-dihydroxyvitamin/NN
D3/NN
(/(
1/CD
alpha,25-(OH)/NN
2D3/NN
)/)
with/IN
substitutions/NNS
on/IN
C-11/NN
were/VBD
synthesized/VBN
./.
====================
Small/JJ
apolar/JJ
substitutions/NNS
(/(
11/CD
alpha-methyl/NN
,/,
11/CD
alpha-fluoromethyl/NN
)/)
did/VBD
not/RB
markedly/RB
decrease/VB
the/DT
affinity/NN
for/IN
the/DT
vitamin/NN
D/NN
receptor/NN
,/,
but/CC
larger/JJR
(/(
11/CD
alpha-chloromethyl/NN
or/CC
11/CD
alpha-/NN
or/CC
11/CD
beta-phenyl/NN
)/)
or/CC
more/RBR
polar/JJ
substitutions/NNS
(/(
11/CD
alpha-hydroxymethyl/NN
,/,
11/CD
alpha-(2-hydroxyethyl/NN
]/)
decreased/VBD
the/DT
affinity/NN
to/TO
less/JJR
than/IN
5/CD
%/NN
of/IN
that/DT
of/IN
1/CD
alpha,25-OH)2D3/NN
./.
====================
Their/PRP$
affinity/NN
for/IN
the/DT
vitamin/NN
D-binding/JJ
protein/NN
,/,
however/RB
,/,
increased/VBD
up/RB
to/TO
4-fold/RB
./.
====================
The/DT
biological/JJ
activity/NN
of/IN
11/CD
alpha-methyl-1/NN
alpha,25-(OH)2D3/NN
closely/RB
resembled/VBD
that/DT
of/IN
the/DT
natural/JJ
hormone/NN
on/IN
normal/JJ
and/CC
leukemic/JJ
cell/NN
proliferation/NN
and/CC
bone/NN
resorption/NN
,/,
whereas/IN
its/PRP$
in/FW
vivo/FW
effect/NN
on/IN
calcium/NN
metabolism/NN
of/IN
the/DT
rachitic/JJ
chick/NN
was/VBD
about/IN
50/CD
%/NN
of/IN
that/DT
of/IN
1/CD
alpha,25-(OH)2D3/NN
./.
====================
The/DT
11/CD
beta-methyl/NN
analog/NN
had/VBD
a/DT
greater/JJR
than/IN
10-fold/RB
lower/JJR
activity/NN
./.
====================
The/DT
differentiating/JJ
effects/NNS
of/IN
the/DT
other/JJ
C-11/NN
analogs/NNS
on/IN
human/JJ
promyeloid/JJ
leukemia/NN
cells/NNS
(/(
HL-60/NN
)/)
agreed/VBD
well/RB
with/IN
their/PRP$
bone-resorbing/JJ
activity/NN
and/CC
receptor/NN
affinity/NN
,/,
but/CC
they/PRP
demonstrated/VBD
lower/JJR
calcemic/JJ
effects/NNS
in/FW
vivo/FW
./.
====================
Large/JJ
or/CC
polar/JJ
substitutions/NNS
on/IN
C-11/NN
of/IN
1/CD
alpha,25-(OH)2D3/NN
thus/RB
impair/VBP
the/DT
binding/NN
of/IN
the/DT
vitamin/NN
D/NN
receptor/NN
but/CC
increase/VBP
the/DT
affinity/NN
to/TO
vitamin/NN
D-binding/JJ
protein/NN
./.
====================
The/DT
effects/NNS
of/IN
many/JJ
C-11-substituted/JJ
1/CD
alpha,25-(OH)2D3/NN
analogs/NNS
on/IN
HL-60/NN
cell/NN
differentiation/NN
exceeded/VBD
their/PRP$
activity/NN
on/IN
calcium/NN
metabolism/NN
./.
====================
UI/LS
-/:
92213189/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptor/NN
binding/NN
in/IN
three/CD
different/JJ
cell/NN
types/NNS
in/IN
major/JJ
depressive/JJ
disorder/NN
:/:
lack/NN
of/IN
evidence/NN
of/IN
receptor/NN
binding/NN
defect/NN
./.
====================
AB/LS
-/:
1/LS
./.
====================
In/IN
order/NN
to/TO
further/RB
understand/VB
the/DT
apparent/JJ
glucocorticoid/NN
resistance/NN
in/IN
major/JJ
depressive/JJ
disorder/NN
,/,
circadian/JJ
variation/NN
in/IN
cortisol/NN
concentration/NN
,/,
dexamethasone/NN
suppression/NN
and/CC
glucocorticoid/NN
receptor/NN
binding/NN
in/IN
mononuclear/JJ
leukocytes/NNS
,/,
polymorphonuclear/JJ
leukocytes/NNS
and/CC
cultured/VBN
skin/NN
fibroblasts/NNS
were/VBD
measured/VBN
in/IN
rigidly/RB
defined/VBN
major/JJ
depressive/JJ
disorder/NN
patients/NNS
and/CC
non-depressed/JJ
psychiatric/JJ
controls/NNS
./.
====================
2/LS
./.
====================
Mononuclear/JJ
leukocytes/NNS
binding/VBG
to/TO
glucocorticoid/NN
correlated/VBD
significantly/RB
with/IN
polymorphonuclear/JJ
leukocytes/NNS
binding/VBG
to/TO
glucocorticoid/NN
,/,
but/CC
both/DT
determinations/NNS
failed/VBD
to/TO
differentiate/VB
major/JJ
depressive/JJ
disorder/NN
and/CC
control/NN
subjects/NNS
./.
====================
3/LS
./.
====================
Initial/JJ
and/CC
post-dexamethasone/JJ
in/FW
vitro/FW
fibroblast/NN
binding/VBG
to/TO
glucocorticoid/NN
was/VBD
not/RB
different/JJ
between/IN
major/JJ
depressive/JJ
disorder/NN
and/CC
non-depressed/JJ
control/NN
subjects/NNS
./.
====================
4/CD
./.
====================
The/DT
phenomenon/NN
of/IN
glucocorticoid/NN
resistance/NN
in/IN
major/JJ
depressive/JJ
disorder/NN
remains/VBZ
unexplained/JJ
./.
====================
UI/LS
-/:
92109743/CD
====================
TI/LS
-/:
High/JJ
affinity/NN
aldosterone/NN
binding/VBG
to/TO
plasma/NN
membrane/NN
rich/JJ
fractions/NNS
from/IN
mononuclear/JJ
leukocytes/NNS
:/:
is/VBZ
there/EX
a/DT
membrane/NN
receptor/NN
for/IN
mineralocorticoids/NNS
?/.
====================
AB/LS
-/:
In/FW
vitro/FW
effects/NNS
of/IN
aldosterone/NN
on/IN
the/DT
intracellular/JJ
concentrations/NNS
of/IN
sodium/NN
,/,
potassium/NN
and/CC
calcium/NN
,/,
cell/NN
volume/NN
and/CC
the/DT
sodium-proton-antiport/NN
have/VBP
been/VBN
described/VBN
in/IN
intact/JJ
human/JJ
mononuclear/JJ
leukocytes/NNS
(/(
HML/NN
)/)
./.
====================
In/IN
the/DT
present/JJ
paper/NN
,/,
the/DT
binding/NN
of/IN
a/DT
[125I]-labeled/JJ
aldosterone/NN
derivative/JJ
to/TO
plasma/NN
membrane/NN
rich/JJ
fractions/NNS
of/IN
HML/NN
was/VBD
studied/VBN
./.
====================
High/JJ
affinity/NN
binding/NN
of/IN
the/DT
radioligand/NN
with/IN
an/DT
apparent/JJ
Kd/NN
of/IN
approximately/RB
0.1/CD
nM/NN
was/VBD
found/VBN
./.
====================
Aldosterone/NN
displaced/VBD
the/DT
tracer/NN
at/IN
a/DT
similar/JJ
Kd/NN
./.
====================
Both/CC
canrenone/NN
and/CC
cortisol/NN
were/VBD
inactive/JJ
as/IN
ligands/NNS
up/RB
to/TO
concentrations/NNS
of/IN
0.1/CD
microM/NN
./.
====================
The/DT
findings/NNS
are/VBP
the/DT
first/JJ
to/TO
demonstrate/VB
membrane/NN
binding/NN
sites/NNS
with/IN
a/DT
high/JJ
affinity/NN
for/IN
aldosterone/NN
,/,
but/CC
not/RB
for/IN
cortisol/NN
./.
====================
These/DT
data/NNS
are/VBP
perfectly/RB
compatible/JJ
with/IN
major/JJ
properties/NNS
of/IN
steroidal/JJ
effects/NNS
on/IN
the/DT
sodium-proton-antiport/NN
in/IN
HML/NN
and/CC
thus/RB
very/RB
likely/RB
represent/VBP
membrane/NN
receptors/NNS
for/IN
aldosterone/NN
./.
====================
UI/LS
-/:
93079901/CD
====================
TI/LS
-/:
Natural/JJ
variants/NNS
of/IN
the/DT
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
:/:
analysis/NN
of/IN
promoters/NNS
with/IN
duplicated/JJ
DNA/NN
regulatory/JJ
motifs/NNS
./.
====================
AB/LS
-/:
Sequence/NN
variation/NN
in/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
region/NN
of/IN
HIV-1/NN
was/VBD
analyzed/VBN
in/IN
viral/JJ
isolates/NNS
of/IN
17/CD
infected/JJ
individuals/NNS
./.
====================
Two/CD
classes/NNS
of/IN
LTR/NN
size/NN
variants/NNS
were/VBD
found/VBN
./.
====================
One/CD
HIV-1/NN
variant/NN
was/VBD
detected/VBN
containing/VBG
an/DT
additional/JJ
binding/VBG
site/NN
for/IN
the/DT
transcription/NN
factor/NN
Sp1/NN
./.
====================
Another/DT
LTR/NN
size/NN
variation/NN
was/VBD
observed/VBN
in/IN
four/CD
patients/NNS
in/IN
a/DT
region/NN
just/RB
upstream/JJ
of/IN
the/DT
NF-kappa/NN
B/NN
enhancer/NN
./.
====================
This/DT
variation/NN
was/VBD
the/DT
result/NN
of/IN
a/DT
duplication/NN
of/IN
a/DT
short/JJ
DNA/NN
sequence/NN
(/(
CTG-motif/NN
)/)
./.
====================
Cell/NN
culture/NN
experiments/NNS
demonstrated/VBD
that/IN
the/DT
natural/JJ
variant/NN
with/IN
four/CD
Sp1/NN
sites/NNS
had/VBD
a/DT
slightly/RB
higher/JJR
promoter/NN
activity/NN
and/CC
viral/JJ
replication/NN
rate/NN
than/IN
the/DT
isogenic/JJ
control/NN
LTR/NN
with/IN
three/CD
Sp1/NN
sites/NNS
./.
====================
No/DT
positive/JJ
effect/NN
of/IN
the/DT
duplicated/JJ
CTG-motif/NN
could/MD
be/VB
detected/VBN
./.
====================
In/IN
order/NN
to/TO
measure/VB
small/JJ
differences/NNS
in/IN
virus/NN
production/NN
more/RBR
accurately/RB
,/,
equal/JJ
amounts/NNS
of/IN
a/DT
size/NN
variant/NN
and/CC
the/DT
wild-type/JJ
plasmid/NN
were/VBD
cotransfected/VBN
into/IN
T-cells/NNS
./.
====================
The/DT
virus/NN
with/IN
four/CD
Sp1/NN
sites/NNS
did/VBD
outgrow/VB
the/DT
three/CD
Sp1/NN
virus/NN
in/IN
35/CD
days/NNS
of/IN
culture/NN
and/CC
CTG-monomer/NN
virus/NN
outcompeted/VBD
the/DT
CTG-dimer/NN
virus/NN
in/IN
42/CD
days/NNS
./.
====================
Based/VBN
on/IN
these/DT
results/NNS
we/PRP
estimate/VBP
a/DT
5-10/CD
%/NN
difference/NN
in/IN
virus/NN
production/NN
of/IN
the/DT
LTR/NN
variants/NNS
when/WRB
compared/VBN
to/TO
that/DT
of/IN
wild-type/NN
./.
====================
UI/LS
-/:
93046624/CD
====================
TI/LS
-/:
A/DT
novel/JJ
B/NN
cell-derived/JJ
coactivator/NN
potentiates/VBZ
the/DT
activation/NN
of/IN
immunoglobulin/NN
promoters/NNS
by/IN
octamer-binding/JJ
transcription/NN
factors/NNS
./.
====================
AB/LS
-/:
A/DT
novel/JJ
B/NN
cell-restricted/JJ
activity/NN
,/,
required/VBN
for/IN
high/JJ
levels/NNS
of/IN
octamer/Oct-dependent/JJ
transcription/NN
from/IN
an/DT
immunoglobulin/NN
heavy/JJ
chain/NN
(/(
IgH/NN
)/)
promoter/NN
,/,
was/VBD
detected/VBN
in/IN
an/DT
in/FW
vitro/FW
system/NN
consisting/VBG
of/IN
HeLa/NN
cell-derived/JJ
extracts/NNS
complemented/VBN
with/IN
fractionated/VBN
B/NN
cell/NN
nuclear/JJ
proteins/NNS
./.
====================
The/DT
factor/NN
responsible/JJ
for/IN
this/DT
activity/NN
was/VBD
designated/VBN
Oct/NN
coactivator/NN
from/IN
B/NN
cells/NNS
(/(
OCA-B/NN
)/)
./.
====================
OCA-B/NN
stimulates/VBZ
the/DT
transcription/NN
from/IN
an/DT
IgH/NN
promoter/NN
in/IN
conjunction/NN
with/IN
either/CC
Oct-1/NN
or/CC
Oct-2/NN
but/CC
shows/VBZ
no/DT
significant/JJ
effect/NN
on/IN
the/DT
octamer/Oct-dependent/JJ
transcription/NN
of/IN
the/DT
ubiquitously/RB
expressed/VBN
histone/NN
H2B/NN
promoter/NN
and/CC
the/DT
transcription/NN
of/IN
USF-/NN
and/CC
Sp1-regulated/JJ
promoters/NNS
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
results/NNS
suggest/VBP
that/IN
OCA-B/NN
is/VBZ
a/DT
tissue-/NN
,/,
promoter-/NN
,/,
and/CC
factor-specific/JJ
coactivator/NN
and/CC
that/IN
OCA-B/NN
may/MD
be/VB
a/DT
major/JJ
determinant/NN
for/IN
B/NN
cell-specific/JJ
activation/NN
of/IN
immunoglobulin/NN
promoters/NNS
./.
====================
In/IN
light/NN
of/IN
the/DT
evidence/NN
showing/VBG
physical/JJ
and/CC
functional/JJ
interactions/NNS
between/IN
Oct/NN
factors/NNS
and/CC
OCA-B/NN
,/,
we/PRP
propose/VBP
a/DT
mechanism/NN
of/IN
action/NN
for/IN
OCA-B/NN
and/CC
discuss/VBP
the/DT
implications/NNS
of/IN
OCA-B/NN
for/IN
the/DT
transcriptional/JJ
regulation/NN
of/IN
other/JJ
tissue-specific/JJ
promoters/NNS
./.
====================
UI/LS
-/:
93085167/CD
====================
TI/LS
-/:
SCL/NN
and/CC
related/JJ
hemopoietic/JJ
helix-loop-helix/JJ
transcription/NN
factors/NNS
./.
====================
AB/LS
-/:
The/DT
helix-loop-helix/JJ
(/(
HLH/JJ
)/)
proteins/NNS
are/VBP
a/DT
family/NN
of/IN
transcription/NN
factors/NNS
that/WDT
include/VBP
proteins/NNS
critical/JJ
to/TO
differentiation/NN
and/CC
development/NN
in/IN
species/NNS
ranging/VBG
from/IN
plants/NNS
to/TO
mammals/NNS
./.
====================
Five/CD
members/NNS
of/IN
this/DT
family/NN
(/(
MYC/NN
,/,
SCL/NN
,/,
TAL-2/NN
,/,
LYL-1/NN
and/CC
E2A/NN
)/)
are/VBP
implicated/VBN
in/IN
oncogenic/JJ
events/NNS
in/IN
human/JJ
lymphoid/JJ
tumors/NNS
because/IN
of/IN
their/PRP$
consistent/JJ
involvement/NN
in/IN
chromosomal/JJ
translocations/NNS
./.
====================
Although/IN
activated/VBN
in/IN
T/NN
cell/NN
leukemias/NNS
,/,
expression/NN
of/IN
SCL/NN
and/CC
LYL-1/NN
is/VBZ
low/JJ
or/CC
undetectable/JJ
in/IN
normal/JJ
T/NN
cell/NN
populations/NNS
./.
====================
SCL/NN
is/VBZ
expressed/VBN
in/IN
erythroid/JJ
,/,
megakaryocyte/NN
and/CC
mast/NN
cell/NN
populations/NNS
(/(
the/DT
same/JJ
cell/NN
lineages/NNS
as/IN
GATA-1/NN
,/,
a/DT
zinc-finger/NN
transcription/NN
factor/NN
)/)
./.
====================
In/IN
addition/NN
,/,
both/CC
SCL/NN
and/CC
GATA-1/NN
undergo/VBP
coordinate/JJ
modulation/NN
during/IN
chemically/RB
induced/VBN
erythroid/JJ
differentiation/NN
of/IN
mouse/NN
erythroleukemia/NN
cells/NNS
and/CC
are/VBP
down-modulated/VBN
during/IN
myeloid/JJ
differentiation/NN
of/IN
human/JJ
K562/NN
cells/NNS
,/,
thus/RB
implying/VBG
a/DT
role/NN
for/IN
SCL/NN
in/IN
erythroid/JJ
differentiation/NN
events/NNS
./.
====================
However/RB
,/,
in/IN
contrast/NN
to/TO
GATA-1/NN
,/,
SCL/NN
is/VBZ
expressed/VBN
in/IN
the/DT
developing/VBG
brain/NN
./.
====================
Studies/NNS
of/IN
the/DT
function/NN
of/IN
SCL/NN
suggest/VBP
it/PRP
is/VBZ
also/RB
important/JJ
in/IN
proliferation/NN
and/CC
self-renewal/JJ
events/NNS
in/IN
erythroid/JJ
cells/NNS
./.
====================
UI/LS
-/:
92318932/CD
====================
TI/LS
-/:
Induction/NN
of/IN
the/DT
POU/NN
domain/NN
transcription/NN
factor/NN
Oct-2/NN
during/IN
T-cell/NN
activation/NN
by/IN
cognate/JJ
antigen/NN
./.
====================
AB/LS
-/:
Oct-2/NN
is/VBZ
a/DT
transcription/NN
factor/NN
that/WDT
binds/VBZ
specifically/RB
to/TO
octamer/NN
DNA/NN
motifs/NNS
in/IN
the/DT
promoters/NNS
of/IN
immunoglobulin/NN
and/CC
interleukin-2/NN
genes/NNS
./.
====================
All/DT
tumor/NN
cell/NN
lines/NNS
from/IN
the/DT
B-cell/NN
lineage/NN
and/CC
a/DT
few/JJ
from/IN
the/DT
T-cell/NN
lineage/NN
express/VBP
Oct-2/NN
./.
====================
To/TO
address/VB
the/DT
role/NN
of/IN
Oct-2/NN
in/IN
the/DT
T-cell/NN
lineage/NN
,/,
we/PRP
studied/VBD
the/DT
expression/NN
of/IN
Oct-2/NN
mRNA/NN
and/CC
protein/NN
in/IN
nontransformed/JJ
human/JJ
and/CC
mouse/NN
T/NN
cells/NNS
./.
====================
Oct-2/NN
was/VBD
found/VBN
in/IN
CD4+/JJ
and/CC
CD8+/JJ
T/NN
cells/NNS
prepared/VBN
from/IN
human/JJ
peripheral/JJ
blood/NN
and/CC
in/IN
mouse/NN
lymph/NN
node/NN
T/NN
cells/NNS
./.
====================
In/IN
a/DT
T-cell/NN
clone/NN
specific/JJ
for/IN
pigeon/NN
cytochrome/NN
c/NN
in/IN
the/DT
context/NN
of/IN
I-Ek/NN
,/,
Oct-2/NN
was/VBD
induced/VBN
by/IN
antigen/NN
stimulation/NN
,/,
with/IN
the/DT
increase/NN
in/IN
Oct-2/NN
protein/NN
seen/VBN
first/RB
at/IN
3/CD
h/NN
after/IN
activation/NN
and/CC
continuing/VBG
for/IN
at/IN
least/JJS
24/CD
h/NN
./.
====================
Oct-2/NN
mRNA/NN
induction/NN
during/IN
antigen-driven/JJ
T-cell/NN
activation/NN
was/VBD
blocked/VBN
by/IN
cyclosporin/NN
A/NN
,/,
as/RB
well/RB
as/IN
by/IN
protein/NN
synthesis/NN
inhibitors/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
Oct-2/NN
participates/VBZ
in/IN
transcriptional/JJ
regulation/NN
during/IN
T-cell/NN
activation/NN
./.
The/DT
relatively/RB
delayed/VBN
kinetics/NNS
of/IN
Oct-2/NN
induction/NN
suggests/VBZ
that/IN
Oct-2/NN
mediates/VBZ
the/DT
changes/NNS
in/IN
gene/NN
expression/NN
which/WDT
occur/VBP
many/JJ
hours/NNS
or/CC
days/NNS
following/VBG
antigen/NN
stimulation/NN
of/IN
T/NN
lymphocytes/NNS
./.
====================
UI/LS
-/:
93020778/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptor/NN
in/IN
patients/NNS
with/IN
lupus/NN
nephritis/NN
:/:
relationship/NN
between/IN
receptor/NN
levels/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
and/CC
effect/NN
of/IN
glucocorticoid/NN
therapy/NN
./.
====================
AB/LS
-/:
We/PRP
investigated/VBD
the/DT
clinical/JJ
significance/NN
of/IN
glucocorticoid/NN
receptor/NN
determination/NN
in/IN
20/CD
patients/NNS
with/IN
systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
who/WP
afterwards/RB
developed/VBD
nephrotic/JJ
syndrome/NN
./.
====================
Glucocorticoid/NN
receptor/NN
concentrations/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
(/(
MNL/NNS
)/)
in/IN
these/DT
patients/NNS
were/VBD
comparable/JJ
with/IN
those/DT
in/IN
both/CC
other/JJ
patients/NNS
with/IN
SLE/NN
and/CC
healthy/JJ
persons/NNS
./.
====================
Improvement/NN
in/IN
urinary/JJ
protein/NN
excretion/NN
and/CC
in/IN
disease/NN
activity/NN
,/,
which/WDT
was/VBD
scored/VBN
according/VBG
to/TO
the/DT
SLE/NNP
Disease/NNP
Activity/NNP
Index/NNP
system/NN
of/IN
the/DT
University/NNP
of/IN
Toronto/NNP
,/,
closely/RB
related/JJ
to/TO
the/DT
glucocorticoid/NN
receptor/NN
concentrations/NNS
in/IN
MNL/NN
isolated/VBN
from/IN
the/DT
corresponding/JJ
patients/NNS
./.
====================
In/IN
summary/NN
,/,
glucocorticoid/NN
receptor/NN
determination/NN
in/IN
patients/NNS
with/IN
lupus/NN
nephritis/NN
may/MD
be/VB
a/DT
predictive/JJ
clue/NN
for/IN
assessing/VBG
responsiveness/NN
to/TO
glucocorticoid/NN
therapy/NN
./.
====================
UI/LS
-/:
92320321/CD
====================
TI/LS
-/:
[/(
Changes/NNS
in/IN
plasma/NN
interleukin-1/NN
and/CC
their/PRP$
possible/JJ
relationship/NN
with/IN
the/DT
changes/NNS
in/IN
glucocorticoid/NN
receptor/NN
in/IN
aged/JJ
long-distance/JJ
runner/NN
]/)
====================
AB/LS
-/:
For/IN
the/DT
study/NN
of/IN
the/DT
changes/NNS
in/IN
plasma/NN
interleukin-1/NN
(/(
IL-1/NN
)/)
and/CC
their/PRP$
possible/JJ
relationship/NN
with/IN
the/DT
changes/NNS
in/IN
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
,/,
plasma/NN
IL-1/NN
and/CC
GR/NN
in/IN
peripheral/JJ
blood/NN
leukocytes/NNS
in/IN
aged/JJ
long-distance/JJ
runner/NN
were/VBD
measured/VBN
simultaneously/RB
./.
====================
The/DT
activity/NN
of/IN
IL-1/NN
was/VBD
expressed/VBN
as/IN
its/PRP$
ability/NN
to/TO
stimulate/VB
3H-TdR/NN
incorporation/NN
in/IN
the/DT
thymocytes/NNS
of/IN
C57/NN
mice/NNS
./.
====================
GR/NN
was/VBD
determined/VBN
by/IN
whole/JJ
cell/NN
assay/NN
with/IN
3H-Dex/NN
./.
====================
The/DT
results/NNS
showed/VBD
that/IN
the/DT
activity/NN
of/IN
plasma/NN
IL-1/NN
in/IN
aged/JJ
long-distance/JJ
runner/NN
was/VBD
209/CD
%/NN
,/,
223/CD
%/NN
and/CC
145/CD
%/NN
of/IN
the/DT
control/NN
at/IN
14.7-18.7/CD
,/,
3.8-7.0/CD
and/CC
1.5-2.6/CD
KD/NN
fractions/NNS
./.
====================
The/DT
GR/NN
in/IN
peripheral/JJ
blood/NN
leukocytes/NNS
in/IN
aged/JJ
runner/NN
was/VBD
65/CD
%/NN
of/IN
the/DT
control/NN
./.
====================
Possible/JJ
relationship/NN
between/IN
the/DT
changes/NNS
in/IN
IL-1/NN
and/CC
GR/NN
in/NN
aged/JJ
long-distance/JJ
runner/NN
and/CC
its/PRP$
physiological/JJ
significance/NN
are/VBP
discussed/VBN
./.
====================
UI/LS
-/:
92193472/CD
====================
TI/LS
-/:
Mineralocorticoid/NN
effector/NN
mechanism/NN
in/IN
preeclampsia/NN
./.
====================
AB/LS
-/:
Mineralocorticoid/NN
effector/NN
mechanisms/NNS
were/VBD
evaluated/VBN
in/IN
29/CD
patients/NNS
with/IN
preeclampsia/NN
and/CC
in/IN
25/CD
uncomplicated/JJ
pregnancies/NNS
by/IN
measurement/NN
of/IN
plasma/NN
aldosterone/NN
,/,
levels/NNS
of/IN
mineralocorticoid/NN
receptor/NN
(/(
MR/NN
)/)
in/IN
mononuclear/JJ
leucocytes/NNS
,/,
and/CC
subtraction/NN
potential/NN
difference/NN
(/(
SPD/NN
;/:
rectal/JJ
minus/CC
oral/JJ
values/NNS
)/)
./.
====================
Mean/NN
values/NNS
for/IN
plasma/NN
aldosterone/NN
were/VBD
not/RB
different/JJ
between/IN
the/DT
two/CD
groups/NNS
,/,
but/CC
significant/JJ
differences/NNS
were/VBD
observed/VBN
for/IN
MR/NN
(/(
preeclampsia/NN
,/,
81/CD
+/-/CC
44/CD
receptors/cell/NNS
;/:
controls/NNS
,/,
306/CD
+/-/CC
168/CD
)/)
and/CC
SPD/NN
(/(
preeclampsia/NN
,/,
65/CD
+/-/CC
7/CD
mV/NN
;/:
controls/NNS
,/,
12/CD
+/-/CC
5/CD
mV/NN
)/)
./.
====================
In/IN
six/CD
cases/NNS
we/PRP
determined/VBD
MR/NN
,/,
plasma/NN
aldosterone/NN
,/,
and/CC
SPD/NN
in/IN
patients/NNS
with/IN
preeclampsia/NN
before/IN
and/CC
3/CD
months/NNS
after/IN
delivery/NN
./.
====================
MR/NNS
were/VBD
reduced/VBN
before/IN
delivery/NN
(/(
96/CD
+/-/CC
27/CD
receptors/cell/NNS
)/)
,/,
and/CC
SPD/NN
increased/VBD
(/(
64/CD
+/-/CC
8/CD
mV/NN
)/)
,/,
with/IN
both/DT
parameters/NNS
normalizing/VBG
after/IN
delivery/NN
(/(
MR/NN
,/,
242/CD
+/-/CC
79/CD
;/:
SPD/NN
,/,
14.0/CD
+/-/CC
4/CD
mV/NN
)/)
./.
====================
Aldosterone/NN
levels/NNS
returned/VBD
to/TO
normal/JJ
nonpregnant/JJ
values/NNS
after/IN
delivery/NN
./.
====================
These/DT
data/NNS
suggest/VBP
an/DT
important/JJ
role/NN
for/IN
abnormalities/NNS
in/IN
mineralocorticoid/NN
effector/NN
mechanisms/NNS
in/IN
the/DT
etiology/NN
of/IN
preeclampsia/NN
and/CC
could/MD
be/VB
an/DT
useful/JJ
marker/NN
for/IN
diagnosis/NN
./.
====================
UI/LS
-/:
92215726/CD
====================
TI/LS
-/:
Kinetics/NNS
of/IN
nuclear/JJ
translocation/NN
and/CC
turnover/NN
of/IN
the/DT
vitamin/NN
D/NN
receptor/NN
in/IN
human/JJ
HL60/NN
leukemia/NN
cells/NNS
and/CC
peripheral/JJ
blood/NN
lymphocytes/NNS
--/:
coincident/JJ
rise/NN
of/IN
DNA-relaxing/JJ
activity/NN
in/IN
nuclear/JJ
extracts/NNS
./.
====================
AB/LS
-/:
High/JJ
affinity/NN
receptors/NNS
(/(
VDR/NN
)/)
for/IN
1,25-dihydroxycholecalciferol/NN
(/(
calcitriol/NN
)/)
are/VBP
expressed/VBN
in/IN
HL60/NN
human/JJ
leukemia/NN
cells/NNS
and/CC
in/IN
low/JJ
numbers/NNS
in/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
(/(
PBL/NN
)/)
./.
====================
HL60/NN
cells/NNS
,/,
expressing/VBG
some/DT
characteristics/NNS
of/IN
promyelocytes/NNS
,/,
can/MD
be/VB
induced/VBN
to/TO
monocytoid/NN
differentiation/NN
by/IN
calcitriol/NN
./.
====================
Specific/JJ
nuclear/JJ
translocation/NN
of/IN
[3H]calcitriol/VDR/NN
was/VBD
examined/VBN
after/IN
exposure/NN
of/IN
whole/JJ
cells/NNS
to/TO
10/CD
(/(
-9/CD
)/)
M/l/NN
calcitriol/NN
in/IN
the/DT
presence/NN
and/CC
absence/NN
of/IN
a/DT
500-fold/JJ
excess/NN
of/IN
unlabeled/JJ
ligand/NN
and/CC
subsequent/JJ
isolation/NN
of/IN
nuclei/NNS
./.
====================
Specific/JJ
nuclear/JJ
translocation/NN
of/IN
[3H]calcitriol/VDR/NN
was/VBD
found/VBN
to/TO
be/VB
time/NN
dependent/JJ
reaching/VBG
a/DT
maximum/NN
of/IN
approximately/RB
2100/CD
binding/VBG
sites/nucleus/NNS
after/IN
3/CD
h/NN
of/IN
incubation/NN
in/IN
HL60/NN
cells/NNS
,/,
whereas/IN
a/DT
maximum/NN
of/IN
approximately/RB
310/CD
binding/VBG
sites/nucleus/NNS
was/VBD
found/VBN
after/IN
3/CD
h/NN
in/IN
PBL/NN
./.
====================
Pulse/NN
exposure/NN
of/IN
HL60/NN
to/TO
radiolabeled/VBN
hormone/NN
for/IN
3/CD
h/NN
followed/VBN
by/IN
culture/NN
in/IN
medium/NN
without/IN
serum/NN
and/CC
calcitriol/NN
lead/VBD
to/TO
nuclear/JJ
retention/NN
of/IN
approximately/RB
1600/CD
radiolabeled/VBN
VDR/NN
by/IN
8/CD
h/NN
and/CC
approximately/RB
1000/CD
VDR/NN
by/IN
24/CD
h/NN
./.
====================
Radiolabeled/VBN
VDR/NN
disappeared/VBD
from/IN
the/DT
nuclear/JJ
compartment/NN
with/IN
a/DT
halflife/NN
of/IN
approximately/RB
30/CD
min/NN
if/IN
cells/NNS
were/VBD
cultured/VBN
with/IN
identical/JJ
concentrations/NNS
of/IN
unlabeled/JJ
hormone/NN
after/IN
the/DT
pulse/NN
(/(
pulse/chase-experiments/NNS
)/)
./.
====================
No/DT
difference/NN
of/IN
VDR/NN
retention/NN
in/IN
pulse/NN
and/CC
pulse/chase-experiments/NNS
was/VBD
seen/VBN
in/IN
PBL/NN
,/,
where/WRB
VDR/NN
halflife/NN
was/VBD
approximately/RB
30/CD
min/NN
./.
====================
No/DT
specific/JJ
translocation/NN
into/IN
the/DT
nuclear/JJ
compartment/NN
was/VBD
seen/VBN
when/WRB
isolated/VBN
nuclei/NNS
were/VBD
incubated/VBN
in/IN
[3H]calcitriol/NN
./.
====================
Radiolabeled/VBN
hormone/receptor/NN
complexes/NNS
of/IN
nuclei/NNS
isolated/VBN
from/IN
cells/NNS
exposed/VBN
for/IN
3/CD
h/NN
to/TO
radiolabeled/VBN
hormone/NN
--/:
in/IN
contrast/NN
to/TO
identical/JJ
experiments/NNS
with/IN
intact/JJ
cells/NNS
--/:
did/VBD
not/RB
disappear/VB
from/IN
the/DT
nuclear/JJ
compartment/NN
upon/IN
incubation/NN
of/IN
nuclei/NNS
with/IN
identical/JJ
concentrations/NNS
of/IN
the/DT
unlabeled/JJ
compound/NN
./.
====================
The/DT
activity/NN
of/IN
DNA/NN
relaxing/NN
enzymes/NNS
(/(
e.g./FW
topoisomerases/NNS
I/CD
and/CC
II/CD
)/)
in/IN
nuclear/JJ
extracts/NNS
was/VBD
measured/VBN
using/VBG
a/DT
PBR/NN
322-relaxation-assay/NN
./.
====================
Enhanced/VBN
overall/JJ
enzyme/NN
activity/NN
was/VBD
found/VBN
in/IN
nuclear/JJ
extracts/NNS
by/IN
1/CD
h/NN
after/IN
incubation/NN
with/IN
calcitriol/NN
(/(
final/JJ
ethanol/NN
concentration/NN
0.0001/CD
%/NN
v/v/NN
)/)
in/IN
HL60/NN
and/CC
PBL/NN
./.
====================
The/DT
enhanced/VBN
activity/NN
disappeared/VBD
after/IN
2/CD
h/NN
in/IN
PBL/NN
,/,
whereas/IN
it/PRP
was/VBD
still/RB
enhanced/VBN
by/IN
4/CD
h/NN
in/IN
HL60/NN
./.
====================
No/DT
effect/NN
was/VBD
seen/VBN
in/IN
ethanol/NN
treated/JJ
controls/NNS
./.
====================
We/PRP
conclude/VBP
that/IN
a/DT
specific/JJ
nuclear/JJ
translocation/NN
mechanism/NN
exists/VBZ
for/IN
calcitriol/NN
in/IN
both/DT
cell/NN
types/NNS
examined/VBN
,/,
most/RBS
likely/RB
due/IN
to/TO
translocation/NN
of/IN
receptor/NN
proteins/NNS
after/IN
hormone/NN
binding/NN
./.
====================
Translocated/VBN
hormone/receptor/NN
complexes/NNS
compete/VBP
for/IN
a/DT
limited/JJ
number/NN
of/IN
specific/JJ
nuclear/JJ
binding/VBG
sites/NNS
./.
====================
Enhanced/VBN
activity/NN
of/IN
topoisomerases/NNS
in/IN
nuclear/JJ
extracts/NNS
upon/IN
translocation/NN
of/IN
VDR/NN
might/MD
reflect/VB
interaction/NN
of/IN
both/DT
within/IN
the/DT
nuclear/JJ
compartment/NN
,/,
thus/RB
initiating/VBG
DNA-unwinding/NN
,/,
a/DT
prerequisite/NN
of/IN
transcription/NN
initiation/NN
./.
====================
UI/LS
-/:
92135176/CD
====================
TI/LS
-/:
Influence/NN
of/IN
estradiol/NN
and/CC
tamoxifen/NN
on/IN
susceptibility/NN
of/IN
human/JJ
breast/NN
cancer/NN
cell/NN
lines/NNS
to/TO
lysis/NN
by/IN
lymphokine-activated/JJ
killer/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
design/NN
of/IN
combination/NN
hormonal/JJ
and/CC
immunotherapeutic/JJ
protocols/NNS
for/IN
breast/NN
cancer/NN
patients/NNS
may/MD
be/VB
facilitated/VBN
by/IN
analysis/NN
of/IN
preclinical/JJ
in/FW
vitro/FW
model/JJ
systems/NNS
./.
====================
Estrogen/NN
receptor/NN
positive/JJ
(/(
ER+/JJ
:/:
MCF-7/NN
)/)
and/CC
negative/JJ
(/(
ER-/JJ
:/:
MDA-MB-231/NN
)/)
human/JJ
breast/NN
cancer/NN
cell/NN
lines/NNS
were/VBD
utilized/VBN
to/TO
evaluate/VB
the/DT
effects/NNS
of/IN
tamoxifen/NN
(/(
TAM/NN
)/)
and/CC
estradiol/NN
(/(
E2/NN
)/)
on/IN
modulation/NN
of/IN
breast/NN
cancer/NN
target/NN
susceptibility/NN
to/TO
lysis/NN
by/IN
lymphokine-activated/JJ
killer/NN
(/(
LAK/NN
)/)
cells/NNS
./.
====================
E2-stimulated/JJ
ER+/JJ
cells/NNS
were/VBD
more/RBR
susceptible/JJ
to/TO
lysis/NN
by/IN
LAK/NN
cells/NNS
than/IN
corresponding/VBG
TAM-treated/JJ
or/CC
control/NN
cells/NNS
,/,
while/IN
treatment/NN
of/IN
ER- cells/NNS
with/IN
either/CC
E2/NN
or/CC
TAM/NN
alone/RB
did/VBD
not/RB
alter/VB
from/IN
control/NN
their/PRP$
susceptibility/NN
to/TO
this/DT
immune-mediated/JJ
lysis/NN
./.
====================
All/DT
ER+/JJ
and/CC
ER-cells/NNS
tested/VBN
remained/VBD
sensitive/JJ
after/IN
treatment/NN
with/IN
TAM/NN
to/TO
lysis/NN
by/IN
LAK/NN
cells/NNS
./.
====================
In/IN
addition/NN
,/,
an/DT
adenocarcinoma/NN
reactive/JJ
human-mouse/JJ
chimeric/JJ
monoclonal/JJ
antibody/NN
(/(
ING-1/NN
)/)
was/VBD
able/JJ
to/TO
significantly/RB
boost/VB
in/FW
vivo/FW
generated/VBN
LAK/NN
cell-mediated/JJ
lysis/NN
of/IN
control/NN
,/,
E2-treated/JJ
,/,
and/CC
TAM-treated/JJ
ER+/JJ
and/CC
ER-cells/NNS
./.
====================
These/DT
in/FW
vitro/FW
results/NNS
provide/VBP
a/DT
preclinical/JJ
rationale/NN
for/IN
in/FW
vivo/FW
testing/NN
of/IN
TAM/NN
,/,
interleukin-2/NN
(/(
IL-2/NN
)/)
,/,
and/CC
breast/NN
cancer/NN
reactive/JJ
antibody-dependent/JJ
cellular/JJ
cytotoxicity/NN
facilitating/VBG
antibody/NN
in/IN
patients/NNS
with/IN
refractory/JJ
or/CC
high/JJ
risk/NN
breast/NN
cancer/NN
./.
====================
UI/LS
-/:
92107162/CD
====================
TI/LS
-/:
The/DT
cellular/JJ
oncogene/NN
c-myb/NN
can/MD
interact/VB
synergistically/RB
with/IN
the/DT
Epstein-Barr/JJ
virus/NN
BZLF1/NN
transactivator/NN
in/IN
lymphoid/JJ
cells/NNS
./.
====================
AB/LS
-/:
Regulation/NN
of/IN
replicative/JJ
functions/NNS
in/IN
the/DT
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
genome/NN
is/VBZ
mediated/VBN
through/IN
activation/NN
of/IN
a/DT
virally/RB
encoded/VBN
transcription/NN
factor/NN
,/,
Z/NN
(/(
BZLF1/NN
)/)
./.
====================
We/PRP
have/VBP
shown/VBN
that/IN
the/DT
Z/NN
gene/NN
product/NN
,/,
which/WDT
binds/VBZ
to/TO
AP-1/NN
sites/NNS
as/IN
a/DT
homodimer/NN
and/CC
has/VBZ
sequence/NN
similarity/NN
to/TO
c-Fos/NN
,/,
can/MD
efficiently/RB
activate/VB
the/DT
EBV/NN
early/JJ
promoter/NN
,/,
BMRF1/NN
,/,
in/IN
certain/JJ
cell/NN
types/NNS
(/(
i.e./FW
,/,
HeLa/NN
cells/NNS
)/)
but/CC
not/RB
others/NNS
(/(
i.e./FW
,/,
Jurkat/NN
cells/NNS
)/)
./.
====================
Here/RB
we/PRP
demonstrate/VBP
that/IN
the/DT
c-myb/NN
proto-oncogene/NN
product/NN
,/,
which/WDT
is/VBZ
itself/PRP
a/DT
DNA-binding/JJ
protein/NN
and/CC
transcriptional/JJ
transactivator/NN
,/,
can/MD
interact/VB
synergistically/RB
with/IN
Z/NN
in/IN
activating/VBG
the/DT
BMRF1/NN
promoter/NN
in/IN
Jurkat/NN
cells/NNS
(/(
a/DT
T-cell/NN
line/NN
)/)
or/CC
Raji/NN
cells/NNS
(/(
an/DT
EBV-positive/JJ
B-cell/NN
)/)
,/,
whereas/IN
the/DT
c-myb/NN
gene/NN
product/NN
by/IN
itself/PRP
has/VBZ
little/JJ
effect/NN
./.
====================
The/DT
simian/JJ
virus/NN
40/CD
early/JJ
promoter/NN
is/VBZ
also/RB
synergistically/RB
activated/VBN
by/IN
the/DT
Z/c-myb/NN
combination/NN
./.
====================
Synergistic/JJ
transactivation/NN
of/IN
the/DT
BMRF1/NN
promoter/NN
by/IN
the/DT
Z/c-myb/NN
combination/NN
appears/VBZ
to/TO
involve/VB
direct/JJ
binding/NN
by/IN
the/DT
Z/NN
protein/NN
but/CC
not/RB
the/DT
c-myb/NN
protein/NN
./.
====================
A/DT
30-bp/JJ
sequence/NN
in/IN
the/DT
BMRF1/NN
promoter/NN
which/WDT
contains/VBZ
a/DT
Z/NN
binding/NN
site/NN
(/(
a/DT
consensus/NN
AP-1/NN
site/NN
)/)
is/VBZ
sufficient/JJ
to/TO
transfer/VB
high-level/JJ
lymphoid-specific/JJ
responsiveness/NN
to/TO
the/DT
Z/c-myb/NN
combination/NN
to/TO
a/DT
heterologous/JJ
promoter/NN
./.
====================
That/IN
the/DT
c-myb/NN
oncogene/NN
product/NN
can/MD
interact/VB
synergistically/RB
with/IN
an/DT
EBV-encoded/JJ
member/NN
of/IN
the/DT
leucine/NN
zipper/NN
protein/NN
family/NN
suggests/VBZ
c-myb/NN
is/VBZ
likely/JJ
to/TO
engage/VB
in/IN
similar/JJ
interactions/NNS
with/IN
cellularly/RB
encoded/VBN
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
93129248/CD
====================
TI/LS
-/:
Alpha-lipoic/JJ
acid/NN
is/VBZ
a/DT
potent/JJ
inhibitor/NN
of/IN
NF-kappa/NN
B/NN
activation/NN
in/IN
human/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Acquired/VBN
immunodeficiency/NN
syndrome/NN
(/(
AIDS/NN
)/)
results/VBZ
from/IN
infection/NN
with/IN
a/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
./.
====================
The/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
region/NN
of/IN
HIV/NN
proviral/JJ
DNA/NN
contains/VBZ
binding/VBG
sites/NNS
for/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
,/,
and/CC
this/DT
transcriptional/JJ
activator/NN
appears/VBZ
to/TO
regulate/VB
HIV/NN
activation/NN
./.
====================
Recent/JJ
findings/NNS
suggest/VBP
an/DT
involvement/NN
of/IN
reactive/JJ
oxygen/NN
species/NNS
(/(
ROS/NN
)/)
in/IN
signal/NN
transduction/NN
pathways/NNS
leading/VBG
to/TO
NF-kappa/NN
B/NN
activation/NN
./.
====================
The/DT
present/JJ
study/NN
was/VBD
based/VBN
on/IN
reports/NNS
that/IN
antioxidants/NNS
which/WDT
eliminate/VBP
ROS/NN
should/MD
block/VB
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
and/CC
subsequently/RB
HIV/NN
transcription/NN
,/,
and/CC
thus/RB
antioxidants/NNS
can/MD
be/VB
used/VBN
as/IN
therapeutic/JJ
agents/NNS
for/IN
AIDS/NN
./.
====================
Incubation/NN
of/IN
Jurkat/NN
T/NN
cells/NNS
(/(
1/CD
x/NN
10/CD
(/(
6/CD
)/)
cells/ml/NNS
)/)
with/IN
a/DT
natural/JJ
thiol/NN
antioxidant/NN
,/,
alpha-lipoic/JJ
acid/NN
,/,
prior/JJ
to/TO
the/DT
stimulation/NN
of/IN
cells/NNS
was/VBD
found/VBN
to/TO
inhibit/VB
NF-kappa/NN
B/NN
activation/NN
induced/VBN
by/IN
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
25/CD
ng/ml/NN
)/)
or/CC
by/IN
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
50/CD
ng/ml/NN
)/)
./.
====================
The/DT
inhibitory/JJ
action/NN
of/IN
alpha-lipoic/JJ
acid/NN
was/VBD
found/VBN
to/TO
be/VB
very/RB
potent/JJ
as/IN
only/RB
4/CD
mM/NN
was/VBD
needed/VBN
for/IN
a/DT
complete/JJ
inhibition/NN
,/,
whereas/IN
20/CD
mM/NN
was/VBD
required/VBN
for/IN
N-acetylcysteine/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
alpha-lipoic/JJ
acid/NN
may/MD
be/VB
effective/JJ
in/IN
AIDS/NN
therapeutics/NNS
./.
====================
UI/LS
-/:
93077034/CD
====================
TI/LS
-/:
Reticuloendotheliosis/NN
virus/NN
long/JJ
terminal/JJ
repeat/NN
elements/NNS
are/VBP
efficient/JJ
promoters/NNS
in/IN
cells/NNS
of/IN
various/JJ
species/NNS
and/CC
tissue/NN
origin/NN
,/,
including/VBG
human/JJ
lymphoid/JJ
cells/NNS
./.
====================
AB/LS
-/:
Promiscuous/JJ
transcriptional/JJ
activity/NN
of/IN
the/DT
reticuloendotheliosis/NN
virus/NN
(/(
REV/NN
)/)
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
was/VBD
detected/VBN
in/IN
transient/JJ
expression/NN
assays/NNS
using/VBG
LTR-chloramphenicol/NN
acetyltransferase-encoding/JJ
gene/NN
chimeras/NNS
,/,
and/CC
cells/NNS
of/IN
diverse/JJ
species/NNS
and/CC
tissue/NN
type/NN
;/:
levels/NNS
of/IN
expression/NN
from/IN
two/CD
different/JJ
REV/NN
LTRs/NNS
correlate/VBP
with/IN
reports/NNS
of/IN
pathogenicity/NN
of/IN
the/DT
respective/JJ
viruses/NNS
in/FW
vivo/FW
./.
====================
REVs/NNS
do/VBP
not/RB
encode/VB
a/DT
transactivator/NN
targeted/VBN
to/TO
the/DT
viral/JJ
LTR/NN
,/,
and/CC
cells/NNS
infected/VBN
with/IN
Marek/NN
's/POS
disease/NN
virus/NN
,/,
a/DT
herpesvirus/NN
with/IN
an/DT
overlapping/VBG
host/NN
range/NN
,/,
do/VBP
not/RB
express/VB
factors/NNS
that/WDT
preferentially/RB
enhance/VBP
expression/NN
from/IN
REV/NN
or/CC
avian/JJ
sarcoma/leukemia/NN
virus/NN
LTRs/NNS
./.
====================
REV/NN
LTRs/NNS
work/VBP
efficiently/RB
in/IN
human/JJ
lymphoid/JJ
cells/NNS
,/,
and/CC
are/VBP
viable/JJ
alternatives/NNS
to/TO
promoters/NNS
commonly/RB
used/VBN
for/IN
expression/NN
of/IN
cloned/VBN
genes/NNS
./.
====================
They/PRP
may/MD
also/RB
prove/VB
useful/JJ
in/IN
the/DT
identification/NN
of/IN
new/JJ
,/,
ubiquitous/JJ
cellular/JJ
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
92407982/CD
====================
TI/LS
-/:
A/DT
novel/JJ
Ets-related/JJ
transcription/NN
factor/NN
,/,
Elf-1/NN
,/,
binds/VBZ
to/TO
human/JJ
immunodeficiency/NN
virus/NN
type/NN
2/CD
regulatory/JJ
elements/NNS
that/WDT
are/VBP
required/VBN
for/IN
inducible/JJ
trans/JJ
activation/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
and/CC
HIV-2/NN
are/VBP
structurally/RB
related/JJ
retroviruses/NNS
which/WDT
both/DT
cause/VBP
AIDS/NN
in/IN
humans/NNS
./.
====================
Although/IN
both/DT
viruses/NNS
establish/VBP
latency/NN
in/IN
quiescent/JJ
human-peripheral-blood/JJ
T/NN
cells/NNS
,/,
the/DT
asymptomatic/JJ
phase/NN
of/IN
HIV-2/NN
infection/NN
may/MD
be/VB
more/JJR
prolonged/JJ
than/IN
that/DT
of/IN
HIV-1/NN
./.
====================
The/DT
latent/JJ
phases/NNS
of/IN
both/CC
HIV-1/NN
and/CC
HIV-2/NN
infection/NN
have/VBP
been/VBN
shown/VBN
to/TO
be/VB
disrupted/VBN
by/IN
T-cell/NN
activation/NN
,/,
a/DT
process/NN
that/WDT
requires/VBZ
host/NN
cell/NN
transcription/NN
factors/NNS
./.
====================
In/IN
the/DT
case/NN
of/IN
HIV-1/NN
,/,
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
is/VBZ
sufficient/JJ
for/IN
inducible/JJ
transcriptional/JJ
activation/NN
./.
====================
In/IN
contrast/NN
,/,
factors/NNS
in/IN
addition/NN
to/TO
NF-kappa/NN
B/NN
are/VBP
required/VBN
to/TO
activate/VB
HIV-2/NN
transcription/NN
in/IN
infected/JJ
T/NN
cells/NNS
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
demonstrate/VBP
that/IN
a/DT
novel/JJ
Ets-related/JJ
transcription/NN
factor/NN
,/,
Elf-1/NN
,/,
binds/VBZ
specifically/RB
to/TO
two/CD
purine-rich/JJ
motifs/NNS
in/IN
the/DT
HIV-2/NN
enhancer/NN
./.
====================
Mutagenesis/NN
experiments/NNS
demonstrated/VBD
that/IN
these/DT
Elf-1/NN
binding/NN
sites/NNS
are/VBP
required/VBN
for/IN
induction/NN
of/IN
HIV-2/NN
transcription/NN
following/VBG
T-cell-receptor-mediated/JJ
T-cell/NN
activation/NN
./.
====================
Moreover/RB
,/,
Elf-1/NN
is/VBZ
the/DT
only/JJ
factor/NN
present/JJ
in/IN
activated/VBN
T-cell/NN
nuclear/JJ
extracts/NNS
that/WDT
binds/VBZ
to/TO
these/DT
sites/NNS
in/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
./.
====================
Thus/RB
,/,
Elf-1/NN
is/VBZ
a/DT
novel/JJ
transcription/NN
factor/NN
that/WDT
appears/VBZ
to/TO
be/VB
required/VBN
for/IN
the/DT
T-cell-receptor-mediated/JJ
trans/JJ
activation/NN
of/IN
HIV-2/NN
gene/NN
expression/NN
./.
====================
These/DT
results/NNS
may/MD
explain/VB
differences/NNS
in/IN
the/DT
clinical/JJ
spectra/NNS
of/IN
diseases/NNS
caused/VBN
by/IN
HIV-1/NN
and/CC
HIV-2/NN
and/CC
may/MD
also/RB
have/VB
implications/NNS
for/IN
the/DT
design/NN
of/IN
therapeutic/JJ
approaches/NNS
to/TO
HIV-2/NN
infection/NN
./.
====================
UI/LS
-/:
92392375/CD
====================
TI/LS
-/:
Okadaic/JJ
acid/NN
is/VBZ
a/DT
potent/JJ
inducer/NN
of/IN
AP-1/NN
,/,
NF-kappa/NN
B/NN
,/,
and/CC
tumor/NN
necrosis/NN
factor-alpha/NN
in/IN
human/JJ
B/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Treatment/NN
of/IN
human/JJ
B/NN
lymphocytes/NNS
with/IN
an/DT
optimal/JJ
concentration/NN
of/IN
okadaic/JJ
acid/NN
,/,
an/DT
inhibitor/NN
of/IN
phosphatases/NNS
1/CD
and/CC
2A/NN
,/,
resulted/VBD
in/IN
the/DT
induction/NN
of/IN
the/DT
transcription/NN
factor/NN
,/,
AP-1/NN
and/CC
a/DT
marked/JJ
increase/NN
in/IN
NF-kappa/NN
B/NN
levels/NNS
./.
====================
In/IN
contrast/NN
,/,
no/DT
effect/NN
on/IN
the/DT
levels/NNS
of/IN
the/DT
octamer/NN
binding/NN
proteins/NNS
,/,
Oct-1/NN
or/CC
Oct-2/NN
,/,
were/VBD
found/VBN
./.
====================
Since/IN
both/CC
AP-1/NN
and/CC
NF-kappa/NN
B/NN
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
important/JJ
in/IN
the/DT
induction/NN
of/IN
the/DT
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
gene/NN
we/PRP
examined/VBD
the/DT
effects/NNS
of/IN
okadaic/JJ
acid/NN
on/IN
TNF-alpha/NN
mRNA/NN
levels/NNS
./.
====================
Treatment/NN
with/IN
okadaic/JJ
acid/NN
resulted/VBD
in/IN
a/DT
striking/JJ
increase/NN
in/IN
TNF-alpha/NN
mRNA/NN
transcripts/NNS
within/IN
1/CD
h/NN
of/IN
stimulation/NN
and/CC
large/JJ
amounts/NNS
of/IN
TNF-alpha/NN
were/VBD
released/VBN
into/IN
the/DT
culture/NN
media/NNS
./.
====================
Although/IN
okadaic/JJ
acid/NN
provides/VBZ
a/DT
potent/JJ
inductive/JJ
signal/NN
for/IN
AP-1/NN
and/CC
NF-kappa/NN
B/NN
it/PRP
did/VBD
not/RB
induce/VB
either/CC
B/NN
cell/NN
proliferation/NN
or/CC
immunoglobulin/NN
secretion/NN
./.
====================
UI/LS
-/:
92317168/CD
====================
TI/LS
-/:
Heterodimerization/NN
and/CC
transcriptional/JJ
activation/NN
in/FW
vitro/FW
by/IN
NF-kappa/NN
B/NN
proteins/NNS
./.
====================
AB/LS
-/:
The/DT
NF-kappa/NN
B/NN
family/NN
of/IN
transcription/NN
proteins/NNS
represents/VBZ
multiple/JJ
DNA/NN
binding/NN
,/,
rel/NN
related/JJ
polypeptides/NNS
that/WDT
contribute/VBP
to/TO
regulation/NN
of/IN
genes/NNS
involved/VBN
in/IN
immune/JJ
responsiveness/NN
and/CC
inflammation/NN
,/,
as/RB
well/RB
as/IN
activation/NN
of/IN
the/DT
HIV/NN
long/JJ
terminal/JJ
repeat/NN
./.
====================
In/IN
this/DT
study/NN
multiple/JJ
NF-kappa/NN
B/NN
related/JJ
polypeptides/NNS
ranging/VBG
from/IN
85/CD
to/TO
45/CD
kDa/NN
were/VBD
examined/VBN
for/IN
their/PRP$
capacity/NN
to/TO
interact/VB
with/IN
the/DT
PRDII/NN
regulatory/JJ
element/NN
of/IN
interferon/NN
beta/NN
and/CC
were/VBD
shown/VBN
to/TO
possess/VB
distinct/JJ
intrinsic/JJ
DNA/NN
binding/NN
affinities/NNS
for/IN
this/DT
NF-kappa/NN
B/NN
site/NN
and/CC
form/VB
multiple/JJ
DNA/NN
binding/NN
homo-/JJ
and/CC
heterodimer/NN
complexes/NNS
in/IN
co-renaturation/NN
experiments/NNS
./.
====================
Furthermore/RB
,/,
using/VBG
DNA/NN
templates/NNS
containing/VBG
two/CD
copies/NNS
of/IN
the/DT
PRDII/NN
domain/NN
linked/VBN
to/TO
the/DT
rabbit/NN
beta/NN
globin/NN
gene/NN
,/,
the/DT
purified/VBN
polypeptides/NNS
specifically/RB
stimulated/VBD
NF-kappa/NN
B/NN
dependent/JJ
transcription/NN
in/IN
an/DT
in/FW
vitro/FW
reconstitution/NN
assay/NN
as/IN
heterodimers/NNS
but/CC
not/RB
as/IN
p50/NN
homodimers/NNS
./.
====================
These/DT
experiments/NNS
emphasize/VBP
the/DT
role/NN
of/IN
NF-kappa/NN
B/NN
dimerization/NN
as/IN
a/DT
distinct/JJ
level/NN
of/IN
transcriptional/JJ
control/NN
that/WDT
may/MD
permit/VB
functional/JJ
diversification/NN
of/IN
a/DT
limited/JJ
number/NN
of/IN
regulatory/JJ
proteins/NNS
./.
====================
UI/LS
-/:
92309248/CD
====================
TI/LS
-/:
c-myc/NN
mRNA/NN
expression/NN
in/IN
minor/JJ
salivary/JJ
glands/NNS
of/IN
patients/NNS
with/IN
Sjogren/NN
's/POS
syndrome/NN
./.
====================
AB/LS
-/:
c-myc/NN
protooncogene/NN
is/VBZ
implicated/VBN
in/IN
the/DT
pathogenesis/NN
of/IN
B/NN
cell/NN
lymphoid/JJ
malignancies/NNS
and/CC
high/JJ
levels/NNS
of/IN
c-myc/NN
mRNA/NN
expression/NN
are/VBP
observed/VBN
in/IN
activated/VBN
blood/NN
mononuclear/JJ
cells/NNS
./.
====================
Sjogren/NN
's/POS
syndrome/NN
(/(
SS/NN
)/)
is/VBZ
characterized/VBN
by/IN
lymphocytic/JJ
infiltrates/NNS
of/IN
exocrine/JJ
glands/NNS
,/,
remarkable/JJ
B/NN
cell/NN
hyperreactivity/NN
and/CC
a/DT
strong/JJ
predisposition/NN
to/TO
B/NN
cell/NN
neoplasia/NN
./.
====================
In/IN
this/DT
study/NN
,/,
c-myc/NN
protooncogene/NN
mRNA/NN
expression/NN
in/IN
29/CD
labial/JJ
minor/JJ
salivary/JJ
gland/NN
biopsies/NNS
from/IN
patients/NNS
with/IN
primary/JJ
SS/NNS
and/CC
15/CD
controls/NNS
was/VBD
examined/VBN
using/VBG
in/FW
situ/FW
hybridization/NN
histochemistry/NN
./.
====================
Two/CD
40mer/JJ
oligonucleotides/NNS
from/IN
the/DT
1st/JJ
and/CC
the/DT
2nd/JJ
exon/NN
of/IN
the/DT
c-myc/NN
gene/NN
,/,
labeled/VBN
with/IN
35S/NN
,/,
were/VBD
used/VBN
as/IN
probes/NNS
./.
====================
To/TO
detect/VB
the/DT
origin/NN
of/IN
the/DT
cell/NN
hybridized/VBN
with/IN
a/DT
c-myc/NN
probe/NN
,/,
a/DT
combined/JJ
immunochemistry/NN
in/FW
situ/FW
hybridization/NN
histochemistry/NN
technique/NN
was/VBD
used/VBN
./.
====================
High/JJ
c-myc/NN
mRNA/NN
expression/NN
was/VBD
detected/VBN
on/IN
acinar/JJ
epithelial/JJ
cells/NNS
./.
====================
c-myc/NN
did/VBD
not/RB
correlate/VB
with/IN
c-fos/NN
and/CC
c-jun/NN
protein/NN
expression/NN
./.
====================
Stronger/JJR
c-myc/NN
mRNA/NN
expression/NN
was/VBD
detected/VBN
in/IN
labial/JJ
salivary/JJ
glands/NNS
of/IN
patients/NNS
with/IN
longer/JJR
disease/NN
duration/NN
(/(
p/NN
less/JJR
than/IN
or/CC
equal/JJ
to/TO
0.002/CD
)/)
and/CC
more/RBR
intense/JJ
T/NN
lymphocyte/NN
infiltrates/NNS
(/(
p/NN
less/JJR
than/IN
0.05/CD
)/)
although/IN
these/DT
patients/NNS
revealed/VBD
no/DT
hypergammaglobulinemia/NN
./.
====================
No/DT
correlation/NN
was/VBD
observed/VBN
between/IN
c-myc/NN
mRNA/NN
and/CC
B/NN
lymphocyte/NN
monoclonicity/NN
or/CC
lymphoma/NN
./.
====================
In/IN
conclusion/NN
,/,
strong/JJ
c-myc/NN
mRNA/NN
expression/NN
was/VBD
observed/VBN
on/IN
epithelial/JJ
cells/NNS
of/IN
labial/JJ
salivary/JJ
glands/NNS
from/IN
patients/NNS
with/IN
primary/JJ
SS/NN
./.
====================
Our/PRP$
findings/NNS
may/MD
indicate/VB
the/DT
presence/NN
of/IN
a/DT
reactivated/VBN
virus/NN
hosted/VBN
in/IN
these/DT
cells/NNS
./.
====================
UI/LS
-/:
92230800/CD
====================
TI/LS
-/:
Corticosteroid/NN
receptors/NNS
and/CC
lymphocyte/NN
subsets/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
in/IN
aging/NN
./.
====================
AB/LS
-/:
Plasma/NN
cortisol/NN
and/CC
aldosterone/NN
levels/NNS
and/CC
number/NN
of/IN
related/JJ
receptors/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
were/VBD
measured/VBN
in/IN
49/CD
healthy/JJ
aged/JJ
subjects/NNS
(/(
62-97/CD
yr/NN
)/)
and/CC
in/IN
21/CD
adult/JJ
controls/NNS
(/(
21-50/CD
yr/NN
)/)
./.
====================
In/IN
all/DT
subjects/NNS
,/,
in/IN
addition/NN
,/,
lymphocyte/NN
subsets/NNS
were/VBD
determined/VBN
as/IN
an/DT
index/NN
of/IN
corticosteroid/NN
action/NN
./.
====================
The/DT
mean/NN
number/NN
of/IN
type/NN
I/CD
and/CC
type/NN
II/CD
receptors/NNS
was/VBD
significantly/RB
lower/JJR
in/IN
aged/JJ
subjects/NNS
than/IN
in/IN
controls/NNS
(/(
respectively/RB
,/,
198/CD
+/-/CC
96/CD
and/CC
272/CD
+/-/CC
97/CD
receptors/cell/NNS
for/IN
type/NN
I/CD
,/,
and/CC
1,794/CD
+/-/CC
803/CD
and/CC
3,339/CD
+/-/CC
918/CD
for/IN
type/NN
II/CD
receptors/NNS
)/)
./.
====================
Plasma/NN
aldosterone/NN
and/CC
cortisol/NN
and/CC
lymphocyte/NN
subsets/NNS
were/VBD
not/RB
different/JJ
in/IN
the/DT
two/CD
groups/NNS
./.
====================
All/DT
of/IN
the/DT
parameters/NNS
were/VBD
also/RB
tested/VBN
for/IN
correlation/NN
,/,
and/CC
a/DT
significant/JJ
inverse/JJ
correlation/NN
was/VBD
found/VBN
between/IN
age/NN
and/CC
type/NN
I/CD
and/CC
type/NN
II/CD
receptors/NNS
when/WRB
all/DT
subjects/NNS
were/VBD
plotted/VBN
and/CC
between/IN
aged/JJ
and/CC
CD4/NN
and/CC
age/NN
and/CC
CD4/CD8/NN
in/IN
the/DT
aged/JJ
group/NN
./.
====================
These/DT
data/NNS
show/VBP
that/IN
aged/JJ
subjects/NNS
have/VBP
reductions/NNS
of/IN
corticosteroid/NN
receptors/NNS
that/WDT
are/VBP
not/RB
associated/VBN
with/IN
increase/NN
of/IN
related/JJ
steroids/NNS
and/CC
that/IN
this/DT
situation/NN
probably/RB
represents/VBZ
a/DT
concomitant/NN
of/IN
the/DT
normal/JJ
aging/NN
process/NN
./.
====================
UI/LS
-/:
92176657/CD
====================
TI/LS
-/:
T/NN
cell-specific/JJ
negative/JJ
regulation/NN
of/IN
transcription/NN
of/IN
the/DT
human/JJ
cytokine/NN
IL-4/NN
./.
====================
AB/LS
-/:
IL-4/NN
secreted/VBN
by/IN
activated/VBN
T/NN
cells/NNS
is/VBZ
a/DT
pleiotropic/JJ
cytokine/NN
affecting/VBG
growth/NN
and/CC
differentiation/NN
of/IN
diverse/JJ
cell/NN
types/NNS
such/JJ
as/IN
T/NN
cells/NNS
,/,
B/NN
cells/NNS
,/,
and/CC
mast/NN
cells/NNS
./.
====================
We/PRP
investigated/VBD
the/DT
upstream/JJ
regulatory/JJ
elements/NNS
of/IN
the/DT
human/JJ
IL-4/NN
promoter/NN
./.
====================
A/DT
novel/JJ
T/NN
cell-specific/JJ
negative/JJ
regulatory/JJ
element/NN
(/(
NRE/NN
)/)
composed/VBN
of/IN
two/CD
protein-binding/JJ
sites/NNS
were/VBD
mapped/VBN
in/IN
the/DT
5'/JJ
flanking/JJ
region/NN
of/IN
the/DT
IL-4/NN
gene/NN
:/:
-311CTCCCTTCT-303/NN
(/(
NRE-I/NN
)/)
and/CC
-288CTTTTTGCTT-TGC-300/NN
(/(
NRE-II/NN
)/)
./.
====================
A/DT
T/NN
cell-specific/JJ
protein/NN
Neg-1/NN
and/CC
a/DT
ubiquitous/JJ
protein/NN
Neg-2/NN
binding/VBG
to/TO
NRE-I/NN
and/CC
NRE-II/NN
,/,
respectively/RB
,/,
were/VBD
identified/VBN
./.
====================
Furthermore/RB
,/,
a/DT
positive/JJ
regulatory/JJ
element/NN
was/VBD
found/VBN
45/CD
bp/NN
downstream/RB
of/IN
the/DT
NRE/NN
./.
====================
The/DT
enhancer/NN
activity/NN
of/IN
the/DT
PRE/NN
was/VBD
completely/RB
suppressed/VBN
when/WRB
the/DT
NRE/NN
was/VBD
present/JJ
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
IL-4/NN
promoter/NN
activity/NN
is/VBZ
normally/RB
down-regulated/VBN
by/IN
an/DT
NRE/NN
via/IN
repression/NN
of/IN
the/DT
enhancer/NN
positive/JJ
regulatory/JJ
element/NN
./.
====================
These/DT
data/NNS
may/MD
have/VB
implications/NNS
for/IN
the/DT
stringent/JJ
control/NN
of/IN
IL-4/NN
expression/NN
in/IN
T/NN
cells/NNS
./.
====================
UI/LS
-/:
92164748/CD
====================
TI/LS
-/:
Interleukin/NN
6-induced/JJ
differentiation/NN
of/IN
a/DT
human/JJ
B/NN
cell/NN
line/NN
into/IN
IgM-secreting/JJ
plasma/NN
cells/NNS
is/VBZ
mediated/VBN
by/IN
c-fos/NN
./.
====================
AB/LS
-/:
The/DT
role/NN
of/IN
the/DT
protooncogene/NN
c-fos/NN
in/IN
interleukin/NN
(/(
IL/NN
)/)
6-induced/JJ
B/NN
cell/NN
differentiation/NN
was/VBD
assessed/VBN
./.
====================
Treatment/NN
of/IN
SKW/NN
6.4/CD
cells/NNS
with/IN
IL/NN
6/CD
induced/VBD
a/DT
transient/JJ
and/CC
early/JJ
stimulation/NN
of/IN
c-fos/NN
sense/NN
mRNA/NN
expression/NN
./.
====================
The/DT
effect/NN
appeared/VBD
within/IN
30/CD
min/NN
and/CC
returned/VBD
to/TO
basal/JJ
levels/NNS
after/IN
2/CD
h/NN
./.
====================
The/DT
addition/NN
of/IN
antisense/JJ
oligonucleotides/NNS
to/TO
c-fos/NN
significantly/RB
inhibited/VBD
IL/NN
6-induced/JJ
IgM/NN
production/NN
by/IN
SKW/NN
6.4/CD
cells/NNS
(/(
p/NN
less/JJR
than/IN
0.001/CD
)/)
,/,
whereas/IN
control/NN
oligonucleotides/NNS
had/VBD
no/DT
inhibitory/JJ
effect/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
activation/NN
of/IN
c-fos/NN
is/VBZ
involved/VBN
in/IN
IL/NN
6-induced/JJ
differentiation/NN
of/IN
SKW/NN
6.4/CD
cells/NNS
into/IN
IgM-secreting/JJ
cells/NNS
./.
====================
UI/LS
-/:
92153263/CD
====================
TI/LS
-/:
Transcriptional/JJ
regulation/NN
during/IN
T-cell/NN
development/NN
:/:
the/DT
alpha/NN
TCR/NN
gene/NN
as/IN
a/DT
molecular/JJ
model/NN
./.
====================
AB/LS
-/:
The/DT
regulation/NN
of/IN
gene/NN
expression/NN
during/IN
lymphocyte/NN
differentiation/NN
is/VBZ
a/DT
complex/JJ
process/NN
involving/VBG
interactions/NNS
between/IN
multiple/JJ
positive/JJ
and/CC
negative/JJ
transcriptional/JJ
regulatory/JJ
elements/NNS
./.
====================
In/IN
this/DT
article/NN
,/,
transcriptional/JJ
regulation/NN
of/IN
the/DT
archetypal/JJ
T-cell-specific/JJ
gene/NN
,/,
alpha/NN
TCR/NN
,/,
is/VBZ
discussed/VBN
./.
====================
Major/JJ
recent/JJ
developments/NNS
,/,
including/VBG
the/DT
identification/NN
of/IN
novel/JJ
families/NNS
of/IN
transcription/NN
factors/NNS
that/WDT
regulate/VBP
multiple/JJ
T-cell/NN
genes/NNS
during/IN
thymocyte/NN
ontogeny/NN
and/CC
T-cell/NN
activation/NN
,/,
are/VBP
described/VBN
./.
====================
UI/LS
-/:
93129206/CD
====================
TI/LS
-/:
Photoaffinity/NN
labeling/NN
of/IN
plasma/NN
membrane/NN
receptors/NNS
for/IN
aldosterone/NN
from/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
./.
====================
AB/LS
-/:
Non-genomic/JJ
effects/NNS
of/IN
aldosterone/NN
on/IN
the/DT
sodium-proton-antiport/NN
have/VBP
been/VBN
shown/VBN
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
which/WDT
could/MD
be/VB
related/JJ
to/TO
a/DT
new/JJ
aldosterone/NN
membrane/NN
receptor/NN
./.
====================
In/IN
the/DT
present/JJ
paper/NN
plasma/NN
membranes/NNS
from/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
were/VBD
covalently/RB
photolabeled/VBN
with/IN
a/DT
[125I]-aldosterone/NN
derivative/NN
./.
====================
Sodium/NN
dodecyl/NN
sulfate-polyacrylamide/JJ
gel/NN
electrophoresis/NN
showed/VBD
significant/JJ
aldosterone/NN
binding/NN
at/IN
a/DT
molecular/JJ
weight/NN
of/IN
approximately/RB
50000/CD
Dalton/NN
which/WDT
was/VBD
absent/JJ
with/IN
1/CD
microM/NN
cold/JJ
aldosterone/NN
,/,
but/CC
not/RB
cortisol/NN
in/IN
the/DT
binding/VBG
media/NNS
./.
====================
The/DT
presence/NN
of/IN
the/DT
sulfhydryl/NN
agent/NN
dithiothreitol/NN
did/VBD
not/RB
affect/VB
results/NNS
suggesting/VBG
the/DT
absence/NN
of/IN
disulfide/NN
bridges/NNS
in/IN
the/DT
steroid/NN
binding/NN
domain/NN
of/IN
the/DT
receptor/NN
./.
====================
These/DT
data/NNS
are/VBP
the/DT
first/JJ
to/TO
define/VB
the/DT
molecular/JJ
weight/NN
of/IN
the/DT
membrane/NN
receptor/NN
for/IN
aldosterone/NN
./.
====================
UI/LS
-/:
93056505/CD
====================
TI/LS
-/:
Redox/NN
status/NN
of/IN
cells/NNS
influences/VBZ
constitutive/JJ
or/CC
induced/VBN
NF-kappa/NN
B/NN
translocation/NN
and/CC
HIV/NN
long/JJ
terminal/JJ
repeat/NN
activity/NN
in/IN
human/JJ
T/NN
and/CC
monocytic/JJ
cell/NN
lines/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
tested/VBN
the/DT
hypothesis/NN
that/IN
cellular/JJ
activation/NN
events/NNS
occurring/VBG
in/IN
T/NN
lymphocytes/NNS
and/CC
monocytes/NNS
and/CC
mediated/VBN
through/IN
translocation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
are/VBP
dependent/JJ
upon/IN
the/DT
constitutive/JJ
redox/NN
status/NN
of/IN
these/DT
cells/NNS
./.
====================
We/PRP
used/VBD
phenolic/JJ
,/,
lipid-soluble/JJ
,/,
chain-breaking/JJ
antioxidants/NNS
(/(
butylated/VBN
hydroxyanisole/NN
(/(
BHA/NN
)/)
,/,
nordihydroquairetic/JJ
acid/NN
,/,
or/CC
alpha-tocopherol/NN
(/(
vitamin/NN
E/NN
)/)
to/TO
show/VB
that/IN
peroxyl/JJ
radical/JJ
scavenging/NN
in/IN
unstimulated/JJ
and/CC
PMA-/NN
or/CC
TNF-stimulated/JJ
cells/NNS
blocks/VBZ
the/DT
functions/NNS
depending/VBG
on/IN
NF-kappa/NN
B/NN
activation/NN
./.
====================
BHA/NN
was/VBD
found/VBN
to/TO
suppress/VB
not/RB
only/RB
PMA-/NN
or/CC
TNF-induced/JJ
,/,
but/CC
also/RB
constitutive/JJ
,/,
HIV-enhancer/JJ
activity/NN
concomitant/JJ
to/TO
an/DT
inhibition/NN
of/IN
NF-kappa/NN
B/NN
binding/NN
activity/NN
in/IN
both/CC
lymphoblastoid/JJ
T/NN
(/(
J.Jhan/NN
)/)
and/CC
monocytic/JJ
(/(
U937/NN
)/)
cell/NN
lines/NNS
./.
====================
This/DT
was/VBD
also/RB
true/JJ
for/IN
KBF/NN
(/(
p50/NN
homodimer/NN
)/)
binding/NN
activity/NN
in/IN
U937/NN
cells/NNS
./.
====================
Secretion/NN
of/IN
TNF/NN
,/,
the/DT
product/NN
of/IN
another/DT
NF-kappa/NN
B-dependent/JJ
gene/NN
,/,
was/VBD
abolished/VBN
by/IN
BHA/NN
in/IN
PMA-stimulated/JJ
U937/NN
cells/NNS
./.
====================
The/DT
anti-oxidative/JJ
effect/NN
of/IN
BHA/NN
was/VBD
accompanied/VBN
by/IN
an/DT
increase/NN
in/IN
thiol/NN
,/,
but/CC
not/RB
glutathione/NN
,/,
content/NN
in/IN
stimulated/VBN
and/CC
unstimulated/JJ
T/NN
cell/NN
,/,
whereas/IN
TNF/NN
stimulation/NN
itself/PRP
barely/RB
modified/VBD
the/DT
cellular/JJ
thiol/NN
level/NN
./.
====================
Oxidative/JJ
stress/NN
obtained/VBN
by/IN
the/DT
addition/NN
of/IN
H2O2/NN
to/TO
the/DT
culture/NN
medium/NN
of/IN
J.Jhan/NN
or/CC
U937/NN
cells/NNS
could/MD
not/RB
by/IN
itself/PRP
induce/VB
NF-kappa/NN
B/NN
activation/NN
./.
====================
These/DT
observations/NNS
suggest/VBP
that/IN
TNF/NN
and/CC
PMA/NN
do/VBP
not/RB
lead/VB
to/TO
NF-kappa/NN
B/NN
activation/NN
through/IN
induction/NN
of/IN
changes/NNS
in/IN
the/DT
cell/NN
redox/NN
status/NN
./.
====================
Rather/RB
,/,
TNF/NN
and/CC
PMA/NN
can/MD
exert/VB
their/PRP$
effect/NN
only/RB
if/IN
cells/NNS
are/VBP
in/IN
an/DT
appropriate/JJ
redox/NN
status/NN
,/,
because/IN
prior/JJ
modification/NN
toward/IN
reduction/NN
with/IN
BHA/NN
treatment/NN
prevents/VBZ
this/DT
activation/NN
./.
====================
It/PRP
appears/VBZ
that/IN
a/DT
basal/JJ
redox/NN
equilibrium/NN
tending/VBG
toward/IN
oxidation/NN
is/VBZ
a/DT
prerequisite/NN
for/IN
full/JJ
activation/NN
of/IN
transduction/NN
pathways/NNS
regulating/VBG
the/DT
activity/NN
of/IN
NF-kappa/NN
B-dependent/JJ
genes/NNS
./.
====================
UI/LS
-/:
93024383/CD
====================
TI/LS
-/:
Selection/NN
of/IN
optimal/JJ
kappa/NN
B/Rel/NN
DNA-binding/JJ
motifs/NNS
:/:
interaction/NN
of/IN
both/DT
subunits/NNS
of/IN
NF-kappa/NN
B/NN
with/IN
DNA/NN
is/VBZ
required/VBN
for/IN
transcriptional/JJ
activation/NN
./.
====================
AB/LS
-/:
Analysis/NN
of/IN
the/DT
p50/NN
and/CC
p65/NN
subunits/NNS
of/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
complex/NN
has/VBZ
revealed/VBN
that/IN
both/DT
proteins/NNS
can/MD
interact/VB
with/IN
related/JJ
DNA/NN
sequences/NNS
through/IN
either/CC
homo-/JJ
or/CC
heterodimer/NN
formation/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
product/NN
of/IN
the/DT
proto-oncogene/NN
c-rel/NN
can/MD
bind/VB
to/TO
similar/JJ
DNA/NN
motifs/NNS
by/IN
itself/PRP
or/CC
as/IN
a/DT
heterodimer/NN
with/IN
p50/NN
or/CC
p65/NN
./.
====================
However/RB
,/,
these/DT
studies/NNS
have/VBP
used/VBN
a/DT
limited/JJ
number/NN
of/IN
known/JJ
kappa/NN
B/NN
DNA/NN
motifs/NNS
,/,
and/CC
the/DT
question/NN
of/IN
the/DT
optimal/JJ
DNA/NN
sequences/NNS
preferred/VBN
by/IN
each/DT
homodimer/NN
has/VBZ
not/RB
been/VBN
addressed/VBN
./.
====================
Using/VBG
purified/VBN
recombinant/JJ
p50/NN
,/,
p65/NN
,/,
and/CC
c-Rel/NN
proteins/NNS
,/,
optimal/JJ
DNA-binding/JJ
motifs/NNS
were/VBD
selected/VBN
from/IN
a/DT
pool/NN
of/IN
random/JJ
oligonucleotides/NNS
./.
====================
Alignment/NN
of/IN
the/DT
selected/VBN
sequences/NNS
allowed/VBD
us/PRP
to/TO
predict/VB
a/DT
consensus/NN
sequence/NN
for/IN
binding/NN
of/IN
the/DT
individual/JJ
homodimeric/JJ
Rel-related/JJ
proteins/NNS
,/,
and/CC
DNA-protein/NN
binding/NN
analysis/NN
of/IN
the/DT
selected/VBN
DNA/NN
sequences/VBZ
revealed/VBD
sequence/NN
specificity/NN
of/IN
the/DT
proteins/NNS
./.
====================
Contrary/JJ
to/TO
previous/JJ
assumptions/NNS
,/,
we/PRP
observed/VBD
that/IN
p65/NN
homodimers/NNS
can/MD
interact/VB
with/IN
a/DT
subset/NN
of/IN
DNA/NN
sequences/VBZ
not/RB
recognized/VBN
by/IN
p50/NN
homodimers/NNS
./.
====================
Differential/JJ
binding/NN
affinities/NNS
were/VBD
also/RB
obtained/VBN
with/IN
p50-/NN
and/CC
c-Rel-selected/JJ
sequences/NNS
./.
====================
Using/VBG
either/CC
a/DT
p50-/NN
or/CC
p65-selected/JJ
kappa/NN
B/NN
motif/NN
,/,
which/WDT
displayed/VBD
differential/JJ
binding/NN
with/IN
respect/NN
to/TO
the/DT
other/JJ
protein/NN
,/,
little/JJ
to/TO
no/DT
binding/NN
was/VBD
observed/VBN
with/IN
the/DT
heterodimeric/JJ
NF-kappa/NN
B/NN
complex/NN
./.
====================
Similarly/RB
,/,
in/IN
transfection/NN
experiments/NNS
in/IN
which/WDT
the/DT
selective/JJ
kappa/NN
B/NN
binding/NN
sites/NNS
were/VBD
used/VBN
to/TO
drive/VB
the/DT
expression/NN
of/IN
a/DT
chloramphenicol/NN
acetyltransferase/NN
reporter/NN
construct/NN
,/,
the/DT
p65-/NN
and/CC
p50-selected/JJ
motifs/NNS
were/VBD
activated/VBN
only/RB
in/IN
the/DT
presence/NN
of/IN
p65/NN
and/CC
p50/65/NN
(/(
a/DT
chimeric/JJ
protein/NN
with/IN
the/DT
p50/NN
DNA/NN
binding/NN
domain/NN
and/CC
p65/NN
activation/NN
domain/NN
)/)
expression/NN
vectors/NNS
,/,
respectively/RB
,/,
and/CC
neither/DT
demonstrated/VBD
a/DT
significant/JJ
response/NN
to/TO
stimuli/NNS
that/WDT
induce/VBP
NF-kappa/NN
B/NN
activity/NN
./.
====================
These/DT
findings/NNS
demonstrate/VBP
that/IN
interaction/NN
of/IN
both/DT
subunits/NNS
of/IN
the/DT
heterodimeric/JJ
NF-kappa/NN
B/NN
complex/NN
with/IN
DNA/NN
is/VBZ
required/VBN
for/IN
DNA/NN
binding/NN
and/CC
transcriptional/JJ
activation/NN
and/CC
suggest/VBP
that/IN
transcriptional/JJ
activation/NN
mediated/VBN
by/IN
the/DT
individual/JJ
rel-related/JJ
proteins/NNS
will/MD
differ/VB
dramatically/RB
,/,
depending/VBG
on/IN
the/DT
specific/JJ
kappa/NN
B/NN
motifs/NNS
present/JJ
./.
====================
UI/LS
-/:
92366555/CD
====================
TI/LS
-/:
NF-kappa/NN
B-dependent/JJ
induction/NN
of/IN
the/DT
NF-kappa/NN
B/NN
p50/NN
subunit/NN
gene/NN
promoter/NN
underlies/VBZ
self-perpetuation/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
transcription/NN
in/IN
monocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
The/DT
molecular/JJ
mechanisms/NNS
underlying/VBG
the/DT
sustained/JJ
nuclear/JJ
translocation/NN
of/IN
NF-kappa/NN
B/NN
observed/VBN
in/IN
U937/NN
monocytic/JJ
cells/NNS
chronically/RB
infected/VBN
with/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
were/VBD
studied/VBN
./.
====================
The/DT
activity/NN
of/IN
the/DT
promoter/NN
regulating/VBG
the/DT
synthesis/NN
of/IN
the/DT
p105/NN
precursor/NN
of/IN
the/DT
NF-kappa/NN
B/NN
p50/NN
subunit/NN
was/VBD
enhanced/VBN
in/IN
these/DT
cells/NNS
./.
====================
Deletions/NNS
in/IN
this/DT
promoter/NN
indicated/VBD
that/IN
this/DT
upregulation/NN
was/VBD
mediated/VBN
through/IN
the/DT
NF-kappa/NN
B-/NN
but/CC
not/RB
the/DT
AP-1-binding/JJ
motif/NN
,/,
by/IN
bona/FW
fide/FW
p50/p65/NN
heterodimers/NNS
./.
====================
Analysis/NN
of/IN
cytosolic/JJ
extracts/NNS
indicated/VBD
that/IN
NF-kappa/NN
B/NN
levels/NNS
were/VBD
increased/VBN
in/IN
HIV-infected/JJ
cells/NNS
./.
====================
In/IN
contrast/NN
to/TO
the/DT
transient/JJ
NF-kappa/NN
B/NN
activation/NN
induced/VBN
by/IN
phorbol/NN
ester/NN
,/,
the/DT
permanent/JJ
NF-kappa/NN
B/NN
translocation/NN
induced/VBN
by/IN
HIV/NN
infection/NN
was/VBD
not/RB
dependent/JJ
on/IN
PKC/NN
isoenzymes/NNS
alpha/NN
and/CC
beta/NN
as/IN
shown/VBN
by/IN
the/DT
use/NN
of/IN
a/DT
specific/JJ
inhibitor/NN
(/(
GF/NN
109203X/NN
)/)
./.
====================
These/DT
observations/NNS
indicate/VBP
that/IN
during/IN
chronic/JJ
HIV/NN
infection/NN
of/IN
U937/NN
cells/NNS
,/,
continuous/JJ
NF-kappa/NN
B/NN
(/(
p50/p65/NN
)/)
translocation/NN
results/VBZ
in/IN
p105/NN
promoter/NN
upregulation/NN
with/IN
subsequent/JJ
cytosolic/JJ
NF-kappa/NN
B/NN
accumulation/NN
,/,
ready/JJ
for/IN
further/JJ
translocation/NN
./.
====================
This/DT
HIV-mediated/JJ
mechanism/NN
results/VBZ
in/IN
a/DT
self-perpetuating/JJ
loop/NN
of/IN
NF-kappa/NN
B/NN
production/NN
./.
====================
UI/LS
-/:
93041375/CD
====================
TI/LS
-/:
Activation/NN
of/IN
NF-kappa/NN
B/NN
by/IN
interleukin/NN
2/CD
in/IN
human/JJ
blood/NN
monocytes/NNS
./.
====================
AB/LS
-/:
We/PRP
report/VBP
here/RB
that/IN
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
acts/VBZ
on/IN
human/JJ
blood/NN
monocytes/NNS
by/IN
enhancing/VBG
binding/NN
activity/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
to/TO
its/PRP$
consensus/NN
sequence/NN
in/IN
the/DT
5'/JJ
regulatory/JJ
enhancer/NN
region/NN
of/IN
the/DT
IL-2/NN
receptor/NN
alpha/NN
chain/NN
(/(
p55/NN
)/)
./.
====================
Similarly/RB
,/,
IL-2/NN
activates/VBZ
NF-kappa/NN
B/NN
in/IN
the/DT
human/JJ
monocytic/JJ
cell/NN
line/NN
U/NN
937/CD
,/,
but/CC
not/RB
in/IN
resting/VBG
human/JJ
T-cells/NNS
./.
====================
This/DT
effect/NN
is/VBZ
detectable/JJ
within/IN
15/CD
min/NN
and/CC
peaks/VBZ
1/CD
h/NN
after/IN
exposure/NN
to/TO
IL-2/NN
./.
====================
Enhanced/VBN
NF-kappa/NN
B/NN
binding/NN
activity/NN
is/VBZ
followed/VBN
by/IN
functional/JJ
activation/NN
in/IN
that/IN
inducibility/NN
of/IN
the/DT
IL-2/NN
receptor/NN
alpha/NN
chain/NN
is/VBZ
mediated/VBN
by/IN
enhanced/VBN
NF-kappa/NN
B/NN
binding/NN
and/CC
that/IN
a/DT
heterologous/JJ
promoter/NN
containing/VBG
the/DT
NF-kappa/NN
B/NN
consensus/NN
sequence/NN
(/(
-291/CD
to/TO
-245/CD
)/)
of/IN
the/DT
IL-2/NN
receptor/NN
alpha/NN
chain/NN
gene/NN
is/VBZ
activated/VBN
./.
====================
In/IN
addition/NN
,/,
IL-2/NN
is/VBZ
capable/JJ
of/IN
increasing/VBG
transcript/NN
levels/NNS
of/IN
the/DT
p50/NN
gene/NN
coding/VBG
for/IN
the/DT
p50/NN
subunit/NN
of/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
,/,
whereas/IN
mRNA/NN
levels/NNS
of/IN
the/DT
p65/NN
NF-kappa/NN
B/NN
gene/NN
remained/VBD
unchanged/JJ
./.
====================
UI/LS
-/:
92235212/CD
====================
TI/LS
-/:
Studies/NNS
on/IN
the/DT
biological/JJ
activity/NN
of/IN
triiodothyronine/NN
sulfate/NN
./.
====================
AB/LS
-/:
Hepatic/JJ
microsomes/NNS
and/CC
isolated/VBN
hepatocytes/NNS
in/IN
short/JJ
term/NN
culture/NN
desulfate/VBP
T3/NN
sulfate/NN
(/(
T3SO4/NN
)/)
./.
====================
We/PRP
,/,
therefore/RB
,/,
wished/VBD
to/TO
determine/VB
whether/IN
T3SO4/NN
could/MD
mimic/VB
the/DT
action/NN
of/IN
thyroid/NN
hormone/NN
in/FW
vitro/FW
./.
====================
T3SO4/NN
had/VBD
no/DT
thyromimetic/JJ
effect/NN
on/IN
the/DT
activity/NN
of/IN
Ca(2+)-ATPase/NN
in/IN
human/JJ
erythrocyte/NN
membranes/NNS
at/IN
doses/NNS
up/RB
to/TO
10,000/CD
times/NNS
the/DT
maximally/RB
effective/JJ
dose/NN
of/IN
T3/NN
(/(
10/CD
(/(
-10/CD
)/)
mol/L/NN
)/)
./.
====================
In/IN
GH4C1/NN
pituitary/JJ
cells/NNS
,/,
T3SO4/NN
failed/VBD
to/TO
displace/VB
[125I]T3/NN
from/IN
nuclear/JJ
receptors/NNS
in/IN
intact/JJ
cells/NNS
or/CC
soluble/JJ
preparations/NNS
./.
====================
Thus/RB
,/,
T3SO4/NN
was/VBD
not/RB
directly/RB
thyromimetic/JJ
in/IN
either/CC
an/DT
isolated/VBN
human/JJ
membrane/NN
system/NN
or/CC
a/DT
pituitary/JJ
cell/NN
system/NN
in/IN
which/WDT
nuclear/JJ
receptor/NN
occupancy/NN
correlates/VBZ
with/IN
GH/NN
synthesis/NN
./.
====================
Thyroid/NN
hormones/NNS
inhibit/VBP
[3H]glycosaminoglycan/NN
synthesis/NN
by/IN
cultured/VBN
human/JJ
dermal/JJ
fibroblasts/NNS
,/,
and/CC
T3SO4/NN
displayed/VBN
about/IN
0.5/CD
%/NN
the/DT
activity/NN
of/IN
T3/NN
at/IN
72/CD
h/NN
./.
====================
Human/JJ
fibroblasts/NNS
contained/VBD
roughly/RB
the/DT
same/JJ
level/NN
of/IN
microsomal/JJ
p-nitrophenyl/NN
sulfatase/NN
activity/NN
as/IN
that/DT
previously/RB
observed/VBN
in/IN
hepatic/JJ
microsomes/NNS
./.
====================
Propylthiouracil/NN
(/(
50/CD
mumol/L/NN
)/)
did/VBD
not/RB
affect/VB
the/DT
action/NN
of/IN
T3SO4/NN
,/,
suggesting/VBG
that/IN
deiodination/NN
was/VBD
not/RB
important/JJ
for/IN
this/DT
activity/NN
of/IN
T3SO4/NN
./.
====================
Thus/RB
,/,
it/PRP
appears/VBZ
T3SO4/NN
has/VBZ
no/DT
intrinsic/JJ
biological/JJ
activity/NN
,/,
but/CC
,/,
under/IN
certain/JJ
circumstances/NNS
,/,
may/MD
be/VB
reactivated/VBN
by/IN
desulfation/NN
./.
====================
UI/LS
-/:
92185243/CD
====================
TI/LS
-/:
Human/JJ
T/NN
cell/NN
activation/NN
through/IN
the/DT
activation-inducer/JJ
molecule/CD69/NN
enhances/VBZ
the/DT
activity/NN
of/IN
transcription/NN
factor/NN
AP-1/NN
./.
====================
AB/LS
-/:
The/DT
induction/NN
of/IN
the/DT
AP-1/NN
transcription/NN
factor/NN
has/VBZ
been/VBN
ascribed/VBN
to/TO
the/DT
early/JJ
events/NNS
leading/VBG
to/TO
T/NN
cell/NN
differentiation/NN
and/CC
activation/NN
./.
====================
We/PRP
have/VBP
studied/VBN
the/DT
regulation/NN
of/IN
AP-1/NN
activity/NN
in/IN
human/JJ
peripheral/JJ
blood/NN
T/NN
lymphocytes/NNS
stimulated/VBN
through/IN
the/DT
activation/NN
inducer/NN
molecule/NN
(/(
AIM/NN
)/)
/CD69/NN
activation/NN
pathway/NN
./.
====================
Phorbol/NN
esters/NNS
are/VBP
required/VBN
to/TO
induce/VB
AIM/CD69/NN
cell-surface/JJ
expression/NN
as/RB
well/RB
as/IN
for/IN
triggering/VBG
the/DT
proliferation/NN
of/IN
T/NN
cells/NNS
in/IN
conjunction/NN
with/IN
anti-AIM/JJ
mAb/NN
./.
====================
Mobility/NN
shift/NN
assays/NNS
showed/VBD
that/IN
addition/NN
of/IN
anti-AIM/JJ
mAb/NN
to/TO
PMA-treated/JJ
T/NN
lymphocytes/NNS
markedly/RB
enhanced/VBD
the/DT
binding/NN
activity/NN
of/IN
AP-1/NN
to/TO
its/PRP$
cognate/JJ
sequence/NN
,/,
the/DT
phorbol/NN
ester/NN
response/NN
element/NN
./.
====================
In/IN
contrast/NN
,/,
anti-AIM/NN
mAb/NN
did/VBD
not/RB
induce/VB
any/DT
change/NN
in/IN
the/DT
binding/NN
activity/NN
of/IN
NF-kappa/NN
B/NN
,/,
a/DT
transcription/NN
factor/NN
whose/WP$
activity/NN
is/VBZ
also/RB
regulated/VBN
by/IN
protein/NN
kinase/NN
C/NN
./.
====================
The/DT
increase/NN
in/IN
AP-1-binding/JJ
activity/NN
was/VBD
accompanied/VBN
by/IN
the/DT
marked/JJ
stimulation/NN
of/IN
the/DT
transcription/NN
of/IN
c-fos/NN
but/CC
not/RB
that/DT
of/IN
c-jun/NN
./.
====================
Blockade/NN
of/IN
the/DT
DNA-binding/JJ
complexes/NNS
with/IN
an/DT
anti-Fos/JJ
mAb/NN
demonstrated/VBD
a/DT
direct/JJ
participation/NN
of/IN
c-Fos/NN
in/IN
the/DT
AP-1/NN
complexes/NNS
induced/VBN
by/IN
anti-AIM/NN
mAb/NN
./.
====================
Most/JJS
of/IN
the/DT
AP-1/NN
activity/NN
could/MD
be/VB
eliminated/VBN
when/WRB
the/DT
anti-AIM/NN
mAb/NN
was/VBD
added/VBN
to/TO
the/DT
culture/NN
medium/NN
in/IN
the/DT
presence/NN
of/IN
cycloheximide/NN
,/,
suggesting/VBG
that/IN
de/FW
novo/FW
protein/NN
synthesis/NN
is/VBZ
crucial/JJ
for/IN
the/DT
induction/NN
of/IN
AP-1-binding/JJ
activity/NN
./.
====================
These/DT
data/NNS
provide/VBP
the/DT
evidence/NN
that/IN
activation/NN
of/IN
human/JJ
peripheral/JJ
blood/NN
T/NN
cells/NNS
through/IN
the/DT
AIM/NN
activation/NN
pathway/NN
regulate/VBP
the/DT
activity/NN
of/IN
AP-1/NN
./.
====================
Therefore/RB
,/,
this/DT
pathway/NN
appears/VBZ
as/IN
a/DT
crucial/JJ
step/NN
in/IN
the/DT
initiation/NN
of/IN
early/JJ
T/NN
cell/NN
activation/NN
events/NNS
./.
====================
UI/LS
-/:
92176633/CD
====================
TI/LS
-/:
Gangliosides/NN
suppress/VBP
tumor/NN
necrosis/NN
factor/NN
production/NN
in/IN
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
Both/CC
normal/JJ
and/CC
malignant/JJ
cells/NNS
contain/VBP
gangliosides/NNS
as/IN
important/JJ
cell/NN
membrane/NN
constituents/NNS
that/WDT
,/,
after/IN
being/VBG
shed/VBN
,/,
may/MD
influence/VB
cells/NNS
of/IN
the/DT
immune/JJ
system/NN
./.
====================
We/PRP
have/VBP
studied/VBN
the/DT
impact/NN
of/IN
gangliosides/NNS
on/IN
the/DT
expression/NN
of/IN
TNF/NN
in/IN
blood/NN
monocytes/NNS
and/CC
in/IN
the/DT
monocytic/JJ
cell/NN
line/NN
Mono/NN
Mac/NN
6/CD
./.
====================
Although/IN
under/IN
standard/JJ
culture/NN
conditions/NNS
,/,
bovine/JJ
brain/NN
gangliosides/NNS
(/(
100/CD
micrograms/ml/NNS
)/)
suppressed/VBD
LPS-stimulated/JJ
TNF/NN
production/NN
5-fold/RB
in/IN
PBMC/NN
and/CC
10-fold/RB
in/IN
Mono/NN
Mac/NN
6/CD
cells/NNS
,/,
suppression/NN
was/VBD
more/RBR
efficient/JJ
under/IN
serum-free/JJ
conditions/NNS
./.
====================
Looking/VBG
at/IN
highly/RB
purified/VBN
gangliosides/NNS
,/,
GD3/NN
,/,
GD1a/NN
,/,
GM3/NN
,/,
GM2/NN
,/,
and/CC
GM1/NN
were/VBD
all/DT
effective/JJ
in/IN
reducing/VBG
TNF/NN
production/NN
in/IN
PBMC/NN
,/,
and/CC
in/IN
Mono/NN
Mac/NN
6/CD
by/IN
factor/NN
10/CD
to/TO
50/CD
./.
====================
The/DT
suppressive/JJ
activity/NN
was/VBD
lost/VBN
in/IN
molecules/NNS
,/,
lacking/VBG
the/DT
sugar/NN
moiety/NN
or/CC
the/DT
lipid/NN
moiety/NN
./.
====================
Gangliosides/NNS
appear/VBP
to/TO
act/VB
at/IN
an/DT
early/JJ
step/NN
of/IN
activation/NN
in/IN
that/IN
TNF/NN
transcripts/NNS
were/VBD
reduced/VBN
and/CC
the/DT
mobilization/NN
of/IN
the/DT
nuclear/JJ
factor/NN
kappa/NN
B/NN
was/VBD
blocked/VBN
./.
====================
Furthermore/RB
,/,
in/IN
time/NN
kinetics/NNS
,/,
gangliosides/NNS
were/VBD
effective/JJ
for/IN
up/RB
to/TO
30/CD
min/NN
after/IN
addition/NN
of/IN
LPS/NN
,/,
but/CC
not/RB
thereafter/RB
./.
====================
However/RB
,/,
the/DT
expression/NN
of/IN
the/DT
CD14/NN
Ag/NN
,/,
a/DT
receptor/NN
molecule/NN
for/IN
LPS-LPS/NN
binding/NN
protein/NN
complexes/NNS
,/,
was/VBD
unaffected/JJ
by/IN
gangliosides/NNS
./.
====================
Finally/RB
,/,
when/WRB
using/VBG
Staphylococcus/FW
aureus/FW
or/CC
platelet/NN
activating/NN
factor/NN
as/IN
a/DT
stimulus/NN
,/,
gangliosides/NNS
were/VBD
able/JJ
to/TO
suppress/VB
TNF/NN
production/NN
in/IN
Mono/NN
Mac/NN
6/CD
cells/NNS
by/IN
factor/NN
5/CD
to/TO
10/CD
,/,
as/RB
well/RB
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
phorbol/NN
ester-induced/JJ
production/NN
of/IN
O2-/NN
was/VBD
similar/JJ
in/IN
cells/NNS
treated/VBN
with/IN
and/CC
without/IN
gangliosides/NNS
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
data/NNS
demonstrate/VBP
that/IN
TNF/NN
gene/NN
expression/NN
in/IN
monocytes/NNS
induced/VBN
by/IN
different/JJ
types/NNS
of/IN
stimuli/NNS
can/MD
be/VB
blocked/VBN
by/IN
gangliosides/NNS
at/IN
an/DT
early/JJ
step/NN
of/IN
signal/JJ
transduction/NN
./.
====================
UI/LS
-/:
92123193/CD
====================
TI/LS
-/:
A/DT
novel/JJ
mitogen-inducible/JJ
gene/NN
product/NN
related/JJ
to/TO
p50/p105-NF-kappa/NN
B/NN
participates/VBZ
in/IN
transactivation/NN
through/IN
a/DT
kappa/NN
B/NN
site/NN
./.
====================
AB/LS
-/:
A/DT
Rel-related/JJ
,/,
mitogen-inducible/JJ
,/,
kappa/NN
B-binding/JJ
protein/NN
has/VBZ
been/VBN
cloned/VBN
as/IN
an/DT
immediate-early/JJ
activation/NN
gene/NN
of/IN
human/JJ
peripheral/JJ
blood/NN
T/NN
cells/NNS
./.
====================
The/DT
cDNA/NN
has/VBZ
an/DT
open/JJ
reading/NN
frame/NN
of/IN
900/CD
amino/NN
acids/NNS
capable/JJ
of/IN
encoding/VBG
a/DT
97-kDa/JJ
protein/NN
./.
====================
This/DT
protein/NN
is/VBZ
most/RBS
similar/JJ
to/TO
the/DT
105-kDa/JJ
precursor/NN
polypeptide/NN
of/IN
p50-NF-kappa/NN
B/NN
./.
====================
Like/IN
the/DT
105-kDa/JJ
precursor/NN
,/,
it/PRP
contains/VBZ
an/DT
amino-terminal/JJ
Rel-related/JJ
domain/NN
of/IN
about/IN
300/CD
amino/NN
acids/NNS
and/CC
a/DT
carboxy-terminal/JJ
domain/NN
containing/VBG
six/CD
full/JJ
cell/NN
cycle/NN
or/CC
ankyrin/NN
repeats/NNS
./.
====================
In/FW
vitro-translated/JJ
proteins/NNS
,/,
truncated/VBN
downstream/RB
of/IN
the/DT
Rel/NN
domain/NN
and/CC
excluding/VBG
the/DT
repeats/NNS
,/,
bind/VBP
kappa/NN
B/NN
sites/NNS
./.
====================
We/PRP
refer/VBP
to/TO
the/DT
kappa/NN
B-binding/JJ
,/,
truncated/VBN
protein/NN
as/IN
p50B/NN
by/IN
analogy/NN
with/IN
p50-NF-kappa/NN
B/NN
and/CC
to/TO
the/DT
full-length/JJ
protein/NN
as/IN
p97/NN
./.
====================
p50B/NN
is/VBZ
able/JJ
to/TO
form/VB
heteromeric/JJ
kappa/NN
B-binding/JJ
complexes/NNS
with/IN
RelB/NN
,/,
as/RB
well/RB
as/IN
with/IN
p65/NN
and/CC
p50/NN
,/,
the/DT
two/CD
subunits/NNS
of/IN
NF-kappa/NN
B/NN
./.
====================
Transient-transfection/NN
experiments/NNS
in/IN
embryonal/JJ
carcinoma/NN
cells/NNS
demonstrate/VBP
a/DT
functional/JJ
cooperation/NN
between/IN
p50B/NN
and/CC
RelB/NN
or/CC
p65/NN
in/IN
transactivation/NN
of/IN
a/DT
reporter/NN
plasmid/NN
dependent/JJ
on/IN
a/DT
kappa/NN
B/NN
site/NN
./.
====================
The/DT
data/NNS
imply/VBP
the/DT
existence/NN
of/IN
a/DT
complex/JJ
family/NN
of/IN
NF-kappa/NN
B-like/JJ
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
93153207/CD
====================
TI/LS
-/:
Surrogate/NN
thyroglobulin/NN
receptors/NNS
and/CC
T/NN
cell/NN
proliferation/NN
in/IN
Hashimoto/NN
's/POS
thyroiditis/NN
./.
====================
AB/LS
-/:
Immunoglobulin/NN
molecules/NNS
on/IN
the/DT
surface/NN
of/IN
a/DT
B/NN
lymphocyte/NN
are/VBP
the/DT
endogenous/JJ
"/``
receptors/NNS
"/''
to/TO
which/WDT
specific/JJ
antigens/NNS
bind/VBP
./.
====================
Studies/NNS
in/IN
mice/NNS
have/VBP
shown/VBN
that/IN
a/DT
monoclonal/JJ
antibody/NN
,/,
conjugated/VBN
with/IN
palmitate/NN
to/TO
provide/VB
a/DT
lipid/NN
tail/NN
,/,
can/MD
be/VB
inserted/VBN
into/IN
the/DT
cell/NN
membrane/NN
to/TO
provide/VB
a/DT
"/``
surrogate/JJ
"/''
antigen/NN
receptor/NN
./.
====================
We/PRP
have/VBP
investigated/VBN
whether/IN
a/DT
palmitate/JJ
conjugate/NN
of/IN
a/DT
human/JJ
monoclonal/JJ
antibody/NN
specific/JJ
for/IN
thyroglobulin/NN
(/(
TG/NN
)/)
could/MD
function/VB
as/IN
a/DT
surrogate/JJ
TG/NN
receptor/NN
on/IN
blood/NN
mononuclear/JJ
cells/NNS
separated/VBN
into/IN
fractions/NNS
enriched/VBN
for/IN
T/NN
cells/NNS
or/CC
depleted/VBN
of/IN
T/NN
cells/NNS
(/(
non-T/JJ
cells/NNS
)/)
./.
====================
Using/VBG
flow/NN
cytometry/NN
,/,
we/PRP
detected/VBD
surrogate/JJ
TG/NN
receptors/NNS
on/IN
non-T/JJ
(/(
but/CC
not/RB
on/IN
T/NN
)/)
cells/NNS
from/IN
11/CD
of/IN
11/CD
individuals/NNS
studied/VBN
(/(
5/CD
Hashimoto/NN
patients/NNS
and/CC
6/CD
control/NN
donors/NNS
)/)
./.
====================
In/IN
contrast/NN
,/,
endogenous/JJ
TG/NN
receptors/NNS
could/MD
only/RB
be/VB
detected/VBN
on/IN
non-T/JJ
cells/NNS
from/IN
1/CD
of/IN
3/CD
Hashimoto/NN
patients/NNS
and/CC
from/IN
0/CD
of/IN
4/CD
control/NN
donors/NNS
./.
====================
Because/IN
of/IN
the/DT
efficient/JJ
binding/NN
of/IN
TG/NN
by/IN
surrogate/JJ
receptors/NNS
on/IN
non-T/JJ
cells/NNS
,/,
we/PRP
assessed/VBD
the/DT
ability/NN
of/IN
such/JJ
cells/NNS
to/TO
present/VB
TG/NN
to/TO
T/NN
cells/NNS
./.
====================
Proliferation/NN
in/IN
response/NN
to/TO
TG/NN
was/VBD
observed/VBN
in/IN
T/NN
cells/NNS
from/IN
only/RB
1/CD
of/IN
5/CD
Hashimoto/NN
patients/NNS
./.
====================
This/DT
low/JJ
frequency/NN
of/IN
response/NN
was/VBD
no/RB
different/JJ
from/IN
that/DT
previously/RB
detected/VBN
using/VBG
cultures/NNS
of/IN
T/NN
cells/NNS
and/CC
autologous/JJ
dendritic/JJ
cells/NNS
./.
====================
Therefore/RB
,/,
the/DT
successful/JJ
generation/NN
of/IN
surrogate/JJ
receptors/NNS
on/IN
non-T/JJ
cells/NNS
is/VBZ
not/RB
associated/VBN
with/IN
more/RBR
efficient/JJ
TG/NN
presentation/NN
of/IN
T/NN
cells/NNS
./.
====================
Furthermore/RB
,/,
the/DT
significance/NN
of/IN
the/DT
present/JJ
study/NN
is/VBZ
that/IN
the/DT
T/NN
cells/NNS
,/,
not/RB
the/DT
antigen-presenting/JJ
cells/NNS
,/,
are/VBP
likely/JJ
to/TO
be/VB
the/DT
limiting/VBG
element/NN
in/IN
the/DT
T/NN
cell/NN
proliferative/JJ
response/NN
to/TO
TG/NN
and/CC
other/JJ
thyroid/NN
autoantigens/NNS
./.
====================
UI/LS
-/:
93110357/CD
====================
TI/LS
-/:
Targeted/VBN
degradation/NN
of/IN
c-Fos/NN
,/,
but/CC
not/RB
v-Fos/NN
,/,
by/IN
a/DT
phosphorylation-dependent/JJ
signal/NN
on/IN
c-Jun/NN
./.
====================
AB/LS
-/:
The/DT
proto-oncogene/NN
products/NNS
c-Fos/NN
and/CC
c-Jun/NN
heterodimerize/VBP
through/IN
their/PRP$
leucine/NN
zippers/NNS
to/TO
form/VB
the/DT
AP-1/NN
transcription/NN
factor/NN
./.
====================
The/DT
transcriptional/JJ
activity/NN
of/IN
the/DT
heterodimer/NN
is/VBZ
regulated/VBN
by/IN
signal-dependent/JJ
phosphorylation/NN
and/CC
dephosphorylation/NN
events/NNS
./.
====================
The/DT
stability/NN
of/IN
c-Fos/NN
was/VBD
found/VBN
to/TO
also/RB
be/VB
controlled/VBN
by/IN
intracellular/JJ
signal/NN
transduction/NN
./.
====================
In/IN
transient/JJ
expression/NN
and/CC
in/FW
vitro/FW
degradation/NN
experiments/NNS
,/,
the/DT
stability/NN
of/IN
c-Fos/NN
was/VBD
decreased/VBN
when/WRB
the/DT
protein/NN
was/VBD
dimerized/JJ
with/IN
phosphorylated/VBN
c-Jun/NN
./.
====================
c-Jun/NN
protein/NN
isolated/VBN
from/IN
phorbol/NN
ester-induced/JJ
cells/NNS
did/VBD
not/RB
target/VB
c-Fos/NN
for/IN
degradation/NN
,/,
which/WDT
suggests/VBZ
that/IN
c-Fos/NN
is/VBZ
transiently/RB
stabilized/VBN
after/IN
stimulation/NN
of/IN
cell/NN
growth/NN
./.
====================
v-Fos/NN
protein/NN
,/,
the/DT
retroviral/JJ
counterpart/NN
of/IN
c-Fos/NN
,/,
was/VBD
not/RB
susceptible/JJ
to/TO
degradation/NN
targeted/VBN
by/IN
c-Jun/NN
./.
====================
UI/LS
-/:
93054486/CD
====================
TI/LS
-/:
The/DT
regulation/NN
of/IN
the/DT
human/JJ
tumor/NN
necrosis/NN
factor/NN
alpha/NN
promoter/NN
region/NN
in/IN
macrophage/NN
,/,
T/NN
cell/NN
,/,
and/CC
B/NN
cell/NN
lines/NNS
./.
====================
AB/LS
-/:
The/DT
1311-base/JJ
pair/NN
human/JJ
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
)/)
alpha/NN
promoter/NN
region/NN
was/VBD
fused/VBN
to/TO
the/DT
luciferase/NN
(/(
Luc/NN
)/)
reporter/NN
gene/NN
and/CC
studied/VBN
in/IN
a/DT
transient/JJ
transfection/NN
system/NN
in/IN
three/CD
TNF/NN
producing/NN
cell/NN
lines/NNS
,/,
the/DT
U937/NN
macrophage/NN
cell/NN
line/NN
,/,
the/DT
MLA/NN
144/CD
T/NN
cell/NN
line/NN
,/,
and/CC
the/DT
729-6/CD
B/NN
cell/NN
line/NN
./.
====================
This/DT
full/JJ
length/NN
promoter/NN
construct/NN
can/MD
be/VB
induced/VBN
by/IN
phorbol/NN
13-myristate/NN
acetate/NN
(/(
PMA/NN
)/)
in/IN
each/DT
of/IN
these/DT
cell/NN
types/NNS
./.
====================
Analysis/NN
of/IN
a/DT
series/NN
of/IN
5'-truncations/NNS
showed/VBD
several/JJ
peaks/NNS
of/IN
basal/JJ
and/CC
PMA/NN
induced/JJ
activity/NN
suggesting/VBG
the/DT
presence/NN
of/IN
several/JJ
positive/JJ
and/CC
negative/JJ
regulatory/JJ
elements/NNS
./.
====================
A/DT
PMA/NN
responsive/JJ
element/NN
was/VBD
localized/JJ
to/TO
a/DT
region/NN
between/IN
-95/CD
and/CC
-36/CD
bp/NN
relative/JJ
to/TO
the/DT
transcription/NN
start/NN
site/NN
./.
====================
Within/IN
this/DT
region/NN
,/,
single/JJ
AP-2-/NN
and/CC
AP-1-like/JJ
consensus/NN
sequences/NNS
were/VBD
noted/VBN
./.
====================
These/DT
AP-2/NN
and/CC
AP-1/NN
sites/NNS
were/VBD
each/DT
modified/VBN
with/IN
a/DT
double/JJ
point/NN
mutation/NN
./.
====================
A/DT
modest/JJ
(/(
20-50/CD
%/NN
)/)
reduction/NN
in/IN
TNF/NN
promoter/NN
activity/NN
was/VBD
observed/VBN
with/IN
the/DT
AP-2/NN
site/NN
mutation/NN
./.
====================
However/RB
,/,
mutation/NN
of/IN
the/DT
AP-1/NN
site/NN
markedly/RB
diminished/VBD
both/CC
the/DT
basal/JJ
and/CC
PMA-activated/JJ
promoter/NN
activity/NN
./.
====================
Also/RB
co-transfections/NNS
of/IN
the/DT
wild-type/JJ
promoter/NN
construct/NN
with/IN
an/DT
AP-1/c-jun/NN
expression/NN
vector/NN
resulted/VBD
in/IN
augmented/JJ
basal/JJ
and/CC
PMA-induced/JJ
promoter/NN
activity/NN
./.
====================
UI/LS
-/:
93018835/CD
====================
TI/LS
-/:
Stable/JJ
expression/NN
of/IN
transdominant/JJ
Rev/NN
protein/NN
in/IN
human/JJ
T/NN
cells/NNS
inhibits/VBZ
human/JJ
immunodeficiency/NN
virus/NN
replication/NN
./.
====================
AB/LS
-/:
The/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
Rev/NN
protein/NN
is/VBZ
essential/JJ
for/IN
viral/JJ
structural/JJ
protein/NN
expression/NN
(/(
Gag/NN
,/,
Pol/NN
,/,
and/CC
Env/NN
)/)
and/CC
,/,
hence/RB
,/,
for/IN
viral/JJ
replication/NN
./.
====================
In/IN
transient/JJ
transfection/NN
assays/NNS
,/,
mutant/JJ
forms/NNS
of/IN
Rev/NN
have/VBP
been/VBN
identified/VBN
that/WDT
inhibit/VBP
wild-type/JJ
Rev/NN
activity/NN
and/CC
therefore/RB
suppress/VBP
viral/JJ
replication/NN
./.
====================
To/TO
determine/VB
whether/IN
such/JJ
transdominant/JJ
Rev/NN
proteins/NNS
could/MD
provide/VB
long-term/JJ
protection/NN
against/IN
HIV/NN
infection/NN
without/IN
affecting/VBG
T/NN
cell/NN
function/NN
,/,
T/NN
leukemia/NN
cell/NN
lines/NNS
were/VBD
stably/RB
transduced/VBN
with/IN
a/DT
retroviral/JJ
vector/NN
encoding/VBG
a/DT
transdominant/JJ
mutant/NN
of/IN
the/DT
Rev/NN
protein/NN
,/,
M10/NN
./.
====================
While/IN
all/PDT
the/DT
M10-expressing/JJ
cell/NN
lines/NNS
remained/VBD
infectable/JJ
by/IN
HIV-1/NN
,/,
these/DT
same/JJ
cells/NNS
failed/VBD
to/TO
support/VB
a/DT
productive/JJ
replication/NN
cycle/NN
when/WRB
infected/VBN
with/IN
a/DT
cloned/VBN
isolate/NN
of/IN
HIV-1/NN
./.
====================
In/IN
addition/NN
,/,
two/CD
out/IN
of/IN
three/CD
M10-expressing/JJ
CEM/NN
clones/NNS
were/VBD
also/RB
resistant/JJ
to/TO
highly/RB
productive/JJ
infection/NN
by/IN
a/DT
heterogeneous/JJ
HIV-1/NN
pool/NN
./.
====================
Expression/NN
of/IN
M10/NN
did/VBD
not/RB
affect/VB
induction/NN
of/IN
HIV/NN
transcription/NN
mediated/VBN
by/IN
the/DT
kappa/NN
B/NN
regulatory/JJ
element/NN
or/CC
Tat/NN
./.
====================
Importantly/RB
,/,
constitutive/JJ
expression/NN
of/IN
Rev/NN
M10/NN
did/VBD
not/RB
alter/VB
the/DT
secretion/NN
of/IN
interleukin/NN
2/CD
in/IN
response/NN
to/TO
mitogen/NN
stimulation/NN
of/IN
EL-4/NN
and/CC
Jurkat/NN
cells/NNS
./.
====================
The/DT
inhibition/NN
of/IN
HIV/NN
infection/NN
in/IN
cells/NNS
stably/RB
expressing/VBG
a/DT
transdominant/JJ
Rev/NN
protein/NN
,/,
in/IN
the/DT
absence/NN
of/IN
any/DT
deleterious/JJ
effect/NN
on/IN
T/NN
cell/NN
function/NN
,/,
suggests/VBZ
that/IN
such/PDT
a/DT
strategy/NN
could/MD
provide/VB
a/DT
therapeutic/JJ
effect/NN
in/IN
the/DT
T/NN
lymphocytes/NNS
of/IN
acquired/VBN
immunodeficiency/NN
syndrome/NN
patients/NNS
./.
====================
UI/LS
-/:
92366521/CD
====================
TI/LS
-/:
Simple/JJ
derivation/NN
of/IN
TFIID-dependent/JJ
RNA/NN
polymerase/NN
II/CD
transcription/NN
systems/NNS
from/IN
Schizosaccharomyces/FW
pombe/FW
and/CC
other/JJ
organisms/NNS
,/,
and/CC
factors/NNS
required/VBN
for/IN
transcriptional/JJ
activation/NN
./.
====================
AB/LS
-/:
Resolution/NN
of/IN
whole/JJ
cell/NN
extract/NN
through/IN
two/CD
chromatographic/JJ
steps/NNS
yields/VBZ
a/DT
single/JJ
protein/NN
fraction/NN
requiring/VBG
only/RB
the/DT
addition/NN
of/IN
TFIID/NN
for/IN
the/DT
initiation/NN
of/IN
transcription/NN
at/IN
RNA/NN
polymerase/NN
II/CD
promoters/NNS
./.
====================
This/DT
approach/NN
allows/VBZ
the/DT
convenient/JJ
generation/NN
of/IN
RNA/NN
polymerase/NN
II/CD
transcription/NN
systems/NNS
from/IN
Saccharomyces/FW
cerevisiae/FW
,/,
human/JJ
lymphocytes/NNS
,/,
and/CC
Schizosaccharomyces/FW
pombe/FW
./.
====================
TFIIDs/NNS
from/IN
all/DT
three/CD
organisms/NNS
are/VBP
interchangeable/JJ
among/IN
all/DT
three/CD
systems/NNS
./.
====================
The/DT
S./FW
cerevisiae/FW
and/CC
Sch./FW
pombe/FW
systems/NNS
support/VBP
effects/NNS
of/IN
acidic/JJ
activator/NN
proteins/NNS
,/,
provided/VBN
a/DT
further/JJ
protein/NN
fraction/NN
from/IN
S./FW
cerevisiae/FW
is/VBZ
supplied/VBN
./.
====================
This/DT
further/JJ
fraction/NN
is/VBZ
distinct/JJ
from/IN
the/DT
mediator/NN
of/IN
transcriptional/JJ
activation/NN
described/VBN
previously/RB
and/CC
represents/VBZ
a/DT
second/JJ
component/NN
in/IN
addition/NN
to/TO
general/JJ
initiation/NN
factors/NNS
that/WDT
may/MD
facilitate/VB
a/DT
response/NN
to/TO
acidic/JJ
activators/NNS
./.
====================
UI/LS
-/:
93041372/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
c-jun/NN
expression/NN
during/IN
induction/NN
of/IN
monocytic/JJ
differentiation/NN
by/IN
okadaic/JJ
acid/NN
./.
====================
AB/LS
-/:
The/DT
present/JJ
work/NN
has/VBZ
examined/VBN
the/DT
effects/NNS
of/IN
okadaic/JJ
acid/NN
,/,
an/DT
inhibitor/NN
of/IN
type/NN
1/CD
and/CC
2A/NN
protein/NN
phosphatases/NNS
,/,
on/IN
the/DT
regulation/NN
of/IN
c-jun/NN
expression/NN
during/IN
monocytic/JJ
differentiation/NN
of/IN
U-937/NN
leukemia/NN
cells/NNS
./.
====================
The/DT
results/NNS
demonstrate/VBP
that/IN
okadaic/JJ
acid/NN
treatment/NN
is/VBZ
associated/VBN
with/IN
induction/NN
of/IN
a/DT
differentiated/VBN
monocyte/NN
phenotype/NN
characterized/VBN
by/IN
:/:
(/(
a/LS
)/)
growth/NN
arrest/NN
;/:
(/(
b/LS
)/)
increases/NNS
in/IN
Mac-1/NN
cell/NN
surface/NN
antigen/NN
expression/NN
;/:
(/(
c/LS
)/)
down-regulation/NN
of/IN
c-myc/NN
transcripts/NNS
;/:
and/CC
(/(
d/LS
)/)
induction/NN
of/IN
tumor/NN
necrosis/NN
factor/NN
gene/NN
expression/NN
./.
====================
This/DT
induction/NN
of/IN
monocytic/JJ
differentiation/NN
was/VBD
associated/VBN
with/IN
transient/JJ
increases/NNS
in/IN
c-jun/NN
mRNA/NN
levels/NNS
,/,
which/WDT
were/VBD
maximal/JJ
at/IN
6/CD
h/NN
./.
====================
Similar/JJ
effects/NNS
were/VBD
obtained/VBN
for/IN
the/DT
c-fos/NN
gene/NN
./.
====================
Run-on/JJ
analysis/NN
demonstrated/VBD
detectable/JJ
levels/NNS
of/IN
c-jun/NN
transcription/NN
in/IN
U-937/NN
cells/NNS
and/CC
that/IN
this/DT
rate/NN
is/VBZ
increased/VBN
approximately/RB
40-fold/RB
following/VBG
okadaic/JJ
acid/NN
exposure/NN
./.
====================
c-jun/NN
mRNA/NN
levels/NNS
were/VBD
superinduced/VBN
in/IN
cells/NNS
treated/VBN
with/IN
both/CC
okadaic/JJ
acid/NN
and/CC
cycloheximide/NN
,/,
whereas/IN
inhibition/NN
of/IN
protein/NN
synthesis/NN
had/VBD
little/JJ
,/,
if/IN
any/DT
,/,
effect/NN
on/IN
okadaic/JJ
acid-induced/JJ
c-jun/NN
transcription/NN
./.
====================
The/DT
half-life/NN
of/IN
c-jun/NN
mRNA/NN
was/VBD
similar/JJ
(/(
45-50/CD
min/NN
)/)
in/IN
both/CC
untreated/JJ
and/CC
okadaic/JJ
acid-induced/JJ
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
treatment/NN
with/IN
both/DT
okadaic/JJ
acid/NN
and/CC
cycloheximide/NN
was/VBD
associated/VBN
with/IN
stabilization/NN
(/(
t/NN
1/2/CD
=/JJ
90/CD
min/NN
)/)
of/IN
c-jun/NN
transcripts/NNS
./.
====================
Taken/VBN
together/RB
,/,
these/DT
findings/NNS
indicate/VBP
that/IN
the/DT
induction/NN
of/IN
c-jun/NN
transcription/NN
by/IN
okadaic/JJ
acid/NN
is/VBZ
controlled/VBN
primarily/RB
by/IN
a/DT
transcriptional/JJ
mechanism/NN
./.
====================
Since/IN
previous/JJ
studies/NNS
have/VBP
demonstrated/VBN
that/IN
the/DT
c-jun/NN
gene/NN
is/VBZ
autoinduced/VBN
by/IN
Jun/AP-1/NN
,/,
we/PRP
also/RB
studied/VBD
transcription/NN
of/IN
c-jun/NN
promoter/NN
(/(
positions/NNS
-132/+170/CD
)/)
-reporter/JJ
gene/NN
constructs/NNS
with/IN
and/CC
without/IN
a/DT
mutated/VBN
AP-1/NN
element/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
92378895/CD
====================
TI/LS
-/:
Mitogen/NN
stimulation/NN
of/IN
T-cells/NNS
increases/VBZ
c-Fos/NN
and/CC
c-Jun/NN
protein/NN
levels/NNS
,/,
AP-1/NN
binding/NN
and/CC
AP-1/NN
transcriptional/JJ
activity/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
analysed/VBN
the/DT
effect/NN
of/IN
mitogenic/JJ
lectins/NNS
on/IN
c-Fos/NN
and/CC
c-Jun/NN
protein/NN
levels/NNS
as/RB
well/RB
as/IN
on/IN
activator/NN
protein-1/NN
(/(
AP-1/NN
)/)
binding/NN
and/CC
enhancer/NN
activity/NN
in/IN
Jurkat/NN
T-cells/NNS
./.
====================
Both/CC
c-Fos/NN
and/CC
c-Jun/NN
protein/NN
levels/NNS
were/VBD
increased/VBN
after/IN
Con/NN
A/NN
and/CC
PHA/NN
stimulation/NN
./.
====================
Since/IN
T-cell/NN
stimulation/NN
increases/VBZ
both/CC
intracellular/JJ
Ca2+/NN
and/CC
cAMP/NN
levels/NNS
and/CC
activates/VBZ
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
,/,
the/DT
possible/JJ
involvement/NN
of/IN
these/DT
intracellular/JJ
messengers/NNS
in/IN
c-Fos/NN
and/CC
c-Jun/NN
induction/NN
was/VBD
tested/VBN
./.
====================
PMA/NN
,/,
which/WDT
directly/RB
activates/VBZ
PKC/NN
,/,
mimicked/VBD
the/DT
effect/NN
of/IN
the/DT
lectins/NNS
on/IN
c-Fos/NN
and/CC
c-Jun/NN
,/,
but/CC
elevation/NN
of/IN
either/CC
intracellular/JJ
Ca2+/NN
or/CC
cAMP/NN
levels/NNS
had/VBD
little/JJ
or/CC
no/DT
effect/NN
./.
====================
The/DT
mitogen-induced/JJ
increase/NN
of/IN
c-Fos/NN
and/CC
c-Jun/NN
immunoreactivity/NN
was/VBD
inhibited/VBN
by/IN
H-7/NN
,/,
a/DT
kinase/NN
inhibitor/NN
with/IN
relatively/RB
high/JJ
specificity/NN
for/IN
PKC/NN
,/,
and/CC
less/RBR
efficiently/RB
by/IN
H-8/NN
,/,
a/DT
structurally/RB
related/JJ
kinase/NN
inhibitor/NN
less/RBR
active/JJ
on/IN
PKC/NN
,/,
but/CC
more/RBR
active/JJ
on/IN
cyclic/JJ
nucleotide-dependent/JJ
kinases/NNS
./.
====================
Con/NN
A/NN
stimulation/NN
was/VBD
found/VBN
to/TO
increase/VB
both/CC
binding/NN
of/IN
AP-1/NN
to/TO
the/DT
AP-1/NN
consensus/NN
sequence/NN
,/,
TRE/NN
,/,
and/CC
AP-1/NN
enhancer/NN
activity/NN
,/,
in/IN
Jurkat/NN
cells/NNS
./.
====================
PMA/NN
was/VBD
also/RB
found/VBN
to/TO
increase/VB
the/DT
AP-1/NN
enhancer/NN
activity/NN
,/,
whereas/IN
elevation/NN
of/IN
Ca2+/NN
or/CC
cAMP/NN
had/VBD
only/RB
minor/JJ
effects/NNS
./.
====================
We/PRP
conclude/VBP
that/IN
stimulation/NN
with/IN
mitogenic/JJ
lectins/NNS
is/VBZ
sufficient/JJ
to/TO
increase/VB
both/CC
c-Fos/NN
and/CC
c-Jun/NN
protein/NN
levels/NNS
,/,
AP-1/NN
binding/NN
and/CC
AP-1/NN
enhancer/NN
activity/NN
in/IN
Jurkat/NN
cells/NNS
and/CC
that/IN
they/PRP
act/VBP
via/IN
mechanisms/NNS
that/WDT
could/MD
involve/VB
the/DT
activation/NN
of/IN
PKC/NN
./.
====================
UI/LS
-/:
92212930/CD
====================
TI/LS
-/:
An/DT
11-base-pair/JJ
DNA/NN
sequence/NN
motif/NN
apparently/RB
unique/JJ
to/TO
the/DT
human/JJ
interleukin/NN
4/CD
gene/NN
confers/VBZ
responsiveness/NN
to/TO
T-cell/NN
activation/NN
signals/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
identified/VBN
a/DT
DNA/NN
segment/NN
that/WDT
confers/VBZ
responsiveness/NN
to/TO
antigen/NN
stimulation/NN
signals/NNS
on/IN
the/DT
human/JJ
interleukin/NN
(/(
IL/NN
)/)
4/CD
gene/NN
in/IN
Jurkat/NN
cells/NNS
./.
====================
The/DT
human/JJ
IL-4/NN
gene/NN
,/,
of/IN
10/CD
kilobases/NNS
,/,
is/VBZ
composed/VBN
of/IN
four/CD
exons/NNS
and/CC
three/CD
introns/NNS
./.
====================
A/DT
cis-acting/JJ
element/NN
(/(
P/NN
sequence/NN
)/)
resides/VBZ
in/IN
the/DT
5'/JJ
upstream/JJ
region/NN
;/:
no/DT
additional/JJ
DNA/NN
segments/NNS
with/IN
enhancer/NN
activity/NN
were/VBD
identified/VBN
in/IN
the/DT
human/JJ
IL-4/NN
gene/NN
./.
====================
For/IN
further/JJ
mapping/NN
purposes/NNS
,/,
a/DT
fusion/NN
promoter/NN
was/VBD
constructed/VBN
with/IN
the/DT
granulocyte/macrophage/JJ
colony-stimulating/JJ
factor/NN
basic/JJ
promoter/NN
containing/VBG
60/CD
base/NN
pairs/NNS
of/IN
sequence/NN
upstream/JJ
from/IN
the/DT
cap/NN
site/NN
of/IN
the/DT
mouse/NN
granulocyte/macrophage/JJ
colony-stimulating/JJ
factor/NN
gene/NN
and/CC
various/JJ
lengths/NNS
of/IN
the/DT
5'/JJ
upstream/JJ
sequence/NN
of/IN
the/DT
IL-4/NN
gene/NN
./.
====================
The/DT
P/NN
sequence/NN
was/VBD
located/JJ
between/IN
positions/NNS
-79/CD
and/CC
-69/CD
relative/JJ
to/TO
the/DT
transcription/NN
start/NN
site/NN
of/IN
the/DT
human/JJ
IL-4/NN
gene/NN
,/,
and/CC
this/DT
location/NN
was/VBD
confirmed/VBN
by/IN
base-substitution/NN
mutations/NNS
./.
====================
The/DT
plasmids/NNS
carrying/VBG
multiple/JJ
copies/NNS
of/IN
the/DT
P/NN
sequence/NN
showed/VBD
higher/JJR
responsiveness/NN
to/TO
the/DT
stimulation/NN
./.
====================
The/DT
binding/VBG
protein/NN
(/(
s/NNS
)/)
that/WDT
recognize/VBP
the/DT
P/NN
sequence/NN
of/IN
the/DT
IL-4/NN
gene/NN
were/VBD
identified/VBN
by/IN
DNA-mobility-shift/JJ
assays/NNS
./.
====================
The/DT
binding/NN
of/IN
NF/NN
(/(
P/NN
)/)
(/(
a/DT
DNA/NN
binding/NN
protein/NN
that/WDT
specifically/RB
recognizes/VBZ
the/DT
P/NN
sequence/NN
)/)
to/TO
the/DT
P/NN
sequence/NN
was/VBD
abolished/VBN
when/WRB
oligonucleotides/NNS
carrying/VBG
base/NN
substitutions/NNS
were/VBD
used/VBN
,/,
indicating/VBG
that/IN
the/DT
NF/NN
(/(
P/NN
)/)
interaction/NN
is/VBZ
sequence-specific/JJ
and/CC
that/IN
binding/NN
specificity/NN
of/IN
the/DT
protein/NN
paralleled/VBD
the/DT
sequence/NN
requirements/NNS
for/IN
IL-4/NN
expression/NN
in/FW
vivo/FW
./.
====================
The/DT
P/NN
sequence/NN
does/VBZ
not/RB
share/VB
homology/NN
with/IN
the/DT
5'/JJ
upstream/JJ
sequence/NN
of/IN
the/DT
IL-2/NN
gene/NN
,/,
even/RB
though/IN
surrounding/VBG
sequences/NNS
of/IN
the/DT
IL-4/NN
gene/NN
share/NN
high/JJ
homology/NN
with/IN
the/DT
IL-2/NN
gene/NN
./.
====================
We/PRP
conclude/VBP
that/IN
a/DT
different/JJ
set/NN
of/IN
proteins/NNS
recognize/VBP
IL-2/NN
and/CC
IL-4/NN
genes/NNS
./.
====================
UI/LS
-/:
92207144/CD
====================
TI/LS
-/:
Leukotriene/NN
B4/NN
stimulates/VBZ
c-fos/NN
and/CC
c-jun/NN
gene/NN
transcription/NN
and/CC
AP-1/NN
binding/NN
activity/NN
in/IN
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
examined/VBN
the/DT
effect/NN
of/IN
leukotriene/NN
B4/NN
(/(
LTB4/NN
)/)
,/,
a/DT
potent/JJ
lipid/NN
proinflammatory/JJ
mediator/NN
,/,
on/IN
the/DT
expression/NN
of/IN
the/DT
proto-oncogenes/NNS
c-jun/NN
and/CC
c-fos/NN
./.
====================
In/IN
addition/NN
,/,
we/PRP
looked/VBD
at/IN
the/DT
modulation/NN
of/IN
nuclear/JJ
factors/NNS
binding/VBG
specifically/RB
to/TO
the/DT
AP-1/NN
element/NN
after/IN
LTB4/NN
stimulation/NN
./.
====================
LTB4/NN
increased/VBD
the/DT
expression/NN
of/IN
the/DT
c-fos/NN
gene/NN
in/IN
a/DT
time-/NN
and/CC
concentration-dependent/JJ
manner/NN
./.
====================
The/DT
c-jun/NN
mRNA/NN
,/,
which/WDT
is/VBZ
constitutively/RB
expressed/VBN
in/IN
human/JJ
peripheral-blood/NN
monocytes/NNS
at/IN
relatively/RB
high/JJ
levels/NNS
,/,
was/VBD
also/RB
slightly/RB
augmented/JJ
by/IN
LTB4/NN
,/,
although/IN
to/TO
a/DT
much/RB
lower/JJR
extent/NN
than/IN
c-fos/NN
./.
====================
The/DT
kinetics/NNS
of/IN
expression/NN
of/IN
the/DT
two/CD
genes/NNS
were/VBD
also/RB
slightly/RB
different/JJ
,/,
with/IN
c-fos/NN
mRNA/NN
reaching/VBG
a/DT
peak/NN
at/IN
15/CD
min/NN
after/IN
stimulation/NN
and/CC
c-jun/NN
at/IN
30/CD
min/NN
./.
====================
Both/DT
messages/NNS
rapidly/RB
declined/VBD
thereafter/RB
./.
====================
Stability/NN
of/IN
the/DT
c-fos/NN
and/CC
c-jun/NN
mRNA/NN
was/VBD
not/RB
affected/VBN
by/IN
LTB4/NN
,/,
as/IN
assessed/VBN
after/IN
actinomycin/NN
D/NN
treatment/NN
./.
====================
Nuclear/JJ
transcription/NN
studies/NNS
in/FW
vitro/FW
showed/VBD
that/IN
LTB4/NN
increased/VBD
the/DT
transcription/NN
of/IN
the/DT
c-fos/NN
gene/NN
7-fold/RB
and/CC
the/DT
c-jun/NN
gene/NN
1.4-fold/RB
./.
====================
Resting/VBG
monocytes/NNS
contained/VBD
nuclear/JJ
factors/NNS
binding/VBG
to/TO
the/DT
AP-1/NN
element/NN
,/,
but/CC
stimulation/NN
of/IN
monocytes/NNS
with/IN
LTB4/NN
induced/VBD
greater/JJR
AP-1-binding/JJ
activity/NN
of/IN
nuclear/JJ
proteins/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
LTB4/NN
may/MD
regulate/VB
the/DT
production/NN
of/IN
different/JJ
cytokines/NNS
by/IN
modulating/VBG
the/DT
yield/NN
and/or/CC
the/DT
function/NN
of/IN
transcription/NN
factors/NNS
such/JJ
as/IN
AP-1-binding/JJ
proto-oncogene/NN
products/NNS
./.
====================
UI/LS
-/:
92195648/CD
====================
TI/LS
-/:
Modulation/NN
of/IN
normal/JJ
erythroid/JJ
differentiation/NN
by/IN
the/DT
endogenous/JJ
thyroid/NN
hormone/NN
and/CC
retinoic/JJ
acid/NN
receptors/NNS
:/:
a/DT
possible/JJ
target/NN
for/IN
v-erbA/NN
oncogene/NN
action/NN
./.
====================
AB/LS
-/:
The/DT
v-erbA/NN
oncogene/NN
,/,
a/DT
mutated/VBN
version/NN
of/IN
the/DT
thyroid/NN
hormone/NN
receptor/NN
alpha/NN
(/(
c-erbA/TR-alpha/NN
)/)
,/,
inhibits/VBZ
erythroid/JJ
differentiation/NN
and/CC
constitutively/RB
represses/VBZ
transcription/NN
of/IN
certain/JJ
erythrocyte/NN
genes/NNS
,/,
suggesting/VBG
a/DT
normal/JJ
function/NN
of/IN
the/DT
proto-oncogene/NN
c-erbA/NN
in/IN
erythropoiesis/NN
./.
====================
Here/RB
we/PRP
demonstrate/VBP
that/IN
the/DT
endogenous/JJ
thyroid/NN
hormone/NN
receptor/NN
alpha/NN
(/(
c-erbA/TR-alpha/NN
)/)
and/CC
the/DT
closely/RB
related/JJ
retinoic/JJ
acid/NN
receptor/NN
alpha/NN
(/(
RAR-alpha/NN
)/)
play/VBP
a/DT
role/NN
in/IN
the/DT
regulation/NN
of/IN
normal/JJ
erythroid/JJ
differentiation/NN
./.
====================
Retinoic/JJ
acid/NN
(/(
RA/NN
)/)
distinctly/RB
modulated/VBD
the/DT
erythroid/JJ
differentiation/NN
program/NN
of/IN
normal/JJ
erythroid/JJ
progenitors/NNS
and/CC
erythroblasts/NNS
reversibly/RB
transformed/VBN
by/IN
a/DT
conditional/JJ
tyrosine/NN
kinase/NN
oncogene/NN
./.
====================
When/WRB
added/VBN
pulsewise/RB
to/TO
immature/JJ
cells/NNS
,/,
differentiation/NN
was/VBD
accelerated/VBN
while/IN
more/RBR
mature/JJ
cells/NNS
underwent/VBD
premature/JJ
cell/NN
death/NN
./.
====================
Thyroid/NN
hormone/NN
(/(
T3/NN
)/)
alone/RB
caused/VBD
similar/JJ
but/CC
weaker/JJR
effects/NNS
./.
====================
Interestingly/RB
,/,
T3/NN
strongly/RB
enhanced/VBD
the/DT
action/NN
of/IN
RA/NN
,/,
suggesting/VBG
cooperative/JJ
action/NN
of/IN
the/DT
two/CD
receptors/NNS
in/IN
modulating/VBG
erythroid/JJ
differentiation/NN
./.
====================
Expression/NN
of/IN
the/DT
human/JJ
RAR-alpha/NN
in/IN
receptor-negative/JJ
erythroblasts/NNS
conferred/VBD
RA-induced/JJ
regulation/NN
of/IN
differentiation/NN
to/TO
the/DT
otherwise/RB
unresponsive/JJ
cells/NNS
,/,
thus/RB
showing/VBG
that/IN
the/DT
RAR-alpha/NN
is/VBZ
essential/JJ
for/IN
the/DT
RA/NN
effect/NN
./.
====================
Likewise/RB
,/,
enhanced/VBN
expression/NN
of/IN
exogenous/JJ
c-erbA/TR-alpha/NN
in/IN
erythroblasts/NNS
rendered/VBD
them/PRP
susceptible/JJ
to/TO
modulation/NN
of/IN
differentiation/NN
by/IN
T3/NN
,/,
suggesting/VBG
a/DT
similar/JJ
function/NN
of/IN
both/DT
receptors/NNS
./.
====================
UI/LS
-/:
93150054/CD
====================
TI/LS
-/:
Activation/NN
of/IN
lymphokine/NN
genes/NNS
in/IN
T/NN
cells/NNS
:/:
role/NN
of/IN
cis-acting/JJ
DNA/NN
elements/NNS
that/WDT
respond/VBP
to/TO
T/NN
cell/NN
activation/NN
signals/NNS
./.
====================
AB/LS
-/:
Activation/NN
of/IN
T/NN
cells/NNS
is/VBZ
initiated/VBN
by/IN
the/DT
recognition/NN
of/IN
antigen/NN
on/IN
antigen/NN
presenting/NN
cells/NNS
to/TO
exert/VB
the/DT
effector/NN
functions/NNS
in/IN
immune/JJ
and/CC
inflammatory/JJ
responses/NNS
./.
====================
Two/CD
types/NNS
of/IN
helper/NN
T/NN
cell/NN
(/(
Th/NN
)/)
clones/NNS
(/(
Th1/NN
and/CC
Th2/NN
)/)
are/VBP
defined/VBN
on/IN
the/DT
basis/NN
of/IN
different/JJ
patterns/NNS
of/IN
cytokine/NN
(/(
lymphokine/NN
)/)
secretion/NN
./.
====================
They/PRP
determine/VBP
the/DT
outcome/NN
of/IN
an/DT
antigenic/JJ
response/NN
toward/IN
humoral/JJ
or/CC
cell-mediated/JJ
immunity/NN
./.
====================
Although/IN
lymphokine/NN
genes/NNS
are/VBP
coordinately/RB
regulated/VBN
upon/IN
antigen/NN
stimulation/NN
,/,
they/PRP
are/VBP
regulated/VBN
by/IN
the/DT
mechanisms/NNS
common/JJ
to/TO
all/DT
as/RB
well/RB
as/IN
those/DT
which/WDT
are/VBP
unique/JJ
to/TO
each/DT
gene/NN
./.
====================
For/IN
most/JJS
lymphokine/NN
genes/NNS
,/,
a/DT
combination/NN
of/IN
phorbol/NN
esters/NNS
(/(
phorbol/NN
12-myristate/NN
13/CD
acetate/NN
,/,
PMA/NN
)/)
and/CC
calcium/NN
ionophores/NNS
(/(
A23187/NN
)/)
is/VBZ
required/VBN
for/IN
their/PRP$
maximal/JJ
induction/NN
./.
====================
Yet/RB
phorbol/NN
ester/NN
alone/RB
or/CC
calcium/NN
ionophore/NN
alone/RB
produce/VBP
several/JJ
lymphokines/NNS
./.
====================
The/DT
production/NN
of/IN
the/DT
granulocyte-macrophage/JJ
colony/NN
stimulating/NN
factor/NN
(/(
GM-CSF/NN
)/)
is/VBZ
completely/RB
dependent/JJ
on/IN
the/DT
two/CD
signals/NNS
./.
====================
We/PRP
have/VBP
previously/RB
found/VBN
a/DT
cis-acting/JJ
region/NN
spanning/VBG
the/DT
GM-CSF/NN
promoter/NN
region/NN
(/(
positions/NNS
-95/CD
to/TO
+27/CD
)/)
that/WDT
confers/VBZ
inducibility/NN
to/TO
reporter/NN
genes/NNS
in/IN
transient/JJ
transfection/NN
assays/NNS
./.
====================
Further/JJ
analysis/NN
identified/VBD
three/CD
elements/NNS
required/VBN
for/IN
efficient/JJ
induction/NN
,/,
referred/VBN
to/TO
as/IN
GM2/NN
,/,
GC-box/NN
and/CC
conserved/VBN
lymphokine/NN
element/NN
(/(
CLE0/NN
)/)
./.
====================
GM2/NN
defines/VBZ
a/DT
binding/VBG
site/NN
for/IN
protein/NN
(/(
s/NNS
)/)
whose/WP$
binding/NN
is/VBZ
inducible/JJ
by/IN
PMA/NN
./.
====================
One/CD
protein/NN
,/,
NF-GM2/NN
is/VBZ
similar/JJ
to/TO
the/DT
transcription/NN
factor/NN
NF-kB/NN
./.
====================
GC-box/NN
is/VBZ
a/DT
binding/VBG
site/NN
for/IN
constitutively/RB
bound/VBN
proteins/NNS
./.
====================
CLEO/NN
defines/VBZ
a/DT
binding/VBG
site/NN
for/IN
protein/NN
(/(
s/NNS
)/)
whose/WP$
optimum/NN
binding/NN
is/VBZ
stimulated/VBN
by/IN
PMA/NN
and/CC
A23187/NN
./.
====================
Viral/JJ
trans-activators/NNS
such/JJ
as/IN
Tax/NN
(/(
human/JJ
T/NN
cell/NN
leukemia/NN
virus-1/NN
,/,
HTLV-1/NN
)/)
and/CC
E2/NN
(/(
bovine/JJ
papilloma/NN
virus/NN
,/,
BPV/NN
)/)
proteins/NNS
are/VBP
other/JJ
agents/NNS
which/WDT
activate/VBP
lymphokine/NN
gene/NN
expression/NN
by/IN
bypassing/VBG
T/NN
cell/NN
receptor/NN
(/(
TCR/NN
)/)
mediated/JJ
signaling/NN
./.
====================
The/DT
trans-activation/NN
domain/NN
of/IN
E2/NN
and/CC
Tax/NN
is/VBZ
interchangeable/JJ
although/IN
they/PRP
have/VBP
no/DT
obvious/JJ
sequence/NN
homology/NN
between/IN
them/PRP
./.
====================
The/DT
viral/JJ
trans-activators/NNS
appear/VBP
to/TO
target/VB
specific/JJ
DNA/NN
binding/NN
protein/NN
such/JJ
as/IN
NF-kB/NN
and/CC
Sp1/NN
to/TO
cis-acting/JJ
DNA/NN
site/NN
and/CC
promote/VB
lymphokine/NN
gene/NN
expression/NN
without/IN
TCR-mediated/JJ
stimulation/NN
./.
====================
UI/LS
-/:
93112057/CD
====================
TI/LS
-/:
Mutations/NNS
in/IN
the/DT
Pit-1/NN
gene/NN
in/IN
children/NNS
with/IN
combined/JJ
pituitary/JJ
hormone/NN
deficiency/NN
./.
====================
AB/LS
-/:
Pit-1/NN
is/VBZ
a/DT
pituitary-specific/JJ
transcription/NN
factor/NN
that/WDT
binds/VBZ
to/TO
and/CC
transactivates/VBZ
promoters/NNS
of/IN
growth/NN
hormone/NN
and/CC
prolactin/NN
genes/NNS
./.
====================
In/IN
three/CD
unrelated/JJ
Japanese/JJ
children/NNS
with/IN
combined/JJ
pituitary/JJ
hormone/NN
deficiency/NN
,/,
we/PRP
identified/VBD
three/CD
point/NN
mutations/NNS
in/IN
the/DT
Pit-1/NN
gene/NN
,/,
Pro24Leu/NN
,/,
Arg143Gln/NN
,/,
and/CC
Arg271Trp/NN
,/,
located/JJ
on/IN
the/DT
major/JJ
transactivation/NN
region/NN
,/,
POU-specific/JJ
domain/NN
,/,
and/CC
POU-homeodomain/NN
,/,
respectively/RB
./.
====================
UI/LS
-/:
93114357/CD
====================
TI/LS
-/:
Activation/NN
of/IN
protein/NN
kinase/NN
C/NN
and/CC
elevation/NN
of/IN
cAMP/NN
interact/VBP
synergistically/RB
to/TO
raise/VB
c-Fos/NN
and/CC
AP-1/NN
activity/NN
in/IN
Jurkat/NN
cells/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
earlier/RBR
found/VBN
that/IN
in/IN
Jurkat/NN
cells/NNS
activation/NN
of/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
enhances/VBZ
the/DT
cyclic/JJ
adenosine/NN
monophosphate/NN
(/(
cAMP/NN
)/)
accumulation/NN
induced/VBN
by/IN
adenosine/NN
receptor/NN
stimulation/NN
or/CC
activation/NN
of/IN
Gs/NN
./.
====================
Here/RB
we/PRP
have/VBP
therefore/RB
examined/VBN
the/DT
effect/NN
of/IN
the/DT
phorbol/NN
ester/NN
PMA/NN
(/(
phorbol/NN
12-myristate/NN
13-acetate/NN
)/)
which/WDT
stimulates/VBZ
PKC/NN
and/CC
a/DT
combination/NN
of/IN
the/DT
adenosine/NN
receptor/NN
agonist/NN
NECA/NN
(/(
5'-(N-ethyl)-carboxamido/JJ|NN
adenosine/NN
)/)
and/CC
forskolin/NN
to/TO
raise/VB
cAMP/NN
,/,
on/IN
the/DT
levels/NNS
of/IN
c-Fos/NN
and/CC
Jun/NN
and/CC
on/IN
the/DT
binding/VBG
and/CC
transcriptional/JJ
activity/NN
of/IN
the/DT
transcription/NN
factor/NN
,/,
activator/NN
protein-1/NN
(/(
AP-1/NN
)/)
./.
====================
PMA/NN
treatment/NN
caused/VBD
a/DT
concentration-/NN
and/CC
time-dependent/JJ
increase/NN
in/IN
both/CC
c-Fos/NN
and/CC
Jun/NN
immunoreactivity/NN
in/IN
contrast/NN
to/TO
cAMP/NN
elevation/NN
that/WDT
had/VBD
only/RB
a/DT
slight/JJ
effect/NN
./.
====================
Both/CC
PMA/NN
and/CC
the/DT
combination/NN
of/IN
NECA/NN
and/CC
forskolin/NN
acted/VBD
together/RB
either/CC
to/TO
increase/VB
(/(
c-Fos/NN
)/)
or/CC
decrease/VB
(/(
Jun/NN
)/)
protein/NN
levels/NNS
as/RB
well/RB
as/IN
increasing/VBG
AP-1/NN
binding/NN
,/,
as/IN
judged/VBN
by/IN
gel-shift/NN
assay/NN
,/,
and/CC
AP-1/NN
transcriptional/JJ
activity/NN
./.
====================
Furthermore/RB
there/EX
was/VBD
a/DT
clear-cut/JJ
synergy/NN
between/IN
the/DT
PKC/NN
stimulator/NN
and/CC
the/DT
cAMP/NN
elevating/NN
agents/NNS
./.
====================
The/DT
results/NNS
demonstrate/VBP
that/IN
the/DT
simultaneous/JJ
activation/NN
of/IN
PKC/NN
and/CC
elevation/NN
of/IN
cAMP/NN
leads/VBZ
to/TO
an/DT
enhanced/VBN
AP-1/NN
transcriptional/JJ
activity/NN
in/IN
a/DT
T-leukemia/NN
cell/NN
line/NN
,/,
suggesting/VBG
that/IN
the/DT
previously/RB
observed/VBN
interaction/NN
between/IN
the/DT
parallel/JJ
signal/NN
transduction/NN
pathways/NNS
may/MD
have/VB
functional/JJ
consequences/NNS
at/IN
the/DT
level/NN
of/IN
gene/NN
transcription/NN
./.
====================
UI/LS
-/:
93105477/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
anti-CD3/JJ
monoclonal/JJ
antibody-induced/JJ
T-cell/NN
proliferation/NN
by/IN
dexamethasone/NN
,/,
isoproterenol/NN
,/,
or/CC
prostaglandin/NN
E2/NN
either/CC
alone/RB
or/CC
in/IN
combination/NN
./.
====================
AB/LS
-/:
1/LS
./.
====================
The/DT
purpose/NN
of/IN
these/DT
studies/NNS
was/VBD
to/TO
investigate/VB
the/DT
modulation/NN
of/IN
the/DT
proliferation/NN
of/IN
human/JJ
T/NN
cells/NNS
obtained/VBN
from/IN
peripheral/JJ
blood/NN
by/IN
dexamethasone/NN
(/(
DEX/NN
)/)
,/,
isoproterenol/NN
(/(
ISO/NN
)/)
,/,
and/CC
prostaglandin/NN
E2/NN
(/(
PGE2/NN
)/)
./.
====================
The/DT
former/JJ
two/CD
substances/NNS
interact/VBP
with/IN
T/NN
cells/NNS
via/IN
the/DT
glucocorticoid/NN
and/CC
beta-adrenergic/JJ
receptors/NNS
respectively/RB
./.
====================
When/WRB
occupied/VBN
by/IN
their/PRP$
natural/JJ
ligands/NNS
,/,
glucocorticosteroids/NNS
and/CC
catecholamines/NNS
,/,
these/DT
receptors/NNS
have/VBP
a/DT
role/NN
in/IN
modulating/VBG
T-cell/NN
function/NN
during/IN
stress/NN
./.
====================
During/IN
the/DT
inflammatory/JJ
response/NN
increased/VBN
levels/NNS
of/IN
PGE2/NN
bind/VBP
to/TO
their/PRP$
receptors/NNS
on/IN
T/NN
cells/NNS
and/CC
thus/RB
alter/VBP
responsiveness/NN
./.
====================
Proliferation/NN
of/IN
T/NN
cells/NNS
was/VBD
induced/VBN
by/IN
immobilized/VBN
anti-CD3/JJ
monoclonal/JJ
antibody/NN
(/(
mAb/NN
)/)
in/IN
the/DT
presence/NN
or/CC
absence/NN
of/IN
an/DT
additional/JJ
costimulatory/JJ
signal/NN
delivered/VBN
by/IN
anti-CD28/JJ
mAb/NN
./.
====================
2/LS
./.
====================
Various/JJ
physiologic/JJ
concentrations/NNS
of/IN
DEX/NN
,/,
ISO/NN
,/,
or/CC
PGE2/NN
were/VBD
added/VBN
at/IN
the/DT
time/NN
of/IN
initiation/NN
of/IN
the/DT
cultures/NNS
and/CC
subsequent/JJ
proliferation/NN
of/IN
the/DT
unstimulated/JJ
T/NN
cells/NNS
was/VBD
determined/VBN
./.
====================
The/DT
results/NNS
demonstrate/VBP
that/IN
physiologic/JJ
concentrations/NNS
of/IN
all/DT
three/CD
of/IN
these/DT
agents/NNS
inhibit/VBP
the/DT
anti-CD3/JJ
mAb-induced/JJ
proliferation/NN
of/IN
T/NN
cells/NNS
./.
====================
3/LS
./.
====================
Although/IN
DEX/NN
and/CC
PGE2/NN
were/VBD
equipotent/JJ
in/IN
suppressing/JJ
T-cell/NN
proliferation/NN
,/,
ISO/NN
was/VBD
much/RB
less/RBR
effective/JJ
./.
====================
4/LS
./.
====================
Because/IN
concomitant/JJ
elevations/NNS
in/IN
the/DT
peripheral/JJ
levels/NNS
of/IN
these/DT
substances/NNS
may/MD
occur/VB
,/,
experiments/NNS
were/VBD
performed/VBN
to/TO
determine/VB
the/DT
T-cell/NN
inhibitory/JJ
effects/NNS
of/IN
DEX/NN
together/RB
with/IN
either/CC
PGE2/NN
or/CC
ISO/NN
./.
====================
Synergistic/JJ
suppression/NN
of/IN
T-cell/NN
proliferation/NN
was/VBD
observed/VBN
when/WRB
various/JJ
concentrations/NNS
of/IN
DEX/NN
and/CC
PGE2/NN
,/,
but/CC
not/RB
DEX/NN
and/CC
ISO/NN
,/,
were/VBD
added/VBN
to/TO
cultures/NNS
./.
====================
This/DT
synergistic/JJ
suppression/NN
could/MD
not/RB
be/VB
explained/VBN
by/IN
an/DT
increase/NN
in/IN
cAMP/NN
accumulation/NN
in/IN
T/NN
cells/NNS
stimulated/VBN
with/IN
DEX/NN
and/CC
PGE2/NN
./.
====================
5/LS
./.
====================
Finally/RB
,/,
the/DT
addition/NN
of/IN
anti-CD28/JJ
mAb/NN
to/TO
anti-CD3/JJ
mAb-stimulated/JJ
T/NN
cells/NNS
overcame/VBD
much/JJ
of/IN
the/DT
suppression/NN
of/IN
proliferation/NN
induced/VBN
by/IN
PGE2/NN
or/CC
ISO/NN
but/CC
less/RBR
so/RB
than/IN
that/DT
induced/VBN
by/IN
DEX/NN
./.
====================
UI/LS
-/:
92366509/CD
====================
TI/LS
-/:
In/FW
vivo/FW
footprint/NN
analysis/NN
of/IN
the/DT
HLA-DRA/NN
gene/NN
promoter/NN
:/:
cell-specific/JJ
interaction/NN
at/IN
the/DT
octamer/NN
site/NN
and/CC
up-regulation/NN
of/IN
X/NN
box/NN
binding/NN
by/IN
interferon/NN
gamma/NN
./.
====================
AB/LS
-/:
Analysis/NN
of/IN
the/DT
major/JJ
histocompatibility/NN
complex/NN
class/NN
II/CD
gene/NN
promoter/NN
DRA/NN
has/VBZ
previously/RB
identified/VBN
at/IN
least/JJS
five/CD
cis-acting/JJ
regions/NNS
required/VBN
for/IN
maximal/JJ
expression/NN
./.
====================
We/PRP
have/VBP
examined/VBN
the/DT
DRA/NN
promoter/NN
for/IN
protein-DNA/JJ
interactions/NNS
in/IN
the/DT
intact/JJ
cell/NN
,/,
which/WDT
may/MD
mediate/VB
transcriptional/JJ
activation/NN
./.
====================
Using/VBG
in/FW
vivo/FW
genomic/JJ
footprinting/NN
we/PRP
identified/VBD
interactions/NNS
in/IN
B-cell/NN
lines/NNS
at/IN
the/DT
octamer/NN
site/NN
and/CC
the/DT
Y/NN
,/,
X1/NN
,/,
and/CC
X2/NN
boxes/NNS
./.
====================
Class/NN
II/CD
antigen/NN
expressing/VBG
T-cell/NN
lines/NNS
maintained/VBD
contacts/NNS
identical/JJ
to/TO
B-cell/NN
lines/NNS
,/,
while/IN
class/NN
II-negative/JJ
T-cell/NN
lines/NNS
exhibited/VBD
no/DT
interactions/NNS
./.
====================
In/IN
lymphoid/JJ
cell/NN
lines/NNS
,/,
the/DT
octamer/NN
site/NN
is/VBZ
occupied/VBN
and/CC
required/VBN
for/IN
maximal/JJ
expression/NN
./.
====================
This/DT
is/VBZ
most/RBS
likely/RB
due/JJ
to/TO
the/DT
presence/NN
of/IN
the/DT
lymphoid-specific/JJ
OTF-2/NN
factor/NN
./.
====================
In/IN
contrast/NN
,/,
the/DT
class/NN
II-positive/JJ
nonlymphoid/JJ
glioblastoma/NN
cell/NN
line/NN
does/VBZ
not/RB
exhibit/VB
interactions/NNS
at/IN
the/DT
octamer/NN
site/NN
despite/IN
the/DT
presence/NN
of/IN
the/DT
ubiquitous/JJ
OTF-1/NN
factor/NN
and/CC
an/DT
open/JJ
binding/VBG
site/NN
./.
====================
Thus/RB
,/,
the/DT
DRA/NN
promoter/NN
discriminates/VBZ
against/IN
OTF-1/NN
activation/NN
at/IN
the/DT
level/NN
of/IN
DNA/NN
binding/NN
in/IN
the/DT
glioblastoma/NN
line/NN
./.
====================
Interferon/NN
gamma/NN
induces/VBZ
class/NN
II/CD
expression/NN
in/IN
this/DT
glioblastoma/NN
cell/NN
line/NN
and/CC
,/,
in/IN
parallel/NN
,/,
up-regulates/VBZ
X1/NN
and/CC
X2/NN
box/NN
protein-DNA/JJ
interactions/NNS
,/,
while/IN
all/DT
other/JJ
interactions/NNS
remain/VBP
unchanged/JJ
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
interferon/NN
gamma/NN
functions/VBZ
on/IN
a/DT
poised/VBN
promoter/NN
by/IN
altering/VBG
weak/JJ
,/,
nonproductive/JJ
interactions/NNS
at/IN
the/DT
X/NN
boxes/NNS
to/TO
strong/JJ
interactions/NNS
./.
====================
These/DT
findings/NNS
provide/VBP
direct/JJ
in/FW
vivo/FW
evidence/NN
to/TO
strongly/RB
suggest/VB
that/IN
the/DT
modulation/NN
of/IN
X1/NN
and/CC
X2/NN
interactions/NNS
is/VBZ
an/DT
important/JJ
constituent/NN
of/IN
the/DT
interferon/NN
gamma/NN
induction/NN
pathway/NN
./.
====================
UI/LS
-/:
93012816/CD
====================
TI/LS
-/:
Estrogen/NN
binding/NN
sites/NNS
in/IN
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
effects/NNS
of/IN
danazol/NN
on/IN
their/PRP$
sites/NNS
in/FW
vitro/FW
./.
====================
AB/LS
-/:
1/LS
./.
====================
This/DT
study/NN
was/VBD
designed/VBN
to/TO
investigate/VB
the/DT
presence/NN
of/IN
estrogen/NN
type/NN
I/CD
(/(
high/JJ
affinity/NN
,/,
low/JJ
capacity/NN
)/)
and/CC
type/NN
II/CD
(/(
low/JJ
affinity/NN
,/,
high/JJ
capacity/NN
)/)
binding/NN
sites/NNS
in/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
the/DT
effects/NNS
of/IN
danazol/NN
on/IN
these/DT
sites/NNS
./.
====================
2/LS
./.
====================
These/DT
two/CD
types/NNS
of/IN
estrogen/NN
binding/NN
sites/NNS
existed/VBD
in/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
./.
====================
3/LS
./.
====================
Danazol/NN
bound/VBD
to/TO
these/DT
sites/NNS
in/IN
high/JJ
concentration/NN
(/(
10/CD
(/(
-6/CD
)/)
M/NN
,/,
clinical/JJ
serum/NN
concentration/NN
during/IN
danazol/NN
therapy/NN
)/)
and/CC
decreased/VBD
the/DT
number/NN
of/IN
both/DT
sites/NNS
./.
====================
4/LS
./.
====================
It/PRP
is/VBZ
suggested/VBN
that/IN
danazol/NN
has/VBZ
an/DT
anti-estrogenic/JJ
action/NN
to/TO
the/DT
monocytes/NNS
through/IN
the/DT
competition/NN
and/CC
suppression/NN
of/IN
estrogen/NN
binding/NN
sites/NNS
as/IN
seen/VBN
in/IN
the/DT
estrogen/NN
target/NN
organ/NN
./.
====================
UI/LS
-/:
93030402/CD
====================
TI/LS
-/:
A/DT
microtitre/NN
assay/NN
system/NN
for/IN
glucocorticoid/NN
receptors/NNS
:/:
decreased/VBN
receptor/NN
concentration/NN
in/IN
myocardial/JJ
infarction/NN
./.
====================
AB/LS
-/:
A/DT
major/JJ
difficulty/NN
in/IN
determination/NN
of/IN
glucocorticoid/NN
receptor/NN
sites/NNS
is/VBZ
the/DT
very/RB
complicated/JJ
assay/NN
procedure/NN
./.
====================
Therefore/RB
,/,
we/PRP
describe/VBP
a/DT
microtitre/NN
assay/NN
system/NN
for/IN
glucocorticoid/NN
receptors/NNS
which/WDT
is/VBZ
a/DT
whole-cell/JJ
competitive/JJ
binding/NN
radioassay/NN
using/VBG
[3H]-dexamethasone/NN
as/IN
radioligand/NN
./.
====================
This/DT
modification/NN
of/IN
a/DT
previously/RB
described/VBN
protocol/NN
simplifies/VBZ
and/CC
reduces/VBZ
laboratory/NN
work/NN
and/CC
allows/VBZ
assay/NN
reproducibility/NN
to/TO
be/VB
controlled/VBN
more/RBR
reliably/RB
./.
====================
Thus/RB
enabled/VBN
to/TO
perform/VB
the/DT
test/NN
on/IN
multiple/JJ
blood/NN
samples/NNS
in/IN
parallel/NN
,/,
we/PRP
investigated/VBD
cardiac/JJ
infarction/NN
patients/NNS
over/IN
a/DT
12-day/JJ
period/NN
to/TO
test/VB
if/IN
glucocorticoid/NN
receptor/NN
binding/NN
is/VBZ
altered/VBN
in/IN
this/DT
'/``
stressful/JJ
'/''
disease/NN
./.
====================
On/IN
the/DT
first/JJ
day/NN
of/IN
the/DT
disease/NN
,/,
glucocorticoid/NN
receptor/NN
capacity/NN
was/VBD
significantly/RB
decreased/VBN
without/IN
alteration/NN
of/IN
the/DT
receptor-ligand/JJ
affinity/NN
,/,
whereas/IN
on/IN
days/NNS
4/CD
and/CC
12/CD
the/DT
number/NN
of/IN
receptor/NN
sites/NNS
was/VBD
normal/JJ
again/RB
./.
====================
This/DT
result/NN
fits/VBZ
well/RB
into/IN
the/DT
general/JJ
observation/NN
of/IN
stress-induced/JJ
down-regulation/NN
of/IN
immune/JJ
responses/NNS
./.
====================
UI/LS
-/:
92368408/CD
====================
TI/LS
-/:
SRC-related/JJ
proto-oncogenes/NNS
and/CC
transcription/NN
factors/NNS
in/IN
primary/JJ
human/JJ
T/NN
cells/NNS
:/:
modulation/NN
by/IN
cyclosporin/NN
A/NN
and/CC
FK506/NN
./.
====================
AB/LS
-/:
Activation/NN
of/IN
T/NN
lymphocytes/NNS
induces/VBZ
transcription/NN
of/IN
genes/NNS
encoding/VBG
for/IN
lymphokines/NNS
./.
====================
Interleukin-2/NN
(/(
IL-2/NN
)/)
gene/NN
expression/NN
is/VBZ
controlled/VBN
transcriptionally/RB
by/IN
the/DT
cooperative/JJ
activity/NN
of/IN
specific/JJ
trans-activating/JJ
factors/NNS
that/WDT
bind/VBP
to/TO
the/DT
IL-2/NN
enhancer/NN
./.
====================
Cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
and/CC
FK506/NN
inhibit/VBP
the/DT
production/NN
of/IN
IL-2/NN
in/IN
T/NN
lymphocytes/NNS
at/IN
the/DT
level/NN
of/IN
gene/NN
transcription/NN
./.
====================
A/DT
member/NN
of/IN
the/DT
src/NN
gene/NN
family/NN
,/,
the/DT
lymphocyte-specific/JJ
protein/NN
tyrosine/NN
kinase/NN
,/,
p56lck/NN
,/,
has/VBZ
been/VBN
implicated/VBN
in/IN
IL-2/NN
production/NN
./.
====================
CsA/NN
was/VBD
found/VBN
not/RB
to/TO
inhibit/VB
lck/NN
gene/NN
expression/NN
,/,
nor/CC
the/DT
activity/NN
of/IN
the/DT
lck/NN
gene/NN
product/NN
./.
====================
However/RB
,/,
CsA/NN
and/CC
FK506/NN
inhibit/VBP
the/DT
appearance/NN
of/IN
DNA/NN
binding/NN
activity/NN
of/IN
factors/NNS
that/WDT
bind/VBP
to/TO
the/DT
NF-AT/NN
and/CC
AP-1/NN
sites/NNS
in/IN
the/DT
IL-2/NN
enhancer/NN
./.
====================
Since/IN
the/DT
induction/NN
of/IN
NF-AT/NN
and/CC
AP-1/NN
is/VBZ
induced/VBN
by/IN
the/DT
same/JJ
stimuli/NNS
that/WDT
stimulate/VBP
IL-2/NN
production/NN
,/,
these/DT
results/NNS
indicate/VBP
that/IN
the/DT
immunosuppressant/JJ
action/NN
of/IN
CsA/NN
and/CC
FK506/NN
is/VBZ
exerted/VBN
at/IN
the/DT
level/NN
of/IN
these/DT
trans-activating/JJ
factors/NNS
./.
====================
UI/LS
-/:
92156807/CD
====================
TI/LS
-/:
The/DT
AP-1/NN
site/NN
at/IN
-150/CD
bp/NN
,/,
but/CC
not/RB
the/DT
NF-kappa/NN
B/NN
site/NN
,/,
is/VBZ
likely/JJ
to/TO
represent/VB
the/DT
major/JJ
target/NN
of/IN
protein/NN
kinase/NN
C/NN
in/IN
the/DT
interleukin/NN
2/CD
promoter/NN
./.
====================
AB/LS
-/:
Stimulation/NN
of/IN
T/NN
cells/NNS
with/IN
antigen/NN
results/VBZ
in/IN
activation/NN
of/IN
several/JJ
kinases/NNS
,/,
including/VBG
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
,/,
that/WDT
may/MD
mediate/VB
the/DT
later/JJ
induction/NN
of/IN
activation-related/JJ
genes/NNS
./.
====================
We/PRP
have/VBP
examined/VBN
the/DT
potential/JJ
role/NN
of/IN
PKC/NN
in/IN
induction/NN
of/IN
the/DT
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
gene/NN
in/IN
T/NN
cells/NNS
stimulated/VBN
through/IN
the/DT
T/NN
cell/NN
receptor/CD3/NN
complex/NN
./.
====================
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
prolonged/JJ
treatment/NN
of/IN
the/DT
untransformed/JJ
T/NN
cell/NN
clone/NN
Ar-5/NN
with/IN
phorbol/NN
esters/NNS
results/VBZ
in/IN
downmodulation/NN
of/IN
the/DT
alpha/NN
and/CC
beta/NN
isozymes/NNS
of/IN
PKC/NN
,/,
and/CC
abrogates/VBZ
induction/NN
of/IN
IL-2/NN
mRNA/NN
and/CC
protein/NN
./.
====================
Here/RB
we/PRP
show/VBP
that/IN
phorbol/NN
ester/NN
treatment/NN
also/RB
abolishes/VBZ
induction/NN
of/IN
chloramphenicol/JJ
acetyltransferase/NN
activity/NN
in/IN
Ar-5/NN
cells/NNS
transfected/VBN
with/IN
a/DT
plasmid/NN
containing/VBG
the/DT
IL-2/NN
promoter/NN
linked/VBN
to/TO
this/DT
reporter/NN
gene/NN
./.
====================
The/DT
IL-2/NN
promoter/NN
contains/VBZ
binding/VBG
sites/NNS
for/IN
nuclear/JJ
factors/NNS
including/VBG
NFAT-1/NN
,/,
Oct/NN
,/,
NF-kappa/NN
B/NN
,/,
and/CC
AP-1/NN
,/,
which/WDT
are/VBP
all/DT
potentially/RB
sensitive/JJ
to/TO
activation/NN
of/IN
PKC/NN
./.
====================
We/PRP
show/VBP
that/IN
induction/NN
of/IN
a/DT
trimer/NN
of/IN
the/DT
NFAT/NN
and/CC
Oct/NN
sites/NNS
is/VBZ
not/RB
sensitive/JJ
to/TO
phorbol/NN
ester/NN
treatment/NN
,/,
and/CC
that/IN
mutations/NNS
in/IN
the/DT
NF-kappa/NN
B/NN
site/NN
have/VBP
no/DT
effect/NN
on/IN
inducibility/NN
of/IN
the/DT
IL-2/NN
promoter/NN
./.
====================
In/IN
contrast/NN
,/,
mutations/NNS
in/IN
the/DT
AP-1/NN
site/NN
located/JJ
at/IN
-150/CD
bp/NN
almost/RB
completely/RB
abrogate/VBP
induction/NN
of/IN
the/DT
IL-2/NN
promoter/NN
,/,
and/CC
appearance/NN
of/IN
an/DT
inducible/JJ
nuclear/JJ
factor/NN
binding/VBG
to/TO
this/DT
site/NN
is/VBZ
sensitive/JJ
to/TO
PKC/NN
depletion/NN
./.
====================
Moreover/RB
,/,
cotransfections/NNS
with/IN
c-fos/NN
and/CC
c-jun/NN
expression/NN
plasmids/NNS
markedly/RB
enhance/VBP
induction/NN
of/IN
the/DT
IL-2/NN
promoter/NN
in/IN
minimally/RB
stimulated/VBN
T/NN
cells/NNS
./.
====================
Our/PRP$
results/NNS
indicate/VBP
that/IN
the/DT
AP-1/NN
site/NN
at/IN
-150/CD
bp/NN
represents/VBZ
a/DT
major/JJ
,/,
if/IN
not/RB
the/DT
only/JJ
,/,
site/NN
of/IN
PKC/NN
responsiveness/NN
in/IN
the/DT
IL-2/NN
promoter/NN
./.
====================
UI/LS
-/:
92408125/CD
====================
TI/LS
-/:
[/(
Effect/NN
of/IN
antihypertensive/JJ
therapy/NN
with/IN
captopril/NN
on/IN
gluco-/JJ
and/CC
mineralocorticoid/NN
receptors/NNS
of/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
in/IN
hypertensive/JJ
patients/NNS
of/IN
various/JJ
age/NN
]/)
====================
AB/LS
-/:
Binding/NN
of/IN
3H-dexamethasone/NN
and/CC
3H-aldosterone/NN
by/IN
peripheral/JJ
lymphocyte/NN
receptors/NNS
was/VBD
investigated/VBN
in/IN
healthy/JJ
persons/NNS
and/CC
hypertensive/JJ
patients/NNS
before/IN
and/CC
after/IN
2-week/JJ
captopril/NN
treatment/NN
./.
====================
The/DT
number/NN
of/IN
glucocorticoid/NN
and/CC
mineralocorticoid/NN
binding/NN
sites/NNS
was/VBD
increased/VBN
in/IN
hypertensives/NNS
vs/CC
normotensives/NNS
./.
====================
The/DT
treatment/NN
with/IN
the/DT
ACE/NN
inhibitor/NN
captopril/NN
led/VBD
to/TO
activation/NN
of/IN
hormone-receptor/NN
interactions/NNS
./.
====================
There/EX
was/VBD
a/DT
more/RBR
marked/JJ
rise/NN
of/IN
the/DT
number/NN
of/IN
receptors/NNS
in/IN
middle-aged/JJ
(/(
44-55/CD
years/NNS
)/)
hypertensives/NNS
vs/CC
elderly/JJ
(/(
61-80/CD
years/NNS
)/)
subjects/NNS
after/IN
captopril/NN
treatment/NN
./.
====================
UI/LS
-/:
93121695/CD
====================
TI/LS
-/:
The/DT
use/NN
of/IN
interferon-gamma-treated/JJ
U937/NN
cells/NNS
in/IN
chemiluminescence/NN
assays/NNS
to/TO
detect/VB
red/JJ
cell/NN
,/,
platelet/NN
and/CC
granulocyte/NN
antibodies/NNS
of/IN
potential/JJ
clinical/JJ
significance/NN
./.
====================
AB/LS
-/:
The/DT
chemiluminescent/JJ
(/(
CL/JJ
)/)
response/NN
of/IN
interferon-gamma-treated/JJ
U937/NN
(/(
IFN-U937/NN
)/)
cells/NNS
to/TO
sensitized/VBN
target/NN
cells/NNS
has/VBZ
been/VBN
used/VBN
to/TO
detect/VB
red/JJ
cell/NN
,/,
platelet/NN
and/CC
granulocyte/NN
antibodies/NNS
./.
====================
A/DT
clone/NN
of/IN
U937/NN
cells/NNS
was/VBD
selected/VBN
which/WDT
expressed/VBD
Fc/NN
receptor/NN
I/NN
(/(
Fc/NN
gamma/NN
RI/NN
)/)
and/CC
which/WDT
,/,
after/IN
incubation/NN
with/IN
IFN-gamma/NN
for/IN
72/CD
h/NN
,/,
was/VBD
capable/JJ
of/IN
generating/VBG
high/JJ
levels/NNS
of/IN
lucigenin-enhanced/JJ
CL/NN
./.
====================
The/DT
CL/NN
responses/NNS
of/IN
IFN-U937/NN
cells/NNS
and/CC
peripheral/JJ
blood/NN
human/JJ
monocytes/NNS
to/TO
sensitized/VBN
red/JJ
cells/NNS
,/,
platelets/NNS
or/CC
granulocytes/NNS
were/VBD
then/RB
compared/VBN
./.
====================
Assays/NNS
using/VBG
monocytes/NNS
or/CC
IFN-U937/NN
cells/NNS
were/VBD
of/IN
comparable/JJ
sensitivity/NN
for/IN
detection/NN
of/IN
antibodies/NNS
against/IN
all/DT
three/CD
types/NNS
of/IN
target/NN
cell/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
use/NN
of/IN
IFN-U937/NN
cells/NNS
reduced/VBD
interassay/JJ
variation/NN
and/CC
simplified/VBD|VBN
assay/NN
performance/NN
./.
====================
The/DT
potential/JJ
clinical/JJ
usefulness/NN
of/IN
these/DT
CL/NN
assays/NNS
was/VBD
suggested/VBN
by/IN
the/DT
ability/NN
of/IN
both/CC
monocytes/NNS
and/CC
IFN-U937/NN
cells/NNS
to/TO
respond/VB
to/TO
red/JJ
cells/NNS
,/,
platelets/NNS
or/CC
granulocytes/NNS
sensitized/VBN
with/IN
sera/NN
from/IN
pregnant/JJ
women/NNS
whose/WP$
babies/NNS
had/VBD
either/CC
haemolytic/JJ
disease/NN
of/IN
the/DT
newborn/JJ
(/(
HDN/NN
)/)
,/,
alloimmune/JJ
thrombocytopenia/NN
or/CC
alloimmune/JJ
neutropenia/NN
respectively/RB
./.
====================
In/IN
addition/NN
,/,
monocytes/NNS
and/CC
IFN-U937/NN
cells/NNS
both/DT
responded/VBD
to/TO
red/JJ
cells/NNS
sensitized/VBN
with/IN
antibodies/NNS
against/IN
a/DT
variety/NN
of/IN
specificities/NNS
of/IN
assumed/VBN
(/(
although/IN
not/RB
documented/VBN
)/)
clinical/JJ
significance/NN
for/IN
blood/NN
transfusion/NN
recipients/NNS
./.
====================
In/IN
contrast/NN
,/,
monocytes/NNS
and/CC
IFN-U937/NN
cells/NNS
responded/VBD
only/RB
weakly/RB
to/TO
red/JJ
cells/NNS
sensitized/VBN
with/IN
either/CC
anti-D/JJ
in/IN
sera/NN
from/IN
mothers/NNS
of/IN
babies/NNS
unaffected/JJ
by/IN
HDN/NN
,/,
or/CC
with/IN
antisera/NNS
containing/VBG
high/JJ
titre/NN
antibodies/NNS
with/IN
specificities/NNS
not/RB
normally/RB
associated/VBN
with/IN
significantly/RB
reduced/VBN
red/JJ
cell/NN
survival/NN
./.
====================
UI/LS
-/:
93101981/CD
====================
TI/LS
-/:
Ablation/NN
of/IN
transplanted/VBN
HTLV-I/NN
Tax-transformed/JJ
tumors/NNS
in/IN
mice/NNS
by/IN
antisense/JJ
inhibition/NN
of/IN
NF-kappa/NN
B/NN
[/(
published/VBN
erratum/NN
appears/VBZ
in/IN
Science/NNP
1993/CD
Mar/NNP
12/CD
;/:
259/CD
(/(
5101/CD
)/)
:/:
1523/CD
]/)
====================
AB/LS
-/:
Mice/NNS
transgenic/JJ
for/IN
the/DT
human/JJ
T/NN
cell/NN
leukemia/NN
virus/NN
(/(
HTLV-I/NN
)/)
Tax/NN
gene/NN
develop/VBP
fibroblastic/JJ
tumors/NNS
that/WDT
express/VBP
NF-kappa/NN
B-inducible/JJ
early/JJ
genes/NNS
./.
====================
In/FW
vitro/FW
inhibition/NN
of/IN
NF-kappa/NN
B/NN
expression/NN
by/IN
antisense/JJ
oligodeoxynucleotides/NNS
(/(
ODNs/NNS
)/)
inhibited/VBD
growth/NN
of/IN
these/DT
culture-adapted/JJ
Tax-transformed/JJ
fibroblasts/NNS
as/RB
well/RB
as/IN
an/DT
HTLV-I-transformed/JJ
human/JJ
lymphocyte/NN
line/NN
./.
====================
In/IN
contrast/NN
,/,
antisense/JJ
inhibition/NN
of/IN
Tax/NN
itself/PRP
had/VBD
no/DT
apparent/JJ
effect/NN
on/IN
cell/NN
growth/NN
./.
====================
Mice/NNS
treated/VBN
with/IN
antisense/NN
to/TO
NF-kappa/NN
B/NN
ODNs/NNS
showed/VBD
rapid/JJ
regression/NN
of/IN
transplanted/VBN
fibrosarcomas/NNS
./.
====================
This/DT
suggests/VBZ
that/IN
NF-kappa/NN
B/NN
expression/NN
may/MD
be/VB
necessary/JJ
for/IN
the/DT
maintenance/NN
of/IN
the/DT
malignant/JJ
phenotype/NN
and/CC
provides/VBZ
a/DT
therapeutic/JJ
approach/NN
for/IN
HTLV-I-associated/JJ
disease/NN
./.
====================
UI/LS
-/:
93072349/CD
====================
TI/LS
-/:
Membrane/NN
receptors/NNS
for/IN
aldosterone/NN
:/:
a/DT
novel/JJ
pathway/NN
for/IN
mineralocorticoid/NN
action/NN
./.
====================
AB/LS
-/:
Rapid/JJ
nongenomic/JJ
in/FW
vitro/FW
effects/NNS
of/IN
aldosterone/NN
on/IN
intracellular/JJ
electrolytes/NNS
,/,
cell/NN
volume/NN
,/,
and/CC
Na(+)-H+/JJ
antiport/NN
have/VBP
been/VBN
found/VBN
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
(/(
HML/NN
)/)
./.
====================
Binding/NN
of/IN
125I-labeled/JJ
aldosterone/NN
to/TO
plasma/NN
membranes/NNS
of/IN
HML/NN
shares/VBZ
important/JJ
features/NNS
with/IN
these/DT
functional/JJ
data/NNS
./.
====================
This/DT
includes/VBZ
a/DT
very/RB
low/JJ
apparent/JJ
dissociation/NN
constant/NN
(/(
Kd/NN
)/)
of/IN
0.1/CD
nM/NN
for/IN
both/CC
aldosterone/NN
and/CC
the/DT
effect/NN
on/IN
the/DT
Na(+)-H(+)-antiport/NN
,/,
a/DT
high/JJ
turnover/NN
rate/NN
,/,
and/CC
the/DT
almost/RB
exclusive/JJ
binding/NN
selectivity/NN
for/IN
aldosterone/NN
./.
====================
Dexamethasone/NN
,/,
RU/NN
26988/CD
,/,
corticosterone/NN
,/,
ouabain/NN
,/,
amiloride/NN
,/,
and/CC
18-hydroxyprogesterone/NN
were/VBD
inactive/JJ
as/IN
ligands/NNS
./.
====================
Deoxycorticosterone/NN
acetate/NN
had/VBD
an/DT
intermediate/JJ
activity/NN
with/IN
an/DT
apparent/JJ
Kd/NN
of/IN
100/CD
nM/NN
./.
====================
These/DT
findings/NNS
are/VBP
the/DT
first/JJ
to/TO
demonstrate/VB
membrane/NN
binding/NN
of/IN
aldosterone/NN
being/VBG
compatible/JJ
with/IN
major/JJ
aspects/NNS
of/IN
its/PRP$
nongenomic/JJ
effects/NNS
./.
====================
UI/LS
-/:
93011470/CD
====================
TI/LS
-/:
Leukotriene/NN
B4/NN
transcriptionally/RB
activates/VBZ
interleukin-6/NN
expression/NN
involving/VBG
NK-chi/NN
B/NN
and/CC
NF-IL6/NN
./.
====================
AB/LS
-/:
Leukotriene/NN
B4/NN
(/(
LTB4/NN
)/)
is/VBZ
a/DT
notable/JJ
participant/NN
in/IN
inflammation/NN
and/CC
chemotaxis/NN
./.
====================
It/PRP
is/VBZ
,/,
however/RB
,/,
still/RB
unclear/JJ
whether/IN
LTB4/NN
acts/VBZ
in/IN
this/DT
regard/NN
directly/RB
or/CC
indirectly/RB
by/IN
stimulating/VBG
the/DT
release/NN
of/IN
chemotactic/JJ
and/CC
inflammatory/JJ
cytokines/NNS
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
LTB4/NN
induces/VBZ
synthesis/NN
of/IN
interleukin/NN
(/(
IL/NN
)/)
-6/CD
by/IN
human/JJ
blood/NN
monocytes/NNS
through/IN
transcriptional/JJ
activation/NN
of/IN
the/DT
IL-6/NN
gene/NN
./.
====================
We/PRP
furthermore/RB
demonstrate/VBP
that/IN
this/DT
process/NN
involves/VBZ
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-chi/NN
B/NN
and/CC
,/,
to/TO
a/DT
lesser/JJR
extent/NN
,/,
of/IN
NF-IL6/NN
,/,
while/IN
the/DT
activity/NN
of/IN
the/DT
transcription/NN
factor/NN
AP-1/NN
,/,
shown/VBN
to/TO
otherwise/RB
confer/VB
IL-6/NN
inducibility/NN
,/,
appeared/VBD
to/TO
be/VB
unaffected/JJ
by/IN
LTB4/NN
./.
====================
Involvement/NN
of/IN
NF-chi/NN
B/NN
and/CC
NF-IL6/NN
in/IN
induction/NN
of/IN
IL-6/NN
transcription/NN
by/IN
monocytes/NNS
was/VBD
demonstrated/VBN
using/VBG
deleted/JJ
forms/NNS
of/IN
the/DT
IL-6/NN
promoter/NN
./.
====================
Activation/NN
of/IN
the/DT
IL-6/NN
promoter/NN
by/IN
LTB4/NN
was/VBD
not/RB
only/RB
associated/VBN
with/IN
accumulation/NN
of/IN
the/DT
respective/JJ
transcripts/NNS
but/CC
resulted/VBD
in/IN
synthesis/NN
of/IN
functional/JJ
IL-6/NN
protein/NN
as/RB
well/RB
./.
====================
In/IN
addition/NN
,/,
LTB4/NN
mediated/VBD
transactivation/NN
of/IN
a/DT
heterologous/JJ
promoter/NN
construct/NN
containing/VBG
the/DT
NF-chi/NN
B/NN
or/CC
the/DT
NF-IL6/NN
enhancer/NN
,/,
but/CC
not/RB
the/DT
AP-1/NN
enhancer/NN
./.
====================
The/DT
signaling/NN
events/NNS
mediating/VBG
this/DT
effect/NN
appeared/VBD
to/TO
involve/VB
the/DT
release/NN
of/IN
H2O2/NN
,/,
since/IN
LTB4/NN
failed/VBD
to/TO
induce/VB
NF-chi/NN
B/NN
or/CC
NF-IL6/NN
in/IN
the/DT
presence/NN
of/IN
the/DT
scavenger/NN
of/IN
H2O2/NN
,/,
N-acetyl-L-cysteine/NN
./.
====================
UI/LS
-/:
92378748/CD
====================
TI/LS
-/:
Bcl-2/NN
:/:
a/DT
repressor/NN
of/IN
lymphocyte/NN
death/NN
./.
====================
AB/LS
-/:
The/DT
genes/NNS
and/CC
mechanisms/NNS
that/WDT
control/VBP
programmed/VBN
cell/NN
death/NN
are/VBP
currently/RB
the/DT
subject/NN
of/IN
intense/JJ
study/NN
./.
====================
The/DT
bcl-2/NN
gene/NN
,/,
a/DT
repressor/NN
of/IN
lymphocyte/NN
death/NN
,/,
is/VBZ
perhaps/RB
the/DT
best/JJS
understood/VBN
of/IN
the/DT
programmed/VBN
cell/NN
death/NN
associated/JJ
genes/NNS
./.
====================
Here/RB
,/,
Stanley/NNP
Korsmeyer/NNP
provides/VBZ
a/DT
brief/JJ
overview/NN
of/IN
bcl-2/NN
,/,
concentrating/VBG
on/IN
its/PRP$
roles/NNS
in/IN
B-/NN
and/CC
T-cell/NN
development/NN
and/CC
in/IN
oncogenesis/NN
./.
====================
UI/LS
-/:
92311659/CD
====================
TI/LS
-/:
Cytoplasmic/JJ
domain/NN
heterogeneity/NN
and/CC
functions/NNS
of/IN
IgG/NN
Fc/NN
receptors/NNS
in/IN
B/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
B/NN
lymphocytes/NNS
and/CC
macrophages/NNS
express/VBP
closely/RB
related/JJ
immunoglobulin/NN
G/NN
(/(
IgG/NN
)/)
Fc/NN
receptors/NNS
(/(
Fc/NN
gamma/NN
RII/NN
)/)
that/WDT
differ/VBP
only/RB
in/IN
the/DT
structures/NNS
of/IN
their/PRP$
cytoplasmic/JJ
domains/NNS
./.
====================
Because/IN
of/IN
cell/NN
type-specific/JJ
alternative/JJ
messenger/NN
RNA/NN
splicing/NN
,/,
B-cell/NN
Fc/NN
gamma/NN
RII/NN
contains/VBZ
an/DT
insertion/NN
of/IN
47/CD
amino/NN
acids/NNS
that/WDT
participates/VBZ
in/IN
determining/VBG
receptor/NN
function/NN
in/IN
these/DT
cells/NNS
./.
====================
Transfection/NN
of/IN
an/DT
Fc/NN
gamma/NN
RII-negative/JJ
B-cell/NN
line/NN
with/IN
complementary/JJ
DNA/NN
's/POS
encoding/VBG
the/DT
two/CD
splice/NN
products/NNS
and/CC
various/JJ
receptor/NN
mutants/NNS
indicated/VBD
that/IN
the/DT
insertion/NN
was/VBD
responsible/JJ
for/IN
preventing/VBG
both/CC
Fc/NN
gamma/NN
RII-mediated/JJ
endocytosis/NN
and/CC
Fc/NN
gamma/NN
RII-mediated/JJ
antigen/NN
presentation/NN
./.
====================
The/DT
insertion/NN
was/VBD
not/RB
required/VBN
for/IN
Fc/NN
gamma/NN
RII/NN
to/TO
modulate/VB
surface/NN
immunoglobulin-triggered/JJ
B-cell/NN
activation/NN
./.
====================
Instead/RB
,/,
regulation/NN
of/IN
activation/NN
involved/VBD
a/DT
region/NN
of/IN
the/DT
cytoplasmic/JJ
domain/NN
common/JJ
to/TO
both/CC
the/DT
lymphocyte/NN
and/CC
macrophage/NN
receptor/NN
isoforms/NNS
./.
====================
In/IN
contrast/NN
,/,
the/DT
insertion/NN
did/VBD
contribute/VB
to/TO
the/DT
formation/NN
of/IN
caps/NNS
in/IN
response/NN
to/TO
receptor/NN
cross-linking/NN
,/,
consistent/JJ
with/IN
suggestions/NNS
that/IN
the/DT
lymphocyte/NN
but/CC
not/RB
macrophage/NN
form/NN
of/IN
the/DT
receptor/NN
can/MD
associate/VB
with/IN
the/DT
detergent-insoluble/JJ
cytoskeleton/NN
./.
====================
UI/LS
-/:
92362919/CD
====================
TI/LS
-/:
[/(
Age-related/JJ
changes/NNS
in/IN
glucocorticoid/NN
and/CC
mineralocorticoid/NN
receptors/NNS
in/IN
lymphocytes/NNS
of/IN
healthy/JJ
persons/NNS
and/CC
patients/NNS
with/IN
hypertension/NN
]/)
====================
AB/LS
-/:
It/PRP
has/VBZ
been/VBN
found/VBN
that/IN
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
lymphocytes/NNS
of/IN
the/DT
peripheral/JJ
blood/NN
of/IN
healthy/JJ
elderly/JJ
subjects/NNS
increases/VBZ
,/,
while/IN
the/DT
number/NN
of/IN
mineralocorticoid/NN
receptors/NNS
decreases/VBZ
./.
====================
The/DT
mechanisms/NNS
of/IN
hormone-receptor/NN
interactions/NNS
in/IN
hypertension/NN
are/VBP
activated/VBN
:/:
the/DT
number/NN
of/IN
glucocorticoid/NN
and/CC
mineralocorticoid/NN
binding/NN
sites/NNS
grows/VBZ
in/IN
hypertensive/JJ
patients/NNS
./.
====================
Still/RB
a/DT
more/RBR
essential/JJ
rise/NN
in/IN
the/DT
number/NN
of/IN
receptors/NNS
is/VBZ
observed/VBN
in/IN
mid-age/JJ
hypertensive/NN
patients/NNS
than/IN
in/IN
elderly/JJ
ones/NNS
./.
====================
UI/LS
-/:
92255823/CD
====================
TI/LS
-/:
The/DT
mechanism/NN
of/IN
action/NN
of/IN
cyclosporin/NN
A/NN
and/CC
FK506/NN
./.
====================
AB/LS
-/:
CsA/NN
and/CC
FK506/NN
are/VBP
powerful/JJ
suppressors/NNS
of/IN
the/DT
immune/JJ
system/NN
,/,
most/RBS
notably/RB
of/IN
T/NN
cells/NNS
./.
====================
They/PRP
act/VBP
at/IN
a/DT
point/NN
in/IN
activation/NN
that/WDT
lies/VBZ
between/IN
receptor/NN
ligation/NN
and/CC
the/DT
transcription/NN
of/IN
early/JJ
genes/NNS
./.
====================
Here/RB
,/,
Stuart/NNP
Schreiber/NNP
and/CC
Gerald/NNP
Crabtree/NNP
review/VBP
recent/JJ
findings/NNS
that/WDT
indicate/VBP
CsA/NN
and/CC
FK506/NN
operate/VBP
as/IN
prodrugs/NNS
:/:
they/PRP
bind/VBP
endogenous/JJ
intracellular/JJ
receptors/NNS
,/,
the/DT
immunophilins/NNS
,/,
and/CC
the/DT
resulting/VBG
complex/NN
targets/VBZ
the/DT
protein/NN
phosphatase/NN
,/,
calcineurin/NN
,/,
to/TO
exert/VB
the/DT
immunosuppressive/JJ
effect/NN
./.
====================
UI/LS
-/:
92156797/CD
====================
TI/LS
-/:
Induction/NN
of/IN
monocytic/JJ
differentiation/NN
and/CC
NF-kappa/NN
B-like/JJ
activities/NNS
by/IN
human/JJ
immunodeficiency/NN
virus/NN
1/CD
infection/NN
of/IN
myelomonoblastic/JJ
cells/NNS
./.
====================
AB/LS
-/:
The/DT
effects/NNS
of/IN
human/JJ
immunodeficiency/NN
virus/NN
1/CD
(/(
HIV-1/NN
)/)
infection/NN
on/IN
cellular/JJ
differentiation/NN
and/CC
NF-kappa/NN
B/NN
DNA/NN
binding/NN
activity/NN
have/VBP
been/VBN
investigated/VBN
in/IN
a/DT
new/JJ
model/NN
of/IN
myeloid/JJ
differentiation/NN
./.
====================
PLB-985/NN
cells/NNS
represent/VBP
a/DT
bipotential/JJ
myelomonoblastic/JJ
cell/NN
population/NN
capable/JJ
of/IN
either/CC
granulocytic/JJ
or/CC
monocytic/JJ
differentiation/NN
after/IN
induction/NN
with/IN
appropriate/JJ
inducers/NNS
./.
====================
By/IN
virtue/NN
of/IN
the/DT
presence/NN
of/IN
CD4/NN
on/IN
the/DT
cell/NN
surface/NN
,/,
PLB-985/NN
cells/NNS
were/VBD
chronically/RB
infected/VBN
with/IN
HIV-1/NN
strain/NN
IIIB/NN
./.
====================
PLB-IIIB/NN
cells/NNS
clearly/RB
possessed/VBD
a/DT
more/RBR
monocytic/JJ
phenotype/NN
than/IN
the/DT
parental/JJ
myeloblasts/NNS
,/,
as/IN
determined/VBN
by/IN
differential/JJ
staining/NN
,/,
increased/VBN
expression/NN
of/IN
the/DT
myeloid-specific/JJ
surface/NN
markers/NNS
,/,
and/CC
transcription/NN
of/IN
the/DT
c-fms/NN
proto-oncogene/NN
./.
====================
NF-kappa/NN
B/NN
binding/NN
activity/NN
was/VBD
inducible/JJ
by/IN
tumor/NN
necrosis/NN
factor/NN
and/CC
phorbol/NN
myristate/NN
acetate/NN
in/IN
PLB-985/NN
./.
====================
However/RB
,/,
in/IN
PLB-IIIB/NN
cells/NNS
,/,
constitutive/JJ
expression/NN
of/IN
a/DT
novel/JJ
NF-kappa/NN
B/NN
complex/NN
was/VBD
detected/VBN
,/,
composed/VBN
of/IN
proteins/NNS
ranging/VBG
between/IN
70/CD
and/CC
110/CD
kD/NN
./.
====================
These/DT
proteins/NNS
interacted/VBD
specifically/RB
with/IN
the/DT
symmetric/JJ
NF-kappa/NN
B/NN
site/NN
from/IN
the/DT
interferon/NN
beta/NN
(/(
IFN-beta/NN
)/)
promoter/NN
./.
====================
Mutations/NNS
affecting/VBG
the/DT
5'/JJ
guanine/JJ
residues/NNS
of/IN
the/DT
kappa/NN
B/NN
site/NN
were/VBD
unable/JJ
to/TO
compete/VB
for/IN
these/DT
NF-kappa/NN
B-related/JJ
proteins/NNS
./.
====================
Inducibility/NN
of/IN
endogenous/JJ
IFN-beta/NN
and/CC
IFN-alpha/NN
RNA/NN
was/VBD
also/RB
increased/VBN
in/IN
PLB-IIIB/NN
cells/NNS
./.
====================
These/DT
studies/NNS
indicate/VBP
that/IN
HIV-1/NN
infection/NN
of/IN
myelomonoblastic/JJ
cells/NNS
may/MD
select/VB
for/IN
a/DT
more/RBR
mature/JJ
monocytic/JJ
phenotype/NN
and/CC
that/IN
unique/JJ
subunit/NN
associations/NNS
of/IN
NF-kappa/NN
B/NN
DNA/NN
binding/NN
proteins/NNS
may/MD
contribute/VB
to/TO
differential/JJ
NF-kappa/NN
B-mediated/JJ
gene/NN
expression/NN
./.
====================
UI/LS
-/:
92113075/CD
====================
TI/LS
-/:
Cortisol/NN
receptor/NN
resistance/NN
:/:
the/DT
variability/NN
of/IN
its/PRP$
clinical/JJ
presentation/NN
and/CC
response/NN
to/TO
treatment/NN
./.
====================
AB/LS
-/:
Primary/JJ
(/(
partial/JJ
)/)
cortisol/NN
receptor/NN
resistance/NN
was/VBD
previously/RB
reported/VBN
in/IN
a/DT
total/NN
of/IN
7/CD
patients/NNS
and/CC
14/CD
asymptomatic/JJ
family/NN
members/NNS
./.
====================
Its/PRP$
occurrence/NN
is/VBZ
considered/VBN
to/TO
be/VB
extremely/RB
rare/JJ
./.
====================
In/IN
the/DT
present/JJ
study/NN
we/PRP
report/VBP
on/IN
6/CD
patients/NNS
(/(
2/CD
males/NNS
and/CC
4/CD
females/NNS
)/)
with/IN
the/DT
syndrome/NN
./.
====================
The/DT
first/JJ
male/JJ
patient/NN
presented/VBD
with/IN
mild/JJ
hypertension/NN
./.
====================
Hydrochlorothiazide/NN
therapy/NN
resulted/VBD
in/IN
life-threatening/JJ
hypokalemia/NN
./.
====================
The/DT
second/JJ
male/JJ
patient/NN
had/VBD
slight/JJ
hypertension/NN
without/IN
hypokalemia/NN
./.
====================
All/DT
four/CD
female/JJ
patients/NNS
presented/VBD
between/IN
the/DT
age/NN
of/IN
20-30/CD
yr/NN
with/IN
acne/NN
,/,
hirsutism/NN
,/,
and/CC
irregular/JJ
menstruations/NNS
./.
====================
Low/JJ
dose/NN
dexamethasone/NN
therapy/NN
(/(
1-1.5/CD
mg/day/NN
)/)
was/VBD
of/IN
clinical/JJ
benefit/NN
in/IN
these/DT
patients/NNS
./.
====================
All/DT
patients/NNS
showed/VBD
insufficient/JJ
suppression/NN
of/IN
serum/NN
cortisol/NN
concentrations/NNS
in/IN
the/DT
overnight/JJ
1-mg/JJ
dexamethasone/NN
test/NN
./.
====================
The/DT
diurnal/JJ
rhythm/NN
of/IN
ACTH/NN
and/CC
cortisol/NN
was/VBD
intact/JJ
,/,
albeit/IN
at/IN
an/DT
elevated/JJ
level/NN
./.
====================
There/EX
was/VBD
a/DT
normal/JJ
increase/NN
in/IN
ACTH/NN
,/,
cortisol/NN
,/,
and/CC
GH/NN
(/(
except/IN
in/IN
one/CD
obese/JJ
patient/NN
)/)
in/IN
response/NN
to/TO
insulin-induced/JJ
hypoglycemia/NN
,/,
while/IN
cortisol/NN
production/NN
was/VBD
elevated/JJ
in/IN
three/CD
patients/NNS
./.
====================
Circulating/VBG
adrenal/JJ
androgen/NN
levels/NNS
were/VBD
increased/VBN
in/IN
all/DT
patients/NNS
./.
====================
Glucocorticoid/NN
receptors/NNS
were/VBD
investigated/VBN
in/IN
a/DT
whole/JJ
cell/NN
dexamethasone/NN
binding/NN
assay/NN
in/IN
mononuclear/JJ
leukocytes/NNS
./.
====================
In/IN
the/DT
first/JJ
male/JJ
patient/NN
,/,
the/DT
number/NN
of/IN
receptors/NNS
was/VBD
very/RB
low/JJ
,/,
while/IN
the/DT
affinity/NN
was/VBD
lower/JJR
than/IN
that/DT
in/IN
controls/NNS
./.
====================
A/DT
lowered/JJ
affinity/NN
to/TO
dexamethasone/NN
was/VBD
found/VBN
in/IN
one/CD
female/JJ
patient/NN
,/,
while/IN
a/DT
lowered/JJ
number/NN
of/IN
receptors/NNS
was/VBD
found/VBN
in/IN
three/CD
patients/NNS
./.
====================
In/IN
the/DT
second/JJ
male/JJ
patient/NN
,/,
no/DT
abnormalities/NNS
were/VBD
found/VBN
./.
====================
As/IN
a/DT
bioassay/NN
for/IN
glucocorticoid/NN
action/NN
we/PRP
also/RB
measured/VBD
dexamethasone/NN
suppressibility/NN
of/IN
mitogen-stimulated/JJ
incorporation/NN
of/IN
[3H]thymidine/NN
in/IN
mononuclear/JJ
leukocytes/NNS
./.
====================
In/IN
the/DT
male/JJ
patient/NN
with/IN
normal/JJ
receptor/NN
status/NN
,/,
dexamethasone/NN
suppressibility/NN
of/IN
[3H]thymidine/NN
incorporation/NN
was/VBD
significantly/RB
lower/JJR
than/IN
that/DT
in/IN
healthy/JJ
controls/NNS
with/IN
respect/NN
to/TO
both/CC
maximal/JJ
suppression/NN
and/CC
IC50/NN
./.
====================
Partial/JJ
cortisol/NN
receptor/NN
resistance/NN
might/MD
be/VB
less/RBR
rare/JJ
than/IN
previously/RB
thought/VBN
./.
====================
In/IN
the/DT
six/CD
patients/NNS
presented/VBN
,/,
at/IN
least/JJS
three/CD
different/JJ
forms/NNS
can/MD
be/VB
recognized/VBN
./.
====================
Therapy/NN
with/IN
dexamethasone/NN
was/VBD
successful/JJ
in/IN
female/JJ
patients/NNS
with/IN
acne/NN
and/CC
hirsutism/NN
,/,
as/IN
the/DT
secondary/JJ
increase/NN
in/IN
the/DT
production/NN
of/IN
adrenal/JJ
androgens/NNS
was/VBD
effectively/RB
controlled/VBN
./.
====================
UI/LS
-/:
92367617/CD
====================
TI/LS
-/:
The/DT
development/NN
of/IN
functionally/RB
responsive/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
work/NN
reviewed/VBN
in/IN
this/DT
article/NN
separates/VBZ
T/NN
cell/NN
development/NN
into/IN
four/CD
phases/NNS
./.
====================
First/JJ
is/VBZ
an/DT
expansion/NN
phase/NN
prior/RB
to/TO
TCR/NN
rearrangement/NN
,/,
which/WDT
appears/VBZ
to/TO
be/VB
correlated/VBN
with/IN
programming/NN
of/IN
at/IN
least/JJS
some/DT
response/NN
genes/NNS
for/IN
inducibility/NN
./.
====================
This/DT
phase/NN
can/MD
occur/VB
to/TO
some/DT
extent/NN
outside/IN
of/IN
the/DT
thymus/NN
./.
====================
However/RB
,/,
the/DT
profound/JJ
T/NN
cell/NN
deficit/NN
of/IN
nude/JJ
mice/NNS
indicates/VBZ
that/IN
the/DT
thymus/NN
is/VBZ
by/IN
far/RB
the/DT
most/RBS
potent/JJ
site/NN
for/IN
inducing/VBG
the/DT
expansion/NN
per/FW
se/FW
,/,
even/RB
if/IN
other/JJ
sites/NNS
can/MD
induce/VB
some/DT
response/NN
acquisition/NN
./.
====================
Second/JJ
is/VBZ
a/DT
controlled/JJ
phase/NN
of/IN
TCR/NN
gene/NN
rearrangement/NN
./.
====================
The/DT
details/NNS
of/IN
the/DT
regulatory/JJ
mechanism/NN
that/WDT
selects/VBZ
particular/JJ
loci/NNS
for/IN
rearrangement/NN
are/VBP
still/RB
not/RB
known/VBN
./.
====================
It/PRP
seems/VBZ
that/IN
the/DT
rearrangement/NN
of/IN
the/DT
TCR/NN
gamma/NN
loci/NNS
in/IN
the/DT
gamma/NN
delta/NN
lineage/NN
may/MD
not/RB
always/RB
take/VB
place/NN
at/IN
a/DT
developmental/JJ
stage/NN
strictly/RB
equivalent/JJ
to/TO
the/DT
rearrangement/NN
of/IN
TCR/NN
beta/NN
in/IN
the/DT
alpha/NN
beta/NN
lineage/NN
,/,
and/CC
it/PRP
is/VBZ
not/RB
clear/JJ
just/RB
how/WRB
early/RB
the/DT
two/CD
lineages/NNS
diverge/VBP
./.
====================
In/IN
the/DT
TCR/NN
alpha/NN
beta/NN
lineage/NN
,/,
however/RB
,/,
the/DT
final/JJ
gene/NN
rearrangement/NN
events/NNS
are/VBP
accompanied/VBN
by/IN
rapid/JJ
proliferation/NN
and/CC
an/DT
interruption/NN
in/IN
cellular/JJ
response/NN
gene/NN
inducibility/NN
./.
====================
The/DT
loss/NN
of/IN
conventional/JJ
responsiveness/NN
is/VBZ
probably/RB
caused/VBN
by/IN
alterations/NNS
at/IN
the/DT
level/NN
of/IN
signaling/NN
,/,
and/CC
may/MD
be/VB
a/DT
manifestation/NN
of/IN
the/DT
physiological/JJ
state/NN
that/WDT
is/VBZ
a/DT
precondition/NN
for/IN
selection/NN
./.
====================
Third/JJ
is/VBZ
the/DT
complex/JJ
process/NN
of/IN
selection/NN
./.
====================
Whereas/IN
peripheral/JJ
T/NN
cells/NNS
can/MD
undergo/VB
forms/NNS
of/IN
positive/JJ
selection/NN
(/(
by/IN
antigen-driven/JJ
clonal/JJ
expansion/NN
)/)
and/CC
negative/JJ
selection/NN
(/(
by/IN
abortive/JJ
stimulation/NN
leading/VBG
to/TO
anergy/NN
or/CC
death/NN
)/)
,/,
neither/DT
is/VBZ
exactly/RB
the/DT
same/JJ
phenomenon/NN
that/WDT
occurs/VBZ
in/IN
the/DT
thymic/JJ
cortex/NN
./.
====================
Negative/JJ
selection/NN
in/IN
the/DT
cortex/NN
appears/VBZ
to/TO
be/VB
a/DT
suicidal/JJ
inversion/NN
of/IN
antigen/NN
responsiveness/NN
:/:
instead/RB
of/IN
turning/VBG
on/IN
IL-2/NN
expression/NN
,/,
the/DT
activated/VBN
cell/NN
destroys/VBZ
its/PRP$
own/JJ
chromatin/NN
./.
====================
The/DT
genes/NNS
that/WDT
need/VBP
to/TO
be/VB
induced/VBN
for/IN
this/DT
response/NN
are/VBP
not/RB
yet/RB
identified/VBN
,/,
but/CC
it/PRP
is/VBZ
unquestionably/RB
a/DT
form/NN
of/IN
activation/NN
./.
====================
It/PRP
is/VBZ
interesting/JJ
that/IN
in/IN
humans/NNS
and/CC
rats/NNS
,/,
cortical/JJ
thymocytes/NNS
undergoing/VBG
negative/JJ
selection/NN
can/MD
still/RB
induce/VB
IL-2R/NN
alpha/NN
expression/NN
and/CC
even/RB
be/VB
rescued/VBN
in/FW
vitro/FW
,/,
if/IN
exogenous/JJ
IL-2/NN
is/VBZ
provided/VBN
./.
====================
Perhaps/RB
murine/JJ
thymocytes/NNS
are/VBP
denied/VBN
this/DT
form/NN
of/IN
rescue/NN
because/IN
they/PRP
shut/VBD
off/RP
IL-2R/NN
beta/NN
chain/NN
expression/NN
at/IN
an/DT
earlier/JJR
stage/NN
or/CC
because/IN
they/PRP
may/MD
be/VB
uncommonly/RB
Bcl-2/NN
deficient/JJ
(/(
cf./VBP
Sentman/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Strasser/NNP
et/FW
al./FW
,/,
1991/CD
)/)
./.
====================
Even/RB
so/RB
,/,
medullary/JJ
thymocytes/NNS
remain/VBP
at/IN
least/JJS
partially/RB
susceptible/JJ
to/TO
negative/JJ
selection/NN
even/RB
as/IN
they/PRP
continue/VBP
to/TO
mature/VB
./.
====================
UI/LS
-/:
93153017/CD
====================
TI/LS
-/:
I/NN
kappa/NN
B/MAD-3/NN
masks/VBZ
the/DT
nuclear/JJ
localization/NN
signal/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
and/CC
requires/VBZ
the/DT
transactivation/NN
domain/NN
to/TO
inhibit/VB
NF-kappa/NN
B/NN
p65/NN
DNA/NN
binding/NN
./.
====================
AB/LS
-/:
The/DT
active/JJ
nuclear/JJ
form/NN
of/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
complex/NN
is/VBZ
composed/VBN
of/IN
two/CD
DNA/NN
binding/NN
subunits/NNS
,/,
NF-kappa/NN
B/NN
p65/NN
and/CC
NF-kappa/NN
B/NN
p50/NN
,/,
both/DT
of/IN
which/WDT
share/VBP
extensive/JJ
N-terminal/JJ
sequence/NN
homology/NN
with/IN
the/DT
v-rel/NN
oncogene/NN
product/NN
./.
====================
The/DT
NF-kappa/NN
B/NN
p65/NN
subunit/NN
provides/VBZ
the/DT
transactivation/NN
activity/NN
in/IN
this/DT
complex/JJ
and/CC
serves/VBZ
as/IN
an/DT
intracellular/JJ
receptor/NN
for/IN
a/DT
cytoplasmic/JJ
inhibitor/NN
of/IN
NF-kappa/NN
B/NN
,/,
termed/VBN
I/NN
kappa/NN
B/NN
./.
====================
In/IN
contrast/NN
,/,
NF-kappa/NN
B/NN
p50/NN
alone/RB
fails/VBZ
to/TO
stimulate/VB
kappa/NN
B-directed/JJ
transcription/NN
,/,
and/CC
based/VBN
on/IN
prior/JJ
in/FW
vitro/FW
studies/NNS
,/,
is/VBZ
not/RB
directly/RB
regulated/VBN
by/IN
I/NN
kappa/NN
B/NN
./.
====================
To/TO
investigate/VB
the/DT
molecular/JJ
basis/NN
for/IN
the/DT
critical/JJ
regulatory/JJ
interaction/NN
between/IN
NF-kappa/NN
B/NN
and/CC
I/NN
kappa/NN
B/MAD-3/NN
,/,
a/DT
series/NN
of/IN
human/JJ
NF-kappa/NN
B/NN
p65/NN
mutants/NNS
was/VBD
identified/VBN
that/WDT
functionally/RB
segregated/VBD
DNA/NN
binding/NN
,/,
I/NN
kappa/NN
B-mediated/JJ
inhibition/NN
,/,
and/CC
I/NN
kappa/NN
B-induced/JJ
nuclear/JJ
exclusion/NN
of/IN
this/DT
transcription/NN
factor/NN
./.
====================
Results/NNS
from/IN
in/FW
vivo/FW
expression/NN
studies/NNS
performed/VBN
with/IN
these/DT
NF-kappa/NN
B/NN
p65/NN
mutants/NNS
revealed/VBD
the/DT
following/NN
:/:
1/LS
)/)
I/NN
kappa/NN
B/MAD-3/NN
completely/RB
inhibits/VBZ
NF-kappa/NN
B/NN
p65-dependent/JJ
transcriptional/JJ
activation/NN
mediated/VBN
through/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
kappa/NN
B/NN
enhancer/NN
in/IN
human/JJ
T/NN
lymphocytes/NNS
,/,
2/LS
)/)
the/DT
binding/NN
of/IN
I/NN
kappa/NN
B/MAD-3/NN
to/TO
NF-kappa/NN
B/NN
p65/NN
is/VBZ
sufficient/JJ
to/TO
retarget/VB
NF-kappa/NN
B/NN
p65/NN
from/IN
the/DT
nucleus/NN
to/TO
the/DT
cytoplasm/NN
,/,
3/LS
)/)
selective/JJ
deletion/NN
of/IN
the/DT
functional/JJ
nuclear/JJ
localization/NN
signal/NN
present/JJ
in/IN
the/DT
Rel/NN
homology/NN
domain/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
disrupts/VBZ
its/PRP$
ability/NN
to/TO
engage/VB
I/NN
kappa/NN
B/MAD-3/NN
,/,
and/CC
4/LS
)/)
the/DT
unique/JJ
C-terminus/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
attenuates/VBZ
its/PRP$
own/JJ
nuclear/JJ
localization/NN
and/CC
contains/VBZ
sequences/NNS
that/WDT
are/VBP
required/VBN
for/IN
I/NN
kappa/NN
B-mediated/JJ
inhibition/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
DNA/NN
binding/NN
activity/NN
./.
====================
Together/RB
,/,
these/DT
findings/NNS
suggest/VBP
that/IN
the/DT
nuclear/JJ
localization/NN
signal/NN
and/CC
transactivation/NN
domain/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
constitute/VBP
a/DT
bipartite/JJ
system/NN
that/WDT
is/VBZ
critically/RB
involved/VBN
in/IN
the/DT
inhibitory/JJ
function/NN
of/IN
I/NN
kappa/NN
B/MAD-3/NN
./.
====================
Unexpectedly/RB
,/,
our/PRP$
in/FW
vivo/FW
studies/NNS
also/RB
demonstrate/VBP
that/IN
I/NN
kappa/NN
B/MAD-3/NN
binds/VBZ
directly/RB
to/TO
NF-kappa/NN
B/NN
p50/NN
./.
====================
This/DT
interaction/NN
is/VBZ
functional/JJ
as/IN
it/PRP
leads/VBZ
to/TO
retargeting/NN
of/IN
NF-kappa/NN
B/NN
p50/NN
from/IN
the/DT
nucleus/NN
to/TO
the/DT
cytoplasm/NN
./.
====================
However/RB
,/,
no/DT
loss/NN
of/IN
DNA/NN
binding/NN
activity/NN
is/VBZ
observed/VBN
,/,
presumably/RB
reflecting/VBG
the/DT
unique/JJ
C-terminal/JJ
domain/NN
that/WDT
is/VBZ
distinct/JJ
from/IN
that/DT
present/JJ
in/IN
NF-kappa/NN
B/NN
p65/NN
./.
====================
UI/LS
-/:
93024468/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
a/DT
new/JJ
tissue-specific/JJ
transcription/NN
factor/NN
binding/VBG
to/TO
the/DT
simian/JJ
virus/NN
40/CD
enhancer/NN
TC-II/NN
(/(
NF-kappa/NN
B/NN
)/)
element/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
biochemically/RB
and/CC
functionally/RB
characterized/VBN
a/DT
new/JJ
transcription/NN
factor/NN
,/,
NP-TCII/NN
,/,
which/WDT
is/VBZ
present/JJ
in/IN
nuclei/NNS
from/IN
unstimulated/JJ
T/NN
and/CC
B/NN
lymphocytes/NNS
but/CC
is/VBZ
not/RB
found/VBN
in/IN
nonhematopoietic/JJ
cells/NNS
./.
====================
This/DT
factor/NN
has/VBZ
a/DT
DNA-binding/JJ
specificity/NN
similar/JJ
to/TO
that/DT
of/IN
NF-kappa/NN
B/NN
but/CC
is/VBZ
unrelated/JJ
to/TO
this/DT
or/CC
other/JJ
Rel/NN
proteins/NNS
by/IN
functional/JJ
and/CC
biochemical/JJ
criteria/NNS
./.
====================
It/PRP
can/MD
also/RB
be/VB
distinguished/VBN
from/IN
other/JJ
previously/RB
described/VBN
lymphocyte-specific/JJ
DNA-binding/JJ
proteins/NNS
./.
====================
UI/LS
-/:
93024882/CD
====================
TI/LS
-/:
The/DT
candidate/NN
oncoprotein/NN
Bcl-3/NN
is/VBZ
an/DT
antagonist/NN
of/IN
p50/NF-kappa/NN
B-mediated/JJ
inhibition/NN
./.
====================
AB/LS
-/:
The/DT
candidate/NN
oncogene/NN
bcl-3/NN
was/VBD
discovered/VBN
as/IN
a/DT
translocation/NN
into/IN
the/DT
immunoglobulin/NN
alpha-locus/NN
in/IN
some/DT
cases/NNS
of/IN
B-cell/NN
chronic/JJ
lymphocytic/JJ
leukaemias/NNS
./.
====================
The/DT
protein/NN
Bcl-3/NN
contains/VBZ
seven/CD
so-called/JJ
ankyrin/NN
repeats/NNS
./.
====================
Similar/JJ
repeat/NN
motifs/NNS
are/VBP
found/VBN
in/IN
a/DT
number/NN
of/IN
diverse/JJ
regulatory/JJ
proteins/NNS
but/CC
the/DT
motifs/NNS
of/IN
Bcl-3/NN
are/VBP
most/RBS
closely/RB
related/JJ
to/TO
those/DT
found/VBN
in/IN
I/NN
kappa/NN
B/NN
proteins/NNS
in/IN
which/WDT
the/DT
ankyrin/NN
repeat/NN
domain/NN
is/VBZ
thought/VBN
to/TO
be/VB
directly/RB
involved/VBN
in/IN
inhibition/NN
of/IN
NF-kappa/NN
B/NN
activity/NN
./.
====================
No/DT
biological/JJ
function/NN
has/VBZ
yet/RB
been/VBN
described/VBN
for/IN
Bcl-3/NN
,/,
but/CC
it/PRP
was/VBD
noted/VBN
recently/RB
that/IN
Bcl-3/NN
interferes/VBZ
with/IN
DNA-binding/NN
of/IN
the/DT
p50/NN
subunit/NN
of/IN
NF-kappa/NN
B/NN
in/FW
vitro/FW
./.
====================
Here/RB
we/PRP
demonstrate/VBP
that/IN
Bcl-3/NN
can/MD
aid/VB
kappa/NN
B/NN
site-dependent/JJ
transcription/NN
in/FW
vivo/FW
by/IN
counteracting/VBG
the/DT
inhibitory/JJ
effects/NNS
of/IN
p50/NF-kappa/NN
B/NN
homodimers/NNS
./.
====================
Bcl-3/NN
may/MD
therefore/RB
aid/VB
activation/NN
of/IN
select/JJ
NF-kappa/NN
B-regulated/JJ
genes/NNS
,/,
including/VBG
those/DT
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
./.
====================
UI/LS
-/:
93013114/CD
====================
TI/LS
-/:
[/(
Mechanism/NN
of/IN
action/NN
of/IN
steroid/NN
hormones/NNS
./.
I/LS
./.
Estrogens/NNS
]/)
====================
AB/LS
-/:
The/DT
steroid/NN
hormone/NN
are/VBP
very/RB
versatile/JJ
molecules/NNS
:/:
although/IN
they/PRP
are/VBP
related/JJ
among/IN
them/PRP
by/IN
their/PRP$
chemical/JJ
structure/NN
,/,
they/PRP
have/VBP
very/RB
diverse/JJ
functions/NNS
and/CC
including/VBG
antagonic/JJ
./.
====================
Their/PRP$
action/NN
mechanism/NN
is/VBZ
not/RB
completely/RB
cleared/VBN
./.
====================
The/DT
estrogens/NNS
participate/VBP
in/IN
the/DT
regulation/NN
of/IN
practically/RB
all/PDT
the/DT
reproductive/JJ
and/CC
sexual/JJ
events/NNS
of/IN
the/DT
female/NN
,/,
although/IN
the/DT
intracellular/JJ
actions/NNS
by/IN
which/WDT
they/PRP
take/VBP
place/NN
are/VBP
not/RB
well/RB
known/VBN
and/CC
the/DT
proposed/JJ
models/NNS
do/VBP
not/RB
adequately/RB
satisfy/VB
the/DT
questions/NNS
./.
====================
Currently/RB
it/PRP
is/VBZ
accepted/VBN
the/DT
existence/NN
of/IN
a/DT
cytoplasmic/JJ
and/or/CC
nuclear/JJ
receptor/NN
,/,
without/IN
explaining/VBG
satisfactorily/RB
how/WRB
the/DT
hormones/NNS
come/VBN
to/TO
the/DT
nucleus/NN
./.
====================
The/DT
endocrine/JJ
events/NNS
that/WDT
are/VBP
rapidly/RB
expressed/VBN
(/(
seconds/NNS
)/)
are/VBP
due/JJ
to/TO
a/DT
possible/JJ
interaction/NN
with/IN
cellular/JJ
membrane/NN
./.
====================
The/DT
purpose/NN
of/IN
this/DT
review/NN
is/VBZ
to/TO
analyze/VB
and/CC
concilliate/VB
the/DT
reported/VBN
data/NNS
on/IN
the/DT
mechanism/NN
of/IN
action/NN
of/IN
estrogens/NNS
./.
====================
UI/LS
-/:
92291523/CD
====================
TI/LS
-/:
Reduced/VBN
susceptibility/NN
to/TO
HIV-1/NN
infection/NN
of/IN
ethyl-methanesulfonate-treated/JJ
CEM/NN
subclones/NNS
correlates/VBZ
with/IN
a/DT
blockade/NN
in/IN
their/PRP$
protein/NN
kinase/NN
C/NN
signaling/NN
pathway/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
described/VBN
the/DT
isolation/NN
of/IN
chemically/RB
induced/VBN
CEM/NN
subclones/NNS
that/WDT
express/VBP
CD4/NN
receptors/NNS
and/CC
bind/VBP
soluble/JJ
gp120/NN
,/,
yet/RB
show/VBP
a/DT
markedly/RB
reduced/VBN
susceptibility/NN
to/TO
infection/NN
with/IN
HIV-1/NN
./.
====================
Two/CD
subclones/NNS
were/VBD
found/VBN
to/TO
have/VB
an/DT
abnormal/JJ
response/NN
to/TO
the/DT
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
activator/NN
PMA/NN
./.
====================
PMA/NN
treatment/NN
induced/VBD
CD3/NN
and/CC
CD25/NN
(/(
IL-2R/NN
)/)
receptors/NNS
on/IN
the/DT
parental/JJ
line/NN
and/CC
on/IN
other/JJ
ethyl-methanesulfonate-derived/JJ
subclones/NNS
,/,
but/CC
not/RB
on/IN
these/DT
two/CD
mutants/NNS
./.
====================
Direct/JJ
assays/NNS
of/IN
PKC/NN
activity/NN
were/VBD
conducted/VBN
./.
====================
Total/JJ
cellular/JJ
PKC/NN
enzymatic/JJ
activity/NN
was/VBD
found/VBN
to/TO
be/VB
normal/JJ
in/IN
these/DT
subclones/NNS
./.
====================
PMA-induced/JJ
CD4/NN
down-modulation/NN
occurred/VBD
normally/RB
./.
====================
In/IN
addition/NN
,/,
activation/NN
of/IN
c-raf/NN
kinase/NN
was/VBD
normal/JJ
./.
====================
Since/IN
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
contains/VBZ
two/CD
functional/JJ
nuclear/JJ
factor/NN
kB/NN
(/(
NF-kB/NN
)/)
regulatory/JJ
elements/NNS
,/,
we/PRP
studied/VBD
the/DT
ability/NN
of/IN
PMA/NN
to/TO
induce/VB
NF-kB/NN
binding/NN
activity/NN
by/IN
different/JJ
assays/NNS
./.
====================
Chloramphenicol/NN
acetyl/NN
transferase/NN
(/(
CAT/NN
)/)
assays/NNS
using/VBG
the/DT
HIV-1/NN
(/(
-139/CD
)/)
long/JJ
terminal/JJ
repeat-CAT/JJ
construct/NN
showed/VBD
no/DT
PMA/NN
induction/NN
of/IN
CAT/NN
activity/NN
in/IN
these/DT
subclones/NNS
(/(
unlike/IN
the/DT
parental/JJ
line/NN
and/CC
other/JJ
subclones/NNS
)/)
./.
====================
Okadaic/JJ
acid/NN
,/,
an/DT
inhibitor/NN
of/IN
phosphatases/NNS
1/CD
and/CC
2A/NN
,/,
did/VBD
not/RB
overcome/VB
the/DT
defect/NN
in/IN
these/DT
subclones/NNS
./.
====================
Gel/NN
retardation/NN
assays/NNS
,/,
using/VBG
a/DT
32P-probe/NN
containing/VBG
the/DT
HIV-1/NN
NF-kB/NN
probe/NN
and/CC
nuclear/JJ
extracts/NNS
from/IN
PMA-treated/JJ
cells/NNS
,/,
showed/VBD
significantly/RB
reduced/VBN
induction/NN
of/IN
nuclear/JJ
NF-kB/NN
binding/NN
proteins/NNS
in/IN
these/DT
two/CD
subclones/NNS
compared/VBN
with/IN
wild/JJ
type/NN
CEM/NN
and/CC
a/DT
control/NN
subclone/NN
./.
====================
Deoxycholate/JJ
treatment/NN
of/IN
cytoplasmic/JJ
extracts/NNS
from/IN
these/DT
subclones/NNS
released/VBD
much/JJ
reduced/VBN
NF-kB/NN
binding/NN
proteins/NNS
from/IN
their/PRP$
cytoplasmic/JJ
pools/NNS
./.
====================
Thus/RB
,/,
reduced/JJ
levels/NNS
of/IN
PKC-induced/JJ
nuclear/JJ
NF-kB/NN
activity/NN
in/IN
two/CD
T/NN
cell/NN
subclones/NNS
did/VBD
not/RB
affect/VB
their/PRP$
normal/JJ
cell/NN
growth/NN
,/,
but/CC
correlated/VBD
with/IN
a/DT
pronounced/JJ
reduction/NN
in/IN
their/PRP$
susceptibility/NN
to/TO
HIV-1/NN
infection/NN
./.
====================
UI/LS
-/:
92244343/CD
====================
TI/LS
-/:
Nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
contains/VBZ
Fos/NN
and/CC
Jun/NN
./.
====================
AB/LS
-/:
The/DT
nuclear/JJ
factor/NN
NF-AT/NN
(/(
ref./NN
1/CD
)/)
is/VBZ
induced/VBN
in/IN
T/NN
cells/NNS
stimulated/VBN
through/IN
the/DT
T-cell/NN
receptor/CD3/NN
complex/NN
,/,
and/CC
is/VBZ
required/VBN
for/IN
interleukin-2/NN
(/(
IL-2/NN
)/)
gene/NN
induction/NN
./.
====================
Although/IN
NF-AT/NN
has/VBZ
not/RB
been/VBN
cloned/VBN
or/CC
purified/VBN
,/,
there/EX
is/VBZ
evidence/NN
that/IN
it/PRP
is/VBZ
a/DT
major/JJ
target/NN
for/IN
immunosuppression/NN
by/IN
cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
and/CC
FK506/NN
(/(
refs/NNS
2-7/CD
)/)
./.
====================
NF-AT/NN
induction/NN
may/MD
require/VB
two/CD
activation-dependent/JJ
events/NNS
:/:
the/DT
CsA-sensitive/JJ
translocation/NN
of/IN
a/DT
pre-existing/JJ
component/NN
and/CC
the/DT
CsA-resistant/JJ
synthesis/NN
of/IN
a/DT
nuclear/JJ
component/NN
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
the/DT
newly/RB
synthesized/VBN
nuclear/JJ
component/NN
of/IN
NF-AT/NN
is/VBZ
the/DT
transcription/NN
factor/NN
AP-1/NN
./.
====================
We/PRP
show/VBP
that/IN
the/DT
inducible/JJ
nuclear/JJ
form/NN
of/IN
NF-AT/NN
contains/VBZ
Fos/NN
and/CC
Jun/NN
proteins/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
identify/VBP
a/DT
pre-existing/JJ
NF-AT-binding/JJ
factor/NN
that/WDT
is/VBZ
present/JJ
in/IN
hypotonic/JJ
extracts/NNS
of/IN
unstimulated/JJ
T/NN
cells/NNS
./.
====================
On/IN
the/DT
basis/NN
of/IN
binding/NN
,/,
reconstitution/NN
and/CC
cotransfection/NN
experiments/NNS
,/,
we/PRP
propose/VBP
that/IN
activation/NN
of/IN
NF-AT/NN
occurs/VBZ
in/IN
at/IN
least/JJS
two/CD
stages/NNS
:/:
a/DT
CsA-sensitive/JJ
stage/NN
involving/VBG
modification/NN
and/or/CC
translocation/NN
of/IN
the/DT
pre-existing/JJ
NF-AT/NN
complex/NN
,/,
and/CC
a/DT
CsA-insensitive/JJ
stage/NN
involving/VBG
the/DT
addition/NN
of/IN
newly/RB
synthesized/VBN
Fos/NN
or/CC
Fos/Jun/NN
proteins/NNS
to/TO
the/DT
pre-existing/JJ
complex/NN
./.
====================
UI/LS
-/:
92195320/CD
====================
TI/LS
-/:
A/DT
lymphoid/JJ
cell-specific/JJ
nuclear/JJ
factor/NN
containing/VBG
c-Rel-like/JJ
proteins/NNS
preferentially/RB
interacts/VBZ
with/IN
interleukin-6/NN
kappa/NN
B-related/JJ
motifs/NNS
whose/WP$
activities/NNS
are/VBP
repressed/VBN
in/IN
lymphoid/JJ
cells/NNS
./.
====================
AB/LS
-/:
The/DT
proto-oncoprotein/NN
c-Rel/NN
is/VBZ
a/DT
member/NN
of/IN
the/DT
nuclear/JJ
factor/NN
kappa/NN
B/NN
transcription/NN
factor/NN
family/NN
,/,
which/WDT
includes/VBZ
the/DT
p50/NN
and/CC
p65/NN
subunits/NNS
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
./.
====================
We/PRP
show/VBP
here/RB
that/IN
c-Rel/NN
binds/VBZ
to/TO
kappa/NN
B/NN
sites/NNS
as/IN
homodimers/NNS
as/RB
well/RB
as/IN
heterodimers/NNS
with/IN
p50/NN
./.
====================
These/DT
homodimers/NNS
and/CC
heterodimers/NNS
show/VBP
distinct/JJ
DNA-binding/JJ
specificities/NNS
and/CC
affinities/NNS
for/IN
various/JJ
kappa/NN
B/NN
motifs/NNS
./.
====================
In/IN
particular/JJ
,/,
the/DT
c-Rel/NN
homodimer/NN
has/VBZ
a/DT
high/JJ
affinity/NN
for/IN
interleukin-6/NN
(/(
IL-6/NN
)/)
and/CC
beta/NN
interferon/NN
kappa/NN
B/NN
sites/NNS
./.
====================
In/IN
spite/NN
of/IN
its/PRP$
association/NN
with/IN
p50/NN
in/FW
vitro/FW
,/,
however/RB
,/,
we/PRP
found/VBD
a/DT
lymphoid/JJ
cell-specific/JJ
nuclear/JJ
factor/NN
in/FW
vivo/FW
that/WDT
contains/VBZ
c-Rel/NN
but/CC
not/RB
p50/NN
epitopes/NNS
;/:
this/DT
factor/NN
,/,
termed/VBN
IL-6/NN
kappa/NN
B/NN
binding/NN
factor/NN
II/CD
,/,
appears/VBZ
to/TO
contain/VB
the/DT
c-Rel/NN
homodimer/NN
and/CC
preferentially/RB
recognizes/VBZ
several/JJ
IL-6/NN
kappa/NN
B-related/JJ
kappa/NN
B/NN
motifs/NNS
./.
====================
Although/IN
it/PRP
has/VBZ
been/VBN
previously/RB
shown/VBN
that/IN
the/DT
IL-6/NN
kappa/NN
B/NN
motif/NN
functions/VBZ
as/IN
a/DT
potent/JJ
IL-1/tumor/NN
necrosis/NN
factor-responsive/JJ
element/NN
in/IN
nonlymphoid/JJ
cells/NNS
,/,
its/PRP$
activity/NN
was/VBD
found/VBN
to/TO
be/VB
repressed/VBN
in/IN
lymphoid/JJ
cells/NNS
such/JJ
as/IN
a/DT
Jurkat/NN
T-cell/NN
line/NN
./.
====================
We/PRP
also/RB
present/VBP
evidence/NN
that/IN
IL-6/NN
kappa/NN
B/NN
binding/NN
factor/NN
II/CD
functions/VBZ
as/IN
a/DT
repressor/NN
specific/JJ
for/IN
IL-6/NN
kappa/NN
B-related/JJ
kappa/NN
B/NN
motifs/NNS
in/IN
lymphoid/JJ
cells/NNS
./.
====================
UI/LS
-/:
92156261/CD
====================
TI/LS
-/:
Cortisol/NN
resistance/NN
in/IN
acquired/VBN
immunodeficiency/NN
syndrome/NN
./.
====================
AB/LS
-/:
This/DT
study/NN
concerns/VBZ
9/CD
iv/NN
drug/NN
abusers/NNS
with/IN
acquired/VBN
immunodeficiency/NN
syndrome/NN
(/(
AIDS/NN
)/)
who/WP
developed/VBD
hypercortisolism/NN
without/IN
the/DT
clinical/JJ
signs/NNS
or/CC
metabolic/JJ
consequences/NNS
of/IN
hypercortisolism/NN
./.
====================
All/DT
patients/NNS
were/VBD
characterized/VBN
by/IN
an/DT
Addisonian/JJ
picture/NN
(/(
weakness/NN
,/,
weight/NN
loss/NN
,/,
hypotension/NN
,/,
hyponatremia/NN
,/,
and/CC
intense/JJ
mucocutaneous/JJ
melanosis/NN
)/)
./.
====================
An/DT
acquired/JJ
form/NN
of/IN
peripheral/JJ
resistance/NN
to/TO
glucocorticoids/NNS
was/VBD
suspected/VBN
./.
====================
We/PRP
,/,
therefore/RB
,/,
examined/VBD
glucocorticoid/NN
receptor/NN
characteristics/NNS
on/IN
mononuclear/JJ
leukocytes/NNS
by/IN
measuring/VBG
[3H]dexamethasone/NN
binding/NN
and/CC
the/DT
effect/NN
of/IN
dexamethasone/NN
on/IN
[3H]thymidine/NN
incorporation/NN
,/,
which/WDT
is/VBZ
one/CD
of/IN
the/DT
effects/NNS
of/IN
glucocorticoid/NN
receptor/NN
activation/NN
./.
====================
Glucocorticoid/NN
receptor/NN
density/NN
was/VBD
increased/VBN
in/IN
AIDS/NN
patients/NNS
with/IN
an/DT
Addisonian/JJ
picture/NN
(/(
group/NN
1/CD
;/:
16.2/CD
+/-/CC
9.4/CD
fmol/million/NN
cells/NNS
)/)
compared/VBN
to/TO
values/NNS
in/IN
12/CD
AIDS/NN
patients/NNS
without/IN
an/DT
Addisonian/JJ
picture/NN
(/(
group/NN
2/CD
;/:
6.05/CD
+/-/CC
2.6/CD
fmol/million/NN
cells/NNS
;/:
P/NN
less/JJR
than/IN
0.01/CD
)/)
and/CC
sex-/NN
and/CC
age-matched/JJ
controls/NNS
(/(
3.15/CD
+/-/CC
2.3/CD
fmol/million/NN
cells/NNS
;/:
P/NN
less/JJR
than/IN
0.01/CD
)/)
./.
====================
The/DT
affinity/NN
of/IN
glucocorticoid/NN
receptors/NNS
(/(
Kd/NN
)/)
was/VBD
strikingly/RB
decreased/VBN
(/(
9.36/CD
+/-/CC
3.44/CD
nM/NN
in/IN
group/NN
1/CD
;/:
3.2/CD
+/-/CC
1.5/CD
nM/NN
in/IN
group/NN
2/CD
;/:
2.0/CD
+/-/CC
0.8/CD
nM/NN
in/IN
controls/NNS
;/:
P/NN
less/JJR
than/IN
0.01/CD
)/)
./.
====================
[3H]Thymidine/NN
incorporation/NN
was/VBD
decreased/VBN
dose-dependently/RB
by/IN
dexamethasone/NN
in/IN
controls/NNS
and/CC
patients/NNS
;/:
the/DT
effect/NN
was/VBD
significantly/RB
blunted/VBN
(/(
P/NN
less/JJR
than/IN
0.05/CD
)/)
in/IN
group/NN
1/CD
patients/NNS
,/,
which/WDT
suggests/VBZ
that/IN
activation/NN
of/IN
glucocorticoid/NN
receptor/NN
is/VBZ
impaired/JJ
as/IN
a/DT
result/NN
of/IN
the/DT
glucocorticoid/NN
receptor/NN
abnormality/NN
./.
====================
In/IN
conclusion/NN
,/,
AIDS/NN
patients/NNS
with/IN
hypercortisolism/NN
and/CC
clinical/JJ
features/NNS
of/IN
peripheral/JJ
resistance/NN
to/TO
glucocorticoids/NNS
are/VBP
characterized/VBN
by/IN
abnormal/JJ
glucocorticoid/NN
receptors/NNS
on/IN
lymphocytes/NNS
./.
====================
Resistance/NN
to/TO
glucocorticoids/NNS
implies/VBZ
a/DT
complex/JJ
change/NN
in/IN
immune-endocrine/JJ
function/NN
,/,
which/WDT
may/MD
be/VB
important/JJ
in/IN
the/DT
course/NN
of/IN
immunodeficiency/NN
syndrome/NN
./.
====================
UI/LS
-/:
92134262/CD
====================
TI/LS
-/:
A/DT
novel/JJ
primer/NN
extension/NN
method/NN
to/TO
detect/VB
the/DT
number/NN
of/IN
CAG/NN
repeats/NNS
in/IN
the/DT
androgen/NN
receptor/NN
gene/NN
in/IN
families/NNS
with/IN
X-linked/JJ
spinal/JJ
and/CC
bulbar/JJ
muscular/JJ
atrophy/NN
./.
====================
AB/LS
-/:
X-linked/JJ
spinal/JJ
and/CC
bulbar/JJ
muscular/JJ
atrophy/NN
(/(
SBMA/NN
)/)
,/,
an/DT
adult-onset/JJ
form/NN
of/IN
motor/NN
neuron/NN
disease/NN
,/,
was/VBD
recently/RB
reported/VBN
to/TO
be/VB
caused/VBN
by/IN
amplification/NN
of/IN
the/DT
CAG/NN
repeats/NNS
in/IN
the/DT
androgen/NN
receptor/NN
gene/NN
./.
====================
We/PRP
report/VBP
here/RB
a/DT
simple/JJ
and/CC
rapid/JJ
strategy/NN
to/TO
detect/VB
the/DT
precise/JJ
number/NN
of/IN
the/DT
CAGs/NNS
./.
====================
After/IN
the/DT
DNA/NN
fragment/NN
containing/VBG
the/DT
CAG/NN
repeats/NNS
is/VBZ
amplified/VBN
by/IN
the/DT
polymerase/NN
chain/NN
reaction/NN
,/,
a/DT
primer/NN
extension/NN
is/VBZ
carried/VBN
out/RP
;/:
the/DT
extension/NN
of/IN
the/DT
end-labelled/JJ
reverse/JJ
primer/NN
adjacent/JJ
to/TO
3'/JJ
end/NN
of/IN
CAG/NN
repeats/NNS
stops/VBZ
at/IN
the/DT
first/JJ
T/NN
after/IN
CAG/NN
repeats/NNS
with/IN
the/DT
incorporation/NN
of/IN
dideoxy/JJ
ATP/NN
in/IN
the/DT
reaction/NN
mixture/NN
./.
====================
The/DT
resultant/JJ
primer/NN
products/NNS
are/VBP
analysed/VBN
by/IN
denaturing/VBG
polyacrylamide/NN
gel/NN
electrophoresis/NN
and/CC
autoradiography/NN
./.
====================
This/DT
method/NN
could/MD
be/VB
quite/RB
useful/JJ
to/TO
detect/VB
not/RB
only/RB
CAG/NN
repeats/NNS
in/IN
SBMA/NN
but/CC
also/RB
other/JJ
polymorphic/JJ
dinucleotide/JJ
and/CC
trinucleotide/JJ
repeats/NNS
./.
====================
UI/LS
-/:
94051535/CD
====================
TI/LS
-/:
Cellular/JJ
immune/JJ
and/CC
cytokine/NN
pathways/NNS
resulting/VBG
in/IN
tissue/NN
factor/NN
expression/NN
and/CC
relevance/NN
to/TO
septic/JJ
shock/NN
./.
====================
AB/LS
-/:
Cells/NNS
of/IN
monocyte/NN
lineage/NN
serve/VBP
as/IN
effector/NN
cells/NNS
in/IN
the/DT
cellular/JJ
immune/JJ
response/NN
./.
====================
In/IN
addition/NN
,/,
they/PRP
respond/VBP
to/TO
LPS/NN
and/CC
cytokines/NNS
with/IN
activation/NN
and/CC
expression/NN
of/IN
inflammatory/JJ
effector/NN
gene/NN
products/NNS
similar/JJ
to/TO
those/DT
elicited/VBN
by/IN
the/DT
antigen/NN
driven/JJ
response/NN
./.
====================
The/DT
response/NN
to/TO
antigen/NN
proceeds/VBZ
at/IN
the/DT
T/NN
helper/NN
cell/NN
level/NN
through/IN
two/CD
independent/JJ
forms/NNS
of/IN
cellular/JJ
collaboration/NN
,/,
contact/NN
and/CC
lymphokine/NN
./.
====================
We/PRP
review/VBP
the/DT
control/NN
of/IN
expression/NN
of/IN
the/DT
Tissue/NN
Factor/NN
(/(
TF/NN
)/)
gene/NN
and/CC
the/DT
function/NN
of/IN
the/DT
TF/NN
protein/NN
./.
====================
The/DT
enhanced/VBN
initiation/NN
of/IN
transcription/NN
of/IN
the/DT
TF/NN
gene/NN
appears/VBZ
to/TO
require/VB
engagement/NN
of/IN
a/DT
56/CD
bp/NN
LPS/NN
Response/NN
Element/NN
,/,
an/DT
enhancer/NN
that/WDT
is/VBZ
engaged/VBN
by/IN
both/DT
AP-1/NN
type/NN
heterodimeric/JJ
complexes/NNS
as/RB
well/RB
as/IN
NF/NN
kappa/NN
B/NN
like/IN
heterodimeric/JJ
complexes/NNS
./.
====================
Dissociation/NN
of/IN
NF/NN
kappa/NN
B/NN
from/IN
Ig/NN
kappa/NN
B/NN
by/IN
cytokine/NN
and/CC
LPS/NN
stimulation/NN
,/,
and/CC
possibly/RB
activated/VBN
T/NN
cells/NNS
,/,
may/MD
represent/VB
a/DT
common/JJ
pathway/NN
to/TO
induction/NN
of/IN
the/DT
TF/NN
and/CC
other/JJ
inflammatory/JJ
genes/NNS
./.
====================
Enhancement/NN
of/IN
expression/NN
of/IN
TF/NN
is/VBZ
observed/VBN
upon/IN
adhesion/NN
of/IN
Mo/NN
to/TO
endothelial/JJ
cells/NNS
and/CC
extracellular/JJ
matrix/JJ
proteins/NNS
,/,
as/RB
well/RB
as/IN
upon/IN
engagement/NN
of/IN
leukocyte/NN
integrins/NNS
./.
====================
The/DT
biological/JJ
effects/NNS
that/WDT
follow/VBP
from/IN
expression/NN
of/IN
TF/NN
by/IN
vascular/JJ
cells/NNS
have/VBP
been/VBN
resolved/VBN
by/IN
analysis/NN
of/IN
function/NN
aided/VBN
by/IN
the/DT
use/NN
of/IN
recombinant/JJ
full/JJ
length/NN
TF/NN
and/CC
truncated/VBN
surface/NN
domain/NN
of/IN
TF/NN
./.
====================
The/DT
rules/NNS
of/IN
assembly/NN
of/IN
the/DT
cognate/JJ
ligands/NNS
of/IN
TF/NN
,/,
namely/RB
the/DT
zymogen/NN
plasma/NN
factors/NNS
VII/NN
and/CC
the/DT
serine/NN
protease/NN
factor/NN
VIIa/NN
,/,
with/IN
the/DT
soluble/JJ
surface/NN
domain/NN
of/IN
TF/NN
in/IN
free/JJ
solution/NN
,/,
in/IN
the/DT
presence/NN
of/IN
phospholipid/JJ
surfaces/NNS
and/CC
cell/NN
surface/NN
and/CC
of/IN
the/DT
anchored/VBN
TF/NN
molecule/NN
have/VBP
been/VBN
described/VBN
./.
====================
It/PRP
is/VBZ
evident/JJ
that/IN
assembly/NN
of/IN
the/DT
surface/NN
domain/NN
of/IN
TF/NN
with/IN
VIIa/NN
to/TO
form/VB
the/DT
binary/JJ
TF.VIIa/NN
complex/NN
induces/VBZ
a/DT
significant/JJ
increase/NN
in/IN
the/DT
Kcat/NN
of/IN
the/DT
catalytic/JJ
domain/NN
of/IN
VIIa/NN
for/IN
small/JJ
peptidyl/JJ
substrates/NNS
and/CC
more/JJR
profoundly/RB
for/IN
protein/NN
substrate/NN
./.
====================
This/DT
provides/VBZ
substantial/JJ
evidence/NN
for/IN
an/DT
allosteric/JJ
effect/NN
on/IN
the/DT
catalytic/JJ
cleft/NN
of/IN
VIIa/NN
that/WDT
is/VBZ
imparted/VBN
by/IN
binding/VBG
to/TO
TF/NN
,/,
its/PRP$
cognate/JJ
catalytic/JJ
cofactor/NN
./.
====================
It/PRP
is/VBZ
also/RB
evident/JJ
that/IN
the/DT
TF.VIIa/NN
complex/NN
is/VBZ
proteolytically/RB
active/JJ
and/CC
can/MD
activate/VB
the/DT
zymogen/NN
plasma/NN
factor/NN
X/NN
to/TO
the/DT
serine/NN
protease/NN
Xa/NN
in/IN
free/JJ
solution/NN
,/,
inferring/VBG
that/IN
extended/VBN
substrate/NN
recognition/NN
by/IN
induced/VBN
structural/JJ
loci/NNS
of/IN
the/DT
TF.VIIa/NN
complex/NN
are/VBP
created/VBN
from/IN
either/DT
or/CC
both/DT
proteins/NNS
to/TO
constitute/VB
a/DT
new/JJ
recognition/NN
structure/NN
./.
====================
It/PRP
is/VBZ
also/RB
evident/JJ
that/IN
association/NN
of/IN
X/NN
with/IN
charged/JJ
phospholipid/JJ
surfaces/NNS
enhances/VBZ
the/DT
proteolytic/JJ
activation/NN
of/IN
this/DT
zymogen/NN
by/IN
increasing/VBG
recognition/NN
and/CC
susceptibility/NN
of/IN
the/DT
sessile/NN
peptide/NN
bond/NN
deduced/VBN
from/IN
the/DT
markedly/RB
decreased/VBN
Km/NN
and/CC
increased/VBN
Kcat/NN
./.
====================
UI/LS
-/:
93100507/CD
====================
TI/LS
-/:
Phorbol/NN
ester/NN
reduces/VBZ
constitutive/JJ
nuclear/JJ
NF/NN
kappa/NN
B/NN
and/CC
inhibits/VBZ
HIV-1/NN
production/NN
in/IN
mature/JJ
human/JJ
monocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
NF/NN
kappa/NN
B/NN
is/VBZ
a/DT
potent/JJ
mediator/NN
of/IN
specific/JJ
gene/NN
expression/NN
in/IN
human/JJ
monocytes/NNS
and/CC
has/VBZ
been/VBN
shown/VBN
to/TO
play/VB
a/DT
role/NN
in/IN
transcription/NN
of/IN
the/DT
HIV-1/NN
genome/NN
in/IN
promonocytic/JJ
leukemias/NNS
./.
====================
There/EX
is/VBZ
little/JJ
information/NN
available/JJ
on/IN
the/DT
response/NN
of/IN
NF/NN
kappa/NN
B/NN
to/TO
cytokines/NNS
in/IN
normal/JJ
human/JJ
monocytes/NNS
./.
====================
We/PRP
have/VBP
used/VBN
a/DT
32P-labeled/JJ
oligonucleotide/NN
derived/VBN
from/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV-1/NN
)/)
long/JJ
terminal/JJ
repeat/NN
,/,
which/WDT
contains/VBZ
a/DT
tandem/JJ
repeat/NN
of/IN
the/DT
NF/NN
kappa/NN
B/NN
binding/NN
sequence/NN
,/,
as/IN
a/DT
probe/NN
in/IN
a/DT
gel/NN
retardation/NN
assay/NN
to/TO
study/VB
this/DT
transcription/NN
factor/NN
./.
====================
Using/VBG
this/DT
assay/NN
,/,
we/PRP
have/VBP
detected/VBN
NF/NN
kappa/NN
B/NN
in/IN
extracts/NNS
of/IN
nuclei/NNS
from/IN
normal/JJ
human/JJ
monocytes/NNS
./.
====================
Treatment/NN
of/IN
normal/JJ
monocytes/NNS
with/IN
12-0-/NN
tetradecanoyl/NN
phorbol-13-acetate/NN
(/(
TPA/NN
)/)
for/IN
4-24/CD
h/NN
caused/VBD
the/DT
complete/JJ
disappearance/NN
of/IN
NF/NN
kappa/NN
B/NN
from/IN
nuclear/JJ
extracts/NNS
of/IN
monocytes/NNS
./.
====================
A/DT
similar/JJ
result/NN
was/VBD
obtained/VBN
with/IN
the/DT
mature/JJ
monocytic/JJ
leukemia/NN
cell/NN
line/NN
THP-1/NN
./.
====================
The/DT
constitutive/JJ
transcription/NN
factor/NN
SP1/NN
was/VBD
unaffected/JJ
by/IN
addition/NN
of/IN
TPA/NN
./.
====================
The/DT
disappearance/NN
of/IN
NF/NN
kappa/NN
B/NN
from/IN
the/DT
nucleus/NN
was/VBD
concentration/NN
dependent/JJ
between/IN
10/CD
and/CC
50/CD
ng/ml/NN
of/IN
phorbol/NN
ester/NN
./.
====================
In/IN
THP-1/NN
cells/NNS
,/,
TPA/NN
also/RB
induced/VBD
a/DT
new/JJ
,/,
faster-migrating/JJ
NF/NN
kappa/NN
B/NN
species/NNS
not/RB
induced/VBN
in/IN
monocytes/NNS
./.
====================
Protein/NN
kinase/NN
C/NN
inhibitor/NN
staurosporine/NN
,/,
but/CC
not/RB
cyclic/JJ
nucleotide-dependent/JJ
protein/NN
kinase/NN
inhibitor/NN
HA-1004/NN
,/,
also/RB
dramatically/RB
reduced/VBD
constitutive/JJ
levels/NNS
of/IN
nuclear/JJ
NF/NN
kappa/NN
B/NN
./.
====================
Finally/RB
,/,
TPA/NN
addition/NN
to/TO
monocytes/NNS
infected/VBN
with/IN
HIV-1/NN
inhibited/VBD
HIV-1/NN
replication/NN
,/,
as/IN
determined/VBN
by/IN
reverse/JJ
transcriptase/NN
assays/NNS
,/,
in/IN
a/DT
concentration-dependent/JJ
manner/NN
./.
====================
These/DT
results/NNS
are/VBP
in/IN
striking/JJ
contrast/NN
to/TO
the/DT
increase/NN
in/IN
nuclear/JJ
NF/NN
kappa/NN
B/NN
and/CC
HIV-1/NN
replication/NN
induced/VBN
by/IN
phorbol/NN
esters/NNS
in/IN
promonocytic/JJ
leukemia/NN
cells/NNS
U937/NN
and/CC
HL-60/NN
,/,
and/CC
emphasize/VBP
the/DT
importance/NN
of/IN
studying/VBG
cytokine/NN
regulation/NN
of/IN
HIV-1/NN
in/IN
normal/JJ
monocytes/NNS
./.
====================
UI/LS
-/:
93066282/CD
====================
TI/LS
-/:
A/DT
mechanism/NN
for/IN
the/DT
antiinflammatory/JJ
effects/NNS
of/IN
corticosteroids/NNS
:/:
the/DT
glucocorticoid/NN
receptor/NN
regulates/VBZ
leukocyte/NN
adhesion/NN
to/TO
endothelial/JJ
cells/NNS
and/CC
expression/NN
of/IN
endothelial-leukocyte/JJ
adhesion/NN
molecule/NN
1/CD
and/CC
intercellular/JJ
adhesion/NN
molecule/NN
1/CD
./.
====================
AB/LS
-/:
Corticosteroids/NNS
are/VBP
the/DT
preeminent/JJ
antiinflammatory/JJ
agents/NNS
although/IN
the/DT
molecular/JJ
mechanisms/NNS
that/WDT
impart/VBP
their/PRP$
efficacy/NN
have/VBP
not/RB
been/VBN
defined/VBN
./.
====================
The/DT
endothelium/NN
plays/VBZ
a/DT
critical/JJ
role/NN
in/IN
inflammation/NN
by/IN
directing/VBG
circulating/VBG
leukocytes/NNS
into/IN
extravascular/JJ
tissues/NNS
by/IN
expressing/VBG
adhesive/JJ
molecules/NNS
for/IN
leukocytes/NNS
[/(
e.g./FW
,/,
endothelial-leukocyte/JJ
adhesion/NN
molecule/NN
1/CD
(/(
ELAM-1/NN
)/)
and/CC
intercellular/JJ
adhesion/NN
molecule/NN
1/CD
(/(
ICAM-1/NN
)/)
]/)
./.
====================
We/PRP
therefore/RB
determined/VBD
whether/IN
corticosteroids/NNS
suppress/VBP
inflammation/NN
by/IN
inhibiting/VBG
endothelial/JJ
expression/NN
of/IN
adhesion/NN
molecules/NNS
for/IN
neutrophils/NNS
(/(
polymorphonuclear/JJ
leukocytes/NNS
)/)
./.
====================
Preincubation/NN
of/IN
endothelial/JJ
cells/NNS
with/IN
endotoxin/NN
[/(
lipopolysaccharide/NN
(/(
LPS/NN
)/)
,/,
1/CD
microgram/ml/NN
]/)
led/VBD
to/TO
a/DT
4-fold/JJ
increase/NN
in/IN
subsequent/JJ
adherence/NN
of/IN
polymorphonuclear/JJ
leukocytes/NNS
(/(
P/NN
</JJR
0.0001/CD
,/,
n/NN
=/JJ
10/CD
)/)
to/TO
endothelial/JJ
cells/NNS
,/,
an/DT
increase/NN
that/WDT
was/VBD
markedly/RB
attenuated/VBN
when/WRB
endothelial/JJ
cells/NNS
were/VBD
treated/VBN
with/IN
dexamethasone/NN
(/(
IC50/NN
</JJR
1/CD
nM/NN
,/,
P/NN
</JJR
0.0001/CD
,/,
n/NN
=/JJ
6/CD
or/CC
7/CD
)/)
during/IN
preincubation/NN
with/IN
LPS/NN
./.
====================
Moreover/RB
,/,
the/DT
steroid/NN
receptor/NN
agonist/NN
cortisol/NN
(/(
10/CD
microM/NN
)/)
,/,
but/CC
not/RB
its/PRP$
inactive/JJ
metabolite/NN
tetrahydrocortisol/NN
(/(
10/CD
microM/NN
)/)
,/,
diminished/VBD
LPS-induced/JJ
endothelial/JJ
cell/NN
adhesiveness/NN
./.
====================
Further/JJ
evidence/NN
that/IN
the/DT
action/NN
of/IN
dexamethasone/NN
was/VBD
mediated/VBN
through/IN
ligation/NN
of/IN
corticosteroid/NN
receptors/NNS
[/(
human/JJ
glucocorticoid/NN
receptors/NNS
(/(
hGRs/NNS
)/)
]/)
was/VBD
provided/VBN
by/IN
experiments/NNS
utilizing/VBG
the/DT
steroid/NN
antagonist/NN
RU-486/NN
./.
====================
RU-486/NN
(/(
10/CD
microM/NN
)/)
,/,
which/WDT
prevents/VBZ
translocation/NN
of/IN
ligated/VBN
hGR/NN
to/TO
the/DT
nucleus/NN
by/IN
inhibiting/VBG
dissociation/NN
of/IN
hGR/NN
from/IN
heat/NN
shock/NN
protein/NN
90/CD
,/,
completely/RB
aborted/VBD
the/DT
effect/NN
of/IN
dexamethasone/NN
on/IN
adhesiveness/NN
of/IN
endothelial/JJ
cells/NNS
(/(
P/NN
</JJR
0.0005/CD
,/,
n/NN
=/JJ
3/CD
)/)
./.
====================
Treatment/NN
of/IN
endothelial/JJ
cells/NNS
with/IN
LPS/NN
(/(
1/CD
microgram/ml/NN
)/)
stimulated/VBD
transcription/NN
of/IN
ELAM-1/NN
,/,
as/IN
shown/VBN
by/IN
Northern/NN
blot/NN
analysis/NN
,/,
and/CC
expression/NN
of/IN
membrane-associated/JJ
ELAM-1/NN
and/CC
ICAM-1/NN
,/,
as/IN
shown/VBN
by/IN
quantitative/JJ
immunofluorescence/NN
(/(
both/DT
P/NN
</JJR
0.001/CD
,/,
n/NN
=/JJ
9/CD
)/)
./.
====================
Dexamethasone/NN
markedly/RB
inhibited/VBD
LPS-stimulated/JJ
accumulation/NN
of/IN
mRNA/NN
for/IN
ELAM-1/NN
and/CC
expression/NN
of/IN
ELAM-1/NN
and/CC
ICAM-1/NN
(/(
IC50/NN
</JJR
10/CD
nM/NN
,/,
both/DT
P/NN
</JJR
0.001/CD
,/,
n/NN
=/JJ
4-9/CD
)/)
;/:
inhibition/NN
of/IN
expression/NN
by/IN
dexamethasone/NN
was/VBD
reversed/VBN
by/IN
RU-486/NN
(/(
both/DT
P/NN
</JJR
0.005/CD
,/,
n/NN
=/JJ
4-6/CD
)/)
./.
====================
As/IN
in/IN
the/DT
adhesion/NN
studies/NNS
,/,
cortisol/NN
but/CC
not/RB
tetrahydrocortisol/NN
inhibited/VBD
expression/NN
of/IN
ELAM-1/NN
and/CC
ICAM-1/NN
(/(
both/DT
P/NN
</JJR
0.005/CD
,/,
n/NN
=/JJ
3/CD
or/CC
4/CD
)/)
./.
====================
In/IN
contrast/NN
,/,
sodium/NN
salicylate/NN
(/(
1/CD
mM/NN
)/)
inhibited/VBD
neither/CC
adhesion/NN
nor/CC
expression/NN
of/IN
these/DT
adhesion/NN
molecules/NNS
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
antagonism/NN
by/IN
dexamethasone/NN
of/IN
endotoxin-induced/JJ
inflammation/NN
is/VBZ
a/DT
specific/JJ
instance/NN
of/IN
the/DT
general/JJ
biological/JJ
principle/NN
that/IN
the/DT
glucocorticoid/NN
receptor/NN
is/VBZ
a/DT
hormone-dependent/JJ
regulator/NN
of/IN
transcription/NN
./.
====================
UI/LS
-/:
92387536/CD
====================
TI/LS
-/:
Pax-5/NN
encodes/VBZ
the/DT
transcription/NN
factor/NN
BSAP/NN
and/CC
is/VBZ
expressed/VBN
in/IN
B/NN
lymphocytes/NNS
,/,
the/DT
developing/VBG
CNS/NNS
,/,
and/CC
adult/JJ
testis/NN
./.
====================
AB/LS
-/:
BSAP/NN
has/VBZ
been/VBN
identified/VBN
previously/RB
as/IN
a/DT
transcription/NN
factor/NN
that/WDT
is/VBZ
expressed/VBN
at/IN
early/JJ
,/,
but/CC
not/RB
late/JJ
,/,
stages/NNS
of/IN
B-cell/NN
differentiation/NN
./.
====================
Biochemical/JJ
purification/NN
and/CC
cDNA/NN
cloning/NN
has/VBZ
now/RB
revealed/VBN
that/IN
BSAP/NN
belongs/VBZ
to/TO
the/DT
family/NN
of/IN
paired/JJ
domain/NN
proteins/NNS
./.
====================
BSAP/NN
is/VBZ
encoded/VBN
by/IN
the/DT
Pax-5/NN
gene/NN
and/CC
has/VBZ
been/VBN
highly/RB
conserved/VBN
between/IN
human/JJ
and/CC
mouse/NN
./.
====================
An/DT
intact/JJ
paired/JJ
domain/NN
was/VBD
shown/VBN
to/TO
be/VB
both/CC
necessary/JJ
and/CC
sufficient/JJ
for/IN
DNA/NN
binding/NN
of/IN
BSAP/NN
./.
====================
Binding/VBG
studies/NNS
with/IN
several/JJ
BSAP/NN
recognition/NN
sequences/NNS
demonstrated/VBD
that/IN
the/DT
sequence/NN
specificity/NN
of/IN
BSAP/NN
differs/VBZ
from/IN
that/DT
of/IN
the/DT
distantly/RB
related/JJ
paired/JJ
domain/NN
protein/NN
Pax-1/NN
./.
====================
During/IN
embryogenesis/NN
,/,
the/DT
BSAP/NN
gene/NN
is/VBZ
transiently/RB
expressed/VBN
in/IN
the/DT
mesencephalon/NN
and/CC
spinal/JJ
cord/NN
with/IN
a/DT
spatial/JJ
and/CC
temporal/JJ
expression/NN
pattern/NN
that/WDT
is/VBZ
distinct/JJ
from/IN
that/DT
of/IN
other/JJ
Pax/NN
genes/NNS
in/IN
the/DT
developing/VBG
central/JJ
nervous/JJ
system/NN
(/(
CNS/NN
)/)
./.
====================
Later/RB
,/,
the/DT
expression/NN
of/IN
the/DT
BSAP/NN
gene/NN
shifts/VBZ
to/TO
the/DT
fetal/JJ
liver/NN
where/WRB
it/PRP
correlates/VBZ
with/IN
the/DT
onset/NN
of/IN
B/NN
lymphopoiesis/NN
./.
====================
BSAP/NN
expression/NN
persists/VBZ
in/IN
B/NN
lymphocytes/NNS
and/CC
is/VBZ
also/RB
seen/VBN
in/IN
the/DT
testis/NN
of/IN
the/DT
adult/JJ
mouse/NN
./.
====================
All/DT
of/IN
this/DT
evidence/NN
indicates/VBZ
that/IN
the/DT
transcription/NN
factor/NN
BSAP/NN
may/MD
not/RB
only/RB
play/VB
an/DT
important/JJ
role/NN
in/IN
B-cell/NN
differentiation/NN
but/CC
also/RB
in/IN
neural/JJ
development/NN
and/CC
spermatogenesis/NN
./.
====================
UI/LS
-/:
92335296/CD
====================
TI/LS
-/:
Cell/NN
cycle-dependent/JJ
initiation/NN
and/CC
lineage-dependent/JJ
abrogation/NN
of/IN
GATA-1/NN
expression/NN
in/IN
pure/JJ
differentiating/VBG
hematopoietic/JJ
progenitors/NNS
./.
====================
AB/LS
-/:
The/DT
programmed/VBN
activation/repression/NN
of/IN
transcription/NN
factors/NNS
in/IN
early/JJ
hematopoietic/JJ
differentiation/NN
has/VBZ
not/RB
yet/RB
been/VBN
explored/VBN
./.
====================
The/DT
DNA-binding/JJ
protein/NN
GATA-1/NN
is/VBZ
required/VBN
for/IN
normal/JJ
erythroid/JJ
development/NN
and/CC
regulates/VBZ
erythroid-expressed/JJ
genes/NNS
in/IN
maturing/VBG
erythroblasts/NNS
./.
====================
We/PRP
analyzed/VBD
GATA-1/NN
expression/NN
in/IN
early/JJ
human/JJ
adult/JJ
hematopoiesis/NN
by/IN
using/VBG
an/DT
in/FW
vitro/FW
system/NN
in/IN
which/WDT
"/``
pure/JJ
"/''
early/JJ
hematopoietic/JJ
progenitors/NNS
are/VBP
induced/VBN
to/TO
gradual/JJ
and/CC
synchronized/VBD
differentiation/NN
selectively/RB
along/IN
the/DT
erythroid/JJ
or/CC
granulocyte-macrophage/JJ
pathway/NN
by/IN
differential/JJ
treatment/NN
with/IN
hematopoietic/JJ
growth/NN
factors/NNS
./.
====================
The/DT
GATA-1/NN
gene/NN
,/,
though/IN
virtually/RB
silent/JJ
in/IN
quiescent/JJ
progenitors/NNS
,/,
is/VBZ
activated/VBN
after/IN
entrance/NN
into/IN
the/DT
cell/NN
cycle/NN
upon/IN
stimulation/NN
with/IN
hematopoietic/JJ
growth/NN
factors/NNS
./.
====================
Subsequently/RB
,/,
increasing/VBG
expression/NN
along/IN
the/DT
erythroid/JJ
pathway/NN
contrasts/VBZ
with/IN
an/DT
abrupt/JJ
downregulation/NN
in/IN
the/DT
granulocyte-macrophage/JJ
lineage/NN
./.
====================
These/DT
results/NNS
suggest/VBP
a/DT
microenvironment-directed/JJ
,/,
two-step/JJ
model/NN
for/IN
GATA-1/NN
expression/NN
in/IN
differentiating/VBG
hematopoietic/JJ
progenitors/NNS
that/WDT
involves/VBZ
(/(
i/LS
)/)
cycle-dependent/JJ
initiation/NN
and/CC
(/(
ii/LS
)/)
lineage-dependent/JJ
maintenance/NN
or/CC
suppression/NN
./.
====================
Hypothetically/RB
,/,
on/off/JJ
switches/NNS
of/IN
lineage-restricted/JJ
transactivators/NNS
may/MD
underlie/VB
the/DT
binary/JJ
fate/NN
decisions/NNS
of/IN
hematopoietic/JJ
progenitors/NNS
./.
====================
UI/LS
-/:
92260664/CD
====================
TI/LS
-/:
Specific/JJ
NF-kappa/NN
B/NN
subunits/NNS
act/VBP
in/IN
concert/NN
with/IN
Tat/NN
to/TO
stimulate/VB
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
transcription/NN
./.
====================
AB/LS
-/:
NF-kappa/NN
B/NN
is/VBZ
a/DT
protein/NN
complex/NN
which/WDT
functions/VBZ
in/IN
concert/NN
with/IN
the/DT
tat-I/NN
gene/NN
product/NN
to/TO
stimulate/VB
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
transcription/NN
./.
====================
To/TO
determine/VB
whether/IN
specific/JJ
members/NNS
of/IN
the/DT
NF-kappa/NN
B/NN
family/NN
contribute/VBP
to/TO
this/DT
effect/NN
,/,
we/PRP
have/VBP
examined/VBN
the/DT
abilities/NNS
of/IN
different/JJ
NF-kappa/NN
B/NN
subunits/NNS
to/TO
act/VB
with/IN
Tat-I/NN
to/TO
stimulate/VB
transcription/NN
of/IN
HIV/NN
in/IN
Jurkat/NN
T-leukemia/NN
cells/NNS
./.
====================
We/PRP
have/VBP
found/VBN
that/IN
the/DT
p49/NN
(/(
100/CD
)/)
DNA/NN
binding/NN
subunit/NN
,/,
together/RB
with/IN
p65/NN
,/,
can/MD
act/VB
in/IN
concert/NN
with/IN
Tat-I/NN
to/TO
stimulate/VB
the/DT
expression/NN
of/IN
HIV-CAT/NN
plasmid/NN
./.
====================
Little/JJ
effect/NN
was/VBD
observed/VBN
with/IN
50-kDa/JJ
forms/NNS
of/IN
p105/NN
NF-kappa/NN
B/NN
or/CC
rel/NN
,/,
in/IN
combination/NN
with/IN
p65/NN
or/CC
full-length/JJ
c-rel/NN
,/,
which/WDT
do/VBP
not/RB
stimulate/VB
the/DT
HIV/NN
enhancer/NN
in/IN
these/DT
cells/NNS
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
the/DT
combination/NN
of/IN
p49/NN
(/(
100/CD
)/)
and/CC
p65/NN
NF-kappa/NN
B/NN
can/MD
act/VB
in/IN
concert/NN
with/IN
the/DT
tat-I/NN
gene/NN
product/NN
to/TO
stimulate/VB
the/DT
synthesis/NN
of/IN
HIV/NN
RNA/NN
./.
====================
UI/LS
-/:
92235036/CD
====================
TI/LS
-/:
Stable/JJ
expression/NN
of/IN
HB24/NN
,/,
a/DT
diverged/JJ
human/JJ
homeobox/NN
gene/NN
,/,
in/IN
T/NN
lymphocytes/NNS
induces/VBZ
genes/NNS
involved/VBN
in/IN
T/NN
cell/NN
activation/NN
and/CC
growth/NN
./.
====================
AB/LS
-/:
A/DT
diverged/JJ
homeobox/NN
gene/NN
,/,
HB24/NN
,/,
which/WDT
is/VBZ
known/VBN
to/TO
be/VB
induced/VBN
following/VBG
lymphocyte/NN
activation/NN
,/,
was/VBD
introduced/VBN
into/IN
Jurkat/NN
T/NN
cells/NNS
under/IN
the/DT
control/NN
of/IN
a/DT
constitutive/JJ
promoter/NN
./.
====================
Stable/JJ
transfectants/NNS
of/IN
HB24/NN
were/VBD
established/VBN
that/WDT
expressed/VBD
high/JJ
levels/NNS
of/IN
HB24/NN
mRNA/NN
and/CC
possessed/VBD
an/DT
altered/JJ
phenotype/NN
suggestive/JJ
of/IN
activated/VBN
T/NN
cells/NNS
./.
====================
A/DT
number/NN
of/IN
genes/NNS
known/VBN
to/TO
be/VB
induced/VBN
following/VBG
T/NN
cell/NN
activation/NN
and/CC
associated/VBN
with/IN
cell/NN
growth/NN
were/VBD
increased/VBN
in/IN
the/DT
transfectants/NNS
,/,
including/VBG
c-fos/NN
,/,
c-myc/NN
,/,
c-myb/NN
,/,
HLA-DR/NN
,/,
lck/NN
,/,
NF-kappa/NN
B/NN
,/,
interleukin-2/NN
and/CC
interleukin-2/NN
receptor/NN
alpha/NN
(/(
IL-2R/NN
alpha/NN
)/)
./.
====================
Analysis/NN
of/IN
IL-2R/NN
alpha/NN
expression/NN
by/IN
transient/JJ
transfection/NN
of/IN
IL-2R/NN
alpha/NN
promoter/NN
constructs/NNS
into/IN
the/DT
HB24/NN
transfectants/NNS
revealed/VBD
constitutive/JJ
expression/NN
(/(
about/RB
60/CD
%/NN
of/IN
phytohemagglutinin-/NN
and/CC
phorbol/NN
ester-activated/JJ
Jurkat/NN
cells/NNS
)/)
that/WDT
was/VBD
dependent/JJ
on/IN
the/DT
kappa/NN
B/NN
site/NN
in/IN
the/DT
IL-2R/NN
alpha/NN
promoter/NN
./.
====================
Furthermore/RB
,/,
as/IN
a/DT
consequence/NN
of/IN
the/DT
increased/VBN
HB24/NN
mRNA/NN
levels/NNS
,/,
the/DT
Jurkat/NN
HB24/NN
transfectants/NNS
proliferated/VBD
more/RBR
rapidly/RB
than/IN
control/NN
cell/NN
lines/NNS
./.
====================
Thus/RB
,/,
stable/JJ
expression/NN
of/IN
HB24/NN
confers/VBZ
an/DT
activation/NN
phenotype/NN
on/IN
a/DT
human/JJ
T/NN
cell/NN
line/NN
,/,
implicating/VBG
this/DT
gene/NN
as/IN
an/DT
important/JJ
transcriptional/JJ
factor/NN
during/IN
T/NN
cell/NN
activation/NN
and/CC
growth/NN
./.
====================
UI/LS
-/:
92385366/CD
====================
TI/LS
-/:
Functional/JJ
interaction/NN
between/IN
the/DT
two/CD
zinc/NN
finger/NN
domains/NNS
of/IN
the/DT
v-erb/NN
A/NN
oncoprotein/NN
./.
====================
AB/LS
-/:
The/DT
v-erb/NN
A/NN
oncogene/NN
of/IN
avian/JJ
erythroblastosis/NN
virus/NN
is/VBZ
a/DT
mutated/VBN
and/CC
virally/RB
transduced/VBN
copy/NN
of/IN
a/DT
host/NN
cell/NN
gene/NN
encoding/VBG
a/DT
thyroid/NN
hormone/NN
receptor/NN
./.
====================
The/DT
protein/NN
expressed/VBN
by/IN
the/DT
v-erb/NN
A/NN
oncogene/NN
binds/VBZ
to/TO
DNA/NN
and/CC
acts/VBZ
as/IN
a/DT
dominant/JJ
negative/JJ
inhibitor/NN
of/IN
both/CC
the/DT
thyroid/NN
hormone/NN
receptor/NN
and/CC
the/DT
closely/RB
related/JJ
retinoic/JJ
acid/NN
receptor/NN
./.
====================
The/DT
v-erb/NN
A/NN
protein/NN
has/VBZ
sustained/VBN
two/CD
amino/NN
acid/NN
alterations/NNS
within/IN
its/PRP$
DNA-binding/JJ
domain/NN
relative/JJ
to/TO
that/DT
of/IN
c-erb/NN
A/NN
,/,
one/CD
of/IN
which/WDT
,/,
at/IN
serine/NN
61/CD
,/,
is/VBZ
known/VBN
to/TO
be/VB
important/JJ
for/IN
v-erb/NN
A/NN
function/NN
in/IN
the/DT
neoplastic/JJ
cell/NN
./.
====================
We/PRP
report/VBP
here/RB
that/IN
the/DT
second/JJ
alteration/NN
,/,
at/IN
threonine/NN
78/CD
,/,
also/RB
plays/VBZ
an/DT
important/JJ
,/,
although/IN
more/RBR
indirect/JJ
,/,
role/NN
:/:
alteration/NN
of/IN
the/DT
sequence/NN
at/IN
threonine/NN
78/CD
such/JJ
that/IN
it/PRP
resembles/VBZ
that/DT
of/IN
c-erb/NN
A/NN
can/MD
act/VB
as/IN
an/DT
intragenic/JJ
suppressor/NN
and/CC
can/MD
partially/RB
restore/VB
function/NN
to/TO
a/DT
v-erb/NN
A/NN
protein/NN
rendered/VBN
defective/JJ
due/JJ
to/TO
a/DT
mutation/NN
at/IN
position/NN
61/CD
./.
====================
Threonine/NN
78/CD
lies/VBZ
within/IN
the/DT
D-box/NN
of/IN
the/DT
v-erb/NN
A/NN
protein/NN
,/,
a/DT
region/NN
thought/VBN
to/TO
mediate/VB
receptor-receptor/JJ
dimerizations/NNS
,/,
and/CC
is/VBZ
not/RB
in/IN
physical/JJ
proximity/NN
to/TO
the/DT
serine/NN
at/IN
position/NN
61/CD
./.
====================
It/PRP
therefore/RB
appears/VBZ
that/IN
an/DT
indirect/JJ
interaction/NN
occurs/VBZ
between/IN
these/DT
two/CD
sites/NNS
and/CC
that/IN
this/DT
interaction/NN
is/VBZ
crucial/JJ
for/IN
v-erb/NN
A/NN
function/NN
./.
====================
UI/LS
-/:
92186836/CD
====================
TI/LS
-/:
cis-acting/JJ
sequences/NNS
required/VBN
for/IN
inducible/JJ
interleukin-2/NN
enhancer/NN
function/NN
bind/VBP
a/DT
novel/JJ
Ets-related/JJ
protein/NN
,/,
Elf-1/NN
./.
====================
AB/LS
-/:
The/DT
recent/JJ
definition/NN
of/IN
a/DT
consensus/NN
DNA/NN
binding/NN
sequence/NN
for/IN
the/DT
Ets/NN
family/NN
of/IN
transcription/NN
factors/NNS
has/VBZ
allowed/VBN
the/DT
identification/NN
of/IN
potential/JJ
Ets/NN
binding/NN
sites/NNS
in/IN
the/DT
promoters/NNS
and/CC
enhancers/NNS
of/IN
many/JJ
inducible/JJ
T-cell/NN
genes/NNS
./.
====================
In/IN
the/DT
studies/NNS
described/VBN
in/IN
this/DT
report/NN
,/,
we/PRP
have/VBP
identified/VBN
two/CD
potential/JJ
Ets/NNS
binding/NN
sites/NNS
,/,
EBS1/NN
and/CC
EBS2/NN
,/,
which/WDT
are/VBP
conserved/VBN
in/IN
both/CC
the/DT
human/JJ
and/CC
murine/JJ
interleukin-2/NN
enhancers/NNS
./.
====================
Within/IN
the/DT
human/JJ
enhancer/NN
,/,
these/DT
two/CD
sites/NNS
are/VBP
located/JJ
within/IN
the/DT
previously/RB
defined/VBN
DNase/NN
I/CD
footprints/NNS
,/,
NFAT-1/NN
and/CC
NFIL-2B/NN
,/,
respectively/RB
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
and/CC
methylation/NN
interference/NN
analyses/NNS
demonstrated/VBD
that/IN
EBS1/NN
and/CC
EBS2/NN
are/VBP
essential/JJ
for/IN
the/DT
formation/NN
of/IN
the/DT
NFAT-1/NN
and/CC
NFIL-2B/NN
nuclear/JJ
protein/NN
complexes/NNS
./.
====================
Furthermore/RB
,/,
in/FW
vitro/FW
mutagenesis/NN
experiments/NNS
demonstrated/VBD
that/IN
inducible/JJ
interleukin-2/NN
enhancer/NN
function/NN
requires/VBZ
the/DT
presence/NN
of/IN
either/CC
EBS1/NN
or/CC
EBS2/NN
./.
====================
Two/CD
well-characterized/JJ
Ets/NN
family/NN
members/NNS
,/,
Ets-1/NN
and/CC
Ets-2/NN
,/,
are/VBP
reciprocally/RB
expressed/VBN
during/IN
T-cell/NN
activation/NN
./.
====================
Surprisingly/RB
,/,
however/RB
,/,
neither/DT
of/IN
these/DT
proteins/NNS
bound/VBD
in/FW
vitro/FW
to/TO
EBS1/NN
or/CC
EBS2/NN
./.
====================
We/PRP
therefore/RB
screened/VBD
a/DT
T-cell/NN
cDNA/NN
library/NN
under/IN
low-stringency/NN
conditions/NNS
with/IN
a/DT
probe/NN
from/IN
the/DT
DNA/NN
binding/NN
domain/NN
of/IN
Ets-1/NN
and/CC
isolated/VBD
a/DT
novel/JJ
Ets/NN
family/NN
member/NN
,/,
Elf-1/NN
./.
====================
Elf-1/NN
contains/VBZ
a/DT
DNA/NN
binding/NN
domain/NN
that/WDT
is/VBZ
nearly/RB
identical/JJ
to/TO
that/DT
of/IN
E74/NN
,/,
the/DT
ecdysone-inducible/JJ
Drosophila/NN
transcription/NN
factor/NN
required/VBN
for/IN
metamorphosis/NN
(/(
hence/RB
the/DT
name/NN
Elf-1/NN
,/,
for/IN
E74-like/JJ
factor/NN
1/CD
)/)
./.
====================
Elf-1/NN
bound/VBD
specifically/RB
to/TO
both/CC
EBS1/NN
and/CC
EBS2/NN
in/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
./.
====================
It/PRP
also/RB
bound/VBD
to/TO
the/DT
purine-rich/JJ
CD3R/NN
element/NN
from/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
2/CD
long/JJ
terminal/JJ
repeat/NN
,/,
which/WDT
is/VBZ
required/VBN
for/IN
inducible/JJ
virus/NN
expression/NN
in/IN
response/NN
to/TO
signalling/NN
through/IN
the/DT
T-cell/NN
receptor/NN
./.
====================
Taken/VBN
together/RB
,/,
these/DT
results/NNS
demonstrate/VBP
that/IN
multiple/JJ
Ets/NN
family/NN
members/NNS
with/IN
apparently/RB
distinct/JJ
DNA/NN
binding/NN
specificities/NNS
regulate/VBP
differential/JJ
gene/NN
expression/NN
in/IN
resting/VBG
and/CC
activated/VBN
T/NN
cells/NNS
./.
====================
UI/LS
-/:
92165059/CD
====================
TI/LS
-/:
Binding/NN
of/IN
erythroid/JJ
and/CC
non-erythroid/JJ
nuclear/JJ
proteins/NNS
to/TO
the/DT
silencer/NN
of/IN
the/DT
human/JJ
epsilon-globin-encoding/JJ
gene/NN
./.
====================
AB/LS
-/:
To/TO
clarify/VB
the/DT
molecular/JJ
mechanisms/NNS
involved/VBN
in/IN
the/DT
developmental/JJ
control/NN
of/IN
hemoglobin-encoding/JJ
genes/NNS
we/PRP
have/VBP
been/VBN
studying/VBG
the/DT
expression/NN
of/IN
these/DT
genes/NNS
in/IN
human/JJ
cells/NNS
in/IN
continuous/JJ
culture/NN
./.
====================
We/PRP
have/VBP
previously/RB
reported/VBN
the/DT
presence/NN
of/IN
a/DT
transcriptional/JJ
control/NN
element/NN
with/IN
the/DT
properties/NNS
of/IN
a/DT
silencer/NN
extending/VBG
from/IN
-392/CD
to/TO
-177/CD
bp/NN
relative/JJ
to/TO
the/DT
cap/NN
site/NN
of/IN
the/DT
human/JJ
epsilon-globin-encoding/JJ
gene/NN
[/(
Cao/NNP
et/FW
al./FW
,/,
Proc.Natl.Acad.Sci.USA/NNP
86/CD
(/(
1989/CD
)/)
5306-5309/CD
]/)
./.
====================
We/PRP
also/RB
showed/VBD
that/IN
this/DT
silencer/NN
has/VBZ
stronger/JJR
inhibitory/JJ
activity/NN
in/IN
HeLa/NN
cells/NNS
,/,
as/IN
compared/VBN
to/TO
K562/NN
human/JJ
erythroleukemia/NN
cells/NNS
./.
====================
Using/VBG
deletion/NN
mutants/NNS
and/CC
cis-cloned/JJ
synthetic/JJ
oligodeoxyribonucleotides/NNS
in/IN
transient/JJ
expression/NN
assays/NNS
,/,
nucleotide/NN
sequences/NNS
responsible/JJ
for/IN
this/DT
effect/NN
have/VBP
now/RB
been/VBN
further/RBR
delimited/VBN
to/TO
44/CD
bp/NN
located/JJ
from/IN
-294/CD
to/TO
-251/CD
bp/NN
./.
====================
Gel/NN
electrophoresis/NN
mobility/NN
shift/NN
assays/NNS
and/CC
DNaseI/NN
footprinting/NN
assays/NNS
demonstrate/VBP
that/IN
these/DT
negative/JJ
regulatory/JJ
sequences/NNS
are/VBP
recognized/VBN
differently/RB
by/IN
proteins/NNS
present/JJ
in/IN
nuclear/JJ
extracts/NNS
obtained/VBN
from/IN
HeLa/NN
and/CC
K562/NN
cells/NNS
./.
====================
Two/CD
binding/VBG
proteins/NNS
are/VBP
detected/VBN
in/IN
K562/NN
nuclear/JJ
extracts/NNS
,/,
while/IN
only/RB
one/CD
is/VBZ
found/VBN
in/IN
extracts/NNS
from/IN
HeLa/NN
cells/NNS
./.
====================
Possible/JJ
mechanisms/NNS
by/IN
which/WDT
these/DT
proteins/NNS
may/MD
regulate/VB
transcription/NN
of/IN
the/DT
epsilon-globin-encoding/JJ
gene/NN
in/IN
erythroid/JJ
and/CC
non-erythroid/JJ
cells/NNS
are/VBP
discussed/VBN
./.
====================
UI/LS
-/:
93113611/CD
====================
TI/LS
-/:
Calcitriol/NN
:/:
a/DT
hematolymphopoietrope/NN
?/.
[/(
editorial/NN
]/)
====================
AB/LS
-/:
A/DT
MEDLINE/NN
search/NN
of/IN
the/DT
English-language/JJ
literature/NN
was/VBD
conducted/VBN
using/VBG
the/DT
indexing/NN
terms/NNS
'/``
immunology/NN
,/,
calcitriol/NN
and/CC
vitamin/NN
D/NN
'/''
to/TO
identify/VB
studies/NNS
indicating/VBG
a/DT
role/NN
for/IN
calcitriol/NN
as/IN
a/DT
primary/JJ
immunomodulator/NN
./.
====================
Sixty-six/CD
papers/NNS
published/VBN
between/IN
January/NNP
1956/CD
and/CC
June/NNP
1991/CD
were/VBD
identified/VBN
./.
====================
Forty-five/CD
of/IN
these/DT
reports/NNS
are/VBP
cited/VBN
in/IN
this/DT
review/NN
./.
====================
The/DT
data/NNS
strongly/RB
suggest/VBP
an/DT
endocrine/NN
,/,
autocrine/NN
and/or/CC
paracrine/NN
role/NN
for/IN
calcitriol/NN
in/IN
immune/JJ
regulation/NN
./.
====================
No/DT
unifying/JJ
hypothesis/NN
has/VBZ
yet/RB
emerged/VBN
explaining/VBG
this/DT
collection/NN
of/IN
data/NNS
./.
====================
This/DT
paper/NN
provides/VBZ
a/DT
brief/JJ
review/NN
of/IN
immune/JJ
properties/NNS
currently/RB
attributed/VBN
to/TO
calcitriol/NN
./.
====================
UI/LS
-/:
93087498/CD
====================
TI/LS
-/:
Transcription/NN
of/IN
the/DT
hypersensitive/JJ
site/NN
HS2/NN
enhancer/NN
in/IN
erythroid/JJ
cells/NNS
./.
====================
AB/LS
-/:
In/IN
the/DT
human/JJ
genome/NN
,/,
the/DT
erythroid-specific/JJ
hypersensitive/JJ
site/NN
HS2/NN
enhancer/NN
regulates/VBZ
the/DT
transcription/NN
of/IN
the/DT
downstream/JJ
beta-like/JJ
globin/NN
genes/NNS
10-50/CD
kilobases/NNS
away/RB
./.
====================
The/DT
mechanism/NN
of/IN
HS2/NN
enhancer/NN
function/NN
is/VBZ
not/RB
known/VBN
./.
====================
The/DT
present/JJ
study/NN
employs/VBZ
RNA/NN
protection/NN
assays/NNS
to/TO
analyze/VB
the/DT
transcriptional/JJ
status/NN
of/IN
the/DT
HS2/NN
enhancer/NN
in/IN
transfected/VBN
recombinant/JJ
chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
plasmids/NNS
./.
====================
In/IN
erythroid/JJ
K562/NN
cells/NNS
in/IN
which/WDT
the/DT
HS2/NN
enhancer/NN
is/VBZ
active/JJ
,/,
the/DT
HS2/NN
sequence/NN
directs/VBZ
the/DT
synthesis/NN
of/IN
long/JJ
enhancer/NN
transcripts/NNS
that/WDT
are/VBP
initiated/VBN
apparently/RB
from/IN
within/IN
the/DT
enhancer/NN
and/CC
elongated/VBN
through/IN
the/DT
intervening/VBG
DNA/NN
into/IN
the/DT
cis-linked/JJ
CAT/NN
gene/NN
./.
====================
In/IN
nonerythroid/JJ
HL-60/NN
cells/NNS
in/IN
which/WDT
the/DT
HS2/NN
enhancer/NN
is/VBZ
inactive/JJ
,/,
long/JJ
enhancer/NN
transcripts/NNS
are/VBP
not/RB
detectable/JJ
./.
====================
Splitting/VBG
the/DT
HS2/NN
enhancer/NN
between/IN
two/CD
tandem/JJ
Ap1/NN
sites/NNS
abolishes/VBZ
the/DT
synthesis/NN
of/IN
a/DT
group/NN
of/IN
long/JJ
enhancer/NN
transcripts/NNS
and/CC
results/VBZ
in/IN
loss/NN
of/IN
enhancer/NN
function/NN
and/CC
transcriptional/JJ
silencing/NN
of/IN
the/DT
cis-linked/JJ
CAT/NN
gene/NN
./.
====================
In/IN
directing/VBG
the/DT
synthesis/NN
of/IN
RNA/NN
through/IN
the/DT
intervening/VBG
DNA/NN
and/CC
the/DT
gene/NN
by/IN
a/DT
tracking/NN
and/CC
transcription/NN
mechanism/NN
,/,
the/DT
HS2/NN
enhancer/NN
may/MD
(/(
i/LS
)/)
open/VB
up/RP
the/DT
chromatin/NN
structure/NN
of/IN
a/DT
gene/NN
domain/NN
and/CC
(/(
ii/LS
)/)
deliver/VB
enhancer/NN
binding/NN
proteins/NNS
to/TO
the/DT
promoter/NN
sequence/NN
where/WRB
they/PRP
may/MD
stimulate/VB
the/DT
transcription/NN
of/IN
the/DT
gene/NN
at/IN
the/DT
cap/NN
site/NN
./.
====================
UI/LS
-/:
93065212/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
a/DT
novel/JJ
T/NN
lymphocyte/NN
protein/NN
which/WDT
binds/VBZ
to/TO
a/DT
site/NN
related/JJ
to/TO
steroid/thyroid/JJ
hormone/NN
receptor/NN
response/NN
elements/NNS
in/IN
the/DT
negative/JJ
regulatory/JJ
sequence/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
long/JJ
terminal/JJ
repeat/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
previously/RB
identified/VBN
a/DT
T/NN
lymphocyte/NN
protein/NN
which/WDT
binds/VBZ
to/TO
a/DT
site/NN
within/IN
the/DT
LTR/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
and/CC
exerts/VBZ
an/DT
inhibitory/JJ
effect/NN
on/IN
virus/NN
gene/NN
expression/NN
./.
====================
The/DT
palindromic/JJ
site/NN
(/(
site/NN
B/NN
)/)
recognized/VBN
by/IN
this/DT
protein/NN
is/VBZ
related/JJ
to/TO
the/DT
palindromic/JJ
binding/VBG
sites/NNS
of/IN
members/NNS
of/IN
the/DT
steroid/thyroid/JJ
hormone/NN
receptor/NN
family/NN
./.
====================
Here/RB
we/PRP
characterize/VBP
the/DT
T/NN
cell/NN
protein/NN
binding/VBG
to/TO
this/DT
site/NN
as/IN
a/DT
100/CD
kD/NN
protein/NN
which/WDT
is/VBZ
most/RBS
abundant/JJ
in/IN
T/NN
cells/NNS
and/CC
which/WDT
binds/VBZ
to/TO
site/NN
B/NN
as/IN
a/DT
200/CD
kD/NN
complex/NN
./.
====================
This/DT
protein/NN
is/VBZ
distinct/JJ
from/IN
other/JJ
members/NNS
of/IN
the/DT
steroid/thyroid/JJ
hormone/NN
receptor/NN
family/NN
including/VBG
the/DT
COUP/NN
protein/NN
which/WDT
has/VBZ
a/DT
closely/RB
related/JJ
DNA/NN
binding/NN
specificity/NN
./.
====================
UI/LS
-/:
92371447/CD
====================
TI/LS
-/:
TAR-independent/JJ
transactivation/NN
by/IN
Tat/NN
in/IN
cells/NNS
derived/VBN
from/IN
the/DT
CNS/NN
:/:
a/DT
novel/JJ
mechanism/NN
of/IN
HIV-1/NN
gene/NN
regulation/NN
./.
====================
AB/LS
-/:
The/DT
Tat/NN
protein/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
is/VBZ
essential/JJ
for/IN
productive/JJ
infection/NN
and/CC
is/VBZ
a/DT
potential/JJ
target/NN
for/IN
antiviral/JJ
therapy/NN
./.
====================
Tat/NN
,/,
a/DT
potent/JJ
activator/NN
of/IN
HIV-1/NN
gene/NN
expression/NN
,/,
serves/VBZ
to/TO
greatly/RB
increase/VB
the/DT
rate/NN
of/IN
transcription/NN
directed/VBN
by/IN
the/DT
viral/JJ
promoter/NN
./.
====================
This/DT
induction/NN
,/,
which/WDT
seems/VBZ
to/TO
be/VB
an/DT
important/JJ
component/NN
in/IN
the/DT
progression/NN
of/IN
acquired/VBN
immune/JJ
deficiency/NN
syndrome/NN
(/(
AIDS/NN
)/)
,/,
may/MD
be/VB
due/JJ
to/TO
increased/VBN
transcriptional/JJ
initiation/NN
,/,
increased/VBN
transcriptional/JJ
elongation/NN
,/,
or/CC
a/DT
combination/NN
of/IN
these/DT
processes/NNS
./.
====================
Much/JJ
attention/NN
has/VBZ
been/VBN
focused/VBN
on/IN
the/DT
interaction/NN
of/IN
Tat/NN
with/IN
a/DT
specific/JJ
RNA/NN
target/NN
termed/VBN
TAR/NN
(/(
transactivation/NN
responsive/NN
)/)
which/WDT
is/VBZ
present/JJ
in/IN
the/DT
leader/NN
sequence/NN
of/IN
all/DT
HIV-1/NN
mRNAs/NNS
./.
====================
This/DT
interaction/NN
is/VBZ
believed/VBN
to/TO
be/VB
an/DT
important/JJ
component/NN
of/IN
the/DT
mechanism/NN
of/IN
transactivation/NN
./.
====================
In/IN
this/DT
report/NN
we/PRP
demonstrate/VBP
that/IN
in/IN
certain/JJ
CNS-derived/JJ
cells/NNS
Tat/NN
is/VBZ
capable/JJ
of/IN
activating/VBG
HIV-1/NN
through/IN
a/DT
TAR-independent/JJ
pathway/NN
./.
====================
A/DT
Tat-responsive/JJ
element/NN
is/VBZ
found/VBN
upstream/RB
within/IN
the/DT
viral/JJ
promoter/NN
that/WDT
in/IN
glial-derived/JJ
cell/NN
lines/NNS
allows/VBZ
transactivation/NN
in/IN
the/DT
absence/NN
of/IN
TAR/NN
./.
====================
Deletion/NN
mapping/NN
and/CC
hybrid/NN
promoter/NN
constructs/NNS
demonstrate/VBP
that/IN
the/DT
newly/RB
identified/VBN
Tat-responsive/JJ
element/NN
corresponds/VBZ
to/TO
a/DT
sequence/NN
within/IN
the/DT
viral/JJ
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
previously/RB
identified/VBN
as/IN
the/DT
HIV-1/NN
enhancer/NN
,/,
or/CC
NF-kappa/NN
B/NN
domain/NN
./.
====================
DNA/NN
band-shift/JJ
analysis/NN
reveals/VBZ
NF-kappa/NN
B/NN
binding/NN
activity/NN
in/IN
glial/JJ
cells/NNS
that/WDT
differs/VBZ
from/IN
that/DT
present/JJ
in/IN
T/NN
lymphoid/JJ
cells/NNS
./.
====================
Further/RB
,/,
we/PRP
observe/VBP
that/IN
TAR-deleted/JJ
mutants/NNS
of/IN
HIV-1/NN
demonstrate/VBP
normal/JJ
late/JJ
gene/NN
expression/NN
in/IN
glial/JJ
cells/NNS
as/IN
evidenced/VBN
by/IN
syncytia/NN
formation/NN
and/CC
production/NN
of/IN
viral/JJ
p24/NN
antigen/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
92331609/CD
====================
TI/LS
-/:
Transcription/NN
factor/NN
AP-2/NN
activates/VBZ
gene/NN
expression/NN
of/IN
HTLV-I/NN
./.
====================
AB/LS
-/:
The/DT
HTLV-I/NN
LTR/NN
contains/VBZ
three/CD
conserved/VBN
regulatory/JJ
elements/NNS
known/VBN
as/IN
21/CD
base/NN
pair/NN
repeats/NNS
which/WDT
are/VBP
required/VBN
for/IN
stimulation/NN
of/IN
gene/NN
expression/NN
by/IN
the/DT
transactivator/NN
protein/NN
tax/NN
./.
====================
Mutagenesis/NN
indicates/VBZ
that/IN
the/DT
21/CD
bp/NN
repeats/NNS
can/MD
be/VB
subdivided/VBN
into/IN
three/CD
motifs/NNS
,/,
A/NN
,/,
B/NN
and/CC
C/NN
,/,
each/DT
of/IN
which/WDT
influences/VBZ
the/DT
level/NN
of/IN
tax/NN
activation/NN
./.
====================
The/DT
A/NN
site/NN
in/IN
the/DT
21/CD
bp/NN
repeat/NN
has/VBZ
strong/JJ
homology/NN
with/IN
previously/RB
described/VBN
binding/VBG
sites/NNS
for/IN
the/DT
transcription/NN
factor/NN
AP-2/NN
./.
====================
We/PRP
demonstrated/VBD
that/IN
AP-2/NN
mRNA/NN
was/VBD
present/JJ
in/IN
T-lymphocytes/NNS
and/CC
that/IN
cellular/JJ
factors/NNS
from/IN
both/CC
non-transformed/JJ
and/CC
transformed/VBN
T-lymphocytes/NNS
specifically/RB
bound/VBD
to/TO
the/DT
consensus/NN
motif/NN
for/IN
AP-2/NN
in/IN
each/DT
21/CD
bp/NN
./.
====================
To/TO
determine/VB
the/DT
role/NN
of/IN
AP-2/NN
in/IN
the/DT
regulation/NN
of/IN
the/DT
HTLV-I/NN
LTR/NN
gene/NN
expression/NN
,/,
we/PRP
used/VBD
an/DT
AP-2/NN
cDNA/NN
in/IN
DNA/NN
binding/NN
and/CC
transient/JJ
expression/NN
assays/NNS
./.
====================
Gel/NN
retardation/NN
and/CC
methylation/NN
interference/NN
studies/NNS
revealed/VBD
that/IN
bacterially/RB
produced/VBN
AP-2/NN
bound/VBD
specifically/RB
and/CC
with/IN
high/JJ
affinity/NN
to/TO
all/DT
three/CD
21/CD
bp/NN
repeats/NNS
,/,
and/CC
that/IN
it/PRP
required/VBD
the/DT
core/NN
sequence/NN
AGGC/NN
for/IN
specific/JJ
binding/NN
./.
====================
Binding/NN
of/IN
AP-2/NN
prevented/VBD
the/DT
subsequent/JJ
binding/NN
of/IN
members/NNS
of/IN
the/DT
CREB/ATF/NN
family/NN
to/TO
an/DT
adjacent/JJ
regulatory/JJ
motif/NN
in/IN
the/DT
21/CD
bp/NN
repeat/NN
./.
====================
Transfection/NN
of/IN
an/DT
AP-2/NN
expression/NN
construct/NN
into/IN
T-lymphocytes/NNS
activated/VBD
gene/NN
expression/NN
from/IN
the/DT
HTLV-I/NN
LTR/NN
./.
====================
At/IN
least/JJS
two/CD
21/CD
bp/NN
repeats/NNS
were/VBD
required/VBN
for/IN
high/JJ
levels/NNS
of/IN
AP-2/NN
activation/NN
and/CC
mutagenesis/NN
of/IN
the/DT
AP-2/NN
consensus/NN
binding/NN
sequences/NNS
in/IN
the/DT
21/CD
bp/NN
repeats/NNS
eliminate/VBP
this/DT
activation/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
92260679/CD
====================
TI/LS
-/:
Activation/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
enhancer/NN
is/VBZ
not/RB
dependent/JJ
on/IN
NFAT-1/NN
./.
====================
AB/LS
-/:
The/DT
function/NN
of/IN
a/DT
putative/JJ
NFAT-1/NN
site/NN
in/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
enhancer/NN
has/VBZ
been/VBN
analyzed/VBN
./.
====================
Activation/NN
by/IN
the/DT
T-cell/NN
antigen/NN
receptor/NN
is/VBZ
minimal/JJ
in/IN
Jurkat/NN
cells/NNS
and/CC
is/VBZ
mediated/VBN
by/IN
the/DT
kappa/NN
B/NN
sites/NNS
./.
====================
The/DT
putative/JJ
NFAT-1/NN
region/NN
is/VBZ
not/RB
required/VBN
for/IN
the/DT
response/NN
to/TO
anti-CD3/NN
or/CC
to/TO
mitogens/NNS
in/IN
T-cell/NN
,/,
B-cell/NN
,/,
or/CC
monocyte/macrophage/NN
leukemia/NN
lines/NNS
,/,
nor/CC
is/VBZ
it/PRP
a/DT
cis-acting/JJ
negative/JJ
regulatory/JJ
element/NN
./.
====================
UI/LS
-/:
92218428/CD
====================
TI/LS
-/:
The/DT
B/NN
cell-specific/JJ
nuclear/JJ
factor/NN
OTF-2/NN
positively/RB
regulates/VBZ
transcription/NN
of/IN
the/DT
human/JJ
class/NN
II/CD
transplantation/NN
gene/NN
,/,
DRA/NN
./.
====================
AB/LS
-/:
The/DT
promoter/NN
of/IN
the/DT
major/JJ
histocompatibility/NN
class/NN
II/CD
gene/NN
DRA/NN
contains/VBZ
an/DT
octamer/NN
element/NN
(/(
ATTTGCAT/NN
)/)
that/WDT
is/VBZ
required/VBN
for/IN
efficient/JJ
DRA/NN
expression/NN
in/IN
B/NN
cells/NNS
./.
====================
Several/JJ
DNA-binding/JJ
proteins/NNS
are/VBP
known/VBN
to/TO
bind/VB
this/DT
sequence/NN
./.
====================
The/DT
best/RBS
characterized/VBN
are/VBP
the/DT
B/NN
cell-specific/JJ
OTF-2/NN
and/CC
the/DT
ubiquitous/JJ
OTF-1/NN
./.
====================
This/DT
report/NN
directly/RB
demonstrates/VBZ
that/IN
OTF-2/NN
but/CC
not/RB
OTF-1/NN
regulates/VBZ
the/DT
DRA/NN
gene/NN
./.
====================
In/FW
vitro/FW
transcription/NN
analysis/NN
using/VBG
protein/NN
fractions/NNS
enriched/VBN
for/IN
the/DT
octamer-binding/JJ
protein/NN
OTF-2/NN
demonstrate/VBP
a/DT
positive/JJ
functional/JJ
role/NN
for/IN
OTF-2/NN
in/IN
DRA/NN
gene/NN
transcription/NN
./.
====================
In/IN
contrast/NN
,/,
OTF-1-enriched/JJ
protein/NN
fractions/NNS
did/VBD
not/RB
affect/VB
DRA/NN
gene/NN
transcription/NN
although/IN
it/PRP
functionally/RB
enhanced/VBD
the/DT
transcription/NN
of/IN
another/DT
gene/NN
./.
====================
Recombinant/JJ
OTF-2/NN
protein/NN
produced/VBN
by/IN
in/FW
vitro/FW
transcription/translation/NN
could/MD
also/RB
enhance/VB
DRA/NN
gene/NN
transcription/NN
in/FW
vitro/FW
./.
====================
In/FW
vivo/FW
transient/JJ
transfection/NN
studies/NNS
utilizing/VBG
an/DT
OTF-2/NN
expression/NN
vector/NN
resulted/VBD
in/IN
similar/JJ
findings/NNS
:/:
that/IN
OTF-2/NN
protein/NN
enhanced/VBD
DRA/NN
gene/NN
transcription/NN
,/,
and/CC
that/IN
this/DT
effect/NN
requires/VBZ
an/DT
intact/JJ
octamer/NN
element/NN
./.
====================
Together/RB
these/DT
results/NNS
constitute/VBP
the/DT
first/JJ
direct/JJ
evidence/NN
of/IN
a/DT
positive/JJ
role/NN
for/IN
the/DT
lymphoid-specific/JJ
octamer-binding/JJ
factor/NN
in/IN
DRA/NN
gene/NN
transcription/NN
./.
====================
UI/LS
-/:
92251244/CD
====================
TI/LS
-/:
Interferon-gamma/NN
potentiates/VBZ
the/DT
antiviral/JJ
activity/NN
and/CC
the/DT
expression/NN
of/IN
interferon-stimulated/JJ
genes/NNS
induced/VBN
by/IN
interferon-alpha/NN
in/IN
U937/NN
cells/NNS
./.
====================
AB/LS
-/:
Binding/NN
of/IN
type/NN
I/CD
interferon/NN
(/(
IFN-alpha/beta/NN
)/)
to/TO
specific/JJ
receptors/NNS
results/VBZ
in/IN
the/DT
rapid/JJ
transcriptional/JJ
activation/NN
,/,
independent/JJ
of/IN
protein/NN
synthesis/NN
,/,
of/IN
IFN-alpha-stimulated/JJ
genes/NNS
(/(
ISGs/NNS
)/)
in/IN
human/JJ
fibroblasts/NNS
and/CC
HeLa/NN
and/CC
Daudi/NN
cell/NN
lines/NNS
./.
====================
The/DT
binding/NN
of/IN
ISGF3/NN
(/(
IFN-stimulated/JJ
gene/NN
factor/NN
3/CD
)/)
to/TO
the/DT
conserved/VBN
IFN-stimulated/JJ
response/NN
element/NN
(/(
ISRE/NN
)/)
results/VBZ
in/IN
transcriptional/JJ
activation/NN
./.
====================
This/DT
factor/NN
is/VBZ
composed/VBN
of/IN
a/DT
DNA-binding/JJ
protein/NN
(/(
ISGF3/NN
gamma/NN
)/)
,/,
which/WDT
normally/RB
is/VBZ
present/JJ
in/IN
the/DT
cytoplasm/NN
,/,
and/CC
other/JJ
IFN-alpha-activated/JJ
proteins/NNS
which/WDT
preexist/VBP
as/IN
latent/JJ
cytoplasmic/JJ
precursors/NNS
(/(
ISGF3/NN
alpha/NN
)/)
./.
====================
We/PRP
have/VBP
found/VBN
that/IN
ISG/NN
expression/NN
in/IN
the/DT
monocytic/JJ
U937/NN
cell/NN
line/NN
differs/VBZ
from/IN
most/JJS
cell/NN
lines/NNS
previously/RB
examined/VBN
./.
====================
U937/NN
cells/NNS
express/VBP
both/CC
type/NN
I/CD
and/CC
type/NN
II/CD
IFN/NN
receptors/NNS
,/,
but/CC
only/RB
IFN-alpha/NN
is/VBZ
capable/JJ
of/IN
inducing/VBG
antiviral/JJ
protection/NN
in/IN
these/DT
cells/NNS
./.
====================
Pretreatment/NN
with/IN
IFN-gamma/NN
potentiates/VBZ
the/DT
IFN-alpha-induced/JJ
protection/NN
,/,
but/CC
IFN-gamma/NN
alone/RB
does/VBZ
not/RB
have/VB
any/DT
antiviral/JJ
activity/NN
./.
====================
ISG15/NN
mRNA/NN
accumulation/NN
in/IN
U937/NN
cells/NNS
is/VBZ
not/RB
detectable/JJ
before/IN
6/CD
h/NN
of/IN
IFN-alpha/NN
treatment/NN
,/,
peaks/VBZ
at/IN
24/CD
h/NN
,/,
and/CC
requires/VBZ
protein/NN
synthesis/NN
./.
====================
Although/IN
IFN-gamma/NN
alone/RB
does/VBZ
not/RB
induce/VB
ISG/NN
expression/NN
,/,
IFN-gamma/NN
pretreatment/NN
markedly/RB
increases/VBZ
and/CC
hastens/VBZ
ISG/NN
expression/NN
and/CC
transcriptional/JJ
induction/NN
./.
====================
Nuclear/JJ
extracts/NNS
assayed/VBN
for/IN
the/DT
presence/NN
of/IN
ISRE/NN
binding/NN
factors/NNS
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
show/VBP
that/IN
ISGF3/NN
is/VBZ
induced/VBN
by/IN
IFN-alpha/NN
within/IN
6/CD
h/NN
from/IN
undetectable/JJ
basal/JJ
levels/NNS
in/IN
untreated/JJ
U937/NN
cells/NNS
./.
====================
Activation/NN
of/IN
ISGF3/NN
alpha/NN
,/,
the/DT
latent/JJ
component/NN
of/IN
ISGF3/NN
,/,
occurs/VBZ
rapidly/RB
./.
====================
However/RB
,/,
the/DT
increase/NN
in/IN
ISGF3/NN
activity/NN
ultimately/RB
correlates/VBZ
with/IN
the/DT
accumulation/NN
of/IN
ISGF3/NN
gamma/NN
induced/VBN
by/IN
IFN-alpha/NN
or/CC
IFN-gamma/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
93043110/CD
====================
TI/LS
-/:
Single/JJ
point/NN
estimation/NN
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
lymphocytes/NNS
of/IN
normal/JJ
subjects/NNS
and/CC
of/IN
children/NNS
under/IN
long/JJ
term/NN
glucocorticoid/NN
treatment/NN
./.
====================
AB/LS
-/:
A/DT
single/JJ
point/NN
assay/NN
of/IN
glucocorticoid/NN
receptors/NNS
(/(
GR/NN
)/)
in/IN
human/JJ
lymphocytes/NNS
based/VBN
on/IN
the/DT
measurement/NN
of/IN
specific/JJ
dexamethasone/NN
binding/NN
has/VBZ
been/VBN
developed/VBN
and/CC
compared/VBN
with/IN
a/DT
common/JJ
multi-point/JJ
Scatchard/NN
analysis/NN
./.
====================
The/DT
assay/NN
conditions-concentration/NN
of/IN
the/DT
ligand/NN
20/CD
nmol/l/NN
,/,
incubation/NN
time/NN
2/CD
h/NN
and/CC
the/DT
cell/NN
count/NN
2-6/CD
mil./CD
====================
cells/tube/NNS
in/IN
the/DT
assay/NN
volume/NN
0.25/CD
ml/NN
were/VBD
found/VBN
to/TO
be/VB
optimal/JJ
./.
====================
An/DT
attempt/NN
was/VBD
also/RB
undertaken/VBN
to/TO
use/VB
a/DT
cell/NN
harvester/NN
for/IN
the/DT
separation/NN
of/IN
cells/NNS
from/IN
unbound/JJ
ligand/NN
./.
====================
Though/IN
specifically/RB
bound/VBN
dexamethasone/NN
measured/VBN
by/IN
whole-cell/JJ
assay/NN
and/CC
that/DT
using/VBG
cell/NN
harvester/NN
correlated/VBD
well/RB
,/,
almost/RB
by/IN
one/CD
order/NN
lower/JJR
values/NNS
obtained/VBN
with/IN
the/DT
latter/JJ
method/NN
render/VBP
it/PRP
non-applicable/JJ
for/IN
receptor/NN
quantitation/NN
./.
====================
The/DT
results/NNS
from/IN
9/CD
healthy/JJ
volunteers/NNS
(/(
average/JJ
GR/NN
concentration/NN
7131/CD
+/-/CC
1256/CD
sites/cell/NNS
)/)
correlated/VBD
excellently/RB
with/IN
those/DT
obtained/VBN
by/IN
the/DT
Scatchard/NN
analysis/NN
./.
====================
The/DT
single/JJ
point/NN
assay/NN
has/VBZ
been/VBN
also/RB
applied/VBN
for/IN
determination/NN
of/IN
GH/NN
in/IN
10/CD
children/NNS
treated/VBN
with/IN
large/JJ
doses/NNS
of/IN
prednisone/NN
./.
====================
The/DT
average/JJ
values/NNS
from/IN
healthy/JJ
volunteers/NNS
did/VBD
not/RB
differ/VB
significantly/RB
from/IN
those/DT
found/VBN
in/IN
these/DT
children/NNS
,/,
though/RB
much/RB
broader/JJR
range/NN
was/VBD
found/VBN
in/IN
patients/NNS
./.
====================
UI/LS
-/:
92142646/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptor/NN
and/CC
inhibition/NN
of/IN
3-O-methyl-D-glucose/NN
uptake/NN
by/IN
glucocorticoids/NNS
in/IN
peripheral/JJ
blood/NN
leukocytes/NNS
from/IN
normal/JJ
humans/NNS
:/:
correlation/NN
between/IN
receptor/NN
level/NN
and/CC
hormone/NN
effect/NN
in/FW
vitro/FW
./.
====================
AB/LS
-/:
We/PRP
have/VBP
measured/VBN
the/DT
glucocorticoid/NN
receptor/NN
concentration/NN
in/IN
mononuclear/JJ
and/CC
polymorphonuclear/JJ
leukocytes/NNS
,/,
both/DT
of/IN
which/WDT
were/VBD
isolated/VBN
from/IN
peripheral/JJ
blood/NN
from/IN
ten/CD
healthy/JJ
male/JJ
volunteers/NNS
./.
====================
In/IN
parallel/NN
,/,
the/DT
inhibitory/JJ
effect/NN
of/IN
dexamethasone/NN
on/IN
3-O-methyl-D-glucose/NN
uptake/NN
was/VBD
assayed/VBN
in/IN
the/DT
corresponding/JJ
mononuclear/JJ
leukocytes/NNS
./.
====================
The/DT
glucocorticoid/NN
receptor/NN
levels/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
correlated/VBD
with/IN
those/DT
in/IN
polymorphonuclear/JJ
leukocytes/NNS
,/,
and/CC
there/EX
was/VBD
a/DT
linear/JJ
relationship/NN
between/IN
the/DT
cellular/JJ
glucocorticoid/NN
receptor/NN
levels/NNS
and/CC
glucocorticoid-mediated/JJ
inhibition/NN
of/IN
the/DT
uptake/NN
of/IN
3-O-methyl-D-glucose/NN
in/IN
mononuclear/JJ
leukocytes/NNS
./.
====================
When/WRB
mononuclear/JJ
leukocytes/NNS
were/VBD
incubated/VBN
in/IN
the/DT
presence/NN
of/IN
8-bromo-cAMP/NN
,/,
cellular/JJ
glucocorticoid/NN
receptor/NN
levels/NNS
increased/VBD
and/CC
a/DT
more/RBR
pronounced/JJ
inhibitory/JJ
effect/NN
of/IN
dexamethasone/NN
was/VBD
observed/VBN
on/IN
the/DT
transport/NN
of/IN
3-O-methyl-D-glucose/NN
./.
====================
We/PRP
conclude/VBP
that/IN
the/DT
cellular/JJ
glucocorticoid/NN
receptor/NN
levels/NNS
in/IN
peripheral/JJ
blood/NN
leukocytes/NNS
reflect/VBP
in/FW
vitro/FW
responsiveness/NN
to/TO
glucocorticoids/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
from/IN
healthy/JJ
males/NNS
,/,
and/CC
that/IN
the/DT
individual/JJ
responsiveness/NN
may/MD
alter/VB
upon/IN
changes/NNS
in/IN
the/DT
cellular/JJ
levels/NNS
of/IN
glucocorticoid/NN
receptor/NN
./.
====================
UI/LS
-/:
92224250/CD
====================
TI/LS
-/:
Transcription/NN
factor/NN
activation/NN
and/CC
functional/JJ
stimulation/NN
of/IN
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
Activation/NN
of/IN
expression/NN
of/IN
genes/NNS
encoding/VBG
transcription/NN
factors/NNS
:/:
c-fos/NN
and/CC
c-jun/NN
and/CC
formation/NN
of/IN
AP1/NN
transcriptional/JJ
complex/NN
in/IN
human/JJ
monocytes/NNS
was/VBD
investigated/VBN
./.
====================
It/PRP
was/VBD
found/VBN
that/IN
lipopolysaccharide/NN
induced/VBD
strongly/RB
both/CC
c-fos/NN
and/CC
c-jun/NN
expression/NN
as/RB
well/RB
as/IN
AP1/NN
formation/NN
./.
====================
Interferon/NN
gamma/NN
activated/VBD
strongly/RB
c-fos/NN
and/CC
weakly/RB
c-jun/NN
and/CC
AP1/NN
./.
====================
Tumor/NN
necrosis/NN
factor/NN
induced/VBD
slightly/RB
c-fos/NN
and/CC
had/VBD
almost/RB
no/DT
effect/NN
on/IN
c-jun/NN
and/CC
AP1/NN
./.
====================
The/DT
data/NNS
suggest/VBP
that/IN
differences/NNS
in/IN
functional/JJ
responses/NNS
elicited/VBN
in/IN
monocytes/NNS
by/IN
all/DT
three/CD
factors/NNS
may/MD
be/VB
dependent/JJ
on/IN
different/JJ
routes/NNS
on/IN
nuclear/JJ
signalling/NN
employed/VBN
by/IN
the/DT
factors/NNS
./.
====================
UI/LS
-/:
92062170/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
interleukin-1/NN
beta/NN
production/NN
by/IN
glucocorticoids/NNS
in/IN
human/JJ
monocytes/NNS
:/:
the/DT
mechanism/NN
of/IN
action/NN
depends/VBZ
on/IN
the/DT
activation/NN
signal/NN
./.
====================
AB/LS
-/:
Glucocorticoids/NNS
are/VBP
known/VBN
to/TO
downregulate/VB
interleukin-1/NN
beta/NN
production/NN
in/IN
monocytic/JJ
cells/NNS
by/IN
two/CD
different/JJ
mechanims/NNS
:/:
direct/JJ
inhibition/NN
of/IN
the/DT
gene/NN
transcription/NN
and/CC
destabilization/NN
of/IN
the/DT
preformed/JJ
interleukin-1/NN
beta/NN
mRNA/NN
./.
====================
Now/RB
we/PRP
have/VBP
examined/VBN
the/DT
effect/NN
of/IN
the/DT
nature/NN
of/IN
the/DT
monocyte/NN
activating/NN
signal/NN
on/IN
these/DT
two/CD
inhibitory/JJ
mechanims/NNS
./.
====================
When/WRB
human/JJ
monocytes/NNS
were/VBD
preincubated/VBN
with/IN
dexamethasone/NN
for/IN
1/CD
hour/NN
and/CC
then/RB
stimulated/VBN
either/CC
with/IN
bacterial/JJ
lipopolysaccharide/NN
or/CC
phorbol/NN
myristate/NN
,/,
it/PRP
was/VBD
found/VBN
that/IN
dexamethasone/NN
inhibited/VBD
the/DT
lipopolysaccharide-induced/JJ
interleukin-1/NN
beta/NN
protein/NN
production/NN
,/,
but/CC
the/DT
phorbol/NN
myristate-induced/JJ
production/NN
was/VBD
increased/VBN
3-10/CD
fold/RB
./.
====================
This/DT
difference/NN
was/VBD
also/RB
seen/VBN
at/IN
the/DT
mRNA/NN
level/NN
./.
====================
When/WRB
dexamethasone/NN
was/VBD
added/VBN
to/TO
the/DT
cultures/NNS
3/CD
hours/NNS
after/IN
the/DT
stimulators/NNS
,/,
it/PRP
clearly/RB
decreased/VBD
the/DT
interleukin-1/NN
beta/NN
mRNA/NN
levels/NNS
regardless/RB
of/IN
the/DT
stimulator/NN
used/VBN
(/(
although/IN
the/DT
effect/NN
was/VBD
clearly/RB
weaker/JJR
on/IN
the/DT
PMA-induced/JJ
mRNA/NN
)/)
./.
====================
Thus/RB
these/DT
data/NNS
suggest/VBP
that/IN
the/DT
phorbol/NN
myristate-induced/JJ
signal/NN
(/(
prolonged/JJ
protein/NN
kinase/NN
C/NN
activation/NN
?/.
)/)
can/MD
not/RB
be/VB
inhibited/VBN
by/IN
prior/JJ
incubation/NN
with/IN
dexamethasone/NN
and/CC
it/PRP
also/RB
protects/VBZ
the/DT
induced/VBN
mRNA/NN
for/IN
the/DT
degradative/JJ
action/NN
of/IN
dexamethasone/NN
./.
====================
UI/LS
-/:
92013087/CD
====================
TI/LS
-/:
Nuclear/JJ
transcription/NN
factors/NNS
that/WDT
bind/VBP
to/TO
elements/NNS
of/IN
the/DT
IL-2/NN
promoter/NN
./.
====================
Induction/NN
requirements/NNS
in/IN
primary/JJ
human/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Prior/JJ
studies/NNS
have/VBP
identified/VBN
several/JJ
elements/NNS
that/WDT
contribute/VBP
to/TO
the/DT
activity/NN
of/IN
the/DT
IL-2/NN
promoter/NN
in/IN
the/DT
stimulated/VBN
T/NN
cell/NN
line/NN
,/,
Jurkat/NN
./.
====================
The/DT
sites/NNS
and/CC
their/PRP$
corresponding/JJ
nuclear/JJ
binding/VBG
factors/NNS
include/VBP
:/:
NF-kappa/NN
B/NN
,/,
AP-1/NN
,/,
AP-3/NN
,/,
OCT-1/NN
,/,
and/CC
NF-AT/NN
./.
====================
The/DT
latter/JJ
"/``
nuclear/JJ
factor/NN
for/IN
activated/VBN
T/NN
cells/NNS
"/''
likely/RB
contributes/VBZ
to/TO
the/DT
tissue/NN
specificity/NN
of/IN
IL-2/NN
gene/NN
expression/NN
./.
====================
Using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
,/,
we/PRP
have/VBP
studied/VBN
these/DT
transcription/NN
factors/NNS
in/IN
primary/JJ
T/NN
cells/NNS
from/IN
human/JJ
blood/NN
to/TO
verify/VB
their/PRP$
presence/NN
in/IN
a/DT
physiologic/JJ
setting/NN
and/CC
to/TO
identify/VB
the/DT
signals/NNS
that/WDT
stimulate/VBP
factor/NN
activity/NN
./.
====================
All/DT
factors/NNS
are/VBP
induced/VBN
in/IN
the/DT
nuclei/NNS
of/IN
T/NN
cells/NNS
upon/IN
activation/NN
with/IN
mitogens/NNS
but/CC
not/RB
with/IN
exogenous/JJ
IL-2/NN
growth/NN
factor/NN
./.
====================
However/RB
,/,
the/DT
signaling/NN
requirements/NNS
and/CC
sensitivity/NN
to/TO
protein/NN
synthesis/NN
inhibitors/NNS
differ/VBP
considerably/RB
./.
====================
Only/RB
the/DT
activities/NNS
for/IN
NF-AT/NN
and/CC
AP-1/NN
sites/NNS
require/VBP
two/CD
signals/NNS
for/IN
optimal/JJ
induction/NN
,/,
i.e./FW
,/,
PMA/NN
plus/CC
either/CC
lectin/NN
or/CC
antibody/NN
to/TO
the/DT
CD3/NN
or/CC
CD28/NN
surface/NN
molecules/NNS
./.
====================
Other/JJ
factors/NNS
are/VBP
induced/VBN
by/IN
lectin/NN
,/,
antibody/NN
,/,
and/or/CC
PMA/NN
alone/RB
./.
====================
After/IN
appropriate/JJ
stimulation/NN
,/,
both/CC
NF-AT/NN
and/CC
AP-1/NN
are/VBP
peculiarly/RB
sensitive/JJ
to/TO
the/DT
protein/NN
synthesis/NN
inhibitor/NN
anisomycin/NN
./.
====================
Our/PRP$
data/NNS
correlate/VBP
the/DT
activity/NN
of/IN
NF-AT/NN
and/CC
AP-1/NN
in/IN
gel/NN
shift/NN
assays/NNS
with/IN
the/DT
two/CD
signals/NNS
requirements/NNS
for/IN
IL-2/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
91361546/CD
====================
TI/LS
-/:
NF-kappa/NN
B/NN
activity/NN
in/IN
T/NN
cells/NNS
stably/RB
expressing/VBG
the/DT
Tax/NN
protein/NN
of/IN
human/JJ
T/NN
cell/NN
lymphotropic/JJ
virus/NN
type/NN
I/CD
./.
====================
AB/LS
-/:
The/DT
effect/NN
of/IN
constitutive/JJ
Tax/NN
expression/NN
on/IN
the/DT
interaction/NN
of/IN
NF-kappa/NN
B/NN
with/IN
its/PRP$
recognition/NN
sequence/NN
and/CC
on/IN
NF-kappa/NN
B-dependent/JJ
gene/NN
expression/NN
was/VBD
examined/VBN
in/IN
T/NN
lymphoid/JJ
Jurkat/NN
cell/NN
lines/NNS
(/(
19D/NN
and/CC
9J/NN
)/)
stably/RB
transformed/VBN
with/IN
a/DT
Tax/NN
expression/NN
vector/NN
./.
====================
Tax/NN
expressing/NN
T/NN
cell/NN
lines/NNS
contained/VBD
a/DT
constitutive/JJ
level/NN
of/IN
NF-kappa/NN
B/NN
binding/NN
activity/NN
,/,
detectable/JJ
by/IN
mobility/NN
shift/NN
assay/NN
and/CC
uv/NN
cross-linking/NN
using/VBG
a/DT
palindromic/JJ
NF-kappa/NN
B/NN
probe/NN
homologous/JJ
to/TO
the/DT
interferon/NN
beta/NN
PRDII/NN
site/NN
./.
====================
In/IN
Jurkat/NN
and/CC
NC2.10/NN
induction/NN
with/IN
phorbol/NN
esters/NNS
resulted/VBD
in/IN
the/DT
appearance/NN
of/IN
new/JJ
DNA/NN
binding/NN
proteins/NNS
of/IN
85/CD
,/,
75/CD
,/,
and/CC
54/CD
kDa/NN
,/,
whereas/IN
in/IN
Tax/NN
expressing/NN
cells/NNS
the/DT
85-kDa/JJ
protein/NN
and/CC
a/DT
92-kDa/JJ
DNA/NN
binding/NN
protein/NN
were/VBD
constitutively/RB
induced/VBN
./.
====================
Expression/NN
of/IN
Tax/NN
protein/NN
in/IN
19D/NN
and/CC
9J/NN
resulted/VBD
in/IN
transcription/NN
of/IN
the/DT
endogenous/JJ
NF-kappa/NN
B-dependent/JJ
granulocyte-macrophage/JJ
colony/NN
stimulating/NN
factor/NN
gene/NN
and/CC
increased/VBD
basal/JJ
level/NN
expression/NN
of/IN
transfected/VBN
NF-kappa/NN
B-regulated/JJ
promoters/NNS
./.
====================
Nonetheless/RB
transcription/NN
of/IN
both/CC
the/DT
endogenous/JJ
and/CC
the/DT
transfected/VBN
gene/NN
was/VBD
inducible/JJ
by/IN
PMA/NN
treatment/NN
./.
====================
Tax/NN
expression/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
may/MD
alter/VB
the/DT
stoichiometry/NN
of/IN
NF-kappa/NN
B/NN
DNA/NN
binding/NN
proteins/NNS
and/CC
thus/RB
change/VB
the/DT
expression/NN
of/IN
NF-kappa/NN
B-regulated/JJ
promoters/NNS
./.
====================
UI/LS
-/:
92001749/CD
====================
TI/LS
-/:
A/DT
nuclear/JJ
factor/NN
NF-GM2/NN
that/WDT
interacts/VBZ
with/IN
a/DT
regulatory/JJ
region/NN
of/IN
the/DT
GM-CSF/NN
gene/NN
essential/JJ
for/IN
its/PRP$
induction/NN
in/IN
responses/NNS
to/TO
T-cell/NN
activation/NN
:/:
purification/NN
from/IN
human/JJ
T-cell/NN
leukemia/NN
line/NN
Jurkat/NN
cells/NNS
and/CC
similarity/NN
to/TO
NF-kappa/NN
B/NN
./.
====================
AB/LS
-/:
Activation/NN
of/IN
T/NN
cells/NNS
by/IN
antigen/NN
,/,
lectin/NN
,/,
or/CC
a/DT
combination/NN
of/IN
phorbol-12-myristate/NN
acetate/NN
(/(
PMA/NN
)/)
and/CC
calcium/NN
ionophore/NN
(/(
A23187/NN
)/)
leads/VBZ
to/TO
the/DT
induction/NN
of/IN
genes/NNS
for/IN
a/DT
set/NN
of/IN
lymphokines/NNS
,/,
including/VBG
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
./.
====================
We/PRP
demonstrated/VBD
in/IN
earlier/JJR
studies/NNS
that/IN
the/DT
upstream/JJ
region/NN
of/IN
the/DT
mouse/NN
GM-CSF/NN
promoter/NN
at/IN
positions/NNS
between/IN
-95/CD
and/CC
-73/CD
is/VBZ
essential/JJ
for/IN
transcriptional/JJ
activation/NN
in/IN
response/NN
to/TO
PMA/A23187/NN
./.
====================
This/DT
region/NN
contains/VBZ
two/CD
DNA-binding/JJ
motifs/NNS
,/,
GM2/NN
and/CC
GC-box/NN
./.
====================
The/DT
GM2/NN
sequence/NN
(/(
GGTAGTTCCC/NN
)/)
is/VBZ
recognized/VBN
by/IN
an/DT
inducible/JJ
factor/NN
NF-GM2/NN
;/:
the/DT
other/JJ
(/(
CCGCCC/NN
)/)
by/IN
constitutive/JJ
factors/NNS
A1/NN
,/,
A2/NN
,/,
and/CC
B/NN
./.
====================
To/TO
elucidate/VB
the/DT
mechanism/NN
of/IN
GM-CSF/NN
gene/NN
activation/NN
,/,
we/PRP
have/VBP
purified/VBN
the/DT
inducible/JJ
factor/NN
NF-GM2/NN
from/IN
the/DT
nuclear/JJ
extract/NN
of/IN
stimulated/VBN
Jurkat/NN
cells/NNS
on/IN
the/DT
basis/NN
of/IN
specific/JJ
DNA-binding/JJ
activity/NN
./.
====================
The/DT
purified/VBN
NF-GM2/NN
consists/VBZ
of/IN
50/CD
(/(
p50/NN
)/)
and/CC
65/CD
kDa/NN
(/(
p65/NN
)/)
polypeptides/NNS
and/CC
has/VBZ
a/DT
binding/NN
activity/NN
specific/JJ
for/IN
both/CC
the/DT
GM-CSF/NN
and/CC
immunoglobulin/NN
kappa/NN
(/(
GGAAAGTCCC/NN
)/)
enhancers/NNS
./.
====================
Electrophoretically/RB
purified/VBN
p50/NN
alone/RB
can/MD
form/VB
a/DT
protein-DNA/JJ
complex/NN
,/,
but/CC
in/IN
the/DT
mixture/NN
,/,
p50/NN
associates/VBZ
preferentially/RB
with/IN
p65/NN
to/TO
form/VB
the/DT
NF-GM2/NN
complex/NN
./.
====================
In/IN
addition/NN
,/,
p65/NN
gave/VBD
per/FW
se/FW
,/,
with/IN
low/JJ
affinity/NN
,/,
a/DT
protein-DNA/JJ
complex/NN
that/WDT
migrated/VBD
more/RBR
slowly/RB
than/IN
native/JJ
NF-GM2/NN
complex/NN
./.
====================
Furthermore/RB
,/,
an/DT
antiserum/NN
against/IN
KBF1/NN
(/(
identical/JJ
to/TO
50/CD
kDa/NN
NF-kappa/NN
B/NN
protein/NN
)/)
reacted/VBD
with/IN
the/DT
p50/NN
of/IN
NF-GM2/NN
,/,
indicating/VBG
that/IN
the/DT
NF-GM2/NN
polypeptide/NN
can/MD
not/RB
be/VB
immunologically/RB
differentiated/VBN
from/IN
the/DT
50/CD
kDa/NN
subunit/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
The/DT
purified/VBN
NF-GM2/NN
activated/VBD
in/FW
vitro/FW
transcription/NN
from/IN
the/DT
kappa/NN
B/NN
enhancer/NN
,/,
while/IN
it/PRP
failed/VBD
to/TO
stimulate/VB
transcription/NN
from/IN
the/DT
GM-CSF/NN
promoter/NN
harboring/VBG
the/DT
GM2/NN
sequence/NN
./.
====================
This/DT
suggests/VBZ
that/IN
the/DT
activation/NN
mechanism/NN
of/IN
the/DT
GM-CSF/NN
gene/NN
through/IN
the/DT
GM2/GC-box/JJ|NN
sequence/NN
is/VBZ
different/JJ
from/IN
that/DT
of/IN
genes/NNS
carrying/VBG
the/DT
kappa/NN
B/NN
enhancer/NN
alone/RB
./.
====================
UI/LS
-/:
91292530/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
an/DT
immediate-early/JJ
gene/NN
induced/VBN
in/IN
adherent/JJ
monocytes/NNS
that/WDT
encodes/VBZ
I/NN
kappa/NN
B-like/JJ
activity/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
cloned/VBN
a/DT
group/NN
of/IN
cDNAs/NNS
representing/VBG
mRNAs/NNS
that/WDT
are/VBP
rapidly/RB
induced/VBN
following/VBG
adherence/NN
of/IN
human/JJ
monocytes/NNS
./.
====================
One/CD
of/IN
the/DT
induced/VBN
transcripts/NNS
(/(
MAD-3/NN
)/)
encodes/VBZ
a/DT
protein/NN
of/IN
317/CD
amino/NN
acids/NNS
with/IN
one/CD
domain/NN
containing/VBG
five/CD
tandem/JJ
repeats/NNS
of/IN
the/DT
cdc10/ankyrin/JJ
motif/NN
,/,
which/WDT
is/VBZ
60/CD
%/NN
similar/JJ
(/(
46/CD
%/NN
identical/JJ
)/)
to/TO
the/DT
ankyrin/NN
repeat/NN
region/NN
of/IN
the/DT
precursor/NN
of/IN
NF-kappa/NN
B/KBF1/NN
p50/NN
./.
====================
The/DT
C-terminus/NN
has/VBZ
a/DT
putative/JJ
protein/NN
kinase/NN
C/NN
phosphorylation/NN
site/NN
./.
====================
In/FW
vitro/FW
translated/VBN
MAD-3/NN
protein/NN
was/VBD
found/VBN
to/TO
specifically/RB
inhibit/VB
the/DT
DNA-binding/JJ
activity/NN
of/IN
the/DT
p50/p65/NN
NF-kappa/NN
B/NN
complex/NN
but/CC
not/RB
that/DT
of/IN
the/DT
p50/p50/NN
KBF1/NN
factor/NN
or/CC
of/IN
other/JJ
DNA-binding/JJ
proteins/NNS
./.
====================
The/DT
MAD-3/NN
cDNA/NN
encodes/VBZ
an/DT
I/NN
kappa/NN
B-like/JJ
protein/NN
that/WDT
is/VBZ
likely/JJ
to/TO
be/VB
involved/VBN
in/IN
regulation/NN
of/IN
transcriptional/JJ
responses/NNS
to/TO
NF-kappa/NN
B/NN
,/,
including/VBG
adhesion-dependent/JJ
pathways/NNS
of/IN
monocyte/NN
activation/NN
./.
====================
UI/LS
-/:
91248763/CD
====================
TI/LS
-/:
Cortivazol/NN
mediated/VBD
induction/NN
of/IN
glucocorticoid/NN
receptor/NN
messenger/NN
ribonucleic/JJ
acid/NN
in/IN
wild-type/JJ
and/CC
dexamethasone-resistant/JJ
human/JJ
leukemic/NN
(/(
CEM/NN
)/)
cells/NNS
./.
====================
AB/LS
-/:
Cortivazol/NN
is/VBZ
a/DT
phenylpyrazolo/JJ
glucocorticoid/NN
of/IN
high/JJ
potency/NN
and/CC
unusual/JJ
structure/NN
./.
====================
In/IN
both/CC
wild-type/JJ
and/CC
highly/RB
dexamethasone/NN
(/(
dex/NN
)/)
-resistant/JJ
clones/NNS
of/IN
the/DT
human/JJ
leukemic/JJ
cell/NN
line/NN
CEM/NN
,/,
exposure/NN
to/TO
cortivazol/NN
leads/VBZ
to/TO
cell/NN
death/NN
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
recently/RB
that/IN
in/IN
wild-type/JJ
CEM/NN
cells/NNS
but/CC
not/RB
in/IN
a/DT
dex-resistant/JJ
,/,
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
-defective/JJ
clone/NN
ICR-27/NN
TK-3/NN
,/,
dex/NN
induces/VBZ
GR/NN
mRNA/NN
./.
====================
To/TO
test/VB
the/DT
hypothesis/NN
that/IN
cortivazol/NN
acts/VBZ
in/IN
dex-resistant/JJ
cells/NNS
by/IN
making/VBG
use/NN
of/IN
the/DT
residual/JJ
GR/NN
found/VBN
there/RB
,/,
wild-type/JJ
and/CC
dex-resistant/JJ
clones/NNS
were/VBD
treated/VBN
with/IN
various/JJ
concentrations/NNS
of/IN
cortivazol/NN
and/CC
induction/NN
of/IN
GR/NN
mRNA/NN
was/VBD
studied/VBN
./.
====================
Cortivazol/NN
significantly/RB
induced/VBD
GR/NN
mRNA/NN
in/IN
the/DT
normal/JJ
CEM-C7/NN
as/RB
well/RB
as/IN
in/IN
two/CD
classes/NNS
of/IN
dex-resistant/JJ
clones/NNS
,/,
although/IN
the/DT
dex-resistant/JJ
clones/NNS
needed/VBD
at/IN
least/JJS
10/CD
times/NNS
more/JJR
cortivazol/NN
than/IN
the/DT
normal/JJ
cells/NNS
for/IN
significant/JJ
GR/NN
mRNA/NN
induction/NN
./.
====================
Increased/VBN
levels/NNS
of/IN
GR/NN
mRNA/NN
were/VBD
noticed/VBN
as/RB
early/RB
as/IN
3/CD
h/NN
after/IN
treatment/NN
./.
====================
A/DT
general/JJ
correlation/NN
between/IN
induction/NN
of/IN
GR/NN
mRNA/NN
and/CC
lysis/NN
of/IN
the/DT
normal/JJ
and/CC
dex-resistant/JJ
cells/NNS
was/VBD
found/VBN
./.
====================
Positive/JJ
induction/NN
of/IN
GR/NN
mRNA/NN
might/MD
be/VB
one/CD
of/IN
the/DT
earliest/JJS
crucial/JJ
steps/NNS
in/IN
the/DT
lysis/NN
of/IN
normal/JJ
and/CC
dex-resistant/JJ
CEM/NN
cells/NNS
,/,
or/CC
might/MD
serve/VB
as/IN
a/DT
marker/NN
for/IN
the/DT
process/NN
./.
====================
However/RB
,/,
the/DT
lysis/NN
pathway/NN
in/IN
the/DT
dex-resistant/JJ
cells/NNS
is/VBZ
defective/JJ
in/IN
that/IN
dex-resistant/JJ
clones/NNS
needed/VBD
significantly/RB
more/JJR
cortivazol/NN
than/IN
the/DT
normal/JJ
cells/NNS
for/IN
lysis/NN
of/IN
the/DT
cells/NNS
./.
====================
UI/LS
-/:
91218850/CD
====================
TI/LS
-/:
HIV/NN
enhancer/NN
activity/NN
perpetuated/VBN
by/IN
NF-kappa/NN
B/NN
induction/NN
on/IN
infection/NN
of/IN
monocytes/NNS
[/(
see/VB
comments/NNS
]/)
====================
AB/LS
-/:
Permissiveness/NN
to/TO
replication/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
differs/VBZ
in/IN
T/NN
lymphocytes/NNS
and/CC
macrophages/NNS
./.
====================
In/IN
T/NN
cells/NNS
,/,
HIV/NN
transcription/NN
is/VBZ
poorly/RB
detected/VBN
in/FW
vivo/FW
./.
====================
Cloned/VBN
,/,
normal/JJ
T/NN
lymphocytes/NNS
show/VBP
very/RB
little/JJ
,/,
if/IN
any/DT
,/,
basal/JJ
activity/NN
of/IN
the/DT
HIV/NN
enhancer/NN
and/CC
low/JJ
nuclear/JJ
expression/NN
of/IN
NF-kappa/NN
B/NN
,/,
a/DT
potent/JJ
transcriptional/JJ
activator/NN
of/IN
the/DT
HIV/NN
enhancer/NN
./.
====================
In/IN
contrast/NN
,/,
fixed/JJ
tissue/NN
macrophages/NNS
express/VBP
detectable/JJ
HIV/NN
proteins/NNS
,/,
indicating/VBG
permanent/JJ
virus/NN
transcription/NN
./.
====================
One/CD
explanation/NN
for/IN
the/DT
perpetuation/NN
of/IN
virus/NN
infection/NN
in/IN
macrophages/NNS
could/MD
be/VB
sustained/JJ
nuclear/JJ
NF-kappa/NN
B/NN
expression/NN
./.
====================
However/RB
,/,
the/DT
U937/NN
monocytic/JJ
cell/NN
line/NN
,/,
which/WDT
is/VBZ
fully/RB
permissive/JJ
to/TO
HIV/NN
replication/NN
,/,
is/VBZ
known/VBN
to/TO
express/VB
only/RB
low/JJ
levels/NNS
of/IN
nuclear/JJ
NF-kappa/NN
B/NN
./.
====================
We/PRP
show/VBP
here/RB
that/IN
chronic/JJ
HIV/VBP
infection/NN
results/VBZ
in/IN
both/CC
induction/NN
of/IN
a/DT
nuclear/JJ
factor/NN
with/IN
antigenic/JJ
properties/NNS
indistinguishable/JJ
from/IN
those/DT
of/IN
NF-kappa/NN
B/NN
and/CC
permanently/RB
increased/VBN
HIV/NN
enhancer/NN
activity/NN
./.
====================
This/DT
phenomenon/NN
,/,
which/WDT
is/VBZ
independent/JJ
of/IN
tumour/NN
necrosis/NN
factor/NN
,/,
is/VBZ
associated/VBN
with/IN
HIV/NN
replication/NN
,/,
and/CC
is/VBZ
thus/RB
likely/JJ
to/TO
explain/VB
at/IN
least/JJS
in/IN
part/NN
the/DT
perpetuation/NN
of/IN
HIV/NN
infection/NN
in/IN
monocytes/NNS
./.
====================
UI/LS
-/:
91173312/CD
====================
TI/LS
-/:
Isolation/NN
of/IN
a/DT
rel-related/JJ
human/JJ
cDNA/NN
that/WDT
potentially/RB
encodes/VBZ
the/DT
65-kD/JJ
subunit/NN
of/IN
NF-kappa/NN
B/NN
[/(
published/VBN
erratum/NN
appears/VBZ
in/IN
Science/NNP
1991/CD
Oct/NNP
4/CD
;/:
254/CD
(/(
5028/CD
)/)
:/:
11/CD
]/)
====================
AB/LS
-/:
A/DT
DNA/NN
probe/NN
that/WDT
spanned/VBD
a/DT
domain/NN
conserved/VBN
among/IN
the/DT
proto-oncogene/NN
c-rel/NN
,/,
the/DT
Drosophila/NN
morphogen/NN
dorsal/NN
,/,
and/CC
the/DT
p50/NN
DNA/NN
binding/NN
subunit/NN
of/IN
NF-kappa/NN
B/NN
was/VBD
generated/VBN
from/IN
Jurkat/NN
T/NN
cell/NN
complementary/JJ
DNA/NN
with/IN
the/DT
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
and/CC
degenerate/JJ
oligonucleotides/NNS
./.
====================
This/DT
probe/NN
was/VBD
used/VBN
to/TO
identify/VB
a/DT
rel-related/JJ
complementary/JJ
DNA/NN
that/WDT
hybridized/VBD
to/TO
a/DT
2.6-kilobase/JJ
messenger/NN
RNA/NN
present/JJ
in/IN
human/JJ
T/NN
and/CC
B/NN
lymphocytes/NNS
./.
====================
In/FW
vitro/FW
transcription/NN
and/CC
translation/NN
of/IN
the/DT
complementary/JJ
DNA/NN
resulted/VBD
in/IN
the/DT
synthesis/NN
of/IN
a/DT
protein/NN
with/IN
an/DT
apparent/JJ
molecular/JJ
size/NN
of/IN
65/CD
kilodaltons/NNS
(/(
kD/NN
)/)
./.
====================
The/DT
translated/VBN
protein/NN
showed/VBD
weak/JJ
DNA/NN
binding/NN
with/IN
a/DT
specificity/NN
for/IN
the/DT
kappa/NN
B/NN
binding/VBG
motif/NN
./.
====================
This/DT
protein-DNA/JJ
complex/JJ
comigrated/VBN
with/IN
the/DT
complex/NN
obtained/VBN
with/IN
the/DT
purified/VBN
human/JJ
p65/NN
NF-kappa/NN
B/NN
subunit/NN
and/CC
binding/NN
was/VBD
inhibited/VBN
by/IN
I/NN
kappa/NN
B-alpha/NN
and/CC
-beta/NN
proteins/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
65-kD/JJ
protein/NN
associated/VBN
with/IN
the/DT
p50/NN
subunit/NN
of/IN
NF-kappa/NN
B/NN
and/CC
the/DT
kappa/NN
B/NN
probe/NN
to/TO
form/VB
a/DT
complex/NN
with/IN
the/DT
same/JJ
electrophoretic/JJ
mobility/NN
as/IN
the/DT
NF-kappa/NN
B-DNA/JJ
complex/NN
./.
====================
Therefore/RB
the/DT
rel-related/JJ
65-kD/JJ
protein/NN
may/MD
represent/VB
the/DT
p65/NN
subunit/NN
of/IN
the/DT
active/JJ
NF-kappa/NN
B/NN
transcription/NN
factor/NN
complex/NN
./.
====================
UI/LS
-/:
91246215/CD
====================
TI/LS
-/:
The/DT
human/JJ
myelomonocytic/JJ
cell/NN
line/NN
U-937/NN
as/IN
a/DT
model/NN
for/IN
studying/VBG
alterations/NNS
in/IN
steroid-induced/JJ
monokine/NN
gene/NN
expression/NN
:/:
marked/JJ
enhancement/NN
of/IN
lipopolysaccharide-stimulated/JJ
interleukin-1/NN
beta/NN
messenger/NN
RNA/NN
levels/NNS
by/IN
1,25-dihydroxyvitamin/NN
D3/NN
./.
====================
AB/LS
-/:
The/DT
active/JJ
metabolite/NN
of/IN
vitamin/NN
D/NN
,/,
1,25-dihydroxyvitamin/NN
D3/NN
[/(
1,25-(OH)2D3/NN
]/)
,/,
is/VBZ
a/DT
potent/JJ
regulator/NN
of/IN
human/JJ
monocyte/macrophage/JJ
function/NN
in/FW
vitro/FW
./.
====================
To/TO
establish/VB
a/DT
model/NN
for/IN
1,25-(OH)2D3/NN
regulation/NN
of/IN
human/JJ
monocyte/NN
monokine/NN
synthesis/NN
,/,
three/CD
human/JJ
cell/NN
lines/NNS
(/(
U-937/NN
,/,
THP-1/NN
,/,
and/CC
HL-60/NN
)/)
were/VBD
examined/VBN
for/IN
:/:
1/LS
)/)
the/DT
presence/NN
of/IN
functional/JJ
1,25-(OH)2D3/NN
receptors/NNS
;/:
2/LS
)/)
the/DT
accumulation/NN
of/IN
interleukin-1/NN
beta/NN
(/(
IL-1/NN
beta/NN
)/)
mRNA/NN
and/CC
IL-1/NN
beta/NN
protein/NN
in/IN
response/NN
to/TO
lipopolysaccharide/NN
(/(
LPS/NN
)/)
;/:
and/CC
3/LS
)/)
the/DT
regulation/NN
of/IN
this/DT
response/NN
by/IN
1,25-(OH)2D3/NN
./.
====================
All/DT
three/CD
cell/NN
lines/NNS
expressed/VBD
vitamin/NN
D/NN
receptor/NN
and/CC
had/VBD
increased/VBN
levels/NNS
of/IN
IL-1/NN
beta/NN
mRNA/NN
in/IN
response/NN
to/TO
LPS/NN
./.
====================
Preincubation/NN
of/IN
cells/NNS
with/IN
1,25-(OH)2D3/NN
augmented/VBD
IL-1/NN
beta/NN
mRNA/NN
levels/NNS
only/RB
in/IN
U-937/NN
and/CC
HL-60/NN
cells/NNS
./.
====================
From/IN
these/DT
data/NNS
,/,
and/CC
taking/VBG
into/IN
consideration/NN
their/PRP$
state/NN
of/IN
differentiation/NN
and/CC
relative/JJ
ease/NN
of/IN
culture/NN
,/,
U-937/NN
was/VBD
chosen/VBN
over/IN
HL-60/NN
and/CC
THP-1/NN
as/IN
the/DT
cell/NN
line/NN
we/PRP
further/RB
characterized/VBD
./.
====================
In/IN
U-937/NN
cells/NNS
,/,
optimum/JJ
time/NN
and/CC
dose/NN
of/IN
pretreatment/NN
with/IN
1,25-(OH)2D3/NN
were/VBD
determined/VBN
to/TO
be/VB
12-24/CD
h/NN
at/IN
a/DT
receptor/NN
saturating/JJ
concentration/NN
of/IN
1,25-(OH)2D3/NN
(/(
10/CD
nM/NN
)/)
./.
====================
Preincubation/NN
of/IN
cells/NNS
with/IN
1,25-(OH)2D3/NN
had/VBD
no/DT
effect/NN
on/IN
the/DT
time/NN
course/NN
of/IN
IL-1/NN
beta/NN
mRNA/NN
appearance/NN
in/IN
response/NN
to/TO
LPS/NN
./.
====================
However/RB
,/,
exposure/NN
of/IN
U-937/NN
cells/NNS
to/TO
1,25-(OH)2D3/NN
increased/VBD
by/IN
200/CD
%/NN
the/DT
level/NN
of/IN
IL-1/NN
beta/NN
mRNA/NN
detected/VBD
and/CC
decreased/VBD
by/IN
three/CD
orders/NNS
of/IN
magnitude/NN
the/DT
concentration/NN
of/IN
LPS/NN
required/VBN
to/TO
achieve/VB
steady/JJ
state/NN
mRNA/NN
levels/NNS
equivalent/JJ
to/TO
those/DT
observed/VBN
in/IN
U-937/NN
cells/NNS
not/RB
preincubated/VBN
with/IN
the/DT
hormone.2+o/NN
====================
UI/LS
-/:
91354520/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
M-CSF/NN
expression/NN
by/IN
M-CSF/NN
:/:
role/NN
of/IN
protein/NN
kinase/NN
C/NN
and/CC
transcription/NN
factor/NN
NF/NN
kappa/NN
B/NN
./.
====================
AB/LS
-/:
Macrophage-colony-stimulating/JJ
factor/NN
(/(
M-CSF/NN
)/)
,/,
also/RB
referred/VBN
to/TO
as/IN
CSF-1/NN
,/,
regulates/VBZ
the/DT
survival/NN
,/,
growth/NN
,/,
differentiation/NN
and/CC
functional/JJ
activity/NN
of/IN
monocytes/NNS
by/IN
binding/VBG
to/TO
a/DT
single/JJ
class/NN
of/IN
high-affinity/JJ
cell/NN
surface/NN
receptors/NNS
,/,
known/VBN
to/TO
be/VB
the/DT
product/NN
of/IN
the/DT
c-fms/NN
protooncogene/NN
./.
====================
The/DT
detection/NN
of/IN
both/CC
M-CSF/NN
and/CC
c-fms/NN
expression/NN
by/IN
cells/NNS
of/IN
the/DT
monocyte/NN
lineage/NN
has/VBZ
suggested/VBN
that/IN
M-CSF/NN
may/MD
act/VB
by/IN
an/DT
autocrine/JJ
mechanism/NN
./.
====================
Interestingly/RB
,/,
it/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
M-CSF/NN
can/MD
induce/VB
the/DT
expression/NN
of/IN
its/PRP$
own/JJ
gene/NN
./.
====================
Although/IN
sensitivity/NN
to/TO
M-CSF/NN
can/MD
be/VB
modulated/VBN
by/IN
regulation/NN
of/IN
receptor/NN
expression/NN
and/CC
function/NN
,/,
M-CSF/NN
responsiveness/NN
is/VBZ
largely/RB
determined/VBN
at/IN
a/DT
postreceptor/NN
level/NN
./.
====================
To/TO
date/NN
,/,
little/JJ
is/VBZ
known/VBN
about/IN
the/DT
intracellular/JJ
pathway/NN
of/IN
M-CSF/NN
signal/NN
transduction/NN
./.
====================
We/PRP
have/VBP
therefore/RB
investigated/VBN
the/DT
changes/NNS
in/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
activity/NN
upon/IN
exposure/NN
of/IN
monocytes/NNS
to/TO
M-CSF/NN
./.
====================
We/PRP
show/VBP
that/IN
M-CSF/NN
activates/VBZ
and/CC
translocates/VBZ
PKC/NN
./.
====================
Inhibition/NN
of/IN
PKC/NN
by/IN
the/DT
isoquinoline/NN
derivative/JJ
H7/NN
abolishes/VBZ
induction/NN
of/IN
M-CSF/NN
by/IN
M-CSF/NN
./.
====================
Furthermore/RB
,/,
activation/NN
of/IN
PKC/NN
was/VBD
pertussis-toxin-sensitive/JJ
and/CC
was/VBD
associated/VBN
with/IN
the/DT
detection/NN
of/IN
an/DT
NF/NN
kappa/NN
B/NN
protein/NN
in/IN
nuclear/JJ
extracts/NNS
of/IN
M-CSF-induced/JJ
blood/NN
monocytes/NNS
but/CC
not/RB
in/IN
monocytes/NNS
exposed/VBN
to/TO
medium/NN
treatment/NN
only/RB
./.
====================
The/DT
results/NNS
suggest/VBP
that/IN
M-CSF/NN
induction/NN
of/IN
M-CSF/NN
involves/VBZ
G/NN
proteins/NNS
,/,
PKC/NN
and/CC
NF/NN
kappa/NN
B/NN
./.
====================
UI/LS
-/:
92052214/CD
====================
TI/LS
-/:
Clone/NN
pAT/NN
133/CD
identifies/VBZ
a/DT
gene/NN
that/WDT
encodes/VBZ
another/DT
human/JJ
member/NN
of/IN
a/DT
class/NN
of/IN
growth/NN
factor-induced/JJ
genes/NNS
with/IN
almost/RB
identical/JJ
zinc-finger/NN
domains/NNS
./.
====================
AB/LS
-/:
We/PRP
report/VBP
the/DT
structure/NN
and/CC
regulation/NN
of/IN
a/DT
gene/NN
represented/VBN
by/IN
clone/NN
pAT/NN
133/CD
,/,
which/WDT
is/VBZ
induced/VBN
upon/IN
transition/NN
from/IN
a/DT
resting/JJ
state/NN
(/(
G0/NN
)/)
through/IN
the/DT
early/JJ
phase/NN
of/IN
the/DT
cell/NN
cycle/NN
(/(
G1/NN
)/)
./.
====================
The/DT
pAT/NN
133/CD
gene/NN
is/VBZ
immediately/RB
induced/VBN
,/,
with/IN
FOS-like/JJ
kinetics/NNS
,/,
in/IN
human/JJ
T/NN
cells/NNS
and/CC
in/IN
fibroblasts/NNS
./.
====================
Primary/JJ
structure/NN
analysis/NN
showed/VBD
that/IN
the/DT
encoded/VBN
protein/NN
contains/VBZ
three/CD
tandem/JJ
zinc-finger/NN
sequences/NNS
of/IN
the/DT
type/NN
Cys2-Xaa12-His2/NN
./.
====================
This/DT
zinc-finger/NN
region/NN
,/,
which/WDT
is/VBZ
thought/VBN
to/TO
bind/VB
DNA/NN
in/IN
a/DT
sequence-specific/JJ
manner/NN
,/,
is/VBZ
similar/JJ
(/(
greater/JJR
than/IN
80/CD
%/NN
on/IN
the/DT
amino/NN
acid/NN
level/NN
)/)
to/TO
two/CD
previously/RB
described/VBN
transcription/NN
factors/NNS
pAT/NN
225/EGR1/NN
and/CC
pAT/NN
591/EGR2/NN
./.
====================
Except/IN
for/IN
the/DT
conserved/VBN
zinc-finger/NN
domains/NNS
,/,
the/DT
amino/NN
acid/NN
sequences/NNS
of/IN
the/DT
three/CD
proteins/NNS
are/VBP
distinct/JJ
./.
====================
This/DT
structural/JJ
similarity/NN
suggests/VBZ
that/IN
the/DT
pAT/NN
133/CD
gene/NN
encodes/VBZ
a/DT
transcription/NN
factor/NN
with/IN
a/DT
specific/JJ
biological/JJ
function/NN
./.
====================
Comparing/VBG
the/DT
regulation/NN
of/IN
these/DT
related/JJ
zinc-finger-encoding/JJ
genes/NNS
showed/VBD
coordinate/JJ
induction/NN
upon/IN
mitogenic/JJ
stimulation/NN
of/IN
resting/VBG
T/NN
lymphocytes/NNS
and/CC
of/IN
resting/VBG
fibroblasts/NNS
./.
====================
However/RB
,/,
upon/IN
transition/NN
from/IN
a/DT
proliferating/JJ
(/(
G1/NN
)/)
to/TO
a/DT
resting/JJ
state/NN
of/IN
the/DT
cell/NN
cycle/NN
the/DT
three/CD
genes/NNS
were/VBD
differently/RB
regulated/VBN
./.
====================
In/IN
human/JJ
histiocytic/JJ
U937/NN
cells/NNS
mRNA/NN
of/IN
clone/NN
pAT/NN
133/CD
was/VBD
constitutively/RB
expressed/VBN
,/,
whereas/IN
mRNA/NN
of/IN
pAT/NN
225/EGR1/NN
was/VBD
induced/VBN
upon/IN
induction/NN
of/IN
terminal/JJ
differentiation/NN
./.
====================
In/IN
contrast/NN
mRNA/NN
representing/VBG
pAT/NN
591/EGR2/NN
was/VBD
not/RB
expressed/VBN
in/IN
these/DT
cells/NNS
./.
====================
This/DT
difference/NN
in/IN
gene/NN
regulation/NN
suggests/VBZ
distinct/JJ
biological/JJ
roles/NNS
in/IN
the/DT
control/NN
of/IN
cell/NN
proliferation/NN
for/IN
the/DT
respective/JJ
proteins/NNS
./.
====================
UI/LS
-/:
92038993/CD
====================
TI/LS
-/:
v-erbA/NN
overexpression/NN
is/VBZ
required/VBN
to/TO
extinguish/VB
c-erbA/NN
function/NN
in/IN
erythroid/JJ
cell/NN
differentiation/NN
and/CC
regulation/NN
of/IN
the/DT
erbA/NN
target/NN
gene/NN
CAII/NN
./.
====================
AB/LS
-/:
The/DT
v-erbA/NN
oncoprotein/NN
represents/VBZ
a/DT
retrovirus-transduced/JJ
oncogenic/JJ
version/NN
of/IN
the/DT
thyroid/NN
hormone/NN
(/(
T3/T4/NN
)/)
receptor/NN
c-erbA/NN
(/(
type/NN
alpha/NN
)/)
./.
====================
It/PRP
contributes/VBZ
to/TO
virus-induced/JJ
erythroleukemia/NN
by/IN
efficiently/RB
arresting/VBG
differentiation/NN
of/IN
red/JJ
cell/NN
progenitors/NNS
and/CC
by/IN
suppressing/VBG
transcription/NN
of/IN
erythrocyte-specific/JJ
genes/NNS
./.
====================
Here/RB
,/,
we/PRP
show/VBP
that/IN
v-erbA/NN
and/CC
c-erbA/NN
bind/VBP
directly/RB
to/TO
sequences/NNS
within/IN
the/DT
promoter/NN
of/IN
the/DT
erythrocyte-specific/JJ
carbonic/JJ
anhydrase/NN
II/CD
(/(
CAII/NN
)/)
,/,
a/DT
gene/NN
whose/WP$
transcription/NN
is/VBZ
efficiently/RB
suppressed/VBN
by/IN
v-erbA/NN
./.
====================
This/DT
erbA-binding/JJ
site/NN
confers/VBZ
thyroid/NN
hormone/NN
responsiveness/NN
to/TO
a/DT
heterologous/JJ
promoter/NN
in/IN
transient/JJ
expression/NN
experiments/NNS
and/CC
is/VBZ
a/DT
target/NN
for/IN
efficient/JJ
down-regulation/NN
of/IN
CAII/NN
transcription/NN
by/IN
the/DT
v-erbA/NN
oncoprotein/NN
./.
====================
In/IN
stably/RB
transformed/VBN
erythroblasts/NNS
coexpressing/VBG
the/DT
v-erbA/NN
oncoprotein/NN
and/CC
the/DT
c-erbA/T3/NN
receptor/NN
at/IN
an/DT
approximately/RB
equimolar/JJ
ratio/NN
,/,
c-erbA/NN
activity/NN
is/VBZ
dominant/JJ
over/IN
v-erbA/NN
./.
====================
T3/NN
efficiently/RB
induced/VBD
erythroid/JJ
differentiation/NN
in/IN
these/DT
cells/NNS
,/,
thus/RB
overcoming/VBG
the/DT
v-erbA-mediated/JJ
differentiation/NN
arrest/NN
./.
====================
Likewise/RB
,/,
T3/NN
activated/VBD
CAII/NN
transcription/NN
as/RB
well/RB
as/IN
transient/JJ
expression/NN
of/IN
a/DT
T3-responsive/JJ
reporter/NN
gene/NN
containing/VBG
the/DT
CAII-specific/JJ
erbA-binding/JJ
site/NN
./.
====================
The/DT
c-erbA-dependent/JJ
activation/NN
of/IN
this/DT
CAII/NN
reporter/NN
construct/NN
could/MD
only/RB
be/VB
suppressed/VBN
by/IN
very/RB
high/JJ
amounts/NNS
of/IN
v-erbA/NN
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
overexpression/NN
of/IN
v-erbA/NN
is/VBZ
required/VBN
for/IN
its/PRP$
function/NN
as/IN
an/DT
oncoprotein/NN
./.
====================
UI/LS
-/:
92013023/CD
====================
TI/LS
-/:
Anti-CD2/JJ
receptor/NN
antibodies/NNS
activate/VBP
the/DT
HIV/NN
long/JJ
terminal/JJ
repeat/NN
in/IN
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
The/DT
CD2/NN
T/NN
lymphocyte/NN
glycoprotein/NN
surface/NN
molecule/NN
mediates/VBZ
both/CC
cell/NN
to/TO
cell/NN
adhesion/NN
and/CC
T/NN
cell/NN
activation/NN
,/,
two/CD
processes/NNS
that/WDT
are/VBP
involved/VBN
in/IN
the/DT
spread/NN
of/IN
HIV/NN
infection/NN
./.
====================
Treatment/NN
of/IN
chronically/RB
HIV-infected/JJ
PBMC/NN
with/IN
anti-CD2/JJ
mAb/NN
has/VBZ
been/VBN
shown/VBN
to/TO
induce/VB
the/DT
expression/NN
of/IN
infectious/JJ
virus/NN
from/IN
these/DT
cultures/NNS
./.
====================
In/IN
this/DT
study/NN
we/PRP
investigated/VBD
the/DT
mechanisms/NNS
whereby/WRB
anti-CD2/JJ
antibodies/NNS
stimulate/VBP
viral/JJ
production/NN
./.
====================
We/PRP
demonstrate/VBP
that/IN
treatment/NN
of/IN
transiently/RB
transfected/VBN
T/NN
lymphocytes/NNS
with/IN
anti-CD2/JJ
antibodies/NNS
results/VBZ
in/IN
activation/NN
of/IN
the/DT
HIV/NN
long/JJ
terminal/JJ
repeat/NN
./.
====================
Furthermore/RB
,/,
CAT/NN
assays/NNS
using/VBG
mutated/VBN
HIV/NN
long/JJ
terminal/JJ
repeat-CAT/NN
constructs/NNS
and/CC
gel/NN
shift/NN
assays/NNS
demonstrate/VBP
that/IN
this/DT
activation/NN
is/VBZ
dependent/JJ
on/IN
the/DT
NF-kappa/NN
B/NN
enhancer/NN
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
interaction/NN
of/IN
CD2/NN
with/IN
its/PRP$
natural/JJ
ligand/NN
,/,
LFA-3/NN
,/,
may/MD
play/VB
a/DT
role/NN
in/IN
regulation/NN
of/IN
HIV/NN
expression/NN
./.
====================
UI/LS
-/:
91293101/CD
====================
TI/LS
-/:
Reactive/JJ
oxygen/NN
intermediates/NNS
as/IN
apparently/RB
widely/RB
used/VBN
messengers/NNS
in/IN
the/DT
activation/NN
of/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
and/CC
HIV-1/NN
./.
====================
AB/LS
-/:
Hydrogen/NN
peroxide/NN
and/CC
oxygen/NN
radicals/NNS
are/VBP
agents/NNS
commonly/RB
produced/VBN
during/IN
inflammatory/JJ
processes/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
show/VBP
that/IN
micromolar/JJ
concentrations/NNS
of/IN
H2O2/NN
can/MD
induce/VB
the/DT
expression/NN
and/CC
replication/NN
of/IN
HIV-1/NN
in/IN
a/DT
human/JJ
T/NN
cell/NN
line/NN
./.
====================
The/DT
effect/NN
is/VBZ
mediated/VBN
by/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
which/WDT
is/VBZ
potently/RB
and/CC
rapidly/RB
activated/VBN
by/IN
an/DT
H2O2/NN
treatment/NN
of/IN
cells/NNS
from/IN
its/PRP$
inactive/JJ
cytoplasmic/JJ
form/NN
./.
====================
N-acetyl-L-cysteine/NN
(/(
NAC/NN
)/)
,/,
a/DT
well/RB
characterized/VBN
antioxidant/NN
which/WDT
counteracts/VBZ
the/DT
effects/NNS
of/IN
reactive/JJ
oxygen/NN
intermediates/NNS
(/(
ROI/NN
)/)
in/IN
living/VBG
cells/NNS
,/,
prevented/VBD
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
by/IN
H2O2/NN
./.
====================
NAC/NN
and/CC
other/JJ
thiol/JJ
compounds/NNS
also/RB
blocked/VBD
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
by/IN
cycloheximide/NN
,/,
double-stranded/JJ
RNA/NN
,/,
calcium/NN
ionophore/NN
,/,
TNF-alpha/NN
,/,
active/JJ
phorbol/NN
ester/NN
,/,
interleukin-1/NN
,/,
lipopolysaccharide/NN
and/CC
lectin/NN
./.
====================
This/DT
suggests/VBZ
that/IN
diverse/JJ
agents/NNS
thought/VBN
to/TO
activate/VB
NF-kappa/NN
B/NN
by/IN
distinct/JJ
intracellular/JJ
pathways/NNS
might/MD
all/DT
act/VB
through/IN
a/DT
common/JJ
mechanism/NN
involving/VBG
the/DT
synthesis/NN
of/IN
ROI/NN
./.
====================
ROI/NN
appear/VBP
to/TO
serve/VB
as/IN
messengers/NNS
mediating/VBG
directly/RB
or/CC
indirectly/RB
the/DT
release/NN
of/IN
the/DT
inhibitory/JJ
subunit/NN
I/NN
kappa/NN
B/NN
from/IN
NF-kappa/NN
B/NN
./.
====================
UI/LS
-/:
91266912/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
transcription/NN
factors/NNS
belonging/VBG
to/TO
the/DT
rel/NF-kappa/NN
B/NN
family/NN
by/IN
a/DT
transdominant/JJ
negative/JJ
mutant/NN
./.
====================
AB/LS
-/:
The/DT
KBF1/NN
factor/NN
,/,
which/WDT
binds/VBZ
to/TO
the/DT
enhancer/NN
A/NN
located/JJ
in/IN
the/DT
promoter/NN
of/IN
the/DT
mouse/NN
MHC/NN
class/NN
I/CD
gene/NN
H-2Kb/NN
,/,
is/VBZ
indistinguishable/JJ
from/IN
the/DT
p50/NN
DNA/NN
binding/NN
subunit/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
,/,
which/WDT
regulates/VBZ
a/DT
series/NN
of/IN
genes/NNS
involved/VBN
in/IN
immune/JJ
and/CC
inflammatory/JJ
responses/NNS
./.
====================
The/DT
KBF1/p50/NN
factor/NN
binds/VBZ
as/IN
a/DT
homodimer/NN
but/CC
can/MD
also/RB
form/VB
heterodimers/NNS
with/IN
the/DT
products/NNS
of/IN
other/JJ
members/NNS
of/IN
the/DT
same/JJ
family/NN
,/,
like/IN
the/DT
c-rel/NN
and/CC
v-rel/NN
(/(
proto/NN
)/)
oncogenes/NNS
./.
====================
The/DT
dimerization/NN
domain/NN
of/IN
KBF1/p50/NN
is/VBZ
contained/VBN
between/IN
amino/NN
acids/NNS
201/CD
and/CC
367/CD
./.
====================
A/DT
mutant/NN
of/IN
KBF1/p50/NN
(/(
delta/NN
SP/NN
)/)
,/,
unable/JJ
to/TO
bind/VB
to/TO
DNA/NN
but/CC
able/JJ
to/TO
form/VB
homo-/JJ
or/CC
heterodimers/NNS
,/,
has/VBZ
been/VBN
constructed/VBN
./.
====================
This/DT
protein/NN
reduces/VBZ
or/CC
abolishes/VBZ
in/FW
vitro/FW
the/DT
DNA/NN
binding/NN
activity/NN
of/IN
wild-type/JJ
proteins/NNS
of/IN
the/DT
same/JJ
family/NN
(/(
KBF1/p50/NN
,/,
c-/NN
and/CC
v-rel/NN
)/)
./.
====================
This/DT
mutant/JJ
also/RB
functions/NNS
in/FW
vivo/FW
as/IN
a/DT
trans-acting/JJ
dominant/JJ
negative/JJ
regulator/NN
:/:
the/DT
transcriptional/JJ
inducibility/NN
of/IN
the/DT
HIV/NN
long/JJ
terminal/JJ
repeat/NN
(/(
which/WDT
contains/VBZ
two/CD
potential/JJ
NF-kappa/NN
B/NN
binding/NN
sites/NNS
)/)
by/IN
phorbol/NN
ester/NN
(/(
PMA/NN
)/)
is/VBZ
inhibited/VBN
when/WRB
it/PRP
is/VBZ
co-transfected/VBN
into/IN
CD4+/JJ
T/NN
cells/NNS
with/IN
the/DT
delta/NN
SP/NN
mutant/NN
./.
====================
Similarly/RB
the/DT
basal/JJ
as/RB
well/RB
as/IN
TNF/NN
or/CC
IL1-induced/JJ
activity/NN
of/IN
the/DT
MHC/NN
class/NN
I/CD
H-2Kb/NN
promoter/NN
can/MD
be/VB
inhibited/VBN
by/IN
this/DT
mutant/NN
in/IN
two/CD
different/JJ
cell/NN
lines/NNS
./.
====================
These/DT
results/NNS
constitute/VBP
the/DT
first/JJ
formal/JJ
demonstration/NN
that/IN
these/DT
genes/NNS
are/VBP
regulated/VBN
by/IN
members/NNS
of/IN
the/DT
rel/NF-kappa/NN
B/NN
family/NN
./.
====================
UI/LS
-/:
91224990/CD
====================
TI/LS
-/:
Tissue-specific/JJ
expression/NN
of/IN
the/DT
platelet/NN
GPIIb/NN
gene/NN
./.
====================
AB/LS
-/:
One/CD
of/IN
the/DT
major/JJ
objectives/NNS
in/IN
the/DT
study/NN
of/IN
thrombogenesis/NN
is/VBZ
to/TO
determine/VB
the/DT
mechanisms/NNS
by/IN
which/WDT
a/DT
hematopoietic/JJ
progenitor/NN
is/VBZ
activated/VBN
and/CC
committed/VBN
to/TO
the/DT
megakaryocytic/JJ
lineage/NN
./.
====================
Recent/JJ
development/NN
of/IN
primary/JJ
cultures/NNS
of/IN
human/JJ
megakaryocytes/NNS
and/CC
the/DT
molecular/JJ
cloning/NN
of/IN
genes/NNS
that/WDT
are/VBP
specific/JJ
to/TO
this/DT
lineage/NN
offer/VBP
the/DT
possibility/NN
of/IN
getting/VBG
some/DT
insights/NNS
into/IN
the/DT
genetic/JJ
mechanisms/NNS
that/WDT
control/VBP
megakaryocytopoiesis/NNS
./.
====================
One/CD
gene/NN
of/IN
interest/NN
is/VBZ
the/DT
glycoprotein/NN
IIb/NN
(/(
GPIIb/NN
)/)
gene/NN
;/:
GPIIb/NN
,/,
the/DT
alpha/NN
subunit/NN
of/IN
the/DT
platelet/NN
cytoadhesin/NN
GPIIb-IIIa/NN
,/,
is/VBZ
produced/VBN
in/IN
megakaryocytes/NNS
at/IN
an/DT
early/JJ
stage/NN
of/IN
the/DT
differentiation/NN
,/,
whereas/IN
the/DT
other/JJ
subunit/NN
of/IN
this/DT
complex/NN
,/,
GPIIIa/NN
,/,
is/VBZ
expressed/VBN
in/IN
other/JJ
cells/NNS
./.
====================
For/IN
these/DT
reasons/NNS
,/,
the/DT
5'-flanking/JJ
region/NN
of/IN
the/DT
GPIIb/NN
gene/NN
was/VBD
used/VBN
to/TO
identify/VB
the/DT
regions/NNS
that/WDT
interact/VBP
with/IN
DNA-binding/JJ
nuclear/JJ
factors/NNS
./.
====================
A/DT
fragment/NN
extending/VBG
from/IN
-643/CD
to/TO
+33/CD
is/VBZ
capable/JJ
of/IN
controlling/VBG
the/DT
tissue-specific/JJ
expression/NN
of/IN
the/DT
CAT/NN
gene/NN
in/IN
transfection/NN
experiments/NNS
./.
====================
Within/IN
this/DT
region/NN
,/,
we/PRP
have/VBP
identified/VBN
several/JJ
sequences/NNS
that/WDT
are/VBP
implicated/VBN
in/IN
DNA/NN
protein/NN
interactions/NNS
as/IN
shown/VBN
in/IN
DNAse/NN
I/NN
footprints/NNS
and/CC
gel/NN
mobility/NN
shift/NN
assays/NNS
./.
====================
One/CD
region/NN
,/,
centered/VBN
at/IN
-54/CD
,/,
is/VBZ
similar/JJ
to/TO
a/DT
nuclear/JJ
factor/NN
E1-binding/JJ
site/NN
,/,
and/CC
a/DT
region/NN
located/JJ
at/IN
position/NN
-233/CD
contains/VBZ
a/DT
CCAAT/NN
motif/NN
./.
====================
Two/CD
domains/NNS
centered/VBN
at/IN
positions/NNS
-345/CD
and/CC
-540/CD
,/,
respectively/RB
,/,
bind/VBP
proteins/NNS
that/WDT
are/VBP
present/JJ
in/IN
megakaryocytic/JJ
cells/NNS
and/CC
nonrelated/JJ
cells/NNS
as/RB
well/RB
./.
====================
Finally/RB
,/,
two/CD
other/JJ
domains/NNS
,/,
located/JJ
at/IN
positions/NNS
-460/CD
and/CC
-510/CD
,/,
interact/VBP
with/IN
proteins/NNS
that/WDT
are/VBP
only/RB
present/JJ
in/IN
megakaryocytic/JJ
cells/NNS
./.
====================
In/IN
addition/NN
,/,
deletion/NN
of/IN
the/DT
region/NN
containing/VBG
these/DT
two/CD
domains/NNS
results/VBZ
in/IN
a/DT
significant/JJ
decrease/NN
of/IN
the/DT
promoter/NN
activity/NN
./.
====================
It/PRP
is/VBZ
very/RB
likely/JJ
that/IN
these/DT
domains/NNS
bind/VBP
megakaryocyte-specific/JJ
nuclear/JJ
proteins/NNS
acting/VBG
as/IN
positive/JJ
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
91349414/CD
====================
TI/LS
-/:
Lymphocyte/NN
glucocorticoid/NN
receptor/NN
binding/NN
during/IN
depression/NN
and/CC
after/IN
clinical/JJ
recovery/NN
./.
====================
AB/LS
-/:
Lymphocyte/NN
glucocorticoid/NN
receptor/NN
binding/NN
parameters/NNS
were/VBD
studied/VBN
in/IN
15/CD
severely/RB
depressed/JJ
patients/NNS
during/IN
depression/NN
and/CC
after/IN
clinical/JJ
recovery/NN
,/,
and/CC
in/IN
15/CD
healthy/JJ
controls/NNS
./.
====================
There/EX
was/VBD
no/DT
difference/NN
in/IN
glucocorticoid/NN
receptor/NN
number/NN
or/CC
affinity/NN
between/IN
depressed/JJ
patients/NNS
and/CC
recovered/JJ
or/CC
control/NN
subjects/NNS
./.
====================
Afternoon/NN
ACTH/NN
and/CC
cortisol/NN
concentrations/NNS
did/VBD
not/RB
differ/VB
significantly/RB
between/IN
the/DT
three/CD
groups/NNS
./.
====================
No/DT
relationship/NN
could/MD
be/VB
established/VBN
between/IN
glucocorticoid/NN
receptor/NN
binding/NN
and/CC
antidepressant/JJ
medication/NN
./.
====================
These/DT
data/NNS
support/VBP
the/DT
view/NN
of/IN
an/DT
impaired/JJ
ligand-induced/JJ
plasticity/NN
of/IN
glucocorticoid/NN
receptor/NN
regulation/NN
rather/RB
than/IN
the/DT
hypothesis/NN
of/IN
decreased/VBN
glucocorticoid/NN
receptor/NN
numbers/NNS
during/IN
depression/NN
./.
====================
UI/LS
-/:
92314696/CD
====================
TI/LS
-/:
Every/DT
enhancer/NN
works/VBZ
with/IN
every/DT
promoter/NN
for/IN
all/PDT
the/DT
combinations/NNS
tested/VBN
:/:
could/MD
new/JJ
regulatory/JJ
pathways/NNS
evolve/VBP
by/IN
enhancer/NN
shuffling/NN
?/.
====================
AB/LS
-/:
The/DT
promoters/NNS
and/CC
enhancers/NNS
of/IN
cell/NN
type-specific/JJ
genes/NNS
are/VBP
often/RB
conserved/VBN
in/IN
evolution/NN
,/,
and/CC
hence/RB
one/NN
might/MD
expect/VB
that/IN
a/DT
given/JJ
enhancer/NN
has/VBZ
evolved/VBN
to/TO
work/VB
best/RBS
with/IN
its/PRP$
own/JJ
promoter/NN
./.
====================
While/IN
this/DT
expectation/NN
may/MD
be/VB
realized/VBN
in/IN
some/DT
cases/NNS
,/,
we/PRP
have/VBP
not/RB
found/VBN
evidence/NN
for/IN
it/PRP
./.
====================
A/DT
total/NN
of/IN
27/CD
combinations/NNS
of/IN
different/JJ
promoters/NNS
and/CC
enhancers/NNS
were/VBD
tested/VBN
by/IN
transfection/NN
into/IN
cultured/VBN
cells/NNS
./.
====================
We/PRP
found/VBD
that/IN
the/DT
relative/JJ
efficiency/NN
of/IN
the/DT
enhancers/NNS
is/VBZ
approximately/RB
the/DT
same/JJ
,/,
irrespective/JJ
of/IN
the/DT
type/NN
of/IN
promoter/NN
used/VBN
,/,
i.e./FW
,/,
there/EX
was/VBD
no/DT
strong/JJ
preference/NN
for/IN
any/DT
given/JJ
enhancer/promoter/JJ
combination/NN
./.
====================
Notably/RB
,/,
we/PRP
do/VBP
not/RB
see/VB
particularly/RB
strong/JJ
transcription/NN
when/WRB
the/DT
immunoglobulin/NN
kappa/NN
enhancer/NN
(/(
or/CC
the/DT
immunoglobulin/NN
heavy/JJ
chain/NN
enhancer/NN
)/)
is/VBZ
used/VBN
to/TO
activate/VB
a/DT
kappa/NN
gene/NN
promoter/NN
./.
====================
We/PRP
propose/VBP
that/IN
a/DT
generally/RB
permissive/JJ
enhancer/promoter/JJ
interaction/NN
is/VBZ
of/IN
evolutionary/JJ
benefit/NN
for/IN
higher/JJR
eukaryotes/NNS
:/:
by/IN
enhancer/NN
shuffling/NN
,/,
genes/NNS
could/MD
be/VB
easily/RB
brought/VBN
under/IN
a/DT
new/JJ
type/NN
of/IN
inducibility/cell/NN
type/NN
specificity/NN
./.
====================
UI/LS
-/:
91282927/CD
====================
TI/LS
-/:
Towards/IN
a/DT
molecular/JJ
understanding/NN
of/IN
T-cell/NN
differentiation/NN
./.
====================
AB/LS
-/:
Lymphoid/JJ
differentiation/NN
is/VBZ
one/CD
of/IN
the/DT
best/RBS
studied/VBN
examples/NNS
of/IN
mammalian/JJ
development/NN
./.
====================
Here/RB
Hans/NNP
Clevers/NNP
and/CC
Michael/NNP
Owen/NNP
describe/VBP
how/WRB
the/DT
cloning/NN
of/IN
the/DT
genes/NNS
that/WDT
encode/VBP
T-cell-specific/JJ
membrane/NN
proteins/NNS
allows/VBZ
the/DT
identification/NN
of/IN
transcription/NN
factors/NNS
that/WDT
control/VBP
the/DT
expression/NN
of/IN
these/DT
T-cell/NN
genes/NNS
./.
====================
Such/JJ
transcription/NN
factors/NNS
play/VBP
a/DT
key/JJ
role/NN
in/IN
the/DT
development/NN
of/IN
the/DT
mature/JJ
T-cell/NN
phenotype/NN
by/IN
functioning/VBG
as/IN
'/``
master/JJ
regulators/NNS
of/IN
T-cell/NN
differentiation/NN
'/''
./.
====================
UI/LS
-/:
91187152/CD
====================
TI/LS
-/:
A/DT
study/NN
on/IN
the/DT
circadian/JJ
rhythm/NN
of/IN
glucocorticoid/NN
receptor/NN
./.
====================
AB/LS
-/:
Circadian/JJ
rhythm/NN
in/IN
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
was/VBD
studied/VBN
in/IN
the/DT
rat/NN
liver/NN
and/CC
human/JJ
peripheral/JJ
leukocytes/NNS
./.
====================
For/IN
rats/NNS
exposed/VBN
to/TO
a/DT
natural/JJ
environmental/JJ
photic/JJ
cycle/NN
or/CC
a/DT
12L/NN
:/:
12D/NN
artificial/JJ
light/NN
regime/NN
,/,
peak/JJ
values/NNS
of/IN
hepatic/JJ
GR/NN
were/VBD
detected/VBN
between/IN
23/CD
:/:
00/CD
and/CC
02/CD
:/:
00/CD
h/NN
./.
====================
Except/IN
for/IN
a/DT
4-hour/JJ
advancement/NN
of/IN
the/DT
peak/NN
,/,
a/DT
similar/JJ
circadian/JJ
rhythm/NN
of/IN
hepatic/JJ
GR/NN
was/VBD
detected/VBN
in/IN
rats/NNS
reared/VBN
under/IN
a/DT
reversed/VBN
lighting/NN
regimen/NNS
(/(
12D/NN
:/:
12L/NN
;/:
lights/NNS
on/IN
between/IN
18/CD
:/:
30/CD
and/CC
06/CD
:/:
30/CD
h/NN
)/)
./.
====================
In/IN
human/JJ
leukocytes/NNS
,/,
the/DT
peak/JJ
value/NN
of/IN
GR/NN
was/VBD
found/VBN
to/TO
parallel/VB
that/DT
of/IN
plasma/NN
cortisol/NN
with/IN
high/JJ
and/CC
low/JJ
values/NNS
detected/VBN
at/IN
04:00-08:00/CD
h/NN
and/CC
23:00-24:00/CD
h/NN
,/,
respectively/RB
./.
====================
In/IN
patients/NNS
suffering/VBG
from/IN
Cushing/NN
's/POS
syndrome/NN
,/,
the/DT
circadian/JJ
rhythm/NN
of/IN
plasma/NN
cortisol/NN
either/CC
disappeared/VBD
or/CC
was/VBD
inverted/VBN
while/IN
that/DT
of/IN
GR/NN
did/VBD
not/RB
significantly/RB
deviate/VB
from/IN
the/DT
normal/JJ
subjects/NNS
./.
====================
For/IN
apoplexic/JJ
patients/NNS
with/IN
lesions/NNS
localized/JJ
to/TO
the/DT
base/NN
of/IN
the/DT
brain/NN
as/IN
indicated/VBN
by/IN
computerized/VBN
tomography/NN
,/,
the/DT
diurnal/JJ
variation/NN
of/IN
GR/NN
was/VBD
abolished/VBN
./.
====================
Conversely/RB
,/,
diurnal/JJ
rhythmicity/NN
persisted/VBD
in/IN
apoplexy/NN
patients/NNS
whose/WP$
lesions/NNS
were/VBD
in/IN
the/DT
cerebral/JJ
cortex/NN
./.
====================
Thus/RB
,/,
we/PRP
postulated/VBD
that/IN
the/DT
circadian/JJ
modification/NN
of/IN
GR/NN
was/VBD
independent/JJ
of/IN
the/DT
diurnal/JJ
fluctuations/NNS
in/IN
plasma/NN
cortisol/NN
level/NN
or/CC
the/DT
circadian/JJ
variations/NNS
in/IN
environmental/JJ
lighting/NN
and/CC
that/IN
the/DT
rhythmicity/NN
might/MD
be/VB
regulated/VBN
by/IN
the/DT
'/``
circadian/JJ
pacemaker/NN
'/''
located/JJ
in/IN
the/DT
human/JJ
basal/JJ
brain/NN
./.
====================
These/DT
diurnal/JJ
variations/NNS
in/IN
GR/NN
might/MD
serve/VB
to/TO
coordinate/VB
the/DT
reactivity/NN
of/IN
the/DT
target/NN
cells/NNS
to/TO
cortisol/NN
because/IN
the/DT
diurnal/JJ
rhythms/NNS
of/IN
a/DT
GR-mediated/JJ
response/NN
,/,
the/DT
fractional/JJ
inhibition/NN
of/IN
chemotactic/JJ
migration/NN
rate/NN
of/IN
polymorphonuclear/JJ
leukocytes/NNS
by/IN
cortisol/NN
,/,
were/VBD
found/VBN
to/TO
be/VB
synchronous/JJ
with/IN
those/DT
of/IN
GR/NN
./.
====================
UI/LS
-/:
92112059/CD
====================
TI/LS
-/:
Transcription/NN
factor/NN
requirements/NNS
for/IN
U2/NN
snRNA-encoding/JJ
gene/NN
activation/NN
in/IN
B/NN
lymphoid/JJ
cells/NNS
./.
====================
AB/LS
-/:
Transcription/NN
of/IN
a/DT
human/JJ
U2/NN
small/JJ
nuclear/JJ
RNA/NN
(/(
snRNA/NN
)/)
-encoding/JJ
gene/NN
in/IN
HeLa/NN
cells/NNS
requires/VBZ
a/DT
distal/JJ
enhancer/NN
element/NN
,/,
which/WDT
is/VBZ
composed/VBN
of/IN
one/CD
octamer/NN
motif/NN
(/(
Oct/NN
)/)
and/CC
three/CD
Sp/NN
1-binding/JJ
sites/NNS
./.
====================
To/TO
study/VB
the/DT
transcription/NN
factor/NN
requirement/NN
in/IN
B-cells/NNS
,/,
different/JJ
U2/NN
enhancer/NN
constructions/NNS
were/VBD
transfected/VBN
into/IN
the/DT
lymphoid/JJ
cell/NN
line/NN
,/,
BJA-B/NN
./.
====================
The/DT
results/NNS
showed/VBD
that/IN
the/DT
activation/NN
of/IN
U2/NN
snRNA/NN
transcription/NN
in/IN
B-cells/NNS
also/RB
requires/VBZ
an/DT
enhancer/NN
comprising/VBG
both/CC
the/DT
Oct/NN
and/CC
at/IN
least/JJS
one/CD
Sp/NN
1-binding/JJ
site/NN
./.
====================
Deletion/NN
of/IN
all/PDT
the/DT
Sp/NN
1-binding/JJ
sites/NNS
from/IN
the/DT
enhancer/NN
reduces/VBZ
transcription/NN
by/IN
80-90/CD
%/NN
in/IN
HeLa/NN
,/,
as/RB
well/RB
as/IN
in/IN
BJA-B/NN
cells/NNS
,/,
whereas/IN
the/DT
removal/NN
of/IN
the/DT
octamer-binding/JJ
site/NN
reduces/VBZ
transcription/NN
to/TO
levels/NNS
below/IN
detection/NN
in/IN
both/DT
cell/NN
types/NNS
./.
====================
Enhancers/NNS
containing/VBG
a/DT
single/JJ
Oct/NN
have/VBP
,/,
nevertheless/RB
,/,
the/DT
capacity/NN
to/TO
partially/RB
activate/VB
U2/NN
snRNA/NN
transcription/NN
in/IN
both/DT
HeLa/NN
cells/NNS
,/,
in/IN
which/WDT
only/RB
OTF-1/NN
is/VBZ
expressed/VBN
,/,
and/CC
in/IN
BJA-B/NN
cells/NNS
in/IN
which/WDT
OTF-2/NN
is/VBZ
the/DT
predominantly/RB
expressed/VBN
octamer-binding/JJ
factor/NN
./.
====================
The/DT
most/RBS
likely/JJ
interpretation/NN
of/IN
our/PRP$
results/NNS
is/VBZ
that/IN
both/CC
the/DT
ubiquitous/JJ
transcription/NN
factor/NN
,/,
OTF-1/NN
,/,
and/CC
the/DT
B-cell-specific/JJ
transcription/NN
factor/NN
,/,
OTF-2/NN
,/,
can/MD
activate/VB
U2/NN
snRNA/NN
transcription/NN
./.
====================
The/DT
results/NNS
also/RB
revealed/VBD
a/DT
similar/JJ
functional/JJ
cooperation/NN
between/IN
the/DT
transcription/NN
factors/NNS
which/WDT
bind/VBP
to/TO
the/DT
Oct/NN
and/CC
the/DT
adjacent/JJ
Sp/NN
1-binding/JJ
site/NN
in/IN
BJA-B/NN
cells/NNS
,/,
as/IN
has/VBZ
been/VBN
observed/VBN
in/IN
HeLa/NN
cells/NNS
,/,
since/IN
a/DT
template/NN
which/WDT
contains/VBZ
a/DT
weak/JJ
binding/VBG
site/NN
for/IN
OTFs/NNS
expresses/VBZ
wild-type/JJ
levels/NNS
of/IN
U2/NN
snRNA/NN
in/IN
both/DT
cell/NN
types/NNS
when/WRB
the/DT
weak/JJ
octamer-binding/JJ
site/NN
is/VBZ
combined/VBN
with/IN
a/DT
Sp/NN
1-binding/JJ
site/NN
./.
====================
UI/LS
-/:
92051383/CD
====================
TI/LS
-/:
One/CD
base/NN
pair/NN
change/NN
abolishes/VBZ
the/DT
T/NN
cell-restricted/JJ
activity/NN
of/IN
a/DT
kB-like/JJ
proto-enhancer/NN
element/NN
from/IN
the/DT
interleukin/NN
2/CD
promoter/NN
./.
====================
AB/LS
-/:
The/DT
inducible/JJ
,/,
T/NN
cell-specific/JJ
enhancers/NNS
of/IN
murine/JJ
and/CC
human/JJ
Interleukin/NN
2/CD
(/(
Il-2/NN
)/)
genes/NNS
contain/VBP
the/DT
kB-like/JJ
sequence/NN
GGGATTTCACC/NN
as/IN
an/DT
essential/JJ
cis-acting/JJ
enhancer/NN
motif/NN
./.
====================
When/WRB
cloned/VBN
in/IN
multiple/JJ
copies/NNS
this/DT
so-called/JJ
TCEd/NN
(/(
distal/JJ
T/NN
cell/NN
element/NN
)/)
acts/VBZ
as/IN
an/DT
inducible/JJ
proto-enhancer/NN
element/NN
in/IN
E14/NN
T/NN
lymphoma/NN
cells/NNS
,/,
but/CC
not/RB
in/IN
HeLa/NN
cells/NNS
./.
====================
In/IN
extracts/NNS
of/IN
induced/VBN
,/,
Il-2/NN
secreting/NN
El4/NN
cells/NNS
three/CD
individual/JJ
protein/NN
factors/NNS
bind/VBP
to/TO
TCEd/NN
DNA/NN
./.
====================
The/DT
binding/NN
of/IN
the/DT
most/RBS
prominent/JJ
factor/NN
,/,
named/VBN
TCF-1/NN
(/(
T/NN
cell/NN
factor/NN
1/CD
)/)
,/,
is/VBZ
correlated/VBN
with/IN
the/DT
proto-enhancer/NN
activity/NN
of/IN
TCEd/NN
./.
====================
TCF-1/NN
consists/VBZ
of/IN
two/CD
polypeptides/NNS
of/IN
about/RB
50/CD
kD/NN
and/CC
105/CD
kD/NN
;/:
the/DT
former/JJ
seems/VBZ
to/TO
be/VB
related/JJ
to/TO
the/DT
50/CD
kD/NN
polypeptide/NN
of/IN
NF-kB/NN
./.
====================
Purified/VBN
NF-kB/NN
is/VBZ
also/RB
able/JJ
to/TO
bind/VB
to/TO
the/DT
TCEd/NN
,/,
but/CC
TCF-1/NN
binds/VBZ
stronger/JJR
than/IN
NF-kB/NN
to/TO
TCEd/NN
DNA/NN
./.
====================
The/DT
conversion/NN
of/IN
the/DT
TCEd/NN
to/TO
a/DT
'/``
perfect/JJ
'/''
NF-kB/NN
binding/NN
site/NN
leads/VBZ
to/TO
a/DT
tighter/JJR
binding/NN
of/IN
NF-kB/NN
to/TO
TCEd/NN
DNA/NN
and/CC
,/,
as/IN
a/DT
functional/JJ
consequence/NN
,/,
to/TO
the/DT
activity/NN
of/IN
the/DT
'/``
converted/VBN
'/''
TCEd/NN
motifs/NNS
in/IN
HeLa/NN
cells/NNS
./.
====================
Thus/RB
,/,
the/DT
substitution/NN
of/IN
the/DT
underlined/VBN
A/NN
residue/NN
to/TO
a/DT
C/NN
within/IN
the/DT
GGGATTTCACC/NN
motif/NN
abolishes/VBZ
its/PRP$
T/NN
cell-restricted/JJ
activity/NN
and/CC
leads/VBZ
to/TO
its/PRP$
functioning/VBG
in/IN
both/CC
El4/NN
cells/NNS
and/CC
HeLa/NN
cells/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
lymphocyte-specific/JJ
factors/NNS
binding/VBG
to/TO
the/DT
TCEd/NN
are/VBP
involved/VBN
in/IN
the/DT
control/NN
of/IN
T/NN
cell/NN
specific-transcription/NN
of/IN
the/DT
Il-2/NN
gene/NN
./.
====================
UI/LS
-/:
92020218/CD
====================
TI/LS
-/:
An/DT
erythroid/JJ
specific/JJ
enhancer/NN
upstream/JJ
to/TO
the/DT
gene/NN
encoding/VBG
the/DT
cell-type/JJ
specific/JJ
transcription/NN
factor/NN
GATA-1/NN
./.
====================
AB/LS
-/:
The/DT
transcription/NN
factor/NN
GATA-1/NN
is/VBZ
expressed/VBN
in/IN
a/DT
subset/NN
of/IN
hemopoietic/JJ
cells/NNS
,/,
where/WRB
it/PRP
mediates/VBZ
the/DT
cell-type/JJ
specific/JJ
expression/NN
of/IN
several/JJ
genes/NNS
./.
====================
We/PRP
have/VBP
cloned/VBN
the/DT
mouse/NN
and/CC
human/JJ
GATA-1/NN
genes/NNS
./.
====================
A/DT
region/NN
upstream/JJ
to/TO
the/DT
first/JJ
exon/NN
,/,
and/CC
highly/RB
conserved/VBN
between/IN
mouse/NN
and/CC
man/NN
,/,
acts/VBZ
as/IN
an/DT
erythroid/JJ
specific/JJ
enhancer/NN
in/IN
transient/JJ
assays/NNS
,/,
if/IN
linked/VBN
to/TO
the/DT
GATA-1/NN
or/CC
to/TO
the/DT
SV40/NN
promoter/NN
./.
====================
The/DT
activity/NN
of/IN
the/DT
enhancer/NN
is/VBZ
almost/RB
completely/RB
dependent/JJ
on/IN
the/DT
integrity/NN
of/IN
a/DT
dimeric/JJ
GATA-1/NN
binding/NN
site/NN
./.
====================
UI/LS
-/:
92020850/CD
====================
TI/LS
-/:
Demonstration/NN
of/IN
a/DT
1,25-dihydroxyvitamin/NN
D3-responsive/JJ
protein/NN
in/IN
human/JJ
lymphocytes/NNS
:/:
immunologic/JJ
crossreactivity/NN
and/CC
inverse/JJ
regulation/NN
with/IN
the/DT
vitamin/NN
D/NN
receptor/NN
./.
====================
AB/LS
-/:
Using/VBG
Western/NN
blot/NN
analysis/NN
with/IN
a/DT
monoclonal/JJ
antibody/NN
recognizing/VBG
a/DT
17-amino/NN
acid/NN
epitope/NN
of/IN
the/DT
1,25-dihydroxyvitamin/NN
D3/NN
[/(
1,25(OH)2D3/NN
]/)
receptor/NN
,/,
we/PRP
have/VBP
detected/VBN
two/CD
crossreacting/VBG
proteins/NNS
in/IN
activated/VBN
normal/JJ
human/JJ
lymphocytes/NNS
./.
====================
The/DT
smaller/JJR
of/IN
the/DT
two/CD
proteins/NNS
(/(
50/CD
kDa/NN
)/)
was/VBD
indistinguishable/JJ
from/IN
the/DT
classical/JJ
1,25(OH)2D3/NN
receptor/NN
and/CC
,/,
similar/JJ
to/TO
the/DT
classical/JJ
1,25(OH)2D3/NN
receptor/NN
,/,
was/VBD
upregulated/VBN
in/IN
a/DT
dose-dependent/JJ
fashion/NN
by/IN
1,25(OH)2D3/NN
./.
====================
The/DT
larger/JJR
crossreacting/VBG
protein/NN
exhibited/VBD
an/DT
electrophoretic/JJ
mobility/NN
of/IN
80/CD
kDa/NN
,/,
was/VBD
localized/JJ
in/IN
the/DT
cell/NN
cytosol/NN
,/,
and/CC
appeared/VBD
to/TO
be/VB
specific/JJ
for/IN
activated/VBN
lymphocytes/NNS
since/IN
it/PRP
was/VBD
not/RB
detected/VBN
in/IN
several/JJ
other/JJ
human/JJ
cells/NNS
including/VBG
monocytes/NNS
./.
====================
More/RBR
strikingly/RB
,/,
the/DT
80-kDa/JJ
protein/NN
was/VBD
downregulated/VBN
in/IN
a/DT
dose-dependent/JJ
fashion/NN
by/IN
1,25(OH)2D3/NN
;/:
this/DT
effect/NN
was/VBD
independent/JJ
of/IN
the/DT
mode/NN
of/IN
lymphocyte/NN
activation/NN
and/CC
specific/JJ
for/IN
the/DT
1,25(OH)2D3/NN
metabolite/NN
of/IN
vitamin/NN
D3/NN
./.
====================
However/RB
,/,
two/CD
potent/JJ
immunosuppressive/JJ
agents/NNS
,/,
glucocorticoids/NNS
and/CC
cyclosporin/NN
A/DT
,/,
also/RB
inhibited/VBD
the/DT
80-kDa/JJ
protein/NN
./.
====================
UI/LS
-/:
91363265/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
human/JJ
mononuclear/JJ
cells/NNS
:/:
effects/NNS
of/IN
glucocorticoid/NN
treatment/NN
,/,
Cushing/NN
's/POS
disease/NN
and/CC
ketoconazole/NN
./.
====================
AB/LS
-/:
Glucocorticoid/NN
receptors/NNS
(/(
GcR/NN
)/)
were/VBD
determined/VBN
by/IN
a/DT
whole/JJ
cell/NN
assay/NN
in/IN
human/JJ
mononulear/JJ
leukocytes/NNS
(/(
hMNL/NN
)/)
from/IN
control/NN
subjects/NNS
,/,
patients/NNS
receiving/VBG
glucocorticoid/NN
therapy/NN
for/IN
systemic/JJ
diseases/NNS
and/CC
Cushing/NN
's/POS
disease/NN
patients/NNS
with/IN
or/CC
without/IN
ketoconazole/NN
therapy/NN
./.
====================
Prolonged/JJ
corticosteroid/NN
treatment/NN
resulted/VBD
in/IN
down-regulation/NN
of/IN
GcR/NN
,/,
while/IN
the/DT
mean/NN
level/NN
of/IN
GcR/NN
in/IN
Cushing/NN
's/POS
disease/NN
was/VBD
normal/JJ
./.
====================
In/IN
this/DT
group/NN
,/,
however/RB
,/,
receptor/NN
levels/NNS
and/CC
morning/NN
plasma/NN
cortisol/NN
values/NNS
showed/VBD
a/DT
negative/JJ
correlation/NN
,/,
indicating/VBG
a/DT
subtle/JJ
down-regulatory/JJ
effect/NN
./.
====================
Furthermore/RB
,/,
GcR/NN
were/VBD
unaltered/JJ
after/IN
these/DT
patients/NNS
received/VBD
ketoconazole/NN
,/,
in/IN
spite/NN
of/IN
a/DT
marked/JJ
reduction/NN
in/IN
morning/NN
plasma/NN
cortisol/NN
and/CC
urinary/JJ
free/JJ
cortisol/NN
./.
====================
We/PRP
also/RB
observed/VBD
that/IN
ketoconazole/NN
was/VBD
a/DT
weak/JJ
competitor/NN
of/IN
GcR/NN
in/IN
intact/JJ
cells/NNS
,/,
although/IN
it/PRP
significantly/RB
inhibited/VBD
[3H]/NN
dexamethasone/NN
binding/NN
in/IN
cytosolic/JJ
preparations/NNS
from/IN
rat/NN
tissues/NNS
./.
====================
The/DT
results/NNS
suggested/VBD
that/IN
GcR/NN
in/IN
hMNL/NN
are/VBP
down-regulated/VBN
by/IN
synthetic/JJ
steroids/NNS
given/VBN
in/FW
vivo/FW
,/,
but/CC
they/PRP
showed/VBD
very/RB
mild/JJ
down-regulation/NN
in/IN
hypercortisolemic/JJ
patients/NNS
suffering/VBG
from/IN
Cushing/NN
's/POS
disease/NN
./.
====================
Finally/RB
,/,
we/PRP
did/VBD
not/RB
observed/VBN
either/CC
up-regulation/NN
or/CC
antagonism/NN
of/IN
GcR/NN
by/IN
ketoconazole/NN
treatment/NN
,/,
at/IN
the/DT
time/NN
that/IN
cortisol/NN
levels/NNS
of/IN
patients/NNS
with/IN
Cushing/NN
's/POS
disease/NN
were/VBD
reduced/VBN
./.
====================
This/DT
indicates/VBZ
that/IN
the/DT
beneficial/JJ
effects/NNS
of/IN
ketoconazole/NN
in/IN
Cushing/NN
's/POS
disease/NN
are/VBP
due/JJ
to/TO
adrenal/JJ
cortisol/NN
suppression/NN
and/CC
not/RB
to/TO
interaction/NN
with/IN
GcR/NN
of/IN
target/NN
cells/NNS
,/,
and/CC
that/IN
the/DT
process/NN
of/IN
GcR/NN
regulation/NN
in/IN
hMNL/NN
is/VBZ
a/DT
complex/JJ
phenomenon/NN
awaiting/VBG
further/RBR
elucidation/NN
./.
====================
UI/LS
-/:
91296379/CD
====================
TI/LS
-/:
HTLV-1/NN
Tax/NN
induces/VBZ
expression/NN
of/IN
various/JJ
immediate/JJ
early/JJ
serum/NN
responsive/JJ
genes/NNS
./.
====================
AB/LS
-/:
Human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
1/CD
(/(
HTLV-1/NN
)/)
is/VBZ
an/DT
etiological/JJ
agent/NN
of/IN
adult/JJ
T-cell/NN
leukemia/NN
(/(
ATL/NN
)/)
./.
====================
We/PRP
showed/VBD
here/RB
by/IN
mobility-shift/NN
assay/NN
that/IN
T-cell/NN
lines/NNS
transformed/VBN
with/IN
the/DT
virus/NN
contained/VBD
high/JJ
levels/NNS
of/IN
AP-1/NN
activities/NNS
./.
====================
Consistent/JJ
with/IN
this/DT
result/NN
,/,
these/DT
cell/NN
lines/NNS
expressed/VBD
increased/VBN
levels/NNS
of/IN
mRNAs/NNS
encoding/VBG
the/DT
AP-1/NN
proteins/NNS
,/,
c-Fos/NN
,/,
Fra-1/NN
,/,
c-Jun/NN
,/,
JunB/NN
,/,
and/CC
JunD/NN
./.
====================
Previously/RB
,/,
transcription/NN
of/IN
the/DT
c-fos/NN
gene/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
transactivated/VBN
by/IN
the/DT
viral/JJ
transcription/NN
factor/NN
,/,
Tax1/NN
./.
====================
By/IN
using/VBG
the/DT
human/JJ
T-cell/NN
line/NN
(/(
JPX-9/NN
)/)
,/,
in/IN
which/WDT
expression/NN
of/IN
the/DT
Tax1/NN
is/VBZ
inducible/JJ
,/,
we/PRP
showed/VBD
that/IN
expression/NN
of/IN
mRNAs/NNS
for/IN
Fra-1/NN
,/,
c-Jun/NN
,/,
and/CC
JunD/NN
was/VBD
also/RB
transactivated/VBN
by/IN
Tax1/NN
./.
====================
Moreover/RB
,/,
Tax1/NN
activated/VBD
expression/NN
of/IN
two/CD
other/JJ
transcription/NN
factors/NNS
having/VBG
zinc/NN
finger/NN
motifs/NNS
,/,
Egr-1/NN
and/CC
Egr-2/NN
,/,
in/IN
the/DT
same/JJ
cells/NNS
./.
====================
The/DT
Tax1-inducible/JJ
transcription/NN
factors/NNS
identified/VBN
here/RB
are/VBP
encoded/VBN
by/IN
the/DT
members/NNS
of/IN
immediate/JJ
early/JJ
genes/NNS
under/IN
the/DT
control/NN
of/IN
growth/NN
signals/NNS
./.
====================
Thus/RB
,/,
Tax1/NN
was/VBD
suggested/VBN
to/TO
replace/VB
growth/NN
signals/NNS
,/,
at/IN
least/JJS
in/IN
part/NN
,/,
by/IN
this/DT
mechanism/NN
./.
====================
UI/LS
-/:
91221358/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptor/NN
characteristics/NNS
in/IN
monocytes/NNS
of/IN
patients/NNS
with/IN
corticosteroid-resistant/JJ
bronchial/JJ
asthma/NN
./.
====================
AB/LS
-/:
The/DT
mechanism/NN
of/IN
corticosteroid/NN
resistance/NN
in/IN
bronchial/JJ
asthma/NN
has/VBZ
been/VBN
studied/VBN
by/IN
determining/VBG
the/DT
rank/NN
order/NN
of/IN
potency/NN
for/IN
different/JJ
corticosteroids/NNS
in/IN
inhibiting/VBG
the/DT
generation/NN
of/IN
a/DT
3/CD
kD/NN
molecule/NN
from/IN
peripheral/JJ
blood/NN
monocytes/NNS
isolated/VBN
from/IN
corticosteroid-sensitive/JJ
(/(
CS/JJ
)/)
and/CC
corticosteroid-resistant/JJ
(/(
CR/JJ
)/)
asthmatic/JJ
subjects/NNS
,/,
which/WDT
augments/VBZ
leukotriene/NN
B4/NN
(/(
LTB4/NN
)/)
generation/NN
by/IN
human/JJ
neutrophils/NNS
(/(
PMN/NN
)/)
stimulated/VBN
by/IN
calcium/NN
ionophore/NN
./.
====================
In/IN
addition/NN
,/,
binding/VBG
studies/NNS
with/IN
(/(
3H/NN
)/)
dexamethasone/NN
have/VBP
been/VBN
performed/VBN
to/TO
determine/VB
the/DT
dissociation/NN
constant/NN
(/(
Kd/NN
)/)
and/CC
receptor/NN
numbers/NNS
(/(
Ro/NN
)/)
in/IN
the/DT
monocytes/NNS
of/IN
these/DT
two/CD
groups/NNS
of/IN
subjects/NNS
./.
====================
The/DT
concentration/NN
of/IN
corticosteroid/NN
producing/VBG
50/CD
%/NN
inhibition/NN
(/(
IC50/NN
)/)
was/VBD
600/CD
nM/NN
,/,
70/CD
nM/NN
,/,
and/CC
0.5/CD
nM/NN
for/IN
hydrocortisone/NN
,/,
methylprednisolone/NN
,/,
and/CC
dexamethasone/NN
,/,
respectively/RB
,/,
in/IN
monocytes/NNS
from/IN
CS/JJ
individuals/NNS
./.
====================
There/EX
was/VBD
only/RB
weak/JJ
inhibition/NN
of/IN
the/DT
generation/NN
of/IN
enhancing/NN
activity/NN
by/IN
the/DT
corticosteroids/NNS
in/IN
the/DT
CR/JJ
asthmatic/JJ
individuals/NNS
./.
====================
The/DT
dexamethasone/NN
Kd/NN
was/VBD
2.45/CD
+/-/CC
0.58/CD
nM/NN
(/(
mean/NN
+/-/CC
SEM/NN
,/,
n/NN
=/JJ
6/CD
)/)
in/IN
the/DT
CS/JJ
group/NN
and/CC
1.6/CD
+/-/CC
0.35/CD
nM/NN
(/(
mean/NN
+/-/CC
SEM/NN
,/,
n/NN
=/JJ
6/CD
)/)
in/IN
the/DT
CR/JJ
group/NN
of/IN
patients/NNS
(/(
p/NN
=/JJ
0.14/CD
)/)
./.
====================
The/DT
Ro/NN
in/IN
the/DT
CS/JJ
group/NN
was/VBD
3,605/CD
+/-/CC
984/CD
binding/VBG
sites/NNS
per/IN
nucleus/NN
(/(
mean/NN
+/-/CC
SEM/NN
,/,
n/NN
=/JJ
6/CD
)/)
and/CC
4,757/CD
+/-/CC
692/CD
binding/VBG
sites/NNS
per/IN
nucleus/NN
(/(
mean/NN
+/-/CC
SEM/NN
,/,
n/NN
=/JJ
6/CD
)/)
in/IN
the/DT
CR/JJ
group/NN
(/(
p/NN
=/JJ
0.23/CD
)/)
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
corticosteroid/NN
resistance/NN
in/IN
bronchial/JJ
asthma/NN
can/MD
not/RB
be/VB
explained/VBN
by/IN
abnormalities/NNS
in/IN
corticosteroid/NN
receptor/NN
characteristics/NNS
./.
====================
UI/LS
-/:
91210272/CD
====================
TI/LS
-/:
Vitamin/NN
D/NN
receptor/NN
expression/NN
in/IN
human/JJ
lymphocytes/NNS
./.
====================
Signal/NN
requirements/NNS
and/CC
characterization/NN
by/IN
western/NN
blots/NNS
and/CC
DNA/NN
sequencing/NN
./.
====================
AB/LS
-/:
The/DT
signals/NNS
controlling/VBG
the/DT
expression/NN
of/IN
the/DT
receptor/NN
protein/NN
for/IN
1/CD
alpha,25-dihydroxyvitamin/NN
D3/NN
in/IN
normal/JJ
human/JJ
lymphocytes/NNS
and/CC
the/DT
relationship/NN
of/IN
this/DT
protein/NN
to/TO
the/DT
classical/JJ
vitamin/NN
D/NN
receptor/NN
were/VBD
examined/VBN
./.
====================
Lymphocytes/NNS
activated/VBN
with/IN
the/DT
OKT3/NN
antibody/NN
to/TO
the/DT
T-cell/NN
antigen/NN
receptor/NN
expressed/VBD
fewer/JJR
binding/VBG
sites/NNS
as/IN
compared/VBN
to/TO
lymphocytes/NNS
that/WDT
were/VBD
activated/VBN
by/IN
the/DT
polyclonal/JJ
activator/NN
phytohemagglutinin/NN
(/(
PHA/NN
)/)
./.
====================
However/RB
,/,
combination/NN
of/IN
OKT3/NN
and/CC
phorbol/NN
myristate/NN
acetate/NN
produced/VBD
a/DT
concentration/NN
of/IN
binding/VBG
sites/NNS
similar/JJ
to/TO
the/DT
PHA-activated/JJ
cells/NNS
./.
====================
The/DT
receptor/NN
from/IN
OKT3/NN
and/CC
OKT3/NN
+/CC
phorbol/NN
myristate/NN
acetate-activated/JJ
lymphocytes/NNS
exhibited/VBD
decreased/VBN
binding/NN
to/TO
DNA-cellulose/NN
compared/VBN
to/TO
PHA-activated/JJ
lymphocytes/NNS
./.
====================
In/IN
lymphocytes/NNS
activated/VBN
either/CC
by/IN
PHA/NN
or/CC
OKT3/NN
(/(
but/CC
not/RB
in/IN
resting/VBG
cells/NNS
)/)
,/,
a/DT
50-kDa/JJ
species/NNS
cross-reacting/VBG
with/IN
a/DT
monoclonal/JJ
antibody/NN
against/IN
the/DT
intestinal/JJ
vitamin/NN
D/NN
receptor/NN
was/VBD
detected/VBN
./.
====================
Finally/RB
,/,
RNA/NN
from/IN
activated/VBN
lymphocytes/NNS
was/VBD
amplified/VBN
by/IN
polymerase/NN
chain/NN
reaction/NN
using/VBG
oligonucleotide/NN
primers/NNS
flanking/VBG
the/DT
196/CD
base/NN
pair/NN
long/JJ
region/NN
encoding/VBG
the/DT
DNA-binding/JJ
domain/NN
of/IN
the/DT
human/JJ
intestinal/JJ
receptor/NN
./.
====================
The/DT
amplified/VBN
product/NN
showed/VBD
an/DT
identical/JJ
nucleotide/NN
sequence/NN
to/TO
the/DT
DNA-binding/JJ
domain/NN
of/IN
the/DT
human/JJ
intestinal/JJ
receptor/NN
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
expression/NN
of/IN
the/DT
1,25-(OH)2D3/NN
receptor/NN
in/IN
lymphocytes/NNS
is/VBZ
triggered/VBN
by/IN
distinct/JJ
and/CC
contingent/JJ
signals/NNS
,/,
and/CC
that/IN
the/DT
protein/NN
and/CC
the/DT
mRNA/NN
encoding/VBG
it/PRP
are/VBP
identical/JJ
to/TO
the/DT
classical/JJ
vitamin/NN
D/NN
receptor/NN
./.
====================
UI/LS
-/:
91172768/CD
====================
TI/LS
-/:
Comparison/NN
of/IN
constitutive/JJ
and/CC
inducible/JJ
transcriptional/JJ
enhancement/NN
mediated/VBN
by/IN
kappa/NN
B-related/JJ
sequences/NNS
:/:
modulation/NN
of/IN
activity/NN
in/IN
B/NN
cells/NNS
by/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
tax/NN
gene/NN
./.
====================
AB/LS
-/:
The/DT
kappa/NN
B/NN
sequence/NN
(/(
GGGACTTTCC/NN
)/)
binds/VBZ
a/DT
factor/NN
,/,
NF-kappa/NN
B/NN
,/,
that/WDT
is/VBZ
constitutively/RB
found/VBN
in/IN
its/PRP$
functional/JJ
,/,
DNA/NN
binding/NN
form/NN
only/RB
in/IN
B/NN
lymphocytes/NNS
./.
====================
A/DT
factor/NN
with/IN
apparently/RB
indistinguishable/JJ
sequence/NN
specificity/NN
can/MD
be/VB
induced/VBN
in/IN
many/JJ
other/JJ
cell/NN
types/NNS
,/,
where/WRB
it/PRP
is/VBZ
used/VBN
to/TO
regulate/VB
inducible/JJ
gene/NN
expression/NN
./.
====================
For/IN
example/NN
,/,
kappa/NN
B-related/JJ
sequences/NNS
have/VBP
been/VBN
shown/VBN
to/TO
be/VB
important/JJ
for/IN
the/DT
transcription/NN
of/IN
a/DT
few/JJ
inducible/JJ
genes/NNS
,/,
such/JJ
as/IN
the/DT
interleukin/NN
2/CD
receptor/NN
alpha-chain/NN
gene/NN
and/CC
the/DT
beta-interferon/NN
gene/NN
./.
====================
However/RB
,/,
these/DT
genes/NNS
are/VBP
not/RB
constitutively/RB
active/JJ
in/IN
B/NN
lymphocytes/NNS
,/,
suggesting/VBG
that/IN
other/JJ
regulatory/JJ
mechanisms/NNS
must/MD
play/VB
a/DT
role/NN
in/IN
determining/VBG
the/DT
patterns/NNS
of/IN
expression/NN
./.
====================
We/PRP
have/VBP
investigated/VBN
the/DT
constitutive/JJ
and/CC
inducible/JJ
transcriptional/JJ
activity/NN
mediated/VBN
by/IN
five/CD
kappa/NN
B-related/JJ
sequence/NN
elements/NNS
in/IN
two/CD
different/JJ
cell/NN
types/NNS
./.
====================
We/PRP
show/VBP
that/IN
in/IN
S194/NN
plasma/NN
cells/NNS
the/DT
activity/NN
of/IN
each/DT
element/NN
correlates/VBZ
well/RB
with/IN
the/DT
relative/JJ
affinity/NN
of/IN
B-cell-derived/JJ
NF-kappa/NN
B/NN
for/IN
that/DT
element/NN
./.
====================
This/DT
leads/VBZ
to/TO
significantly/RB
lower/RBR
transcription/NN
enhancement/NN
by/IN
sites/NNS
derived/VBN
from/IN
the/DT
interleukin/NN
2/CD
receptor/NN
or/CC
T-cell/NN
receptor/NN
genes/NNS
in/IN
S194/NN
cells/NNS
./.
====================
However/RB
,/,
in/IN
either/CC
EL-4/NN
(/(
T/NN
)/)
cells/NNS
or/CC
S194/NN
cells/NNS
,/,
both/DT
lower-affinity/JJ
sites/NNS
can/MD
be/VB
significantly/RB
induced/VBN
by/IN
the/DT
tax/NN
gene/NN
product/NN
of/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
,/,
showing/VBG
that/IN
NF-kappa/NN
B/NN
activity/NN
can/MD
be/VB
modulated/VBN
even/RB
in/IN
a/DT
B-cell/NN
line/NN
that/WDT
constitutively/RB
expresses/VBZ
this/DT
factor/NN
./.
====================
UI/LS
-/:
91110562/CD
====================
TI/LS
-/:
Specific/JJ
depletion/NN
of/IN
the/DT
B-cell/NN
population/NN
induced/VBN
by/IN
aberrant/JJ
expression/NN
of/IN
human/JJ
interferon/NN
regulatory/JJ
factor/NN
1/CD
gene/NN
in/IN
transgenic/JJ
mice/NNS
./.
====================
AB/LS
-/:
Interferons/NNS
(/(
IFNs/NNS
)/)
are/VBP
well/RB
known/VBN
both/CC
as/IN
antiviral/JJ
proteins/NNS
and/CC
as/IN
potent/JJ
regulators/NNS
of/IN
cell/NN
growth/NN
and/CC
differentiation/NN
./.
====================
In/IN
fact/NN
,/,
IFNs/NNS
inhibit/VBP
growth/NN
of/IN
various/JJ
normal/JJ
and/CC
transformed/VBN
cell/NN
types/NNS
./.
====================
Previously/RB
,/,
a/DT
nuclear/JJ
factor/NN
,/,
IRF-1/NN
(/(
interferon/NN
regulatory/JJ
factor/NN
1/CD
)/)
,/,
which/WDT
binds/VBZ
to/TO
type/NN
I/CD
IFN/NN
and/CC
some/DT
IFN-inducible/JJ
gene/NN
promoters/NNS
,/,
was/VBD
identified/VBN
and/CC
cloned/VBN
./.
====================
Since/IN
the/DT
IRF-1/NN
gene/NN
is/VBZ
both/CC
virus/NN
and/CC
IFN/NN
inducible/JJ
,/,
an/DT
intriguing/JJ
issue/NN
is/VBZ
raised/VBN
as/IN
to/TO
whether/IN
the/DT
IRF-1/NN
gene/NN
is/VBZ
functioning/VBG
in/IN
IFN-mediated/JJ
regulation/NN
of/IN
cell/NN
growth/NN
and/CC
differentiation/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
generated/VBD
transgenic/JJ
mice/NNS
carrying/VBG
the/DT
human/JJ
IRF-1/NN
gene/NN
linked/VBN
to/TO
the/DT
human/JJ
immunoglobulin/NN
heavy-chain/JJ
enhancer/NN
./.
====================
In/IN
the/DT
transgenic/JJ
mice/NNS
,/,
all/PDT
the/DT
lymphoid/JJ
tissues/NNS
examined/VBN
showed/VBD
a/DT
dramatic/JJ
reduction/NN
in/IN
the/DT
number/NN
of/IN
B/NN
lymphocytes/NNS
(/(
B/NN
cells/NNS
)/)
./.
====================
Preparation/NN
and/CC
analysis/NN
of/IN
bone/NN
marrow/NN
cells/NNS
from/IN
the/DT
chimeric/JJ
mice/NNS
indicated/VBD
that/IN
the/DT
bone/NN
marrow/NN
is/VBZ
the/DT
effective/JJ
site/NN
for/IN
specific/JJ
depletion/NN
of/IN
the/DT
B-cell/NN
population/NN
./.
====================
In/IN
fact/NN
,/,
transgenic/JJ
bone/NN
marrow/NN
cells/NNS
cocultured/VBN
with/IN
a/DT
bone/NN
marrow-derived/JJ
stromal/JJ
cell/NN
line/NN
revealed/VBD
an/DT
altered/JJ
B-cell/NN
maturation/NN
pattern/NN
./.
====================
UI/LS
-/:
92108417/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
a/DT
cofactor/NN
that/WDT
regulates/VBZ
dimerization/NN
of/IN
a/DT
mammalian/JJ
homeodomain/NN
protein/NN
./.
====================
AB/LS
-/:
Dimerization/NN
among/IN
transcription/NN
factors/NNS
has/VBZ
become/VBN
a/DT
recurrent/JJ
theme/NN
in/IN
the/DT
regulation/NN
of/IN
eukaryotic/JJ
gene/NN
expression/NN
./.
====================
Hepatocyte/NN
nuclear/JJ
factor-1/NN
alpha/NN
(/(
HNF-1/NN
alpha/NN
)/)
is/VBZ
a/DT
homeodomain-containing/JJ
protein/NN
that/WDT
functions/VBZ
as/IN
a/DT
dimer/NN
./.
====================
A/DT
dimerization/NN
cofactor/NN
of/IN
HNF-1/NN
alpha/NN
(/(
DCoH/NN
)/)
was/VBD
identified/VBN
that/WDT
displayed/VBD
a/DT
restricted/JJ
tissue/NN
distribution/NN
and/CC
did/VBD
not/RB
bind/VB
to/TO
DNA/NN
,/,
but/CC
,/,
rather/RB
,/,
selectively/RB
stabilized/VBD
HNF-1/NN
alpha/NN
dimers/NNS
./.
====================
The/DT
formation/NN
of/IN
a/DT
stable/JJ
tetrameric/JJ
DCoH-HNF-1/NN
alpha/NN
complex/NN
,/,
which/WDT
required/VBD
the/DT
dimerization/NN
domain/NN
of/IN
HNF-1/NN
alpha/NN
,/,
did/VBD
not/RB
change/VB
the/DT
DNA/NN
binding/NN
characteristics/NNS
of/IN
HNF-1/NN
alpha/NN
,/,
but/CC
enhanced/VBD
its/PRP$
transcriptional/JJ
activity/NN
./.
====================
However/RB
,/,
DCoH/NN
did/VBD
not/RB
confer/VB
transcriptional/JJ
activation/NN
to/TO
the/DT
GAL4/NN
DNA/NN
binding/NN
domain/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
DCoH/NN
regulates/VBZ
formation/NN
of/IN
transcriptionally/RB
active/JJ
tetrameric/JJ
complexes/NNS
and/CC
may/MD
contribute/VB
to/TO
the/DT
developmental/JJ
specificity/NN
of/IN
the/DT
complex/NN
./.
====================
UI/LS
-/:
92060325/CD
====================
TI/LS
-/:
Glucocorticoid/NN
resistance/NN
in/IN
chronic/JJ
asthma/NN
./.
====================
Glucocorticoid/NN
pharmacokinetics/NNS
,/,
glucocorticoid/NN
receptor/NN
characteristics/NNS
,/,
and/CC
inhibition/NN
of/IN
peripheral/JJ
blood/NN
T/NN
cell/NN
proliferation/NN
by/IN
glucocorticoids/NNS
in/FW
vitro/FW
./.
====================
AB/LS
-/:
A/DT
total/NN
of/IN
37/CD
chronic/JJ
,/,
severe/JJ
,/,
nonsmoking/JJ
asthmatic/JJ
patients/NNS
with/IN
documented/JJ|VBN
reversible/JJ
airways/NNS
obstruction/NN
were/VBD
classified/VBN
as/IN
glucocorticoid-sensitive/JJ
or/CC
-resistant/JJ
on/IN
the/DT
basis/NN
of/IN
changes/NNS
in/IN
FEV1/NN
,/,
FVC/NN
,/,
and/CC
peak/JJ
expiratory/NN
flow/NN
(/(
PEF/NN
)/)
after/IN
oral/JJ
prednisolone/NN
./.
====================
The/DT
resistant/JJ
patients/NNS
showed/VBD
no/DT
significant/JJ
improvements/NNS
in/IN
airflow/NN
limitation/NN
./.
====================
Phytohemagglutinin/NN
(/(
PHA/NN
)/)
-induced/JJ
proliferation/NN
of/IN
peripheral/JJ
blood/NN
T/NN
lymphocytes/NNS
from/IN
the/DT
sensitive/JJ
but/CC
not/RB
the/DT
resistant/JJ
asthmatic/JJ
patients/NNS
was/VBD
significantly/RB
(/(
p/NN
less/JJR
than/IN
0.01/CD
)/)
inhibited/VBN
by/IN
dexamethasone/NN
(/(
10/CD
(/(
-7/CD
)/)
mol/L/NN
)/)
,/,
reflecting/VBG
a/DT
shift/NN
of/IN
the/DT
dose-response/JJ
curve/NN
./.
====================
When/WRB
all/PDT
the/DT
asthmatic/JJ
patients/NNS
were/VBD
analyzed/VBN
together/RB
,/,
there/EX
was/VBD
a/DT
significant/JJ
correlation/NN
between/IN
the/DT
degree/NN
of/IN
sensitivity/NN
of/IN
T/NN
cells/NNS
to/TO
dexamethasone/NN
and/CC
the/DT
clinical/JJ
responsiveness/NN
to/TO
prednisolone/JJ
(/(
p/NN
less/RBR
than/IN
0.01/CD
)/)
./.
====================
No/DT
differences/NNS
were/VBD
observed/VBN
between/IN
six/CD
of/IN
the/DT
sensitive/JJ
and/CC
resistant/JJ
patients/NNS
in/IN
the/DT
clearance/NN
of/IN
plasma/NN
prednisolone/JJ
derived/VBN
from/IN
orally/RB
administered/VBN
prednisone/NN
./.
====================
Peripheral/JJ
blood/NN
mononuclear/JJ
cell/NN
glucocorticoid/NN
receptors/NNS
were/VBD
also/RB
characterized/VBN
in/IN
five/CD
sensitive/JJ
and/CC
seven/CD
resistant/JJ
patients/NNS
./.
====================
The/DT
numbers/NNS
and/CC
binding/NN
affinities/NNS
of/IN
these/DT
receptors/NNS
could/MD
not/RB
account/VB
for/IN
the/DT
observed/VBN
difference/NN
in/IN
the/DT
susceptibility/NN
of/IN
these/DT
cells/NNS
to/TO
functional/JJ
inhibition/NN
by/IN
dexamethasone/NN
in/FW
vitro/FW
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
clinical/JJ
glucocorticoid/NN
resistance/NN
in/IN
chronic/JJ
asthma/NN
does/VBZ
not/RB
reflect/VB
abnormal/JJ
glucocorticoid/NN
clearance/NN
but/CC
may/MD
be/VB
due/JJ
at/IN
least/JJS
partly/RB
to/TO
a/DT
relative/JJ
insensitivity/NN
of/IN
T/NN
lymphocytes/NNS
to/TO
glucocorticoids/NNS
./.
====================
This/DT
lack/NN
of/IN
sensitivity/NN
is/VBZ
unexplained/JJ
but/CC
is/VBZ
not/RB
attributable/JJ
to/TO
abnormalities/NNS
of/IN
cellular/JJ
glucocorticoid/NN
receptors/NNS
./.
====================
UI/LS
-/:
92042309/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
phorbol/NN
ester-induced/JJ
monocytic/JJ
differentiation/NN
by/IN
dexamethasone/NN
is/VBZ
associated/VBN
with/IN
down-regulation/NN
of/IN
c-fos/NN
and/CC
c-jun/NN
(/(
AP-1/NN
)/)
./.
====================
AB/LS
-/:
Previous/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
treatment/NN
of/IN
human/JJ
myeloid/JJ
leukemia/NN
cells/NNS
with/IN
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
is/VBZ
associated/VBN
with/IN
induction/NN
of/IN
monocytic/JJ
differentiation/NN
and/CC
expression/NN
of/IN
the/DT
c-jun/NN
and/CC
c-fos/NN
early/JJ
response/NN
genes/NNS
./.
====================
The/DT
present/JJ
work/NN
demonstrates/VBZ
that/IN
the/DT
glucocorticoid/NN
dexamethasone/NN
inhibits/VBZ
TPA-induced/JJ
increases/NNS
in/IN
c-jun/NN
and/CC
c-fos/NN
mRNA/NN
levels/NNS
in/IN
U-937/NN
leukemia/NN
cells/NNS
./.
====================
These/DT
findings/NNS
were/VBD
associated/VBN
with/IN
a/DT
block/NN
in/IN
appearance/NN
of/IN
the/DT
monocytic/JJ
phenotype/NN
,/,
including/VBG
inhibition/NN
of/IN
TPA-induced/JJ
increases/NNS
in/IN
lamin/NN
A/NN
,/,
lamin/NN
C/NN
,/,
and/CC
vimentin/NN
transcripts/NNS
./.
====================
Other/JJ
studies/NNS
have/VBP
demonstrated/VBN
that/IN
TPA-induced/JJ
monocytic/JJ
differentiation/NN
and/CC
expression/NN
of/IN
the/DT
c-jun/NN
and/CC
c-fos/NN
genes/NNS
in/IN
myeloid/JJ
leukemia/NN
cells/NNS
are/VBP
regulated/VBN
by/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
./.
====================
The/DT
finding/NN
that/IN
dexamethasone/NN
has/VBZ
no/DT
effect/NN
on/IN
TPA-induced/JJ
activation/NN
of/IN
PKC/NN
suggests/VBZ
that/IN
this/DT
glucocorticoid/NN
inhibits/VBZ
signals/NNS
downstream/JJ
or/CC
parallel/JJ
to/TO
this/DT
enzyme/NN
./.
====================
Nuclear/JJ
run-on/JJ
assays/NNS
demonstrate/VBP
that/IN
:/:
(/(
1/LS
)/)
induction/NN
of/IN
c-jun/NN
and/CC
c-fos/NN
expression/NN
by/IN
TPA/NN
is/VBZ
regulated/VBN
by/IN
transcriptional/JJ
mechanisms/NNS
,/,
(/(
2/LS
)/)
TPA-induced/JJ
expression/NN
of/IN
c-jun/NN
and/CC
c-fos/NN
does/VBZ
not/RB
require/VB
protein/NN
synthesis/NN
,/,
and/CC
(/(
3/LS
)/)
TPA-induced/JJ
expression/NN
of/IN
both/DT
genes/NNS
is/VBZ
inhibited/VBN
at/IN
the/DT
transcriptional/JJ
level/NN
by/IN
dexamethasone/NN
./.
====================
To/TO
further/RB
define/VB
the/DT
effects/NNS
of/IN
dexamethasone/NN
at/IN
the/DT
molecular/JJ
level/NN
,/,
we/PRP
prepared/VBD
a/DT
series/NN
of/IN
deleted/VBN
c-jun/NN
promoter/NN
fragments/NNS
linked/VBN
to/TO
the/DT
chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
gene/NN
./.
====================
Increases/NNS
in/IN
CAT/NN
activity/NN
during/IN
transient/JJ
expression/NN
of/IN
these/DT
constructs/NNS
in/IN
TPA-treated/JJ
U-937/NN
cells/NNS
could/MD
be/VB
assigned/VBN
to/TO
the/DT
region/NN
(/(
-97/CD
to/TO
-20/CD
)/)
of/IN
the/DT
promoter/NN
that/WDT
contains/VBZ
the/DT
AP-1/NN
binding/NN
site/NN
./.
====================
This/DT
induction/NN
of/IN
CAT/NN
activity/NN
was/VBD
sensitive/JJ
to/TO
dexamethasone/NN
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
dexamethasone/NN
down-regulates/VBZ
TPA-induced/JJ
transcription/NN
of/IN
the/DT
c-jun/NN
gene/NN
during/IN
monocytic/JJ
differentiation/NN
by/IN
inhibiting/VBG
activation/NN
of/IN
the/DT
AP-1/NN
site/NN
./.
====================
UI/LS
-/:
91366165/CD
====================
TI/LS
-/:
Tumor/NN
necrosis/NN
factor-alpha/NN
mRNA/NN
accumulation/NN
in/IN
human/JJ
myelomonocytic/JJ
cell/NN
lines/NNS
./.
====================
Role/NN
of/IN
transcriptional/JJ
regulation/NN
by/IN
DNA/NN
sequence/NN
motifs/NNS
and/CC
mRNA/NN
stabilization/NN
./.
====================
AB/LS
-/:
The/DT
cytokine/NN
TNF/NN
mediates/VBZ
many/JJ
of/IN
the/DT
pathologic/JJ
signs/NNS
of/IN
cachexia/NN
,/,
inflammation/NN
,/,
and/CC
sepsis/NN
./.
====================
The/DT
current/JJ
work/NN
describes/VBZ
the/DT
regulation/NN
of/IN
TNF/NN
in/IN
human/JJ
myelomonocytic/JJ
cell/NN
lines/NNS
after/IN
PMA/NN
stimulation/NN
./.
====================
The/DT
cell/NN
lines/NNS
exhibit/VBP
a/DT
low/JJ
level/NN
of/IN
constitutive/JJ
TNF/NN
mRNA/NN
expression/NN
./.
====================
Within/IN
2/CD
to/TO
4/CD
h/NN
of/IN
PMA/NN
exposure/NN
,/,
steady/JJ
state/NN
levels/NNS
of/IN
TNF/NN
mRNA/NN
are/VBP
markedly/RB
elevated/JJ
in/IN
all/DT
myelomonocytic/JJ
cell/NN
lines/NNS
studied/VBN
./.
====================
This/DT
rise/NN
is/VBZ
due/JJ
to/TO
increased/VBN
mRNA/NN
stability/NN
,/,
which/WDT
increased/VBD
by/IN
almost/RB
twofold/RB
,/,
and/CC
to/TO
an/DT
overall/JJ
increase/NN
in/IN
transcription/NN
,/,
which/WDT
rises/VBZ
by/IN
more/JJR
than/IN
sixfold/RB
./.
====================
At/IN
the/DT
level/NN
of/IN
the/DT
genomic/JJ
TNF/NN
gene/NN
,/,
a/DT
DNase/NN
I/CD
hypersensitive/JJ
site/NN
is/VBZ
detected/VBN
within/IN
the/DT
TNF/NN
promoter/NN
between/IN
-200/CD
to/TO
-100/CD
bp/NN
relative/JJ
to/TO
the/DT
transcription/NN
initiation/NN
site/NN
./.
====================
Although/IN
absent/JJ
in/IN
nonexpressing/VBG
erythroleukemia/NN
cell/NN
lines/NNS
,/,
the/DT
DNase/NN
I/CD
site/NN
is/VBZ
present/JJ
in/IN
uninduced/JJ
myelomonocytic/JJ
cell/NN
lines/NNS
and/CC
is/VBZ
not/RB
changed/VBN
after/IN
PMA/NN
induction/NN
./.
====================
The/DT
PMA/NN
induction/NN
of/IN
c-fos/NN
mRNA/NN
correlated/VBD
well/RB
with/IN
TNF/NN
gene/NN
induction/NN
;/:
expression/NN
of/IN
genes/NNS
encoding/VBG
other/JJ
proteins/NNS
in/IN
the/DT
AP-1/NN
complex/NN
(/(
junB/NN
and/CC
junD/NN
)/)
were/VBD
also/RB
induced/VBN
by/IN
PMA/NN
./.
====================
The/DT
nuclear/JJ
extracts/NNS
from/IN
resting/VBG
and/CC
induced/VBN
ML-1/NN
cells/NNS
contain/VBP
proteins/NNS
binding/VBG
specifically/RB
to/TO
the/DT
AP-1/NN
,/,
AP-2/NN
,/,
and/CC
NF/NN
kappa/NN
B/NN
sequence/NN
located/JJ
within/IN
the/DT
TNF/NN
promoter/NN
./.
====================
PMA/NN
induction/NN
increases/VBZ
the/DT
level/NN
of/IN
a/DT
number/NN
of/IN
specific/JJ
binding/VBG
complexes/NNS
relative/JJ
to/TO
the/DT
resting/VBG
cells/NNS
./.
====================
The/DT
regulatory/JJ
mechanisms/NNS
of/IN
the/DT
human/JJ
and/CC
murine/JJ
TNF/NN
genes/NNS
are/VBP
discussed/VBN
./.
====================
UI/LS
-/:
91319738/CD
====================
TI/LS
-/:
Enhancement/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
1/CD
replication/NN
in/IN
monocytes/NNS
by/IN
1,25-dihydroxycholecalciferol/NN
./.
====================
AB/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
expression/NN
and/CC
replication/NN
are/VBP
under/IN
tight/JJ
regulatory/JJ
control/NN
./.
====================
We/PRP
demonstrate/VBP
that/IN
1,25-dihydroxycholecalciferol/NN
[/(
1,25-(OH)2D3/NN
]/)
enhances/VBZ
the/DT
replication/NN
of/IN
monocyte-/NN
and/CC
lymphocyte-tropic/JJ
strains/NNS
of/IN
HIV-1/NN
up/IN
to/TO
10,000-fold/RB
in/IN
monocyte/NN
cell/NN
lines/NNS
,/,
peripheral/JJ
blood/NN
monocytes/NNS
,/,
and/CC
unfractionated/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
./.
====================
1,25(OH)2D3/NN
is/VBZ
therefore/RB
one/CD
of/IN
the/DT
most/RBS
potent/JJ
regulators/NNS
of/IN
HIV-1/NN
replication/NN
described/VBN
to/TO
date/NN
./.
====================
Precursors/NNS
of/IN
1,25(OH)2D3/NN
enhance/VBP
HIV-1/NN
replication/NN
in/IN
proportion/NN
to/TO
their/PRP$
affinity/NN
for/IN
the/DT
1,25(OH)2D3/NN
intracellular/JJ
receptor/NN
,/,
suggesting/VBG
that/IN
1,25(OH)2D3/NN
influences/VBZ
HIV-1/NN
replication/NN
by/IN
mechanisms/NNS
involving/VBG
this/DT
receptor/NN
./.
====================
These/DT
studies/NNS
may/MD
have/VB
important/JJ
implications/NNS
for/IN
the/DT
design/NN
of/IN
effective/JJ
therapy/NN
of/IN
HIV-1/NN
infection/NN
./.
====================
UI/LS
-/:
91237114/CD
====================
TI/LS
-/:
Transforming/VBG
growth/NN
factor-beta/NN
suppresses/VBZ
human/JJ
B/NN
lymphocyte/NN
Ig/NN
production/NN
by/IN
inhibiting/VBG
synthesis/NN
and/CC
the/DT
switch/NN
from/IN
the/DT
membrane/NN
form/NN
to/TO
the/DT
secreted/JJ
form/NN
of/IN
Ig/NN
mRNA/NN
./.
====================
AB/LS
-/:
Transforming/VBG
growth/NN
factor-beta/NN
(/(
TGF-beta/NN
)/)
inhibits/VBZ
B/NN
cell/NN
Ig/NN
secretion/NN
and/CC
reduces/VBZ
B/NN
cell/NN
membrane/NN
Ig/NN
expression/NN
./.
====================
The/DT
addition/NN
of/IN
TGF-beta/NN
to/TO
human/JJ
B/NN
lymphocyte/NN
cultures/NNS
stimulated/VBN
with/IN
Staphylococcus/FW
aureus/FW
Cowan/NN
strain/NN
I/NN
and/CC
IL-2/NN
completely/RB
inhibited/VBD
B/NN
cell/NN
Ig/NN
secretion/NN
(/(
greater/JJR
than/IN
90/CD
%/NN
)/)
and/CC
decreased/VBD
B/NN
cell/NN
surface/NN
IgM/NN
,/,
IgD/NN
,/,
kappa/NN
L/NN
chain/NN
,/,
and/CC
lambda/NN
L/NN
chain/NN
expression/NN
./.
====================
In/IN
contrast/NN
,/,
TGF-beta/NN
had/VBD
only/RB
minimal/JJ
effects/NNS
on/IN
two/CD
other/JJ
B/NN
cell/NN
membrane/NN
proteins/NNS
,/,
HLA-DR/NN
and/CC
CD20/NN
./.
====================
Internal/JJ
labeling/NN
with/IN
[35S]methionine/NN
and/CC
immunoprecipitation/NN
with/IN
anti-IgM/JJ
,/,
anti-kappa/JJ
,/,
and/CC
anti-lambda/JJ
antibodies/NNS
revealed/VBD
a/DT
striking/JJ
reduction/NN
in/IN
kappa/NN
L/NN
chain/NN
in/IN
the/DT
presence/NN
of/IN
TGF-beta/NN
./.
====================
A/DT
less/RBR
pronounced/JJ
reduction/NN
in/IN
lambda/NN
L/NN
chain/NN
and/CC
microH/NN
chain/NN
was/VBD
also/RB
noted/VBN
./.
====================
Northern/NN
blot/NN
analysis/NN
of/IN
RNA/NN
purified/VBN
from/IN
B/NN
cells/NNS
treated/VBN
with/IN
TGF-beta/NN
for/IN
varying/VBG
time/NN
intervals/NNS
revealed/VBD
a/DT
significant/JJ
decrease/NN
in/IN
steady/JJ
state/NN
kappa/NN
and/CC
lambda/NN
L/NN
chain/NN
mRNA/NN
levels/NNS
./.
====================
Furthermore/RB
,/,
a/DT
significant/JJ
decrease/NN
in/IN
the/DT
switch/NN
from/IN
the/DT
membrane/NN
forms/NNS
of/IN
mu/NN
and/CC
gamma/NN
to/TO
their/PRP$
respective/JJ
secreted/JJ
forms/NNS
was/VBD
noted/VBN
in/IN
the/DT
presence/NN
of/IN
TGF-beta/NN
./.
====================
Nuclear/JJ
run-on/JJ
experiments/NNS
demonstrated/VBD
decreased/VBN
transcription/NN
of/IN
kappa/NN
L/NN
chain/NN
./.
====================
The/DT
effects/NNS
of/IN
TGF-beta/NN
on/IN
two/CD
transcriptional/JJ
regulatory/JJ
factors/NNS
,/,
Oct-2/NN
and/CC
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
kappa/NN
B/NN
,/,
known/VBN
to/TO
be/VB
important/JJ
in/IN
Ig/NN
gene/NN
transcription/NN
were/VBD
examined/VBN
./.
====================
Oct-2/NN
mRNA/NN
levels/NNS
and/CC
both/DT
Oct-2/NN
and/CC
NF-kappa/NN
B/NN
proteins/NNS
in/IN
nuclear/JJ
extracts/NNS
were/VBD
not/RB
altered/VBN
by/IN
treatment/NN
with/IN
TGF-beta/NN
./.
====================
In/IN
contrast/NN
,/,
levels/NNS
of/IN
the/DT
transcriptional/JJ
factor/NN
AP-1/NN
,/,
which/WDT
is/VBZ
not/RB
known/VBN
to/TO
be/VB
important/JJ
in/IN
B/NN
cell/NN
Ig/NN
production/NN
,/,
were/VBD
reduced/VBN
by/IN
TGF-beta/NN
./.
====================
These/DT
findings/NNS
demonstrate/VBP
that/IN
TGF-beta/NN
decreases/VBZ
B/NN
lymphocyte/NN
Ig/NN
secretion/NN
by/IN
inhibiting/VBG
the/DT
synthesis/NN
of/IN
Ig/NN
mRNA/NN
and/CC
inhibiting/VBG
the/DT
switch/NN
from/IN
the/DT
membrane/NN
form/NN
to/TO
the/DT
secreted/JJ
forms/NNS
of/IN
mu/NN
and/CC
gamma/NN
mRNA/NN
./.
====================
The/DT
mechanism/NN
by/IN
which/WDT
TGF-beta/NN
inhibits/VBZ
Ig/NN
chain/NN
synthesis/NN
is/VBZ
unclear/JJ
although/IN
it/PRP
does/VBZ
not/RB
involve/VB
inhibition/NN
of/IN
the/DT
binding/NN
of/IN
NF-kappa/NN
B/NN
or/CC
Oct-2/NN
to/TO
their/PRP$
respective/JJ
target/NN
sequences/NNS
./.
====================
UI/LS
-/:
91203899/CD
====================
TI/LS
-/:
Murine/JJ
and/CC
human/JJ
T-lymphocyte/NN
GATA-3/NN
factors/NNS
mediate/VBP
transcription/NN
through/IN
a/DT
cis-regulatory/JJ
element/NN
within/IN
the/DT
human/JJ
T-cell/NN
receptor/NN
delta/NN
gene/NN
enhancer/NN
./.
====================
AB/LS
-/:
A/DT
family/NN
of/IN
transcriptional/JJ
activators/NNS
has/VBZ
recently/RB
been/VBN
identified/VBN
in/IN
chickens/NNS
;/:
these/DT
transcriptional/JJ
activators/NNS
recognize/VBP
a/DT
common/JJ
consensus/NN
motif/NN
(/(
WGATAR/NN
)/)
through/IN
a/DT
conserved/VBN
C4/NN
zinc/NN
finger/NN
DNA-binding/JJ
domain/NN
./.
====================
One/CD
of/IN
the/DT
members/NNS
of/IN
this/DT
multigene/JJ
family/NN
,/,
cGATA-3/NN
,/,
is/VBZ
most/RBS
abundantly/RB
expressed/VBN
in/IN
the/DT
T-lymphocyte/NN
cell/NN
lineage/NN
./.
====================
Analysis/NN
of/IN
human/JJ
and/CC
murine/JJ
GATA-3/NN
factors/NNS
shows/VBZ
a/DT
striking/JJ
degree/NN
of/IN
amino/NN
acid/NN
sequence/NN
identity/NN
and/CC
similar/JJ
patterns/NNS
of/IN
tissue/NN
specificity/NN
of/IN
expression/NN
in/IN
these/DT
three/CD
organisms/NNS
./.
====================
The/DT
murine/JJ
and/CC
human/JJ
factors/NNS
are/VBP
abundantly/RB
expressed/VBN
in/IN
a/DT
variety/NN
of/IN
human/JJ
and/CC
murine/JJ
T-cell/NN
lines/NNS
and/CC
can/MD
activate/VB
transcription/NN
through/IN
a/DT
tissue-specific/JJ
GATA-binding/JJ
site/NN
identified/VBN
within/IN
the/DT
human/JJ
T-cell/NN
receptor/NN
delta/NN
gene/NN
enhancer/NN
./.
====================
We/PRP
infer/VBP
that/IN
the/DT
murine/JJ
and/CC
human/JJ
GATA-3/NN
proteins/NNS
play/VBP
a/DT
central/JJ
and/CC
highly/RB
conserved/VBN
role/NN
in/IN
vertebrate/NN
T-cell-specific/JJ
transcriptional/JJ
regulation/NN
./.
====================
UI/LS
-/:
91204058/CD
====================
TI/LS
-/:
Processing/NN
of/IN
the/DT
precursor/NN
of/IN
NF-kappa/NN
B/NN
by/IN
the/DT
HIV-1/NN
protease/NN
during/IN
acute/JJ
infection/NN
./.
====================
AB/LS
-/:
Transcription/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type-1/NN
(/(
HIV-1/NN
)/)
genome/NN
is/VBZ
regulated/VBN
in/IN
part/NN
by/IN
cellular/JJ
factors/NNS
and/CC
is/VBZ
stimulated/VBN
by/IN
activation/NN
of/IN
latently/RB
infected/JJ
T/NN
cells/NNS
./.
====================
T-cell/NN
activation/NN
also/RB
correlates/VBZ
with/IN
the/DT
induction/NN
of/IN
the/DT
factor/NN
NF-kappa/NN
B/NN
which/WDT
binds/VBZ
to/TO
two/CD
adjacent/JJ
sites/NNS
in/IN
the/DT
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
./.
====================
This/DT
factor/NN
consists/VBZ
of/IN
two/CD
DNA-binding/JJ
subunits/NNS
of/IN
relative/JJ
molecular/JJ
mass/NN
50,000/CD
(/(
50K/CD
)/)
associated/VBN
with/IN
two/CD
65K/CD
subunits/NNS
./.
====================
It/PRP
is/VBZ
located/JJ
in/IN
the/DT
nucleus/NN
in/IN
mature/JJ
B/NN
cells/NNS
,/,
but/CC
is/VBZ
present/JJ
in/IN
other/JJ
cell/NN
types/NNS
as/IN
an/DT
inactive/JJ
cytoplasmic/JJ
complex/NN
./.
====================
External/JJ
stimuli/NNS
,/,
including/VBG
those/DT
that/WDT
activate/VBP
T/NN
cells/NNS
,/,
result/VBP
in/IN
nuclear/JJ
translocation/NN
of/IN
active/JJ
NF-kappa/NN
B/NN
./.
====================
The/DT
cloning/NN
of/IN
the/DT
complementary/JJ
DNA/NN
for/IN
the/DT
50K/CD
subunit/NN
helped/VBD
to/TO
identify/VB
an/DT
exclusively/RB
cytoplasmic/JJ
105K/CD
precursor/NN
(/(
p105/NN
)/)
(/(
V.B./NNP
,/,
P.K./NNP
and/CC
A.I./NNP
,/,
manuscript/NN
submitted/VBN
)/)
./.
====================
The/DT
expression/NN
of/IN
active/JJ
NF-kappa/NN
B/NN
might/MD
therefore/RB
also/RB
be/VB
regulated/VBN
by/IN
the/DT
extent/NN
of/IN
processing/NN
of/IN
p105/NN
./.
====================
Because/IN
HIV-1/NN
requires/VBZ
active/JJ
NF-kappa/NN
B/NN
for/IN
efficient/JJ
transcription/NN
,/,
we/PRP
tested/VBD
the/DT
effect/NN
of/IN
HIV-1/NN
infection/NN
on/IN
the/DT
processing/NN
of/IN
the/DT
human/JJ
105K/CD
precursor/NN
./.
====================
We/PRP
show/VBP
here/RB
that/IN
the/DT
HIV-1/NN
protease/NN
can/MD
process/VB
p105/NN
and/CC
increases/VBZ
levels/NNS
of/IN
active/JJ
nuclear/JJ
NF-kappa/NN
B/NN
complex/NN
./.
====================
UI/LS
-/:
91159628/CD
====================
TI/LS
-/:
1,25-Dihydroxyvitamin/NN
D3/NN
receptor/NN
RNA/NN
:/:
expression/NN
in/IN
hematopoietic/JJ
cells/NNS
./.
====================
AB/LS
-/:
1,25-Dihydroxyvitamin/NN
D3/NN
[/(
1,25(OH)2D3/NN
]/)
induces/VBZ
differentiation/NN
and/CC
inhibits/VBZ
proliferation/NN
of/IN
myeloid/JJ
leukemic/JJ
cells/NNS
from/IN
various/JJ
lines/NNS
and/CC
patients/NNS
;/:
these/DT
effects/NNS
are/VBP
probably/RB
mediated/VBN
through/IN
the/DT
1,25(OH)2D3/NN
receptor/NN
./.
====================
Little/JJ
is/VBZ
known/VBN
of/IN
expression/NN
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
in/IN
hematopoietic/JJ
cells/NNS
./.
====================
We/PRP
examined/VBD
the/DT
expression/NN
and/CC
modulation/NN
of/IN
expression/NN
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
in/IN
various/JJ
proliferating/VBG
and/CC
nonproliferating/JJ
hematopoietic/JJ
cells/NNS
./.
====================
Constitutive/JJ
expression/NN
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
was/VBD
detected/VBN
in/IN
various/JJ
kinds/NNS
of/IN
hematopoietic/JJ
cells/NNS
,/,
including/VBG
macrophages/NNS
and/CC
activated/VBN
T/NN
lymphocytes/NNS
,/,
as/RB
well/RB
as/IN
in/IN
cell/NN
lines/NNS
KG-1/NN
(/(
myeloblasts/NNS
)/)
,/,
HL-60/NN
(/(
promyelocytes/NNS
)/)
,/,
ML-3/NN
(/(
myelomonoblasts/NNS
)/)
,/,
U937/NN
,/,
THP-1/NN
(/(
monoblasts/NNS
)/)
,/,
K562/NN
(/(
erythroblasts/NNS
)/)
,/,
and/CC
S-LB1/NN
(/(
HTLV-1-transfected/JJ
T/NN
lymphocytes/NNS
)/)
./.
====================
Receptor/NN
transcripts/NNS
were/VBD
4.6/CD
kilobases/NNS
(/(
kb/NN
)/)
,/,
and/CC
no/DT
variant/JJ
sizes/NNS
were/VBD
observed/VBN
./.
====================
All/DT
cell/NN
lines/NNS
examined/VBN
in/IN
this/DT
group/NN
also/RB
expressed/VBD
1,25(OH)2D3/NN
receptors/NNS
./.
====================
Most/JJS
B/NN
lymphocyte/NN
lines/NNS
expressed/VBD
negligible/JJ
levels/NNS
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
and/CC
protein/NN
;/:
however/RB
;/:
analysis/NN
of/IN
a/DT
lymphoid/myeloid/JJ
somatic/JJ
hybrid/NN
suggested/VBD
that/IN
suppression/NN
of/IN
expression/NN
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
in/IN
B/NN
lymphocytes/NNS
may/MD
be/VB
a/DT
dominant/JJ
characteristic/NN
./.
====================
HL-60/NN
cells/NNS
were/VBD
cultured/VBN
with/IN
10/CD
(/(
-7/CD
)/)
mol/L/NN
1,25(OH)2D3/NN
for/IN
24/CD
to/TO
72/CD
hours/NNS
,/,
and/CC
levels/NNS
of/IN
expression/NN
of/IN
1,25(OH)2D3/NN
receptor/NN
and/CC
its/PRP$
RNA/NN
were/VBD
examined/VBN
./.
====================
Levels/NNS
of/IN
RNA/NN
coding/NN
for/IN
the/DT
receptor/NN
were/VBD
not/RB
modulated/VBN
by/IN
exposure/NN
to/TO
high/JJ
levels/NNS
of/IN
ligand/NN
./.
====================
Levels/NNS
of/IN
occupied/VBN
1,25(OH)2D3/NN
receptor/NN
protein/NN
increased/VBD
in/IN
these/DT
HL-60/NN
cells/NNS
;/:
but/CC
the/DT
total/JJ
number/NN
of/IN
1,25(OH)2D3/NN
receptors/NNS
decreased/VBD
about/RB
50/CD
%/NN
at/IN
24/CD
hours/NNS
and/CC
returned/VBD
toward/IN
normal/JJ
at/IN
72/CD
hours/NNS
./.
====================
Steady-state/JJ
levels/NNS
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
were/VBD
not/RB
affected/VBN
by/IN
terminal/JJ
differentiation/NN
of/IN
HL-60/NN
toward/IN
either/CC
granulocytes/NNS
or/CC
macrophages/NNS
./.
====================
Nondividing/JJ
macrophages/NNS
from/IN
normal/JJ
individuals/NNS
also/RB
expressed/VBD
1,25(OH)2D3/NN
receptor/NN
RNA/NN
./.
====================
In/IN
contrast/NN
,/,
nondividing/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
from/IN
normal/JJ
individuals/NNS
did/VBD
not/RB
express/VB
1,25(OH)2D3/NN
receptor/NN
RNA/NN
;/:
with/IN
stimulation/NN
of/IN
proliferation/NN
of/IN
these/DT
cells/NNS
,/,
accumulation/NN
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
increased/VBD
markedly/RB
./.
====================
Half-life/NN
(/(
t1/2/NN
)/)
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
in/IN
T/NN
lymphocytes/NNS
was/VBD
short/JJ
(/(
1/CD
hour/NN
)/)
as/IN
determined/VBN
by/IN
measuring/VBG
decay/NN
of/IN
the/DT
message/NN
after/IN
addition/NN
of/IN
actinomycin/NN
D/NN
./.
====================
Consistent/JJ
with/IN
this/DT
short/JJ
t1/2/NN
,/,
accumulation/NN
of/IN
1,25(OH)2D3/NN
receptor/NN
RNA/NN
increased/VBD
in/IN
cells/NNS
as/IN
their/PRP$
protein/NN
synthesis/NN
was/VBD
inhibited/VBN
./.
====================
Further/JJ
studies/NNS
are/VBP
required/VBN
to/TO
understand/VB
the/DT
physiologic/JJ
role/NN
of/IN
1,25(OH)2D3/NN
receptors/NNS
in/IN
myeloid/JJ
cells/NNS
and/CC
proliferating/VBG
T/NN
lymphocytes/NNS
./.
====================
UI/LS
-/:
91119580/CD
====================
TI/LS
-/:
Expression/NN
of/IN
c-jun/NN
,/,
jun/NN
B/NN
and/CC
jun/NN
D/NN
proto-oncogenes/NNS
in/IN
human/JJ
peripheral-blood/JJ
granulocytes/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
found/VBN
that/IN
purified/VBN
human/JJ
peripheral-blood/JJ
granulocytes/NNS
express/VBP
constitutively/RB
significant/JJ
levels/NNS
of/IN
proto-oncogenes/NNS
c-jun/NN
,/,
jun/NN
B/NN
and/CC
jun/NN
D/NN
mRNA/NN
./.
====================
Upon/IN
functional/JJ
activation/NN
of/IN
granulocytes/NNS
by/IN
4/CD
beta-phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
,/,
the/DT
levels/NNS
of/IN
c-jun/NN
,/,
jun/NN
B/NN
and/CC
jun/NN
D/NN
transcripts/NNS
were/VBD
increased/VBN
./.
====================
The/DT
three/CD
jun/NN
genes/NNS
showed/VBD
a/DT
similar/JJ
time/NN
course/NN
in/IN
their/PRP$
induction/NN
by/IN
PMA/NN
,/,
maximal/JJ
mRNA/NN
levels/NNS
being/VBG
reached/VBN
after/IN
60/CD
min/NN
of/IN
induction/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
expression/NN
of/IN
c-jun/NN
,/,
jun/NN
B/NN
and/CC
jun/NN
D/NN
genes/NNS
might/MD
be/VB
involved/VBN
in/IN
terminal/JJ
granulocyte/NN
differentiation/NN
or/CC
in/IN
regulating/VBG
granulocyte/NN
functionality/NN
./.
====================
UI/LS
-/:
92107919/CD
====================
TI/LS
-/:
The/DT
29-kDa/JJ
proteins/NNS
phosphorylated/VBN
in/IN
thrombin-activated/JJ
human/JJ
platelets/NNS
are/VBP
forms/NNS
of/IN
the/DT
estrogen/NN
receptor-related/JJ
27-kDa/JJ
heat/NN
shock/NN
protein/NN
./.
====================
AB/LS
-/:
Thrombin/NN
plays/VBZ
a/DT
critical/JJ
role/NN
in/IN
platelet/NN
activation/NN
,/,
hemostasis/NN
,/,
and/CC
thrombosis/NN
./.
====================
Cellular/JJ
activation/NN
by/IN
thrombin/NN
leads/VBZ
to/TO
the/DT
phosphorylation/NN
of/IN
multiple/JJ
proteins/NNS
,/,
most/JJS
of/IN
which/WDT
are/VBP
unidentified/JJ
./.
====================
We/PRP
have/VBP
characterized/VBN
several/JJ
29-kDa/JJ
proteins/NNS
that/WDT
are/VBP
rapidly/RB
phosphorylated/VBN
following/VBG
exposure/NN
of/IN
intact/JJ
human/JJ
platelets/NNS
to/TO
thrombin/NN
./.
====================
A/DT
murine/JJ
monoclonal/JJ
antibody/NN
raised/VBN
to/TO
an/DT
unidentified/JJ
estrogen/NN
receptor-related/JJ
29-kDa/JJ
protein/NN
selectively/RB
recognized/VBD
these/DT
proteins/NNS
as/RB
well/RB
as/IN
a/DT
more/RBR
basic/JJ
,/,
unphosphorylated/JJ
27-kDa/JJ
protein/NN
./.
====================
Cellular/JJ
activation/NN
by/IN
thrombin/NN
led/VBN
to/TO
a/DT
marked/JJ
shift/NN
in/IN
the/DT
proportion/NN
of/IN
protein/NN
from/IN
the/DT
27-kDa/JJ
unphosphorylated/JJ
form/NN
to/TO
the/DT
29-kDa/JJ
phosphoprotein/NN
species/NNS
./.
====================
Using/VBG
this/DT
antibody/NN
,/,
we/PRP
isolated/VBD
and/CC
sequenced/VBD
a/DT
human/JJ
cDNA/NN
clone/NN
encoding/VBG
a/DT
protein/NN
that/WDT
was/VBD
identical/JJ
to/TO
the/DT
mammalian/JJ
27-kDa/JJ
heat/NN
shock/NN
protein/NN
(/(
HSP27/NN
)/)
,/,
a/DT
protein/NN
of/IN
uncertain/JJ
function/NN
that/WDT
is/VBZ
known/VBN
to/TO
be/VB
phosphorylated/VBN
to/TO
several/JJ
forms/NNS
and/CC
to/TO
be/VB
transcriptionally/RB
induced/VBN
by/IN
estrogen/NN
./.
====================
The/DT
29-kDa/JJ
proteins/NNS
were/VBD
confirmed/VBN
to/TO
be/VB
phosphorylated/VBN
forms/NNS
of/IN
HSP27/NN
by/IN
immunoprecipitation/NN
studies/NNS
./.
====================
Thus/RB
,/,
the/DT
"/``
estrogen/NN
receptor-related/JJ
protein/NN
"/''
is/VBZ
HSP27/NN
,/,
and/CC
the/DT
three/CD
major/JJ
29-kDa/JJ
proteins/NNS
phosphorylated/VBN
in/IN
thrombin-activated/JJ
platelets/NNS
are/VBP
forms/NNS
of/IN
HSP27/NN
./.
====================
These/DT
data/NNS
suggest/VBP
a/DT
role/NN
for/IN
HSP27/NN
in/IN
the/DT
signal/NN
transduction/NN
events/NNS
of/IN
platelet/NN
activation/NN
./.
====================
UI/LS
-/:
92052179/CD
====================
TI/LS
-/:
Isolation/NN
of/IN
a/DT
candidate/NN
repressor/activator/NN
,/,
NF-E1/NN
(/(
YY-1/NN
,/,
delta/NN
)/)
,/,
that/WDT
binds/VBZ
to/TO
the/DT
immunoglobulin/NN
kappa/NN
3'/JJ
enhancer/NN
and/CC
the/DT
immunoglobulin/NN
heavy-chain/NN
mu/NN
E1/NN
site/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
determined/VBN
that/IN
the/DT
developmental/JJ
control/NN
of/IN
immunoglobulin/NN
kappa/NN
3'/JJ
enhancer/NN
(/(
kappa/NN
E3'/NN
)/)
activity/NN
is/VBZ
the/DT
result/NN
of/IN
the/DT
combined/JJ
influence/NN
of/IN
positive-/JJ
and/CC
negative-acting/JJ
elements/NNS
./.
====================
We/PRP
show/VBP
that/IN
a/DT
central/JJ
core/NN
in/IN
the/DT
kappa/NN
E3'/NN
enhancer/NN
is/VBZ
active/JJ
at/IN
the/DT
pre-B-cell/JJ
stage/NN
but/CC
is/VBZ
repressed/VBN
by/IN
flanking/VBG
negative-acting/JJ
elements/NNS
./.
====================
The/DT
negative-acting/JJ
sequences/NNS
repress/VBP
enhancer/NN
activity/NN
in/IN
a/DT
position-/NN
and/CC
orientation-independent/JJ
manner/NN
at/IN
the/DT
pre-B-cell/JJ
stage/NN
./.
====================
We/PRP
have/VBP
isolated/VBN
a/DT
human/JJ
cDNA/NN
clone/NN
encoding/VBG
a/DT
zinc/NN
finger/NN
protein/NN
(/(
NF-E1/NN
)/)
that/WDT
binds/VBZ
to/TO
the/DT
negative-acting/JJ
segment/NN
of/IN
the/DT
kappa/NN
E3'/NN
enhancer/NN
./.
====================
This/DT
protein/NN
also/RB
binds/VBZ
to/TO
the/DT
immunoglobulin/NN
heavy-chain/NN
enhancer/NN
mu/NN
E1/NN
site/NN
./.
====================
NF-E1/NN
is/VBZ
encoded/VBN
by/IN
the/DT
same/JJ
gene/NN
as/IN
the/DT
YY-1/NN
protein/NN
,/,
which/WDT
binds/VBZ
to/TO
the/DT
adeno-associated/JJ
virus/NN
P5/NN
promoter/NN
./.
====================
NF-E1/NN
is/VBZ
also/RB
the/DT
human/JJ
homologue/NN
of/IN
the/DT
mouse/NN
delta/NN
protein/NN
,/,
which/WDT
binds/VBZ
to/TO
ribosomal/JJ
protein/NN
gene/NN
promoters/NNS
./.
====================
The/DT
predicted/VBN
amino/NN
acid/NN
sequence/NN
of/IN
this/DT
protein/NN
contains/VBZ
features/NNS
characteristic/JJ
of/IN
transcriptional/JJ
activators/NNS
as/RB
well/RB
as/IN
transcriptional/JJ
repressors/NNS
./.
====================
Cotransfection/NN
studies/NNS
with/IN
this/DT
cDNA/NN
indicate/VBP
that/IN
it/PRP
can/MD
repress/VB
basal/JJ
promoter/NN
activity/NN
./.
====================
The/DT
apparent/JJ
dual/JJ
function/NN
of/IN
this/DT
protein/NN
is/VBZ
discussed/VBN
./.
====================
UI/LS
-/:
92029620/CD
====================
TI/LS
-/:
A/DT
human/JJ
putative/JJ
lymphocyte/NN
G0/G1/NN
switch/NN
gene/NN
containing/VBG
a/DT
CpG-rich/JJ
island/NN
encodes/VBZ
a/DT
small/JJ
basic/JJ
protein/NN
with/IN
the/DT
potential/NN
to/TO
be/VB
phosphorylated/VBN
./.
====================
AB/LS
-/:
Genes/NNS
actively/RB
involved/VBN
in/IN
the/DT
G0/G1/NN
switch/NN
(/(
G0S/NN
genes/NNS
)/)
may/MD
be/VB
differentially/RB
expressed/VBN
during/IN
the/DT
lectin-induced/JJ
switch/NN
of/IN
lymphocytes/NNS
from/IN
the/DT
G0/NN
to/TO
the/DT
G1/NN
phases/NNS
of/IN
the/DT
cell/NN
cycle/NN
./.
====================
This/DT
paper/NN
presents/VBZ
studies/NNS
of/IN
G0S2/NN
,/,
a/DT
member/NN
of/IN
a/DT
set/NN
of/IN
putative/JJ
G0S/NN
genes/NNS
,/,
for/IN
which/WDT
cDNAs/NNS
were/VBD
cloned/VBN
and/CC
selected/VBN
on/IN
the/DT
basis/NN
of/IN
differential/JJ
cDNA/NN
hybridization/NN
./.
====================
G0S2/NN
mRNA/NN
increases/VBZ
transiently/RB
within/IN
1-2/CD
hr/NN
of/IN
the/DT
addition/NN
of/IN
lectin/NN
or/CC
cycloheximide/NN
to/TO
cultured/VBN
blood/NN
mononuclear/JJ
cells/NNS
./.
====================
Comparison/NN
of/IN
a/DT
nearly/RB
full-length/JJ
cDNA/NN
sequence/NN
with/IN
the/DT
corresponding/JJ
genomic/JJ
sequence/NN
reveals/VBZ
one/CD
small/JJ
intron/NN
and/CC
an/DT
open/JJ
reading/NN
frame/NN
in/IN
the/DT
second/JJ
exon/NN
./.
====================
The/DT
derived/VBN
103-amino-acid/JJ
basic/JJ
protein/NN
has/VBZ
two/CD
potential/JJ
alpha-helical/JJ
domains/NNS
separated/VBN
by/IN
a/DT
hydrophobic/JJ
region/NN
with/IN
the/DT
potential/NN
to/TO
generate/VB
turns/NNS
and/CC
assume/VB
a/DT
beta-sheet/JJ
conformation/NN
./.
====================
Consistent/JJ
with/IN
involvement/NN
in/IN
the/DT
G0/G1/NN
switch/NN
,/,
the/DT
protein/NN
contains/VBZ
potential/JJ
sites/NNS
for/IN
phosphorylation/NN
by/IN
protein/NN
kinase/NN
C/NN
and/CC
casein/NN
kinase/NN
II/CD
./.
====================
The/DT
gene/NN
contains/VBZ
a/DT
CpG-rich/JJ
island/NN
suggesting/VBG
expression/NN
in/IN
the/DT
germ/NN
line/NN
./.
====================
An/DT
upstream/JJ
segment/NN
contains/VBZ
tandem/JJ
dinucleotide/NN
repeats/NNS
(CT)19/(CA)16/NN
./.
====================
There/EX
is/VBZ
a/DT
suitably/RB
located/JJ
TATA/NN
box/NN
,/,
but/CC
potential/JJ
sites/NNS
for/IN
CCAAT-box/NN
binding/NN
factors/NNS
are/VBP
far/RB
upstream/JJ
,/,
embedded/JJ
in/IN
a/DT
42-nucleotide/JJ
repeat/NN
element/NN
./.
====================
Potential/JJ
sites/NNS
for/IN
transcription/NN
factors/NNS
AP1/NN
,/,
AP2/NN
,/,
and/CC
AP3/NN
are/VBP
consistent/JJ
with/IN
rapid/JJ
transcriptional/JJ
activation/NN
in/IN
response/NN
to/TO
inducing/VBG
agents/NNS
./.
====================
UI/LS
-/:
91367666/CD
====================
TI/LS
-/:
USF-related/JJ
transcription/NN
factor/NN
,/,
HIV-TF1/NN
,/,
stimulates/VBZ
transcription/NN
of/IN
human/JJ
immunodeficiency/NN
virus-1/NN
./.
====================
AB/LS
-/:
The/DT
transcription/NN
factor/NN
HIV-TF1/NN
,/,
which/WDT
binds/VBZ
to/TO
a/DT
region/NN
about/IN
60/CD
bp/NN
upstream/JJ
from/IN
the/DT
enhancer/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus-1/NN
(/(
HIV-1/NN
)/)
,/,
was/VBD
purified/VBN
from/IN
human/JJ
B/NN
cells/NNS
./.
====================
HIV-TF1/NN
had/VBD
a/DT
molecular/JJ
weight/NN
of/IN
39,000/CD
./.
====================
Binding/NN
of/IN
HIV-TF1/NN
to/TO
the/DT
HIV/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
activated/VBD
transcription/NN
from/IN
the/DT
HIV/NN
promoter/NN
in/FW
vitro/FW
./.
====================
The/DT
HIV-TF1-binding/JJ
site/NN
in/IN
HIV/NN
LTR/NN
was/VBD
similar/JJ
to/TO
the/DT
site/NN
recognized/VBN
by/IN
upstream/JJ
stimulatory/JJ
factor/NN
(/(
USF/NN
)/)
in/IN
the/DT
adenovirus/NN
major/JJ
late/JJ
promoter/NN
./.
====================
DNA-binding/JJ
properties/NNS
of/IN
HIV-TF1/NN
suggested/VBD
that/IN
HIV-TF1/NN
might/MD
be/VB
identical/JJ
or/CC
related/JJ
to/TO
USF/NN
./.
====================
Interestingly/RB
,/,
treatment/NN
of/IN
purified/VBN
HIV-TF1/NN
by/IN
phosphatase/NN
greatly/RB
reduced/VBD
its/PRP$
DNA-binding/JJ
activity/NN
,/,
suggesting/VBG
that/IN
phosphorylation/NN
of/IN
HIV-TF1/NN
was/VBD
essential/JJ
for/IN
DNA/NN
binding/NN
./.
====================
The/DT
disruption/NN
of/IN
HIV-TF1-binding/JJ
site/NN
induced/VBD
a/DT
60/CD
%/NN
decrease/NN
in/IN
the/DT
level/NN
of/IN
transcription/NN
from/IN
the/DT
HIV/NN
promoter/NN
in/FW
vivo/FW
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
HIV-TF1/NN
is/VBZ
involved/VBN
in/IN
transcriptional/JJ
regulation/NN
of/IN
HIV-1/NN
./.
====================
UI/LS
-/:
91292396/CD
====================
TI/LS
-/:
Severe/JJ
5-fluorouracil/NN
toxicity/NN
secondary/JJ
to/TO
dihydropyrimidine/NN
dehydrogenase/NN
deficiency/NN
./.
====================
A/DT
potentially/RB
more/RBR
common/JJ
pharmacogenetic/JJ
syndrome/NN
./.
====================
AB/LS
-/:
This/DT
study/NN
describes/VBZ
the/DT
inheritance/NN
of/IN
a/DT
defect/NN
in/IN
pyrimidine/NN
catabolism/NN
and/CC
its/PRP$
association/NN
with/IN
drug-induced/JJ
toxicity/NN
in/IN
a/DT
patient/NN
receiving/VBG
5-fluorouracil/NN
(/(
FUra/NN
)/)
as/IN
adjuvant/JJ
chemotherapy/NN
for/IN
breast/NN
carcinoma/NN
./.
====================
The/DT
study/NN
population/NN
included/VBD
the/DT
affected/VBN
patient/NN
(/(
proband/NN
)/)
,/,
nine/CD
of/IN
her/PRP$
blood/NN
relatives/NNS
,/,
and/CC
seven/CD
healthy/JJ
volunteers/NNS
./.
====================
The/DT
activity/NN
of/IN
dihydropyrimidine/NN
dehydrogenase/NN
(/(
DPD/NN
)/)
,/,
the/DT
initial/JJ
enzyme/NN
of/IN
pyrimidine/NN
(/(
and/CC
FUra/NN
)/)
catabolism/NN
,/,
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
was/VBD
measured/VBN
in/IN
each/DT
subject/NN
by/IN
a/DT
specific/JJ
radiometric/JJ
assay/NN
using/VBG
FUra/NN
as/IN
the/DT
substrate/NN
./.
====================
The/DT
proband/NN
had/VBD
no/DT
detectable/JJ
DPD/NN
activity/NN
./.
====================
When/WRB
enzyme/NN
levels/NNS
in/IN
the/DT
proband/NN
and/CC
relatives/NNS
were/VBD
compared/VBN
with/IN
that/DT
in/NN
controls/NNS
,/,
an/DT
autosomal/JJ
recessive/JJ
pattern/NN
of/IN
inheritance/NN
was/VBD
demonstrated/VBN
./.
====================
This/DT
is/VBZ
the/DT
third/JJ
patient/NN
with/IN
severe/JJ
FUra/NN
toxicity/NN
secondary/JJ
to/TO
an/DT
alteration/NN
in/IN
pyrimidine/NN
catabolism/NN
and/CC
the/DT
second/NN
from/IN
our/PRP$
clinic/NN
population/NN
suggesting/VBG
that/IN
the/DT
frequency/NN
of/IN
this/DT
genetic/JJ
defect/NN
may/MD
be/VB
greater/JJR
than/IN
previously/RB
thought/VBN
./.
====================
Monitoring/VBG
DPD/NN
activity/NN
may/MD
be/VB
important/JJ
in/IN
the/DT
management/NN
of/IN
patients/NNS
experiencing/VBG
severe/JJ
toxicity/NN
secondary/JJ
to/TO
FUra/NN
chemotherapy/NN
./.
====================
UI/LS
-/:
91237803/CD
====================
TI/LS
-/:
Transactivation/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
promoter/NN
by/IN
human/JJ
herpesvirus/NN
6/CD
(/(
HHV-6/NN
)/)
strains/VBZ
GS/NN
and/CC
Z-29/NN
in/IN
primary/JJ
human/JJ
T/NN
lymphocytes/NNS
and/CC
identification/NN
of/IN
transactivating/VBG
HHV-6/NN
(/(
GS/NN
)/)
gene/NN
fragments/NNS
./.
====================
AB/LS
-/:
Human/JJ
herpesvirus/NN
6/CD
(/(
HHV-6/NN
)/)
can/MD
activate/VB
the/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
promoter/NN
and/CC
accelerate/VB
cytopathic/JJ
effects/NNS
in/IN
HIV-infected/JJ
human/JJ
T/NN
cells/NNS
./.
====================
This/DT
study/NN
examines/VBZ
the/DT
regions/NNS
of/IN
the/DT
HIV/NN
promoter/NN
required/VBN
for/IN
HHV-6/NN
transactivation/NN
in/IN
a/DT
heterogeneous/JJ
population/NN
of/IN
primary/JJ
human/JJ
T/NN
lymphocytes/NNS
with/IN
or/CC
without/IN
antigenic/JJ
stimulation/NN
./.
====================
Two/CD
different/JJ
strains/NNS
of/IN
HHV-6/NN
,/,
GS/NN
and/CC
Z29/NN
,/,
transactivated/VBD
the/DT
HIV/NN
promoter/NN
./.
====================
The/DT
GS/NN
strain/NN
transactivated/VBD
the/DT
promoter/NN
in/IN
both/CC
stimulated/VBN
and/CC
resting/VBG
T/NN
cells/NNS
,/,
while/IN
the/DT
Z29/NN
strain/NN
increased/VBD
HIV/NN
promoter/NN
activity/NN
only/RB
in/IN
stimulated/VBN
T/NN
cells/NNS
./.
====================
Three/CD
DNA/NN
clones/NNS
containing/VBG
HHV-6/NN
(/(
GS/NN
)/)
genomic/JJ
fragments/NNS
transactivated/VBD
the/DT
HIV/NN
promoter/NN
in/IN
cotransfected/VBN
T/NN
cells/NNS
./.
====================
A/DT
21.4-kb/JJ
DNA/NN
clone/NN
,/,
pZVB70/NN
,/,
showed/VBD
the/DT
highest/JJS
transactivating/NN
ability/NN
,/,
while/IN
two/CD
other/JJ
DNA/NN
fragments/NNS
,/,
pZVB10/NN
(/(
6.2/CD
kb/NN
)/)
and/CC
pZVH14/NN
(/(
8.7/CD
kb/NN
)/)
,/,
showed/VBD
lower/JJR
activity/NN
./.
====================
One/CD
of/IN
these/DT
clones/NNS
,/,
pZVH14/NN
,/,
activated/VBD
the/DT
HIV/NN
promoter/NN
construct/NN
containing/VBG
a/DT
mutation/NN
in/IN
the/DT
NF/NN
kappa/NN
B/NN
site/NN
./.
====================
However/RB
,/,
this/DT
mutated/VBN
NF/NN
kappa/NN
B/NN
promoter/NN
was/VBD
not/RB
transactivated/VBN
during/IN
HHV-6/NN
(/(
GS/NN
)/)
infection/NN
or/CC
after/IN
cotransfection/NN
with/IN
pZVB70/NN
or/CC
pZVB10/NN
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
the/DT
NF/NN
kappa/NN
B/NN
sites/NNS
of/IN
the/DT
HIV/NN
promoter/NN
are/VBP
essential/JJ
for/IN
its/PRP$
transactivation/NN
during/IN
HHV-6/NN
(/(
GS/NN
)/)
infection/NN
./.
====================
By/IN
increasing/VBG
HIV/NN
promoter/NN
activity/NN
in/IN
primary/JJ
T/NN
lymphocytes/NNS
,/,
HHV-6/NN
may/MD
consequently/RB
increase/VB
HIV/NN
replication/NN
,/,
leading/VBG
to/TO
an/DT
increase/NN
in/IN
the/DT
cytopathic/JJ
effect/NN
on/IN
coinfected/VBN
human/JJ
T/NN
cells/NNS
./.
====================
UI/LS
-/:
91321794/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
HIV-1/NN
replication/NN
and/CC
NF-kappa/NN
B/NN
activity/NN
by/IN
cysteine/NN
and/CC
cysteine/NN
derivatives/NNS
./.
====================
AB/LS
-/:
HIV-1/NN
proviral/JJ
DNA/NN
contains/VBZ
two/CD
binding/VBG
sites/NNS
for/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
./.
====================
HIV-1-infected/JJ
individuals/NNS
have/VBP
,/,
on/IN
average/NN
,/,
abnormally/RB
high/JJ
levels/NNS
of/IN
tumour/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF/NN
alpha/NN
)/)
and/CC
abnormally/RB
low/JJ
plasma/NN
cysteine/NN
levels/NNS
./.
====================
We/PRP
therefore/RB
investigated/VBD
the/DT
effects/NNS
of/IN
cysteine/NN
and/CC
related/JJ
thiols/NNS
on/IN
HIV-1/NN
replication/NN
and/CC
NF-kappa/NN
B/NN
expression/NN
./.
====================
The/DT
experiments/NNS
in/IN
this/DT
report/NN
show/VBP
that/IN
cysteine/NN
or/CC
N-acetylcysteine/NN
(/(
NAC/NN
)/)
raise/VBP
the/DT
intracellular/JJ
glutathione/NN
(/(
GSH/NN
)/)
level/NN
and/CC
inhibit/VBP
HIV-1/NN
replication/NN
in/IN
persistently/RB
infected/JJ
Molt-4/NN
and/CC
U937/NN
cells/NNS
./.
====================
However/RB
,/,
inhibition/NN
of/IN
HIV-1/NN
replication/NN
appears/VBZ
not/RB
to/TO
be/VB
directly/RB
correlated/VBN
with/IN
GSH/NN
levels/NNS
./.
====================
Cysteine/NN
and/CC
NAC/NN
also/RB
inhibit/VBP
NF-kappa/NN
B/NN
activity/NN
as/IN
determined/VBN
by/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
and/CC
chloramphenicol/NN
acetyl-transferase/NN
(/(
CAT/NN
)/)
gene/NN
expression/NN
under/IN
control/NN
of/IN
NF-kappa/NN
B/NN
binding/NN
sites/NNS
in/IN
uninfected/JJ
cells/NNS
./.
====================
This/DT
suggests/VBZ
that/IN
the/DT
cysteine/NN
deficiency/NN
in/IN
HIV-1-infected/JJ
individuals/NNS
may/MD
cause/VB
an/DT
over-expression/NN
of/IN
NF-kappa/NN
B-dependent/JJ
genes/NNS
and/CC
enhance/VB
HIV-1/NN
replication/NN
./.
====================
NAC/NN
may/MD
be/VB
considered/VBN
for/IN
the/DT
treatment/NN
of/IN
HIV-1-infected/JJ
individuals/NNS
./.
====================
UI/LS
-/:
91184620/CD
====================
TI/LS
-/:
A/DT
thymus-specific/JJ
member/NN
of/IN
the/DT
HMG/NN
protein/NN
family/NN
regulates/VBZ
the/DT
human/JJ
T/NN
cell/NN
receptor/NN
C/NN
alpha/NN
enhancer/NN
./.
====================
AB/LS
-/:
The/DT
human/JJ
T/NN
cell-specific/JJ
transcription/NN
factor/NN
TCF-1/NN
alpha/NN
plays/VBZ
a/DT
key/JJ
role/NN
in/IN
the/DT
tissue-specific/JJ
activation/NN
of/IN
the/DT
T/NN
cell/NN
receptor/NN
(/(
TCR/NN
)/)
C/NN
alpha/NN
enhancer/NN
and/CC
binds/VBZ
to/TO
pyrimidine-rich/JJ
elements/NNS
(/(
5'-PyCTTTG-3'/NN
)/)
present/JJ
in/IN
a/DT
variety/NN
of/IN
other/JJ
T/NN
cell-specific/JJ
control/NN
regions/NNS
./.
====================
Using/VBG
amino/NN
acid/NN
sequence/NN
information/NN
derived/VBN
from/IN
the/DT
DNA/NN
affinity-purified/JJ
protein/NN
,/,
we/PRP
have/VBP
now/RB
isolated/VBN
cDNA/NN
clones/NNS
encoding/VBG
TCF-1/NN
alpha/NN
./.
====================
The/DT
TCF-1/NN
alpha/NN
cDNA/NN
contains/VBZ
a/DT
single/JJ
68-amino-acid/JJ
domain/NN
that/WDT
is/VBZ
homologous/JJ
to/TO
a/DT
region/NN
conserved/VBN
among/IN
high-mobility/JJ
group/NN
(/(
HMG/NN
)/)
and/CC
nonhistone/JJ
chromosomal/JJ
proteins/NNS
./.
====================
Expression/NN
of/IN
full-length/JJ
and/CC
mutant/JJ
cDNA/NN
clones/NNS
in/IN
bacteria/NNS
reveal/VBP
that/IN
the/DT
single/JJ
HMG/NN
motif/NN
,/,
which/WDT
is/VBZ
predicted/VBN
to/TO
contain/VB
two/CD
extended/VBN
alpha-helical/JJ
segments/NNS
,/,
is/VBZ
sufficient/JJ
to/TO
direct/VB
the/DT
sequence-specific/JJ
binding/NN
of/IN
TCF-1/NN
alpha/NN
to/TO
DNA/NN
./.
====================
Northern/NN
blot/NN
experiments/NNS
demonstrate/VBP
further/RBR
that/IN
TCF-1/NN
alpha/NN
mRNA/NN
is/VBZ
highly/RB
tissue/NN
specific/JJ
,/,
found/VBN
primarily/RB
in/IN
the/DT
thymus/NN
or/CC
T/NN
cell/NN
lines/NNS
./.
====================
The/DT
immature/JJ
CEM/NN
T/NN
cell/NN
line/NN
expresses/VBZ
relatively/RB
low/JJ
levels/NNS
of/IN
TCF-1/NN
alpha/NN
mRNA/NN
,/,
which/WDT
are/VBP
increased/VBN
upon/IN
activation/NN
of/IN
these/DT
cells/NNS
by/IN
phorbol/NN
esters/NNS
./.
====================
Interestingly/RB
,/,
the/DT
cloned/VBN
TCF-1/NN
alpha/NN
protein/NN
is/VBZ
a/DT
potent/JJ
transcriptional/JJ
activator/NN
of/IN
the/DT
human/JJ
TCR/NN
alpha/NN
enhancer/NN
in/IN
nonlymphoid/JJ
cell/NN
lines/NNS
,/,
whereas/IN
the/DT
activity/NN
of/IN
the/DT
endogenous/JJ
protein/NN
in/IN
T/NN
cell/NN
lines/NNS
is/VBZ
strongly/RB
dependent/JJ
on/IN
an/DT
additional/JJ
T/NN
cell-specific/JJ
protein/NN
that/WDT
interacts/VBZ
with/IN
the/DT
core/NN
enhancer/NN
./.
====================
TCF-1/NN
alpha/NN
is/VBZ
currently/RB
unique/JJ
among/IN
the/DT
newly/RB
emerging/VBG
family/NN
of/IN
DNA-binding/JJ
regulatory/JJ
proteins/NNS
that/WDT
share/VBP
the/DT
HMG/NN
motif/NN
in/IN
that/IN
it/PRP
is/VBZ
a/DT
highly/RB
tissue-specific/JJ
RNA/NN
polymerase/NN
II/CD
transcription/NN
factor/NN
./.
====================
UI/LS
-/:
91134976/CD
====================
TI/LS
-/:
A/DT
novel/JJ
HIV-1/NN
isolate/JJ
containing/VBG
alterations/NNS
affecting/VBG
the/DT
NF-kappa/NN
B/NN
element/NN
./.
====================
AB/LS
-/:
Three/CD
molecular/JJ
clones/NNS
of/IN
HIV-1/NN
,/,
derived/VBN
from/IN
a/DT
single/JJ
isolate/NN
(/(
AL1/NN
)/)
,/,
exhibited/VBD
distinct/JJ
replicative/JJ
and/CC
cytopathic/JJ
properties/NNS
during/IN
propagation/NN
in/IN
a/DT
human/JJ
T/NN
cell/NN
line/NN
./.
====================
The/DT
phenotypic/JJ
differences/NNS
observed/VBN
were/VBD
attributable/JJ
,/,
in/IN
large/JJ
part/NN
,/,
to/TO
changes/NNS
affecting/VBG
the/DT
viral/JJ
LTR/NN
./.
====================
Nucleotide/NN
sequence/NN
and/CC
PCR/NN
analyses/NNS
demonstrated/VBD
the/DT
presence/NN
of/IN
novel/JJ
duplications/NNS
or/CC
deletions/NNS
involving/VBG
the/DT
NF-kappa/NN
B/NN
motif/NN
./.
====================
These/DT
changes/NNS
in/IN
the/DT
enhancer/NN
element/NN
were/VBD
identified/VBN
in/IN
the/DT
original/JJ
AL1/NN
virus/NN
stock/NN
./.
====================
Subcloning/NN
of/IN
the/DT
variant/JJ
NF-kappa/NN
B/NN
segments/NNS
into/IN
LTR-driven/JJ
CAT/NN
expression/NN
vectors/NNS
confirmed/VBD
a/DT
correlation/NN
between/IN
promoter/JJ
activity/NN
and/CC
replicative/cytopathic/JJ
capacity/NN
./.
====================
UI/LS
-/:
91187647/CD
====================
TI/LS
-/:
Multiple/JJ
Oct2/NN
isoforms/NNS
are/VBP
generated/VBN
by/IN
alternative/JJ
splicing/NN
./.
====================
AB/LS
-/:
The/DT
interaction/NN
of/IN
the/DT
Oct2/NN
transcription/NN
factor/NN
with/IN
the/DT
cognate/JJ
octamer/NN
motif/NN
ATGCAAAT/NN
is/VBZ
a/DT
critical/JJ
determinant/NN
of/IN
the/DT
lymphoid-specific/JJ
expression/NN
of/IN
immunoglobulin/NN
genes/NNS
./.
====================
Ectopic/JJ
expression/NN
of/IN
cloned/VBN
Oct2/NN
cDNA/NN
was/VBD
shown/VBN
to/TO
be/VB
sufficient/JJ
to/TO
reconstitute/VB
at/IN
least/JJS
some/DT
aspects/NNS
of/IN
this/DT
regulation/NN
in/IN
non-lymphoid/JJ
cells/NNS
./.
====================
We/PRP
describe/VBP
the/DT
isolation/NN
and/CC
characterization/NN
of/IN
multiple/JJ
cDNAs/NNS
encoding/VBG
mouse/NN
Oct2/NN
from/IN
a/DT
mature/JJ
B-cell/NN
line/NN
and/CC
we/PRP
show/VBP
that/IN
a/DT
variety/NN
of/IN
isoforms/NNS
of/IN
this/DT
transcription/NN
factor/NN
is/VBZ
generated/VBN
from/IN
a/DT
single/JJ
gene/NN
by/IN
an/DT
alternative/JJ
splicing/NN
mechanism/NN
./.
====================
All/PDT
the/DT
isoforms/NNS
retain/VBP
the/DT
previously/RB
characterized/VBN
POU-domain/NN
and/CC
are/VBP
therefore/RB
able/JJ
to/TO
bind/VB
to/TO
the/DT
octamer/NN
motif/NN
./.
====================
Different/JJ
amounts/NNS
of/IN
the/DT
various/JJ
isoforms/NNS
are/VBP
present/JJ
within/IN
the/DT
same/JJ
B-cell/NN
regardless/RB
of/IN
the/DT
developmental/JJ
stage/NN
of/IN
B-cell/NN
differentiation/NN
and/CC
at/IN
least/JJS
some/DT
of/IN
the/DT
isoforms/NNS
are/VBP
conserved/VBN
between/IN
mouse/NN
and/CC
humans/NNS
./.
====================
In/IN
cotransfection/NN
experiments/NNS
we/PRP
show/VBP
that/IN
all/PDT
the/DT
isoforms/NNS
are/VBP
able/JJ
to/TO
activate/VB
an/DT
octamer/NN
containing/VBG
promoter/NN
element/NN
in/IN
fibroblasts/NNS
revealing/VBG
an/DT
unexpected/JJ
functional/JJ
redundancy/NN
./.
====================
Finally/RB
,/,
we/PRP
show/VBP
that/IN
one/CD
of/IN
the/DT
isoforms/NNS
encodes/VBZ
the/DT
previously/RB
described/VBN
lymphoid-specific/JJ
Oct2B/NN
protein/NN
which/WDT
has/VBZ
been/VBN
suggested/VBN
to/TO
be/VB
involved/VBN
in/IN
the/DT
function/NN
of/IN
the/DT
octamer/NN
motif/NN
in/IN
the/DT
context/NN
of/IN
the/DT
immunoglobulin/NN
heavy-chain/NN
(/(
IgH/NN
)/)
enhancer/NN
./.
====================
UI/LS
-/:
92223210/CD
====================
TI/LS
-/:
[/(
Regulation/NN
of/IN
intracellular/JJ
cholesterol/NN
synthesis/NN
in/IN
hypercholesterolemia/NN
by/IN
glucocorticoids/NNS
]/)
====================
AB/LS
-/:
The/DT
rate/NN
of/IN
endogenous/JJ
cholesterol/NN
synthesis/NN
in/IN
blood/NN
lymphocytes/NNS
and/CC
skin/NN
fibroblasts/NNS
from/IN
patients/NNS
with/IN
type/NN
IIa/NN
hyperlipidemia/NN
was/VBD
found/VBN
to/TO
be/VB
increased/VBN
in/IN
comparison/NN
with/IN
healthy/JJ
donors/NNS
./.
====================
The/DT
cells/NNS
of/IN
hyperlipidemic/JJ
patients/NNS
had/VBD
lowered/JJ
levels/NNS
of/IN
glucocorticoid/NN
receptors/NNS
concomitantly/RB
with/IN
a/DT
partial/JJ
loss/NN
of/IN
their/PRP$
sensitivity/NN
to/TO
glucocorticoids/NNS
./.
====================
In/IN
fibroblasts/NNS
from/IN
patients/NNS
with/IN
hereditary/JJ
hypercholesteremia/NN
of/IN
homozygous/JJ
type/NN
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
did/VBD
not/RB
exceed/VB
10/CD
%/NN
of/IN
their/PRP$
content/NN
in/IN
normal/JJ
cells/NNS
./.
====================
The/DT
decrease/NN
of/IN
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
patients/NNS
with/IN
type/NN
IIa/NN
hyperlipidemia/NN
seems/VBZ
to/TO
be/VB
a/DT
compensatory/JJ
response/NN
of/IN
cells/NNS
culminating/VBG
in/IN
activation/NN
of/IN
endogenous/JJ
cholesterol/NN
synthesis/NN
./.
====================
UI/LS
-/:
92052106/CD
====================
TI/LS
-/:
Negative/JJ
regulation/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
expression/NN
in/IN
monocytes/NNS
:/:
role/NN
of/IN
the/DT
65-kDa/JJ
plus/CC
50-kDa/JJ
NF-kappa/NN
B/NN
dimer/NN
./.
====================
AB/LS
-/:
Although/IN
monocytic/JJ
cells/NNS
can/MD
provide/VB
a/DT
reservoir/NN
for/IN
viral/JJ
production/NN
in/FW
vivo/FW
,/,
their/PRP$
regulation/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
transcription/NN
can/MD
be/VB
either/CC
latent/JJ
,/,
restricted/JJ
,/,
or/CC
productive/JJ
./.
====================
These/DT
differences/NNS
in/IN
gene/NN
expression/NN
have/VBP
not/RB
been/VBN
molecularly/RB
defined/VBN
./.
====================
In/IN
THP-1/NN
cells/NNS
with/IN
restricted/JJ
HIV/NN
expression/NN
,/,
there/EX
is/VBZ
an/DT
absence/NN
of/IN
DNA-protein/JJ
binding/NN
complex/NN
formation/NN
with/IN
the/DT
HIV-1/NN
promoter-enhancer/NN
associated/VBN
with/IN
markedly/RB
less/JJR
viral/JJ
RNA/NN
production/NN
./.
====================
This/DT
absence/NN
of/IN
binding/NN
was/VBD
localized/JJ
to/TO
the/DT
NF-kappa/NN
B/NN
region/NN
of/IN
the/DT
HIV-1/NN
enhancer/NN
;/:
the/DT
65-kDa/JJ
plus/CC
50-kDa/JJ
NF-kappa/NN
B/NN
heterodimer/NN
was/VBD
preferentially/RB
lost/VBN
./.
====================
Adding/VBG
purified/VBN
NF-kappa/NN
B/NN
protein/NN
to/TO
nuclear/JJ
extracts/NNS
from/IN
cells/NNS
with/IN
restricted/JJ
expression/NN
overcomes/VBZ
this/DT
lack/NN
of/IN
binding/NN
./.
====================
In/IN
addition/NN
,/,
treatment/NN
of/IN
these/DT
nuclear/JJ
extracts/NNS
with/IN
sodium/NN
deoxycholate/NN
restored/VBD
their/PRP$
ability/NN
to/TO
form/VB
the/DT
heterodimer/NN
,/,
suggesting/VBG
the/DT
presence/NN
of/IN
an/DT
inhibitor/NN
of/IN
NF-kappa/NN
B/NN
activity/NN
./.
====================
Furthermore/RB
,/,
treatment/NN
of/IN
nuclear/JJ
extracts/NNS
from/IN
these/DT
cells/NNS
that/WDT
had/VBD
restricted/JJ
expression/NN
with/IN
lipopolysaccharide/NN
increased/VBD
viral/JJ
production/NN
and/CC
NF-kappa/NN
B/NN
activity/NN
./.
====================
Antiserum/NN
specific/JJ
for/IN
NF-kappa/NN
B/NN
binding/NN
proteins/NNS
,/,
but/CC
not/RB
c-rel-specific/JJ
antiserum/NN
,/,
disrupted/VBD
heterodimer/NN
complex/NN
formation/NN
./.
====================
Thus/RB
,/,
both/DT
NF-kappa/NN
B-binding/JJ
complexes/NNS
are/VBP
needed/VBN
for/IN
optimal/JJ
viral/JJ
transcription/NN
./.
====================
Binding/NN
of/IN
the/DT
65-kDa/JJ
plus/CC
50-kDa/JJ
heterodimer/NN
to/TO
the/DT
HIV-1/NN
enhancer/NN
can/MD
be/VB
negatively/RB
regulated/VBN
in/IN
monocytes/NNS
,/,
providing/VBG
one/CD
mechanism/NN
restricting/VBG
HIV-1/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
92006162/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptors/NNS
in/IN
normal/JJ
leukocytes/NNS
:/:
effects/NNS
of/IN
age/NN
,/,
gender/NN
,/,
season/NN
,/,
and/CC
plasma/NN
cortisol/NN
concentrations/NNS
./.
====================
AB/LS
-/:
We/PRP
measured/VBD
glucocorticoid/NN
receptors/NNS
(/(
GR/NN
)/)
in/IN
mononuclear/JJ
leukocytes/NNS
(/(
MNL/NN
)/)
isolated/VBN
from/IN
peripheral/JJ
blood/NN
of/IN
145/CD
apparently/RB
healthy/JJ
volunteers/NNS
(/(
86/CD
men/NNS
and/CC
59/CD
women/NNS
)/)
./.
====================
An/DT
age-related/JJ
decrease/NN
in/IN
the/DT
number/NN
of/IN
GR/NN
was/VBD
suggested/VBN
between/IN
subjects/NNS
younger/JJR
than/IN
20/CD
years/NNS
and/CC
elderly/JJ
subjects/NNS
;/:
there/EX
was/VBD
no/DT
apparent/JJ
seasonal/JJ
variation/NN
in/IN
GR/NN
./.
====================
Gender/NN
difference/NN
in/IN
the/DT
number/NN
of/IN
GR/NN
was/VBD
not/RB
significant/JJ
,/,
although/IN
women/NNS
showed/VBD
slightly/RB
fewer/JJR
GR/NN
./.
====================
Eight/CD
patients/NNS
with/IN
dermatomyositis/polymyositis/NN
were/VBD
examined/VBN
to/TO
determine/VB
whether/IN
the/DT
number/NN
of/IN
GR/NN
in/IN
MNL/NN
could/MD
be/VB
down-regulated/VBN
by/IN
their/PRP$
cognate/JJ
ligands/NNS
./.
====================
The/DT
number/NN
of/IN
GR/NN
in/IN
MNL/NN
from/IN
these/DT
patients/NNS
was/VBD
significantly/RB
decreased/VBN
one/CD
month/NN
after/IN
the/DT
initiation/NN
of/IN
prednisolone/NN
therapy/NN
./.
====================
However/RB
,/,
in/IN
normal/JJ
subjects/NNS
,/,
the/DT
GR/NN
in/IN
MNL/NN
did/VBD
not/RB
demonstrate/VB
circadian/JJ
variation/NN
,/,
in/IN
contrast/NN
to/TO
concentrations/NNS
of/IN
plasma/NN
cortisol/NN
./.
====================
UI/LS
-/:
92031293/CD
====================
TI/LS
-/:
Synergism/NN
between/IN
two/CD
distinct/JJ
elements/NNS
of/IN
the/DT
HTLV-I/NN
enhancer/NN
during/IN
activation/NN
by/IN
the/DT
trans-activator/NN
of/IN
HTLV-I/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
conducted/VBN
functional/JJ
studies/NNS
of/IN
the/DT
enhancer/NN
elements/NNS
of/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
using/VBG
the/DT
human/JJ
T-cell/NN
lines/NNS
Jurkat/NN
and/CC
MOLT/NN
4/CD
,/,
which/WDT
are/VBP
negative/JJ
for/IN
HTLV-I/NN
,/,
and/CC
MT-2/NN
and/CC
TL-Mor/NN
,/,
which/WDT
carry/VBP
the/DT
proviral/JJ
genome/NN
of/IN
HTLV-I/NN
./.
====================
Two/CD
distinct/JJ
elements/NNS
have/VBP
been/VBN
implicated/VBN
in/IN
function/NN
of/IN
the/DT
HTLV-I/NN
enhancer/NN
./.
====================
One/CD
is/VBZ
the/DT
21-base-pair/JJ
(/(
bp/NN
)/)
core/NN
element/NN
that/WDT
is/VBZ
responsible/JJ
for/IN
trans-activation/NN
by/IN
the/DT
HTLV-I/NN
trans-activator/NN
p40tax/NN
and/CC
that/WDT
has/VBZ
the/DT
ability/NN
to/TO
bind/VB
to/TO
cyclic-AMP/NN
responsive/JJ
element/NN
binding/NN
factor/NN
(/(
CREB/NN
)/)
-like/JJ
factor/NN
(/(
s/NNS
)/)
./.
====================
The/DT
other/JJ
is/VBZ
a/DT
region/NN
interposed/VBN
between/IN
the/DT
21-bp/JJ
elements/NNS
./.
====================
In/IN
this/DT
study/NN
we/PRP
demonstrate/VBP
that/IN
a/DT
subfragment/NN
(/(
C26/NN
)/)
in/IN
the/DT
region/NN
between/IN
the/DT
21-bp/JJ
elements/NNS
is/VBZ
involved/VBN
in/IN
trans-activation/NN
by/IN
p40tax/NN
,/,
possibly/RB
through/IN
binding/NN
to/TO
an/DT
NF-kappa/NN
B-like/JJ
nuclear/JJ
factor/NN
or/CC
factors/NNS
./.
====================
Formation/NN
of/IN
the/DT
protein-DNA/JJ
complex/NN
with/IN
the/DT
C26/NN
subfragment/NN
was/VBD
positively/RB
affected/VBN
by/IN
p40tax/NN
./.
====================
The/DT
C26/NN
element/NN
conferred/VBD
partial/JJ
responsiveness/NN
to/TO
p40tax/NN
when/WRB
linked/VBN
to/TO
one/CD
copy/NN
of/IN
the/DT
21-bp/JJ
element/NN
that/WDT
,/,
by/IN
itself/PRP
,/,
showed/VBD
little/JJ
activation/NN
in/IN
response/NN
to/TO
p40tax/NN
./.
====================
However/RB
,/,
the/DT
C26/NN
element/NN
alone/RB
,/,
even/RB
when/WRB
repeated/VBN
,/,
could/MD
not/RB
be/VB
activated/VBN
by/IN
p40tax/NN
,/,
unlike/IN
other/JJ
NF-kappa/NN
B-binding/JJ
elements/NNS
./.
====================
In/IN
contrast/NN
,/,
the/DT
C26/NN
element/NN
itself/PRP
was/VBD
profoundly/RB
activated/VBN
upon/IN
stimulation/NN
with/IN
12-O-tetradecanoylphorbol-13-acetate/NN
./.
====================
These/DT
findings/NNS
therefore/RB
suggest/VBP
that/IN
the/DT
HTLV-I/NN
enhancer/NN
contains/VBZ
multiple/JJ
functional/JJ
elements/NNS
,/,
including/VBG
binding/VBG
sites/NNS
for/IN
at/IN
least/JJS
CREB-/NN
and/CC
NF-kappa/NN
B-like/JJ
factors/NNS
,/,
which/WDT
synergistically/RB
cooperate/VBP
in/IN
activation/NN
of/IN
the/DT
HTLV-I/NN
enhancer/NN
in/IN
response/NN
to/TO
p40tax/NN
./.
====================
Our/PRP$
results/NNS
also/RB
demonstrate/VBP
that/IN
TPA-dependent/JJ
activation/NN
of/IN
the/DT
HTLV-I/NN
enhancer/NN
may/MD
be/VB
mediated/VBN
through/IN
the/DT
C26/NN
element/NN
./.
====================
UI/LS
-/:
91277630/CD
====================
TI/LS
-/:
Human/JJ
tumor/NN
necrosis/NN
factor/NN
alpha/NN
gene/NN
regulation/NN
in/IN
phorbol/NN
ester/NN
stimulated/VBD
T/NN
and/CC
B/NN
cell/NN
lines/NNS
./.
====================
AB/LS
-/:
The/DT
minimal/JJ
region/NN
of/IN
the/DT
human/JJ
tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF-alpha/NN
)/)
gene/NN
promoter/NN
necessary/JJ
for/IN
its/PRP$
transcriptional/JJ
induction/NN
by/IN
phorbol/NN
esters/NNS
(/(
PMA/NN
)/)
in/IN
human/JJ
T/NN
and/CC
B/NN
lymphocyte/NN
cell/NN
lines/NNS
has/VBZ
been/VBN
localized/JJ
between/IN
-52/CD
and/CC
+89/CD
nucleotides/NNS
(/(
nt/NN
)/)
relative/JJ
to/TO
the/DT
gene/NN
's/POS
transcriptional/JJ
start/NN
site/NN
./.
====================
Comparison/NN
of/IN
these/DT
sequences/NNS
to/TO
those/DT
required/VBN
to/TO
mediate/VB
virus/NN
or/CC
lipopolysaccharide/NN
(/(
LPS/NN
)/)
induction/NN
of/IN
the/DT
gene/NN
reveal/VB
significant/JJ
differences/NNS
,/,
and/CC
thus/RB
,/,
the/DT
sequence/NN
requirements/NNS
for/IN
PMA/NN
induction/NN
are/VBP
distinct/JJ
from/IN
those/DT
that/WDT
mediate/VBP
induction/NN
by/IN
virus/NN
or/CC
LPS/NN
./.
====================
Although/IN
three/CD
sites/NNS
in/IN
the/DT
TNF-alpha/NN
promoter/NN
(/(
kappa/NN
1/CD
,/,
kappa/NN
2/CD
,/,
and/CC
kappa/NN
3/CD
)/)
specifically/RB
bind/VBP
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
in/IN
lymphoid/JJ
nuclear/JJ
extracts/NNS
,/,
TNF-alpha/NN
mRNA/NN
induction/NN
by/IN
PMA/NN
does/VBZ
not/RB
correlate/VB
with/IN
NF-kappa/NN
B/NN
binding/NN
activities/NNS
displayed/VBN
by/IN
different/JJ
T/NN
and/CC
B/NN
cell/NN
lines/NNS
./.
====================
Moreover/RB
,/,
kappa/NN
1/CD
-/:
kappa/NN
3/CD
can/MD
each/DT
be/VB
deleted/VBN
from/IN
the/DT
TNF-alpha/NN
promoter/NN
with/IN
little/JJ
effect/NN
on/IN
the/DT
gene/NN
's/POS
inducibility/NN
by/IN
PMA/NN
./.
====================
Therefore/RB
,/,
TNF-alpha/NN
mRNA/NN
induction/NN
by/IN
PMA/NN
,/,
like/IN
its/PRP$
induction/NN
by/IN
virus/NN
and/CC
LPS/NN
,/,
is/VBZ
not/RB
primarily/RB
mediated/VBN
by/IN
NF-kappa/NN
B/NN
,/,
but/CC
rather/RB
is/VBZ
mediated/VBN
through/IN
other/JJ
sequences/NNS
and/CC
protein/NN
factors/NNS
./.
====================
Surprisingly/RB
,/,
multimers/NNS
of/IN
kappa/NN
1/CD
-/:
kappa/NN
3/CD
can/MD
confer/VB
PMA/NN
inducibility/NN
on/IN
a/DT
heterologous/JJ
promoter/NN
in/IN
a/DT
B/NN
(/(
Raji/NN
)/)
,/,
but/CC
not/RB
a/DT
T/NN
(/(
HUT78/NN
)/)
cell/NN
line/NN
./.
====================
However/WRB
they/PRP
are/VBP
not/RB
functional/JJ
on/IN
a/DT
truncated/VBN
TNF-alpha/NN
promoter/NN
,/,
indicating/VBG
that/IN
promoter/NN
context/NN
and/CC
cell/NN
type/NN
specificity/NN
influence/VBP
the/DT
PMA/NN
inducible/JJ
function/NN
of/IN
these/DT
NF-kappa/NN
B/NN
binding/NN
sites/NNS
./.
====================
UI/LS
-/:
91237800/CD
====================
TI/LS
-/:
Differentiation-associated/JJ
expression/NN
of/IN
the/DT
Epstein-Barr/JJ
virus/NN
BZLF1/NN
transactivator/NN
protein/NN
in/IN
oral/JJ
hairy/JJ
leukoplakia/NN
./.
====================
AB/LS
-/:
The/DT
BZLF1/NN
protein/NN
of/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
is/VBZ
a/DT
key/JJ
immediate-early/JJ
protein/NN
which/WDT
has/VBZ
been/VBN
shown/VBN
to/TO
disrupt/VB
virus/NN
latency/NN
in/IN
EBV-infected/JJ
B/NN
cells/NNS
./.
====================
We/PRP
have/VBP
generated/VBN
a/DT
monoclonal/JJ
antibody/NN
,/,
BZ1/NN
,/,
to/TO
BZLF1/NN
which/WDT
reacts/VBZ
in/IN
immunohistology/NN
,/,
immunoblotting/NN
,/,
and/CC
immunoprecipitation/NN
and/CC
which/WDT
recognizes/VBZ
both/CC
the/DT
active/JJ
,/,
dimeric/JJ
form/NN
and/CC
the/DT
inactive/JJ
,/,
monomeric/JJ
form/NN
of/IN
the/DT
protein/NN
./.
====================
Biopsies/NNS
of/IN
oral/JJ
hairy/JJ
leukoplakia/NN
,/,
an/DT
AIDS-associated/JJ
lesion/NN
characterized/VBN
by/IN
high-level/JJ
EBV/NN
replication/NN
,/,
were/VBD
examined/VBN
by/IN
immunohistochemistry/NN
using/VBG
the/DT
BZ1/NN
monoclonal/JJ
antibody/NN
./.
====================
A/DT
differentiation-associated/JJ
pattern/NN
of/IN
BZLF1/NN
expression/NN
was/VBD
observed/VBN
,/,
BZ1/NN
reacting/VBG
with/IN
nuclei/NNS
of/IN
the/DT
upper/JJ
spinous/JJ
layer/NN
of/IN
the/DT
lesion/NN
./.
====================
This/DT
finding/NN
suggests/VBZ
that/IN
the/DT
BZLF1/NN
promoter/NN
may/MD
be/VB
regulated/VBN
by/IN
the/DT
degree/NN
of/IN
squamous/JJ
differentiation/NN
./.
====================
A/DT
comparison/NN
of/IN
in/FW
situ/FW
hybridization/NN
to/TO
EBV/NN
DNA/NN
and/CC
viral/JJ
capsid/NN
antigen/NN
staining/VBG
with/IN
BZ1/NN
reactivity/NN
suggested/VBD
that/IN
BZLF1/NN
expression/NN
precedes/VBZ
rampant/JJ
virus/NN
replication/NN
./.
====================
The/DT
inability/NN
to/TO
detect/VB
EBV/NN
in/IN
the/DT
lower/RBR
epithelial/JJ
layers/NNS
of/IN
oral/JJ
hairy/JJ
leukoplakia/NN
raises/VBZ
questions/NNS
concerning/VBG
the/DT
nature/NN
of/IN
EBV/NN
latency/NN
and/CC
persistence/NN
in/IN
stratified/JJ
squamous/JJ
epithelium/NN
./.
====================
UI/LS
-/:
91347784/CD
====================
TI/LS
-/:
[/(
Changes/NNS
in/IN
levels/NNS
of/IN
leucocytic/JJ
estrogen/NN
receptor/NN
in/IN
patients/NNS
with/IN
menopausal/JJ
type/NN
II/CD
diabetes/NNS
and/CC
its/PRP$
significance/NN
]/)
====================
AB/LS
-/:
The/DT
number/NN
of/IN
estrogen/NN
receptors/NNS
(/(
ER/NN
)/)
in/IN
human/JJ
peripheral/JJ
leucocytes/NNS
in/IN
12/CD
women/NNS
with/IN
menopausal/JJ
type/NN
II/CD
diabetes/NNS
was/VBD
measured/VBN
with/IN
radio-ligand/JJ
binding/NN
method/NN
./.
====================
The/DT
results/NNS
were/VBD
compared/VBN
with/IN
those/DT
of/IN
12/CD
menopausal/JJ
women/NNS
without/IN
diabetes/NNS
and/CC
12/CD
normal/JJ
women/NNS
of/IN
childbearing/JJ
age/NN
./.
====================
It/PRP
was/VBD
found/VBN
that/IN
the/DT
number/NN
of/IN
ER/NN
in/IN
the/DT
patients/NNS
was/VBD
significantly/RB
decreased/VBN
./.
====================
Our/PRP$
data/NNS
indicate/VBP
that/IN
decrease/NN
of/IN
ER/NN
level/NN
in/IN
leukocytes/NNS
may/MD
be/VB
related/JJ
to/TO
the/DT
pathogenesis/NN
of/IN
type/NN
II/CD
diabetes/NNS
in/IN
menopausal/JJ
period/NN
./.
====================
UI/LS
-/:
91174087/CD
====================
TI/LS
-/:
Lymphocyte/NN
glucocorticoid/NN
receptor/NN
number/NN
in/IN
posttraumatic/JJ
stress/NN
disorder/NN
./.
====================
AB/LS
-/:
OBJECTIVE/NN
:/:
The/DT
authors/NNS
'/POS
objective/NN
was/VBD
to/TO
investigate/VB
the/DT
possibility/NN
that/IN
glucocorticoid/NN
receptor/NN
changes/NNS
may/MD
be/VB
involved/VBN
in/IN
the/DT
dysregulation/NN
of/IN
the/DT
hypothalamic-pituitary-adrenal/JJ
(/(
HPA/JJ
)/)
axis/NN
in/IN
posttraumatic/JJ
stress/NN
disorder/NN
(/(
PTSD/NN
)/)
./.
====================
METHOD/NN
:/:
They/PRP
measured/VBD
the/DT
number/NN
of/IN
lymphocyte/NN
cytosolic/JJ
glucocorticoid/NN
receptors/NNS
and/CC
plasma/NN
cortisol/NN
concentrations/NNS
in/IN
15/CD
consecutively/RB
admitted/VBN
male/JJ
combat/NN
Vietnam/NN
veterans/NNS
with/IN
PTSD/NN
and/CC
in/IN
a/DT
normal/JJ
comparison/NN
group/NN
of/IN
11/CD
subjects/NNS
./.
====================
RESULTS/NNS
:/:
Both/CC
the/DT
patients/NNS
and/CC
the/DT
normal/JJ
comparison/NN
subjects/NNS
showed/VBD
a/DT
morning-to-afternoon/JJ
decline/NN
in/IN
glucocorticoid/NN
receptor/NN
concentrations/NNS
,/,
paralleling/VBG
the/DT
normal/JJ
diurnal/JJ
decline/NN
in/IN
cortisol/NN
levels/NNS
./.
====================
The/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
was/VBD
63/CD
%/NN
greater/JJR
in/IN
the/DT
morning/NN
and/CC
26/CD
%/NN
greater/JJR
in/IN
the/DT
afternoon/NN
in/IN
the/DT
patients/NNS
with/IN
PTSD/NN
than/IN
in/IN
the/DT
normal/JJ
subjects/NNS
./.
====================
No/DT
group/NN
differences/NNS
in/IN
cortisol/NN
levels/NNS
were/VBD
observed/VBN
,/,
nor/CC
were/VBD
glucocorticoid/NN
receptor/NN
number/NN
and/CC
cortisol/NN
levels/NNS
correlated/VBD
./.
====================
The/DT
number/NN
of/IN
morning/NN
glucocorticoid/NN
receptors/NNS
was/VBD
positively/RB
correlated/VBN
with/IN
symptoms/NNS
of/IN
PTSD/NN
and/CC
anxiety/NN
./.
====================
CONCLUSIONS/NNS
:/:
These/DT
results/NNS
provide/VBP
further/JJ
evidence/NN
for/IN
a/DT
dysregulation/NN
of/IN
the/DT
HPA/JJ
axis/NN
in/IN
PTSD/NN
./.
====================
The/DT
finding/NN
that/IN
patients/NNS
with/IN
PTSD/NN
had/VBD
a/DT
substantially/RB
greater/JJR
number/NN
of/IN
lymphocyte/NN
glucocorticoid/NN
receptors/NNS
than/IN
normal/JJ
comparison/NN
subjects/NNS
is/VBZ
consistent/JJ
with/IN
the/DT
authors/NNS
'/POS
previous/JJ
observations/NNS
of/IN
low/JJ
24-hour/JJ
urinary/JJ
cortisol/NN
excretion/NN
in/IN
subjects/NNS
with/IN
PTSD/NN
./.
====================
Furthermore/RB
,/,
the/DT
receptor/NN
changes/NNS
observed/VBN
are/VBP
opposite/JJ
of/IN
those/DT
reported/VBN
in/IN
major/JJ
depressive/JJ
disorder/NN
./.
====================
The/DT
present/JJ
data/NNS
,/,
along/IN
with/IN
other/JJ
findings/NNS
of/IN
HPA/JJ
abnormalities/NNS
in/IN
PTSD/NN
,/,
support/VBP
the/DT
possibility/NN
of/IN
a/DT
greater/JJR
negative/JJ
feedback/NN
sensitivity/NN
at/IN
one/CD
or/CC
more/JJR
levels/NNS
of/IN
the/DT
HPA/JJ
axis/NN
./.
====================
UI/LS
-/:
91376384/CD
====================
TI/LS
-/:
Induction/NN
of/IN
NF-kappa/NN
B/NN
during/IN
monocyte/NN
differentiation/NN
is/VBZ
associated/VBN
with/IN
activation/NN
of/IN
HIV-gene/JJ
expression/NN
./.
====================
AB/LS
-/:
Cells/NNS
of/IN
the/DT
monocyte-macrophage/JJ
lineage/NN
are/VBP
important/JJ
targets/NNS
of/IN
HIV/NN
infection/NN
./.
====================
We/PRP
report/VBP
here/RB
that/IN
the/DT
phenotypic/JJ
differentiation/NN
of/IN
monocyte/NN
cell/NN
lines/NNS
induced/VBN
by/IN
phorbol/NN
esters/NNS
or/CC
tumour/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF/NN
alpha/NN
)/)
is/VBZ
associated/VBN
with/IN
expression/NN
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
./.
====================
In/IN
parallel/NN
with/IN
such/JJ
differentiation/NN
,/,
HIV/NN
transcription/NN
,/,
monitored/VBN
using/VBG
an/DT
HIV/NN
long/JJ
terminal/JJ
repeat/NN
reporter/NN
gene/NN
construct/NN
,/,
is/VBZ
activated/VBN
in/IN
such/JJ
cells/NNS
under/IN
the/DT
influence/NN
of/IN
enhanced/VBN
NF-kappa/NN
B/NN
expression/NN
./.
====================
Also/RB
,/,
in/IN
a/DT
promonocyte/JJ
cell/NN
line/NN
chronically/RB
infected/VBN
with/IN
HIV/NN
,/,
NF-kappa/NN
B/NN
expression/NN
and/CC
HIV/NN
transcription/NN
were/VBD
enhanced/VBN
on/IN
stimulation/NN
with/IN
phorbol/NN
ester/NN
or/CC
TNF/NN
alpha/NN
./.
====================
Thus/RB
,/,
stimulation/NN
of/IN
monocyte/NN
cell/NN
lines/NNS
by/IN
phorbol/NN
esters/NNS
or/CC
TNF/NN
alpha/NN
induces/VBZ
cell/NN
differentiation/NN
and/CC
activates/VBZ
HIV/NN
transcription/NN
./.
====================
Such/PDT
a/DT
process/NN
may/MD
have/VB
fundamental/JJ
implications/NNS
in/IN
AIDS/NN
pathogenesis/NN
in/FW
vivo/FW
and/CC
may/MD
be/VB
important/JJ
in/IN
disease/NN
progression/NN
induced/VBN
by/IN
opportunistic/JJ
infections/NNS
directly/RB
or/CC
indirectly/RB
involving/VBG
macrophages/NNS
./.
====================
UI/LS
-/:
91236793/CD
====================
TI/LS
-/:
Demonstration/NN
of/IN
estrogen/NN
and/CC
progesterone/NN
receptors/NNS
as/RB
well/RB
as/IN
Ki-67/NN
and/CC
p-145/NN
antigens/NNS
in/IN
single/JJ
tumor/NN
cells/NNS
from/IN
blood/NN
and/CC
pleural/JJ
effusions/NNS
using/VBG
a/DT
slide/NN
assay/NN
./.
====================
AB/LS
-/:
We/PRP
describe/VBP
a/DT
slide/NN
assay/NN
that/WDT
allows/VBZ
the/DT
demonstration/NN
of/IN
antigens/NNS
localized/JJ
in/IN
the/DT
nucleus/NN
from/IN
isolated/VBN
white/JJ
blood/NN
cells/NNS
as/RB
well/RB
as/IN
from/IN
single/JJ
tumor/NN
cells/NNS
derived/VBN
from/IN
malignant/JJ
effusions/NNS
./.
====================
With/IN
the/DT
antibodies/NNS
Ki-67/NN
and/CC
anti-p-145/NN
an/DT
increased/VBN
rate/NN
of/IN
nuclear/JJ
and/CC
nucleolar/JJ
staining/NN
resulted/VBD
in/IN
cells/NNS
from/IN
highly/RB
malignant/JJ
lymphomas/NNS
./.
====================
An/DT
almost/RB
identical/JJ
reaction/NN
was/VBD
obtained/VBN
when/WRB
tumor/NN
cells/NNS
from/IN
malignant/JJ
effusions/NNS
were/VBD
tested/VBN
./.
====================
Cells/NNS
isolated/VBN
from/IN
the/DT
blood/NN
of/IN
patients/NNS
with/IN
leukemic/JJ
spread/NN
of/IN
lymphomas/NNS
of/IN
low/JJ
malignancy/NN
yielded/VBD
a/DT
weak/JJ
staining/NN
comparable/JJ
to/TO
that/DT
of/IN
normal/JJ
mesothelial/JJ
cells/NNS
from/IN
non-tumorous/JJ
cavity/NN
fluids/NNS
./.
====================
The/DT
detection/NN
of/IN
estrogen/NN
and/CC
progesterone/NN
receptors/NNS
(/(
ER/NN
and/CC
PR/NN
)/)
localized/JJ
in/IN
the/DT
cell/NN
nucleus/NN
can/MD
be/VB
achieved/VBN
by/IN
the/DT
same/JJ
assay/NN
./.
====================
The/DT
reaction/NN
is/VBZ
enhanced/VBN
by/IN
incubation/NN
of/IN
the/DT
tumor/NN
cells/NNS
for/IN
30/CD
min/NN
at/IN
37/CD
degrees/NNS
C/NN
prior/RB
to/TO
fixation/NN
./.
====================
Pleural/JJ
effusions/NNS
from/IN
20/CD
patients/NNS
with/IN
breast/NN
cancer/NN
were/VBD
tested/VBN
./.
====================
ER/NN
was/VBD
positive/JJ
in/IN
13/CD
and/CC
PR/NN
was/VBD
positive/JJ
in/IN
12/CD
of/IN
the/DT
20/CD
samples/NNS
./.
====================
In/IN
5/CD
cases/NNS
there/EX
was/VBD
a/DT
divergent/JJ
reaction/NN
with/IN
ER/NN
and/CC
PR/NN
antibody/NN
./.
====================
The/DT
hormone/NN
receptors/NNS
of/IN
the/DT
primary/JJ
tumor/NN
were/VBD
known/VBN
in/IN
15/CD
(/(
ER/NN
)/)
and/CC
14/CD
(/(
PR/NN
)/)
patients/NNS
,/,
respectively/RB
./.
====================
In/IN
each/DT
cohort/NN
there/EX
was/VBD
only/RB
one/CD
case/NN
with/IN
a/DT
negative/JJ
reaction/NN
of/IN
the/DT
primary/JJ
tumor/NN
and/CC
a/DT
positive/JJ
reaction/NN
with/IN
the/DT
isolated/VBN
tumor/NN
cells/NNS
from/IN
the/DT
pleural/JJ
effusions/NNS
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
the/DT
demonstration/NN
of/IN
hormone/NN
receptor/NN
proteins/NNS
in/IN
cells/NNS
from/IN
malignant/JJ
effusions/NNS
is/VBZ
possible/JJ
and/CC
that/IN
there/EX
is/VBZ
a/DT
correlation/NN
with/IN
the/DT
status/NN
of/IN
the/DT
primary/JJ
site/NN
of/IN
cancer/NN
./.
====================
UI/LS
-/:
92068245/CD
====================
TI/LS
-/:
Constitutive/JJ
activation/NN
of/IN
NF-kB/NN
in/IN
human/JJ
thymocytes/NNS
./.
====================
AB/LS
-/:
NF-kB/NN
is/VBZ
a/DT
eukaryotic/JJ
transcription/NN
regulatory/JJ
factor/NN
./.
====================
In/IN
T/NN
cells/NNS
and/CC
T/NN
cell/NN
lines/NNS
,/,
NF-kB/NN
is/VBZ
bound/VBN
to/TO
a/DT
cytoplasmic/JJ
proteic/JJ
inhibitor/NN
,/,
the/DT
IkB/NN
./.
====================
Treatment/NN
of/IN
T/NN
cells/NNS
with/IN
mitogens/NNS
(/(
phorbol/NN
esters/NNS
)/)
or/CC
cytokines/NNS
(/(
TNF/NN
alpha/NN
)/)
induces/VBZ
NF-kB/NN
nuclear/JJ
translocation/NN
and/CC
the/DT
subsequent/JJ
expression/NN
of/IN
NF-kB/NN
dependent/JJ
T/NN
cell/NN
genes/NNS
./.
====================
Here/RB
we/PRP
examined/VBD
the/DT
activation/NN
of/IN
NF-kB/NN
in/IN
human/JJ
T/NN
cell/NN
thymic/JJ
progenitors/NNS
./.
====================
We/PRP
report/VBP
differences/NNS
in/IN
(Ca2+)i/NN
requirement/NN
for/IN
NF-kB/NN
activation/NN
in/IN
thymocytes/NNS
as/IN
compared/VBN
to/TO
mature/JJ
T/NN
cells/NNS
./.
====================
Furthermore/RB
,/,
our/PRP$
results/NNS
indicated/VBD
that/IN
thymocytes/NNS
have/VBP
a/DT
constitutively/RB
active/JJ
form/NN
of/IN
NF-kB/NN
,/,
suggesting/VBG
that/IN
they/PRP
are/VBP
activated/VBN
in/FW
vivo/FW
./.
====================
UI/LS
-/:
92103005/CD
====================
TI/LS
-/:
TCF-1/NN
,/,
a/DT
T/NN
cell-specific/JJ
transcription/NN
factor/NN
of/IN
the/DT
HMG/NN
box/NN
family/NN
,/,
interacts/VBZ
with/IN
sequence/NN
motifs/NNS
in/IN
the/DT
TCR/NN
beta/NN
and/CC
TCR/NN
delta/NN
enhancers/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
recently/RB
identified/VBN
and/CC
cloned/VBN
TCF-1/NN
,/,
a/DT
T/NN
cell-specific/JJ
transcription/NN
factor/NN
with/IN
specificity/NN
for/IN
the/DT
AACAAAG/NN
motif/NN
in/IN
the/DT
CD3/NN
epsilon/NN
enhancer/NN
and/CC
for/IN
the/DT
TTCAAAG/NN
motif/NN
in/IN
the/DT
TCR/NN
alpha/NN
enhancer/NN
./.
====================
TCF-1/NN
belongs/VBZ
to/TO
the/DT
family/NN
of/IN
transcription-regulating/JJ
proteins/NNS
which/WDT
share/VBP
a/DT
region/NN
of/IN
homology/NN
termed/VBN
the/DT
HMG-box/NN
./.
====================
Here/RB
,/,
we/PRP
show/VBP
by/IN
gel/NN
retardation/NN
analysis/NN
that/IN
TCF-1/NN
specifically/RB
recognizes/VBZ
the/DT
T/NN
beta/NN
5/CD
element/NN
of/IN
the/DT
TCR/NN
beta/NN
enhancer/NN
and/CC
the/DT
T/NN
delta/NN
7/CD
element/NN
of/IN
the/DT
TCR/NN
delta/NN
enhancer/NN
./.
====================
Comparison/NN
of/IN
the/DT
sequences/NNS
of/IN
all/DT
elements/NNS
recognized/VBN
by/IN
TCF-1/NN
defines/VBZ
a/DT
consensus/NN
motif/NN
A/T/NN
A/T/NN
C/NN
A/NN
A/G/NN
A/NN
G/NN
./.
====================
These/DT
observations/NNS
imply/VBP
that/IN
TCF-1/NN
is/VBZ
involved/VBN
in/IN
the/DT
control/NN
of/IN
several/JJ
T/NN
cell-specific/JJ
genes/NNS
and/CC
might/MD
thus/RB
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
establishment/NN
and/CC
maintenance/NN
of/IN
the/DT
mature/JJ
T/NN
cell/NN
phenotype/NN
./.
====================
UI/LS
-/:
92179751/CD
====================
TI/LS
-/:
[/(
Regulatory/JJ
effect/NN
of/IN
insulin/NN
on/IN
glucocorticoid/NN
receptor/NN
in/IN
human/JJ
peripheral/JJ
leukocytes/NNS
]/)
====================
AB/LS
-/:
The/DT
regulatory/JJ
effect/NN
of/IN
insulin/NN
on/IN
the/DT
specific/JJ
binding/VBG
power/NN
of/IN
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
of/IN
human/JJ
leukocytes/NNS
was/VBD
assessed/VBN
by/IN
the/DT
unoccupied/JJ
receptor/NN
sites/NNS
capable/JJ
of/IN
combining/VBG
with/IN
[3H]/NN
labelled/JJ
dexamethasone/NN
measured/VBN
at/IN
3/CD
and/CC
24/CD
h/NN
after/IN
incubation/NN
with/IN
various/JJ
concentrations/NNS
of/IN
insulin/NN
added/VBN
to/TO
the/DT
medium/NN
./.
====================
After/IN
3/CD
h/NN
incubation/NN
the/DT
specific/JJ
binding/VBG
power/NN
with/IN
[3H]/NN
Dex/NN
was/VBD
decreased/VBN
by/IN
23.3/CD
+/-/CC
10.0/CD
,/,
32.2/CD
+/-/CC
13.2/CD
and/CC
54.3/CD
+/-/CC
9.2/CD
%/NN
(/(
P/NN
greater/JJR
than/IN
0.05/CD
,/,
P/NN
greater/JJR
than/IN
0.05/CD
and/CC
P/NN
less/JJR
than/IN
0.01/CD
as/IN
compared/VBN
with/IN
the/DT
control/NN
value/NN
of/IN
100/CD
in/IN
the/DT
absence/NN
of/IN
insulin/NN
)/)
respectively/RB
in/IN
the/DT
presence/NN
of/IN
20/CD
mU/L/NN
(/(
physiological/JJ
testing/NN
concentration/NN
)/)
,/,
200/CD
mU/L/NN
(/(
physiological/JJ
upper/JJ
limit/NN
)/)
and/CC
2,000/CD
mU/L/NN
(/(
pharmacological/JJ
concentration/NN
)/)
insulin/NN
in/IN
the/DT
incubation/NN
medium/NN
./.
====================
After/IN
24/CD
h/NN
incubation/NN
the/DT
decrease/NN
of/IN
these/DT
values/NNS
increased/VBD
respectively/RB
to/TO
43.5/CD
+/-/CC
19.0/CD
,/,
56.1/CD
+/-/CC
20.7/CD
and/CC
80.2/CD
+/-/CC
15.5/CD
(/(
P/NN
less/JJR
than/IN
0.05/CD
,/,
P/NN
less/JJR
than/IN
0.01/CD
and/CC
P/NN
less/JJR
than/IN
0.01/CD
compared/VBN
with/IN
control/NN
)/)
./.
====================
Thus/RB
the/DT
inhibitory/JJ
effect/NN
of/IN
insulin/NN
on/IN
the/DT
GR/NN
binding/NN
power/NN
is/VBZ
both/CC
dose-/NN
and/CC
time-dependent/JJ
,/,
which/WDT
strongly/RB
suggests/VBZ
that/IN
GR/NN
is/VBZ
tonically/RB
controlled/VBN
by/IN
insulin/NN
concentration/NN
change/NN
under/IN
physiological/JJ
conditions/NNS
./.
====================
UI/LS
-/:
91369589/CD
====================
TI/LS
-/:
The/DT
effect/NN
of/IN
toremifene/NN
therapy/NN
on/IN
serum/NN
immunoglobulin/NN
levels/NNS
in/IN
breast/NN
cancer/NN
./.
====================
AB/LS
-/:
Estrogens/NNS
and/CC
anti-estrogens/NNS
enhance/VBP
the/DT
number/NN
of/IN
immunoglobulin/NN
(/(
Ig/NN
)/)
-secreting/NN
cells/NNS
in/IN
pokeweed/NN
mitogen/NN
(/(
PWM/NN
)/)
-stimulated/JJ
lymphocyte/NN
cultures/NNS
./.
====================
Lymphocytes/NNS
from/IN
patients/NNS
who/WP
have/VBP
received/VBN
anti-estrogen/NN
therapy/NN
show/VBP
similar/JJ
enhancement/NN
of/IN
Ig-secreting/JJ
cells/NNS
after/IN
PWM/NN
stimulation/NN
./.
====================
In/IN
this/DT
study/NN
the/DT
effect/NN
of/IN
anti-estrogen/NN
(/(
toremifene/NN
)/)
therapy/NN
on/IN
serum/NN
immunoglobulin/NN
(/(
IgA/NN
,/,
IgM/NN
,/,
IgG/NN
)/)
levels/NNS
in/IN
breast/NN
cancer/NN
patients/NNS
was/VBD
investigated/VBN
./.
====================
Serum/NN
Ig/NN
levels/NNS
were/VBD
followed/VBN
up/RB
to/TO
two/CD
years/NNS
after/IN
or/CC
during/IN
the/DT
therapy/NN
./.
====================
An/DT
unexpected/JJ
finding/NN
was/VBD
that/IN
the/DT
Ig/NN
levels/NNS
decreased/VBD
during/IN
the/DT
follow-up/JJ
period/NN
./.
====================
This/DT
decrease/NN
was/VBD
seen/VBN
in/IN
patients/NNS
who/WP
responded/VBD
to/TO
the/DT
therapy/NN
as/RB
well/RB
as/IN
in/IN
those/DT
who/WP
did/VBD
not/RB
./.
====================
UI/LS
-/:
91266919/CD
====================
TI/LS
-/:
Human/JJ
erythroid/JJ
5-aminolevulinate/NN
synthase/NN
:/:
promoter/NN
analysis/NN
and/CC
identification/NN
of/IN
an/DT
iron-responsive/JJ
element/NN
in/IN
the/DT
mRNA/NN
./.
====================
AB/LS
-/:
5-Aminolevulinate/NN
synthase/NN
(/(
ALAS/NN
)/)
catalyzes/VBZ
the/DT
first/JJ
step/NN
of/IN
the/DT
heme/NN
biosynthetic/JJ
pathway/NN
./.
====================
cDNA/NN
clones/NNS
for/IN
the/DT
human/JJ
erythroid/JJ
ALAS/NN
isozyme/NN
were/VBD
isolated/VBN
from/IN
a/DT
fetal/JJ
liver/NN
library/NN
./.
====================
It/PRP
can/MD
be/VB
deduced/VBN
that/IN
the/DT
erythroid/JJ
ALAS/NN
precursor/NN
protein/NN
has/VBZ
a/DT
molecular/JJ
weight/NN
of/IN
64.6/CD
kd/NN
,/,
and/CC
is/VBZ
similar/JJ
in/IN
size/NN
to/TO
the/DT
previously/RB
isolated/VBN
human/JJ
housekeeping/JJ
ALAS/NN
precursor/NN
of/IN
molecular/JJ
weight/NN
70.6/CD
kd/NN
./.
====================
The/DT
mature/JJ
mitochondrial/JJ
forms/NNS
of/IN
the/DT
erythroid/JJ
and/CC
housekeeping/JJ
ALAS/NN
isozymes/NNS
are/VBP
predicted/VBN
to/TO
have/VB
molecular/JJ
weights/NNS
of/IN
59.5/CD
kd/NN
and/CC
64.6/CD
kd/NN
,/,
respectively/RB
./.
====================
The/DT
two/CD
isozymes/NNS
show/VBP
little/JJ
amino/NN
acid/NN
identity/NN
in/IN
their/PRP$
N-terminal/JJ
signal/NN
sequences/NNS
but/CC
have/VBP
considerable/JJ
sequence/NN
identity/NN
in/IN
the/DT
C-terminal/JJ
two-thirds/CD
of/IN
their/PRP$
proteins/NNS
./.
====================
An/DT
analysis/NN
of/IN
the/DT
immediate/JJ
promoter/NN
of/IN
the/DT
human/JJ
erythroid/JJ
ALAS/NN
gene/NN
revealed/VBD
several/JJ
putative/JJ
erythroid-specific/JJ
cis-acting/JJ
elements/NNS
including/VBG
both/PDT
a/DT
GATA-1/NN
and/CC
an/DT
NF-E2/NN
binding/NN
site/NN
./.
====================
An/DT
iron-responsive/JJ
element/NN
(/(
IRE/NN
)/)
motif/NN
has/VBZ
been/VBN
identified/VBN
in/IN
the/DT
5'-untranslated/JJ
region/NN
of/IN
the/DT
human/JJ
erythroid/JJ
ALAS/NN
mRNA/NN
,/,
but/CC
is/VBZ
not/RB
present/JJ
in/IN
the/DT
housekeeping/JJ
ALAS/NN
mRNA/NN
./.
====================
Gel/NN
retardation/NN
experiments/NNS
established/VBD
that/IN
this/DT
IRE/NN
motif/NN
formed/VBD
a/DT
protein - RNA/JJ
complex/NN
with/IN
cytosolic/JJ
extracts/NNS
from/IN
human/JJ
K562/NN
cells/NNS
and/CC
this/DT
binding/NN
was/VBD
strongly/RB
competed/VBN
with/IN
IRE/NN
transcripts/NNS
from/IN
ferritin/NN
or/CC
transferrin/NN
receptor/NN
mRNAs/NNS
./.
====================
A/DT
transcript/NN
of/IN
the/DT
ALAS/NN
IRE/NN
,/,
mutated/VBN
in/IN
the/DT
conserved/VBN
loop/NN
of/IN
the/DT
IRE/NN
,/,
did/VBD
not/RB
readily/RB
form/VB
this/DT
protein - RNA/JJ
complex/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
IRE/NN
motif/NN
in/IN
the/DT
ALAS/NN
mRNA/NN
is/VBZ
functional/JJ
and/CC
imply/VBP
that/IN
translation/NN
of/IN
the/DT
mRNA/NN
is/VBZ
controlled/VBN
by/IN
cellular/JJ
iron/NN
availability/NN
during/IN
erythropoiesis/NN
./.
====================
UI/LS
-/:
91291720/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
jun/NN
and/CC
fos/NN
gene/NN
expression/NN
in/IN
human/JJ
monocytes/NNS
by/IN
the/DT
macrophage/NN
colony-stimulating/JJ
factor/NN
./.
====================
AB/LS
-/:
The/DT
macrophage/NN
colony-stimulating/JJ
factor/NN
(/(
M-CSF/NN
)/)
is/VBZ
required/VBN
for/IN
the/DT
growth/NN
and/CC
differentiation/NN
of/IN
mononuclear/JJ
phagocytes/NNS
./.
====================
However/RB
,/,
the/DT
signaling/NN
events/NNS
responsible/JJ
for/IN
these/DT
effects/NNS
remain/VBP
unclear/JJ
./.
====================
The/DT
present/JJ
studies/NNS
have/VBP
examined/VBN
the/DT
effects/NNS
of/IN
M-CSF/NN
on/IN
potential/JJ
signaling/NN
pathways/NNS
involving/VBG
expression/NN
of/IN
the/DT
jun/NN
and/CC
fos/NN
early/JJ
response/NN
genes/NNS
./.
====================
Low/JJ
levels/NNS
of/IN
c-jun/NN
transcripts/NNS
were/VBD
detectable/JJ
in/IN
resting/VBG
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
./.
====================
Treatment/NN
of/IN
these/DT
cells/NNS
with/IN
10/CD
(/(
3/CD
)/)
units/ml/NNS
human/JJ
recombinant/JJ
M-CSF/NN
was/VBD
associated/VBN
with/IN
rapid/JJ
and/CC
transient/JJ
increases/NNS
in/IN
c-jun/NN
mRNA/NN
levels/NNS
./.
====================
Nuclear/JJ
run-on/JJ
assays/NNS
and/CC
mRNA/NN
stability/NN
studies/NNS
demonstrated/VBD
that/IN
M-CSF/NN
regulates/VBZ
c-jun/NN
expression/NN
by/IN
both/CC
an/DT
increase/NN
in/IN
transcription/NN
rate/NN
and/CC
a/DT
prolongation/NN
in/IN
the/DT
half-life/NN
of/IN
c-jun/NN
transcripts/NNS
./.
====================
M-CSF/NN
treatment/NN
was/VBD
also/RB
associated/VBN
with/IN
a/DT
rapid/JJ
induction/NN
of/IN
the/DT
jun-B/NN
gene/NN
,/,
although/IN
expression/NN
of/IN
this/DT
gene/NN
was/VBD
prolonged/JJ
compared/VBN
to/TO
that/DT
of/IN
c-jun/NN
./.
====================
We/PRP
further/RB
demonstrate/VBP
that/IN
M-CSF/NN
increases/VBZ
c-fos/NN
mRNA/NN
levels/NNS
in/IN
human/JJ
monocytes/NNS
through/IN
control/NN
at/IN
both/CC
the/DT
transcriptional/JJ
and/CC
posttranscriptional/JJ
levels/NNS
./.
====================
Maximal/JJ
induction/NN
of/IN
the/DT
c-fos/NN
gene/NN
was/VBD
followed/VBN
by/IN
that/DT
for/IN
the/DT
fos-B/NN
gene/NN
./.
====================
Moreover/RB
,/,
M-CSF-induced/JJ
expression/NN
of/IN
the/DT
fos-related/JJ
gene/NN
,/,
fra-1/NN
,/,
was/VBD
delayed/VBN
compared/VBN
to/TO
that/DT
for/IN
both/DT
c-fos/NN
and/CC
fos-B/NN
./.
====================
Taken/VBN
together/RB
,/,
the/DT
results/NNS
indicate/VBP
that/IN
M-CSF/NN
treatment/NN
is/VBZ
associated/VBN
with/IN
differential/JJ
activation/NN
of/IN
multiple/JJ
members/NNS
of/IN
the/DT
jun/fos/NN
family/NN
and/CC
that/IN
expression/NN
of/IN
these/DT
genes/NNS
could/MD
contribute/VB
to/TO
nuclear/JJ
signaling/NN
mechanisms/NNS
that/WDT
regulate/VBP
a/DT
specific/JJ
program/NN
of/IN
monocyte/NN
differentiation/NN
./.
====================
UI/LS
-/:
91325181/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptors/NNS
in/IN
systemic/JJ
lupus/NN
erythematosus/NN
./.
====================
AB/LS
-/:
Glucocorticosteroids/NNS
remain/VBP
the/DT
major/JJ
treatment/NN
modality/NN
for/IN
systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
,/,
but/CC
their/PRP$
mechanism/NN
of/IN
action/NN
is/VBZ
unclear/JJ
./.
====================
Over/IN
the/DT
past/JJ
decade/NN
it/PRP
has/VBZ
become/VBN
clear/JJ
that/IN
glucocorticosteroid/NN
receptors/NNS
play/VBP
a/DT
significant/JJ
role/NN
in/IN
the/DT
mechanism/NN
of/IN
glucocorticosteroid/NN
action/NN
./.
====================
We/PRP
studied/VBD
glucocorticosteroid/NN
receptor/NN
density/NN
and/CC
affinity/NN
on/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
by/IN
the/DT
glucocorticosteroid/NN
binding/NN
assay/NN
in/IN
33/CD
patients/NNS
with/IN
SLE/NN
who/WP
had/VBD
taken/VBN
no/DT
glucocorticosteroid/NN
for/IN
the/DT
previous/JJ
6/CD
months/NNS
and/CC
in/IN
32/CD
healthy/JJ
controls/NNS
./.
====================
Patients/NNS
'/POS
disease/NN
activity/NN
was/VBD
measured/VBN
by/IN
the/DT
SLE/NN
Disease/NN
Activity/NN
Index/NN
(/(
SLEDAI/NN
)/)
./.
====================
Glucocorticosteroid/NN
receptors/NNS
on/IN
leukocytes/NNS
of/IN
patients/NNS
with/IN
SLE/NN
were/VBD
significantly/RB
higher/JJR
than/IN
in/IN
healthy/JJ
controls/NNS
(/(
4419/CD
+/-/CC
306/CD
vs/CC
3369/CD
+/-/CC
196/CD
,/,
p/NN
less/JJR
than/IN
0.005/CD
)/)
./.
====================
The/DT
binding/NN
affinity/NN
was/VBD
not/RB
different/JJ
between/IN
patients/NNS
and/CC
controls/NNS
./.
====================
There/EX
was/VBD
no/DT
correlation/NN
between/IN
glucocorticosteroid/NN
receptor/NN
number/NN
and/CC
SLE/NN
disease/NN
activity/NN
./.
====================
UI/LS
-/:
91170801/CD
====================
TI/LS
-/:
Kappa/NN
B/NN
binding/NN
proteins/NNS
are/VBP
constitutively/RB
expressed/VBN
in/IN
an/DT
IL-2/NN
autocrine/NN
human/JJ
T/NN
cell/NN
line/NN
./.
====================
AB/LS
-/:
The/DT
IL-2/NN
and/CC
the/DT
IL-2-R/NN
alpha/NN
genes/NNS
are/VBP
both/DT
expressed/VBN
transiently/RB
in/IN
normal/JJ
T/NN
lymphocytes/NNS
after/IN
Ag/NN
or/CC
mitogen/NN
activation/NN
./.
====================
In/IN
contrast/NN
,/,
the/DT
human/JJ
T/NN
cell/NN
line/NN
,/,
IARC/NN
301/CD
,/,
expresses/VBZ
these/DT
two/CD
genes/NNS
constitutively/RB
and/CC
we/PRP
have/VBP
previously/RB
demonstrated/VBN
that/IN
its/PRP$
growth/NN
depends/VBZ
on/IN
the/DT
autocrine/JJ
production/NN
of/IN
this/DT
T/NN
cell/NN
growth/NN
factor/NN
and/CC
high/JJ
affinity/NN
IL-2R/NN
./.
====================
To/TO
dissect/VB
the/DT
molecular/JJ
basis/NN
for/IN
the/DT
unusual/JJ
persistent/JJ
expression/NN
of/IN
the/DT
IL-2/NN
and/CC
IL-2-R/NN
alpha/NN
genes/NNS
in/IN
these/DT
IARC/NN
301/CD
T/NN
cells/NNS
,/,
we/PRP
have/VBP
analyzed/VBN
the/DT
interactions/NNS
of/IN
constitutively/RB
expressed/VBN
nuclear/JJ
proteins/NNS
with/IN
the/DT
5'/JJ
flanking/JJ
regions/NNS
of/IN
the/DT
IL-2/NN
and/CC
IL-2-R/NN
alpha/NN
genes/NNS
using/VBG
both/DT
DNase/NN
I/CD
footprinting/NN
and/CC
gel/NN
retardation/NN
techniques/NNS
./.
====================
We/PRP
have/VBP
found/VBN
that/IN
a/DT
region/NN
in/IN
both/DT
genes/NNS
(/(
-276/CD
to/TO
-250/CD
for/IN
IL-2-R/NN
alpha/NN
and/CC
-203/CD
to/TO
-183/CD
for/IN
IL-2/NN
)/)
,/,
which/WDT
corresponds/VBZ
to/TO
a/DT
kappa/NN
B/NN
enhancer/NN
element/NN
,/,
is/VBZ
specifically/RB
protected/VBN
by/IN
nuclear/JJ
proteins/NNS
from/IN
IARC/NN
301/CD
./.
====================
In/IN
agreement/NN
with/IN
this/DT
finding/NN
,/,
both/CC
the/DT
IL-2/NN
and/CC
IL-2-R/NN
alpha/NN
promoters/NNS
are/VBP
active/JJ
in/IN
transient/JJ
transfection/NN
assays/NNS
in/IN
IARC/NN
301/CD
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
mutation/NN
of/IN
the/DT
kappa/NN
B/NN
enhancer/NN
results/VBZ
in/IN
markedly/RB
attenuated/VBN
activities/NNS
of/IN
both/DT
promoters/NNS
./.
====================
Two/CD
proteins/NNS
binding/VBG
the/DT
kappa/NN
B/NN
sequence/NN
,/,
NF-kappa/NN
B/NN
and/CC
KBF1/NN
,/,
are/VBP
constitutively/RB
expressed/VBN
in/IN
IARC/NN
301/CD
nuclei/NNS
and/CC
induced/VBN
by/IN
PMA/NN
and/CC
PHA/NN
in/IN
Jurkat/NN
./.
====================
They/PRP
bind/VBP
to/TO
the/DT
kappa/NN
B/NN
motifs/NNS
with/IN
different/JJ
relative/JJ
affinities/NNS
that/WDT
may/MD
reflect/VB
their/PRP$
different/JJ
contribution/NN
in/IN
the/DT
expression/NN
of/IN
various/JJ
promoters/NNS
./.
====================
UI/LS
-/:
91376383/CD
====================
TI/LS
-/:
HIV1/NN
infection/NN
of/IN
human/JJ
monocytes/NNS
and/CC
macrophages/NNS
promotes/VBZ
induction/NN
or/CC
translocation/NN
of/IN
NF-KB-related/JJ
factors/NNS
./.
====================
AB/LS
-/:
In/IN
1991/CD
,/,
we/PRP
demonstrated/VBD
,/,
using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
,/,
that/IN
3/CD
different/JJ
factors/NNS
(/(
termed/VBN
B1/NN
,/,
B2/NN
and/CC
B3/NN
)/)
with/IN
affinity/NN
for/IN
the/DT
KB-enhancer/JJ|NN
target/NN
sequence/NN
were/VBD
specifically/RB
detected/VBN
in/IN
nuclear/JJ
extracts/NNS
from/IN
HIV1-infected/JJ
monocytes/NNS
and/CC
macrophages/NNS
./.
====================
The/DT
B2/NN
factor/NN
was/VBD
induced/VBN
in/IN
the/DT
nuclei/NNS
of/IN
these/DT
cells/NNS
only/RB
upon/IN
HIV1/NN
infection/NN
./.
====================
The/DT
B3/NN
factor/NN
was/VBD
only/RB
slightly/RB
evident/JJ
in/IN
nuclei/NNS
of/IN
uninfected/JJ
cells/NNS
but/CC
was/VBD
readily/RB
detectable/JJ
in/IN
nuclei/NNS
of/IN
infected/JJ
monocytes/NNS
./.
====================
Its/PRP$
expression/NN
remained/VBD
very/RB
low/JJ
in/IN
nuclei/NNS
of/IN
HIV1-infected/JJ
macrophages/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
demonstrate/VBP
that/IN
the/DT
B2/NN
factor/NN
is/VBZ
expressed/VBN
in/IN
the/DT
cytosol/NN
of/IN
monocytes/NNS
and/CC
macrophages/NNS
as/IN
a/DT
DNA-binding/JJ
protein/NN
,/,
indicating/VBG
that/IN
it/PRP
is/VBZ
not/RB
associated/VBN
with/IN
an/DT
inhibitor/NN
(/(
IKB/NN
)/)
./.
====================
This/DT
factor/NN
remained/VBD
clustered/VBN
in/IN
the/DT
cytosol/NN
and/CC
was/VBD
translocated/VBN
to/TO
the/DT
nuclei/NNS
only/RB
after/IN
HIV1/NN
infection/NN
./.
====================
The/DT
B3/NN
factor/NN
is/VBZ
detected/VBN
in/IN
the/DT
cytosol/NN
only/RB
when/WRB
cells/NNS
are/VBP
HIV1-infected/JJ
./.
====================
The/DT
role/NN
of/IN
HIV1/NN
infection/NN
in/IN
the/DT
expression/NN
and/CC
the/DT
translocation/NN
of/IN
these/DT
factors/NNS
is/VBZ
discussed/VBN
./.
====================
UI/LS
-/:
91114695/CD
====================
TI/LS
-/:
Identification/NN
and/CC
cloning/NN
of/IN
TCF-1/NN
,/,
a/DT
T/NN
lymphocyte-specific/JJ
transcription/NN
factor/NN
containing/VBG
a/DT
sequence-specific/JJ
HMG/NN
box/NN
./.
====================
AB/LS
-/:
CD3-epsilon/NN
expression/NN
is/VBZ
controlled/VBN
by/IN
a/DT
downstream/JJ
T/NN
lymphocyte-specific/JJ
enhancer/NN
element/NN
./.
====================
We/PRP
report/VBP
the/DT
identification/NN
of/IN
a/DT
T/NN
cell-specific/JJ
transcription/NN
factor/NN
,/,
TCF-1/NN
,/,
binding/VBG
to/TO
this/DT
element/NN
./.
====================
The/DT
multimerized/JJ
recognition/NN
motif/NN
of/IN
TCF-1/NN
constituted/VBD
a/DT
T/NN
cell-specific/JJ
enhancer/NN
./.
====================
Subsequent/JJ
cloning/NN
of/IN
TCF-1/NN
identified/VBD
three/CD
splice/NN
alternatives/NNS
./.
====================
TCF-1/NN
contained/VBD
a/DT
single/JJ
DNA-binding/JJ
HMG/NN
box/NN
most/RBS
closely/RB
related/JJ
to/TO
similar/JJ
boxes/NNS
in/IN
the/DT
putative/JJ
mammalian/JJ
sex-determining/JJ
gene/NN
SRY/NN
and/CC
in/IN
the/DT
Schizosaccharomyces/FW
pombe/FW
Mc/NN
mating/NN
type/NN
gene/NN
./.
====================
TCF-1/NN
mRNA/NN
was/VBD
expressed/VBN
uniquely/RB
in/IN
T/NN
lymphocytes/NNS
./.
====================
Upon/IN
cotransfection/NN
into/IN
non-T/JJ
cells/NNS
,/,
TCF-1/NN
could/MD
transactivate/VB
through/IN
its/PRP$
cognate/JJ
motif/NN
./.
====================
These/DT
results/NNS
identify/VBP
TCF-1/NN
as/IN
a/DT
T/NN
cell-specific/JJ
transcription/NN
factor/NN
,/,
which/WDT
might/MD
play/VB
a/DT
role/NN
in/IN
the/DT
establishment/NN
of/IN
the/DT
mature/JJ
T/NN
cell/NN
phenotype/NN
./.
====================
UI/LS
-/:
92066454/CD
====================
TI/LS
-/:
Identification/NN
of/IN
transcriptional/JJ
suppressor/NN
proteins/NNS
that/WDT
bind/VBP
to/TO
the/DT
negative/JJ
regulatory/JJ
element/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
./.
====================
AB/LS
-/:
Two/CD
different/JJ
proteins/NNS
which/WDT
independently/RB
bound/VBD
to/TO
neighboring/VBG
sequences/NNS
within/IN
the/DT
negative/JJ
regulatory/JJ
element/NN
(/(
NRE/NN
)/)
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
were/VBD
detected/VBN
in/IN
the/DT
nuclear/JJ
extract/NN
of/IN
a/DT
virus-infected/JJ
human/JJ
T/NN
cell/NN
line/NN
./.
====================
One/CD
of/IN
the/DT
factors/NNS
bound/VBD
to/TO
a/DT
novel/JJ
dyad/NN
symmetrical/JJ
sequence/NN
./.
====================
This/DT
sequence/NN
is/VBZ
well/RB
conserved/VBN
in/IN
various/JJ
HIV-1/NN
isolates/NNS
and/CC
partial/JJ
homology/NN
was/VBD
found/VBN
with/IN
the/DT
promoter/JJ
region/NN
of/IN
the/DT
human/JJ
retinoblastoma/NN
gene/NN
./.
====================
Similar/JJ
DNA/NN
binding/NN
activity/NN
was/VBD
detected/VBN
in/IN
a/DT
variety/NN
of/IN
virus-uninfected/JJ
human/JJ
T/NN
cell/NN
lines/NNS
and/CC
HeLa/NN
cells/NNS
by/IN
means/NNS
of/IN
a/DT
gel/NN
mobility/NN
shift/NN
assay/NN
./.
====================
The/DT
other/JJ
factor/NN
bound/VBN
to/TO
a/DT
putative/JJ
AP-1/NN
recognition/NN
sequence/NN
predicted/VBD
for/IN
the/DT
HIV-1/NN
NRE/NN
./.
====================
However/RB
,/,
this/DT
factor/NN
did/VBD
not/RB
bind/VB
to/TO
a/DT
typical/JJ
AP-1/NN
site/NN
./.
====================
The/DT
insertion/NN
of/IN
multiple/JJ
copies/NNS
of/IN
the/DT
binding/VBG
site/NN
for/IN
the/DT
former/JJ
or/CC
latter/JJ
factor/NN
into/IN
a/DT
heterologous/JJ
promoter/NN
reduced/VBD
the/DT
promoter/NN
activity/NN
to/TO
one-tenth/CD
or/CC
one-third/CD
,/,
respectively/RB
./.
====================
Thus/RB
,/,
each/DT
factor/NN
may/MD
function/VB
as/IN
a/DT
novel/JJ
negative/JJ
regulator/NN
of/IN
transcription/NN
./.
====================
UI/LS
-/:
92265660/CD
====================
TI/LS
-/:
Protein/NN
kinase/NN
C/NN
activation/NN
and/CC
protooncogene/NN
expression/NN
in/IN
differentiation/retrodifferentiation/NN
of/IN
human/JJ
U-937/NN
leukemia/NN
cells/NNS
./.
====================
AB/LS
-/:
Human/JJ
U-937/NN
leukemia/NN
cells/NNS
differentiate/VBP
along/IN
the/DT
monocytic/JJ
lineage/NN
following/VBG
3-day/JJ
exposures/NNS
to/TO
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
./.
====================
This/DT
induction/NN
of/IN
differentiation/NN
is/VBZ
accompanied/VBN
by/IN
adherence/NN
and/CC
loss/NN
of/IN
proliferation/NN
,/,
as/RB
well/RB
as/IN
expression/repression/NN
of/IN
differentiation-associated/JJ
genes/NNS
./.
====================
Long/JJ
term/NN
culture/NN
of/IN
TPA-differentiated/JJ
U-937/NN
cells/NNS
in/IN
the/DT
absence/NN
of/IN
phorbol/NN
ester/NN
for/IN
32-36/CD
days/NNS
resulted/VBD
in/IN
a/DT
process/NN
of/IN
retrodifferentiation/NN
./.
====================
The/DT
retrodifferentiated/VBN
cells/NNS
detached/VBD
from/IN
the/DT
substrate/NN
and/CC
reinitiated/VBD
proliferation/NN
./.
====================
Other/JJ
cellular/JJ
parameters/NNS
,/,
such/JJ
as/IN
glycosidase/NN
activities/NNS
,/,
cytokine/NN
release/NN
,/,
and/CC
filament/NN
expression/NN
,/,
returned/VBD
to/TO
levels/NNS
similar/JJ
to/TO
that/DT
observed/VBN
in/IN
uninduced/JJ
cells/NNS
./.
====================
Treatment/NN
of/IN
U-937/NN
cells/NNS
with/IN
TPA/NN
resulted/VBD
in/IN
a/DT
rapid/JJ
translocation/NN
of/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
from/IN
the/DT
cytosol/NN
to/TO
cell/NN
membrane/NN
fractions/NNS
within/IN
2-8/CD
min/NN
./.
====================
Increased/VBN
levels/NNS
of/IN
membrane-associated/JJ
PKC/NN
activity/NN
persisted/VBD
until/IN
17-29/CD
days/NNS
./.
====================
However/RB
,/,
longer/JJR
periods/NNS
of/IN
incubation/NN
were/VBD
associated/VBN
with/IN
a/DT
return/NN
to/TO
the/DT
distribution/NN
of/IN
PKC/NN
in/IN
control/NN
cells/NNS
./.
====================
Activation/NN
of/IN
PKC/NN
has/VBZ
been/VBN
implicated/VBN
in/IN
the/DT
regulation/NN
of/IN
certain/JJ
immediate/JJ
early/JJ
response/NN
genes/NNS
,/,
and/CC
in/IN
the/DT
present/JJ
studies/NNS
,/,
TPA/NN
rapidly/RB
induced/VBD
c-fos/NN
and/CC
c-jun/NN
gene/NN
expression/NN
./.
====================
Levels/NNS
of/IN
c-fos/NN
and/CC
c-jun/NN
transcripts/NNS
remained/VBD
elevated/JJ
during/IN
periods/NNS
of/IN
PKC/NN
activation/NN
and/CC
also/RB
returned/VBD
to/TO
levels/NNS
observed/VBN
in/IN
control/NN
cells/NNS
by/IN
30-36/CD
days/NNS
,/,
when/WRB
the/DT
cells/NNS
entered/VBD
retrodifferentiation/NN
./.
====================
Staurosporine/NN
,/,
a/DT
nonspecific/JJ
inhibitor/NN
of/IN
PKC/NN
,/,
partially/RB
blocked/VBD
TPA-induced/JJ
adherence/NN
and/CC
growth/NN
inhibition/NN
and/CC
concomitantly/RB
prevented/VBD
TPA-induced/JJ
c-fos/NN
and/CC
c-jun/NN
gene/NN
expression/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
92118719/CD
====================
TI/LS
-/:
Kappa/NN
B-specific/JJ
DNA/NN
binding/NN
proteins/NNS
are/VBP
differentially/RB
inhibited/VBN
by/IN
enhancer/NN
mutations/NNS
and/CC
biological/JJ
oxidation/NN
./.
====================
AB/LS
-/:
Kappa/NN
B/NN
(/(
kappa/NN
B/NN
)/)
enhancer/NN
binding/NN
proteins/NNS
isolated/VBN
from/IN
the/DT
nuclei/NNS
of/IN
activated/VBN
human/JJ
T/NN
cells/NNS
produce/VBP
two/CD
distinct/JJ
nucleoprotein/NN
complexes/NNS
when/WRB
incubated/VBN
with/IN
the/DT
kappa/NN
B/NN
element/NN
from/IN
the/DT
interleukin-2/NN
receptor-alpha/NN
(/(
IL-2R/NN
alpha/NN
)/)
gene/NN
./.
====================
These/DT
two/CD
DNA-protein/JJ
complexes/NNS
are/VBP
composed/VBN
of/IN
at/IN
least/JJS
four/CD
host/NN
proteins/NNS
(/(
p50/NN
,/,
p55/NN
,/,
p75/NN
,/,
p85/NN
)/)
,/,
each/DT
of/IN
which/WDT
shares/VBZ
structural/JJ
similarity/NN
with/IN
the/DT
v-rel/NN
oncogene/NN
product/NN
./.
====================
Nuclear/JJ
expression/NN
of/IN
these/DT
proteins/NNS
is/VBZ
induced/VBN
with/IN
distinctly/RB
biphasic/JJ
kinetics/NNS
following/VBG
phorbol/NN
ester/NN
activation/NN
of/IN
T/NN
cells/NNS
(/(
p55/p75/NN
early/JJ
and/CC
p50/p85/NN
late/JJ
)/)
./.
====================
DNA-protein/JJ
crosslinking/NN
studies/NNS
have/VBP
revealed/VBN
that/IN
the/DT
more/RBR
rapidly/RB
migrating/VBG
B2/NN
complex/NN
contains/VBZ
both/CC
p50/NN
and/CC
p55/NN
while/IN
the/DT
more/RBR
slowly/RB
migrating/VBG
B1/NN
complex/NN
is/VBZ
composed/VBN
of/IN
p50/NN
,/,
p55/NN
,/,
p75/NN
,/,
and/CC
p85/NN
./.
====================
Site-directed/JJ
mutagenesis/NN
of/IN
the/DT
wild-type/JJ
IL-2R/NN
alpha/NN
kappa/NN
B/NN
enhancer/NN
(/(
GGGGAATCTCCC/NN
)/)
has/VBZ
revealed/VBN
that/IN
the/DT
binding/NN
of/IN
p50/NN
and/CC
p55/NN
(/(
B2/NN
complex/NN
)/)
is/VBZ
particularly/RB
sensitive/JJ
to/TO
alteration/NN
of/IN
the/DT
5'/JJ
triplet/NN
of/IN
deoxyguanosine/NN
residues/NNS
./.
====================
In/IN
contrast/NN
,/,
formation/NN
of/IN
the/DT
B1/NN
complex/NN
,/,
reflecting/VBG
the/DT
binding/NN
of/IN
p75/NN
and/CC
p85/NN
,/,
critically/RB
depends/VBZ
upon/IN
the/DT
more/RBR
3'/JJ
sequences/NNS
of/IN
this/DT
enhancer/NN
element/NN
./.
====================
DNA/NN
binding/NN
by/IN
all/DT
four/CD
of/IN
these/DT
Rel-related/JJ
factors/NNS
is/VBZ
blocked/VBN
by/IN
selective/JJ
chemical/JJ
modification/NN
of/IN
lysine/NN
and/CC
arginine/NN
residues/NNS
,/,
suggesting/VBG
that/IN
both/DT
of/IN
these/DT
basic/JJ
amino/NN
acids/NNS
are/VBP
required/VBN
for/IN
binding/VBG
to/TO
the/DT
kappa/NN
B/NN
element/NN
./.
====================
Similarly/RB
,/,
covalent/JJ
modification/NN
of/IN
free/JJ
sulfhydryl/NN
groups/NNS
with/IN
diamide/NN
(/(
reversible/JJ
)/)
or/CC
N-ethylmaleimide/NN
(/(
irreversible/JJ
)/)
results/VBZ
in/IN
a/DT
complete/JJ
loss/NN
of/IN
DNA/NN
binding/NN
activity/NN
./.
====================
In/IN
contrast/NN
,/,
mild/JJ
oxidation/NN
with/IN
glucose/NN
oxidase/NN
selectively/RB
inhibits/VBZ
p75/NN
and/CC
p85/NN
binding/NN
while/IN
not/RB
blocking/VBG
p50/NN
and/CC
p55/NN
interactions/NNS
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
reduced/VBN
cysteine/NN
thiols/NNS
play/VBP
an/DT
important/JJ
role/NN
in/IN
the/DT
DNA/NN
binding/NN
activity/NN
of/IN
this/DT
family/NN
of/IN
Rel-related/JJ
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
92127655/CD
====================
TI/LS
-/:
[/(
Changes/NNS
in/IN
leucocytic/JJ
estrogen/NN
receptor/NN
levels/NNS
in/IN
patients/NNS
with/IN
climacteric/JJ
syndrome/NN
and/CC
therapeutic/JJ
effect/NN
of/IN
liuwei/FW
dihuang/FW
pills/NNS
]/)
====================
AB/LS
-/:
The/DT
numbers/NNS
of/IN
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
in/IN
human/JJ
peripheral/JJ
leucocytes/NNS
in/IN
22/CD
women/NNS
with/IN
climacteric/JJ
syndrome/NN
were/VBD
measured/VBN
by/IN
radioligand/NN
method/NN
./.
====================
The/DT
results/NNS
were/VBD
compared/VBN
with/IN
those/DT
of/IN
12/CD
normal/JJ
child-bearing-age/JJ
women/NNS
./.
====================
It/PRP
wat/VBD
found/VBN
that/IN
the/DT
contents/NNS
of/IN
leucocytic/JJ
ER/NN
in/IN
climacteric/JJ
syndrome/NN
patients/NNS
were/VBD
significantly/RB
lower/JJR
than/IN
normal/JJ
child-bearing-age/JJ
women/NNS
./.
====================
The/DT
authors/NNS
used/VBD
a/DT
Chinese/JJ
prescription/NN
--/:
Liuwei/FW
Dihuang/FW
Pills/NNS
(/(
LDP/NN
)/)
to/TO
treat/VB
the/DT
patients/NNS
for/IN
2/CD
months/NNS
./.
====================
The/DT
numbers/NNS
of/IN
leucocytic/JJ
ER/NN
were/VBD
significantly/RB
increased/VBN
after/IN
treatment/NN
./.
====================
The/DT
data/NNS
indicate/VBP
that/IN
decrease/NN
of/IN
ER/NN
levels/NNS
in/IN
cell/NN
may/MD
involve/VB
in/IN
the/DT
pathogenesis/NN
of/IN
climacteric/JJ
syndrome/NN
./.
====================
LDP/NN
not/RB
only/RB
increases/VBZ
plasma/NN
estradiol/NN
levels/NNS
,/,
but/CC
also/RB
increases/VBZ
the/DT
leucocytic/JJ
ER/NN
levels/NNS
./.
====================
This/DT
may/MD
be/VB
the/DT
basis/NN
of/IN
the/DT
therapeutic/JJ
effect/NN
on/IN
the/DT
disease/NN
./.
====================
UI/LS
-/:
92049367/CD
====================
TI/LS
-/:
Evaluation/NN
of/IN
the/DT
role/NN
of/IN
ligand/NN
and/CC
thermal/JJ
activation/NN
of/IN
specific/JJ
DNA/NN
binding/NN
by/IN
in/FW
vitro/FW
synthesized/VBN
human/JJ
glucocorticoid/NN
receptor/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
used/VBN
a/DT
DNA-binding/immunoprecipitation/JJ
assay/NN
to/TO
analyze/VB
the/DT
capacity/NN
of/IN
human/JJ
glucocorticoid/NN
receptor/NN
(/(
hGR/NN
)/)
,/,
generated/VBN
in/IN
rabbit/NN
reticulocyte/NN
lysates/NNS
,/,
to/TO
bind/VB
DNA/NN
./.
====================
In/FW
vitro/FW
translated/VBN
hGR/NN
was/VBD
indistinguishable/JJ
from/IN
native/JJ
hGR/NN
,/,
as/IN
determined/VBN
by/IN
migration/NN
on/IN
sodium/NN
dodecyl/NN
sulfate-polyacrylamide/JJ
gels/NNS
,/,
sedimentation/NN
on/IN
sucrose/NN
density/NN
gradients/NNS
,/,
and/CC
reactivity/NN
with/IN
antipeptide/JJ
antibodies/NNS
generated/VBN
against/IN
hGR/NN
./.
====================
In/IN
addition/NN
,/,
cell-free/JJ
synthesized/VBN
hGR/NN
was/VBD
capable/JJ
of/IN
specific/JJ
binding/NN
to/TO
glucocorticoid/NN
response/NN
element/NN
(/(
GRE/NN
)/)
-containing/JJ
DNA/NN
fragments/NNS
./.
====================
Using/VBG
this/DT
assay/NN
system/NN
,/,
we/PRP
have/VBP
evaluated/VBN
the/DT
contributions/NNS
of/IN
ligand/NN
binding/NN
and/CC
heat/NN
activation/NN
to/TO
DNA/NN
binding/NN
by/IN
these/DT
glucocorticoid/NN
receptors/NNS
./.
====================
In/FW
vitro/FW
translated/VBN
hGR/NN
was/VBD
capable/JJ
of/IN
selective/JJ
DNA/NN
binding/NN
even/RB
in/IN
the/DT
absence/NN
of/IN
glucocorticoid/NN
./.
====================
Treatment/NN
with/IN
dexamethasone/NN
or/CC
the/DT
antiglucocorticoid/JJ
RU486/NN
had/VBD
no/DT
additional/JJ
effect/NN
on/IN
the/DT
DNA-binding/JJ
capacity/NN
when/WRB
receptor/NN
preparations/NNS
were/VBD
maintained/VBN
at/IN
0/CD
C/NN
(/(
no/DT
activation/NN
)/)
./.
====================
In/IN
contrast/NN
,/,
addition/NN
of/IN
either/CC
ligand/NN
or/CC
antagonist/NN
in/IN
combination/NN
with/IN
a/DT
heat/NN
activation/NN
step/NN
promoted/VBD
DNA/NN
binding/NN
by/IN
approximately/RB
3-fold/RB
over/IN
that/DT
of/IN
heat-activated/JJ
unliganded/JJ
receptors/NNS
./.
====================
Agonist/NN
(/(
dexamethasone/NN
)/)
was/VBD
slightly/RB
more/JJR
effective/JJ
in/IN
supporting/VBG
specific/JJ
DNA/NN
binding/NN
than/IN
antagonist/NN
(/(
RU486/NN
)/)
./.
====================
DNA/NN
binding/NN
by/IN
in/FW
vitro/FW
synthesized/VBN
GR/NN
was/VBD
blocked/VBN
by/IN
the/DT
addition/NN
of/IN
sodium/NN
molybdate/NN
to/TO
the/DT
receptor/NN
preparations/NNS
before/IN
steroid/NN
addition/NN
and/CC
thermal/JJ
activation/NN
./.
====================
Addition/NN
of/IN
KCl/NN
resulted/VBD
in/IN
less/RBR
DNA/NN
binding/NN
either/CC
due/JJ
to/TO
blockage/NN
of/IN
DNA-receptor/JJ
complex/NN
formation/NN
or/CC
disruption/NN
of/IN
the/DT
complexes/NNS
./.
====================
The/DT
specificity/NN
of/IN
DNA/NN
binding/NN
by/IN
cell-free/JJ
synthesized/VBN
hGR/NN
was/VBD
analyzed/VBN
further/RB
by/IN
examining/VBG
the/DT
abilities/NNS
of/IN
various/JJ
DNAs/NNS
to/TO
compete/VB
for/IN
binding/VBG
to/TO
a/DT
naturally/RB
occurring/VBG
GRE/NN
found/VBD
in/IN
the/DT
mouse/NN
mammary/JJ
tumor/NN
virus-long/JJ
terminal/JJ
repeat/NN
./.
====================
Oligonucleotides/NNS
containing/VBG
the/DT
consensus/NN
GRE/NN
were/VBD
the/DT
most/RBS
efficient/JJ
competitors/NNS
,/,
and/CC
fragments/NNS
containing/VBG
regulatory/JJ
sequences/NNS
from/IN
glucocorticoid-repressible/JJ
genes/NNS
were/VBD
somewhat/RB
competitive/JJ
,/,
whereas/IN
single/JJ
stranded/JJ
oligonucleotides/NNS
were/VBD
unable/JJ
to/TO
compete/VB
for/IN
mouse/NN
mammary/JJ
tumor/NN
virus-long/JJ
terminal/JJ
repeat/NN
DNA/NN
binding/NN
,/,
except/IN
when/WRB
competitor/NN
was/VBD
present/JJ
at/IN
extremely/RB
high/JJ
concentrations/NNS
./.
====================
Together/RB
these/DT
studies/NNS
indicate/VBP
that/IN
hGR/NN
synthesized/VBN
in/IN
rabbit/NN
reticulocyte/NN
lysates/NNS
displays/VBZ
many/JJ
of/IN
the/DT
same/JJ
properties/NNS
,/,
including/VBG
GRE-specific/JJ
DNA/NN
binding/NN
,/,
observed/VBN
for/IN
glucocorticoid/NN
receptor/NN
present/JJ
in/IN
cytosolic/JJ
extracts/NNS
of/IN
mammalian/JJ
cells/NNS
and/CC
tissues/NNS
./.
====================
Similarities/NNS
between/IN
the/DT
effects/NNS
of/IN
dexamethasone/NN
and/CC
RU486/NN
suggest/VBP
that/IN
the/DT
antiglucocorticoid/JJ
properties/NNS
of/IN
RU486/NN
do/VBP
not/RB
occur/VB
at/IN
the/DT
level/NN
of/IN
specific/JJ
DNA/NN
binding/NN
./.
====================
UI/LS
-/:
91264362/CD
====================
TI/LS
-/:
Expression/NN
of/IN
1,25(OH)2D3/NN
receptors/NNS
on/IN
alveolar/JJ
lymphocytes/NNS
from/IN
patients/NNS
with/IN
pulmonary/JJ
granulomatous/JJ
diseases/NNS
./.
====================
AB/LS
-/:
1,25(OH)2D3/NN
is/VBZ
known/VBN
to/TO
be/VB
produced/VBN
at/IN
sites/NNS
of/IN
granulomatous/JJ
reactions/NNS
./.
====================
In/IN
order/NN
to/TO
characterize/VB
the/DT
cell/NN
types/NNS
that/WDT
are/VBP
targets/NNS
for/IN
this/DT
immunoregulatory/JJ
hormone/NN
,/,
we/PRP
have/VBP
evaluated/VBN
the/DT
expression/NN
of/IN
1,25(OH)2D3/NN
receptors/NNS
on/IN
peripheral/JJ
blood/NN
T-lymphocytes/NNS
and/CC
those/DT
recovered/VBN
from/IN
the/DT
lung/NN
by/IN
bronchoalveolar/JJ
lavage/NN
from/IN
patients/NNS
with/IN
pulmonary/JJ
granulomatous/JJ
diseases/NNS
(/(
tuberculosis/NN
and/CC
sarcoidosis/NN
)/)
and/CC
from/IN
normal/JJ
control/NN
subjects/NNS
using/VBG
combined/JJ
autoradiographic/JJ
and/CC
immunohistochemical/JJ
techniques/NNS
./.
====================
Lavage/NN
T-lymphocytes/NNS
from/IN
patients/NNS
with/IN
tuberculosis/NN
or/CC
with/IN
sarcoidosis/NN
,/,
but/CC
not/RB
those/DT
from/IN
normal/JJ
control/NN
subjects/NNS
,/,
expressed/VBD
1,25(OH)2D3/NN
receptors/NNS
as/IN
demonstrated/VBN
by/IN
binding/NN
of/IN
[3H]1,25(OH)2D3/NN
,/,
which/WDT
was/VBD
inhibited/VBN
by/IN
the/DT
presence/NN
of/IN
excess/JJ
unlabeled/JJ
1,25(OH)2D3/NN
,/,
but/CC
not/RB
by/IN
the/DT
presence/NN
of/IN
unlabeled/JJ
25/CD
(/(
OH/NN
)/)
D3/NN
(/(
receptor-positive/JJ
lymphocytes/NNS
:/:
sarcoidosis/NN
,/,
20/CD
+/-/CC
12/CD
%/NN
;/:
tuberculosis/NN
,/,
31/CD
+/-/CC
17/CD
%/NN
)/)
./.
====================
In/IN
contrast/NN
,/,
blood/NN
lymphocytes/NNS
from/IN
patients/NNS
with/IN
granulomatous/JJ
diseases/NNS
did/VBD
not/RB
express/VB
detectable/JJ
1,25(OH)2D3/NN
receptors/NNS
./.
====================
The/DT
percentage/NN
of/IN
lavage/NN
T-lymphocytes/NNS
expressing/VBG
1,25(OH)2D3/NN
receptors/NNS
was/VBD
significantly/RB
greater/JJR
for/IN
patients/NNS
with/IN
tuberculosis/NN
presenting/VBG
with/IN
isolated/VBN
hilar/JJ
adenopathy/JJ
than/IN
for/IN
patients/NNS
with/IN
pulmonary/JJ
infiltrates/NNS
and/or/CC
cavities/NNS
./.
====================
1,25(OH)2D3/NN
receptors/NNS
were/VBD
expressed/VBN
to/TO
a/DT
greater/JJR
extent/NN
on/IN
CD8+/JJ
T-lymphocytes/NNS
than/IN
on/IN
CD4+/JJ
T-lymphocytes/NNS
in/IN
sarcoidosis/NN
,/,
whereas/IN
a/DT
greater/JJR
proportion/NN
of/IN
CD4+/JJ
than/IN
of/IN
CD8+/JJ
T-lymphocytes/NNS
from/IN
patients/NNS
with/IN
tuberculosis/NN
were/VBD
receptor-positive/JJ
./.
====================
These/DT
findings/NNS
support/VBP
the/DT
conclusion/NN
that/IN
the/DT
interaction/NN
of/IN
1,25(OH)2D3/NN
with/IN
its/PRP$
receptor/NN
on/IN
T-lymphocytes/NNS
may/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
regulation/NN
of/IN
granulomatous/JJ
reactions/NNS
,/,
but/CC
because/IN
these/DT
receptors/NNS
are/VBP
expressed/VBN
on/IN
different/JJ
lymphocyte/NN
populations/NNS
,/,
the/DT
net/JJ
effect/NN
of/IN
this/DT
potent/JJ
immunoregulatory/JJ
molecule/NN
is/VBZ
likely/RB
different/JJ
in/IN
sarcoidosis/NN
and/CC
tuberculosis/NN
./.
====================
UI/LS
-/:
91219488/CD
====================
TI/LS
-/:
Role/NN
for/IN
the/DT
Epstein-Barr/JJ
virus/NN
nuclear/JJ
antigen/NN
2/CD
in/IN
viral/JJ
promoter/NN
switching/VBG
during/IN
initial/JJ
stages/NNS
of/IN
infection/NN
./.
====================
AB/LS
-/:
During/IN
latent/JJ
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
infection/NN
of/IN
human/JJ
B/NN
lymphocytes/NNS
,/,
six/CD
viral/JJ
nuclear/JJ
antigen/NN
(/(
EBNAs/NNS
)/)
are/VBP
expressed/VBN
from/IN
long/JJ
primary/JJ
transcripts/NNS
by/IN
means/NNS
of/IN
alternative/JJ
splicing/NN
and/CC
alternative/JJ
polyadenylylation/NN
sites/NNS
./.
====================
These/DT
transcripts/NNS
initiate/VBP
from/IN
one/CD
of/IN
two/CD
promoters/NNS
,/,
Cp/NN
or/CC
Wp/NN
,/,
that/WDT
function/VBP
in/IN
a/DT
mutually/RB
exclusive/JJ
fashion/NN
./.
====================
Wp/NN
is/VBZ
exclusively/RB
utilized/VBN
during/IN
the/DT
initial/JJ
stages/NNS
of/IN
infection/NN
of/IN
primary/JJ
B/NN
lymphocytes/NNS
,/,
followed/VBN
by/IN
a/DT
switch/NN
to/TO
Cp/NN
usage/NN
./.
====================
These/DT
studies/NNS
have/VBP
been/VBN
extended/VBN
to/TO
show/VB
that/IN
(/(
i/LS
)/)
a/DT
mutant/JJ
EBV/NN
strain/NN
lacking/VBG
the/DT
gene/NN
encoding/VBG
EBNA/NN
2/CD
fails/VBZ
to/TO
switch/VB
from/IN
Wp/NN
to/TO
Cp/NN
usage/NN
in/IN
primary/JJ
B/NN
lymphocytes/NNS
,/,
although/IN
the/DT
virus/NN
contains/VBZ
a/DT
functional/JJ
Cp/NN
;/:
(/(
ii/LS
)/)
a/DT
region/NN
from/IN
-429/CD
to/TO
-245/CD
base/NN
pairs/NNS
upstream/JJ
of/IN
Cp/NN
is/VBZ
essential/JJ
for/IN
Cp/NN
activity/NN
in/IN
B/NN
lymphocytes/NNS
,/,
but/CC
only/RB
in/IN
the/DT
context/NN
of/IN
upstream/JJ
and/CC
downstream/JJ
sequences/NNS
;/:
(/(
iii/LS
)/)
this/DT
region/NN
contains/VBZ
an/DT
EBNA/NN
2-dependent/JJ
enhancer/NN
;/:
and/CC
(/(
iv/LS
)/)
DNase/NN
I/CD
protection/NN
employing/VBG
nuclear/JJ
extracts/NNS
from/IN
B/NN
and/CC
T/NN
lymphocytes/NNS
revealed/VBD
a/DT
B-cell-specific/JJ
footprint/NN
in/IN
the/DT
region/NN
of/IN
the/DT
EBNA/NN
2-dependent/JJ
enhancer/NN
./.
====================
These/DT
results/NNS
support/VBP
a/DT
model/NN
for/IN
viral/JJ
promoter/NN
switching/NN
during/IN
the/DT
initial/JJ
stages/NNS
of/IN
infection/NN
in/IN
which/WDT
Wp/NN
activity/NN
leads/VBZ
to/TO
the/DT
expression/NN
of/IN
EBNA/NN
2/CD
,/,
followed/VBN
by/IN
activation/NN
of/IN
Cp/NN
through/IN
the/DT
EBNA/NN
2-dependent/JJ
enhancer/NN
./.
====================
UI/LS
-/:
91184714/CD
====================
TI/LS
-/:
Immune/JJ
response/NN
of/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
to/TO
HBx-antigen/NN
of/IN
hepatitis/NN
B/NN
virus/NN
./.
====================
AB/LS
-/:
The/DT
hepatitis/NN
B/NN
virus/NN
genome/NN
encodes/VBZ
a/DT
transcriptional/JJ
transactivator/NN
protein/NN
designated/VBN
HBxAg/NN
./.
====================
We/PRP
have/VBP
investigated/VBN
whether/IN
this/DT
antigen/NN
is/VBZ
a/DT
target/NN
structure/NN
for/IN
human/JJ
T-lymphocytes/NNS
./.
====================
Using/VBG
recombinant/JJ
HBxAg/NN
protein/NN
,/,
we/PRP
found/VBD
HBxAg-specific/JJ
stimulation/NN
of/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
in/IN
patients/NNS
with/IN
acute/JJ
hepatitis/NN
B/NN
virus/NN
infection/NN
(/(
6/CD
of/IN
6/CD
)/)
and/CC
chronic/JJ
hepatitis/NN
B/NN
virus/NN
infection/NN
(/(
6/CD
of/IN
17/CD
)/)
but/CC
not/RB
in/IN
healthy/JJ
individuals/NNS
./.
====================
With/IN
HBxAg-specific/JJ
synthetic/JJ
polypeptides/NNS
,/,
several/JJ
T-cell/NN
epitopes/NNS
were/VBD
identified/VBN
./.
====================
Most/JJS
were/VBD
located/JJ
in/IN
the/DT
carboxyterminal/JJ
half/NN
of/IN
the/DT
HBxAg/NN
protein/NN
./.
====================
Five/CD
T-cell/NN
clones/NNS
specific/JJ
for/IN
a/DT
T-cell/NN
epitope/NN
located/JJ
at/IN
the/DT
carboxyterminal/JJ
region/NN
of/IN
HBxAg/NN
were/VBD
established/VBN
and/CC
found/VBN
to/TO
belong/VB
to/TO
the/DT
CD2/CD4-positive/JJ
,/,
CD8-negative/JJ
subtype/NN
./.
====================
These/DT
data/NNS
establish/VBP
for/IN
the/DT
first/JJ
time/NN
HBxAg/NN
as/IN
an/DT
antigen/NN
in/IN
the/DT
cellular/JJ
immune/JJ
response/NN
./.
====================
UI/LS
-/:
91339573/CD
====================
TI/LS
-/:
[/(
Changes/NNS
in/IN
leucocytic/JJ
estrogen/NN
receptor/NN
levels/NNS
in/IN
patients/NNS
with/IN
gynecomastia/NN
]/)
====================
AB/LS
-/:
The/DT
number/NN
of/IN
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
in/IN
human/JJ
peripheral/JJ
leucocytes/NNS
in/IN
13/CD
men/NNS
with/IN
gynecomastia/NNS
were/VBD
measured/VBN
by/IN
radioligand/NN
binding/NN
method/NN
./.
The/DT
results/NNS
were/VBD
compared/VBN
with/IN
those/DT
of/IN
13/CD
sex-/NN
and/CC
age-matched/JJ
healthy/JJ
subjects/NNS
./.
====================
It/PRP
was/VBD
found/VBN
that/IN
the/DT
number/NN
of/IN
ER/NN
in/IN
leucocytes/NNS
was/VBD
significantly/RB
increased/VBN
in/IN
gynecomastia/NN
(/(
Rs/NN
of/IN
leucocytes/NNS
were/VBD
1054/CD
+/-/CC
254/CD
sites/cell/NN
)/)
./.
====================
It/PRP
suggested/VBD
that/IN
increase/NN
of/IN
ER/NN
levels/NNS
play/VBP
an/DT
important/JJ
role/NN
in/IN
the/DT
pathogenesis/NN
of/IN
gynecomastia/NN
./.
====================
UI/LS
-/:
91101115/CD
====================
TI/LS
-/:
The/DT
NF/NN
kappa/NN
B/NN
independent/JJ
cis-acting/JJ
sequences/NNS
in/IN
HIV-1/NN
LTR/NN
responsive/NN
to/TO
T-cell/NN
activation/NN
./.
====================
AB/LS
-/:
The/DT
rate/NN
of/IN
transcription/NN
initiation/NN
directed/VBN
by/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
of/IN
HIV-1/NN
increases/VBZ
in/IN
response/NN
to/TO
mitogenic/JJ
stimuli/NNS
of/IN
T/NN
cells/NNS
./.
====================
Here/RB
we/PRP
show/VBP
that/IN
the/DT
response/NN
of/IN
the/DT
HIV-1/NN
LTR/NN
may/MD
be/VB
governed/VBN
by/IN
two/CD
independent/JJ
sequences/NNS
located/JJ
5'/JJ
to/TO
the/DT
site/NN
of/IN
transcription/NN
initiation/NN
sequences/NNS
that/WDT
bind/VBP
either/CC
NFAT-1/NN
or/CC
NF/NN
kappa/NN
B/NN
./.
====================
The/DT
rate/NN
of/IN
LTR-directed/JJ
gene/NN
expression/NN
increased/VBD
in/IN
response/NN
to/TO
treatment/NN
with/IN
either/CC
a/DT
phorbol/NN
ester/NN
or/CC
tumor/NN
necrosis/NN
factor/NN
alpha/NN
if/IN
either/CC
the/DT
NFAT-1/NN
or/CC
NF/NN
kappa/NN
B/NN
binding/NN
sites/NNS
were/VBD
deleted/VBN
,/,
but/CC
failed/VBD
to/TO
respond/VB
to/TO
these/DT
mitogenic/JJ
stimuli/NNS
if/IN
both/DT
sequences/NNS
were/VBD
absent/JJ
./.
====================
The/DT
HIV-1/NN
mutant/JJ
virus/NN
containing/VBG
both/CC
NF/NN
kappa/NN
B/NN
and/CC
NFAT-1/NN
deletion/NN
was/VBD
able/JJ
to/TO
replicate/VB
although/IN
at/IN
a/DT
much/JJ
decreased/VBN
growth/NN
rate/NN
,/,
while/IN
the/DT
deletion/NN
of/IN
NFAT-1/NN
alone/RB
increased/VBD
the/DT
viral/JJ
growth/NN
rate/NN
in/IN
Jurkat/NN
cells/NNS
./.
====================
Neither/CC
deletion/NN
of/IN
NF/NN
kappa/NN
B/NN
nor/CC
deletion/NN
of/IN
NFAT-1/NN
decreased/VBD
activation/NN
of/IN
viral/JJ
replication/NN
by/IN
phorbol/NN
ester/NN
./.
====================
UI/LS
-/:
92052243/CD
====================
TI/LS
-/:
cAMP-dependent/JJ
regulation/NN
of/IN
proenkephalin/NN
by/IN
JunD/NN
and/CC
JunB/NN
:/:
positive/JJ
and/CC
negative/JJ
effects/NNS
of/IN
AP-1/NN
proteins/NNS
./.
====================
AB/LS
-/:
We/PRP
demonstrate/VBP
that/IN
JunD/NN
,/,
a/DT
component/NN
of/IN
the/DT
AP-1/NN
transcription/NN
factor/NN
complex/NN
,/,
activates/VBZ
transcription/NN
of/IN
the/DT
human/JJ
proenkephalin/NN
gene/NN
in/IN
a/DT
fashion/NN
that/WDT
is/VBZ
completely/RB
dependent/JJ
upon/IN
the/DT
cAMP-dependent/JJ
protein/NN
kinase/NN
,/,
protein/NN
kinase/NN
A/NN
./.
====================
Activation/NN
of/IN
proenkephalin/NN
transcription/NN
by/IN
JunD/NN
is/VBZ
dependent/JJ
upon/IN
a/DT
previously/RB
characterized/VBN
cAMP-/NN
,/,
phorbol/NN
ester-/NN
,/,
and/CC
Ca(2+)-inducible/JJ
enhancer/NN
,/,
and/CC
JunD/NN
is/VBZ
shown/VBN
to/TO
bind/VB
the/DT
enhancer/NN
as/IN
a/DT
homodimer/NN
./.
====================
Another/DT
component/NN
of/IN
the/DT
AP-1/NN
transcription/NN
complex/NN
,/,
JunB/NN
,/,
is/VBZ
shown/VBN
to/TO
inhibit/VB
activation/NN
mediated/VBN
by/IN
JunD/NN
./.
====================
As/IN
a/DT
homodimer/NN
JunB/NN
is/VBZ
unable/JJ
to/TO
bind/VB
the/DT
enhancer/NN
;/:
however/RB
in/IN
the/DT
presence/NN
of/IN
c-Fos/NN
,/,
high-affinity/JJ
binding/NN
is/VBZ
observed/VBN
./.
====================
Furthermore/RB
,/,
JunD/NN
is/VBZ
shown/VBN
to/TO
activate/VB
transcription/NN
of/IN
genes/NNS
linked/VBN
to/TO
both/CC
cAMP/NN
and/CC
phorbol/NN
ester/NN
response/NN
elements/NNS
in/IN
a/DT
protein/NN
kinase/NN
A-dependent/JJ
fashion/NN
,/,
further/RB
blurring/VBG
the/DT
distinction/NN
between/IN
these/DT
response/NN
elements/NNS
./.
====================
These/DT
results/NNS
demonstrate/VBP
that/IN
the/DT
transcriptional/JJ
activity/NN
of/IN
an/DT
AP-1-related/JJ
protein/NN
is/VBZ
regulated/VBN
by/IN
the/DT
cAMP-dependent/JJ
second-messenger/NN
pathway/NN
and/CC
suggest/VBP
that/IN
JunD/NN
and/CC
other/JJ
AP-1-related/JJ
proteins/NNS
may/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
regulation/NN
of/IN
gene/NN
expression/NN
by/IN
cAMP-dependent/JJ
intracellular/JJ
signaling/NN
pathways/NNS
./.
====================
UI/LS
-/:
92257680/CD
====================
TI/LS
-/:
[/(
Plasma/NN
cortisol/NN
concentration/NN
and/CC
blood/NN
leukocyte/NN
content/NN
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
patients/NNS
with/IN
deficiency-cold/JJ
vs/CC
deficiency-heat/JJ
syndromes/NNS
]/)
====================
AB/LS
-/:
Plasma/NN
cortisol/NN
concentration/NN
and/CC
blood/NN
leukocyte/NN
content/NN
of/IN
glucocorticoid/NN
receptors/NNS
(/(
GCR/NN
)/)
were/VBD
assayed/VBN
in/IN
20/CD
patients/NNS
with/IN
deficiency/NN
syndromes/NNS
,/,
10/CD
cold/JJ
in/IN
property/NN
(/(
deficiency-cold/JJ
)/)
,/,
the/DT
other/JJ
10/CD
hot/JJ
in/IN
property/NN
(/(
deficiency-heat/JJ
)/)
,/,
and/CC
also/RB
in/IN
10/CD
healthy/JJ
individuals/NNS
as/IN
normal/JJ
control/NN
for/IN
the/DT
purpose/NN
of/IN
investigating/VBG
the/DT
nature/NN
of/IN
cold/NN
and/CC
heat/NN
syndromes/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
the/DT
cases/NNS
of/IN
deficiency-cold/JJ
syndrome/NN
(/(
DCS/NN
)/)
had/VBD
a/DT
normal/JJ
concentration/NN
of/IN
plasma/NN
cortisol/NN
but/CC
a/DT
lowered/JJ
content/NN
of/IN
GCR/NN
in/IN
leukocytes/NNS
when/WRB
compared/VBN
with/IN
the/DT
normal/JJ
control/NN
(/(
P/NN
less/JJR
than/IN
0.05/CD
)/)
;/:
the/DT
cases/NNS
of/IN
deficiency-heat/JJ
syndrome/NN
(/(
DHS/NN
)/)
had/VBD
a/DT
higher/JJR
concentration/NN
of/IN
plasma/NN
cortisol/NN
than/IN
the/DT
normal/JJ
control/NN
(/(
P/NN
less/JJR
than/IN
0.05/CD
)/)
and/CC
a/DT
slightly/RB
higher/JJR
content/NN
of/IN
GCR/NN
in/IN
leukocytes/NNS
./.
====================
It/PRP
was/VBD
concluded/VBN
that/IN
the/DT
DCS/NN
is/VBZ
characterized/VBN
by/IN
diminished/VBN
biological/JJ
effects/NNS
of/IN
adrenocortical/JJ
activity/NN
,/,
while/IN
the/DT
DHS/NN
,/,
by/IN
augmented/JJ
biological/JJ
effects/NNS
of/IN
adrenocortical/JJ
activity/NN
./.
====================
UI/LS
-/:
92088960/CD
====================
TI/LS
-/:
The/DT
role/NN
of/IN
jun/NN
and/CC
fos/NN
gene/NN
family/NN
members/NNS
in/IN
12-O-tetradecanoylphorbol-13-acetate/NN
induced/VBD
hemopoietic/JJ
differentiation/NN
./.
====================
AB/LS
-/:
Terminal/JJ
differentiation/NN
of/IN
the/DT
leukemic/JJ
cell/NN
lines/NNS
U-937/NN
and/CC
HL-60/NN
by/IN
12-O-tetradecanoylphorbol-13-acetate/NN
is/VBZ
accompanied/VBN
by/IN
marked/JJ
changes/NNS
in/IN
gene/NN
expression/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
demonstrate/VBP
that/IN
the/DT
expression/NN
of/IN
jun/NN
and/CC
fos/NN
gene/NN
family/NN
members/NNS
is/VBZ
induced/VBN
with/IN
variable/JJ
kinetics/NNS
during/IN
12-O-tetradecanoylphorbol-13-acetate/NN
induced/VBD
differentiation/NN
,/,
with/IN
c-jun/NN
expression/NN
best/RB
paralleling/JJ
differentiation/NN
./.
====================
The/DT
generation/NN
of/IN
AP-1/NN
complexes/NNS
,/,
as/IN
measured/VBN
by/IN
DNA/NN
binding/NN
activity/NN
,/,
closely/RB
parallels/VBZ
morphological/JJ
differentiation/NN
./.
====================
Furthermore/RB
,/,
the/DT
ability/NN
of/IN
these/DT
complexes/NNS
to/TO
regulate/VB
gene/NN
expression/NN
is/VBZ
demonstrated/VBN
by/IN
increased/VBN
transcription/NN
from/IN
an/DT
AP-1/NN
driven/VBN
reporter/NN
construct/NN
and/CC
marked/JJ
increases/NNS
in/IN
the/DT
expression/NN
of/IN
endogenous/JJ
AP-1/NN
regulated/JJ
genes/NNS
./.
====================
Differentiation/NN
assays/NNS
using/VBG
water/NN
soluble/JJ
phorbol/NN
esters/NNS
reveal/VBP
that/IN
differentiation/NN
becomes/VBZ
irreversible/JJ
soon/RB
after/IN
AP-1/NN
appears/VBZ
./.
====================
This/DT
tight/JJ
correlation/NN
between/IN
c-jun/NN
expression/NN
,/,
the/DT
generation/NN
of/IN
AP-1/NN
activity/NN
,/,
and/CC
differentiation/NN
suggests/VBZ
a/DT
critical/JJ
role/NN
for/IN
this/DT
gene/NN
and/CC
transcriptional/JJ
complex/NN
during/IN
this/DT
process/NN
./.
====================
UI/LS
-/:
91351285/CD
====================
TI/LS
-/:
Nuclear/JJ
association/NN
of/IN
a/DT
T-cell/NN
transcription/NN
factor/NN
blocked/VBN
by/IN
FK-506/NN
and/CC
cyclosporin/NN
A/NN
[/(
see/VB
comments/NNS
]/)
====================
AB/LS
-/:
Cyclosporin/NN
A/NN
and/CC
FK506/NN
inhibit/VBP
T-/NN
and/CC
B-cell/NN
activation/NN
and/CC
other/JJ
processes/NNS
essential/JJ
to/TO
an/DT
effective/JJ
immune/JJ
response/NN
./.
====================
In/IN
T/NN
lymphocytes/NNS
these/DT
drugs/NNS
disrupt/VBP
an/DT
unknown/JJ
step/NN
in/IN
the/DT
transmission/NN
of/IN
signals/NNS
from/IN
the/DT
T-cell/NN
antigen/NN
receptor/NN
to/TO
cytokine/NN
genes/NNS
that/WDT
coordinate/VBP
the/DT
immune/JJ
response/NN
./.
====================
The/DT
putative/JJ
intracellular/JJ
receptors/NNS
for/IN
FK506/NN
and/CC
cyclosporin/NN
are/VBP
cis-trans/JJ
prolyl/JJ
isomerases/NNS
./.
====================
Binding/NN
of/IN
the/DT
drug/NN
inhibits/VBZ
isomerase/NN
activity/NN
,/,
but/CC
studies/NNS
with/IN
other/JJ
prolyl/JJ
isomerase/NN
inhibitors/NNS
and/CC
analysis/NN
of/IN
cyclosporin-resistant/JJ
mutants/NNS
in/IN
yeast/NN
suggest/VBP
that/IN
the/DT
effects/NNS
of/IN
the/DT
drug/NN
result/VBP
from/IN
the/DT
formation/NN
of/IN
an/DT
inhibitory/JJ
complex/NN
between/IN
the/DT
drug/NN
and/CC
isomerase/NN
,/,
and/CC
not/RB
from/IN
inhibition/NN
of/IN
isomerase/NN
activity/NN
./.
====================
A/DT
transcription/NN
factor/NN
,/,
NF-AT/NN
,/,
which/WDT
is/VBZ
essential/JJ
for/IN
early/JJ
T-cell/NN
gene/NN
activation/NN
,/,
seems/VBZ
to/TO
be/VB
a/DT
specific/JJ
target/NN
of/IN
cyclosporin/NN
A/NN
and/CC
FK506/NN
action/NN
because/IN
transcription/NN
directed/VBN
by/IN
this/DT
protein/NN
is/VBZ
blocked/VBN
in/IN
T/NN
cells/NNS
treated/VBN
with/IN
these/DT
drugs/NNS
,/,
with/IN
little/JJ
or/CC
no/DT
effect/NN
on/IN
other/JJ
transcription/NN
factors/NNS
such/JJ
as/IN
AP-1/NN
and/CC
NF-kappa/NN
B/NN
./.
====================
Here/RB
we/PRP
demonstrate/VBP
that/IN
NF-AT/NN
is/VBZ
formed/VBN
when/WRB
a/DT
signal/NN
from/IN
the/DT
antigen/NN
receptor/NN
induces/VBZ
a/DT
pre-existing/JJ
cytoplasmic/JJ
subunit/NN
to/TO
translocate/VB
to/TO
the/DT
nucleus/NN
and/CC
combine/VB
with/IN
a/DT
newly/RB
synthesized/VBN
nuclear/JJ
subunit/NN
of/IN
NF-AT/NN
./.
====================
FK506/NN
and/CC
cyclosporin/NN
A/NN
block/VBP
translocation/NN
of/IN
the/DT
cytoplasmic/JJ
component/NN
without/IN
affecting/VBG
synthesis/NN
of/IN
the/DT
nuclear/JJ
subunit/NN
./.
====================
UI/LS
-/:
91364264/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptors/NNS
in/IN
lymphocytes/NNS
in/IN
anorexia/NN
nervosa/NN
./.
====================
AB/LS
-/:
OBJECTIVE/NN
:/:
The/DT
aim/NN
was/VBD
to/TO
explore/VB
the/DT
down-regulation/NN
of/IN
the/DT
glucocorticoid/NN
receptors/NNS
during/IN
hypercortisolaemia/NN
in/IN
anorexia/NN
nervosa/NN
./.
====================
DESIGN/NN
:/:
Urine/NN
and/CC
plasma/NN
samples/NNS
were/VBD
obtained/VBN
for/IN
cortisol/NN
determination/NN
and/CC
blood/NN
lymphocytes/NNS
were/VBD
isolated/VBN
for/IN
receptor/NN
binding/NN
studies/NNS
./.
====================
PATIENTS/NNS
:/:
Sixteen/CD
anorexic/JJ
patients/NNS
,/,
aged/JJ
16-27/CD
years/NNS
,/,
with/IN
a/DT
mean/NN
+/-/CC
SEM/NN
body/NN
mass/NN
index/NN
of/IN
14.2/CD
+/-/CC
2.0/CD
(/(
ranging/VBG
from/IN
11.1/CD
to/TO
17.4/CD
)/)
,/,
and/CC
15/CD
normal/JJ
women/NNS
were/VBD
studied/VBN
./.
====================
Six/CD
patients/NNS
were/VBD
reinvestigated/VBN
after/IN
a/DT
significant/JJ
weight/NN
gain/NN
./.
====================
MEASUREMENTS/NNS
:/:
The/DT
binding/NN
capacity/NN
and/CC
affinity/NN
of/IN
the/DT
glucocorticoid/NN
receptors/NNS
were/VBD
measured/VBN
with/IN
dexamethasone/NN
as/IN
ligand/NN
on/IN
lymphocytes/NNS
./.
====================
RESULTS/NNS
:/:
In/IN
patients/NNS
,/,
both/DT
total/JJ
and/CC
free/JJ
plasma/NN
cortisol/NN
concentrations/NNS
were/VBD
higher/JJR
than/IN
in/IN
the/DT
normal/JJ
women/NNS
,/,
as/IN
was/VBD
their/PRP$
urinary/JJ
free/JJ
cortisol/NN
;/:
the/DT
number/NN
of/IN
glucocorticoid/NN
receptors/NNS
per/IN
cell/NN
(/(
Ro/NN
)/)
and/CC
the/DT
binding/NN
affinity/NN
(/(
Kd/NN
)/)
for/IN
dexamethasone/NN
were/VBD
,/,
however/RB
,/,
not/RB
significantly/RB
different/JJ
(/(
Ro/NN
:/:
7687/CD
+/-/CC
1750/CD
vs/CC
7347/CD
+/-/CC
1285/CD
sites/cell/NN
;/:
Kd/NN
:/:
7.7/CD
+/-/CC
2.4/CD
vs/CC
7.4/CD
+/-/CC
1.7/CD
nM/NN
at/IN
24/CD
degrees/NNS
C/NN
)/)
./.
====================
After/IN
weight/NN
gain/NN
(/(
14/CD
+/-/CC
2/CD
to/TO
16/CD
+/-/CC
2/CD
kg/m2/NN
)/)
,/,
receptor/NN
numbers/NNS
were/VBD
8421/CD
+/-/CC
2126/CD
(/(
pre/JJ|RB
)/)
and/CC
9011/CD
+/-/CC
500/CD
(/(
post/JJ|RB
)/)
sites/cell/NN
,/,
which/WDT
are/VBP
not/RB
significantly/RB
different/JJ
(/(
P/NN
greater/JJR
than/IN
0.2/CD
)/)
;/:
the/DT
Kd/NN
was/VBD
unchanged/JJ
(/(
9.3/CD
+/-/CC
2.6/CD
vs/CC
9.2/CD
+/-/CC
2.4/CD
nM/NN
)/)
./.
====================
CONCLUSIONS/NNS
Hypercortisolaemia/NN
does/VBZ
not/RB
down-regulate/VB
the/DT
lymphocyte/NN
glucocorticoid/NN
receptors/NNS
in/IN
anorexia/NN
nervosa/NN
and/CC
a/DT
post-receptor/JJ
defect/NN
might/MD
be/VB
involved/VBN
in/IN
peripheral/JJ
tissue/NN
resistance/NN
to/TO
the/DT
effects/NNS
of/IN
glucocorticoid/NN
hormones/NNS
in/IN
undernutrition/NN
./.
====================
UI/LS
-/:
91236696/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
protein/NN
phosphatases/NNS
by/IN
okadaic/JJ
acid/NN
induces/VBZ
AP1/NN
in/IN
human/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
To/TO
examine/VB
the/DT
role/NN
of/IN
protein/NN
phosphatases/NNS
in/IN
T/NN
cell/NN
activation/NN
,/,
Jurkat/NN
cells/NNS
were/VBD
treated/VBN
with/IN
okadaic/JJ
acid/NN
,/,
an/DT
inhibitor/NN
of/IN
type/NN
1/CD
and/CC
2A/NN
phosphatases/NNS
,/,
and/CC
nuclear/JJ
extracts/NNS
were/VBD
examined/VBN
for/IN
the/DT
presence/NN
of/IN
AP1/NN
as/IN
a/DT
measure/NN
of/IN
early/JJ
T/NN
cell/NN
activation/NN
./.
====================
Okadaic/JJ
acid/NN
was/VBD
found/VBN
to/TO
be/VB
a/DT
potent/JJ
inducer/NN
of/IN
AP1/NN
./.
====================
In/IN
contrast/NN
to/TO
phorbol/NN
esters/NNS
such/JJ
as/IN
phorbol/NN
myristate/NN
acetate/NN
(/(
PMA/NN
)/)
,/,
the/DT
induction/NN
of/IN
AP1/NN
by/IN
okadaic/JJ
acid/NN
occurs/VBZ
predominantly/RB
by/IN
transcriptional/JJ
activation/NN
of/IN
the/DT
jun/NN
and/CC
fos/NN
family/NN
of/IN
proto-oncogenes/NNS
./.
====================
Surprisingly/RB
,/,
while/IN
the/DT
addition/NN
of/IN
phytohemagglutinin/NN
further/RB
enhanced/VBD
the/DT
induction/NN
of/IN
AP1/NN
,/,
the/DT
addition/NN
of/IN
PMA/NN
inhibited/VBD
it/PRP
./.
====================
Okadaic/JJ
acid/NN
treatment/NN
was/VBD
found/VBN
to/TO
dramatically/RB
increase/VB
mRNA/NN
transcripts/NNS
of/IN
the/DT
jun/NN
family/NN
of/IN
proto-oncogenes/NNS
including/VBG
c-jun/NN
,/,
junD/NN
,/,
and/CC
junB/NN
and/CC
to/TO
a/DT
lesser/JJR
extent/NN
the/DT
fos/NN
family/NN
including/VBG
c-fos/NN
and/CC
fra-1/NN
./.
====================
By/IN
comparison/NN
,/,
PMA/NN
is/VBZ
a/DT
very/RB
inefficient/JJ
inducer/NN
of/IN
the/DT
jun/NN
gene/NN
family/NN
in/IN
Jurkat/NN
cells/NNS
./.
====================
Similar/JJ
to/TO
its/PRP$
effect/NN
on/IN
the/DT
induction/NN
of/IN
AP1/NN
by/IN
okadaic/JJ
acid/NN
,/,
PMA/NN
inhibits/VBZ
the/DT
induction/NN
of/IN
c-jun/NN
mRNA/NN
by/IN
okadaic/JJ
acid/NN
./.
====================
Transfection/NN
of/IN
c-jun/NN
promoter/NN
constructs/NNS
confirmed/VBD
the/DT
marked/JJ
difference/NN
between/IN
PMA/NN
and/CC
okadaic/JJ
acid/NN
in/IN
inducing/VBG
c-jun/NN
transcription/NN
./.
====================
The/DT
induction/NN
of/IN
AP1/NN
by/IN
okadaic/JJ
acid/NN
suggests/VBZ
that/IN
protein/NN
phosphatases/NNS
1/CD
and/CC
2A/NN
(/(
PP1/NN
and/CC
PP2A/NN
)/)
may/MD
be/VB
involved/VBN
in/IN
T/NN
cell/NN
activation/NN
as/IN
important/JJ
negative/JJ
regulators/NNS
of/IN
the/DT
transcription/NN
factor/NN
AP1/NN
./.
====================
UI/LS
-/:
91217625/CD
====================
TI/LS
-/:
Cloning/NN
of/IN
murine/JJ
TCF-1/NN
,/,
a/DT
T/NN
cell-specific/JJ
transcription/NN
factor/NN
interacting/VBG
with/IN
functional/JJ
motifs/NNS
in/IN
the/DT
CD3-epsilon/NN
and/CC
T/NN
cell/NN
receptor/NN
alpha/NN
enhancers/NNS
./.
====================
AB/LS
-/:
CD3-epsilon/NN
gene/NN
expression/NN
is/VBZ
confined/VBN
to/TO
the/DT
T/NN
cell/NN
lineage/NN
./.
====================
We/PRP
have/VBP
recently/RB
identified/VBN
and/CC
cloned/VBN
a/DT
human/JJ
transcription/NN
factor/NN
,/,
TCF-1/NN
,/,
that/WDT
binds/VBZ
to/TO
a/DT
functional/JJ
element/NN
in/IN
the/DT
T/NN
lymphocyte-specific/JJ
enhancer/NN
of/IN
CD3-epsilon/NN
./.
====================
In/IN
a/DT
panel/NN
of/IN
human/JJ
cell/NN
lines/NNS
,/,
TCF-1/NN
expression/NN
was/VBD
restricted/JJ
to/TO
T/NN
lineage/NN
cells/NNS
./.
====================
TCF-1/NN
belonged/VBD
to/TO
a/DT
novel/JJ
family/NN
of/IN
genes/NNS
that/WDT
contain/VBP
the/DT
so-called/JJ
high/JJ
mobility/NN
group/NN
1/CD
(/(
HMG/NN
)/)
box/NN
./.
====================
Here/RB
we/PRP
report/VBP
the/DT
cloning/NN
of/IN
murine/JJ
TCF-1/NN
./.
====================
Two/CD
splice/NN
alternatives/NNS
were/VBD
identified/VBN
that/WDT
were/VBD
not/RB
previously/RB
observed/VBN
in/IN
human/JJ
TCF-1/NN
./.
====================
Murine/JJ
and/CC
human/JJ
TCF-1/NN
displayed/VBD
a/DT
95.5/CD
%/NN
overall/JJ
amino/NN
acid/NN
homology/NN
./.
====================
Recombinant/JJ
murine/JJ
and/CC
human/JJ
TCF-1/NN
recognized/VBD
the/DT
same/JJ
sequence/NN
motif/NN
in/IN
the/DT
CD3-epsilon/NN
enhancer/NN
as/IN
judged/VBN
by/IN
gel/NN
retardation/NN
and/CC
methylation/NN
interference/NN
assays/NNS
./.
====================
With/IN
the/DT
murine/JJ
cDNA/NN
clones/NNS
several/JJ
aspects/NNS
of/IN
TCF-1/NN
were/VBD
analyzed/VBN
./.
====================
First/RB
,/,
deletion/NN
analysis/NN
revealed/VBD
that/IN
a/DT
region/NN
of/IN
TCF-1/NN
containing/VBG
the/DT
HMG/NN
box/NN
was/VBD
sufficient/JJ
for/IN
sequence-specific/JJ
binding/NN
./.
====================
Second/RB
,/,
by/IN
high/JJ
stringency/NN
Northern/NN
blotting/NN
and/CC
in/FW
situ/FW
hybridization/NN
,/,
TCF-1/NN
expression/NN
was/VBD
shown/VBN
to/TO
be/VB
confined/VBN
to/TO
the/DT
thymus/NN
and/CC
to/TO
the/DT
T/NN
cell/NN
areas/NNS
of/IN
the/DT
spleen/NN
./.
====================
Third/RB
,/,
TCF-1/NN
bound/VBD
specifically/RB
to/TO
a/DT
functional/JJ
T/NN
cell-specific/JJ
element/NN
in/IN
the/DT
T/NN
cell/NN
receptor/NN
alpha/NN
(/(
TCR-alpha/NN
)/)
enhancer/NN
./.
====================
The/DT
T/NN
lineage-specific/JJ
expression/NN
and/CC
the/DT
affinity/NN
for/IN
functional/JJ
motifs/NNS
in/IN
the/DT
TCR-alpha/NN
and/CC
CD3-epsilon/NN
enhancers/NNS
imply/VBP
an/DT
important/JJ
role/NN
for/IN
TCF-1/NN
in/IN
the/DT
establishment/NN
of/IN
the/DT
mature/JJ
T/NN
cell/NN
phenotype/NN
./.
====================
UI/LS
-/:
91291757/CD
====================
TI/LS
-/:
Cloning/NN
of/IN
a/DT
human/JJ
homeobox/NN
gene/NN
that/WDT
resembles/VBZ
a/DT
diverged/JJ
Drosophila/NN
homeobox/NN
gene/NN
and/CC
is/VBZ
expressed/VBN
in/IN
activated/VBN
lymphocytes/NNS
./.
====================
AB/LS
-/:
A/DT
new/JJ
homeobox/NN
gene/NN
,/,
HB24/NN
,/,
has/VBZ
been/VBN
isolated/VBN
from/IN
a/DT
human/JJ
B-lymphocyte/NN
cDNA/NN
library/NN
./.
====================
Northern/JJ|NN
blot/NN
analysis/NN
of/IN
polyadenylated/JJ
RNA/NN
purified/VBN
from/IN
activated/VBN
human/JJ
B/NN
cells/NNS
revealed/VBD
a/DT
single/JJ
mRNA/NN
transcript/NN
of/IN
approximately/RB
2.3/CD
kb/NN
./.
====================
Two/CD
cDNA/NN
clones/NNS
were/VBD
sequenced/VBN
and/CC
provided/VBN
2,250/CD
nucleotides/NNS
(/(
nt/NN
)/)
of/IN
DNA/NN
sequence/NN
information/NN
./.
====================
There/EX
is/VBZ
a/DT
single/JJ
methionine/NN
codon-initiated/JJ
open/JJ
reading/NN
frame/NN
of/IN
1,458/CD
nt/NN
in/IN
frame/NN
with/IN
a/DT
homeobox/NN
and/CC
a/DT
CAX/NN
repeat/NN
,/,
and/CC
the/DT
open/JJ
reading/NN
frame/NN
is/VBZ
predicted/VBN
to/TO
encode/VB
a/DT
protein/NN
of/IN
51,659/CD
daltons/NNS
./.
====================
When/WRB
the/DT
homeodomain/NN
from/IN
HB24/NN
was/VBD
compared/VBN
to/TO
known/JJ
mammalian/JJ
and/CC
Drosophila/NN
homeodomains/NNS
it/PRP
was/VBD
found/VBN
to/TO
be/VB
only/RB
moderately/RB
conserved/VBN
,/,
but/CC
when/WRB
it/PRP
was/VBD
compared/VBN
to/TO
a/DT
highly/RB
diverged/JJ
Drosophila/FW
homeodomain/NN
,/,
H2.0/NN
,/,
it/PRP
was/VBD
found/VBN
to/TO
be/VB
80/CD
%/NN
identical/JJ
./.
====================
The/DT
HB24/NN
mRNA/NN
was/VBD
absent/JJ
or/CC
present/JJ
at/IN
low/JJ
levels/NNS
in/IN
normal/JJ
B/NN
and/CC
T/NN
lymphocytes/NNS
;/:
however/RB
,/,
with/IN
the/DT
appropriate/JJ
activation/NN
signal/NN
HB24/NN
mRNA/NN
was/VBD
induced/VBN
within/IN
several/JJ
hours/NNS
even/RB
in/IN
the/DT
presence/NN
of/IN
cycloheximide/NN
./.
====================
Characterization/NN
of/IN
HB24/NN
expression/NN
in/IN
lymphoid/JJ
and/CC
select/JJ
developing/VBG
tissues/NNS
was/VBD
performed/VBN
by/IN
in/FW
situ/FW
hybridization/NN
./.
====================
Positive/JJ
hybridization/NN
was/VBD
found/VBN
in/IN
thymus/NN
,/,
tonsil/NN
,/,
bone/NN
marrow/NN
,/,
developing/VBG
vessels/NNS
,/,
and/CC
in/IN
fetal/JJ
brain/NN
./.
====================
HB24/NN
is/VBZ
likely/JJ
to/TO
have/VB
an/DT
important/JJ
role/NN
in/IN
lymphocytes/NNS
as/RB
well/RB
as/IN
in/IN
certain/JJ
developing/VBG
tissues/NNS
./.
====================
UI/LS
-/:
91132035/CD
====================
TI/LS
-/:
Platelet-activating/JJ
factor/NN
induces/VBZ
phospholipid/JJ
turnover/NN
,/,
calcium/NN
flux/NN
,/,
arachidonic/JJ
acid/NN
liberation/NN
,/,
eicosanoid/NN
generation/NN
,/,
and/CC
oncogene/JJ
expression/NN
in/IN
a/DT
human/JJ
B/NN
cell/NN
line/NN
./.
====================
AB/LS
-/:
Platelet-activating/JJ
factor/NN
is/VBZ
a/DT
potent/JJ
mediator/NN
of/IN
the/DT
inflammatory/JJ
response/NN
./.
====================
Studies/NNS
of/IN
the/DT
actions/NNS
of/IN
platelet-activating/JJ
factor/NN
have/VBP
centered/VBN
mainly/RB
around/IN
neutrophils/NNS
,/,
monocytes/NNS
,/,
and/CC
platelets/NNS
./.
====================
In/IN
this/DT
report/NN
we/PRP
begin/VBP
to/TO
uncover/VB
the/DT
influence/NN
of/IN
platelet-activating/NN
factor/NN
on/IN
B/NN
lymphocytes/NNS
./.
====================
Employing/VBG
the/DT
EBV-transformed/JJ
human/JJ
B/NN
cell/NN
line/NN
SKW6.4/NN
,/,
we/PRP
demonstrate/VBP
that/IN
platelet-activating/JJ
factor/NN
significantly/RB
alters/VBZ
membrane/NN
phospholipid/JJ
metabolism/NN
indicated/VBN
by/IN
the/DT
incorporation/NN
of/IN
32P/NN
into/IN
phosphatidylcholine/NN
,/,
phosphatidylinositol/NN
,/,
and/CC
phosphatidic/JJ
acid/NN
but/CC
not/RB
significantly/RB
into/IN
phosphatidylethanolamine/NN
at/IN
concentrations/NNS
ranging/VBG
from/IN
10/CD
(/(
-9/CD
)/)
to/TO
10/CD
(/(
-6/CD
)/)
M/NN
./.
====================
The/DT
inactive/JJ
precursor/NN
,/,
lyso-platelet-activating/JJ
factor/NN
,/,
at/IN
a/DT
concentration/NN
as/RB
high/JJ
as/IN
10/CD
(/(
-7/CD
)/)
M/NN
had/VBD
no/DT
effect/NN
on/IN
any/DT
of/IN
the/DT
membrane/NN
phospholipids/NNS
./.
====================
We/PRP
also/RB
show/VBP
that/IN
platelet-activating/JJ
factor/NN
from/IN
10/CD
(/(
-12/CD
)/)
to/TO
10/CD
(/(
-6/CD
)/)
M/NN
induced/VBD
rapid/JJ
and/CC
significant/JJ
elevation/NN
in/IN
intracellular/JJ
calcium/NN
levels/NNS
,/,
whereas/IN
lyso-platelet-activating/JJ
factor/NN
was/VBD
again/RB
ineffective/JJ
./.
====================
We/PRP
further/RB
demonstrate/VBP
the/DT
impact/NN
of/IN
platelet-activating/JJ
factor/NN
binding/VBG
to/TO
B/NN
cells/NNS
by/IN
measuring/VBG
platelet-activating/JJ
factor/NN
induced/JJ
arachidonic/JJ
acid/NN
release/NN
and/CC
5-hydroxyeicosatetraenoic/JJ
acid/NN
production/NN
./.
====================
Moreover/RB
,/,
platelet-activating/JJ
factor/NN
was/VBD
capable/JJ
of/IN
inducing/VBG
transcription/NN
of/IN
the/DT
nuclear/JJ
proto-oncogenes/NNS
c-fos/NN
and/CC
c-jun/NN
./.
====================
Finally/RB
we/PRP
explored/VBD
the/DT
possible/JJ
role/NN
of/IN
5-hydroxyeicosatetraenoic/JJ
acid/NN
as/IN
a/DT
regulator/NN
of/IN
arachidonic/JJ
acid/NN
liberation/NN
demonstrating/VBG
that/IN
endogenous/JJ
5-lipoxygenase/NN
activity/NN
modulates/VBZ
platelet-activating/JJ
factor/NN
induced/JJ
arachidonic/JJ
acid/NN
release/NN
perhaps/RB
acting/VBG
at/IN
the/DT
level/NN
of/IN
phospholipase/NN
A2/NN
./.
====================
In/IN
summary/NN
,/,
platelet-activating/JJ
factor/NN
is/VBZ
shown/VBN
here/RB
to/TO
have/VB
a/DT
direct/JJ
and/CC
profound/JJ
effect/NN
on/IN
a/DT
pure/JJ
B/NN
cell/NN
line/NN
./.
====================
UI/LS
-/:
91094881/CD
====================
TI/LS
-/:
Positive/JJ
and/CC
negative/JJ
regulation/NN
of/IN
immunoglobulin/NN
gene/NN
expression/NN
by/IN
a/DT
novel/JJ
B-cell-specific/JJ
enhancer/NN
element/NN
./.
====================
AB/LS
-/:
A/DT
new/JJ
B-cell-specific/JJ
enhancer/NN
element/NN
has/VBZ
been/VBN
identified/VBN
3'/JJ
of/IN
E4/NN
and/CC
the/DT
octamerlike/JJ
motifs/NNS
in/IN
the/DT
human/JJ
immunoglobulin/NN
heavy-chain/NN
gene/NN
enhancer/NN
./.
====================
Tandem/JJ
copies/NNS
of/IN
this/DT
67-bp/JJ
MnlI-AluI/NN
fragment/NN
,/,
when/WRB
fused/VBN
to/TO
the/DT
chloramphenicol/JJ
acetyltransferase/NN
gene/NN
driven/VBN
by/IN
the/DT
conalbumin/JJ
promoter/NN
,/,
stimulated/VBD
transcription/NN
in/IN
B/NN
cells/NNS
but/CC
not/RB
in/IN
Jurkat/NN
T/NN
cells/NNS
or/CC
HeLa/NN
cells/NNS
./.
====================
Footprinting/NN
analysis/NN
revealed/VBD
that/IN
the/DT
identical/JJ
sequence/NN
CCGAAACTGAAAAGG/NN
,/,
designated/VBN
E6/NN
,/,
was/VBD
protected/VBN
by/IN
nuclear/JJ
extracts/NNS
from/IN
B/NN
cells/NNS
,/,
T/NN
cells/NNS
,/,
or/CC
HeLa/NN
cells/NNS
./.
====================
Gel/NN
mobility/NN
shift/NN
assays/NNS
using/VBG
a/DT
synthetic/JJ
E6/NN
motif/NN
detected/VBD
a/DT
B-cell-specific/JJ
complex/NN
in/IN
addition/NN
to/TO
a/DT
ubiquitous/JJ
band/NN
found/VBN
also/RB
in/IN
T/NN
cells/NNS
and/CC
HeLa/NN
cells/NNS
./.
====================
In/IN
agreement/NN
with/IN
the/DT
results/NNS
of/IN
gel/NN
retardation/NN
assays/NNS
,/,
tandem/JJ
copies/NNS
of/IN
the/DT
E6/NN
motif/NN
stimulated/VBD
transcription/NN
in/IN
ARH77/NN
and/CC
Raji/NN
cells/NNS
but/CC
not/RB
in/IN
Jurkat/NN
or/CC
HeLa/NN
cells/NNS
./.
====================
Furthermore/RB
,/,
a/DT
mutant/JJ
E6/NN
motif/NN
lost/VBD
both/CC
in/FW
vitro/FW
binding/NN
activity/NN
and/CC
in/FW
vivo/FW
enhancer/NN
activity/NN
./.
====================
In/IN
striking/JJ
contrast/NN
to/TO
the/DT
mouse/NN
Ig/NN
heavy-chain/JJ
enhancer/NN
,/,
in/IN
which/WDT
the/DT
octamer/NN
motif/NN
acts/VBZ
as/IN
a/DT
B-cell-specific/JJ
enhancer/NN
element/NN
,/,
the/DT
human/JJ
enhancer/NN
contains/VBZ
an/DT
octamerlike/JJ
sequence/NN
with/IN
one/CD
base/NN
substitution/NN
which/WDT
bound/VBD
octamer-binding/JJ
proteins/NNS
with/IN
only/RB
very/RB
low/JJ
affinity/NN
and/CC
showed/VBD
no/DT
enhancer/NN
activity/NN
of/IN
its/PRP$
own/JJ
./.
====================
Interestingly/RB
,/,
the/DT
MnlI-AluI/NN
fragment/NN
could/MD
suppress/VB
the/DT
basal-level/JJ
activity/NN
of/IN
the/DT
conalbumin/JJ
promoter/NN
in/IN
both/CC
Jurkat/NN
and/CC
HeLa/NN
cells/NNS
./.
====================
Moreover/RB
,/,
simian/JJ
virus/NN
40/CD
enhancer/NN
activity/NN
was/VBD
blocked/VBN
by/IN
the/DT
MnlI-AluI/NN
fragment/NN
in/IN
HeLa/NN
cells/NNS
but/CC
not/RB
in/IN
B/NN
cells/NNS
./.
====================
Thus/RB
,/,
the/DT
novel/JJ
enhancer/NN
element/NN
identified/VBN
in/IN
this/DT
study/NN
is/VBZ
probably/RB
a/DT
target/NN
site/NN
for/IN
both/CC
positive/JJ
and/CC
negative/JJ
factors/NNS
./.
====================
UI/LS
-/:
92043714/CD
====================
TI/LS
-/:
Charybdotoxin-sensitive/JJ
,/,
Ca(2+)-dependent/JJ
membrane/NN
potential/JJ
changes/NNS
are/VBP
not/RB
involved/VBN
in/IN
human/JJ
T/NN
or/CC
B/NN
cell/NN
activation/NN
and/CC
proliferation/NN
./.
====================
AB/LS
-/:
The/DT
involvement/NN
of/IN
ion/NN
channels/NNS
in/IN
B/NN
and/CC
T/NN
lymphocyte/NN
activation/NN
is/VBZ
supported/VBN
by/IN
many/JJ
reports/NNS
of/IN
changes/NNS
in/IN
ion/NN
fluxes/NNS
and/CC
membrane/NN
potential/NN
after/IN
mitogen/NN
binding/NN
./.
====================
Human/JJ
T/NN
and/CC
B/NN
lymphocytes/NNS
demonstrate/VBP
an/DT
early/JJ
and/CC
transient/JJ
hyperpolarization/NN
after/IN
ligand/JJ
binding/NN
./.
====================
Inasmuch/RB
as/IN
the/DT
change/NN
in/IN
membrane/NN
potential/NN
is/VBZ
dependent/JJ
on/IN
elevation/NN
of/IN
free/JJ
cytosolic/JJ
calcium/NN
,/,
the/DT
hyperpolarization/NN
is/VBZ
presumably/RB
through/IN
opening/NN
of/IN
Ca(2+)-stimulated/JJ
K+/NN
channels/NNS
./.
====================
We/PRP
have/VBP
used/VBN
charybdotoxin/NN
,/,
a/DT
known/JJ
inhibitor/NN
of/IN
Ca(2+)-dependent/JJ
K+/NN
channels/NNS
,/,
to/TO
study/VB
the/DT
role/NN
of/IN
these/DT
channels/NNS
in/IN
lymphocyte/NN
activation/NN
and/CC
mitogenesis/NN
./.
====================
We/PRP
demonstrate/VBP
that/IN
charybdotoxin/NN
inhibits/VBZ
the/DT
ligand-induced/JJ
transient/JJ
membrane/NN
hyperpolarization/NN
in/IN
B/NN
and/CC
T/NN
cells/NNS
in/IN
a/DT
dose-dependent/JJ
fashion/NN
,/,
without/IN
affecting/VBG
changes/NNS
in/IN
cytosolic/JJ
Ca2+/NN
./.
====================
However/RB
,/,
blockade/NN
of/IN
the/DT
Ca(2+)-activated/JJ
K+/NN
channel/NN
is/VBZ
not/RB
associated/VBN
with/IN
changes/NNS
in/IN
cell-cycle/JJ
gene/NN
activation/NN
,/,
IL-2/NN
production/NN
,/,
IL-2R/NN
expression/NN
or/CC
B/NN
and/CC
T/NN
cell/NN
mitogenesis/NN
./.
====================
These/DT
results/NNS
imply/VBP
that/IN
membrane/NN
potential/JJ
changes/NNS
secondary/JJ
to/TO
the/DT
ligand-dependent/JJ
opening/NN
of/IN
Ca(2+)-activated/JJ
K+/NN
channels/NNS
are/VBP
not/RB
involved/VBN
in/IN
B/NN
and/CC
T/NN
lymphocyte/NN
activation/NN
and/CC
mitogenesis/NN
./.
====================
UI/LS
-/:
92135145/CD
====================
TI/LS
-/:
Activity/NN
of/IN
the/DT
kappa/NN
B/NN
enhancer/NN
of/IN
the/DT
interleukin-2/NN
receptor/NN
alpha/NN
chain/NN
in/IN
somatic/JJ
cell/NN
hybrids/NNS
is/VBZ
accompanied/VBN
by/IN
the/DT
nuclear/JJ
localization/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
AB/LS
-/:
The/DT
two/CD
nuclear/JJ
proteins/NNS
NF-kappa/NN
B/NN
(/(
consisting/VBG
of/IN
subunits/NNS
p50/NN
an/DT
dp65/NN
)/)
and/CC
the/DT
DNA-binding/JJ
subunit/NN
of/IN
NF-kappa/NN
B/NN
(/(
p50/NN
)/)
by/IN
itself/PRP
,/,
also/RB
called/VBN
KBF1/NN
,/,
are/VBP
constitutively/RB
expressed/VBN
and/CC
localized/JJ
in/IN
the/DT
nucleus/NN
of/IN
the/DT
human/JJ
T-cell/NN
line/NN
IARC/NN
301.5/CD
./.
====================
In/IN
order/NN
to/TO
define/VB
the/DT
roles/NNS
of/IN
these/DT
two/CD
factors/NNS
,/,
which/WDT
bind/VBP
to/TO
the/DT
same/JJ
kappa/NN
B/NN
enhancers/NNS
,/,
in/IN
transcription/NN
activation/NN
we/PRP
have/VBP
prepared/VBN
somatic/JJ
cell/NN
hybrids/NNS
between/IN
IARC/NN
301.5/CD
and/CC
a/DT
murine/JJ
myeloma/NN
./.
====================
Most/JJS
hybrids/NNS
express/VBP
both/CC
KBF1/NN
and/CC
NF-kappa/NN
B/NN
in/IN
their/PRP$
nuclei/NNS
,/,
but/CC
one/CD
hybrid/NN
expresses/VBZ
only/RB
KBF1/NN
./.
====================
The/DT
kappa/NN
B/NN
enhancer/NN
of/IN
the/DT
gene/NN
encoding/VBG
the/DT
interleukin-2/NN
(/(
IL-2/NN
)/)
receptor/NN
alpha/NN
chain/NN
(/(
IL-2R/NN
alpha/NN
)/)
is/VBZ
functional/JJ
only/RB
in/IN
the/DT
hybrids/NNS
expressing/VBG
nuclear/JJ
NF-kappa/NN
B/NN
./.
====================
These/DT
findings/NNS
show/VBP
that/IN
nuclear/JJ
NF-kappa/NN
B/NN
is/VBZ
necessary/JJ
to/TO
activate/VB
the/DT
kappa/NN
B/NN
enhancer/NN
,/,
while/IN
KBF1/NN
by/IN
itself/PRP
is/VBZ
not/RB
sufficient/JJ
./.
====================
We/PRP
propose/VBP
that/IN
KBF1/NN
is/VBZ
a/DT
competitive/JJ
inhibitor/NN
of/IN
NF-kappa/NN
B/NN
and/CC
discuss/VB
how/WRB
these/DT
factors/NNS
may/MD
be/VB
involved/VBN
in/IN
the/DT
transient/JJ
expression/NN
of/IN
IL-2/NN
and/CC
IL-2/NN
alpha/NN
genes/NNS
during/IN
the/DT
immune/JJ
response/NN
./.
====================
UI/LS
-/:
92022337/CD
====================
TI/LS
-/:
T-helper-cell/JJ
determinants/NNS
in/IN
protein/NN
antigens/NNS
are/VBP
preferentially/RB
located/JJ
in/IN
cysteine-rich/JJ
antigen/NN
segments/NNS
resistant/JJ
to/TO
proteolytic/JJ
cleavage/NN
by/IN
cathepsin/NN
B/NN
,/,
L/NN
,/,
and/CC
D/NN
./.
====================
AB/LS
-/:
We/PRP
report/VBP
on/IN
a/DT
computer/NN
algorithm/NN
capable/JJ
of/IN
predicting/VBG
the/DT
location/NN
of/IN
T-helper-cell/NN
epitopes/NNS
in/IN
protein/NN
antigen/NN
(/(
Ag/NN
)/)
by/IN
analysing/VBG
the/DT
Ag/NN
amino/NN
acid/NN
sequence/NN
./.
====================
The/DT
algorithm/NN
was/VBD
constructed/VBN
with/IN
the/DT
aim/NN
of/IN
identifying/VBG
segments/NNS
in/IN
Ag/NN
which/WDT
are/VBP
resistant/JJ
to/TO
proteolytic/JJ
degradation/NN
by/IN
the/DT
enzymes/NNS
cathepsin/NN
B/NN
,/,
L/NN
,/,
and/CC
D/NN
./.
====================
These/DT
are/VBP
prominent/JJ
enzymes/NNS
in/IN
the/DT
endocytic/JJ
pathway/NN
through/IN
which/WDT
soluble/JJ
protein/NN
Ag/NN
enter/VBP
APC/NN
,/,
and/CC
resistant/JJ
segments/NNS
in/IN
Ag/NN
may/MD
,/,
therefore/RB
,/,
be/VB
expected/VBN
to/TO
contain/VB
more/JJR
T-cell/NN
determinants/NNS
than/IN
susceptible/JJ
segments/NNS
./.
====================
From/IN
information/NN
available/JJ
in/IN
the/DT
literature/NN
on/IN
the/DT
substrate/JJ
specificity/NN
of/IN
the/DT
three/CD
enzymes/NNS
,/,
it/PRP
is/VBZ
clear/JJ
that/IN
a/DT
cysteine/NN
is/VBZ
not/RB
accepted/VBN
in/IN
any/DT
of/IN
the/DT
S2/NN
,/,
S1/NN
,/,
S1'/NN
,/,
and/CC
S2'/NN
subsites/NNS
of/IN
cathepsin/NN
B/NN
and/CC
L/NN
,/,
and/CC
not/RB
in/IN
the/DT
S1/NN
and/CC
S1'/NN
subsites/NNS
of/IN
cathepsin/NN
D/NN
./.
====================
Moreover/RB
,/,
we/PRP
have/VBP
noticed/VBN
that/IN
cysteine-containing/JJ
T-cell/NN
determinants/NNS
in/IN
a/DT
number/NN
of/IN
protein/NN
Ag/NN
are/VBP
particularly/RB
rich/JJ
in/IN
the/DT
amino/NN
acids/NNS
alanine/NN
,/,
glycine/NN
,/,
lysine/NN
,/,
leucine/NN
,/,
serine/NN
,/,
threonine/NN
,/,
and/CC
valine/NN
./.
====================
By/IN
searching/VBG
protein/NN
Ag/NN
for/IN
clusters/NNS
of/IN
amino/NN
acids/NNS
containing/VBG
cysteine/NN
and/CC
two/CD
of/IN
the/DT
other/JJ
amino/NN
acids/NNS
we/PRP
were/VBD
able/JJ
to/TO
predict/VB
17/CD
out/IN
of/IN
23/CD
empirically/RB
known/VBN
T-cell/NN
determinants/NNS
in/IN
the/DT
Ag/NN
with/IN
a/DT
relatively/RB
low/JJ
number/NN
of/IN
false/JJ
(/(
positive/JJ
)/)
predictions/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
present/VBP
a/DT
new/JJ
principle/NN
for/IN
searching/VBG
Ag/NN
for/IN
potential/JJ
amphipatic/JJ
alpha-helical/JJ
protein/NN
segments/NNS
./.
====================
Such/JJ
segments/NNS
accord/VBP
well/RB
with/IN
empirically/RB
known/JJ
T-cell/NN
determinants/NNS
and/CC
our/PRP$
algorithm/NN
produces/VBZ
a/DT
lower/JJR
number/NN
of/IN
false/JJ
positive/JJ
predictions/NNS
than/IN
the/DT
principle/NN
based/VBN
on/IN
discrete/JJ
Fourier/NN
transformations/NNS
previously/RB
described/VBN
./.
====================
UI/LS
-/:
91303691/CD
====================
TI/LS
-/:
Contribution/NN
of/IN
NF-kappa/NN
B/NN
and/CC
Sp1/NN
binding/NN
motifs/NNS
to/TO
the/DT
replicative/JJ
capacity/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
:/:
distinct/JJ
patterns/NNS
of/IN
viral/JJ
growth/NN
are/VBP
determined/VBN
by/IN
T-cell/NN
types/NNS
./.
====================
AB/LS
-/:
Starting/VBG
with/IN
a/DT
replication-incompetent/JJ
molecular/JJ
clone/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
,/,
lacking/VBG
all/PDT
the/DT
NF-kappa/NN
B/NN
and/CC
Sp1/NN
binding/NN
sites/NNS
present/JJ
in/IN
the/DT
native/JJ
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
,/,
proviruses/NNS
containing/VBG
reconstructed/VBN
LTRs/NNS
with/IN
individual/JJ
or/CC
combinations/NNS
of/IN
NF-kappa/NN
B/NN
and/CC
Sp1/NN
elements/NNS
were/VBD
generated/VBN
and/CC
evaluated/VBN
for/IN
their/PRP$
capacity/NN
to/TO
produce/VB
virus/NN
progeny/NN
following/VBG
transfection-cocultivation/NN
./.
====================
Virus/NN
stocks/NNS
obtained/VBN
from/IN
these/DT
experiments/NNS
exhibited/VBD
a/DT
continuum/NN
of/IN
replicative/JJ
capacities/NNS
in/IN
different/JJ
human/JJ
T-cell/NN
types/NNS
depending/VBG
on/IN
which/WDT
element/NN
(/(
s/NNS
)/)
was/VBD
present/JJ
in/IN
the/DT
LTR/NN
./.
====================
For/IN
example/NN
,/,
in/IN
experiments/NNS
involving/VBG
proviral/JJ
clones/NNS
with/IN
LTRs/NNS
containing/VBG
one/CD
or/CC
two/CD
NF-kappa/NN
B/NN
elements/NNS
(/(
and/CC
no/DT
Sp1/NN
binding/NN
sites/NNS
)/)
,/,
a/DT
hierarchy/NN
of/IN
cellular/JJ
permissivity/NN
to/TO
virus/NN
replication/NN
(/(
peripheral/JJ
blood/NN
lymphocytes/NNS
=/JJ
MT4/NN
greater/JJR
than/IN
H9/NN
greater/JJR
than/IN
CEM/NN
greater/JJR
than/IN
Jurkat/NN
)/)
was/VBD
observed/VBN
./.
====================
Of/IN
note/NN
was/VBD
the/DT
associated/VBN
emergence/NN
of/IN
second-site/JJ
LTR/NN
revertants/NNS
which/WDT
involved/VBD
an/DT
alteration/NN
of/IN
the/DT
TATA/NN
box/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
LTR/NN
possesses/VBZ
functional/JJ
redundancy/NN
which/WDT
ensures/VBZ
virus/NN
replication/NN
in/IN
different/JJ
T-cell/NN
types/NNS
and/CC
is/VBZ
capable/JJ
of/IN
changing/VBG
depending/VBG
on/IN
the/DT
particular/JJ
combination/NN
of/IN
transcriptional/JJ
factors/NNS
present/JJ
./.
====================
UI/LS
-/:
92144438/CD
====================
TI/LS
-/:
Stimulation/NN
of/IN
interferon/NN
beta/NN
gene/NN
transcription/NN
in/FW
vitro/FW
by/IN
purified/VBN
NF-kappa/NN
B/NN
and/CC
a/DT
novel/JJ
TH/NN
protein/NN
./.
====================
AB/LS
-/:
The/DT
human/JJ
interferon/NN
beta/NN
(/(
IFN-beta/NN
)/)
regulatory/JJ
element/NN
consists/VBZ
of/IN
multiple/JJ
enhanson/NN
domains/NNS
which/WDT
are/VBP
targets/NNS
for/IN
transcription/NN
factors/NNS
involved/VBN
in/IN
inducible/JJ
expression/NN
of/IN
the/DT
promoter/NN
./.
====================
To/TO
further/RB
characterize/VB
the/DT
protein-DNA/JJ
interactions/NNS
mediating/VBG
IFN-beta/NN
induction/NN
,/,
positive/JJ
regulatory/JJ
domain/NN
(/(
PRD/NN
)/)
II/CD
binding/NN
proteins/NNS
were/VBD
purified/VBN
from/IN
phorbol/NN
ester/NN
induced/JJ
Jurkat/NN
T-cells/NNS
and/CC
from/IN
IFN/NN
primed/VBN
,/,
cycloheximide/polyinosinic-polycytidylic/JJ
acid/NN
treated/VBN
HeLa/NN
S3/NN
cells/NNS
./.
====================
From/IN
HeLa/NN
cells/NNS
,/,
two/CD
major/JJ
proteins/NNS
of/IN
52/CD
and/CC
45/CD
kilodaltons/NNS
(/(
kD/NN
)/)
copurified/VBD
with/IN
DNA/NN
binding/NN
activity/NN
,/,
whereas/IN
from/IN
T-cells/NNS
,/,
four/CD
proteins/NNS
--/:
a/DT
major/JJ
protein/NN
of/IN
52/CD
kD/NN
and/CC
three/CD
minor/JJ
proteins/NNS
of/IN
82/CD
,/,
67/CD
,/,
and/CC
43-47/CD
kD/NN
--/:
were/VBD
purified/VBN
./.
====================
Also/RB
,/,
an/DT
induction/NN
specific/JJ
DNA/NN
binding/NN
protein/NN
was/VBD
purified/VBN
from/IN
HeLa/NN
cells/NNS
that/WDT
interacted/VBD
with/IN
the/DT
(/(
AAGTGA/NN
)/)
4/CD
tetrahexamer/NN
sequence/NN
and/CC
the/DT
PRDI/NN
domain/NN
./.
====================
This/DT
protein/NN
is/VBZ
immunologically/RB
distinct/JJ
from/IN
IRF-1/ISGF2/NN
./.
====================
Uninduced/JJ
or/CC
Sendai/NN
virus/NN
induced/JJ
HeLa/NN
extracts/NNS
were/VBD
used/VBN
to/TO
examine/VB
transcription/NN
in/FW
vitro/FW
using/VBG
a/DT
series/NN
of/IN
IFN/NN
beta/NN
promoter/NN
deletions/NNS
./.
====================
Deletions/NNS
upstream/JJ
of/IN
the/DT
PRDII/NN
element/NN
increased/VBD
transcription/NN
in/IN
the/DT
uninduced/JJ
extract/NN
,/,
indicating/VBG
predominantly/RB
negative/JJ
regulation/NN
of/IN
the/DT
promoter/NN
./.
====================
A/DT
2-4-fold/JJ
increase/NN
in/IN
IFN-beta/NN
promoter/NN
transcription/NN
was/VBD
observed/VBN
in/IN
Sendai/NN
virus/NN
induced/JJ
extracts/NNS
,/,
and/CC
deletion/NN
of/IN
PRDI/NN
and/CC
PRDII/NN
elements/NNS
decreased/VBD
this/DT
induced/VBN
level/NN
of/IN
transcription/NN
./.
====================
When/WRB
purified/VBN
PRDII/NN
and/CC
tetrahexamer/NN
binding/NN
proteins/NNS
were/VBD
added/VBN
to/TO
the/DT
induced/VBN
extract/NN
,/,
a/DT
4-fold/JJ
increase/NN
in/IN
transcription/NN
was/VBD
observed/VBN
./.
====================
These/DT
experiments/NNS
demonstrate/VBP
that/IN
it/PRP
is/VBZ
possible/JJ
to/TO
modulate/VB
IFN-beta/NN
transcription/NN
in/FW
vitro/FW
but/CC
indicate/VBP
that/IN
additional/JJ
proteins/NNS
may/MD
be/VB
required/VBN
to/TO
fully/RB
activate/VB
IFN-beta/NN
transcription/NN
./.
====================
UI/LS
-/:
91239569/CD
====================
TI/LS
-/:
The/DT
rhombotin/NN
family/NN
of/IN
cysteine-rich/JJ
LIM-domain/JJ
oncogenes/NNS
:/:
distinct/JJ
members/NNS
are/VBP
involved/VBN
in/IN
T-cell/NN
translocations/NNS
to/TO
human/JJ
chromosomes/NNS
11p15/NN
and/CC
11p13/NN
./.
====================
AB/LS
-/:
A/DT
chromosomal/NN
translocation/NN
in/IN
a/DT
T-cell/NN
leukemia/NN
involving/VBG
the/DT
short/JJ
arm/NN
of/IN
human/JJ
chromosome/NN
11/CD
at/IN
band/NN
11p15/NN
disrupts/VBZ
the/DT
rhombotin/NN
gene/NN
./.
====================
This/DT
gene/NN
encodes/VBZ
a/DT
protein/NN
with/IN
duplicated/JJ
cysteine-rich/JJ
regions/NNS
called/VBN
LIM/NN
domains/NNS
,/,
which/WDT
show/VBP
homology/NN
to/TO
zinc-binding/JJ
proteins/NNS
and/CC
to/TO
iron-sulfur/JJ
centers/NNS
of/IN
ferredoxins/NNS
./.
====================
Two/CD
homologues/NNS
of/IN
the/DT
rhombotin/NN
gene/NN
have/VBP
now/RB
been/VBN
isolated/VBN
./.
====================
One/CD
of/IN
these/DT
,/,
designated/VBN
Rhom-2/NN
,/,
is/VBZ
located/JJ
on/IN
human/JJ
chromosome/NN
11/CD
at/IN
band/NN
11p13/NN
,/,
where/WRB
a/DT
cluster/NN
of/IN
T-cell/NN
leukemia-specific/JJ
translocations/NNS
occur/VBP
;/:
all/DT
translocation/NN
breakpoints/NNS
at/IN
11p13/NN
are/VBP
upstream/JJ
of/IN
the/DT
Rhom-2/NN
gene/NN
./.
====================
Human/JJ
and/CC
mouse/NN
Rhom-2/NN
are/VBP
highly/RB
conserved/VBN
and/CC
,/,
like/IN
rhombotin/NN
,/,
encode/VBP
two/CD
tandem/JJ
cysteine-rich/JJ
LIM/NN
domains/NNS
./.
====================
Rhom-2/NN
mRNA/NN
is/VBZ
expressed/VBN
in/IN
early/JJ
mouse/NN
development/NN
in/IN
central/JJ
nervous/JJ
system/NN
,/,
lung/NN
,/,
kidney/NN
,/,
liver/NN
,/,
and/CC
spleen/NN
but/CC
only/RB
very/RB
low/JJ
levels/NNS
occur/VBP
in/IN
thymus/NN
./.
====================
The/DT
other/JJ
gene/NN
,/,
designated/VBN
Rhom-3/NN
,/,
is/VBZ
not/RB
on/IN
chromosome/NN
11/CD
but/CC
also/RB
retains/VBZ
homology/NN
to/TO
the/DT
LIM/NN
domain/NN
of/IN
rhombotin/NN
./.
====================
Since/IN
the/DT
Rhom-2/NN
gene/NN
is/VBZ
such/JJ
a/DT
common/JJ
site/NN
of/IN
chromosomal/JJ
damage/NN
in/IN
T-cell/NN
tumors/NNS
,/,
the/DT
consistency/NN
of/IN
translocations/NNS
near/IN
the/DT
rhombotin/NN
gene/NN
was/VBD
further/RB
examined/VBN
./.
====================
A/DT
second/JJ
translocation/NN
adjacent/JJ
to/TO
rhombotin/NN
was/VBD
found/VBN
and/CC
at/IN
the/DT
same/JJ
position/NN
as/IN
in/IN
the/DT
previous/JJ
example/NN
./.
====================
Therefore/RB
,/,
chromosome/NN
bands/NNS
11p15/NN
(/(
rhombotin/NN
)/)
and/CC
11p13/NN
(/(
Rhom-2/NN
)/)
are/VBP
consistent/JJ
sites/NNS
of/IN
chromosome/NN
translocation/NN
in/IN
T-cell/NN
leukemia/NN
,/,
with/IN
the/DT
11p15/NN
target/NN
more/RBR
rarely/RB
involved/VBN
./.
====================
The/DT
results/NNS
define/VBP
the/DT
rhombotin/NN
gene/NN
family/NN
as/IN
a/DT
class/NN
of/IN
T-cell/NN
oncogenes/NNS
with/IN
duplicated/JJ
cysteine-rich/JJ
LIM/NN
domains/NNS
./.
====================
UI/LS
-/:
91355651/CD
====================
TI/LS
-/:
NF-kappa/NN
B/NN
activation/NN
by/IN
tumor/NN
necrosis/NN
factor/NN
alpha/NN
in/IN
the/DT
Jurkat/NN
T/NN
cell/NN
line/NN
is/VBZ
independent/JJ
of/IN
protein/NN
kinase/NN
A/NN
,/,
protein/NN
kinase/NN
C/NN
,/,
and/CC
Ca(2+)-regulated/JJ
kinases/NNS
./.
====================
AB/LS
-/:
NF-kappa/NN
B/NN
is/VBZ
a/DT
DNA-binding/JJ
regulatory/JJ
factor/NN
able/JJ
to/TO
control/VB
transcription/NN
of/IN
a/DT
number/NN
of/IN
genes/NNS
,/,
including/VBG
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
genes/NNS
./.
====================
In/IN
T/NN
cells/NNS
,/,
NF-kappa/NN
B/NN
is/VBZ
activated/VBN
upon/IN
cellular/JJ
treatment/NN
by/IN
phorbol/NN
esters/NNS
and/CC
the/DT
cytokine/NN
tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF/NN
alpha/NN
)/)
./.
====================
In/IN
the/DT
present/JJ
work/NN
,/,
we/PRP
investigated/VBD
the/DT
molecular/JJ
events/NNS
leading/VBG
to/TO
NF-kappa/NN
B/NN
activation/NN
by/IN
TNF/NN
alpha/NN
in/IN
a/DT
human/JJ
T/NN
cell/NN
line/NN
(/(
Jurkat/NN
)/)
and/CC
its/PRP$
subclone/JJ
JCT6/NN
,/,
which/WDT
presents/VBZ
a/DT
deficiency/NN
in/IN
the/DT
PKA/NN
transduction/NN
pathway/NN
./.
====================
We/PRP
found/VBD
that/IN
in/IN
both/DT
cell/NN
lines/NNS
,/,
both/CC
phorbol/NN
ester/NN
and/CC
TNF/NN
alpha/NN
were/VBD
able/JJ
to/TO
activate/VB
NF-kappa/NN
B/NN
./.
====================
Phorbol/NN
activation/NN
was/VBD
positively/RB
modulated/VBN
by/IN
Ca2+/NN
influx/NN
while/IN
TNF/NN
alpha/NN
activation/NN
was/VBD
not/RB
./.
====================
Furthermore/RB
,/,
while/IN
PMA/NN
activation/NN
was/VBD
inhibited/VBN
by/IN
the/DT
PKC/NN
inhibitor/NN
staurosporin/NN
,/,
the/DT
TNF/NN
alpha/NN
effect/NN
was/VBD
unchanged/JJ
./.
====================
TNF/NN
alpha/NN
did/VBD
not/RB
activate/VB
cAMP/NN
production/NN
and/CC
its/PRP$
signal/NN
was/VBD
not/RB
modulated/VBN
by/IN
cAMP/NN
activators/NNS
./.
====================
Moreover/RB
,/,
cAMP/NN
activators/NNS
did/VBD
not/RB
activate/VB
NF-kappa/NN
B/NN
in/IN
Jurkat/NN
cells/NNS
./.
====================
Thus/RB
,/,
TNF/NN
alpha-induced/JJ
NF-kappa/NN
B/NN
activation/NN
was/VBD
found/VBN
to/TO
be/VB
mediated/VBN
by/IN
none/NN
of/IN
the/DT
major/JJ
signal-mediating/JJ
kinases/NNS
such/JJ
as/IN
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
,/,
protein/NN
kinase/NN
A/NN
,/,
or/CC
Ca(2+)-regulated/JJ
kinases/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
found/VBD
that/IN
cytoplasmic/JJ
acidification/NN
facilitated/VBD
NF-kappa/NN
B/NN
activation/NN
by/IN
both/CC
TNF/NN
alpha/NN
and/CC
PKC/NN
,/,
by/IN
a/DT
mechanism/NN
that/WDT
increases/VBZ
NF-kappa/NN
B/I/NN
kappa/NN
B/NN
dissociation/NN
without/IN
affecting/VBG
the/DT
NF-kappa/NN
B/NN
translocation/NN
step/NN
./.
====================
UI/LS
-/:
91172211/CD
====================
TI/LS
-/:
The/DT
functional/JJ
domains/NNS
of/IN
the/DT
murine/JJ
Thy-1/NN
gene/NN
promoter/NN
./.
====================
AB/LS
-/:
The/DT
Thy-1/NN
gene/NN
promoter/NN
resembles/VBZ
a/DT
"/``
housekeeping/JJ
"/''
promoter/NN
in/IN
that/IN
it/PRP
is/VBZ
located/JJ
within/IN
a/DT
methylation-free/JJ
island/NN
,/,
lacks/VBZ
a/DT
canonical/JJ
TATA/NN
box/NN
,/,
and/CC
displays/VBZ
heterogeneity/NN
in/IN
the/DT
5'-end/JJ
termini/NNS
of/IN
the/DT
mRNA/NN
./.
====================
Using/VBG
transgenic/JJ
mice/NNS
,/,
we/PRP
show/VBP
that/IN
this/DT
promoter/NN
does/VBZ
not/RB
confer/VB
any/DT
tissue/NN
specificity/NN
and/CC
is/VBZ
active/JJ
only/RB
in/IN
a/DT
position-dependent/JJ
manner/NN
./.
====================
It/PRP
can/MD
only/RB
be/VB
activated/VBN
in/IN
a/DT
tissue-specific/JJ
manner/NN
by/IN
elements/NNS
that/WDT
lie/VBP
downstream/RB
of/IN
the/DT
initiation/NN
site/NN
./.
====================
We/PRP
have/VBP
analyzed/VBN
the/DT
functional/JJ
domains/NNS
of/IN
the/DT
minimal/JJ
Thy-1/NN
promoter/NN
and/CC
show/VB
that/IN
the/DT
dominant/JJ
promoter/NN
elements/NNS
consist/VBP
of/IN
multiple/JJ
binding/VBG
sites/NNS
for/IN
the/DT
transcription/NN
factor/NN
Sp1/NN
,/,
an/DT
inverted/JJ
CCAAT/NN
box/NN
,/,
and/CC
sequences/VBZ
proximal/JJ
to/TO
the/DT
transcription/NN
start/NN
site/NN
./.
====================
DNase/NN
I/CD
and/CC
gel/NN
mobility/NN
shift/NN
assays/NNS
show/VBP
the/DT
binding/NN
of/IN
a/DT
number/NN
of/IN
nuclear/JJ
factors/NNS
to/TO
these/DT
elements/NNS
,/,
including/VBG
Sp1/NN
and/CC
CP1/NN
./.
====================
Our/PRP$
results/NNS
show/VBP
that/IN
the/DT
structure/NN
of/IN
this/DT
promoter/NN
only/RB
permits/VBZ
productive/JJ
interactions/NNS
of/IN
the/DT
two/CD
transcription/NN
factors/NNS
Sp1/NN
and/CC
CP1/NN
with/IN
the/DT
basal/JJ
transcription/NN
machinery/NN
in/IN
the/DT
presence/NN
of/IN
enhancer/NN
sequences/NNS
./.
====================
UI/LS
-/:
91117203/CD
====================
TI/LS
-/:
Nuclear/JJ
factor/NN
kappa/NN
B/NN
activates/VBZ
proenkephalin/NN
transcription/NN
in/IN
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Upon/IN
activation/NN
,/,
T/NN
lymphocytes/NNS
accumulate/VBP
high/JJ
levels/NNS
of/IN
the/DT
neuropeptide/NN
enkephalin/NN
which/WDT
correlate/VBP
with/IN
high/JJ
levels/NNS
of/IN
proenkephalin/NN
mRNA/NN
in/IN
the/DT
cells/NNS
./.
====================
Here/RB
we/PRP
investigated/VBD
the/DT
transcriptional/JJ
basis/NN
for/IN
these/DT
changes/NNS
./.
====================
The/DT
proenkephalin/NN
promoter/NN
contains/VBZ
a/DT
sequence/NN
GGGGACGTCCCC/NN
,/,
named/VBN
B2/NN
,/,
which/WDT
is/VBZ
similar/JJ
to/TO
the/DT
kappa/NN
B/NN
sequence/NN
GGGGACTTTCC/NN
,/,
the/DT
binding/VBG
site/NN
of/IN
the/DT
transcription/NN
factor/NN
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
-kappa/NN
B/NN
./.
====================
Activation/NN
of/IN
T/NN
lymphocytes/NNS
induces/VBZ
an/DT
NF-kappa/NN
B-like/JJ
binding/NN
activity/NN
to/TO
the/DT
B2/NN
site/NN
,/,
concomitant/JJ
with/IN
activation/NN
of/IN
the/DT
proenkephalin/NN
promoter/NN
./.
====================
Mutations/NNS
at/IN
the/DT
B2/NN
site/NN
abolish/VBP
this/DT
transcriptional/JJ
activation/NN
./.
====================
The/DT
purified/VBN
homodimer/NN
(/(
two/CD
p50s/NNS
)/)
of/IN
the/DT
DNA-binding/JJ
subunit/NN
of/IN
NF-kappa/NN
B/NN
binds/VBZ
the/DT
B2/NN
site/NN
of/IN
proenkephalin/NN
relatively/RB
better/JJR
than/IN
does/VBZ
the/DT
heterotetramer/NN
(/(
two/CD
p65s/NNS
plus/CC
two/CD
p50s/NNS
)/)
form/NN
of/IN
the/DT
factor/NN
./.
====================
Thus/RB
,/,
it/PRP
appears/VBZ
that/IN
the/DT
T-cell-specific/JJ
activation/NN
of/IN
the/DT
proenkephalin/NN
promoter/NN
is/VBZ
mediated/VBN
by/IN
NF-kappa/NN
B/NN
./.
====================
However/RB
,/,
as/IN
NF-kappa/NN
B/NN
is/VBZ
ubiquitous/JJ
and/CC
the/DT
transcriptional/JJ
activation/NN
through/IN
the/DT
B2/NN
site/NN
is/VBZ
T/NN
cell/NN
specific/JJ
,/,
yet/RB
another/DT
T-cell-specific/JJ
factor/NN
which/WDT
synergizes/VBZ
with/IN
NF-kappa/NN
B/NN
should/MD
be/VB
considered/VBN
./.
====================
UI/LS
-/:
91079577/CD
====================
TI/LS
-/:
Induction/NN
of/IN
NF-KB/NN
during/IN
monocyte/NN
differentiation/NN
by/IN
HIV/NN
type/NN
1/CD
infection/NN
./.
====================
AB/LS
-/:
The/DT
production/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
progeny/NN
was/VBD
followed/VBN
in/IN
the/DT
U937/NN
promonocytic/JJ
cell/NN
line/NN
after/IN
stimulation/NN
either/CC
with/IN
retinoic/JJ
acid/NN
or/CC
PMA/NN
,/,
and/CC
in/IN
purified/VBN
human/JJ
monocytes/NNS
and/CC
macrophages/NNS
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
and/CC
Southwestern/NN
blotting/NN
experiments/NNS
were/VBD
used/VBN
to/TO
detect/VB
the/DT
binding/NN
of/IN
cellular/JJ
transactivation/NN
factor/NN
NF-KB/NN
to/TO
the/DT
double/JJ
repeat-KB/JJ|NN
enhancer/NN
sequence/NN
located/JJ
in/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
./.
====================
PMA/NN
treatment/NN
,/,
and/CC
not/RB
retinoic/JJ
acid/NN
treatment/NN
of/IN
the/DT
U937/NN
cells/NNS
acts/VBZ
in/IN
inducing/VBG
NF-KB/NN
expression/NN
in/IN
the/DT
nuclei/NNS
./.
====================
In/IN
nuclear/JJ
extracts/NNS
from/IN
monocytes/NNS
or/CC
macrophages/NNS
,/,
induction/NN
of/IN
NF-KB/NN
occurred/VBD
only/RB
if/IN
the/DT
cells/NNS
were/VBD
previously/RB
infected/VBN
with/IN
HIV-1/NN
./.
====================
When/WRB
U937/NN
cells/NNS
were/VBD
infected/VBN
with/IN
HIV-1/NN
,/,
no/DT
induction/NN
of/IN
NF-KB/NN
factor/NN
was/VBD
detected/VBN
,/,
whereas/IN
high/JJ
level/NN
of/IN
progeny/NN
virions/NNS
was/VBD
produced/VBN
,/,
suggesting/VBG
that/IN
this/DT
factor/NN
was/VBD
not/RB
required/VBN
for/IN
viral/JJ
replication/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
in/IN
monocytic/JJ
cell/NN
lineage/NN
,/,
HIV-1/NN
could/MD
mimic/VB
some/DT
differentiation/activation/JJ
stimuli/NNS
allowing/VBG
nuclear/JJ
NF-KB/NN
expression/NN
./.
====================
UI/LS
-/:
91075236/CD
====================
TI/LS
-/:
Disruption/NN
of/IN
the/DT
human/JJ
SCL/NN
locus/NN
by/IN
"/``
illegitimate/JJ
"/''
V-(D)-J/NN
recombinase/NN
activity/NN
./.
====================
AB/LS
-/:
A/DT
fusion/NN
complementary/JJ
DNA/NN
in/IN
the/DT
T/NN
cell/NN
line/NN
HSB-2/NN
elucidates/VBZ
a/DT
provocative/JJ
mechanism/NN
for/IN
the/DT
disruption/NN
of/IN
the/DT
putative/JJ
hematopoietic/JJ
transcription/NN
factor/NN
SCL/NN
./.
====================
The/DT
fusion/NN
cDNA/NN
results/VBZ
from/IN
an/DT
interstitial/JJ
deletion/NN
between/IN
a/DT
previously/RB
unknown/JJ
locus/NN
,/,
SIL/NN
(/(
SCL/NN
interrupting/NN
locus/NN
)/)
,/,
and/CC
the/DT
5'/JJ
untranslated/JJ
region/NN
of/IN
SCL/NN
./.
====================
Similar/JJ
to/TO
1/CD
;/:
14/CD
translocations/NNS
,/,
this/DT
deletion/NN
disrupts/VBZ
the/DT
SCL/NN
5'/JJ
regulatory/JJ
region/NN
./.
====================
This/DT
event/NN
is/VBZ
probably/RB
mediated/VBN
by/IN
V-(D)-J/NN
recombinase/NN
activity/NN
,/,
although/IN
neither/DT
locus/NN
is/VBZ
an/DT
immunoglobulin/NN
or/CC
a/DT
T/NN
cell/NN
receptor/NN
./.
====================
Two/CD
other/JJ
T/NN
cell/NN
lines/NNS
,/,
CEM/NN
and/CC
RPMI/NN
8402/CD
,/,
have/VBP
essentially/RB
identical/JJ
deletions/NNS
./.
====================
Thus/RB
,/,
in/IN
lymphocytes/NNS
,/,
growth-affecting/JJ
genes/NNS
other/JJ
than/IN
immune/JJ
receptors/NNS
risk/VBP
rearrangements/NNS
./.
====================
UI/LS
-/:
91125342/CD
====================
TI/LS
-/:
Thyroid/NN
hormone/NN
receptors/NNS
form/VBP
distinct/JJ
nuclear/JJ
protein-dependent/JJ
and/CC
independent/JJ
complexes/NNS
with/IN
a/DT
thyroid/NN
hormone/NN
response/NN
element/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
examined/VBN
the/DT
binding/NN
of/IN
nuclear/JJ
proteins/NNS
and/CC
recombinant/JJ
thyroid/NN
hormone/NN
receptors/NNS
(/(
TRs/NNS
)/)
to/TO
the/DT
palindromic/JJ
thyroid/NN
hormone/NN
responsive/JJ
element/NN
AGGTCATGACCT/NN
(/(
TREp/NN
)/)
using/VBG
a/DT
gel/NN
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
./.
====================
Four/CD
specific/JJ
protein-DNA/JJ
complexes/NNS
were/VBD
detected/VBN
after/IN
incubation/NN
of/IN
nuclear/JJ
extracts/NNS
(/(
NE/NNS
)/)
from/IN
T3-responsive/JJ
pituitary/NN
(/(
GH3/NN
)/)
cells/NNS
with/IN
a/DT
TREp-containing/JJ
DNA/NN
fragment/NN
./.
====================
This/DT
was/VBD
compared/VBN
with/IN
the/DT
TREp/NN
binding/NN
of/IN
reticulocyte/NN
lysate-synthesized/JJ
TRs/NNS
./.
====================
TR/NN
alpha/NN
1/CD
and/CC
TR/NN
beta/NN
2/CD
each/DT
formed/VBD
a/DT
single/JJ
major/JJ
TR/NN
:/:
TREp/NN
complex/NN
which/WDT
comigrated/VBD
with/IN
the/DT
least/RBS
retarded/VBN
complex/NN
formed/VBN
by/IN
GH3/NN
NE/NNS
,/,
while/IN
TR/NN
beta/NN
1/CD
formed/VBD
multiple/JJ
complexes/NNS
suggesting/VBG
that/IN
it/PRP
can/MD
bind/VB
to/TO
TREp/NN
as/IN
an/DT
oligomer/NN
./.
====================
Interestingly/RB
,/,
coincubation/NN
of/IN
35S-TR/NN
alpha/NN
1/CD
,/,
GH3/NN
NE/NNS
,/,
and/CC
unlabeled/JJ
TREp/NN
resulted/VBD
in/IN
not/RB
only/RB
the/DT
35S-TR/NN
:/:
TREp/NN
complex/NN
,/,
but/CC
in/IN
two/CD
additional/JJ
more/RBR
greatly/RB
retarded/VBN
complexes/NNS
containing/VBG
35S-TR/NN
alpha/NN
1/CD
and/CC
comigrating/VBG
with/IN
those/DT
formed/VBN
by/IN
GH3/NN
extract/NN
alone/RB
./.
====================
Incubation/NN
of/IN
each/DT
of/IN
the/DT
TRs/NNS
with/IN
NE/NNS
from/IN
COS-7/NN
cells/NNS
,/,
which/WDT
do/VBP
not/RB
possess/VB
sufficient/JJ
endogenous/JJ
TRs/NNS
to/TO
mediate/VB
T3-responses/NNS
,/,
resulted/VBD
in/IN
formation/NN
of/IN
a/DT
new/JJ
,/,
more/RBR
greatly/RB
shifted/VBN
complex/NN
./.
====================
A/DT
similar/JJ
,/,
heat/NN
labile/JJ
activity/NN
which/WDT
altered/VBD
mobility/NN
of/IN
the/DT
TR/NN
:/:
TRE/NN
complex/NN
was/VBD
also/RB
present/JJ
in/IN
NE/NNS
from/IN
T3-unresponsive/JJ
JEG-3/NN
cells/NNS
./.
====================
At/IN
high/JJ
concentration/NN
of/IN
NE/NNS
,/,
all/DT
of/IN
the/DT
TR/NN
bound/VBN
to/TO
TREp/NN
was/VBD
more/JJR
greatly/RB
retarded/VBN
than/IN
in/IN
the/DT
absence/NN
of/IN
NE/NNS
./.
====================
Truncation/NN
of/IN
TR/NN
alpha/NN
1/CD
at/IN
amino/NN
acid/NN
210/CD
prevented/VBD
additional/JJ
complex/NN
formation/NN
in/IN
the/DT
presence/NN
of/IN
NE/NNS
without/IN
affecting/VBG
DNA/NN
binding/NN
,/,
suggesting/VBG
that/IN
the/DT
carboxyl-terminus/NN
of/IN
the/DT
TRs/NNS
is/VBZ
essential/JJ
for/IN
interaction/NN
with/IN
nuclear/JJ
proteins/NNS
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
90376424/CD
====================
TI/LS
-/:
Cell-specific/JJ
differences/NNS
in/IN
activation/NN
of/IN
NF-kappa/NN
B/NN
regulatory/JJ
elements/NNS
of/IN
human/JJ
immunodeficiency/NN
virus/NN
and/CC
beta/NN
interferon/NN
promoters/NNS
by/IN
tumor/NN
necrosis/NN
factor/NN
./.
====================
AB/LS
-/:
Three/CD
aspects/NNS
of/IN
the/DT
involvement/NN
of/IN
tumor/NN
necrosis/NN
factor/NN
in/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
pathogenesis/NN
were/VBD
examined/VBN
./.
====================
Tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNF-alpha/NN
)/)
mRNA/NN
production/NN
was/VBD
analyzed/VBN
by/IN
polymerase/NN
chain/NN
reaction/NN
amplification/NN
in/IN
monocytic/JJ
U937/NN
cells/NNS
and/CC
in/IN
a/DT
chronically/RB
HIV/NN
infected/JJ
U937/NN
cell/NN
line/NN
(/(
U9-IIIB/NN
)/)
./.
====================
TNF-alpha/NN
RNA/NN
was/VBD
undetectable/JJ
in/IN
U937/NN
cells/NNS
,/,
whereas/IN
a/DT
low/JJ
constitutive/JJ
level/NN
was/VBD
detected/VBN
in/IN
U9-IIIB/NN
cells/NNS
./.
====================
Paramyxovirus/NN
infection/NN
induced/VBD
a/DT
5-/CD
to/TO
10-fold/JJ
increase/NN
in/IN
the/DT
steady-state/JJ
level/NN
of/IN
TNF-alpha/NN
RNA/NN
in/IN
U9-IIIB/NN
cells/NNS
compared/VBN
with/IN
U937/NN
cells/NNS
,/,
suggesting/VBG
that/IN
HIV-infected/JJ
monocytic/JJ
cells/NNS
produced/VBD
higher/JJR
levels/NNS
of/IN
TNF-alpha/NN
than/IN
did/VBD
normal/JJ
cells/NNS
after/IN
a/DT
secondary/JJ
virus/NN
infection/NN
./.
====================
The/DT
effects/NNS
of/IN
TNF-alpha/NN
on/IN
gene/NN
expression/NN
were/VBD
examined/VBN
by/IN
transient/JJ
expression/NN
assays/NNS
using/VBG
reporter/NN
chloramphenicol/NN
acetyltransferase/NN
plasmids/NNS
linked/VBN
to/TO
regulatory/JJ
elements/NNS
from/IN
the/DT
HIV/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
and/CC
the/DT
beta/NN
interferon/NN
promoter/NN
./.
====================
In/IN
U937/NN
and/CC
Jurkat/NN
T/NN
lymphoid/JJ
cells/NNS
,/,
the/DT
inducibility/NN
of/IN
the/DT
different/JJ
hybrid/NN
promoters/NNS
by/IN
TNF-alpha/NN
or/CC
phorbol/NN
ester/NN
varied/VBD
in/IN
a/DT
cell/NN
type-/NN
and/CC
promoter/NN
context-specific/JJ
manner/NN
;/:
the/DT
levels/NNS
of/IN
gene/NN
activity/NN
of/IN
NF-kappa/NN
B-containing/JJ
plasmids/NNS
correlated/VBD
directly/RB
with/IN
induction/NN
of/IN
NF-kappa/NN
B/NN
DNA-binding/JJ
activity/NN
./.
====================
Although/IN
the/DT
intact/JJ
beta/NN
interferon/NN
promoter/NN
was/VBD
only/RB
weakly/RB
stimulated/VBN
by/IN
phorbol/NN
ester/NN
or/CC
TNF-alpha/NN
,/,
multimers/NNS
of/IN
the/DT
PRDII/NN
NF-kappa/NN
B-binding/JJ
domain/NN
were/VBD
inducible/JJ
by/IN
both/DT
agents/NNS
./.
====================
TNF-alpha/NN
was/VBD
able/JJ
to/TO
increase/VB
expression/NN
of/IN
the/DT
HIV/NN
LTR/NN
in/IN
T/NN
cells/NNS
,/,
but/CC
in/IN
monocytic/JJ
cells/NNS
,/,
TNF-alpha/NN
did/VBD
not/RB
induce/VB
the/DT
HIV/NN
LTR/NN
above/IN
a/DT
constitutive/JJ
level/NN
of/IN
activity/NN
./.
====================
This/DT
level/NN
of/IN
NF-kappa/NN
B-independent/JJ
activity/NN
appears/VBZ
to/TO
be/VB
sufficient/JJ
for/IN
virus/NN
multiplication/NN
,/,
since/IN
TNF-alpha/NN
treatment/NN
had/VBD
no/DT
effect/NN
on/IN
the/DT
kinetics/NNS
of/IN
de/FW
novo/FW
HIV/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
infection/NN
and/CC
viral/JJ
RNA/NN
production/NN
in/IN
U937/NN
cells/NNS
./.
====================
However/RB
,/,
in/IN
Jurkat/NN
cells/NNS
,/,
TNF-alpha/NN
dramatically/RB
enhanced/VBD
the/DT
spread/NN
of/IN
HIV-1/NN
through/IN
the/DT
cell/NN
population/NN
and/CC
increased/VBD
viral/JJ
RNA/NN
synthesis/NN
,/,
indicating/VBG
that/IN
in/IN
T/NN
cells/NNS
HIV-1/NN
multiplication/NN
was/VBD
stimulated/VBN
by/IN
TNF-alpha/NN
treatment/NN
./.
====================
UI/LS
-/:
91118160/CD
====================
TI/LS
-/:
Functional/JJ
analysis/NN
of/IN
cis-linked/JJ
regulatory/JJ
sequences/NNS
in/IN
the/DT
HLA/NN
DRA/NN
promoter/NN
by/IN
transcription/NN
in/FW
vitro/FW
./.
====================
AB/LS
-/:
Two/CD
consensus/NN
sequences/NNS
,/,
called/VBN
X/NN
and/CC
Y/NN
boxes/NNS
,/,
capable/JJ
of/IN
binding/VBG
nuclear/JJ
proteins/NNS
and/CC
regulating/VBG
expression/NN
in/IN
B/NN
cells/NNS
have/VBP
been/VBN
defined/VBN
within/IN
the/DT
immediate/JJ
upstream/JJ
region/NN
of/IN
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
class/NN
II/CD
promoters/NNS
./.
====================
Unlike/IN
other/JJ
class/NN
II/CD
promoters/NNS
,/,
the/DT
HLA-DR/NN
alpha/NN
(/(
DRA/NN
)/)
promoter/NN
also/RB
contains/VBZ
one/CD
element/NN
identical/JJ
to/TO
the/DT
"/``
octamer/NN
"/''
motif/NN
of/IN
immunoglobulin/NN
variable/JJ
region/NN
promoters/NNS
that/WDT
is/VBZ
responsible/JJ
for/IN
B/NN
cell-specific/JJ
transcription/NN
./.
====================
This/DT
"/``
octamer/NN
"/''
in/IN
the/DT
context/NN
of/IN
DRA/NN
appears/VBZ
capable/JJ
of/IN
binding/VBG
both/CC
the/DT
ubiquitous/JJ
(/(
OTF-1/NN
)/)
and/CC
lymphoid-specific/JJ
(/(
OTF-2/NN
)/)
"/``
octamer/NN
"/''
binding/NN
proteins/NNS
,/,
but/CC
at/IN
least/JJS
one/CD
other/JJ
distinct/JJ
"/``
octamer/NN
"/''
complex/NN
was/VBD
found/VBN
./.
====================
In/IN
order/NN
to/TO
characterize/VB
the/DT
function/NN
of/IN
cis-acting/JJ
elements/NNS
,/,
we/PRP
have/VBP
developed/VBN
an/DT
in/FW
vitro/FW
system/NN
in/IN
which/WDT
a/DT
DRA/NN
promoter/NN
construct/NN
is/VBZ
transcribed/VBN
more/RBR
efficiently/RB
in/IN
extracts/NNS
from/IN
B/NN
cells/NNS
than/IN
in/IN
extracts/NNS
from/IN
class/NN
II-negative/JJ
HeLa/NN
cells/NNS
./.
====================
5'/JJ
deletion/NN
constructs/NNS
which/WDT
lacked/VBD
the/DT
Y/NN
box/NN
,/,
but/CC
retained/VBD
the/DT
"/``
octamer/NN
"/''
motif/NN
and/CC
TATA/NN
box/NN
were/VBD
completely/RB
inactive/JJ
,/,
and/CC
internal/JJ
deletion/NN
of/IN
the/DT
Y/NN
box/NN
reduced/VBD
transcription/NN
by/IN
95/CD
%/NN
./.
====================
Using/VBG
supercoiled/JJ
,/,
but/CC
not/RB
linear/JJ
templates/NNS
,/,
we/PRP
observed/VBD
differences/NNS
in/IN
transcription/NN
efficiencies/NNS
from/IN
templates/NNS
lacking/VBG
or/CC
disrupting/VBG
the/DT
X/NN
consensus/NN
element/NN
that/WDT
reflect/VBP
effects/NNS
of/IN
random/JJ
replacement/NN
of/IN
X/NN
box/NN
sequences/NNS
in/IN
transient/JJ
expression/NN
assays/NNS
./.
====================
Demonstration/NN
of/IN
the/DT
complete/JJ
dependence/NN
on/IN
the/DT
Y/NN
box/NN
in/IN
this/DT
system/NN
suggests/VBZ
that/IN
,/,
despite/IN
its/PRP$
demonstrated/VBN
importance/NN
in/IN
the/DT
DRA/NN
promoter/NN
,/,
the/DT
DRA/NN
"/``
octamer/NN
"/''
does/VBZ
not/RB
utilize/VB
OTF-2/NNP
in/IN
a/DT
manner/NN
analogous/JJ
to/TO
immunoglobulin/NN
promoters/NNS
in/IN
B/NN
cells/NNS
./.
====================
UI/LS
-/:
90293687/CD
====================
TI/LS
-/:
Lipopolysaccharide/NN
is/VBZ
a/DT
potent/JJ
monocyte/macrophage-specific/JJ
stimulator/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
expression/NN
./.
====================
AB/LS
-/:
Lipopolysaccharide/NN
(/(
LPS/NN
)/)
potently/RB
stimulates/VBZ
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1-long/JJ
terminal/JJ
repeat/NN
(/(
HIV-1-LTR/NN
)/)
CAT/NN
constructs/NNS
transfected/VBN
into/IN
monocyte/macrophage-like/JJ
cell/NN
lines/NNS
but/CC
not/RB
a/DT
T/NN
cell/NN
line/NN
./.
====================
This/DT
effect/NN
appears/VBZ
to/TO
be/VB
mediated/VBN
through/IN
the/DT
induction/NN
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
demonstrate/VBP
that/IN
LPS/NN
induces/VBZ
a/DT
DNA/NN
binding/NN
activity/NN
indistinguishable/JJ
from/IN
NF-kappa/NN
B/NN
in/IN
U937/NN
and/CC
THP-1/NN
cells/NNS
./.
====================
LPS/NN
is/VBZ
also/RB
shown/VBN
to/TO
dramatically/RB
increase/VB
HIV-1/NN
production/NN
from/IN
a/DT
chronically/RB
infected/JJ
monocyte/macrophage-like/JJ
cloned/VBN
cell/NN
line/NN
,/,
U1/NN
,/,
which/WDT
produces/VBZ
very/RB
low/JJ
levels/NNS
of/IN
HIV-1/NN
at/IN
baseline/NN
./.
====================
The/DT
stimulation/NN
of/IN
viral/JJ
production/NN
from/IN
this/DT
cell/NN
line/NN
occurs/VBZ
only/RB
if/IN
these/DT
cells/NNS
are/VBP
treated/VBN
with/IN
granulocyte/macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
before/IN
treatment/NN
with/IN
LPS/NN
./.
====================
This/DT
stimulation/NN
of/IN
HIV-1/NN
production/NN
is/VBZ
correlated/VBN
with/IN
an/DT
increase/NN
in/IN
the/DT
level/NN
of/IN
HIV-1/NN
RNA/NN
and/CC
and/CC
activation/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
LPS/NN
is/VBZ
not/RB
able/JJ
to/TO
induce/VB
HIV-1/NN
production/NN
in/IN
a/DT
cloned/VBN
T/NN
cell/NN
line/NN
./.
====================
The/DT
effect/NN
of/IN
LPS/NN
on/IN
HIV-1/NN
replication/NN
occurs/VBZ
at/IN
picogram/NN
per/IN
milliliter/NN
concentrations/NNS
and/CC
may/MD
be/VB
clinically/RB
significant/JJ
in/IN
understanding/VBG
the/DT
variability/NN
of/IN
the/DT
natural/JJ
history/NN
of/IN
HIV-1/NN
infection/NN
./.
====================
UI/LS
-/:
90285430/CD
====================
TI/LS
-/:
Steroid/NN
dose/NN
sparing/NN
:/:
pharmacodynamic/JJ
responses/NNS
to/TO
single/JJ
versus/CC
divided/JJ
doses/NNS
of/IN
methylprednisolone/NN
in/IN
man/NN
./.
====================
AB/LS
-/:
Inhibitory/JJ
drug/NN
interactions/NNS
affecting/VBG
the/DT
metabolism/NN
of/IN
methylprednisolone/NN
(/(
MP/NN
)/)
may/MD
produce/VB
either/CC
steroid/NN
sparing/NN
or/CC
adverse/JJ
effects/NNS
partly/RB
by/IN
increasing/VBG
the/DT
exposure/NN
time/NN
to/TO
the/DT
steroid/NN
./.
====================
This/DT
phenomenon/NN
can/MD
be/VB
mimicked/VBN
by/IN
administering/VBG
MP/NN
in/IN
divided/JJ
doses/NNS
./.
====================
Two/CD
types/NNS
of/IN
responses/NNS
were/VBD
compared/VBN
after/IN
a/DT
single/JJ
MP/NN
dose/NN
(/(
40/CD
mg/NN
bolus/NN
)/)
and/CC
a/DT
divided/JJ
regimen/NN
(/(
20/CD
mg/NN
bolus/NN
and/CC
a/DT
5/CD
mg/NN
bolus/NN
8/CD
hours/NNS
later/RB
)/)
in/IN
six/CD
healthy/JJ
male/JJ
volunteers/NNS
./.
====================
The/DT
suppression/NN
of/IN
basophils/NNS
measured/VBN
as/IN
whole/JJ
blood/NN
histamine/NN
and/CC
plasma/NN
cortisol/NN
concentrations/NNS
was/VBD
assessed/VBN
during/IN
32/CD
hours/NNS
./.
====================
The/DT
37.5/CD
%/NN
reduction/NN
in/IN
dose/NN
produced/VBD
a/DT
23/CD
%/NN
overall/RB
decreased/VBN
blood/NN
histamine/NN
response/NN
./.
====================
A/DT
pharmacodynamic/JJ
model/NN
for/IN
basophil/NN
cell/NN
distribution/NN
to/TO
and/CC
from/IN
an/DT
extravascular/JJ
compartment/NN
describes/VBZ
the/DT
effects/NNS
of/IN
MP/NN
after/IN
both/DT
regimens/NNS
./.
====================
A/DT
slower/JJR
initial/JJ
decline/NN
in/IN
blood/NN
histamine/NN
after/IN
the/DT
divided/JJ
regimen/NNS
may/MD
be/VB
related/JJ
to/TO
incomplete/JJ
suppression/NN
of/IN
basophil/NN
cell/NN
return/NN
to/TO
blood/NN
./.
====================
The/DT
50/CD
%/NN
inhibitory/JJ
concentrations/NNS
of/IN
MP/NN
of/IN
about/RB
5/CD
ng/ml/NN
were/VBD
similar/JJ
for/IN
both/DT
regimens/NNS
./.
====================
The/DT
decline/NN
and/CC
return/NN
of/IN
cortisol/NN
concentrations/NNS
were/VBD
similar/JJ
between/IN
MP/NN
treatments/NNS
with/IN
suppression/NN
continuing/VBG
for/IN
24/CD
hours/NNS
./.
====================
The/DT
50/CD
%/NN
inhibitory/JJ
concentrations/NNS
of/IN
MP/NN
values/NNS
for/IN
adrenal/JJ
suppression/NN
were/VBD
about/RB
1/CD
ng/ml/NN
./.
====================
Pharmacodynamic/JJ
modeling/NN
is/VBZ
useful/JJ
in/IN
quantitating/VBG
corticosteroid/NN
responses/NNS
and/CC
generally/RB
predicted/VBD
the/DT
"/``
dose-sparing/JJ
"/''
effects/NNS
that/WDT
were/VBD
achieved/VBN
by/IN
prolonging/VBG
MP/NN
plasma/NN
concentrations/NNS
./.
====================
This/DT
study/NN
supports/VBZ
previous/JJ
clinical/JJ
observations/NNS
that/IN
patients/NNS
may/MD
require/VB
morning/NN
through/IN
evening/NN
exposure/NN
to/TO
MP/NN
to/TO
optimize/VB
efficacy/NN
while/IN
adrenal/JJ
suppression/NN
is/VBZ
being/VBG
minimized/VBN
./.
====================
UI/LS
-/:
90237240/CD
====================
TI/LS
-/:
1,25(OH)2D2/NN
production/NN
by/IN
T/NN
lymphocytes/NNS
and/CC
alveolar/JJ
macrophages/NNS
recovered/VBN
by/IN
lavage/NN
from/IN
normocalcemic/JJ
patients/NNS
with/IN
tuberculosis/NN
./.
====================
AB/LS
-/:
To/TO
compare/VB
extra-renal/JJ
1,25(OH)2D3/NN
production/NN
in/IN
different/JJ
types/NNS
of/IN
granulomatous/JJ
disease/NN
,/,
and/CC
to/TO
identify/VB
the/DT
cell/NN
types/NNS
responsible/JJ
,/,
we/PRP
have/VBP
evaluated/VBN
the/DT
conversion/NN
of/IN
25(OH)D3/NN
in/IN
1,25(OH)2D3/NN
by/IN
uncultured/JJ
cells/NNS
recovered/VBN
by/IN
bronchoalveolar/JJ
lavage/NN
and/CC
blood/NN
mononuclear/JJ
cells/NNS
from/IN
normocalcemic/JJ
patients/NNS
with/IN
sarcoidosis/NN
and/CC
tuberculosis/NN
./.
====================
1,25(OH)2D3/NN
was/VBD
produced/VBN
both/CC
by/IN
lavage/NN
cells/NNS
(/(
12/12/CD
tuberculosis/NN
patients/NNS
,/,
2/6/CD
sarcoidosis/NN
patients/NNS
)/)
and/CC
blood/NN
mononuclear/JJ
cells/NNS
(/(
3/5/CD
tuberculosis/NN
patients/NNS
,/,
0/3/CD
sarcoidosis/NN
patients/NNS
)/)
from/IN
patients/NNS
but/CC
not/RB
controls/NNS
,/,
but/CC
significantly/RB
greater/JJR
amounts/NNS
were/VBD
produced/VBN
by/IN
lavage/NN
cells/NNS
from/IN
tuberculosis/NN
patients/NNS
than/IN
those/DT
of/IN
sarcoidosis/NN
patients/NNS
(/(
P/NN
less/JJR
than/IN
0.001/CD
)/)
./.
====================
1,25(OH)2D3/NN
production/NN
by/IN
lavage/NN
cells/NNS
from/IN
tuberculosis/NN
patients/NNS
correlated/VBD
with/IN
the/DT
number/NN
of/IN
CD8+/JJ
T/NN
lymphocytes/NNS
present/JJ
but/CC
not/RB
other/JJ
cell/NN
types/NNS
./.
====================
T/NN
lymphocytes/NNS
appeared/VBD
to/TO
be/VB
an/DT
important/JJ
source/NN
of/IN
1,25(OH)2D3/NN
production/NN
,/,
since/IN
purified/VBN
T/NN
lymphocytes/NNS
from/IN
all/DT
patients/NNS
with/IN
tuberculosis/NN
produced/VBD
1,25(OH)2D3/NN
,/,
and/CC
1,25(OH)2D3/NN
production/NN
by/IN
these/DT
cells/NNS
correlated/VBD
closely/RB
with/IN
that/DT
produced/VBN
by/IN
unseparated/JJ
lavage/NN
cells/NNS
./.
====================
Because/IN
1,25(OH)2D3/NN
can/MD
improve/VB
the/DT
capacity/NN
of/IN
macrophages/NNS
to/TO
kill/VB
mycobacteria/NNS
,/,
our/PRP$
results/NNS
support/VBP
the/DT
conclusion/NN
that/IN
macrophage-lymphocyte/JJ
interactions/NNS
,/,
mediated/VBN
at/IN
least/JJS
in/IN
part/NN
by/IN
1,25(OH)2D3/NN
,/,
may/MD
be/VB
an/DT
important/JJ
component/NN
of/IN
a/DT
successful/JJ
antituberculous/JJ
immune/JJ
response/NN
./.
====================
UI/LS
-/:
90206049/CD
====================
TI/LS
-/:
Megakaryocytic/JJ
and/CC
erythrocytic/JJ
lineages/NNS
share/VBP
specific/JJ
transcription/NN
factors/NNS
./.
====================
AB/LS
-/:
Erythroid-specific/JJ
genes/NNS
contain/VBP
binding/VBG
sites/NNS
for/IN
NF-E1/NN
(/(
also/RB
called/VBN
GF-1/NN
and/CC
Eryf-1/NN
;/:
refs/NNS
1-3/CD
respectively/RB
)/)
,/,
the/DT
principal/JJ
DNA-binding/JJ
protein/NN
of/IN
the/DT
erythrocytic/JJ
lineage/NN
./.
====================
NF-E1/NN
expression/NN
seems/VBZ
to/TO
be/VB
restricted/JJ
to/TO
the/DT
erythrocytic/JJ
lineage/NN
./.
====================
A/DT
closely/RB
related/JJ
(/(
if/IN
not/RB
identical/JJ
)/)
protein/NN
is/VBZ
found/VBN
in/IN
both/CC
a/DT
human/JJ
megakaryocytic/JJ
cell/NN
line/NN
and/CC
purified/VBN
human/JJ
megakaryocytes/NNS
;/:
it/PRP
binds/VBZ
to/TO
promoter/NN
regions/NNS
of/IN
two/CD
megakaryocytic-specific/JJ
genes/NNS
./.
====================
The/DT
binding/VBG
sites/NNS
and/CC
partial/JJ
proteolysis/NN
profile/NN
of/IN
this/DT
protein/NN
are/VBP
indistinguishable/JJ
from/IN
those/DT
of/IN
the/DT
erythroid/JJ
protein/NN
;/:
also/RB
,/,
NF-E1/NN
messenger/NN
RNA/NN
is/VBZ
the/DT
same/JJ
size/NN
in/IN
both/CC
the/DT
megakaryocytic/JJ
and/CC
erythroid/JJ
cell/NN
lines/NNS
./.
====================
Furthermore/RB
,/,
point/NN
mutations/NNS
that/WDT
abolish/VBP
binding/NN
of/IN
NF-E1/NN
result/VBP
in/IN
a/DT
70/CD
%/NN
decrease/NN
in/IN
the/DT
transcriptional/JJ
activity/NN
of/IN
a/DT
megakaryocytic-specific/JJ
promoter/NN
./.
====================
We/PRP
also/RB
find/VBP
that/IN
NF-E2/NN
,/,
another/DT
trans-acting/JJ
factor/NN
of/IN
the/DT
erythrocytic/JJ
lineage/NN
,/,
is/VBZ
present/JJ
in/IN
megakaryocytes/NNS
./.
====================
Transcriptional/JJ
effects/NNS
in/IN
both/DT
lineages/NNS
might/MD
then/RB
be/VB
mediated/VBN
in/IN
part/NN
by/IN
the/DT
same/JJ
specific/JJ
trans-acting/JJ
factors/NNS
./.
====================
Our/PRP$
data/NNS
strengthen/VBP
the/DT
idea/NN
of/IN
a/DT
close/JJ
association/NN
between/IN
the/DT
erythrocytic/JJ
and/CC
the/DT
megakaryocytic/JJ
lineages/NNS
and/CC
could/MD
also/RB
explain/VB
the/DT
expression/NN
of/IN
markers/NNS
specific/JJ
to/TO
the/DT
erythrocytic/JJ
and/CC
megakaryocytic/JJ
lineages/NNS
in/IN
most/JJS
erythroblastic/JJ
and/CC
megakaryoblastic/JJ
permanent/JJ
cell/NN
lines/NNS
./.
====================
UI/LS
-/:
91175478/CD
====================
TI/LS
-/:
Transcriptional/JJ
down-regulation/NN
of/IN
c-myc/NN
expression/NN
by/IN
protein/NN
synthesis-dependent/JJ
and/CC
-independent/JJ
pathways/NNS
in/IN
a/DT
human/JJ
T/NN
lymphoblastic/JJ
tumor/NN
cell/NN
line/NN
./.
====================
AB/LS
-/:
We/PRP
show/VBP
that/IN
in/IN
the/DT
human/JJ
T/NN
lymphoblastic/JJ
tumor/NN
cell/NN
line/NN
Molt4/NN
c-myc/NN
mRNA/NN
and/CC
protein/NN
expression/NN
is/VBZ
down-regulated/VBN
after/IN
exposure/NN
to/TO
dimethyl/JJ
sulfoxide/NN
,/,
to/TO
phorbol/NN
myristate/NN
acetate/NN
,/,
or/CC
to/TO
the/DT
calcium/NN
ionophore/NN
A23187/NN
,/,
which/WDT
raises/VBZ
the/DT
intracellular/JJ
calcium/NN
concentration/NN
./.
====================
A/DT
block/NN
to/TO
RNA/NN
elongation/NN
is/VBZ
largely/RB
responsible/JJ
for/IN
decreased/VBN
c-myc/NN
transcription/NN
./.
====================
Although/IN
negative/JJ
regulation/NN
by/IN
dimethyl/JJ
sulfoxide/NN
takes/VBZ
place/NN
even/RB
when/WRB
protein/NN
synthesis/NN
is/VBZ
inhibited/VBN
by/IN
cycloheximide/NN
,/,
the/DT
phorbol/NN
myristate/NN
acetate/NN
effect/NN
is/VBZ
blocked/VBN
to/TO
some/DT
extent/NN
only/RB
by/IN
cycloheximide/NN
./.
====================
The/DT
calcium/NN
ionophore-induced/JJ
c-myc/NN
suppression/NN
,/,
however/RB
,/,
strictly/RB
requires/VBZ
de/FW
novo/FW
protein/NN
synthesis/NN
./.
====================
Therefore/RB
,/,
two/CD
different/JJ
negative/JJ
regulatory/JJ
pathways/NNS
are/VBP
involved/VBN
in/IN
c-myc/NN
regulation/NN
:/:
one/CD
which/WDT
is/VBZ
independent/JJ
and/CC
one/CD
which/WDT
depends/VBZ
on/IN
de/FW
novo/FW
protein/NN
synthesis/NN
./.
====================
The/DT
latter/JJ
one/CD
appears/VBZ
to/TO
be/VB
mediated/VBN
by/IN
a/DT
rapidly/RB
calcium-dependent/JJ
induced/VBN
gene/NN
product/NN
./.
====================
UI/LS
-/:
91124866/CD
====================
TI/LS
-/:
Oestrogen/NN
receptor/NN
(/(
ER/NN
)/)
analysis/NN
in/IN
B-cell/NN
chronic/JJ
lymphocytic/JJ
leukemia/NN
:/:
correlation/NN
of/IN
biochemical/JJ
and/CC
immunocytochemical/JJ
methods/NNS
./.
====================
AB/LS
-/:
Oestrogen/NN
receptors/NNS
(/(
ER/NN
)/)
are/VBP
present/JJ
in/IN
neoplastic/JJ
lymphoid/JJ
cells/NNS
and/CC
have/VBP
been/VBN
considered/VBN
a/DT
physiological/JJ
marker/NN
of/IN
growth/NN
rate/NN
or/CC
differentiation/NN
./.
====================
Tamoxifen/NN
,/,
an/DT
oestrogen/NN
antagonist/NN
,/,
has/VBZ
been/VBN
given/VBN
in/IN
some/DT
patients/NNS
with/IN
CLL/NN
and/CC
Hodgkin/NN
's/POS
disease/NN
,/,
with/IN
dramatic/JJ
response/NN
in/IN
single/JJ
cases/NNS
./.
====================
Until/IN
now/NN
,/,
ER/NN
status/NN
has/VBZ
been/VBN
assessed/VBN
using/VBG
a/DT
steroid/NN
binding/NN
assay/NN
(/(
SBA/NN
)/)
which/WDT
has/VBZ
many/JJ
inherent/JJ
problems/NNS
./.
====================
Recently/RB
,/,
the/DT
development/NN
of/IN
monoclonal/JJ
antibodies/NNS
directed/VBN
against/IN
ER/NN
has/VBZ
been/VBN
applied/VBN
to/TO
the/DT
study/NN
of/IN
breast/NN
carcinomas/NNS
and/CC
results/NNS
obtained/VBN
show/VBP
good/JJ
correlation/NN
with/IN
the/DT
quantitative/JJ
SBA/NN
./.
====================
We/PRP
studied/VBD
49/CD
cases/NNS
of/IN
B-cell/NN
chronic/JJ
lymphocytic/JJ
leukemia/NN
(/(
CLL/NN
)/)
using/VBG
immunostaining/NN
of/IN
cytospin/NN
preparations/NNS
./.
====================
In/IN
30/CD
of/IN
these/DT
cases/NNS
ER/NN
enzyme/NN
immunoassay/NN
(/(
ER-EIA/NN
)/)
was/VBD
also/RB
performed/VBN
./.
====================
Cultured/VBN
MCF-7/NN
cells/NNS
,/,
derived/VBN
from/IN
a/DT
pleural/JJ
effusion/NN
of/IN
a/DT
breast/NN
cancer/NN
patient/NN
,/,
known/VBN
to/TO
contain/VB
high/JJ
levels/NNS
of/IN
ER/NN
were/VBD
used/VBN
as/IN
a/DT
positive/JJ
control/NN
(/(
40-48/CD
%/NN
ER/NN
positive/JJ
cells/NNS
by/IN
immunocytochemistry/NN
;/:
200/CD
fmol/mg/NN
protein/NN
by/IN
EIA/NN
)/)
./.
====================
All/DT
of/IN
the/DT
CLL/NN
cases/NNS
except/IN
two/CD
(/(
96/CD
%/NN
)/)
were/VBD
negative/JJ
for/IN
ER/NN
(/(
less/JJR
than/IN
1/CD
%/NN
staining/NN
;/:
less/JJR
than/IN
4/CD
fmol/mg/NN
protein/NN
)/)
./.
====================
The/DT
two/CD
positive/JJ
cases/NNS
expressed/VBD
granular/JJ
ER/NN
staining/NN
over/IN
the/DT
nucleus/NN
(/(
9.2/CD
and/CC
12.1/CD
%/NN
positive/JJ
cells/NNS
)/)
and/CC
were/VBD
positive/JJ
by/IN
EIA/NN
and/CC
SBA/NN
./.
====================
It/PRP
is/VBZ
concluded/VBN
that/IN
(/(
i/LS
)/)
patients/NNS
with/IN
CLL/NN
rarely/RB
express/VBP
ER/NN
and/CC
(/(
ii/LS
)/)
immunocytochemical/JJ
staining/NN
of/IN
cytospin/NN
preparations/NNS
is/VBZ
a/DT
valid/JJ
technique/NN
for/IN
the/DT
measurement/NN
of/IN
ER/NN
./.
====================
It/PRP
is/VBZ
of/IN
interest/NN
that/IN
one/CD
of/IN
the/DT
positive/JJ
cases/NNS
was/VBD
diagnosed/VBN
as/IN
CLL/NNP
with/IN
Richter/NN
's/POS
transformation/NN
confirming/VBG
earlier/JJR
findings/NNS
./.
====================
UI/LS
-/:
91065749/CD
====================
TI/LS
-/:
Type-II/JJ
estrogen/NN
binding/NN
sites/NNS
in/IN
a/DT
lymphoblastoid/JJ
cell/NN
line/NN
and/CC
growth-inhibitory/JJ
effect/NN
of/IN
estrogen/NN
,/,
anti-estrogen/NN
and/CC
bioflavonoids/NNS
./.
====================
AB/LS
-/:
Type-II/JJ
estrogen-binding/JJ
sites/NNS
(/(
type-II/JJ
EBS/NNS
)/)
have/VBP
been/VBN
demonstrated/VBN
in/IN
the/DT
human/JJ
lymphoblastoid/JJ
cell/NN
line/NN
IM-9/NN
using/VBG
a/DT
whole-cell/JJ
assay/NN
with/IN
(/(
6,7-3H/NN
)/)
estradiol/NN
(/(
3H-E2/NN
)/)
as/IN
tracer/NN
./.
====================
Competition/NN
analysis/NN
showed/VBD
that/IN
the/DT
anti-estrogen/JJ
tamoxifen/NN
and/CC
the/DT
flavonoids/NNS
quercetin/NN
and/CC
rutin/NN
competed/VBD
for/IN
(3H)-E2/NN
binding/NN
to/TO
type-II/JJ
EBS/NNS
./.
====================
Growth/NN
experiments/NNS
demonstrated/VBD
that/IN
diethylstilbestrol/NN
(/(
DES/NN
)/)
tamoxifen/NN
(/(
TAM/NN
)/)
,/,
quercetin/NN
and/CC
rutin/NN
exerted/VBD
a/DT
reversible/JJ
dose-dependent/JJ
inhibition/NN
of/IN
cell/NN
proliferation/NN
in/IN
the/DT
range/NN
of/IN
concentrations/NNS
between/IN
10/CD
nM/NN
and/CC
10/CD
microM/NN
./.
====================
The/DT
relative/JJ
binding/NN
affinity/NN
of/IN
quercetin/NN
,/,
rutin/NN
,/,
DES/NN
and/CC
TAM/NNP
for/IN
type-II/JJ
EBS/NNS
correlated/VBD
well/RB
with/IN
their/PRP$
potency/NN
as/IN
cell/NN
growth/NN
inhibitors/NNS
./.
====================
Moreover/RB
,/,
hesperidin/NN
,/,
a/DT
flavonoid/NN
which/WDT
does/VBZ
not/RB
bind/VB
to/TO
type-II/JJ
EBS/NNS
,/,
was/VBD
ineffective/JJ
in/IN
inhibiting/VBG
cell/NN
growth/NN
./.
====================
Cell-cycle/JJ
analysis/NN
showed/VBD
that/IN
the/DT
growth-inhibitory/JJ
effect/NN
of/IN
DES/NN
,/,
TAM/NN
or/CC
quercetin/NN
was/VBD
due/JJ
to/TO
a/DT
blocking/NN
effect/NN
in/IN
the/DT
G0-G1/JJ
phases/NNS
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
high/JJ
estrogen/NN
and/CC
anti-estrogen/JJ
concentrations/NNS
and/CC
flavonoids/NNS
may/MD
regulate/VB
IM-9/NN
cell/NN
growth/NN
through/IN
a/DT
common/JJ
mechanism/NN
involving/VBG
a/DT
binding/NN
interaction/NN
with/IN
type-II/JJ
EBS/NNS
./.
====================
UI/LS
-/:
91132900/CD
====================
TI/LS
-/:
[/(
Glucocorticoid/NN
receptors/NNS
in/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
of/IN
patients/NNS
with/IN
bronchial/JJ
asthma/NN
]/)
====================
AB/LS
-/:
Quantitation/NN
of/IN
glucocorticoid/NN
receptors/NNS
(/(
GCR/NN
)/)
and/CC
the/DT
study/NN
of/IN
their/PRP$
affinity/NN
for/IN
glucocorticosteroids/NNS
(/(
GCS/NNS
)/)
were/VBD
made/VBN
in/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
of/IN
bronchial/JJ
asthma/NN
(/(
BA/NN
)/)
patients/NNS
in/IN
consideration/NN
of/IN
GCR/NN
treatment/NN
and/CC
serum/NN
levels/NNS
of/IN
endogenous/JJ
cortisol/NN
./.
====================
It/PRP
is/VBZ
stated/VBN
that/IN
GCR/NN
of/IN
healthy/JJ
controls/NNS
and/CC
GCS-untreated/JJ
patients/NNS
outnumbered/VBD
those/DT
of/IN
cortisol-dependent/JJ
BA/NN
patients/NNS
on/IN
hormone/NN
therapy/NN
./.
====================
Following/VBG
discontinuation/NN
of/IN
glucocorticoid/NN
drugs/NNS
GCR/NN
count/NN
in/IN
cortisol-dependent/JJ
BA/NN
tends/VBZ
to/TO
rise/VB
./.
====================
Endogenous/JJ
cortisol/NN
has/VBZ
no/DT
effect/NN
on/IN
GCR/NN
level/NN
estimated/VBN
by/IN
3H-triamcinolone/NN
acetonide/NN
./.
====================
UI/LS
-/:
90382324/CD
====================
TI/LS
-/:
Two/CD
glucocorticoid/NN
binding/NN
sites/NNS
on/IN
the/DT
human/JJ
glucocorticoid/NN
receptor/NN
./.
====================
AB/LS
-/:
Glucocorticoids/NNS
are/VBP
known/VBN
to/TO
have/VB
a/DT
lytic/JJ
effect/NN
in/IN
leukemic/JJ
cells/NNS
via/IN
interactions/NNS
with/IN
the/DT
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
./.
====================
Cortisol/NN
and/CC
various/JJ
synthetic/JJ
glucocorticoids/NNS
bind/VBP
to/TO
the/DT
GR/NN
with/IN
one-site/JJ
kinetics/NNS
./.
====================
Cortivazol/NN
(/(
CVZ/NN
)/)
is/VBZ
a/DT
unique/JJ
,/,
high/JJ
potency/NN
synthetic/JJ
glucocorticoid/NN
,/,
which/WDT
has/VBZ
a/DT
phenylpyrazol/JJ
fused/VBN
to/TO
the/DT
A-ring/NN
of/IN
the/DT
steroid/NN
nucleus/NN
and/CC
displays/VBZ
binding/NN
consistent/JJ
with/IN
two/CD
or/CC
more/JJR
sites/NNS
in/IN
the/DT
cytosol/NN
from/IN
CEM/NN
C7/NN
cells/NNS
(/(
a/DT
human/JJ
acute/JJ
lymphoblastic/JJ
T-cell/NN
line/NN
)/)
./.
====================
It/PRP
has/VBZ
previously/RB
been/VBN
shown/VBN
that/IN
the/DT
lower/JJR
affinity/NN
class/NN
of/IN
sites/NNS
are/VBP
similar/JJ
in/IN
affinity/NN
and/CC
site/NN
molarity/NN
to/TO
those/DT
recognized/VBN
by/IN
dexamethasone/NN
./.
====================
The/DT
higher/JJR
affinity/NN
sites/NNS
bind/VBP
CVZ/NN
with/IN
20-/CD
to/TO
50-fold/RB
greater/JJR
affinity/NN
,/,
consistent/JJ
with/IN
CVZ/NN
's/POS
enhanced/VBN
biological/JJ
effects/NNS
./.
====================
In/IN
mutant/JJ
leukemic/JJ
cells/NNS
resistant/JJ
to/TO
the/DT
lytic/JJ
effects/NNS
of/IN
dexamethasone/NN
,/,
CVZ/NN
both/CC
lyses/VBZ
the/DT
cells/NNS
and/CC
recognizes/VBZ
a/DT
single/JJ
class/NN
of/IN
sites/NNS
similar/JJ
to/TO
the/DT
high/JJ
affinity/NN
site/NN
in/IN
CEM/NN
C7/NN
cells/NNS
./.
====================
We/PRP
have/VBP
carried/VBN
out/RP
experiments/NNS
to/TO
define/VB
the/DT
nature/NN
of/IN
the/DT
higher/JJR
affinity/NN
CVZ/NN
binding/NN
site/NN
./.
====================
We/PRP
now/RB
show/VBP
that/IN
:/:
1/LS
)/)
CVZ/NN
has/VBZ
more/JJR
than/IN
one/CD
binding/VBG
site/NN
in/IN
a/DT
second/JJ
,/,
independent/JJ
,/,
B-cell/NN
line/NN
,/,
IM-9/NN
;/:
2/LS
)/)
the/DT
antiglucocorticoid/JJ
RU/NN
38486/CD
is/VBZ
able/JJ
to/TO
block/VB
both/CC
CVZ/NN
's/POS
higher/JJR
and/CC
lower/JJR
affinity/NN
sites/NNS
;/:
3/LS
)/)
all/DT
of/IN
CVZ/NN
's/POS
binding/VBG
sites/NNS
are/VBP
on/IN
a/DT
protein/NN
immunologically/RB
indistinguishable/JJ
from/IN
the/DT
human/JJ
GR/NN
;/:
and/CC
4/LS
)/)
freshly/RB
isolated/VBN
clones/NNS
of/IN
CVZ-resistant/JJ
cells/NNS
have/VBP
lost/VBN
all/DT
binding/VBG
sites/NNS
for/IN
CVZ/NN
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
CVZ/NN
is/VBZ
recognizing/VBG
two/CD
glucocorticoid/NN
binding/NN
sites/NNS
on/IN
the/DT
human/JJ
GR/NN
or/CC
a/DT
protein/NN
very/RB
similar/JJ
to/TO
it/PRP
./.
====================
UI/LS
-/:
90381363/CD
====================
TI/LS
-/:
Retroviral/JJ
mediated/VBN
transfer/NN
and/CC
expression/NN
of/IN
exogenous/JJ
genes/NNS
in/IN
primary/JJ
lymphoid/JJ
cells/NNS
:/:
assaying/VBG
for/IN
a/DT
viral/JJ
transactivator/NN
activity/NN
in/IN
normal/JJ
and/CC
malignant/JJ
cells/NNS
./.
====================
AB/LS
-/:
In/IN
this/DT
report/NN
we/PRP
describe/VBP
the/DT
use/NN
of/IN
recombinant/JJ
retroviruses/NNS
to/TO
characterize/VB
the/DT
activity/NN
of/IN
an/DT
exogenous/JJ
promoter/NN
in/IN
primary/JJ
cells/NNS
obtained/VBN
from/IN
patients/NNS
with/IN
lymphoproliferative/JJ
disorders/NNS
./.
====================
The/DT
infection/NN
of/IN
a/DT
variety/NN
of/IN
cultured/VBN
and/CC
primary/JJ
lymphoid/JJ
cells/NNS
with/IN
a/DT
recombinant/JJ
retrovirus/NN
containing/VBG
a/DT
histone/NN
promoter-driven/JJ
beta-galactosidase/NN
gene/NN
is/VBZ
shown/VBN
to/TO
result/VB
in/IN
the/DT
expression/NN
of/IN
beta-galactosidase/NN
in/IN
50/CD
%/NN
to/TO
100/CD
%/NN
of/IN
the/DT
cells/NNS
./.
====================
A/DT
similar/JJ
infection/NN
with/IN
a/DT
recombinant/JJ
retrovirus/NN
containing/VBG
the/DT
beta-galactosidase/NN
gene/NN
with/IN
an/DT
adenovirus/NN
E2/NN
promoter/NN
,/,
results/VBZ
in/IN
beta-galactosidase/NN
activity/NN
in/IN
a/DT
limited/JJ
number/NN
of/IN
cultured/VBN
and/CC
primary/JJ
cells/NNS
./.
====================
Since/IN
the/DT
adenovirus/NN
E2/NN
promoter/NN
has/VBZ
been/VBN
well/RB
characterized/VBN
and/CC
is/VBZ
known/VBN
to/TO
be/VB
regulated/VBN
by/IN
transactivators/NNS
encoded/VBN
by/IN
many/JJ
viruses/NNS
,/,
the/DT
activity/NN
of/IN
this/DT
promoter/NN
in/IN
specific/JJ
cell/NN
types/NNS
is/VBZ
discussed/VBN
in/IN
reference/NN
to/TO
both/CC
the/DT
biology/NN
of/IN
the/DT
cell/NN
and/CC
the/DT
possible/JJ
presence/NN
of/IN
as/RB
yet/RB
undetected/JJ
viral/JJ
gene/NN
products/NNS
./.
====================
UI/LS
-/:
91049522/CD
====================
TI/LS
-/:
[/(
The/DT
effect/NN
of/IN
24,25-dihydroxyvitamin/NN
D3/NN
(/(
dioxyvit/NN
)/)
on/IN
Ca/NN
metabolism/NN
and/CC
immune/JJ
status/NN
during/IN
chronic/JJ
kidney/NN
failure/NN
]/)
====================
AB/LS
-/:
Active/JJ
metabolite/NN
of/IN
vitamin/NN
D3/NN
,/,
24R,25 (OH)2D3/NN
(/(
dioxyvit/NN
)/)
was/VBD
used/VBN
at/IN
a/DT
daily/JJ
dose/NN
of/IN
100/CD
micrograms/NNS
in/IN
treatment/NN
of/IN
children/NNS
affected/VBN
with/IN
tubulointerstitial/JJ
disease/NN
of/IN
kidney/NN
and/CC
with/IN
chronic/JJ
glomerulonephritis/NN
under/IN
conditions/NNS
of/IN
kidney/NN
insufficiency/NN
./.
====================
The/DT
drug/NN
exhibited/VBD
distinct/JJ
normalizing/NN
effect/NN
on/IN
patterns/NNS
of/IN
calcium/NN
metabolism/NN
:/:
increase/NN
of/IN
total/JJ
and/CC
ionized/VBN
Ca2+/NN
and/CC
of/IN
25-OHD/NN
,/,
decrease/NN
in/IN
concentration/NN
of/IN
parath/NN
hormone/NN
and/CC
osteocalcine/NN
in/IN
blood/NN
serum/NN
as/RB
well/RB
as/IN
on/IN
immunological/JJ
parameters/NNS
:/:
restoration/NN
of/IN
decreased/VBN
content/NN
of/IN
T-/NN
and/CC
0-lymphocytes/NNS
./.
====================
Concentration/NN
of/IN
receptors/NNS
of/IN
hormonal/JJ
form/NN
of/IN
1,25(OH)2D3/NN
was/VBD
found/VBN
to/TO
be/VB
minimal/JJ
in/IN
lymphocytes/NNS
under/IN
conditions/NNS
of/IN
chronic/JJ
kidney/NN
insufficiency/NN
,/,
while/IN
their/PRP$
expression/NN
,/,
after/IN
the/DT
dioxyvit/NN
action/NN
,/,
was/VBD
detected/VBN
only/RB
in/IN
patients/NNS
with/IN
glomerulonephritis/NN
./.
====================
Specific/JJ
calcitropic/JJ
effect/NN
of/IN
dioxyvit/NN
with/IN
simultaneous/JJ
correction/NN
of/IN
vitamin/NN
D/NN
deficiency/NN
were/VBD
apparently/RB
responsible/JJ
for/IN
high/JJ
efficacy/NN
of/IN
the/DT
drug/NN
in/IN
treatment/NN
of/IN
calcium/NN
metabolism/NN
and/CC
immunity/NN
impairments/NNS
in/IN
children/NNS
with/IN
renal/JJ
deteriorations/NNS
at/IN
the/DT
step/NN
of/IN
chronic/JJ
kidney/NN
insufficiency/NN
./.
====================
UI/LS
-/:
91013631/CD
====================
TI/LS
-/:
[/(
The/DT
role/NN
of/IN
glucocorticoid/NN
receptors/NNS
and/CC
HLA/NN
antigens/NNS
in/IN
the/DT
pathogenesis/NN
of/IN
Cushing/NN
's/POS
syndrome/NN
]/)
====================
AB/LS
-/:
Lymphocytic/JJ
levels/NNS
of/IN
glucocorticoid/NN
receptors/NNS
were/VBD
evaluated/VBN
in/IN
114/CD
patients/NNS
suffering/VBG
from/IN
Icenko-Cushing/NN
's/POS
syndrome/NN
./.
====================
Incidence/NN
of/IN
HLA/NN
antigens/NNS
was/VBD
determined/VBN
in/IN
94/CD
of/IN
them/PRP
./.
====================
A/DT
significant/JJ
rise/NN
of/IN
A10/NN
and/CC
B27/NN
antigen/NN
incidence/NN
compared/VBN
to/TO
that/DT
in/IN
normal/JJ
subjects/NNS
allows/VBZ
these/DT
antigens/NNS
to/TO
be/VB
considered/VBN
genetic/JJ
markers/NNS
of/IN
Icenko-Cushing/NN
's/POS
syndrome/NN
./.
====================
The/DT
levels/NNS
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
lymphocytes/NNS
of/IN
the/DT
patients/NNS
are/VBP
lower/JJR
than/IN
in/IN
normal/JJ
subjects/NNS
both/CC
in/IN
the/DT
active/JJ
stage/NN
of/IN
the/DT
disease/NN
and/CC
following/VBG
bilateral/JJ
total/JJ
adrenalectomy/NN
./.
====================
The/DT
patients/NNS
carrying/VBG
B27/NN
antigen/NN
had/VBD
lymphocytic/JJ
receptor/NN
concentrations/NNS
under/IN
the/DT
levels/NNS
of/IN
such/JJ
in/IN
patients/NNS
free/JJ
of/IN
the/DT
antigen/JJ
carriage/NN
./.
====================
Antigen/NN
B27/NN
seems/VBZ
to/TO
be/VB
a/DT
cause/NN
of/IN
lower/JJR
levels/NNS
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
blood/NN
lymphocytes/NNS
./.
====================
UI/LS
-/:
90242285/CD
====================
TI/LS
-/:
Effects/NNS
of/IN
1/CD
alpha/NN
,/,
25-dihydroxyvitamin/NN
D3/NN
on/IN
the/DT
human/JJ
chronic/JJ
myelogenous/JJ
leukemia/NN
cell/NN
line/NN
RWLeu-4/NN
./.
====================
AB/LS
-/:
The/DT
effects/NNS
of/IN
1/CD
alpha/NN
,/,
25-dihydroxyvitamin/NN
D3/NN
(/(
VD3/NN
)/)
on/IN
proliferation/NN
,/,
differentiation/NN
,/,
and/CC
macromolecular/JJ
synthesis/NN
in/IN
the/DT
new/JJ
Philadelphia/NN
chromosome-positive/JJ
chronic/JJ
myelogenous/JJ
leukemia/NN
cell/NN
line/NN
,/,
RWLeu-4/NN
,/,
were/VBD
investigated/VBN
./.
====================
Binding/NN
of/IN
[3H]VD3/NN
was/VBD
saturable/JJ
,/,
with/IN
approximately/RB
2000-3000/CD
sites/cell/NNS
,/,
and/CC
half-maximal/JJ
binding/NN
occurring/VBG
at/IN
0.21-0.33/CD
nM/NN
./.
====================
Treatment/NN
of/IN
RWLeu-4/NN
cells/NNS
with/IN
VD3/NN
induced/VBD
24R-hydroxylase/NN
activity/NN
,/,
a/DT
marker/NN
of/IN
vitamin/NN
D3/NN
responsiveness/NN
in/IN
many/JJ
tissues/NNS
./.
====================
Exposure/NN
of/IN
RWLeu-4/NN
cells/NNS
to/TO
VD3/NN
also/RB
inhibited/VBD
proliferation/NN
and/CC
DNA/NN
synthesis/NN
with/IN
a/DT
50/CD
%/NN
effective/JJ
dose/NN
of/IN
3.5-10/CD
nM/NN
within/IN
72/CD
h/NN
;/:
in/IN
addition/NN
,/,
protein/NN
and/CC
RNA/NN
synthesis/NN
were/VBD
inhibited/VBN
by/IN
VD3/NN
treatment/NN
./.
====================
Exposure/NN
of/IN
RWLeu-4/NN
cells/NNS
to/TO
5/CD
nM/NN
VD3/NN
for/IN
72/CD
h/NN
caused/VBD
50/CD
%/NN
of/IN
the/DT
cells/NNS
to/TO
differentiate/VB
into/IN
macrophage/monocyte/JJ
type/NN
cells/NNS
as/IN
judged/VBN
by/IN
nitroblue/JJ
tetrazolium/NN
staining/NN
and/CC
adherence/NN
to/TO
plastic/NN
./.
====================
Progressive/JJ
expression/NN
of/IN
cell/NN
surface/NN
maturation-specific/JJ
antigens/NNS
of/IN
the/DT
monocyte/macrophage/JJ
lineage/NN
was/VBD
induced/VBN
by/IN
treatment/NN
of/IN
RWLeu-4/NN
cells/NNS
with/IN
VD3/NN
for/IN
24/CD
to/TO
72/CD
h/NN
at/IN
doses/NNS
that/WDT
inhibited/VBD
cellular/JJ
proliferation/NN
./.
====================
c-myc/NN
RNA/NN
,/,
which/WDT
is/VBZ
constitutively/RB
expressed/VBN
in/IN
RWLeu-4/NN
cells/NNS
,/,
increased/VBD
after/IN
0.5/CD
h/NN
of/IN
treatment/NN
with/IN
50/CD
nM/NN
VD3/NN
and/CC
then/RB
rapidly/RB
decreased/VBD
to/TO
barely/RB
detectable/JJ
levels/NNS
after/IN
4/CD
h/NN
of/IN
treatment/NN
./.
====================
Finally/RB
,/,
the/DT
in/FW
vitro/FW
tyrosine/NN
kinase/NN
activity/NN
associated/VBN
with/IN
the/DT
p210bcr-abl/NN
oncogene/NN
product/NN
was/VBD
decreased/VBN
approximately/RB
50/CD
%/NN
by/IN
VD3/NN
treatment/NN
./.
====================
Because/IN
of/IN
the/DT
presence/NN
of/IN
a/DT
functional/JJ
receptor-effector/JJ
system/NN
for/IN
VD3/NN
and/CC
multiple/JJ
biological/JJ
responses/NNS
to/TO
the/DT
hormone/NN
,/,
these/DT
cells/NNS
provide/VBP
a/DT
unique/JJ
model/NN
system/NN
with/IN
which/WDT
to/TO
probe/VB
the/DT
specific/JJ
effects/NNS
of/IN
VD3/NN
on/IN
cell/NN
growth/NN
and/CC
differentiation/NN
in/IN
chronic/JJ
myelogenous/JJ
leukemia/NN
./.
====================
UI/LS
-/:
90208323/CD
====================
TI/LS
-/:
A/DT
new/JJ
member/NN
of/IN
the/DT
leucine/NN
zipper/NN
class/NN
of/IN
proteins/NNS
that/WDT
binds/VBZ
to/TO
the/DT
HLA/NN
DR/NN
alpha/NN
promoter/NN
./.
====================
AB/LS
-/:
Several/JJ
mutants/NNS
derived/VBN
from/IN
transformed/VBN
human/JJ
B/NN
cell/NN
lines/NNS
are/VBP
defective/JJ
in/IN
expressing/VBG
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
class/NN
II/CD
genes/NNS
./.
====================
The/DT
failure/NN
to/TO
express/VB
a/DT
class/NN
II/CD
gene/NN
in/IN
at/IN
least/JJS
one/CD
such/JJ
mutant/JJ
line/NN
has/VBZ
been/VBN
mapped/VBN
to/TO
the/DT
MHC/NN
class/NN
II/CD
X/NN
box/NN
,/,
a/DT
conserved/VBN
transcriptional/JJ
element/NN
in/IN
the/DT
promoter/NN
region/NN
./.
====================
A/DT
complementary/JJ
DNA/NN
encoding/VBG
a/DT
DNA-binding/JJ
protein/NN
(/(
human/JJ
X/NN
box/NN
binding/NN
protein/NN
,/,
hXBP-1/NN
)/)
whose/WP$
target/NN
is/VBZ
the/DT
human/JJ
DR/NN
alpha/NN
X/NN
box/NN
and/CC
the/DT
3'/JJ
flanking/JJ
region/NN
has/VBZ
now/RB
been/VBN
cloned/VBN
./.
====================
This/DT
complementary/JJ
DNA/NN
encoded/VBD
a/DT
protein/NN
with/IN
structural/JJ
similarities/NNS
to/TO
the/DT
c-jun/NN
proto-oncogene/NN
product/NN
,/,
and/CC
its/PRP$
target/NN
sequence/NN
was/VBD
closely/RB
related/JJ
to/TO
the/DT
palindromic/JJ
target/NN
sequence/NN
of/IN
c-jun/NN
./.
====================
Mutation/NN
of/IN
the/DT
hXBP-1/NN
DNA/NN
target/NN
sequence/NN
decreased/VBD
DR/NN
alpha/NN
promoter/NN
activity/NN
in/FW
vivo/FW
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
the/DT
hXBP-1/NN
protein/NN
acts/VBZ
as/IN
a/DT
transcription/NN
factor/NN
in/IN
B/NN
cells/NNS
./.
====================
UI/LS
-/:
90171176/CD
====================
TI/LS
-/:
Pseudohypoaldosteronism/NN
in/IN
eight/CD
families/NNS
:/:
different/JJ
forms/NNS
of/IN
inheritance/NN
are/VBP
evidence/NN
for/IN
various/JJ
genetic/JJ
defects/NNS
./.
====================
AB/LS
-/:
Pseudohypoaldosteronism/NN
is/VBZ
a/DT
rare/JJ
hereditary/JJ
disorder/NN
presenting/VBG
in/IN
early/JJ
infancy/NN
with/IN
renal/JJ
salt/NN
loss/NN
leading/VBG
to/TO
hyponatremia/NN
and/CC
hyperkalemia/NN
despite/IN
high/JJ
levels/NNS
of/IN
plasma/NN
aldosterone/NN
./.
====================
The/DT
patients/NNS
are/VBP
insensitive/JJ
to/TO
mineralocorticoids/NNS
;/:
however/RB
,/,
sodium/NN
supplementation/NN
is/VBZ
able/JJ
to/TO
correct/VB
electrolyte/NN
abnormalities/NNS
./.
====================
Absent/JJ
or/CC
greatly/RB
diminished/VBN
type/NN
I/CD
aldosterone/NN
receptors/NNS
in/IN
peripheral/JJ
mononuclear/JJ
leucocytes/NNS
have/VBP
been/VBN
recently/RB
demonstrated/VBN
and/CC
explain/VB
the/DT
lack/NN
of/IN
response/NN
to/TO
mineralocorticoids/NNS
./.
====================
We/PRP
have/VBP
studied/VBN
the/DT
mode/NN
of/IN
inheritance/NN
in/IN
eight/CD
families/NNS
with/IN
a/DT
total/NN
of/IN
nine/CD
patients/NNS
./.
====================
There/EX
was/VBD
evidence/NN
for/IN
an/DT
autosomal/JJ
recessive/JJ
form/NN
of/IN
inheritance/NN
in/IN
four/CD
families/NNS
,/,
while/IN
the/DT
other/JJ
four/CD
families/NNS
appeared/VBD
to/TO
have/VB
an/DT
autosomal/JJ
dominant/JJ
mode/NN
of/IN
transmission/NN
./.
====================
In/IN
three/CD
families/NNS
the/DT
autosomal/JJ
recessive/JJ
form/NN
was/VBD
characterized/VBN
by/IN
normal/JJ
receptor/NN
as/RB
well/RB
as/IN
hormone/NN
data/NNS
in/IN
both/DT
parents/NNS
,/,
while/IN
in/IN
one/CD
family/NN
receptor/NN
levels/NNS
in/IN
both/DT
parents/NNS
were/VBD
greatly/RB
reduced/VBN
,/,
but/CC
hormone/NN
levels/NNS
were/VBD
normal/JJ
./.
====================
In/IN
the/DT
four/CD
families/NNS
with/IN
an/DT
autosomal/JJ
dominant/JJ
mode/NN
of/IN
transmission/NN
there/RB
was/VBD
always/RB
one/CD
parent/NN
with/IN
reduced/VBN
receptor/NN
binding/NN
in/IN
peripheral/JJ
mononuclear/JJ
leucocytes/NNS
and/CC
elevated/JJ
serum/NN
hormone/NN
levels/NNS
./.
====================
These/DT
parents/NNS
were/VBD
entirely/RB
asymptomatic/JJ
./.
====================
In/IN
an/DT
extended/VBN
family/NN
we/PRP
were/VBD
able/JJ
to/TO
study/VB
an/DT
aunt/NN
and/CC
her/PRP$
newborn/JJ
daughter/NN
,/,
who/WP
were/VBD
both/DT
also/RB
biochemically/RB
affected/VBN
but/CC
clinically/RB
asymptomatic/JJ
./.
====================
It/PRP
,/,
therefore/RB
,/,
appears/VBZ
that/IN
this/DT
dual/JJ
pattern/NN
of/IN
genetic/JJ
transmission/NN
may/MD
indicate/VB
differing/VBG
genetic/JJ
defects/NNS
which/WDT
cause/VBP
the/DT
same/JJ
clinical/JJ
picture/NN
of/IN
pseudohypoaldosteronism/NN
./.
====================
UI/LS
-/:
90161003/CD
====================
TI/LS
-/:
Perceived/VBN
social/JJ
support/NN
and/CC
tumor/NN
estrogen/progesterone/JJ
receptor/NN
status/NN
as/IN
predictors/NNS
of/IN
natural/JJ
killer/NN
cell/NN
activity/NN
in/IN
breast/NN
cancer/NN
patients/NNS
./.
====================
AB/LS
-/:
This/DT
report/NN
is/VBZ
concerned/VBN
with/IN
the/DT
prediction/NN
of/IN
natural/JJ
killer/NN
(/(
NK/NN
)/)
cell/NN
activity/NN
in/IN
61/CD
Stage/NN
I/CD
and/CC
II/CD
breast/NN
cancer/NN
patients/NNS
,/,
between/IN
the/DT
ages/NNS
of/IN
25/CD
and/CC
70/CD
,/,
who/WP
were/VBD
accrued/VBN
to/TO
this/DT
project/NN
./.
====================
All/DT
baseline/NN
interview/NN
and/CC
testing/NN
data/NNS
were/VBD
obtained/VBN
either/CC
just/RB
before/IN
patients/NNS
were/VBD
discharged/VBN
from/IN
the/DT
hospital/NN
,/,
or/CC
at/IN
their/PRP$
first/JJ
outpatient/JJ
visit/NN
,/,
within/IN
two/CD
weeks/NNS
of/IN
discharge/NN
./.
====================
A/DT
major/JJ
interest/NN
of/IN
this/DT
project/NN
is/VBZ
the/DT
predictive/JJ
value/NN
of/IN
perceived/VBN
social/JJ
support/NN
,/,
as/IN
a/DT
potential/JJ
"/``
stress/NN
"/''
buffer/NN
,/,
related/VBN
to/TO
NK/NN
activity/NN
./.
====================
In/IN
the/DT
main/JJ
model/NN
reported/VBN
here/RB
,/,
we/PRP
found/VBD
that/IN
a/DT
significant/JJ
amount/NN
of/IN
NK/NN
activity/NN
variance/NN
could/MD
be/VB
explained/VBN
by/IN
five/CD
variables/NNS
./.
====================
Higher/JJR
NK/NN
activity/NN
could/MD
be/VB
predicted/VBN
by/IN
the/DT
perception/NN
of/IN
high/JJ
quality/NN
emotional/JJ
support/NN
from/IN
a/DT
spouse/NN
or/CC
intimate/JJ
other/JJ
,/,
perceived/VBN
social/JJ
support/NN
from/IN
the/DT
patient/NN
's/POS
physician/NN
,/,
estrogen/NN
receptor-negative/JJ
tumor/NN
status/NN
,/,
having/VBG
an/DT
excisional/JJ
biopsy/NN
as/IN
surgical/JJ
treatment/NN
,/,
and/CC
actively/RB
seeking/VBG
social/JJ
support/NN
as/IN
a/DT
major/JJ
coping/NN
strategy/NN
(/(
R2/NN
=/JJ
0.33/CD
,/,
F/NN
(/(
5/CD
,/,
55/CD
)/)
=/JJ
5.5/CD
,/,
p/NN
less/JJR
than/IN
0.0004/CD
)/)
./.
====================
Findings/NNS
are/VBP
discussed/VBN
in/IN
terms/NNS
of/IN
host/NN
interaction/NN
with/IN
tumor/NN
endocrine/JJ
status/NN
,/,
and/CC
the/DT
role/NN
that/WDT
social/JJ
support/NN
might/MD
play/VB
in/IN
modulating/VBG
such/JJ
activity/NN
./.
====================
UI/LS
-/:
91215472/CD
====================
TI/LS
-/:
[/(
Estrogen/NN
receptor/NN
content/NN
of/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
in/IN
patients/NNS
with/IN
systemic/JJ
lupus/NN
erythematosus/NN
]/)
====================
AB/LS
-/:
ER/NN
content/NN
in/IN
lymphocytes/NNS
of/IN
peripheral/JJ
blood/NN
from/IN
27/CD
SLE/NN
patients/NNS
and/CC
20/CD
healthy/JJ
controls/NNS
were/VBD
determined/VBN
by/IN
dextran-coated/JJ
charcoal/NN
assay/NN
./.
====================
ER/NN
content/NN
in/IN
lymphocytes/NNS
of/IN
each/DT
sample/NN
was/VBD
expressed/VBN
by/IN
both/CC
fmol/mg/NN
of/IN
lymphocyte/NN
cytosolic/JJ
protein/NN
and/CC
fmol/micrograms/NN
of/IN
lymphocyte/NN
DNA/NN
./.
====================
The/DT
results/NNS
showed/VBD
that/IN
there/EX
was/VBD
no/DT
significant/JJ
difference/NN
between/IN
the/DT
ER/NN
content/NN
of/IN
lymphocytes/NNS
from/IN
the/DT
controls/NNS
and/CC
that/DT
from/IN
patients/NNS
with/IN
SLE/NN
./.
====================
But/CC
the/DT
logarithmic/JJ
mean/NN
of/IN
ER/NN
content/NN
in/IN
lymphocytes/NNS
,/,
expressed/VBN
by/IN
fmol/mg/NN
of/IN
cytosolic/JJ
protein/NN
,/,
in/IN
14/CD
patients/NNS
with/IN
active/JJ
SLE/NN
(/(
0.9356/CD
+/-/CC
0.31/CD
)/)
was/VBD
significantly/RB
higher/JJR
than/IN
that/DT
in/IN
13/CD
patients/NNS
with/IN
inactive/JJ
SLE/NN
(/(
0.2979/CD
+/-/CC
0.23/CD
,/,
P/NN
less/JJR
than/IN
0.001/CD
)/)
and/CC
in/IN
the/DT
controls/NNS
(/(
0.6204/CD
+/-/CC
0.52/CD
,/,
P/NN
less/JJR
than/IN
0.001/CD
)/)
./.
====================
The/DT
normal/JJ
upper/JJ
limit/NN
of/IN
ER/NN
content/NN
in/IN
lymphocytes/NNS
,/,
expressed/VBN
by/IN
fmol/micrograms/NN
of/IN
DNA/NN
,/,
was/VBD
0.136/CD
./.
====================
The/DT
elevated/JJ
rate/NN
of/IN
ER/NN
content/NN
in/IN
lymphocytes/NNS
in/IN
14/CD
active/JJ
SLE/NN
(/(
92.9/CD
%/NN
)/)
was/VBD
also/RB
higher/JJR
than/IN
that/DT
in/IN
quieiescent/JJ
patients/NNS
(/(
23.1/CD
%/NN
,/,
P/NN
less/JJR
than/IN
0.001/CD
)/)
and/CC
in/IN
the/DT
controls/NNS
(/(
10/CD
%/NN
,/,
P/NN
less/JJR
than/IN
0.001/CD
)/)
./.
====================
Moreover/RB
,/,
the/DT
elevated/JJ
level/NN
of/IN
ER/NN
content/NN
was/VBD
found/VBN
to/TO
be/VB
related/JJ
to/TO
the/DT
positive/JJ
antidsDNA/JJ|NN
antibody/NN
and/CC
hypocomplementemia/NN
./.
====================
UI/LS
-/:
91099657/CD
====================
TI/LS
-/:
An/DT
in/FW
vitro/FW
globin/NN
gene/NN
switching/NN
model/NN
based/VBN
on/IN
differentiated/VBN
embryonic/JJ
stem/NN
cells/NNS
./.
====================
AB/LS
-/:
We/PRP
used/VBD
mouse/NN
embryonic/JJ
stem/NN
(/(
ES/NN
)/)
cells/NNS
to/TO
study/VB
globin/NN
gene/NN
expression/NN
and/CC
switching/NN
in/FW
vitro/FW
./.
====================
We/PRP
show/VBP
that/IN
ES-derived/JJ
embryoid/JJ
bodies/NNS
express/VBP
the/DT
full/JJ
complement/NN
of/IN
mouse/NN
embryonic/JJ
globin/NN
genes/NNS
in/IN
the/DT
correct/JJ
temporal/JJ
order/NN
and/CC
that/IN
on/IN
further/JJ
differentiation/NN
,/,
a/DT
switch/NN
occurs/VBZ
to/TO
the/DT
fetal/adult/JJ
genes/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
erythroid-specific/JJ
transcription/NN
factor/NN
NF-E1/NN
was/VBD
shown/VBN
to/TO
be/VB
expressed/VBN
coordinately/RB
with/IN
that/DT
of/IN
globin/NN
in/IN
embryoid/JJ
bodies/NNS
./.
====================
We/PRP
conclude/VBP
from/IN
these/DT
experiments/NNS
that/IN
the/DT
ES/NN
cell/NN
system/NN
provides/VBZ
a/DT
good/JJ
model/NN
to/TO
study/VB
hematopoietic/JJ
development/NN
./.
====================
When/WRB
the/DT
human/JJ
epsilon-/NN
or/CC
beta-globin/NN
genes/NNS
driven/VBN
by/IN
the/DT
dominant/JJ
control/JJ
region/NN
(/(
DCR/NN
)/)
are/VBP
introduced/VBN
into/IN
this/DT
system/NN
,/,
the/DT
human/JJ
epsilon-globin/NN
gene/NN
,/,
in/IN
contrast/NN
to/TO
the/DT
beta-globin/NN
gene/NN
,/,
is/VBZ
not/RB
deregulated/VBN
by/IN
the/DT
presence/NN
of/IN
the/DT
DCR/NN
and/CC
is/VBZ
expressed/VBN
strictly/RB
as/IN
an/DT
embryonic/JJ
gene/NN
./.
====================
We/PRP
conclude/VBP
from/IN
this/DT
that/IN
the/DT
epsilon-globin/NN
gene/NN
is/VBZ
not/RB
regulated/VBN
by/IN
competition/NN
with/IN
other/JJ
genes/NNS
in/IN
the/DT
human/JJ
beta-globin/NN
locus/NN
./.
====================
UI/LS
-/:
91043047/CD
====================
TI/LS
-/:
Cloning/NN
of/IN
a/DT
mitogen-inducible/JJ
gene/NN
encoding/VBG
a/DT
kappa/NN
B/NN
DNA-binding/JJ
protein/NN
with/IN
homology/NN
to/TO
the/DT
rel/NN
oncogene/NN
and/CC
to/TO
cell-cycle/JJ
motifs/NNS
./.
====================
AB/LS
-/:
We/PRP
have/VBP
cloned/VBN
and/CC
characterized/VBN
a/DT
mitogen-inducible/JJ
gene/NN
isolated/VBN
from/IN
human/JJ
T/NN
cells/NNS
that/WDT
predicts/VBZ
a/DT
protein/NN
of/IN
968/CD
amino/NN
acids/NNS
./.
====================
The/DT
amino-terminal/JJ
domain/NN
has/VBZ
regions/NNS
homologous/JJ
to/TO
the/DT
oncogene/NN
rel/NN
and/CC
to/TO
the/DT
developmentally/RB
important/JJ
gene/NN
dorsal/NN
of/IN
Drosophila/FW
./.
====================
The/DT
carboxy-terminal/JJ
domain/NN
contains/VBZ
repeat/NN
structures/NNS
found/VBN
in/IN
a/DT
variety/NN
of/IN
proteins/NNS
that/WDT
are/VBP
involved/VBN
in/IN
cell-cycle/JJ
control/NN
of/IN
yeast/NN
and/CC
in/IN
tissue/NN
differentiation/NN
in/IN
Drosophila/FW
and/CC
Ceanorhabditis/FW
elegans/FW
,/,
as/RB
well/RB
as/IN
in/IN
the/DT
putative/JJ
human/JJ
oncogene/NN
bcl-3/NN
and/CC
in/IN
the/DT
ankyrin/NN
protein/NN
./.
====================
A/DT
truncated/JJ
form/NN
of/IN
the/DT
product/NN
of/IN
this/DT
gene/NN
translated/VBN
in/FW
vitro/FW
is/VBZ
a/DT
DNA-binding/NN
protein/NN
which/WDT
interacts/VBZ
specifically/RB
with/IN
the/DT
kappa/NN
B/NN
binding/NN
site/NN
found/VBN
in/IN
many/JJ
inducible/JJ
genes/NNS
,/,
including/VBG
the/DT
enhancer/NN
in/IN
human/JJ
immunodeficiency/NN
virus/NN
./.
====================
This/DT
gene/NN
is/VBZ
yet/RB
another/DT
in/IN
a/DT
growing/VBG
list/NN
of/IN
important/JJ
regulatory/JJ
molecules/NNS
whose/WP$
expression/NN
is/VBZ
transcriptionally/RB
induced/VBN
upon/IN
cellular/JJ
activation/NN
./.
====================
UI/LS
-/:
91050279/CD
====================
TI/LS
-/:
Extrarenal/JJ
receptor-effector-mechanisms/NNS
for/IN
aldosterone/NN
:/:
the/DT
sequence/NN
of/IN
effects/NNS
on/IN
the/DT
cellular/JJ
electrolyte/NN
transport/NN
in/IN
human/JJ
lymphocytes/NNS
and/CC
their/PRP$
implications/NNS
for/IN
disorders/NNS
of/IN
the/DT
water/NN
and/CC
electrolyte/NN
balances/NNS
./.
====================
AB/LS
-/:
High/JJ
affinity/NN
aldosterone/NN
binding/NN
sites/NNS
have/VBP
not/RB
only/RB
been/VBN
described/VBN
in/IN
the/DT
classic/JJ
target/NN
tissues/NNS
such/JJ
as/IN
the/DT
renal/JJ
tubules/NNS
,/,
but/CC
also/RB
in/IN
non-classic/JJ
target/NN
tissues/NNS
such/JJ
as/IN
the/DT
hippocampus/NN
,/,
mammary/JJ
gland/NN
,/,
endothelial/JJ
cells/NNS
and/CC
,/,
recently/RB
,/,
human/JJ
mononuclear/JJ
leukocytes/NNS
./.
====================
An/DT
in/FW
vitro/FW
effect/NN
of/IN
aldosterone/NN
on/IN
intracellular/JJ
sodium/NN
,/,
potassium/NN
and/CC
calcium/NN
concentrations/NNS
and/CC
cell/NN
volume/NN
was/VBD
shown/VBN
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
./.
====================
In/IN
the/DT
absence/NN
of/IN
aldosterone/NN
,/,
the/DT
intracellular/JJ
Na+/NN
,/,
K+/NN
and/CC
Ca2+/NN
concentrations/NNS
and/CC
the/DT
cell/NN
volume/NN
decreased/VBD
significantly/RB
,/,
but/CC
remained/VBD
constant/JJ
when/WRB
aldosterone/NN
(/(
1.4/CD
nmol/l/NN
)/)
was/VBD
added/VBN
to/TO
the/DT
incubation/NN
medium/NN
./.
====================
These/DT
effects/NNS
of/IN
aldosterone/NN
were/VBD
blocked/VBN
by/IN
the/DT
aldosterone/NN
antagonist/NN
canrenone/NN
(/(
140/CD
nmol/l/NN
)/)
./.
====================
The/DT
sodium/proton/JJ
exchanger/NN
of/IN
the/DT
cell/NN
membrane/NN
could/MD
be/VB
identified/VBN
as/IN
the/DT
primary/JJ
target/NN
of/IN
the/DT
aldosterone/NN
action/NN
,/,
possibly/RB
non-genomically/RB
mediated/VBN
through/IN
membrane/NN
receptors/NNS
./.
====================
The/DT
clinical/JJ
significance/NN
of/IN
this/DT
model/NN
was/VBD
underlined/VBN
by/IN
the/DT
demonstration/NN
of/IN
absent/JJ
or/CC
a/DT
decreased/VBN
number/NN
of/IN
mineralocorticoid/NN
receptors/NNS
and/CC
the/DT
lack/NN
of/IN
electrolyte/NN
response/NN
to/TO
aldosterone/NN
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
of/IN
patients/NNS
with/IN
pseudohypoaldosteronism/NN
and/CC
aldosteronism/NN
./.
====================
Additionally/RB
,/,
an/DT
abnormal/JJ
effector/NN
mechanism/NN
could/MD
be/VB
demonstrated/VBN
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
from/IN
essential/JJ
hypertensives/NNS
./.
====================
These/DT
studies/NNS
are/VBP
the/DT
first/JJ
to/TO
demonstrate/VB
the/DT
significance/NN
of/IN
extrarenal/JJ
,/,
nonepithelial/JJ
mineralocorticoid/NN
receptors/NNS
and/CC
the/DT
related/JJ
effector/NN
mechanism/NN
in/IN
different/JJ
disorders/NNS
of/IN
the/DT
water/NN
and/CC
electrolyte/NN
balance/NN
in/IN
man/NN
./.
====================
UI/LS
-/:
91037456/CD
====================
TI/LS
-/:
Immunohistochemical/JJ
study/NN
of/IN
steroid/NN
hormones/NNS
and/CC
an/DT
estrogen/NN
binding/NN
assay/NN
in/IN
malignant/JJ
soft/JJ
tissue/NN
tumors/NNS
./.
====================
AB/LS
-/:
Immunohistochemically/RB
,/,
the/DT
immunoreaction/NN
against/IN
5/CD
steroid/NN
hormone/NN
anti-sera/NNS
(/(
estradiol/NN
,/,
estriol/NN
,/,
cortisol/NN
,/,
progesterone/NN
and/CC
testosterone/NN
)/)
was/VBD
examined/VBN
in/IN
39/CD
cases/NNS
with/IN
the/DT
malignant/JJ
soft/JJ
tissue/NN
tumors/NNS
(/(
fibrosarcoma/NN
:/:
8/CD
,/,
malignant/JJ
fibrous/JJ
histiocytoma/NN
:/:
6/CD
,/,
rhabdomyosarcoma/NN
:/:
10/CD
,/,
leiomyosarcoma/NN
:/:
10/CD
,/,
liposarcoma/NN
:/:
5/CD
)/)
./.
====================
Seventeen/CD
cases/NNS
revealed/VBD
distinct/JJ
immunostaining/NN
against/IN
at/IN
least/JJS
1/CD
of/IN
the/DT
5/CD
steroid/NN
hormones/NNS
./.
====================
Immunostained/VBN
tumor/NN
cells/NNS
were/VBD
more/RBR
frequently/RB
distributed/VBN
in/IN
the/DT
area/NN
where/WRB
tumor/NN
cell/NN
infiltration/NN
was/VBD
more/RBR
invasive/JJ
./.
====================
The/DT
majority/NN
of/IN
the/DT
positive/JJ
cases/NNS
occurred/VBD
in/IN
female/JJ
cases/NNS
./.
====================
Furthermore/RB
,/,
the/DT
existence/NN
of/IN
estrogen/NN
receptor/NN
(/(
estrogen/NN
binding/NN
activity/NN
)/)
was/VBD
examined/VBN
histochemically/RB
in/IN
39/CD
cases/NNS
and/CC
it/PRP
was/VBD
detected/VBN
in/IN
8/CD
./.
====================
We/PRP
concluded/VBD
that/IN
steroid/NN
hormones/NNS
might/MD
be/VB
closely/RB
related/JJ
to/TO
tumor/NN
cell/NN
infiltration/NN
of/IN
some/DT
malignant/JJ
soft/JJ
tissue/NN
tumors/NNS
./.
====================
UI/LS
-/:
90287178/CD
====================
TI/LS
-/:
Involvement/NN
of/IN
cyclic/JJ
AMP-dependent/JJ
protein/NN
kinases/NNS
in/IN
the/DT
signal/NN
transduction/NN
pathway/NN
for/IN
interleukin-1/NN
./.
====================
AB/LS
-/:
Expression/NN
of/IN
a/DT
highly/RB
specific/JJ
protein/NN
inhibitor/NN
for/IN
cyclic/JJ
AMP-dependent/JJ
protein/NN
kinases/NNS
in/IN
interleukin-1/NN
(/(
IL-1/NN
)/)
-responsive/JJ
cells/NNS
blocked/VBD
IL-1-induced/JJ
gene/NN
transcription/NN
that/WDT
was/VBD
driven/VBN
by/IN
the/DT
kappa/NN
immunoglobulin/NN
enhancer/NN
or/CC
the/DT
human/JJ
immunodeficiency/NN
virus/NN
long/JJ
terminal/JJ
repeat/NN
./.
====================
This/DT
inhibitor/NN
did/VBD
not/RB
affect/VB
protein/NN
kinase/NN
C-mediated/JJ
gene/NN
transcription/NN
,/,
suggesting/VBG
that/IN
cyclic/JJ
AMP-dependent/JJ
protein/NN
kinases/NNS
are/VBP
involved/VBN
in/IN
the/DT
signal/NN
transduction/NN
pathway/NN
for/IN
IL-1/NN
in/IN
a/DT
number/NN
of/IN
responsive/JJ
cell/NN
types/NNS
./.
====================
UI/LS
-/:
90244395/CD
====================
TI/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
ORI1yt/NN
enhancer/NN
is/VBZ
not/RB
B-cell/NN
specific/JJ
and/CC
does/VBZ
not/RB
respond/VB
synergistically/RB
to/TO
the/DT
EBV/NN
transcription/NN
factors/NNS
R/NN
and/CC
Z/NN
./.
====================
AB/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
DR/NN
promoter/NN
is/VBZ
located/JJ
upstream/RB
of/IN
the/DT
PstI/NN
repeats/NNS
,/,
and/CC
in/IN
addition/NN
to/TO
the/DT
TATA/NN
box/NN
,/,
it/PRP
contains/VBZ
an/DT
upstream/JJ
region/NN
(/(
positions/NNS
-69/CD
to/TO
-220/CD
)/)
responsive/JJ
to/TO
EB1/NN
(Z)/NN
(/(
the/DT
BZLF1-encoded/JJ
transcription/NN
factor/NN
)/)
and/CC
an/DT
enhancer/NN
with/IN
two/CD
functionally/RB
distinct/JJ
domains/NNS
,/,
A/NN
and/CC
B/NN
./.
====================
Domain/NN
B/NN
has/VBZ
been/VBN
described/VBN
as/IN
a/DT
B-cell-specific/JJ
EB1-responsive/JJ
element/NN
(/(
P.M.Lieberman/NNP
,/,
J.M.Hardwick/NNP
,/,
and/CC
S.D.Hayward/NNP
,/,
J.Virol.63/NNP
:/:
3040-3050/CD
,/,
1989/CD
)/)
activated/VBN
synergistically/RB
by/IN
EB1/NN
and/CC
R/NN
,/,
an/DT
EBV/NN
early/JJ
product/NN
encoded/VBN
by/IN
the/DT
open/JJ
reading/NN
frame/NN
BRLF1/NN
(/(
M.A./NNP
Cox/NNP
,/,
J.Leahy/NNP
,/,
and/CC
J.M.Hardwick/NNP
,/,
J.Virol.64/NNP
:/:
313-321/CD
,/,
1990/CD
)/)
./.
====================
We/PRP
show/VBP
here/RB
that/IN
domain/NN
B/NN
is/VBZ
an/DT
R-responsive/JJ
element/NN
in/IN
HeLa/NN
cells/NNS
and/CC
is/VBZ
therefore/RB
not/RB
an/DT
EB1-responsive/JJ
B-cell-specific/JJ
element/NN
./.
====================
However/RB
,/,
there/EX
is/VBZ
an/DT
EB1-binding/JJ
site/NN
(/(
ZRE-B/NN
)/)
located/JJ
within/IN
the/DT
R-responsive/JJ
enhancer/NN
region/NN
./.
====================
ZRE-B/NN
can/MD
be/VB
deleted/VBN
without/IN
affecting/VBG
the/DT
R-dependent/JJ
enhancer/NN
activity/NN
./.
====================
Moreover/RB
,/,
there/EX
is/VBZ
no/DT
cooperation/NN
or/CC
synergy/NN
between/IN
R/NN
and/CC
EB1/NN
when/WRB
activating/VBG
the/DT
B/NN
domain/NN
(/(
ZRE-B/NN
plus/CC
the/DT
R-responsive/JJ
element/NN
)/)
positioned/JJ
as/IN
an/DT
enhancer/NN
./.
====================
ZRE-B/NN
is/VBZ
therefore/RB
not/RB
part/NN
of/IN
the/DT
R- inducible/JJ
enhancer/NN
./.
====================
We/PRP
have/VBP
tested/VBN
several/JJ
subregions/NNS
of/IN
the/DT
DR/NN
enhancer/NN
B/NN
domain/NN
,/,
either/CC
alone/RB
or/CC
in/IN
combination/NN
,/,
for/IN
their/PRP$
capacity/NN
to/TO
transmit/VB
the/DT
R-activating/JJ
signal/NN
to/TO
the/DT
rabbit/NN
beta-globin/NN
promoter/NN
./.
====================
We/PRP
found/VBD
that/IN
the/DT
R-responsive/JJ
element/NN
is/VBZ
composed/VBN
of/IN
four/CD
protoenhancers/NNS
that/WDT
span/VBP
the/DT
whole/JJ
B/NN
domain/NN
./.
====================
These/DT
protoenhancers/NNS
alone/RB
are/VBP
weakly/JJ
or/CC
not/RB
responsive/JJ
to/TO
R/NN
./.
====================
One/CD
of/IN
the/DT
protoenhancers/NNS
contains/VBZ
the/DT
overlapping/VBG
palindromes/NNS
5'-TTGTCCcgtGGACAAaTGTCC-3'/NN
./.
====================
However/RB
,/,
one/CD
palindrome/NN
,/,
either/CC
alone/RB
or/CC
duplicated/JJ
,/,
or/CC
the/DT
overlapping/VBG
palindromes/NNS
did/VBD
not/RB
respond/VB
to/TO
R/NN
./.
====================
UI/LS
-/:
90360678/CD
====================
TI/LS
-/:
Nuclear/JJ
3,5,3'-triiodothyronine/NN
receptors/NNS
(/(
T3R/NNS
)/)
of/IN
circulating/VBG
human/JJ
lymphocytes/NNS
in/IN
hyper-/JJ
and/CC
hypothyroidism/NN
and/CC
nonthyroidal/JJ
diseases/NNS
./.
====================
AB/LS
-/:
The/DT
clinical/JJ
implications/NNS
of/IN
nuclear/JJ
T3R/NN
alterations/NNS
of/IN
circulating/VBG
lymphocytes/NNS
in/IN
hyperthyroidism/NN
,/,
hypothyroidism/NN
and/CC
nonthyroidal/JJ
diseases/NNS
were/VBD
investigated/VBN
./.
====================
Nuclear/JJ
T3R/NN
in/IN
lymphocytes/NNS
was/VBD
determined/VBN
by/IN
radio-ligand/JJ
binding/NN
analysis/NN
./.
====================
The/DT
results/NNS
showed/VBD
that/IN
in/IN
hyper-/JJ
and/CC
hypothyroid/JJ
patients/NNS
the/DT
nuclear/JJ
affinity/NN
(/(
Ka/NN
)/)
for/IN
T3/NN
was/VBD
similar/JJ
to/TO
that/DT
of/IN
normal/JJ
subjects/NNS
./.
====================
In/IN
hyperthyroidism/NN
nuclear/JJ
T3/NN
maximal/JJ
binding/NN
capacity/NN
(/(
MBC/NN
)/)
was/VBD
unaltered/JJ
,/,
whereas/IN
in/IN
hypothyroidism/NN
the/DT
MBC/NN
was/VBD
significantly/RB
increased/VBN
./.
====================
In/IN
the/DT
patients/NNS
with/IN
diabetes/NN
mellitus/NN
,/,
chronic/JJ
renal/JJ
failure/NN
and/CC
hepatic/JJ
cirrhosis/NN
,/,
the/DT
nuclear/JJ
T3R/NN
MBC/NN
of/IN
lymphocytes/NNS
was/VBD
about/RB
1.5-1.6/CD
times/NNS
of/IN
the/DT
normal/JJ
controls/NNS
./.
====================
It/PRP
was/VBD
concluded/VBN
that/IN
there/EX
existed/VBD
hormonal/JJ
regulation/NN
of/IN
nuclear/JJ
T3R/NN
,/,
and/CC
up-regulation/NN
was/VBD
seen/VBN
in/IN
hypothyroidism/NN
and/CC
low/JJ
T3/NN
syndrome/NN
./.
====================
UI/LS
-/:
90255794/CD
====================
TI/LS
-/:
Lymphocyte/NN
cell/NN
lines/NNS
from/IN
vitamin/NN
D-dependent/JJ
rickets/NN
type/NN
II/CD
show/VBP
functional/JJ
defects/NNS
in/IN
the/DT
1/CD
alpha,25-dihydroxyvitamin/NN
D3/NN
receptor/NN
./.
====================
AB/LS
-/:
Lymphocyte/NN
cell/NN
lines/NNS
were/VBD
established/VBN
from/IN
five/CD
patients/NNS
with/IN
vitamin/NN
D-dependent/JJ
rickets/NN
,/,
type/NN
II/CD
(/(
VDDR-II/NN
)/)
./.
====================
These/DT
lines/NNS
were/VBD
established/VBN
by/IN
infection/NN
with/IN
human/JJ
T-lymphotrophic/JJ
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
./.
====================
Binding/NN
of/IN
[3H]1/NN
alpha,25-dihydroxyvitamin/NN
D3/NN
(/(
1,25(OH)2D3/NN
)/)
to/TO
its/PRP$
receptor/NN
in/IN
these/DT
cell/NN
lines/NNS
was/VBD
compared/VBN
to/TO
binding/NN
studies/NNS
using/VBG
a/DT
T-lymphocyte/NN
cell/NN
line/NN
(/(
S-LB1/NN
)/)
from/IN
a/DT
normal/JJ
individual/NN
./.
====================
The/DT
1,25(OH)2D3/NN
receptor/NN
of/IN
S-LB1/NN
was/VBD
comparable/JJ
to/TO
the/DT
well-characterized/JJ
chick/NN
intestinal/JJ
1,25(OH)2D3/NN
receptor/NN
in/IN
terms/NNS
of/IN
its/PRP$
ligand/NN
binding/NN
affinity/NN
and/CC
capacity/NN
,/,
its/PRP$
mobility/NN
on/IN
5-20/CD
%/NN
sucrose/NN
gradients/NNS
,/,
and/CC
its/PRP$
adsorption/NN
to/TO
and/CC
elution/NN
properties/NNS
from/IN
DNA-cellulose/NN
./.
====================
Three/CD
cell/NN
lines/NNS
established/VBN
from/IN
patients/NNS
with/IN
VDDR-II/NN
(/(
Rh-VDR/NN
,/,
Sh-VDR/NN
,/,
and/CC
Ab-VDR/NN
)/)
showed/VBD
no/DT
specific/JJ
binding/NN
of/IN
1,25(OH)2D3/NN
to/TO
a/DT
receptor/NN
and/CC
treatment/NN
of/IN
the/DT
cultured/VBN
cells/NNS
with/IN
1,25(OH)2D3/NN
did/VBD
not/RB
stimulate/VB
production/NN
of/IN
24,25-dihydroxy-vitamin/NN
D3/NN
(/(
24,25(OH)2D3/NN
)/)
,/,
a/DT
response/NN
which/WDT
is/VBZ
diagnostic/JJ
of/IN
the/DT
presence/NN
of/IN
a/DT
functional/JJ
1,25(OH)2D3/NN
receptor/NN
./.
====================
In/IN
a/DT
fourth/JJ
cell/NN
line/NN
,/,
A1-VDR/NN
,/,
the/DT
receptor/NN
for/IN
1,25(OH)2D3/NN
had/VBD
a/DT
low/JJ
binding/NN
capacity/NN
and/CC
25(OH)D3-24-hydroxylase/NN
activity/NN
was/VBD
not/RB
detectable/JJ
./.
====================
Induction/NN
of/IN
24,25-(OH)2D3/NN
synthesis/NN
by/IN
1,25(OH)2D3/NN
was/VBD
observed/VBN
in/IN
the/DT
fifth/JJ
cell/NN
line/NN
,/,
designated/VBN
Ro-VDR/NN
,/,
although/IN
the/DT
sensitivity/NN
to/TO
hormone/NN
treatment/NN
was/VBD
lower/JJR
than/IN
in/IN
the/DT
control/JJ
cell/NN
line/NN
from/IN
a/DT
normal/JJ
donor/NN
./.
====================
The/DT
capacity/NN
of/IN
the/DT
receptor/NN
for/IN
1,25(OH)2D3/NN
was/VBD
low/JJ
in/IN
Ro-VDR/NN
./.
====================
In/IN
all/DT
cell/NN
lines/NNS
where/WRB
1,25(OH)2D3/NN
binding/NN
to/TO
a/DT
receptor/NN
was/VBD
detectable/JJ
,/,
the/DT
receptor/NN
had/VBD
the/DT
typical/JJ
sedimentation/NN
coefficient/NN
of/IN
3.7/CD
S/NN
on/IN
sucrose/NN
density/NN
gradient/NN
analysis/NN
./.
====================
Binding/NN
and/CC
elution/NN
properties/NNS
to/TO
DNA-cellulose/NN
,/,
however/RB
,/,
differed/VBD
from/IN
normal/JJ
in/IN
both/CC
Ro-VDR/NN
and/CC
A1-VDR/NN
cells/NNS
where/WRB
elution/NN
from/IN
DNA-cellulose/NN
occurred/VBD
at/IN
a/DT
lower/JJR
salt/NN
concentration/NN
than/IN
is/VBZ
typical/JJ
of/IN
the/DT
1,25(OH)2D3/NN
receptor/NN
./.
====================
While/IN
Ro-VDR/NN
cells/NNS
showed/VBD
typical/JJ
nuclear/JJ
localization/NN
of/IN
the/DT
unoccupied/JJ
1,25(OH)2D3/NN
receptor/NN
,/,
neither/CC
the/DT
unoccupied/JJ
nor/CC
the/DT
occupied/JJ
receptor/NN
from/IN
A1-VDR/NN
cells/NNS
was/VBD
completely/RB
localized/JJ
in/IN
the/DT
nucleus/NN
./.
====================
In/IN
a/DT
series/NN
of/IN
functional/JJ
studies/NNS
we/PRP
found/VBD
that/IN
modulation/NN
of/IN
the/DT
level/NN
of/IN
the/DT
mRNAs/NNS
coding/VBG
for/IN
both/CC
the/DT
c-myc/NN
oncogene/NN
and/CC
the/DT
growth/NN
factor/NN
known/VBN
as/IN
granulocyte-monocyte/JJ
colony/NN
stimulating/NN
activity/NN
by/IN
1,25(OH)2D3/NN
correlated/VBD
with/IN
the/DT
1,25(OH)2D3/NN
receptor/NN
status/NN
of/IN
these/DT
cells/NNS
./.
====================
Use/NN
of/IN
these/DT
cell/NN
lines/NNS
will/MD
facilitate/VB
further/JJ
study/NN
of/IN
the/DT
molecular/JJ
defect/NN
(/(
s/NNS
)/)
in/IN
the/DT
receptor/NN
for/IN
1,25(OH)2D3/NN
in/IN
vitamin/NN
D-dependent/JJ
rickets/NN
type/NN
II/CD
and/CC
will/MD
allow/VB
a/DT
correlation/NN
with/IN
impairment/NN
of/IN
cellular/JJ
functions/NNS
./.
====================
UI/LS
-/:
90153985/CD
====================
TI/LS
-/:
Transcriptional/JJ
and/CC
post-transcriptional/JJ
regulation/NN
of/IN
c-jun/NN
expression/NN
during/IN
monocytic/JJ
differentiation/NN
of/IN
human/JJ
myeloid/JJ
leukemic/JJ
cells/NNS
./.
====================
AB/LS
-/:
AP-1/NN
,/,
the/DT
polypeptide/NN
product/NN
of/IN
c-jun/NN
,/,
recognizes/VBZ
and/CC
binds/VBZ
to/TO
specific/JJ
DNA/NN
sequences/NNS
and/CC
stimulates/VBZ
transcription/NN
of/IN
genes/NNS
responsive/JJ
to/TO
certain/JJ
growth/NN
factors/NNS
and/CC
phorbol/NN
esters/NNS
such/JJ
as/IN
12-O-tetradecanoylphorbol-13-acetate/NN
(/(
TPA/NN
)/)
./.
====================
We/PRP
studied/VBD
the/DT
effects/NNS
of/IN
TPA/NN
on/IN
the/DT
regulation/NN
of/IN
c-jun/NN
gene/NN
expression/NN
in/IN
HL-60/NN
cells/NNS
during/IN
monocytic/JJ
differentiation/NN
./.
====================
Low/JJ
levels/NNS
of/IN
c-jun/NN
transcripts/NNS
were/VBD
detectable/JJ
in/IN
untreated/JJ
HL-60/NN
leukemic/JJ
cells/NNS
,/,
increased/VBD
significantly/RB
by/IN
6/CD
h/NN
,/,
and/CC
reached/VBD
near/IN
maximal/JJ
levels/NNS
by/IN
24/CD
h/NN
of/IN
exposure/NN
to/TO
32/CD
nM/NN
TPA/NN
./.
====================
Similar/JJ
kinetics/NNS
of/IN
c-jun/NN
induction/NN
by/IN
TPA/NN
were/VBD
observed/VBN
in/IN
human/JJ
U-937/NN
and/CC
THP-1/NN
monocytic/JJ
leukemia/NN
cells/NNS
./.
====================
Similar/JJ
findings/NNS
were/VBD
obtained/VBN
with/IN
bryostatin/NN
1/CD
(/(
10/CD
nM/NN
)/)
,/,
another/DT
activator/NN
of/IN
protein/NN
kinase/NN
C/NN
and/CC
inducer/NN
of/IN
monocytic/JJ
differentiation/NN
./.
====================
Furthermore/RB
,/,
1,25-dihydroxyvitamin/NN
D3/NN
(/(
0.5/CD
microM/NN
)/)
,/,
a/DT
structurally/RB
distinct/JJ
agent/NN
which/WDT
also/RB
induces/VBZ
HL-60/NN
monocytic/JJ
differentiation/NN
,/,
increased/VBD
c-jun/NN
expression/NN
./.
====================
TPA/NN
treatment/NN
of/IN
HL-60/NN
cells/NNS
in/IN
the/DT
presence/NN
of/IN
cycloheximide/NN
was/VBD
associated/VBN
with/IN
superinduction/NN
of/IN
c-jun/NN
transcripts/NNS
./.
====================
Run-on/JJ
analysis/NN
demonstrated/VBD
detectable/JJ
levels/NNS
of/IN
c-jun/NN
gene/NN
transcription/NN
in/IN
untreated/JJ
HL-60/NN
cells/NNS
,/,
and/CC
that/IN
exposure/NN
to/TO
TPA/NN
increases/VBZ
this/DT
rate/NN
3.3-fold/RB
./.
====================
Treatment/NN
of/IN
HL-60/NN
cells/NNS
with/IN
both/CC
TPA/NN
and/CC
cycloheximide/NN
had/VBD
no/DT
effect/NN
on/IN
the/DT
rates/NNS
of/IN
c-jun/NN
transcription/NN
./.
====================
The/DT
half-life/NN
of/IN
c-jun/NN
RNA/NN
as/IN
determined/VBN
by/IN
treating/VBG
HL-60/NN
cells/NNS
with/IN
TPA/NN
and/CC
actinomycin/NN
D/NN
was/VBD
30/CD
min/NN
./.
====================
In/IN
contrast/NN
,/,
the/DT
half-life/NN
of/IN
c-jun/NN
RNA/NN
in/NN
TPA-treated/JJ
HL-60/NN
cells/NNS
exposed/VBN
to/TO
cycloheximide/NN
and/CC
actinomycin/NN
D/NN
was/VBD
greater/JJR
than/IN
2/CD
h/NN
./.
====================
These/DT
findings/NNS
suggested/VBD
that/IN
the/DT
increase/NN
in/IN
c-jun/NN
RNA/NN
observed/VBN
during/IN
TPA-induced/JJ
monocytic/JJ
differentiation/NN
is/VBZ
mediated/VBN
by/IN
both/CC
transcriptional/JJ
and/CC
post-transcriptional/JJ
mechanisms/NNS
./.
====================
UI/LS
-/:
92213636/CD
====================
TI/LS
-/:
[/(
Hormonal/JJ
interactions/NNS
and/CC
glucocorticoid/NN
receptors/NNS
in/IN
patients/NNS
with/IN
the/DT
nephrotic/JJ
syndrome/NN
]/)
====================
AB/LS
-/:
As/RB
many/JJ
as/IN
27/CD
children/NNS
aged/JJ
6/CD
to/TO
15/CD
years/NNS
with/IN
morphologically/RB
verified/VBN
nephropathies/NNS
were/VBD
examined/VBN
./.
====================
Four/CD
variants/NNS
of/IN
changes/NNS
in/IN
the/DT
thyroid/NN
status/NN
,/,
characteristic/JJ
of/IN
children/NNS
with/IN
different/JJ
variants/NNS
of/IN
nephrotic/JJ
syndrome/NN
were/VBD
distinguished/VBN
:/:
1/LS
)/)
biochemical/JJ
signs/NNS
of/IN
primary/JJ
hypothyroidism/NN
,/,
2/LS
)/)
biochemical/JJ
signs/NNS
of/IN
secondary/JJ
hypothyroidism/NN
,/,
3/LS
)/)
low/JJ
content/NN
of/IN
T3/NN
,/,
4/LS
)/)
dysfunction/NN
of/IN
the/DT
hypophyseal/NN
and/CC
thyroid/NN
system/NN
./.
====================
It/PRP
is/VBZ
shown/VBN
that/IN
the/DT
low/JJ
level/NN
of/IN
steroid/NN
receptors/NNS
,/,
thyroid/NN
hormones/NNS
that/IN
the/DT
low/JJ
level/NN
of/IN
steroid/NN
receptors/NNS
,/,
thyroid/NN
hormones/NNS
(/(
T3/NN
and/CC
T4/NN
)/)
and/CC
cortisol/NN
is/VBZ
typical/JJ
of/IN
children/NNS
with/IN
the/DT
signs/NNS
of/IN
renal/JJ
dysplasia/NN
./.
====================
It/PRP
is/VBZ
assumed/VBN
that/IN
superaddition/NN
under/IN
such/JJ
conditions/NNS
of/IN
immune/JJ
glomerulopathy/NN
(/(
glomerulonephritis/NN
and/CC
nephrotic/JJ
syndrome/NN
)/)
gives/VBZ
rise/NN
to/TO
the/DT
resistance/NN
to/TO
the/DT
treatment/NN
with/IN
glucocorticoids/NNS
./.
====================
UI/LS
-/:
91092268/CD
====================
TI/LS
-/:
Lymphoid/JJ
specific/JJ
gene/NN
expression/NN
of/IN
the/DT
adenovirus/NN
early/JJ
region/NN
3/CD
promoter/NN
is/VBZ
mediated/VBN
by/IN
NF-kappa/NN
B/NN
binding/NN
motifs/NNS
./.
====================
AB/LS
-/:
A/DT
primary/JJ
site/NN
of/IN
infection/NN
by/IN
human/JJ
adenoviruses/NNS
is/VBZ
lymphoid/JJ
cells/NNS
./.
====================
However/RB
,/,
analysis/NN
of/IN
the/DT
viral/JJ
control/NN
elements/NNS
and/CC
the/DT
cellular/JJ
factors/NNS
that/WDT
regulate/VBP
adenoviral/JJ
gene/NN
expression/NN
in/IN
lymphocytes/NNS
has/VBZ
not/RB
been/VBN
reported/VBN
./.
====================
The/DT
adenovirus/NN
early/JJ
region/NN
3/CD
(/(
ES/NN
)/)
gene/NN
products/NNS
are/VBP
involved/VBN
in/IN
the/DT
maintenance/NN
of/IN
viral/JJ
persistence/NN
by/IN
complexing/VBG
with/IN
the/DT
class/NN
I/CD
MHC/NN
antigens/NNS
,/,
thus/RB
preventing/VBG
their/PRP$
cell/NN
surface/NN
expression/NN
with/IN
a/DT
resultant/JJ
decrease/NN
in/IN
host/NN
immunologic/JJ
destruction/NN
./.
====================
To/TO
determine/VB
whether/IN
different/JJ
cellular/JJ
factors/NNS
were/VBD
involved/VBN
in/IN
E3/NN
regulation/NN
in/IN
lymphocytes/NNS
as/IN
compared/VBN
with/IN
HeLa/NN
cells/NNS
,/,
both/CC
DNA/NN
binding/NN
and/CC
transfection/NN
analysis/NN
with/IN
the/DT
E3/NN
promoter/NN
in/IN
both/DT
cell/NN
types/NNS
were/VBD
performed/VBN
./.
====================
These/DT
studies/NNS
detected/VBD
two/CD
novel/JJ
domains/NNS
referred/VBN
to/TO
as/RB
L1/NN
and/CC
L2/NN
with/IN
a/DT
variety/NN
of/IN
lymphoid/JJ
but/CC
not/RB
HeLa/NN
extracts/NNS
./.
====================
Each/DT
of/IN
these/DT
domains/NNS
possessed/VBD
strong/JJ
homology/NN
to/TO
motifs/NNS
previously/RB
found/VBN
to/TO
bind/VB
the/DT
cellular/JJ
factor/NN
NF-kappa/NN
B/NN
./.
====================
Transfections/NNS
of/IN
E3/NN
constructs/NNS
linked/VBN
to/TO
the/DT
chloramphenicol/NN
acetyltransferase/NN
gene/NN
revealed/VBD
that/IN
mutagenesis/NN
of/IN
the/DT
distal/JJ
NF-kappa/NN
B/NN
motif/NN
(/(
L2/NN
)/)
had/VBD
minimal/JJ
effects/NNS
on/IN
promoter/NN
expression/NN
in/IN
HeLa/NN
cells/NNS
,/,
but/CC
resulted/VBD
in/IN
dramatic/JJ
decreases/NNS
in/IN
expression/NN
by/IN
lymphoid/JJ
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
mutagenesis/NN
of/IN
proximal/JJ
NF-kappa/NN
B/NN
motif/NN
(/(
L1/NN
)/)
had/VBD
minimal/JJ
effects/NNS
on/IN
gene/NN
expression/NN
in/IN
both/CC
HeLa/NN
cells/NNS
and/CC
lymphoid/JJ
cells/NNS
but/CC
resulted/VBD
in/IN
a/DT
small/JJ
,/,
but/CC
reproducible/JJ
,/,
increase/NN
in/IN
gene/NN
expression/NN
in/IN
lymphoid/JJ
cells/NNS
when/WRB
coupled/VBN
to/TO
the/DT
L2/NN
mutation/NN
./.
====================
Reversing/VBG
the/DT
position/NN
and/CC
subsequent/JJ
mutagenesis/NN
of/IN
the/DT
L1/NN
and/CC
L2/NN
domains/NNS
indicated/VBD
that/IN
the/DT
primary/JJ
sequence/NN
of/IN
these/DT
motifs/NNS
rather/RB
than/IN
their/PRP$
position/NN
in/IN
the/DT
E3/NN
promoter/NN
was/VBD
critical/JJ
for/IN
regulating/VBG
gene/NN
expression/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
91034184/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
defensin/NN
resistance/NN
phenotypes/NNS
associated/VBN
with/IN
mutations/NNS
in/IN
the/DT
phoP/NN
virulence/NN
regulon/NN
of/IN
Salmonella/FW
typhimurium/FW
./.
====================
AB/LS
-/:
The/DT
defensin/NN
sensitivities/NNS
of/IN
Salmonella/FW
typhimurium/FW
strains/NNS
with/IN
mutations/NNS
in/IN
the/DT
phoP/phoQ/NN
two-component/JJ
virulence/NN
regulon/NN
were/VBD
tested/VBN
by/IN
using/VBG
purified/VBN
defensins/NNS
NP-1/NN
and/CC
NP-2/NN
./.
====================
Strains/NNS
with/IN
mutations/NNS
in/IN
either/DT
gene/NN
of/IN
the/DT
regulatory/JJ
pair/NN
(/(
phoP/NN
[/(
transcriptional/JJ
activator/NN
]/)
or/CC
phoQ/JJ
[/(
membrane/NN
sensor/NN
kinase/NN
]/)
)/)
had/VBD
increased/VBN
sensitivities/NNS
to/TO
defensin/NN
./.
====================
The/DT
predicted/VBN
periplasmic/JJ
domain/NN
of/IN
the/DT
PhoQ/NN
protein/NN
contained/VBD
a/DT
markedly/RB
anionic/JJ
domain/NN
that/WDT
could/MD
interact/VB
with/IN
cationic/JJ
proteins/NNS
and/CC
that/WDT
could/MD
be/VB
responsible/JJ
for/IN
resistance/NN
to/TO
defensin/NN
./.
====================
Because/IN
insertion/NN
mutations/NNS
in/IN
phoP/NN
are/VBP
polar/JJ
on/IN
phoQ/NN
,/,
we/PRP
constructed/VBD
strains/NNS
that/WDT
expressed/VBD
the/DT
PhoQ/NN
protein/NN
in/IN
the/DT
absence/NN
of/IN
PhoP/NN
to/TO
test/VB
whether/IN
resistance/NN
to/TO
defensin/NN
requires/VBZ
only/RB
the/DT
phoQ/NN
gene/NN
product/NN
./.
====================
We/PRP
found/VBD
that/IN
resistance/NN
to/TO
defensin/NN
requires/VBZ
the/DT
function/NN
of/IN
both/DT
components/NNS
of/IN
this/DT
regulatory/JJ
system/NN
,/,
because/IN
strains/NNS
expressing/VBG
PhoQ/NN
without/IN
PhoP/NN
were/VBD
still/RB
markedly/RB
sensitive/JJ
to/TO
defensins/NNS
./.
====================
This/DT
implied/VBD
that/IN
a/DT
pag/NN
(/(
phoP-activated/JJ
gene/NN
)/)
product/NN
is/VBZ
responsible/JJ
for/IN
defensin/NN
resistance/NN
./.
====================
We/PRP
also/RB
tested/VBD
for/IN
the/DT
ability/NN
of/IN
defensins/NNS
NP-1/NN
,/,
NP-5/NN
,/,
and/CC
HNP-1/NNP
to/TO
activate/VB
pag/NN
expression/NN
and/CC
found/VBD
that/IN
these/DT
peptides/NNS
have/VBP
no/DT
effect/NN
./.
====================
Defensin/NN
resistance/NN
is/VBZ
not/RB
the/DT
only/JJ
virulence/NN
characteristic/NN
controlled/VBN
by/IN
the/DT
PhoP-PhoQ/JJ
regulon/NN
because/IN
mutations/NNS
in/IN
pagC/NN
,/,
as/RB
well/RB
as/IN
ones/NNS
in/IN
the/DT
phoP/NN
locus/NN
that/WDT
resulted/VBD
in/IN
constitutive/JJ
pag/NN
activation/NN
(/(
phenotype/NN
PhoPc/NN
)/)
,/,
had/VBD
no/DT
effect/NN
on/IN
defensin/NN
resistance/NN
,/,
even/RB
though/IN
they/PRP
rendered/VBD
the/DT
organism/NN
avirulent/JJ
and/CC
deficient/JJ
in/IN
survival/NN
within/IN
macrophages/NNS
./.
====================
The/DT
virulence/NN
defect/NN
conferred/VBN
by/IN
mutations/NNS
in/IN
the/DT
phoP-phoQ/JJ
two-component/NN
regulatory/JJ
system/NN
is/VBZ
not/RB
completely/RB
explained/VBN
by/IN
alterations/NNS
in/IN
resistance/NN
to/TO
cationic/JJ
proteins/NNS
and/CC
involves/VBZ
the/DT
control/NN
of/IN
other/JJ
proteins/NNS
necessary/JJ
for/IN
S./FW
typhimurium/FW
survival/NN
within/IN
macrophages/NNS
./.
====================
UI/LS
-/:
91045897/CD
====================
TI/LS
-/:
Stimulation/NN
of/IN
a/DT
human/JJ
T-cell/NN
clone/NN
with/IN
anti-CD3/JJ
or/CC
tumor/NN
necrosis/NN
factor/NN
induces/VBZ
NF-kappa/NN
B/NN
translocation/NN
but/CC
not/RB
human/JJ
immunodeficiency/NN
virus/NN
1/CD
enhancer-dependent/JJ
transcription/NN
./.
====================
AB/LS
-/:
The/DT
expression/NN
of/IN
transiently/RB
transfected/VBN
expression/NN
vectors/NNS
under/IN
the/DT
control/NN
of/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
or/CC
its/PRP$
enhancer/NN
sequence/NN
and/CC
the/DT
translocation/NN
of/IN
the/DT
HIV/NN
enhancer-binding/JJ
protein/NN
NF-kappa/NN
B/NN
were/VBD
analyzed/VBN
in/IN
two/CD
human/JJ
T-cell/NN
clones/NNS
stimulated/VBN
through/IN
their/PRP$
T-cell/NN
receptor/NN
complex/NN
or/CC
by/IN
tumor/NN
necrosis/NN
factor/NN
or/CC
phorbol/NN
12-myristate/NN
13-acetate/NN
./.
====================
We/PRP
found/VBD
a/DT
dissociation/NN
of/IN
NF-kappa/NN
B/NN
translocation/NN
from/IN
transactivation/NN
of/IN
either/CC
the/DT
HIV/NN
LTR/NN
or/CC
the/DT
HIV/NN
enhancer/NN
./.
====================
Interleukin/NN
2/CD
induced/VBD
proliferation/NN
but/CC
not/RB
NF-kappa/NN
B/NN
translocation/NN
or/CC
LTR/NN
transactivation/NN
./.
====================
Phorbol/NN
ester/NN
or/CC
specific/JJ
antigen/NN
recognition/NN
induced/VBD
HIV/NN
LTR/NN
transactivation/NN
,/,
whereas/IN
stimulation/NN
with/IN
tumor/NN
necrosis/NN
factor/NN
or/CC
antibody/NN
to/TO
CD3/NN
did/VBD
not/RB
./.
====================
The/DT
two/CD
latter/JJ
signals/NNS
were/VBD
nevertheless/RB
able/JJ
to/TO
induce/VB
NF-kappa/NN
B/NN
translocation/NN
with/IN
a/DT
pattern/NN
in/IN
the/DT
band-shift/JJ
assay/NN
indistinguishable/JJ
from/IN
that/DT
observed/VBN
using/VBG
phorbol/NN
ester/NN
./.
====================
Our/PRP$
finding/NN
that/IN
induction/NN
of/IN
NF-kappa/NN
B/NN
by/IN
tumor/NN
necrosis/NN
factor/NN
or/CC
antibody/NN
to/TO
CD3/NN
is/VBZ
not/RB
sufficient/JJ
to/TO
induce/VB
HIV/NN
enhancer-dependent/JJ
transcription/NN
in/IN
cloned/VBN
T/NN
cells/NNS
contrasts/VBZ
with/IN
results/NNS
obtained/VBN
in/IN
most/JJS
lymphoblastoid/JJ
T-cell/NN
lines/NNS
and/CC
indicates/VBZ
that/IN
normal/JJ
T/NN
lymphocytes/NNS
differ/VBP
from/IN
tumoral/JJ
T/NN
cells/NNS
in/IN
terms/NNS
of/IN
requirements/NNS
for/IN
HIV/NN
LTR/NN
activation/NN
./.
====================
Furthermore/RB
,/,
our/PRP$
results/NNS
suggest/VBP
that/IN
events/NNS
linked/VBN
to/TO
T-cell/NN
activation/NN
,/,
in/IN
addition/NN
to/TO
NF-kappa/NN
B/NN
translocation/NN
per/FW
se/FW
,/,
induce/VBP
functional/JJ
interactions/NNS
of/IN
the/DT
NF-kappa/NN
B/NN
complex/NN
with/IN
the/DT
HIV/NN
enhancer/NN
./.
====================
UI/LS
-/:
91028334/CD
====================
TI/LS
-/:
Decreased/VBN
concentration/NN
of/IN
1,25-dihydroxyvitamin/NN
D3/NN
receptors/NNS
in/IN
peripheral/JJ
mononuclear/JJ
cells/NNS
of/IN
patients/NNS
with/IN
X-linked/JJ
hypophosphatemic/JJ
rickets/NN
:/:
effect/NN
of/IN
phosphate/NN
supplementation/NN
./.
====================
AB/LS
-/:
Abnormal/JJ
renal/JJ
tubular/JJ
phosphate/NN
transport/NN
is/VBZ
considered/VBN
to/TO
be/VB
the/DT
primary/JJ
defect/NN
in/IN
X-linked/JJ
hypophosphatemic/JJ
rickets/NN
(/(
XLH/NN
)/)
./.
====================
However/RB
,/,
the/DT
resistance/NN
to/TO
vitamin/NN
D/NN
treatment/NN
in/IN
XLH/NN
can/MD
not/RB
be/VB
explained/VBN
by/IN
hypophosphatemia/NN
alone/RB
./.
====================
Since/IN
most/JJS
of/IN
the/DT
actions/NNS
of/IN
vitamin/NN
D/NN
are/VBP
mediated/VBN
by/IN
its/PRP$
receptors/NNS
(/(
VDR/NN
)/)
,/,
abnormalities/NNS
of/IN
VDR/NN
have/VBP
been/VBN
postulated/VBN
in/IN
XLH/NN
./.
====================
In/IN
order/NN
to/TO
investigate/VB
this/DT
possibility/NN
,/,
we/PRP
measured/VBD
the/DT
concentration/NN
of/IN
VDR/NN
in/IN
PHA-activated/JJ
peripheral/JJ
mononuclear/JJ
cells/NNS
from/IN
10/CD
XLH/NN
patients/NNS
./.
====================
Patients/NNS
without/IN
phosphate/NN
supplementation/NN
showed/VBD
significantly/RB
lower/JJR
concentration/NN
(/(
21.7/CD
+/-/CC
5.1/CD
fmol/mg/NN
protein/NN
,/,
mean/NN
+/-/CC
SEM/NN
)/)
compared/VBN
to/TO
the/DT
normal/JJ
controls/NNS
(/(
60.7/CD
+/-/CC
4.0/CD
)/)
./.
====================
On/IN
the/DT
contrary/JJ
,/,
there/EX
was/VBD
no/DT
significant/JJ
difference/NN
between/IN
the/DT
phosphate-supplemented/JJ
patients/NNS
(/(
58.3/CD
+/-/CC
2.7/CD
)/)
and/CC
controls/NNS
./.
====================
There/EX
was/VBD
a/DT
significant/JJ
positive/JJ
correlation/NN
between/IN
VDR/NN
concentration/NN
and/CC
serum/NN
phosphate/NN
(/(
P/NN
less/JJR
than/IN
0.05/CD
)/)
./.
====================
In/IN
two/CD
patients/NNS
,/,
VDR/NN
was/VBD
increased/VBN
after/IN
daily/JJ
phosphate/NN
supplementation/NN
was/VBD
started/VBN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
a/DT
decreased/VBN
concentration/NN
of/IN
VDR/NN
secondary/JJ
to/TO
persistent/JJ
hypophosphatemia/NN
is/VBZ
one/CD
of/IN
the/DT
causes/NNS
of/IN
vitamin/NN
D/NN
resistance/NN
in/IN
XLH/NN
./.
====================
UI/LS
-/:
90319091/CD
====================
TI/LS
-/:
Two/CD
distinct/JJ
forms/NNS
of/IN
active/JJ
transcription/NN
factor/NN
CREB/NN
(/(
cAMP/NN
response/NN
element/NN
binding/NN
protein/NN
)/)
./.
====================
AB/LS
-/:
Mammalian/JJ
cells/NNS
express/VBP
two/CD
distinct/JJ
forms/NNS
of/IN
transcription/NN
factor/NN
CREB/NN
(/(
cAMP/NN
response/NN
element/NN
binding/NN
protein/NN
)/)
that/WDT
are/VBP
apparently/RB
the/DT
products/NNS
of/IN
alternative/JJ
splicing/NN
of/IN
the/DT
CREB/NN
gene/NN
transcript/NN
./.
====================
The/DT
two/CD
proteins/NNS
differ/VBP
by/IN
a/DT
14-amino/NN
acid/NN
serine-rich/JJ
insertion/NN
present/JJ
in/IN
one/CD
of/IN
the/DT
CREB/NN
isoforms/NNS
./.
====================
We/PRP
show/VBP
that/IN
both/DT
CREB/NN
isoforms/NNS
are/VBP
expressed/VBN
in/IN
many/JJ
cell/NN
types/NNS
and/CC
mammalian/JJ
species/NNS
./.
====================
Both/DT
encode/VBP
proteins/NNS
that/WDT
bind/VBP
specifically/RB
to/TO
a/DT
cAMP/NN
response/NN
element/NN
in/FW
vitro/FW
./.
====================
As/IN
expected/VBN
for/IN
proteins/NNS
of/IN
this/DT
class/NN
,/,
the/DT
CREB/NN
proteins/NNS
bind/VBP
DNA/NN
as/IN
dimers/NNS
./.
====================
Both/DT
proteins/NNS
impart/VBP
cAMP-regulated/JJ
transcriptional/JJ
activity/NN
to/TO
a/DT
heterologous/JJ
DNA-binding/JJ
domain/NN
,/,
showing/VBG
that/IN
cAMP/NN
directly/RB
modulates/VBZ
the/DT
transcriptional/JJ
stimulatory/JJ
activity/NN
of/IN
CREB/NN
./.
====================
The/DT
presence/NN
of/IN
multiple/JJ
CREB/NN
isoforms/NNS
with/IN
identical/JJ
DNA-binding/JJ
specificities/NNS
but/CC
differences/NNS
in/IN
the/DT
presumed/JJ
regulatory/JJ
domain/NN
raises/VBZ
the/DT
possibility/NN
that/IN
CREB/NN
proteins/NNS
may/MD
be/VB
able/JJ
to/TO
integrate/VB
distinct/JJ
regulatory/JJ
signals/NNS
at/IN
the/DT
level/NN
of/IN
gene/NN
transcription/NN
./.
====================
UI/LS
-/:
90244434/CD
====================
TI/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
vpr/NN
product/NN
is/VBZ
a/DT
virion-associated/JJ
regulatory/JJ
protein/NN
./.
====================
AB/LS
-/:
The/DT
vpr/NN
product/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
acts/VBZ
in/IN
trans/NN
to/TO
accelerate/VB
virus/NN
replication/NN
and/CC
cytopathic/JJ
effect/NN
in/IN
T/NN
cells/NNS
./.
====================
Here/RB
it/PRP
is/VBZ
shown/VBN
that/IN
the/DT
HIV-1/NN
viral/JJ
particle/NN
contains/VBZ
multiple/JJ
copies/NNS
of/IN
the/DT
vpr/NN
protein/NN
./.
====================
The/DT
vpr/NN
product/NN
is/VBZ
the/DT
first/JJ
regulatory/JJ
protein/NN
of/IN
HIV-1/NN
to/TO
be/VB
found/VBN
in/IN
the/DT
virus/NN
particle/NN
./.
====================
This/DT
observation/NN
raises/VBZ
the/DT
possibility/NN
that/IN
vpr/NN
acts/VBZ
to/TO
facilitate/VB
the/DT
early/JJ
steps/NNS
of/IN
infection/NN
before/IN
de/FW
novo/FW
viral/JJ
protein/NN
synthesis/NN
occurs/VBZ
./.
====================
UI/LS
-/:
90337320/CD
====================
TI/LS
-/:
A/DT
novel/JJ
B-cell/NN
lineage-specific/JJ
transcription/NN
factor/NN
present/JJ
at/IN
early/JJ
but/CC
not/RB
late/JJ
stages/NNS
of/IN
differentiation/NN
./.
====================
AB/LS
-/:
A/DT
novel/JJ
B-cell-specific/JJ
transcription/NN
factor/NN
,/,
BSAP/NN
,/,
was/VBD
identified/VBN
as/IN
a/DT
mammalian/JJ
homolog/NN
of/IN
the/DT
sea/NN
urchin/NN
protein/NN
TSAP/NN
,/,
which/WDT
interacts/VBZ
with/IN
the/DT
promoters/NNS
of/IN
four/CD
tissue-specific/JJ
late/JJ
histone/NN
H2A-2/NN
and/CC
H2B-2/NN
genes/NNS
./.
====================
As/IN
shown/VBN
by/IN
mobility-shift/JJ
,/,
methylation/NN
interference/NN
,/,
and/CC
mutational/JJ
analyses/NNS
,/,
the/DT
mammalian/JJ
protein/NN
BSAP/NN
recognizes/VBZ
all/DT
four/CD
sea/NN
urchin/NN
binding/NN
sites/NNS
in/IN
a/DT
manner/NN
indistinguishable/JJ
from/IN
TSAP/NN
;/:
however/RB
,/,
the/DT
two/CD
proteins/NNS
differ/VBP
in/IN
molecular/JJ
weight/NN
./.
====================
BSAP/NN
is/VBZ
exclusively/RB
restricted/JJ
to/TO
the/DT
B-cell/NN
lineage/NN
of/IN
lymphoid/JJ
differentiation/NN
./.
====================
Its/PRP$
expression/NN
appears/VBZ
to/TO
be/VB
activated/VBN
during/IN
pro-B-cell/JJ
development/NN
,/,
is/VBZ
abundant/JJ
at/IN
the/DT
pre-B-/JJ
and/CC
mature/JJ
B-cell/NN
stages/NNS
,/,
but/CC
is/VBZ
absent/JJ
in/IN
terminally/RB
differentiated/VBN
plasma/NN
cells/NNS
./.
====================
Moreover/RB
,/,
BSAP/NN
is/VBZ
clearly/RB
a/DT
B-cell-specific/JJ
transcription/NN
factor/NN
,/,
as/IN
a/DT
wild-type/JJ
but/CC
not/RB
a/DT
mutant/JJ
TSAP-binding/JJ
site/NN
of/IN
the/DT
sea/NN
urchin/NN
functions/NNS
only/RB
in/IN
transfected/VBN
B/NN
cells/NNS
as/IN
an/DT
upstream/JJ
promoter/NN
element/NN
./.
====================
Competition/NN
experiments/NNS
did/VBD
not/RB
reveal/VB
any/DT
high-affinity/JJ
binding/VBG
site/NN
for/IN
BSAP/NN
in/IN
known/JJ
regulatory/JJ
regions/NNS
of/IN
immunoglobulin/NN
and/CC
class/NN
II/CD
major/JJ
histocompatibility/NN
(/(
MHC/NN
)/)
genes/NNS
,/,
suggesting/VBG
that/IN
BSAP/NN
is/VBZ
a/DT
regulator/NN
of/IN
a/DT
different/JJ
set/NN
of/IN
B-lymphoid-specific/JJ
genes/NNS
./.
====================
UI/LS
-/:
90169371/CD
====================
TI/LS
-/:
Octamer/NN
transcription/NN
factors/NNS
and/CC
the/DT
cell/NN
type-specificity/NN
of/IN
immunoglobulin/NN
gene/NN
expression/NN
./.
====================
AB/LS
-/:
Antibodies/NNS
are/VBP
produced/VBN
exclusively/RB
in/IN
B/NN
lymphocytes/NNS
./.
====================
The/DT
expression/NN
of/IN
the/DT
antibody-encoding/JJ
genes/NNS
,/,
the/DT
immunoglobulin/NN
(/(
Ig/NN
)/)
genes/NNS
,/,
is/VBZ
also/RB
restricted/JJ
to/TO
B/NN
cells/NNS
./.
====================
The/DT
octamer/NN
sequence/NN
ATGCAAAT/NN
is/VBZ
present/JJ
in/IN
the/DT
promoter/NN
and/CC
the/DT
enhancer/NN
of/IN
Ig/NN
genes/NNS
,/,
and/CC
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
its/PRP$
tissue-specific/JJ
expression/NN
./.
====================
This/DT
sequence/NN
motif/NN
is/VBZ
a/DT
binding/VBG
site/NN
for/IN
nuclear/JJ
proteins/NNS
,/,
the/DT
so-called/JJ
octamer/NN
transcription/NN
factors/NNS
(/(
Oct/NN
or/CC
OTF/NN
factors/NNS
)/)
./.
====================
The/DT
Oct-1/NN
protein/NN
is/VBZ
present/JJ
in/IN
all/DT
cell/NN
types/NNS
analyzed/VBN
so/RB
far/RB
,/,
whereas/IN
Oct-2A/NN
and/CC
Oct-2B/NN
are/VBP
found/VBN
mainly/RB
in/IN
B/NN
lymphocytes/NNS
./.
====================
All/DT
three/CD
proteins/NNS
show/VBP
the/DT
same/JJ
sequence/NN
specificity/NN
and/CC
binding/NN
affinity/NN
./.
====================
It/PRP
appears/VBZ
that/IN
the/DT
B/NN
cell-specific/JJ
expression/NN
of/IN
Ig/NN
genes/NNS
is/VBZ
mediated/VBN
at/IN
least/JJS
in/IN
part/NN
by/IN
cell/NN
type-specific/JJ
Oct/NN
factors/NNS
,/,
and/CC
that/IN
there/EX
are/VBP
both/CC
quantitative/JJ
and/CC
qualitative/JJ
differences/NNS
between/IN
Oct-1/NN
and/CC
Oct-2/NN
factors/NNS
./.
====================
Recently/RB
,/,
a/DT
number/NN
of/IN
other/JJ
octamer/NN
factor/NN
variants/NNS
were/VBD
identified/VBN
./.
====================
Many/JJ
of/IN
these/DT
may/MD
be/VB
created/VBN
by/IN
alternative/JJ
splicing/NN
of/IN
a/DT
primary/JJ
transcript/NN
of/IN
one/CD
Oct/NN
factor/NN
gene/NN
and/CC
may/MD
serve/VB
a/DT
specific/JJ
function/NN
in/IN
the/DT
fine/JJ
tuning/NN
of/IN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
90151654/CD
====================
TI/LS
-/:
A/DT
factor/NN
known/VBN
to/TO
bind/VB
to/TO
endogenous/JJ
Ig/NN
heavy/JJ
chain/NN
enhancer/NN
only/RB
in/IN
lymphocytes/NNS
is/VBZ
a/DT
ubiquitously/RB
active/JJ
transcription/NN
factor/NN
./.
====================
AB/LS
-/:
The/DT
transcriptional/JJ
enhancer/NN
located/JJ
in/IN
the/DT
first/JJ
intron/NN
of/IN
the/DT
immunoglobulin/NN
heavy/JJ
chain/NN
constant/JJ
region/NN
is/VBZ
a/DT
major/JJ
determinant/NN
of/IN
B-cell-specific/JJ
expression/NN
of/IN
immunoglobulin/NN
genes/NNS
./.
====================
Like/IN
other/JJ
enhancers/NNS
,/,
the/DT
Ig/NN
heavy/JJ
chain/NN
enhancer/NN
contains/VBZ
several/JJ
short/JJ
sequence/NN
motifs/NNS
that/WDT
bind/VBP
specific/JJ
transcription/NN
factors/NNS
./.
====================
Each/DT
binding/VBG
site/NN
contributes/VBZ
to/TO
the/DT
overall/JJ
activity/NN
of/IN
the/DT
enhancer/NN
,/,
however/RB
no/DT
single/JJ
element/NN
seems/VBZ
absolutely/RB
required/VBN
for/IN
activity/NN
./.
====================
For/IN
a/DT
better/JJR
understanding/NN
of/IN
the/DT
Ig/NN
heavy/JJ
chain/NN
enhancer/NN
components/NNS
,/,
we/PRP
have/VBP
cloned/VBN
and/CC
analyzed/VBN
individual/JJ
sequence/NN
elements/NNS
./.
====================
We/PRP
find/VBP
that/IN
the/DT
factor/NN
that/WDT
binds/VBZ
to/TO
the/DT
E3/NN
enhancer/NN
motif/NN
,/,
CATGTGGC/NN
,/,
is/VBZ
a/DT
ubiquitous/JJ
transcription/NN
factor/NN
./.
====================
It/PRP
is/VBZ
present/JJ
in/IN
an/DT
active/JJ
form/NN
in/IN
both/CC
B/NN
cells/NNS
and/CC
non-B/JJ
cells/NNS
,/,
where/WRB
it/PRP
can/MD
mediate/VB
transcriptional/JJ
activation/NN
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
./.
====================
However/RB
,/,
despite/IN
its/PRP$
ability/NN
to/TO
activate/VB
transcription/NN
of/IN
a/DT
transfected/VBN
reporter/NN
gene/NN
,/,
the/DT
factor/NN
is/VBZ
apparently/RB
unable/JJ
to/TO
bind/VB
to/TO
the/DT
endogenous/JJ
Ig/NN
heavy/JJ
chain/NN
enhancer/NN
in/IN
non-lymphoid/JJ
cells/NNS
:/:
In/IN
previous/JJ
experiments/NNS
by/IN
others/NNS
,/,
the/DT
characteristic/JJ
in/FW
vivo/FW
footprint/NN
of/IN
this/DT
factor/NN
,/,
designated/VBN
NF-muE3/NN
,/,
was/VBD
detected/VBN
in/IN
B/NN
cells/NNS
but/CC
not/RB
in/IN
non-B/JJ
cells/NNS
./.
====================
From/IN
this/DT
and/CC
other/JJ
findings/NNS
the/DT
picture/NN
emerges/VBZ
that/IN
there/EX
are/VBP
at/IN
least/JJS
three/CD
categories/NNS
of/IN
factors/NNS
which/WDT
mediate/VBP
cell-type-specific/JJ
transcription/NN
in/IN
B/NN
lymphocytes/NNS
:/:
(/(
a/LS
)/)
cell-specific/JJ
factors/NNS
such/JJ
as/IN
Oct-2A/NN
and/CC
Oct-2B/NN
that/WDT
are/VBP
not/RB
expressed/VBN
in/IN
most/JJS
other/JJ
cell/NN
types/NNS
:/:
(/(
b/LS
)/)
ubiquitous/JJ
factors/NNS
such/JJ
as/IN
NF-kappa/NN
B/NN
that/WDT
are/VBP
constitutively/RB
active/JJ
in/IN
B/NN
cells/NNS
but/CC
are/VBP
sequestered/VBN
in/IN
an/DT
inactive/JJ
form/NN
in/IN
other/JJ
cells/NNS
;/:
(/(
c/LS
)/)
ubiquitously/RB
active/JJ
factors/NNS
,/,
exemplified/VBN
by/IN
the/DT
one/NN
binding/VBG
to/TO
the/DT
E3/NN
sequence/NN
motif/NN
./.
====================
This/DT
factor/NN
is/VBZ
present/JJ
in/IN
an/DT
active/JJ
form/NN
in/IN
a/DT
variety/NN
of/IN
cell/NN
types/NNS
but/CC
is/VBZ
apparently/RB
unable/JJ
to/TO
bind/VB
to/TO
the/DT
endogenous/JJ
Ig/NN
heavy/JJ
chain/NN
enhancer/NN
in/IN
non-B/JJ
cells/NNS
,/,
perhaps/RB
due/JJ
to/TO
a/DT
non-permissive/JJ
chromatin/NN
structure/NN
of/IN
the/DT
Ig/NN
heavy/JJ
chain/NN
locus/NN
./.
====================
UI/LS
-/:
92107586/CD
====================
TI/LS
-/:
[/(
Endocrine/JJ
status/NN
changes/NNS
in/IN
children/NNS
with/IN
bronchial/JJ
asthma/NN
]/)
====================
AB/LS
-/:
A/DT
study/NN
was/VBD
made/VBN
of/IN
adrenocortical/JJ
function/NN
by/IN
measuring/VBG
blood/NN
plasma/NN
cortisol/NN
concentration/NN
and/CC
amount/NN
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
lymphocytes/NNS
as/RB
well/RB
as/IN
thyroid/NN
function/NN
by/IN
measuring/VBG
blood/NN
plasma/NN
triidothyronine/NN
and/CC
thyroxine/JJ
concentration/NN
in/IN
58/CD
bronchial/JJ
asthma/NN
children/NNS
aged/JJ
1/CD
to/TO
14/CD
years/NNS
./.
====================
The/DT
authors/NNS
revealed/VBD
alterations/NNS
in/IN
the/DT
functional/JJ
activity/NN
of/IN
the/DT
indicated/VBN
endocrine/JJ
glands/NNS
depending/VBG
on/IN
the/DT
intensity/NN
of/IN
bronchial/JJ
patency/NN
disorders/NNS
and/CC
the/DT
nature/NN
of/IN
the/DT
therapeutic/JJ
measures/NNS
carried/VBN
out/RP
./.
====================
UI/LS
-/:
91092266/CD
====================
TI/LS
-/:
TAR/NN
independent/JJ
activation/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
in/IN
phorbol/NN
ester/NN
stimulated/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Multiple/JJ
regulatory/JJ
elements/NNS
in/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
long/JJ
terminal/JJ
repeat/NN
(/(
HIV/NN
LTR/NN
)/)
are/VBP
required/VBN
for/IN
activation/NN
of/IN
HIV/NN
gene/NN
expression/NN
./.
====================
Previous/JJ
transfection/NN
studies/NNS
of/IN
HIV/NN
LTR/NN
constructs/NNS
linked/VBN
to/TO
the/DT
chloramphenicol/NN
acetyltransferase/NN
gene/NN
indicated/VBD
that/IN
multiple/JJ
regulatory/JJ
regions/NNS
including/VBG
the/DT
enhancer/NN
,/,
SP1/NN
,/,
TATA/NN
and/CC
TAR/NN
regions/NNS
were/VBD
important/JJ
for/IN
HIV/NN
gene/NN
expression/NN
./.
====================
To/TO
characterize/VB
these/DT
regulatory/JJ
elements/NNS
further/RBR
,/,
mutations/NNS
in/IN
these/DT
regions/NNS
were/VBD
inserted/VBN
into/IN
both/CC
the/DT
5'/JJ
and/CC
3'/JJ
HIV/NN
LTRs/NNS
and/CC
infectious/JJ
proviral/JJ
constructs/NNS
were/VBD
assembled/VBN
./.
====================
These/DT
constructs/NNS
were/VBD
transfected/VBN
into/IN
either/CC
HeLa/NN
cells/NNS
,/,
Jurkat/NN
cells/NNS
or/CC
U937/NN
cells/NNS
in/IN
both/CC
the/DT
presence/NN
and/CC
absence/NN
of/IN
phorbol/NN
esters/NNS
which/WDT
have/VBP
previously/RB
been/VBN
demonstrated/VBN
to/TO
activate/VB
HIV/NN
gene/NN
expression/NN
./.
====================
Viral/JJ
gene/NN
expression/NN
was/VBD
assayed/VBN
by/IN
the/DT
level/NN
of/IN
p24/NN
gag/NN
protein/NN
released/VBN
from/IN
cultures/NNS
transfected/VBN
with/IN
the/DT
proviral/JJ
constructs/NNS
./.
====================
Results/NNS
in/IN
all/DT
cell/NN
lines/NNS
indicated/VBD
that/IN
mutations/NNS
of/IN
the/DT
SP1/NN
,/,
TATA/NN
and/CC
the/DT
TAR/NN
loop/NN
and/CC
stem/NN
secondary/JJ
structure/NN
resulted/VBD
in/IN
marked/JJ
decreases/NNS
in/IN
gene/NN
expression/NN
while/IN
mutations/NNS
of/IN
the/DT
enhancer/NN
motif/NN
or/CC
TAR/NN
primary/JJ
sequence/NN
resulted/VBD
in/IN
only/RB
slight/JJ
decreases/NNS
./.
====================
However/RB
,/,
viruses/NNS
containing/VBG
mutations/NNS
in/IN
either/CC
the/DT
TAR/NN
loop/NN
sequences/NNS
or/CC
stem/NN
secondary/JJ
structure/NN
which/WDT
were/VBD
very/RB
defective/JJ
for/IN
gene/NN
expression/NN
in/IN
untreated/JJ
Jurkat/NN
cells/NNS
,/,
gave/VBD
nearly/RB
wild-type/JJ
levels/NNS
of/IN
gene/NN
expression/NN
in/IN
phorbol/NN
ester-treated/JJ
Jurkat/NN
cells/NNS
but/CC
not/RB
in/IN
phorbol/NN
ester-treated/JJ
HeLa/NN
or/CC
U937/NN
cells/NNS
./.
====================
High/JJ
level/NN
gene/NN
expression/NN
of/IN
these/DT
TAR/NN
mutant/JJ
constructs/NNS
in/IN
phorbol/NN
ester-treated/JJ
Jurkat/NN
cells/NNS
was/VBD
eliminated/VBN
by/IN
second/JJ
site/NN
mutations/NNS
in/IN
the/DT
enhancer/NN
region/NN
or/CC
by/IN
disruption/NN
of/IN
the/DT
tat/NN
gene/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
91258741/CD
====================
TI/LS
-/:
A/DT
case/NN
of/IN
hypersensitivity/NN
to/TO
thyroid/NN
hormones/NNS
with/IN
normally/RB
functioning/VBG
thyroid/NN
gland/NN
and/CC
increased/VBN
nuclear/JJ
triiodothyronine/NN
receptors/NNS
./.
====================
AB/LS
-/:
A/DT
52-year-old/JJ
male/NN
presented/VBD
himself/PRP
with/IN
tachycardia/NN
crises/NNS
which/WDT
appeared/VBD
first/RB
during/IN
childhood/NN
,/,
increased/VBD
in/IN
frequency/NN
without/IN
goiter/NN
or/CC
exophthalmos/NNS
./.
====================
Cardiac/JJ
and/CC
adrenergic/JJ
diseases/NNS
were/VBD
excluded/VBN
./.
====================
The/DT
thyroid/NN
function/NN
was/VBD
normal/JJ
regarding/VBG
T4/NN
,/,
free/JJ
T4/NN
and/CC
T3/NN
,/,
TBG/NN
,/,
radioiodine/NN
uptake/NN
,/,
TSH/NN
and/CC
T3/NN
suppressibility/NN
;/:
however/RB
the/DT
TSH/NN
response/NN
to/TO
TRH/NN
was/VBD
decreased/VBN
./.
====================
The/DT
lymphocyte/NN
nuclear/JJ
T3/NN
receptor/NN
was/VBD
found/VBN
with/IN
an/DT
affinity/NN
close/JJ
to/TO
that/DT
of/IN
normal/JJ
volunteers/NNS
(/(
Ka/NN
:/:
1.42/CD
x/CC
10(10)/CD
M-1/NN
vs/CC
1.95/CD
+/-/CC
0.35/CD
x/CC
10(10)/CD
M-1/NN
)/)
and/CC
a/DT
binding/NN
capacity/NN
markedly/RB
increased/VBD
(/(
9.9/CD
vs/CC
3.7/CD
+/-/CC
0.4/CD
fmol/NN
T3/NN
//:
100/CD
micrograms/NNS
DNA/NN
)/)
./.
====================
Pindolol/NN
was/VBD
inefficient/JJ
on/IN
the/DT
dysrhythmia/NN
which/WDT
disappeared/VBD
with/IN
carbimazole/NN
and/CC
relapsed/VBD
after/IN
withdrawal/NN
of/IN
the/DT
antithyroid/NN
drug/NN
./.
====================
Under/IN
carbimazole/NN
,/,
the/DT
plasma/NN
T4/NN
markedly/RB
decreased/VBD
(/(
27.7/CD
+/-/CC
3.6/CD
nmol/l/NN
)/)
but/CC
the/DT
patient/NN
remained/VBD
euthyroid/NN
./.
====================
The/DT
clinical/JJ
course/NN
and/CC
the/DT
laboratory/NN
data/NNS
suggest/VBP
that/IN
the/DT
tachycardia/NN
crises/NNS
are/VBP
the/DT
consequence/NN
of/IN
a/DT
hypersensitivity/NN
of/IN
the/DT
heart/NN
to/TO
thyroid/NN
hormones/NNS
,/,
associated/VBN
with/IN
an/DT
increased/VBN
number/NN
of/IN
T3/NN
nuclear/JJ
receptor/NN
sites/NNS
in/IN
lymphocytes/NNS
./.
====================
UI/LS
-/:
90375934/CD
====================
TI/LS
-/:
Induction/NN
of/IN
immediate/JJ
early/JJ
response/NN
genes/NNS
by/IN
macrophage/NN
colony-stimulating/JJ
factor/NN
in/IN
normal/JJ
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
A/DT
group/NN
of/IN
coordinately/RB
induced/VBN
protooncogenes/NNS
,/,
cytoskeletal/JJ
,/,
and/CC
extracellular/JJ
matrix/NN
genes/NNS
have/VBP
been/VBN
termed/VBN
immediate/JJ
early/JJ
response/NN
genes/NNS
,/,
and/CC
their/PRP$
induction/NN
has/VBZ
been/VBN
associated/VBN
with/IN
growth/NN
factor-stimulated/JJ
cell/NN
proliferation/NN
./.
====================
We/PRP
have/VBP
investigated/VBN
the/DT
induction/NN
of/IN
these/DT
genes/NNS
by/IN
macrophage-CSF/NN
(/(
M-CSF/NN
)/)
in/IN
human/JJ
monocytes/NNS
that/WDT
do/VBP
not/RB
proliferate/VB
in/IN
response/NN
to/TO
M-CSF/NN
but/CC
require/VBP
the/DT
factor/NN
for/IN
optimal/JJ
cell/NN
differentiation/NN
./.
====================
Normal/JJ
human/JJ
monocytes/NNS
were/VBD
isolated/VBN
,/,
carefully/RB
washed/VBN
,/,
and/CC
incubated/VBN
for/IN
36/CD
to/TO
48/CD
h/NN
in/IN
fetal/JJ
bovine/NN
serum-containing/JJ
medium/NN
./.
====================
At/IN
the/DT
end/NN
of/IN
this/DT
incubation/NN
the/DT
resting/VBG
cells/NNS
were/VBD
stimulated/VBN
with/IN
M-CSF/NN
,/,
and/CC
RNA/NN
was/VBD
isolated/VBN
for/IN
analysis/NN
by/IN
Northern/JJ
blotting/NN
./.
====================
RNA/NN
from/IN
control/JJ
resting/VBG
cells/NNS
contained/VBD
low/JJ
to/TO
undetectable/JJ
levels/NNS
of/IN
c-jun/NN
,/,
fibronectin/NN
receptor/NN
,/,
and/CC
actin/NN
mRNA/NN
./.
====================
Within/IN
15/CD
to/TO
30/CD
min/NN
of/IN
addition/NN
of/IN
M-CSF/NN
,/,
however/RB
,/,
there/EX
was/VBD
a/DT
dramatic/JJ
coordinate/JJ
induction/NN
of/IN
these/DT
genes/NNS
./.
====================
The/DT
c-jun/NN
gene/NN
expression/NN
was/VBD
very/RB
transient/JJ
and/CC
was/VBD
not/RB
detectable/JJ
by/IN
60/CD
min/NN
after/IN
M-CSF/NN
addition/NN
./.
====================
In/IN
contrast/NN
,/,
the/DT
expression/NN
of/IN
actin/NN
and/CC
fibronectin/NN
receptor/NN
mRNA/NN
was/VBD
more/RBR
sustained/VBN
,/,
and/CC
the/DT
expression/NN
of/IN
these/DT
genes/NNS
remained/VBD
elevated/JJ
at/IN
24/CD
to/TO
48/CD
h/NN
after/IN
M-CSF/NN
addition/NN
./.
====================
We/PRP
also/RB
observed/VBD
the/DT
induction/NN
of/IN
the/DT
myelomonocytic/JJ
specific/JJ
tyrosine/NN
kinase/NN
hck/NN
gene/NN
simultaneously/RB
with/IN
the/DT
other/JJ
immediate/JJ
early/JJ
response/NN
genes/NNS
./.
====================
The/DT
protein/NN
synthesis/NN
inhibitor/NN
cycloheximide/NN
did/VBD
not/RB
block/VB
the/DT
induction/NN
of/IN
any/DT
of/IN
these/DT
genes/NNS
,/,
and/CC
in/IN
fact/NN
,/,
super-induced/VBD
the/DT
expression/NN
of/IN
c-jun/NN
and/CC
hck/NN
./.
====================
Nuclear/JJ
run/NN
on/IN
transcription/NN
of/IN
the/DT
c-jun/NN
,/,
hck/NN
,/,
and/CC
actin/NN
genes/NNS
./.
====================
Therefore/RB
,/,
in/IN
normal/JJ
human/JJ
monocytes/NNS
M-CSF/NN
induces/VBZ
immediate/JJ
early/JJ
response/NN
genes/NNS
without/IN
inducing/VBG
cell/NN
proliferation/NN
./.
====================
These/DT
genes/NNS
may/MD
then/RB
play/VB
a/DT
role/NN
in/IN
altering/VBG
the/DT
physiologic/JJ
status/NN
of/IN
the/DT
cells/NNS
in/IN
response/NN
to/TO
CSF/NN
./.
====================
UI/LS
-/:
90317911/CD
====================
TI/LS
-/:
Inducible/JJ
nuclear/JJ
factor/NN
binding/NN
to/TO
the/DT
kappa/NN
B/NN
elements/NNS
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
enhancer/NN
in/IN
T/NN
cells/NNS
can/MD
be/VB
blocked/VBN
by/IN
cyclosporin/NN
A/NN
in/IN
a/DT
signal-dependent/JJ
manner/NN
./.
====================
AB/LS
-/:
Cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
is/VBZ
thought/VBN
to/TO
exert/VB
its/PRP$
immunosuppressive/JJ
effects/NNS
by/IN
inhibiting/VBG
the/DT
expression/NN
of/IN
a/DT
distinct/JJ
set/NN
of/IN
lymphokine/NN
genes/NNS
which/WDT
are/VBP
induced/VBN
upon/IN
T-cell/NN
activation/NN
,/,
among/IN
them/PRP
the/DT
gene/NN
coding/VBG
for/IN
interleukin-2/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
activation/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
is/VBZ
partially/RB
suppressed/VBN
./.
====================
To/TO
better/RBR
understand/VB
the/DT
molecular/JJ
mechanisms/NNS
underlying/VBG
suppression/NN
by/IN
CsA/NN
,/,
we/PRP
have/VBP
investigated/VBN
the/DT
effects/NNS
of/IN
this/DT
drug/NN
on/IN
transcription/NN
factors/NNS
in/IN
T/NN
cells/NNS
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
the/DT
formation/NN
of/IN
two/CD
distinct/JJ
mitogen-inducible/JJ
DNA-binding/JJ
complexes/NNS
,/,
the/DT
kappa/NN
B/NN
complex/NN
within/IN
the/DT
HIV/NN
enhancer/NN
and/CC
the/DT
NFAT-1/NN
complex/NN
within/IN
the/DT
interleukin-2/NN
enhancer/NN
,/,
is/VBZ
inhibited/VBN
in/IN
the/DT
presence/NN
of/IN
CsA/NN
./.
====================
The/DT
kappa/NN
B-binding/JJ
activity/NN
with/IN
the/DT
HIV/NN
enhancer/NN
is/VBZ
inhibited/VBN
only/RB
if/IN
it/PRP
is/VBZ
activated/VBN
via/IN
the/DT
mitogen/NN
phytohemagglutinin/NN
whereas/IN
phorbol/NN
myristate/NN
acetate-mediated/JJ
activation/NN
is/VBZ
completely/RB
insensitive/JJ
to/TO
the/DT
drug/NN
./.
====================
This/DT
suggests/VBZ
a/DT
model/NN
in/IN
which/WDT
functionally/RB
indistinguishable/JJ
kappa/NN
B/NN
complexes/NNS
can/MD
be/VB
activated/VBN
via/IN
two/CD
separate/JJ
pathways/NNS
of/IN
signal/NN
transduction/NN
distinguishable/JJ
by/IN
CsA/NN
./.
====================
UI/LS
-/:
91190842/CD
====================
TI/LS
-/:
Purification/NN
of/IN
TCF-1/NN
alpha/NN
,/,
a/DT
T-cell-specific/JJ
transcription/NN
factor/NN
that/WDT
activates/VBZ
the/DT
T-cell/NN
receptor/NN
C/NN
alpha/NN
gene/NN
enhancer/NN
in/IN
a/DT
context-dependent/JJ
manner/NN
./.
====================
AB/LS
-/:
The/DT
differentiation/NN
of/IN
T/NN
cells/NNS
into/IN
functionally/RB
diverse/JJ
subpopulations/NNS
is/VBZ
controlled/VBN
in/IN
part/NN
,/,
by/IN
transcriptional/JJ
activation/NN
and/CC
silencing/NN
;/:
however/RB
,/,
little/JJ
is/VBZ
known/VBN
in/IN
detail/NN
about/IN
the/DT
proteins/NNS
that/WDT
influence/VBP
this/DT
developmental/JJ
process/NN
./.
====================
We/PRP
have/VBP
purified/VBN
a/DT
new/JJ
T-cell-specific/JJ
factor/NN
,/,
TCF-1/NN
alpha/NN
,/,
that/WDT
is/VBZ
implicated/VBN
in/IN
the/DT
activation/NN
of/IN
genes/NNS
encoding/VBG
a/DT
major/JJ
component/NN
of/IN
the/DT
human/JJ
T-cell/NN
receptor/NN
(/(
TCR/NN
)/)
./.
====================
TCF-1/NN
alpha/NN
,/,
originally/RB
identified/VBN
and/CC
purified/VBN
through/IN
its/PRP$
binding/VBG
sites/NNS
on/IN
the/DT
HIV-1/NN
promoter/NN
,/,
was/VBD
found/VBN
to/TO
bind/VB
to/TO
the/DT
TCR/NN
alpha/NN
enhancer/NN
and/CC
to/TO
promoters/NNS
for/IN
several/JJ
genes/NNS
expressed/VBN
at/IN
significantly/RB
earlier/JJR
stages/NNS
of/IN
T-cell/NN
development/NN
than/IN
the/DT
TCR/NN
alpha/NN
gene/NN
(/(
e.g./FW
,/,
p56lck/NN
and/CC
CD3/NN
delta/NN
)/)
./.
====================
Sequences/NNS
related/JJ
to/TO
the/DT
TCF-1/NN
alpha/NN
binding/NN
motif/NN
(/(
5'-GGCACCCTTTGA-3'/NN
)/)
are/VBP
also/RB
found/VBN
in/IN
the/DT
human/JJ
TCR/NN
delta/NN
(/(
and/CC
possibly/RB
TCR/NN
beta/NN
)/)
enhancers/NNS
./.
====================
Southwestern/JJ
and/CC
gel/NN
renaturation/NN
experiments/NNS
with/IN
the/DT
use/NN
of/IN
purified/VBN
protein/NN
fractions/NNS
revealed/VBD
that/IN
TCF-1/NN
alpha/NN
activity/NN
is/VBZ
derived/VBN
from/IN
a/DT
family/NN
of/IN
57-/CD
to/TO
53-kD/JJ
proteins/NNS
that/WDT
are/VBP
abundantly/RB
expressed/VBN
in/IN
mature/JJ
and/CC
immature/JJ
T-cell/NN
lines/NNS
(/(
Jurkat/NN
,/,
CCRF-CEM/NN
)/)
and/CC
not/RB
in/IN
mature/JJ
B/NN
cells/NNS
(/(
JY/NN
,/,
Namalwa/NN
)/)
or/CC
nonlymphoid/JJ
(/(
HeLa/NN
)/)
cell/NN
lines/NNS
./.
====================
A/DT
small/JJ
95-bp/JJ
fragment/NN
of/IN
the/DT
TCR/NN
alpha/NN
control/NN
region/NN
that/WDT
contains/VBZ
the/DT
TCF-1/NN
alpha/NN
binding/NN
site/NN
juxtaposed/VBD
between/IN
a/DT
cAMP-response/NN
element/NN
(/(
the/DT
CRE/NN
or/CC
T/NN
alpha/NN
1/CD
motif/NN
)/)
and/CC
the/DT
binding/VBG
site/NN
for/IN
a/DT
distinct/JJ
lymphoid-specific/JJ
protein/NN
(/(
TCF-2/NN
alpha/NN
)/)
behaved/VBD
as/IN
a/DT
potent/JJ
T-cell-specific/JJ
enhancer/NN
in/FW
vivo/FW
./.
====================
Tandem/JJ
copies/NNS
of/IN
this/DT
enhancer/NN
functioned/VBD
synergistically/RB
in/IN
mature/JJ
(/(
Jurkat/NN
)/)
T-cell/NN
lines/NNS
as/RB
well/RB
as/IN
resting/VBG
and/CC
activated/VBN
immature/JJ
(/(
CCRF-CEM/NN
)/)
T-cell/NN
lines/NNS
./.
====================
Mutation/NN
of/IN
the/DT
TCF-1/NN
alpha/NN
binding/NN
site/NN
diminished/VBD
enhancer/NN
activity/NN
and/CC
disrupted/VBD
the/DT
synergism/NN
observed/VBN
in/FW
vivo/FW
between/IN
tandem/JJ
enhancer/NN
repeats/NNS
./.
====================
The/DT
TCF-1/NN
alpha/NN
binding/NN
site/NN
was/VBD
also/RB
required/VBN
for/IN
TCR/NN
alpha/NN
enhancer/NN
activity/NN
in/IN
transcriptionally/RB
active/JJ
extracts/NNS
from/IN
Jurkat/NN
but/CC
not/RB
HeLa/NN
cells/NNS
,/,
confirming/VBG
that/IN
TCF-1/NN
alpha/NN
is/VBZ
a/DT
T-cell-specific/JJ
transcription/NN
factor/NN
./.
====================
Curiously/RB
,/,
the/DT
TCF-1/NN
alpha/NN
binding/NN
element/NN
was/VBD
inactive/JJ
in/FW
vivo/FW
when/WRB
removed/VBN
from/IN
its/PRP$
neighboring/JJ
elements/NNS
on/IN
the/DT
TCR/NN
alpha/NN
enhancer/NN
and/CC
positioned/JJ
in/IN
one/CD
or/CC
more/JJR
copies/NNS
upstream/RB
of/IN
a/DT
heterologous/JJ
promoter/NN
./.
====================
Thus/RB
,/,
the/DT
transcriptional/JJ
activity/NN
of/IN
TCF-1/NN
alpha/NN
appears/VBZ
to/TO
depend/VB
on/IN
the/DT
TCF-2/NN
alpha/NN
and/CC
T/NN
alpha/NN
1/CD
(/(
CREB/NN
)/)
transcription/NN
factors/NNS
and/CC
the/DT
context/NN
of/IN
its/PRP$
binding/VBG
site/NN
within/IN
the/DT
TCR/NN
alpha/NN
enhancer/NN
./.
====================
UI/LS
-/:
90346297/CD
====================
TI/LS
-/:
Tandem/JJ
AP-1-binding/JJ
sites/NNS
within/IN
the/DT
human/JJ
beta-globin/NN
dominant/JJ
control/NN
region/NN
function/VBP
as/IN
an/DT
inducible/JJ
enhancer/NN
in/IN
erythroid/JJ
cells/NNS
./.
====================
AB/LS
-/:
A/DT
powerful/JJ
enhancer/NN
has/VBZ
been/VBN
mapped/VBN
to/TO
an/DT
18-bp/JJ
DNA/NN
segment/NN
located/JJ
11/CD
kb/NN
5'/JJ
to/TO
the/DT
human/JJ
epsilon-globin/NN
gene/NN
within/IN
the/DT
dominant/JJ
control/NN
or/CC
locus-activating/JJ
region/NN
./.
====================
This/DT
enhancer/NN
is/VBZ
inducible/JJ
in/IN
K562/NN
human/JJ
erythroleukemia/NN
cells/NNS
,/,
increasing/VBG
linked/VBN
gamma-globin/NN
promoter/luciferase/NN
gene/NN
expression/NN
to/TO
170-fold/RB
over/IN
an/DT
enhancerless/JJ
construct/NN
./.
====================
The/DT
enhancer/NN
consists/VBZ
of/IN
tandem/JJ
AP-1-binding/JJ
sites/NNS
,/,
phased/JJ
10/CD
bp/NN
apart/RB
,/,
which/WDT
are/VBP
both/DT
required/VBN
for/IN
full/JJ
activity/NN
./.
====================
DNA-protein/NN
binding/NN
assays/NNS
with/IN
nuclear/JJ
extracts/NNS
from/IN
induced/VBN
cells/NNS
demonstrate/VBP
a/DT
high/JJ
molecular/JJ
weight/NN
complex/NN
on/IN
the/DT
enhancer/NN
./.
====================
The/DT
formation/NN
of/IN
this/DT
complex/NN
also/RB
requires/VBZ
both/DT
AP-1/NN
sites/NNS
and/CC
correlates/VBZ
with/IN
maximal/JJ
enhancer/NN
activity/NN
./.
====================
Induction/NN
of/IN
the/DT
enhancer/NN
may/MD
have/VB
a/DT
role/NN
in/IN
the/DT
increase/NN
in/IN
globin/NN
gene/NN
transcription/NN
that/WDT
characterizes/VBZ
erythroid/JJ
maturation/NN
./.
====================
Enhancer/NN
activity/NN
appears/VBZ
to/TO
be/VB
mediated/VBN
by/IN
the/DT
binding/NN
of/IN
a/DT
complex/NN
of/IN
proteins/NNS
from/IN
the/DT
jun/NN
and/CC
fos/NN
families/NNS
to/TO
tandem/JJ
AP-1/NN
consensus/NN
sequences/NNS
./.
====================
UI/LS
-/:
90220600/CD
====================
TI/LS
-/:
Identification/NN
of/IN
a/DT
novel/JJ
factor/NN
that/WDT
interacts/VBZ
with/IN
an/DT
immunoglobulin/NN
heavy-chain/JJ
promoter/NN
and/CC
stimulates/VBZ
transcription/NN
in/IN
conjunction/NN
with/IN
the/DT
lymphoid/JJ
cell-specific/JJ
factor/NN
OTF2/NN
./.
====================
AB/LS
-/:
The/DT
tissue-specific/JJ
expression/NN
of/IN
the/DT
MOPC/NN
141/CD
immunoglobulin/NN
heavy-chain/JJ
gene/NN
was/VBD
studied/VBN
by/IN
using/VBG
in/FW
vitro/FW
transcription/NN
./.
====================
B-cell-specific/JJ
transcription/NN
of/IN
this/DT
gene/NN
was/VBD
dependent/JJ
on/IN
the/DT
octamer/NN
element/NN
5'-ATGCAAAG-3'/NN
,/,
located/JJ
in/IN
the/DT
upstream/JJ
region/NN
of/IN
this/DT
promoter/NN
and/CC
in/IN
the/DT
promoters/NNS
of/IN
all/DT
other/JJ
immunoglobulin/NN
heavy-/JJ
and/CC
light-chain/JJ
genes/NNS
./.
====================
The/DT
interaction/NN
of/IN
purified/VBN
octamer/NN
transcription/NN
factors/NNS
1/CD
and/CC
2/CD
(/(
OTF1/NN
and/CC
OTF2/NN
)/)
with/IN
the/DT
MOPC/NN
141/CD
promoter/NN
was/VBD
studied/VBN
by/IN
using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
and/CC
DNase/NN
I/CD
footprinting/NN
./.
====================
Purified/VBN
OTF1/NN
from/IN
HeLa/NN
cells/NNS
and/CC
OTF1/NN
and/CC
OTF2/NN
from/IN
B/NN
cells/NNS
bound/VBD
to/TO
identical/JJ
sequences/NNS
within/IN
the/DT
heavy-chain/JJ
promoter/NN
./.
====================
The/DT
OTF/NN
interactions/NNS
we/PRP
observed/VBD
extended/VBD
over/IN
the/DT
heptamer/NN
element/NN
5'-CTCAGGA-3'/NN
,/,
and/CC
it/PRP
seems/VBZ
likely/RB
that/IN
the/DT
binding/NN
of/IN
the/DT
purified/VBN
factors/NNS
involves/VBZ
cooperation/NN
between/IN
octamer/NN
and/CC
heptamer/NN
sites/NNS
in/IN
this/DT
promoter/NN
./.
====================
In/IN
addition/NN
to/TO
these/DT
elements/NNS
,/,
we/PRP
identified/VBD
a/DT
second/JJ
regulatory/JJ
element/NN
,/,
the/DT
N/NN
element/NN
with/IN
the/DT
sequence/NN
5'-GGAACCTCCCCC-3'/NN
./.
====================
The/DT
N/NN
element/NN
could/MD
independently/RB
mediate/VB
low/JJ
levels/NNS
of/IN
transcription/NN
in/IN
both/CC
B-cell/NN
and/CC
HeLa-cell/JJ
extracts/NNS
,/,
and/CC
,/,
in/IN
conjunction/NN
with/IN
the/DT
octamer/NN
element/NN
,/,
it/PRP
can/MD
promote/VB
high/JJ
levels/NNS
of/IN
transcription/NN
in/IN
B-cell/NN
extracts/NNS
./.
====================
The/DT
N/NN
element/NN
bound/VBD
a/DT
transcription/NN
factor/NN
,/,
NTF/NN
,/,
that/WDT
is/VBZ
ubiquitous/JJ
in/IN
cell-type/JJ
distribution/NN
,/,
and/CC
NTF/NN
was/VBD
distinct/JJ
from/IN
any/DT
of/IN
the/DT
previously/RB
described/VBN
proteins/NNS
that/WDT
bind/VBP
to/TO
similar/JJ
sequences/NNS
./.
====================
Based/VBN
on/IN
these/DT
results/NNS
,/,
we/PRP
propose/VBP
that/IN
NTF/NN
and/CC
OTF2/NN
interactions/NNS
(/(
both/CC
with/IN
their/PRP$
cognate/JJ
DNA/NN
elements/NNS
and/CC
possibly/RB
at/IN
the/DT
protein-protein/JJ
level/NN
)/)
may/MD
be/VB
critical/JJ
to/TO
B-cell-specific/JJ
expression/NN
and/CC
that/IN
these/DT
interactions/NNS
provide/VBP
additional/JJ
pathways/NNS
for/IN
regulating/VBG
gene/NN
expression/NN
./.
====================
UI/LS
-/:
90158596/CD
====================
TI/LS
-/:
NF-kappa/NN
B/NN
as/IN
inducible/JJ
transcriptional/JJ
activator/NN
of/IN
the/DT
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
gene/NN
./.
====================
AB/LS
-/:
The/DT
expression/NN
of/IN
the/DT
gene/NN
encoding/VBG
the/DT
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
is/VBZ
induced/VBN
upon/IN
activation/NN
of/IN
T/NN
cells/NNS
with/IN
phytohemagglutinin/NN
and/CC
active/JJ
phorbolester/NN
and/CC
upon/IN
expression/NN
of/IN
tax1/NN
,/,
a/DT
transactivating/VBG
protein/NN
of/IN
the/DT
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
./.
====================
The/DT
same/JJ
agents/NNS
induce/VBP
transcription/NN
from/IN
the/DT
interleukin-2/NN
receptor/NN
alpha-chain/NN
and/CC
interleukin-2/NN
genes/NNS
,/,
depending/VBG
on/IN
promoter/NN
elements/NNS
that/WDT
bind/VBP
the/DT
inducible/JJ
transcription/NN
factor/NN
NF-kappa/NN
B/NN
(/(
or/CC
an/DT
NF-kappa/NN
B-like/JJ
factor/NN
)/)
./.
====================
We/PRP
therefore/RB
tested/VBD
the/DT
possibility/NN
that/IN
the/DT
GM-CSF/NN
gene/NN
is/VBZ
also/RB
regulated/VBN
by/IN
a/DT
cognate/JJ
motif/NN
for/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
./.
====================
A/DT
recent/JJ
functional/JJ
analysis/NN
by/IN
Miyatake/NNP
et/FW
al./FW
(/(
S./NNP
Miyatake/NNP
,/,
M./NNP
Seiki/NNP
,/,
M./NNP
Yoshida/NNP
,/,
and/CC
K./NNP
Arai/NNP
,/,
Mol./NNP
Cell./NNP
Biol./NNP
8/CD
:/:
5581-5587/CD
,/,
1988/CD
)/)
described/VBD
a/DT
short/JJ
promoter/NN
region/NN
in/IN
the/DT
GM-CSF/NN
gene/NN
that/WDT
conferred/VBD
strong/JJ
inducibility/NN
by/IN
T-cell-activating/JJ
signals/NNS
and/CC
tax1/NN
,/,
but/CC
no/DT
NF-kappa/NN
B-binding/NN
motifs/NNS
were/VBD
identified/VBN
./.
====================
Using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
,/,
we/PRP
showed/VBD
binding/NN
of/IN
purified/VBN
human/JJ
NF-kappa/NN
B/NN
and/CC
of/IN
the/DT
NF-kappa/NN
B/NN
activated/VBN
in/IN
Jurkat/NN
T/NN
cells/NNS
to/TO
an/DT
oligonucleotide/NN
comprising/VBG
the/DT
GM-CSF/NN
promoter/NN
element/NN
responsible/JJ
for/IN
mediating/VBG
responsiveness/NN
to/TO
T-cell-activating/JJ
signals/NNS
and/CC
tax1/NN
./.
====================
As/IN
shown/VBN
by/IN
a/DT
methylation/NN
interference/NN
analysis/NN
and/CC
oligonucleotide/NN
competition/NN
experiments/NNS
,/,
purified/VBN
NF-kappa/NN
B/NN
binds/VBZ
at/IN
positions/NNS
-82/CD
to/TO
-91/CD
(/(
GGGAACTACC/NN
)/)
of/IN
the/DT
GM-CSF/NN
promoter/NN
sequence/NN
with/IN
an/DT
affinity/NN
similar/JJ
to/TO
that/DT
with/IN
which/WDT
it/PRP
binds/VBZ
to/TO
the/DT
biologically/RB
functional/JJ
kappa/NN
B/NN
motif/NN
in/IN
the/DT
beta/NN
interferon/NN
promoter/NN
(/(
GGGAAATTCC/NN
)/)
./.
====================
Two/CD
kappa/NN
B-like/JJ
motifs/NNS
at/IN
positions/NNS
-98/CD
to/TO
-108/CD
of/IN
the/DT
GM-CSF/NN
promoter/NN
were/VBD
also/RB
recognized/VBN
but/CC
with/IN
much/JJ
lower/JJR
affinities/NNS
./.
====================
Our/PRP$
data/NNS
provide/VBP
strong/JJ
evidence/NN
that/IN
the/DT
expression/NN
of/IN
the/DT
GM-CSF/NN
gene/NN
following/VBG
T-cell/NN
activation/NN
is/VBZ
controlled/VBN
by/IN
binding/NN
of/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
to/TO
a/DT
high-affinity/JJ
binding/NN
site/NN
in/IN
the/DT
GM-CSF/NN
promoter/NN
./.
====================
UI/LS
-/:
90254291/CD
====================
TI/LS
-/:
Effects/NNS
of/IN
mitogenic/JJ
agents/NNS
upon/IN
glucocorticoid/NN
action/NN
in/IN
human/JJ
tonsillar/NN
T-lymphocytes/NNS
./.
====================
AB/LS
-/:
The/DT
treatment/NN
of/IN
human/JJ
tonsillar/NN
T-lymphocytes/NNS
with/IN
4-phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
PMA/NN
)/)
,/,
resulted/VBD
in/IN
about/RB
two/CD
fold/JJ
increase/NN
in/IN
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
number/NN
,/,
without/IN
any/DT
significant/JJ
change/NN
in/IN
the/DT
receptor/NN
affinity/NN
./.
====================
This/DT
increase/NN
disappeared/VBD
in/IN
the/DT
presence/NN
of/IN
cycloheximide/NN
./.
====================
Alone/RB
,/,
PMA/NN
and/CC
calcium/NN
ionophore/NN
A23187/NN
did/VBD
not/RB
affect/VB
,/,
but/CC
together/RB
stimulated/VBD
,/,
like/IN
phytohaemagglutinin/NN
(/(
PHA/NN
)/)
,/,
leucine/NN
and/CC
,/,
in/IN
particular/JJ
,/,
thymidine/NN
incorporation/NN
./.
====================
PMA/NN
enhanced/VBD
slightly/RB
the/DT
stimulatory/JJ
effect/NN
of/IN
PHA/NN
./.
====================
Alone/RB
,/,
these/DT
agents/NNS
failed/VBD
to/TO
alter/VB
the/DT
suppressive/JJ
effect/NN
of/IN
dexamethasone/NN
on/IN
thymidine/NN
and/CC
leucine/NN
incorporation/NN
;/:
however/RB
,/,
PMA-A23187/JJ
and/CC
PMA-PHA/JJ
combinations/NNS
appeared/VBD
to/TO
antagonize/VB
the/DT
suppression/NN
by/IN
dexamethasone/NN
./.
====================
UI/LS
-/:
92010096/CD
====================
TI/LS
-/:
To/TO
be/VB
or/CC
not/RB
to/TO
be/VB
a/DT
responder/NN
in/IN
T-cell/NN
responses/NNS
:/:
ubiquitous/JJ
oligopeptides/NNS
in/IN
all/DT
proteins/NNS
./.
====================
AB/LS
-/:
Amino/NN
acid/NN
sequences/NNS
of/IN
all/DT
proteins/NNS
are/VBP
essays/NNS
written/VBN
in/IN
the/DT
same/JJ
language/NN
./.
====================
Accordingly/RB
,/,
the/DT
same/JJ
set/NN
of/IN
words/NNS
and/CC
phrases/NNS
(/(
oligopeptides/NNS
)/)
appear/VBP
in/IN
totally/RB
unrelated/JJ
proteins/NNS
./.
====================
The/DT
reason/NN
that/IN
only/RB
certain/JJ
individuals/NNS
of/IN
particular/JJ
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
haplotypes/NNS
can/MD
mount/VB
T-cell/NN
responses/NNS
against/IN
a/DT
given/JJ
antigen/NN
of/IN
pathogens/NNS
is/VBZ
found/VBN
in/IN
the/DT
fact/NN
that/IN
T-cell/NN
receptors/NNS
are/VBP
designed/VBN
to/TO
recognize/VB
18-20/CD
residue-long/JJ
peptide/NN
fragments/NNS
sandwiched/JJ
between/IN
two/CD
alpha-helices/NNS
of/IN
class/NN
I/CD
or/CC
class/NN
II/CD
MHC/NN
molecules/NNS
./.
====================
At/IN
this/DT
range/NN
of/IN
peptide/NN
lengths/NNS
,/,
most/JJS
would/MD
appear/VB
as/IN
self/NN
,/,
while/IN
nonselfness/NN
of/IN
the/DT
remainders/NNS
are/VBP
destined/VBN
to/TO
be/VB
quite/RB
ambiguous/JJ
,/,
hence/RB
creating/VBG
responders/NNS
and/CC
nonresponders/NNS
./.
====================
UI/LS
-/:
91067681/CD
====================
TI/LS
-/:
Two/CD
distinct/JJ
signal/NN
transmission/NN
pathways/NNS
in/IN
T/NN
lymphocytes/NNS
are/VBP
inhibited/VBN
by/IN
complexes/NNS
formed/VBN
between/IN
an/DT
immunophilin/NN
and/CC
either/CC
FK506/NN
or/CC
rapamycin/NN
./.
====================
AB/LS
-/:
Proliferation/NN
and/CC
immunologic/JJ
function/NN
of/IN
T/NN
lymphocytes/NNS
are/VBP
initiated/VBN
by/IN
signals/NNS
from/IN
the/DT
antigen/NN
receptor/NN
that/WDT
are/VBP
inhibited/VBN
by/IN
the/DT
immunosuppressant/JJ
FK506/NN
but/CC
not/RB
by/IN
its/PRP$
structural/JJ
analog/NN
,/,
rapamycin/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
-induced/JJ
signals/NNS
are/VBP
blocked/VBN
by/IN
rapamycin/NN
but/CC
not/RB
by/IN
FK506/NN
./.
====================
Remarkably/RB
,/,
these/DT
two/CD
drugs/NNS
inhibit/VBP
each/DT
other/JJ
's/POS
actions/NNS
,/,
raising/VBG
the/DT
possibility/NN
that/IN
both/DT
act/VBP
by/IN
means/NNS
of/IN
a/DT
common/JJ
immunophilin/NN
(/(
immunosuppressant/JJ
binding/NN
protein/NN
)/)
./.
====================
We/PRP
find/VBP
that/IN
the/DT
dissociation/NN
constant/NN
of/IN
rapamycin/NN
to/TO
the/DT
FK506/NN
binding/NN
protein/NN
FKBP/NN
(/(
Kd/NN
=/JJ
0.2/CD
nM/NN
)/)
is/VBZ
close/JJ
to/TO
the/DT
dissociation/NN
constant/NN
of/IN
FK506/NN
to/TO
FKBP/NN
(/(
Kd/NN
=/JJ
0.4/CD
nM/NN
)/)
and/CC
to/TO
their/PRP$
effective/JJ
biologic/JJ
inhibitory/JJ
concentrations/NNS
./.
====================
However/RB
,/,
an/DT
excess/NN
of/IN
rapamycin/NN
is/VBZ
needed/VBN
to/TO
revert/VB
FK506-mediated/JJ
inhibition/NN
of/IN
IL-2/NN
production/NN
,/,
apoptosis/NN
,/,
and/CC
transcriptional/JJ
activation/NN
of/IN
NF-AT/NN
,/,
a/DT
T-cell-specific/JJ
transcription/NN
factor/NN
necessary/JJ
for/IN
IL-2/NN
gene/NN
activation/NN
./.
====================
Similarly/RB
,/,
an/DT
excess/NN
of/IN
FK506/NN
is/VBZ
needed/VBN
to/TO
revert/VB
rapamycin-mediated/JJ
inhibition/NN
of/IN
IL-2-induced/JJ
proliferation/NN
./.
====================
The/DT
drug/NN
concentrations/NNS
required/VBN
for/IN
antagonism/NN
may/MD
be/VB
explained/VBN
by/IN
the/DT
relative/JJ
affinity/NN
of/IN
the/DT
drugs/NNS
to/TO
,/,
and/CC
by/IN
the/DT
abundance/NN
of/IN
,/,
the/DT
immunophilin/NN
FKBP/NN
./.
====================
FKBP/NN
has/VBZ
been/VBN
shown/VBN
to/TO
catalyze/VB
the/DT
interconversion/NN
of/IN
the/DT
cis-/JJ
and/CC
trans-rotamers/NNS
of/IN
the/DT
peptidyl-prolyl/JJ
amide/NN
bond/NN
of/IN
peptide/NN
substrates/NNS
;/:
here/RB
we/PRP
show/VBP
that/IN
rapamycin/NN
,/,
like/IN
FK506/NN
,/,
is/VBZ
a/DT
potent/JJ
inhibitor/NN
of/IN
the/DT
rotamase/NN
activity/NN
of/IN
FKBP/NN
(/(
Ki/NN
=/JJ
0.2/CD
nM/NN
)/)
./.
====================
Neither/CC
FKBP/NN
binding/NN
nor/CC
inhibition/NN
of/IN
rotamase/NN
activity/NN
of/IN
FKBP/NN
alone/RB
is/VBZ
sufficient/JJ
to/TO
explain/VB
the/DT
biologic/JJ
actions/NNS
of/IN
these/DT
drugs/NNS
./.
====================
Rather/RB
,/,
these/DT
findings/NNS
suggest/VBP
that/IN
immunophilin/NN
bound/VBN
to/TO
FK506/NN
interferes/VBZ
with/IN
antigen/NN
receptor-induced/JJ
signals/NNS
,/,
while/IN
rapamycin/NN
bound/VBN
to/TO
the/DT
immunophilin/NN
interferes/VBZ
with/IN
IL-2-induced/JJ
signals/NNS
./.
====================
UI/LS
-/:
91035625/CD
====================
TI/LS
-/:
Adherence-dependent/JJ
increase/NN
in/IN
human/JJ
monocyte/NN
PDGF(B)/NN
mRNA/NN
is/VBZ
associated/VBN
with/IN
increases/NNS
in/IN
c-fos/NN
,/,
c-jun/NN
,/,
and/CC
EGR2/NN
mRNA/NN
./.
====================
AB/LS
-/:
Adherence/NN
is/VBZ
an/DT
important/JJ
initial/JJ
step/NN
in/IN
the/DT
transition/NN
of/IN
a/DT
circulating/VBG
monocyte/NN
to/TO
a/DT
tissue/NN
macrophage/NN
./.
====================
This/DT
differentiation/NN
is/VBZ
accompanied/VBN
by/IN
an/DT
augmented/JJ
capacity/NN
to/TO
generate/VB
growth/NN
factors/NNS
./.
====================
We/PRP
hypothesized/VBD
that/IN
adherence/NN
itself/PRP
might/MD
be/VB
an/DT
important/JJ
trigger/NN
for/IN
a/DT
sequence/NN
of/IN
gene/NN
activation/NN
culminating/VBG
in/IN
cells/NNS
with/IN
increased/VBN
mRNA/NN
encoding/VBG
profibrotic/JJ
growth/NN
factors/NNS
such/JJ
as/IN
platelet-derived/JJ
growth/NN
factor/NN
B/NN
subunit/NN
(/(
PDGF[B]/NN
)/)
and/CC
transforming/VBG
growth/NN
factor-beta/NN
(/(
TGF-beta/NN
)/)
./.
====================
After/IN
in/FW
vitro/FW
adherence/NN
,/,
human/JJ
monocytes/NNS
had/VBD
a/DT
biphasic/JJ
increase/NN
in/IN
PDGF(B)/NN
mRNA/NN
with/IN
peaks/NNS
at/IN
6/CD
h/NN
and/CC
13/CD
d/NN
./.
====================
No/DT
increase/NN
in/IN
TGF-beta/NN
mRNA/NN
was/VBD
observed/VBN
./.
====================
The/DT
6-h/JJ
increase/NN
in/IN
PDGF(B)/NN
mRNA/NN
was/VBD
adherence/NN
dependent/JJ
,/,
and/CC
in/IN
addition/NN
,/,
was/VBD
abrogated/VBN
when/WRB
the/DT
cytoskeletal/JJ
integrity/NN
was/VBD
compromised/VBN
by/IN
cytochalasin/NN
D/NN
./.
====================
The/DT
6-h/JJ
increase/NN
in/IN
PDGF(B)/NN
mRNA/NN
was/VBD
unaltered/JJ
by/IN
adherence/NN
in/IN
the/DT
presence/NN
of/IN
the/DT
monocyte/NN
stimulus/NN
lipopolysaccharide/NN
./.
====================
Adherence/NN
to/TO
either/CC
fibronectin/NN
or/CC
collagen-coated/JJ
plastic/NN
had/VBD
little/JJ
consistent/JJ
effect/NN
on/IN
PDGF(B)/NN
mRNA/NN
accumulation/NN
./.
====================
The/DT
increased/VBN
PDGF(B)/NN
mRNA/NN
observed/VBN
in/IN
adherent/JJ
monocytes/NNS
was/VBD
accompanied/VBN
by/IN
increases/NNS
in/IN
mRNAs/NNS
of/IN
the/DT
early/JJ
growth/NN
response/NN
genes/NNS
c-fos/NN
(/(
maximal/JJ
at/IN
20/CD
min/NN
)/)
,/,
c-jun/NN
,/,
and/CC
EGR2/NN
(/(
maximal/JJ
at/IN
6-24/CD
h/NN
)/)
./.
====================
The/DT
increase/NN
in/IN
c-jun/NN
and/CC
EGR2/NN
,/,
but/CC
not/RB
c-fos/NN
,/,
mRNA/NN
was/VBD
also/RB
abrogated/VBN
by/IN
cytochalasin/NN
D/NN
./.
====================
These/DT
observations/NNS
suggest/VBP
that/IN
adherence/NN
results/VBZ
in/IN
increases/NNS
of/IN
c-fos/NN
,/,
c-jun/NN
,/,
EGR2/NN
,/,
and/CC
PDGF(B)/NN
mRNA/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
increases/NNS
in/IN
c-jun/NN
,/,
EGR2/NN
,/,
and/CC
PDGF(B)/NN
may/MD
depend/VB
on/IN
cytoskeletal/JJ
rearrangement/NN
./.
====================
Modulation/NN
of/IN
these/DT
events/NNS
at/IN
the/DT
time/NN
of/IN
adherence/NN
offers/VBZ
a/DT
mechanism/NN
by/IN
which/WDT
differential/JJ
priming/NN
of/IN
the/DT
cells/NNS
may/MD
be/VB
accomplished/VBN
./.
====================
UI/LS
-/:
91065527/CD
====================
TI/LS
-/:
Single/JJ
cell/NN
assay/NN
of/IN
a/DT
transcription/NN
factor/NN
reveals/VBZ
a/DT
threshold/NN
in/IN
transcription/NN
activated/VBN
by/IN
signals/NNS
emanating/VBG
from/IN
the/DT
T-cell/NN
antigen/NN
receptor/NN
./.
====================
AB/LS
-/:
Stimulation/NN
of/IN
T/NN
lymphocytes/NNS
through/IN
their/PRP$
antigen/NN
receptor/NN
leads/VBZ
to/TO
the/DT
appearance/NN
of/IN
several/JJ
transcription/NN
factors/NNS
,/,
including/VBG
NF-AT/NN
and/CC
NF-kappa/NN
B/NN
,/,
which/WDT
are/VBP
involved/VBN
in/IN
regulating/VBG
genes/NNS
required/VBN
for/IN
immunologic/JJ
activation/NN
./.
====================
To/TO
investigate/VB
the/DT
activity/NN
of/IN
a/DT
single/JJ
transcription/NN
factor/NN
in/IN
individual/JJ
viable/JJ
cells/NNS
,/,
we/PRP
have/VBP
applied/VBN
an/DT
assay/NN
that/WDT
uses/VBZ
the/DT
fluorescence-activated/JJ
cell/NN
sorter/NN
to/TO
quantitate/VB
beta-galactosidase/NN
(/(
beta-gal/NN
)/)
./.
====================
We/PRP
have/VBP
analyzed/VBN
the/DT
distribution/NN
of/IN
NF-AT/NN
transcriptional/JJ
activity/NN
among/IN
T/NN
cells/NNS
undergoing/VBG
activation/NN
by/IN
using/VBG
a/DT
construct/NN
in/IN
which/WDT
three/CD
tandem/JJ
copies/NNS
of/IN
the/DT
NF-AT-binding/NN
site/NN
directs/VBZ
transcription/NN
of/IN
the/DT
lacZ/NN
gene/NN
./.
====================
Unexpectedly/RB
,/,
stimulation/NN
of/IN
cloned/VBN
stably/RB
transfected/VBN
Jurkat/NN
T/NN
cells/NNS
leads/VBZ
to/TO
a/DT
bimodal/JJ
pattern/NN
of/IN
beta-gal/NN
expression/NN
in/IN
which/WDT
some/DT
cells/NNS
express/VBP
no/DT
beta-gal/NN
and/CC
others/NNS
express/VBP
high/JJ
levels/NNS
./.
====================
This/DT
expression/NN
pattern/NN
can/MD
not/RB
be/VB
accounted/VBN
for/IN
by/IN
cell-cycle/JJ
position/NN
or/CC
heritable/JJ
variation/NN
./.
====================
Further/JJ
results/NNS
,/,
in/IN
which/WDT
beta-gal/NN
activity/NN
is/VBZ
correlated/VBN
with/IN
NF-AT-binding/NN
activity/NN
,/,
indicate/VBP
that/IN
the/DT
concentration/NN
of/IN
NF-AT/NN
must/MD
exceed/VB
a/DT
critical/JJ
threshold/NN
before/IN
transcription/NN
initiates/VBZ
./.
====================
This/DT
threshold/NN
likely/RB
reflects/VBZ
the/DT
NF-AT/NN
concentration-dependent/JJ
assembly/NN
of/IN
transcription/NN
complexes/NNS
at/IN
the/DT
promoter/NN
./.
====================
Similar/JJ
constructs/NNS
controlled/VBN
by/IN
NF-kappa/NN
B/NN
or/CC
the/DT
entire/JJ
interleukin-2/NN
enhancer/NN
show/VBP
bimodal/JJ
expression/NN
patterns/NNS
during/IN
induction/NN
,/,
suggesting/VBG
that/IN
thresholds/NNS
set/VBN
by/IN
the/DT
concentration/NN
of/IN
transcription/NN
factors/NNS
may/MD
be/VB
a/DT
common/JJ
property/NN
of/IN
inducible/JJ
genes/NNS
./.
====================
UI/LS
-/:
90317873/CD
====================
TI/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
BMRF1/NN
promoter/NN
for/IN
early/JJ
antigen/NN
(/(
EA-D/NN
)/)
is/VBZ
regulated/VBN
by/IN
the/DT
EBV/NN
transactivators/NNS
,/,
BRLF1/NN
and/CC
BZLF1/NN
,/,
in/IN
a/DT
cell-specific/JJ
manner/NN
./.
====================
AB/LS
-/:
The/DT
Epstein-Barr/JJ
virus/NN
early/JJ
antigen/NN
diffuse/NN
component/NN
(/(
EA-D/NN
)/)
is/VBZ
essential/JJ
for/IN
Epstein-Barr/JJ
virus/NN
DNA/NN
polymerase/NN
activity/NN
,/,
and/CC
its/PRP$
activity/NN
is/VBZ
suppressed/VBN
during/IN
latent/JJ
infection/NN
./.
====================
We/PRP
investigated/VBD
the/DT
regulation/NN
of/IN
the/DT
promoter/NN
(/(
BMRF1/NN
)/)
for/IN
this/DT
early/JJ
gene/NN
by/IN
studying/VBG
its/PRP$
responsiveness/NN
in/FW
vitro/FW
to/TO
two/CD
immediate-early/JJ
viral/JJ
transactivators/NNS
,/,
BZLF1/NN
(/(
Z/NN
)/)
and/CC
BRLF1/NN
(/(
R/NN
)/)
,/,
focusing/VBG
on/IN
the/DT
differences/NNS
in/IN
response/NN
in/IN
lymphoid/JJ
cells/NNS
and/CC
epithelial/JJ
cells/NNS
./.
====================
In/IN
lymphoid/JJ
cells/NNS
,/,
Z/NN
or/CC
R/NN
alone/RB
produced/VBD
only/RB
small/JJ
increases/NNS
in/IN
EA-D/NN
promoter/NN
activity/NN
,/,
whereas/IN
both/DT
transactivators/NNS
together/RB
produced/VBD
a/DT
large/JJ
stimulatory/JJ
effect/NN
./.
====================
In/IN
epithelial/JJ
cells/NNS
,/,
the/DT
Z/NN
transactivator/NN
alone/RB
produced/VBD
maximal/JJ
stimulation/NN
of/IN
the/DT
EA-D/NN
promoter/NN
;/:
the/DT
effect/NN
of/IN
R/NN
and/CC
Z/NN
together/RB
was/VBD
no/DT
greater/JJR
than/IN
that/DT
of/IN
Z/NN
alone/RB
./.
====================
Deletional/JJ
analysis/NN
and/CC
site-directed/JJ
mutagenesis/NN
of/IN
the/DT
EA-D/NN
promoter/NN
demonstrated/VBD
that/IN
in/IN
epithelial/JJ
cells/NNS
the/DT
potential/JJ
AP-1/NN
binding/NN
site/NN
plays/VBZ
an/DT
essential/JJ
role/NN
in/IN
Z/NN
responsiveness/NN
,/,
although/IN
sequences/NNS
further/RB
upstream/JJ
are/VBP
also/RB
important/JJ
./.
====================
In/IN
lymphoid/JJ
cells/NNS
,/,
only/RB
the/DT
upstream/JJ
sequences/NNS
are/VBP
required/VBN
for/IN
transactivation/NN
by/IN
the/DT
Z/R/NN
combination/NN
,/,
and/CC
the/DT
AP-1/NN
site/NN
is/VBZ
dispensable/JJ
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
EA-D/NN
(/(
BMRF1/NN
)/)
promoter/NN
regulation/NN
by/IN
Z/NN
and/CC
R/NN
is/VBZ
cell/NN
type/NN
specific/JJ
and/CC
appears/VBZ
to/TO
involve/VB
different/JJ
mechanisms/NNS
in/IN
each/DT
cell/NN
type/NN
./.
====================
UI/LS
-/:
90319127/CD
====================
TI/LS
-/:
Complementary/JJ
DNA/NN
encoding/VBG
the/DT
human/JJ
T-cell/NN
FK506-binding/JJ
protein/NN
,/,
a/DT
peptidylprolyl/JJ
cis-trans/JJ
isomerase/NN
distinct/JJ
from/IN
cyclophilin/NN
./.
====================
AB/LS
-/:
The/DT
recently/RB
discovered/VBN
macrolide/NN
FK506/NN
has/VBZ
been/VBN
demonstrated/VBN
to/TO
have/VB
potent/JJ
immunosuppressive/JJ
activity/NN
at/IN
concentrations/NNS
100-fold/RB
lower/JJR
than/IN
cyclosporin/NN
A/NN
,/,
a/DT
cyclic/JJ
undecapeptide/NN
that/WDT
is/VBZ
used/VBN
to/TO
prevent/VB
rejection/NN
after/IN
transplantation/NN
of/IN
bone/NN
marrow/NN
and/CC
organs/NNS
,/,
such/JJ
as/IN
kidney/NN
,/,
heart/NN
,/,
and/CC
liver/NN
./.
====================
After/IN
the/DT
recent/JJ
discovery/NN
that/IN
the/DT
cyclosporin/NN
A-binding/NN
protein/NN
cyclophilin/NN
is/VBZ
identical/JJ
to/TO
peptidylprolyl/JJ
cis-trans/JJ
isomerase/NN
,/,
a/DT
cellular/JJ
binding/NN
protein/NN
for/IN
FK506/NN
was/VBD
found/VBN
to/TO
be/VB
distinct/JJ
from/IN
cyclophilin/NN
but/CC
to/TO
have/VB
the/DT
same/JJ
enzymatic/JJ
activity/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
isolated/VBD
a/DT
cDNA/NN
coding/VBG
for/IN
FK506-binding/JJ
protein/NN
(/(
FKBP/NN
)/)
from/IN
human/JJ
peripheral/JJ
blood/NN
T/NN
cells/NNS
by/IN
using/VBG
mixed/JJ
20-mer/JJ
oligonucleotide/NN
probes/NNS
synthesized/VBN
on/IN
the/DT
basis/NN
of/IN
the/DT
sequence/NN
,/,
Glu-Asp-Gly-Lys-Lys-Phe-Asp/NN
,/,
reported/VBN
for/IN
bovine/JJ
FKBP/NN
./.
====================
The/DT
DNA/NN
isolated/VBN
contained/VBD
an/DT
open/JJ
reading/NN
frame/NN
encoding/VBG
108/CD
amino/NN
acid/NN
residues/NNS
./.
====================
The/DT
first/JJ
40/CD
residues/NNS
of/IN
the/DT
deduced/VBN
amino/NN
acid/NN
sequence/NN
were/VBD
identical/JJ
to/TO
those/DT
of/IN
the/DT
reported/VBN
amino-terminal/JJ
sequence/NN
of/IN
bovine/JJ
FKBP/NN
,/,
indicating/VBG
that/IN
the/DT
DNA/NN
sequence/NN
isolated/VBN
represents/VBZ
the/DT
gene/NN
coding/VBG
for/IN
FKBP/NN
./.
====================
Computer-assisted/JJ
analysis/NN
of/IN
the/DT
deduced/VBN
amino/NN
acid/NN
sequence/NN
indicates/VBZ
that/IN
FKBP/NN
exhibits/VBZ
no/DT
internal/JJ
homology/NN
and/CC
does/VBZ
not/RB
have/VB
significant/JJ
sequence/NN
similarity/NN
to/TO
any/DT
other/JJ
amino/NN
acid/NN
sequences/NNS
of/IN
known/JJ
proteins/NNS
,/,
including/VBG
cyclophilin/NN
./.
====================
This/DT
result/NN
suggests/VBZ
that/IN
two/CD
catalytically/RB
similar/JJ
proteins/NNS
,/,
cyclophilin/NN
and/CC
FKBP/NN
,/,
evolved/VBD
independently/RB
./.
====================
In/IN
Northern/NN
blot/NN
analysis/NN
,/,
mRNA/NN
species/NNS
of/IN
approximately/RB
1.8/CD
kilobases/NNS
that/WDT
hybridized/VBD
with/IN
human/JJ
FKBP/NN
cDNA/NN
were/VBD
detected/VBN
in/IN
poly(A)+/JJ
RNAs/NNS
from/IN
brain/NN
,/,
lung/NN
,/,
liver/NN
,/,
and/CC
placental/JJ
cells/NNS
and/CC
leukocytes/NNS
./.
====================
Induction/NN
of/IN
Jurkat/NN
leukemic/JJ
T/NN
cells/NNS
with/IN
phorbol/NN
12-myristate/NN
13-acetate/NN
and/CC
ionomycin/NN
did/VBD
not/RB
affect/VB
the/DT
level/NN
of/IN
FKBP/NN
mRNA/NN
./.
====================
Southern/NN
blot/NN
analysis/NN
of/IN
human/JJ
genomic/JJ
DNA/NN
digested/VBN
with/IN
different/JJ
restriction/NN
enzymes/NNS
suggests/VBZ
the/DT
existence/NN
of/IN
only/RB
a/DT
few/JJ
copies/NNS
of/IN
the/DT
DNA/NN
sequence/NN
encoding/VBG
FKBP/NN
./.
====================
This/DT
is/VBZ
in/IN
contrast/NN
to/TO
the/DT
result/NN
that/IN
as/RB
many/JJ
as/IN
20/CD
copies/NNS
of/IN
the/DT
cyclophilin/NN
gene/NN
and/CC
possible/JJ
pseudogenes/NNS
may/MD
be/VB
present/JJ
in/IN
the/DT
mammalian/JJ
genome/NN
./.
====================
UI/LS
-/:
90258907/CD
====================
TI/LS
-/:
Involvement/NN
of/IN
a/DT
second/JJ
lymphoid-specific/JJ
enhancer/NN
element/NN
in/IN
the/DT
regulation/NN
of/IN
immunoglobulin/NN
heavy-chain/NN
gene/NN
expression/NN
./.
====================
AB/LS
-/:
To/TO
determine/VB
whether/IN
enhancer/NN
elements/NNS
in/IN
addition/NN
to/TO
the/DT
highly/RB
conserved/VBN
octamer/NN
(/(
OCTA/NN
)/)
-nucleotide/JJ
motif/NN
are/VBP
important/JJ
for/IN
lymphoid-specific/JJ
expression/NN
of/IN
the/DT
immunoglobulin/NN
heavy-chain/NN
(/(
IgH/NN
)/)
gene/NN
,/,
we/PRP
have/VBP
investigated/VBN
the/DT
effect/NN
of/IN
mutating/VBG
the/DT
binding/VBG
site/NN
for/IN
a/DT
putative/JJ
additional/JJ
lymphoid-specific/JJ
transcription/NN
factor/NN
,/,
designated/VBN
NF-microB/NN
,/,
in/IN
the/DT
murine/JJ
IgH/NN
enhancer/NN
./.
====================
We/PRP
demonstrate/VBP
that/IN
the/DT
NF-microB-binding/JJ
site/NN
plays/VBZ
a/DT
critical/JJ
role/NN
in/IN
the/DT
IgH/NN
enhancer/NN
,/,
because/IN
mutation/NN
of/IN
the/DT
microB/NN
DNA/NN
motif/NN
decreased/VBD
transcriptional/JJ
activity/NN
of/IN
the/DT
IgH/NN
enhancer/NN
in/IN
cells/NNS
of/IN
the/DT
B-cell/NN
lineage/NN
but/CC
not/RB
in/IN
nonlymphoid/JJ
cells/NNS
./.
====================
This/DT
effect/NN
was/VBD
comparable/JJ
to/TO
or/CC
even/RB
stronger/JJR
than/IN
the/DT
effect/NN
of/IN
a/DT
mutation/NN
in/IN
the/DT
OCTA/NN
site/NN
./.
====================
Moreover/RB
,/,
combined/JJ
mutation/NN
of/IN
both/CC
microB/NN
and/CC
OCTA/NN
sites/NNS
further/RBR
reduced/VBD
enhancer/NN
activity/NN
in/IN
lymphoid/JJ
cells/NNS
./.
====================
Interestingly/RB
,/,
alteration/NN
of/IN
either/CC
the/DT
microB/NN
or/CC
E3/NN
site/NN
in/IN
a/DT
70-base-pair/JJ
fragment/NN
of/IN
the/DT
IgH/NN
enhancer/NN
that/WDT
lacks/VBZ
the/DT
binding/VBG
site/NN
for/IN
OCTA/NN
abolished/VBD
enhancer/NN
activity/NN
in/IN
lymphoid/JJ
cells/NNS
completely/RB
./.
====================
Nevertheless/RB
,/,
a/DT
multimer/NN
of/IN
the/DT
microB/NN
motif/NN
alone/RB
showed/VBD
no/DT
enhancer/NN
activity/NN
./.
====================
DNase/NN
footprinting/NN
analysis/NN
corroborated/VBD
the/DT
functional/JJ
data/NNS
showing/VBG
that/IN
a/DT
lymphoid-specific/JJ
protein/NN
binds/VBZ
to/TO
the/DT
microB/NN
DNA/NN
motif/NN
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
the/DT
microB/NN
element/NN
is/VBZ
a/DT
new/JJ
crucial/JJ
element/NN
important/JJ
for/IN
lymphoid-specific/JJ
expression/NN
of/IN
the/DT
IgH/NN
gene/NN
but/CC
that/IN
interaction/NN
with/IN
another/DT
enhancer/NN
element/NN
is/VBZ
essential/JJ
for/IN
its/PRP$
activity/NN
./.
====================
UI/LS
-/:
90298081/CD
====================
TI/LS
-/:
Stimulation/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
2/CD
(/(
HIV-2/NN
)/)
gene/NN
expression/NN
by/IN
the/DT
cytomegalovirus/NN
and/CC
HIV-2/NN
transactivator/NN
gene/NN
./.
====================
AB/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
often/RB
causes/VBZ
latent/JJ
infection/NN
./.
====================
Transactivation/NN
by/IN
some/DT
DNA/NN
viruses/NNS
has/VBZ
been/VBN
implicated/VBN
in/IN
inducing/VBG
HIV-1/NN
replication/NN
and/CC
pathogenesis/NN
./.
====================
The/DT
transactivator/NN
(/(
IE-2/NN
)/)
gene/NN
of/IN
the/DT
human/JJ
cytomegalovirus/NN
(/(
CMV/NN
)/)
can/MD
enhance/VB
HIV-2/NN
as/RB
well/RB
as/IN
HIV-1/NN
gene/NN
expression/NN
in/FW
vitro/FW
./.
====================
This/DT
inducer/NN
can/MD
act/VB
in/IN
concert/NN
with/IN
the/DT
HIV-2/NN
tat/NN
gene/NN
and/CC
T-cell/NN
activation/NN
in/IN
enhancing/VBG
gene/NN
expression/NN
in/IN
human/JJ
CD4+/JJ
lymphocytes/NNS
./.
====================
While/IN
the/DT
HIV-2/NN
and/CC
HIV-1/NN
tat/NN
genes/NNS
and/CC
T-cell/NN
activators/NNS
apparently/RB
employ/VBP
independent/JJ
modes/NNS
of/IN
action/NN
,/,
the/DT
CMV/NN
transactivator/NN
in/IN
combination/NN
with/IN
the/DT
HIV-2/NN
tat/NN
or/CC
T-cell/NN
activators/NNS
may/MD
employ/VB
a/DT
gene/NN
activation/NN
pathway/NN
with/IN
some/DT
common/JJ
and/CC
some/DT
distinct/JJ
components/NNS
./.
====================
Both/CC
HIV-2/NN
and/CC
CMV/NN
transactivators/NNS
enhance/VBP
HIV-2/NN
gene/NN
expression/NN
by/IN
transcriptional/JJ
activation/NN
involving/VBG
transcript/NN
initiation/NN
as/RB
well/RB
as/IN
elongation/NN
,/,
with/IN
CMV/NN
transactivator/NN
affecting/VBG
elongation/NN
more/JJR
than/IN
the/DT
initiation/NN
./.
====================
A/DT
significant/JJ
proportion/NN
of/IN
transcripts/NNS
appear/VBP
to/TO
terminate/VB
prematurely/RB
in/IN
the/DT
absence/NN
of/IN
transactivators/NNS
./.
====================
Deletion/NN
mutation/NN
analysis/NN
of/IN
the/DT
HIV-2/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
suggests/VBZ
that/IN
the/DT
element/NN
that/WDT
responds/VBZ
to/TO
CMV/NN
transactivation/NN
in/IN
human/JJ
CD4+/JJ
lymphocytes/NNS
is/VBZ
either/CC
a/DT
diffuse/JJ
one/CD
or/CC
located/JJ
downstream/RB
of/IN
the/DT
HIV-2/NN
enhancer/NN
element/NN
./.
====================
UI/LS
-/:
90244306/CD
====================
TI/LS
-/:
Quantitative/JJ
immunohistochemical/JJ
analysis/NN
of/IN
mononuclear/JJ
infiltrates/NNS
in/IN
breast/NN
carcinomas/NNS
--/:
correlation/NN
with/IN
tumour/JJ
differentiation/NN
./.
====================
AB/LS
-/:
Inflammatory/JJ
infiltrates/NNS
were/VBD
analysed/VBN
in/IN
tissue/NN
sections/NNS
of/IN
76/CD
breast/NN
carcinomas/NNS
by/IN
counting/VBG
the/DT
percentage/NN
of/IN
macrophages/NNS
,/,
IgA+/JJ
and/CC
IgG+/JJ
plasma/NN
cells/NNS
,/,
T/NN
cells/NNS
with/IN
their/PRP$
subpopulations/NNS
,/,
and/CC
natural/JJ
killer/NN
cells/NNS
,/,
and/CC
by/IN
measuring/VBG
postcapillary/JJ
venules/NNS
(/(
PCVs/NNS
,/,
found/VBN
in/IN
12/CD
cases/NNS
)/)
within/IN
the/DT
infiltrates/NNS
./.
====================
These/DT
parameters/NNS
were/VBD
correlated/VBN
with/IN
nuclear/JJ
grade/NN
and/CC
biochemically/RB
determined/VBN
hormone/NN
receptor/NN
status/NN
,/,
known/JJ
markers/NNS
of/IN
tumour/NN
differentiation/NN
./.
====================
A/DT
direct/JJ
correlation/NN
was/VBD
found/VBN
between/IN
the/DT
extent/NN
of/IN
inflammation/NN
and/CC
nuclear/JJ
grade/NN
(/(
P/NN
less/JJR
than/IN
0.0001/CD
)/)
,/,
and/CC
an/DT
inverse/JJ
correlation/NN
between/IN
inflammation/NN
and/CC
oestrogen/NN
receptor/NN
(/(
OR/NN
)/)
positivity/NN
(/(
P/NN
less/JJR
than/IN
0.05/CD
)/)
as/RB
well/RB
as/IN
inflammation/NN
and/CC
progesterone/NN
receptor/NN
(/(
PR/NN
)/)
positivity/NN
(/(
P/NN
less/JJR
than/IN
0.05/CD
)/)
./.
====================
The/DT
percentage/NN
of/IN
the/DT
OKT8+/JJ
suppressor/cytotoxic/JJ
T/NN
cells/NNS
increased/VBD
when/WRB
the/DT
inflammation/NN
expanded/VBD
from/IN
scanty/JJ
to/TO
moderate/JJ
(/(
P/NN
less/JJR
than/IN
0.02/CD
)/)
./.
====================
The/DT
diameter/NN
of/IN
the/DT
PCVs/NNS
also/RB
increased/VBD
with/IN
increasing/VBG
inflammatory/JJ
infiltrate/NN
(/(
P/NN
less/JJR
than/IN
0.02/CD
)/)
./.
====================
In/IN
addition/NN
,/,
a/DT
direct/JJ
correlation/NN
exists/VBZ
between/IN
the/DT
diameter/NN
of/IN
the/DT
PCVs/NNS
and/CC
both/CC
the/DT
percentage/NN
of/IN
the/DT
OKT8+/JJ
T/NN
cells/NNS
(/(
P/NN
less/JJR
than/IN
0.04/CD
)/)
and/CC
the/DT
Leu-7+/JJ
natural/JJ
killer/NN
cells/NNS
(/(
P/NN
less/JJR
than/IN
0.03/CD
)/)
./.
====================
UI/LS
-/:
90124644/CD
====================
TI/LS
-/:
Reactivity/NN
of/IN
lymphocytes/NNS
to/TO
a/DT
progesterone/NN
receptor-specific/JJ
monoclonal/JJ
antibody/NN
./.
====================
AB/LS
-/:
In/IN
this/DT
study/NN
we/PRP
present/VBP
evidence/NN
for/IN
reactivity/NN
of/IN
pregnancy/NN
lymphocytes/NNS
,/,
but/CC
not/RB
nonpregnancy/JJ
lymphocytes/NNS
,/,
with/IN
the/DT
progesterone/NN
receptor-specific/JJ
monoclonal/JJ
antibody/NN
mPRI/NN
./.
====================
Using/VBG
an/DT
avidin-biotin/JJ
peroxidase/NN
detection/NN
system/NN
,/,
we/PRP
found/VBD
a/DT
nuclear/JJ
staining/NN
in/IN
14.6/CD
+/-/CC
3.7/CD
%/NN
(/(
mean/NN
+/-/CC
SEM/NN
,/,
N/NN
=/JJ
27/CD
)/)
of/IN
pregnancy/NN
lymphocytes/NNS
,/,
while/IN
only/RB
0.47/CD
+/-/CC
0.33/CD
%/NN
(/(
mean/NN
+/-/CC
SEM/NN
,/,
N/NN
=/JJ
15/CD
)/)
of/IN
nonpregnancy/NN
lymphocytes/NNS
reacted/VBD
with/IN
the/DT
antibody/NN
./.
====================
To/TO
characterize/VB
the/DT
receptor-bearing/JJ
subset/NN
,/,
CD8+/JJ
and/CC
CD4+/JJ
cells/NNS
were/VBD
depleted/VBN
by/IN
complement-dependent/JJ
lysis/NN
./.
====================
Depletion/NN
of/IN
CD8+/JJ
cells/NNS
was/VBD
accompanied/VBN
by/IN
62/CD
+/-/CC
18/CD
%/NN
loss/NN
of/IN
progesterone/NN
receptor-bearing/JJ
cells/NNS
,/,
while/IN
depletion/NN
of/IN
CD4+/JJ
cells/NNS
resulted/VBD
in/IN
a/DT
twofold/JJ
increase/NN
in/IN
the/DT
number/NN
of/IN
positively/RB
staining/VBG
lymphocytes/NNS
./.
====================
In/IN
nonpregnancy/NN
lymphocytes/NNS
a/DT
3-day/JJ
PHA/NN
treatment/NN
,/,
as/RB
well/RB
as/IN
allogeneic/JJ
stimulation/NN
,/,
resulted/VBD
in/IN
a/DT
significant/JJ
increase/NN
in/IN
the/DT
number/NN
of/IN
receptor-containing/JJ
cells/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
pregnancy/NN
,/,
but/CC
not/RB
nonpregnancy/NN
,/,
lymphocytes/NNS
contain/VBP
progesterone/NN
binding/NN
structures/NNS
,/,
and/CC
that/IN
these/DT
are/VBP
inducible/JJ
by/IN
mitogenic/JJ
or/CC
alloantigenic/JJ
stimuli/NNS
./.
====================
UI/LS
-/:
91079583/CD
====================
TI/LS
-/:
Activation/NN
of/IN
human/JJ
CD4/NN
T/NN
lymphocytes/NNS
./.
====================
Interaction/NN
of/IN
fibronectin/NN
with/IN
VLA-5/NN
receptor/NN
on/IN
CD4/NN
cells/NNS
induces/VBZ
the/DT
AP-1/NN
transcription/NN
factor/NN
./.
====================
AB/LS
-/:
Fibronectin/NN
synergized/VBD
with/IN
anti-CD3/JJ
antibody/NN
to/TO
promote/VB
CD4/NN
cell/NN
proliferation/NN
in/IN
a/DT
serum-free/JJ
culture/NN
system/NN
whereas/IN
no/DT
proliferation/NN
was/VBD
observed/VBN
when/WRB
CD4/NN
cells/NNS
were/VBD
cultured/VBN
with/IN
anti-CD3/NN
alone/RB
or/CC
fibronectin/NN
alone/RB
./.
====================
In/IN
addition/NN
,/,
anti-CD29/JJ
(/(
integrin/NN
beta/NN
1/CD
)/)
as/RB
well/RB
as/IN
anti-VLA-5/JJ
(/(
human/JJ
fibronectin/NN
receptor/NN
)/)
antibodies/NNS
blocked/VBD
this/DT
CD4/NN
cell/NN
activation/NN
in/IN
this/DT
system/NN
./.
====================
Although/IN
anti-CD3/NN
alone/RB
or/CC
fibronectin/NN
alone/RB
can/MD
not/RB
induce/VB
IL-2/NN
message/NN
by/IN
CD4/NN
cells/NNS
,/,
the/DT
combination/NN
of/IN
anti-CD3/NN
plus/CC
fibronectin/NN
induced/VBD
IL-2/NN
message/NN
by/IN
CD4/NN
cells/NNS
./.
====================
In/IN
an/DT
analysis/NN
of/IN
the/DT
molecular/JJ
mechanism/NN
by/IN
which/WDT
IL-2/NN
message/NN
was/VBD
generated/VBN
,/,
we/PRP
showed/VBD
that/IN
a/DT
fibronectin-VLA-5/NN
fibronectin/NN
receptor/NN
interaction/NN
may/MD
contribute/VB
an/DT
independent/JJ
signal/NN
distinct/JJ
from/IN
the/DT
CD3/NN
pathway/NN
of/IN
activation/NN
by/IN
the/DT
induction/NN
of/IN
an/DT
AP-1/NN
transcriptional/JJ
factor/NN
./.
====================
Thus/RB
the/DT
VLA-5/NN
fibronectin/NN
receptor/NN
on/IN
CD4/NN
cells/NNS
can/MD
play/VB
a/DT
complementary/JJ
role/NN
in/IN
CD3-TCR-mediated/JJ
signal/NN
transduction/NN
through/IN
its/PRP$
interaction/NN
with/IN
fibronectin/NNS
./.
====================
UI/LS
-/:
91164434/CD
====================
TI/LS
-/:
Glucocorticoid/NN
receptors/NNS
on/IN
mononuclear/JJ
leukocytes/NNS
in/IN
Alzheimer/NN
's/POS
disease/NN
./.
====================
AB/LS
-/:
Several/JJ
lines/NNS
of/IN
evidence/NN
suggest/VBP
disturbances/NNS
of/IN
the/DT
hypothalamic-pituitary-adrenal/JJ
(/(
HPA/NN
)/)
system/NN
in/IN
Alzheimer/NN
's/POS
disease/NN
(/(
AD/NN
)/)
./.
====================
In/IN
an/DT
exploration/NN
of/IN
the/DT
potential/JJ
role/NN
of/IN
the/DT
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
in/IN
AD/NN
,/,
GR/NN
density/NN
and/CC
affinity/NN
were/VBD
assessed/VBN
on/IN
mononuclear/JJ
leukocytes/NNS
of/IN
12/CD
AD/NN
patients/NNS
and/CC
12/CD
healthy/JJ
controls/NNS
./.
====================
GR/NN
binding/NN
characteristics/NNS
did/VBD
not/RB
differ/VB
between/IN
patients/NNS
and/CC
controls/NNS
or/CC
between/IN
patients/NNS
subdivided/VBN
according/VBG
to/TO
diagnosis/NN
or/CC
associated/VBN
clinical/JJ
features/NNS
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
the/DT
abnormalities/NNS
of/IN
the/DT
HPA/NN
system/NN
in/IN
AD/NN
are/VBP
not/RB
related/JJ
to/TO
a/DT
GR/NN
deficiency/NN
./.
====================
UI/LS
-/:
91100449/CD
====================
TI/LS
-/:
Oncogene/NN
amplification/NN
correlates/VBZ
with/IN
dense/JJ
lymphocyte/NN
infiltration/NN
in/IN
human/JJ
breast/NN
cancers/NNS
:/:
a/DT
role/NN
for/IN
hematopoietic/JJ
growth/NN
factor/NN
release/NN
by/IN
tumor/NN
cells/NNS
?/.
====================
AB/LS
-/:
One/CD
hundred/CD
six/CD
primary/JJ
breast/NN
cancer/NN
samples/NNS
were/VBD
analysed/VBN
for/IN
c-erbB2/NN
,/,
int-2/NN
,/,
and/CC
c-myc/NN
gene/NN
amplification/NN
./.
====================
Surgically/RB
confirmed/VBN
nodal/JJ
involvement/NN
was/VBD
observed/VBN
in/IN
42/CD
%/NN
./.
====================
Level/NN
of/IN
gene/NN
amplification/NN
was/VBD
studied/VBN
by/IN
Southern/NN
and/or/CC
slot/NN
blot/NN
techniques/NNS
./.
====================
Amplified/VBN
c-erbB2/NN
gene/NN
sequences/NNS
were/VBD
present/JJ
in/IN
21.5/CD
%/NN
of/IN
all/DT
samples/NNS
./.
====================
Int-2/NN
was/VBD
amplified/VBN
in/IN
13.1/CD
%/NN
and/CC
c-myc/NN
was/VBD
amplified/VBN
in/IN
10.3/CD
%/NN
./.
====================
In/IN
a/DT
non-parametric/JJ
test/NN
(/(
Kruskal-Wallis/NN
)/)
a/DT
strong/JJ
negative/JJ
association/NN
was/VBD
found/VBN
between/IN
high/JJ
levels/NNS
of/IN
c-erbB2/NN
amplification/NN
and/CC
absence/NN
of/IN
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
(/(
P/NN
=/JJ
.0009/CD
)/)
or/CC
progesterone/NN
receptor/NN
(/(
PR/NN
)/)
(/(
P/NN
=/JJ
.011/CD
)/)
expression/NN
./.
====================
No/DT
correlations/NNS
were/VBD
found/VBN
between/IN
all/DT
or/CC
high/JJ
levels/NNS
of/IN
amplification/NN
of/IN
each/DT
oncogene/NN
separately/RB
or/CC
combined/VBN
with/IN
T/NN
,/,
N/NN
,/,
grade/NN
,/,
multifocality/NN
of/IN
tumor/NN
,/,
or/CC
associated/VBN
carcinoma/NN
in/FW
situ/FW
./.
====================
There/EX
was/VBD
a/DT
trend/NN
approaching/VBG
statistical/JJ
significance/NN
for/IN
patients/NNS
with/IN
c-erbB2/NN
amplifications/NNS
to/TO
have/VB
positive/JJ
lymph/NN
nodes/NNS
at/IN
surgery/NN
(/(
P/NN
=/JJ
0.09/CD
)/)
./.
====================
A/DT
somewhat/RB
surprising/JJ
finding/NN
however/RB
was/VBD
a/DT
very/RB
strong/JJ
association/NN
between/IN
oncogene/NN
amplification/NN
and/CC
dense/JJ
lymphocyte/NN
infiltration/NN
of/IN
the/DT
tumor/NN
(/(
P/NN
=/JJ
.05/CD
)/)
./.
This/DT
correlation/NN
is/VBZ
even/RB
stronger/JJR
when/WRB
only/RB
high/JJ
levels/NNS
of/IN
amplification/NN
are/VBP
considered/VBN
,/,
either/CC
for/IN
each/DT
oncogene/NN
separately/RB
(/(
P/NN
=/JJ
.0048/CD
)/)
or/CC
in/IN
combination/NN
(/(
P/NN
=/JJ
.0007/CD
)/)
./.
====================
We/PRP
propose/VBP
that/IN
malignant/JJ
cell/NN
cytokine/NN
production/NN
may/MD
help/VB
explain/VB
this/DT
observation/NN
./.
====================
UI/LS
-/:
91175707/CD
====================
TI/LS
-/:
Suppression/NN
of/IN
signals/NNS
required/VBN
for/IN
activation/NN
of/IN
transcription/NN
factor/NN
NF-kappa/NN
B/NN
in/IN
cells/NNS
constitutively/RB
expressing/VBG
the/DT
HTLV-I/NN
Tax/NN
protein/NN
./.
====================
AB/LS
-/:
Transient/JJ
short-term/JJ
expression/NN
of/IN
the/DT
Tax/NN
protein/NN
of/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type-I/NN
(/(
HTLV-I/NN
)/)
leads/VBZ
to/TO
activation/NN
of/IN
the/DT
pleiotropic/JJ
transcription/NN
factor/NN
NF-kappa/NN
B/NN
./.
====================
Consistent/JJ
with/IN
findings/NNS
obtained/VBN
with/IN
transient/JJ
expression/NN
assays/NNS
,/,
we/PRP
observed/VBD
marked/JJ
accumulation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
in/IN
the/DT
nucleus/NN
of/IN
Namalwa/NN
B/NN
lymphoid/JJ
cells/NNS
,/,
which/WDT
constitutively/RB
express/VBP
Tax/NN
./.
====================
In/IN
contrast/NN
,/,
NF-kappa/NN
B/NN
activity/NN
was/VBD
not/RB
detected/VBN
in/IN
the/DT
nucleus/NN
following/VBG
long-term/JJ
expression/NN
of/IN
Tax/NN
in/IN
Jurkat/NN
T/NN
lymphocytes/NNS
./.
====================
The/DT
ability/NN
of/IN
both/CC
mitogens/NNS
and/CC
cytokines/NNS
to/TO
activate/VB
NF-kappa/NN
B/NN
was/VBD
also/RB
blocked/VBN
in/IN
Jurkat/NN
cells/NNS
constitutively/RB
expressing/VBG
Tax/NN
./.
====================
However/RB
,/,
the/DT
activation/NN
of/IN
other/JJ
mitogen-inducible/JJ
transcription/NN
factors/NNS
,/,
such/JJ
as/IN
Fos/NN
and/CC
Jun/NN
,/,
was/VBD
unaffected/JJ
./.
====================
Thus/RB
,/,
depending/VBG
on/IN
the/DT
cellular/JJ
environment/NN
,/,
the/DT
short-/JJ
and/CC
long-term/JJ
effects/NNS
of/IN
Tax/NN
expression/NN
can/MD
be/VB
quite/RB
different/JJ
./.
====================
Consequently/RB
,/,
one/CD
function/NN
of/IN
Tax/NN
in/IN
cells/NNS
infected/VBN
with/IN
HTLV-I/NN
might/MD
involve/VB
cell-type-specific/JJ
suppression/NN
,/,
as/IN
opposed/VBN
to/TO
activation/NN
,/,
of/IN
distinct/JJ
signal/NN
pathways/NNS
./.
====================
The/DT
cells/NNS
lines/NNS
described/VBN
here/RB
should/MD
be/VB
useful/JJ
for/IN
the/DT
delineation/NN
of/IN
signaling/NN
pathways/NNS
utilized/VBN
in/IN
the/DT
selective/JJ
regulation/NN
of/IN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
91041706/CD
====================
TI/LS
-/:
Interferon-gamma/NN
and/CC
the/DT
sexual/JJ
dimorphism/NN
of/IN
autoimmunity/NN
./.
====================
AB/LS
-/:
The/DT
sexual/JJ
difference/NN
in/IN
the/DT
incidence/NN
of/IN
autoimmune/JJ
diseases/NNS
has/VBZ
remained/VBN
an/DT
enigma/NN
for/IN
many/JJ
years/NNS
./.
====================
In/IN
the/DT
examination/NN
of/IN
the/DT
induction/NN
of/IN
autoimmunity/NN
in/IN
transgenic/JJ
mice/NNS
,/,
evidence/NN
has/VBZ
been/VBN
obtained/VBN
further/JJ
implicating/VBG
the/DT
lymphokine/NN
interferon-gamma/NN
in/IN
the/DT
etiology/NN
of/IN
autoimmunity/NN
./.
====================
Sex/NN
steroid/NN
regulation/NN
of/IN
the/DT
production/NN
of/IN
this/DT
molecule/NN
,/,
as/RB
well/RB
as/IN
other/JJ
cytokines/NNS
,/,
may/MD
help/VB
explain/VB
the/DT
gender-specific/JJ
differences/NNS
in/IN
the/DT
immune/JJ
system/NN
,/,
including/VBG
autoimmunity/NN
./.
====================
UI/LS
-/:
90302010/CD
====================
TI/LS
-/:
Cloning/NN
of/IN
a/DT
transcriptionally/RB
active/JJ
human/JJ
TATA/NN
binding/NN
factor/NN
./.
====================
AB/LS
-/:
Transcription/NN
factor/NN
IID/NN
(/(
TFIID/NN
)/)
binds/VBZ
to/TO
the/DT
TATA/NN
box/NN
promoter/NN
element/NN
and/CC
regulates/VBZ
the/DT
expression/NN
of/IN
most/JJS
eukaryotic/JJ
genes/NNS
transcribed/VBN
by/IN
RNA/NN
polymerase/NN
II/CD
./.
====================
Complementary/JJ
DNA/NN
(/(
cDNA/NN
)/)
encoding/VBG
a/DT
human/JJ
TFIID/NN
protein/NN
has/VBZ
been/VBN
cloned/VBN
./.
====================
The/DT
human/JJ
TFIID/NN
polypeptide/NN
has/VBZ
339/CD
amino/NN
acids/NNS
and/CC
a/DT
molecular/JJ
size/NN
of/IN
37,745/CD
daltons/NNS
./.
====================
The/DT
carboxyl-terminal/JJ
181/CD
amino/NN
acids/NNS
of/IN
the/DT
human/JJ
TFIID/NN
protein/NN
shares/VBZ
80/CD
%/NN
identity/NN
with/IN
the/DT
TFIID/NN
protein/NN
from/IN
Saccharomyces/FW
cerevisiae/FW
./.
====================
The/DT
amino/NN
terminus/NN
contains/VBZ
an/DT
unusual/JJ
repeat/NN
of/IN
38/CD
consecutive/JJ
glutamine/NN
residues/NNS
and/CC
an/DT
X-Thr-Pro/NN
repeat/NN
./.
====================
Expression/NN
of/IN
DNA/NN
in/IN
reticulocyte/NN
lysates/NNS
or/CC
in/IN
Escherichia/FW
coli/FW
yielded/VBD
a/DT
protein/NN
that/WDT
was/VBD
competent/JJ
for/IN
both/CC
DNA/NN
binding/NN
and/CC
transcription/NN
activation/NN
./.
====================
UI/LS
-/:
91208110/CD
====================
TI/LS
-/:
A/DT
novel/JJ
T-cell/NN
trans-activator/NN
that/WDT
recognizes/VBZ
a/DT
phorbol/NN
ester-inducible/JJ
element/NN
of/IN
the/DT
interleukin-2/NN
promoter/NN
./.
====================
AB/LS
-/:
The/DT
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
gene/NN
promoter/NN
is/VBZ
recognized/VBN
by/IN
several/JJ
cell-type-specific/JJ
and/CC
ubiquitous/JJ
transcriptional/JJ
regulators/NNS
that/WDT
integrate/VBP
information/NN
transmitted/VBN
by/IN
various/JJ
signaling/NN
systems/NNS
leading/VBG
to/TO
IL-2/NN
production/NN
and/CC
T-cell/NN
activation/NN
./.
====================
Using/VBG
a/DT
combination/NN
of/IN
transfection/NN
,/,
protein-DNA/JJ
binding/NN
,/,
and/CC
in/FW
vitro/FW
transcription/NN
methods/NNS
,/,
we/PRP
have/VBP
discovered/VBN
the/DT
novel/JJ
T-cell-specific/JJ
transcriptional/JJ
activator/NN
TCF-1/NN
(/(
for/IN
T-Cell/NN
Factor-1/NN
)/)
,/,
which/WDT
recognizes/VBZ
a/DT
T-cell-specific/JJ
response/NN
element/NN
(/(
TCE/NN
)/)
located/JJ
within/IN
the/DT
IL-2/NN
promoter/NN
./.
====================
Although/IN
the/DT
TCE/NN
is/VBZ
similar/JJ
in/IN
sequence/NN
to/TO
a/DT
consensus/NN
NF/NN
kappa/NN
B/NN
site/NN
,/,
several/JJ
criteria/NNS
indicate/VBP
that/IN
TCF-1/NN
is/VBZ
distinct/JJ
from/IN
NF/NN
kappa/NN
B/NN
./.
====================
However/RB
,/,
like/IN
NF/NN
kappa/NN
B/NN
,/,
TCF-1/NN
activity/NN
is/VBZ
induced/VBN
by/IN
phorbol/NN
esters/NNS
and/CC
other/JJ
T-cell/NN
activators/NNS
./.
====================
UI/LS
-/:
90199680/CD
====================
TI/LS
-/:
Risk/NN
factors/NNS
for/IN
breast/NN
recurrence/NN
in/IN
premenopausal/JJ
and/CC
postmenopausal/JJ
patients/NNS
with/IN
ductal/JJ
cancers/NNS
treated/VBN
by/IN
conservation/NN
therapy/NN
./.
====================
AB/LS
-/:
Risk/NN
factors/NNS
for/IN
local/JJ
failure/NN
were/VBD
evaluated/VBN
for/IN
496/CD
clinical/JJ
Stage/NN
I-II/CD
patients/NNS
with/IN
infiltrating/JJ
ductal/JJ
carcinomas/NNS
(/(
median/NN
follow-up/NN
,/,
71/CD
months/NNS
)/)
treated/VBN
by/IN
conservative/JJ
surgery/NN
and/CC
radiotherapy/NN
./.
====================
Monofactorial/JJ
analysis/NN
identified/VBD
the/DT
following/JJ
factors/NNS
to/TO
be/VB
correlated/VBN
with/IN
increased/VBN
risk/NN
:/:
moderate/marked/JJ
mononuclear/JJ
cell/NN
reaction/NN
(/(
MCR/NN
)/)
,/,
high/JJ
histologic/JJ
grade/NN
(/(
G/NN
)/)
,/,
extensive/JJ
intraductal/JJ
component/NN
(/(
EIC/NN
)/)
,/,
tumor/NN
necrosis/NN
,/,
macroscopic/JJ
multiplicity/NN
,/,
estrogen/NN
receptor/NN
negativity/NN
,/,
anatomic/JJ
tumor/NN
size/NN
,/,
age/NN
younger/JJR
than/IN
40/CD
years/NNS
,/,
and/CC
vascular/JJ
invasion/NN
./.
====================
Only/RB
MCR/NN
,/,
G/NN
,/,
and/CC
EIC/NN
proved/VBD
significant/JJ
in/IN
Cox/NN
multivariate/JJ
analysis/NN
./.
====================
These/DT
risk/NN
factors/NNS
were/VBD
highly/RB
age/NN
dependent/JJ
,/,
with/IN
EIC/NN
markedly/RB
more/RBR
prevalent/JJ
in/IN
women/NNS
younger/JJR
than/IN
50/CD
,/,
MCR/NN
and/CC
G/NN
in/IN
women/NNS
younger/JJR
than/IN
40/CD
./.
====================
Separate/JJ
Cox/NN
analysis/NN
for/IN
premenopausal/JJ
patients/NNS
showed/VBD
that/IN
MCR/EIC/NN
determined/VBD
risk/NN
independent/JJ
of/IN
resection/NN
margins/NNS
:/:
tumors/NNS
with/IN
MCR/NN
had/VBD
a/DT
28/CD
%/NN
,/,
and/CC
with/IN
EIC/NN
a/DT
22/CD
%/NN
probability/NN
of/IN
recurring/VBG
locally/RB
by/IN
5/CD
years/NNS
./.
====================
Premenopausal/JJ
patients/NNS
with/IN
neither/DT
risk/NN
factor/NN
had/VBD
a/DT
very/RB
low/JJ
failure/NN
rate/NN
(/(
2.6/CD
%/NN
at/IN
5/CD
years/NNS
)/)
,/,
regardless/RB
of/IN
age/NN
./.
====================
For/IN
postmenopausal/JJ
patients/NNS
risk/NN
of/IN
breast/NN
recurrence/NN
was/VBD
determined/VBN
both/CC
by/IN
adequacy/NN
of/IN
resection/NN
margins/NNS
and/CC
grade/NN
,/,
with/IN
a/DT
high/JJ
local/JJ
failure/NN
rate/NN
for/IN
patients/NNS
having/VBG
G3/NN
tumors/NNS
with/IN
positive/JJ
or/CC
indeterminate/JJ
margins/NNS
(/(
31/CD
%/NN
at/IN
5/CD
years/NNS
)/)
./.
====================
The/DT
authors/NNS
conclude/VBP
that/IN
the/DT
microscopic/JJ
examination/NN
is/VBZ
the/DT
only/JJ
useful/JJ
tool/NN
for/IN
assessing/VBG
the/DT
risk/NN
of/IN
local/JJ
failure/NN
,/,
which/WDT
is/VBZ
quite/RB
low/JJ
for/IN
the/DT
majority/NN
of/IN
patients/NNS
treated/VBN
with/IN
breast/NN
conservation/NN
./.
====================
High-risk/JJ
patients/NNS
can/MD
be/VB
recognized/VBN
morphologically/RB
./.
====================
The/DT
age/NN
dependence/NN
of/IN
morphologic/JJ
risk/NN
factors/NNS
appears/VBZ
to/TO
explain/VB
the/DT
high/JJ
local/JJ
failure/NN
rate/NN
seen/VBN
in/IN
patients/NNS
younger/JJR
than/IN
40/CD
./.
====================
UI/LS
-/:
90191722/CD
====================
TI/LS
-/:
Tax-independent/JJ
binding/NN
of/IN
multiple/JJ
cellular/JJ
factors/NNS
to/TO
Tax-response/JJ
element/NN
DNA/NN
of/IN
HTLV-I/NN
./.
====================
AB/LS
-/:
The/DT
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
promoter/NN
contains/VBZ
three/CD
copies/NNS
of/IN
imperfect/JJ
repeats/NNS
of/IN
a/DT
21-base/JJ
pair/NN
sequence/NN
designated/VBN
here/RB
as/IN
TRE/NN
(/(
Tax-response/JJ
element/NN
)/)
that/WDT
is/VBZ
responsive/JJ
to/TO
the/DT
virally/RB
encoded/VBN
transactivator/NN
protein/NN
Tax/NN
./.
====================
We/PRP
have/VBP
identified/VBN
and/CC
separated/VBN
four/CD
nuclear/JJ
proteins/NNS
from/IN
C81-66-45/NN
cells/NNS
,/,
an/DT
HTLV-I/NN
immortalized/JJ
Tax-expressing/VBG
human/JJ
T-lymphocyte/NN
line/NN
(/(
Salahuddin/NNP
et/FW
al./FW
,/,
1983/CD
)/)
,/,
that/WDT
interact/VBP
with/IN
the/DT
TRE-DNA/NN
,/,
none/NN
of/IN
which/WDT
are/VBP
identical/JJ
with/IN
the/DT
Tax-protein/NN
./.
====================
The/DT
proteins/NNS
identified/VBN
have/VBP
molecular/JJ
weights/NNS
of/IN
about/RB
32/CD
,/,
36/CD
to/TO
42/CD
,/,
50/CD
and/CC
110/CD
kD/NN
./.
====================
Four/CD
different/JJ
methods/NNS
were/VBD
used/VBN
to/TO
identify/VB
the/DT
proteins/NNS
./.
====================
First/RB
,/,
from/IN
different/JJ
cell/NN
lines/NNS
three/CD
or/CC
all/DT
four/CD
of/IN
the/DT
nuclear/JJ
proteins/NNS
were/VBD
specifically/RB
cross-linked/VBN
by/IN
UV/NN
irradiation/NN
to/TO
the/DT
radioactively/RB
labeled/VBN
TRE-DNA/NN
fragment/NN
./.
====================
Second/RB
,/,
TRE-DNA/NN
binding/NN
proteins/NNS
sedimented/VBD
through/IN
a/DT
glycerol/NN
density/NN
gradient/NN
at/IN
rates/NNS
corresponding/VBG
to/TO
proteins/NNS
of/IN
native/JJ
molecular/JJ
weights/NNS
of/IN
35/CD
to/TO
50/CD
kD/NN
and/CC
110/CD
kD/NN
./.
====================
Third/RB
,/,
only/RB
the/DT
50/CD
kD/NN
protein/NN
was/VBD
retained/VBN
on/IN
a/DT
biotinylated/VBN
DNA-streptavidin/NN
matrix/NN
when/WRB
the/DT
DNA/NN
fragment/NN
contained/VBD
the/DT
TRE-DNA/NN
./.
====================
Fourth/RB
,/,
extensive/JJ
purification/NN
by/IN
several/JJ
cycles/NNS
of/IN
TRE-DNA/JJ
affinity/NN
chromatography/NN
resulted/VBD
in/IN
the/DT
32/CD
,/,
36/CD
to/TO
42/CD
and/CC
110/CD
kD/NN
proteins/NNS
and/CC
to/TO
less/JJR
extent/NN
the/DT
50/CD
kD/NN
factor/NN
./.
====================
Two/CD
abundant/JJ
proteins/NNS
of/IN
75/CD
and/CC
80/CD
kD/NN
were/VBD
competed/VBN
out/RP
by/IN
poly[d(I-C)]/NN
in/IN
all/DT
reactions/NNS
./.
====================
The/DT
cAMP-response/JJ
element/NN
CRE/NN
,/,
TGACGTCA/NN
,/,
present/JJ
in/IN
the/DT
21/CD
base-pair/NN
sequence/NN
,/,
appears/VBZ
to/TO
be/VB
essential/JJ
for/IN
specific/JJ
protein-TRE-DNA/JJ
interactions/NNS
because/IN
mutation/NN
of/IN
the/DT
two/CD
G/NN
's/NNS
destroys/VBZ
this/DT
complex/NN
./.
====================
This/DT
result/NN
suggests/VBZ
that/IN
the/DT
cAMP/NN
response/NN
element/NN
binding/NN
protein/NN
,/,
CREB/NN
,/,
is/VBZ
involved/VBN
in/IN
the/DT
protein-TRE-DNA/JJ
complex/NN
and/CC
in/IN
mediating/VBG
the/DT
Tax/NN
response/NN
./.
====================
UI/LS
-/:
90140708/CD
====================
TI/LS
-/:
Two/CD
distinct/JJ
transcription/NN
factors/NNS
that/WDT
bind/VBP
the/DT
immunoglobulin/NN
enhancer/NN
microE5/kappa/NN
2/CD
motif/NN
./.
====================
AB/LS
-/:
Activity/NN
of/IN
the/DT
immunoglobulin/NN
heavy/JJ
and/CC
kappa/NN
light/JJ
chain/NN
gene/NN
enhancers/NNS
depends/VBZ
on/IN
a/DT
complex/JJ
interplay/NN
of/IN
ubiquitous/JJ
and/CC
developmentally/RB
regulated/VBN
proteins/NNS
./.
====================
Two/CD
complementary/JJ
DNAs/NNS
were/VBD
isolated/VBN
that/WDT
encode/VBP
proteins/NNS
,/,
denoted/VBN
ITF-1/NN
and/CC
ITF-2/NN
,/,
that/WDT
are/VBP
expressed/VBN
in/IN
a/DT
variety/NN
of/IN
cell/NN
types/NNS
and/CC
bind/VBP
the/DT
microE5/kappa/NN
2/CD
motif/NN
found/VBN
in/IN
both/CC
heavy/JJ
and/CC
kappa/NN
light/JJ
chain/NN
enhancers/NNS
./.
====================
The/DT
complementary/JJ
DNAs/NNS
are/VBP
the/DT
products/NNS
of/IN
distinct/JJ
genes/NNS
,/,
yet/CC
both/CC
ITF-1/NN
and/CC
ITF-2/NN
are/VBP
structurally/RB
and/CC
functionally/RB
similar/JJ
./.
====================
The/DT
two/CD
proteins/NNS
interact/VBP
with/IN
one/CD
another/DT
through/IN
their/PRP$
putative/JJ
helix-loop-helix/JJ
motifs/NNS
and/CC
each/DT
possesses/VBZ
a/DT
distinct/JJ
domain/NN
that/WDT
dictates/VBZ
transcription/NN
activation/NN
./.
====================
UI/LS
-/:
92077236/CD
====================
TI/LS
-/:
Elevated/JJ
glucocorticoid/NN
receptor/NN
concentrations/NNS
before/IN
and/CC
after/IN
glucocorticoid/NN
therapy/NN
in/IN
peripheral/JJ
mononuclear/JJ
leukocytes/NNS
of/IN
patients/NNS
with/IN
atopic/JJ
dermatitis/NN
./.
====================
AB/LS
-/:
The/DT
number/NN
and/CC
affinity/NN
of/IN
glucocorticoid/NN
binding/NN
sites/NNS
in/IN
peripheral/JJ
mononuclear/JJ
leukocytes/NNS
of/IN
patients/NNS
with/IN
atopic/JJ
dermatitis/NN
(/(
AD/NN
)/)
and/CC
healthy/JJ
controls/NNS
were/VBD
determined/VBN
under/IN
baseline/NN
conditions/NNS
and/CC
after/IN
a/DT
defined/VBN
oral/JJ
glucocorticoid/NN
treatment/NN
./.
====================
Patients/NNS
with/IN
AD/NN
(/(
n/NN
=/JJ
15/CD
)/)
exhibited/VBD
significantly/RB
more/JJR
glucocorticoid/NN
receptors/NNS
(/(
GR/NN
)/)
per/IN
cell/NN
than/IN
the/DT
control/NN
group/NN
(/(
n/NN
=/JJ
22/CD
)/)
,/,
while/IN
the/DT
GR/NN
affinity/NN
did/VBD
not/RB
differ/VB
./.
====================
Methylprednisolone/NN
treatment/NN
resulted/VBD
in/IN
a/DT
significant/JJ
reduction/NN
of/IN
the/DT
GR/NN
sites/NNS
per/IN
cell/NN
in/IN
the/DT
steroid-treated/JJ
control/NN
group/NN
(/(
n/NN
=/JJ
10/CD
)/)
in/IN
contrast/NN
to/TO
the/DT
patients/NNS
./.
====================
The/DT
dissociation/NN
constant/NN
was/VBD
not/RB
affected/VBN
by/IN
methylprednisolone/JJ
treatment/NN
in/IN
either/DT
group/NN
./.
====================
In/IN
view/NN
of/IN
the/DT
therapeutic/JJ
efficiency/NN
of/IN
glucocorticoids/NNS
in/IN
AD/NN
and/CC
findings/NNS
of/IN
abnormal/JJ
cAMP/NN
and/CC
cAMP-phosphodiesterase/NN
activity/NN
,/,
the/DT
elevated/JJ
GR/NN
concentrations/NNS
in/IN
AD/NN
lend/VBP
support/NN
to/TO
the/DT
hypothesis/NN
of/IN
a/DT
compensatory/JJ
GR/NN
upregulation/NN
due/JJ
to/TO
an/DT
insufficient/JJ
action/NN
of/IN
endogenous/JJ
cortisol/NN
or/CC
to/TO
altered/JJ
cAMP-induced/JJ
GR/NN
expression/NN
./.
====================
UI/LS
-/:
91092267/CD
====================
TI/LS
-/:
The/DT
actions/NNS
of/IN
cyclosporin/NN
A/NN
and/CC
FK506/NN
suggest/VBP
a/DT
novel/JJ
step/NN
in/IN
the/DT
activation/NN
of/IN
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Cyclosporin/NN
A/NN
and/CC
FK506/NN
are/VBP
immunosuppressive/JJ
compounds/NNS
that/WDT
have/VBP
similar/JJ
inhibitory/JJ
effects/NNS
on/IN
the/DT
expression/NN
of/IN
several/JJ
lymphokines/NNS
produced/VBN
by/IN
T/NN
lymphocytes/NNS
./.
====================
Despite/IN
their/PRP$
similar/JJ
effects/NNS
the/DT
drugs/NNS
bind/VBP
to/TO
two/CD
different/JJ
cytosolic/JJ
protein/NN
,/,
cyclophilin/NN
and/CC
FKBP/NN
respectively/RB
,/,
which/WDT
raises/VBZ
the/DT
possibility/NN
that/IN
they/PRP
have/VBP
different/JJ
modes/NNS
of/IN
action/NN
./.
====================
Using/VBG
constructs/NNS
in/IN
which/WDT
mRNA/NN
production/NN
controlled/VBN
by/IN
a/DT
specific/JJ
transcription/NN
factor/NN
could/MD
be/VB
readily/RB
measured/VBN
we/PRP
found/VBD
that/IN
both/CC
cyclosporin/NN
A/NN
and/CC
FK506/NN
completely/RB
inhibited/VBD
transcription/NN
activated/VBN
by/IN
NF-AT/NN
,/,
NFIL2/NN
A/NN
,/,
NFIL2/NN
B/NN
and/CC
partially/RB
inhibited/VBD
transcription/NN
activated/VBN
by/IN
NF/NN
kappa/NN
B/NN
./.
====================
Cyclosporin/NN
A/NN
and/CC
FK506/NN
inhibited/VBD
only/RB
transcriptional/JJ
activation/NN
that/WDT
was/VBD
dependent/JJ
on/IN
Ca2+/NN
mobilization/NN
./.
====================
However/RB
,/,
cyclosporin/NN
A/NN
and/CC
FK506/NN
did/VBD
not/RB
inhibit/VB
Ca2+/NN
mobilization/NN
dependent/JJ
expression/NN
of/IN
c-fos/NN
mRNA/NN
indicating/VBG
that/IN
only/RB
a/DT
subset/NN
of/IN
signalling/NN
pathways/NNS
regulated/VBN
by/IN
Ca2+/NN
is/VBZ
sensitive/JJ
to/TO
these/DT
drugs/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
did/VBD
not/RB
observe/VB
any/DT
qualitative/JJ
differences/NNS
between/IN
the/DT
effect/NN
of/IN
cyclosporin/NN
A/NN
and/CC
FK506/NN
on/IN
six/CD
different/JJ
transcription/NN
factors/NNS
which/WDT
suggests/VBZ
that/IN
these/DT
drugs/NNS
may/MD
interfere/VB
with/IN
the/DT
activity/NN
of/IN
a/DT
novel/JJ
Ca2+/NN
dependent/JJ
step/NN
that/WDT
regulates/VBZ
several/JJ
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
90376447/CD
====================
TI/LS
-/:
The/DT
internal/JJ
methionine/NN
codons/NNS
of/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
II/CD
rex/NN
gene/NN
are/VBP
not/RB
required/VBN
for/IN
p24rex/NN
production/NN
or/CC
virus/NN
replication/NN
and/CC
transformation/NN
./.
====================
AB/LS
-/:
Human/JJ
T-cell/NN
leukemia/NN
virus/NN
types/NNS
I/CD
(/(
HTLV-I/NN
)/)
and/CC
II/CD
(/(
HTLV-II/NN
)/)
have/VBP
two/CD
nonstructural/JJ
trans-acting/JJ
regulatory/JJ
genes/NNS
,/,
tax/NN
and/CC
rex/NN
,/,
located/JJ
in/IN
the/DT
3'/JJ
region/NN
of/IN
the/DT
viral/JJ
genome/NN
./.
====================
The/DT
tax/NN
gene/NN
product/NN
(/(
HTLV-I/NN
p40tax/NN
and/CC
HTLV-II/NN
p37tax/NN
)/)
is/VBZ
the/DT
transcriptional/JJ
activator/NN
of/IN
the/DT
viral/JJ
long/JJ
terminal/JJ
repeat/NN
./.
====================
The/DT
rex/NN
gene/NN
encodes/VBZ
two/CD
protein/NN
products/NNS
,/,
p27rex/p21rex/NN
and/CC
p26rex/p24rex/NN
in/IN
HTLV-I/NN
and/CC
HTLV-II/NN
,/,
respectively/RB
./.
====================
Rex/NN
acts/VBZ
posttranscriptionally/RB
to/TO
facilitate/VB
accumulation/NN
of/IN
full-length/JJ
gag/pol/NN
and/CC
singly/RB
spliced/VBN
env/NN
mRNA/NN
in/IN
the/DT
cytoplasm/NN
of/IN
HTLV-infected/JJ
cells/NNS
./.
====================
Previous/JJ
studies/NNS
showed/VBD
that/IN
the/DT
first/JJ
ATG/NN
of/IN
the/DT
rex/NN
gene/NN
is/VBZ
critical/JJ
for/IN
Rex/NN
production/NN
and/CC
function/NN
./.
====================
The/DT
importance/NN
of/IN
the/DT
internal/JJ
ATGs/NNS
to/TO
Rex/NN
function/NN
is/VBZ
not/RB
known/VBN
./.
====================
However/RB
,/,
in/FW
vitro/FW
mutagenesis/NN
of/IN
the/DT
HTLV-I/NN
rex/NN
gene/NN
has/VBZ
provided/VBN
indirect/JJ
evidence/NN
which/WDT
suggests/VBZ
that/IN
p21rex/NN
,/,
and/CC
by/IN
analogy/NN
HTLV-II/NN
p24rex/NN
,/,
results/VBZ
from/IN
initiation/NN
at/IN
an/DT
internal/JJ
AUG/NN
of/IN
the/DT
tax/rex/NN
mRNA/NN
./.
====================
By/IN
using/VBG
an/DT
infectious/JJ
molecular/JJ
clone/NN
of/IN
HTLV-II/NN
,/,
we/PRP
investigated/VBD
the/DT
importance/NN
of/IN
the/DT
internal/JJ
ATGs/NNS
of/IN
the/DT
rex/NN
gene/NN
on/IN
Rex/NN
protein/NN
production/NN
and/CC
function/NN
./.
====================
Our/PRP$
results/NNS
indicate/VBP
that/IN
p24rex/NN
of/IN
HTLV-II/NN
is/VBZ
not/RB
initiated/VBN
at/IN
an/DT
internal/JJ
AUG/NN
and/CC
that/IN
the/DT
internal/JJ
methionine/NN
codons/NNS
are/VBP
not/RB
crucial/JJ
to/TO
the/DT
function/NN
of/IN
the/DT
rex/NN
gene/NN
and/CC
,/,
ultimately/RB
,/,
the/DT
transforming/NN
properties/NNS
of/IN
the/DT
virus/NN
./.
====================
UI/LS
-/:
91016834/CD
====================
TI/LS
-/:
Astrocytes/NNS
and/CC
glioblastoma/NN
cells/NNS
express/VBP
novel/JJ
octamer-DNA/NN
binding/NN
proteins/NNS
distinct/JJ
from/IN
the/DT
ubiquitous/JJ
Oct-1/NN
and/CC
B/NN
cell/NN
type/NN
Oct-2/NN
proteins/NNS
./.
====================
AB/LS
-/:
The/DT
'/``
octamer/NN
'/''
sequence/NN
,/,
ATGCAAAT/NN
or/CC
its/PRP$
complement/NN
ATTTGCAT/NN
,/,
is/VBZ
a/DT
key/JJ
element/NN
for/IN
the/DT
transcriptional/JJ
regulation/NN
of/IN
immunoglobulin/NN
genes/NNS
in/IN
B-lymphocytes/NNS
as/RB
well/RB
as/IN
a/DT
number/NN
of/IN
housekeeping/JJ
genes/NNS
in/IN
all/DT
cell/NN
types/NNS
./.
====================
In/IN
lymphocytes/NNS
,/,
the/DT
octamer-binding/JJ
protein/NN
Oct-2A/NN
and/CC
variants/NNS
thereof/RB
are/VBP
thought/VBN
to/TO
contribute/VB
to/TO
the/DT
B-cell/NN
specific/JJ
gene/NN
expression/NN
,/,
while/IN
the/DT
ubiquitous/JJ
protein/NN
Oct-1/NN
seems/VBZ
to/TO
control/VB
general/JJ
octamer/NN
site-dependent/JJ
transcription/NN
./.
====================
Various/JJ
other/JJ
genes/NNS
,/,
for/IN
example/NN
interleukin-1/NN
and/CC
MHC/NN
class/NN
II/CD
genes/NNS
,/,
contain/VBP
an/DT
octamer/NN
sequence/NN
in/IN
the/DT
promoter/NN
and/CC
are/VBP
expressed/VBN
in/IN
cells/NNS
of/IN
both/CC
the/DT
immune/JJ
and/CC
nervous/JJ
systems/NNS
./.
====================
This/DT
prompted/VBD
us/PRP
to/TO
analyze/VB
the/DT
octamer-binding/JJ
proteins/NNS
in/IN
the/DT
latter/JJ
cells/NNS
./.
====================
Using/VBG
the/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
,/,
at/IN
least/JJS
six/CD
novel/JJ
octamer/NN
binding/NN
proteins/NNS
were/VBD
detected/VBN
in/IN
nuclear/JJ
extracts/NNS
of/IN
cultured/VBN
mouse/NN
astrocytes/NNS
./.
====================
These/DT
proteins/NNS
are/VBP
differentially/RB
expressed/VBN
in/IN
human/JJ
glioblastoma/NN
and/CC
neuroblastoma/NN
cell/NN
lines/NNS
./.
====================
The/DT
nervous/JJ
system-derived/JJ
(/(
N-Oct/NN
)/)
proteins/NNS
bound/VBD
to/TO
the/DT
octamer/NN
DNA/NN
sequence/NN
in/IN
a/DT
manner/NN
which/WDT
is/VBZ
indistinguishable/JJ
from/IN
the/DT
Oct-1/NN
and/CC
Oct-2A/NN
proteins/NNS
./.
====================
The/DT
relationship/NN
of/IN
the/DT
N-Oct/NN
proteins/NNS
to/TO
Oct-1/NN
and/CC
Oct-2A/NN
was/VBD
analyzed/VBN
by/IN
proteolytic/JJ
clipping/JJ
bandshift/NN
assays/NNS
and/CC
by/IN
their/PRP$
reactivity/NN
towards/IN
antisera/NNS
raised/VBN
against/IN
recombinant/JJ
Oct-1/NN
and/CC
Oct-2A/NN
proteins/NNS
./.
====================
On/IN
the/DT
basis/NN
of/IN
these/DT
assays/NNS
,/,
all/DT
N-Oct-factors/NNS
were/VBD
found/VBN
to/TO
be/VB
distinct/JJ
from/IN
the/DT
ubiquitous/JJ
Oct-1/NN
and/CC
the/DT
lymphoid-specific/JJ
Oct-2A/NN
proteins/NNS
./.
====================
In/IN
melanoma/NN
cells/NNS
that/WDT
contain/VBP
the/DT
N-Oct-3/NN
factor/NN
,/,
a/DT
transfected/VBN
lymphocyte-specific/JJ
promoter/NN
was/VBD
neither/CC
activated/VBN
nor/CC
was/VBD
it/PRP
repressed/VBN
upon/IN
contransfection/NN
with/IN
an/DT
Oct-2A/NN
expression/NN
vector/NN
./.
====================
We/PRP
therefore/RB
speculate/VBP
that/IN
N-Oct-3/NN
and/CC
other/JJ
N-Oct/NN
factors/NNS
have/VBP
a/DT
specific/JJ
role/NN
in/IN
gene/NN
expression/NN
in/IN
cells/NNS
of/IN
the/DT
nervous/JJ
system/NN
./.
====================
UI/LS
-/:
90351381/CD
====================
TI/LS
-/:
Detection/NN
in/IN
non-erythroid/JJ
cells/NNS
of/IN
a/DT
factor/NN
with/IN
the/DT
binding/NN
characteristics/NNS
of/IN
the/DT
erythroid/JJ
cell/NN
transcription/NN
factor/NN
EF1/NN
./.
====================
AB/LS
-/:
The/DT
erythroid/JJ
transcription/NN
factor/NN
erythroid/JJ
factor-1/NN
(/(
EF1/NN
)/)
plays/VBZ
a/DT
critical/JJ
role/NN
in/IN
the/DT
transcription/NN
of/IN
erythroid-specific/JJ
genes/NNS
./.
====================
Here/RB
we/PRP
report/VBP
the/DT
presence/NN
of/IN
a/DT
factor/NN
with/IN
the/DT
mobility/NN
and/CC
sequence-specific/JJ
DNA-binding/JJ
characteristics/NNS
of/IN
EF1/NN
at/IN
low/JJ
abundance/NN
in/IN
a/DT
wide/JJ
variety/NN
of/IN
non-erythroid/JJ
cell/NN
types/NNS
./.
====================
This/DT
is/VBZ
the/DT
first/JJ
report/NN
of/IN
an/DT
EF1-like/JJ
activity/NN
in/IN
non-erythroid/JJ
cells/NNS
and/CC
indicates/VBZ
that/IN
this/DT
factor/NN
may/MD
play/VB
a/DT
role/NN
in/IN
the/DT
regulation/NN
of/IN
genes/NNS
expressed/VBN
in/IN
such/JJ
cells/NNS
./.
====================
UI/LS
-/:
90290483/CD
====================
TI/LS
-/:
Protein/NN
kinase/NN
inhibitor/NN
H-7/NN
blocks/VBZ
accumulation/NN
of/IN
unspliced/JJ
mRNA/NN
of/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
./.
====================
AB/LS
-/:
Rex/NN
,/,
the/DT
post-transcriptional/JJ
regulator/NN
of/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
,/,
is/VBZ
known/VBN
to/TO
induce/VB
accumulation/NN
of/IN
the/DT
unspliced/JJ
viral/JJ
gag-pol/NN
mRNA/NN
./.
====================
Rex/NN
is/VBZ
a/DT
phosphoprotein/NN
found/VBN
in/IN
the/DT
cell/NN
nucleolus/NN
,/,
whose/WP$
function/NN
may/MD
be/VB
regulated/VBN
by/IN
its/PRP$
localization/NN
and/CC
phosphorylation/NN
./.
====================
We/PRP
have/VBP
examined/VBN
the/DT
role/NN
of/IN
phosphorylation/NN
on/IN
Rex/NN
function/NN
by/IN
using/VBG
a/DT
protein/NN
kinase/NN
inhibitor/NN
,/,
H-7/NN
[/(
1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine/NN
]/)
./.
====================
Treatment/NN
of/IN
an/DT
HTLV-I/NN
infected/JJ
human/JJ
T-cell/NN
line/NN
with/IN
H-7/NN
blocked/VBD
specifically/RB
accumulation/NN
of/IN
the/DT
unspliced/JJ
gag-pol/NN
mRNA/NN
,/,
resulting/VBG
in/IN
the/DT
decreased/VBN
Gag/NN
protein/NN
synthesis/NN
that/WDT
corresponds/VBZ
with/IN
the/DT
decreased/VBN
in/FW
vivo/FW
phosphorylation/NN
of/IN
Rex/NN
./.
====================
In/IN
contrast/NN
,/,
other/JJ
viral/JJ
and/CC
cellular/JJ
products/NNS
have/VBP
not/RB
been/VBN
influenced/VBN
by/IN
the/DT
level/NN
of/IN
H-7/NN
used/VBN
./.
====================
Therefore/RB
,/,
the/DT
phosphorylation/NN
of/IN
Rex/NN
is/VBZ
required/VBN
for/IN
the/DT
viral/JJ
RNA/NN
partition/NN
of/IN
HTLV-I/NN
./.
====================
UI/LS
-/:
90292959/CD
====================
TI/LS
-/:
Increased/VBN
glucocorticoid/NN
responsiveness/NN
of/IN
CD4+/JJ
T-cell/NN
clonal/JJ
lines/NNS
grown/VBN
in/IN
serum-free/JJ
media/NNS
./.
====================
AB/LS
-/:
CEM-C7/NN
,/,
a/DT
human/JJ
leukemic/JJ
CD4+/JJ
T-lymphocyte/NN
cell/NN
line/NN
and/CC
three/CD
of/IN
its/PRP$
subclones/NNS
,/,
CEM-4R4/NN
,/,
CEM-3R43/NN
,/,
and/CC
ICR-27/NN
,/,
previously/RB
cultured/VBN
in/IN
a/DT
medium/NN
supplemented/VBN
with/IN
5/CD
to/TO
10/CD
%/NN
fetal/JJ
bovine/JJ
serum/NN
,/,
have/VBP
been/VBN
adapted/VBN
to/TO
serum-free/JJ
media/NNS
./.
====================
The/DT
best/JJS
medium/NN
of/IN
those/DT
tested/VBN
was/VBD
RPMI/NN
1640/CD
supplemented/VBN
with/IN
5/CD
micrograms/ml/NNS
each/DT
transferrin/NN
and/CC
insulin/NN
+/CC
5/CD
ng/ml/NN
sodium/NN
selenite/NN
+/-/CC
0.1/CD
%/NN
bovine/JJ
serum/NN
albumin/NN
./.
====================
While/IN
growing/VBG
either/CC
with/IN
or/CC
without/IN
albumin/NN
,/,
the/DT
several/JJ
clonal/JJ
lines/NNS
of/IN
CEM/NN
cells/NNS
displayed/VBD
growth/NN
similar/JJ
to/TO
serum-supplemented/JJ
cultures/NNS
./.
====================
Cell/NN
proliferation/NN
of/IN
CEM-C7/NN
cells/NNS
cultured/VBN
in/IN
both/DT
serum-free/JJ
media/NNS
has/VBZ
been/VBN
sustained/JJ
for/IN
3/CD
mo./NN
====================
with/IN
culture/NN
doubling/VBG
times/NNS
of/IN
about/RB
25/CD
h/NN
for/IN
both/CC
serum-supplemented/JJ
and/CC
serum-free/JJ
cultures/NNS
(/(
viability/NN
greater/JJR
than/IN
or/CC
equal/JJ
to/TO
90/CD
%/NN
)/)
./.
====================
Cell/NN
morphology/NN
remained/VBD
essentially/RB
the/DT
same/JJ
in/IN
serum-free/JJ
or/CC
serum/NN
containing/NN
media/NNS
./.
====================
The/DT
expression/NN
of/IN
CD4/NN
,/,
a/DT
marker/NN
for/IN
T-derived/JJ
lymphoid/JJ
cells/NNS
,/,
was/VBD
not/RB
significantly/RB
different/JJ
in/IN
serum-free/JJ
medium/NN
./.
====================
When/WRB
grown/VBN
in/IN
serum-free/JJ
medium/NN
,/,
CEM-C7/NN
cells/NNS
exhibited/VBD
increased/VBN
steroid/NN
responsiveness/NN
as/IN
evidenced/VBN
by/IN
increased/VBN
glucocorticoid/NN
receptor/NN
binding/NN
sites/NNS
,/,
increased/VBN
induction/NN
of/IN
glutamine/NN
synthetase/NN
,/,
and/CC
cell/NN
lysis/NN
at/IN
lower/JJR
concentrations/NNS
of/IN
steroid/NN
./.
====================
Receptor/NN
mutant/NN
subclones/NNS
of/IN
CEM-C7/NN
,/,
which/WDT
are/VBP
proven/VBN
to/TO
be/VB
completely/RB
unresponsive/JJ
to/TO
micromolar/JJ
concentrations/NNS
of/IN
dexamethasone/NN
when/WRB
grown/VBN
in/IN
serum-supplemented/JJ
medium/NN
,/,
become/VBP
partially/RB
sensitive/JJ
to/TO
the/DT
hormone/NN
after/IN
growth/NN
in/IN
defined/VBN
medium/NN
./.
====================
The/DT
increased/VBN
sensitivity/NN
of/IN
CEM-C7/NN
cells/NNS
and/CC
its/PRP$
subclones/NNS
to/TO
dexamethasone/NN
in/IN
serum-free/JJ
medium/NN
returned/VBD
to/TO
previous/JJ
levels/NNS
when/WRB
these/DT
cells/NNS
were/VBD
recultured/VBN
in/IN
serum-containing/JJ
medium/NN
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
substances/NNS
in/IN
serum/NN
influence/VBP
steroid/NN
effects/NNS
on/IN
these/DT
cells/NNS
and/CC
that/IN
the/DT
molecular/JJ
details/NNS
of/IN
glucocorticoid/NN
hormone/NN
action/NN
may/MD
be/VB
pursued/VBN
more/RBR
precisely/RB
in/IN
a/DT
clearly/RB
defined/VBN
culture/NN
medium/NN
./.
====================
UI/LS
-/:
90381807/CD
====================
TI/LS
-/:
[/(
Glucocorticoid/NN
receptors/NNS
on/IN
human/JJ
peripheral/JJ
mononuclear/JJ
and/CC
polymorphonuclear/JJ
leucocytes/NNS
:/:
changes/NNS
in/IN
patients/NNS
with/IN
yang-deficiency/NN
]/)
====================
AB/LS
-/:
It/PRP
was/VBD
found/VBN
that/IN
,/,
in/IN
former/JJ
works/NNS
,/,
the/DT
glucocorticoid/NN
receptors/NNS
(/(
GCR/NN
)/)
on/IN
peripheral/JJ
mixed/JJ
leucocytes/NNS
in/IN
patients/NNS
with/IN
Yang-deficiency/NN
were/VBD
decreased/VBN
./.
====================
In/IN
this/DT
work/NN
,/,
the/DT
mixed/JJ
leucocytes/NNS
were/VBD
further/RB
separated/VBN
into/IN
mononuclear/JJ
(/(
MNL/NN
)/)
and/CC
polymorphonuclear/NN
(/(
PML/NN
)/)
leucocytes/NNS
,/,
and/CC
GCR/NN
were/VBD
determined/VBN
in/IN
each/DT
part/NN
of/IN
leucocytes/NNS
./.
====================
GCR/NN
on/IN
MNL/NN
and/CC
PML/NN
in/IN
6/CD
Yang/NN
deficient/JJ
patients/NNS
were/VBD
3473/CD
+/-/CC
413/CD
and/CC
4433/CD
+/-/CC
651/CD
sites/cell/NNS
respectively/RB
,/,
statistically/RB
significant/JJ
from/IN
the/DT
normal/JJ
control/JJ
group/NN
(/(
4462/CD
+/-/CC
962/CD
and/CC
5622/CD
+/-/CC
782/CD
sites/cell/NNS
respectively/RB
,/,
P/NN
less/JJR
than/IN
0.05/CD
)/)
./.
====================
GCR/NN
on/IN
MNL/NN
,/,
PML/NN
and/CC
mixed/JJ
leucocytes/NNS
in/IN
5/CD
patients/NNS
were/VBD
determined/VBN
simultaneously/RB
,/,
and/CC
all/DT
lowered/VBD
from/IN
the/DT
control/JJ
group/NN
./.
====================
The/DT
results/NNS
were/VBD
3369/CD
+/-/CC
370/CD
,/,
4986/CD
+/-/CC
419/CD
and/CC
4524/CD
+/-/CC
852/CD
sites/cell/NNS
respectively/RB
,/,
with/IN
the/DT
lowest/JJS
GCR/NN
on/IN
MNL/NN
and/CC
highest/JJS
on/IN
PML/NN
./.
====================
UI/LS
-/:
90158614/CD
====================
TI/LS
-/:
The/DT
ubiquitous/JJ
octamer-binding/JJ
protein/NN
(/(
s/NNS
)/)
is/VBZ
sufficient/JJ
for/IN
transcription/NN
of/IN
immunoglobulin/NN
genes/NNS
./.
====================
AB/LS
-/:
All/DT
immunoglobulin/NN
genes/NNS
contain/VBP
a/DT
conserved/VBN
octanucleotide/NN
promoter/NN
element/NN
,/,
ATGCAAAT/NN
,/,
which/WDT
has/VBZ
been/VBN
shown/VBN
to/TO
be/VB
required/VBN
for/IN
their/PRP$
normal/JJ
B-cell-specific/JJ
transcription/NN
./.
====================
Proteins/NNS
that/WDT
bind/VBP
this/DT
octamer/NN
have/VBP
been/VBN
purified/VBN
,/,
and/CC
cDNAs/NNS
encoding/VBG
octamer-binding/JJ
proteins/NNS
have/VBP
been/VBN
cloned/VBN
./.
====================
Some/DT
of/IN
these/DT
proteins/NNS
(/(
referred/VBN
to/TO
as/IN
OTF-2/NN
)/)
are/VBP
lymphoid/JJ
specific/JJ
,/,
whereas/IN
at/IN
least/JJS
one/CD
other/JJ
,/,
and/CC
possibly/RB
more/JJR
(/(
referred/VBN
to/TO
as/IN
OTF-1/NN
)/)
,/,
is/VBZ
found/VBN
ubiquitously/RB
in/IN
all/DT
cell/NN
types/NNS
./.
====================
The/DT
exact/JJ
role/NN
of/IN
these/DT
different/JJ
proteins/NNS
in/IN
directing/VBG
the/DT
tissue-specific/JJ
expression/NN
of/IN
immunoglobulin/NN
genes/NNS
is/VBZ
unclear/JJ
./.
====================
We/PRP
have/VBP
identified/VBN
two/CD
human/JJ
pre-B-cell/NN
lines/NNS
that/WDT
contain/VBP
extremely/RB
low/JJ
levels/NNS
of/IN
OTF-2/NN
yet/CC
still/RB
express/VBP
high/JJ
levels/NNS
of/IN
steady-state/JJ
immunoglobulin/NN
heavy-chain/JJ
mRNA/NN
in/FW
vivo/FW
and/CC
efficiently/RB
transcribe/VBP
an/DT
immunoglobulin/NN
gene/NN
in/FW
vitro/FW
./.
====================
Addition/NN
of/IN
a/DT
highly/RB
enriched/JJ
preparation/NN
of/IN
OTF-1/NN
made/VBN
from/IN
one/CD
of/IN
these/DT
pre-B/NN
cells/NNS
or/CC
from/IN
HeLa/NN
cells/NNS
specifically/RB
stimulated/VBD
in/FW
vitro/FW
transcription/NN
of/IN
an/DT
immunoglobulin/NN
gene/NN
./.
====================
Furthermore/RB
,/,
OFT-1/NN
appeared/VBD
to/TO
have/VB
approximately/RB
the/DT
same/JJ
transactivation/NN
ability/NN
as/IN
OTF-2/NN
when/WRB
normalized/VBN
for/IN
binding/NN
activity/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
OTF-1/NN
,/,
without/IN
OTF-2/NN
,/,
is/VBZ
sufficient/JJ
for/IN
transcription/NN
of/IN
immunoglobulin/NN
genes/NNS
and/CC
that/IN
OTF-2/NN
alone/RB
is/VBZ
not/RB
responsible/JJ
for/IN
the/DT
B-cell-specific/JJ
regulation/NN
of/IN
immunoglobulin/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
90205027/CD
====================
TI/LS
-/:
Effects/NNS
of/IN
aldosterone/NN
on/IN
intralymphocytic/JJ
sodium/NN
and/CC
potassium/NN
in/IN
patients/NNS
with/IN
essential/JJ
hypertension/NN
./.
====================
AB/LS
-/:
In/FW
vitro/FW
binding/NN
of/IN
aldosterone/NN
to/TO
mineralocorticoid/NN
receptors/NNS
on/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
(/(
HML/NNS
)/)
and/CC
its/PRP$
effects/NNS
on/IN
the/DT
intracellular/JJ
sodium/NN
and/CC
potassium/NN
concentrations/NNS
of/IN
HML/NNS
have/VBP
already/RB
been/VBN
described/VBN
./.
====================
In/IN
the/DT
present/JJ
paper/NN
this/DT
easily/RB
accessible/JJ
human/JJ
cell/NN
model/NN
was/VBD
investigated/VBN
in/IN
13/CD
patients/NNS
with/IN
essential/JJ
hypertension/NN
./.
====================
In/IN
only/RB
four/CD
patients/NNS
sodium/NN
in/RP
HML/NNS
without/IN
incubation/NN
was/VBD
elevated/JJ
compared/VBN
with/IN
the/DT
range/NN
for/IN
normal/JJ
persons/NNS
./.
====================
A/DT
decrease/NN
of/IN
intracellular/JJ
sodium/NN
or/CC
potassium/NN
occurred/VBD
during/IN
incubation/NN
without/IN
aldosterone/NN
(/(
P/NN
less/JJR
than/IN
0.02/CD
)/)
./.
====================
The/DT
addition/NN
of/IN
1.4/CD
nM/NN
aldosterone/NN
did/VBD
not/RB
prevent/VB
this/DT
loss/NN
of/IN
electrolytes/NNS
as/IN
observed/VBN
in/IN
normal/JJ
persons/NNS
./.
====================
Plasma/NN
renin/NN
activity/NN
and/CC
aldosterone/NN
were/VBD
not/RB
correlated/VBN
with/IN
the/DT
electrolyte/NN
response/NN
and/CC
were/VBD
within/IN
the/DT
normal/JJ
limits/NNS
./.
====================
The/DT
number/NN
of/IN
mineralocorticoid/NN
receptors/cell/NN
were/VBD
within/IN
or/CC
close/JJ
to/TO
the/DT
normal/JJ
range/NN
(/(
n/NN
=/JJ
9/CD
)/)
./.
====================
The/DT
independence/NN
of/IN
intracellular/JJ
electrolytes/NNS
from/IN
aldosterone/NN
despite/IN
a/DT
normal/JJ
number/NN
of/IN
mineralocorticoid/NN
receptors/NNS
may/MD
reflect/VB
an/DT
impairment/NN
of/IN
the/DT
mineralocorticoid/NN
effector/NN
mechanism/NN
in/IN
the/DT
HML/NNS
of/IN
patients/NNS
with/IN
essential/JJ
hypertension/NN
./.
====================
UI/LS
-/:
91296472/CD
====================
TI/LS
-/:
[/(
Differential/JJ
diagnostic/JJ
value/NN
of/IN
receptors/NNS
of/IN
1,25-dihydroxyvitamin/NN
D3/NN
(/(
calcitriol/NN
)/)
determination/NN
in/IN
lymphocytes/NNS
of/IN
children/NNS
with/IN
rickets/NN
and/CC
rickets-like/JJ
diseases/NNS
]/)
====================
AB/LS
-/:
The/DT
authors/NNS
provide/VBP
the/DT
results/NNS
of/IN
studying/VBG
1,25-dihydroxyvitamin/NN
D3/NN
(/(
calcitriol/NN
)/)
in/IN
lymphocytes/NNS
of/IN
children/NNS
with/IN
rickets/NN
and/CC
rickets-like/JJ
diseases/NNS
./.
====================
It/PRP
is/VBZ
proposed/VBN
that/IN
the/DT
character/NN
of/IN
their/PRP$
expression/NN
under/IN
the/DT
influence/NN
of/IN
vitamin/NN
D/NN
may/MD
be/VB
used/VBN
with/IN
differential/JJ
diagnostic/JJ
purposes/NNS
in/IN
view/NN
./.
====================
UI/LS
-/:
91048014/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
gene/NN
expression/NN
with/IN
double-stranded/JJ
phosphorothioate/NN
oligonucleotides/NNS
./.
====================
AB/LS
-/:
Alteration/NN
of/IN
gene/NN
transcription/NN
by/IN
inhibition/NN
of/IN
specific/JJ
transcriptional/JJ
regulatory/JJ
proteins/NNS
is/VBZ
necessary/JJ
for/IN
determining/VBG
how/WRB
these/DT
factors/NNS
participate/VBP
in/IN
cellular/JJ
differentiation/NN
./.
====================
The/DT
functions/NNS
of/IN
these/DT
proteins/NNS
can/MD
be/VB
antagonized/VBN
by/IN
several/JJ
methods/NNS
,/,
each/DT
with/IN
specific/JJ
limitations/NNS
./.
====================
Inhibition/NN
of/IN
sequence-specific/JJ
DNA-binding/JJ
proteins/NNS
was/VBD
achieved/VBN
with/IN
double-stranded/JJ
(/(
ds/JJ
)/)
phosphorothioate/NN
oligonucleotides/NNS
that/WDT
contained/VBD
octamer/NN
or/CC
kappa/NN
B/NN
consensus/NN
sequences/NNS
./.
====================
The/DT
phosphorothioate/NN
oligonucleotides/NNS
specifically/RB
bound/VBD
either/CC
octamer/NN
transcription/NN
factor/NN
or/CC
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
-kappa/NN
B/NN
./.
====================
The/DT
modified/VBN
oligonucleotides/NNS
accumulated/VBD
in/IN
cells/NNS
more/RBR
effectively/RB
than/IN
standard/JJ
ds/JJ
oligonucleotides/NNS
and/CC
modulated/VBD
gene/NN
expression/NN
in/IN
a/DT
specific/JJ
manner/NN
./.
====================
Octamer-dependent/JJ
activation/NN
of/IN
a/DT
reporter/NN
plasmid/NN
or/CC
NF-kappa/NN
B-dependent/JJ
activation/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
enhancer/NN
was/VBD
inhibited/VBN
when/WRB
the/DT
appropriate/JJ
phosphorothioate/NN
oligonucleotide/NN
was/VBD
added/VBN
to/TO
a/DT
transiently/RB
transfected/VBN
B/NN
cell/NN
line/NN
./.
====================
Addition/NN
of/IN
phosphorothioate/NN
oligonucleotides/NNS
that/WDT
contained/VBD
the/DT
octamer/NN
consensus/NN
to/TO
Jurkat/NN
T/NN
leukemia/NN
cells/NNS
inhibited/VBD
interleukin-2/NN
(/(
IL-2/NN
)/)
secretion/NN
to/TO
a/DT
degree/NN
similar/JJ
to/TO
that/DT
observed/VBN
with/IN
a/DT
mutated/VBN
octamer/NN
site/NN
in/IN
the/DT
IL-2/NN
enhancer/NN
./.
====================
The/DT
ds/JJ
phosphorothioate/NN
oligonucleotides/NNS
probably/RB
compete/VBP
for/IN
binding/NN
of/IN
specific/JJ
transcription/NN
factors/NNS
and/CC
may/MD
provide/VB
anti-viral/JJ
,/,
immunosuppressive/JJ
,/,
or/CC
other/JJ
therapeutic/JJ
effects/NNS
./.
====================
UI/LS
-/:
91098724/CD
====================
TI/LS
-/:
[/(
Effect/NN
of/IN
the/DT
regimen/NN
of/IN
kidney-tonifying/JJ
and/CC
qi-invigorating/JJ
on/IN
aging/NN
changes/NNS
of/IN
glucocorticoid/NN
receptor/NN
]/)
====================
AB/LS
-/:
The/DT
plasma/NN
cortisol/NN
concentration/NN
and/CC
the/DT
sites/NNS
of/IN
glucocorticoid/NN
receptor/NN
(/(
GCR/NN
)/)
in/IN
the/DT
peripheral/JJ
lymphocytes/NNS
were/VBD
measured/VBN
in/IN
32/CD
healthy/JJ
aged/JJ
persons/NNS
and/CC
13/CD
young/JJ
adults/NNS
./.
====================
In/IN
animal/JJ
experiment/NN
,/,
GCR/NN
of/IN
spleen/NN
lymphocytic/JJ
cell/NN
was/VBD
also/RB
measured/VBN
in/IN
18/CD
aged/JJ
rats/NNS
and/CC
9/CD
young/JJ
rats/NNS
./.
====================
The/DT
results/NNS
showed/VBD
that/IN
GCR/NN
was/VBD
significantly/RB
lower/JJR
in/IN
the/DT
aged/JJ
persons/NNS
or/CC
rats/NNS
than/IN
that/DT
in/IN
the/DT
young/JJ
while/IN
the/DT
plasma/NN
cortisol/NN
level/NN
did/VBD
n't/RB
change/VB
with/IN
aging/NN
./.
====================
So/RB
we/PRP
think/VBP
that/IN
GCR/NN
is/VBZ
more/RBR
sensitive/JJ
than/IN
the/DT
plasma/NN
cortisol/NN
level/NN
to/TO
reflect/VB
the/DT
aging/NN
change/NN
of/IN
the/DT
adrenal/JJ
cortex/NN
function/NN
./.
====================
After/IN
the/DT
treatment/NN
with/IN
the/DT
regimen/NN
of/IN
Kidney-tonifying/JJ
and/CC
Qi-invigorating/JJ
,/,
the/DT
GCR/NN
of/IN
the/DT
aged/JJ
persons/NNS
and/CC
rats/NNS
was/VBD
enhanced/VBN
,/,
and/CC
in/IN
this/DT
way/NN
,/,
the/DT
function/NN
of/IN
the/DT
aged/JJ
adrenal/JJ
cortex/NN
was/VBD
improved/VBN
./.
====================
UI/LS
-/:
90381353/CD
====================
TI/LS
-/:
Interferon/NN
affects/VBZ
nuclear/JJ
proteins/NNS
in/IN
cells/NNS
of/IN
clinically/RB
sensitive/JJ
chronic/JJ
myelogenous/JJ
leukemia/NN
patients/NNS
./.
====================
AB/LS
-/:
Cytoplasmic/JJ
protein/NN
extracts/NNS
from/IN
chronic/JJ
myelogenous/JJ
leukemia/NN
(/(
CML/NN
)/)
cells/NNS
contained/VBD
an/DT
activity/NN
that/WDT
altered/VBD
the/DT
electrophoretic/JJ
mobility/NN
of/IN
complexes/NNS
formed/VBN
between/IN
nuclear/JJ
proteins/NNS
and/CC
the/DT
transcriptional/JJ
enhancers/NNS
of/IN
interferon/NN
(/(
IFN/NN
)/)
-inducible/JJ
genes/NNS
./.
====================
Exposure/NN
of/IN
CML/NN
cells/NNS
to/TO
IFN-alpha/NN
diminished/VBD
the/DT
effect/NN
of/IN
the/DT
CML/NN
cytoplasmic/JJ
proteins/NNS
on/IN
these/DT
nuclear/JJ
protein-DNA/JJ
complexes/NNS
./.
====================
The/DT
presence/NN
of/IN
clinical/JJ
responsiveness/NN
to/TO
IFN-alpha/NN
correlated/VBD
with/IN
the/DT
sensitivity/NN
to/TO
the/DT
IFN-induced/JJ
change/NN
in/IN
the/DT
electrophoretic/JJ
mobility/NN
of/IN
nuclear/JJ
protein-DNA/JJ
complexes/NNS
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
the/DT
action/NN
of/IN
IFN-alpha/NN
in/IN
CML/NN
may/MD
be/VB
linked/VBN
to/TO
a/DT
pathway/NN
that/WDT
can/MD
result/VB
in/IN
posttranslational/JJ
modification/NN
of/IN
nuclear/JJ
proteins/NNS
./.
====================
UI/LS
-/:
90279073/CD
====================
TI/LS
-/:
Epstein-Barr/JJ
virus/NN
nuclear/JJ
antigen/NN
2/CD
transactivates/VBZ
latent/JJ
membrane/NN
protein/NN
LMP1/NN
./.
====================
AB/LS
-/:
Several/JJ
lines/NNS
of/IN
evidence/NN
are/VBP
compatible/JJ
with/IN
the/DT
hypothesis/NN
that/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
nuclear/JJ
antigen/NN
2/CD
(/(
EBNA-2/NN
)/)
or/CC
leader/NN
protein/NN
(/(
EBNA-LP/NN
)/)
affects/VBZ
expression/NN
of/IN
the/DT
EBV/NN
latent/JJ
infection/NN
membrane/NN
protein/NN
LMP1/NN
./.
====================
We/PRP
now/RB
demonstrate/VBP
the/DT
following/NN
./.
====================
(/(
i/LS
)/)
Acute/JJ
transfection/NN
and/CC
expression/NN
of/IN
EBNA-2/NN
under/IN
control/NN
of/IN
simian/JJ
virus/NN
40/CD
or/CC
Moloney/NN
murine/JJ
leukemia/NN
virus/NN
promoters/NNS
resulted/VBD
in/IN
increased/VBN
LMP1/NN
expression/NN
in/IN
P3HR-1-infected/JJ
Burkitt/NN
's/POS
lymphoma/NN
cells/NNS
and/CC
the/DT
P3HR-1/NN
or/CC
Daudi/NN
cell/NN
line/NN
./.
====================
(/(
ii/LS
)/)
Transfection/NN
and/CC
expression/NN
of/IN
EBNA-LP/NN
alone/RB
had/VBD
no/DT
effect/NN
on/IN
LMP1/NN
expression/NN
and/CC
did/VBD
not/RB
act/VB
synergistically/RB
with/IN
EBNA-2/NN
to/TO
affect/VB
LMP1/NN
expression/NN
./.
====================
(/(
iii/LS
)/)
LMP1/NN
expression/NN
in/IN
Daudi/NN
and/CC
P3HR-1-infected/JJ
cells/NNS
was/VBD
controlled/VBN
at/IN
the/DT
mRNA/NN
level/NN
,/,
and/CC
EBNA-2/NN
expression/NN
in/IN
Daudi/NN
cells/NNS
increased/VBD
LMP1/NN
mRNA/NN
./.
====================
(/(
iv/LS
)/)
No/DT
other/JJ
EBV/NN
genes/NNS
were/VBD
required/VBN
for/IN
EBNA-2/NN
transactivation/NN
of/IN
LMP1/NN
since/IN
cotransfection/NN
of/IN
recombinant/JJ
EBNA-2/NN
expression/NN
vectors/NNS
and/CC
genomic/JJ
LMP1/NN
DNA/NN
fragments/NNS
enhanced/VBD
LMP1/NN
expression/NN
in/IN
the/DT
EBV-negative/JJ
B-lymphoma/NN
cell/NN
lines/NNS
BJAB/NN
,/,
Louckes/NN
,/,
and/CC
BL30/NN
./.
====================
(/(
v/LS
)/)
An/DT
EBNA-2-responsive/JJ
element/NN
was/VBD
found/VBN
within/IN
the/DT
-512/CD
to/TO
+40/CD
LMP1/NN
DNA/NN
since/IN
this/DT
DNA/NN
linked/VBN
to/TO
a/DT
chloramphenicol/NN
acetyltransferase/NN
reporter/NN
gene/NN
was/VBD
transactivated/VBN
by/IN
cotransfection/NN
with/IN
an/DT
EBNA-2/NN
expression/NN
vector/NN
./.
====================
(/(
vi/LS
)/)
The/DT
EBV/NN
type/NN
2/CD
EBNA-2/NN
transactivated/VBD
LMP1/NN
as/RB
well/RB
as/IN
the/DT
EBV/NN
type/NN
1/CD
EBNA-2/NN
./.
====================
(/(
vii/LS
)/)
Two/CD
deletions/NNS
within/IN
the/DT
EBNA-2/NN
gene/NN
which/WDT
rendered/VBD
EBV/NN
transformation/NN
incompetent/JJ
did/VBD
not/RB
transactivate/VB
LMP1/NN
,/,
whereas/IN
a/DT
transformation-competent/JJ
EBNA-2/NN
deletion/NN
mutant/NN
did/VBD
transactivate/VB
LMP1/NN
./.
====================
LMP1/NN
is/VBZ
a/DT
potent/JJ
effector/NN
of/IN
B-lymphocyte/NN
activation/NN
and/CC
can/MD
act/VB
synergistically/RB
with/IN
EBNA-2/NN
to/TO
induce/VB
cellular/JJ
CD23/NN
gene/NN
expression/NN
./.
====================
Thus/RB
,/,
EBNA-2/NN
transactivation/NN
of/IN
LMP1/NN
amplifies/VBZ
the/DT
biological/JJ
impact/NN
of/IN
EBNA-2/NN
and/CC
underscores/VBZ
its/PRP$
central/JJ
role/NN
in/IN
EBV-induced/JJ
growth/NN
transformation/NN
./.
====================
UI/LS
-/:
90278097/CD
====================
TI/LS
-/:
The/DT
expression/NN
of/IN
c-fos/NN
,/,
c-jun/NN
,/,
and/CC
c-myc/NN
genes/NNS
is/VBZ
regulated/VBN
by/IN
heat/NN
shock/NN
in/IN
human/JJ
lymphoid/JJ
cells/NNS
./.
====================
AB/LS
-/:
The/DT
effect/NN
of/IN
heat/NN
shock/NN
on/IN
the/DT
expression/NN
of/IN
the/DT
nuclear/JJ
protooncogenes/NNS
c-fos/NN
,/,
c-jun/NN
,/,
and/CC
c-myc/NN
was/VBD
studied/VBN
in/IN
human/JJ
lymphoid/JJ
cells/NNS
./.
====================
Heat/NN
shock/NN
caused/VBD
an/DT
increase/NN
in/IN
c-fos/NN
and/CC
c-jun/NN
mRNA/NN
levels/NNS
and/CC
a/DT
decrease/NN
in/IN
c-myc/NN
mRNA/NN
levels/NNS
in/IN
pre-B/JJ
(/(
Hyon/NN
)/)
and/CC
T/NN
(/(
DND-41/NN
)/)
cell/NN
lines/NNS
as/RB
well/RB
as/IN
in/IN
freshly/RB
isolated/VBN
normal/JJ
human/JJ
thymocytes/NNS
./.
====================
The/DT
changes/NNS
in/IN
the/DT
mRNA/NN
levels/NNS
of/IN
these/DT
protooncogenes/NNS
in/IN
Hyon/NN
cells/NNS
were/VBD
most/RBS
pronounced/JJ
at/IN
42/CD
and/CC
43/CD
degrees/NNS
C/NN
;/:
kinetic/JJ
analysis/NN
demonstrated/VBD
that/IN
the/DT
changes/NNS
could/MD
be/VB
detected/VBN
within/IN
30/CD
min/NN
of/IN
heat/NN
shock/NN
./.
====================
Altered/JJ
transcription/NN
of/IN
c-fos/NN
and/CC
c-myc/NN
genes/NNS
was/VBD
the/DT
primary/JJ
effect/NN
of/IN
heat/NN
shock/NN
./.
====================
Secondarily/RB
,/,
heat/NN
shock/NN
of/IN
Hyon/NN
cells/NNS
stabilized/VBD
the/DT
c-myc/NN
mRNA/NN
level/NN
by/IN
increasing/VBG
its/PRP$
half-life/NN
from/IN
24/CD
to/TO
45/CD
min/NN
./.
====================
The/DT
overall/JJ
effect/NN
of/IN
heat/NN
shock/NN
on/IN
c-myc/NN
mRNA/NN
level/NN
,/,
however/RB
,/,
was/VBD
a/DT
marked/JJ
inhibition/NN
of/IN
its/PRP$
transcription/NN
./.
====================
These/DT
results/NNS
demonstrate/VBP
that/IN
the/DT
transcription/NN
of/IN
nuclear/JJ
protooncogenes/NNS
is/VBZ
regulated/VBN
by/IN
heat/NN
shock/NN
indicating/VBG
a/DT
role/NN
for/IN
nuclear/JJ
protooncogenes/NNS
in/IN
the/DT
stress/NN
response/NN
of/IN
lymphoid/JJ
cells/NNS
./.
====================
UI/LS
-/:
90244394/CD
====================
TI/LS
-/:
Mapping/NN
of/IN
B-cell/NN
epitopes/NNS
of/IN
the/DT
human/JJ
hepatitis/NN
B/NN
virus/NN
X/NN
protein/NN
./.
====================
AB/LS
-/:
The/DT
immune/JJ
response/NN
to/TO
the/DT
X/NN
protein/NN
of/IN
human/JJ
hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
was/VBD
studied/VBN
by/IN
epitope/NN
mapping/NN
by/IN
using/VBG
a/DT
set/NN
of/IN
MS2-HBx/NN
fusion/NN
proteins/NNS
and/CC
synthetic/JJ
peptides/NNS
./.
====================
Antibodies/NNS
in/IN
sera/NN
of/IN
patients/NNS
with/IN
acute/JJ
and/CC
chronic/JJ
HBV/NN
infection/NN
showed/VBD
a/DT
multispecific/JJ
immune/JJ
response/NN
./.
====================
Each/DT
serum/NN
contained/VBD
antibodies/NNS
to/TO
a/DT
different/JJ
set/NN
of/IN
epitopes/NNS
,/,
which/WDT
taken/VBN
together/RB
cover/VBP
most/JJS
of/IN
the/DT
HBx/NN
sequence/NN
./.
====================
Some/DT
of/IN
the/DT
epitopes/NNS
were/VBD
detectable/JJ
only/RB
by/IN
immunoblotting/VBG
with/IN
fusion/NN
proteins/NNS
;/:
others/NNS
were/VBD
detectable/JJ
only/RB
by/IN
an/DT
enzyme-linked/JJ
immunosorbent/JJ
assay/NN
(/(
ELISA/NN
)/)
with/IN
synthetic/JJ
peptides/NNS
./.
====================
The/DT
carboxy-terminal/JJ
half/NN
of/IN
the/DT
HBx/NN
protein/NN
was/VBD
preferentially/RB
recognized/VBN
by/IN
antibodies/NNS
from/IN
patients/NNS
with/IN
chronic/JJ
hepatitis/NN
and/CC
contained/VBD
a/DT
short/JJ
immunodominant/JJ
antigenic/JJ
region/NN
with/IN
at/IN
least/JJS
two/CD
major/JJ
nonoverlapping/JJ
epitopes/NNS
./.
====================
Anti-HBx/JJ
antibody/NN
titers/NNS
as/IN
revealed/VBN
by/IN
peptide/NN
ELISAs/NNS
were/VBD
highest/JJS
and/CC
most/RBS
frequent/JJ
in/IN
patients/NNS
with/IN
chronic/JJ
hepatitis/NN
and/CC
usually/RB
low/JJ
in/IN
acutely/RB
infected/JJ
patients/NNS
and/CC
asymptomatic/JJ
carriers/NNS
./.
====================
The/DT
data/NNS
demonstrate/VBP
a/DT
remarkable/JJ
qualitative/JJ
and/CC
quantitative/JJ
heterogeneity/NN
of/IN
the/DT
humoral/JJ
HBx/NN
immune/JJ
response/NN
which/WDT
can/MD
be/VB
monitored/VBN
by/IN
HBx-specific/JJ
peptide/NN
ELISAs/NNS
./.
====================
Such/JJ
tests/NNS
may/MD
become/VB
useful/JJ
diagnostic/JJ
tools/NNS
./.
====================
UI/LS
-/:
90327113/CD
====================
TI/LS
-/:
[/(
The/DT
inhibitory/JJ
effect/NN
of/IN
hydrocortisone/NN
on/IN
the/DT
chemotactic/JJ
migration/NN
of/IN
human/JJ
leukocytes/NNS
]/)
====================
AB/LS
-/:
Random/JJ
migration/NN
(/(
RM/NN
)/)
and/CC
chemotactic/JJ
migration/NN
(/(
ChtM/NN
)/)
of/IN
human/JJ
leukocytes/NNS
to/TO
yeast/NN
activated/JJ
serum/NN
were/VBD
studied/VBN
with/IN
the/DT
modified/VBN
Boyden/NN
chamber/NN
method/NN
./.
====================
Both/CC
RM/NN
and/CC
ChtM/NN
showed/VBD
circadian/JJ
rhythm/NN
./.
====================
Leukocytes/NNS
migrated/VBD
most/RBS
rapidly/RB
at/IN
night/NN
./.
====================
The/DT
difference/NN
between/IN
the/DT
peak/NN
(/(
0/CD
:/:
00/CD
)/)
and/CC
trough/NN
values/NNS
(/(
8/CD
:/:
00/CD
)/)
of/IN
RM/NN
and/CC
ChtM/NN
was/VBD
significant/JJ
statistically/RB
(/(
P/NN
less/JJR
than/IN
0.01/CD
)/)
./.
====================
ChtM/NN
was/VBD
inhibited/VBN
by/IN
hydrocortisone/NN
(/(
F/NN
)/)
of/IN
physiological/JJ
concentration/NN
(/(
10/CD
(/(
-9/CD
)/)
-10/CD
(/(
-7/CD
)/)
mol/L/NN
)/)
which/WDT
was/VBD
dose-dependent/JJ
and/CC
completely/RB
antagonized/VBN
by/IN
the/DT
competitive/JJ
antagonist/NN
,/,
RU38486/NN
./.
====================
The/DT
inhibitory/JJ
effect/NN
was/VBD
much/RB
more/RBR
evident/JJ
with/IN
higher/JJR
dose/NN
(/(
more/JJR
than/IN
10/CD
(/(
-5/CD
)/)
mol/L/NN
)/)
and/CC
it/PRP
was/VBD
also/RB
reversed/VBN
by/IN
RU38486/NN
,/,
but/CC
only/RB
partially/RB
./.
====================
It/PRP
is/VBZ
suggested/VBN
that/IN
glucocorticoids/NNS
(/(
GC/NN
)/)
may/MD
be/VB
a/DT
physiological/JJ
regulator/NN
of/IN
the/DT
activity/NN
of/IN
leukocytes/NNS
and/CC
its/PRP$
inhibitory/JJ
action/NN
on/IN
ChtM/NN
may/MD
be/VB
involved/VBN
in/IN
antiinflammatory/JJ
mechanisms/NNS
of/IN
GC/NN
of/IN
pharmacological/JJ
doses/NNS
./.
====================
The/DT
action/NN
of/IN
physiological/JJ
and/CC
pharmacological/JJ
concentration/NN
of/IN
GC/NN
may/MD
be/VB
mediated/VBN
by/IN
low/JJ
affinity/NN
specific/JJ
binding/VBG
sites/NNS
of/IN
glucocorticoid/NN
receptors/NNS
./.
====================
UI/LS
-/:
90277507/CD
====================
TI/LS
-/:
Heterogeneity/NN
of/IN
antigen/NN
molecules/NNS
recognized/VBN
by/IN
anti-tax1/JJ
monoclonal/JJ
antibody/NN
Lt-4/NN
in/IN
cell/NN
lines/NNS
bearing/VBG
human/JJ
T/NN
cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
and/CC
related/JJ
retroviruses/NNS
./.
====================
AB/LS
-/:
Using/VBG
a/DT
monoclonal/JJ
antibody/NN
,/,
Lt-4/NN
,/,
directed/VBN
against/IN
human/JJ
T/NN
cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
trans-activator/NN
(/(
tax1/NN
)/)
antigen/NN
,/,
we/PRP
examined/VBD
the/DT
expression/NN
of/IN
tax1/NN
and/CC
related/JJ
antigens/NNS
in/IN
a/DT
variety/NN
of/IN
T/NN
cell/NN
lines/NNS
bearing/VBG
HTLV-I/NN
and/CC
related/JJ
retroviruses/NNS
,/,
simian/JJ
T/NN
cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
STLV-I/NN
)/)
and/CC
HTLV-II/NN
,/,
by/IN
immunofluorescence/NN
and/CC
immunoblot/NN
assays/NNS
./.
====================
Lt-4/NN
reacted/VBD
with/IN
all/DT
HTLV-I-bearing/JJ
cell/NN
lines/NNS
tested/VBN
and/CC
five/CD
out/IN
of/IN
eight/CD
simian/JJ
cell/NN
lines/NNS
bearing/VBG
STLV-I/NN
,/,
but/CC
not/RB
with/IN
an/DT
HTLV-II-bearing/JJ
cell/NN
line/NN
./.
====================
Lt-4/NN
detected/VBD
40/CD
kd/NN
tax1/NN
antigen/NN
molecules/NNS
in/IN
most/JJS
HTLV-I/JJ
-bearing/JJ
cell/NN
lines/NNS
except/IN
one/CD
cell/NN
line/NN
that/WDT
expressed/VBD
39/CD
kd/NN
tax1/NN
antigen/NN
./.
====================
In/IN
the/DT
STLV-I-bearing/JJ
T/NN
cell/NN
lines/NNS
,/,
tax1-related/JJ
antigen/NN
molecules/NNS
detected/VBN
by/IN
Lt-4/NN
were/VBD
heterogeneous/JJ
,/,
having/VBG
molecular/JJ
weights/NNS
in/IN
the/DT
range/NN
of/IN
36-41/CD
kd/NN
./.
====================
UI/LS
-/:
90147621/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
enhancer-binding/JJ
proteins/NNS
from/IN
the/DT
human/JJ
T-cell/NN
line/NN
Jurkat/NN
./.
====================
AB/LS
-/:
The/DT
transcription/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
is/VBZ
under/IN
the/DT
control/NN
of/IN
cellular/JJ
proteins/NNS
that/WDT
bind/VBP
to/TO
the/DT
viral/JJ
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
./.
====================
Among/IN
the/DT
protein-binding/JJ
regions/NNS
of/IN
the/DT
HIV-1/NN
LTR/NN
is/VBZ
the/DT
transcription-enhancer/JJ
region/NN
./.
====================
We/PRP
show/VBP
that/IN
at/IN
least/JJS
one/CD
inducible/JJ
,/,
C1/NN
,/,
and/CC
one/CD
constitutive/JJ
,/,
C2/NN
,/,
protein/NN
can/MD
bind/VB
to/TO
the/DT
HIV/NN
enhancer/NN
in/IN
Jurkat/NN
cells/NNS
./.
====================
The/DT
two/CD
proteins/NNS
differ/VBP
in/IN
their/PRP$
surface/NN
charge/NN
,/,
since/IN
they/PRP
are/VBP
separable/JJ
by/IN
anion-exchange/JJ
chromatography/NN
./.
====================
Bivalent/JJ
cations/NNS
such/JJ
as/IN
Mg2+/NN
and/CC
Zn2+/NN
differentially/RB
affect/VBP
their/PRP$
binding/NN
to/TO
oligonucleotides/NNS
which/WDT
contain/VBP
the/DT
HIV-enhancer/NN
domain/NN
./.
====================
Both/CC
C1/NN
and/CC
C2/NN
proteins/NNS
also/RB
bind/VBP
to/TO
a/DT
similar/JJ
sequence/NN
found/VBN
in/IN
the/DT
interleukin-2-receptor/NN
alpha-subunit/NN
enhancer/NN
./.
====================
The/DT
inducible/JJ
C1/NN
protein/NN
was/VBD
partially/RB
purified/VBN
by/IN
three/CD
chromatographic/JJ
steps/NNS
and/CC
characterized/VBN
by/IN
u.v./NN
cross-linking/NN
as/IN
a/DT
47/CD
kDa/NN
protein/NN
./.
====================
UI/LS
-/:
91079526/CD
====================
TI/LS
-/:
Differences/NNS
in/IN
transcriptional/JJ
enhancers/NNS
of/IN
HIV-1/NN
and/CC
HIV-2/NN
./.
====================
Response/NN
to/TO
T/NN
cell/NN
activation/NN
signals/NNS
./.
====================
AB/LS
-/:
T/NN
cell/NN
activation/NN
results/VBZ
in/IN
high/JJ
levels/NNS
of/IN
HIV/NN
replication/NN
and/CC
is/VBZ
thought/VBN
to/TO
be/VB
one/CD
mechanism/NN
leading/VBG
to/TO
the/DT
conversion/NN
from/IN
latent/JJ
to/TO
active/JJ
viral/JJ
infection/NN
./.
====================
In/IN
HIV-1/NN
,/,
the/DT
sequences/NNS
that/WDT
respond/VBP
to/TO
these/DT
signaling/NN
events/NNS
are/VBP
found/VBN
in/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
and/CC
comprise/VBP
the/DT
transcriptional/JJ
enhancer/NN
,/,
which/WDT
contains/VBZ
two/CD
conserved/VBN
binding/VBG
sites/NNS
for/IN
the/DT
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF/NN
kappa/NN
B/NN
)/)
./.
====================
The/DT
corresponding/JJ
region/NN
in/IN
the/DT
second/JJ
AIDS/NN
retrovirus/NN
,/,
HIV-2/NN
,/,
contains/VBZ
a/DT
conserved/VBN
and/CC
a/DT
divergent/JJ
NF/NN
kappa/NN
B/NN
binding/NN
site/NN
./.
====================
We/PRP
demonstrate/VBP
that/IN
the/DT
HIV-1/NN
LTR/NN
responds/VBZ
better/JJR
than/IN
the/DT
HIV-2/NN
LTR/NN
to/TO
T/NN
cell/NN
activation/NN
signals/NNS
./.
====================
These/DT
qualitative/JJ
differences/NNS
in/IN
the/DT
response/NN
to/TO
T/NN
cell/NN
activation/NN
are/VBP
reproduced/VBN
not/RB
only/RB
when/WRB
HIV-1/NN
or/CC
HIV-2/NN
enhancers/NNS
are/VBP
placed/VBN
upstream/RB
of/IN
a/DT
heterologous/JJ
promoter/NN
but/CC
also/RB
when/WRB
these/DT
enhancers/NNS
are/VBP
switched/VBN
between/IN
their/PRP$
respective/JJ
LTR/NN
./.
====================
In/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
,/,
NF/NN
kappa/NN
B/NN
binds/VBZ
to/TO
both/CC
conserved/VBN
sites/NNS
in/IN
the/DT
HIV-1/NN
transcriptional/JJ
enhancer/NN
and/CC
only/RB
to/TO
the/DT
single/JJ
conserved/VBN
site/NN
in/IN
the/DT
HIV-2/NN
transcriptional/JJ
enhancer/NN
./.
====================
Instead/RB
of/IN
NF/NN
kappa/NN
B/NN
,/,
the/DT
activator/NN
protein/NN
3/CD
binds/VBZ
to/TO
the/DT
divergent/JJ
site/NN
in/IN
HIV-2/NN
./.
====================
In/IN
conclusion/NN
,/,
HIV-1/NN
and/CC
HIV-2/NN
are/VBP
differentially/RB
regulated/VBN
by/IN
T/NN
cell/NN
activation/NN
signals/NNS
,/,
and/CC
this/DT
difference/NN
may/MD
account/VB
for/IN
the/DT
longer/JJR
period/NN
of/IN
viral/JJ
latency/NN
observed/VBN
with/IN
HIV-2/NN
than/IN
with/IN
HIV-1/NN
infection/NN
./.
====================
UI/LS
-/:
91036996/CD
====================
TI/LS
-/:
NF-X2/NN
that/WDT
binds/VBZ
to/TO
the/DT
DRA/NN
X2-box/NN
is/VBZ
activator/NN
protein/NN
1/CD
./.
====================
Expression/NN
cloning/NN
of/IN
c-Jun/NN
./.
====================
AB/LS
-/:
Human/JJ
class/NN
II/CD
MHC/NN
Ag/NN
are/VBP
a/DT
family/NN
of/IN
cell/NN
surface/NN
glycoproteins/NNS
./.
====================
Their/PRP$
constitutive/JJ
expression/NN
is/VBZ
limited/JJ
to/TO
B/NN
lymphocytes/NNS
and/CC
thymic/JJ
epithelial/JJ
cells/NNS
./.
====================
In/IN
many/JJ
other/JJ
cells/NNS
their/PRP$
expression/NN
can/MD
be/VB
induced/VBN
by/IN
IFN-gamma/NN
./.
====================
Conserved/VBN
upstream/JJ
promoter/NN
sequences/NNS
regulate/VBP
this/DT
tissue-specific/JJ
expression/NN
of/IN
class/NN
II/CD
genes/NNS
./.
====================
In/IN
the/DT
DRA/NN
promoter/NN
,/,
one/CD
of/IN
these/DT
cis-acting/JJ
regulatory/JJ
motifs/NNS
is/VBZ
the/DT
X2-box/NN
to/TO
which/WDT
nuclear/JJ
factor/NN
X2/NN
(/(
NF-X2/NN
)/)
binds/VBZ
./.
====================
Here/RB
,/,
we/PRP
present/VBP
the/DT
isolation/NN
and/CC
characterization/NN
of/IN
the/DT
full-length/JJ
cDNA/NN
clone/NN
encoding/VBG
NF-X2/NN
./.
====================
This/DT
cDNA/NN
clone/NN
was/VBD
isolated/VBN
by/IN
expression/NN
cDNA/NN
cloning/NN
,/,
and/CC
encodes/VBZ
the/DT
human/JJ
c-Jun/NN
protein/NN
,/,
which/WDT
together/RB
with/IN
c-Fos/NN
forms/VBZ
the/DT
heterodimeric/JJ
activator/NN
protein-1/NN
transcription/NN
complex/NN
./.
====================
Whereas/IN
c-Fos/c-Jun/NN
heterodimers/NNS
do/VBP
not/RB
exist/VB
in/IN
B/NN
cells/NNS
,/,
they/PRP
form/VBP
and/CC
bind/VBP
to/TO
the/DT
X2-box/NN
in/IN
class/NN
II/CD
nonexpressing/JJ
cells/NNS
./.
====================
Thus/RB
,/,
c-Fos/c-Jun/NN
heterodimers/NNS
might/MD
contribute/VB
to/TO
the/DT
repression/NN
of/IN
DRA/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
91098050/CD
====================
TI/LS
-/:
Synthesis/NN
of/IN
4,19-disubstituted/JJ
derivatives/NNS
of/IN
DOC/NN
./.
====================
Radioreceptor/NN
assay/NN
of/IN
some/DT
corticosteroid/NN
derivatives/NNS
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
./.
====================
AB/LS
-/:
Several/JJ
new/JJ
4,19-substituted/JJ
steroids/NNS
and/CC
previously/RB
synthesized/VBN
corticosteroids/NNS
were/VBD
assayed/VBN
for/IN
affinity/NN
to/TO
type/NN
1/CD
receptors/NNS
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
./.
====================
11/CD
beta,19-epoxy-4,21-dihydroxypregn-4-ene-3,20-dione/NN
(/(
2/CD
)/)
was/VBD
hydrogenated/VBN
with/IN
Pd-C/NN
to/TO
yield/VB
a/DT
mixture/NN
of/IN
all/DT
four/CD
dihydro/NN
derivatives/NNS
5/CD
,/,
accompanied/VBN
by/IN
4,21-diacetoxy-11/NN
beta,19-epoxy-3-hydroxypregnan-20-one/NN
(/(
6/CD
)/)
and/CC
21-acetoxy-11/NN
beta,19-epoxy-4-hydroxypregnane-3,20-dione/NN
(/(
7/CD
)/)
./.
====================
With/IN
hot/JJ
acetic/JJ
+/CC
p-toluenesulfonic/JJ
acid/NN
5/CD
underwent/VBD
rearrangement/NN
to/TO
21-acetoxy-11/NN
beta,19-epoxypregn-5-ene-4,20-dione/NN
(/(
8/CD
)/)
Pd-C/NN
hydrogenation/NN
of/IN
3,21-diacetoxy-5/NN
beta,19-cyclopregna-2,9(11)-diene-4,20-dione/NN
(/(
10/CD
)/)
gave/VBD
3,21-diacetoxy-5/NN
beta,19-cyclopregn-5-ene-4,20-dione/NN
(/(
11/CD
)/)
and/CC
the/DT
9,11-dihydro/NN
derivative/NN
of/IN
the/DT
latter/JJ
./.
====================
Treatment/NN
of/IN
10/CD
with/IN
warm/JJ
HCl/NN
furnished/JJ
19-chloro-4,21-dihydroxypregna-4,9(11)-diene-3,20-dione/NN
(13)/CD
./.
====================
Pd-C/NN
hydrogenation/NN
of/IN
its/PRP$
diacetate/NN
14/CD
afforded/VBD
the/DT
4,5-dihydro/NN
derivative/NN
18, 19-chloro-21-acetoxypregn-9(11)-en-20-one/NN
(/(
15/CD
)/)
,/,
its/PRP$
4-acetoxy/NN
derivative/NN
16/CD
and/CC
the/DT
3,4-diacetoxy/NN
derivative/NN
17/CD
./.
====================
When/WRB
tested/VBN
in/IN
a/DT
radioreceptor/NN
assay/NN
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
the/DT
synthesized/VBN
compounds/NNS
showed/VBD
only/RB
low/JJ
relative/JJ
binding/NN
affinities/NNS
(/(
RBA/NNS
)/)
to/TO
type/NN
1/CD
receptor/NN
,/,
the/DT
highest/JJS
being/VBG
0.72/CD
%/NN
for/IN
13/CD
(/(
aldosterone/NN
=/JJ
100/CD
%/NN
)/)
./.
====================
For/IN
comparison/NN
,/,
other/JJ
RBA/NNS
in/IN
this/DT
system/NN
were/VBD
:/:
19-noraldosterone/NN
,/,
20/CD
%/NN
;/:
18-deoxyaldosterone/NN
,/,
5.8/CD
%/NN
;/:
18-deoxy-19-noraldosterone/NN
,/,
4.7/CD
%/NN
;/:
18,21-anhydroaldosterone/NN
,/,
0.37/CD
%/NN
;/:
17-isoaldosterone/NN
,/,
7.6/CD
%/NN
and/CC
apoaldosterone/NN
,/,
4.3/CD
%/NN
====================
UI/LS
-/:
90368794/CD
====================
TI/LS
-/:
Cell/NN
type/NN
specificity/NN
and/CC
activation/NN
requirements/NNS
for/IN
NFAT-1/NN
(/(
nuclear/JJ
factor/NN
of/IN
activated/VBN
T-cells/NNS
)/)
transcriptional/JJ
activity/NN
determined/VBN
by/IN
a/DT
new/JJ
method/NN
using/VBG
transgenic/JJ
mice/NNS
to/TO
assay/VB
transcriptional/JJ
activity/NN
of/IN
an/DT
individual/JJ
nuclear/JJ
factor/NN
./.
====================
AB/LS
-/:
Nuclear/JJ
factor/NN
of/IN
activated/VBN
T-cells/NNS
(/(
NFAT-1/NN
)/)
is/VBZ
a/DT
transcription/NN
factor/NN
which/WDT
is/VBZ
considered/VBN
to/TO
be/VB
an/DT
important/JJ
regulator/NN
in/IN
early/JJ
T-cell/NN
activation/NN
./.
====================
We/PRP
have/VBP
developed/VBN
a/DT
system/NN
to/TO
monitor/VB
the/DT
transcriptional/JJ
activity/NN
of/IN
NFAT-1/NN
at/IN
the/DT
single/JJ
cell/NN
level/NN
in/IN
whole/JJ
animals/NNS
./.
====================
The/DT
system/NN
is/VBZ
based/VBN
on/IN
the/DT
use/NN
of/IN
an/DT
oligomerized/JJ
NFAT-1/NN
binding/NN
motif/NN
that/WDT
directs/VBZ
transcription/NN
of/IN
SV40/NN
T-antigen/NN
in/IN
transgenic/JJ
mice/NNS
./.
====================
This/DT
report/NN
represents/VBZ
the/DT
first/JJ
demonstration/NN
that/IN
a/DT
multimerized/JJ
short/JJ
binding/VBG
motif/NN
can/MD
function/VB
appropriately/RB
in/IN
transgenic/JJ
mice/NNS
./.
====================
NFAT-1/NN
activity/NN
had/VBD
previously/RB
been/VBN
thought/VBN
to/TO
be/VB
confined/VBN
to/TO
activated/VBN
T-lymphocytes/NNS
upon/IN
release/NN
of/IN
intracellular/JJ
calcium/NN
./.
====================
By/IN
targeting/VBG
NFAT-1-dependent/JJ
gene/NN
expression/NN
in/IN
transgenic/JJ
mice/NNS
we/PRP
discovered/VBD
new/JJ
sites/NNS
of/IN
NFAT-1/NN
activity/NN
./.
====================
Besides/IN
in/IN
T-lymphocytes/NNS
NFAT-1/NN
activity/NN
could/MD
also/RB
be/VB
induced/VBN
in/IN
T-lymphocyte-depleted/JJ
spleen/NN
cells/NNS
and/CC
purified/VBN
B-lymphocytes/NNS
and/CC
requires/VBZ
agents/NNS
that/WDT
both/CC
release/VBP
intracellular/JJ
calcium/NN
and/CC
activate/VBP
protein/NN
kinase/NN
C/NN
./.
====================
A/DT
difference/NN
in/IN
the/DT
time/NN
course/NN
of/IN
appearance/NN
of/IN
NFAT-1/NN
activity/NN
between/IN
T-lymphocytes/NNS
and/CC
non-T-lymphocytes/NNS
was/VBD
revealed/VBN
./.
====================
Constitutive/JJ
expression/NN
was/VBD
observed/VBN
in/IN
a/DT
small/JJ
population/NN
of/IN
cells/NNS
in/IN
the/DT
dermis/NN
and/CC
some/DT
mice/NNS
have/VBP
developed/VBN
skin/NN
lesions/NNS
./.
====================
Interestingly/RB
,/,
the/DT
tissue/NN
pattern/NN
of/IN
expression/NN
of/IN
the/DT
NFAT-1/NN
activity/NN
resembles/VBZ
the/DT
expression/NN
pattern/NN
described/VBN
for/IN
HIV-LTR/tat/NN
transgenic/JJ
mice/NNS
(/(
Vogel/NNP
,/,
J./NNP
,/,
Hinrichs/NNP
,/,
S./NNP
H./NNP
,/,
Reynolds/NNP
,/,
R./NNP
K./NNP
,/,
Luciw/NNP
,/,
P./NNP
A./NNP
,/,
and/CC
Jay/NNP
,/,
G./NNP
(/(
1988/CD
)/)
Nature/NNP
335/CD
,/,
606-611/CD
)/)
./.
====================
This/DT
similarity/NN
in/IN
expression/NN
and/CC
the/DT
fact/NN
that/IN
NFAT-1/NN
has/VBZ
been/VBN
shown/VBN
to/TO
bind/VB
functional/JJ
sequences/NNS
in/IN
HIV-LTR/NN
suggest/VBP
a/DT
role/NN
for/IN
NFAT-1/NN
in/IN
dermal/JJ
activation/NN
of/IN
the/DT
HIV-LTR/NN
./.
====================
UI/LS
-/:
90279052/CD
====================
TI/LS
-/:
A/DT
novel/JJ
T-cell/NN
protein/NN
which/WDT
recognizes/VBZ
a/DT
palindromic/JJ
sequence/NN
in/IN
the/DT
negative/JJ
regulatory/JJ
element/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
long/JJ
terminal/JJ
repeat/NN
./.
====================
AB/LS
-/:
Two/CD
major/JJ
protein-binding/JJ
sites/NNS
within/IN
the/DT
negative/JJ
regulatory/JJ
element/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
have/VBP
been/VBN
identified/VBN
./.
====================
One/CD
(/(
site/NN
B/NN
)/)
contained/VBD
a/DT
palindromic/JJ
sequence/NN
with/IN
homology/NN
to/TO
steroid/thyroid/NN
hormone/NN
response/NN
elements/NNS
but/CC
was/VBD
distinct/JJ
from/IN
previously/RB
described/VBN
binding/VBG
sites/NNS
of/IN
this/DT
class/NN
./.
====================
A/DT
novel/JJ
T-cell/NN
protein/NN
recognized/VBD
the/DT
palindromic/JJ
sequence/NN
within/IN
site/NN
B/NN
and/CC
also/RB
bound/VBD
estrogen-/NN
or/CC
thyroid/NN
hormone-response/NN
elements/NNS
with/IN
lower/JJR
affinity/NN
./.
====================
A/DT
7-base-pair/JJ
mutation/NN
in/IN
the/DT
site/NN
B/NN
palindrome/NN
,/,
which/WDT
destroyed/VBD
protein/NN
binding/NN
,/,
resulted/VBD
in/IN
increased/VBN
expression/NN
from/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
in/IN
T/NN
cells/NNS
./.
====================
UI/LS
-/:
91025498/CD
====================
TI/LS
-/:
Progesterone/NN
suppression/NN
of/IN
pregnancy/NN
lymphocytes/NNS
is/VBZ
not/RB
mediated/VBN
by/IN
glucocorticoid/NN
effect/NN
./.
====================
AB/LS
-/:
This/DT
study/NN
investigated/VBD
whether/IN
the/DT
suppressive/JJ
effect/NN
of/IN
progesterone/NN
on/IN
pregnancy/NN
lymphocytes/NNS
is/VBZ
mediated/VBN
by/IN
specific/JJ
progesterone/NN
receptors/NNS
./.
====================
The/DT
effects/NNS
of/IN
a/DT
competitive/JJ
progesterone/NN
antagonist/NN
(/(
RU486/NN
)/)
and/CC
a/DT
specific/JJ
glucocorticoid/NN
receptor/NN
blocker/NN
(/(
RU43044/NN
)/)
were/VBD
tested/VBN
on/IN
the/DT
release/NN
of/IN
a/DT
blocking/NN
factor/NN
by/IN
progesterone-treated/JJ
pregnancy/NN
lymphocytes/NNS
./.
====================
RU/NN
486/CD
tested/VBN
at/IN
an/DT
equal/JJ
concentration/NN
as/IN
progesterone/NN
significantly/RB
inhibited/VBD
the/DT
production/NN
of/IN
the/DT
blocking/NN
factor/NN
,/,
while/IN
RU/NN
43044/CD
was/VBD
without/IN
effect/NN
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
in/IN
pregnancy/NN
,/,
lymphocyte/NN
progesterone/NN
acts/VBZ
on/IN
specific/JJ
progesterone/NN
receptors/NNS
and/CC
glucocorticoid/NN
binding/NN
sites/NNS
are/VBP
not/RB
involved/VBN
./.
====================
UI/LS
-/:
90335211/CD
====================
TI/LS
-/:
The/DT
56-59-kilodalton/JJ
protein/NN
identified/VBN
in/IN
untransformed/JJ
steroid/NN
receptor/NN
complexes/NNS
is/VBZ
a/DT
unique/JJ
protein/NN
that/WDT
exists/VBZ
in/IN
cytosol/NN
in/IN
a/DT
complex/NN
with/IN
both/CC
the/DT
70-/CD
and/CC
90-kilodalton/JJ
heat/NN
shock/NN
proteins/NNS
./.
====================
AB/LS
-/:
It/PRP
has/VBZ
previously/RB
been/VBN
shown/VBN
that/IN
9S/NN
,/,
untransformed/JJ
progestin/NN
,/,
estrogen/NN
,/,
androgen/NN
,/,
and/CC
glucocorticoid/NN
receptor/NN
complexes/NNS
in/IN
rabbit/NN
uterine/NN
and/CC
liver/NN
cytosols/NNS
contain/VBP
a/DT
59-kDa/JJ
protein/NN
[/(
Tai/NNP
,/,
P.K./NNP
,/,
Maeda/NNP
,/,
Y./NNP
,/,
Nakao/NNP
,/,
K./NNP
,/,
Wakim/NNP
,/,
N.G./NNP
,/,
Duhring/NNP
,/,
J.L./NNP
,/,
&/CC
Faber/NNP
,/,
L.E./NNP
(/(
1986/CD
)/)
Biochemistry/NNP
25/CD
,/,
5269-5275/CD
]/)
./.
====================
In/IN
this/DT
work/NN
we/PRP
show/VBP
that/IN
the/DT
monoclonal/JJ
antibody/NN
KN/NN
382/EC1/NN
raised/VBN
against/IN
the/DT
rabbit/NN
59-kDa/JJ
protein/NN
reacts/VBZ
with/IN
9S/NN
,/,
untransformed/JJ
glucocorticoid/NN
receptor/NN
complexes/NNS
in/IN
cytosol/NN
prepared/VBN
from/IN
human/JJ
IM-9/NN
lymphocytes/NNS
but/CC
not/RB
with/IN
4S/NN
salt-transformed/JJ
receptors/NNS
./.
====================
The/DT
human/JJ
protein/NN
recognized/VBN
by/IN
the/DT
EC1/NN
antibody/NN
is/VBZ
a/DT
56-kDa/JJ
protein/NN
(/(
p56/NN
)/)
of/IN
moderate/JJ
abundance/NN
located/JJ
predominantly/RB
in/IN
the/DT
cytoplasm/NN
by/IN
indirect/JJ
immunofluorescence/NN
./.
====================
There/EX
are/VBP
at/IN
least/JJS
six/CD
isomorphs/NNS
of/IN
p56/NN
by/IN
two-dimensional/JJ
gel/NN
analysis/NN
./.
====================
N-Terminal/JJ
sequencing/NN
(/(
20/CD
amino/NN
acids/NNS
)/)
shows/VBZ
that/IN
p56/NN
is/VBZ
a/DT
unique/JJ
human/JJ
protein/NN
./.
====================
When/WRB
p56/NN
is/VBZ
immunoadsorbed/VBN
from/IN
IM-9/NN
cell/NN
cytosol/NN
,/,
both/CC
the/DT
70-/CD
and/CC
90-kDa/JJ
heat/NN
shock/NN
proteins/NNS
are/VBP
coadsorbed/VBN
in/IN
an/DT
immune-specific/JJ
manner/NN
./.
====================
Neither/DT
heat/NN
shock/NN
protein/NN
reacts/VBZ
directly/RB
with/IN
the/DT
EC1/NN
antibody/NN
./.
====================
We/PRP
conclude/VBP
that/IN
p56/NN
exists/VBZ
in/IN
cytosol/NN
in/IN
a/DT
higher/JJR
order/NN
complex/NN
containing/VBG
hsp70/NN
and/CC
hsp90/NN
,/,
both/DT
of/IN
which/WDT
in/IN
turn/NN
have/VBP
been/VBN
found/VBN
to/TO
be/VB
associated/VBN
with/IN
untransformed/JJ
steroid/NN
receptors/NNS
./.
====================
UI/LS
-/:
90299137/CD
====================
TI/LS
-/:
Sequence-specific/JJ
DNA/NN
binding/NN
of/IN
the/DT
proto-oncoprotein/NN
ets-1/NN
defines/VBZ
a/DT
transcriptional/JJ
activator/NN
sequence/NN
within/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
of/IN
the/DT
Moloney/NN
murine/JJ
sarcoma/NN
virus/NN
./.
====================
AB/LS
-/:
The/DT
ets/NN
proto-oncogene/NN
family/NN
is/VBZ
a/DT
group/NN
of/IN
sequence-related/JJ
genes/NNS
whose/WP$
normal/JJ
cellular/JJ
function/NN
is/VBZ
unknown/JJ
./.
====================
In/IN
a/DT
study/NN
of/IN
cellular/JJ
proteins/NNS
involved/VBN
in/IN
the/DT
transcriptional/JJ
regulation/NN
of/IN
murine/JJ
retroviruses/NNS
in/IN
T/NN
lymphocytes/NNS
,/,
we/PRP
have/VBP
discovered/VBN
that/IN
a/DT
member/NN
of/IN
the/DT
ets/NN
gene/NN
family/NN
encodes/VBZ
a/DT
sequence-specific/JJ
DNA-binding/JJ
protein/NN
./.
====================
A/DT
mouse/NN
ets-1/NN
cDNA/NN
clone/NN
was/VBD
obtained/VBN
by/IN
screening/VBG
a/DT
mouse/NN
thymus/NN
cDNA/NN
expression/NN
library/NN
with/IN
a/DT
double-stranded/JJ
oligonucleotide/NN
probe/NN
representing/VBG
20/CD
bp/NN
of/IN
the/DT
Moloney/NN
murine/JJ
sarcoma/NN
virus/NN
(/(
MSV/NN
)/)
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
./.
====================
The/DT
cDNA/NN
sequence/NN
has/VBZ
an/DT
813-bp/JJ
open/JJ
reading/NN
frame/NN
(/(
ORF/NN
)/)
whose/WP$
predicted/VBN
amino/NN
acid/NN
sequence/NN
is/VBZ
97.6/CD
%/NN
identical/JJ
to/TO
the/DT
272/CD
carboxy-terminal/JJ
amino/NN
acids/NNS
of/IN
the/DT
human/JJ
ets-1/NN
protein/NN
./.
====================
The/DT
ORF/NN
was/VBD
expressed/VBN
in/IN
bacteria/NNS
,/,
and/CC
the/DT
30-kD/JJ
protein/NN
product/NN
was/VBD
shown/VBN
to/TO
bind/VB
DNA/NN
in/IN
a/DT
sequence-specific/JJ
manner/NN
by/IN
mobility-shift/JJ
assays/NNS
,/,
Southwestern/NN
blot/NN
analysis/NN
,/,
and/CC
methylation/NN
interference/NN
./.
====================
A/DT
mutant/JJ
LTR/NN
containing/VBG
four/CD
base/NN
pair/NN
substitutions/NNS
in/IN
the/DT
ets-1/NN
binding/NN
site/NN
was/VBD
constructed/VBN
and/CC
was/VBD
shown/VBN
to/TO
have/VB
reduced/VBN
binding/NN
in/FW
vitro/FW
./.
====================
Transcriptional/JJ
efficiency/NN
of/IN
the/DT
MSV/NN
LTR/NN
promoter/NN
containing/VBG
this/DT
disrupted/VBN
ets-1/NN
binding/NN
site/NN
was/VBD
compared/VBN
to/TO
the/DT
activity/NN
of/IN
a/DT
wild-type/JJ
promoter/NN
in/IN
mouse/NN
T/NN
lymphocytes/NNS
in/IN
culture/NN
,/,
and/CC
15-/CD
to/TO
20-fold/JJ
reduction/NN
in/IN
expression/NN
of/IN
a/DT
reporter/NN
gene/NN
was/VBD
observed/VBN
./.
====================
We/PRP
propose/VBP
that/IN
ets-1/NN
functions/VBZ
as/IN
a/DT
transcriptional/JJ
activator/NN
of/IN
mammalian/JJ
type-C/JJ
retroviruses/NNS
and/CC
speculate/VBP
that/IN
ets-related/JJ
genes/NNS
constitute/VBP
a/DT
new/JJ
group/NN
of/IN
eukaryotic/JJ
DNA-binding/JJ
proteins/NNS
./.
====================
UI/LS
-/:
90247097/CD
====================
TI/LS
-/:
Type/NN
II/CD
estrogen/NN
binding/NN
sites/NNS
in/IN
human/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
:/:
variations/NNS
during/IN
the/DT
menstrual/JJ
cycle/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
previously/RB
reported/VBN
that/IN
human/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NNS
)/)
contain/VBP
type/NN
II/CD
estrogen/NN
binding/NN
sites/NNS
(/(
type/NN
II/CD
EBS/NNS
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
fluctuations/NNS
of/IN
type/NN
II/CD
EBS/NNS
during/IN
the/DT
menstrual/JJ
cycle/NN
were/VBD
analyzed/VBN
in/IN
6/CD
normally/RB
menstruating/VBG
women/NNS
./.
====================
Approximately/RB
3/CD
times/NNS
higher/JJR
levels/NNS
of/IN
type/NN
II/CD
EBS/NNS
were/VBD
found/VBN
in/IN
the/DT
periovulatory/JJ
period/NN
with/IN
respect/NN
to/TO
both/CC
follicular/JJ
and/CC
luteal/JJ
phases/NNS
./.
====================
In/IN
postmenopausal/JJ
women/NNS
the/DT
mean/NN
type/NN
II/CD
EBS/NNS
levels/NNS
were/VBD
similar/JJ
to/TO
those/DT
observed/VBN
in/IN
the/DT
follicular/JJ
phase/NN
of/IN
the/DT
cycle/NN
./.
====================
However/RB
,/,
in/IN
3/CD
postmenopausal/JJ
patients/NNS
a/DT
short/JJ
course/NN
of/IN
estrogen/NN
or/CC
tamoxifen/NN
resulted/VBD
in/IN
a/DT
marked/JJ
increase/NN
of/IN
type/NN
II/CD
EBS/NNS
levels/NNS
./.
====================
Tamoxifen/NN
was/VBD
also/RB
found/VBN
to/TO
compete/VB
with/IN
17/CD
beta-estradiol/NN
for/IN
type/NN
II/CD
EBS/NNS
in/IN
PBMC/NNS
,/,
although/IN
to/TO
a/DT
lesser/JJR
extent/NN
than/IN
diethylstilbestrol/NN
./.
====================
UI/LS
-/:
90311515/CD
====================
TI/LS
-/:
Mononuclear/JJ
leukocyte/NN
glucocorticoid/NN
receptor/NN
binding/NN
characteristics/NNS
and/CC
down-regulation/NN
in/IN
major/JJ
depression/NN
./.
====================
AB/LS
-/:
Some/DT
patients/NNS
with/IN
major/JJ
depressive/JJ
disorder/NN
(/(
MDD/NN
)/)
have/VBP
elevated/JJ
plasma/NN
cortisol/NN
concentrations/NNS
and/CC
show/VBP
failure/NN
to/TO
suppress/VB
cortisol/NN
secretion/NN
upon/IN
administration/NN
of/IN
dexamethasone/NN
(/(
DEX/NN
)/)
,/,
yet/CC
they/PRP
do/VBP
not/RB
have/VB
Cushingoid/JJ
features/NNS
./.
====================
To/TO
study/VB
whether/IN
this/DT
represents/VBZ
glucocorticoid/NN
(/(
GC/NN
)/)
resistance/NN
,/,
[3H]-DEX-binding/JJ
assays/NNS
were/VBD
used/VBN
to/TO
measure/VB
,/,
in/FW
vitro/FW
,/,
the/DT
GC/NN
receptor/NN
affinity/NN
(/(
1/Kd/NN
)/)
and/CC
number/NN
(/(
Bmax/NN
)/)
in/IN
mononuclear/JJ
leukocytes/NNS
of/IN
11/CD
MDD/NN
patients/NNS
and/CC
15/CD
control/JJ
subjects/NNS
./.
====================
No/DT
receptor/NN
abnormalities/NNS
were/VBD
detected/VBN
in/IN
the/DT
MDD/NN
group/NN
;/:
thus/RB
any/DT
cellular/JJ
defect/NN
leading/VBG
to/TO
a/DT
lack/NN
of/IN
responsiveness/NN
to/TO
GC/NN
in/IN
the/DT
MDD/NN
patients/NNS
,/,
if/IN
present/JJ
,/,
probably/RB
lies/VBZ
beyond/IN
the/DT
initial/JJ
receptor/NN
binding/NN
./.
====================
DEX/NN
(/(
1.0/CD
mg/NN
orally/RB
)/)
was/VBD
administered/VBN
to/TO
study/VB
in/FW
vivo/FW
GC/NN
receptor/NN
down-regulation/NN
./.
====================
Compared/VBN
to/TO
the/DT
control/JJ
group/NN
,/,
fewer/JJR
depressed/JJ
subjects/NNS
down-regulated/VBD
Bmax/NN
after/IN
DEX/NN
./.
====================
By/IN
paired/JJ
t-test/NN
,/,
Bmax/NN
decreased/VBD
significantly/RB
in/IN
the/DT
control/JJ
group/NN
but/CC
not/RB
in/IN
the/DT
depressed/JJ
group/NN
./.
====================
Receptor/NN
number/NN
on/IN
the/DT
control/JJ
day/NN
did/VBD
not/RB
correlate/VB
significantly/RB
with/IN
the/DT
degree/NN
of/IN
receptor/NN
down-regulation/NN
,/,
severity/NN
of/IN
depression/NN
or/CC
cortisol/NN
concentrations/NNS
across/IN
all/PDT
the/DT
subjects/NNS
./.
====================
These/DT
results/NNS
do/VBP
not/RB
lend/VB
support/NN
to/TO
previous/JJ
reports/NNS
suggesting/VBG
that/IN
GC/NN
resistance/NN
in/IN
MDD/NN
results/VBZ
from/IN
a/DT
GC/NN
receptor-binding/JJ
abnormality/NN
,/,
and/CC
they/PRP
emphasize/VBP
the/DT
importance/NN
of/IN
considering/VBG
receptor/NN
studies/NNS
in/IN
the/DT
context/NN
of/IN
GC-mediated/JJ
cell/NN
processes/NNS
in/IN
order/NN
to/TO
identify/VB
the/DT
exact/JJ
cellular/JJ
defect/NN
(/(
s/NNS
)/)
leading/VBG
to/TO
GC/NN
resistance/NN
./.
====================
UI/LS
-/:
98038598/CD
====================
TI/LS
-/:
Ras-related/JJ
GTP-binding/JJ
proteins/NNS
and/CC
leukocyte/NN
signal/NN
transduction/NN
./.
====================
AB/LS
-/:
Many/JJ
aspects/NNS
of/IN
leukocyte/NN
function/NN
are/VBP
regulated/VBN
by/IN
both/CC
heterotrimeric/JJ
and/CC
Ras-related/JJ
GTP-binding/JJ
proteins/NNS
,/,
but/CC
there/EX
is/VBZ
little/JJ
definite/JJ
information/NN
about/IN
their/PRP$
roles/NNS
in/IN
the/DT
specialized/JJ
processes/NNS
utilized/VBN
by/IN
leukocytes/NNS
for/IN
cell/NN
killing/NN
./.
====================
Recent/JJ
progress/NN
in/IN
understanding/VBG
the/DT
regulation/NN
of/IN
the/DT
phagocyte/NN
NADPH/NN
oxidase/NN
by/IN
the/DT
Rac/NN
GTP-binding/JJ
proteins/NNS
provides/VBZ
a/DT
basis/NN
for/IN
defining/VBG
the/DT
operational/JJ
characteristics/NNS
of/IN
one/CD
such/JJ
phagocyte/NN
system/NN
./.
====================
It/PRP
is/VBZ
clear/JJ
from/IN
various/JJ
studies/NNS
that/IN
the/DT
activity/NN
of/IN
the/DT
NADPH/NN
oxidase/NN
can/MD
be/VB
modulated/VBN
through/IN
the/DT
regulation/NN
of/IN
the/DT
GTP-GDP/JJ
state/NN
of/IN
Rac/NN
./.
====================
Proteins/NNS
exist/VBP
in/IN
leukocytes/NNS
able/JJ
to/TO
modify/VB
GTP-binding/JJ
protein/NN
function/NN
in/IN
this/DT
manner/NN
,/,
and/CC
their/PRP$
activity/NN
may/MD
be/VB
regulated/VBN
by/IN
signals/NNS
generated/VBN
on/IN
phagocyte/NN
stimulation/NN
./.
====================
Proteins/NNS
of/IN
the/DT
Ras/NN
superfamily/NN
are/VBP
likely/JJ
to/TO
be/VB
involved/VBN
in/IN
a/DT
variety/NN
of/IN
normal/JJ
phagocyte/NN
functions/NNS
through/IN
their/PRP$
ability/NN
to/TO
modulate/VB
the/DT
assembly/NN
of/IN
actin/NN
filaments/NNS
,/,
direct/JJ
vesicle/NN
trafficking/NN
and/CC
fusion/NN
,/,
and/CC
so/RB
forth/RB
./.
====================
UI/LS
-/:
96114389/CD
====================
TI/LS
-/:
BSAP/NN
:/:
a/DT
key/JJ
regulator/NN
of/IN
B-cell/NN
development/NN
and/CC
differentiation/NN
./.
====================
AB/LS
-/:
B-cell-specific/JJ
activator/NN
protein/NN
(/(
BSAP/NN
)/)
is/VBZ
a/DT
recently/RB
identified/VBN
member/NN
of/IN
the/DT
Pax-gene/NN
family/NN
of/IN
transcription/NN
factors/NNS
;/:
in/IN
the/DT
lymphoid/JJ
system/NN
,/,
BSAP/NN
is/VBZ
produced/VBN
only/RB
in/IN
B/NN
cells/NNS
./.
====================
Here/RB
,/,
Markus/NNP
Neurath/NNP
,/,
Eckhard/NNP
Stuber/NNP
and/CC
Warren/NNP
Strober/NNP
describe/VBP
the/DT
molecular/JJ
structure/NN
of/IN
BSAP/NN
and/CC
focus/VBP
on/IN
the/DT
ability/NN
of/IN
this/DT
protein/NN
to/TO
regulate/VB
the/DT
expression/NN
of/IN
B-cell-specific/JJ
genes/NNS
./.
====================
They/PRP
propose/VBP
that/IN
BSAP/NN
is/VBZ
a/DT
key/JJ
protein/NN
of/IN
B/NN
cells/NNS
and/CC
that/IN
it/PRP
not/RB
only/RB
influence/VBP
B-cell/NN
development/NN
but/CC
also/RB
influences/VBZ
the/DT
balance/NN
between/IN
B-cell/NN
proliferation/NN
and/CC
immunoglobulin/NN
secretion/NN
at/IN
later/JJR
stages/NNS
of/IN
B-cell/NN
differentiation/NN
./.
====================
UI/LS
-/:
96074632/CD
====================
TI/LS
-/:
Down-regulation/NN
of/IN
NF-kappa/NN
B/NN
protein/NN
levels/NNS
in/IN
activated/VBN
human/JJ
lymphocytes/NNS
by/IN
1,25-dihydroxyvitamin/NN
D3/NN
[/(
published/VBN
erratum/NN
appears/VBZ
in/IN
Proc/NNP
Natl/NNP
Acad/NNP
Sci/NNP
U/NNP
S/NNP
A/NNP
1996/CD
Jan/NNP
9/CD
;/:
93/CD
(/(
1/CD
)/)
:/:
524/CD
]/)
====================
AB/LS
-/:
The/DT
effect/NN
of/IN
1,25-dihydroxyvitamin/NN
D3/NN
[/(
1,25(OH)2)D3/NN
]/)
,/,
a/DT
steroid/NN
hormone/NN
with/IN
immunomodulating/NN
properties/NNS
,/,
on/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
proteins/NNS
was/VBD
examined/VBN
in/IN
in/FW
vitro/FW
activated/VBN
normal/JJ
human/JJ
lymphocytes/NNS
by/IN
Western/NN
blot/NN
analysis/NN
./.
====================
Over/IN
a/DT
72-hr/JJ
period/NN
of/IN
activation/NN
,/,
the/DT
expression/NN
of/IN
the/DT
50-kDa/JJ
NF-kappa/NN
B/NN
,/,
p50/NN
,/,
and/CC
its/PRP$
precursor/NN
,/,
p105/NN
,/,
was/VBD
increased/VBN
progressively/RB
./.
====================
When/WRB
cells/NNS
were/VBD
activated/VBN
in/IN
the/DT
presence/NN
of/IN
1,25(OH)2D3/NN
,/,
the/DT
levels/NNS
of/IN
the/DT
mature/JJ
protein/NN
as/RB
well/RB
as/IN
its/PRP$
precursor/NN
were/VBD
decreased/VBN
./.
====================
The/DT
effect/NN
of/IN
the/DT
hormone/NN
on/IN
the/DT
levels/NNS
of/IN
p50/NN
was/VBD
demonstrable/JJ
in/IN
the/DT
cytosolic/JJ
and/CC
nuclear/JJ
compartments/NNS
;/:
it/PRP
required/VBD
between/IN
4/CD
and/CC
8/CD
hr/NN
and/CC
was/VBD
specific/JJ
,/,
as/IN
25-hydroxyvitamin/NN
D3/NN
and/CC
24,25-dihydroxyvitamin/NN
D3/NN
were/VBD
ineffective/JJ
./.
====================
Besides/IN
p50/NN
,/,
1,25(OH)2D3/NN
decreased/VBD
the/DT
levels/NNS
of/IN
another/DT
NF-kappa/NN
B/NN
protein/NN
,/,
namely/RB
c-rel/NN
./.
====================
In/IN
addition/NN
,/,
1,25(OH)2D3/NN
decreased/VBD
the/DT
abundance/NN
of/IN
a/DT
specific/JJ
DNA-protein/NN
complex/NN
formed/VBN
upon/IN
incubation/NN
of/IN
nuclear/JJ
extracts/NNS
from/IN
activated/VBN
lymphocytes/NNS
with/IN
a/DT
labeled/VBN
NF-kappa/NN
B/NN
DNA/NN
binding/NN
motif/NN
./.
====================
Further/RB
,/,
1,25(OH)2D3/NN
inhibited/VBD
the/DT
transcriptional/JJ
activity/NN
of/IN
NF-kappa/NN
B/NN
in/IN
Jurkat/NN
cells/NNS
transiently/RB
transfected/VBN
with/IN
a/DT
construct/NN
containing/VBG
four/CD
tandem/JJ
repeats/NNS
of/IN
the/DT
NF-kappa/NN
B/NN
binding/NN
sequence/NN
of/IN
the/DT
immunoglobulin/NN
kappa/NN
light/JJ
chain/NN
gene/NN
linked/VBN
to/TO
the/DT
chloramphenicol/NN
acetyltransferase/NN
reporter/NN
gene/NN
./.
====================
These/DT
observations/NNS
demonstrate/VBP
directly/RB
that/IN
there/EX
is/VBZ
de/FW
novo/FW
synthesis/NN
of/IN
NF-kappa/NN
B/NN
during/IN
human/JJ
lymphocyte/NN
activation/NN
and/CC
suggest/VBP
that/IN
this/DT
process/NN
is/VBZ
hormonally/RB
regulated/VBN
./.
====================
UI/LS
-/:
96068726/CD
====================
TI/LS
-/:
The/DT
myeloid/JJ
zinc/NN
finger/NN
gene/NN
,/,
MZF-1/NN
,/,
regulates/VBZ
the/DT
CD34/NN
promoter/NN
in/FW
vitro/FW
./.
====================
AB/LS
-/:
MZF-1/NN
is/VBZ
a/DT
C2H2/NN
zinc/NN
finger/NN
gene/NN
encoding/VBG
a/DT
putative/JJ
transcriptional/JJ
regulator/NN
of/IN
myeloid/JJ
differentiation/NN
./.
====================
The/DT
MZF-1/NN
protein/NN
contains/VBZ
13/CD
C2H2/NN
zinc/NN
fingers/NNS
arranged/VBN
in/IN
bipartite/JJ
DNA/NN
binding/NN
domains/NNS
containing/VBG
zinc/NN
fingers/NNS
through/IN
4/CD
and/CC
,/,
in/IN
the/DT
carboxy-terminus/NN
,/,
5/CD
through/IN
13/CD
./.
====================
We/PRP
previously/RB
identified/VBD
the/DT
DNA/NN
consensus/NN
binding/NN
site/NN
recognized/VBN
by/IN
the/DT
two/CD
DNA/NN
binding/NN
domains/NNS
./.
====================
To/TO
assess/VB
the/DT
transcription/NN
regulatory/JJ
function/NN
of/IN
MZF-1/NN
,/,
the/DT
full-length/JJ
MZF-1/NN
coding/NN
region/NN
was/VBD
fused/VBN
to/TO
the/DT
DNA/NN
binding/NN
domain/NN
of/IN
the/DT
yeast/NN
transactivator/NN
GAL4/NN
./.
====================
The/DT
expression/NN
vector/NN
was/VBD
cotransfected/VBN
with/IN
the/DT
chloramphenicol/NN
acetyl/NN
transferase/NN
(/(
CAT/NN
)/)
reporter/NN
gene/NN
regulated/VBN
by/IN
the/DT
thymidine/NN
kinase/NN
promoter/NN
containing/VBG
GAL4/NN
DNA/NN
binding/NN
sites/NNS
into/IN
NIH/NN
3T3/NN
,/,
293/CD
,/,
K562/NN
,/,
and/CC
Jurkat/NN
cell/NN
lines/NNS
./.
====================
MZF-1/NN
represses/VBZ
CAT/NN
reporter/NN
gene/NN
expression/NN
via/IN
GAL4/NN
binding/NN
sites/NNS
in/IN
the/DT
nonhematopoietic/JJ
cell/NN
lines/NNS
NIH/NN
3T3/NN
and/CC
293/CD
./.
====================
In/IN
contrast/NN
,/,
MZF-1/NN
activates/VBZ
CAT/NN
reporter/NN
gene/NN
expression/NN
in/IN
the/DT
hematopoietic/JJ
cell/NN
lines/NNS
K562/NN
and/CC
Jurkat/NN
./.
====================
The/DT
MZF-1/NN
binding/NN
sites/NNS
are/VBP
present/JJ
in/IN
the/DT
promoters/NNS
of/IN
several/JJ
genes/NNS
expressed/VBN
during/IN
myeloid/JJ
differentiation/NN
,/,
including/VBG
the/DT
CD34/NN
promoter/NN
./.
====================
MZF-1/NN
transcriptional/JJ
regulation/NN
of/IN
this/DT
physiologically/RB
relevant/JJ
promoter/NN
was/VBD
assessed/VBN
in/IN
both/CC
hematopoietic/JJ
and/CC
nonhematopoietic/JJ
cell/NN
lines/NNS
./.
====================
Recombinant/JJ
MZF-1/NN
protein/NN
specifically/RB
binds/VBZ
to/TO
the/DT
consensus/NN
binding/NN
sites/NNS
in/IN
the/DT
CD34/NN
promoter/NN
in/IN
mobility/NN
shift/NN
assays/NNS
./.
====================
MZF-1/NN
expression/NN
vectors/NNS
were/VBD
cotransfected/VBN
with/IN
the/DT
luciferase/NN
reporter/NN
plasmids/NNS
regulated/VBN
by/IN
the/DT
CD34/NN
promoter/NN
into/IN
both/CC
nonhematopoietic/JJ
and/CC
hematopoietic/JJ
cell/NN
lines/NNS
./.
====================
As/IN
with/IN
the/DT
heterologous/JJ
DNA/NN
binding/NN
domain/NN
,/,
MZF-1/NN
represses/VBZ
reporter/NN
gene/NN
expression/NN
in/IN
nonhematopoietic/JJ
cell/NN
lines/NNS
and/CC
activates/VBZ
expression/NN
in/IN
hematopoietic/JJ
cell/NN
lines/NNS
./.
====================
Activation/NN
of/IN
CD34/NN
expression/NN
in/IN
hematopoietic/JJ
cell/NN
lines/NNS
is/VBZ
dependent/JJ
on/IN
the/DT
presence/NN
of/IN
intact/JJ
MZF-1/NN
binding/NN
sites/NNS
./.
====================
The/DT
cell/NN
type-specific/JJ
regulation/NN
of/IN
the/DT
CD34/NN
promoter/NN
by/IN
MZF-1/NN
suggests/VBZ
the/DT
presence/NN
of/IN
tissue-specific/JJ
regulators/adapters/NNS
or/CC
differential/JJ
MZF-1/NN
modifications/NNS
that/WDT
determine/VBP
MZF-1/NN
transcriptional/JJ
regulatory/JJ
function/NN
./.
====================
UI/LS
-/:
96038894/CD
====================
TI/LS
-/:
The/DT
murine/JJ
BCL6/NN
gene/NN
is/VBZ
induced/VBN
in/IN
activated/VBN
lymphocytes/NNS
as/IN
an/DT
immediate/JJ
early/JJ
gene/NN
./.
====================
AB/LS
-/:
The/DT
chromosomal/JJ
translocation/NN
involving/VBG
3q27/NN
is/VBZ
often/RB
detected/VBN
in/IN
human/JJ
B-cell/NN
lymphomas/NNS
,/,
especially/RB
diffuse/JJ
lymphomas/NNS
with/IN
a/DT
large-cell/JJ
component/NN
./.
====================
The/DT
BCL6/NN
gene/NN
has/VBZ
been/VBN
isolated/VBN
from/IN
the/DT
chromosomal/JJ
breakpoint/NN
in/IN
these/DT
lymphomas/NNS
./.
====================
Here/RB
we/PRP
cloned/VBD
the/DT
murine/JJ
BCL6/NN
(/(
mBCL6/NN
)/)
cDNA/NN
from/IN
the/DT
muscle/NN
cDNA/NN
library/NN
using/VBG
the/DT
human/JJ
BCL6/NN
(/(
hBCL6/NN
)/)
cDNA/NN
as/IN
a/DT
probe/NN
./.
====================
The/DT
predicted/VBN
amino/NN
acid/NN
sequence/NN
was/VBD
95/CD
%/NN
identical/JJ
to/TO
that/DT
of/IN
hBCL6/NN
./.
====================
It/PRP
contains/VBZ
six/CD
repeats/NNS
of/IN
the/DT
Kruppel-like/JJ
zinc-finger/JJ
motif/NN
that/WDT
are/VBP
completely/RB
identical/JJ
to/TO
those/DT
of/IN
hBCL6/NN
,/,
indicating/VBG
that/IN
the/DT
BCL6/NN
gene/NN
is/VBZ
well/RB
conserved/VBN
between/IN
humans/NNS
and/CC
mice/NNS
./.
====================
Expression/NN
of/IN
the/DT
mBCL6/NN
gene/NN
was/VBD
ubiquitously/RB
detected/VBN
in/IN
adult/JJ
mouse/NN
tissues/NNS
including/VBG
lymphatic/JJ
organs/NNS
./.
====================
Furthermore/RB
,/,
it/PRP
was/VBD
induced/VBN
in/IN
lymphocytes/NNS
activated/VBN
with/IN
phorbol/NN
ester/NN
and/CC
Ca2+/NN
ionophore/NN
within/IN
30/CD
min/NN
after/IN
stimulation/NN
./.
====================
This/DT
induction/NN
was/VBD
not/RB
inhibited/VBN
by/IN
treatment/NN
of/IN
the/DT
cells/NNS
with/IN
a/DT
protein/NN
synthesis/NN
inhibitor/NN
,/,
cycloheximide/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
BCL6/NN
plays/VBZ
a/DT
role/NN
in/IN
activated/VBN
lymphocytes/NNS
as/IN
an/DT
immediate/JJ
early/JJ
gene/NN
./.
====================
UI/LS
-/:
96114497/CD
====================
TI/LS
-/:
The/DT
role/NN
of/IN
BSAP/NN
(/(
Pax-5/NN
)/)
in/IN
B-cell/NN
development/NN
./.
====================
AB/LS
-/:
The/DT
hierarchy/NN
of/IN
transcriptional/JJ
control/NN
in/IN
B-cell/NN
development/NN
has/VBZ
recently/RB
been/VBN
analyzed/VBN
by/IN
targeted/VBN
gene/NN
inactivation/NN
in/IN
the/DT
mouse/NN
./.
====================
In/IN
this/DT
manner/NN
,/,
the/DT
paired/JJ
box/NN
containing/VBG
gene/NN
Pax-5/NN
,/,
encoding/VBG
the/DT
B/NN
cell/NN
specific/JJ
transcription/NN
factor/NN
BSAP/NN
,/,
has/VBZ
been/VBN
shown/VBN
to/TO
play/VB
a/DT
key/JJ
role/NN
in/IN
early/JJ
B/NN
lymphopoiesis/NN
./.
====================
Other/JJ
experimental/JJ
strategies/NNS
have/VBP
implicated/VBN
BSAP/NN
in/IN
the/DT
control/NN
of/IN
cell/NN
proliferation/NN
,/,
isotype/NN
switching/NN
and/CC
transcription/NN
of/IN
the/DT
immunoglobulin/NN
heavy-chain/NN
gene/NN
at/IN
late/JJ
stages/NNS
of/IN
B-cell/NN
differentiation/NN
./.
====================
UI/LS
-/:
96009551/CD
====================
TI/LS
-/:
The/DT
DNA-binding/JJ
properties/NNS
of/IN
two/CD
heat/NN
shock/NN
factors/NNS
,/,
HSF1/NN
and/CC
HSF3/NN
,/,
are/VBP
induced/VBN
in/IN
the/DT
avian/JJ
erythroblast/NN
cell/NN
line/NN
HD6/NN
./.
====================
AB/LS
-/:
Avian/JJ
cells/NNS
express/VBP
three/CD
heat/NN
shock/NN
transcription/NN
factor/NN
(/(
HSF/NN
)/)
genes/NNS
corresponding/VBG
to/TO
a/DT
novel/JJ
factor/NN
,/,
HSF3/NN
,/,
and/CC
homologs/NNS
of/IN
mouse/NN
and/CC
human/JJ
HSF1/NN
and/CC
HSF2/NN
./.
====================
Analysis/NN
of/IN
the/DT
biochemical/JJ
and/CC
cell/NN
biological/JJ
properties/NNS
of/IN
these/DT
HSFs/NNS
reveals/VBZ
that/IN
HSF3/NN
has/VBZ
properties/NNS
in/IN
common/JJ
with/IN
both/CC
HSF1/NN
and/CC
HSF2/NN
and/CC
yet/RB
has/VBZ
features/NNS
which/WDT
are/VBP
distinct/JJ
from/IN
both/DT
./.
====================
HSF3/NN
is/VBZ
constitutively/RB
expressed/VBN
in/IN
the/DT
erythroblast/NN
cell/NN
line/NN
HD6/NN
,/,
the/DT
lymphoblast/NN
cell/NN
line/NN
MSB/NN
,/,
and/CC
embryo/NN
fibroblasts/NNS
,/,
and/CC
yet/RB
its/PRP$
DNA-binding/JJ
activity/NN
is/VBZ
induced/VBN
only/RB
upon/IN
exposure/NN
of/IN
HD6/NN
cells/NNS
to/TO
heat/NN
shock/NN
./.
====================
Acquisition/NN
of/IN
HSF3/NN
DNA-binding/JJ
activity/NN
in/IN
HD6/NN
cells/NNS
is/VBZ
accompanied/VBN
by/IN
oligomerization/NN
from/IN
a/DT
non-DNA-binding/JJ
dimer/NN
to/TO
a/DT
DNA-binding/JJ
trimer/NN
,/,
whereas/IN
the/DT
effect/NN
of/IN
heat/NN
shock/NN
on/IN
HSF1/NN
is/VBZ
oligomerization/NN
of/IN
an/DT
inert/JJ
monomer/NN
to/TO
a/DT
DNA-binding/JJ
trimer/NN
./.
====================
Induction/NN
of/IN
HSF3/NN
DNA-binding/JJ
activity/NN
is/VBZ
delayed/VBN
compared/VBN
with/IN
that/DT
of/IN
HSF1/NN
./.
====================
As/IN
occurs/VBZ
for/IN
HSF1/NN
,/,
heat/NN
shock/NN
leads/VBZ
to/TO
the/DT
translocation/NN
of/IN
HSF3/NN
to/TO
the/DT
nucleus/NN
./.
====================
HSF/NN
exhibits/VBZ
the/DT
properties/NNS
of/IN
a/DT
transcriptional/JJ
activator/NN
,/,
as/IN
judged/VBN
from/IN
the/DT
stimulatory/JJ
activity/NN
of/IN
transiently/RB
overexpressed/VBN
HSF3/NN
measured/VBN
by/IN
using/VBG
a/DT
heat/NN
shock/NN
element-containing/JJ
reporter/NN
construct/NN
and/CC
as/IN
independently/RB
assayed/VBN
by/IN
the/DT
activity/NN
of/IN
a/DT
chimeric/JJ
GAL4-HSF3/NN
protein/NN
on/IN
a/DT
GAL4/NN
reporter/NN
construct/NN
./.
====================
These/DT
results/NNS
reveal/VBP
that/IN
HSF3/NN
is/VBZ
negatively/RB
regulated/VBN
in/IN
avian/JJ
cells/NNS
and/CC
acquires/VBZ
DNA-binding/JJ
activity/NN
in/IN
certain/JJ
cells/NNS
upon/IN
heat/NN
shock/NN
./.
====================
UI/LS
-/:
95403468/CD
====================
TI/LS
-/:
Direct/JJ
demonstration/NN
of/IN
NFATp/NN
dephosphorylation/NN
and/CC
nuclear/JJ
localization/NN
in/IN
activated/VBN
HT-2/NN
cells/NNS
using/VBG
a/DT
specific/JJ
NFATp/NN
polyclonal/JJ
antibody/NN
./.
====================
AB/LS
-/:
Nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFAT/NN
)/)
regulates/VBZ
transcription/NN
of/IN
a/DT
number/NN
of/IN
cytokine/NN
genes/NNS
,/,
and/CC
NFAT/NN
DNA/NN
binding/NN
activity/NN
is/VBZ
stimulated/VBN
following/VBG
T/NN
cell/NN
activation/NN
./.
====================
Several/JJ
lines/NNS
of/IN
evidence/NN
have/VBP
suggested/VBN
that/IN
NFAT/NN
is/VBZ
a/DT
substrate/NN
for/IN
calcineurin/NN
,/,
a/DT
serine/threonine/NN
phosphatase/NN
./.
====================
Using/VBG
a/DT
polyclonal/JJ
antibody/NN
to/TO
murine/JJ
NFATp/NN
,/,
Western/NN
blot/NN
analysis/NN
of/IN
various/JJ
mouse/NN
tissues/NNS
demonstrated/VBD
that/IN
the/DT
110-130-kDa/JJ
NFATp/NN
protein/NN
was/VBD
highly/RB
expressed/VBN
in/IN
thymus/NN
and/CC
spleen/NN
./.
====================
Treatment/NN
of/IN
immunoprecipitated/VBN
NFATp/NN
from/IN
untreated/JJ
HT-2/NN
cells/NNS
with/IN
calcineurin/NN
resulted/VBD
in/IN
the/DT
dephosphorylation/NN
of/IN
NFATp/NN
,/,
demonstrating/VBG
that/IN
NFATp/NN
is/VBZ
an/DT
in/FW
vitro/FW
substrate/NN
for/IN
calcineurin/NN
./.
====================
NFATp/NN
immunoprecipitated/VBN
from/IN
32P-labeled/JJ
HT-2/NN
cells/NNS
migrated/VBD
as/IN
an/DT
approximately/RB
120-kDa/JJ
protein/NN
that/WDT
was/VBD
localized/JJ
to/TO
the/DT
cytosol/NN
of/IN
the/DT
cells/NNS
./.
====================
Treatment/NN
of/IN
the/DT
cells/NNS
with/IN
ionomycin/NN
resulted/VBD
in/IN
a/DT
decrease/NN
in/IN
the/DT
molecular/JJ
weight/NN
of/IN
NFATp/NN
and/CC
a/DT
loss/NN
of/IN
32P/NN
,/,
consistent/JJ
with/IN
NFATp/NN
dephosphorylation/NN
./.
====================
The/DT
dephosphorylation/NN
of/IN
NFATp/NN
was/VBD
accompanied/VBN
by/IN
localization/NN
of/IN
the/DT
protein/NN
to/TO
the/DT
nuclear/JJ
fraction/NN
./.
====================
Both/DT
of/IN
these/DT
events/NNS
were/VBD
blocked/VBN
by/IN
preincubation/NN
of/IN
the/DT
cells/NNS
with/IN
FK506/NN
,/,
a/DT
calcineurin/NN
inhibitor/NN
,/,
consistent/JJ
with/IN
the/DT
hypothesis/NN
that/IN
NFATp/NN
is/VBZ
a/DT
calcineurin/NN
substrate/NN
in/IN
cells/NNS
./.
====================
UI/LS
-/:
95378799/CD
====================
TI/LS
-/:
Activation/NN
and/CC
expression/NN
of/IN
the/DT
nuclear/JJ
factors/NNS
of/IN
activated/VBN
T/NN
cells/NNS
,/,
NFATp/NN
and/CC
NFATc/NN
,/,
in/IN
human/JJ
natural/JJ
killer/NN
cells/NNS
:/:
regulation/NN
upon/IN
CD16/NN
ligand/NN
binding/NN
./.
====================
AB/LS
-/:
The/DT
putative/JJ
factors/NNS
that/WDT
couple/VBP
the/DT
signal/NN
transduction/NN
from/IN
surface/NN
receptors/NNS
to/TO
the/DT
activation/NN
of/IN
cytokine/NN
synthesis/NN
in/IN
natural/JJ
killer/NN
(/(
NK/NN
)/)
cells/NNS
have/VBP
not/RB
been/VBN
elucidated/VBN
./.
====================
We/PRP
report/VBP
here/RB
that/IN
the/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFATp/NN
)/)
,/,
a/DT
cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
-sensitive/JJ
factor/NN
that/WDT
regulates/VBZ
the/DT
transcription/NN
of/IN
several/JJ
cytokines/NNS
,/,
mediates/VBZ
CD16-induced/JJ
activation/NN
of/IN
cytokine/NN
genes/NNS
in/IN
human/JJ
NK/NN
cells/NNS
./.
====================
CD16/NN
(/(
Fc/NN
gamma/NN
RIIIA/NN
)/)
-induced/JJ
expression/NN
of/IN
cytokine/NN
mRNA/NN
in/IN
NK/NN
cells/NNS
occurs/VBZ
via/IN
a/DT
CsA-sensitive/JJ
and/CC
Ca(2+)-dependent/JJ
mechanism/NN
./.
====================
Stimulation/NN
of/IN
NK/NN
cells/NNS
with/IN
CD16/NN
ligands/NNS
induces/VBZ
NFAT-like/JJ
DNA/NN
binding/NN
activity/NN
in/IN
the/DT
nuclear/JJ
extracts/NNS
from/IN
these/DT
cells/NNS
,/,
as/IN
detected/VBN
in/IN
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
./.
====================
This/DT
occurs/VBZ
with/IN
fast/JJ
kinetics/NNS
after/IN
stimulation/NN
,/,
via/IN
a/DT
CsA-sensitive/JJ
and/CC
Ca(2+)-dependent/JJ
mechanism/NN
that/WDT
does/VBZ
not/RB
require/VB
de/FW
novo/FW
protein/NN
synthesis/NN
./.
====================
NK/NN
cell/NN
NFAT/NN
is/VBZ
present/JJ
in/IN
the/DT
cytosol/NN
of/IN
nonstimulated/JJ
cells/NNS
,/,
migrates/VBZ
to/TO
the/DT
nucleus/NN
upon/IN
stimulation/NN
,/,
and/CC
can/MD
associate/VB
with/IN
AP-1/NN
./.
====================
Two/CD
distinct/JJ
molecules/NNS
,/,
NFATp/NN
and/CC
NFATc/NN
,/,
have/VBP
been/VBN
reported/VBN
to/TO
mediate/VB
NFAT/NN
activity/NN
./.
====================
The/DT
results/NNS
of/IN
supershift/NN
assays/NNS
using/VBG
NFATp-/NN
and/CC
NFATc-specific/JJ
antibodies/NNS
indicate/VBP
that/IN
NK/NN
cell/NN
activation/NN
early/RB
after/IN
CD16/NN
ligand/NN
binding/NN
involves/VBZ
primarily/RB
,/,
if/IN
not/RB
exclusively/RB
,/,
NFATp/NN
,/,
and/CC
Western/NN
blot/NN
analysis/NN
shows/VBZ
that/IN
this/DT
has/VBZ
the/DT
same/JJ
electrophoretic/JJ
mobility/NN
(/(
approximately/RB
120/CD
kD/NN
)/)
as/IN
that/DT
of/IN
T/NN
lymphocytes/NNS
./.
====================
NK/NN
cells/NNS
do/VBP
not/RB
express/VB
NFATc/NN
constitutively/RB
,/,
but/CC
NFATc/NN
mRNA/NN
accumulation/NN
is/VBZ
induced/VBN
in/IN
these/DT
cells/NNS
within/IN
2/CD
h/NN
of/IN
stimulation/NN
with/IN
CD16/NN
ligands/NNS
./.
====================
However/RB
,/,
supershift/NN
assays/NNS
using/VBG
the/DT
available/JJ
mAb/NN
recognizing/VBG
the/DT
T/NN
cell/NN
NFATc/NN
revealed/VBD
no/DT
detectable/JJ
NFATc/NN
protein/NN
in/IN
nuclear/JJ
and/CC
cytoplasmic/JJ
extracts/NNS
from/IN
CD16-/NN
or/CC
phorbol/NN
ester-stimulated/JJ
cells/NNS
at/IN
any/DT
time/NN
tested/VBN
,/,
up/RB
to/TO
4/CD
h/NN
./.
====================
These/DT
results/NNS
provide/VBP
the/DT
first/JJ
direct/JJ
evidence/NN
that/IN
both/DT
CsA-sensitive/JJ
transcription/NN
factors/NNS
,/,
NFATp/NN
and/CC
NFATc/NN
,/,
are/VBP
expressed/VBN
in/IN
human/JJ
NK/NN
cells/NNS
,/,
and/CC
that/IN
their/PRP$
activation/NN
and/or/CC
expression/NN
can/MD
be/VB
regulated/VBN
in/IN
primary/JJ
cells/NNS
by/IN
a/DT
single/JJ
stimulus/NN
,/,
that/WDT
,/,
in/IN
the/DT
case/NN
of/IN
CD16/NN
in/IN
NK/NN
cells/NNS
,/,
results/VBZ
in/IN
early/JJ
activation/NN
of/IN
NFATp/NN
and/CC
subsequently/RB
induced/VBN
expression/NN
of/IN
NFATc/NN
mRNA/NN
./.
====================
UI/LS
-/:
95372363/CD
====================
TI/LS
-/:
Interleukin/NN
2/CD
signaling/NN
involves/VBZ
the/DT
phosphorylation/NN
of/IN
Stat/NN
proteins/NNS
./.
====================
AB/LS
-/:
One/CD
of/IN
the/DT
most/RBS
important/JJ
cytokines/NNS
involved/VBN
in/IN
immune/JJ
response/NN
regulation/NN
is/VBZ
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
,/,
a/DT
potent/JJ
activator/NN
of/IN
the/DT
proliferation/NN
and/CC
function/NN
of/IN
T/NN
lymphocytes/NNS
and/CC
natural/JJ
killer/NN
cells/NNS
./.
====================
The/DT
mechanisms/NNS
by/IN
which/WDT
the/DT
effects/NNS
of/IN
IL-2/NN
are/VBP
propagated/VBN
within/IN
cells/NNS
are/VBP
not/RB
understood/VBN
./.
====================
While/IN
the/DT
binding/NN
of/IN
IL-2/NN
to/TO
its/PRP$
receptor/NN
was/VBD
recently/RB
shown/VBN
to/TO
lead/VB
to/TO
the/DT
activation/NN
of/IN
two/CD
kinases/NNS
,/,
Jak-1/NN
and/CC
Jak-3/CD
,/,
subsequent/JJ
steps/NNS
in/IN
the/DT
signaling/NN
pathway/NN
to/TO
the/DT
nucleus/NN
that/WDT
lead/VBP
to/TO
the/DT
activation/NN
of/IN
specific/JJ
genes/NNS
had/VBD
not/RB
been/VBN
characterized/VBN
./.
====================
Since/IN
many/JJ
cytokines/NNS
that/WDT
activate/VBP
Jak/NN
kinases/NNS
also/RB
lead/VBP
to/TO
the/DT
tyrosine/NN
phosphorylation/NN
and/CC
activation/NN
of/IN
members/NNS
of/IN
the/DT
Stat/NN
family/NN
of/IN
transcription/NN
factors/NNS
,/,
the/DT
ability/NN
of/IN
IL-2/NN
to/TO
trigger/VB
Stat/NN
phosphorylation/NN
was/VBD
examined/VBN
./.
====================
Exposure/NN
of/IN
activated/VBN
human/JJ
T/NN
lymphocytes/NNS
or/CC
of/IN
a/DT
natural/JJ
killer/NN
cell/NN
line/NN
(/(
NKL/NN
)/)
to/TO
IL-2/NN
leads/VBZ
to/TO
the/DT
phosphorylation/NN
of/IN
Stat1/NN
alpha/NN
,/,
Stat1/NN
beta/NN
,/,
and/CC
Stat3/NN
,/,
as/RB
well/RB
as/IN
of/IN
two/CD
Stat-related/JJ
proteins/NNS
,/,
p94/NN
and/CC
p95/NN
./.
====================
p94/NN
and/CC
p95/NN
share/VBP
homology/NN
with/IN
Stat1/NN
at/IN
the/DT
phosphorylation/NN
site/NN
and/CC
in/IN
the/DT
Src/NN
homology/NN
2/CD
(/(
SH2/NN
)/)
domain/NN
,/,
but/CC
otherwise/RB
are/VBP
immunologically/RB
distinct/JJ
from/IN
Stat1/NN
./.
====================
These/DT
Stat/NN
proteins/NNS
were/VBD
found/VBN
to/TO
translocate/VB
to/TO
the/DT
nucleus/NN
and/CC
to/TO
bind/VB
to/TO
a/DT
specific/JJ
DNA/NN
sequence/NN
./.
====================
These/DT
findings/NNS
suggest/VBP
a/DT
mechanism/NN
by/IN
which/WDT
IL-2/NN
binding/VBG
to/TO
its/PRP$
receptor/NN
may/MD
activate/VB
specific/JJ
genes/NNS
involved/VBN
in/IN
immune/JJ
cell/NN
function/NN
./.
====================
UI/LS
-/:
98029486/CD
====================
TI/LS
-/:
Expression/NN
of/IN
c-fos/NN
correlates/VBZ
with/IN
IFN-alpha/NN
responsiveness/NN
in/IN
Philadelphia/NN
chromosome/NN
positive/JJ
chronic/JJ
myelogenous/JJ
leukemia/NN
./.
====================
AB/LS
-/:
This/DT
study/NN
evaluates/VBZ
(/(
i/LS
)/)
constitutive/JJ
levels/NNS
of/IN
oncogene/NN
and/CC
p53/NN
transcripts/NNS
in/IN
chronic/JJ
phase/NN
CML/NN
patients/NNS
and/CC
(/(
ii/LS
)/)
their/PRP$
modulations/NNS
subsequent/JJ
to/TO
in/FW
vivo/FW
therapy/NN
with/IN
rIFN-alpha/NN
2c/NN
./.
====================
Peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
pbmc/NN
)/)
and/CC
bone/NN
marrow/NN
cells/NNS
of/IN
26/CD
patients/NNS
were/VBD
examined/VBN
for/IN
c-fos/NN
,/,
c-myc/NN
,/,
p53/NN
and/CC
the/DT
hybrid/NN
bcr/abl/NN
mRNA/NN
levels/NNS
./.
====================
Results/NNS
indicated/VBD
that/IN
(/(
i/LS
)/)
constitutive/JJ
c-fos/NN
transcript/NN
levels/NNS
are/VBP
significantly/RB
higher/JJR
in/IN
patients/NNS
subsequently/RB
responding/VBG
to/TO
IFN-alpha/NN
therapy/NN
(/(
p/NN
</JJR
0.01/CD
)/)
and/CC
positively/RB
correlated/VBN
with/IN
the/DT
proportion/NN
of/IN
lymphocytes/NNS
(/(
r/NN
=/JJ
0.6895/CD
,/,
p/NN
</JJR
0.01/CD
)/)
and/CC
negatively/RB
with/IN
the/DT
proportion/NN
of/IN
immature/JJ
cells/NNS
(/(
r/NN
=/JJ
-0.568/CD
,/,
p/NN
</JJR
0.01/CD
)/)
contained/VBN
in/IN
the/DT
pbmc/NN
preparations/NNS
tested/VBN
,/,
(/(
ii/LS
)/)
constitutive/JJ
mRNA/NN
levels/NNS
of/IN
the/DT
hybrid/NN
bcr/abl/NN
,/,
c-myc/NN
and/CC
p53/NN
are/VBP
positively/RB
correlated/VBN
with/IN
each/DT
other/JJ
,/,
but/CC
failed/VBD
to/TO
relate/VB
to/TO
disease/NN
parameters/NNS
,/,
and/CC
(/(
iii/LS
)/)
acute/JJ
and/CC
chronic/JJ
in/FW
vivo/FW
exposure/NN
to/TO
IFN-alpha/NN
is/VBZ
accompanied/VBN
by/IN
upregulation/NN
of/IN
c-fos/NN
and/CC
downregulation/NN
of/IN
c-myc/NN
mRNA/NN
levels/NNS
in/IN
responder/NN
patients/NNS
./.
====================
UI/LS
-/:
96191817/CD
====================
TI/LS
-/:
Menopause/NN
is/VBZ
associated/VBN
with/IN
a/DT
significant/JJ
increase/NN
in/IN
blood/NN
monocyte/NN
number/NN
and/CC
a/DT
relative/JJ
decrease/NN
in/IN
the/DT
expression/NN
of/IN
estrogen/NN
receptors/NNS
in/IN
human/JJ
peripheral/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
PROBLEM/NN
:/:
The/DT
clinical/JJ
significance/NN
of/IN
the/DT
differential/JJ
expression/NN
of/IN
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
in/IN
human/JJ
monocytes/NNS
was/VBD
evaluated/VBN
./.
====================
METHOD/NN
:/:
Two/CD
color/NN
flow/NN
cytometry/NN
analysis/NN
was/VBD
used/VBN
on/IN
peripheral/JJ
blood/NN
samples/NNS
of/IN
young/JJ
and/CC
postmenopausal/JJ
females/NNS
and/CC
postmenopausal/JJ
females/NNS
treated/VBN
with/IN
estrogen/NN
replacement/NN
therapy/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
monocyte/NN
and/CC
lymphocyte/NN
counts/NNS
and/CC
the/DT
blood/NN
estrogen/NN
levels/NNS
of/IN
each/DT
patient/NN
were/VBD
determine/VBN
./.
====================
RESULTS/NNS
:/:
During/IN
menopause/NN
there/EX
is/VBZ
a/DT
significant/JJ
decrease/NN
in/IN
the/DT
percentage/NN
of/IN
ER/NN
positive/JJ
monocytes/NNS
,/,
and/CC
an/DT
increase/NN
in/IN
blood/NN
monocyte/NN
number/NN
,/,
which/WDT
declines/VBZ
following/VBG
estrogen/NN
replacement/NN
therapy/NN
to/TO
values/NNS
of/IN
the/DT
young/JJ
./.
====================
CONCLUSIONS/NNS
:/:
These/DT
findings/NNS
suggest/VBP
that/IN
estrogen/NN
modulates/VBZ
the/DT
monocyte/NN
numbers/NNS
and/CC
its/PRP$
effects/NNS
may/MD
be/VB
mediated/VBN
through/IN
the/DT
ER/NN
in/IN
the/DT
monocytes/NNS
./.
====================
UI/LS
-/:
96074633/CD
====================
TI/LS
-/:
Staphylococcal/JJ
enterotoxins/NNS
modulate/VBP
interleukin/NN
2/CD
receptor/NN
expression/NN
and/CC
ligand-induced/JJ
tyrosine/NN
phosphorylation/NN
of/IN
the/DT
Janus/NN
protein-tyrosine/NN
kinase/NN
3/CD
(/(
Jak3/NN
)/)
and/CC
signal/NN
transducers/NNS
and/CC
activators/NNS
of/IN
transcription/NN
(/(
Stat/NN
proteins/NNS
)/)
./.
====================
AB/LS
-/:
Staphylococcal/JJ
enterotoxins/NN
(/(
SE/NNS
)/)
stimulate/VBP
T/NN
cells/NNS
expressing/VBG
the/DT
appropriate/JJ
variable/JJ
region/NN
beta/NN
chain/NN
of/IN
(/(
V/NN
beta/NN
)/)
T-cell/NN
receptors/NNS
and/CC
have/VBP
been/VBN
implicated/VBN
in/IN
the/DT
pathogenesis/NN
of/IN
several/JJ
autoimmune/JJ
diseases/NNS
./.
====================
Depending/VBG
on/IN
costimulatory/JJ
signals/NNS
,/,
SE/NNS
induce/VBP
either/CC
proliferation/NN
or/CC
anergy/NN
in/IN
T/NN
cells/NNS
./.
====================
In/IN
addition/NN
,/,
SE/NNS
can/MD
induce/VB
an/DT
interleukin-2/NN
(/(
IL-2/NN
)/)
nonresponsive/JJ
state/NN
and/CC
apoptosis/NN
./.
====================
Here/RB
,/,
we/PRP
show/VBP
that/IN
SE/NNS
induce/VBP
dynamic/JJ
changes/NNS
in/IN
the/DT
expression/NN
of/IN
and/CC
signal/NN
transduction/NN
through/IN
the/DT
IL-2/NN
receptor/NN
(/(
IL-2R/NN
)/)
beta/NN
and/CC
gamma/NN
chains/NNS
(/(
IL-2R/NN
beta/NN
and/CC
IL-2R/NN
gamma/NN
)/)
in/IN
human/JJ
antigen-specific/JJ
CD4+/JJ
T-cell/NN
lines/NNS
./.
====================
Thus/RB
,/,
after/IN
4/CD
hr/NN
of/IN
exposure/NN
to/TO
SEA/NN
and/CC
SEB/NN
,/,
the/DT
expression/NN
of/IN
IL-2R/NN
beta/NN
was/VBD
down-regulated/VBN
,/,
IL-2R/NN
gamma/NN
was/VBD
slightly/RB
up-regulated/VBN
,/,
while/IN
IL-2R/NN
alpha/NN
remained/VBD
largely/RB
unaffected/JJ
./.
====================
The/DT
changes/NNS
in/IN
the/DT
composition/NN
of/IN
IL-2Rs/NNS
were/VBD
accompanied/VBN
by/IN
inhibition/NN
of/IN
IL-2-induced/JJ
tyrosine/NN
phosphorylation/NN
of/IN
the/DT
Janus/NN
protein-tyrosine/NN
kinase/NN
3/CD
(/(
Jak3/NN
)/)
and/CC
signal/NN
transducers/NNS
and/CC
activators/NNS
of/IN
transcription/NN
called/VBN
Stat3/NN
and/CC
Stat5/NN
./.
====================
In/IN
parallel/JJ
experiments/NNS
,/,
IL-2-driven/JJ
proliferation/NN
was/VBD
inhibited/VBN
significantly/RB
./.
====================
After/IN
16/CD
hr/NN
of/IN
exposure/NN
to/TO
SE/NNS
,/,
the/DT
expression/NN
of/IN
IL-2R/NN
beta/NN
remained/VBD
low/JJ
,/,
while/IN
that/DT
of/IN
IL2R/NN
alpha/NN
and/CC
IL2R/NN
gamma/NN
was/VBD
further/RB
up-regulated/VBN
,/,
and/CC
ligand-induced/JJ
tyrosine/NN
phosphorylation/NN
of/IN
Jak3/NN
and/CC
Stat/NN
proteins/NNS
was/VBD
partly/RB
normalized/VBN
./.
====================
Yet/RB
,/,
IL-2-driven/JJ
proliferation/NN
remained/VBD
profoundly/RB
inhibited/JJ
,/,
suggesting/VBG
that/IN
signaling/NN
events/NNS
other/JJ
than/IN
Jak3/Stat/NN
activation/NN
had/VBD
also/RB
been/VBN
changed/VBN
following/VBG
SE/NNS
stimulation/NN
./.
====================
In/IN
conclusion/NN
,/,
our/PRP$
data/NNS
suggest/VBP
that/IN
SE/NNS
can/MD
modulate/VB
IL-2R/NN
expression/NN
and/CC
signal/NN
transduction/NN
involving/VBG
the/DT
Jak/Stat/NN
pathway/NN
in/IN
CD4+/JJ
T-cell/NN
lines/NNS
./.
====================
UI/LS
-/:
96086826/CD
====================
TI/LS
-/:
Constitutive/JJ
NF-kappa/NN
B/NN
activation/NN
,/,
enhanced/VBN
granulopoiesis/NN
,/,
and/CC
neonatal/JJ
lethality/NN
in/IN
I/NN
kappa/NN
B/NN
alpha-deficient/JJ
mice/NNS
./.
====================
AB/LS
-/:
Transcription/NN
factors/NNS
belonging/VBG
to/TO
the/DT
NF-kappa/NN
B/NN
family/NN
are/VBP
controlled/VBN
by/IN
inhibitory/JJ
I/NN
kappa/NN
B/NN
proteins/NNS
,/,
mainly/RB
I/NN
kappa/NN
B/NN
alpha/NN
and/CC
I/NN
kappa/NN
B/NN
beta/NN
./.
====================
Apparently/RB
normal/JJ
at/IN
birth/NN
,/,
I/NN
kappa/NN
B/NN
alpha-/-/JJ
mice/NNS
exhibit/VBP
severe/JJ
runting/NN
,/,
skin/NN
defects/NNS
,/,
and/CC
extensive/JJ
granulopoiesis/NN
postnatally/RB
,/,
typically/RB
dying/VBG
by/IN
8/CD
days/NNS
./.
====================
Hematopoietic/JJ
tissues/NNS
from/IN
these/DT
mice/NNS
display/VBP
elevated/JJ
levels/NNS
of/IN
both/CC
nuclear/JJ
NF-kappa/NN
B/NN
and/CC
mRNAs/NNS
of/IN
some/DT
,/,
but/CC
not/RB
all/DT
,/,
genes/NNS
thought/VBN
to/TO
be/VB
regulated/VBN
by/IN
NF-kappa/NN
B/NN
./.
====================
NF-kappa/NN
B/NN
elevation/NN
results/VBZ
in/IN
these/DT
phenotypic/JJ
abnormalities/NNS
because/IN
mice/NNS
lacking/VBG
both/CC
I/NN
kappa/NN
B/NN
alpha/NN
and/CC
the/DT
p50/NN
subunit/NN
of/IN
NF-kappa/NN
B/NN
show/VBP
a/DT
dramatically/RB
delayed/VBN
onset/NN
of/IN
abnormalities/NNS
./.
====================
In/IN
contrast/NN
to/TO
hematopoietic/JJ
cells/NNS
,/,
I/NN
kappa/NN
B/NN
alpha-/-/JJ
embryonic/JJ
fibroblasts/NNS
show/VBP
minimal/JJ
constitutive/JJ
NF-kappa/NN
B/NN
,/,
as/RB
well/RB
as/IN
normal/JJ
signal-dependent/JJ
NF-kappa/NN
B/NN
activation/NN
that/WDT
is/VBZ
concomitant/JJ
with/IN
I/NN
kappa/NN
B/NN
beta/NN
degradation/NN
./.
====================
Our/PRP$
results/NNS
indicate/VBP
that/IN
I/NN
kappa/NN
b/NN
beta/NN
,/,
but/CC
not/RB
I/NN
kappa/NN
B/NN
alpha/NN
,/,
is/VBZ
required/VBN
for/IN
the/DT
signal-dependent/JJ
activation/NN
of/IN
NF-kappa/NN
B/NN
in/IN
fibroblasts/NNS
./.
====================
However/RB
,/,
I/NN
kappa/NN
B/NN
alpha/NN
is/VBZ
required/VBN
for/IN
the/DT
postinduction/JJ
repression/NN
of/IN
NF-kappa/NN
B/NN
in/IN
fibroblasts/NNS
./.
====================
These/DT
results/NNS
define/VBP
distinct/JJ
roles/NNS
for/IN
the/DT
two/CD
forms/NNS
of/IN
I/NN
kappa/NN
B/NN
and/CC
demonstrate/VBP
the/DT
necessity/NN
for/IN
stringent/JJ
control/NN
of/IN
NF-kappa/NN
B/NN
./.
====================
UI/LS
-/:
96085174/CD
====================
TI/LS
-/:
Interleukin-7/NN
can/MD
induce/VB
the/DT
activation/NN
of/IN
Jak/NN
1/CD
,/,
Jak/NN
3/CD
and/CC
STAT/NN
5/CD
proteins/NNS
in/IN
murine/JJ
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
activation/NN
of/IN
Janus/NN
protein/NN
tyrosine/NN
kinases/NNS
(/(
Jak/NN
)/)
and/CC
STAT/NN
(/(
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
)/)
proteins/NNS
has/VBZ
recently/RB
been/VBN
linked/VBN
to/TO
the/DT
signal/NN
transduction/NN
mechanism/NN
of/IN
several/JJ
cytokines/NNS
./.
====================
IL-7/NN
was/VBD
observed/VBN
to/TO
induce/VB
a/DT
rapid/JJ
and/CC
dose-dependent/JJ
tyrosine/NN
phosphorylation/NN
of/IN
Jak/NN
1/CD
and/CC
Jak/NN
3/CD
and/CC
concomitantly/RB
,/,
the/DT
tyrosine/NN
phosphorylation/NN
and/CC
DNA/NN
binding/NN
activity/NN
of/IN
multiple/JJ
STAT/NN
proteins/NNS
./.
====================
The/DT
STAT/NN
proteins/NNS
utilized/VBN
by/IN
IL-7/NN
were/VBD
identical/JJ
to/TO
those/DT
induced/VBN
by/IN
IL-2/NN
and/CC
could/MD
be/VB
identified/VBN
as/IN
various/JJ
STAT/NN
5/CD
isoforms/NNS
./.
====================
Moreover/RB
,/,
the/DT
induction/NN
of/IN
both/CC
Jak/NN
1/CD
and/CC
3/CD
,/,
and/CC
STAT/NN
5/CD
activity/NN
strongly/RB
correlated/VBD
with/IN
the/DT
growth-promoting/JJ
effects/NNS
of/IN
IL-7/NN
,/,
suggesting/VBG
that/IN
this/DT
signal/NN
transduction/NN
mechanism/NN
may/MD
play/VB
a/DT
key/JJ
role/NN
in/IN
IL-7-induced/JJ
proliferation/NN
./.
====================
UI/LS
-/:
96288304/CD
====================
TI/LS
-/:
Cytokine-modulating/JJ
activity/NN
of/IN
tepoxalin/NN
,/,
a/DT
new/JJ
potential/JJ
antirheumatic/NN
./.
====================
AB/LS
-/:
Tepoxalin/NN
is/VBZ
a/DT
new/JJ
dual/JJ
cyclooxygenase/5-lipoxygenase/NN
anti-inflammatory/JJ
compound/NN
currently/RB
under/IN
clinical/JJ
investigation/NN
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
to/TO
possess/VB
anti-inflammatory/JJ
activity/NN
in/IN
a/DT
variety/NN
of/IN
animal/NN
models/NNS
and/CC
more/RBR
recently/RB
to/TO
inhibit/VB
IL-2/NN
induced/JJ
signal/NN
transduction/NN
./.
====================
The/DT
current/JJ
study/NN
was/VBD
conducted/VBN
to/TO
evaluate/VB
the/DT
cytokine/NN
modulating/NN
activity/NN
of/IN
tepoxalin/NN
and/CC
the/DT
role/NN
of/IN
iron/NN
in/IN
these/DT
effects/NNS
./.
====================
In/IN
human/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NN
)/)
stimulated/VBN
with/IN
OKT3/PMA/NN
,/,
tepoxalin/NN
inhibited/VBD
lymphocyte/NN
proliferation/NN
with/IN
an/DT
IC50/NN
of/IN
6/CD
microM/NN
./.
====================
Additionally/RB
,/,
it/PRP
inhibited/VBD
the/DT
production/NN
of/IN
LTB4/NN
(/(
IC50/NN
=/JJ
0.5/CD
microM/NN
)/)
and/CC
the/DT
cytokines/NNS
IL-2/NN
,/,
IL-6/NN
and/CC
TNF/NN
alpha/NN
(/(
IC50/NN
=/JJ
10-12/CD
microM/NN
)/)
./.
====================
Cytotoxicity/NN
was/VBD
not/RB
demonstrated/VBN
at/IN
these/DT
concentrations/NNS
./.
====================
Add-back/JJ
experiments/NNS
with/IN
either/CC
cytokines/NNS
(/(
IL-2/NN
or/CC
IL-6/NN
)/)
,/,
LTB4/NN
or/CC
conditioned/JJ
media/NNS
failed/VBD
to/TO
restore/VB
the/DT
proliferative/JJ
response/NN
in/IN
the/DT
presence/NN
of/IN
tepoxalin/NN
./.
====================
However/RB
,/,
the/DT
concurrent/JJ
addition/NN
of/IN
iron/NN
(/(
in/IN
the/DT
form/NN
of/IN
ferrous/JJ
or/CC
ferric/JJ
chloride/NN
and/CC
other/JJ
iron/NN
salts/NNS
)/)
reversed/VBD
the/DT
inhibition/NN
of/IN
proliferation/NN
caused/VBN
by/IN
tepoxalin/NN
./.
====================
Tepoxalin/NN
also/RB
inhibits/VBZ
the/DT
activation/NN
of/IN
NF/NN
kappa/NN
B/NN
,/,
a/DT
transcription/NN
factor/NN
which/WDT
acts/VBZ
on/IN
several/JJ
cytokine/NN
genes/NNS
./.
====================
Tepoxalin/NN
's/POS
effect/NN
on/IN
NF/NN
kappa/NN
B/NN
is/VBZ
also/RB
reversed/VBN
by/IN
the/DT
addition/NN
of/IN
iron/NN
salts/NNS
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
the/DT
action/NN
of/IN
tepoxalin/NN
to/TO
inhibit/VB
proliferation/NN
in/IN
PBMC/NN
may/MD
be/VB
at/IN
least/JJS
in/IN
part/NN
due/JJ
to/TO
its/PRP$
ability/NN
to/TO
reduce/VB
the/DT
amount/NN
of/IN
available/JJ
iron/NN
resulting/VBG
in/IN
decreased/VBN
activation/NN
of/IN
NF/NN
kappa/NN
B/NN
and/CC
subsequent/JJ
inhibition/NN
of/IN
cytokine/NN
production/NN
./.
====================
UI/LS
-/:
96009559/CD
====================
TI/LS
-/:
N-/NN
and/CC
C-terminal/JJ
sequences/NNS
control/VBP
degradation/NN
of/IN
MAD3/I/NN
kappa/NN
B/NN
alpha/NN
in/IN
response/NN
to/TO
inducers/NNS
of/IN
NF-kappa/NN
B/NN
activity/NN
./.
====================
AB/LS
-/:
The/DT
proteolytic/JJ
degradation/NN
of/IN
the/DT
inhibitory/JJ
protein/NN
MAD3/I/NN
kappa/NN
B/NN
alpha/NN
in/IN
response/NN
to/TO
extracellular/JJ
stimulation/NN
is/VBZ
a/DT
prerequisite/JJ
step/NN
in/IN
the/DT
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
./.
====================
Analysis/NN
of/IN
the/DT
expression/NN
of/IN
human/JJ
I/NN
kappa/NN
B/NN
alpha/NN
protein/NN
in/IN
stable/JJ
transfectants/NNS
of/IN
mouse/NN
70Z/3/NN
cells/NNS
shows/VBZ
that/IN
,/,
as/IN
for/IN
the/DT
endogenous/JJ
murine/JJ
protein/NN
,/,
exogenous/JJ
I/NN
kappa/NN
B/NN
alpha/NN
is/VBZ
degraded/VBN
in/IN
response/NN
to/TO
inducers/NNS
of/IN
NF-kappa/NN
B/NN
activity/NN
,/,
such/JJ
as/IN
phorbol/NN
myristate/NN
acetate/NN
or/CC
lipopolysaccharide/NN
./.
====================
In/IN
addition/NN
,/,
pretreatment/NN
of/IN
the/DT
cells/NNS
with/IN
the/DT
proteasome/JJ
inhibitor/NN
N-Ac-Leu-Leu-norleucinal/NN
inhibits/VBZ
this/DT
ligand-induced/JJ
degradation/NN
and/CC
,/,
in/IN
agreement/NN
with/IN
previous/JJ
studies/NNS
,/,
stabilizes/VBZ
a/DT
hyperphosphorylated/JJ
form/NN
of/IN
the/DT
human/JJ
I/NN
kappa/NN
B/NN
alpha/NN
protein/NN
./.
====================
By/IN
expressing/VBG
mutant/JJ
forms/NNS
of/IN
the/DT
human/JJ
protein/NN
in/IN
this/DT
cell/NN
line/NN
,/,
we/PRP
have/VBP
been/VBN
able/JJ
to/TO
delineate/VB
the/DT
sequences/NNS
responsible/JJ
for/IN
both/CC
the/DT
ligand-induced/JJ
phosphorylation/NN
and/CC
the/DT
degradation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
./.
====================
Our/PRP$
results/NNS
show/VBP
that/IN
deletion/NN
of/IN
the/DT
C/NN
terminus/NN
of/IN
the/DT
I/NN
kappa/NN
B/NN
alpha/NN
molecule/NN
up/RB
to/TO
amino/NN
acid/NN
279/CD
abolishes/VBZ
constitutive/JJ
but/CC
not/RB
ligand-inducible/JJ
phosphorylation/NN
and/CC
inhibits/VBZ
ligand-inducible/JJ
degradation/NN
./.
====================
Further/JJ
analysis/NN
reveals/VBZ
that/IN
the/DT
inducible/JJ
phosphorylation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
maps/VBZ
to/TO
two/CD
serines/NNS
in/IN
the/DT
N/NN
terminus/NN
of/IN
the/DT
protein/NN
(/(
residues/NNS
32/CD
and/CC
36/CD
)/)
and/CC
that/IN
the/DT
mutation/NN
of/IN
either/DT
residue/NN
is/VBZ
sufficient/JJ
to/TO
abolish/VB
ligand-induced/JJ
degradation/NN
,/,
whereas/IN
both/DT
residues/NNS
must/MD
be/VB
mutated/VBN
to/TO
abolish/VB
inducible/JJ
phosphorylation/NN
of/IN
the/DT
protein/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
95403403/CD
====================
TI/LS
-/:
Microtubules/NNS
mediate/VBP
cellular/JJ
25-hydroxyvitamin/NN
D3/NN
trafficking/NN
and/CC
the/DT
genomic/JJ
response/NN
to/TO
1,25-dihydroxyvitamin/NN
D3/NN
in/IN
normal/JJ
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
The/DT
genomic/JJ
actions/NNS
of/IN
1,25-dihydroxyvitamin/NN
D3/NN
(/(
1,25(OH)2D3/NN
)/)
are/VBP
mediated/VBN
by/IN
the/DT
intracellular/JJ
vitamin/NN
D/NN
receptor/NN
(/(
VDR/NN
)/)
./.
====================
Although/IN
immunocytochemistry/NN
has/VBZ
shown/VBN
that/IN
disruption/NN
of/IN
microtubular/JJ
assembly/NN
prevents/VBZ
nuclear/JJ
access/NN
of/IN
the/DT
sterol-VDR/NN
complex/NN
,/,
the/DT
role/NN
of/IN
microtubules/NNS
in/IN
the/DT
response/NN
to/TO
1,25(OH)2D3/NN
has/VBZ
not/RB
been/VBN
studied/VBN
in/IN
viable/JJ
cells/NNS
./.
====================
Our/PRP$
studies/NNS
examined/VBD
this/DT
interaction/NN
in/IN
normal/JJ
human/JJ
monocytes/NNS
./.
====================
Monocytes/NNS
convert/VBP
25(OH)D3/NN
to/TO
1,25(OH)2D3/NN
and/CC
to/TO
24-hydroxylated/JJ
metabolites/NNS
more/RBR
polar/JJ
than/IN
1,25(OH)2D3/NN
./.
====================
Microtubule/NN
disruption/NN
totally/RB
abolished/VBD
the/DT
ability/NN
of/IN
exogenous/JJ
1,25(OH)2D3/NN
to/TO
suppress/VB
its/PRP$
own/JJ
synthesis/NN
and/CC
to/TO
induce/VB
24-hydroxylase/NN
mRNA/NN
and/CC
activity/NN
,/,
without/IN
affecting/VBG
either/CC
total/JJ
1,25(OH)2D3/NN
uptake/NN
or/CC
maximal/JJ
1,25(OH)2D3-VDR/JJ
binding/NN
./.
====================
Thus/RB
,/,
intact/JJ
microtubules/NNS
are/VBP
essential/JJ
for/IN
1,25(OH)2D3-dependent/JJ
modulation/NN
of/IN
gene/NN
transcription/NN
./.
====================
Interestingly/RB
,/,
microtubule/NN
disruption/NN
also/RB
decreased/VBD
monocyte/NN
1,25(OH)2D3/NN
synthesis/NN
,/,
not/RB
by/IN
decreasing/VBG
the/DT
Vmax/NN
of/IN
monocyte/NN
mitochondrial/JJ
1/CD
alpha-hydroxylase/NN
but/CC
through/IN
an/DT
increase/NN
in/IN
the/DT
Km/NN
for/IN
25(OH)2D3/NN
./.
====================
We/PRP
examined/VBD
25(OH)D3/NN
transport/NN
./.
====================
Microtubule/NN
disruption/NN
did/VBD
not/RB
affect/VB
total/JJ
cellular/JJ
25(OH)D3/NN
uptake/NN
but/CC
reduced/VBD
its/PRP$
intracellular/JJ
trafficking/NN
to/TO
the/DT
mitochondria/NN
./.
====================
Thus/RB
,/,
microtubules/NNS
participate/VBP
in/IN
intracellular/JJ
25(OH)D3/NN
transport/NN
,/,
and/CC
their/PRP$
integrity/NN
determines/VBZ
normal/JJ
1,25(OH)2D3/NN
synthesis/NN
./.
====================
UI/LS
-/:
95382761/CD
====================
TI/LS
-/:
Relationship/NN
between/IN
Rap1/NN
protein/NN
phosphorylation/NN
and/CC
regulation/NN
of/IN
Ca2+/NN
transport/NN
in/IN
platelets/NNS
:/:
a/DT
new/JJ
approach/NN
./.
====================
AB/LS
-/:
Although/IN
the/DT
interrelationship/NN
between/IN
the/DT
two/CD
messengers/NNS
Ca2+/NN
and/CC
cyclic/JJ
AMP/NN
in/IN
platelet/NN
function/NN
is/VBZ
well/RB
documented/VBN
,/,
its/PRP$
mechanism/NN
of/IN
action/NN
still/RB
remains/VBZ
to/TO
be/VB
established/VBN
./.
====================
We/PRP
investigated/VBD
here/RB
the/DT
question/NN
of/IN
the/DT
regulation/NN
of/IN
platelet/NN
Ca(2+)-ATPases/NNS
by/IN
cyclic/JJ
AMP/NN
through/IN
the/DT
phosphorylation/NN
of/IN
the/DT
Rap1/NN
protein/NN
using/VBG
a/DT
pathological/JJ
model/NN
./.
====================
We/PRP
first/RB
found/VBD
experimental/JJ
conditions/NNS
where/WRB
Ca(2+)-transport/NN
by/IN
platelet/NN
membrane/NN
vesicles/NNS
appeared/VBD
to/TO
be/VB
dependent/JJ
on/IN
the/DT
phosphorylation/NN
of/IN
the/DT
Rap1/NN
protein/NN
./.
====================
Then/RB
,/,
we/PRP
studied/VBD
platelets/NNS
of/IN
patients/NNS
with/IN
congestive/JJ
heart/NN
failure/NN
for/IN
their/PRP$
expression/NN
of/IN
the/DT
potential/JJ
97/CD
kDa/NN
Ca(2+)-ATPase/NN
target/NN
of/IN
regulation/NN
through/IN
the/DT
Rap1/NN
protein/NN
as/RB
well/RB
as/IN
the/DT
phosphorylation/NN
of/IN
the/DT
Rap1/NN
protein/NN
using/VBG
the/DT
catalytic/JJ
subunit/NN
of/IN
the/DT
cyclic/JJ
AMP-dependent/JJ
protein/NN
kinase/NN
(/(
C./JJ
Sub./NN
)/)
./.
====================
In/IN
the/DT
first/JJ
patients/NNS
studied/VBN
,/,
we/PRP
found/VBD
no/DT
significant/JJ
modification/NN
in/IN
the/DT
expression/NN
of/IN
the/DT
97/CD
kDa/NN
Ca(2+)-ATPase/NN
by/IN
Western/NN
blotting/NN
using/VBG
the/DT
PL/IM/NN
430/CD
monoclonal/JJ
antibody/NN
which/WDT
specifically/RB
recognized/VBD
this/DT
isoform/NN
./.
====================
In/IN
contrast/NN
,/,
the/DT
Rap1/NN
protein/NN
was/VBD
differentially/RB
phosphorylated/VBN
when/WRB
using/VBG
15/CD
micrograms/ml/NNS
of/IN
the/DT
C./NN
Sub/NN
./.
====================
These/DT
results/NNS
allowed/VBD
us/PRP
to/TO
use/VB
these/DT
pathological/JJ
platelets/NNS
to/TO
study/VB
the/DT
relationship/NN
between/IN
the/DT
expression/NN
of/IN
Rap1/NN
protein/NN
and/CC
the/DT
regulation/NN
of/IN
Ca2+/NN
transport/NN
by/IN
selecting/VBG
a/DT
patient/NN
with/IN
severe/JJ
heart/NN
failure/NN
./.
====================
We/PRP
could/MD
show/VB
a/DT
decrease/NN
in/IN
the/DT
expression/NN
as/RB
well/RB
as/IN
in/IN
the/DT
phosphorylation/NN
of/IN
Rap1/NN
protein/NN
and/CC
demonstrate/VB
a/DT
lower/JJR
effect/NN
of/IN
C./JJ
Sub./NN
on/IN
Ca2+/NN
transport/NN
./.
====================
Finally/RB
,/,
by/IN
studying/VBG
a/DT
further/JJ
series/NN
of/IN
patients/NNS
,/,
we/PRP
could/MD
confirm/VB
that/IN
the/DT
decrease/NN
in/IN
Rap1/NN
protein/NN
expression/NN
in/IN
heart/NN
failure/NN
,/,
whatever/WDT
its/PRP$
extent/NN
,/,
was/VBD
variable/JJ
,/,
and/CC
could/MD
strictly/RB
correlate/VB
the/DT
expression/NN
of/IN
Rap1/NN
protein/NN
with/IN
the/DT
stimulatory/JJ
effect/NN
of/IN
C./JJ
Sub./NN
on/IN
Ca2+/NN
transport/NN
./.
====================
Besides/IN
the/DT
evidence/NN
for/IN
regulation/NN
of/IN
the/DT
expression/NN
of/IN
the/DT
Rap1/NN
protein/NN
in/IN
platelets/NNS
from/IN
patients/NNS
with/IN
heart/NN
failure/NN
,/,
these/DT
findings/NNS
constitute/VBP
a/DT
new/JJ
approach/NN
in/IN
favour/NN
of/IN
the/DT
regulation/NN
of/IN
platelet/NN
Ca2+/NN
transport/NN
through/IN
the/DT
phosphorylation/NN
of/IN
the/DT
Rap1/NN
protein/NN
./.
====================
UI/LS
-/:
95364954/CD
====================
TI/LS
-/:
An/DT
IRF-1-dependent/JJ
pathway/NN
of/IN
DNA/NN
damage-induced/JJ
apoptosis/NN
in/IN
mitogen-activated/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Lymphocytes/NNS
are/VBP
particularly/RB
susceptible/JJ
to/TO
DNA/NN
damage-induced/JJ
apoptosis/NN
,/,
a/DT
response/NN
which/WDT
may/MD
serve/VB
as/IN
a/DT
form/NN
of/IN
'/``
altruistic/JJ
suicide/NN
'/''
to/TO
counter/VB
their/PRP$
intrinsic/JJ
high/JJ
potential/NN
for/IN
mutation/NN
and/CC
clonal/JJ
expansion/NN
./.
====================
The/DT
tumour/NN
suppressor/NN
p53/NN
has/VBZ
been/VBN
shown/VBN
to/TO
regulate/VB
this/DT
type/NN
of/IN
apoptosis/NN
in/IN
thymocytes/NNS
,/,
but/CC
an/DT
as/RB
yet/RB
unknown/JJ
,/,
p53-independent/JJ
pathway/NN
(/(
s/NNS
)/)
appears/VBZ
to/TO
mediate/VB
the/DT
same/JJ
event/NN
in/IN
mitogen-activated/JJ
mature/JJ
T/NN
lymphocytes/NNS
./.
====================
Here/RB
we/PRP
show/VBP
DNA/NN
damage-induced/JJ
apoptosis/NN
in/IN
these/DT
T/NN
lymphocytes/NNS
is/VBZ
dependent/JJ
on/IN
the/DT
antioncogenic/JJ
transcription/NN
factor/NN
interferon/NN
regulatory/JJ
factor/NN
(/(
IRF/NN
)/)
-1/CD
./.
====================
Thus/RB
two/CD
different/JJ
anti-onco-genic/JJ
transcription/NN
factors/NNS
,/,
p53/NN
and/CC
IRF-1/NN
,/,
are/VBP
required/VBN
for/IN
distinct/JJ
apoptotic/JJ
pathways/NNS
in/IN
T/NN
lymphocytes/NNS
./.
====================
We/PRP
also/RB
show/VBP
that/IN
mitogen/NN
induction/NN
of/IN
the/DT
interleukin-1/NN
beta/NN
converting/NN
enzyme/NN
(/(
ICE/NN
)/)
gene/NN
,/,
a/DT
mammalian/JJ
homologue/NN
of/IN
the/DT
Caenorhabditis/FW
elegans/FW
cell/NN
death/NN
gene/NN
ced-3/NN
,/,
is/VBZ
IRF-1-dependent/JJ
./.
====================
Ectopic/JJ
overexpression/NN
of/IN
IRF-1/NN
results/VBZ
in/IN
the/DT
activation/NN
of/IN
the/DT
endogenous/JJ
gene/NN
for/IN
ICE/NN
and/CC
enhances/VBZ
the/DT
sensitivity/NN
of/IN
cells/NNS
to/TO
radiation-induced/JJ
apoptosis/NN
./.
====================
UI/LS
-/:
91017623/CD
====================
TI/LS
-/:
Circadian/JJ
rhythm/NN
of/IN
glucocorticoid/NN
receptors/NNS
in/IN
human/JJ
peripheral/JJ
leukocytes/NNS
and/CC
their/PRP$
reactivity/NN
to/TO
glucocorticoids/NNS
./.
====================
AB/LS
-/:
1/LS
)/)
There/EX
exists/VBZ
a/DT
CR/NN
of/IN
GR/NN
in/IN
human/JJ
leukocytes/NNS
,/,
PMN/NN
,/,
and/CC
monocytes/NNS
with/IN
the/DT
peak/NN
values/NNS
from/IN
0400/CD
to/TO
0800/CD
hr/NN
and/CC
the/DT
trough/NN
values/NNS
between/IN
2300/CD
and/CC
0000/CD
hr/NN
./.
====================
The/DT
difference/NN
between/IN
them/PRP
was/VBD
significant/JJ
statistically/RB
./.
====================
2/LS
)/)
The/DT
FI/NN
of/IN
the/DT
chemotactic/JJ
migration/NN
rate/NN
of/IN
PMN/NN
by/IN
cortisol/NN
also/RB
showed/VBD
diurnal/JJ
changes/NNS
which/WDT
were/VBD
synchronous/JJ
with/IN
that/DT
of/IN
GR/NN
./.
====================
This/DT
indicates/VBZ
that/IN
the/DT
CR/NN
of/IN
GR/NN
may/MD
be/VB
of/IN
functional/JJ
significance/NN
./.
====================
3/LS
)/)
In/IN
Cushing/NN
's/POS
syndrome/NN
,/,
the/DT
CR/NN
of/IN
GR/NN
was/VBD
normal/JJ
in/IN
spite/NN
of/IN
the/DT
fact/NN
that/IN
the/DT
CR/NN
of/IN
plasma/NN
cortisol/NN
was/VBD
disturbed/VBN
./.
====================
This/DT
indicates/VBZ
the/DT
independency/NN
of/IN
the/DT
CR/NN
of/IN
GR/NN
from/IN
that/DT
of/IN
cortisol/NN
./.
====================
4/LS
)/)
In/IN
apoplexy/NN
caused/VBN
by/IN
brain/NN
ischemia/NN
,/,
the/DT
CR/NN
of/IN
GR/NN
was/VBD
abolished/VBN
in/IN
patients/NNS
with/IN
basal/JJ
lesions/NNS
but/CC
preserved/JJ
when/WRB
the/DT
lesions/NNS
were/VBD
located/JJ
in/IN
the/DT
cerebral/JJ
cortex/NN
./.
====================
These/DT
results/NNS
strongly/RB
suggest/VBP
that/IN
the/DT
main/JJ
"/``
circadian/JJ
pacemaker/NN
"/''
of/IN
GR/NN
is/VBZ
located/JJ
in/IN
the/DT
basal/JJ
brain/NN
,/,
most/RBS
probably/RB
in/IN
the/DT
suprachiasmatic/JJ
nuclei/NNS
as/IN
has/VBZ
been/VBN
suggested/VBN
for/IN
rodents/NNS
./.
====================
UI/LS
-/:
98005316/CD
====================
TI/LS
-/:
B-lymphoblastoid/JJ
cell/NN
lines/NNS
from/IN
multiple/JJ
sclerosis/NN
patients/NNS
and/CC
a/DT
healthy/JJ
control/NN
producing/VBG
a/DT
putative/JJ
new/JJ
human/JJ
retrovirus/NN
and/CC
Epstein-Barr/JJ
virus/NN
./.
====================
AB/LS
-/:
On/IN
several/JJ
occasions/NNS
we/PRP
have/VBP
observed/VBN
retrovirus-like/JJ
particles/NNS
(/(
RVLPs/NNS
)/)
by/IN
transmission/NN
electron/NN
microscopy/NN
(/(
EM/NN
)/)
of/IN
cultured/VBN
T/NN
cells/NNS
from/IN
a/DT
patient/NN
with/IN
MS/NN
./.
====================
Later/RB
we/PRP
established/VBD
spontaneously/RB
formed/VBN
B-lymphoblastoid/JJ
cell/NN
lines/NNS
(/(
LCLs/NNS
)/)
from/IN
a/DT
patient/NN
with/IN
an/DT
MS-like/JJ
disease/NN
and/CC
from/IN
another/DT
patient/NN
with/IN
MS/NN
who/WP
had/VBD
a/DT
reactivated/VBN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
infection/NN
./.
====================
Both/DT
LCLs/NNS
were/VBD
found/VBN
by/IN
EM/NN
to/TO
produce/VB
RVLP/NN
and/CC
EBV/NN
particles/NNS
./.
====================
Reverse/JJ
transcriptase/NN
(/(
RT/NN
)/)
assays/NNS
were/VBD
positive/JJ
in/IN
purified/VBN
viral/JJ
material/NN
from/IN
both/DT
LCLs/NNS
./.
====================
To/TO
substantiate/VB
these/DT
findings/NNS
we/PRP
initiated/VBD
an/DT
intensified/VBN
culturing/NN
procedure/NN
and/CC
were/VBD
able/JJ
to/TO
establish/VB
LCLs/NNS
from/IN
5/CD
out/RB
of/IN
21/CD
consecutive/JJ
MS/NN
patients/NNS
and/CC
1/CD
out/RB
of/IN
13/CD
consecutive/JJ
healthy/JJ
controls/NNS
./.
====================
All/DT
LCLs/NNS
were/VBD
found/VBN
to/TO
produce/VB
both/CC
RVLP/NN
and/CC
EBV/NN
particles/NNS
by/IN
EM/NN
./.
====================
Whether/IN
the/DT
putative/JJ
new/JJ
retrovirus/NN
(/(
es/NNS
)/)
and/CC
EBV/NN
have/VBP
any/DT
causal/JJ
relationship/NN
to/TO
MS/NN
is/VBZ
still/RB
not/RB
known/VBN
,/,
but/CC
the/DT
findings/NNS
support/VBP
this/DT
possibility/NN
./.
====================
UI/LS
-/:
96140672/CD
====================
TI/LS
-/:
Identification/NN
of/IN
an/DT
ionomycin/cyclosporin/NN
A-responsive/JJ
element/NN
within/IN
the/DT
human/JJ
T/NN
cell/NN
receptor/NN
gamma/NN
enhancer/NN
./.
====================
AB/LS
-/:
Activation/NN
through/IN
the/DT
Ca2+/NN
/calcineurin/NN
pathway/NN
is/VBZ
essential/JJ
to/TO
the/DT
transcription/NN
of/IN
many/JJ
cytokine/NN
genes/NNS
./.
====================
The/DT
conserved/VBN
cis-acting/NN
sequence/NN
,/,
GGAAAA/NN
,/,
and/CC
transcription/NN
factors/NNS
binding/VBG
to/TO
this/DT
sequence/NN
are/VBP
involved/VBN
in/IN
the/DT
response/NN
to/TO
increased/VBN
intracellular/JJ
Ca2+/NN
concentrations/NNS
./.
====================
Here/RB
we/PRP
report/VBP
the/DT
identification/NN
and/CC
importance/NN
of/IN
the/DT
same/JJ
sequence/NN
in/IN
a/DT
non-cytokine/JJ
gene/NN
,/,
the/DT
human/JJ
T/NN
cell/NN
receptor/NN
gamma/NN
(/(
TCRG/NN
)/)
enhancer/NN
./.
====================
Results/NNS
from/IN
site-directed/JJ
mutations/NNS
and/CC
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
strongly/RB
suggest/VBP
that/IN
this/DT
sequence/NN
mediates/VBZ
the/DT
ionomycin-induced/JJ
activation/NN
of/IN
the/DT
TCRG/NN
enhancer/NN
./.
====================
Our/PRP$
studies/NNS
provide/VBP
an/DT
explanation/NN
for/IN
a/DT
previous/JJ
observation/NN
that/IN
TCRG/NN
mRNA/NN
levels/NNS
,/,
but/CC
not/RB
mRNA/NN
levels/NNS
for/IN
T/NN
cell/NN
receptor/NN
alpha/NN
and/CC
-beta/NN
,/,
are/VBP
increased/VBN
by/IN
ionomycin/NN
treatment/NN
./.
====================
UI/LS
-/:
96074623/CD
====================
TI/LS
-/:
Coexpression/NN
of/IN
NF-kappa/NN
B/NN
/Rel/NN
and/CC
Sp1/NN
transcription/NN
factors/NNS
in/IN
human/JJ
immunodeficiency/NN
virus/NN
1-induced/JJ
,/,
dendritic/JJ
cell-T-cell/NN
syncytia/NN
./.
====================
AB/LS
-/:
Productive/JJ
infection/NN
of/IN
T/NN
cells/NNS
with/IN
human/JJ
immunodeficiency/NN
virus/NN
1/CD
(/(
HIV-1/NN
)/)
typically/RB
requires/VBZ
that/IN
the/DT
T/NN
cells/NNS
be/VB
stimulated/VBN
with/IN
antigens/NNS
or/CC
mitogens/NNS
./.
====================
This/DT
requirement/NN
has/VBZ
been/VBN
attributed/VBN
to/TO
the/DT
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
,/,
which/WDT
synergizes/VBZ
with/IN
the/DT
constitutive/JJ
transcription/NN
factor/NN
Sp1/NN
to/TO
drive/VB
the/DT
HIV-1/NN
promoter/NN
./.
====================
Recently/RB
,/,
we/PRP
have/VBP
found/VBN
that/IN
vigorous/JJ
replication/NN
of/IN
HIV-1/NN
takes/VBZ
place/NN
in/IN
nonactivated/JJ
memory/NN
T/NN
cells/NNS
after/IN
syncytium/NN
formation/NN
with/IN
dendritic/JJ
cells/NNS
(/(
DCs/NNS
)/)
./.
====================
These/DT
syncytia/NNS
lack/VBP
activated/VBN
cells/NNS
as/IN
determined/VBN
by/IN
an/DT
absence/NN
of/IN
staining/VBG
for/IN
Ki-67/NN
cell/NN
cycle/NN
antigen/NN
./.
====================
The/DT
expression/NN
and/CC
activity/NN
of/IN
NF-kappa/NN
B/NN
and/CC
Sp1/NN
were/VBD
,/,
therefore/RB
,/,
analyzed/VBN
in/IN
isolated/VBN
T/NN
cells/NNS
and/CC
DCs/NNS
from/IN
humans/NNS
and/CC
mice/NNS
./.
====================
We/PRP
have/VBP
used/VBN
immunolabeling/NN
,/,
Western/NN
blot/NN
analysis/NN
,/,
and/CC
electrophoretic/JJ
mobility/NN
shift/NN
and/CC
supershift/NN
assays/NNS
./.
====================
T/NN
cells/NNS
lack/VBP
active/JJ
NF-kappa/NN
B/NN
but/CC
express/VBP
Sp1/NN
as/IN
expected/VBN
./.
====================
DCs/NNS
express/VBP
high/JJ
levels/NNS
of/IN
all/DT
known/JJ
NF-kappa/NN
B/NN
and/CC
Rel/NN
proteins/NNS
,/,
with/IN
activity/NN
residing/VBG
primarily/RB
within/IN
RelB/NN
,/,
p50/NN
,/,
and/CC
p65/NN
./.
====================
However/RB
,/,
DCs/NNS
lack/VBP
Sp1/NN
,/,
which/WDT
may/MD
explain/VB
the/DT
failure/NN
of/IN
HIV-1/NN
to/TO
replicate/VB
in/IN
purified/VBN
DCs/NNS
./.
====================
Coexpression/NN
of/IN
NF-kappa/NN
B/NN
and/CC
Sp1/NN
occurs/VBZ
in/IN
the/DT
heterologous/JJ
DC-T-cell/NN
syncytia/NN
that/WDT
are/VBP
induced/VBN
by/IN
HIV-1/NN
./.
====================
Therefore/RB
,/,
HIV-1-induced/JJ
cell/NN
fusion/NN
brings/VBZ
together/RB
factors/NNS
that/WDT
upregulate/VBP
virus/NN
transcription/NN
./.
====================
Since/IN
DCs/NNS
and/CC
memory/NN
T/NN
cells/NNS
frequently/RB
traffic/VBP
together/RB
in/FW
situ/FW
,/,
these/DT
unusual/JJ
heterologous/JJ
syncytia/NN
could/MD
develop/VB
in/IN
infected/JJ
individuals/NNS
and/CC
lead/VB
to/TO
chronic/JJ
HIV-1/NN
replication/NN
without/IN
ostensible/JJ
immune/JJ
stimulation/NN
./.
====================
UI/LS
-/:
96063646/CD
====================
TI/LS
-/:
Cupric/JJ
ion/NN
blocks/VBZ
NF/NN
kappa/NN
B/NN
activation/NN
through/IN
inhibiting/VBG
the/DT
signal-induced/JJ
phosphorylation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
./.
====================
AB/LS
-/:
A/DT
transcription/NN
factor/NN
NF/NN
kappa/NN
B/NN
,/,
which/WDT
regulates/VBZ
expression/NN
of/IN
various/JJ
cellular/JJ
genes/NNS
involved/VBN
in/IN
immune/JJ
responses/NNS
and/CC
viral/JJ
genes/NNS
including/VBG
HIV/NN
,/,
is/VBZ
sequestered/VBN
in/IN
the/DT
cytoplasm/NN
as/IN
a/DT
complex/NN
with/IN
an/DT
inhibitory/JJ
protein/NN
I/NN
kappa/NN
B/NN
./.
====================
Various/JJ
extracellular/JJ
signals/NNS
induce/VBP
phosphorylation/NN
and/CC
rapid/JJ
degradation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
to/TO
release/VB
NF/NN
kappa/NN
B/NN
./.
====================
Cu2+/NN
was/VBD
found/VBN
to/TO
inhibit/VB
the/DT
activation/NN
of/IN
NF/NN
kappa/NN
B/NN
induced/VBN
by/IN
TNF-alpha/NN
,/,
TPA/NN
,/,
or/CC
H2O2/NN
./.
====================
Deoxycholate/NN
treatment/NN
of/IN
the/DT
cytoplasmic/JJ
extract/NN
prepared/VBN
from/IN
cells/NNS
stimulated/VBN
by/IN
TNF-alpha/NN
in/IN
the/DT
presence/NN
of/IN
Cu2+/NN
resulted/VBD
in/IN
the/DT
release/NN
of/IN
NF/NN
kappa/NN
B/NN
from/IN
I/NN
kappa/NN
B/NN
alpha/NN
,/,
indicating/VBG
that/IN
Cu2+/NN
interferes/VBZ
with/IN
the/DT
dissociation/NN
of/IN
the/DT
NF/NN
kappa/NN
B-I/NN
kappa/NN
B/NN
complex/NN
./.
====================
Neither/CC
phosphorylation/NN
nor/CC
degradation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
was/VBD
observed/VBN
upon/IN
TNF-alpha/NN
stimulation/NN
in/IN
the/DT
presence/NN
of/IN
Cu2+/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
Cu2+/NN
inhibits/VBZ
the/DT
release/NN
of/IN
NF/NN
kappa/NN
B/NN
by/IN
blockade/NN
of/IN
a/DT
signal/NN
leading/VBG
to/TO
the/DT
phosphorylation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
./.
====================
UI/LS
-/:
96038813/CD
====================
TI/LS
-/:
Cloning/VBG
a/DT
cDNA/NN
from/IN
human/JJ
NK/T/NN
cells/NNS
which/WDT
codes/VBZ
for/IN
a/DT
protein/NN
with/IN
high/JJ
proline/NN
content/NN
./.
====================
AB/LS
-/:
A/DT
cDNA/NN
clone/NN
,/,
B4-2/NN
,/,
was/VBD
isolated/VBN
from/IN
a/DT
natural/JJ
killer/NN
(/(
NK/NN
)/)
minus/CC
T/NN
cell/NN
subtractive/JJ
library/NN
./.
====================
The/DT
B4-2/NN
clone/NN
coded/VBD
for/IN
an/DT
mRNA/NN
of/IN
2061/CD
bp/NN
in/IN
length/NN
./.
====================
It/PRP
encodes/VBZ
a/DT
deduced/VBN
327/CD
aa/NN
protein/NN
with/IN
a/DT
calculated/VBN
molecular/JJ
mass/NN
of/IN
35.2/CD
kDa/NN
./.
====================
Searching/NN
of/IN
B4-2/NN
DNA/NN
and/CC
protein/NN
sequences/NNS
against/IN
various/JJ
databases/NNS
revealed/VBD
no/DT
high/JJ
homology/NN
to/TO
other/JJ
sequences/NNS
./.
====================
However/RB
,/,
B4-2/NN
has/VBZ
an/DT
unusually/RB
high/JJ
proline/NN
content/NN
(/(
13/CD
%/NN
)/)
,/,
contains/VBZ
a/DT
putative/JJ
nuclear/JJ
targeting/NN
sequence/NN
,/,
and/CC
has/VBZ
several/JJ
SPXX/NN
motifs/NNS
which/WDT
are/VBP
frequently/RB
found/VBN
in/IN
gene/NN
regulatory/JJ
proteins/NNS
./.
====================
One/CD
of/IN
the/DT
stretches/NNS
of/IN
prolines/NNS
in/IN
B4-2/NN
closely/RB
resembles/VBZ
the/DT
ligand/NN
for/IN
proteins/NNS
with/IN
SH3/NN
domains/NNS
./.
====================
Northern/NN
hybridization/NN
data/NNS
showed/VBD
that/IN
B4-2/NN
is/VBZ
not/RB
a/DT
lymphoid/JJ
specific/JJ
gene/NN
and/CC
is/VBZ
expressed/VBN
in/IN
a/DT
hepatoma/NN
cell/NN
line/NN
and/CC
also/RB
weakly/RB
transcribed/VBN
or/CC
absent/JJ
in/IN
a/DT
variety/NN
of/IN
other/JJ
cells/NNS
./.
====================
A/DT
polyclonal/JJ
antiserum/NN
raised/VBN
against/IN
recombinant/JJ
B4-2/NN
recognizes/VBZ
a/DT
32-34/CD
kDa/NN
protein/NN
in/IN
lymphocytes/NNS
./.
====================
UI/LS
-/:
96127450/CD
====================
TI/LS
-/:
Activation/NN
of/IN
JAK3/NN
,/,
but/CC
not/RB
JAK1/NN
,/,
is/VBZ
critical/JJ
for/IN
IL-2-induced/JJ
proliferation/NN
and/CC
STAT5/NN
recruitment/NN
by/IN
a/DT
COOH-terminal/JJ
region/NN
of/IN
the/DT
IL-2/NN
receptor/NN
beta-chain/NN
./.
====================
AB/LS
-/:
A/DT
number/NN
of/IN
cytokines/NNS
and/CC
growth/NN
factors/NNS
use/VBP
the/DT
JAK-STAT/NN
pathway/NN
to/TO
signal/VB
from/IN
the/DT
cell/NN
membrane/NN
to/TO
the/DT
nucleus/NN
./.
====================
While/IN
homodimerizing/VBG
cytokine/NN
receptors/NNS
may/MD
transmit/VB
signal/NN
via/IN
a/DT
single/JJ
form/NN
of/IN
JAK/NN
(/(
i.e./FW
growth/NN
hormone/NN
receptors/NNS
)/)
,/,
several/JJ
multicomponent/JJ
cytokine/NN
receptors/NNS
have/VBP
been/VBN
shown/VBN
to/TO
require/VB
simultaneous/JJ
activation/NN
of/IN
pairs/NNS
of/IN
different/JJ
JAK/NN
kinases/NNS
(/(
i.e./FW
interferon/NN
receptors/NNS
)/)
./.
====================
Recent/JJ
evidence/NN
for/IN
a/DT
preferential/JJ
coupling/NN
of/IN
JAK3/NN
to/TO
interleukin-2/NN
receptor-gamma/NN
(/(
IL-2R/NN
gamma/NN
)/)
and/CC
JAK1/NN
to/TO
IL-2R/NN
beta/NN
supports/VBZ
the/DT
concept/NN
of/IN
heterotrans-activation/NN
of/IN
JAK1/NN
and/CC
JAK3/NN
caused/VBN
by/IN
IL-2-induced/JJ
heterodimerization/NN
of/IN
their/PRP$
receptor/NN
partners/NNS
./.
====================
The/DT
present/JJ
study/NN
verified/VBD
the/DT
ability/NN
of/IN
IL-2/NN
to/TO
cause/VB
tyrosine/NN
phosphorylation/NN
and/CC
activation/NN
of/IN
JAK1/NN
and/CC
JAK3/NN
,/,
but/CC
demonstrated/VBD
that/IN
IL-2/NN
stimulated/VBD
JAK3/NN
to/TO
a/DT
significantly/RB
larger/JJR
extent/NN
than/IN
JAK1/NN
in/IN
human/JJ
T/NN
lymphocytes/NNS
and/CC
the/DT
YT/NN
cell/NN
line/NN
./.
====================
This/DT
conclusion/NN
was/VBD
based/VBN
upon/IN
several/JJ
independent/JJ
criteria/NNS
,/,
including/VBG
more/RBR
vigorous/JJ
tyrosine/NN
phosphorylation/NN
of/IN
JAK3/NN
,/,
more/RBR
marked/JJ
enzymatic/JJ
activation/NN
of/IN
JAK3/NN
as/RB
well/RB
as/IN
higher/JJR
abundance/NN
of/IN
JAK3/NN
in/IN
activated/VBN
IL-2/NN
receptor/NN
complexes/NNS
./.
====================
Furthermore/RB
,/,
when/WRB
human/JJ
IL-2R/NN
beta/NN
was/VBD
stably/RB
expressed/VBN
in/IN
murine/JJ
BA/F3/NN
cells/NNS
,/,
robust/JJ
IL-2-induced/JJ
proliferation/NN
and/CC
JAK3/NN
activation/NN
occurred/VBD
without/IN
detectable/JJ
involvement/NN
of/IN
either/CC
JAK1/NN
,/,
JAK2/NN
or/CC
TYK2/NN
./.
====================
We/PRP
therefore/RB
propose/VBP
that/IN
IL-2/NN
receptor/NN
signal/NN
transduction/NN
does/VBZ
not/RB
depend/VB
on/IN
equimolar/JJ
heterodimerization/NN
of/IN
JAK1/NN
and/CC
JAK3/NN
following/VBG
IL-2-induced/JJ
heterodimerization/NN
of/IN
IL-2R/NN
beta/NN
and/CC
IL-2R/NN
gamma/NN
./.
====================
Nonetheless/RB
,/,
a/DT
membrane-proximal/JJ
region/NN
of/IN
human/JJ
IL-2R/NN
beta/NN
(/(
Asn240-Leu335/NN
)/)
was/VBD
critical/JJ
for/IN
JAK3/NN
activation/NN
,/,
and/CC
the/DT
amount/NN
of/IN
JAK3/NN
present/JJ
in/IN
activated/VBN
IL-2/NN
receptor/NN
complexes/NNS
increased/VBD
with/IN
time/NN
,/,
suggesting/VBG
that/IN
stabilization/NN
of/IN
JAK3/NN
binding/NN
to/TO
the/DT
receptor/NN
complex/NN
relies/VBZ
on/IN
both/CC
IL-2R/NN
beta/NN
and/CC
IL-2R/NN
gamma/NN
./.
====================
Moreover/RB
,/,
STAT5/NN
was/VBD
found/VBN
to/TO
be/VB
the/DT
predominant/JJ
STAT/NN
transcription/NN
factor/NN
used/VBN
by/IN
IL-2/NN
in/IN
human/JJ
T/NN
cells/NNS
,/,
and/CC
specifically/RB
required/VBD
a/DT
COOH-terminal/JJ
region/NN
of/IN
IL-2R/NN
beta/NN
(/(
Ser386-Val525/NN
)/)
,/,
while/IN
STAT5/NN
recruitment/NN
was/VBD
not/RB
correlated/VBN
to/TO
activation/NN
of/IN
IL-2R/NN
gamma/NN
or/CC
JAK3/NN
./.
====================
UI/LS
-/:
96001293/CD
====================
TI/LS
-/:
Up-regulation/NN
of/IN
high-affinity/JJ
dehydroepiandrosterone/NN
binding/NN
activity/NN
by/IN
dehydroepiandrosterone/NN
in/IN
activated/VBN
human/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Although/IN
evidence/NN
indicates/VBZ
that/IN
dehydroepiandrosterone/NN
(/(
DHEA/NN
)/)
exerts/VBZ
direct/JJ
physiological/JJ
effects/NNS
,/,
its/PRP$
mechanism/NN
of/IN
action/NN
remains/VBZ
unknown/JJ
./.
====================
DHEA/NN
binding/NN
sites/NNS
were/VBD
examined/VBN
using/VBG
a/DT
whole-cell/JJ
binding/NN
assay/NN
in/IN
a/DT
human/JJ
T/NN
lymphoid/JJ
cell/NN
line/NN
,/,
PEER/NN
,/,
revealing/VBG
that/IN
a/DT
single/JJ
class/NN
of/IN
high-affinity/JJ
binding/VBG
sites/NNS
for/IN
DHEA/NN
(/(
dissociation/NN
constant/NN
=/JJ
7.4/CD
+/-/CC
0.53/CD
nmol/L/NN
,/,
mean/NN
+/-/CC
SE/NN
,/,
n/NN
=/JJ
4/CD
)/)
was/VBD
greatly/RB
increased/VBN
when/WRB
treated/VBN
with/IN
DHEA/NN
,/,
phorbol-12-myristate-13-acetate/NN
,/,
and/CC
the/DT
Ca2+/NN
ionophore/NN
A23187/NN
./.
====================
Bound/VBN
[3H]DHEA/NN
was/VBD
displaced/JJ
sensitively/RB
by/IN
DHEA/NN
and/CC
secondarily/RB
by/IN
dihydrotestosterone/NN
,/,
but/CC
not/RB
effectively/RB
by/IN
other/JJ
steroids/NNS
,/,
including/VBG
DHEA/NN
sulfate/NN
./.
====================
These/DT
results/NNS
not/RB
only/RB
indicate/VBP
the/DT
existence/NN
of/IN
a/DT
DHEA/NN
receptor/NN
,/,
but/CC
also/RB
suggest/VBP
that/IN
T/NN
cells/NNS
become/VBP
susceptible/JJ
to/TO
regulation/NN
by/IN
DHEA/NN
during/IN
the/DT
process/NN
of/IN
signal-induced/JJ
activation/NN
./.
====================
UI/LS
-/:
95394931/CD
====================
TI/LS
-/:
Ubiquitin-mediated/JJ
processing/NN
of/IN
NF-kappa/NN
B/NN
transcriptional/JJ
activator/NN
precursor/NN
p105/NN
./.
====================
Reconstitution/NN
of/IN
a/DT
cell-free/JJ
system/NN
and/CC
identification/NN
of/IN
the/DT
ubiquitin-carrier/JJ
protein/NN
,/,
E2/NN
,/,
and/CC
a/DT
novel/JJ
ubiquitin-protein/JJ
ligase/NN
,/,
E3/NN
,/,
involved/VBN
in/IN
conjugation/NN
./.
====================
AB/LS
-/:
In/IN
most/JJS
cases/NNS
,/,
the/DT
transcriptional/JJ
factor/NN
NF-kappa/NN
B/NN
is/VBZ
a/DT
heterodimer/NN
consisting/VBG
of/IN
two/CD
subunits/NNS
,/,
p50/NN
and/CC
p65/NN
,/,
which/WDT
are/VBP
encoded/VBN
by/IN
two/CD
distinct/JJ
genes/NNS
of/IN
the/DT
Rel/NN
family/NN
./.
====================
p50/NN
is/VBZ
translated/VBN
as/IN
a/DT
precursor/NN
of/IN
105/CD
kDa/NN
./.
====================
The/DT
C-terminal/JJ
domain/NN
of/IN
the/DT
precursor/NN
is/VBZ
rapidly/RB
degraded/VBN
,/,
forming/VBG
the/DT
mature/JJ
p50/NN
subunit/NN
consisted/VBN
of/IN
the/DT
N-terminal/JJ
region/NN
of/IN
the/DT
molecule/NN
./.
====================
The/DT
mechanism/NN
of/IN
generation/NN
of/IN
p50/NN
is/VBZ
not/RB
known/VBN
./.
====================
It/PRP
has/VBZ
been/VBN
suggested/VBN
that/IN
the/DT
ubiquitin-proteasome/JJ
system/NN
is/VBZ
involved/VBN
in/IN
the/DT
process/NN
;/:
however/RB
,/,
the/DT
specific/JJ
enzymes/NNS
involved/VBN
and/CC
the/DT
mechanism/NN
of/IN
limited/JJ
proteolysis/NN
,/,
in/IN
which/WDT
half/NN
of/IN
the/DT
molecule/NN
is/VBZ
spared/VBN
,/,
have/VBP
been/VBN
obscure/JJ
./.
====================
Palombella/NNP
and/CC
colleagues/NNS
(/(
Palombella/NNP
,/,
V.J./NNP
,/,
Rando/NNP
,/,
O.J./NNP
,/,
Goldberg/NNP
,/,
A.L./NNP
,/,
and/CC
Maniatis/NNP
,/,
T./NNP
(/(
1994/CD
)/)
Cell/NNP
78/CD
,/,
773-785/CD
)/)
have/VBP
shown/VBN
that/IN
ubiquitin/NN
is/VBZ
required/VBN
for/IN
the/DT
processing/NN
in/IN
a/DT
cell-free/JJ
system/NN
of/IN
a/DT
truncated/VBN
,/,
artificially/RB
constructed/VBN
,/,
60-kDa/JJ
precursor/NN
./.
====================
They/PRP
have/VBP
also/RB
shown/VBN
that/IN
proteasome/NN
inhibitors/NNS
block/VBP
the/DT
processing/NN
both/CC
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
demonstrate/VBP
reconstitution/NN
of/IN
a/DT
cell-free/JJ
processing/NN
system/NN
and/CC
demonstrate/VBP
directly/RB
that/IN
:/:
(/(
a/LS
)/)
the/DT
ubiquitin-proteasome/JJ
system/NN
is/VBZ
involved/VBN
in/IN
processing/NN
of/IN
the/DT
intact/JJ
p105/NN
precursor/NN
,/,
(/(
b/LS
)/)
conjugation/NN
of/IN
ubiquitin/NN
to/TO
the/DT
precursor/NN
is/VBZ
an/DT
essential/JJ
intermediate/JJ
step/NN
in/IN
the/DT
processing/NN
,/,
(/(
c/LS
)/)
the/DT
recently/RB
discovered/VBN
novel/JJ
species/NNS
of/IN
the/DT
ubiquitin-carrier/JJ
protein/NN
,/,
E2-F1/NN
,/,
that/WDT
is/VBZ
involved/VBN
in/IN
the/DT
conjugation/NN
and/CC
degradation/NN
of/IN
p53/NN
,/,
is/VBZ
also/RB
required/VBN
for/IN
the/DT
limited/JJ
processing/NN
of/IN
the/DT
p105/NN
precursor/NN
,/,
and/CC
(/(
d/LS
)/)
a/DT
novel/JJ
,/,
approximately/RB
320-kDa/CD
species/NNS
of/IN
ubiquitin-protein/JJ
ligase/NN
,/,
is/VBZ
involved/VBN
in/IN
the/DT
process/NN
./.
====================
This/DT
novel/JJ
enzyme/NN
is/VBZ
distinct/JJ
from/IN
E6-AP/NN
,/,
the/DT
p53-conjugating/NN
ligase/NN
,/,
and/CC
from/IN
E3/NN
alpha/NN
,/,
the/DT
"/``
N-end/JJ
rule/NN
"/''
ligase/NN
./.
====================
UI/LS
-/:
95369491/CD
====================
TI/LS
-/:
Flutamide/NN
in/IN
the/DT
treatment/NN
of/IN
hirsutism/NN
:/:
long-term/JJ
clinical/JJ
effects/NNS
,/,
endocrine/JJ
changes/NNS
,/,
and/CC
androgen/NN
receptor/NN
behavior/NN
./.
====================
AB/LS
-/:
OBJECTIVE/NN
:/:
To/TO
investigate/VB
the/DT
long-term/JJ
effects/NNS
of/IN
treatment/NN
with/IN
low/JJ
doses/NNS
of/IN
flutamide/NN
on/IN
clinical/JJ
and/CC
hormonal/JJ
parameters/NNS
,/,
as/RB
well/RB
as/IN
on/IN
the/DT
androgen/NN
receptor/NN
status/NN
,/,
in/IN
hirsute/JJ
women/NNS
./.
====================
DESIGN/NN
:/:
Eighteen/CD
hirsute/JJ
patients/NNS
with/IN
regular/JJ
menses/NNS
were/VBD
studied/VBN
basally/RB
and/CC
during/IN
treatment/NN
with/IN
125/CD
mg/NN
flutamide/NN
,/,
three/CD
times/NNS
per/IN
day/NN
for/IN
12/CD
months/NNS
./.
====================
Barrier/NN
or/CC
intrauterine/JJ
contraception/NN
was/VBD
used/VBN
during/IN
the/DT
study/NN
in/IN
sexually/RB
active/JJ
women/NNS
./.
====================
Safety/NN
parameters/NNS
were/VBD
assessed/VBN
throughout/IN
the/DT
study/NN
./.
====================
Hirsutism/NN
,/,
graded/VBN
by/IN
the/DT
modified/VBN
Ferriman-Gallwey/JJ
score/NN
,/,
and/CC
hormonal/JJ
parameters/NNS
were/VBD
evaluated/VBN
basally/RB
and/CC
at/IN
4-month/JJ
intervals/NNS
during/IN
treatment/NN
./.
====================
Gonadotropin-releasing/JJ
hormone/NN
and/CC
ACTH/NN
stimulation/NN
tests/NNS
were/VBD
performed/VBN
before/IN
and/CC
after/IN
3/CD
to/TO
4/CD
months/NNS
of/IN
therapy/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
concentration/NN
of/IN
androgen/NN
receptors/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
was/VBD
measured/VBN
,/,
in/IN
both/CC
the/DT
follicular/JJ
and/CC
luteal/JJ
phases/NNS
of/IN
the/DT
menstrual/JJ
cycle/NN
,/,
basally/RB
and/CC
after/IN
4/CD
months/NNS
of/IN
flutamide/NN
treatment/NN
./.
====================
RESULTS/NNS
:/:
Flutamide/NN
was/VBD
well/RB
tolerated/VBN
in/IN
all/DT
women/NNS
,/,
with/IN
the/DT
noticeable/JJ
exception/NN
of/IN
one/CD
patient/NN
who/WP
presented/VBD
increased/VBN
serum/NN
transaminase/NN
after/IN
8/CD
months/NNS
of/IN
therapy/NN
./.
====================
Hirsutism/NN
markedly/RB
improved/VBD
in/IN
all/DT
women/NNS
during/IN
the/DT
treatment/NN
(/(
Ferriman-Gallwey/JJ
score/NN
after/IN
1/CD
year/NN
:/:
4.1/CD
+/-/CC
0.5/CD
versus/CC
14.1/CD
+/-/CC
0.9/CD
)/)
./.
====================
A/DT
reduction/NN
of/IN
serum/NN
androgens/NNS
was/VBD
found/VBN
,/,
whereas/IN
no/DT
change/NN
was/VBD
observed/VBN
in/IN
either/CC
basal/JJ
or/CC
GnRH-stimulated/JJ
gonadotropins/NNS
or/CC
in/IN
the/DT
cortisol/NN
and/CC
17/CD
alpha-hydroxyprogesterone/NN
response/NN
to/TO
ACTH/NN
./.
====================
Cycles/NNS
remained/VBD
ovulatory/JJ
./.
====================
Before/IN
treatment/NN
,/,
the/DT
number/NN
of/IN
androgen/NN
receptors/NNS
was/VBD
higher/JJR
in/IN
the/DT
luteal/NN
than/IN
in/IN
the/DT
follicular/JJ
phase/NN
./.
====================
This/DT
rhythmic/JJ
differentiation/NN
disappeared/VBD
after/IN
the/DT
patients/NNS
had/VBD
been/VBN
given/VBN
the/DT
antiandrogen/JJ
drug/NN
./.
====================
CONCLUSIONS/NNS
:/:
Flutamide/NN
is/VBZ
effective/JJ
in/IN
the/DT
treatment/NN
of/IN
hirsutism/NN
but/CC
requires/VBZ
constant/JJ
surveillance/NN
of/IN
liver/NN
function/NN
./.
====================
Androgen/NN
receptor/NN
blockade/NN
might/MD
be/VB
potentiated/VBN
by/IN
a/DT
reduction/NN
of/IN
serum/NN
androgens/NNS
./.
====================
Flutamide/NN
affects/VBZ
androgen/NN
receptor/NN
behavior/NN
during/IN
the/DT
menstrual/JJ
cycle/NN
./.
====================
The/DT
meaning/NN
of/IN
this/DT
finding/NN
remains/VBZ
to/TO
be/VB
elucidated/VBN
./.
====================
UI/LS
-/:
90188846/CD
====================
TI/LS
-/:
Constitutive/JJ
expression/NN
of/IN
HIV-1/NN
tat/NN
protein/NN
in/IN
human/JJ
Jurkat/NN
T/NN
cells/NNS
using/VBG
a/DT
BK/NN
virus/NN
vector/NN
./.
====================
AB/LS
-/:
The/DT
production/NN
and/CC
characterization/NN
of/IN
Jurkat/NN
cell/NN
lines/NNS
that/WDT
constitutively/RB
express/VBP
functional/JJ
human/JJ
immune/JJ
deficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
tat/NN
protein/NN
,/,
using/VBG
a/DT
BK/NN
virus/NN
plasmid/NN
expression/NN
vector/NN
and/CC
HIV-1/NN
tat/NN
cDNA/NN
,/,
is/VBZ
described/VBN
./.
====================
An/DT
increased/VBN
growth/NN
rate/NN
of/IN
these/DT
Jurkat-tat/NN
cell/NN
lines/NNS
as/IN
compared/VBN
with/IN
control/JJ
cell/NN
lines/NNS
was/VBD
observed/VBN
./.
====================
UI/LS
-/:
96125073/CD
====================
TI/LS
-/:
A/DT
PEBP2/NN
alpha/AML-1-related/JJ
factor/NN
increases/VBZ
osteocalcin/NN
promoter/NN
activity/NN
through/IN
its/PRP$
binding/NN
to/TO
an/DT
osteoblast-specific/JJ
cis-acting/JJ
element/NN
./.
====================
AB/LS
-/:
To/TO
identify/VB
osteoblast-specific/JJ
cis-acting/JJ
elements/NNS
and/CC
trans-acting/JJ
factors/NNS
,/,
we/PRP
initiated/VBD
an/DT
analysis/NN
of/IN
the/DT
promoter/NN
of/IN
a/DT
mouse/NN
osteocalcin/NN
gene/NN
,/,
an/DT
osteoblast-specific/JJ
gene/NN
./.
====================
In/IN
this/DT
promoter/NN
,/,
we/PRP
identified/VBD
two/CD
osteoblast-specific/JJ
cis-acting/JJ
elements/NNS
(/(
Ducy/NNP
,/,
P./NNP
and/CC
Karsenty/NNP
,/,
G./NNP
(/(
1995/CD
)/)
Mol.Cell.Biol.15/NNP
,/,
1858-1869/CD
)/)
./.
====================
The/DT
sequence/NN
of/IN
one/CD
of/IN
these/DT
elements/NNS
,/,
OSE2/NN
,/,
is/VBZ
identical/JJ
to/TO
the/DT
DNA-binding/JJ
site/NN
of/IN
the/DT
PEBP2/NN
alpha/AML-1/NN
transcription/NN
factors/NNS
,/,
the/DT
mammalian/JJ
homologues/NNS
of/IN
the/DT
Drosophila/FW
Runt/NN
protein/NN
./.
====================
Here/RB
we/PRP
show/VBP
,/,
using/VBG
nuclear/JJ
extracts/NNS
,/,
recombinant/JJ
protein/NN
,/,
and/CC
a/DT
specific/JJ
antiserum/NN
against/IN
AML-1/NN
proteins/NNS
in/IN
DNA-binding/JJ
assays/NNS
,/,
that/IN
one/CD
member/NN
of/IN
this/DT
family/NN
,/,
AML-1B/NN
,/,
binds/VBZ
specifically/RB
to/TO
OSE2/NN
and/CC
is/VBZ
immunologically/RB
related/JJ
to/TO
OSF2/NN
,/,
the/DT
factor/NN
present/JJ
in/IN
osteoblast/NN
nuclear/JJ
extracts/NNS
that/WDT
binds/VBZ
to/TO
OSE2/NN
./.
====================
By/IN
DNA/NN
cotransfection/NN
experiments/NNS
,/,
we/PRP
also/RB
demonstrate/VBP
that/IN
AML-1B/NN
can/MD
increase/VB
the/DT
activity/NN
of/IN
a/DT
short/JJ
osteocalcin/NN
promoter/NN
through/IN
its/PRP$
binding/NN
to/TO
OSE2/NN
./.
====================
Lastly/RB
,/,
the/DT
different/JJ
mobilities/NNS
of/IN
osteoblast/NN
nuclear/JJ
extract-DNA/JJ
complexes/NNS
compared/VBN
with/IN
T-cell/NN
nuclear/JJ
extract-DNA/JJ
complexes/NNS
,/,
along/IN
with/IN
the/DT
inability/NN
of/IN
OSF2/NN
to/TO
be/VB
upregulated/VBN
by/IN
retinoic/JJ
acid/NN
,/,
unlike/IN
the/DT
other/JJ
PEBP2/NN
alpha/NN
factors/NNS
,/,
suggest/VBP
that/IN
OSF2/NN
is/VBZ
a/DT
new/JJ
member/NN
of/IN
this/DT
family/NN
of/IN
transcription/NN
factors/NNS
./.
====================
Thus/RB
,/,
this/DT
study/NN
demonstrates/VBZ
that/IN
AML-1B/NN
can/MD
increase/VB
gene/NN
expression/NN
of/IN
an/DT
osteoblast-specific/JJ
gene/NN
through/IN
its/PRP$
binding/NN
to/TO
an/DT
osteoblast-specific/JJ
cis-acting/JJ
element/NN
and/CC
presents/VBZ
evidence/NN
that/IN
OSF2/NN
is/VBZ
a/DT
member/NN
of/IN
the/DT
PEBP2/NN
alpha/AML-1/NN
family/NN
of/IN
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
96069375/CD
====================
TI/LS
-/:
Initiation/NN
binding/NN
repressor/NN
,/,
a/DT
factor/NN
that/WDT
binds/VBZ
to/TO
the/DT
transcription/NN
initiation/NN
site/NN
of/IN
the/DT
histone/NN
h5/NN
gene/NN
,/,
is/VBZ
a/DT
glycosylated/VBN
member/NN
of/IN
a/DT
family/NN
of/IN
cell/NN
growth/NN
regulators/NNS
[/(
corrected/JJ
]/)
[/(
published/VBN
erratum/NN
appears/VBZ
in/IN
Mol/NNP
Cell/NNP
Biol/NNP
1996/CD
Feb/NNP
;/:
16/CD
(/(
2/CD
)/)
:/:
735/CD
]/)
====================
AB/LS
-/:
Initiation/NN
binding/NN
repressor/NN
[/(
corrected/VBN
]/)
(/(
IBR/NN
)/)
is/VBZ
a/DT
chicken/NN
erythrocyte/NN
factor/NN
(/(
apparent/JJ
molecular/JJ
mass/NN
,/,
70/CD
to/TO
73/CD
kDa/NN
)/)
that/WDT
binds/VBZ
to/TO
the/DT
sequences/NNS
spanning/VBG
the/DT
transcription/NN
initiation/NN
site/NN
of/IN
the/DT
histone/NN
h5/NN
gene/NN
,/,
repressing/VBG
its/PRP$
transcription/NN
./.
====================
A/DT
variety/NN
of/IN
other/JJ
cells/NNS
,/,
including/VBG
transformed/VBN
erythroid/JJ
precursors/NNS
,/,
do/VBP
not/RB
have/VB
IBR/NN
but/CC
a/DT
factor/NN
referred/VBN
to/TO
as/IN
IBF/NN
(/(
68/CD
to/TO
70/CD
kDa/NN
)/)
that/WDT
recognizes/VBZ
the/DT
same/JJ
IBR/NN
sites/NNS
./.
====================
We/PRP
have/VBP
cloned/VBN
the/DT
IBR/NN
cDNA/NN
and/CC
studied/VBN
the/DT
relationship/NN
of/IN
IBR/NN
and/CC
IBF/NN
./.
====================
IBR/NN
is/VBZ
a/DT
503-amino-acid-long/JJ
acidic/JJ
protein/NN
which/WDT
is/VBZ
99.0/CD
%/NN
identical/JJ
to/TO
the/DT
recently/RB
reported/VBN
human/JJ
NRF-1/alpha-Pal/NN
factor/NN
and/CC
highly/RB
related/JJ
to/TO
the/DT
invertebrate/JJ
transcription/NN
factors/NNS
P3A2/NN
and/CC
erected/JJ
wing/NN
gene/NN
product/NN
(/(
EWG/NN
)/)
./.
====================
We/PRP
present/VBP
evidence/NN
that/IN
IBR/NN
and/CC
IBF/NN
are/VBP
most/RBS
likely/RB
identical/JJ
proteins/NNS
,/,
differing/VBG
in/IN
their/PRP$
degree/NN
of/IN
glycosylation/NN
./.
====================
We/PRP
have/VBP
analyzed/VBN
several/JJ
molecular/JJ
aspects/NNS
of/IN
IBR/F/NN
and/CC
shown/VBN
that/IN
the/DT
factor/NN
associates/VBZ
as/IN
stable/JJ
homodimers/NNS
and/CC
that/IN
the/DT
dimer/NN
is/VBZ
the/DT
relevant/JJ
DNA-binding/JJ
species/NNS
./.
====================
The/DT
evolutionarily/RB
conserved/VBN
N-terminal/JJ
half/NN
of/IN
IBR/F/NN
harbors/VBZ
the/DT
DNA-binding/dimerization/JJ
domain/NN
(/(
outer/JJ
limits/NNS
,/,
127/CD
to/TO
283/CD
)/)
,/,
one/CD
or/CC
several/JJ
casein/NN
kinase/NN
II/CD
sites/NNS
(/(
37/CD
to/TO
67/CD
)/)
,/,
and/CC
a/DT
bipartite/JJ
nuclear/JJ
localization/NN
signal/NN
(/(
89/CD
to/TO
106/CD
)/)
which/WDT
appears/VBZ
to/TO
be/VB
necessary/JJ
for/IN
nuclear/JJ
targeting/NN
./.
====================
Binding/VBG
site/NN
selection/NN
revealed/VBD
that/IN
the/DT
alternating/VBG
RCGCRYGCGY/NN
consensus/NN
constitutes/VBZ
high-affinity/JJ
IBR/F/NN
binding/NN
sites/NNS
and/CC
that/IN
the/DT
direct-repeat/JJ
palindrome/NN
TGCGCATGCGCA/NN
is/VBZ
the/DT
optimal/JJ
site/NN
./.
====================
A/DT
survey/NN
of/IN
genes/NNS
potentially/RB
regulated/VBN
by/IN
this/DT
family/NN
of/IN
factors/NNS
primarily/RB
revealed/VBD
genes/NNS
involved/VBN
in/IN
growth-related/JJ
metabolism/NN
./.
====================
UI/LS
-/:
96070930/CD
====================
TI/LS
-/:
Triggering/NN
of/IN
the/DT
human/JJ
interleukin-6/NN
gene/NN
by/IN
interferon-gamma/NN
and/CC
tumor/NN
necrosis/NN
factor-alpha/NN
in/IN
monocytic/JJ
cells/NNS
involves/VBZ
cooperation/NN
between/IN
interferon/NN
regulatory/JJ
factor-1/NN
,/,
NF/NN
kappa/NN
B/NN
,/,
and/CC
Sp1/NN
transcription/NN
factors/NNS
./.
====================
AB/LS
-/:
We/PRP
investigated/VBD
the/DT
molecular/JJ
basis/NN
of/IN
the/DT
synergistic/JJ
induction/NN
by/IN
interferon-gamma/NN
(/(
IFN-gamma/NN
)/)
/tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
of/IN
human/JJ
interleukin-6/NN
(/(
IL-6/NN
)/)
gene/NN
in/IN
THP-1/NN
monocytic/JJ
cells/NNS
,/,
and/CC
compared/VBD
it/PRP
with/IN
the/DT
basis/NN
of/IN
this/DT
induction/NN
by/IN
lipopolysaccharide/NN
(/(
LPS/NN
)/)
./.
====================
Functional/JJ
studies/NNS
with/IN
IL-6/NN
promoter/NN
demonstrated/VBD
that/IN
three/CD
regions/NNS
are/VBP
the/DT
targets/NNS
of/IN
the/DT
IFN-gamma/NN
and/or/CC
TNF-alpha/NN
action/NN
,/,
whereas/IN
only/RB
one/CD
of/IN
these/DT
regions/NNS
seemed/VBD
to/TO
be/VB
implicated/VBN
in/IN
LPS/NN
activation/NN
./.
====================
The/DT
three/CD
regions/NNS
concerned/VBN
are/VBP
:/:
1/LS
)/)
a/DT
region/NN
between/IN
-73/CD
and/CC
-36/CD
,/,
which/WDT
is/VBZ
the/DT
minimal/JJ
element/NN
inducible/JJ
by/IN
LPS/NN
or/CC
TNF-alpha/NN
;/:
2/LS
)/)
an/DT
element/NN
located/JJ
between/IN
-181/CD
and/CC
-73/CD
,/,
which/WDT
appeared/VBD
to/TO
regulate/VB
the/DT
response/NN
to/TO
IFN-gamma/NN
and/CC
TNF-alpha/NN
negatively/RB
;/:
and/CC
3/LS
)/)
a/DT
distal/JJ
element/NN
upstream/JJ
of/IN
-224/CD
,/,
which/WDT
was/VBD
inducible/JJ
by/IN
IFN-gamma/NN
alone/RB
./.
====================
LPS/NN
signaling/NN
was/VBD
found/VBN
to/TO
involve/VB
NF/NN
kappa/NN
B/NN
activation/NN
by/IN
the/DT
p50/NN
/p65/NN
heterodimers/NNS
./.
====================
Synergistic/JJ
induction/NN
of/IN
the/DT
IL-6/NN
gene/NN
by/IN
IFN-gamma/NN
and/CC
TNF-alpha/NN
,/,
in/IN
monocytic/JJ
cells/NNS
,/,
involved/VBD
cooperation/NN
between/IN
the/DT
IRF-1/NN
and/CC
NF/NN
kappa/NN
B/NN
p65/NN
homodimers/NNS
with/IN
concomitant/JJ
removal/NN
of/IN
the/DT
negative/JJ
effect/NN
of/IN
the/DT
retinoblastoma/NN
control/NN
element/NN
present/JJ
in/IN
the/DT
IL-6/NN
promoter/NN
./.
====================
This/DT
removal/NN
occurred/VBD
by/IN
activation/NN
of/IN
the/DT
constitutive/JJ
Sp1/NN
factor/NN
,/,
whose/WP$
increased/VBN
binding/NN
activity/NN
and/CC
phosphorylation/NN
were/VBD
mediated/VBN
by/IN
IFN-gamma/NN
./.
====================
UI/LS
-/:
96055115/CD
====================
TI/LS
-/:
Mutation/NN
of/IN
Jak3/NN
in/IN
a/DT
patient/NN
with/IN
SCID/NN
:/:
essential/JJ
role/NN
of/IN
Jak3/NN
in/IN
lymphoid/JJ
development/NN
./.
====================
AB/LS
-/:
Males/NNS
with/IN
X-linked/JJ
severe/JJ
combined/JJ
immunodeficiency/NN
(/(
XSCID/NN
)/)
have/VBP
defects/NNS
in/IN
the/DT
common/JJ
cytokine/NN
receptor/NN
gamma/NN
chain/NN
(/(
gamma/NN
c/NN
)/)
gene/NN
that/WDT
encodes/VBZ
a/DT
shared/JJ
,/,
essential/JJ
component/NN
of/IN
the/DT
receptors/NNS
of/IN
interleukin-2/NN
(/(
IL-2/NN
)/)
,/,
IL-4/NN
,/,
IL-7/NN
,/,
IL-9/NN
,/,
and/CC
IL-15/NN
./.
====================
The/DT
Janus/NN
family/NN
tyrosine/NN
kinase/NN
Jak3/NN
is/VBZ
the/DT
only/JJ
signaling/VBG
molecule/NN
known/VBN
to/TO
be/VB
associated/VBN
with/IN
gamma/NN
c/NN
,/,
so/IN
it/PRP
was/VBD
hypothesized/VBN
that/IN
defects/NNS
in/IN
Jak3/NN
might/MD
cause/VB
an/DT
XSCID-like/JJ
phenotype/NN
./.
====================
A/DT
girl/NN
with/IN
immunological/JJ
features/NNS
indistinguishable/JJ
from/IN
those/DT
of/IN
XSCID/NN
was/VBD
therefore/RB
selected/VBN
for/IN
analysis/NN
./.
====================
An/DT
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
-transformed/JJ
cell/NN
line/NN
derived/VBN
from/IN
her/PRP$
lymphocytes/NNS
had/VBD
normal/JJ
gamma/NN
c/NN
expression/NN
but/CC
lacked/VBD
Jak3/NN
protein/NN
and/CC
had/VBD
greatly/RB
diminished/VBN
Jak3/NN
messenger/NN
RNA/NN
./.
====================
Sequencing/NN
revealed/VBD
a/DT
different/JJ
mutation/NN
on/IN
each/DT
allele/NN
:/:
a/DT
single/JJ
nucleotide/NN
insertion/NN
resulting/VBG
in/IN
a/DT
frame/NN
shift/NN
and/CC
premature/JJ
termination/NN
in/IN
the/DT
Jak3/NN
JH4/NN
domain/NN
and/CC
a/DT
nonsense/JJ
mutation/NN
in/IN
the/DT
Jak3/NN
JH2/NN
domain/NN
./.
====================
The/DT
lack/NN
of/IN
Jak3/NN
expression/NN
correlated/VBD
with/IN
impaired/JJ
B/NN
cell/NN
signaling/NN
,/,
as/IN
demonstrated/VBN
by/IN
the/DT
inability/NN
of/IN
IL-4/NN
to/TO
activate/VB
Stat6/NN
in/IN
the/DT
EBV-transformed/JJ
cell/NN
line/NN
from/IN
the/DT
patient/NN
./.
These/DT
observations/NNS
indicate/VBP
that/IN
the/DT
functions/NNS
of/IN
gamma/NN
c/NN
are/VBP
dependent/JJ
on/IN
Jak3/NN
and/CC
that/IN
Jak3/NN
is/VBZ
essential/JJ
for/IN
lymphoid/JJ
development/NN
and/CC
signaling/NN
./.
====================
UI/LS
-/:
96017245/CD
====================
TI/LS
-/:
Constitutive/JJ
overexpression/NN
of/IN
the/DT
L-selectin/NN
gene/NN
in/IN
fresh/JJ
leukemic/JJ
cells/NNS
of/IN
adult/JJ
T-cell/NN
leukemia/NN
that/WDT
can/MD
be/VB
transactivated/VBN
by/IN
human/JJ
T-cell/NN
lymphotropic/JJ
virus/NN
type/NN
1/CD
Tax/NN
./.
====================
AB/LS
-/:
L-selectin/NN
is/VBZ
an/DT
adhesion/NN
molecule/NN
of/IN
the/DT
selectin/NN
family/NN
that/WDT
mediates/VBZ
the/DT
initial/JJ
step/NN
of/IN
leukocyte/NN
adhesion/NN
to/TO
vascular/JJ
endothelium/NN
./.
====================
Upon/IN
cellular/JJ
activation/NN
,/,
expression/NN
of/IN
the/DT
L-selectin/NN
gene/NN
is/VBZ
downregulated/VBN
at/IN
both/CC
the/DT
protein/NN
and/CC
mRNA/NN
levels/NNS
./.
====================
To/TO
understand/VB
the/DT
mechanism/NN
of/IN
leukemic/JJ
cell/NN
infiltration/NN
into/IN
organs/NNS
,/,
we/PRP
studied/VBD
the/DT
expression/NN
and/CC
regulation/NN
of/IN
L-selectin/NN
mRNA/NN
in/IN
fresh/JJ
leukemic/JJ
cells/NNS
of/IN
adult/JJ
T-cell/NN
leukemia/NN
(/(
ATL/NN
)/)
patients/NNS
and/CC
investigated/VBD
the/DT
response/NN
of/IN
the/DT
L-selectin/NN
promoter/NN
to/TO
human/JJ
T-cell/NN
lymphotropic/JJ
virus/NN
type/NN
1/CD
(/(
HTLV-1/NN
)/)
Tax/NN
,/,
which/WDT
is/VBZ
a/DT
viral/JJ
transcriptional/JJ
transactivator/NN
./.
====================
Flow/NN
cytometry/NN
showed/VBD
that/IN
L-selectin/NN
was/VBD
expressed/VBN
on/IN
fresh/JJ
ATL/NN
cells/NNS
along/IN
with/IN
other/JJ
activation/NN
antigens/NNS
./.
====================
Northern/NN
blot/NN
analysis/NN
showed/VBD
that/IN
ATL/NN
cells/NNS
overexpressed/VBD
that/DT
L-selectin/NN
mRNA/NN
and/CC
that/IN
the/DT
level/NN
was/VBD
aberrantly/RB
upregulated/VBN
after/IN
PMA/NN
stimulation/NN
./.
====================
Studies/NNS
using/VBG
in/FW
situ/FW
hybridization/NN
showed/VBD
expression/NN
of/IN
the/DT
L-selectin/NN
mRNA/NN
in/IN
the/DT
infiltrating/VBG
leukemic/JJ
cells/NNS
in/IN
the/DT
liver/NN
of/IN
two/CD
ATL/NN
patients/NNS
./.
====================
Intravenous/JJ
injection/NN
of/IN
a/DT
rat/NN
T-cell/NN
line/NN
that/WDT
overexpresses/VBZ
L-selectin/NN
showed/VBD
increased/VBN
organ/NN
infiltration/NN
./.
====================
The/DT
induction/NN
of/IN
Tax/NN
expression/NN
in/IN
JPX9/NN
cells/NNS
resulted/VBD
in/IN
about/RB
a/DT
twofold/JJ
increase/NN
in/IN
the/DT
mRNA/NN
expression/NN
levels/NNS
compared/VBN
with/IN
the/DT
basal/JJ
level/NN
./.
====================
Chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
assay/NN
after/IN
transient/JJ
cotransfection/NN
showed/VBD
about/RB
a/DT
fivefold/JJ
transactivation/NN
of/IN
the/DT
L-selectin/NN
promoter/NN
by/IN
Tax/NN
./.
====================
The/DT
serum/NN
level/NN
of/IN
the/DT
shed/NN
form/NN
of/IN
L-selectin/NN
was/VBD
significantly/RB
increased/VBN
in/IN
ATL/NN
patients/NNS
(/(
mean/NN
+/-/CC
SD/NN
,/,
4,215.4/CD
+/-/CC
4,111/CD
ng/mL/NN
)/)
compared/VBN
with/IN
those/DT
of/IN
asymptomatic/JJ
carriers/NNS
and/CC
healthy/JJ
blood/NN
donors/NNS
(/(
mean/NN
+/-/CC
SD/NN
,/,
1,148.0/CD
+/-/CC
269.0/CD
ng/mL/NN
and/CC
991.9/CD
+/-/CC
224/CD
ng/mL/NN
,/,
respectively/RB
)/)
./.
====================
These/DT
results/NNS
indicated/VBD
that/IN
ATL/NN
cells/NNS
constitutively/RB
overexpress/VBP
the/DT
L-selectin/NN
gene/NN
that/WDT
can/MD
be/VB
transactivated/VBN
by/IN
HTLV-1/NN
Tax/NN
./.
====================
The/DT
overexpression/NN
of/IN
L-selectin/NN
,/,
as/RB
well/RB
as/IN
of/IN
inflammatory/JJ
cytokines/NNS
,/,
by/IN
ATL/NN
cells/NNS
may/MD
provide/VB
a/DT
basis/NN
for/IN
ATL/NN
cells/NNS
to/TO
attach/VB
the/DT
vascular/JJ
endothelium/NN
,/,
leading/VBG
to/TO
transmigration/NN
and/CC
organ/NN
infitration/NN
./.
====================
UI/LS
-/:
96157213/CD
====================
TI/LS
-/:
Human/JJ
herpesvirus/NN
6/CD
variant/NN
A/NN
,/,
but/CC
not/RB
variant/NN
B/NN
,/,
infects/VBZ
EBV-positive/JJ
B/NN
lymphoid/JJ
cells/NNS
,/,
activating/VBG
the/DT
latent/JJ
EBV/NN
genome/NN
through/IN
a/DT
BZLF-1-dependent/JJ
mechanism/NN
./.
====================
AB/LS
-/:
Human/JJ
herpesvirus/NN
6/CD
,/,
a/DT
predominantly/RB
T/NN
lymphotropic/JJ
virus/NN
,/,
has/VBZ
been/VBN
recently/RB
shown/VBN
to/TO
infect/VB
some/DT
EBV/JJ
-positive/JJ
B/NN
cell/NN
lines/NNS
,/,
and/CC
to/TO
induce/VB
in/IN
them/PRP
the/DT
activation/NN
of/IN
the/DT
EBV/NN
lytic/JJ
cycle/NN
./.
====================
Here/RB
we/PRP
have/VBP
confirmed/VBN
and/CC
extended/VBN
such/JJ
observations/NNS
,/,
showing/VBG
that/IN
(/(
1/LS
)/)
this/DT
phenomenon/NN
is/VBZ
restricted/JJ
to/TO
the/DT
variant/NN
A/NN
of/IN
HHV-6/NN
:/:
in/IN
fact/NN
two/CD
isolates/NNS
belonging/VBG
to/TO
the/DT
HHV-6/NN
variant/NN
B/NN
(/(
BA92/NN
and/CC
Z29/NN
)/)
were/VBD
neither/CC
able/JJ
to/TO
infect/VB
any/DT
B/NN
cell/NN
line/NN
,/,
independently/RB
of/IN
the/DT
EBV/NN
status/NN
,/,
nor/CC
to/TO
induce/VB
the/DT
EBV/NN
genome/NN
expression/NN
./.
====================
The/DT
only/JJ
exception/NN
is/VBZ
represented/VBN
by/IN
the/DT
P3HR1/NN
cells/NNS
,/,
in/IN
which/WDT
,/,
however/RB
,/,
the/DT
infection/NN
by/IN
the/DT
variant/NN
B/NN
does/VBZ
not/RB
determine/VB
induction/NN
of/IN
EBV/NN
antigens/NNS
;/:
(/(
2/LS
)/)
the/DT
presence/NN
of/IN
the/DT
EBV/NN
genome/NN
contributes/VBZ
to/TO
the/DT
susceptibility/NN
of/IN
the/DT
B/NN
cell/NN
lines/NNS
to/TO
HHV-6/NN
infection/NN
,/,
increasing/VBG
the/DT
binding/VBG
sites/NNS
and/CC
the/DT
percentage/NN
of/IN
infectable/JJ
cells/NNS
,/,
as/IN
detected/VBN
by/IN
immunoelectron/NN
microscopy/NN
;/:
and/CC
(/(
3/LS
)/)
HHV-6/NN
infected/JJ
T/NN
cells/NNS
,/,
transfected/VBN
with/IN
plasmids/NNS
bearing/VBG
the/DT
promoter/NN
regions/NNS
of/IN
the/DT
EBV/NN
early/RB
genes/NNS
BZLF1/NN
and/CC
BMRF1/NN
,/,
show/VBP
a/DT
strong/JJ
transactivation/NN
of/IN
these/DT
promoters/NNS
./.
====================
UI/LS
-/:
96001288/CD
====================
TI/LS
-/:
Evidence/NN
for/IN
normal/JJ
vitamin/NN
D/NN
receptor/NN
messenger/NN
ribonucleic/JJ
acid/NN
and/CC
genotype/NN
in/IN
absorptive/JJ
hypercalciuria/NN
./.
====================
AB/LS
-/:
Absorptive/JJ
hypercalciuria/NN
(/(
a/DT
stone-forming/JJ
condition/NN
)/)
is/VBZ
characterized/VBN
by/IN
gut/NN
hyperabsorption/NN
of/IN
calcium/NN
,/,
hypercalciuria/NN
,/,
and/CC
reduced/VBN
bone/NN
density/NN
./.
====================
Inasmuch/RB
as/IN
these/DT
features/NNS
implicate/VBP
enhanced/VBN
calcitriol/NN
action/NN
in/IN
gut/NN
and/CC
bone/NN
,/,
we/PRP
analyzed/VBD
the/DT
vitamin/NN
D/NN
receptor/NN
(/(
VDR/NN
)/)
gene/NN
to/TO
ascertain/VB
whether/IN
an/DT
abnormality/NN
of/IN
this/DT
gene/NN
marks/VBZ
patients/NNS
with/IN
intestinal/JJ
hyperabsorption/NN
of/IN
calcium/NN
./.
====================
We/PRP
have/VBP
compared/VBN
the/DT
frequency/NN
of/IN
a/DT
restriction/NN
fragment/NN
length/NN
polymorphism/NN
(/(
Bsm/NN
I/NN
)/)
associated/VBN
with/IN
different/JJ
alleles/NNS
of/IN
the/DT
VDR/NN
gene/NN
in/IN
a/DT
group/NN
of/IN
33/CD
well/RB
characterized/VBN
absorptive/JJ
hypercalciuric/NN
patients/NNS
and/CC
a/DT
group/NN
of/IN
36/CD
normal/JJ
race-/NN
and/CC
age-matched/JJ
control/JJ
subjects/NNS
./.
====================
There/EX
was/VBD
no/DT
difference/NN
between/IN
the/DT
distribution/NN
of/IN
the/DT
VDR/NN
alleles/NNS
in/IN
the/DT
patient/NN
population/NN
when/WRB
compared/VBN
with/IN
the/DT
normal/JJ
population/NN
./.
====================
The/DT
coding/VBG
region/NN
of/IN
VDR/NN
messenger/NN
RNA/NN
was/VBD
also/RB
normal/JJ
,/,
as/IN
determined/VBN
by/IN
both/CC
DNA/NN
sequence/NN
analysis/NN
and/CC
chemical/JJ
mismatch/NN
cleavage/NN
analysis/NN
of/IN
copy/NN
DNA/NN
from/IN
11/CD
index/NN
absorptive/JJ
hypercalciuric/NN
patients/NNS
./.
====================
On/IN
the/DT
basis/NN
of/IN
these/DT
results/NNS
,/,
we/PRP
propose/VBP
that/IN
the/DT
enhanced/VBN
intestinal/JJ
calcium/NN
absorption/NN
invariably/RB
seen/VBN
in/IN
absorptive/JJ
hypercalciuria/NN
and/CC
attendant/JJ
symptoms/NNS
of/IN
this/DT
disorder/NN
are/VBP
not/RB
attributable/JJ
to/TO
mutations/NNS
of/IN
the/DT
VDR/NN
and/CC
are/VBP
not/RB
linked/VBN
to/TO
a/DT
common/JJ
VDR/NN
genotype/NN
./.
====================
UI/LS
-/:
95394907/CD
====================
TI/LS
-/:
Transcriptional/JJ
regulation/NN
of/IN
the/DT
gene/NN
encoding/VBG
the/DT
human/JJ
C-type/JJ
lectin/NN
leukocyte/NN
receptor/NN
AIM/CD69/NN
and/CC
functional/JJ
characterization/NN
of/IN
its/PRP$
tumor/NN
necrosis/NN
factor-alpha-responsive/JJ
elements/NNS
./.
====================
AB/LS
-/:
The/DT
human/JJ
activation/NN
antigen/NN
CD69/NN
is/VBZ
a/DT
member/NN
of/IN
the/DT
C-type/JJ
animal/NN
lectin/NN
superfamily/NN
that/WDT
functions/VBZ
as/IN
a/DT
signal-transmitting/JJ
receptor/NN
./.
====================
Although/IN
the/DT
expression/NN
of/IN
CD69/NN
can/MD
be/VB
induced/VBN
in/FW
vitro/FW
on/IN
cells/NNS
of/IN
most/JJS
hematopoietic/JJ
lineages/NNS
with/IN
a/DT
wide/JJ
variety/NN
of/IN
stimuli/NNS
,/,
in/FW
vivo/FW
it/PRP
is/VBZ
mainly/RB
expressed/VBN
by/IN
T-lymphocytes/NNS
located/JJ
in/IN
the/DT
inflammatory/JJ
infiltrates/NNS
of/IN
several/JJ
human/JJ
diseases/NNS
./.
====================
To/TO
elucidate/VB
the/DT
mechanisms/NNS
that/WDT
regulate/VBP
the/DT
constitutive/JJ
and/CC
inducible/JJ
expression/NN
of/IN
CD69/NN
by/IN
leukocytes/NNS
,/,
we/PRP
isolated/VBD
the/DT
promoter/NN
region/NN
of/IN
the/DT
CD69/NN
gene/NN
and/CC
carried/VBD
out/RP
its/PRP$
functional/JJ
characterization/NN
./.
====================
Sequence/NN
analysis/NN
of/IN
the/DT
5'-flanking/JJ
region/NN
of/IN
the/DT
CD69/NN
gene/NN
revealed/VBD
the/DT
presence/NN
of/IN
a/DT
potential/JJ
TATA/NN
element/NN
30/CD
base/NN
pairs/NNS
upstream/JJ
of/IN
the/DT
major/JJ
transcription/NN
initiation/NN
site/NN
and/CC
several/JJ
putative/JJ
binding/NN
sequences/NNS
for/IN
inducible/JJ
transcription/NN
factors/NNS
(/(
NF-kappa/NN
B/NN
,/,
Egr-1/NN
,/,
AP-1/NN
)/)
,/,
which/WDT
might/MD
mediate/VB
the/DT
inducible/JJ
expression/NN
of/IN
this/DT
gene/NN
./.
====================
Transient/JJ
expression/NN
of/IN
CD69/NN
promoter-based/JJ
reporter/NN
gene/NN
constructs/NNS
in/IN
K562/NN
cells/NNS
indicated/VBD
that/IN
the/DT
proximal/JJ
promoter/NN
region/NN
spanning/VBG
positions/NNS
-78/CD
to/TO
+16/CD
contained/VBD
the/DT
cis-acting/JJ
sequences/NNS
necessary/JJ
for/IN
basal/JJ
and/CC
phorbol/NN
12-myristate/NN
13-acetate-inducible/JJ
transcription/NN
of/IN
the/DT
CD69/NN
gene/NN
./.
====================
Removal/NN
of/IN
the/DT
upstream/JJ
sequences/NNS
located/JJ
between/IN
positions/NNS
-78/CD
and/CC
-38/CD
resulted/VBD
in/IN
decreased/VBN
promoter/NN
strength/NN
and/CC
abolished/VBD
the/DT
response/NN
to/TO
phorbol/NN
12-myristate/NN
13-acetate/NN
./.
====================
We/PRP
also/RB
found/VBD
that/IN
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
is/VBZ
capable/JJ
of/IN
inducing/VBG
the/DT
surface/NN
expression/NN
of/IN
the/DT
CD69/NN
molecule/NN
as/RB
well/RB
as/IN
the/DT
promoter/NN
activity/NN
of/IN
fusion/NN
plasmids/NNS
that/WDT
contain/VBP
5'-flanking/JJ
sequences/NNS
of/IN
the/DT
CD69/NN
gene/NN
,/,
suggesting/VBG
that/IN
this/DT
cytokine/NN
may/MD
regulate/VB
in/FW
vivo/FW
the/DT
expression/NN
of/IN
CD69/NN
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
250/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
95368765/CD
====================
TI/LS
-/:
Characterization/NN
of/IN
5'/JJ
end/NN
of/IN
human/JJ
thromboxane/NN
receptor/NN
gene/NN
./.
====================
Organizational/JJ
analysis/NN
and/CC
mapping/NN
of/IN
protein/NN
kinase/NN
C/NN
--/:
responsive/JJ
elements/NNS
regulating/VBG
expression/NN
in/IN
platelets/NNS
./.
====================
AB/LS
-/:
Platelet/NN
thromboxane/NN
receptors/NNS
are/VBP
acutely/RB
and/CC
reversibly/RB
upregulated/VBN
after/IN
acute/JJ
myocardial/JJ
infarction/NN
./.
====================
To/TO
determine/VB
if/IN
platelet/NN
thromboxane/NN
receptors/NNS
are/VBP
under/IN
transcriptional/JJ
control/NN
,/,
we/PRP
isolated/VBD
and/CC
characterized/VBD
human/JJ
genomic/JJ
DNA/NN
clones/NNS
containing/VBG
the/DT
5'/JJ
flanking/JJ
region/NN
of/IN
the/DT
thromboxane/NN
receptor/NN
gene/NN
./.
====================
The/DT
exon-intron/JJ
structure/NN
of/IN
the/DT
5'/JJ
portion/NN
of/IN
the/DT
thromboxane/NN
receptor/NN
gene/NN
was/VBD
determined/VBN
initially/RB
by/IN
comparing/VBG
the/DT
nucleotide/NN
sequence/NN
of/IN
the/DT
5'/JJ
flanking/JJ
genomic/JJ
clone/NN
with/IN
that/DT
of/IN
a/DT
novel/JJ
human/JJ
uterine/NN
thromboxane/NN
receptor/NN
cDNA/NN
that/WDT
extended/VBD
the/DT
mRNA/NN
141/CD
bp/NN
further/RBR
upstream/RB
than/IN
the/DT
previously/RB
identified/VBN
human/JJ
placental/JJ
cDNA/NN
./.
====================
A/DT
major/JJ
transcription/NN
initiation/NN
site/NN
was/VBD
located/JJ
in/IN
three/CD
human/JJ
tissues/NNS
approximately/RB
560/CD
bp/NN
upstream/JJ
from/IN
the/DT
translation/NN
initiation/NN
codon/NN
and/CC
380/CD
bp/NN
upstream/JJ
from/IN
any/DT
previously/RB
identified/VBN
transcription/NN
initiation/NN
site/NN
./.
====================
The/DT
thromboxane/NN
receptor/NN
gene/NN
has/VBZ
neither/CC
a/DT
TATA/NN
nor/CC
a/DT
CAAT/NN
consensus/NN
site/NN
./.
====================
Promoter/NN
function/NN
of/IN
the/DT
5'/JJ
flanking/JJ
region/NN
of/IN
the/DT
thromboxane/NN
receptor/NN
gene/NN
was/VBD
evaluated/VBN
by/IN
transfection/NN
of/IN
thromboxane/NN
receptor/NN
gene/NN
promoter/chloramphenicol/NN
acetyltransferase/NN
(/(
CAT/NN
)/)
chimera/NN
plasmids/NNS
into/IN
platelet-like/JJ
K562/NN
cells/NNS
./.
====================
Thromboxane/NN
receptor/NN
promoter/NN
activity/NN
,/,
as/IN
assessed/VBN
by/IN
CAT/NN
expression/NN
,/,
was/VBD
relatively/RB
weak/JJ
but/CC
was/VBD
significantly/RB
enhanced/VBN
by/IN
phorbol/NN
ester/NN
treatment/NN
./.
====================
Functional/JJ
analysis/NN
of/IN
5'/JJ
deletion/NN
constructs/NNS
in/IN
transfected/VBN
K562/NN
cells/NNS
and/CC
gel/NN
mobility/NN
shift/NN
localized/VBD
the/DT
major/JJ
phorbol/NN
ester-responsive/JJ
motifs/NNS
in/IN
the/DT
thromboxane/NN
receptor/NN
gene/NN
promoter/NN
to/TO
a/DT
cluster/NN
of/IN
activator/NN
protein-2/NN
(/(
AP-2/NN
)/)
binding/NN
consensus/NN
sites/NNS
located/JJ
approximately/RB
1.8/CD
kb/NN
5'/JJ
from/IN
the/DT
transcription/NN
initiation/NN
site/NN
./.
====================
These/DT
studies/NNS
are/VBP
the/DT
first/JJ
to/TO
determine/VB
the/DT
structure/NN
and/CC
organization/NN
of/IN
the/DT
5'/JJ
end/NN
of/IN
the/DT
thromboxane/NN
receptor/NN
gene/NN
and/CC
demonstrate/VBP
that/IN
thromboxane/NN
receptor/NN
gene/NN
expression/NN
can/MD
be/VB
regulated/VBN
by/IN
activation/NN
of/IN
protein/NN
kinase/NN
C/NN
via/IN
induction/NN
of/IN
an/DT
AP-2-like/JJ
nuclear/JJ
factor/NN
binding/VBG
to/TO
upstream/JJ
promoter/NN
elements/NNS
./.
====================
These/DT
findings/NNS
strongly/RB
suggest/VBP
that/IN
the/DT
mechanism/NN
for/IN
previously/RB
described/VBN
upregulation/NN
of/IN
platelet/NN
thromboxane/NN
receptors/NNS
after/IN
acute/JJ
myocardial/JJ
infarction/NN
is/VBZ
increased/VBN
thromboxane/NN
receptor/NN
gene/NN
transcription/NN
in/IN
platelet-progenitor/JJ
cells/NNS
./.
====================
UI/LS
-/:
91172250/CD
====================
TI/LS
-/:
Estrogen/NN
receptor/NN
concentration/NN
and/CC
social/JJ
factors/NNS
as/IN
predictors/NNS
of/IN
natural/JJ
killer/NN
cell/NN
activity/NN
in/IN
early-stage/JJ
breast/NN
cancer/NN
patients/NNS
./.
====================
Confirmation/NN
of/IN
a/DT
model/NN
./.
====================
AB/LS
-/:
Previous/JJ
work/NN
of/IN
ours/PP
has/VBZ
demonstrated/VBN
that/IN
a/DT
significant/JJ
amount/NN
of/IN
natural/JJ
killer/NN
(/(
NK/NN
)/)
activity/NN
variance/NN
after/IN
surgery/NN
in/IN
stage/NN
I/CD
and/CC
II/CD
breast/NN
cancer/NN
patients/NNS
could/MD
be/VB
accounted/VBN
for/IN
by/IN
both/CC
the/DT
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
status/NN
of/IN
the/DT
tumor/NN
and/CC
by/IN
social/JJ
factors/NNS
,/,
namely/RB
,/,
perceived/VBN
social/JJ
support/NN
and/CC
seeking/VBG
social/JJ
support/NN
as/IN
a/DT
general/JJ
coping/NN
strategy/NN
./.
====================
As/IN
considerable/JJ
evidence/NN
has/VBZ
accumulated/VBN
that/IN
social/JJ
support/NN
in/IN
both/CC
animal/NN
and/CC
human/JJ
populations/NNS
may/MD
have/VB
survival/NN
value/NN
,/,
we/PRP
sought/VBD
to/TO
test/VB
the/DT
reliability/NN
of/IN
this/DT
regression/NN
model/NN
,/,
using/VBG
coping/NN
and/CC
perceived/VBN
support/NN
factor/NN
values/NNS
obtained/VBN
at/IN
3/CD
months/NNS
after/IN
surgery/NN
to/TO
account/VB
for/IN
concurrent/JJ
follow-up/JJ
NK/NN
activity/NN
in/IN
this/DT
serially/RB
assessed/VBN
group/NN
of/IN
patients/NNS
./.
====================
It/PRP
was/VBD
found/VBN
that/IN
the/DT
most/RBS
significant/JJ
variable/NN
predicting/VBG
NK/NN
activity/NN
at/IN
follow-up/NN
was/VBD
tumor/NN
ER/NN
concentration/NN
,/,
with/IN
higher/JJR
NK/NN
activity/NN
associated/VBN
with/IN
ER-/JJ
status/NN
./.
====================
In/IN
addition/NN
,/,
seeking/VBG
social/JJ
support/NN
as/IN
a/DT
coping/NN
strategy/NN
,/,
as/RB
well/RB
as/IN
the/DT
perceived/VBN
quality/NN
of/IN
support/NN
,/,
also/RB
entered/VBD
the/DT
model/NN
to/TO
account/VB
for/IN
a/DT
significant/JJ
amount/NN
of/IN
NK/NN
activity/NN
variance/NN
(/(
multivariate/JJ
F/NN
=/JJ
5.25/CD
,/,
p/NN
less/JJR
than/IN
0.001/CD
)/)
./.
====================
If/IN
,/,
as/IN
the/DT
literature/NN
suggests/VBZ
,/,
NK/NN
activity/NN
is/VBZ
relevant/JJ
to/TO
breast/NN
cancer/NN
control/NN
,/,
and/CC
since/IN
ER-/NN
tumors/NNS
have/VBP
a/DT
worse/JJR
prognosis/NN
,/,
we/PRP
suggest/VBP
here/RB
that/IN
perhaps/RB
such/JJ
tumors/NNS
are/VBP
resistant/JJ
to/TO
control/NN
by/IN
NK/NN
cells/NNS
because/IN
they/PRP
lack/VBP
the/DT
ability/NN
to/TO
attract/VB
an/DT
accumulation/NN
of/IN
effector/NN
cells/NNS
to/TO
the/DT
tumor/NN
site/NN
,/,
or/CC
because/IN
blocking/NN
factors/NNS
at/IN
the/DT
site/NN
of/IN
the/DT
tumor/NN
prevent/VBP
local/JJ
tumor/NN
control/NN
at/IN
the/DT
site/NN
of/IN
action/NN
./.
====================
The/DT
finding/NN
related/JJ
to/TO
social/JJ
support/NN
also/RB
replicates/VBZ
results/NNS
from/IN
an/DT
independent/JJ
sample/NN
of/IN
breast/NN
cancer/NN
patients/NNS
./.
====================
This/DT
finding/NN
,/,
taken/VBN
together/RB
with/IN
other/JJ
evidence/NN
that/IN
this/DT
social/JJ
variable/NN
is/VBZ
associated/VBN
with/IN
longer/JJR
survival/NN
in/IN
breast/NN
cancer/NN
populations/NNS
,/,
underscores/VBZ
the/DT
potential/JJ
importance/NN
of/IN
this/DT
social/JJ
support/NN
variable/NN
./.
====================
Our/PRP$
findings/NNS
also/RB
suggest/VBP
one/CD
possible/JJ
immunological/JJ
variable/NN
involved/JJ
,/,
with/IN
potential/JJ
clinical/JJ
significance/NN
,/,
for/IN
this/DT
patient/NN
population/NN
./.
====================
UI/LS
-/:
96107207/CD
====================
TI/LS
-/:
Solution/NN
structure/NN
of/IN
the/DT
sequence-specific/JJ
HMG/NN
box/NN
of/IN
the/DT
lymphocyte/NN
transcriptional/JJ
activator/NN
Sox-4/NN
./.
====================
AB/LS
-/:
Two/CD
groups/NNS
of/IN
HMG/NN
box/NN
proteins/NNS
are/VBP
distinguished/VBN
./.
====================
Proteins/NNS
in/IN
the/DT
first/JJ
group/NN
contain/VBP
multiple/JJ
HMG/NN
boxes/NNS
,/,
are/VBP
non-sequence-specific/JJ
,/,
and/CC
recognize/VBP
structural/JJ
features/NNS
as/IN
found/VBN
in/IN
cruciform/JJ
DNA/NN
and/CC
cross-over/JJ
DNA/NN
./.
====================
The/DT
abundant/JJ
chromosomal/JJ
protein/NN
HMG-1/NN
belongs/VBZ
to/TO
this/DT
subgroup/NN
./.
====================
Proteins/NNS
in/IN
the/DT
second/JJ
group/NN
carry/VBP
a/DT
single/JJ
HMG/NN
box/NN
with/IN
affinity/NN
for/IN
the/DT
minor/JJ
groove/NN
of/IN
the/DT
heptamer/NN
motif/NN
AACAAAG/NN
or/CC
variations/NNS
thereof/RB
./.
====================
A/DT
solution/NN
structure/NN
for/IN
the/DT
non-sequence-specific/JJ
C-terminal/JJ
HMG/NN
box/NN
of/IN
HMG-1/NN
has/VBZ
recently/RB
been/VBN
proposed/VBN
./.
====================
Now/RB
,/,
we/PRP
report/VBP
the/DT
solution/NN
structure/NN
of/IN
the/DT
sequence-specific/JJ
HMG-box/NN
of/IN
the/DT
SRY-related/JJ
protein/NN
Sox-4/NN
./.
====================
NMR/NN
analysis/NN
demonstrated/VBD
the/DT
presence/NN
of/IN
three/CD
alpha-helices/NNS
(/(
Val10-Gln22/NN
,/,
Glu30-Leu41/NN
and/CC
Phe50-Tyr65/NN
)/)
connected/VBN
by/IN
loop/NN
regions/NNS
(/(
Ser23-Ala49/NN
and/CC
Leu42-Pro49/NN
)/)
./.
====================
Helices/NNS
I/CD
and/CC
II/CD
are/VBP
positioned/JJ
in/IN
an/DT
antiparallel/JJ
mode/NN
and/CC
form/VBP
one/CD
arm/NN
of/IN
the/DT
HMG/NN
box/NN
./.
====================
Helix/NN
III/CD
is/VBZ
less/RBR
rigid/JJ
,/,
makes/VBZ
an/DT
average/JJ
angle/NN
of/IN
about/RB
90/CD
degrees/NNS
with/IN
helices/NNS
I/CD
and/CC
II/CD
,/,
and/CC
constitutes/VBZ
the/DT
other/JJ
arm/NN
of/IN
the/DT
molecule/NN
./.
====================
As/IN
in/IN
HMG1B/NN
,/,
the/DT
overall/JJ
structure/NN
of/IN
the/DT
Sox-4/NN
HMG/NN
box/NN
is/VBZ
L-shaped/JJ
and/CC
is/VBZ
maintained/VBN
by/IN
a/DT
cluster/NN
of/IN
conserved/VBN
,/,
mainly/RB
aromatic/JJ
residues/NNS
./.
====================
UI/LS
-/:
96072803/CD
====================
TI/LS
-/:
Nuclear/JJ
factor-IL6/NN
activates/VBZ
the/DT
human/JJ
IL-4/NN
promoter/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Positive/JJ
regulatory/JJ
element/NN
I/NN
(/(
PRE-I/NN
)/)
is/VBZ
a/DT
strong/JJ
enhancer/NN
element/NN
essential/JJ
for/IN
expression/NN
of/IN
the/DT
human/JJ
IL-4/NN
gene/NN
./.
====================
To/TO
identify/VB
transcription/NN
factors/NNS
binding/VBG
to/TO
PRE-I/NN
,/,
we/PRP
screened/VBD
a/DT
cDNA/NN
expression/NN
library/NN
from/IN
Jurkat/NN
T/NN
cells/NNS
and/CC
isolated/VBD
a/DT
cDNA/NN
encoding/NN
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
-IL6/NN
(/(
also/RB
known/VBN
as/IN
C/EBP/NN
beta/NN
)/)
./.
====================
NF-IL6/NN
mRNA/NN
was/VBD
found/VBN
in/IN
human/JJ
Jurkat/NN
T/NN
cells/NNS
and/CC
in/IN
the/DT
mouse/NN
Th2/NN
clone/NN
D10/NN
,/,
but/CC
not/RB
in/IN
Th1/NN
clone/NN
29/CD
./.
====================
rNF-IL6/NN
expressed/VBN
in/IN
bacteria/NNS
was/VBD
shown/VBN
to/TO
specifically/RB
bind/VB
to/TO
PRE-I/NN
./.
====================
PRE-I/NN
forms/VBZ
multiple/JJ
DNA-protein/NN
complexes/NNS
with/IN
nuclear/JJ
extracts/NNS
from/IN
Jurkat/NN
cells/NNS
./.
====================
Some/DT
of/IN
these/DT
complexes/NNS
were/VBD
demonstrated/VBN
to/TO
contain/VB
NF-IL6/NN
by/IN
using/VBG
anti-C/EBP/JJ
beta/NN
Abs/NNS
./.
====================
Overexpression/NN
of/IN
NF-IL6/NN
enhanced/VBD
expression/NN
of/IN
the/DT
chloramphenicol/NN
acetyl/JJ
transferase/NN
reporter/NN
gene/NN
linked/VBN
to/TO
the/DT
PRE-I-thymidine/NN
kinase/NN
or/CC
the/DT
human/JJ
IL-4/NN
promoter/NN
more/JJR
than/IN
10-fold/RB
in/IN
Jurkat/NN
cells/NNS
./.
====================
Promoter/NN
deletion/NN
studies/NNS
revealed/VBD
two/CD
additional/JJ
NF-IL6/NN
binding/NN
sites/NNS
located/JJ
at/IN
positions/NNS
-44/CD
to/TO
-36/CD
(/(
C/EBP/NN
proximal/JJ
)/)
and/CC
-87/CD
to/TO
-79/CD
(/(
C/EBP/NN
medial/JJ
)/)
,/,
respectively/RB
./.
====================
Our/PRP$
results/NNS
demonstrate/VBP
that/IN
NF-IL6/NN
is/VBZ
involved/VBN
in/IN
transcriptional/JJ
activation/NN
of/IN
the/DT
human/JJ
IL-4/NN
promoter/NN
in/IN
T/NN
cells/NNS
./.
====================
UI/LS
-/:
96070929/CD
====================
TI/LS
-/:
Identification/NN
of/IN
an/DT
I/NN
kappa/NN
B/NN
alpha-associated/JJ
protein/NN
kinase/NN
in/IN
a/DT
human/JJ
monocytic/JJ
cell/NN
line/NN
and/CC
determination/NN
of/IN
its/PRP$
phosphorylation/NN
sites/NNS
on/IN
I/NN
kappa/NN
B/NN
alpha/NN
./.
====================
AB/LS
-/:
Nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
is/VBZ
stored/JJ
in/IN
the/DT
cytoplasm/NN
as/IN
an/DT
inactive/JJ
form/NN
through/IN
interaction/NN
with/IN
I/NN
kappa/NN
B/NN
./.
====================
Stimulation/NN
of/IN
cells/NNS
leads/VBZ
to/TO
a/DT
rapid/JJ
phosphorylation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
,/,
which/WDT
is/VBZ
presumed/VBN
to/TO
be/VB
important/JJ
for/IN
the/DT
subsequent/JJ
degradation/NN
./.
====================
We/PRP
have/VBP
recently/RB
reported/VBN
the/DT
establishment/NN
of/IN
a/DT
lipopolysaccharide/NN
(/(
LPS/NN
)/)
-dependent/JJ
cell-free/JJ
activation/NN
system/NN
of/IN
NF-kappa/NN
B/NN
in/IN
association/NN
with/IN
the/DT
induction/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
phosphorylation/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
identified/VBN
a/DT
kinase/NN
in/IN
cell/NN
extracts/NNS
from/IN
the/DT
LPS-stimulated/JJ
human/JJ
monocytic/JJ
cell/NN
line/NN
,/,
THP-1/NN
,/,
that/WDT
specifically/RB
binds/VBZ
and/CC
phosphorylates/VBZ
I/NN
kappa/NN
B/NN
alpha/NN
./.
====================
LPS/NN
stimulation/NN
transiently/RB
enhanced/VBD
the/DT
I/NN
kappa/NN
B/NN
alpha-bound/JJ
kinase/NN
activity/NN
in/IN
THP-1/NN
cells/NNS
./.
====================
Mutational/JJ
analyses/NNS
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
and/CC
competition/NN
experiments/NNS
with/IN
the/DT
synthetic/JJ
peptides/NNS
identified/VBD
major/JJ
phosphorylation/NN
sites/NNS
by/IN
the/DT
bound/VBN
kinase/NN
as/IN
Ser/NN
and/CC
Thr/NN
residues/NNS
in/IN
the/DT
C-terminal/JJ
acidic/JJ
domain/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
./.
====================
Moreover/RB
,/,
we/PRP
show/VBP
that/IN
the/DT
peptide/NN
,/,
corresponding/VBG
to/TO
the/DT
C-terminal/JJ
acidic/JJ
domain/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
,/,
blocked/VBD
the/DT
LPS-induced/JJ
NF-kappa/NN
B/NN
activation/NN
as/RB
well/RB
as/IN
inducible/JJ
phosphorylation/NN
of/IN
endogenous/JJ
I/NN
kappa/NN
B/NN
alpha/NN
in/IN
a/DT
cell-free/JJ
system/NN
using/VBG
THP-1/NN
cells/NNS
./.
====================
These/DT
results/NNS
suggested/VBD
that/IN
the/DT
bound/JJ
kinase/NN
is/VBZ
involved/VBN
in/IN
the/DT
signaling/NN
pathway/NN
of/IN
LPS/NN
by/IN
inducing/VBG
the/DT
phosphorylation/NN
of/IN
the/DT
C-terminal/JJ
region/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
and/CC
subsequent/JJ
dissociation/NN
of/IN
the/DT
NF-kappa/NN
B.I/NN
kappa/NN
B/NN
alpha/NN
complex/NN
./.
====================
UI/LS
-/:
96068922/CD
====================
TI/LS
-/:
Bik/NN
,/,
a/DT
novel/JJ
death-inducing/JJ
protein/NN
shares/VBZ
a/DT
distinct/JJ
sequence/NN
motif/NN
with/IN
Bcl-2/NN
family/NN
proteins/NNS
and/CC
interacts/VBZ
with/IN
viral/JJ
and/CC
cellular/JJ
survival-promoting/JJ
proteins/NNS
./.
====================
AB/LS
-/:
The/DT
survival-promoting/JJ
activity/NN
of/IN
the/DT
Bcl-2/NN
family/NN
of/IN
proteins/NNS
appears/VBZ
to/TO
be/VB
modulated/VBN
by/IN
interactions/NNS
between/IN
various/JJ
cellular/JJ
proteins/NNS
./.
====================
We/PRP
have/VBP
identified/VBN
a/DT
novel/JJ
cellular/JJ
protein/NN
,/,
Bik/NN
,/,
that/WDT
interacts/VBZ
with/IN
the/DT
cellular/JJ
survival-promoting/JJ
proteins/NNS
,/,
Bcl-2/NN
and/CC
Bcl-xL/NN
,/,
as/RB
well/RB
as/IN
the/DT
viral/JJ
survival-promoting/JJ
proteins/NNS
,/,
Epstein/NN
Barr/NN
virus-BHRF1/NN
and/CC
adenovirus/NN
E1B-19/NN
kDa/NN
./.
====================
In/IN
transient/JJ
transfection/NN
assays/NNS
,/,
Bik/NN
promotes/VBZ
cell/NN
death/NN
in/IN
a/DT
manner/NN
similar/JJ
to/TO
the/DT
death-promoting/JJ
members/NNS
of/IN
the/DT
Bcl-2/NN
family/NN
,/,
Bax/NN
and/CC
Bak/NN
./.
====================
This/DT
death-promoting/JJ
activity/NN
of/IN
Bik/NN
can/MD
be/VB
suppressed/VBN
by/IN
coexpression/NN
of/IN
Bcl-2/NN
,/,
Bcl-XL/NN
,/,
EBV-BHRF1/NN
and/CC
E1B-19/NN
kDa/NN
proteins/NNS
suggesting/VBG
that/IN
Bik/NN
may/MD
be/VB
a/DT
common/JJ
target/NN
for/IN
both/CC
cellular/JJ
and/CC
viral/JJ
anti-apoptotic/JJ
proteins/NNS
./.
====================
While/IN
Bik/NN
does/VBZ
not/RB
show/VB
overt/JJ
homology/NN
to/TO
the/DT
BH1/NN
and/CC
BH2/NN
conserved/JJ
domains/NNS
characteristic/JJ
of/IN
the/DT
Bcl-2/NN
family/NN
,/,
it/PRP
does/VBZ
share/VB
a/DT
9/CD
amino/NN
acid/NN
domain/NN
(/(
BH3/NN
)/)
with/IN
Bax/NN
and/CC
Bak/NN
which/WDT
may/MD
be/VB
a/DT
critical/JJ
determinant/NN
for/IN
the/DT
death-promoting/JJ
activity/NN
of/IN
these/DT
proteins/NNS
./.
====================
UI/LS
-/:
96017239/CD
====================
TI/LS
-/:
The/DT
human/JJ
TCF-1/NN
gene/NN
encodes/VBZ
a/DT
nuclear/JJ
DNA-binding/JJ
protein/NN
uniquely/RB
expressed/VBN
in/IN
normal/JJ
and/CC
neoplastic/JJ
T-lineage/JJ
lymphocytes/NNS
./.
====================
AB/LS
-/:
The/DT
TCF-1/NN
gene/NN
encodes/VBZ
a/DT
putative/JJ
transcription/NN
factor/NN
with/IN
affinity/NN
for/IN
a/DT
sequence/NN
motif/NN
occurring/VBG
in/IN
a/DT
number/NN
of/IN
T-cell/NN
enhancers/NNS
./.
====================
TCF-1/NN
mRNA/NN
was/VBD
originally/RB
found/VBN
to/TO
be/VB
expressed/VBN
in/IN
a/DT
T/NN
cell-specific/JJ
fashion/NN
within/IN
a/DT
set/NN
of/IN
human/JJ
and/CC
mouse/NN
cell/NN
lines/NNS
./.
====================
In/IN
contrast/NN
,/,
expression/NN
reportedly/RB
occurs/VBZ
in/IN
multiple/JJ
nonlymphoid/JJ
tissues/NNS
during/IN
murine/JJ
embryogenesis/NN
./.
====================
We/PRP
have/VBP
now/RB
raised/VBN
a/DT
monoclonal/JJ
antibody/NN
to/TO
document/VB
expression/NN
and/CC
biochemistry/NN
of/IN
the/DT
human/JJ
TCF-1/NN
protein/NN
./.
====================
As/IN
expected/VBN
,/,
the/DT
TCF-1/NN
protein/NN
was/VBD
detectable/JJ
only/RB
in/IN
cell/NN
lines/NNS
of/IN
T/NN
lineage/NN
./.
====================
Its/PRP$
expression/NN
was/VBD
always/RB
restricted/JJ
to/TO
the/DT
nucleus/NN
./.
====================
Immunohistochemistry/NN
on/IN
a/DT
panel/NN
of/IN
human/JJ
tissues/NNS
revealed/VBD
that/IN
the/DT
TCF-1/NN
protein/NN
was/VBD
found/VBN
exclusively/RB
in/IN
thymocytes/NNS
and/CC
in/IN
CD3+/JJ
T/NN
cells/NNS
in/IN
peripheral/JJ
lymphoid/JJ
tissues/NNS
./.
====================
Western/NN
blotting/NN
yielded/VBD
a/DT
set/NN
of/IN
bands/NNS
ranging/VBG
from/IN
25/CD
kD/NN
to/TO
55/CD
kD/NN
,/,
resulting/VBG
from/IN
extensive/JJ
alternative/JJ
splicing/NN
./.
====================
The/DT
TCF-1/NN
protein/NN
was/VBD
detectable/JJ
in/IN
all/DT
samples/NNS
of/IN
a/DT
set/NN
of/IN
22/CD
T-cell/NN
malignancies/NNS
of/IN
various/JJ
stages/NNS
of/IN
maturation/NN
,/,
but/CC
was/VBD
absent/JJ
from/IN
a/DT
large/JJ
number/NN
of/IN
other/JJ
hematologic/JJ
neoplasms/NNS
./.
====================
These/DT
observations/NNS
imply/VBP
a/DT
T/NN
cell-specific/JJ
function/NN
for/IN
TCF-1/NN
,/,
a/DT
notion/NN
corroborated/VBN
by/IN
recent/JJ
observations/NNS
on/IN
Tcf-1/NN
knock-out/JJ
mice/NNS
./.
====================
In/IN
addition/NN
,/,
these/DT
results/NNS
indicate/VBP
that/IN
nuclear/JJ
TCF-1/NN
expression/NN
can/MD
serve/VB
as/IN
a/DT
pan-T-lineage/JJ
marker/NN
in/IN
the/DT
diagnosis/NN
of/IN
lymphoid/JJ
malignancies/NNS
./.
====================
UI/LS
-/:
96128660/CD
====================
TI/LS
-/:
Cross-linking/NN
of/IN
Fc/NN
gamma/NN
receptors/NNS
activates/VBZ
HIV-1/NN
long/JJ
terminal/JJ
repeat-driven/JJ
transcription/NN
in/IN
human/JJ
monocytes/NNS
./.
====================
AB/LS
-/:
Elevation/NN
of/IN
the/DT
levels/NNS
of/IN
circulating/VBG
immune/JJ
complexes/NNS
frequently/RB
accompanies/VBZ
HIV-1/NN
infection/NN
and/CC
is/VBZ
a/DT
prognostic/JJ
indicator/NN
of/IN
clinical/JJ
progression/NN
from/IN
asymptomatic/JJ
infection/NN
to/TO
AIDS/NN
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
cross-linking/NN
of/IN
Fc/NN
gamma/NN
RI/NN
or/CC
Fc/NN
gamma/NN
RII/NN
by/IN
adherent/JJ
human/JJ
IgG/NN
or/CC
by/IN
specific/JJ
anti-Fc/JJ
gamma/NN
R/NN
mAb/NN
activates/VBZ
HIV-1/NN
gene/NN
expression/NN
in/IN
the/DT
human/JJ
monocytic/JJ
cell/NN
line/NN
BF24/NN
and/CC
increased/VBN
HIV/NN
RNA/NN
expression/NN
in/IN
monocytes/NNS
from/IN
HIV/NN
infected/JJ
patients/NNS
as/IN
assayed/VBN
by/IN
reverse/JJ
transcription-PCR/NN
./.
====================
In/IN
THP-1/NN
cells/NNS
,/,
Fc/NN
gamma/NN
R/NN
cross-linking/NN
induced/VBD
NF-kappa/NN
B/NN
,/,
which/WDT
is/VBZ
known/VBN
to/TO
bind/VB
to/TO
the/DT
regulatory/JJ
region/NN
of/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
of/IN
HIV-1/NN
and/CC
to/TO
activate/VB
HIV-1/NN
transcription/NN
./.
Anti-TNF-alpha/JJ
antibody/NN
but/CC
not/RB
anti-IL-1/JJ
beta/NN
antibody/NN
strongly/RB
inhibited/VBD
both/CC
the/DT
induction/NN
of/IN
HIV-1-LTR-driven/JJ
transcription/NN
and/CC
the/DT
induction/NN
of/IN
NF-kappa/NN
B/NN
by/IN
Fc/NN
gamma/NN
R/NN
cross-linking/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
Fc/NN
gamma/NN
R/NN
can/MD
mediate/VB
a/DT
TNF-alpha-dependent/JJ
induction/NN
of/IN
HIV-1/NN
gene/NN
transcription/NN
and/CC
suggest/VBP
that/IN
immune/JJ
complexes/NNS
may/MD
contribute/VB
to/TO
the/DT
pathophysiology/NN
of/IN
HIV-1/NN
infection/NN
by/IN
augmenting/VBG
viral/JJ
replication/NN
in/IN
monocytes/NNS
./.
====================
UI/LS
-/:
96003970/CD
====================
TI/LS
-/:
Signalling/NN
via/IN
CD28/NN
of/IN
human/JJ
naive/JJ
neonatal/JJ
T/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
Accessory/JJ
molecules/NNS
play/VBP
a/DT
crucial/JJ
role/NN
in/IN
the/DT
development/NN
of/IN
the/DT
T/NN
cell/NN
response/NN
to/TO
antigenic/JJ
challenge/NN
./.
====================
We/PRP
have/VBP
examined/VBN
the/DT
role/NN
of/IN
CD28/NN
in/IN
modulating/VBG
the/DT
'/``
naive/JJ
'/''
neonatal/JJ
T/NN
cell/NN
response/NN
to/TO
anti-CD2-mediated/JJ
activation/NN
./.
====================
To/TO
compare/VB
the/DT
role/NN
of/IN
CD28/NN
,/,
neonatal/JJ
and/CC
adult/JJ
T/NN
cells/NNS
were/VBD
stimulated/VBN
with/IN
a/DT
pair/NN
of/IN
mitogenic/JJ
anti-CD2/JJ
antibodies/NNS
in/IN
the/DT
presence/NN
or/CC
absence/NN
of/IN
anti-CD28/JJ
MoAb/NN
./.
====================
With/IN
anti-CD2/NN
alone/RB
,/,
neonatal/JJ
T/NN
cells/NNS
proliferated/VBD
slightly/RB
but/CC
produced/VBD
no/DT
detectable/JJ
IL-2/NN
,/,
whereas/IN
adult/JJ
T/NN
cells/NNS
proliferated/VBD
vigorously/RB
,/,
with/IN
significant/JJ
IL-2/NN
production/NN
./.
====================
Costimulation/NN
with/IN
anti-CD28/JJ
MoAb/NN
greatly/RB
enhanced/VBD
the/DT
proliferative/JJ
response/NN
of/IN
neonatal/JJ
T/NN
cells/NNS
to/TO
levels/NNS
equivalent/JJ
to/TO
those/DT
of/IN
adult/JJ
T/NN
cells/NNS
,/,
whereas/IN
adult/JJ
T/NN
cells/NNS
showed/VBD
only/RB
slight/JJ
increases/NNS
./.
====================
Although/IN
IL-2/NN
secretion/NN
was/VBD
increased/VBN
in/IN
the/DT
presence/NN
of/IN
anti-CD28/JJ
MoAb/NN
,/,
neonatal/JJ
T/NN
cell/NN
IL-2/NN
production/NN
remained/VBD
lower/JJR
than/IN
in/IN
adults/NNS
./.
====================
In/IN
contrast/NN
,/,
enhancement/NN
of/IN
IL-2/NN
mRNA/NN
expression/NN
in/IN
neonates/NNS
was/VBD
similar/JJ
to/TO
adult/JJ
levels/NNS
./.
====================
Anti-CD28/JJ
MoAb/NN
costimulation/NN
increased/VBD
NF/NN
kappa/NN
B/NN
levels/NNS
in/IN
neonates/NNS
,/,
albeit/IN
to/TO
levels/NNS
lower/JJR
than/IN
that/DT
of/IN
adults/NNS
./.
====================
The/DT
cellular/JJ
mechanism/NN
governing/VBG
the/DT
diminished/VBN
proliferative/JJ
response/NN
of/IN
neonatal/JJ
T/NN
lymphocytes/NNS
to/TO
anti-CD2/NN
may/MD
therefore/RB
be/VB
due/JJ
to/TO
decreased/VBN
NF/NN
kappa/NN
B/NN
induction/NN
,/,
reduced/VBN
IL-2/NN
mRNA/NN
expression/NN
and/CC
deficient/JJ
IL-2/NN
production/NN
./.
====================
Although/IN
anti-CD28/JJ
MoAb/NN
costimulation/NN
enhances/VBZ
all/DT
of/IN
the/DT
above/JJ
signals/NNS
,/,
NF/NN
kappa/NN
B/NN
and/CC
IL-2/NN
levels/NNS
remain/VBP
lower/JJR
than/IN
in/IN
adults/NNS
,/,
suggesting/VBG
the/DT
need/NN
for/IN
further/JJ
activation/NN
requirements/NNS
in/IN
the/DT
neonate/NN
./.
====================
UI/LS
-/:
95391995/CD
====================
TI/LS
-/:
TCL1/NN
oncogene/NN
activation/NN
in/IN
preleukemic/JJ
T/NN
cells/NNS
from/IN
a/DT
case/NN
of/IN
ataxia-telangiectasia/NN
./.
====================
AB/LS
-/:
The/DT
TCL1/NN
oncogene/NN
on/IN
human/JJ
chromosome/NN
14q32.1/NN
is/VBZ
involved/VBN
in/IN
chromosome/NN
translocations/NNS
[/(
t(14;14)(q11;q32.1)/NN
and/CC
t(7;14)(q35;q32.1)/NN
]/)
and/CC
inversions/NNS
[/(
inv14(q11;q32.1)/NN
]/)
with/IN
TCR/NN
alpha/beta/NN
loci/NNS
in/IN
T-cell/NN
leukemias/NNS
,/,
such/JJ
as/IN
T-prolymphocytic/JJ
(/(
T-PLL/NN
)/)
./.
====================
It/PRP
is/VBZ
also/RB
involved/VBN
in/IN
T-acute/JJ
and/CC
-chronic/JJ
leukemias/NNS
arising/VBG
in/IN
cases/NNS
of/IN
ataxia-telangiectasia/NN
(/(
AT/NN
)/)
,/,
an/DT
immunodeficiency/NN
syndrome/NN
./.
====================
Similar/JJ
chromosomal/JJ
rearrangements/NNS
occur/VBP
also/RB
in/IN
the/DT
clonally/RB
expanded/VBN
T/NN
cells/NNS
in/IN
AT/NN
patients/NNS
before/IN
the/DT
appearance/NN
of/IN
the/DT
overt/JJ
leukemia/NN
./.
====================
We/PRP
have/VBP
analyzed/VBN
the/DT
expression/NN
of/IN
TCL1/NN
mRNA/NN
and/CC
protein/NN
in/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
(/(
PBLs/NNS
)/)
from/IN
four/CD
AT/NN
cases/NNS
and/CC
from/IN
healthy/JJ
controls/NNS
./.
====================
We/PRP
found/VBD
that/IN
the/DT
TCL1/NN
gene/NN
was/VBD
overexpressed/VBN
in/IN
the/DT
PBLs/NNS
of/IN
an/DT
AT/NN
patient/NN
with/IN
a/DT
large/JJ
clonal/JJ
T-cell/NN
population/NN
exhibiting/VBG
the/DT
t(14;14)/NN
translocation/NN
but/CC
not/RB
in/IN
the/DT
lymphocytes/NNS
of/IN
the/DT
other/JJ
cases/NNS
./.
====================
Fluorescence/NN
in/FW
situ/FW
hybridization/NN
of/IN
the/DT
TCL1/NN
genomic/JJ
locus/NN
to/TO
lymphocyte/NN
metaphases/NNS
from/IN
the/DT
AT/NN
patient/NN
with/IN
the/DT
T-cell/NN
clonal/JJ
expansion/NN
showed/VBD
that/IN
the/DT
breakpoint/NN
of/IN
the/DT
t(14;14)/NN
translocation/NN
lies/VBZ
within/IN
the/DT
TCL1/NN
locus/NN
and/CC
is/VBZ
accompanied/VBN
by/IN
an/DT
inverted/VBN
duplication/NN
of/IN
the/DT
distal/JJ
part/NN
of/IN
chromosome/NN
14/CD
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
TCL1/NN
is/VBZ
activated/VBN
in/IN
preleukemic/JJ
clonal/JJ
cells/NNS
as/IN
a/DT
consequence/NN
of/IN
chromosome/NN
translocation/NN
involving/NN
sequences/NNS
from/IN
the/DT
TCR/NN
locus/NN
at/IN
14q11/NN
./.
====================
Deregulation/NN
of/IN
TCL1/NN
is/VBZ
the/DT
first/JJ
event/NN
in/IN
the/DT
initiation/NN
of/IN
malignancy/NN
in/IN
these/DT
types/NNS
of/IN
leukemias/NNS
and/CC
represents/VBZ
a/DT
potential/JJ
tool/NN
for/IN
clinical/JJ
evaluation/NN
./.
====================
UI/LS
-/:
95363941/CD
====================
TI/LS
-/:
C/EBP/NN
proteins/NNS
activate/VBP
transcription/NN
from/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
long/JJ
terminal/JJ
repeat/NN
in/IN
macrophages/monocytes/NNS
./.
====================
AB/LS
-/:
Three/CD
binding/VBG
sites/NNS
for/IN
C/EBP/NN
proteins/NNS
are/VBP
found/VBN
in/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
(/(
V.M./NNP
Tesmer/NNP
,/,
A.Rajadhyaksha/NNP
,/,
J.Babin/NNP
,/,
and/CC
M.Bina/NNP
,/,
Proc.Natl.Acad.Sci./NNP
USA/NNP
90/CD
:/:
7298-7302/CD
,/,
1993/CD
)/)
./.
====================
We/PRP
have/VBP
determined/VBN
the/DT
functional/JJ
role/NN
of/IN
C/EBP/NN
proteins/NNS
and/CC
C/EBP/NN
sites/NNS
in/IN
regulating/VBG
transcription/NN
from/IN
the/DT
HIV- 1/NN
LTR/NN
in/IN
monocytes/NNS
/macrophages/NNS
./.
====================
Inhibition/NN
of/IN
endogenous/JJ
C/EBP/NN
proteins/NNS
,/,
using/VBG
either/CC
an/DT
excess/NN
of/IN
C/EBP/NN
binding/NN
sites/NNS
or/CC
a/DT
trans- dominant/JJ
negative/JJ
inhibitor/NN
,/,
demonstrated/VBD
that/IN
C/EBP/NN
proteins/NNS
are/VBP
required/VBN
for/IN
basal/JJ
and/CC
activated/VBN
levels/NNS
of/IN
HIV-1/NN
LTR/NN
transcription/NN
in/IN
the/DT
promonocytic/JJ
cell/NN
line/NN
U937/NN
./.
====================
Northern/NN
(/(
RNA/NN
)/)
blots/NNS
and/CC
binding/NN
assays/NNS
showed/VBD
that/IN
NF-IL6/NN
is/VBZ
the/DT
only/RB
known/JJ
C/EBP/NN
family/NN
member/NN
which/WDT
is/VBZ
increased/VBN
when/WRB
U937/NN
cells/NNS
are/VBP
activated/VBN
./.
====================
Mutational/JJ
analyses/NNS
of/IN
the/DT
HIV-1/NN
LTR/NN
showed/VBD
that/IN
one/CD
C/EBP/NN
site/NN
is/VBZ
required/VBN
for/IN
normal/JJ
LTR/NN
transcription/NN
both/CC
before/IN
and/CC
after/IN
cellular/JJ
activation/NN
and/CC
that/IN
the/DT
two/CD
3'/JJ
C/EBP/NN
sites/NNS
are/VBP
functionally/RB
equivalent/JJ
./.
====================
However/RB
,/,
transcription/NN
from/IN
crippled/VBN
HIV-1/NN
LTRs/NNS
lacking/VBG
C/EBP/NN
sites/NNS
can/MD
still/RB
be/VB
induced/VBN
following/VBG
activation/NN
of/IN
U937/NN
cells/NNS
./.
====================
Several/JJ
models/NNS
are/VBP
suggested/VBN
for/IN
how/WRB
elevated/JJ
NF-IL6/NN
may/MD
participate/VB
in/IN
an/DT
autostimulatory/JJ
loop/NN
involving/VBG
HIV/NN
infection/NN
,/,
macrophage/NN
activation/NN
,/,
cytokine/NN
expression/NN
,/,
and/CC
HIV/NN
replication/NN
./.
====================
UI/LS
-/:
91175694/CD
====================
TI/LS
-/:
Human/JJ
immunodeficiency/NN
virus/NN
type-2/JJ
gene/NN
expression/NN
:/:
two/CD
enhancers/NNS
and/CC
their/PRP$
activation/NN
by/IN
T-cell/NN
activators/NNS
./.
====================
AB/LS
-/:
The/DT
human/JJ
immunodeficiency/NN
viruses/NNS
(/(
HIVs/NNS
)/)
may/MD
include/VB
a/DT
spectrum/NN
of/IN
retroviruses/NNS
with/IN
varying/VBG
potential/NN
to/TO
infect/VB
their/PRP$
host/NN
,/,
undergo/VB
long/JJ
periods/NNS
of/IN
latent/JJ
infection/NN
,/,
and/CC
induce/VB
pathology/NN
./.
====================
Since/IN
expression/NN
of/IN
the/DT
viruses/NNS
is/VBZ
in/IN
large/JJ
part/NN
regulated/VBN
by/IN
the/DT
sequence/NN
elements/NNS
in/IN
their/PRP$
long/JJ
terminal/JJ
repeats/NNS
(/(
LTRs/NNS
)/)
,/,
this/DT
study/NN
was/VBD
directed/VBN
to/TO
an/DT
analysis/NN
of/IN
the/DT
regulatory/JJ
elements/NNS
in/IN
the/DT
HIV-2/NN
LTR/NN
./.
====================
The/DT
HIV-2/NN
LTR/NN
was/VBD
found/VBN
to/TO
contain/VB
two/CD
enhancers/NNS
./.
====================
One/CD
of/IN
these/DT
enhancers/NNS
is/VBZ
,/,
in/IN
part/NN
,/,
identical/JJ
to/TO
the/DT
HIV-1/NN
enhancer/NN
./.
====================
This/DT
enhancer/NN
in/IN
HIV-1/NN
is/VBZ
the/DT
T-cell/NN
activation/NN
response/NN
element/NN
;/:
in/IN
HIV-2/NN
,/,
however/RB
,/,
it/PRP
is/VBZ
the/DT
second/JJ
enhancer/NN
that/WDT
is/VBZ
mainly/RB
responsible/JJ
for/IN
activation/NN
in/IN
response/NN
to/TO
T-cell/NN
activators/NNS
./.
====================
The/DT
second/JJ
enhancer/NN
interacts/VBZ
with/IN
two/CD
nuclear/JJ
binding/NN
proteins/NNS
(/(
85/CD
kD/NN
and/CC
27/CD
kD/NN
mobility/NN
)/)
that/WDT
appear/VBP
to/TO
be/VB
required/VBN
for/IN
optimal/JJ
enhancer/NN
function/NN
and/CC
activation/NN
./.
====================
Observations/NNS
such/JJ
as/IN
these/DT
encourage/VBP
the/DT
speculation/NN
that/IN
there/EX
may/MD
be/VB
subtle/JJ
differences/NNS
in/IN
the/DT
regulation/NN
of/IN
HIV-1/NN
and/CC
HIV-2/NN
expression/NN
that/WDT
may/MD
be/VB
relevant/JJ
to/TO
the/DT
possible/JJ
longer/JJR
latency/NN
and/CC
reduced/VBN
pathogenicity/NN
of/IN
HIV-2/NN
./.
====================
UI/LS
-/:
96134911/CD
====================
TI/LS
-/:
NF-M/NN
(/(
chicken/NN
C/EBP/NN
beta/NN
)/)
induces/VBZ
eosinophilic/JJ
differentiation/NN
and/CC
apoptosis/NN
in/IN
a/DT
hematopoietic/JJ
progenitor/NN
cell/NN
line/NN
./.
====================
AB/LS
-/:
CAAT/enhancer/NN
binding/NN
proteins/NNS
(/(
C/EBPs/NNS
)/)
are/VBP
transcriptional/JJ
activators/NNS
implicated/VBN
in/IN
the/DT
differentiation/NN
processes/NNS
of/IN
various/JJ
cell/NN
lineages/NNS
./.
====================
We/PRP
have/VBP
shown/VBN
earlier/RBR
that/IN
NF-M/NN
,/,
the/DT
chicken/NN
homolog/NN
of/IN
C/EBP/NN
beta/NN
,/,
is/VBZ
specifically/RB
expressed/VBN
in/IN
myelomonocytic/JJ
and/CC
eosinophilic/JJ
cells/NNS
of/IN
the/DT
hematopoietic/JJ
system/NN
./.
====================
To/TO
investigate/VB
the/DT
role/NN
of/IN
NF-M/NN
in/IN
hematopoietic/JJ
cell/NN
lineage/NN
commitment/NN
,/,
we/PRP
constructed/VBD
a/DT
conditional/JJ
form/NN
of/IN
the/DT
protein/NN
by/IN
fusing/VBG
it/PRP
to/TO
the/DT
hormone/NN
binding/NN
domain/NN
of/IN
the/DT
human/JJ
estrogen/NN
receptor/NN
./.
====================
This/DT
construct/NN
was/VBD
stably/RB
expressed/VBN
in/IN
a/DT
multipotent/JJ
progenitor/NN
cell/NN
line/NN
transformed/VBN
by/IN
the/DT
Myb-Ets/NN
oncoprotein/NN
./.
====================
We/PRP
report/VBP
here/RB
that/IN
both/CC
NF-M-dependent/JJ
promoter/NN
constructs/NNS
and/CC
resident/JJ
genes/NNS
could/MD
be/VB
activated/VBN
by/IN
addition/NN
of/IN
beta-estradiol/NN
to/TO
the/DT
NF-M-estrogen/NN
receptor/NN
expressing/VBG
progenitors/NNS
./.
====================
At/IN
the/DT
same/JJ
time/NN
,/,
we/PRP
observed/VBD
a/DT
down-regulation/NN
of/IN
progenitor-specific/JJ
surface/NN
markers/NNS
and/CC
the/DT
up-regulation/NN
of/IN
differentiation/NN
markers/NNS
restricted/JJ
to/TO
the/DT
eosinophil/NN
and/CC
myeloid/JJ
lineages/NNS
./.
====================
In/IN
addition/NN
to/TO
the/DT
onset/NN
of/IN
differentiation/NN
,/,
cell/NN
death/NN
was/VBD
induced/VBN
with/IN
typical/JJ
apoptotic/JJ
features/NNS
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
NF-M/NN
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
commitment/NN
along/IN
the/DT
eosinophil/NN
lineage/NN
and/CC
in/IN
the/DT
induction/NN
of/IN
apoptosis/NN
./.
====================
UI/LS
-/:
96079922/CD
====================
TI/LS
-/:
Prolactin/NN
and/CC
interleukin-2/NN
receptors/NNS
in/IN
T/NN
lymphocytes/NNS
signal/VBP
through/IN
a/DT
MGF-STAT5-like/JJ
transcription/NN
factor/NN
./.
====================
AB/LS
-/:
The/DT
cell/NN
surface/NN
receptors/NNS
for/IN
PRL/NN
and/CC
interleukin-2/NN
(/(
IL-2/NN
)/)
are/VBP
structurally/RB
distinct/JJ
,/,
but/CC
share/VBP
regulatory/JJ
tasks/NNS
in/IN
T/NN
lymphocytes/NNS
./.
====================
They/PRP
can/MD
stimulate/VB
proliferation/NN
and/CC
activate/VB
transcription/NN
of/IN
over-lapping/JJ
sets/NNS
of/IN
genes/NNS
of/IN
T/NN
cells/NNS
./.
====================
PRL/NN
and/CC
IL-2/NN
receptor/NN
activation/NN
are/VBP
both/DT
linked/VBN
to/TO
the/DT
Jak/Stat/NN
(/(
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
)/)
pathway/NN
./.
====================
We/PRP
investigated/VBD
the/DT
ability/NN
of/IN
PRL/NN
and/CC
IL-2/NN
to/TO
activate/VB
Stat/NN
proteins/NNS
in/IN
different/JJ
T/NN
cell/NN
lines/NNS
./.
====================
The/DT
DNA/NN
binding/NN
specificities/NNS
,/,
the/DT
reactivities/NNS
toward/IN
Stat-specific/JJ
antisera/NNS
,/,
and/CC
the/DT
mol/NN
wt/NN
of/IN
IL-2-/NN
and/CC
PRL-induced/JJ
DNA-binding/JJ
proteins/NNS
in/IN
Nb2/NN
and/CC
C196/NN
T/NN
cell/NN
lines/NNS
were/VBD
investigated/VBN
./.
====================
A/DT
comparison/NN
with/IN
the/DT
Stat/NN
proteins/NNS
induced/VBN
by/IN
interferon-gamma/NN
,/,
PRL/NN
,/,
and/CC
IL-6/NN
in/IN
T47D/NN
mammary/JJ
tumor/NN
cells/NNS
was/VBD
made/VBN
./.
====================
We/PRP
found/VBD
that/IN
these/DT
parameters/NNS
were/VBD
indistinguishable/JJ
for/IN
one/CD
of/IN
the/DT
PRL-/NN
and/CC
IL-2-induced/JJ
factors/NNS
./.
====================
A/DT
transcription/NN
factor/NN
closely/RB
related/JJ
to/TO
mammary/JJ
gland/NN
factor-Stat5/NN
is/VBZ
rapidly/RB
activated/VBN
upon/IN
interaction/NN
of/IN
IL-2/NN
and/CC
PRL/NN
with/IN
their/PRP$
respective/JJ
receptors/NNS
./.
====================
Activation/NN
of/IN
a/DT
second/JJ
protein/NN
related/JJ
to/TO
Stat1/NN
was/VBD
also/RB
observed/VBN
./.
====================
Our/PRP$
results/NNS
emphasize/VBP
the/DT
role/NN
of/IN
PRL/NN
as/IN
a/DT
regulator/NN
of/IN
the/DT
immune/JJ
response/NN
and/CC
indicate/VBP
that/IN
the/DT
Stat/NN
factors/NNS
mammary/JJ
gland/NN
factor-Stat5/NN
and/CC
Stat1/NN
play/VBP
a/DT
role/NN
in/IN
the/DT
regulation/NN
of/IN
gene/NN
expression/NN
during/IN
T/NN
cell/NN
development/NN
./.
====================
UI/LS
-/:
96074843/CD
====================
TI/LS
-/:
ETS1/NN
transactivates/VBZ
the/DT
human/JJ
GM-CSF/NN
promoter/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
stimulated/VBN
with/IN
PMA/NN
and/CC
ionomycin/NN
./.
====================
AB/LS
-/:
Activation/NN
of/IN
T/NN
helper/NN
cells/NNS
results/VBZ
in/IN
coordinate/JJ
expression/NN
of/IN
a/DT
number/NN
of/IN
cytokines/NNS
involved/VBN
in/IN
differentiation/NN
,/,
proliferation/NN
and/CC
activation/NN
of/IN
the/DT
haematopoietic/JJ
system/NN
./.
====================
Granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
is/VBZ
one/CD
such/JJ
cytokine/NN
whose/WP$
increased/VBN
expression/NN
results/VBZ
partly/RB
from/IN
increases/NNS
in/IN
transcription/NN
./.
====================
Cis-acting/JJ
elements/NNS
with/IN
NF/NN
kappa/NN
B/NN
,/,
AP-1/NN
and/CC
ETS-like/JJ
motifs/NNS
have/VBP
been/VBN
identified/VBN
in/IN
the/DT
promoter/NN
region/NN
of/IN
the/DT
GM-CSF/NN
gene/NN
,/,
which/WDT
are/VBP
important/JJ
for/IN
transcriptional/JJ
activity/NN
following/VBG
PMA/NN
and/CC
ionomycin/NN
stimulation/NN
./.
====================
A/DT
number/NN
of/IN
the/DT
ETS/NN
family/NN
of/IN
transcription/NN
factors/NNS
are/VBP
expressed/VBN
in/IN
T/NN
cells/NNS
,/,
including/VBG
ETS1/NN
and/CC
ELF1/NN
./.
====================
Here/RB
we/PRP
describe/VBP
the/DT
ability/NN
of/IN
these/DT
factors/NNS
to/TO
interact/VB
with/IN
a/DT
site/NN
(/(
GM5/NN
)/)
,/,
located/JJ
within/IN
the/DT
CLE0/NN
element/NN
,/,
-47/CD
to/TO
-40/CD
upstream/RB
of/IN
the/DT
GM-CSF/NN
transcription/NN
initiation/NN
site/NN
./.
====================
Exogenous/JJ
ETS1/NN
,/,
but/CC
not/RB
ELF1/NN
,/,
can/MD
transactivate/VB
GM-CSF/NN
,/,
through/IN
the/DT
GM5/NN
site/NN
,/,
in/IN
a/DT
PMA/NN
/ionomycin/NN
dependent/JJ
manner/NN
./.
====================
Other/JJ
unidentified/JJ
ETS-like/JJ
factors/NNS
present/JJ
in/IN
Jurkat/NN
cells/NNS
are/VBP
also/RB
capable/JJ
of/IN
binding/VBG
GM5/NN
./.
====================
Mutation/NN
of/IN
the/DT
core/NN
ETS/NN
binding/NN
site/NN
from/IN
-GGAA-/NN
to/TO
-GGAT-/NN
prevents/VBZ
the/DT
binding/NN
of/IN
ETS-like/JJ
factors/NNS
with/IN
the/DT
exception/NN
of/IN
ETS1/NN
./.
====================
The/DT
GM-CSF/NN
promoter/NN
,/,
modified/VBN
in/IN
this/DT
way/NN
to/TO
be/VB
ETS1/NN
specific/JJ
,/,
is/VBZ
fully/RB
responsive/JJ
to/TO
PMA/NN
/ionomycin/NN
induction/NN
,/,
in/IN
addition/NN
to/TO
ETS1/NN
transactivation/NN
in/IN
the/DT
presence/NN
of/IN
PMA/NN
and/CC
ionomycin/NN
./.
====================
Together/RB
these/DT
data/NNS
suggest/VBP
that/IN
ETS1/NN
may/MD
be/VB
involved/VBN
in/IN
mediating/VBG
the/DT
increased/VBN
GM-CSF/NN
production/NN
associated/VBN
with/IN
T/NN
cell/NN
activation/NN
./.
====================
UI/LS
-/:
96379940/CD
====================
TI/LS
-/:
Quantitation/NN
of/IN
beta/NN
1/CD
triiodothyronine/NN
receptor/NN
mRNA/NN
in/IN
human/JJ
tissues/NNS
by/IN
competitive/JJ
reverse/JJ
transcription/NN
polymerase/NN
chain/NN
reaction/NN
./.
====================
AB/LS
-/:
Thyroid/NN
hormones/NNS
act/VBP
by/IN
binding/VBG
to/TO
nuclear/JJ
receptor/NN
proteins/NNS
,/,
the/DT
thyroid/NN
hormone/NN
receptors/NNS
(/(
TR/NN
)/)
alpha/NN
and/CC
beta/NN
./.
====================
Data/NNS
from/IN
cell/NN
culture/NN
and/CC
animal/NN
studies/NNS
indicate/VBP
that/IN
TR/NN
expression/NN
may/MD
be/VB
regulated/VBN
to/TO
modulate/VB
target/NN
organ/NN
responsiveness/NN
to/TO
thyroid/NN
hormone/NN
./.
====================
To/TO
investigate/VB
whether/IN
such/JJ
adaptive/JJ
changes/NNS
in/IN
TR/NN
expression/NN
occur/VBP
in/IN
humans/NNS
,/,
we/PRP
determined/VBD
the/DT
mRNA/NN
levels/NNS
of/IN
the/DT
hTR/NN
beta/NN
1/CD
in/IN
various/JJ
thyroid/NN
states/NNS
./.
====================
Patients/NNS
with/IN
overt/JJ
hypo-/JJ
or/CC
hyperthyroidism/NN
were/VBD
enrolled/VBN
in/IN
the/DT
study/NN
./.
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
and/CC
hTR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
determined/VBN
by/IN
quantitative/JJ
competitive/JJ
reverse/JJ
transcription/NN
PCR/NN
./.
====================
For/IN
comparison/NN
,/,
hTR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
were/VBD
determined/VBN
in/IN
lymphocytes/NNS
and/CC
normal/JJ
thyroid/NN
tissue/NN
of/IN
euthyroid/NN
patients/NNS
./.
====================
Human/JJ
TR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
in/IN
lymphocytes/NNS
were/VBD
1.8/CD
+/-/CC
0.4/CD
,/,
1.9/CD
+/-/CC
0.5/CD
,/,
1.1/CD
+/-/CC
0.4/CD
10/CD
(/(
-18/CD
)/)
mol/microgram/NN
RNA/NN
in/IN
hypo-/JJ
,/,
eu-/JJ
and/CC
hyperthyroid/JJ
patients/NNS
,/,
respectively/RB
,/,
corresponding/VBG
to/TO
an/DT
estimated/VBN
0.5 -2/CD
molecules/NNS
per/IN
cell/NN
./.
====================
Although/IN
the/DT
mean/JJ
hTR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
were/VBD
40/CD
%/NN
lower/JJR
in/IN
hyperthyroid/JJ
than/IN
in/IN
euthyroid/JJ
subjects/NNS
,/,
this/DT
difference/NN
did/VBD
not/RB
reach/VB
statistical/JJ
significance/NN
./.
====================
Similar/JJ
levels/NNS
of/IN
hTR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
were/VBD
detected/VBN
in/IN
thyroid/NN
gland/NN
from/IN
euthyroid/JJ
patients/NNS
./.
====================
In/IN
summary/NN
,/,
we/PRP
developed/VBD
an/DT
assay/NN
for/IN
the/DT
quantitative/JJ
determination/NN
of/IN
hTR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
in/IN
small/JJ
human/JJ
tissue/NN
samples/NNS
,/,
containing/VBG
as/RB
little/JJ
as/IN
50/CD
ng/NN
of/IN
total/JJ
RNA/NN
./.
====================
Absolute/JJ
hTR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
are/VBP
very/RB
low/JJ
with/IN
an/DT
estimated/VBN
one/CD
molecule/NN
of/IN
mRNA/NN
being/VBG
present/JJ
in/IN
a/DT
mononuclear/JJ
blood/NN
cell/NN
or/CC
thyrocyte/NN
./.
====================
No/DT
up-regulation/NN
of/IN
hTR/NN
beta/NN
1/CD
was/VBD
seen/VBN
in/IN
hypothyroid/JJ
relative/JJ
to/TO
euthyroid/JJ
patients/NNS
./.
====================
However/RB
,/,
there/EX
is/VBZ
a/DT
non-significant/JJ
trend/NN
towards/IN
a/DT
down-regulation/NN
of/IN
hTR/NN
beta/NN
1/CD
mRNA/NN
levels/NNS
in/IN
hyperthyroid/JJ
patients/NNS
./.
====================
UI/LS
-/:
96025857/CD
====================
TI/LS
-/:
Multiple/JJ
proteins/NNS
interact/VBP
with/IN
the/DT
nuclear/JJ
inhibitory/JJ
protein/NN
repressor/NN
element/NN
in/IN
the/DT
human/JJ
interleukin-3/NN
promoter/NN
./.
====================
AB/LS
-/:
T/NN
cell/NN
expression/NN
of/IN
interleukin/NN
3/CD
(/(
IL-3/NN
)/)
is/VBZ
directed/VBN
by/IN
positive/JJ
and/CC
negative/JJ
cis-acting/JJ
DNA/NN
elements/NNS
clustered/JJ
within/IN
300/CD
base/NN
pairs/NNS
of/IN
the/DT
transcriptional/JJ
start/NN
site/NN
./.
====================
A/DT
strong/JJ
repressor/NN
element/NN
,/,
termed/VBN
nuclear/JJ
inhibitory/JJ
protein/NN
(/(
NIP/NN
)/)
,/,
was/VBD
previously/RB
mapped/VBN
to/TO
a/DT
segment/NN
of/IN
the/DT
IL-3/NN
promoter/NN
between/IN
nucleotides/NNS
-271/CD
and/CC
-250/CD
./.
====================
Functional/JJ
characterization/NN
of/IN
this/DT
element/NN
demonstrates/VBZ
that/IN
it/PRP
can/MD
mediate/VB
repression/NN
when/WRB
linked/VBN
in/IN
cis/NN
to/TO
a/DT
heterologous/JJ
promoter/NN
./.
====================
DNA/NN
binding/NN
experiments/NNS
were/VBD
carried/VBN
out/RP
to/TO
characterize/VB
the/DT
repressor/NN
activity/NN
./.
====================
Using/VBG
varying/JJ
conditions/NNS
,/,
three/CD
distinct/JJ
complexes/NNS
were/VBD
shown/VBN
to/TO
interact/VB
specifically/RB
with/IN
the/DT
NIP/NN
region/NN
,/,
although/IN
only/RB
one/CD
correlates/VBZ
with/IN
repressor/NN
activity/NN
./.
====================
Complex/NN
1/CD
results/VBZ
from/IN
binding/NN
of/IN
a/DT
ubiquitous/JJ
polypeptide/NN
that/WDT
recognizes/VBZ
the/DT
3'/JJ
portion/NN
of/IN
this/DT
sequence/NN
and/CC
is/VBZ
not/RB
required/VBN
for/IN
repression/NN
./.
====================
Complex/NN
2/CD
corresponds/VBZ
to/TO
binding/NN
of/IN
transcription/NN
factor/NN
(/(
upstream/JJ
stimulatory/JJ
factor/NN
)/)
to/TO
an/DT
E-box/NN
motif/NN
in/IN
the/DT
5'/JJ
portion/NN
of/IN
the/DT
NIP/NN
region/NN
./.
====================
DNA/NN
binding/NN
specificity/NN
of/IN
complex/NN
3/CD
overlaps/VBZ
with/IN
that/DT
of/IN
upstream/JJ
stimulatory/JJ
factor/NN
but/CC
is/VBZ
clearly/RB
distinct/JJ
./.
====================
To/TO
determine/VB
which/WDT
of/IN
the/DT
latter/JJ
two/CD
complexes/NNS
represents/VBZ
NIP/NN
activity/NN
,/,
we/PRP
incorporated/VBD
small/JJ
alterations/NNS
into/IN
the/DT
NIP/NN
site/NN
of/IN
an/DT
IL-3/NN
promoter-linked/JJ
reporter/NN
construct/NN
and/CC
examined/VBD
their/PRP$
effects/NNS
on/IN
NIP-mediated/JJ
repression/NN
./.
====================
Functional/JJ
specificity/NN
for/IN
repression/NN
matches/VBZ
the/DT
DNA/NN
binding/NN
specificity/NN
of/IN
complex/NN
3/CD
;/:
both/DT
repressor/NN
activity/NN
and/CC
complex/NN
3/CD
binding/NN
require/VBP
the/DT
consensus/NN
sequence/NN
CTCACNTNC/NN
./.
====================
UI/LS
-/:
95399778/CD
====================
TI/LS
-/:
The/DT
hematopoietic/JJ
transcription/NN
factor/NN
PU.1/NN
is/VBZ
downregulated/VBN
in/IN
human/JJ
multiple/JJ
myeloma/NN
cell/NN
lines/NNS
./.
====================
AB/LS
-/:
PU.1/NN
is/VBZ
a/DT
hematopoietic/JJ
transcription/NN
factor/NN
belonging/VBG
to/TO
the/DT
Ets-family/NN
./.
====================
It/PRP
is/VBZ
identical/JJ
to/TO
the/DT
Spi-1/NN
oncogene/NN
,/,
which/WDT
is/VBZ
implicated/VBN
in/IN
spleen/NN
focus-forming/JJ
virus-induced/JJ
murine/JJ
erythroleukemias/NNS
./.
====================
PU.1/NN
seems/VBZ
to/TO
be/VB
required/VBN
for/IN
early/JJ
development/NN
of/IN
multiple/JJ
hematopoietic/JJ
lineages/NNS
,/,
but/CC
its/PRP$
expression/NN
in/IN
mature/JJ
cells/NNS
is/VBZ
preferentially/RB
observed/VBN
in/IN
cells/NNS
of/IN
the/DT
B-cell-and/NN
monocyte/macrophage-differentiation/NN
lineage/NN
./.
====================
It/PRP
binds/VBZ
the/DT
so-called/JJ
Pu/NN
box/NN
,/,
an/DT
important/JJ
tissue-specific/JJ
regulatory/JJ
DNA/NN
element/NN
present/JJ
in/IN
a/DT
number/NN
of/IN
genes/NNS
expressed/VBN
in/IN
these/DT
cell/NN
lineages/NNS
./.
====================
We/PRP
have/VBP
analyzed/VBN
the/DT
expression/NN
and/CC
activity/NN
of/IN
PU.1/NN
during/IN
human/JJ
B-cell/NN
development/NN
using/VBG
a/DT
panel/NN
of/IN
B-cell/NN
lines/NNS
representing/VBG
different/JJ
stages/NNS
of/IN
maturation/NN
,/,
from/IN
early/JJ
precursors/NNS
to/TO
differentiated/VBN
plasma/NN
cells/NNS
./.
====================
PU.1/NN
mRNA/NN
expression/NN
and/CC
PU.1/NN
DNA/NN
binding/NN
activity/NN
,/,
as/IN
measured/VBN
by/IN
Northern/NN
blot/NN
analysis/NN
and/CC
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
,/,
respectively/RB
,/,
were/VBD
evident/JJ
in/IN
cell/NN
lines/NNS
representing/VBG
pro-B/JJ
,/,
pre-B/JJ
,/,
and/CC
mature/JJ
B/NN
cells/NNS
./.
====================
We/PRP
could/MD
also/RB
show/VB
Pu/NN
box-dependent/JJ
transactivation/NN
of/IN
a/DT
reporter/NN
gene/NN
in/IN
transient/JJ
transfections/NNS
in/IN
these/DT
cell/NN
lines/NNS
./.
====================
In/IN
contrast/NN
,/,
in/IN
a/DT
number/NN
of/IN
multiple/JJ
myeloma/NN
cell/NN
lines/NNS
,/,
representing/VBG
differentiated/VBN
,/,
plasma/NN
cell-like/JJ
B/NN
cells/NNS
,/,
PU.1/NN
DNA/NN
binding/NN
activity/NN
,/,
mRNA/NN
expression/NN
,/,
and/CC
Pu/NN
box-dependent/JJ
transactivation/NN
were/VBD
absent/JJ
or/CC
detectable/JJ
at/IN
a/DT
very/RB
low/JJ
level/NN
./.
====================
In/IN
lymphoblastoid/JJ
cell/NN
lines/NNS
,/,
which/WDT
exemplify/VBP
an/DT
intermediate/JJ
stage/NN
of/IN
B-cell/NN
differentiation/NN
,/,
a/DT
reduced/VBN
expression/NN
and/CC
activity/NN
were/VBD
observed/VBN
./.
====================
The/DT
findings/NNS
in/IN
the/DT
human/JJ
multiple/JJ
myeloma/NN
cell/NN
lines/NNS
represent/VBP
the/DT
first/JJ
examples/NNS
of/IN
B/NN
cells/NNS
with/IN
downregulated/VBN
PU.1/NN
expression/NN
and/CC
apparently/RB
contradict/VBP
observations/NNS
in/IN
the/DT
murine/JJ
system/NN
in/IN
which/WDT
PU.1/NN
is/VBZ
expressed/VBN
and/CC
active/JJ
in/IN
plasmacytoma/NN
cell/NN
lines/NNS
./.
====================
At/IN
present/JJ
,/,
it/PRP
is/VBZ
unclear/JJ
whether/IN
the/DT
lack/NN
of/IN
PU.1/NN
expression/NN
and/CC
activity/NN
in/IN
human/JJ
multiple/JJ
myeloma/NN
cell/NN
lines/NNS
represents/VBZ
a/DT
malignancy-associated/JJ
defect/NN
in/IN
these/DT
cells/NNS
or/CC
exemplifies/VBZ
a/DT
normal/JJ
developmental/JJ
regulation/NN
in/IN
terminally/RB
differentiated/VBN
B/NN
cells/NNS
./.
====================
UI/LS
-/:
95399771/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
and/CC
E-selectin/NN
expression/NN
in/IN
endothelial/JJ
cells/NNS
by/IN
cyclosporin/NN
A/NN
and/CC
the/DT
T-cell/NN
transcription/NN
factor/NN
NFAT/NN
./.
====================
AB/LS
-/:
Nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFAT/NN
)/)
was/VBD
originally/RB
described/VBN
as/IN
a/DT
T-cell-specific/JJ
transcription/NN
factor/NN
athat/WDT
supported/VBD
the/DT
activation/NN
of/IN
cytokine/NN
gene/NN
expression/NN
and/CC
mediated/VBD
the/DT
immunoregulatory/JJ
effects/NNS
of/IN
cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
./.
====================
As/IN
we/PRP
observed/VBD
that/IN
activated/VBN
endothelial/JJ
cells/NNS
also/RB
expressed/VBD
NFAT/NN
,/,
we/PRP
tested/VBD
the/DT
antiinflammatory/JJ
properties/NNS
of/IN
CsA/NN
in/IN
endothelial/JJ
cells/NNS
./.
====================
Significantly/RB
,/,
CsA/NN
completely/RB
suppressed/VBD
the/DT
induction/NN
of/IN
NFAT/NN
in/IN
endothelial/JJ
cells/NNS
and/CC
inhibited/VBD
the/DT
activity/NN
of/IN
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
gene/NN
regulatory/JJ
elements/NNS
that/WDT
use/VBP
NFAT/NN
by/IN
60/CD
%/NN
./.
====================
CsA/NN
similarly/RB
mediated/VBD
a/DT
reduction/NN
of/IN
up/RB
to/TO
65/CD
%/NN
in/IN
GM-CSF/NN
mRNA/NN
and/CC
protein/NN
expression/NN
in/IN
activated/VBN
endothelial/JJ
cells/NNS
./.
====================
CsA/NN
also/RB
suppressed/VBD
E-selectin/NN
,/,
but/CC
not/RB
vascular/JJ
cell/NN
adhesion/NN
molecule-1/NN
(/(
VCAM-1/NN
)/)
expression/NN
in/IN
endothelial/JJ
cells/NNS
,/,
even/RB
though/IN
the/DT
E-selectin/NN
promoter/NN
is/VBZ
activated/VBN
by/IN
NF-kappa/NN
B/NN
rather/RB
than/IN
NFAT/NN
./.
====================
Hence/RB
,/,
induction/NN
of/IN
cell/NN
surface/NN
expression/NN
of/IN
this/DT
leukocyte/NN
adhesion/NN
molecule/NN
by/IN
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
)/)
-alpha/NN
was/VBD
reduced/VBN
by/IN
40/CD
%/NN
in/IN
the/DT
presence/NN
of/IN
CsA/NN
,/,
and/CC
this/DT
was/VBD
reflected/VBN
by/IN
a/DT
29/CD
%/NN
decrease/NN
in/IN
neutrophil/NN
adhesion/NN
./.
====================
The/DT
effects/NNS
of/IN
CsA/NN
on/IN
endothelial/JJ
cells/NNS
were/VBD
also/RB
detected/VBN
at/IN
the/DT
chromatin/NN
structure/NN
level/NN
,/,
as/IN
DNasel/NN
hypersensitive/JJ
sites/NNS
within/IN
both/CC
the/DT
GM-CSF/NN
enhancer/NN
and/CC
the/DT
E-selectin/NN
promoter/NN
were/VBD
suppressed/VBN
by/IN
CsA/NN
./.
====================
This/DT
represents/VBZ
the/DT
first/JJ
report/NN
of/IN
NFAT/NN
in/IN
endothelial/JJ
cells/NNS
and/CC
suggests/VBZ
mechanisms/NNS
by/IN
which/WDT
CsA/NN
could/MD
function/VB
as/IN
an/DT
antiinflammatory/JJ
agent/NN
./.
====================
UI/LS
-/:
96049646/CD
====================
TI/LS
-/:
Costimulation/NN
requirement/NN
for/IN
AP-1/NN
and/CC
NF-kappa/NN
B/NN
transcription/NN
factor/NN
activation/NN
in/IN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
transcriptional/JJ
activity/NN
of/IN
the/DT
IL-2/NN
promoter/NN
requires/VBZ
T-cell/NN
costimulation/NN
delivered/VBN
by/IN
the/DT
TCR/NN
and/CC
the/DT
auxiliary/JJ
receptor/NN
CD28/NN
./.
====================
Several/JJ
transcription/NN
factors/NNS
participate/VBP
in/IN
IL-2/NN
promoter/NN
activation/NN
,/,
among/IN
which/WDT
are/VBP
AP-1-like/JJ
factors/NNS
and/CC
NF-kappa/NN
B/NN
./.
====================
Protein/NN
phosphorylation/NN
has/VBZ
an/DT
important/JJ
role/NN
in/IN
the/DT
regulation/NN
of/IN
these/DT
two/CD
factors/NNS
:/:
(/(
1/LS
)/)
it/PRP
induces/VBZ
the/DT
transactivating/NN
capacity/NN
of/IN
the/DT
AP-1/NN
protein/NN
c-Jun/NN
;/:
and/CC
(/(
2/LS
)/)
it/PRP
is/VBZ
involved/VBN
in/IN
the/DT
release/NN
of/IN
the/DT
cytoplasmic/JJ
inhibitor/NN
,/,
I/NN
kappa/NN
B/NN
,/,
from/IN
NF-kappa/NN
B/NN
,/,
allowing/VBG
translocation/NN
of/IN
the/DT
latter/JJ
into/IN
the/DT
nucleus/NN
./.
====================
We/PRP
have/VBP
recently/RB
shown/VBN
that/IN
both/DT
phosphorylation/NN
processes/NNS
require/VBP
T-cell/NN
costimulation/NN
./.
====================
Furthermore/RB
,/,
in/IN
activated/VBN
T/NN
cells/NNS
,/,
the/DT
kinetics/NNS
of/IN
the/DT
two/CD
phosphorylation/NN
events/NNS
are/VBP
essentially/RB
similar/JJ
./.
====================
According/VBG
to/TO
our/PRP$
results/NNS
,/,
however/RB
,/,
the/DT
kinases/NNS
responsible/JJ
for/IN
the/DT
two/CD
processes/NNS
are/VBP
distinct/JJ
entities/NNS
./.
====================
Whereas/IN
TPCK/NN
inhibits/VBZ
phosphorylation/NN
of/IN
I/NN
kappa/NN
B/NN
and/CC
,/,
consequently/RB
,/,
activation/NN
of/IN
NF-kappa/NN
B/NN
,/,
it/PRP
markedly/RB
enhances/VBZ
the/DT
activity/NN
of/IN
JNK/NN
,/,
the/DT
MAP/NN
kinase-related/JJ
kinase/NN
that/WDT
phosphorylates/VBZ
the/DT
transactivation/NN
domain/NN
of/IN
c-Jun/NN
./.
====================
We/PRP
,/,
therefore/RB
,/,
propose/VBP
the/DT
activation/NN
scheme/NN
presented/VBN
in/IN
FIGURE/NN
3/CD
for/IN
T-cell/NN
costimulation/NN
./.
====================
Costimulation/NN
results/VBZ
in/IN
the/DT
activation/NN
of/IN
a/DT
signaling/NN
pathway/NN
that/WDT
leads/VBZ
to/TO
the/DT
simultaneous/JJ
induction/NN
of/IN
the/DT
two/CD
transcription/NN
factors/NNS
,/,
AP-1/NN
and/CC
NF-kappa/NN
B/NN
./.
====================
Integration/NN
of/IN
the/DT
signals/NNS
generated/VBN
by/IN
TCR/NN
and/CC
CD28/NN
engagement/NN
occurs/VBZ
along/IN
this/DT
pathway/NN
,/,
which/WDT
then/RB
bifurcates/VBZ
to/TO
induce/VB
I/NN
kappa/NN
B/NN
phosphorylation/NN
and/CC
NF-kappa/NN
B/NN
activation/NN
on/IN
the/DT
one/CD
hand/NN
,/,
and/CC
JNK/NN
activation/NN
and/CC
c-Jun/NN
phosphorylation/NN
on/IN
the/DT
other/JJ
./.
====================
We/PRP
are/VBP
currently/RB
engaged/VBN
in/IN
defining/VBG
where/WRB
the/DT
two/CD
signals/NNS
integrate/VBP
along/IN
the/DT
AP-1/NN
/NF-kappa/NN
B/NN
pathway/NN
./.
====================
UI/LS
-/:
96035700/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
and/CC
cytokine/NN
gene/NN
expression/NN
in/IN
myeloid/JJ
cells/NNS
by/IN
NF-kappa/NN
B/NN
/Rel/NN
transcription/NN
factors/NNS
./.
====================
AB/LS
-/:
CD4+/JJ
macrophages/NNS
in/IN
tissues/NNS
such/JJ
as/IN
lung/NN
,/,
skin/NN
,/,
and/CC
lymph/NN
nodes/NNS
,/,
promyelocytic/JJ
cells/NNS
in/IN
bone/NN
marrow/NN
,/,
and/CC
peripheral/JJ
blood/NN
monocytes/NNS
serve/VBP
as/IN
important/JJ
targets/NNS
and/CC
reservoirs/NNS
for/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
replication/NN
./.
====================
HIV-1-infected/JJ
myeloid/JJ
cells/NNS
are/VBP
often/RB
diminished/VBN
in/IN
their/PRP$
ability/NN
to/TO
participate/VB
in/IN
chemotaxis/NN
,/,
phagocytosis/NN
,/,
and/CC
intracellular/JJ
killing/NN
./.
====================
HIV-1/NN
infection/NN
of/IN
myeloid/JJ
cells/NNS
can/MD
lead/VB
to/TO
the/DT
expression/NN
of/IN
surface/NN
receptors/NNS
associated/VBN
with/IN
cellular/JJ
activation/NN
and/or/CC
differentiation/NN
that/WDT
increase/VBP
the/DT
responsiveness/NN
of/IN
these/DT
cells/NNS
to/TO
cytokines/NNS
secreted/VBN
by/IN
neighboring/VBG
cells/NNS
as/RB
well/RB
as/IN
to/TO
bacteria/NNS
or/CC
other/JJ
pathogens/NNS
./.
====================
Enhancement/NN
of/IN
HIV-1/NN
replication/NN
is/VBZ
related/JJ
in/IN
part/NN
to/TO
increased/VBN
DNA-binding/JJ
activity/NN
of/IN
cellular/JJ
transcription/NN
factors/NNS
such/JJ
as/IN
NF-kappa/NN
B/NN
./.
====================
NF-kappa/NN
B/NN
binds/VBZ
to/TO
the/DT
HIV-1/NN
enhancer/NN
region/NN
of/IN
the/DT
long/JJ
terminal/JJ
repeat/NN
and/CC
contributes/VBZ
to/TO
the/DT
inducibility/NN
of/IN
HIV-1/NN
gene/NN
expression/NN
in/IN
response/NN
to/TO
multiple/JJ
activating/VBG
agents/NNS
./.
====================
Phosphorylation/NN
and/CC
degradation/NN
of/IN
the/DT
cytoplasmic/JJ
inhibitor/NN
I/NN
kappa/NN
B/NN
alpha/NN
are/VBP
crucial/JJ
regulatory/JJ
events/NNS
in/IN
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
DNA-binding/JJ
activity/NN
./.
====================
Both/CC
N-/NN
and/CC
C-terminal/JJ
residues/NNS
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
are/VBP
required/VBN
for/IN
inducer-mediated/JJ
degradation/NN
./.
====================
Chronic/JJ
HIV-1/NN
infection/NN
of/IN
myeloid/JJ
cells/NNS
leads/VBZ
to/TO
constitutive/JJ
NF-kappa/NN
B/NN
DNA-binding/JJ
activity/NN
and/CC
provides/VBZ
an/DT
intranuclear/JJ
environment/NN
capable/JJ
of/IN
perpetuating/VBG
HIV-1/NN
replication/NN
./.
====================
Increased/VBN
intracellular/JJ
stores/NNS
of/IN
latent/JJ
NF-kappa/NN
B/NN
may/MD
also/RB
result/VB
in/IN
rapid/JJ
inducibility/NN
of/IN
NF-kappa/NN
B-dependent/JJ
cytokine/NN
gene/NN
expression/NN
./.
====================
In/IN
response/NN
to/TO
secondary/JJ
pathogenic/JJ
infections/NNS
or/CC
antigenic/JJ
challenge/NN
,/,
cytokine/NN
gene/NN
expression/NN
is/VBZ
rapidly/RB
induced/VBN
,/,
enhanced/VBN
,/,
and/CC
sustained/JJ
over/RP
prolonged/JJ
periods/NNS
in/IN
HIV-1-infected/JJ
myeloid/JJ
cells/NNS
compared/VBN
with/IN
uninfected/JJ
cells/NNS
./.
====================
Elevated/JJ
levels/NNS
of/IN
several/JJ
inflammatory/JJ
cytokines/NNS
have/VBP
been/VBN
detected/VBN
in/IN
the/DT
sera/NN
of/IN
HIV-1-infected/JJ
individuals/NNS
./.
====================
Secretion/NN
of/IN
myeloid/JJ
cell-derived/JJ
cytokines/NNS
may/MD
both/CC
increase/VB
virus/NN
production/NN
and/CC
contribute/VB
to/TO
AIDS-associated/JJ
disorders/NNS
./.
====================
UI/LS
-/:
90173249/CD
====================
TI/LS
-/:
Steroid/NN
mediated/JJ
lysis/NN
of/IN
lymphoblasts/NNS
requires/VBZ
the/DT
DNA/NN
binding/NN
region/NN
of/IN
the/DT
steroid/NN
hormone/NN
receptor/NN
./.
====================
AB/LS
-/:
Glucocorticoids/NNS
kill/VBP
certain/JJ
types/NNS
of/IN
lymphoblasts/NNS
,/,
but/CC
the/DT
mechanisms/NNS
are/VBP
unknown/JJ
./.
====================
It/PRP
is/VBZ
clear/JJ
that/IN
sufficient/JJ
numbers/NNS
of/IN
functional/JJ
glucocorticoid/NN
receptors/NNS
are/VBP
required/VBN
to/TO
mediate/VB
lysis/NN
,/,
but/CC
whether/IN
they/PRP
do/VBP
so/RB
through/IN
the/DT
classical/JJ
model/NN
of/IN
steroid/NN
hormone/NN
activation/NN
and/CC
modulation/NN
of/IN
gene/NN
expression/NN
has/VBZ
not/RB
been/VBN
established/VBN
./.
====================
In/IN
this/DT
report/NN
we/PRP
have/VBP
asked/VBN
which/WDT
region/NN
(/(
s/NNS
)/)
of/IN
the/DT
steroid/NN
receptor/NN
are/VBP
important/JJ
for/IN
mediating/VBG
lysis/NN
in/IN
leukemic/JJ
T/NN
lymphoblasts/NNS
./.
====================
CEM-ICR/NN
27/CD
leukemic/JJ
lymphoblasts/NNS
,/,
a/DT
clone/NN
of/IN
CEM/NN
cells/NNS
which/WDT
lack/VBP
functional/JJ
glucocorticoid/NN
receptors/NNS
and/CC
therefore/RB
are/VBP
neither/CC
lysed/VBN
by/IN
dexamethasone/NN
nor/CC
capable/JJ
of/IN
showing/VBG
glutamine/NN
synthetase/NN
induction/NN
,/,
were/VBD
provided/VBN
with/IN
steroid/NN
receptors/NNS
by/IN
DNA/NN
transfections/NNS
of/IN
various/JJ
receptor/NN
gene/NN
constructs/NNS
./.
====================
We/PRP
measured/VBD
steroid/NN
mediated/JJ
lysis/NN
,/,
receptor/NN
number/NN
and/CC
induction/NN
of/IN
glutamine/NN
synthetase/NN
in/IN
the/DT
transfected/VBN
cells/NNS
./.
====================
Our/PRP$
results/NNS
provide/VBP
evidence/NN
that/IN
the/DT
lysis/NN
mechanism/NN
in/IN
the/DT
ICR27/NN
lymphoblasts/NNS
is/VBZ
restored/VBN
when/WRB
functional/JJ
receptor/NN
number/NN
is/VBZ
restored/VBN
./.
====================
The/DT
DNA/NN
binding/NN
region/NN
specifying/VBG
high/JJ
affinity/NN
for/IN
GRE/NN
sites/NNS
is/VBZ
required/VBN
./.
====================
Lysis/NN
is/VBZ
mediated/VBN
by/IN
any/DT
steroid/NN
that/WDT
allows/VBZ
for/IN
activation/NN
of/IN
the/DT
receptor/NN
containing/VBG
such/JJ
a/DT
region/NN
./.
====================
Our/PRP$
data/NNS
support/VBP
the/DT
view/NN
that/IN
steroid-mediated/JJ
cell/NN
death/NN
occurs/VBZ
by/IN
a/DT
process/NN
requiring/VBG
direct/JJ
interaction/NN
of/IN
steroid-receptor/JJ
complexes/NNS
with/IN
the/DT
genome/NN
./.
====================
UI/LS
-/:
96102041/CD
====================
TI/LS
-/:
Functional/JJ
characterization/NN
of/IN
the/DT
murine/JJ
homolog/NN
of/IN
the/DT
B/NN
cell-specific/JJ
coactivator/NN
BOB.1/OBF.1/NN
./.
====================
AB/LS
-/:
B/NN
cell-specific/JJ
transcriptional/JJ
promoter/NN
activity/NN
mediated/VBN
by/IN
the/DT
octamer/NN
motif/NN
requires/VBZ
the/DT
Oct1/NN
or/CC
Oct2/NN
protein/NN
and/CC
additional/JJ
B/NN
cell-restricted/JJ
cofactors/NNS
./.
====================
One/CD
such/JJ
cofactor/NN
,/,
BOB.1/OBF.1/NN
,/,
was/VBD
recently/RB
isolated/VBN
from/IN
human/JJ
B/NN
cells/NNS
./.
====================
Here/RB
,/,
we/PRP
describe/VBP
the/DT
isolation/NN
and/CC
detailed/JJ
characterization/NN
of/IN
the/DT
murine/JJ
homolog/NN
./.
====================
Full-length/JJ
cDNAs/NNS
and/CC
genomic/JJ
clones/NNS
were/VBD
isolated/VBN
,/,
and/CC
the/DT
gene/NN
structure/NN
was/VBD
determined/VBN
./.
Comparison/NN
of/IN
the/DT
deduced/VBN
amino/NN
acids/NNS
shows/VBZ
88/CD
%/NN
sequence/NN
identity/NN
between/IN
mouse/NN
and/CC
human/JJ
BOB.1/OBF.1/NN
./.
====================
The/DT
NH2-terminal/JJ
126/CD
amino/NN
acids/NNS
of/IN
BOB.1/OBF.1/NN
are/VBP
both/CC
essential/JJ
and/CC
sufficient/JJ
for/IN
interaction/NN
with/IN
the/DT
POU/NN
domains/NNS
of/IN
either/CC
Oct1/NN
or/CC
Oct2/NN
./.
====================
This/DT
protein-protein/JJ
interaction/NN
does/VBZ
not/RB
require/VB
the/DT
simultaneous/JJ
binding/NN
of/IN
Oct/NN
proteins/NNS
to/TO
DNA/NN
,/,
and/CC
high/JJ
resolution/NN
footprinting/NN
of/IN
the/DT
Oct-DNA/NN
interaction/NN
reveals/VBZ
that/IN
binding/NN
of/IN
BOB.1/OBF.1/NN
to/TO
Oct1/NN
or/CC
Oct2/NN
does/VBZ
not/RB
alter/VB
the/DT
interaction/NN
with/IN
DNA/NN
./.
====================
BOB.1/OBF.1/NN
can/MD
efficiently/RB
activate/VB
octamer-dependent/JJ
promoters/NNS
in/IN
fibroblasts/NNS
;/:
however/RB
,/,
it/PRP
fails/VBZ
to/TO
stimulate/VB
octamer-dependent/JJ
enhancer/NN
activity/NN
./.
====================
Fusion/NN
of/IN
subdomains/NNS
of/IN
BOB.1/OBF.1/NN
with/IN
the/DT
GAL4/NN
DNA/NN
binding/NN
domain/NN
reveals/VBZ
that/IN
both/CC
NH2-/NN
and/CC
COOH-terminal/JJ
domains/NNS
of/IN
BOB.1/OBF.1/NN
contribute/VBP
to/TO
full/JJ
transactivation/NN
function/NN
,/,
the/DT
COOH-terminal/JJ
domain/NN
is/VBZ
more/RBR
efficient/JJ
in/IN
this/DT
transactivation/NN
assay/NN
./.
====================
Consistent/JJ
with/IN
the/DT
failure/NN
of/IN
full-length/JJ
BOB.1/OBF.1/NN
to/TO
stimulate/VB
octamer-dependent/JJ
enhancer/NN
elements/NNS
in/IN
non/JJ
B/NN
cells/NNS
,/,
the/DT
GAL4/NN
fusions/NNS
likewise/RB
only/RB
stimulate/VBP
from/IN
a/DT
promoter-proximal/JJ
position/NN
./.
====================
UI/LS
-/:
96096469/CD
====================
TI/LS
-/:
Anti-immunoglobulin/NN
M/NN
activates/VBZ
nuclear/JJ
calcium/NN
/calmodulin-dependent/JJ
protein/NN
kinase/NN
II/CD
in/IN
human/JJ
B/NN
lymphocytes/NNS
./.
====================
AB/LS
-/:
We/PRP
and/CC
others/NNS
have/VBP
previously/RB
shown/VBN
that/IN
the/DT
nuclear/JJ
protein/NN
,/,
Ets-1/NN
,/,
is/VBZ
phosphorylated/VBN
in/IN
a/DT
calcium-dependent/JJ
manner/NN
after/IN
ligation/NN
of/IN
immunoglobulin/NN
(/(
Ig/NN
)/)
M/NN
on/IN
B/NN
lymphocytes/NNS
./.
====================
As/IN
this/DT
phosphorylation/NN
was/VBD
independent/JJ
of/IN
protein/NN
kinase/NN
C/NN
activity/NN
,/,
we/PRP
tested/VBD
whether/IN
a/DT
calcium/NN
/calmodulin-dependent/JJ
protein/NN
kinase/NN
(/(
CaM/NN
kinase/NN
)/)
might/MD
phosphorylate/VB
the/DT
Ets-1/NN
protein/NN
after/IN
elevation/NN
of/IN
intracellular/JJ
free/JJ
calcium/NN
concentrations/NNS
./.
====================
The/DT
dephosphorylated/JJ
form/NN
of/IN
Ets-1/NN
has/VBZ
been/VBN
shown/VBN
to/TO
bind/VB
to/TO
chromatin/NN
,/,
suggesting/VBG
that/IN
the/DT
operative/JJ
kinase/NN
should/MD
be/VB
detectable/JJ
in/IN
the/DT
nucleus/NN
./.
====================
We/PRP
prepared/VBD
nuclear/JJ
extracts/NNS
from/IN
two/CD
human/JJ
B/NN
cell/NN
lines/NNS
in/IN
which/WDT
increased/VBN
intracellular/JJ
free/JJ
calcium/NN
levels/NNS
correlated/VBD
with/IN
increased/VBN
phosphorylation/NN
of/IN
the/DT
Ets-1/NN
protein/NN
./.
====================
Activity/NN
of/IN
the/DT
CaM/NN
kinases/NNS
was/VBD
determined/VBN
using/VBG
a/DT
synthetic/JJ
peptide/NN
substrate/NN
both/CC
in/IN
the/DT
absence/NN
and/CC
presence/NN
of/IN
an/DT
inhibitor/NN
specific/JJ
for/IN
the/DT
CaM/NN
kinase/NN
family/NN
,/,
KN-62/NN
./.
====================
Stimulation/NN
of/IN
cells/NNS
with/IN
anti-IgM/NN
led/VBD
to/TO
increased/VBN
activity/NN
of/IN
a/DT
nuclear/JJ
kinase/NN
that/WDT
could/MD
phosphorylate/VB
the/DT
peptide/NN
,/,
and/CC
this/DT
activity/NN
was/VBD
reduced/VBN
by/IN
10/CD
microM/NN
KN-62/NN
./.
====================
Kinase/NN
activity/NN
was/VBD
reduced/VBN
in/IN
lysates/NNS
preadsorbed/VBN
using/VBG
an/DT
antibody/NN
specific/JJ
for/IN
CaM/NN
kinase/NN
II/CD
./.
====================
Two-dimensional/JJ
phosphopeptide/NN
maps/NNS
of/IN
the/DT
Ets-1/NN
protein/NN
from/IN
cells/NNS
incubated/VBN
with/IN
ionomycin/NN
or/CC
anti-IgM/NN
contained/VBD
two/CD
unique/JJ
phosphopeptides/NNS
that/WDT
were/VBD
absent/JJ
in/IN
untreated/JJ
cells/NNS
./.
====================
Incubation/NN
of/IN
isolated/VBN
Ets-1/NN
protein/NN
with/IN
purified/VBN
CaM/NN
kinase/NN
II/CD
produced/VBD
phosphorylation/NN
of/IN
peptides/NNS
that/WDT
migrated/VBD
identically/RB
to/TO
those/DT
found/VBN
in/IN
cells/NNS
incubated/VBN
with/IN
either/CC
anti-IgM/NN
or/CC
ionomycin/NN
./.
====================
These/DT
data/NNS
suggest/VBP
a/DT
model/NN
of/IN
signal/NN
transduction/NN
by/IN
the/DT
antigen/NN
receptor/NN
on/IN
B/NN
lymphocytes/NNS
in/IN
which/WDT
increased/VBN
intracellular/JJ
free/JJ
calcium/NN
can/MD
rapidly/RB
activate/VB
nuclear/JJ
CaM/NN
kinase/NN
II/CD
,/,
potentially/RB
resulting/VBG
in/IN
phosphorylation/NN
and/CC
regulation/NN
of/IN
DNA-binding/JJ
proteins/NNS
./.
====================
UI/LS
-/:
96096754/CD
====================
TI/LS
-/:
Transcriptional/JJ
activation/NN
and/CC
repression/NN
,/,
two/CD
properties/NNS
of/IN
the/DT
lymphoid-specific/JJ
transcription/NN
factor/NN
Oct-2a/NN
./.
====================
AB/LS
-/:
The/DT
lymphoid-specific/JJ
transcription/NN
factor/NN
Oct-2a/NN
contains/VBZ
two/CD
transcriptional/JJ
activation/NN
domains/NNS
which/WDT
are/VBP
located/JJ
within/IN
the/DT
N-terminal/JJ
and/CC
C-terminal/JJ
regions/NNS
./.
====================
To/TO
study/VB
their/PRP$
differential/JJ
activation/NN
properties/NNS
,/,
we/PRP
linked/VBD
the/DT
isolated/VBN
effector/NN
domains/NNS
to/TO
the/DT
GAL4/NN
DNA-binding/JJ
domain/NN
./.
====================
We/PRP
have/VBP
shown/VBN
that/IN
both/DT
activating/VBG
regions/NNS
of/IN
Oct-2a/NN
,/,
isolated/VBN
from/IN
their/PRP$
natural/JJ
context/NN
,/,
can/MD
activate/VB
transcription/NN
as/IN
promoter/NN
factors/NNS
./.
====================
In/IN
contrast/NN
to/TO
the/DT
C-terminus/NN
,/,
activation/NN
by/IN
the/DT
N-terminal/JJ
domain/NN
is/VBZ
dependent/JJ
on/IN
a/DT
yet/RB
unidentified/JJ
factor/NN
(/(
s/NNS
)/)
binding/VBG
to/TO
the/DT
simian/JJ
virus/NN
40/CD
enhancer/NN
./.
====================
The/DT
results/NNS
obtained/VBN
by/IN
duplication/NN
of/IN
activation/NN
domains/NNS
or/CC
their/PRP$
mixed/JJ
combination/NN
suggest/VBP
that/IN
the/DT
domains/NNS
are/VBP
functionally/RB
independent/JJ
./.
====================
However/RB
,/,
activation/NN
from/IN
a/DT
remote/JJ
position/NN
could/MD
only/RB
be/VB
achieved/VBN
with/IN
the/DT
C-terminus/NN
of/IN
Oct-2a/NN
in/IN
B/NN
cells/NNS
./.
====================
In/IN
lymphoid/JJ
cells/NNS
,/,
higher/JJR
activation/NN
levels/NNS
were/VBD
observed/VBN
,/,
suggesting/VBG
that/IN
distinct/JJ
B-cell-specific/JJ
cofactors/NNS
in/IN
concert/NN
with/IN
the/DT
effector/NN
domains/NNS
of/IN
Oct-2a/NN
might/MD
be/VB
involved/VBN
in/IN
mediating/VBG
transcription/NN
from/IN
proximal/JJ
and/CC
remote/JJ
positions/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
identified/VBD
a/DT
repression/NN
domain/NN
at/IN
the/DT
N-terminus/NN
of/IN
Oct-2a/NN
./.
====================
When/WRB
transferred/VBN
to/TO
a/DT
potent/JJ
activator/NN
,/,
transcriptional/JJ
stimulation/NN
was/VBD
inhibited/VBN
efficiently/RB
./.
====================
These/DT
results/NNS
underscore/VBP
the/DT
modular/JJ
structure/NN
of/IN
Oct-2a/NN
with/IN
separable/JJ
domains/NNS
for/IN
activation/NN
and/CC
repression/NN
and/CC
suggest/VBP
that/IN
Oct-2a/NN
might/MD
have/VB
complex/JJ
regulatory/JJ
functions/NNS
in/FW
vivo/FW
./.
====================
UI/LS
-/:
96029754/CD
====================
TI/LS
-/:
Nonopsonic/JJ
phagocytosis/NN
of/IN
Pseudomonas/FW
aeruginosa/FW
by/IN
macrophages/NNS
and/CC
polymorphonuclear/JJ
leukocytes/NNS
requires/VBZ
the/DT
presence/NN
of/IN
the/DT
bacterial/JJ
flagellum/NN
./.
====================
AB/LS
-/:
Whereas/IN
the/DT
mechanism/NN
of/IN
nonopsonic/JJ
phagocytosis/NN
of/IN
Pseudomonas/FW
aeruginosa/FW
has/VBZ
been/VBN
described/VBN
,/,
the/DT
bacterial/JJ
ligands/NNS
required/VBN
are/VBP
poorly/RB
understood/VBN
./.
====================
To/TO
identify/VB
the/DT
requisite/JJ
bacterial/JJ
ligands/NNS
,/,
studies/NNS
with/IN
isogenic/JJ
mutants/NNS
of/IN
P./FW
aeruginosa/FW
PAK/NN
lacking/VBG
pili/NNS
,/,
flagella/NNS
,/,
and/CC
the/DT
RpoN/NN
sigma/NN
factor/NN
were/VBD
undertaken/VBN
./.
====================
The/DT
RpoN/NN
mutant/NN
,/,
lacking/VBG
pili/NNS
,/,
flagella/NNS
,/,
and/CC
nonpilus/JJ
adhesins/NNS
,/,
bound/VBD
poorly/RB
and/CC
was/VBD
resistant/JJ
to/TO
ingestion/NN
by/IN
both/CC
macrophages/NNS
and/CC
neutrophils/NNS
./.
====================
Pili/NNS
were/VBD
not/RB
absolutely/RB
required/VBN
for/IN
binding/NN
or/CC
phagocytosis/NN
of/IN
P./FW
aeruginosa/FW
./.
====================
The/DT
presence/NN
of/IN
a/DT
flagellum/NN
was/VBD
not/RB
required/VBN
for/IN
binding/NN
of/IN
P./FW
aeruginosa/FW
to/TO
macrophages/NNS
but/CC
was/VBD
critical/JJ
for/IN
the/DT
subsequent/JJ
internalization/NN
of/IN
the/DT
bacterium/NN
,/,
suggesting/VBG
that/IN
this/DT
factor/NN
or/CC
a/DT
surface/NN
ligand/NN
associated/VBN
with/IN
its/PRP$
assembly/NN
was/VBD
responsible/JJ
for/IN
stimulation/NN
of/IN
nonopsonic/JJ
phagocytosis/NN
./.
====================
UI/LS
-/:
96025852/CD
====================
TI/LS
-/:
Identification/NN
of/IN
essential/JJ
GATA/NN
and/CC
Ets/NN
binding/NN
motifs/NNS
within/IN
the/DT
promoter/NN
of/IN
the/DT
platelet/NN
glycoprotein/NN
Ib/NN
alpha/NN
gene/NN
./.
====================
AB/LS
-/:
Platelet/NN
glycoprotein/NN
(/(
GP/NN
)/)
Ib-IX-V/NN
is/VBZ
a/DT
multisubunit/JJ
adhesion/NN
receptor/NN
that/WDT
supports/VBZ
platelet/NN
attachment/NN
to/TO
thrombogenic/JJ
surfaces/NNS
at/IN
sites/NNS
of/IN
vascular/JJ
injury/NN
./.
====================
The/DT
congenital/JJ
absence/NN
of/IN
the/DT
receptor/NN
results/VBZ
in/IN
a/DT
bleeding/JJ
disorder/NN
associated/VBN
with/IN
"/``
giant/JJ
"/''
platelets/NNS
,/,
a/DT
condition/NN
linking/VBG
the/DT
expression/NN
of/IN
the/DT
complex/NN
to/TO
platelet/NN
morphogenesis/NN
./.
====================
To/TO
understand/VB
better/JJR
the/DT
expression/NN
of/IN
the/DT
GP/NN
Ib-IX-V/NN
complex/NN
,/,
studies/NNS
were/VBD
undertaken/VBN
to/TO
define/VB
the/DT
essential/JJ
genetic/JJ
elements/NNS
supporting/VBG
the/DT
expression/NN
of/IN
the/DT
alpha-subunit/NN
of/IN
the/DT
complex/NN
(/(
GP/NN
Ib/NN
alpha/NN
)/)
./.
====================
GP/NN
Ib/NN
alpha/NN
promoter/NN
activity/NN
was/VBD
evaluated/VBN
by/IN
transfection/NN
of/IN
human/JJ
erythroleukemia/NN
cells/NNS
with/IN
reporter/NN
plasmids/NNS
coding/VBG
for/IN
the/DT
enzyme/NN
,/,
luciferase/NN
./.
====================
Studies/NNS
were/VBD
initiated/VBN
with/IN
a/DT
fragment/NN
extending/VBG
2,738/CD
nucleotides/NNS
5'/JJ
to/TO
the/DT
transcription/NN
start/NN
site/NN
and/CC
lead/VBD
to/TO
the/DT
identification/NN
of/IN
253/CD
nucleotides/NNS
retaining/VBG
full/JJ
promoter/NN
activity/NN
in/IN
human/JJ
erythroleukemia/NN
cells/NNS
./.
====================
In/IN
cells/NNS
of/IN
nonhematopoietic/JJ
lineage/NN
,/,
human/JJ
endothelial/JJ
and/CC
HeLa/NN
cells/NNS
,/,
the/DT
GP/NN
Ib/NN
alpha/NN
promoter/NN
activity/NN
was/VBD
no/RB
greater/JJR
than/IN
background/NN
levels/NNS
obtained/VBN
with/IN
promoterless/JJ
constructs/NNS
./.
====================
Gel/NN
shift/NN
assays/NNS
and/CC
site-directed/JJ
mutagenesis/NN
studies/NNS
defined/VBD
essential/JJ
GATA/NN
and/CC
Ets/NN
binding/NN
motifs/NNS
93/CD
and/CC
150/CD
nucleotides/NNS
upstream/JJ
of/IN
the/DT
transcription/NN
start/NN
site/NN
,/,
a/DT
finding/NN
which/WDT
further/RB
substantiates/VBZ
these/DT
elements/NNS
as/IN
important/JJ
determinants/NNS
of/IN
megakaryocytic/JJ
gene/NN
expression/NN
./.
====================
The/DT
results/NNS
define/VBP
essential/JJ
cis-acting/JJ
elements/NNS
responsible/JJ
for/IN
the/DT
expression/NN
of/IN
GP/NN
Ib/NN
alpha/NN
and/CC
provide/VBP
insights/NNS
into/IN
molecular/JJ
events/NNS
coinciding/VBG
with/IN
the/DT
release/NN
of/IN
normal/JJ
platelets/NNS
into/IN
the/DT
bloodstream/NN
./.
====================
UI/LS
-/:
96062038/CD
====================
TI/LS
-/:
CD30/NN
ligation/NN
induces/VBZ
nuclear/JJ
factor-kappa/NN
B/NN
activation/NN
in/IN
human/JJ
T/NN
cell/NN
lines/NNS
./.
====================
AB/LS
-/:
CD30/NN
is/VBZ
a/DT
recently/RB
described/VBN
member/NN
of/IN
the/DT
tumor/NN
necrosis/NN
factor/nerve/NN
growth/NN
factor/NN
receptor/NN
superfamily/NN
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
show/VBP
that/IN
following/VBG
incubation/NN
of/IN
L540/NN
cells/NNS
(/(
Hodgkin/NN
's/POS
disease-derived/JJ
,/,
T/NN
cell-like/JJ
,/,
CD30+/JJ
cells/NNS
)/)
with/IN
the/DT
agonistic/JJ
anti-CD30/JJ
monoclonal/JJ
antibodies/NNS
(/(
mAb/NN
)/)
M44/NN
and/CC
M67/NN
,/,
two/CD
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
-kappa/NN
B/NN
DNA/NN
binding/NN
activities/NNS
were/VBD
induced/VBN
in/IN
nuclear/JJ
extracts/NNS
,/,
as/IN
determined/VBN
in/IN
gel/NN
retardation/NN
assays/NNS
./.
====================
The/DT
effect/NN
of/IN
the/DT
mAb/NN
towards/IN
NF-kappa/NN
B/NN
activation/NN
was/VBD
rapid/JJ
,/,
as/IN
it/PRP
occurred/VBD
within/IN
20/CD
min/NN
,/,
and/CC
was/VBD
sustained/JJ
for/IN
up/RB
to/TO
6/CD
h/NN
./.
====================
By/IN
comparison/NN
,/,
an/DT
isotype-matched/JJ
antibody/NN
had/VBD
no/DT
effect/NN
on/IN
NF-kappa/NN
B/NN
activation/NN
./.
====================
Moreover/RB
,/,
in/IN
human/JJ
T/NN
helper/NN
(/(
Th/NN
)/)
clones/NNS
functionally/RB
characterized/VBN
as/IN
being/VBG
of/IN
the/DT
type/NN
0/CD
,/,
type/NN
1/CD
and/CC
type/NN
2/CD
(/(
28/CD
%/NN
,/,
</JJR
1/CD
%/NN
und/CC
93/CD
%/NN
CD30+/JJ
,/,
respectively/RB
)/)
,/,
the/DT
extent/NN
of/IN
CD30-mediated/JJ
NF-kappa/NN
B/NN
activation/NN
correlated/VBD
with/IN
the/DT
proportion/NN
of/IN
CD30+/JJ
cells/NNS
./.
====================
In/IN
all/DT
cell/NN
lines/NNS
investigated/VBN
,/,
the/DT
NF-kappa/NN
B/NN
complexes/NNS
induced/VBN
following/VBG
CD30/NN
engagement/NN
were/VBD
shown/VBN
to/TO
contain/VB
p50/NN
NF-kappa/NN
B1/NN
,/,
p65/NN
RelA/NN
,/,
and/CC
possibly/RB
other/JJ
transcription/NN
factors/NNS
./.
====================
Collectively/RB
,/,
our/PRP$
results/NNS
demonstrate/VBP
that/IN
nuclear/JJ
translocation/NN
and/CC
activation/NN
of/IN
NF-kappa/NN
B/NN
rank/NN
among/IN
the/DT
short-term/JJ
cellular/JJ
responses/NNS
elicited/VBD
following/VBG
CD30/NN
ligation/NN
./.
====================
UI/LS
-/:
96016217/CD
====================
TI/LS
-/:
Pathogenesis/NN
of/IN
atherosclerosis/NN
./.
====================
AB/LS
-/:
The/DT
earliest/JJS
lesion/NN
in/IN
the/DT
development/NN
of/IN
an/DT
atherosclerotic/JJ
plaque/NN
is/VBZ
the/DT
fatty/JJ
streak/NN
./.
====================
This/DT
chronic/JJ
inflammatory/JJ
reaction/NN
results/VBZ
from/IN
a/DT
sequence/NN
of/IN
events/NNS
that/WDT
begins/VBZ
with/IN
the/DT
trapping/NN
of/IN
low/JJ
density/NN
lipoprotein/NN
(/(
LDL/NN
)/)
in/IN
the/DT
subendothelial/JJ
space/NN
of/IN
the/DT
artery/NN
wall/NN
./.
====================
The/DT
trapped/VBN
LDL/NN
is/VBZ
seeded/VBN
with/IN
oxidative/JJ
species/NNS
released/VBN
by/IN
the/DT
overlying/VBG
endothelium/NN
,/,
and/CC
lipid/NN
oxidation/NN
is/VBZ
initiated/VBN
within/IN
the/DT
LDL/NN
particle/NN
./.
Some/DT
of/IN
the/DT
lipids/NNS
that/WDT
result/VBP
lead/VBP
to/TO
the/DT
activation/NN
of/IN
NFkB-like/JJ
transcription/NN
factors/NNS
that/WDT
cause/VBP
the/DT
expression/NN
of/IN
genes/NNS
whose/WP$
protein/NN
products/NNS
mediate/VBP
monocyte/NN
binding/NN
,/,
monocyte/NN
chemotaxis/NN
into/IN
the/DT
subendothelial/JJ
space/NN
,/,
and/CC
conversion/NN
into/IN
macrophages/NNS
./.
====================
At/IN
least/JJS
1/CD
major/JJ
gene/NN
modulates/VBZ
the/DT
oxidation/NN
of/IN
LDL/NN
lipids/NNS
and/or/CC
the/DT
biologic/JJ
response/NN
to/TO
these/DT
lipids/NNS
./.
====================
The/DT
inverse/JJ
relation/NN
between/IN
high/JJ
density/NN
lipoprotein/NN
(/(
HDL/NN
)/)
and/CC
atherosclerotic/JJ
events/NNS
may/MD
in/IN
part/NN
be/VB
due/JJ
to/TO
enzymes/NNS
associated/VBN
with/IN
HDL/NN
that/WDT
destroy/VBP
the/DT
biologically/RB
active/JJ
lipids/NNS
generated/VBN
in/IN
LDL/NN
./.
====================
UI/LS
-/:
97252236/CD
====================
TI/LS
-/:
Estrogen/NN
and/CC
progesterone/NN
receptors/NNS
in/IN
vernal/JJ
keratoconjunctivitis/NN
./.
====================
AB/LS
-/:
PURPOSE/NN
:/:
Sex-related/JJ
influences/NNS
have/VBP
been/VBN
implicated/VBN
in/IN
the/DT
pathogenesis/NN
of/IN
vernal/JJ
keratoconjunctivitis/NN
(/(
VKC/NN
)/)
,/,
an/DT
allergic/JJ
eosinophilic/JJ
disease/NN
./.
====================
METHODS/NNS
:/:
The/DT
authors/NNS
evaluated/VBD
tarsal/JJ
and/CC
bulbar/JJ
conjunctival/JJ
biopsies/NNS
from/IN
seven/CD
patients/NNS
with/IN
severe/JJ
and/CC
symptomatic/JJ
VKC/NN
for/IN
the/DT
presence/NN
of/IN
estrogen/NN
and/CC
progesterone/NN
receptors/NNS
by/IN
using/VBG
monoclonal/JJ
antibodies/NNS
with/IN
a/DT
peroxidase-antiperoxidase/JJ
technique/NN
./.
====================
RESULTS/NNS
:/:
Both/CC
the/DT
epithelium/NN
and/CC
subepithelium/NN
of/IN
the/DT
tarsal/JJ
and/CC
bulbar/JJ
conjunctiva/NN
of/IN
patients/NNS
with/IN
VKC/NN
,/,
but/CC
not/RB
those/DT
of/IN
four/CD
nonatopic/JJ
control/JJ
subjects/NNS
,/,
showed/VBD
intense/JJ
positive/JJ
staining/NN
for/IN
estrogen/NN
and/CC
progesterone/NN
receptors/NNS
./.
====================
Immunofluorescence/NN
colocalization/NN
of/IN
both/CC
estrogen/NN
and/CC
progesterone/NN
receptors/NNS
with/IN
eosinophil/NN
cationic/JJ
protein/NN
showed/VBD
that/IN
approximately/RB
70/CD
%/NN
of/IN
positive/JJ
cells/NNS
were/VBD
eosinophils/NNS
./.
====================
CONCLUSIONS/NNS
:/:
Sexual/JJ
hormones/NNS
,/,
through/IN
their/PRP$
receptors/NNS
,/,
may/MD
influence/VB
the/DT
activity/NN
of/IN
eosinophils/NNS
in/IN
patients/NNS
with/IN
VKC/NN
./.
====================
UI/LS
-/:
96091806/CD
====================
TI/LS
-/:
CIITA/NN
activates/VBZ
the/DT
expression/NN
of/IN
MHC/NN
class/NN
II/CD
genes/NNS
in/IN
mouse/NN
T/NN
cells/NNS
./.
====================
AB/LS
-/:
It/PRP
has/VBZ
long/RB
been/VBN
a/DT
puzzle/NN
that/IN
MHC/NN
class/NN
II/CD
molecules/NNS
are/VBP
expressed/VBN
in/IN
human/JJ
T/NN
cells/NNS
after/IN
activation/NN
but/CC
not/RB
in/IN
mouse/NN
T/NN
cells/NNS
;/:
this/DT
expression/NN
is/VBZ
believed/VBN
to/TO
play/VB
a/DT
role/NN
in/IN
the/DT
cell/NN
mediated/JJ
immune/JJ
response/NN
./.
====================
Recently/RB
the/DT
MHC/NN
class/NN
II/CD
transactivator/NN
(/(
CIITA/NN
)/)
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
a/DT
major/JJ
regulatory/JJ
factor/NN
for/IN
both/CC
the/DT
constitutive/JJ
and/CC
IFN/NN
inducible/JJ
expression/NN
of/IN
MHC/NN
class/NN
II/CD
genes/NNS
./.
====================
Here/RB
we/PRP
show/VBP
that/IN
human/JJ
T/NN
cells/NNS
expressing/VBG
MHC/NN
class/NN
II/CD
have/VBP
CIITA/NN
transcripts/NNS
while/IN
MHC/NN
class/NN
II-negative/JJ
human/JJ
T/NN
cells/NNS
and/CC
mouse/NN
T/NN
cells/NNS
do/VBP
not/RB
./.
====================
The/DT
expression/NN
of/IN
MHC/NN
class/NN
II/CD
genes/NNS
in/IN
mouse/NN
T/NN
cells/NNS
can/MD
be/VB
reconstituted/VBN
upon/IN
transfection/NN
with/IN
the/DT
human/JJ
CIITA/NN
cDNA/NN
./.
====================
These/DT
data/NNS
indicate/VBP
that/IN
the/DT
expression/NN
of/IN
CIITA/NN
explains/VBZ
the/DT
expression/NN
or/CC
lack/NN
of/IN
expression/NN
of/IN
MHC/NN
class/NN
II/CD
in/IN
human/JJ
and/CC
mouse/NN
T/NN
cells/NNS
respectively/RB
./.
====================
UI/LS
-/:
90110496/CD
====================
TI/LS
-/:
Anti-Ro(SSA)/JJ
autoantibodies/NNS
are/VBP
associated/VBN
with/IN
T/NN
cell/NN
receptor/NN
beta/NN
genes/NNS
in/IN
systemic/JJ
lupus/NN
erythematosus/NN
patients/NNS
./.
====================
AB/LS
-/:
Several/JJ
of/IN
the/DT
heterogeneous/JJ
clinical/JJ
manifestations/NNS
of/IN
systemic/JJ
lupus/NN
erythematosus/NN
have/VBP
been/VBN
associated/VBN
with/IN
specific/JJ
autoantibodies/NNS
./.
====================
Associations/NNS
between/IN
HLA/NN
class/NN
II/CD
antigens/NNS
and/CC
autoantibodies/NNS
to/TO
the/DT
ribonucleoproteins/NNS
Ro(SSA)/NN
and/CC
La(SSB)/NN
have/VBP
been/VBN
reported/VBN
in/IN
these/DT
patients/NNS
./.
====================
Because/IN
HLA/NN
class/NN
II/CD
molecules/NNS
present/VBP
antigen/NN
to/TO
T/NN
cell/NN
receptors/NNS
(/(
TCRs/NNS
)/)
,/,
we/PRP
have/VBP
searched/VBN
for/IN
a/DT
TCR/NN
gene/NN
associated/VBN
with/IN
the/DT
production/NN
of/IN
anti-Ro(SSA)/JJ
antibodies/NNS
./.
====================
A/DT
pair/NN
of/IN
restriction/NN
fragment/NN
length/NN
polymorphisms/NNS
(/(
RFLPs/NNS
)/)
,/,
one/CD
of/IN
which/WDT
hybridizes/VBZ
to/TO
the/DT
TCR/NN
constant/JJ
region/NN
C/NN
beta/NN
1/CD
and/CC
the/DT
other/JJ
to/TO
the/DT
C/NN
beta/NN
2/CD
gene/NN
,/,
has/VBZ
been/VBN
identified/VBN
,/,
suggesting/VBG
these/DT
may/MD
be/VB
genotypic/JJ
markers/NNS
for/IN
an/DT
extended/VBN
region/NN
of/IN
the/DT
TCR/NN
beta/NN
locus/NN
./.
====================
This/DT
RFLP/NN
pair/NN
occurs/VBZ
in/IN
76/CD
%/NN
of/IN
patients/NNS
with/IN
Ro(SSA)/NN
precipitins/NNS
,/,
84/CD
%/NN
of/IN
anti-Ro(SSA)-positive/JJ
patients/NNS
lacking/VBG
La(SSB)/NN
precipitins/NNS
,/,
but/CC
only/RB
41/CD
%/NN
of/IN
the/DT
patients/NNS
lacking/VBG
both/DT
precipitins/NNS
(/(
P/NN
=/JJ
0.0004/CD
)/)
./.
====================
This/DT
disproportionate/JJ
occurrence/NN
in/IN
a/DT
subset/NN
of/IN
lupus/NN
patients/NNS
indicates/VBZ
that/IN
these/DT
RFLPs/NNS
are/VBP
not/RB
disease/NN
susceptibility/NN
markers/NNS
,/,
but/CC
rather/RB
are/VBP
important/JJ
markers/NNS
for/IN
TCR/NN
genes/NNS
whose/WP$
products/NNS
are/VBP
involved/VBN
in/IN
the/DT
production/NN
of/IN
anti-Ro(SSA)/JJ
antibodies/NNS
./.
====================
The/DT
majority/NN
of/IN
patients/NNS
who/WP
have/VBP
these/DT
RFLPs/NNS
and/CC
HLA/NN
class/NN
II/CD
antigens/NNS
previously/RB
associated/VBN
with/IN
the/DT
anti-Ro(SSA)/JJ
response/NN
make/VBP
this/DT
antibody/NN
,/,
suggesting/VBG
that/IN
interactions/NNS
between/IN
products/NNS
of/IN
these/DT
loci/NNS
occur/VBP
in/IN
response/NN
to/TO
Ro(SSA)/NN
./.
====================
UI/LS
-/:
96102166/CD
====================
TI/LS
-/:
Inhibition/NN
of/IN
NF-AT-dependent/JJ
transcription/NN
by/IN
NF-kappa/NN
B/NN
:/:
implications/NNS
for/IN
differential/JJ
gene/NN
expression/NN
in/IN
T/NN
helper/NN
cell/NN
subsets/NNS
./.
====================
AB/LS
-/:
Activation/NN
of/IN
individual/JJ
CD4+/JJ
T/NN
cells/NNS
results/VBZ
in/IN
differential/JJ
lymphokine/NN
expression/NN
:/:
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
is/VBZ
preferentially/RB
produced/VBN
by/IN
T/NN
helper/NN
type/NN
1/CD
(/(
TH1/NN
)/)
cells/NNS
,/,
which/WDT
are/VBP
involved/VBN
in/IN
cell-mediated/JJ
immune/JJ
responses/NNS
,/,
whereas/IN
IL-4/NN
is/VBZ
synthesized/VBN
by/IN
TH2/NN
cells/NNS
,/,
which/WDT
are/VBP
essential/JJ
for/IN
humoral/JJ
immunity/NN
./.
====================
The/DT
Ca(2+)-dependent/JJ
factor/NN
NF-ATp/NN
plays/VBZ
a/DT
key/JJ
role/NN
in/IN
the/DT
inducible/JJ
transcription/NN
of/IN
both/DT
these/DT
lymphokine/NN
genes/NNS
./.
====================
However/RB
,/,
while/IN
IL2/NN
expression/NN
requires/VBZ
the/DT
contribution/NN
of/IN
Ca(2+)-/NN
and/CC
protein/NN
kinase/NN
C-dependent/JJ
signals/NNS
,/,
we/PRP
report/VBP
that/IN
activation/NN
of/IN
human/JJ
IL4/NN
transcription/NN
through/IN
the/DT
Ca(2+)-dependent/JJ
pathway/NN
is/VBZ
diminished/VBN
by/IN
protein/NN
kinase/NN
C/NN
stimulation/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
./.
====================
This/DT
phenomenon/NN
is/VBZ
due/JJ
to/TO
mutually/RB
exclusive/JJ
binding/NN
of/IN
NF-ATp/NN
and/CC
NF-kappa/NN
B/NN
to/TO
the/DT
P/NN
sequence/NN
,/,
an/DT
element/NN
located/JJ
69/CD
bp/NN
upstream/RB
of/IN
the/DT
IL4/NN
transcription/NN
initiation/NN
site/NN
./.
====================
Human/JJ
IL4/NN
promoter-mediated/JJ
transcription/NN
is/VBZ
downregulated/VBN
in/IN
Jurkat/NN
cells/NNS
stimulated/VBN
with/IN
the/DT
NF-kappa/NN
B-activating/JJ
cytokine/NN
tumor/NN
necrosis/NN
factor/NN
alpha/NN
and/CC
suppressed/VBN
in/IN
RelA-overexpressing/JJ
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
protein/NN
kinase/NN
C/NN
stimulation/NN
or/CC
RelA/NN
overexpression/NN
does/VBZ
not/RB
affect/VB
the/DT
activity/NN
of/IN
a/DT
human/JJ
IL4/NN
promoter/NN
containing/VBG
a/DT
mouse/NN
P/NN
sequence/NN
,/,
which/WDT
is/VBZ
a/DT
higher-affinity/JJ
site/NN
for/IN
NF-ATp/NN
and/CC
a/DT
lower-affinity/JJ
site/NN
for/IN
RelA/NN
./.
====================
Thus/RB
,/,
competition/NN
between/IN
two/CD
general/JJ
transcriptional/JJ
activators/NNS
,/,
RelA/NN
and/CC
NF-ATp/NN
,/,
mediates/VBZ
the/DT
inhibitory/JJ
effect/NN
of/IN
protein/NN
kinase/NN
C/NN
stimulation/NN
on/IN
IL4/NN
expression/NN
and/CC
may/MD
contribute/VB
to/TO
differential/JJ
gene/NN
expression/NN
in/IN
TH/NN
cells/NNS
./.
====================
UI/LS
-/:
96096457/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
the/DT
balance/NN
of/IN
cytokine/NN
production/NN
and/CC
the/DT
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
(/(
STAT/NN
)/)
transcription/NN
factor/NN
activity/NN
by/IN
cytokines/NNS
and/CC
inflammatory/JJ
synovial/JJ
fluids/NNS
./.
====================
AB/LS
-/:
The/DT
balance/NN
between/IN
type/NN
1/CD
and/CC
2/CD
T/NN
helper/NN
cell/NN
cytokine/NN
production/NN
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
several/JJ
animal/JJ
models/NNS
of/IN
autoimmunity/NN
,/,
and/CC
skewed/JJ
patterns/NNS
of/IN
cytokine/NN
expression/NN
have/VBP
been/VBN
described/VBN
in/IN
human/JJ
inflammatory/JJ
diseases/NNS
./.
====================
Many/JJ
cytokines/NNS
activate/VBP
signal/NN
transducer/NN
and/CC
activation/NN
of/IN
transcription/NN
(/(
STAT/NN
)/)
transcription/NN
factors/NNS
,/,
which/WDT
,/,
in/IN
turn/NN
,/,
activate/VBP
transcription/NN
of/IN
inflammatory/JJ
effector/NN
genes/NNS
./.
====================
We/PRP
used/VBD
mononuclear/JJ
cell/NN
priming/NN
cultures/NNS
and/CC
inflammatory/JJ
synovial/JJ
fluids/NNS
(/(
SFs/NNS
)/)
derived/VBN
from/IN
arthritis/NN
patients/NNS
to/TO
examine/VB
the/DT
regulation/NN
of/IN
cytokine/NN
production/NN
and/CC
STAT/NN
activity/NN
by/IN
an/DT
inflammatory/JJ
synovial/JJ
microenvironment/NN
./.
====================
Exposure/NN
to/TO
SFs/NNS
during/IN
priming/NN
resulted/VBD
in/IN
an/DT
81/CD
%/NN
inhibition/NN
of/IN
interferon/NN
(/(
IFN/NN
)/)
-gamma/NN
,/,
but/CC
not/RB
interleukin/NN
(/(
IL/NN
)/)
4/CD
,/,
production/NN
by/IN
effector/NN
cells/NNS
generated/VBN
in/IN
priming/JJ
cultures/NNS
./.
====================
SF/NN
suppression/NN
was/VBD
mediated/VBN
by/IN
IL-4/NN
and/CC
IL-10/NN
and/CC
inhibition/NN
of/IN
IL-12/NN
expression/NN
,/,
and/CC
it/PRP
was/VBD
reversed/VBN
in/IN
a/DT
dominant/JJ
fashion/NN
by/IN
exogenous/JJ
IL-12/NN
./.
====================
SFs/NNS
blocked/VBD
the/DT
sustained/JJ
activity/NN
of/IN
transcription/NN
factor/NN
Stat1/NN
,/,
but/CC
not/RB
Stat3/NN
,/,
during/IN
the/DT
priming/NN
period/NN
,/,
and/CC
Stat1/NN
activity/NN
was/VBD
differentially/RB
regulated/VBN
by/IN
cytokines/NNS
in/IN
parallel/NN
with/IN
their/PRP$
positive/JJ
or/CC
negative/JJ
regulation/NN
of/IN
IFN-gamma/NN
production/NN
./.
====================
Active/JJ
Stat3/NN
,/,
but/CC
not/RB
Stat1/NN
,/,
was/VBD
detected/VBN
in/IN
cells/NNS
from/IN
inflamed/JJ
joints/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
a/DT
role/NN
for/IN
altered/JJ
balance/NN
of/IN
Stat1/NN
and/CC
Stat3/NN
transcriptional/JJ
activity/NN
in/IN
the/DT
regulation/NN
of/IN
T/NN
cell/NN
differentiation/NN
and/CC
in/IN
the/DT
pathogenesis/NN
of/IN
inflammatory/JJ
synovitis/NN
./.
====================
UI/LS
-/:
96062305/CD
====================
TI/LS
-/:
Triggering/NN
of/IN
complement/NN
receptors/NNS
CR1/NN
(/(
CD35/NN
)/)
and/CC
CR3/NN
(/(
CD11b/CD18/NN
)/)
induces/VBZ
nuclear/JJ
translocation/NN
of/IN
NF-kappa/NN
B/NN
(/(
p50/NN
/p65/NN
)/)
in/IN
human/JJ
monocytes/NNS
and/CC
enhances/VBZ
viral/JJ
replication/NN
in/IN
HIV-infected/JJ
monocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
Monocyte/macrophages/NNS
may/MD
harbor/VB
HIV/NN
in/IN
a/DT
nonproductive/JJ
fashion/NN
for/IN
prolonged/JJ
periods/NNS
of/IN
time/NN
./.
====================
Viral/JJ
gene/NN
expression/NN
may/MD
be/VB
reactivated/VBN
by/IN
stimulation/NN
of/IN
the/DT
cells/NNS
with/IN
LPS/NN
or/CC
cytokines/NNS
such/JJ
as/IN
TNF-alpha/NN
in/FW
vitro/FW
./.
====================
The/DT
effect/NN
of/IN
LPS/NN
and/CC
TNF-alpha/NN
is/VBZ
mediated/VBN
by/IN
their/PRP$
ability/NN
to/TO
induce/VB
nuclear/JJ
translocation/NN
of/IN
the/DT
DNA-binding/JJ
heterodimer/NN
NF-kappa/NN
B/NN
(/(
p50/NN
/p65/NN
)/)
,/,
which/WDT
binds/VBZ
to/TO
a/DT
specific/JJ
sequence/NN
in/IN
the/DT
HIV-long/JJ
terminal/JJ
repeat/NN
./.
====================
The/DT
present/JJ
study/NN
demonstrates/VBZ
that/IN
triggering/NN
of/IN
complement/NN
receptors/NNS
CR1/NN
(/(
CD35/NN
)/)
and/CC
CR3/NN
(/(
CD11b/CD18/NN
)/)
enhances/VBZ
viral/JJ
replication/NN
in/IN
HIV-infected/JJ
human/JJ
monocytic/JJ
cells/NNS
./.
====================
Monocytic/JJ
cell/NN
lines/NNS
and/CC
normal/JJ
peripheral/JJ
blood/NN
monocytes/NNS
were/VBD
infected/VBN
with/IN
HIV-1/NN
in/FW
vitro/FW
and/CC
cultured/VBN
in/IN
the/DT
presence/NN
or/CC
absence/NN
of/IN
F(ab')2/NN
fragments/NNS
of/IN
monoclonal/JJ
anti-CR1/JJ
or/CC
anti-CR3/JJ
Abs/NNS
or/CC
with/IN
C3/NN
fragments/NNS
./.
====================
Stimulation/NN
of/IN
CR1/NN
or/CC
CR3/NN
induces/VBZ
a/DT
two-/CD
to/TO
fourfold/JJ
increase/NN
in/IN
the/DT
amount/NN
of/IN
cell-associated/JJ
and/CC
released/VBN
p24/NN
Ag/NN
in/IN
cell/NN
cultures/NNS
that/WDT
was/VBD
equivalent/JJ
to/TO
that/DT
observed/VBN
in/IN
control/JJ
cultures/NNS
triggered/VBN
with/IN
LPS/NN
./.
====================
We/PRP
further/RB
observed/VBD
that/IN
stimulation/NN
of/IN
CR1/NN
or/CC
CR3/NN
induces/VBZ
the/DT
nuclear/JJ
translocation/NN
of/IN
NF-kappa/NN
B/NN
p50/NN
/p65/NN
in/IN
infected/JJ
cells/NNS
./.
====================
Translocation/NN
of/IN
NF-kappa/NN
B/NN
p50/NN
/p65/NN
was/VBD
also/RB
observed/VBN
following/VBG
stimulation/NN
of/IN
CR1/NN
or/CC
CR3/NN
of/IN
uninfected/JJ
peripheral/JJ
blood/NN
monocytes/NNS
from/IN
HIV-seronegative/JJ
donors/NNS
./.
====================
The/DT
amount/NN
of/IN
protein/NN
translocated/VBN
was/VBD
similar/JJ
to/TO
that/DT
observed/VBN
when/WRB
cells/NNS
were/VBD
stimulated/VBN
with/IN
rhTNF-alpha/NN
./.
====================
TNF-alpha/NN
did/VBD
not/RB
mediate/VB
the/DT
translocation/NN
of/IN
NF-kappa/NN
B/NN
p50/NN
/p65/NN
induced/VBN
by/IN
triggering/NN
of/IN
complement/NN
receptors/NNS
./.
====================
Taken/VBN
together/RB
,/,
these/DT
observations/NNS
suggest/VBP
that/IN
HIV/NN
gene/NN
expression/NN
may/MD
be/VB
activated/VBN
in/IN
infected/JJ
monocytes/NNS
through/IN
interaction/NN
of/IN
the/DT
cells/NNS
with/IN
complement-opsonized/JJ
particles/NNS
and/CC
that/IN
enhanced/VBN
viral/JJ
replication/NN
is/VBZ
associated/VBN
with/IN
C3/NN
receptor-mediated/JJ
nuclear/JJ
translocation/NN
of/IN
the/DT
NF-kappa/NN
B/NN
complex/NN
./.
====================
UI/LS
-/:
96029750/CD
====================
TI/LS
-/:
Attenuation/NN
of/IN
gamma/NN
interferon-induced/JJ
tyrosine/NN
phosphorylation/NN
in/IN
mononuclear/JJ
phagocytes/NNS
infected/VBN
with/IN
Leishmania/FW
donovani/FW
:/:
selective/JJ
inhibition/NN
of/IN
signaling/NN
through/IN
Janus/NN
kinases/NNS
and/CC
Stat1/NN
./.
====================
AB/LS
-/:
The/DT
induction/NN
of/IN
gene/NN
transcription/NN
in/IN
response/NN
to/TO
gamma/NN
interferon/NN
is/VBZ
impaired/JJ
in/IN
mononuclear/JJ
phagocytes/NNS
infected/VBN
with/IN
Leishmania/FW
donovani/FW
,/,
and/CC
the/DT
mechanisms/NNS
involved/VBN
are/VBP
not/RB
fully/RB
understood/VBN
./.
====================
The/DT
changes/NNS
in/IN
gene/NN
expression/NN
brought/VBN
about/RP
by/IN
gamma/NN
interferon/NN
are/VBP
thought/VBN
to/TO
involve/VB
transient/JJ
increases/NNS
in/IN
the/DT
activities/NNS
of/IN
cellular/JJ
protein/NN
tyrosine/NN
kinases/NNS
,/,
including/VBG
the/DT
Janus/NN
kinases/NNS
Jak1/NN
and/CC
Jak2/NN
,/,
leading/VBG
to/TO
tyrosine/NN
phosphorylation/NN
of/IN
the/DT
transcription/NN
factor/NN
Stat1/NN
./.
====================
To/TO
investigate/VB
the/DT
mechanisms/NNS
accounting/VBG
for/IN
the/DT
impaired/JJ
responses/NNS
to/TO
gamma/NN
interferon/NN
,/,
a/DT
model/JJ
system/NN
for/IN
examining/VBG
overall/JJ
changes/NNS
in/IN
protein/NN
tyrosine/NN
phosphorylation/NN
,/,
activation/NN
of/IN
Jak1/NN
and/CC
Jak2/NN
and/CC
phosphorylation/NN
of/IN
Stat1/NN
was/VBD
developed/VBN
in/IN
phorbol/NN
12-myristate/NN
13-acetate-differentiated/JJ
U-937/NN
cells/NNS
./.
====================
Analysis/NN
of/IN
whole-cell/JJ
lysates/NNS
by/IN
antiphosphotyrosine/NN
immunoblotting/NN
showed/VBD
that/IN
incubation/NN
with/IN
gamma/NN
interferon/NN
brought/VBD
about/RP
specific/JJ
increases/NNS
in/IN
phosphotyrosine/NN
labeling/NN
of/IN
several/JJ
proteins/NNS
./.
====================
Increased/VBN
labeling/NN
of/IN
these/DT
proteins/NNS
occurred/VBD
to/TO
similar/JJ
extents/NNS
in/IN
control/JJ
cells/NNS
and/CC
in/IN
cells/NNS
that/WDT
had/VBD
been/VBN
infected/VBN
with/IN
L./FW
donovani/FW
for/IN
16/CD
h/NN
./.
====================
Jak1/NN
,/,
Jak2/NN
,/,
and/CC
Stat1/NN
were/VBD
immunoprecipitated/VBN
from/IN
control/JJ
and/CC
interferon-treated/JJ
cells/NNS
,/,
and/CC
tyrosine/NN
phosphorylation/NN
of/IN
these/DT
proteins/NNS
,/,
detected/VBN
by/IN
antiphosphotyrosine/NN
immunoblotting/NN
was/VBD
used/VBN
to/TO
measured/VBN
their/PRP$
activation/NN
./.
====================
Tyrosine/NN
phosphorylation/NN
of/IN
Jak1/NN
,/,
Jak2/NN
,/,
and/CC
Stat1/NN
increased/VBD
markedly/RB
,/,
in/IN
a/DT
dose-dependent/JJ
manner/NN
,/,
in/IN
U-937/NN
cells/NNS
incubated/VBN
with/IN
gamma/NN
interferon/NN
./.
====================
In/IN
contrast/NN
,/,
in/IN
cells/NNS
infected/VBN
with/IN
L./FW
donovani/FW
,/,
tyrosine/NN
phosphorylation/NN
of/IN
Jak1/NN
,/,
Jak2/NN
,/,
and/CC
Stat1/NN
was/VBD
markedly/RB
impaired/JJ
./.
====================
This/DT
effect/NN
was/VBD
dependent/JJ
upon/IN
the/DT
duration/NN
of/IN
exposure/NN
to/TO
L./FW
donovani/FW
and/CC
was/VBD
maximal/JJ
and/CC
complete/JJ
at/IN
16/CD
h/NN
./.
====================
Results/NNS
similar/JJ
to/TO
those/DT
observed/VBN
with/IN
U-937/NN
cells/NNS
were/VBD
also/RB
obtained/VBN
with/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
infection/NN
of/IN
human/JJ
mononuclear/JJ
phagocytes/NNS
with/IN
L./FW
donovani/FW
leads/VBZ
to/TO
impaired/JJ
gamma/NN
interferon-mediated/JJ
tyrosine/NN
phosphorylation/NN
and/CC
selective/JJ
effects/NNS
on/IN
the/DT
Jak-Stat1/NN
pathway/NN
./.
====================
Unresponsiveness/NN
to/TO
gamma/NN
interferon/NN
for/IN
activation/NN
of/IN
this/DT
pathway/NN
may/MD
explain/VB
impaired/JJ
transcriptional/JJ
responses/NNS
in/IN
leishmania-infected/JJ
cells/NNS
./.
====================
UI/LS
-/:
96025779/CD
====================
TI/LS
-/:
Mutually/RB
exclusive/JJ
interaction/NN
of/IN
a/DT
novel/JJ
matrix/NN
attachment/NN
region/NN
binding/NN
protein/NN
and/CC
the/DT
NF-muNR/NN
enhancer/NN
repressor/NN
./.
====================
Implications/NNS
for/IN
regulation/NN
of/IN
immunoglobulin/NN
heavy/JJ
chain/NN
expression/NN
./.
====================
AB/LS
-/:
The/DT
immunoglobulin/NN
heavy/NN
chain/NN
(/(
IgH/NN
)/)
intronic/JJ
enhancer/NN
stimulates/VBZ
transcription/NN
from/IN
functional/JJ
promoters/NNS
in/IN
B/NN
lymphocytes/NNS
but/CC
not/RB
other/JJ
cell/NN
types/NNS
./.
====================
The/DT
observation/NN
that/IN
binding/VBG
sites/NNS
for/IN
the/DT
nuclear/JJ
factor-mu/NN
negative/JJ
regulator/NN
(/(
NF-muNR/NN
)/)
enhancer/NN
repressor/NN
overlap/VBP
nuclear/JJ
matrix/NN
attachment/NN
regions/NNS
(/(
MARs/NNS
)/)
in/IN
this/DT
enhancer/NN
has/VBZ
lead/VBN
to/TO
the/DT
hypothesis/NN
that/IN
the/DT
cell/NN
type/NN
specificity/NN
of/IN
the/DT
enhancer/NN
might/MD
be/VB
controlled/VBN
by/IN
regulating/VBG
nuclear/JJ
matrix/NN
attachment/NN
(/(
Scheuermann/NNP
,/,
R./NNP
H./NNP
,/,
and/CC
Chen/NNP
,/,
U./NNP
(/(
1989/CD
)/)
Genes/NNP
&/CC
Dev./NNP
3/CD
,/,
1255-1266/CD
)/)
./.
====================
To/TO
understand/VB
the/DT
role/NN
of/IN
MARs/NNS
in/IN
IgH/NN
enhancer/NN
regulation/NN
,/,
we/PRP
have/VBP
identified/VBN
a/DT
novel/JJ
MAR-binding/JJ
protein/NN
,/,
MAR-BP1/NN
,/,
from/IN
soluble/JJ
nuclear/JJ
matrix/NN
preparations/NNS
based/VBN
on/IN
its/PRP$
ability/NN
to/TO
bind/VB
to/TO
the/DT
MARs/NNS
associated/VBN
with/IN
the/DT
IgH/NN
enhancer/NN
./.
====================
Purified/VBN
MAR-BP1/NN
migrates/VBZ
as/IN
a/DT
33-kDa/JJ
protein/NN
,/,
and/CC
it/PRP
can/MD
be/VB
found/VBN
in/IN
nuclear/JJ
matrix/NN
preparations/NNS
from/IN
a/DT
number/NN
of/IN
different/JJ
types/NNS
of/IN
lymphoid/JJ
cell/NN
lines/NNS
./.
====================
Although/IN
specific/JJ
binding/VBG
sites/NNS
have/VBP
been/VBN
difficult/JJ
to/TO
localize/VB
by/IN
chemical/JJ
or/CC
enzymatic/JJ
footprinting/NN
procedures/NNS
,/,
NF-muNR/NN
binding/NN
sites/NNS
are/VBP
critical/JJ
for/IN
efficient/JJ
MAR-BP1/NN
binding/NN
./.
====================
Indeed/RB
,/,
binding/NN
of/IN
the/DT
IgH/NN
enhancer/NN
to/TO
either/CC
intact/JJ
nuclear/JJ
matrix/NN
preparations/NNS
or/CC
to/TO
MAR-BP1/NN
is/VBZ
mutually/RB
exclusive/JJ
to/TO
NF-muNR/NN
binding/NN
./.
====================
These/DT
results/NNS
are/VBP
consistent/JJ
with/IN
a/DT
model/NN
for/IN
cell-type/JJ
specific/JJ
regulation/NN
in/IN
which/WDT
binding/NN
of/IN
the/DT
NF-muNR/NN
repressor/NN
to/TO
the/DT
IgH/NN
enhancer/NN
prevents/VBZ
nuclear/JJ
matrix/NN
attachment/NN
in/IN
inappropriate/JJ
cells/NNS
by/IN
interfering/VBG
with/IN
MAR-BP1/enhancer/NN
interaction/NN
./.
====================
UI/LS
-/:
96009612/CD
====================
TI/LS
-/:
PU.1/NN
(/(
Spi-1/NN
)/)
and/CC
C/EBP/NN
alpha/NN
regulate/VBP
expression/NN
of/IN
the/DT
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
receptor/NN
alpha/NN
gene/NN
./.
====================
AB/LS
-/:
Growth/NN
factor/NN
receptors/NNS
play/VBP
an/DT
important/JJ
role/NN
in/IN
hematopoiesis/NN
./.
====================
In/IN
order/NN
to/TO
further/RB
understand/VB
the/DT
mechanisms/NNS
directing/VBG
the/DT
expression/NN
of/IN
these/DT
key/JJ
regulators/NNS
of/IN
hematopoiesis/NN
,/,
we/PRP
initiated/VBD
a/DT
study/NN
investigating/VBG
the/DT
transcription/NN
factors/NNS
activating/VBG
the/DT
expression/NN
of/IN
the/DT
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
receptor/NN
alpha/NN
gene/NN
./.
====================
Here/RB
,/,
we/PRP
demonstrate/VBP
that/IN
the/DT
human/JJ
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
directs/VBZ
reporter/NN
gene/NN
activity/NN
in/IN
a/DT
tissue-specific/JJ
fashion/NN
in/IN
myelomonocytic/JJ
cells/NNS
,/,
which/WDT
correlates/VBZ
with/IN
its/PRP$
expression/NN
pattern/NN
as/IN
analyzed/VBN
by/IN
reverse/NN
transcription/NN
PCR/NN
./.
====================
The/DT
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
contains/VBZ
an/DT
important/JJ
functional/JJ
site/NN
between/IN
positions/NNS
-53/CD
and/CC
-41/CD
as/IN
identified/VBN
by/IN
deletion/NN
analysis/NN
of/IN
reporter/NN
constructs/NNS
./.
====================
We/PRP
show/VBP
that/IN
the/DT
myeloid/JJ
and/CC
B/NN
cell/NN
transcription/NN
factor/NN
PU.1/NN
binds/VBZ
specifically/RB
to/TO
this/DT
site/NN
./.
====================
Furthermore/RB
,/,
we/PRP
demonstrate/VBP
that/IN
a/DT
CCAAT/NN
site/NN
located/JJ
upstream/RB
of/IN
the/DT
PU.1/NN
site/NN
between/IN
positions/NNS
-70/CD
and/CC
-54/CD
is/VBZ
involved/VBN
in/IN
positive-negative/JJ
regulation/NN
of/IN
the/DT
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
activity/NN
./.
====================
C/EBP/NN
alpha/NN
is/VBZ
the/DT
major/JJ
CCAAT/enhancer-binding/JJ
protein/NN
(/(
C/EBP/NN
)/)
form/NN
binding/VBG
to/TO
this/DT
site/NN
in/IN
nuclear/JJ
extracts/NNS
of/IN
U937/NN
cells/NNS
./.
====================
Point/NN
mutations/NNS
of/IN
either/CC
the/DT
PU.1/NN
site/NN
or/CC
the/DT
C/EBP/NN
site/NN
that/WDT
abolish/VBP
the/DT
binding/NN
of/IN
the/DT
respective/JJ
factors/NNS
result/VBP
in/IN
a/DT
significant/JJ
decrease/NN
of/IN
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
activity/NN
in/IN
myelomonocytic/JJ
cells/NNS
only/RB
./.
====================
Furthermore/RB
,/,
we/PRP
demonstrate/VBP
that/IN
in/IN
myeloid/JJ
and/CC
B/NN
cell/NN
extracts/VBZ
,/,
PU.1/NN
forms/VBZ
a/DT
novel/JJ
,/,
specific/JJ
,/,
more/RBR
slowly/RB
migrating/VBG
complex/NN
(/(
PU-SF/NN
)/)
when/WRB
binding/VBG
the/DT
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
PU.1/NN
site/NN
./.
====================
This/DT
is/VBZ
the/DT
first/JJ
demonstration/NN
of/IN
a/DT
specific/JJ
interaction/NN
with/IN
PU.1/NN
on/IN
a/DT
myeloid/JJ
PU.1/NN
binding/NN
site/NN
./.
====================
The/DT
novel/JJ
complex/NN
is/VBZ
distinct/JJ
from/IN
that/DT
described/VBN
previously/RB
as/IN
binding/VBG
to/TO
B/NN
cell/NN
enhancer/NN
sites/NNS
and/CC
can/MD
be/VB
formed/VBN
by/IN
addition/NN
of/IN
PU.1/NN
to/TO
extracts/NNS
from/IN
certain/JJ
nonmyeloid/JJ
cell/NN
types/NNS
which/WDT
do/VBP
not/RB
express/VB
PU.1/NN
,/,
including/VBG
T/NN
cells/NNS
and/CC
epithelial/JJ
cells/NNS
,/,
but/CC
not/RB
from/IN
erythroid/JJ
cells/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
demonstrate/VBP
that/IN
the/DT
PU-SF/NN
complex/NN
binds/VBZ
to/TO
PU.1/NN
sites/NNS
found/VBN
on/IN
a/DT
number/NN
of/IN
myeloid/JJ
promoters/NNS
,/,
and/CC
its/PRP$
formation/NN
requires/VBZ
an/DT
intact/JJ
PU.1/NN
site/NN
adjacent/JJ
to/TO
a/DT
single-stranded/JJ
region/NN
./.
====================
Expression/NN
of/IN
PU.1/NN
in/IN
nonmyeloid/JJ
cells/NNS
can/MD
activate/VB
the/DT
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
./.
====================
Deletion/NN
of/IN
the/DT
amino-terminal/JJ
region/NN
of/IN
PU.1/NN
results/VBZ
in/IN
a/DT
failure/NN
to/TO
form/VB
the/DT
PU-SF/NN
complex/NN
and/CC
in/IN
a/DT
concomitant/JJ
loss/NN
of/IN
transactivation/NN
,/,
suggesting/VBG
that/IN
formation/NN
of/IN
the/DT
PU-SF/NN
complex/NN
is/VBZ
of/IN
functional/JJ
importance/NN
for/IN
the/DT
activity/NN
of/IN
the/DT
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
./.
====================
Finally/RB
,/,
we/PRP
demonstrate/VBP
that/IN
C/EBP/NN
alpha/NN
can/MD
also/RB
active/JJ
the/DT
GM-CSF/NN
receptor/NN
alpha/NN
promoter/NN
in/IN
nonmyeloid/JJ
cells/NNS
./.
====================
(/(
ABSTRACT/NN
TRUNCATED/VBN
AT/IN
400/CD
WORDS/NNS
)/)
====================
UI/LS
-/:
96024587/CD
====================
TI/LS
-/:
HMG-I/NN
binds/VBZ
to/TO
GATA/NN
motifs/NNS
:/:
implications/NNS
for/IN
an/DT
HPFH/NN
syndrome/NN
./.
====================
AB/LS
-/:
We/PRP
have/VBP
examined/VBN
binding/NN
of/IN
the/DT
nuclear/JJ
protein/NN
HMG-I/NN
to/TO
the/DT
human/JJ
gamma-globin/NN
promoter/NN
./.
====================
We/PRP
find/VBP
that/IN
HMG-I/NN
binds/VBZ
preferentially/RB
to/TO
the/DT
more/JJR
3'/JJ
of/IN
a/DT
pair/NN
of/IN
GATA/NN
motifs/NNS
in/IN
the/DT
gamma-globin/NN
promoter/NN
;/:
this/DT
paired/JJ
motif/NN
is/VBZ
bound/VBN
by/IN
the/DT
erythroid/JJ
factor/NN
GATA-1/NN
./.
====================
A/DT
naturally/RB
occurring/VBG
mutation/NN
(/(
-175/CD
T-C/NN
)/)
in/IN
the/DT
area/NN
bound/VBN
by/IN
HMG-I/NN
results/VBZ
in/IN
overexpression/NN
of/IN
gamma-globin/NN
in/IN
adult/JJ
red/JJ
blood/NN
cells/NNS
(/(
HPFH/NN
)/)
and/CC
up-regulation/NN
of/IN
the/DT
gamma-globin/NN
promoter/NN
in/IN
in/FW
vitro/FW
expression/NN
assays/NNS
;/:
HMG-I/NN
does/VBZ
not/RB
bind/VB
to/TO
this/DT
mutant/JJ
sequence/NN
./.
====================
A/DT
survey/NN
of/IN
GATA/NN
motifs/NNS
from/IN
other/JJ
globin/NN
cis-elements/NNS
demonstrates/VBZ
HMG-I/NN
binding/NN
to/TO
most/JJS
of/IN
them/PRP
./.
====================
These/DT
findings/NNS
implicate/VBP
HMG-I/NN
in/IN
the/DT
HPFH/NN
phenotype/NN
;/:
we/PRP
speculate/VBP
that/IN
it/PRP
may/MD
participate/VB
in/IN
the/DT
formation/NN
of/IN
multiprotein/JJ
complexes/NNS
that/WDT
regulate/VBP
globin/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
95386713/CD
====================
TI/LS
-/:
Constitutive/JJ
activation/NN
of/IN
different/JJ
Jak/NN
tyrosine/NN
kinases/NNS
in/IN
human/JJ
T/NN
cell/NN
leukemia/NN
virus/NN
type/NN
1/CD
(/(
HTLV-1/NN
)/)
tax/NN
protein/NN
or/CC
virus-transformed/JJ
cells/NNS
./.
====================
AB/LS
-/:
HTLV-1/NN
infection/NN
causes/VBZ
an/DT
adult/JJ
T/NN
cell/NN
leukemia/NN
in/IN
humans/NNS
./.
====================
The/DT
viral/JJ
encoded/VBN
protein/NN
tax/NN
,/,
is/VBZ
thought/VBN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
oncogenesis/NN
./.
====================
Our/PRP$
previous/JJ
data/NNS
obtained/VBN
from/IN
a/DT
tax/NN
transgenic/JJ
mouse/NN
model/NN
revealed/VBD
that/IN
tax/NN
transforms/VBZ
mouse/NN
fibroblasts/NNS
but/CC
not/RB
thymocytes/NNS
,/,
despite/IN
comparable/JJ
levels/NNS
of/IN
tax/NN
expression/NN
in/IN
both/DT
tissues/NNS
./.
====================
Constitutive/JJ
tyrosine/NN
phosphorylation/NN
of/IN
a/DT
130-kD/JJ
protein/NN
(/(
s/NNS
)/)
was/VBD
observed/VBN
in/IN
the/DT
tax/NN
transformed/JJ
fibroblast/NN
B/NN
line/NN
and/CC
in/IN
HTLV-1/NN
transformed/JJ
human/JJ
lymphoid/JJ
lines/NNS
,/,
but/CC
not/RB
in/IN
thymocytes/NNS
from/IN
Thy-tax/NN
transgenic/JJ
mice/NNS
./.
====================
Phosphotyrosine/NN
immunoprecipitation/NN
followed/VBN
by/IN
Western/NN
blot/NN
analysis/NN
with/IN
a/DT
set/NN
of/IN
Jak/NN
kinase/NN
specific/JJ
antibodies/NNS
,/,
identified/VBD
p130/NN
as/IN
Jak2/NN
in/IN
the/DT
tax/NN
transformed/JJ
mouse/NN
fibroblastic/JJ
cell/NN
line/NN
and/CC
Jak3/NN
in/IN
HTLV-1/NN
transformed/JJ
human/JJ
T/NN
cell/NN
lines/NNS
./.
====================
Phosphorylation/NN
of/IN
Jak2/NN
in/IN
tax/NN
transformed/JJ
cells/NNS
resulted/VBD
from/IN
high/JJ
expression/NN
of/IN
IL-6/NN
./.
====================
Tyrosine/NN
phosphorylation/NN
of/IN
this/DT
protein/NN
could/MD
also/RB
be/VB
induced/VBN
in/IN
Balb/c3T3/NN
cells/NNS
using/VBG
a/DT
supernatant/NN
from/IN
the/DT
B/NN
line/NN
,/,
which/WDT
was/VBD
associated/VBN
with/IN
induction/NN
of/IN
cell/NN
proliferation/NN
./.
====================
Both/CC
phosphorylation/NN
and/CC
proliferation/NN
were/VBD
inhibited/VBN
by/IN
IL-6/NN
neutralizing/NN
antibodies/NNS
./.
====================
Constitutive/JJ
phosphorylation/NN
of/IN
Jak/NN
kinases/NNS
may/MD
facilitate/VB
tumor/NN
growth/NN
in/IN
both/CC
HTLV-1/NN
infected/JJ
human/JJ
T/NN
cells/NNS
and/CC
the/DT
transgenic/JJ
mouse/NN
model/NN
./.
====================
UI/LS
-/:
95367587/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
c-jun/NN
mRNA/NN
expression/NN
by/IN
hydroxyurea/NN
in/IN
human/JJ
K562/NN
cells/NNS
during/IN
erythroid/JJ
differentiation/NN
[/(
published/VBN
erratum/NN
appears/VBZ
in/IN
Biochim/NNP
Biophys/NNP
Acta/NNP
1995/CD
Dec/NNP
27/CD
;/:
1264/CD
(/(
3/CD
)/)
:/:
409/CD
]/)
====================
AB/LS
-/:
Hydroxyurea/NN
(/(
HU/NN
)/)
is/VBZ
an/DT
antitumor/JJ
agent/NN
which/WDT
also/RB
induces/VBZ
hemoglobinization/NN
during/IN
erythroid/JJ
differentiation/NN
./.
====================
In/IN
addition/NN
,/,
HU/NN
stimulates/VBZ
the/DT
synthesis/NN
of/IN
fetal/JJ
hemoglobin/NN
in/IN
sickle/NN
cell/NN
anemia/NN
patients/NNS
./.
====================
To/TO
further/RB
understand/VB
its/PRP$
mechanism/NN
of/IN
action/NN
,/,
we/PRP
investigated/VBD
the/DT
effects/NNS
of/IN
HU/NN
on/IN
regulation/NN
of/IN
c-jun/NN
expression/NN
prior/RB
to/TO
the/DT
onset/NN
of/IN
erythroid/JJ
differentiation/NN
of/IN
K562/NN
cells/NNS
./.
====================
HU/NN
induced/VBD
a/DT
dose-dependent/JJ
stimulation/NN
of/IN
c-jun/NN
synthesis/NN
./.
====================
The/DT
levels/NNS
of/IN
c-jun/NN
mRNA/NN
was/VBD
elevated/VBN
4/CD
to/TO
7.5-fold/RB
by/IN
HU/NN
within/IN
2/CD
h/NN
./.
====================
This/DT
was/VBD
followed/VBN
by/IN
a/DT
gradual/JJ
decline/NN
to/TO
the/DT
basal/JJ
level/NN
by/IN
24/CD
h/NN
./.
====================
Both/CC
nuclear/JJ
run-on/JJ
and/CC
actinomycin/NN
D/NN
pulse/NN
experiments/NNS
strongly/RB
indicate/VBP
that/IN
HU/NN
regulates/VBZ
c-jun/NN
mRNA/NN
expression/NN
by/IN
increasing/VBG
the/DT
rate/NN
of/IN
synthesis/NN
as/RB
well/RB
as/IN
stabilizing/VBG
the/DT
c-jun/NN
mRNA/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
level/NN
of/IN
jun/NN
protein/NN
was/VBD
elevated/JJ
by/IN
2/CD
to/TO
5-fold/NN
within/IN
4/CD
h/NN
in/IN
HU/NN
treated/JJ
cells/NNS
./.
====================
Furthermore/RB
,/,
concentrations/NNS
of/IN
HU/NN
below/IN
250/CD
microM/NN
slightly/RB
increased/VBD
the/DT
5X/NN
AP-1/CAT/NN
activity/NN
./.
====================
These/DT
results/NNS
strongly/RB
suggest/VBP
that/IN
HU/NN
induces/VBZ
both/CC
transcriptional/JJ
and/CC
post-transcription/JJ
regulation/NN
of/IN
c-jun/NN
during/IN
erythroid/JJ
differentiation/NN
./.
====================
UI/LS
-/:
92187059/CD
====================
TI/LS
-/:
In/FW
vivo/FW
and/CC
in/FW
vitro/FW
effects/NNS
of/IN
glucocorticoids/NNS
on/IN
lymphocyte/NN
proliferation/NN
in/IN
man/NN
:/:
relationship/NN
to/TO
glucocorticoid/NN
receptors/NNS
./.
====================
AB/LS
-/:
Interrelations/NNS
between/IN
the/DT
hypothalamic-pituitary-adrenal/JJ
system/NN
(/(
HPA/NN
)/)
and/CC
the/DT
immune/JJ
system/NN
represent/VBP
a/DT
well-documented/JJ
biological/JJ
phenomenon/NN
./.
====================
While/IN
in/FW
vitro/FW
administration/NN
of/IN
glucocorticoids/NNS
may/MD
inhibit/VB
concanavalin/NN
A/NN
(/(
Con/NN
A/NN
)/)
-/:
and/CC
phytohemagglutinin/NN
(/(
PHA/NN
)/)
-induced/JJ
T-cell/NN
proliferation/NN
,/,
pokeweed/NN
mitogen/NN
(/(
PWM/NN
)/)
-driven/JJ
B-cell/NN
mitogenesis/NN
is/VBZ
relatively/RB
resistant/JJ
to/TO
glucocorticoids/NNS
./.
====================
To/TO
further/RB
explore/VB
the/DT
link/NN
between/IN
the/DT
HPA/NN
and/CC
the/DT
immune/JJ
system/NN
in/IN
relation/NN
to/TO
glucocorticoid/NN
receptor/NN
function/NN
,/,
dose-response/JJ
curves/NNS
were/VBD
obtained/VBN
for/IN
Con/NN
A-/NN
and/CC
PHA/JJ
-induced/JJ
T-cell/NN
mitogenesis/NN
,/,
PWM-generated/JJ
B-cell/NN
mitogenesis/NN
and/CC
spontaneous/JJ
lymphocyte/NN
proliferation/NN
in/IN
13/CD
healthy/JJ
controls/NNS
./.
====================
Glucocorticoid/NN
effects/NNS
were/VBD
assessed/VBN
in/FW
vivo/FW
by/IN
depletion/NN
of/IN
endogenous/JJ
glucocorticoids/NNS
after/IN
oral/JJ
administration/NN
of/IN
1.5/CD
g/NN
metyrapone/NN
(/(
MET/NN
)/)
and/CC
subsequent/JJ
glucocorticoid/NN
replacement/NN
,/,
and/CC
in/FW
vitro/FW
by/IN
incubation/NN
of/IN
the/DT
cells/NNS
with/IN
different/JJ
doses/NNS
of/IN
dexamethasone/NN
(/(
DEX/NN
)/)
./.
====================
There/EX
was/VBD
a/DT
significant/JJ
decrease/NN
in/IN
PWM-induced/JJ
B-cell/NN
mitogenesis/NN
and/CC
a/DT
more/RBR
pronounced/JJ
effect/NN
of/IN
DEX/NN
administered/VBN
in/FW
vitro/FW
on/IN
spontaneous/JJ
lymphocyte/NN
proliferation/NN
after/IN
MET/NN
treatment/NN
when/WRB
compared/VBN
with/IN
the/DT
DEX/NN
plus/CC
MET/NN
pretreated/JJ
condition/NN
in/FW
vivo/FW
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
the/DT
inhibition/NN
of/IN
spontaneous/JJ
lymphocyte/NN
proliferation/NN
by/IN
glucocorticoids/NNS
in/FW
vitro/FW
is/VBZ
related/JJ
to/TO
glucocorticoid/NN
receptor/NN
function/NN
./.
====================
The/DT
decrease/NN
in/IN
PWM-generated/JJ
B-cell/NN
proliferation/NN
following/VBG
cortisol/NN
depletion/NN
by/IN
MET/NN
may/MD
be/VB
seen/VBN
in/IN
connection/NN
with/IN
impaired/JJ
glucocorticoid-mediated/JJ
induction/NN
of/IN
interleukin-1/NN
receptor/NN
synthesis/NN
./.
====================
UI/LS
-/:
96356325/CD
====================
TI/LS
-/:
Transcription/NN
specific/JJ
differences/NNS
visualized/VBN
by/IN
fluorescence/NN
in/FW
situ/FW
hybridization/NN
pattern/NN
on/IN
interphase/JJ
nuclei/NNS
of/IN
different/JJ
cell/NN
types/NNS
./.
====================
AB/LS
-/:
Application/NN
of/IN
a/DT
"/``
formamide/NN
free/JJ
"/''
and/CC
thus/RB
"/``
material/NN
preserving/NN
"/''
in/FW
situ/FW
hybridization/NN
technique/NN
using/VBG
the/DT
cDNA/NN
of/IN
the/DT
myf3/NN
gene/NN
revealed/VBD
the/DT
following/JJ
results/NNS
:/:
Human/JJ
rhabdomyosarcoma/NN
cells/NNS
,/,
characterized/VBN
by/IN
a/DT
high/JJ
expression/NN
of/IN
myf3/NN
show/VBP
intensive/JJ
hybridization/NN
signals/NNS
in/IN
their/PRP$
interphase/NN
./.
====================
RNase/NN
treatment/NN
prior/JJ
to/TO
hybridization/NN
considerably/RB
reduces/VBZ
the/DT
size/NN
of/IN
this/DT
signals/NNS
./.
====================
In/IN
comparison/NN
,/,
isolated/VBN
nuclei/NNS
of/IN
human/JJ
lymphocytes/NNS
in/IN
which/WDT
no/DT
need/NN
for/IN
the/DT
expression/NN
of/IN
this/DT
gene/NN
exists/VBZ
,/,
show/VBP
barely/RB
hybridization/NN
signals/NNS
./.
====================
Correspondingly/RB
,/,
RNase/NN
treatment/NN
had/VBD
no/DT
effect/NN
on/IN
hybridization/NN
pattern/NN
at/IN
all/DT
./.
====================
In/IN
conclusion/NN
an/DT
increased/VBN
transcription/NN
efficiency/NN
of/IN
a/DT
cell/NN
type/NN
specific/JJ
gene/NN
is/VBZ
accompanied/VBN
by/IN
a/DT
higher/JJR
hybridization/NN
accessibility/NN
in/IN
the/DT
corresponding/JJ
cell/NN
nuclei/NNS
./.
====================
UI/LS
-/:
96079009/CD
====================
TI/LS
-/:
Oncogenicity/NN
of/IN
human/JJ
papillomavirus-/NN
or/CC
adenovirus-transformed/JJ
cells/NNS
correlates/VBZ
with/IN
resistance/NN
to/TO
lysis/NN
by/IN
natural/JJ
killer/NN
cells/NNS
./.
====================
AB/LS
-/:
The/DT
reasons/NNS
for/IN
the/DT
dissimilar/JJ
oncogenicities/NNS
of/IN
human/JJ
adenoviruses/NNS
and/CC
human/JJ
papillomaviruses/NNS
(/(
HPV/NNS
)/)
in/IN
humans/NNS
are/VBP
unknown/JJ
but/CC
may/MD
relate/VB
to/TO
differences/NNS
in/IN
the/DT
capacities/NNS
of/IN
the/DT
E1A/NN
and/CC
E7/NN
proteins/NNS
to/TO
target/VB
cells/NNS
for/IN
rejection/NN
by/IN
the/DT
host/NN
natural/JJ
killer/NN
(/(
NK/NN
)/)
cell/NN
response/NN
./.
====================
As/IN
one/CD
test/NN
of/IN
this/DT
hypothesis/NN
,/,
we/PRP
compared/VBD
the/DT
abilities/NNS
of/IN
E1A-/NN
and/CC
E7-expressing/JJ
human/JJ
fibroblastic/JJ
or/CC
keratinocyte-derived/JJ
human/JJ
cells/NNS
to/TO
be/VB
selectively/RB
killed/VBN
by/IN
either/CC
unstimulated/JJ
or/CC
interferon/NN
(/(
IFN/NN
)/)
-activated/JJ
NK/NN
cells/NNS
./.
====================
Cells/NNS
expressing/VBG
the/DT
E1A/NN
oncoprotein/NN
were/VBD
selectively/RB
killed/VBN
by/IN
unstimulated/JJ
NK/NN
cells/NNS
,/,
while/IN
the/DT
same/JJ
parental/JJ
cells/NNS
but/CC
expressing/VBG
the/DT
HPV/NNS
type/NN
16/CD
(/(
HPV-16/NN
)/)
or/CC
HPV-18/NN
E7/NN
oncoprotein/NN
were/VBD
resistant/JJ
to/TO
NK/NN
cell/NN
lysis/NN
./.
====================
The/DT
ability/NN
of/IN
IFN-activated/JJ
NK/NN
cells/NNS
to/TO
selectively/RB
kill/VB
virally/RB
transformed/VBN
cells/NNS
depends/VBZ
on/IN
IFN/NN
's/POS
ability/NN
to/TO
induce/VB
resistance/NN
to/TO
NK/NN
cell/NN
lysis/NN
in/IN
normal/JJ
(/(
i.e./FW
,/,
non-viral/JJ
oncogene-expressing/JJ
)/)
but/CC
not/RB
virally/RB
transformed/VBN
cells/NNS
./.
====================
E1A/NN
blocked/VBD
IFN/NN
's/POS
induction/NN
of/IN
cytolytic/JJ
resistance/NN
,/,
resulting/VBG
in/IN
the/DT
selective/JJ
lysis/NN
of/IN
adenovirus-transformed/JJ
cells/NNS
by/IN
IFN-activated/JJ
NK/NN
cells/NNS
./.
====================
The/DT
extent/NN
of/IN
IFN-induced/JJ
NK/NN
cell/NN
killing/NN
of/IN
E1A-expressing/JJ
cells/NNS
was/VBD
proportional/JJ
to/TO
the/DT
level/NN
of/IN
E1A/NN
expression/NN
and/CC
correlated/VBN
with/IN
the/DT
ability/NN
of/IN
E1A/NN
to/TO
block/VB
IFN-stimulated/JJ
gene/NN
expression/NN
in/IN
target/NN
cells/NNS
./.
====================
In/IN
contrast/NN
,/,
E7/NN
blocked/VBD
neither/CC
IFN-stimulated/JJ
gene/NN
expression/NN
nor/CC
IFN/NN
's/POS
induction/NN
of/IN
cytolytic/JJ
resistance/NN
,/,
thereby/RB
precluding/VBG
the/DT
selective/JJ
lysis/NN
of/IN
HPV-transformed/JJ
cells/NNS
by/IN
IFN-activated/JJ
NK/NN
cells/NNS
./.
====================
In/IN
conclusion/NN
,/,
E1A/NN
expression/NN
marks/VBZ
cells/NNS
for/IN
destruction/NN
by/IN
the/DT
host/NN
NK/NN
cell/NN
response/NN
,/,
whereas/IN
the/DT
E7/NN
oncoprotein/NN
lacks/VBZ
this/DT
activity/NN
./.
====================
UI/LS
-/:
96062284/CD
====================
TI/LS
-/:
Regulation/NN
of/IN
IkB/NN
alpha/NN
phosphorylation/NN
by/IN
PKC-/NN
and/CC
Ca(2+)-dependent/JJ
signal/NN
transduction/NN
pathways/NNS
./.
====================
AB/LS
-/:
The/DT
Ca(2+)-dependent/JJ
phosphatase/NN
calcineurin/NN
,/,
a/DT
target/NN
of/IN
FK506/NN
and/CC
CsA/NN
,/,
synergizes/VBZ
with/IN
PKC-induced/JJ
activation/NN
of/IN
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
-kappa/NN
B/NN
in/IN
T/NN
cell/NN
lines/NNS
./.
====================
We/PRP
have/VBP
investigated/VBN
whether/IN
this/DT
synergy/NN
is/VBZ
present/JJ
in/IN
other/JJ
cell/NN
types/NNS
and/CC
the/DT
mechanism/NN
(/(
s/NNS
)/)
by/IN
which/WDT
these/DT
two/CD
pathways/NNS
lead/VBP
to/TO
NF-kappa/NN
B/NN
activation/NN
./.
====================
While/IN
this/DT
synergy/NN
is/VBZ
present/JJ
in/IN
other/JJ
cell/NN
types/NNS
,/,
in/IN
the/DT
monocytic/JJ
cell/NN
line/NN
U937/NN
calcineurin/NN
is/VBZ
also/RB
sufficient/JJ
to/TO
activate/VB
NF-kappa/NN
B/NN
./.
====================
Having/VBG
previously/RB
shown/VBN
that/IN
Ca(2+)-/NN
and/CC
PKC-/NN
dependent/JJ
pathways/NNS
synergize/VBP
by/IN
accelerating/VBG
the/DT
degradation/NN
of/IN
IkB/NN
alpha/NN
,/,
we/PRP
focused/VBD
on/IN
the/DT
regulation/NN
of/IN
IkB/NN
alpha/NN
phosphorylation/NN
./.
====================
While/IN
PKC-dependent/JJ
pathways/NNS
sequentially/RB
result/VBP
in/IN
the/DT
phosphorylation/NN
and/CC
in/IN
an/DT
incomplete/JJ
degradation/NN
of/IN
IkB/NN
alpha/NN
in/IN
T/NN
cell/NN
lines/NNS
,/,
co-activation/NN
of/IN
Ca(2+)-dependent/JJ
pathways/NNS
accelerates/VBZ
the/DT
rate/NN
of/IN
IkB/NN
alpha/NN
phosphorylation/NN
and/CC
results/VBZ
in/IN
its/PRP$
complete/JJ
degradation/NN
./.
====================
Activation/NN
of/IN
Ca(2+)-dependent/JJ
pathways/NNS
alone/RB
do/VBP
not/RB
result/VB
in/IN
the/DT
phosphorylation/NN
and/or/CC
degradation/NN
of/IN
IkB/NN
alpha/NN
in/IN
Jurkat/NN
T/NN
or/CC
in/IN
U937/NN
cells/NNS
./.
====================
Treatment/NN
of/IN
T/NN
cells/NNS
with/IN
the/DT
selective/JJ
PKC/NN
inhibitor/NN
GF109203X/NN
abrogates/VBZ
the/DT
PMA-induced/JJ
IkB/NN
alpha/NN
phosphorylation/degradation/NN
irrespective/JJ
of/IN
activation/NN
of/IN
Ca(2+)-dependent/JJ
pathways/NNS
,/,
but/CC
not/RB
the/DT
phosphorylation/NN
and/CC
degradation/NN
of/IN
IkB/NN
alpha/NN
induced/VBN
by/IN
TNF-alpha/NN
,/,
a/DT
PKC-independent/JJ
stimulus/NN
./.
====================
Contrary/JJ
to/TO
the/DT
interaction/NN
with/IN
PKC/NN
,/,
Ca(2+)-dependent/JJ
pathways/NNS
synergize/VBP
with/IN
TNF-alpha/NN
not/RB
at/IN
the/DT
level/NN
of/IN
IkB/NN
alpha/NN
phosphorylation/NN
,/,
but/CC
at/IN
the/DT
level/NN
of/IN
its/PRP$
degradation/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
Ca(2+)-dependent/JJ
pathways/NNS
,/,
including/VBG
the/DT
phosphatase/NN
calcineurin/NN
,/,
participate/VBP
in/IN
the/DT
regulation/NN
of/IN
NF-kappa/NN
B/NN
in/IN
a/DT
cell/NN
specific/JJ
fashion/NN
and/CC
synergize/VBP
with/IN
PKC-dependent/JJ
and/CC
-independent/JJ
pathways/NNS
at/IN
the/DT
level/NN
of/IN
IkB/NN
alpha/NN
phosphorylation/NN
and/CC
degradation/NN
./.
====================
UI/LS
-/:
96054968/CD
====================
TI/LS
-/:
Vitamin/NN
E/NN
therapy/NN
of/IN
acute/JJ
CCl4-induced/JJ
hepatic/JJ
injury/NN
in/IN
mice/NNS
is/VBZ
associated/VBN
with/IN
inhibition/NN
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
binding/NN
./.
====================
AB/LS
-/:
Oxidative/JJ
stress/NN
,/,
with/IN
reactive/JJ
oxygen/NN
intermediate/NN
formation/NN
,/,
may/MD
represent/VB
a/DT
common/JJ
mechanism/NN
by/IN
which/WDT
liver/NN
injury/NN
is/VBZ
induced/VBN
by/IN
diverse/JJ
etiologies/NNS
./.
====================
Oxidative/JJ
stress/NN
enhances/VBZ
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
activity/NN
,/,
and/CC
NF-kappa/NN
B/NN
activity/NN
has/VBZ
been/VBN
shown/VBN
to/TO
enhance/VB
the/DT
expression/NN
of/IN
cytotoxic/JJ
cytokines/NNS
./.
====================
Acute/JJ
hepatic/JJ
injury/NN
caused/VBN
by/IN
reactive/JJ
oxygen/NN
intermediate/NN
production/NN
was/VBD
induced/VBN
by/IN
an/DT
intraperitoneal/JJ
injection/NN
of/IN
CCl4/NN
in/IN
mice/NNS
./.
====================
This/DT
injury/NN
was/VBD
significantly/RB
inhibited/VBN
by/IN
intravenous/JJ
pretreatment/NN
of/IN
the/DT
mice/NNS
with/IN
a/DT
water-soluble/JJ
emulsion/NN
of/IN
alpha-tocopherol/NN
./.
====================
Alpha-tocopherol/NN
treatment/NN
of/IN
the/DT
mice/NNS
given/VBN
the/DT
CCl4/NN
also/RB
reduced/VBD
the/DT
NF-kappa/NN
B/NN
binding/NN
to/TO
levels/NNS
approaching/VBG
those/DT
found/VBN
in/IN
normal/JJ
mice/NNS
./.
====================
In/FW
vitro/FW
treatment/NN
of/IN
a/DT
monocyte/macrophage/NN
cell/NN
line/NN
with/IN
CCl4/NN
led/VBD
to/TO
enhanced/VBN
NF-kappa/NN
B/NN
binding/NN
and/CC
an/DT
increase/NN
in/IN
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
messenger/NN
RNA/NN
levels/NNS
./.
====================
Liver/NN
specimens/NNS
taken/VBN
from/IN
patients/NNS
with/IN
acute/JJ
fulminant/JJ
hepatitis/NN
had/VBD
markedly/RB
increased/VBN
NF-kappa/NN
B/NN
binding/NN
activity/NN
in/IN
comparison/NN
with/IN
the/DT
binding/NN
of/IN
normal/JJ
livers/NNS
./.
====================
These/DT
data/NNS
demonstrate/VBP
that/IN
abolishing/VBG
acute/JJ
hepatic/JJ
injury/NN
with/IN
alpha-tocopherol/NN
,/,
a/DT
free/JJ
radical/NN
scavenger/NN
,/,
also/RB
eliminated/VBD
increased/VBN
NF-kappa/NN
B/NN
binding/NN
./.
====================
It/PRP
is/VBZ
tempting/JJ
to/TO
speculate/VB
that/IN
enhanced/VBN
NF-kappa/NN
B/NN
expression/NN
caused/VBN
by/IN
free/JJ
radical/NN
production/oxidative/JJ
stress/NN
may/MD
modulate/VB
liver/NN
injury/NN
,/,
perhaps/RB
through/IN
an/DT
effect/NN
on/IN
cytotoxic/JJ
cytokine/NN
synthesis/NN
./.
====================
UI/LS
-/:
96026328/CD
====================
TI/LS
-/:
Immunosuppression/NN
by/IN
glucocorticoids/NNS
:/:
inhibition/NN
of/IN
NF-kappa/NN
B/NN
activity/NN
through/IN
induction/NN
of/IN
I/NN
kappa/NN
B/NN
synthesis/NN
[/(
see/VB
comments/NNS
]/)
====================
AB/LS
-/:
Glucocorticoids/NNS
are/VBP
among/IN
the/DT
most/RBS
potent/JJ
anti-inflammatory/JJ
and/CC
immunosuppressive/JJ
agents/NNS
./.
====================
They/PRP
inhibit/VBP
synthesis/NN
of/IN
almost/RB
all/DT
known/JJ
cytokines/NNS
and/CC
of/IN
several/JJ
cell/NN
surface/NN
molecules/NNS
required/VBN
for/IN
immune/JJ
function/NN
,/,
but/CC
the/DT
mechanism/NN
underlying/VBG
this/DT
activity/NN
has/VBZ
been/VBN
unclear/JJ
./.
Here/RB
it/PRP
is/VBZ
shown/VBN
that/IN
glucocorticoids/NNS
are/VBP
potent/JJ
inhibitors/NNS
of/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
activation/NN
in/IN
mice/NNS
and/CC
cultured/VBN
cells/NNS
./.
====================
This/DT
inhibition/NN
is/VBZ
mediated/VBN
by/IN
induction/NN
of/IN
the/DT
I/NN
kappa/NN
B/NN
alpha/NN
inhibitory/JJ
protein/NN
,/,
which/WDT
traps/VBZ
activated/VBN
NF-kappa/NN
B/NN
in/IN
inactive/JJ
cytoplasmic/JJ
complexes/NNS
./.
====================
Because/IN
NF-kappa/NN
B/NN
activates/VBZ
many/JJ
immunoregulatory/JJ
genes/NNS
in/IN
response/NN
to/TO
pro-inflammatory/JJ
stimuli/NNS
,/,
the/DT
inhibition/NN
of/IN
its/PRP$
activity/NN
can/MD
be/VB
a/DT
major/JJ
component/NN
of/IN
the/DT
anti-inflammatory/JJ
activity/NN
of/IN
glucocorticoids/NNS
./.
====================
UI/LS
-/:
96009608/CD
====================
TI/LS
-/:
Transcriptional/JJ
repression/NN
of/IN
the/DT
interleukin-2/NN
gene/NN
by/IN
vitamin/NN
D3/NN
:/:
direct/JJ
inhibition/NN
of/IN
NFATp/NN
/AP-1/NN
complex/JJ
formation/NN
by/IN
a/DT
nuclear/JJ
hormone/NN
receptor/NN
./.
====================
AB/LS
-/:
T-lymphocyte/NN
proliferation/NN
is/VBZ
suppressed/VBN
by/IN
1,25-dihydroxyvitamin/NN
D3/NN
[/(
1,25(OH)2D3/NN
]/)
,/,
the/DT
active/JJ
metabolite/NN
of/IN
vitamin/NN
D3/NN
,/,
and/CC
is/VBZ
associated/VBN
with/IN
a/DT
decrease/NN
in/IN
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
,/,
gamma/NN
interferon/NN
,/,
and/CC
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
mRNA/NN
levels/NNS
./.
====================
We/PRP
report/VBP
here/RB
that/IN
1,25(OH)2D3-mediated/JJ
repression/NN
in/IN
Jurkat/NN
cells/NNS
is/VBZ
cycloheximide/NN
resistant/JJ
,/,
suggesting/VBG
that/IN
it/PRP
is/VBZ
a/DT
direct/JJ
transcriptional/JJ
repressive/JJ
effect/NN
on/IN
IL-2/NN
expression/NN
by/IN
the/DT
vitamin/NN
D3/NN
receptor/NN
(/(
VDR/NN
)/)
./.
====================
We/PRP
therefore/RB
examined/VBD
vitamin/NN
D3-mediated/JJ
repression/NN
of/IN
activated/VBN
IL-2/NN
expression/NN
by/IN
cotransfecting/VBG
Jurkat/NN
cells/NNS
with/IN
IL-2/NN
promoter/NN
/reporter/NN
constructs/NNS
and/CC
a/DT
VDR/NN
overexpression/NN
vector/NN
and/CC
by/IN
DNA/NN
binding/NN
./.
====================
We/PRP
delineated/VBD
an/DT
element/NN
conferring/VBG
both/CC
DNA/NN
binding/NN
by/IN
the/DT
receptor/NN
in/FW
vitro/FW
and/CC
1,25(OH)2D3-mediated/JJ
repression/NN
in/FW
vivo/FW
to/TO
a/DT
short/JJ
40-bp/JJ
region/NN
encompassing/VBG
an/DT
important/JJ
positive/JJ
regulatory/JJ
element/NN
,/,
NF-AT-1/NN
,/,
which/WDT
is/VBZ
bound/VBN
by/IN
a/DT
T-cell-specific/JJ
transcription/NN
factor/NN
,/,
NFATp/NN
,/,
as/RB
well/RB
as/IN
by/IN
AP-1/NN
./.
====================
VDR/NN
DNA-binding/JJ
mutants/NNS
were/VBD
unable/JJ
to/TO
either/RB
bind/VB
to/TO
this/DT
element/NN
in/FW
vitro/FW
or/CC
repress/VB
in/FW
vivo/FW
;/:
the/DT
VDR/NN
DNA-binding/JJ
domain/NN
alone/RB
,/,
however/RB
,/,
bound/VBD
the/DT
element/NN
but/CC
also/RB
could/MD
not/RB
repress/VB
IL-2/NN
expression/NN
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
DNA/NN
binding/NN
by/IN
VDR/NN
is/VBZ
necessary/JJ
but/CC
not/RB
sufficient/JJ
to/TO
mediate/VB
IL-2/NN
repression/NN
./.
====================
By/IN
combining/VBG
partially/RB
purified/VBN
proteins/NNS
in/FW
vitro/FW
,/,
we/PRP
observed/VBD
the/DT
loss/NN
of/IN
the/DT
bound/VBN
NFATp/NN
/AP-1-DNA/NN
complex/NN
upon/IN
inclusion/NN
of/IN
VDR/NN
or/CC
VDR-retinoid/NN
X/NN
receptor/NN
./.
====================
Order/NN
of/IN
addition/NN
and/CC
off-rate/JJ
experiments/NNS
indicate/VBP
that/IN
the/DT
VDR-retinoid/NN
X/NN
receptor/NN
heterodimer/NN
blocks/VBZ
NFATp/NN
/AP-1/NN
complex/NN
formation/NN
and/CC
then/RB
stably/RB
associates/VBZ
with/IN
the/DT
NF-AT-1/NN
element/NN
./.
====================
This/DT
direct/JJ
inhibition/NN
by/IN
a/DT
nuclear/JJ
hormone/NN
receptor/NN
of/IN
transcriptional/JJ
activators/NNS
of/IN
the/DT
IL-2/NN
gene/NN
may/MD
provide/VB
a/DT
mechanistic/JJ
explanation/NN
of/IN
how/WRB
vitamin/NN
derivatives/NNS
can/MD
act/VB
as/IN
potent/JJ
immunosuppressive/JJ
agents/NNS
./.
====================
UI/LS
-/:
96017769/CD
====================
TI/LS
-/:
Tissue-specific/JJ
regulation/NN
of/IN
the/DT
rabbit/JJ
15-lipoxygenase/NN
gene/NN
in/IN
erythroid/JJ
cells/NNS
by/IN
a/DT
transcriptional/JJ
silencer/NN
./.
====================
AB/LS
-/:
The/DT
15-lipoxygenase/NN
(/(
lox/NN
)/)
gene/NN
is/VBZ
expressed/VBN
in/IN
a/DT
tissue-specific/JJ
manner/NN
,/,
predominantly/RB
in/IN
erythroid/JJ
cells/NNS
but/CC
also/RB
in/IN
airway/NN
epithelial/JJ
cells/NNS
and/CC
eosinophils/NNS
./.
====================
We/PRP
demonstrate/VBP
in/IN
this/DT
report/NN
that/IN
the/DT
5'/JJ
flanking/JJ
DNA/NN
of/IN
the/DT
15-lox/NN
gene/NN
contains/VBZ
sequences/NNS
which/WDT
down-regulate/VBP
its/PRP$
activity/NN
in/IN
a/DT
variety/NN
of/IN
non-erythroid/JJ
cell/NN
lines/NNS
but/CC
not/RB
in/IN
two/CD
erythroid/JJ
cell/NN
lines/NNS
./.
====================
The/DT
element/NN
has/VBZ
characteristics/NNS
of/IN
a/DT
transcriptional/JJ
'/``
silencer/NN
'/''
since/IN
it/PRP
functions/VBZ
in/IN
both/DT
orientations/NNS
./.
====================
The/DT
main/JJ
activity/NN
of/IN
the/DT
silencer/NN
has/VBZ
been/VBN
mapped/VBN
to/TO
the/DT
first/JJ
900/CD
bp/NN
of/IN
5'/JJ
flanking/JJ
DNA/NN
,/,
which/WDT
contains/VBZ
nine/CD
binding/VBG
sites/NNS
for/IN
a/DT
nuclear/JJ
factor/NN
present/JJ
in/IN
non-erythroid/JJ
cells/NNS
but/CC
not/RB
in/IN
erythroid/JJ
cells/NNS
./.
====================
These/DT
binding/VBG
sites/NNS
have/VBP
similar/JJ
sequences/NNS
and/CC
multiple/JJ
copies/NNS
of/IN
the/DT
binding/VBG
sites/NNS
confer/VBP
tissue-specific/JJ
down-regulation/NN
when/WRB
attached/VBN
to/TO
a/DT
minimal/JJ
lox/NN
promoter/NN
fragment/NN
./.
====================
The/DT
5'/JJ
flanking/JJ
DNA/NN
also/RB
contains/VBZ
a/DT
cluster/NN
of/IN
three/CD
binding/VBG
sites/NNS
for/IN
the/DT
GATA/NN
family/NN
of/IN
transcription/NN
factors/NNS
./.
====================
UI/LS
-/:
95386516/CD
====================
TI/LS
-/:
Phosphorylation/NN
of/IN
the/DT
transcription/NN
factor/NN
NFATp/NN
inhibits/VBZ
its/PRP$
DNA/NN
binding/NN
activity/NN
in/IN
cyclosporin/NN
A-treated/JJ
human/JJ
B/NN
and/CC
T/NN
cells/NNS
./.
====================
AB/LS
-/:
Cyclosporin/NN
A/NN
(/(
CsA/NN
)/)
exerts/VBZ
its/PRP$
immunosuppressive/JJ
effect/NN
by/IN
inhibiting/VBG
the/DT
activity/NN
of/IN
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cells/NNS
(/(
NFAT/NN
)/)
,/,
thus/RB
preventing/VBG
transcriptional/JJ
induction/NN
of/IN
several/JJ
cytokine/NN
genes/NNS
./.
====================
This/DT
effect/NN
is/VBZ
thought/VBN
to/TO
be/VB
largely/RB
mediated/VBN
through/IN
inactivation/NN
of/IN
the/DT
phosphatase/NN
calcineurin/NN
,/,
which/WDT
in/IN
turn/NN
inhibits/VBZ
translocation/NN
of/IN
an/DT
NFAT/NN
component/NN
to/TO
the/DT
nucleus/NN
./.
====================
Here/RB
we/PRP
report/VBP
that/IN
CsA/NN
treatment/NN
of/IN
Raji/NN
B/NN
and/CC
Jurkat/NN
T/NN
cell/NN
lines/NNS
yields/VBZ
a/DT
phosphorylated/JJ
form/NN
of/IN
NFATp/NN
that/WDT
is/VBZ
inhibited/VBN
in/IN
DNA-binding/JJ
and/CC
in/IN
its/PRP$
ability/NN
to/TO
form/VB
an/DT
NFAT/NN
complex/NN
with/IN
Fos/NN
and/CC
Jun/NN
./.
====================
Immunoblot/NN
analyses/NNS
and/CC
metabolic/JJ
labeling/NN
with/IN
[32P]orthophosphate/NN
show/VBP
that/IN
CsA/NN
alters/VBZ
NFATp/NN
migration/NN
on/IN
SDS-polyacrylamide/NN
gel/NN
electrophoresis/NN
by/IN
increasing/VBG
its/PRP$
phosphorylation/NN
level/NN
without/IN
affecting/VBG
subcellular/JJ
distribution/NN
./.
====================
Dephosphorylation/NN
by/IN
in/FW
vitro/FW
treatment/NN
with/IN
calcineurin/NN
or/CC
alkaline/NN
phosphatase/NN
restores/VBZ
NFATp/NN
DNA/NN
binding/NN
activity/NN
and/CC
its/PRP$
ability/NN
to/TO
reconstitute/VB
an/DT
NFAT/NN
complex/NN
with/IN
Fos/NN
and/CC
Jun/NN
proteins/NNS
./.
====================
These/DT
data/NNS
point/VBP
to/TO
a/DT
new/JJ
mechanism/NN
for/IN
CsA-sensitive/JJ
regulation/NN
of/IN
NFATp/NN
in/IN
which/WDT
dephosphorylation/NN
is/VBZ
critical/JJ
for/IN
DNA/NN
binding/NN
./.
====================
UI/LS
-/:
95367586/CD
====================
TI/LS
-/:
Transcription/NN
factors/NNS
as/IN
targets/NNS
for/IN
oxidative/JJ
signalling/NN
during/IN
lymphocyte/NN
activation/NN
./.
====================
AB/LS
-/:
We/PRP
previously/RB
have/VBP
demonstrated/VBN
a/DT
requirement/NN
for/IN
oxidative/JJ
events/NNS
during/IN
cell/NN
cycle/NN
entry/NN
in/IN
T/NN
lymphocytes/NNS
and/CC
have/VBP
hypothesised/VBN
that/IN
reactive/JJ
oxygen/NN
species/NNS
may/MD
act/VB
as/IN
intracellular/JJ
signalling/VBG
agents/NNS
during/IN
lymphocyte/NN
activation/NN
./.
====================
In/IN
the/DT
current/JJ
study/NN
,/,
cysteamine/NN
,/,
an/DT
aminothiol/NN
compound/NN
with/IN
antioxidant/JJ
activity/NN
,/,
has/VBZ
been/VBN
used/VBN
to/TO
further/RB
investigate/VB
the/DT
role/NN
of/IN
oxidative/JJ
signalling/NN
during/IN
lymphocyte/NN
activation/NN
./.
====================
Treatment/NN
of/IN
normal/JJ
human/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
with/IN
cysteamine/NN
in/FW
vitro/FW
was/VBD
found/VBN
to/TO
inhibit/VB
proliferation/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
,/,
with/IN
essentially/RB
complete/JJ
inhibition/NN
occurring/VBG
at/IN
a/DT
dose/NN
of/IN
400/CD
microM/NN
./.
====================
This/DT
inhibitory/JJ
effect/NN
was/VBD
limited/JJ
to/TO
the/DT
first/JJ
2/CD
h/NN
after/IN
mitogenic/JJ
activation/NN
,/,
localizing/VBG
the/DT
time-frame/NN
of/IN
action/NN
of/IN
cysteamine/NN
to/TO
within/IN
the/DT
commitment/NN
period/NN
./.
====================
It/PRP
therefore/RB
was/VBD
of/IN
interest/NN
to/TO
establish/VB
which/WDT
,/,
if/IN
any/DT
,/,
commitment/NN
events/NNS
were/VBD
affected/VBN
by/IN
oxidative/JJ
signalling/NN
during/IN
cell/NN
cycle/NN
entry/NN
./.
====================
Taking/VBG
the/DT
IL-2/NN
gene/NN
as/IN
a/DT
candidate/NN
,/,
we/PRP
examined/VBD
the/DT
effect/NN
of/IN
cysteamine/NN
treatment/NN
on/IN
early/JJ
gene/NN
expression/NN
during/IN
lymphocyte/NN
activation/NN
,/,
and/CC
on/IN
the/DT
activity/NN
of/IN
transcription/NN
factors/NNS
AP-1/NN
,/,
NF-kappa/NN
B/NN
,/,
NF-AT/NN
and/CC
Oct1/NN
,/,
whose/WP$
functions/NNS
are/VBP
required/VBN
for/IN
expression/NN
of/IN
the/DT
IL-2/NN
mRNA/NN
./.
====================
Cysteamine/NN
treatment/NN
inhibited/VBD
both/CC
expression/NN
of/IN
the/DT
IL-2/NN
mRNA/NN
and/CC
secretion/NN
of/IN
IL-2/NN
into/IN
the/DT
culture/NN
medium/NN
./.
====================
The/DT
inhibitory/JJ
effect/NN
of/IN
cysteamine/NN
may/MD
be/VB
mediated/VBN
at/IN
least/JJS
in/IN
part/NN
by/IN
an/DT
effect/NN
on/IN
transcription/NN
factor/NN
function/NN
,/,
as/IN
the/DT
DNA/NN
binding/NN
activities/NNS
of/IN
AP-1/NN
and/CC
NF-kappa/NN
B/NN
extracted/VBN
from/IN
mitogen-stimulated/JJ
cells/NNS
were/VBD
significantly/RB
inhibited/VBN
by/IN
cysteamine/NN
treatment/NN
./.
====================
Interestingly/RB
,/,
Oct1/NN
and/CC
NF-AT/NN
DNA/NN
binding/NN
activity/NN
were/VBD
not/RB
affected/VBN
by/IN
cysteamine/NN
treatment/NN
,/,
suggesting/VBG
that/IN
oxidative/JJ
signalling/NN
processes/NNS
operate/VBP
in/IN
a/DT
selective/JJ
manner/NN
./.
====================
The/DT
identification/NN
of/IN
regulatory/JJ
proteins/NNS
,/,
such/JJ
as/IN
transcription/NN
factors/NNS
,/,
as/IN
molecular/JJ
targets/NNS
for/IN
oxidative/JJ
signalling/NN
provides/VBZ
further/JJ
evidence/NN
to/TO
implicate/VB
oxidative/JJ
signalling/NN
as/IN
being/VBG
intimately/RB
involved/VBN
in/IN
the/DT
G0/NN
to/TO
G1/NN
phase/NN
transition/NN
in/IN
T/NN
lymphocytes/NNS
./.
====================
UI/LS
-/:
91175240/CD
====================
TI/LS
-/:
Sex/NN
and/CC
age/NN
distribution/NN
of/IN
1,25(OH)2D3/NN
receptors/NNS
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
from/IN
normal/JJ
human/JJ
subjects/NNS
./.
====================
AB/LS
-/:
Specific/JJ
receptors/NNS
for/IN
1,25/CD
Dihydroxyvitamin/NN
D3/NN
have/VBP
been/VBN
described/VBN
in/IN
human/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NNS
)/)
./.
====================
We/PRP
have/VBP
tried/VBN
to/TO
find/VB
out/RP
whether/IN
these/DT
receptors/NNS
could/MD
show/VB
any/DT
difference/NN
in/IN
sex/NN
or/CC
age/NN
distribution/NN
./.
====================
Twenty/CD
two/CD
healthy/JJ
men/NNS
aged/JJ
21-66/CD
yr/NN
(/(
mean/NN
+/-/CC
SD/NN
41.0/CD
+/-/CC
13.6/CD
)/)
and/CC
nineteen/CD
healthy/JJ
women/NNS
aged/JJ
22-60/CD
yr/NN
(/(
38.9/CD
+/-/CC
13.9/CD
)/)
have/VBP
been/VBN
studied/VBN
./.
====================
The/DT
mean/NN
dissociation/NN
constant/NN
(/(
Kd/NN
)/)
was/VBD
similar/JJ
in/IN
both/DT
sexes/NNS
(/(
1.35/CD
+/-/CC
0.70/CD
x/NN
10(-10)/CD
M/NN
in/IN
males/NNS
,/,
1.13/CD
+/-/CC
0.66/CD
x/NN
10(-10)/CD
M/NN
in/IN
females/NNS
)/)
,/,
but/CC
the/DT
concentration/NN
of/IN
binding/VBG
sites/NNS
(/(
Nmax/NN
)/)
was/VBD
significantly/RB
lower/JJR
in/IN
females/NNS
(/(
2.32/CD
+/-/CC
0.92/CD
fmol/10/CD
(/(
7/CD
)/)
PBMC/NNS
vs/CC
4.43/CD
+/-/CC
1.38/CD
fmol/10(7)/NN
PBMC/NNS
in/IN
males/NNS
;/:
p/NN
=/JJ
0.0001/CD
)/)
./.
====================
Neither/CC
Kd/NN
nor/CC
Nmax/NN
were/VBD
significantly/RB
correlated/VBN
with/IN
age/NN
./.
====================
No/DT
difference/NN
was/VBD
found/VBN
between/IN
pre/JJ
and/CC
postmenopausal/JJ
women/NNS
./.
====================
Further/JJ
studies/NNS
are/VBP
needed/VBN
to/TO
elucidate/VB
if/IN
this/DT
sex/NN
difference/NN
in/IN
PBMC/NN
receptors/NNS
for/IN
1.25/CD
Dihydroxyvitamin/NN
D3/NN
is/VBZ
of/IN
any/DT
pathophysiological/JJ
relevance/NN
./.
====================
UI/LS
-/:
96226053/CD
====================
TI/LS
-/:
Expression/NN
of/IN
Id2/NN
and/CC
Id3/NN
mRNA/NN
in/IN
human/JJ
lymphocytes/NNS
./.
====================
AB/LS
-/:
Helix-loop-helix/JJ
(/(
HLH/JJ
)/)
transcription/NN
factors/NNS
are/VBP
involved/VBN
in/IN
cellular/JJ
growth/NN
and/CC
differentiation/NN
./.
====================
The/DT
Id/NN
(/(
inhibitor/NN
of/IN
DNA/NN
binding/NN
and/CC
differentiation/NN
)/)
HLH/JJ
proteins/NNS
,/,
in/IN
a/DT
dominantly/RB
negative/JJ
fashion/NN
,/,
regulate/VBP
transcriptional/JJ
activities/NNS
of/IN
basic/JJ
HLH/JJ
proteins/NNS
./.
====================
We/PRP
examined/VBD
by/IN
northern/JJ|NN
hybridization/NN
the/DT
expression/NN
of/IN
Id2/NN
and/CC
Id3/NN
mRNA/NN
in/IN
human/JJ
leukemia/lymphoma/NN
lines/NNS
and/CC
patient/NN
samples/NNS
,/,
as/RB
well/RB
as/IN
resting/VBG
and/CC
activated/VBN
normal/JJ
human/JJ
lymphocytes/NNS
from/IN
peripheral/JJ
blood/NN
(/(
PBL/NN
)/)
./.
====================
The/DT
Id2/NN
mRNA/NN
was/VBD
abundantly/RB
expressed/VBN
in/IN
5/12/CD
T-cell/NN
and/CC
3/4/CD
B-cell/NN
lines/NNS
,/,
and/CC
Id3/NN
mRNA/NN
was/VBD
detected/VBN
in/IN
4/12/CD
T-cell/NN
and/CC
3/4/CD
B-cell/NN
lines/NNS
./.
====================
Interestingly/RB
,/,
Id2/NN
,/,
but/CC
not/RB
Id3/NN
,/,
mRNA/NN
was/VBD
strongly/RB
expressed/VBN
in/IN
4/5/CD
T-cell/NN
lines/NNS
infected/VBN
with/IN
human/JJ
T-cell/NN
leukemia/NN
virus/NN
type/NN
I/CD
(/(
HTLV-I/NN
)/)
(/(
ATL-1k/NN
,/,
MT-2/NN
,/,
S-LB1/NN
)/)
and/CC
type/NN
II/CD
(/(
Mo/NN
)/)
./.
====================
Another/DT
unexpected/JJ
finding/NN
was/VBD
that/IN
T-cell/NN
leukemias/NNS
and/CC
T-cell/NN
lines/NNS
often/RB
expressed/VBD
either/CC
Id2/NN
or/CC
Id3/NN
mRNA/NN
./.
====================
In/IN
addition/NN
,/,
resting/VBG
PBL/NN
constitutively/RB
expressed/VBD
prominent/JJ
levels/NNS
of/IN
Id2/NN
mRNA/NN
,/,
but/CC
not/RB
Id3/NN
mRNA/NN
./.
====================
Upon/IN
PHA-stimulation/NN
,/,
Id2/NN
expression/NN
decreased/VBD
and/CC
Id3/NN
levels/NNS
increased/VBD
with/IN
biphasic/JJ
kinetics/NNS
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
studies/NNS
revealed/VBD
three/CD
unexpected/JJ
findings/NNS
which/WDT
require/VBP
further/JJ
analysis/NN
:/:
(/(
1/LS
)/)
expression/NN
of/IN
Id2/NN
mRNA/NN
is/VBZ
often/RB
associated/VBN
with/IN
lymphocytic/JJ
transformation/NN
by/IN
HTLV-I/NN
or/CC
-II/CD
;/:
(/(
2/LS
)/)
T-cells/NNS
usually/RB
express/VBP
either/CC
Id2/NN
or/CC
Id3/NN
mRNA/NN
,/,
but/CC
B-cells/NNS
often/RB
express/VBP
both/DT
simultaneously/RB
;/:
(/(
3/LS
)/)
non-dividing/JJ
,/,
normal/JJ
PBL/NN
express/VBP
high/JJ
levels/NNS
of/IN
Id2/NN
and/CC
no/DT
Id3/NN
mRNA/NN
;/:
and/CC
with/IN
the/DT
onset/NN
of/IN
cellular/JJ
proliferation/NN
,/,
levels/NNS
of/IN
Id2/NN
mRNA/NN
decrease/VBP
while/IN
levels/NNS
of/IN
Id3/NN
mRNA/NN
increase/VBP
,/,
suggesting/VBG
that/IN
regulation/NN
of/IN
expression/NN
of/IN
these/DT
closely/RB
related/JJ
genes/NNS
is/VBZ
disparate/JJ
./.
====================
UI/LS
-/:
96082168/CD
====================
TI/LS
-/:
Salicylates/NNS
inhibit/VBP
lipopolysaccharide-induced/JJ
transcriptional/JJ
activation/NN
of/IN
the/DT
tissue/NN
factor/NN
gene/NN
in/IN
human/JJ
monocytic/JJ
cells/NNS
./.
====================
AB/LS
-/:
Binding/NN
of/IN
plasma/NN
Factor/NN
VII/VIIa/NN
to/TO
the/DT
tissue/NN
factor/NN
(/(
TF/NN
)/)
receptor/NN
initiates/VBZ
the/DT
coagulation/NN
protease/NN
cascades/NNS
./.
====================
TF/NN
expression/NN
by/IN
circulating/VBG
monocytes/NNS
is/VBZ
associated/VBN
with/IN
thrombotic/JJ
and/CC
inflammatory/JJ
complications/NNS
in/IN
a/DT
variety/NN
of/IN
diseases/NNS
./.
====================
Transcriptional/JJ
activation/NN
of/IN
the/DT
human/JJ
TF/NN
gene/NN
in/IN
monocytic/JJ
cells/NNS
exposed/VBN
to/TO
bacterial/JJ
lipopolysaccharide/NN
(/(
LPS/NN
)/)
is/VBZ
mediated/VBN
by/IN
binding/NN
of/IN
c-Rel/NN
/p65/NN
heterodimers/NNS
to/TO
a/DT
kappa/NN
B/NN
site/NN
in/IN
the/DT
TF/NN
promoter/NN
./.
====================
Here/RB
,/,
we/PRP
report/VBP
that/IN
a/DT
family/NN
of/IN
anti-inflammatory/JJ
agents/NNS
,/,
known/VBN
as/IN
the/DT
salicylates/NNS
,/,
inhibited/VBD
LPS/NN
induction/NN
of/IN
TF/NN
activity/NN
and/CC
TF/NN
gene/NN
transcription/NN
in/IN
human/JJ
monocytes/NNS
and/CC
monocytic/JJ
THP-1/NN
cells/NNS
at/IN
clinically/RB
relevant/JJ
doses/NNS
./.
====================
Furthermore/RB
,/,
sodium/NN
salicylate/NN
blocked/VBD
the/DT
LPS-induced/JJ
proteolytic/JJ
degradation/NN
of/IN
I/NN
kappa/NN
B/NN
alpha/NN
,/,
which/WDT
prevented/VBD
the/DT
nuclear/JJ
translocation/NN
of/IN
c-Rel/NN
/p65/NN
heterodimers/NNS
./.
====================
In/IN
contrast/NN
,/,
two/CD
other/JJ
nonsteroidal/JJ
anti-inflammatory/JJ
drugs/NNS
,/,
ibuprofen/NN
and/CC
indomethacin/NN
,/,
did/VBD
not/RB
inhibit/VB
LPS/NN
induction/NN
of/IN
the/DT
TF/NN
gene/NN
./.
====================
These/DT
results/NNS
indicated/VBD
that/IN
salicylates/NNS
inhibited/VBD
LPS/NN
induction/NN
of/IN
TF/NN
gene/NN
transcription/NN
in/IN
monocytic/JJ
cells/NNS
by/IN
preventing/VBG
nuclear/JJ
translocation/NN
of/IN
c-Rel/NN
/p65/NN
heterodimers/NNS
./.
====================
The/DT
clinical/JJ
benefits/NNS
of/IN
salicylates/NNS
in/IN
the/DT
treatment/NN
of/IN
several/JJ
diseases/NNS
,/,
including/VBG
atherosclerosis/NN
and/CC
rheumatoid/NN
arthritis/NN
,/,
may/MD
be/VB
related/JJ
to/TO
their/PRP$
ability/NN
to/TO
reduce/VB
monocyte/NN
gene/NN
expression/NN
./.
====================
UI/LS
-/:
96062272/CD
====================
TI/LS
-/:
Activation/NN
of/IN
the/DT
signal/NN
transducer/NN
and/CC
transcription/NN
(/(
STAT/NN
)/)
signaling/NN
pathway/NN
in/IN
a/DT
primary/JJ
T/NN
cell/NN
response/NN
./.
====================
Critical/JJ
role/NN
for/IN
IL-6/NN
./.
====================
AB/LS
-/:
The/DT
T/NN
cell/NN
activation/NN
is/VBZ
initiated/VBN
by/IN
interaction/NN
of/IN
specific/JJ
Ags/NNS
with/IN
TCR/NN
,/,
followed/VBN
by/IN
activation/NN
of/IN
intracellular/JJ
biochemical/JJ
events/NNS
leading/VBG
to/TO
activation/NN
of/IN
several/JJ
genes/NNS
./.
====================
The/DT
activation/NN
of/IN
signal/JJ
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
(/(
STAT/NN
)/)
proteins/NNS
in/IN
a/DT
primary/JJ
TCR-mediated/JJ
activation/NN
of/IN
T/NN
cells/NNS
have/VBP
been/VBN
explored/VBN
./.
====================
In/IN
purified/VBN
human/JJ
peripheral/JJ
blood/NN
T/NN
cells/NNS
,/,
nuclear/JJ
STAT/NN
proteins/NNS
were/VBD
activated/VBN
approximately/RB
3/CD
h/NN
after/IN
activation/NN
by/IN
cross-linked/JJ
anti-CD3/JJ
Abs/NNS
./.
====================
These/DT
STAT/NN
proteins/NNS
were/VBD
detected/VBN
by/IN
using/VBG
the/DT
IFN-gamma-activated/JJ
sequence/NN
(/(
GAS/NN
)/)
and/CC
related/JJ
oligonucleotides/NNS
as/IN
probes/NNS
in/IN
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
./.
====================
Analysis/NN
of/IN
the/DT
nuclear/JJ
extracts/NNS
with/IN
anti-STAT/JJ
Abs/NNS
indicated/VBD
that/IN
they/PRP
contained/VBD
STAT-3/NN
and/CC
additional/JJ
proteins/NNS
crossreactive/JJ
with/IN
the/DT
STAT/NN
family/NN
./.
====================
The/DT
induction/NN
of/IN
STAT/NN
activity/NN
was/VBD
inhibited/VBN
completely/RB
by/IN
pretreatment/NN
with/IN
either/CC
cycloheximide/NN
or/CC
cyclosporin/NN
A/NN
,/,
thus/RB
indicating/VBG
that/IN
the/DT
induction/NN
was/VBD
due/JJ
to/TO
a/DT
secondary/JJ
factor/NN
produced/VBN
by/IN
the/DT
activated/VBN
T/NN
cells/NNS
./.
====================
As/IN
neutralizing/NN
anti-IL-6/JJ
Abs/NNS
effectively/RB
down-regulated/VBD
the/DT
early/JJ
induction/NN
of/IN
STAT/NN
proteins/NNS
and/CC
as/IN
exogenously/RB
added/VBN
IL-6/NN
rapidly/RB
activated/VBD
DNA/NN
binding/NN
similar/JJ
to/TO
TCR-mediated/JJ
bindings/NNS
,/,
it/PRP
can/MD
be/VB
concluded/VBN
that/IN
IL-6/NN
is/VBZ
the/DT
factor/NN
responsible/JJ
for/IN
the/DT
activation/NN
of/IN
STAT/NN
proteins/NNS
in/IN
a/DT
primary/JJ
T/NN
cell/NN
response/NN
./.
====================
UI/LS
-/:
96046572/CD
====================
TI/LS
-/:
The/DT
normal/JJ
cell/NN
cycle/NN
activation/NN
program/NN
is/VBZ
exploited/VBN
during/IN
the/DT
infection/NN
of/IN
quiescent/JJ
B/NN
lymphocytes/NNS
by/IN
Epstein-Barr/JJ
virus/NN
./.
====================
AB/LS
-/:
B/NN
lymphocytes/NNS
in/IN
the/DT
peripheral/JJ
circulation/NN
are/VBP
maintained/JJ
in/IN
a/DT
non-proliferative/JJ
state/NN
./.
====================
Antigen/NN
recognition/NN
stimulates/VBZ
limited/JJ
proliferation/NN
,/,
whereas/IN
infection/NN
with/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
results/VBZ
in/IN
continual/JJ
proliferation/NN
and/CC
the/DT
outgrowth/NN
of/IN
immortal/JJ
cell/NN
lines/NNS
./.
====================
Because/IN
it/PRP
is/VBZ
not/RB
clear/JJ
at/IN
which/WDT
point/NN
in/IN
cell/NN
cycle/NN
the/DT
peripheral/JJ
B/NN
lymphocytes/NNS
are/VBP
arrested/VBN
,/,
we/PRP
characterized/VBD
the/DT
expression/NN
of/IN
several/JJ
cell/NN
cycle-associated/JJ
genes/NNS
in/IN
quiescent/JJ
and/CC
stimulated/VBN
cells/NNS
./.
====================
We/PRP
show/VBP
that/IN
the/DT
expression/NN
of/IN
four/CD
cell/NN
genes/NNS
,/,
cdc-2/NN
,/,
cyclin/NN
E/NN
,/,
CD23/NN
,/,
and/CC
cyclin/NN
D2/NN
,/,
are/VBP
up-regulated/VBN
approximately/RB
100-fold/RB
as/IN
a/DT
result/NN
of/IN
EBV-mediated/JJ
immortalization/NN
./.
====================
Because/IN
these/DT
genes/NNS
play/VBP
a/DT
positive/JJ
role/NN
in/IN
cell/NN
proliferation/NN
,/,
we/PRP
suggest/VBP
that/IN
this/DT
regulatory/JJ
switch/NN
contributes/VBZ
to/TO
controlling/VBG
entry/NN
into/IN
the/DT
cell/NN
cycle/NN
./.
====================
Transient/JJ
stimulation/NN
of/IN
quiescent/JJ
B/NN
lymphocytes/NNS
with/IN
either/CC
a/DT
cocktail/NN
of/IN
anti-CD40/NN
,/,
anti-IgM/NN
,/,
and/CC
IL4/NN
,/,
or/CC
EBV/NN
results/VBZ
in/IN
the/DT
rapid/JJ
expression/NN
of/IN
the/DT
same/JJ
four/CD
genes/NNS
,/,
suggesting/VBG
that/IN
,/,
after/IN
infection/NN
,/,
EBV/NN
exploits/VBZ
the/DT
normal/JJ
program/NN
of/IN
B-lymphocyte/NN
cell/NN
cycle/NN
activation/NN
./.
====================
UI/LS
-/:
96011839/CD
====================
TI/LS
-/:
Expression/NN
of/IN
the/DT
chemokine/NN
receptor/NN
BLR2/EBI1/NN
is/VBZ
specifically/RB
transactivated/VBN
by/IN
Epstein-Barr/JJ
virus/NN
nuclear/JJ
antigen/NN
2/CD
./.
====================
AB/LS
-/:
In/IN
our/PRP$
attempt/NN
to/TO
identify/VB
chemokine/NN
receptors/NNS
that/WDT
are/VBP
related/JJ
to/TO
Burkitt/NN
's/POS
lymphoma/NN
receptor/NN
1/CD
(/(
BLR1/NN
)/)
and/CC
are/VBP
expressed/VBN
in/IN
activated/VBN
lymphocytes/NNS
we/PRP
used/VBD
RT-PCR/NN
resulting/VBG
in/IN
the/DT
isolation/NN
of/IN
a/DT
cDNA/NN
encoding/VBG
a/DT
seven/CD
transmembrane/NN
receptor/NN
termed/VBN
BLR2/NN
./.
====================
The/DT
protein/NN
shows/VBZ
significant/JJ
sequence/NN
similarities/NNS
to/TO
the/DT
family/NN
of/IN
G-protein/NN
coupled/JJ
chemokine/NN
receptors/NNS
and/CC
turned/VBD
out/RP
to/TO
be/VB
identical/JJ
to/TO
the/DT
recently/RB
described/VBN
receptor/NN
EBI1/NN
./.
====================
Northern/NN
blot/NN
analysis/NN
revealed/VBD
that/IN
BLR2/NN
mRNA/NN
could/MD
be/VB
highly/RB
stimulated/VBN
in/IN
mitogen-/NN
and/CC
anti-CD3-treated/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
./.
====================
BLR2-specific/JJ
mRNA/NN
could/MD
be/VB
detected/VBN
in/IN
all/DT
Epstein-Barr/JJ
virus/NN
positive/JJ
B/NN
cell/NN
lines/NNS
./.
====================
We/PRP
show/VBP
that/IN
transcription/NN
of/IN
the/DT
BLR2/NN
gene/NN
could/MD
be/VB
specifically/RB
induced/VBN
in/IN
Epstein-Barr/JJ
virus/NN
negative/JJ
BL/NN
41/CD
cells/NNS
via/IN
estrogen-mediated/JJ
activation/NN
of/IN
Epstein-Barr/JJ
virus/NN
nuclear/JJ
antigen/NN
2/CD
,/,
a/DT
key/JJ
regulator/NN
of/IN
viral/JJ
and/CC
cellular/JJ
genes/NNS
in/IN
immortalized/VBN
B/NN
cells/NNS
./.
====================
Our/PRP$
data/NNS
suggest/VBP
an/DT
involvement/NN
of/IN
BLR2/NN
in/IN
the/DT
regulation/NN
of/IN
migration/NN
in/IN
activated/VBN
lymphocytes/NNS
and/CC
in/IN
viral/JJ
pathogenesis/NN
./.
====================
UI/LS
-/:
96009598/CD
====================
TI/LS
-/:
A/DT
central/JJ
role/NN
for/IN
a/DT
single/JJ
c-Myb/NN
binding/NN
site/NN
in/IN
a/DT
thymic/JJ
locus/NN
control/NN
region/NN
./.
====================
AB/LS
-/:
Locus/NN
control/NN
regions/NNS
(/(
LCRs/NNS
)/)
are/VBP
powerful/JJ
assemblies/NNS
of/IN
cis/JJ
elements/NNS
that/WDT
organize/VBP
the/DT
actions/NNS
of/IN
cell-type-specific/JJ
trans-acting/JJ
factors/NNS
./.
====================
A/DT
2.3-kb/JJ
LCR/NN
in/IN
the/DT
human/JJ
adenosine/NN
deaminase/NN
(/(
ADA/NN
)/)
gene/NN
first/JJ
intron/NN
,/,
which/WDT
controls/VBZ
expression/NN
in/IN
thymocytes/NNS
,/,
is/VBZ
composed/VBN
of/IN
a/DT
200-bp/JJ
enhancer/NN
domain/NN
and/CC
extended/JJ
flanking/NN
sequences/NNS
that/WDT
facilitate/VBP
activation/NN
from/IN
within/IN
chromatin/NN
./.
====================
Prior/RB
analyses/NNS
have/VBP
demonstrated/VBN
that/IN
the/DT
enhancer/NN
contains/VBZ
a/DT
28-bp/JJ
core/NN
region/NN
and/CC
local/JJ
adjacent/JJ
augmentative/JJ
cis/JJ
elements/NNS
./.
====================
We/PRP
now/RB
show/VBP
that/IN
the/DT
core/NN
contains/VBZ
a/DT
single/JJ
critical/JJ
c-Myb/NN
binding/NN
site/NN
./.
====================
In/IN
both/CC
transiently/RB
cotransfected/VBN
human/JJ
cells/NNS
and/CC
stable/JJ
chromatin-integrated/JJ
yeast/NN
cells/NNS
,/,
c-Myb/NN
strongly/RB
transactivated/VBD
reporter/NN
constructs/NNS
that/WDT
contained/VBD
polymerized/JJ
core/NN
sequences/NNS
./.
====================
c-Myb/NN
protein/NN
was/VBD
strongly/RB
evident/JJ
in/IN
T/NN
lymphoblasts/NNS
in/IN
which/WDT
the/DT
enhancer/NN
was/VBD
active/JJ
and/CC
was/VBD
localized/JJ
within/IN
discrete/JJ
nuclear/JJ
structures/NNS
./.
====================
Fetal/JJ
murine/NN
thymus/NN
exhibited/VBD
a/DT
striking/JJ
concordance/NN
of/IN
endogenous/JJ
c-myb/NN
expression/NN
with/IN
that/DT
of/IN
mouse/NN
ADA/NN
and/CC
human/JJ
ADA/NN
LCR-directed/JJ
transgene/NN
expression/NN
./.
====================
Point/NN
mutation/NN
of/IN
the/DT
c-Myb/NN
site/NN
within/IN
the/DT
intact/JJ
2.3-kb/JJ
LCR/NN
severely/RB
attenuated/VBD
enhancer/NN
activity/NN
in/IN
transfections/NNS
and/CC
LCR/NN
activity/NN
in/IN
transgenic/JJ
thymocytes/NNS
./.
====================
Within/IN
the/DT
context/NN
of/IN
a/DT
complex/NN
enhancer/NN
and/CC
LCR/NN
,/,
c-Myb/NN
can/MD
act/VB
as/IN
an/DT
organizer/NN
of/IN
thymocyte-specific/JJ
gene/NN
expression/NN
via/IN
a/DT
single/JJ
binding/VBG
site/NN
./.
====================
UI/LS
-/:
95403454/CD
====================
TI/LS
-/:
A/DT
regulatory/JJ
element/NN
in/IN
the/DT
human/JJ
interleukin/NN
2/CD
gene/NN
promoter/NN
is/VBZ
a/DT
binding/VBG
site/NN
for/IN
the/DT
zinc/NN
finger/NN
proteins/NNS
Sp1/NN
and/CC
EGR-1/NN
./.
====================
AB/LS
-/:
Activation/NN
of/IN
the/DT
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
gene/NN
after/IN
antigen/NN
recognition/NN
is/VBZ
a/DT
critical/JJ
event/NN
for/IN
T/NN
cell/NN
proliferation/NN
and/CC
effector/NN
function/NN
./.
====================
Prior/JJ
studies/NNS
have/VBP
identified/VBN
several/JJ
transcription/NN
factors/NNS
that/WDT
contribute/VBP
to/TO
the/DT
activity/NN
of/IN
the/DT
IL-2/NN
promoter/NN
in/IN
stimulated/VBN
T/NN
lymphocytes/NNS
./.
====================
Here/RB
we/PRP
describe/VBP
a/DT
novel/JJ
regulatory/JJ
element/NN
within/IN
the/DT
IL-2/NN
promoter/NN
located/JJ
immediately/RB
upstream/RB
of/IN
the/DT
nuclear/JJ
factor/NN
of/IN
activated/VBN
T/NN
cell/NN
(/(
NFAT/NN
)/)
domain/NN
./.
====================
This/DT
region/NN
(/(
termed/VBN
the/DT
zinc/NN
finger/NN
protein/NN
binding/NN
region/NN
(/(
ZIP/NN
)/)
)/)
serves/VBZ
as/IN
binding/VBG
site/NN
for/IN
two/CD
differently/RB
regulated/VBN
zinc/NN
finger/NN
proteins/NNS
:/:
the/DT
constitutively/RB
expressed/VBN
transcription/NN
factor/NN
Sp1/NN
and/CC
the/DT
inducible/JJ
early/JJ
growth/NN
response/NN
protein/NN
EGR-1/NN
./.
====================
In/IN
unstimulated/JJ
cells/NNS
which/WDT
do/VBP
not/RB
secrete/VB
IL-2/NN
,/,
only/RB
Sp1/NN
binds/VBZ
to/TO
this/DT
region/NN
,/,
while/IN
in/IN
stimulated/VBN
IL-2/NN
secreting/NN
cells/NNS
the/DT
inducible/JJ
EGR-1/NN
protein/NN
recognizes/VBZ
this/DT
element/NN
./.
====================
In/IN
Jurkat/NN
T/NN
cells/NNS
,/,
the/DT
ZIP/NN
site/NN
serves/VBZ
as/IN
an/DT
activator/NN
for/IN
IL-2/NN
gene/NN
expression/NN
,/,
and/CC
a/DT
combination/NN
of/IN
ZIP/NN
and/CC
NFAT/NN
binding/NN
sites/NNS
is/VBZ
required/VBN
for/IN
maximal/JJ
IL-2/NN
promoter/NN
activity/NN
./.
====================
These/DT
results/NNS
suggest/VBP
a/DT
critical/JJ
role/NN
of/IN
the/DT
ZIP/NN
site/NN
for/IN
IL-2/NN
promoter/NN
activity/NN
./.
====================
UI/LS
-/:
95385995/CD
====================
TI/LS
-/:
Activation/NN
of/IN
the/DT
HIV-1/NN
enhancer/NN
by/IN
the/DT
LEF-1/NN
HMG/NN
protein/NN
on/IN
nucleosome-assembled/JJ
DNA/NN
in/FW
vitro/FW
./.
====================
AB/LS
-/:
Lymphoid/NN
enhancer-binding/JJ
factor/NN
1/CD
(/(
LEF-1/NN
)/)
is/VBZ
a/DT
regulatory/JJ
high/JJ
mobility/NN
group/NN
(/(
HMG/NN
)/)
protein/NN
that/WDT
activates/VBZ
the/DT
T/NN
cell/NN
receptor/NN
alpha/NN
(/(
TCR/NN
alpha/NN
)/)
enhancer/NN
in/IN
a/DT
context-restricted/JJ
manner/NN
in/IN
T/NN
cells/NNS
./.
====================
In/IN
this/DT
paper/NN
we/PRP
demonstrate/VBP
that/IN
the/DT
distal/JJ
region/NN
of/IN
the/DT
human/JJ
immunodeficiency/NN
virus-1/NN
(/(
HIV-1/NN
)/)
enhancer/NN
,/,
which/WDT
contains/VBZ
DNA-binding/JJ
sites/NNS
for/IN
LEF-1/NN
and/CC
Ets-1/NN
,/,
also/RB
provides/VBZ
a/DT
functional/JJ
context/NN
for/IN
activation/NN
by/IN
LEF-1/NN
./.
====================
First/RB
,/,
we/PRP
show/VBP
that/IN
mutations/NNS
in/IN
the/DT
LEF-1-binding/JJ
site/NN
inhibit/VBP
the/DT
activity/NN
of/IN
multimerized/JJ
copies/NNS
of/IN
the/DT
HIV-1/NN
enhancer/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
,/,
and/CC
that/IN
LEF-1/GAL4/NN
can/MD
activate/VB
a/DT
GAL4-substituted/JJ
HIV-1/NN
enhancer/NN
80-/CD
to/TO
100-fold/RB
in/FW
vivo/FW
./.
====================
Second/RB
,/,
recombinant/JJ
LEF-1/NN
is/VBZ
shown/VBN
to/TO
activate/VB
HIV-1/NN
transcription/NN
on/IN
chromatin-assembled/JJ
DNA/NN
in/FW
vitro/FW
./.
====================
By/IN
using/VBG
a/DT
nucleosome-assembly/JJ
system/NN
derived/VBN
from/IN
Drosophila/FW
embryos/NNS
,/,
we/PRP
find/VBP
that/IN
the/DT
packaging/NN
of/IN
DNA/NN
into/IN
chromatin/NN
in/FW
vitro/FW
strongly/RB
represses/VBZ
HIV-1/NN
transcription/NN
and/CC
that/IN
repression/NN
can/MD
be/VB
counteracted/VBN
efficiently/RB
by/IN
preincubation/NN
of/IN
the/DT
DNA/NN
with/IN
LEF-1/NN
(/(
or/CC
LEF-1/NN
and/CC
Ets-1/NN
)/)
supplemented/VBN
with/IN
fractions/NNS
containing/VBG
the/DT
promoter-binding/JJ
protein/NN
,/,
Sp1/NN
./.
====================
Addition/NN
of/IN
TFE-3/NN
,/,
which/WDT
binds/VBZ
to/TO
an/DT
E-box/NN
motif/NN
upstream/JJ
of/IN
the/DT
LEF-1/NN
and/CC
Ets-1/NN
sites/NNS
,/,
further/RB
augments/VBZ
transcription/NN
in/IN
this/DT
system/NN
./.
====================
Individually/RB
or/CC
collectively/RB
,/,
none/NN
of/IN
the/DT
three/CD
enhancer-binding/JJ
proteins/NNS
(/(
LEF-1/NN
,/,
Ets-1/NN
,/,
and/CC
TFE-3/NN
)/)
could/MD
activate/VB
transcription/NN
in/IN
the/DT
absence/NN
of/IN
Sp1/NN
./.
====================
A/DT
truncation/NN
mutant/NN
of/IN
LEF-1/NN
(/(
HMG-88/CD
)/)
,/,
which/WDT
contains/VBZ
the/DT
HMG/NN
box/NN
but/CC
lacks/VBZ
the/DT
trans-activation/JJ
domain/NN
,/,
did/VBD
not/RB
activate/VB
transcription/NN
from/IN
nucleosomal/JJ
DNA/NN
,/,
indicating/VBG
that/IN
bending/NN
of/IN
DNA/NN
by/IN
the/DT
HMG/NN
domain/NN
is/VBZ
not/RB
sufficient/JJ
to/TO
activate/VB
transcription/NN
in/FW
vitro/FW
./.
====================
We/PRP
conclude/VBP
that/IN
transcription/NN
activation/NN
by/IN
LEF-1/NN
in/FW
vitro/FW
is/VBZ
a/DT
chromatin-dependent/JJ
process/NN
that/WDT
requires/VBZ
a/DT
functional/JJ
trans-activation/NN
domain/NN
in/IN
addition/NN
to/TO
the/DT
HMG/NN
domain/NN
./.
====================
UI/LS
-/:
95370270/CD
====================
TI/LS
-/:
HIV-1/NN
envelope/NN
glycoproteins/NNS
induce/VBP
activation/NN
of/IN
activated/VBN
protein-1/NN
in/IN
CD4+/JJ
T/NN
cells/NNS
[/(
published/VBN
erratum/NN
appears/VBZ
in/IN
J/NNP
Biol/NNP
Chem/NNP
1995/CD
Dec/NNP
1/CD
;/:
270/CD
(/(
48/CD
)/)
:/:
29038/CD
]/)
====================
AB/LS
-/:
Activation/NN
of/IN
CD4/NN
positive/JJ
T/NN
cells/NNS
is/VBZ
a/DT
primary/JJ
requirement/NN
for/IN
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
entry/NN
,/,
efficient/JJ
HIV/NN
replication/NN
,/,
and/CC
progression/NN
to/TO
AIDS/NN
,/,
Utilizing/VBG
CD4/NN
positive/JJ
T/NN
cell/NN
lines/NNS
and/CC
purified/VBN
T/NN
cells/NNS
from/IN
normal/JJ
individuals/NNS
,/,
we/PRP
have/VBP
demonstrated/VBN
that/IN
native/JJ
envelope/NN
glycoproteins/NNS
of/IN
HIV/NN
,/,
gp/NN
160/CD
,/,
can/MD
induce/VB
activation/NN
of/IN
transcription/NN
factor/NN
,/,
activated/VBN
protein-1/NN
(/(
AP-1/NN
)/)
./.
====================
The/DT
stimulatory/JJ
effects/NNS
of/IN
gp160/NN
are/VBP
mediated/VBN
through/IN
the/DT
CD4/NN
molecule/NN
,/,
since/IN
treatment/NN
of/IN
gp160/NN
with/IN
soluble/JJ
CD4-IgG/NN
abrogates/VBZ
its/PRP$
activity/NN
,/,
and/CC
CD4/NN
negative/JJ
T/NN
cell/NN
lines/NNS
fail/VBP
to/TO
be/VB
stimulated/VBN
with/IN
gp160/NN
./.
====================
Immunoprecipitation/NN
of/IN
the/DT
gp/NN
160-induced/JJ
nuclear/JJ
extracts/NNS
with/IN
polyclonal/JJ
antibodies/NNS
to/TO
Fos/NN
and/CC
Jun/NN
proteins/NNS
indicates/VBZ
that/IN
AP-1/NN
complex/NN
is/VBZ
comprised/VBN
of/IN
members/NNS
of/IN
these/DT
family/NN
of/IN
proteins/NNS
./.
====================
The/DT
gp160-induced/JJ
AP-1/NN
complex/NN
is/VBZ
dependent/JJ
upon/IN
protein/NN
tyrosine/NN
phosphorylation/NN
and/CC
is/VBZ
protein/NN
synthesis-independent/JJ
./.
====================
This/DT
stimulation/NN
can/MD
also/RB
be/VB
abolished/VBN
by/IN
inhibitors/NNS
of/IN
protein/NN
kinase/NN
C/NN
,/,
but/CC
it/PRP
is/VBZ
unaffected/JJ
by/IN
calcium/NN
channel/NN
blocker/NN
or/CC
cyclosporine/NN
A/NN
./.
====================
This/DT
gp160/NN
treatment/NN
adversely/RB
affects/VBZ
the/DT
functional/JJ
capabilities/NNS
of/IN
T/NN
cells/NNS
:/:
pre-treatment/NN
of/IN
CD4+/JJ
T/NN
cells/NNS
with/IN
gp160/NN
for/IN
4/CD
h/NN
at/IN
37/CD
degrees/NNS
C/NN
inhibited/VBD
anti-CD3-induced/JJ
interleukin-2/NN
secretion/NN
./.
====================
Effects/NNS
similar/JJ
to/TO
gp160/NN
were/VBD
seen/VBN
with/IN
anti-CD4/JJ
mAb/NN
./.
====================
The/DT
aberrant/JJ
activation/NN
of/IN
AP-1/NN
by/IN
gp160/NN
in/IN
CD4/NN
positive/JJ
T/NN
cells/NNS
could/MD
result/VB
in/IN
up-regulation/NN
of/IN
cytokines/NNS
containing/VBG
AP-1/NN
sites/NNS
,/,
e.g./FW
interleukin-3/NN
and/CC
granulocyte/NN
macrophage/NN
colony-stimulating/JJ
factor/NN
,/,
and/CC
concurrently/RB
lead/VBP
to/TO
T/NN
cell/NN
unresponsiveness/NN
by/IN
inhibiting/VBG
interleukin-2/NN
secretion/NN
./.
====================